<SEC-DOCUMENT>0000875045-22-000016.txt : 20220503
<SEC-HEADER>0000875045-22-000016.hdr.sgml : 20220503
<ACCEPTANCE-DATETIME>20220503161645
ACCESSION NUMBER:		0000875045-22-000016
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		121
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220503
DATE AS OF CHANGE:		20220503

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOGEN INC.
		CENTRAL INDEX KEY:			0000875045
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				330112644
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19311
		FILM NUMBER:		22887115

	BUSINESS ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		7814642000

	MAIL ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC.
		DATE OF NAME CHANGE:	20070427

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC
		DATE OF NAME CHANGE:	20031112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IDEC PHARMACEUTICALS CORP / DE
		DATE OF NAME CHANGE:	19970530
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>biib-20220331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:c574431f-8208-4dea-bcfe-8d8f5f068522,g:425f524b-de43-4dfe-85cc-ae50a1579d49,d:e9658fba2baf4e3799b1175f69eaed46--><html xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:biib="http://www.biogenidec.com/20220331" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns="http://www.w3.org/1999/xhtml" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>biib-20220331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80L2ZyYWc6NDkyNWZkZmFjYjZkNDY0ZmE1NmExNmRkMTU5ZjcxZmMvdGFibGU6NzFjOTI1Y2UzMGQwNGI2MGIyMTEyZmIyODBkN2Y3NjIvdGFibGVyYW5nZTo3MWM5MjVjZTMwZDA0YjYwYjIxMTJmYjI4MGQ3Zjc2Ml8xLTEtMS0xLTc1MTQw_fc4c4863-128e-4f45-8760-c0c02cca8d64">0000875045</ix:nonNumeric><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80L2ZyYWc6NDkyNWZkZmFjYjZkNDY0ZmE1NmExNmRkMTU5ZjcxZmMvdGFibGU6NzFjOTI1Y2UzMGQwNGI2MGIyMTEyZmIyODBkN2Y3NjIvdGFibGVyYW5nZTo3MWM5MjVjZTMwZDA0YjYwYjIxMTJmYjI4MGQ3Zjc2Ml8yLTEtMS0xLTc1MTQw_69d39f3e-c17a-42de-a0ed-6b55ea848958">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80L2ZyYWc6NDkyNWZkZmFjYjZkNDY0ZmE1NmExNmRkMTU5ZjcxZmMvdGFibGU6NzFjOTI1Y2UzMGQwNGI2MGIyMTEyZmIyODBkN2Y3NjIvdGFibGVyYW5nZTo3MWM5MjVjZTMwZDA0YjYwYjIxMTJmYjI4MGQ3Zjc2Ml8zLTEtMS0xLTc1MTQw_a8cf6183-4a38-4621-b77a-c4b92c8dd29c">2022</ix:nonNumeric><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80L2ZyYWc6NDkyNWZkZmFjYjZkNDY0ZmE1NmExNmRkMTU5ZjcxZmMvdGFibGU6NzFjOTI1Y2UzMGQwNGI2MGIyMTEyZmIyODBkN2Y3NjIvdGFibGVyYW5nZTo3MWM5MjVjZTMwZDA0YjYwYjIxMTJmYjI4MGQ3Zjc2Ml80LTEtMS0xLTc1MTQw_e98e6de0-879b-4444-a0ca-eef7eff61c46">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80L2ZyYWc6NDkyNWZkZmFjYjZkNDY0ZmE1NmExNmRkMTU5ZjcxZmMvdGFibGU6NzFjOTI1Y2UzMGQwNGI2MGIyMTEyZmIyODBkN2Y3NjIvdGFibGVyYW5nZTo3MWM5MjVjZTMwZDA0YjYwYjIxMTJmYjI4MGQ3Zjc2Ml81LTEtMS0xLTc1MTQw_2b6ea03e-d673-4001-9a13-c3044d2542ec">false</ix:nonNumeric><ix:nonFraction unitRef="shares" contextRef="ica34c492e95e460da92f264a157fc2cc_I20220502" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80L2ZyYWc6NDkyNWZkZmFjYjZkNDY0ZmE1NmExNmRkMTU5ZjcxZmMvdGFibGU6NzFjOTI1Y2UzMGQwNGI2MGIyMTEyZmIyODBkN2Y3NjIvdGFibGVyYW5nZTo3MWM5MjVjZTMwZDA0YjYwYjIxMTJmYjI4MGQ3Zjc2Ml82LTItMS0xLTc1MTQw_9960cfcc-ab45-40ca-b29c-a02b0d470ed1">146,452,013</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yOC9mcmFnOjEyNDU0MDQ4MDVjNjQxNGJiMjVjNGI5NGZiM2UxOWFiL3RhYmxlOjkzMmZiMTZkNTA4YTRhZTY4MjEyNWY0MjE5NGQ4OGZhL3RhYmxlcmFuZ2U6OTMyZmIxNmQ1MDhhNGFlNjgyMTI1ZjQyMTk0ZDg4ZmFfMS0xLTEtMS03NTE0MA_eb8f1bdd-a933-431c-a940-e7e9ba793c9b">0.001</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yOC9mcmFnOjEyNDU0MDQ4MDVjNjQxNGJiMjVjNGI5NGZiM2UxOWFiL3RhYmxlOjkzMmZiMTZkNTA4YTRhZTY4MjEyNWY0MjE5NGQ4OGZhL3RhYmxlcmFuZ2U6OTMyZmIxNmQ1MDhhNGFlNjgyMTI1ZjQyMTk0ZDg4ZmFfMS0zLTEtMS03NTE0MA_8196c2cb-a6a0-4817-8f74-c4dc8af37ae0">0.001</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yOC9mcmFnOjEyNDU0MDQ4MDVjNjQxNGJiMjVjNGI5NGZiM2UxOWFiL3RhYmxlOjkzMmZiMTZkNTA4YTRhZTY4MjEyNWY0MjE5NGQ4OGZhL3RhYmxlcmFuZ2U6OTMyZmIxNmQ1MDhhNGFlNjgyMTI1ZjQyMTk0ZDg4ZmFfMi0xLTEtMS03NTE0MA_d6043e13-c92d-41b0-a2f0-e6838f143091">0.0005</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yOC9mcmFnOjEyNDU0MDQ4MDVjNjQxNGJiMjVjNGI5NGZiM2UxOWFiL3RhYmxlOjkzMmZiMTZkNTA4YTRhZTY4MjEyNWY0MjE5NGQ4OGZhL3RhYmxlcmFuZ2U6OTMyZmIxNmQ1MDhhNGFlNjgyMTI1ZjQyMTk0ZDg4ZmFfMi0zLTEtMS03NTE0MA_1e652cbf-bd85-4033-ae7e-1bba4ac3c86b">0.0005</ix:nonFraction><ix:nonNumeric contextRef="ia54a50706b514096bba4ab26af0acaa8_D20220101-20220331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82NC9mcmFnOjk5ZmIzMTVmZDM2NDQyOWJhZTc4NDNkNTc2YzkyZmFkL3RhYmxlOjYwYTUxMGU2YzUyNTRmZmQ5OWExYjAzZDkwZjYwOTdhL3RhYmxlcmFuZ2U6NjBhNTEwZTZjNTI1NGZmZDk5YTFiMDNkOTBmNjA5N2FfMS0xLTEtMS03NTE0MA_3f301b5e-16d0-4e3d-8772-1ba3b53397f3">4</ix:nonNumeric><ix:nonNumeric contextRef="ic399f673115248b988b9405c7bf5aa12_D20220101-20220331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82NC9mcmFnOjk5ZmIzMTVmZDM2NDQyOWJhZTc4NDNkNTc2YzkyZmFkL3RhYmxlOjYwYTUxMGU2YzUyNTRmZmQ5OWExYjAzZDkwZjYwOTdhL3RhYmxlcmFuZ2U6NjBhNTEwZTZjNTI1NGZmZDk5YTFiMDNkOTBmNjA5N2FfMi0xLTEtMS03NTE0MA_af06af3f-bdef-4b8e-9e62-f41e7161d0a1">28</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="ic6518b6b1ff547bda3f65b2aff26f52a_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83MC9mcmFnOmVkNTg1ZWY1YTMxNDRhYTQ5MTljZDhmNDY2YzNkNzdiL3RhYmxlOjg5OTEwMWI0YjlmODQwY2E4YzUzMzI4NWU5ZDZiYjk3L3RhYmxlcmFuZ2U6ODk5MTAxYjRiOWY4NDBjYThjNTMzMjg1ZTlkNmJiOTdfNi0xLTEtMS03NTE0MA_657af6c6-122c-488c-a3e3-2671f9883256">3.625</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i59761a7057b84b83b94391f9934d130e_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83MC9mcmFnOmVkNTg1ZWY1YTMxNDRhYTQ5MTljZDhmNDY2YzNkNzdiL3RhYmxlOjg5OTEwMWI0YjlmODQwY2E4YzUzMzI4NWU5ZDZiYjk3L3RhYmxlcmFuZ2U6ODk5MTAxYjRiOWY4NDBjYThjNTMzMjg1ZTlkNmJiOTdfNy0xLTEtMS03NTE0MA_80b654a9-4358-4da6-b763-9d31bcf9230e">4.050</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i9f6dd011d88b4ac782dc7a1775ddccb8_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83MC9mcmFnOmVkNTg1ZWY1YTMxNDRhYTQ5MTljZDhmNDY2YzNkNzdiL3RhYmxlOjg5OTEwMWI0YjlmODQwY2E4YzUzMzI4NWU5ZDZiYjk3L3RhYmxlcmFuZ2U6ODk5MTAxYjRiOWY4NDBjYThjNTMzMjg1ZTlkNmJiOTdfOC0xLTEtMS03NTE0MA_eba8fb05-cb02-4c76-8dd1-6f8145f190b9">5.200</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i53483a1cc9e941e09201232721818ef2_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83MC9mcmFnOmVkNTg1ZWY1YTMxNDRhYTQ5MTljZDhmNDY2YzNkNzdiL3RhYmxlOjg5OTEwMWI0YjlmODQwY2E4YzUzMzI4NWU5ZDZiYjk3L3RhYmxlcmFuZ2U6ODk5MTAxYjRiOWY4NDBjYThjNTMzMjg1ZTlkNmJiOTdfOS0xLTEtMS03NTE0MA_8b30fbfb-019d-4aea-95ee-b9b59648859c">2.250</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ib6864de98b5c49cab9140ebeace06324_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83MC9mcmFnOmVkNTg1ZWY1YTMxNDRhYTQ5MTljZDhmNDY2YzNkNzdiL3RhYmxlOjg5OTEwMWI0YjlmODQwY2E4YzUzMzI4NWU5ZDZiYjk3L3RhYmxlcmFuZ2U6ODk5MTAxYjRiOWY4NDBjYThjNTMzMjg1ZTlkNmJiOTdfMTAtMS0xLTEtNzUxNDA_fe74fc16-c47d-47bc-9f2d-084fcaa3a8b3">3.150</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i3f6d74e47a314e6c9c9ceec4cbe4c782_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83MC9mcmFnOmVkNTg1ZWY1YTMxNDRhYTQ5MTljZDhmNDY2YzNkNzdiL3RhYmxlOjg5OTEwMWI0YjlmODQwY2E4YzUzMzI4NWU5ZDZiYjk3L3RhYmxlcmFuZ2U6ODk5MTAxYjRiOWY4NDBjYThjNTMzMjg1ZTlkNmJiOTdfMTEtMS0xLTEtNzUxNDA_eb3a8507-e014-46bd-a651-06df60e31d74">3.250</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="0" name="us-gaap:AssetImpairmentCharges" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83MC9mcmFnOmVkNTg1ZWY1YTMxNDRhYTQ5MTljZDhmNDY2YzNkNzdiL3RleHRyZWdpb246ZWQ1ODVlZjVhMzE0NGFhNDkxOWNkOGY0NjZjM2Q3N2JfOQ_161050dc-2a2e-4209-ad49-d26ae82d2e45">0</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="biib-20220331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica34c492e95e460da92f264a157fc2cc_I20220502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-05-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i70fc67330ce0470db37abf6a0dc4fb6a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i22a0a13c266f4d788d5ba6423911ebd9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5e84907dfd54cd09fdf7dc476b17545_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6b11452af4d4ae0bf50278351f22899_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36b52f54c6e84045a18f6f934ed61b63_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee301b6f981549919f1dd915c03e2623_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="id525e35f363e449aa36c9833e703f6f9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i609afa0be8424634b9ec333da2c2f549_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8f47af926b14294931310a85ceac0ce_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8239e2124c804a2ea880e06ae55914e8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie941cd89b1e6451a9094413808a742ce_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78d18bc7ad434dbbb7aebc8184bdf0b7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ec0412c74a64f2a8f0fe89d886801fd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59bfec7053f64e28a514a578cced1277_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7bb17477f1d45768747b659ec408858_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia38ac114688d4dc79f2cdfac46866743_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2ab94bf8dc040fba955fc08e64b5851_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cab2b42650840b8ad130b5ce90c072e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a99695583d54417b14f147c2e47f0ce_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i548f861f837e49619231dee37689ae5e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d4017cf2e7f4c638778c899d7ee5f81_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i377219a6f8954472a10644270fc0f641_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8cfe2b3484547cb8b869f3703fbe7c6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ba81a995fb24572ac4a052b330190f7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie711522c60db4065b671794dadaf1a8a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17ade9377df944b2b6a0b1d325fc48e3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5517a2fe985436cb5f65e1183b54903_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac6522198e5e47e2a87d575d4f0cf5fb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d4a878ad70149fc8ebc17f38fb2c3bb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i623c94faf2524ab6b84a4328c9fbfc71_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib24a1c0ce66c4661bdc85bb559c07e50_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf88a450e4df44f4ad8703ca0a5d3d6f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic54a4fcce0664582818adb93f242f27f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4f31a85cb5f4aeb9edd4a49ddc2205a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic33c429907664938b302242bae096aa3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95735dc725534e82a2c616cddefbdcd3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83d657be8c0141d3bbd283fd85ddc533_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7af6de98bde64694848ffc34847a8d52_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedf3697c5b544792bd0663883b4528a0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45721a1b1a8a4773b726c7ab76d5f1ec_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2ccdc021de64ec580af92fa350db35b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00c0c236fb7541c28d07fbbdf09baf1a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8b2525325d746868ee2c18985898556_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie16d6112315b4c80ab9519df7448188a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c1a3584d9f04422972632d1a69a2814_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ef7dff5a368420bbd853026208ceb4c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8035064229a94dc1909b26988c0c3fc7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide815a728f624d74849b4eae66187c0b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7810c7b681664742a2f6a5378d83f3f8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9609a3cc1f21413e9387d3f994a752ea_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35b4f4d780094f18808d017b4f134084_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if08130086aa74dc58e95ffbe7e3e1cc2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic151146309d249e6b3efce405c9339a7_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07a17833f117433192dfb2a5c084ff23_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62a58c1e7d3f4fa9bef57b7a1f8c7c8e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9948ac905c84412a859b84aa29f53e12_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1ecc04b333e4da4ac25243469cdb953_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i763b233fe41d42f8aa4eb102c4f5c9e1_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e4fb5422af74378bdf258c1594fe372_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaad911ccb4124b46ace623b2c56be18b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>biib:segment</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i8c3728b044d743d0b57e33fc6e523b46_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4afdc1a2dcdf424eabd0653274b690c7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4b04ecc1818447ebb524096be801f20_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:WorkforceReductionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i929ddd179174497bb90c576f4da728fd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:WorkforceReductionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60bd213e6b2f4cef984449f784cce8aa_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:WorkforceReductionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4019bfee1947475697fa8390601cf107_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d56b6894b294cb3b2fbfc394c2be8f3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45e6439716cb4f31b5a5f0feef64721a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9ae9e65490748f2acefb5047af75a92_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8085faadc8004a108e4be4098084c970_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40537541890549888c403ef75418b3d7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f199ee2171447a5b18611c5c256d297_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i958877fcc74e4539915b329079fa6389_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i757cf428860849798a536a290e69a744_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80aabd0ba40a4666859ae614cdd27a07_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f4e5fdc87be405f92ffd881cb8662ce_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4c2e7acd9be4bfea25698309d8d8828_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i487df1d2304e478d8603ddfb4616b0f6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icea6a5dee2a24c37ac79226e11fc7e81_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49af7fbee4534ecc9b44e33e68ad9bac_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b15c52761ae42e58d6abc7911f80917_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5540cfaf99944f5fa1f892083859fd1b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2efe312a1ed4c21bc651416d90150b4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4cb5e1b131d44a689b572c1d03b1392_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f8158b854de46d7949a3f0ff441a7c9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie44c413a93ec48a59784c0ea0623dded_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if54e432976f24dfa9de95d847fc16af1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7331caa9ccd84bd5be10521a9f0d0481_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ec978dde6374ab7a39346cd84c5c36c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie66c008431754250a1c7ad1581031751_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d4fca69d176447480f070d481fc6e1d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55f4f5b3d91e4c279119147eedb46915_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf5d43d131c84980b40ac7f048729534_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a4ea8f03c0f42738c05eac690b20806_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60267e464f984999be2095717c97a319_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c070dfe729642198b279735cad93c30_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78c6eccdad234026bb1aeeb838de571d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6828112d9c4f41f0bf08dd88efb7662e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1098dcaf54d41aca1af33ac1c235c78_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iceae2cc273d1444eae0aa9c381b2d61b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8ac52ff6b5e42babf12a9c71a39395c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f41e9d658b94408b5d6df1021553899_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id06f574f06e14c8ba3b25d199ce88210_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i722a1d8416ce4b6b9e7ebbb4433afb51_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i816d25b468bc4d96aab34518cf3f4c6c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1004f5d220be40cd9e39fe595414dfaa_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30b4707892bc4fec9b74d5cc51e6529e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7921192dedf4f4a988ac6e9ce17c61b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8e1bccba2b844138516eb1ac75d4fdf_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e8b6707e4854fa388edc206ac7d95bd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i670a74b23f5f4caea6103368f4c95973_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if08c5715a87047d6916a728b0059e603_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id811739973f8445d958ab0cb2731f205_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ed53a25b23d434ebf3a733a39cbbcb7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i403756a186e6453a9c24141d0b5678f5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i534b8a9915d9400f837298b0f6d411f1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66f6ed4993f14e3290ab6c4742235f3d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6f7347790a54edbabf24343e2257691_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68ba8dee324c40978fe4ee8211658faa_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic81d1b50ecdb40b391c62c6287303f8b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32b306330d79453787a5388f0c9b87dd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61d231d430914084bd5b37c094531f73_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic570d7e37f3246c9a7c17df8eb70bf29_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cb87c336f514d67ab337ffa3b0d63a2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1049089607294f30837a3ada694dc739_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d04af7411eb4ffd942a725be50edb92_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15bc81eea1fc4013a923d18d25b1aee3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifaf74ee71f7f4592b819c8e204ed6c90_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36dbeb0ba18e4a5b94216f5fdfb3a00a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i057f89827dbc42819caa6b53dc6ff8c7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic026373e31634ffb9f84acb0c02d47ac_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ae65a6ea2994e1da2df20adab69bd79_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f713481ad2048ecae97763950260fd1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee11fd74051f4269a45be312fa23f68f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98bd7ced87284d89af6b6ae7d70f8d7d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i782884b4f8aa48df9e97e2cb2755409f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e33621ceef64fc2ad12d006a54bc1b8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56fe223e37e040f490923df9b519d2a6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbd8a4f5465946c0aa38c26ef4752572_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifeeb3b4588f74e0586c4e89af4306f7b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7ae353a26bd4fff8785a4632e4afbfa_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="wholesaler"><xbrli:measure>biib:wholesaler</xbrli:measure></xbrli:unit><xbrli:context id="i03f9978c12b14dfc8ee889cdf2bdb6f0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d6f800c7c994872a26f2506f98306ad_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94c39b003aff4990a1610f96586f03dd_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5db3734293a4e20858f95205c4aac6c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i724aaa93e18442fc9a55e613a9dda9bd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67b699450f32425283dbf73b59e9a343_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c857804af6a41aeb371a364d6599e30_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29cfc0f0c2944f219a39cbd064853d72_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f9240206d2e4fdfa0bf34f005ce7fdc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0962864d41e04b9897a3e8d3c6267a4e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06abbb84d032422fb1a3f75785252f65_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc6e75dd023146aeb4a6678f69c4242c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia76f9cf51eab4d948a5698ec20d971c9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id33287c4ca8e4b7c9960bc9a3c2091e4_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaac99eb6afb34c03b2e78fd08137df46_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bdcfb675756479fa2aa02a4f8a3a6ce_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d7e46af1def46ae846f93734361fcc5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddf807d85db941d0a2233de6ebb901c4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a4a7cbdeb574c34acd8f0fd4451328e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35f562ab50824cc2bc7a3c789fec1b1c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9173e074bac74af1b3732b3d6a272a0e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6985304f226c46fca0470a43faf8887c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a84089481564844bfa9bc6d09008d08_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fc4bd215e8a4eda8144b5304af45e97_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf64235b712a458e82807e9c3b0ae91f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a8520df9645495bbf150a3c973688bb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">biib:CentersForMedicareAndMedicaidServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a12e5f049a6452f9e97a9998e1ce4b6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20495f1f0a824d538aee78626f0d54b7_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a241cb8f282478689ee6d7bba151c98_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idee35b744e58496a91eb6fe7628d49eb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6011e1fbb7ec4eafa87167881be73a90_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96046c4bfde14c4a9405390c5dd1681e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c9e43d132c24282b7716b0c5a1f9cfc_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fb812dd0c044aa5a8506c4bc6e9c90a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica5c719f9e5e4e2d9b3c6b1da3536e36_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c35d264b82c493ba58144b8a17842a9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46b4be49d678422682879c3bf61b0688_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:VixotrigineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c345c953cb94d34804e7d2a988c33be_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:TGNMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia54a50706b514096bba4ab26af0acaa8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic399f673115248b988b9405c7bf5aa12_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia69f061a62954ac7af98aa5c677f4971_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64a5ad19dcce4cf8b7c43a569fe0c245_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42f910d9635f4c0480b7fb380b5fe276_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3396020533494d35b8c27ddcd8a5252e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bb9349b48fb4c629485bfe7b5880e8c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2a85ce0b81243eba23da6278ed1f57e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3e9c1bab79f40279289b0b3dcc2c161_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec22cc68ef57484183e4ae80b280d372_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1f4d496ec7641838d1ecec434c28f66_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c661d66c6224d4a81bd51c24ea79d40_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac84ce7144dd4bcc82d4253f927d2752_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if398ac5e39c747a6af59aeb27650b335_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09eff9f500604711ab6a499956c8d5f3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ccde35ecf6c42b486ba8b193205887c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i289d8737ebbf49019c8cd089b87cc769_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f9738b4665048cfa86018d909055f8e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i264ccf816a664702a7ba8ff1332adb5a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie241349e66f143e1b0f96548fcc184b5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b5576a00f6d4d15946a9368e3767e64_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i421472e2622c437d8bf685a39d6aecc3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8cec5ba41ae343fba33cd31f8de35a45_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied9fbb6e460240998c2c685327f742f9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if386e194b1a943d8871f1a74fa3cf259_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91224f4cdc6744fbae4bcd98dc85a3a0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id787117c37b84ec99ac24ed6b36b3e3f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3422e6ed664422993d44483803e8115_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a7eda1ce0584e48809dc53d22b2b031_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec70156770664cf39f79a786ae051946_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia81961b9f3eb48868302e49901fb6144_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i239a26613bda429395a6a963a2cde2c7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib469728d72fa415a9631ce58a0a2133d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99b3022f714c46afa3ad4d95b9e0cc1c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a551835cbc34cf1af2a3029ace704ab_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2985054f44d640bd846c15c69370c8e1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i939e4f82661e4da6ab148f59a8ec8270_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i708bc707f83a45a6b58bb6226275def9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6518b6b1ff547bda3f65b2aff26f52a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief5ba800372a46ebb499feb08bd01f68_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59761a7057b84b83b94391f9934d130e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0eb428de5f74817b5197dce23437c27_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f6dd011d88b4ac782dc7a1775ddccb8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id66b49914ec440e8ade962aeaba44c27_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53483a1cc9e941e09201232721818ef2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bed4b676403412ba1adb6018bde8953_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6864de98b5c49cab9140ebeace06324_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e6a4a2c46af47cd94c9fdc6dd993664_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f6d74e47a314e6c9c9ceec4cbe4c782_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3250SeniorNotesDueFebruary152051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ec2168b953d46088128b4f2e3774ed2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3250SeniorNotesDueFebruary152051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief3a3f71bf3549c59cbe89249ff122bd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f6c7df5e15646bebd2254ac4e7a08fa_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1a0391f5d734ca4b2c1b7de94fd8721_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c2efbd4b9c74a8da864a279a9e91498_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieed6ef51023543d0bb40d96a559c5941_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c8bc783a7334b3d8875f060ac7bb1a2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i185e162f6d4545b68e3749067e1070d6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1e2bbc4c00345d494de8e8b436b2968_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bf885a6fb7c456e9521985a665b058e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11d469fdaeea46ac984f86f25cf7aefd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i154d489ea3c6499a8e77ce72f6e567a2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabd8430987f44ff08faf10d31756ef75_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf11806fefce4b389ac4b64510af48f2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie09432231a464e39a944c6a44cd6b69c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96ee067d94d34ad18d8184a7addb8ae6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cd3f693083d457bbe88209270fd1b39_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d92b30f82ea4eed911cc841fff8bf84_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3b43bd6e13a4a9c9403015c85ba502f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4c19e0ddd2b4245bded3c176e7644d5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7202374646d4a99bbde3c93490e6ecd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd0e0d8d79a54c8e9e1b178519ddc273_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib018ee899f4e4ac48084e28043d8cddf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d2052cb740a446b8e69b4604e07264e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e32269d553441f28cfce5965c1b73f6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4753836c14c24f67acbeca373ca2d5d4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i441022c1a0eb4576a80a097476642f3d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf0a6c3fc8694a58a8f2838a236b6959_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3803e965a1724d08a4f85f6e2e7521f4_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fc3a5a6750b4a08b8ea8136ff17e32f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i272a8c61f3584e998890821513df00d8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i406fa505aaae46879e51842eed75d4ce_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i249928d43b8e4fa299b055c1da71dd67_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bd066a82d6840d8b01775d5dad75db4_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id58fea331b54435bbde5915e58d7c5a1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bbc3b1e9fdb469cb4328efd19cda789_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39a50582990a42dcb07d38607ad68af5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i240c4ec54c41471f939a44ea69015b0a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28837dfd41bf48e4a23a28d077a47405_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0736edb3bf194531887102c104754d6b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i598f0b3c24fe484495f6ccb41c9c3f69_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e3ec7e46b3849eab9fbf5b26dbd2c8c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i694ddc9c46354d1e860c687aa876734c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac85fcf21047427c834103ba4c06b629_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id06b33f7f9d2442c99ed5a3715b1fb03_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic777b57bc84141bcbc813beba9a72c17_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59dedd55a80f4d2a830844b533c8f387_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c177fb43a1c4b4e8e78a519ab0c6de9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i317559ce8f9e4b26a225b70d06a61b25_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfad3eb157664139a953f3e9ba192977_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i930b3a82003f4bec8f1d94de444724dc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b9c2fab12ac4d2bb51603b6415c4055_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i355096b3d6354bf5a1914fc120d6d527_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2469406df0d54a489bd5f64e3dea3d36_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabceb3a0623e41c4a664ac8948832356_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ea5c7e3d1434a96a8496e2352fabe5b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8992ee77c09249988dad3a68bcc5843f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62cbd491b5784eedb300e49ae6efc87a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b7ac531239c4d9aac8a7b0c71f6fdf5_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5fabf9c71294456a0158d60a5f483a4_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76b1491614cc49378a38f3c27aafce95_D20181101-20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="krw"><xbrli:measure>iso4217:KRW</xbrli:measure></xbrli:unit><xbrli:context id="ifb6cf45b64754d4b88c6cd9ba8980d50_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0df6dbddbff746298274ecd0b63baf47_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib51e9913c2884e49a66dce4cf9163f6d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5062e91336b74ad5ab0ffa4f2982b8e3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1d439a992034e5a880d6b7d7d1fd8ff_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04123d710b8e48c89a62fd25aa7cc3dc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49647cb8da844b74bee321a532e55b36_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f94fcf078da46ef9117103ab626567e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d28240f464f4a5c8cc87e17a9a57d40_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife02cc8b68b74e45a4550426f8f6e028_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55597e78171f481ea55329770d91ef68_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f169aefbf5349eb87fe05cb8688fca5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb5afc172aec4efebd6f1b568ac8ba97_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadd2bb0a22624c17a5f24102ad78024e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ca7b68a94cf428e9116acf90742cf4c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a575848d988444ca4869d5a47cae38a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib79aa8e4e7624556b3ddeed5fa194e23_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i493a11d6c18c49269d42f6e6982e8f44_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i639c896977df489fbc54f9088f6147de_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0a4f26886de44beaaa9fd8add3e3cd9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46e754dc01c0498393cd6a5acbb81bc2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52be7c4aa2b64ac78381cc2d75fa44bd_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic91d51f7faa640ed87d6899c2a544613_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f64e07d384c415c831dd4b33c3b6b7f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:BiologicsManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i099a9481f0f445269310c0321517d33c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:WarehouseUtilitiesAndSupportSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieed6363c4f674d66a54d0dc0c55f0f52_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:AdministrativeSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e94ec2413a34ad39baef4a302252a4a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie078509e1f7d4077a083b848308445a3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id425e7508d5f4fcf9ccfcc07674b63de_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3968065f0a74bfead74be1f343078f9_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3250SeniorNotesDueFebruary152051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id164d47b16824f0c874ceeea51fbbcbc_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if242145ab9704eacb41a099fd01ce221_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i927398c21f2c4253b9e5fc9aa1970ccb_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8aed478a3bb84a26a97e98654c7ce707_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia823c01230e94f078e3bd77c94d36863_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89079b4dcd7340cc8676a18916e07cce_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1ba18679af24668b4316adb5b46bbeb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic535854c80b1412f924435f8c91f63b8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib29fa61175a74b01bcdc01a071bd7d48_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e87abb1f9db4300857139f5ddaa4d14_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc0ec6584c7c4d459947e00620f435cd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d0f10b22c834ba396c8b4c6a3188b23_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5838303fd7294f56a6ba30fc62e8ecac_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b54fa2358e34e17ae6d8739b9b3339b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b84e664424c4f9c9c3be2725156b218_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i405ecf1b53c842e8ab96a5daf031a812_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ac817d516214d4294329c0c3985e64a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie992e5401cf74a7eb8a5100825da7530_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9dc7e3bd5af43b9ae44d024af7d45ee_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b8f47e6df9047dc9800a3ef46b3a47a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c403b59149b4448b3ab41d54ea6da30_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07e5a2d28d8644f0a7750374306253d1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic788e2af1c2a42bdad2a187fa0f3f0f9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9905d8e67a1c49bba25ddc2283754bd9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56c6c6dbd77141ebb3ba11ea6d1906c2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21cbbb23fa0942b0b38de55781a30060_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76808577ee454761a0b2fc6e21960006_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6abbeadb96ac4f689ba74b0475350c98_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf39efdb65104bcb856efd226f4e02aa_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd3f194d4161459fa9fc9aaed46498ea_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70ab7808a4b842c9925eda0753188c9f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8c8dc8cb4ac4de98e44bab2c31b1282_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4e7315860ff46c0acb88d0816fd6daf_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52bad0c11e3144e899c81a5bb55aabb2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54a289067eb44a92a43277cf25c506fe_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaaff40b00b8a475aa7213303ae060f69_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82e69258ff2a411eb0af8d55689ed83c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia89aa06c882742e4a448659b8c11481c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53aa42306e12421f90d4b595dc6b62f5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9477047c7de34040997c009eedbe4518_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4e4d15b86ad443eb9d3edf6dee5f7b5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie709fcb90ef24b93b760d2540d00088a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i810555191bc946a183d59137a3d60baf_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i091a772781f844e0996d9dd61c0fbb5f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39e928655ba643399618f0c17b2b0812_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6d836e623c94a73a4c74c493f93fee4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddfb71709ed840e98b85ca08ce7bdeaf_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9afd12c183494d549b839596293da75e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida7d6be5a5da461dbf5390a92f2c5e9d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0163dd5e3d654e748b422f150d2d5a9c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4eff7cd113a74d2e910753e991374627_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i286ad499ff5d462799e0f941ef3e205f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib96d4930fa9c4ea4920b41bc8432568c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa0242e914b24b17a8a259457c37203f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7e00bf0cede4201ac36bccc9be5e5fd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i650e185cf72a422c97cc333e4de95e3e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie511e6e4286f476b8bf2a94aa1d42b95_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6dc6984b1c814916847de41632ad1d34_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e2fa4eb32484e43801f3346334b0be3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7c53ba95781468ab194b339910b54ea_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadfc29fbc15b47a0bb4c9a7e11d2d1f6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b5373d736be447fa8c13cecb1075da6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fecd952a0f246f4bc6ae41add94430d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11b85385e04c4d72bb460d8796578ce0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i350f52cf56ca419f9abcc85ddabdf66a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fcfddd14c424cd095a98f9df64e862f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8cc3940c5a604d08b1a0524870f97a03_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20649c5c9db8492a84683240d40b1cc8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:IonisSangamoDenaliAndSageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7720f6aec35b4d8da3f83be28c73da37_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic53a168048b7491ea87c3962591ce459_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic988722c1187407388795922a811a006_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5eb97d60723b4bd0984e9c72d9e41857_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfdf8192d59c42ea96f70ac07a430dab_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica3cdddcf72b46f8b05a616e0b059254_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20e19171955440b582851c5ac5d45b30_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90093effd3884afba4d3e630d74c241a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95c7cf13e2f1475ea47f58a3f48df9e2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i534d34ae3d78433f9a80a80261d8c791_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i535bbd28d8064cd99845c7aad7ef40b6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i140fc83df9b443f8947b6e9c5a831662_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11a20f8ab31748a3a765230d484a950c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30f95d1127004fdb916215bc0644001f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e6c000a5c1747719d713bf44ab5594d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i385de3e6fdd648569c6459df74a3f24c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81ff85ba433e49f3bf5366754bf14dfd_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6f28921d58149e88f70f267093af3ed_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84748af08d094521ad62103f37c3ba5e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9f8dc7db02f46a382226b3a06689770_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccef06de5f364c6e864a306f6c4d2222_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22e581ce75fe402f95badbea9059a2fd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0323b821ee4490ab9cd6f46708b92d2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cab4c6e22304f01a6e538f0a28da4a6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SangamoTherapeuticsInc.AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2f3b87f1c704bfeaa184c005c15f509_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1980e9c4bcf04c69813dff866529db3b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i416b5c2161cb4be49401dc463e803f6e_D20210801-20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:InnoCarePharmaLimitedInnoCareAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i871bd576e8054a32a94dd16a50cc8f38_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69f6f1c65f31482a9985575399db62f4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17a7835e9c634cd3898253b27970e1ae_I20181107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3777c8eb44d147d2bc71177545a1a119_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InventoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81aebf0e69b74044934ae698e82a35a4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6783744f49842d8974c9aa1108f7b92_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb43218ef58b4c47acc0ed3d32fc1c8a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54ef960b3f344a6284182d87fe3863d1_D20220101-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a34f5e20a214f4fb6abb8675f411f59_I20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice9f6a67517e4256bcc4feff2a07a95c_I20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtFirstAnniversaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbc3564cb9f74c5e96af956bdb92ace9_I20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtSecondAnniversaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8140a335ecc449f6bb7f8e4660aac8ea_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c93649201d542fd82a365350912101f_I20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0074296436b4840ada078b60b901e66_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9e98bb878a84e13ac251a6b98a15e94_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33310cbd0d8e4927a25d422f87b6a6e3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e6825d4d7fc4c049bc35822d827b16a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie40c7dd8da0c4c3d8730bcde07b49856_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08f827f32a3b446c825d77324ed50eb7_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22cd2c200d674e7185cf096a998f436a_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i179745ea816f45eeb6066bd1ea79e129_I20210715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-07-15</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ie9658fba2baf4e3799b1175f69eaed46_1"></div><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington,&#160;D.C. 20549</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Form&#160;<ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xL2ZyYWc6YTlkNWJiMWM2YTA4NGVlOGE4NTdjOTJlZGQyZGRiN2YvdGV4dHJlZ2lvbjphOWQ1YmIxYzZhMDg0ZWU4YTg1N2M5MmVkZDJkZGI3Zl8yMDA4_77e55ad9-aa66-4098-9f57-39ff689a0d70">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:14pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xL2ZyYWc6YTlkNWJiMWM2YTA4NGVlOGE4NTdjOTJlZGQyZGRiN2YvdGFibGU6NjI2MDAxYjk0NzExNDQ2Y2JhZjMxMDViNmY5ZjYwNGQvdGFibGVyYW5nZTo2MjYwMDFiOTQ3MTE0NDZjYmFmMzEwNWI2ZjlmNjA0ZF8wLTAtMS0xLTc1MTQw_f484645b-d3a8-45c5-856a-e811b38d7b93">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xL2ZyYWc6YTlkNWJiMWM2YTA4NGVlOGE4NTdjOTJlZGQyZGRiN2YvdGV4dHJlZ2lvbjphOWQ1YmIxYzZhMDg0ZWU4YTg1N2M5MmVkZDJkZGI3Zl8xMjM_9c966c9c-f070-4e25-808f-aae65be16dbe">March 31, 2022</ix:nonNumeric> </span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:14pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xL2ZyYWc6YTlkNWJiMWM2YTA4NGVlOGE4NTdjOTJlZGQyZGRiN2YvdGFibGU6ZWQ0YTA3ZDAzNjFkNDkwZjllMWY1YjliYjEzMzhiZmEvdGFibGVyYW5nZTplZDRhMDdkMDM2MWQ0OTBmOWUxZjViOWJiMTMzOGJmYV8wLTAtMS0xLTc1MTQw_a2f8f233-5ec7-4059-911d-1c9cf09dd635">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number <ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xL2ZyYWc6YTlkNWJiMWM2YTA4NGVlOGE4NTdjOTJlZGQyZGRiN2YvdGV4dHJlZ2lvbjphOWQ1YmIxYzZhMDg0ZWU4YTg1N2M5MmVkZDJkZGI3Zl8yMDA5_0ed15201-5f1c-4a67-8b3d-4edd0c561b85">0-19311</ix:nonNumeric></span></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><img src="biib-20220331_g1.jpg" alt="biib-20220331_g1.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:92px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xL2ZyYWc6YTlkNWJiMWM2YTA4NGVlOGE4NTdjOTJlZGQyZGRiN2YvdGV4dHJlZ2lvbjphOWQ1YmIxYzZhMDg0ZWU4YTg1N2M5MmVkZDJkZGI3Zl8yMDEw_5ebbfc6f-85c7-47c7-bc6b-b1c61dbfdc54">BIOGEN INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:47.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.192%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xL2ZyYWc6YTlkNWJiMWM2YTA4NGVlOGE4NTdjOTJlZGQyZGRiN2YvdGFibGU6YjNiMWQxZTYzZGZkNDFmZWJlZjNlNGNkZWYyODJhZjgvdGFibGVyYW5nZTpiM2IxZDFlNjNkZmQ0MWZlYmVmM2U0Y2RlZjI4MmFmOF8wLTAtMS0xLTc1MTQw_ecb93006-5771-4a3c-8ad8-4cfbb19e8232">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xL2ZyYWc6YTlkNWJiMWM2YTA4NGVlOGE4NTdjOTJlZGQyZGRiN2YvdGFibGU6YjNiMWQxZTYzZGZkNDFmZWJlZjNlNGNkZWYyODJhZjgvdGFibGVyYW5nZTpiM2IxZDFlNjNkZmQ0MWZlYmVmM2U0Y2RlZjI4MmFmOF8wLTItMS0xLTc1MTQw_b7534640-fbf6-4f37-895e-cee1e647980b">33-0112644</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xL2ZyYWc6YTlkNWJiMWM2YTA4NGVlOGE4NTdjOTJlZGQyZGRiN2YvdGV4dHJlZ2lvbjphOWQ1YmIxYzZhMDg0ZWU4YTg1N2M5MmVkZDJkZGI3Zl8yMDEx_007a929f-130e-4f0c-82f8-9ec82729ca02">225 Binney Street</ix:nonNumeric>, <ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xL2ZyYWc6YTlkNWJiMWM2YTA4NGVlOGE4NTdjOTJlZGQyZGRiN2YvdGV4dHJlZ2lvbjphOWQ1YmIxYzZhMDg0ZWU4YTg1N2M5MmVkZDJkZGI3Zl8yMDA2_986dbfae-400c-48a0-958a-b9d406f55a5b">Cambridge</ix:nonNumeric>, <ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xL2ZyYWc6YTlkNWJiMWM2YTA4NGVlOGE4NTdjOTJlZGQyZGRiN2YvdGV4dHJlZ2lvbjphOWQ1YmIxYzZhMDg0ZWU4YTg1N2M5MmVkZDJkZGI3Zl8yMDE0_031ed8d5-1fbd-4f4c-83ec-5d48150fc327">MA</ix:nonNumeric> <ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xL2ZyYWc6YTlkNWJiMWM2YTA4NGVlOGE4NTdjOTJlZGQyZGRiN2YvdGV4dHJlZ2lvbjphOWQ1YmIxYzZhMDg0ZWU4YTg1N2M5MmVkZDJkZGI3Zl8yMDA3_9321bffa-47b8-43e7-844f-f32ce6c9a2d9">02142</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xL2ZyYWc6YTlkNWJiMWM2YTA4NGVlOGE4NTdjOTJlZGQyZGRiN2YvdGV4dHJlZ2lvbjphOWQ1YmIxYzZhMDg0ZWU4YTg1N2M5MmVkZDJkZGI3Zl8yMDE1_57c18591-6202-4aa0-a877-e9ae70d6d8cb">617</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xL2ZyYWc6YTlkNWJiMWM2YTA4NGVlOGE4NTdjOTJlZGQyZGRiN2YvdGV4dHJlZ2lvbjphOWQ1YmIxYzZhMDg0ZWU4YTg1N2M5MmVkZDJkZGI3Zl8yMDE2_a84ddf84-38a0-4fd8-8507-f7d8278913c7">679-2000</ix:nonNumeric> </span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Address, including zip code, and telephone number, including</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">area code, of registrant&#8217;s principal executive offices)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:35.463%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.080%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xL2ZyYWc6YTlkNWJiMWM2YTA4NGVlOGE4NTdjOTJlZGQyZGRiN2YvdGFibGU6NmEyODk3NzAwMjJkNDhmNmI5NWIyZWU3Yzg4NGRkNDgvdGFibGVyYW5nZTo2YTI4OTc3MDAyMmQ0OGY2Yjk1YjJlZTdjODg0ZGQ0OF8xLTAtMS0xLTc1MTQw_668b6d8d-8da8-49fd-8c6b-c55d5cae492b">Common Stock, $0.0005 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xL2ZyYWc6YTlkNWJiMWM2YTA4NGVlOGE4NTdjOTJlZGQyZGRiN2YvdGFibGU6NmEyODk3NzAwMjJkNDhmNmI5NWIyZWU3Yzg4NGRkNDgvdGFibGVyYW5nZTo2YTI4OTc3MDAyMmQ0OGY2Yjk1YjJlZTdjODg0ZGQ0OF8xLTItMS0xLTc1MTQw_a0e0ebf6-6e38-4c70-b3aa-4a98629a9585">BIIB</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xL2ZyYWc6YTlkNWJiMWM2YTA4NGVlOGE4NTdjOTJlZGQyZGRiN2YvdGFibGU6NmEyODk3NzAwMjJkNDhmNmI5NWIyZWU3Yzg4NGRkNDgvdGFibGVyYW5nZTo2YTI4OTc3MDAyMmQ0OGY2Yjk1YjJlZTdjODg0ZGQ0OF8xLTQtMS0xLTc1MTQw_72251eb3-1b25-4a16-b223-9d3f38fa88b6">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:1pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days:&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xL2ZyYWc6YTlkNWJiMWM2YTA4NGVlOGE4NTdjOTJlZGQyZGRiN2YvdGV4dHJlZ2lvbjphOWQ1YmIxYzZhMDg0ZWU4YTg1N2M5MmVkZDJkZGI3Zl8yMDE3_84ac3625-6e2f-4c6b-90cd-870ae699bb00">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files):&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xL2ZyYWc6YTlkNWJiMWM2YTA4NGVlOGE4NTdjOTJlZGQyZGRiN2YvdGV4dHJlZ2lvbjphOWQ1YmIxYzZhMDg0ZWU4YTg1N2M5MmVkZDJkZGI3Zl8yMDEy_d1c99633-a010-4a4b-a163-10ef6d39681e">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:21.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.981%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xL2ZyYWc6YTlkNWJiMWM2YTA4NGVlOGE4NTdjOTJlZGQyZGRiN2YvdGFibGU6NTRhZjMwYzgxOTUyNDRkN2JkMDhhODJiNzk3MDdmZmQvdGFibGVyYW5nZTo1NGFmMzBjODE5NTI0NGQ3YmQwOGE4MmI3OTcwN2ZmZF8wLTAtMS0xLTc1MTQw_cfc53e27-42a7-4e3b-8cb5-e952c7678cac">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xL2ZyYWc6YTlkNWJiMWM2YTA4NGVlOGE4NTdjOTJlZGQyZGRiN2YvdGFibGU6NTRhZjMwYzgxOTUyNDRkN2JkMDhhODJiNzk3MDdmZmQvdGFibGVyYW5nZTo1NGFmMzBjODE5NTI0NGQ3YmQwOGE4MmI3OTcwN2ZmZF8xLTQtMS0xLTc1MTQw_ff1f080e-06bf-4b74-b9c0-8b4ff83ffece">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xL2ZyYWc6YTlkNWJiMWM2YTA4NGVlOGE4NTdjOTJlZGQyZGRiN2YvdGFibGU6NTRhZjMwYzgxOTUyNDRkN2JkMDhhODJiNzk3MDdmZmQvdGFibGVyYW5nZTo1NGFmMzBjODE5NTI0NGQ3YmQwOGE4MmI3OTcwN2ZmZF8yLTQtMS0xLTc1MTQw_d1091690-510b-42a4-adb6-f4c90b547890">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:1pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xL2ZyYWc6YTlkNWJiMWM2YTA4NGVlOGE4NTdjOTJlZGQyZGRiN2YvdGV4dHJlZ2lvbjphOWQ1YmIxYzZhMDg0ZWU4YTg1N2M5MmVkZDJkZGI3Zl8yMDEz_cd0a7340-5fab-4d95-bd54-a588218916aa">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;No&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of the issuer&#8217;s Common Stock, $0.0005&#160;par value, outstanding as of May&#160;2, 2022, was <ix:nonFraction unitRef="shares" contextRef="ica34c492e95e460da92f264a157fc2cc_I20220502" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xL2ZyYWc6YTlkNWJiMWM2YTA4NGVlOGE4NTdjOTJlZGQyZGRiN2YvdGV4dHJlZ2lvbjphOWQ1YmIxYzZhMDg0ZWU4YTg1N2M5MmVkZDJkZGI3Zl8xOTk1_9960cfcc-ab45-40ca-b29c-a02b0d470ed1">146,452,013</ix:nonFraction> shares.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ie9658fba2baf4e3799b1175f69eaed46_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC.</span></div><div style="text-align:center"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM&#160;10-Q &#8212; Quarterly Report</span></div><div style="text-align:center"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">For the Quarterly Period Ended March 31, 2022 </span></div><div style="margin-top:14pt;text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.866%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.710%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PART&#160;I&#160;&#8212; </span><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_13">FINANCIAL INFORMATION</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_16">Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_19">Condensed Consolidated Statements of Income&#160;&#8212; For the Three Months Ended March 31, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_19">5</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_22">Condensed Consolidated Statements of Comprehensive Income &#8212; For the Three Months Ended March 31, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_22">6</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_25">Condensed Consolidated Balance Sheets&#160;&#8212; As of March 31, 2022 and December&#160;31, 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_25">7</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_31">Condensed Consolidated Statements of Cash Flow&#160;&#8212; For the Three Months Ended March 31, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_31">8</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_34">Condensed Consolidated Statements of Equity &#8212; For the Three Months Ended March 31, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_34">9</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_37">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_37">11</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_133">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_133">40</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_214">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_214">65</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_217">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_217">67</a></span></div></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PART&#160;II&#160;&#8212; </span><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_220">OTHER INFORMATION</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_223">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_223">68</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_226">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_226">68</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_229">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_229">84</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_232">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_232">85</a></span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_238">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_238">86</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ie9658fba2baf4e3799b1175f69eaed46_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report contains forward-looking statements that are being made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995 (the Act) with the intention of obtaining the benefits of the &#8220;Safe Harbor&#8221; provisions of the Act. These forward-looking statements may be accompanied by such words as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; "goal," &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;possible,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and other words and terms of similar meaning. Reference is made in particular to forward-looking statements regarding:</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the anticipated amount, timing and accounting of revenue; contingent, milestone, royalty and other payments under licensing, collaboration, acquisition or divestiture agreements; tax positions and contingencies; collectability of receivables; pre-approval inventory; cost of sales; research and development costs; compensation and other selling, general and administrative expense; amortization of intangible assets; foreign currency exchange risk; estimated fair value of assets and liabilities; and impairment assessments;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">expectations, plans and prospects relating to sales, pricing, growth and launch of our marketed and pipeline products;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the potential impact of increased product competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our plans and investments in our portfolio as well as implementation of our corporate strategy;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the drivers for growing our business, including our plans and intention to commit resources relating to discovery, research and development programs and business development opportunities as well as the potential benefits and results of, and the anticipated completion of, certain business development transactions;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the expectations, development plans and anticipated timelines, including costs and timing of potential clinical trials, filings and approvals, of our products, drug candidates and pipeline programs, including collaborations with third-parties, as well as the potential therapeutic scope of the development and commercialization of our and our collaborators&#8217; pipeline products;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability and other matters;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to finance our operations and business initiatives and obtain funding for such activities;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">adverse safety events involving our marketed products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the direct and indirect impact of the COVID-19 pandemic on our business and operations, including sales, expense, reserves and allowances, the supply chain, manufacturing, cyber-attacks or other privacy or data security incidents, research and development costs, clinical trials and employees;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the current and potential impacts of the conflict in Ukraine, including impacts on our operations, sales and the possible disruptions or delays in our plans to conduct clinical trial activities in affected regions;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the potential impact of healthcare reform in the United States (U.S.) and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities, activities in new or existing manufacturing facilities and the expected timeline for the Solothurn manufacturing facility to begin manufacturing products or product candidates and for the gene therapy manufacturing facility in Research Triangle Park (RTP), North Carolina to be operational;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the impact of the continued uncertainty of the credit and economic conditions in certain countries and our collection of accounts receivable in such countries;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the impact of new laws (including tax), regulatory requirements, judicial decisions and accounting standards.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements involve risks and uncertainties, including those that are described in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in this report and elsewhere in this report, that could cause actual results to differ materially from those reflected in such statements. You should not place undue reliance on these statements. Forward-looking statements speak only as of the date of this report. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.</span></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTE REGARDING COMPANY AND PRODUCT REFERENCES</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in this report to:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">&#8220;Biogen,&#8221; the &#8220;company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Biogen Inc. and its consolidated subsidiaries; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">&#8220;RITUXAN&#8221; refers to both RITUXAN (the trade name for rituximab in the U.S., Canada and Japan) and MabThera (the trade name for rituximab outside the U.S., Canada and Japan).</span></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTE&#160;REGARDING TRADEMARKS</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AVONEX&#174;, PLEGRIDY&#174;, RITUXAN&#174;, RITUXAN HYCELA&#174;, SPINRAZA&#174;, TECFIDERA&#174;, TYSABRI&#174; and VUMERITY&#174; are registered trademarks of Biogen. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ADUHELM&#8482;, BENEPALI&#8482;, BYOOVIZ&#8482;, FLIXABI&#8482;, FUMADERM&#8482; and IMRALDI&#8482; are trademarks of Biogen.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CIMZIA&#174;, ENBREL&#174;, EYLEA&#174;, FAMPYRA&#8482;, GAZYVA&#174;, HUMIRA&#174;, LUCENTIS&#174;, OCREVUS&#174;, REMICADE&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and other trademarks referenced in this report are the property of their respective owners. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ie9658fba2baf4e3799b1175f69eaed46_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART&#160;I FINANCIAL INFORMATION</span></div><div id="ie9658fba2baf4e3799b1175f69eaed46_16"></div><div style="text-align:center"><span><br/></span></div><div id="ie9658fba2baf4e3799b1175f69eaed46_19"></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions, except per share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product, net</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70fc67330ce0470db37abf6a0dc4fb6a_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMy0xLTEtMS03NTE0MA_af3207d6-e1d6-4a5c-b9cc-77b6d3547b81">2,066.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22a0a13c266f4d788d5ba6423911ebd9_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMy0zLTEtMS03NTE0MA_775ea51e-2921-43c4-9b93-d60c743c2720">2,211.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue from anti-CD20 therapeutic programs</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5e84907dfd54cd09fdf7dc476b17545_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfNC0xLTEtMS03NTE0MA_423ab823-662f-438e-95df-7e317571cbe3">399.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6b11452af4d4ae0bf50278351f22899_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfNC0zLTEtMS03NTE0MA_bb2bb5ba-30d6-4e93-af45-67781a4e1003">389.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36b52f54c6e84045a18f6f934ed61b63_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfNS0xLTEtMS03NTE0MA_1538e6ce-5262-4178-aec3-fc0945b503c8">66.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee301b6f981549919f1dd915c03e2623_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfNS0zLTEtMS03NTE0MA_5dd6b1fb-54bb-4f46-b364-82da6ace0990">93.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfNi0xLTEtMS03NTE0MA_ccf75f54-c903-46cb-8de8-c384ee8ebe14">2,531.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfNi0zLTEtMS03NTE0MA_8dd9856b-4c8b-4850-b271-58296a0bf6ae">2,694.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost and expense:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales, excluding amortization and impairment of acquired intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfOC0xLTEtMS03NTE0MA_ed392968-6637-436e-bd1c-c6c8b4c37299">753.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfOC0zLTEtMS03NTE0MA_83a3f53b-8420-493e-81da-427d444ad79b">478.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfOS0xLTEtMS03NTE0MA_23409b29-6b8c-498d-91f4-6e2b1dee275c">551.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfOS0zLTEtMS03NTE0MA_f388dcf9-02b4-4f1e-beb3-26e30d313431">514.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMTAtMS0xLTEtNzUxNDA_6ae67d1e-3c70-475a-a78b-c31fd8d68664">634.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMTAtMy0xLTEtNzUxNDA_d57a977e-6bad-4ae5-85ce-cb66dbdf70d2">595.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization and impairment of acquired intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMTEtMS0xLTEtNzUxNDA_35824f57-87e7-4005-a133-6ebc714e8bff">66.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMTEtMy0xLTEtNzUxNDA_8514b729-4696-4885-a867-5953ecef18ed">98.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Collaboration profit (loss) sharing</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" sign="-" name="biib:Collaborationprofitlosssharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMTItMS0xLTEtNzUxNDA_dc518c33-9deb-4738-ba0c-4a07622da5d5">117.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="biib:Collaborationprofitlosssharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMTItMy0xLTEtNzUxNDA_09f8b830-f87d-412b-8c0b-a9d5b5da04bc">68.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gain) loss on fair value remeasurement of contingent consideration</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMTQtMS0xLTEtNzUxNDA_f0806090-8db0-4b8e-8e2e-a4616edb32b1">7.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMTQtMy0xLTEtNzUxNDA_5ff1c09a-2d2b-4f86-8c47-84ecbdc3d19b">33.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMTYtMS0xLTEtNzUxNDA_4264e842-5ab8-4179-960a-c2bef867af5c">38.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMTYtMy0xLTEtNzUxNDA_ba14be48-97fb-4009-b4f3-46fd53f4bd21">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cost and expense</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMTctMS0xLTEtNzUxNDA_ec34d0bf-63bc-4faa-8452-b7de24b30937">1,921.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMTctMy0xLTEtNzUxNDA_2de997fc-ee98-443d-b290-711abd3e9e36">1,720.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMTgtMS0xLTEtNzUxNDA_f07e2e7b-be24-40c1-9f99-e76e1cd21da5">610.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMTgtMy0xLTEtNzUxNDA_c40b69ff-d450-412c-bc29-fd4686ee9bf0">973.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMTktMS0xLTEtNzUxNDA_1731991f-2f1c-4480-9560-120ae3e163fa">263.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMTktMy0xLTEtNzUxNDA_86991e09-55bf-4425-b692-72ae572c7dcb">506.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income tax expense and equity in loss of investee, net of tax</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMjAtMS0xLTEtNzUxNDA_54ae3d68-bef2-4697-a14d-eda4f321f03c">347.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMjAtMy0xLTEtNzUxNDA_46479eb0-91ff-4100-9315-63d117a89bda">467.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMjEtMS0xLTEtNzUxNDA_08131bf3-cc36-4d9b-ae8a-d2a02709c9e1">125.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMjEtMy0xLTEtNzUxNDA_4a929279-8140-4d33-a547-5382cf333997">44.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity in (income) loss of investee, net of tax</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" sign="-" name="biib:IncomeLossFromEquityMethodInvestmentsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMjItMS0xLTEtNzUxNDA_1461d274-5a86-4233-94dc-4c9ac27c58cf">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" sign="-" name="biib:IncomeLossFromEquityMethodInvestmentsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMjItMy0xLTEtNzUxNDA_373c9097-f81f-4957-a7e9-e669ac4dbf14">18.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMjMtMS0xLTEtNzUxNDA_f24d4a71-28b7-4a86-9966-84c007d19791">218.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMjMtMy0xLTEtNzUxNDA_3c707c8f-62b9-4d5f-a8e7-d4fa358db100">404.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net&#160;income (loss) attributable to noncontrolling interests, net&#160;of&#160;tax</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMjQtMS0xLTEtNzUxNDA_ea091d31-908b-4695-80af-ddbc72ae44a1">85.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMjQtMy0xLTEtNzUxNDA_6bf14db9-6d0f-4719-b6fc-bef54e4ab17b">5.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMjUtMS0xLTEtNzUxNDA_6c52809a-f550-4c58-a5cd-ee28cf287ec2">303.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMjUtMy0xLTEtNzUxNDA_7807fd1e-f962-4718-aadb-c9d7552c82cb">410.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic earnings per share attributable to Biogen Inc.</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMjgtMS0xLTEtNzUxNDA_c8dcb420-c95e-4600-9731-083b0cf29f37">2.06</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMjgtMy0xLTEtNzUxNDA_6b2fab92-92d5-4de1-b865-98e72066586c">2.70</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to Biogen Inc.</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMjktMS0xLTEtNzUxNDA_62f008f8-e626-4ed1-8297-f0c2197d436f">2.06</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMjktMy0xLTEtNzUxNDA_3f90afbf-a321-4de2-909b-0531ec276ec2">2.69</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares used in calculating:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic earnings per share attributable to Biogen Inc.</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMzItMS0xLTEtNzUxNDA_a0bf2124-9e10-46c6-93d2-6d813151a599">147.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMzItMy0xLTEtNzUxNDA_e1734bd6-7a2b-4bc4-b308-fe9cd8304a6a">151.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to Biogen Inc.</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMzMtMS0xLTEtNzUxNDA_20b38ca0-ad7a-4eef-8785-d39fc85ec996">147.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMzMtMy0xLTEtNzUxNDA_9bfa4cfe-090a-4024-83be-cfa34fdd1987">152.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="ie9658fba2baf4e3799b1175f69eaed46_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMi9mcmFnOjg2Yjc1MDkyMjBmMTQ1ZTlhNjUzNTkzNWRmYzRmZWNiL3RhYmxlOmY5NzE1NDQyNzcxMTRmNTA5MTE1Y2RmZDI3MDRkOTIyL3RhYmxlcmFuZ2U6Zjk3MTU0NDI3NzExNGY1MDkxMTVjZGZkMjcwNGQ5MjJfMi0xLTEtMS03NTE0MA_e6624722-adeb-47d4-aa70-333845803d83">303.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMi9mcmFnOjg2Yjc1MDkyMjBmMTQ1ZTlhNjUzNTkzNWRmYzRmZWNiL3RhYmxlOmY5NzE1NDQyNzcxMTRmNTA5MTE1Y2RmZDI3MDRkOTIyL3RhYmxlcmFuZ2U6Zjk3MTU0NDI3NzExNGY1MDkxMTVjZGZkMjcwNGQ5MjJfMi0zLTEtMS03NTE0MA_55640f2c-0621-469e-889b-daff28e1b6b7">410.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains (losses) on securities available for sale, net of tax</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMi9mcmFnOjg2Yjc1MDkyMjBmMTQ1ZTlhNjUzNTkzNWRmYzRmZWNiL3RhYmxlOmY5NzE1NDQyNzcxMTRmNTA5MTE1Y2RmZDI3MDRkOTIyL3RhYmxlcmFuZ2U6Zjk3MTU0NDI3NzExNGY1MDkxMTVjZGZkMjcwNGQ5MjJfNC0xLTEtMS03NTE0MA_e1b66e28-8534-43a1-be79-89bc5c123400">9.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMi9mcmFnOjg2Yjc1MDkyMjBmMTQ1ZTlhNjUzNTkzNWRmYzRmZWNiL3RhYmxlOmY5NzE1NDQyNzcxMTRmNTA5MTE1Y2RmZDI3MDRkOTIyL3RhYmxlcmFuZ2U6Zjk3MTU0NDI3NzExNGY1MDkxMTVjZGZkMjcwNGQ5MjJfNC0zLTEtMS03NTE0MA_28529811-d87d-430c-a512-439be9e2e799">0.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains (losses) on cash flow hedges, net of tax</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMi9mcmFnOjg2Yjc1MDkyMjBmMTQ1ZTlhNjUzNTkzNWRmYzRmZWNiL3RhYmxlOmY5NzE1NDQyNzcxMTRmNTA5MTE1Y2RmZDI3MDRkOTIyL3RhYmxlcmFuZ2U6Zjk3MTU0NDI3NzExNGY1MDkxMTVjZGZkMjcwNGQ5MjJfNS0xLTEtMS03NTE0MA_bd8cb233-7261-491c-9bdd-bb949c61fb08">15.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMi9mcmFnOjg2Yjc1MDkyMjBmMTQ1ZTlhNjUzNTkzNWRmYzRmZWNiL3RhYmxlOmY5NzE1NDQyNzcxMTRmNTA5MTE1Y2RmZDI3MDRkOTIyL3RhYmxlcmFuZ2U6Zjk3MTU0NDI3NzExNGY1MDkxMTVjZGZkMjcwNGQ5MjJfNS0zLTEtMS03NTE0MA_9eae2cd2-55b8-453f-b5af-a5ff0d990ac1">149.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedges, net of tax</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMi9mcmFnOjg2Yjc1MDkyMjBmMTQ1ZTlhNjUzNTkzNWRmYzRmZWNiL3RhYmxlOmY5NzE1NDQyNzcxMTRmNTA5MTE1Y2RmZDI3MDRkOTIyL3RhYmxlcmFuZ2U6Zjk3MTU0NDI3NzExNGY1MDkxMTVjZGZkMjcwNGQ5MjJfNi0xLTEtMS03NTE0MA_73ed8e04-a5ba-4a15-8531-f8e59d63a4ac">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMi9mcmFnOjg2Yjc1MDkyMjBmMTQ1ZTlhNjUzNTkzNWRmYzRmZWNiL3RhYmxlOmY5NzE1NDQyNzcxMTRmNTA5MTE1Y2RmZDI3MDRkOTIyL3RhYmxlcmFuZ2U6Zjk3MTU0NDI3NzExNGY1MDkxMTVjZGZkMjcwNGQ5MjJfNi0zLTEtMS03NTE0MA_81590992-2867-44b3-9c30-82999cadbe2c">22.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains (losses) on pension benefit obligation, net of tax</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMi9mcmFnOjg2Yjc1MDkyMjBmMTQ1ZTlhNjUzNTkzNWRmYzRmZWNiL3RhYmxlOmY5NzE1NDQyNzcxMTRmNTA5MTE1Y2RmZDI3MDRkOTIyL3RhYmxlcmFuZ2U6Zjk3MTU0NDI3NzExNGY1MDkxMTVjZGZkMjcwNGQ5MjJfNy0xLTEtMS03NTE0MA_b55493b8-7603-4437-a4c3-88c68b825f7c">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMi9mcmFnOjg2Yjc1MDkyMjBmMTQ1ZTlhNjUzNTkzNWRmYzRmZWNiL3RhYmxlOmY5NzE1NDQyNzcxMTRmNTA5MTE1Y2RmZDI3MDRkOTIyL3RhYmxlcmFuZ2U6Zjk3MTU0NDI3NzExNGY1MDkxMTVjZGZkMjcwNGQ5MjJfNy0zLTEtMS03NTE0MA_b4bf5ba1-2c11-4866-8eda-55179bfeac27">2.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation adjustment</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMi9mcmFnOjg2Yjc1MDkyMjBmMTQ1ZTlhNjUzNTkzNWRmYzRmZWNiL3RhYmxlOmY5NzE1NDQyNzcxMTRmNTA5MTE1Y2RmZDI3MDRkOTIyL3RhYmxlcmFuZ2U6Zjk3MTU0NDI3NzExNGY1MDkxMTVjZGZkMjcwNGQ5MjJfOC0xLTEtMS03NTE0MA_a82eb78d-5aa9-4007-86db-e249275ddf71">21.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMi9mcmFnOjg2Yjc1MDkyMjBmMTQ1ZTlhNjUzNTkzNWRmYzRmZWNiL3RhYmxlOmY5NzE1NDQyNzcxMTRmNTA5MTE1Y2RmZDI3MDRkOTIyL3RhYmxlcmFuZ2U6Zjk3MTU0NDI3NzExNGY1MDkxMTVjZGZkMjcwNGQ5MjJfOC0zLTEtMS03NTE0MA_aaec0529-1c84-44be-82c7-1530265bd32e">48.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMi9mcmFnOjg2Yjc1MDkyMjBmMTQ1ZTlhNjUzNTkzNWRmYzRmZWNiL3RhYmxlOmY5NzE1NDQyNzcxMTRmNTA5MTE1Y2RmZDI3MDRkOTIyL3RhYmxlcmFuZ2U6Zjk3MTU0NDI3NzExNGY1MDkxMTVjZGZkMjcwNGQ5MjJfOS0xLTEtMS03NTE0MA_18a7e384-cbd5-4664-8995-56d8391e883e">8.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMi9mcmFnOjg2Yjc1MDkyMjBmMTQ1ZTlhNjUzNTkzNWRmYzRmZWNiL3RhYmxlOmY5NzE1NDQyNzcxMTRmNTA5MTE1Y2RmZDI3MDRkOTIyL3RhYmxlcmFuZ2U6Zjk3MTU0NDI3NzExNGY1MDkxMTVjZGZkMjcwNGQ5MjJfOS0zLTEtMS03NTE0MA_626eab0e-e848-4608-9b94-0520a618b930">124.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income (loss) attributable to Biogen Inc.</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMi9mcmFnOjg2Yjc1MDkyMjBmMTQ1ZTlhNjUzNTkzNWRmYzRmZWNiL3RhYmxlOmY5NzE1NDQyNzcxMTRmNTA5MTE1Y2RmZDI3MDRkOTIyL3RhYmxlcmFuZ2U6Zjk3MTU0NDI3NzExNGY1MDkxMTVjZGZkMjcwNGQ5MjJfMTAtMS0xLTEtNzUxNDA_516f6cc4-b34f-4365-9415-628a89bc1db3">295.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMi9mcmFnOjg2Yjc1MDkyMjBmMTQ1ZTlhNjUzNTkzNWRmYzRmZWNiL3RhYmxlOmY5NzE1NDQyNzcxMTRmNTA5MTE1Y2RmZDI3MDRkOTIyL3RhYmxlcmFuZ2U6Zjk3MTU0NDI3NzExNGY1MDkxMTVjZGZkMjcwNGQ5MjJfMTAtMy0xLTEtNzUxNDA_3e5c6a9b-defa-4b31-adac-dbfaaa942da4">534.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMi9mcmFnOjg2Yjc1MDkyMjBmMTQ1ZTlhNjUzNTkzNWRmYzRmZWNiL3RhYmxlOmY5NzE1NDQyNzcxMTRmNTA5MTE1Y2RmZDI3MDRkOTIyL3RhYmxlcmFuZ2U6Zjk3MTU0NDI3NzExNGY1MDkxMTVjZGZkMjcwNGQ5MjJfMTEtMS0xLTEtNzUxNDA_6a7f29e4-9e95-4934-a58e-3e9f538094e5">85.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMi9mcmFnOjg2Yjc1MDkyMjBmMTQ1ZTlhNjUzNTkzNWRmYzRmZWNiL3RhYmxlOmY5NzE1NDQyNzcxMTRmNTA5MTE1Y2RmZDI3MDRkOTIyL3RhYmxlcmFuZ2U6Zjk3MTU0NDI3NzExNGY1MDkxMTVjZGZkMjcwNGQ5MjJfMTEtMy0xLTEtNzUxNDA_54100a99-0701-4e12-bb65-a850707b1def">4.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMi9mcmFnOjg2Yjc1MDkyMjBmMTQ1ZTlhNjUzNTkzNWRmYzRmZWNiL3RhYmxlOmY5NzE1NDQyNzcxMTRmNTA5MTE1Y2RmZDI3MDRkOTIyL3RhYmxlcmFuZ2U6Zjk3MTU0NDI3NzExNGY1MDkxMTVjZGZkMjcwNGQ5MjJfMTItMS0xLTEtNzUxNDA_5caab16b-31d3-49b2-ba01-7a4933eab4fb">210.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMi9mcmFnOjg2Yjc1MDkyMjBmMTQ1ZTlhNjUzNTkzNWRmYzRmZWNiL3RhYmxlOmY5NzE1NDQyNzcxMTRmNTA5MTE1Y2RmZDI3MDRkOTIyL3RhYmxlcmFuZ2U6Zjk3MTU0NDI3NzExNGY1MDkxMTVjZGZkMjcwNGQ5MjJfMTItMy0xLTEtNzUxNDA_6b9b06da-b7c4-48e2-bc5e-d643c94349f2">530.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="ie9658fba2baf4e3799b1175f69eaed46_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions, except per share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMy0xLTEtMS03NTE0MA_d06e4ca1-fec4-41af-8f60-0671f4601f36">1,749.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMy0zLTEtMS03NTE0MA_72a13fb3-e84f-4ffb-8311-0f8a8847cdd5">2,261.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfNC0xLTEtMS03NTE0MA_51beb278-8694-4cb3-85c8-8cc5f8e432ab">2,002.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfNC0zLTEtMS03NTE0MA_c48b8fd3-f782-4ac5-9ad1-95ec2baf4105">1,541.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfNS0xLTEtMS03NTE0MA_15babc22-f4d5-4d53-9995-bfa0d9c06efc">1,632.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfNS0zLTEtMS03NTE0MA_d3fb7dcf-d812-41f3-8c96-93019eaecdb1">1,549.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due from anti-CD20 therapeutic programs</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="biib:DuefromantiCD20therapeuticprograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfNi0xLTEtMS03NTE0MA_2f037684-5135-4c74-9204-b6b877d341c0">389.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="biib:DuefromantiCD20therapeuticprograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfNi0zLTEtMS03NTE0MA_157d57f3-e1e1-472f-b58a-19536b7b9a7c">412.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfNy0xLTEtMS03NTE0MA_6f9ffac2-925c-4647-a459-84757d34f28b">1,215.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfNy0zLTEtMS03NTE0MA_38818a66-7f4f-42db-8ae1-f7c38c4f22ef">1,351.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfOC0xLTEtMS03NTE0MA_7df30da5-5fe7-4ee5-9880-1e3a97353cb2">927.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfOC0zLTEtMS03NTE0MA_4184c856-342f-4fbe-a5ca-4f2d2e4e5055">740.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfOS0xLTEtMS03NTE0MA_2b7ff05a-7436-482f-8ad1-55684949a0a6">7,915.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfOS0zLTEtMS03NTE0MA_685c9fbd-f661-477a-944f-4fbc80cfbbfc">7,856.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMTAtMS0xLTEtNzUxNDA_3806dc3d-293b-413b-854c-86a83f441ae9">1,001.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMTAtMy0xLTEtNzUxNDA_03746a57-7eab-4a70-b730-ed2151c1c197">892.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMTEtMS0xLTEtNzUxNDA_33a3d467-4024-4433-a5a7-536dc72cb21d">3,372.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMTEtMy0xLTEtNzUxNDA_28a0a869-9552-42a9-acba-718c110026d1">3,416.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMTItMS0xLTEtNzUxNDA_a2a290d5-3832-4926-b35a-2e3d0e9e15d0">359.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMTItMy0xLTEtNzUxNDA_51b80276-7843-47ef-b3ef-699aab98b38c">375.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMTMtMS0xLTEtNzUxNDA_abf936e7-f140-46f0-87e1-108af94a3a2d">2,150.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMTMtMy0xLTEtNzUxNDA_ad31bd98-dc2a-4080-ad2e-57de755fe2d5">2,221.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMTQtMS0xLTEtNzUxNDA_9bae4871-7030-49ad-acc4-e48d7ebfe89f">5,758.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMTQtMy0xLTEtNzUxNDA_54f46cd6-dfd4-409b-a3a4-43343e84b85f">5,761.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax asset</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMTUtMS0xLTEtNzUxNDA_9ecc3e8c-b6a2-4181-a2c6-bc120bcc72a8">1,288.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMTUtMy0xLTEtNzUxNDA_bd29300a-5cf5-474d-9eb8-370c5ff91bd9">1,415.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMTYtMS0xLTEtNzUxNDA_8b8aead6-35a3-486e-9547-d0e83486896f">1,767.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMTYtMy0xLTEtNzUxNDA_e078e268-48ed-49bf-9fad-e952300afcdb">1,939.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMTctMS0xLTEtNzUxNDA_a6f4818b-11ad-428c-8f73-54a030caeae7">23,614.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMTctMy0xLTEtNzUxNDA_e4ab488b-1bb4-4fc4-8cc5-0b0855d4aaa3">23,877.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of notes payable</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:NotesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMjAtMS0xLTEtNzUxNDA_3328ab25-b772-4145-8169-8408c1c9fa84">999.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:NotesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMjAtMy0xLTEtNzUxNDA_54631e37-920a-4e27-afcb-de581b04d0ef">999.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taxes payable</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMjEtMS0xLTEtNzUxNDA_f95bfdff-4c72-42d2-b440-e86a3b258b33">317.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMjEtMy0xLTEtNzUxNDA_157b0cfa-a881-4141-9998-78e3c92742f9">174.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMjItMS0xLTEtNzUxNDA_08419938-24b4-4fbc-9d8b-2306302c30f3">398.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMjItMy0xLTEtNzUxNDA_b38639b0-d862-445b-bd18-8d80cc97c9ed">589.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMjMtMS0xLTEtNzUxNDA_d8515f2d-5c34-4a06-ac3d-2e7660a67213">2,231.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMjMtMy0xLTEtNzUxNDA_5fb31e60-8834-4e3c-b136-2d311762a7e2">2,535.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMjQtMS0xLTEtNzUxNDA_44706d82-c739-4543-93ae-159fb5fb6412">3,946.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMjQtMy0xLTEtNzUxNDA_e529c4e2-3b60-4eac-969e-dd46f397a2f1">4,298.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Notes payable</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMjUtMS0xLTEtNzUxNDA_554eb3ee-bb44-4850-87db-49227497b6b4">6,275.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMjUtMy0xLTEtNzUxNDA_523a2d76-07f7-482b-b744-90a15cd8f0ab">6,274.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMjYtMS0xLTEtNzUxNDA_6e1b71dc-2d6e-4835-87b8-403c8f2bdaf8">571.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMjYtMy0xLTEtNzUxNDA_2ddd193d-8199-42df-9f54-ae3463fe815b">694.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMjctMS0xLTEtNzUxNDA_a3758c18-86de-425c-aaab-740ed256fea2">312.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMjctMy0xLTEtNzUxNDA_79b4511a-b486-4ebf-8660-260292b24d28">330.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMjgtMS0xLTEtNzUxNDA_ae9b79e7-c50a-4224-bacb-005459810b00">1,287.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMjgtMy0xLTEtNzUxNDA_2b393ea2-2d62-4e7f-b365-49ddd66c9824">1,320.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMjktMS0xLTEtNzUxNDA_cd9d06ec-7284-4937-aaf8-06a089c00faa">12,393.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMjktMy0xLTEtNzUxNDA_c4966121-7634-45be-91de-00e229bd625c">12,917.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments, contingencies and guarantees</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMzAtMS0xLTEtNzUxNDA_7060e6ab-126a-485d-b387-0c72b9121115"></ix:nonFraction></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMzAtMy0xLTEtNzUxNDA_d835182d-c73b-4063-b6dc-db91f81c1c28"></ix:nonFraction></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Biogen Inc. shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, par value $0.001 per share</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMzMtMS0xLTEtNzUxNDA_298a4fa9-bc8a-4793-ac0e-120938008c47">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMzMtMy0xLTEtNzUxNDA_d1840a06-bd26-4695-b159-08a7b5f75b5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, par value $0.0005 per share</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMzQtMS0xLTEtNzUxNDA_2dc960d8-a5b8-41d7-b070-b91f768e4ca1">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMzQtMy0xLTEtNzUxNDA_f9dbbff8-7102-464c-9e9e-9d1cbaa777fa">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:AdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMzUtMS0xLTEtNzUxNDA_a39f8864-3a36-4d7e-918d-2cea1cbcfb49">119.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:AdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMzUtMy0xLTEtNzUxNDA_38ee2fae-0e3c-4fc6-ac06-37c848efb74a">68.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMzYtMS0xLTEtNzUxNDA_c6a1ab44-8a89-413a-8939-7dfcc6a08460">115.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMzYtMy0xLTEtNzUxNDA_a384e6e0-571e-47fb-a1c2-b454ef7219f2">106.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMzctMS0xLTEtNzUxNDA_95457275-cf2e-4d9d-b6cb-b6e9391ce5c6">14,215.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMzctMy0xLTEtNzUxNDA_fdf62bc1-3e11-4e52-8fd6-68b9e39098d9">13,911.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury stock, at cost</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMzgtMS0xLTEtNzUxNDA_0d3e8dbf-7670-45cd-95d7-160b7eeda179">2,977.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMzgtMy0xLTEtNzUxNDA_d5792b37-3e51-4734-a4db-a4354c373032">2,977.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Biogen Inc. shareholders&#8217; equity</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMzktMS0xLTEtNzUxNDA_26adb43f-6cda-47e4-b3d7-109945d2ae1c">11,242.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMzktMy0xLTEtNzUxNDA_b508ed4c-d589-4818-aeea-559b1e36540d">10,896.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" sign="-" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfNDAtMS0xLTEtNzUxNDA_6cd4f492-8df6-4589-85a4-ed6681824388">21.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfNDAtMy0xLTEtNzUxNDA_7d3ebae2-00ca-4db9-8167-7da98d6512e4">63.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfNDEtMS0xLTEtNzUxNDA_7f933b33-769f-4558-ab08-c1af5130f6dd">11,220.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfNDEtMy0xLTEtNzUxNDA_6e9ebb14-3e9f-40b1-96ec-8f11d311e5f2">10,959.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfNDItMS0xLTEtNzUxNDA_dcce3b69-0040-41fb-8561-7623e228e4dd">23,614.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfNDItMy0xLTEtNzUxNDA_be15d785-3fdf-4f16-b826-8322195300be">23,877.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="ie9658fba2baf4e3799b1175f69eaed46_31"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:700;line-height:100%">Cash flow from operating activities:</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMy0xLTEtMS03NTE0MA_7942bf81-e159-4da8-b094-5a28507affe3">218.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMy0zLTEtMS03NTE0MA_52051140-afd8-41d2-8934-ec66d60c2bb9">404.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash flow from operating activities:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfNS0xLTEtMS03NTE0MA_13d9cb21-3967-4556-8f4d-835e7b0c3e49">143.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfNS0zLTEtMS03NTE0MA_23c9b3a1-fa84-44dc-a5b0-45133cf32915">102.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment of intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfNi0xLTEtMS03NTE0MA_0369c383-44d8-4420-b52e-4bf78af810d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfNi0zLTEtMS03NTE0MA_a29b029d-523e-48de-85b7-d4f3079cfeff">44.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Excess and obsolescence charges related to inventory</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:InventoryWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfNy0xLTEtMS03NTE0MA_cec9e047-e276-4a48-9791-856c1b9ad753">281.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:InventoryWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfNy0zLTEtMS03NTE0MA_b8938434-9c0d-40db-a3de-1bdf0d9609a1">11.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfOS0xLTEtMS03NTE0MA_7de3d05c-d1cf-4a76-a42f-5a3f7f6eb036">67.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfOS0zLTEtMS03NTE0MA_8eaa64e0-e531-4a80-aeca-0f8c669757df">70.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMTAtMS0xLTEtNzUxNDA_16d55c8d-ca4e-44a9-b0ff-19581628ccfc">7.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMTAtMy0xLTEtNzUxNDA_a865cad2-2453-4b71-ba4b-b9e093538440">33.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMTEtMS0xLTEtNzUxNDA_28c0f8f0-77d7-431b-a620-a9081538c6f7">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMTEtMy0xLTEtNzUxNDA_2e6b9102-abaf-4157-950b-1d20996d5d7d">15.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gain) loss on strategic investments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMTItMS0xLTEtNzUxNDA_394c2b6d-6d77-4e97-b925-c36d57c82ddc">191.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMTItMy0xLTEtNzUxNDA_7fcbaa6a-e9f9-4718-9864-2c0ff4f57c81">437.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gain) loss on equity method investments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMTMtMS0xLTEtNzUxNDA_89ac0c0b-4349-48c7-8800-e89e135202b2">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMTMtMy0xLTEtNzUxNDA_efdc588a-fd49-493b-8931-337b977afdc5">18.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMTQtMS0xLTEtNzUxNDA_4b141fa5-89d5-4c45-a6e4-c7c9e92e3d69">43.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMTQtMy0xLTEtNzUxNDA_815fb112-f702-436d-a26b-9eae2982cae7">59.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities, net:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMTYtMS0xLTEtNzUxNDA_9c0864f6-cf6e-4654-a35c-89290a7d5f36">87.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMTYtMy0xLTEtNzUxNDA_13e095c1-8b75-4471-9d6d-0947be4d6dfc">37.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Due from anti-CD20 therapeutic programs</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMTctMS0xLTEtNzUxNDA_46d8cc02-d79f-4e85-9668-5baa6c1eb971">22.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMTctMy0xLTEtNzUxNDA_a30729c0-808b-4ed6-8297-4bb084bf3a78">43.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMTgtMS0xLTEtNzUxNDA_e7e0eb5d-6c67-4038-b5e7-6cb7798175c5">142.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMTgtMy0xLTEtNzUxNDA_13333115-a399-4b6a-aca8-0e6bb3dfeaf1">112.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Accrued expense and other current liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMTktMS0xLTEtNzUxNDA_441eec7d-22f9-4010-9fd9-4a9d4ddfc75a">461.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMTktMy0xLTEtNzUxNDA_993f1d57-98fe-4fd1-9acd-d5cbea05198a">283.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Income tax assets and liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMjAtMS0xLTEtNzUxNDA_1ae1cc71-b7e0-4476-be45-480b8c247ad7">101.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMjAtMy0xLTEtNzUxNDA_87e9854b-88bb-42ff-baa8-a32f4816feb4">64.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Other changes in operating assets and liabilities, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMjEtMS0xLTEtNzUxNDA_3496527f-ba12-49ac-be0d-41385525260d">213.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMjEtMy0xLTEtNzUxNDA_db393018-5402-4f57-a230-4c31146b089b">80.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Net cash flow provided by (used in) operating activities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMjItMS0xLTEtNzUxNDA_c7d49393-2afc-44cd-9d01-b76495865e8f">161.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMjItMy0xLTEtNzUxNDA_e31c7de8-9e6f-48f7-b17c-3e11255725ef">769.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:700;line-height:100%">Cash flow from investing activities:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMjQtMS0xLTEtNzUxNDA_795442cd-0818-4f9e-96a1-40ca68e9bb13">57.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMjQtMy0xLTEtNzUxNDA_63bfa1c2-8584-4cc8-afaf-6d807fb81c38">92.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of marketable securities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMjUtMS0xLTEtNzUxNDA_736a63c6-c21e-478f-8b00-0ff98022b2a3">543.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMjUtMy0xLTEtNzUxNDA_61a1e701-eab7-4eed-96f3-846f38687c90">819.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMjYtMS0xLTEtNzUxNDA_4ae4f9f8-3315-40ff-abc3-597d2552b7ed">1,133.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMjYtMy0xLTEtNzUxNDA_08ae293a-15d2-4b7c-9e37-6ffc151fbb82">913.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Proceeds from divestiture of Hiller&#248;d, Denmark manufacturing operations</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMjctMS0xLTEtNzUxNDA_d63bd475-3238-4a6f-88dd-5aaad21c066a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:ProceedsFromDivestitureOfBusinesses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMjctMy0xLTEtNzUxNDA_9e2e8262-18ae-41c6-9ec6-86eef01a281e">28.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Proceeds from the sales of strategic investments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMzAtMS0xLTEtNzUxNDA_2e4c70b6-ce8d-48c2-b957-9c132503fd16">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMzAtMy0xLTEtNzUxNDA_07e00d9f-22de-494b-b3f1-dd4987e6f128">91.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMzEtMS0xLTEtNzUxNDA_5027c699-3185-4ad9-97db-efb231855c5d">0.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMzEtMy0xLTEtNzUxNDA_71e44140-b4e3-4162-8796-8355698e6799">2.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Net cash flow provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMzYtMS0xLTEtNzUxNDA_9cc60a7c-19b3-46e8-a900-98f02bb386f0">648.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMzYtMy0xLTEtNzUxNDA_244aadd6-60a8-4685-8a8a-70a6c6aa2e7d">64.7</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:700;line-height:100%">Cash flow from financing activities:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Purchases of treasury stock</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMzgtMS0xLTEtNzUxNDA_865bd96b-3b72-4a6c-975e-8d04250a9fde">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMzgtMy0xLTEtNzUxNDA_0b05912c-4029-4186-98c5-4025fa2dfc34">600.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Payments related to issuance of stock for share-based compensation arrangements, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMzktMS0xLTEtNzUxNDA_d2f460b4-7b2c-4ec1-a6b7-09134942a4b9">20.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMzktMy0xLTEtNzUxNDA_a0d6df23-bbbc-4c1f-90b4-9556baeed4bc">27.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Repayment of borrowings and premiums paid on debt exchange</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfNDAtMS0xLTEtNzUxNDA_681fedba-8e9f-4541-9b05-244a42811620">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfNDAtMy0xLTEtNzUxNDA_422b2099-ae1f-4a06-9bc0-9af3bae54242">169.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Net (distribution) contribution to noncontrolling interest</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:ProceedsFromPaymentsToMinorityShareholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfNDQtMS0xLTEtNzUxNDA_f88bce75-3f74-4811-ac66-a28324b7324d">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:ProceedsFromPaymentsToMinorityShareholders" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfNDQtMy0xLTEtNzUxNDA_c80140a7-7424-43a8-93aa-848edfce824c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfNDUtMS0xLTEtNzUxNDA_64b51915-ec1e-4582-b582-f6fcdfee2df7">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfNDUtMy0xLTEtNzUxNDA_5da38ae0-9d6e-4449-834e-f56abbb4a096">11.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Net cash flow provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfNDYtMS0xLTEtNzUxNDA_3a7c61d2-0976-4bc9-91ae-1f96ee87c2b7">16.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfNDYtMy0xLTEtNzUxNDA_80983bb4-71e8-44e0-a90e-f1cc48efd459">785.0</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfNDctMS0xLTEtNzUxNDA_8c63eea2-3902-4941-9f04-f0e1b826d88e">502.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfNDctMy0xLTEtNzUxNDA_63d8356b-99e5-4c0a-8f2a-99b91cbc04b3">80.7</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfNDgtMS0xLTEtNzUxNDA_8c7fd04b-5ebe-4858-ab33-6d761fc3ea0a">9.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfNDgtMy0xLTEtNzUxNDA_05792b07-9b88-40d9-94b6-9b88b52cea7e">33.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of the period</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfNDktMS0xLTEtNzUxNDA_fd826ab7-6e36-4b52-a998-a3806e7f70eb">2,261.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f47af926b14294931310a85ceac0ce_I20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfNDktMy0xLTEtNzUxNDA_e5019d67-529c-4213-84b3-9dcc1dcbaee1">1,331.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Cash and cash equivalents, end of the period</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfNTAtMS0xLTEtNzUxNDA_5c29cea5-64a0-4b45-b890-d2b4bb54c89e">1,749.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8239e2124c804a2ea880e06ae55914e8_I20210331" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfNTAtMy0xLTEtNzUxNDA_ef669221-b6e3-4a95-8183-3e5c4e5f8916">1,217.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="ie9658fba2baf4e3799b1175f69eaed46_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.675%"><tr><td style="width:1.0%"></td><td style="width:19.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.351%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.351%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.871%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.523%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.785%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.826%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.586%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.105%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Biogen Inc.<br/>shareholders&#8217;<br/>equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling<br/>interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>equity</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie941cd89b1e6451a9094413808a742ce_I20211231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMi0xLTEtMS03NTE0MA_fe410720-a5af-45cf-866e-c601fc542b5a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie941cd89b1e6451a9094413808a742ce_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMi0zLTEtMS03NTE0MA_980405d6-9837-4ed5-b92d-ce30fb17bed5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i78d18bc7ad434dbbb7aebc8184bdf0b7_I20211231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMi01LTEtMS03NTE0MA_f1b415db-0f82-4bea-9cea-9aa38ea12ead">170.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78d18bc7ad434dbbb7aebc8184bdf0b7_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMi03LTEtMS03NTE0MA_317f25ff-653b-4d50-8534-30ff3a18f628">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ec0412c74a64f2a8f0fe89d886801fd_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMi05LTEtMS03NTE0MA_f2bca02e-3576-4c66-943a-66baa30ac8dd">68.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i59bfec7053f64e28a514a578cced1277_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMi0xMS0xLTEtNzUxNDA_c5c79645-2c50-40f5-93de-be3e1dbdc4ee">106.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7bb17477f1d45768747b659ec408858_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMi0xMy0xLTEtNzUxNDA_9a0b9a9d-bc41-4fe7-9e36-8f6ccdcf7641">13,911.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia38ac114688d4dc79f2cdfac46866743_I20211231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMi0xNS0xLTEtNzUxNDA_af747a62-137f-45c8-b085-382a67e7d8e9">23.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia38ac114688d4dc79f2cdfac46866743_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMi0xNy0xLTEtNzUxNDA_90c7d685-687e-4b17-913a-a8e8d45e229b">2,977.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ab94bf8dc040fba955fc08e64b5851_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMi0xOS0xLTEtNzUxNDA_c5828e0b-484c-4434-a5df-cf1264a007db">10,896.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cab2b42650840b8ad130b5ce90c072e_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMi0yMS0xLTEtNzUxNDA_26babcfc-e82a-475f-9a15-4f1649fd9d58">63.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMi0yMy0xLTEtNzUxNDA_8d421417-c323-47c9-b99c-fc8f0da5a657">10,959.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a99695583d54417b14f147c2e47f0ce_D20220101-20220331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMy0xMy0xLTEtNzUxNDA_58bc0f0a-1207-4676-a619-d0a670a4fc3c">303.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i548f861f837e49619231dee37689ae5e_D20220101-20220331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMy0xOS0xLTEtNzUxNDA_b4d2e789-f976-4dda-ba60-3f90cdb6e8eb">303.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d4017cf2e7f4c638778c899d7ee5f81_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMy0yMS0xLTEtNzUxNDA_3d92208f-b9f1-44b9-8b99-c76ed4176acf">85.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMy0yMy0xLTEtNzUxNDA_35f16ec6-f6b8-4b31-ba96-1e77df005317">218.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i377219a6f8954472a10644270fc0f641_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfNC0xMS0xLTEtNzUxNDA_d621429d-7f8e-4f1c-a491-7b76de513ac1">8.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i548f861f837e49619231dee37689ae5e_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfNC0xOS0xLTEtNzUxNDA_b1d9e91b-0746-463b-a782-e7339f150db7">8.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfNC0yMy0xLTEtNzUxNDA_805f203a-a4f3-46e9-9350-fd2daae4368e">8.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital contribution from noncontrolling interest</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d4017cf2e7f4c638778c899d7ee5f81_D20220101-20220331" decimals="-5" name="biib:NoncontrollingInterestIncreaseDecreaseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfNi0yMS0xLTEtNzUxNDA_67951dd9-c434-4140-8c14-59a9b264d4eb">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="biib:NoncontrollingInterestIncreaseDecreaseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfNi0yMy0xLTEtNzUxNDA_e7cba5c8-e25a-462f-a58d-ae2f753b1cbf">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock option and stock purchase plans</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie8cfe2b3484547cb8b869f3703fbe7c6_D20220101-20220331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfOS01LTEtMS03NTE0MA_164b6f55-e91f-47b2-99b0-6fa6a791a85f">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ba81a995fb24572ac4a052b330190f7_D20220101-20220331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfOS05LTEtMS03NTE0MA_33299b18-708f-4843-bd63-2684e212bfed">18.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i548f861f837e49619231dee37689ae5e_D20220101-20220331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfOS0xOS0xLTEtNzUxNDA_2ef83a2a-1936-4d7d-bdb8-e5f1344bc865">18.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfOS0yMy0xLTEtNzUxNDA_f0becc34-476d-467d-be46-089c9b3cc936">18.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock award plan</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie8cfe2b3484547cb8b869f3703fbe7c6_D20220101-20220331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMTAtNS0xLTEtNzUxNDA_1400f2fa-47c8-436b-9ff5-23269361acf5">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ba81a995fb24572ac4a052b330190f7_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMTAtOS0xLTEtNzUxNDA_249f41af-e536-45f7-8b2d-41d5777bced3">39.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a99695583d54417b14f147c2e47f0ce_D20220101-20220331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMTAtMTMtMS0xLTc1MTQw_269bbfc8-2712-4b60-82d8-ecbd48aaed08">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i548f861f837e49619231dee37689ae5e_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMTAtMTktMS0xLTc1MTQw_e92f37c9-dbb0-4559-8ef0-94a32871248a">39.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMTAtMjMtMS0xLTc1MTQw_52309363-6b50-40e1-bbac-f4621b950486">39.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compensation related to share-based payments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ba81a995fb24572ac4a052b330190f7_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMTEtOS0xLTEtNzUxNDA_aaf6fb93-e99d-4a56-8f24-031c67350c55">70.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i548f861f837e49619231dee37689ae5e_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMTEtMTktMS0xLTc1MTQw_4d248946-8742-487a-a768-f3c69665db00">70.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMTEtMjMtMS0xLTc1MTQw_18a6ba13-4e18-4749-9c25-6789ea4da80f">70.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ba81a995fb24572ac4a052b330190f7_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMTItOS0xLTEtNzUxNDA_5f32987c-167c-43bf-8a3d-51cde2e0483c">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i548f861f837e49619231dee37689ae5e_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMTItMTktMS0xLTc1MTQw_d9317180-9130-46ea-9019-91db620c46b9">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMTItMjMtMS0xLTc1MTQw_2e0b257a-9028-45ec-8f53-be1b2dfeaf38">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, March 31, 2022</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie711522c60db4065b671794dadaf1a8a_I20220331" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMTMtMS0xLTEtNzUxNDA_63aed028-78df-443c-a906-12a474af65d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie711522c60db4065b671794dadaf1a8a_I20220331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMTMtMy0xLTEtNzUxNDA_8fbebe13-1f79-4755-ae2f-c9cfc48d4d2e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i17ade9377df944b2b6a0b1d325fc48e3_I20220331" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMTMtNS0xLTEtNzUxNDA_db024e01-f1ad-40c4-82c1-6a646488bbe4">171.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17ade9377df944b2b6a0b1d325fc48e3_I20220331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMTMtNy0xLTEtNzUxNDA_b2c0413f-7083-4a7b-a48f-e05d2e918e1f">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5517a2fe985436cb5f65e1183b54903_I20220331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMTMtOS0xLTEtNzUxNDA_203abdaf-d637-4f0d-b839-0366028f5401">119.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac6522198e5e47e2a87d575d4f0cf5fb_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMTMtMTEtMS0xLTc1MTQw_3baad367-dd57-4d5b-9387-817234e367a9">115.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d4a878ad70149fc8ebc17f38fb2c3bb_I20220331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMTMtMTMtMS0xLTc1MTQw_8467b910-b94f-4ec5-bec8-b3ec9973af99">14,215.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i623c94faf2524ab6b84a4328c9fbfc71_I20220331" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMTMtMTUtMS0xLTc1MTQw_f3f694c2-1a3a-48fa-8ea8-5270f018897b">23.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i623c94faf2524ab6b84a4328c9fbfc71_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMTMtMTctMS0xLTc1MTQw_b8b37a03-85a0-4efb-b676-3da3b1b6dc43">2,977.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib24a1c0ce66c4661bdc85bb559c07e50_I20220331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMTMtMTktMS0xLTc1MTQw_84fb9c04-7f13-4c8a-9c60-209abe8f0d9b">11,242.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf88a450e4df44f4ad8703ca0a5d3d6f_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMTMtMjEtMS0xLTc1MTQw_598d411a-54a5-4125-9ffb-ec8aa680b902">21.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMTMtMjMtMS0xLTc1MTQw_0e2c10e0-2673-4b46-ac6f-e702fe630922">11,220.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:54pt;padding-right:54pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY - (Continued)</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.458%"><tr><td style="width:1.0%"></td><td style="width:19.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.169%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.755%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.408%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.061%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.872%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Preferred stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Retained<br/>earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Treasury stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total<br/>Biogen Inc.<br/>shareholders&#8217;<br/>equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Noncontrolling<br/>interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total<br/>equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic54a4fcce0664582818adb93f242f27f_I20201231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMi0xLTEtMS03NTE0MA_a9a5dae6-b2dd-47e8-853c-4547e7cc19a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic54a4fcce0664582818adb93f242f27f_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMi0zLTEtMS03NTE0MA_eba9f936-bf01-486f-84b1-989a179b2089">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie4f31a85cb5f4aeb9edd4a49ddc2205a_I20201231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMi01LTEtMS03NTE0MA_aa967147-f092-4613-93ba-cea65805770e">176.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4f31a85cb5f4aeb9edd4a49ddc2205a_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMi03LTEtMS03NTE0MA_e98fd788-1c1f-42a9-9caa-e1f7d100e766">0.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic33c429907664938b302242bae096aa3_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMi05LTEtMS03NTE0MA_62a0a2c5-6edf-48b4-86f8-5368399b9854">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95735dc725534e82a2c616cddefbdcd3_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMi0xMS0xLTEtNzUxNDA_9ed113b0-40f0-417f-a556-b84e9ef12bac">299.0</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d657be8c0141d3bbd283fd85ddc533_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMi0xMy0xLTEtNzUxNDA_230696c4-4b05-4c47-8fd4-8fe84995948b">13,976.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7af6de98bde64694848ffc34847a8d52_I20201231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMi0xNS0xLTEtNzUxNDA_72d4a52f-46a2-4390-91ba-c1b8766399ed">23.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7af6de98bde64694848ffc34847a8d52_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMi0xNy0xLTEtNzUxNDA_7c875249-ae1c-4c2e-8510-7f7c80c05c8e">2,977.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedf3697c5b544792bd0663883b4528a0_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMi0xOS0xLTEtNzUxNDA_322921cc-4f9c-4e86-9663-c2bec3f7db34">10,700.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45721a1b1a8a4773b726c7ab76d5f1ec_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMi0yMS0xLTEtNzUxNDA_95ca5eec-6f8e-49d3-b307-9db99fe6f5bc">14.2</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f47af926b14294931310a85ceac0ce_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMi0yMy0xLTEtNzUxNDA_e8527bdd-af18-4418-90b4-2b111fa0da74">10,686.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ccdc021de64ec580af92fa350db35b_D20210101-20210331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMy0xMy0xLTEtNzUxNDA_c202ce80-00ce-48fa-b189-793c7cc0e58e">410.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00c0c236fb7541c28d07fbbdf09baf1a_D20210101-20210331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMy0xOS0xLTEtNzUxNDA_46b540ed-7109-4ff4-83d0-b32a8c7fa489">410.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8b2525325d746868ee2c18985898556_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMy0yMS0xLTEtNzUxNDA_5cd42720-10df-42f2-acfe-fcfe123ff216">5.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMy0yMy0xLTEtNzUxNDA_c0c35089-c1a3-4794-ab0e-c89d12a84a37">404.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16d6112315b4c80ab9519df7448188a_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfNC0xMS0xLTEtNzUxNDA_158dff6f-ca20-4ec8-86eb-719b610bae5e">124.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00c0c236fb7541c28d07fbbdf09baf1a_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfNC0xOS0xLTEtNzUxNDA_45b65d51-f9fe-408b-84a3-3c447f322742">124.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8b2525325d746868ee2c18985898556_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfNC0yMS0xLTEtNzUxNDA_b4068c7a-f237-4503-8b91-244d6e1d561d">0.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfNC0yMy0xLTEtNzUxNDA_7b289b75-7b48-474a-b328-75c27c5b517f">125.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital contribution from noncontrolling interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8b2525325d746868ee2c18985898556_D20210101-20210331" decimals="-5" name="biib:NoncontrollingInterestIncreaseDecreaseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfNi0yMS0xLTEtNzUxNDA_6aa78885-c48a-4fa7-ad56-2b681923608a">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="biib:NoncontrollingInterestIncreaseDecreaseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfNi0yMy0xLTEtNzUxNDA_5a064d43-4072-4ca6-aada-8cde084dafd3">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock pursuant to the 2020 Share Repurchase Program, at cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i2c1a3584d9f04422972632d1a69a2814_D20210101-20210331" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfNy0xNS0xLTEtNzUxNDA_ff3926e4-8f30-4012-a6cf-f59d2d78fa0e">2.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c1a3584d9f04422972632d1a69a2814_D20210101-20210331" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfNy0xNy0xLTEtNzUxNDA_7720fb69-5f2f-4898-8e99-5daf913c6a3b">600.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ef7dff5a368420bbd853026208ceb4c_D20210101-20210331" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfNy0xOS0xLTEtNzUxNDA_3e7b9673-a5ed-4b01-b37a-b9952a85a159">600.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8035064229a94dc1909b26988c0c3fc7_D20210101-20210331" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfNy0yMy0xLTEtNzUxNDA_afcd8a7b-bb71-4c4c-8d0b-2bdbcc79cbe2">600.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retirement of common stock pursuant to the 2020 Share Repurchase Program, at cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ide815a728f624d74849b4eae66187c0b_D20210101-20210331" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfOC01LTEtMS03NTE0MA_126cd726-a4f7-432e-8cec-893d438edfdc">2.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7810c7b681664742a2f6a5378d83f3f8_D20210101-20210331" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfOC05LTEtMS03NTE0MA_67f043e3-8ac4-41b2-b7c4-902168e9537c">93.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9609a3cc1f21413e9387d3f994a752ea_D20210101-20210331" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfOC0xMy0xLTEtNzUxNDA_057a7560-d510-4b46-b808-4b8bb8614b66">506.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2c1a3584d9f04422972632d1a69a2814_D20210101-20210331" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfOC0xNS0xLTEtNzUxNDA_32037939-4556-41f3-b482-9ef1fd3b30e6">2.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c1a3584d9f04422972632d1a69a2814_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfOC0xNy0xLTEtNzUxNDA_643073de-000b-43fa-a32e-42d02cd653b9">600.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock option and stock purchase plans</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i35b4f4d780094f18808d017b4f134084_D20210101-20210331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfOS01LTEtMS03NTE0MA_aac9a66e-7358-462b-b4fc-30e8919259e2">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08130086aa74dc58e95ffbe7e3e1cc2_D20210101-20210331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfOS05LTEtMS03NTE0MA_28640237-2778-4cc9-a2b8-d69aaeb026dd">19.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00c0c236fb7541c28d07fbbdf09baf1a_D20210101-20210331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfOS0xOS0xLTEtNzUxNDA_2d7e90f1-98c6-420d-b7ed-2f2c98c37506">19.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfOS0yMy0xLTEtNzUxNDA_7bdf9f28-c4fb-42b6-b321-d8a2681a0d31">19.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock award plan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i35b4f4d780094f18808d017b4f134084_D20210101-20210331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMTAtNS0xLTEtNzUxNDA_073e2b4d-99ac-45ce-a35e-bac679572946">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2ccdc021de64ec580af92fa350db35b_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMTAtMTMtMS0xLTc1MTQw_1260b6ef-97a9-4f28-bcbe-2d3eae77787b">46.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00c0c236fb7541c28d07fbbdf09baf1a_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMTAtMTktMS0xLTc1MTQw_a8794c03-7418-449d-803a-6b2bbce07d32">46.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMTAtMjMtMS0xLTc1MTQw_d9d4ab14-e045-4f58-b870-a3da03c3c570">46.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compensation related to share-based payments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08130086aa74dc58e95ffbe7e3e1cc2_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMTEtOS0xLTEtNzUxNDA_8e144597-ff50-4f37-bbb6-1c0758e830b9">72.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00c0c236fb7541c28d07fbbdf09baf1a_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMTEtMTktMS0xLTc1MTQw_755da92f-bb26-485a-862f-b6c41ca626c1">72.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMTEtMjMtMS0xLTc1MTQw_e6b056e7-fd56-44e3-b046-aefd9ccc0661">72.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08130086aa74dc58e95ffbe7e3e1cc2_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMTItOS0xLTEtNzUxNDA_b22d6c6a-c293-4863-b293-ce8d579bdaf2">1.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00c0c236fb7541c28d07fbbdf09baf1a_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMTItMTktMS0xLTc1MTQw_e4ef3db6-eb6d-4f8f-bab3-9fa927aa5bd3">1.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMTItMjMtMS0xLTc1MTQw_ce401cb2-6427-4d49-a0a9-44b00dfac0c8">1.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, March 31, 2021</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic151146309d249e6b3efce405c9339a7_I20210331" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMTUtMS0xLTEtNzUxNDA_20af5440-08d6-40c1-9460-fbdff165d71b">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic151146309d249e6b3efce405c9339a7_I20210331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMTUtMy0xLTEtNzUxNDA_4948dd58-ef9c-42a0-b304-06e9be61f5eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i07a17833f117433192dfb2a5c084ff23_I20210331" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMTUtNS0xLTEtNzUxNDA_93d3dfe6-e358-406f-8787-aa35fcf1351b">174.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07a17833f117433192dfb2a5c084ff23_I20210331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMTUtNy0xLTEtNzUxNDA_a435947d-e48e-4b4d-a4d1-4b201b0debd9">0.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62a58c1e7d3f4fa9bef57b7a1f8c7c8e_I20210331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMTUtOS0xLTEtNzUxNDA_6afe4259-cd8d-42a3-8f0f-d1243f6207f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9948ac905c84412a859b84aa29f53e12_I20210331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMTUtMTEtMS0xLTc1MTQw_8e3a80f2-8cf3-4dce-bf86-8d7b2a0b7e35">174.3</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1ecc04b333e4da4ac25243469cdb953_I20210331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMTUtMTMtMS0xLTc1MTQw_3a7293b2-d94c-4c8f-91f1-04e03d208aed">13,833.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i763b233fe41d42f8aa4eb102c4f5c9e1_I20210331" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMTUtMTUtMS0xLTc1MTQw_59ae222c-bf03-4b3a-9ecf-9aa7c947a672">23.8</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i763b233fe41d42f8aa4eb102c4f5c9e1_I20210331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMTUtMTctMS0xLTc1MTQw_67813a2e-02cd-455a-8887-b290bea08cde">2,977.1</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4fb5422af74378bdf258c1594fe372_I20210331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMTUtMTktMS0xLTc1MTQw_508d4e76-5535-471f-a314-3c9bf2ba664e">10,682.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaad911ccb4124b46ace623b2c56be18b_I20210331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMTUtMjEtMS0xLTc1MTQw_70335091-4a30-4c28-9a02-e4cdd00e02b3">19.0</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8239e2124c804a2ea880e06ae55914e8_I20210331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMTUtMjMtMS0xLTc1MTQw_19aad92f-b5bf-4c29-8935-cbbfb73c8749">10,663.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="ie9658fba2baf4e3799b1175f69eaed46_37"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><div><span><br/></span></div><div id="ie9658fba2baf4e3799b1175f69eaed46_40"></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </span></div><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80MC9mcmFnOjExMzk3NzJmZWM1MjQ0MTNhZGU3YjY3NzQ2MTk5OGQyL3RleHRyZWdpb246MTEzOTc3MmZlYzUyNDQxM2FkZTdiNjc3NDYxOTk4ZDJfODA4Mw_e7d6cc37-e126-4a9c-b1f4-ccfbc2e9ab70" continuedAt="i7f503c336d554bbf8da2abe8b0f1cb2f" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Overview</span></div><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="biib:BusinessOverviewPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80MC9mcmFnOjExMzk3NzJmZWM1MjQ0MTNhZGU3YjY3NzQ2MTk5OGQyL3RleHRyZWdpb246MTEzOTc3MmZlYzUyNDQxM2FkZTdiNjc3NDYxOTk4ZDJfODEwMw_796a99f0-2867-4e17-9f1f-c8f722bf61d5" continuedAt="id0ce35c4b7554d6d9274e3ac35080cdf" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. We have a leading portfolio of medicines to treat multiple sclerosis (MS), have introduced the first approved treatment for spinal muscular atrophy (SMA) and are providing the first and only approved treatment to address a defining pathology of Alzheimer's disease. We also commercialize biosimilars of advanced biologics and focus on advancing our pipeline in neuroscience and specialized immunology. Lastly, we are focused on accelerating our efforts in digital health to support our commercial and pipeline programs while also creating opportunities for potential digital therapeutics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS); and other potential anti-CD20 therapies, including mosunetuzumab, pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our audited consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended December 31, 2021 (2021 Form&#160;10-K).</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:24.75pt"><ix:continuation id="id0ce35c4b7554d6d9274e3ac35080cdf" continuedAt="i1d75f49ddf9845debaf4f733d0ce7236"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through our collaboration with Samsung Bioepis Co., Ltd. (Samsung Bioepis) we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe. We have also secured the exclusive rights to commercialize BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS, which was approved in the U.S., the European Union (E.U.) and the United Kingdom (U.K.) during the third quarter of 2021. For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span></ix:continuation><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1d75f49ddf9845debaf4f733d0ce7236"> to these unaudited condensed consolidated financial statements (condensed consolidated financial statements).</ix:continuation> </span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80MC9mcmFnOjExMzk3NzJmZWM1MjQ0MTNhZGU3YjY3NzQ2MTk5OGQyL3RleHRyZWdpb246MTEzOTc3MmZlYzUyNDQxM2FkZTdiNjc3NDYxOTk4ZDJfODA4OQ_add1087f-d5d5-4b24-8971-3a5b198feeee" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2021 Form&#160;10-K. Our accounting policies are described in the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2021 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three months ended March 31, 2022, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate as <ix:nonFraction unitRef="segment" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80MC9mcmFnOjExMzk3NzJmZWM1MjQ0MTNhZGU3YjY3NzQ2MTk5OGQyL3RleHRyZWdpb246MTEzOTc3MmZlYzUyNDQxM2FkZTdiNjc3NDYxOTk4ZDJfNDA0Ng_7cad88b5-e533-40ce-8216-5359a7ac2edf">one</ix:nonFraction> operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.</span></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i7f503c336d554bbf8da2abe8b0f1cb2f"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation</span></div><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80MC9mcmFnOjExMzk3NzJmZWM1MjQ0MTNhZGU3YjY3NzQ2MTk5OGQyL3RleHRyZWdpb246MTEzOTc3MmZlYzUyNDQxM2FkZTdiNjc3NDYxOTk4ZDJfODA3MA_dd23339a-b18d-4c5f-80b8-be927dae88e6" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than <ix:nonFraction unitRef="number" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="INF" name="biib:InterestInSubsidiary" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80MC9mcmFnOjExMzk3NzJmZWM1MjQ0MTNhZGU3YjY3NzQ2MTk5OGQyL3RleHRyZWdpb246MTEzOTc3MmZlYzUyNDQxM2FkZTdiNjc3NDYxOTk4ZDJfNDU1Ng_036c4327-c66a-43cb-94f1-8597a3c0fc09">100.0</ix:nonFraction>% of the economics, we record net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</span></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80MC9mcmFnOjExMzk3NzJmZWM1MjQ0MTNhZGU3YjY3NzQ2MTk5OGQyL3RleHRyZWdpb246MTEzOTc3MmZlYzUyNDQxM2FkZTdiNjc3NDYxOTk4ZDJfODEwMg_6c4613f7-817b-4fac-9934-7df3b68f7a7d" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including sales, expense, reserves and allowances, the supply chain, manufacturing, clinical trials, research and development costs and employee-related costs, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets. Additionally, the ongoing geopolitical tensions related to Russia's invasion of Ukraine, and the related sanctions and other penalties imposed, are creating substantial uncertainty in the global economy. The extent and duration of the conflict, sanctions and resulting market disruptions are highly unpredictable. We have made estimates of the impact of the COVID-19 pandemic and the ongoing geopolitical conflict within our condensed consolidated financial statements and there may be changes to those estimates in future periods.</span></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Accounting Pronouncements</span></div><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80MC9mcmFnOjExMzk3NzJmZWM1MjQ0MTNhZGU3YjY3NzQ2MTk5OGQyL3RleHRyZWdpb246MTEzOTc3MmZlYzUyNDQxM2FkZTdiNjc3NDYxOTk4ZDJfODA4Ng_4c53dc7e-1380-4989-ae26-7e5a1105f16a" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that we adopt as of the specified effective date. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe that the adoption of recently issued standards have had or may have a material impact on our condensed consolidated financial statements or disclosures.</span></div></ix:nonNumeric></ix:continuation><div id="ie9658fba2baf4e3799b1175f69eaed46_49"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80OS9mcmFnOjE1NzM2OWY1MWM3OTRkMGI4N2Y2MjZhYWZkNTVjYjc1L3RleHRyZWdpb246MTU3MzY5ZjUxYzc5NGQwYjg3ZjYyNmFhZmQ1NWNiNzVfMTMxOTQxMzk1NDY5NjM_cd90bf51-6bc6-4a16-a64c-88c2e7b11c91" continuedAt="ic3b24ddc5f96430baa19464a90d646fb" escape="true">RESTRUCTURING, BUSINESS TRANSFORMATION AND OTHER COST SAVING INITIATIVES </ix:nonNumeric></span></div><ix:continuation id="ic3b24ddc5f96430baa19464a90d646fb" continuedAt="i53e847613e184da09bfe55dd04a202e8"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2022 Cost Saving Initiatives</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021 and May 2022 we announced our plans to implement a series of cost-reduction measures during 2022. These savings are expected to be achieved through a number of initiatives, including reductions to our workforce, primarily within our global Alzheimer's infrastructure, the consolidation of certain real estate locations and operating efficiency gains across our selling, general and administrative and research and development functions.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under these initiatives, we expect to incur restructuring charges ranging from approximately $<ix:nonFraction unitRef="usd" contextRef="i8c3728b044d743d0b57e33fc6e523b46_D20220101-20221231" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80OS9mcmFnOjE1NzM2OWY1MWM3OTRkMGI4N2Y2MjZhYWZkNTVjYjc1L3RleHRyZWdpb246MTU3MzY5ZjUxYzc5NGQwYjg3ZjYyNmFhZmQ1NWNiNzVfMTA5OTUxMTY0MDMxMA_7757f36e-1765-477c-9ac4-fd5bc273bada">100.0</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="i4afdc1a2dcdf424eabd0653274b690c7_D20220101-20221231" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80OS9mcmFnOjE1NzM2OWY1MWM3OTRkMGI4N2Y2MjZhYWZkNTVjYjc1L3RleHRyZWdpb246MTU3MzY5ZjUxYzc5NGQwYjg3ZjYyNmFhZmQ1NWNiNzVfMTA5OTUxMTYzMTU4OA_5d273450-c405-446c-829b-c2ef58f66cc6">150.0</ix:nonFraction>&#160;million. These amounts are primarily related to severance and are expected to be substantially incurred and paid by the end of 2022.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i53e847613e184da09bfe55dd04a202e8"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, we recognized $<ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80OS9mcmFnOjE1NzM2OWY1MWM3OTRkMGI4N2Y2MjZhYWZkNTVjYjc1L3RleHRyZWdpb246MTU3MzY5ZjUxYzc5NGQwYjg3ZjYyNmFhZmQ1NWNiNzVfMTA5OTUxMTYzNjU5OQ_2c710b30-fdbd-439d-92d1-0718cace4812">27.7</ix:nonFraction>&#160;million of employee related costs, primarily related to severance. These costs were recorded in restructuring charges in our condensed consolidated statements of income. Our restructuring reserve is included in accrued expense and other in our condensed consolidated balance sheets.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following an evaluation of our current capacity needs, in March 2022 we ceased using a patient services office space in Durham, North Carolina. We are marketing the space for sublease. Our decision to cease using the facility resulted in the immediate expense of certain leasehold improvements and other assets at this facility, which we do not believe can be adequately recovered in a sublease. As a result, for the three months ended March 31, 2022, we recognized approximately $<ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:RestructuringReserveAcceleratedDepreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80OS9mcmFnOjE1NzM2OWY1MWM3OTRkMGI4N2Y2MjZhYWZkNTVjYjc1L3RleHRyZWdpb246MTU3MzY5ZjUxYzc5NGQwYjg3ZjYyNmFhZmQ1NWNiNzVfMTA5OTUxMTYzNzUwNQ_12834c9a-8f35-46a1-964e-850e14779284">10.4</ix:nonFraction>&#160;million of accelerated depreciation expense, which was recorded in restructuring charges in our condensed consolidated statements of income.</span></div><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80OS9mcmFnOjE1NzM2OWY1MWM3OTRkMGI4N2Y2MjZhYWZkNTVjYjc1L3RleHRyZWdpb246MTU3MzY5ZjUxYzc5NGQwYjg3ZjYyNmFhZmQ1NWNiNzVfMTMxOTQxMzk1NDY5NjI_2876449a-d4a4-4e85-93f9-8afc108559d7" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the charges and spending related to our 2022 cost saving initiatives for the three months ended March 31, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Workforce Reduction</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4b04ecc1818447ebb524096be801f20_I20211231" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80OS9mcmFnOjE1NzM2OWY1MWM3OTRkMGI4N2Y2MjZhYWZkNTVjYjc1L3RhYmxlOmExNWU5MDgxYjRhNjQyYzJhZGUwNWEzNjZjOWQ1MThkL3RhYmxlcmFuZ2U6YTE1ZTkwODFiNGE2NDJjMmFkZTA1YTM2NmM5ZDUxOGRfMS0yLTEtMS05MTM3MA_163b9aaf-593d-4b96-802b-420f17dabc39">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4b04ecc1818447ebb524096be801f20_I20211231" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80OS9mcmFnOjE1NzM2OWY1MWM3OTRkMGI4N2Y2MjZhYWZkNTVjYjc1L3RhYmxlOmExNWU5MDgxYjRhNjQyYzJhZGUwNWEzNjZjOWQ1MThkL3RhYmxlcmFuZ2U6YTE1ZTkwODFiNGE2NDJjMmFkZTA1YTM2NmM5ZDUxOGRfMS00LTEtMS0xMDUwMjc_4aa18866-3248-4b4c-8f50-80024000a3af">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i929ddd179174497bb90c576f4da728fd_D20220101-20220331" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80OS9mcmFnOjE1NzM2OWY1MWM3OTRkMGI4N2Y2MjZhYWZkNTVjYjc1L3RhYmxlOmExNWU5MDgxYjRhNjQyYzJhZGUwNWEzNjZjOWQ1MThkL3RhYmxlcmFuZ2U6YTE1ZTkwODFiNGE2NDJjMmFkZTA1YTM2NmM5ZDUxOGRfMi0yLTEtMS05MTM3MA_5514dae4-7ecc-4239-a5ae-5686ec7fe363">27.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i929ddd179174497bb90c576f4da728fd_D20220101-20220331" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80OS9mcmFnOjE1NzM2OWY1MWM3OTRkMGI4N2Y2MjZhYWZkNTVjYjc1L3RhYmxlOmExNWU5MDgxYjRhNjQyYzJhZGUwNWEzNjZjOWQ1MThkL3RhYmxlcmFuZ2U6YTE1ZTkwODFiNGE2NDJjMmFkZTA1YTM2NmM5ZDUxOGRfMi00LTEtMS0xMDUwMjc_ea074121-b3b1-468e-a286-13e279f98fc2">27.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i929ddd179174497bb90c576f4da728fd_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80OS9mcmFnOjE1NzM2OWY1MWM3OTRkMGI4N2Y2MjZhYWZkNTVjYjc1L3RhYmxlOmExNWU5MDgxYjRhNjQyYzJhZGUwNWEzNjZjOWQ1MThkL3RhYmxlcmFuZ2U6YTE1ZTkwODFiNGE2NDJjMmFkZTA1YTM2NmM5ZDUxOGRfMy0yLTEtMS05MTM3MA_4e784a52-630c-4700-8b5f-dcf2dbbe50a3">6.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i929ddd179174497bb90c576f4da728fd_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80OS9mcmFnOjE1NzM2OWY1MWM3OTRkMGI4N2Y2MjZhYWZkNTVjYjc1L3RhYmxlOmExNWU5MDgxYjRhNjQyYzJhZGUwNWEzNjZjOWQ1MThkL3RhYmxlcmFuZ2U6YTE1ZTkwODFiNGE2NDJjMmFkZTA1YTM2NmM5ZDUxOGRfMy00LTEtMS0xMDUwMjc_73a3f8e5-c54a-4998-8002-6756e2eb5458">6.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60bd213e6b2f4cef984449f784cce8aa_I20220331" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80OS9mcmFnOjE1NzM2OWY1MWM3OTRkMGI4N2Y2MjZhYWZkNTVjYjc1L3RhYmxlOmExNWU5MDgxYjRhNjQyYzJhZGUwNWEzNjZjOWQ1MThkL3RhYmxlcmFuZ2U6YTE1ZTkwODFiNGE2NDJjMmFkZTA1YTM2NmM5ZDUxOGRfNS0yLTEtMS0xMDUwMjQ_96844c9b-fd58-4384-90b9-455cbbbe9cb0">21.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60bd213e6b2f4cef984449f784cce8aa_I20220331" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80OS9mcmFnOjE1NzM2OWY1MWM3OTRkMGI4N2Y2MjZhYWZkNTVjYjc1L3RhYmxlOmExNWU5MDgxYjRhNjQyYzJhZGUwNWEzNjZjOWQ1MThkL3RhYmxlcmFuZ2U6YTE1ZTkwODFiNGE2NDJjMmFkZTA1YTM2NmM5ZDUxOGRfNS00LTEtMS0xMDUwMjc_5275d055-192c-4836-9b83-39f678d7dd3e">21.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ie9658fba2baf4e3799b1175f69eaed46_52"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;REVENUE </span></div><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RleHRyZWdpb246YTIyMjQwMjQ3OTQ4NGY5ZTg3OTE5ZmYwNTMwYWFmYjhfMjA0OQ_50370079-f5dd-4f1f-b9e2-346fc92c774b" continuedAt="ie1f5f559b1124e06a10d9cc70f1269cc" escape="true"><div style="margin-top:6pt"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenue</span></div><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RleHRyZWdpb246YTIyMjQwMjQ3OTQ4NGY5ZTg3OTE5ZmYwNTMwYWFmYjhfMjA1Ng_6536dd4d-2fdd-4629-a2a4-c0b500434138" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by product is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.550%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis (MS):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fumarate</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4019bfee1947475697fa8390601cf107_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfNC0yLTEtMS03NTE0MA_e23932ce-e38b-467c-be93-62bdb8e9ffd5">242.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d56b6894b294cb3b2fbfc394c2be8f3_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfNC00LTEtMS03NTE0MA_69a524b8-efc0-4038-896c-7c5b6f1e9f65">295.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45e6439716cb4f31b5a5f0feef64721a_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfNC02LTEtMS03NTE0MA_ee7fbfba-fffd-4b10-b9b9-e7e13a039a42">537.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9ae9e65490748f2acefb5047af75a92_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfNC04LTEtMS03NTE0MA_ebaf91bb-8a9b-40a0-be23-4acffbeb8c63">236.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8085faadc8004a108e4be4098084c970_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfNC0xMC0xLTEtNzUxNDA_1428b2c2-f506-4d90-aa37-3caa4360eaf1">316.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40537541890549888c403ef75418b3d7_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfNC0xMi0xLTEtNzUxNDA_6659c253-53d4-4abc-8146-a52a77b73aa2">552.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interferon</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f199ee2171447a5b18611c5c256d297_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfNS0yLTEtMS03NTE0MA_6b60328f-f9d9-4759-9c39-e47f6047cc2c">182.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i958877fcc74e4539915b329079fa6389_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfNS00LTEtMS03NTE0MA_fada9a83-8c4e-4655-952f-3467252bb274">127.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i757cf428860849798a536a290e69a744_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfNS02LTEtMS03NTE0MA_9fd3f65a-850d-49cc-ac3c-8c5be3e6a5d2">309.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80aabd0ba40a4666859ae614cdd27a07_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfNS04LTEtMS03NTE0MA_fc152246-8862-4d5a-8a26-a2df644175e3">241.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f4e5fdc87be405f92ffd881cb8662ce_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfNS0xMC0xLTEtNzUxNDA_94c5ff86-5b3b-423d-a1bd-a6fb10c85fe9">158.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4c2e7acd9be4bfea25698309d8d8828_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfNS0xMi0xLTEtNzUxNDA_4d8a5e6b-ed64-462c-8545-af5f562d5552">400.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i487df1d2304e478d8603ddfb4616b0f6_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfNi0yLTEtMS03NTE0MA_8d6d34b8-53e5-4a2a-afc3-5dbcb5e1e8ce">284.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea6a5dee2a24c37ac79226e11fc7e81_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfNi00LTEtMS03NTE0MA_bb6057bc-0636-4721-96ea-96b24443ea89">236.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49af7fbee4534ecc9b44e33e68ad9bac_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfNi02LTEtMS03NTE0MA_0efce265-e368-41ce-bda2-077bfa1fb204">520.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b15c52761ae42e58d6abc7911f80917_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfNi04LTEtMS03NTE0MA_3c710fa6-df79-4c2f-a04e-a7caf6214b2a">273.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5540cfaf99944f5fa1f892083859fd1b_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfNi0xMC0xLTEtNzUxNDA_6f86c958-2c53-41aa-9d7d-81b0a919233c">230.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2efe312a1ed4c21bc651416d90150b4_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfNi0xMi0xLTEtNzUxNDA_4844d062-b3d5-4d06-89e3-c5261253412d">503.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4cb5e1b131d44a689b572c1d03b1392_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfNy0yLTEtMS03NTE0MA_a9311108-16cc-4b8d-8bd9-bddd7276fde2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f8158b854de46d7949a3f0ff441a7c9_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfNy00LTEtMS03NTE0MA_d63460e3-11a5-442d-a499-45283e9b5dc5">26.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie44c413a93ec48a59784c0ea0623dded_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfNy02LTEtMS03NTE0MA_5a584146-bc31-425e-b7e3-fdd6f09f272b">26.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if54e432976f24dfa9de95d847fc16af1_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfNy04LTEtMS03NTE0MA_f961e95e-cf9e-4073-989b-25ca5913ecf9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7331caa9ccd84bd5be10521a9f0d0481_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfNy0xMC0xLTEtNzUxNDA_f31eb4c2-740a-4564-8031-d017ce11c0f8">26.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ec978dde6374ab7a39346cd84c5c36c_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfNy0xMi0xLTEtNzUxNDA_df9edc0d-6e17-409f-8336-0b54b695cc39">26.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: MS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66c008431754250a1c7ad1581031751_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfOC0yLTEtMS03NTE0MA_885ad4ba-0e7d-43bb-b7c9-500fc3e65f11">709.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d4fca69d176447480f070d481fc6e1d_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfOC00LTEtMS03NTE0MA_44853856-0e96-4a4c-b8de-c8016cf6fc97">685.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55f4f5b3d91e4c279119147eedb46915_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfOC02LTEtMS03NTE0MA_e87d69b6-49c5-455d-901a-17ceec3008f1">1,394.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf5d43d131c84980b40ac7f048729534_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfOC04LTEtMS03NTE0MA_fbc39eb2-f177-4452-87d0-3a685eaec869">751.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a4ea8f03c0f42738c05eac690b20806_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfOC0xMC0xLTEtNzUxNDA_4fa4fe47-2616-41bc-b0fa-75b8fc2ba19a">732.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60267e464f984999be2095717c97a319_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfOC0xMi0xLTEtNzUxNDA_46c2ff58-7695-4027-9a87-eaf6bbb03565">1,483.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c070dfe729642198b279735cad93c30_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTEtMi0xLTEtNzUxNDA_8d3f5992-3cab-46d4-ad37-e8ad866c7828">163.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78c6eccdad234026bb1aeeb838de571d_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTEtNC0xLTEtNzUxNDA_41f3c44d-7b01-4379-b57d-595be44d260d">309.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6828112d9c4f41f0bf08dd88efb7662e_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTEtNi0xLTEtNzUxNDA_ad6dde6e-faeb-42bc-9615-03ea26c56d90">472.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1098dcaf54d41aca1af33ac1c235c78_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTEtOC0xLTEtNzUxNDA_f984507c-75ff-4f6b-8a8c-c4a5283900b7">148.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iceae2cc273d1444eae0aa9c381b2d61b_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTEtMTAtMS0xLTc1MTQw_23204f4f-22a8-4f45-8239-25b3e76bd25d">371.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8ac52ff6b5e42babf12a9c71a39395c_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTEtMTItMS0xLTc1MTQw_5d2a817f-170f-4f8a-aa1c-fe06c5caae30">520.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alzheimer's disease:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ADUHELM</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f41e9d658b94408b5d6df1021553899_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTQtMi0xLTEtNzUxNDA_d0b66127-1707-4221-a1e9-b8d9236edbfd">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id06f574f06e14c8ba3b25d199ce88210_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTQtNC0xLTEtNzUxNDA_56c91f1b-c19b-4efd-9ab2-48c6e2ff8f0e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i722a1d8416ce4b6b9e7ebbb4433afb51_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTQtNi0xLTEtNzUxNDA_ccb9eea1-6ffb-4d72-8d7b-69a505342331">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816d25b468bc4d96aab34518cf3f4c6c_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTQtOC0xLTEtNzUxNDA_533df871-7777-4ddc-809b-a4acfd239703">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1004f5d220be40cd9e39fe595414dfaa_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTQtMTAtMS0xLTc1MTQw_6d0c3225-8e88-495f-9e3f-08368233c2b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b4707892bc4fec9b74d5cc51e6529e_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTQtMTItMS0xLTc1MTQw_719596c1-4179-45c2-976a-982039b4c8b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7921192dedf4f4a988ac6e9ce17c61b_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTctMi0xLTEtNzUxNDA_fc68729d-47bf-43e8-b7a7-d4ee80b2f9b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e1bccba2b844138516eb1ac75d4fdf_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTctNC0xLTEtNzUxNDA_31a50909-1de5-4c2a-bb2e-a0ea12a61a37">114.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e8b6707e4854fa388edc206ac7d95bd_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTctNi0xLTEtNzUxNDA_3a5c5977-1f9c-4fbf-975b-00e4031d03b5">114.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i670a74b23f5f4caea6103368f4c95973_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTctOC0xLTEtNzUxNDA_523d7ecd-b819-4d0d-8864-f49804ef2843">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08c5715a87047d6916a728b0059e603_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTctMTAtMS0xLTc1MTQw_2eb96090-c471-462e-b62f-88c05ef46578">121.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id811739973f8445d958ab0cb2731f205_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTctMTItMS0xLTc1MTQw_cabf90d5-a05a-4c82-b1a8-8c45dae5ad8c">121.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ed53a25b23d434ebf3a733a39cbbcb7_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTgtMi0xLTEtNzUxNDA_b371f05b-ffb3-45b9-84fb-f832a9c53490">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i403756a186e6453a9c24141d0b5678f5_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTgtNC0xLTEtNzUxNDA_7afe5ae4-a991-4d79-91bd-8ef870a09365">57.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i534b8a9915d9400f837298b0f6d411f1_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTgtNi0xLTEtNzUxNDA_89e9a356-cd0c-4e14-a8a7-b39dcfbe8381">57.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66f6ed4993f14e3290ab6c4742235f3d_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTgtOC0xLTEtNzUxNDA_75e52fb3-9725-4797-897a-ff6044eb9904">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6f7347790a54edbabf24343e2257691_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTgtMTAtMS0xLTc1MTQw_27f8bd7e-96d5-47de-a289-8200d7054111">57.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68ba8dee324c40978fe4ee8211658faa_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTgtMTItMS0xLTc1MTQw_eaee56de-149b-45d7-8932-cdb2b14d588d">57.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic81d1b50ecdb40b391c62c6287303f8b_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTktMi0xLTEtNzUxNDA_21e929d2-af26-4178-ad75-8a80b244baf1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32b306330d79453787a5388f0c9b87dd_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTktNC0xLTEtNzUxNDA_abd94eca-cf66-4f63-85ee-5981f49e8760">22.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61d231d430914084bd5b37c094531f73_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTktNi0xLTEtNzUxNDA_797263fa-4031-4bf2-87ed-22863db4f5aa">22.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic570d7e37f3246c9a7c17df8eb70bf29_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTktOC0xLTEtNzUxNDA_df26a5c0-b501-402a-8fde-f142bdbed3f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cb87c336f514d67ab337ffa3b0d63a2_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTktMTAtMS0xLTc1MTQw_f2ca52af-404f-4eb2-8dc3-55cc8cb16748">25.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1049089607294f30837a3ada694dc739_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTktMTItMS0xLTc1MTQw_4da4ff3b-d841-4075-b822-ebedfb754d00">25.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilars</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d04af7411eb4ffd942a725be50edb92_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMjAtMi0xLTEtNzUxNDA_cc9a9f2f-fefe-409e-b77a-2205b23096fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15bc81eea1fc4013a923d18d25b1aee3_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMjAtNC0xLTEtNzUxNDA_4683fbdd-0130-4038-a901-ec5dbeefac07">194.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaf74ee71f7f4592b819c8e204ed6c90_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMjAtNi0xLTEtNzUxNDA_be3aa97c-c4fd-4810-8e29-a1aca89bb46f">194.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36dbeb0ba18e4a5b94216f5fdfb3a00a_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMjAtOC0xLTEtNzUxNDA_de261273-e4fe-48ee-8c38-29b3cca8b10c">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i057f89827dbc42819caa6b53dc6ff8c7_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMjAtMTAtMS0xLTc1MTQw_d33f5dbf-b517-46b0-a884-75586d5abe3f">205.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic026373e31634ffb9f84acb0c02d47ac_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMjAtMTItMS0xLTc1MTQw_6f4724e9-1b78-4f4f-be8d-0482d35bdbd1">205.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FUMADERM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ae65a6ea2994e1da2df20adab69bd79_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMjMtMi0xLTEtNzUxNDA_37eec983-a069-4832-b468-cce2b02c9227">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f713481ad2048ecae97763950260fd1_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMjMtNC0xLTEtNzUxNDA_1521ddb9-2955-4bec-a54b-1578133d99b1">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee11fd74051f4269a45be312fa23f68f_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMjMtNi0xLTEtNzUxNDA_43cb533b-4d83-40eb-bdb9-57682c0aa15a">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98bd7ced87284d89af6b6ae7d70f8d7d_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMjMtOC0xLTEtNzUxNDA_74bc531d-7a62-4c08-966c-57fc29fe3240">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i782884b4f8aa48df9e97e2cb2755409f_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMjMtMTAtMS0xLTc1MTQw_3123852a-7887-48e2-9876-3eb6e1d8775d">2.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e33621ceef64fc2ad12d006a54bc1b8_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMjMtMTItMS0xLTc1MTQw_5ebb2dd9-d256-4187-9803-15bfbc31ac6a">2.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56fe223e37e040f490923df9b519d2a6_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMjQtMi0xLTEtNzUxNDA_7bd75a5e-f9b8-4365-ae0a-54638609e9ab">875.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbd8a4f5465946c0aa38c26ef4752572_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMjQtNC0xLTEtNzUxNDA_14819aad-1213-494a-8947-aa6947940284">1,191.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70fc67330ce0470db37abf6a0dc4fb6a_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMjQtNi0xLTEtNzUxNDA_6a739c72-f5bc-4219-a8a9-664684ce2e49">2,066.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeeb3b4588f74e0586c4e89af4306f7b_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMjQtOC0xLTEtNzUxNDA_f5617f0c-d458-4dd4-8d09-101027d71036">899.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ae353a26bd4fff8785a4632e4afbfa_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMjQtMTAtMS0xLTc1MTQw_fb129bb6-43be-40f7-b6b2-d7249570ed13">1,311.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22a0a13c266f4d788d5ba6423911ebd9_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMjQtMTItMS0xLTc1MTQw_5022e5a6-c3d8-4d22-8794-19c192c2b971">2,211.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fumarate includes TECFIDERA and VUMERITY. VUMERITY became commercially available in the E.U. during the fourth quarter of 2021.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Interferon includes AVONEX and PLEGRIDY.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In June 2021 the U.S. Food and Drug Administration (FDA) granted accelerated approval of ADUHELM, which became commercially available in the U.S. during the second quarter of 2021. For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships - Eisai Co., Ltd. - ADUHELM Collaboration Agreement, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="ie1f5f559b1124e06a10d9cc70f1269cc"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue from <ix:nonFraction unitRef="wholesaler" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="INF" name="biib:NumberOfWholesalers" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RleHRyZWdpb246YTIyMjQwMjQ3OTQ4NGY5ZTg3OTE5ZmYwNTMwYWFmYjhfNzc0_6896be53-2a2c-4e25-a48c-8e55869bd7c5"><ix:nonFraction unitRef="wholesaler" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="INF" name="biib:NumberOfWholesalers" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RleHRyZWdpb246YTIyMjQwMjQ3OTQ4NGY5ZTg3OTE5ZmYwNTMwYWFmYjhfNzc0_d1d00e1d-2220-4b94-a544-0af680e7c8ab">two</ix:nonFraction></ix:nonFraction> wholesalers accounting for <ix:nonFraction unitRef="number" contextRef="i03f9978c12b14dfc8ee889cdf2bdb6f0_D20220101-20220331" decimals="INF" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RleHRyZWdpb246YTIyMjQwMjQ3OTQ4NGY5ZTg3OTE5ZmYwNTMwYWFmYjhfODA0_19ebe6a7-8048-40a8-983b-4cc08a4a5d25">26.3</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i7d6f800c7c994872a26f2506f98306ad_D20220101-20220331" decimals="INF" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RleHRyZWdpb246YTIyMjQwMjQ3OTQ4NGY5ZTg3OTE5ZmYwNTMwYWFmYjhfODEx_b367c0ab-c0c6-42db-8004-378f572c9009">10.5</ix:nonFraction>% of gross product revenue for the three months ended March 31, 2022, and <ix:nonFraction unitRef="number" contextRef="i94c39b003aff4990a1610f96586f03dd_D20210101-20210331" decimals="3" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RleHRyZWdpb246YTIyMjQwMjQ3OTQ4NGY5ZTg3OTE5ZmYwNTMwYWFmYjhfMTA5OTUxMTYzMDExNw_f5e6af32-46b1-42af-8c79-b7fe66faaf08">30.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ic5db3734293a4e20858f95205c4aac6c_D20210101-20210331" decimals="3" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RleHRyZWdpb246YTIyMjQwMjQ3OTQ4NGY5ZTg3OTE5ZmYwNTMwYWFmYjhfMTA5OTUxMTYzMDEyMQ_0a7a3bf1-cc60-4000-b4d3-38e6e6787102">9.3</ix:nonFraction>% of gross product revenue for the three months ended March 31, 2021.</span></div><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RleHRyZWdpb246YTIyMjQwMjQ3OTQ4NGY5ZTg3OTE5ZmYwNTMwYWFmYjhfMjA0NA_7d2cd41d-91ef-4b99-b98b-75dd6e6d4f9a" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.155%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i724aaa93e18442fc9a55e613a9dda9bd_I20211231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjk0Yzk5NGIyN2ZjZTQwNWVhODU0NjA5MmYyYWE0ZDJlL3RhYmxlcmFuZ2U6OTRjOTk0YjI3ZmNlNDA1ZWE4NTQ2MDkyZjJhYTRkMmVfMS0yLTEtMS03NTE0MA_1574063e-35ab-4760-8915-19c714668a83">137.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67b699450f32425283dbf73b59e9a343_I20211231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjk0Yzk5NGIyN2ZjZTQwNWVhODU0NjA5MmYyYWE0ZDJlL3RhYmxlcmFuZ2U6OTRjOTk0YjI3ZmNlNDA1ZWE4NTQ2MDkyZjJhYTRkMmVfMS00LTEtMS03NTE0MA_4c06ca6d-fca0-458e-9b9f-b59654270504">759.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c857804af6a41aeb371a364d6599e30_I20211231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjk0Yzk5NGIyN2ZjZTQwNWVhODU0NjA5MmYyYWE0ZDJlL3RhYmxlcmFuZ2U6OTRjOTk0YjI3ZmNlNDA1ZWE4NTQ2MDkyZjJhYTRkMmVfMS02LTEtMS03NTE0MA_2c6632f1-3e1a-41ec-8ede-d09c0b9713ab">38.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjk0Yzk5NGIyN2ZjZTQwNWVhODU0NjA5MmYyYWE0ZDJlL3RhYmxlcmFuZ2U6OTRjOTk0YjI3ZmNlNDA1ZWE4NTQ2MDkyZjJhYTRkMmVfMS04LTEtMS03NTE0MA_5be7fd09-a242-460a-91b7-7a35cd341c36">935.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current provisions relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29cfc0f0c2944f219a39cbd064853d72_D20220101-20220331" decimals="-5" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjk0Yzk5NGIyN2ZjZTQwNWVhODU0NjA5MmYyYWE0ZDJlL3RhYmxlcmFuZ2U6OTRjOTk0YjI3ZmNlNDA1ZWE4NTQ2MDkyZjJhYTRkMmVfMi0yLTEtMS03NTE0MA_0869fb6d-b606-46cb-8320-67fde057bcb6">169.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f9240206d2e4fdfa0bf34f005ce7fdc_D20220101-20220331" decimals="-5" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjk0Yzk5NGIyN2ZjZTQwNWVhODU0NjA5MmYyYWE0ZDJlL3RhYmxlcmFuZ2U6OTRjOTk0YjI3ZmNlNDA1ZWE4NTQ2MDkyZjJhYTRkMmVfMi00LTEtMS03NTE0MA_b2ad1e2e-2627-4f10-badd-f2c02a5c1579">659.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0962864d41e04b9897a3e8d3c6267a4e_D20220101-20220331" decimals="-5" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjk0Yzk5NGIyN2ZjZTQwNWVhODU0NjA5MmYyYWE0ZDJlL3RhYmxlcmFuZ2U6OTRjOTk0YjI3ZmNlNDA1ZWE4NTQ2MDkyZjJhYTRkMmVfMi02LTEtMS03NTE0MA_c21aa08a-1c2d-4930-bb5e-e5ec4867fa9c">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjk0Yzk5NGIyN2ZjZTQwNWVhODU0NjA5MmYyYWE0ZDJlL3RhYmxlcmFuZ2U6OTRjOTk0YjI3ZmNlNDA1ZWE4NTQ2MDkyZjJhYTRkMmVfMi04LTEtMS03NTE0MA_8b41c8a1-be05-4354-a421-378269d626c2">832.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29cfc0f0c2944f219a39cbd064853d72_D20220101-20220331" decimals="-5" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjk0Yzk5NGIyN2ZjZTQwNWVhODU0NjA5MmYyYWE0ZDJlL3RhYmxlcmFuZ2U6OTRjOTk0YjI3ZmNlNDA1ZWE4NTQ2MDkyZjJhYTRkMmVfMy0yLTEtMS03NTE0MA_8c46bc57-68d6-4c32-9d53-b5389f2d8759">3.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f9240206d2e4fdfa0bf34f005ce7fdc_D20220101-20220331" decimals="-5" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjk0Yzk5NGIyN2ZjZTQwNWVhODU0NjA5MmYyYWE0ZDJlL3RhYmxlcmFuZ2U6OTRjOTk0YjI3ZmNlNDA1ZWE4NTQ2MDkyZjJhYTRkMmVfMy00LTEtMS03NTE0MA_37b17000-9296-47a7-b62e-c83da8a4da21">40.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0962864d41e04b9897a3e8d3c6267a4e_D20220101-20220331" decimals="-5" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjk0Yzk5NGIyN2ZjZTQwNWVhODU0NjA5MmYyYWE0ZDJlL3RhYmxlcmFuZ2U6OTRjOTk0YjI3ZmNlNDA1ZWE4NTQ2MDkyZjJhYTRkMmVfMy02LTEtMS03NTE0MA_49fadcd1-fb9c-4383-aad3-1e15c4b409a1">2.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjk0Yzk5NGIyN2ZjZTQwNWVhODU0NjA5MmYyYWE0ZDJlL3RhYmxlcmFuZ2U6OTRjOTk0YjI3ZmNlNDA1ZWE4NTQ2MDkyZjJhYTRkMmVfMy04LTEtMS03NTE0MA_33bc0b6f-212b-4cf2-b26f-5e2286c3e15d">46.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29cfc0f0c2944f219a39cbd064853d72_D20220101-20220331" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjk0Yzk5NGIyN2ZjZTQwNWVhODU0NjA5MmYyYWE0ZDJlL3RhYmxlcmFuZ2U6OTRjOTk0YjI3ZmNlNDA1ZWE4NTQ2MDkyZjJhYTRkMmVfNC0yLTEtMS03NTE0MA_b0dca2ba-716b-4b76-81fc-4311fffe0b70">101.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f9240206d2e4fdfa0bf34f005ce7fdc_D20220101-20220331" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjk0Yzk5NGIyN2ZjZTQwNWVhODU0NjA5MmYyYWE0ZDJlL3RhYmxlcmFuZ2U6OTRjOTk0YjI3ZmNlNDA1ZWE4NTQ2MDkyZjJhYTRkMmVfNC00LTEtMS03NTE0MA_8bda8452-f0fd-4f82-b101-c82c22a5e8f5">271.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0962864d41e04b9897a3e8d3c6267a4e_D20220101-20220331" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjk0Yzk5NGIyN2ZjZTQwNWVhODU0NjA5MmYyYWE0ZDJlL3RhYmxlcmFuZ2U6OTRjOTk0YjI3ZmNlNDA1ZWE4NTQ2MDkyZjJhYTRkMmVfNC02LTEtMS03NTE0MA_d52b3e7c-5762-4896-9299-b8c0f01f39a6">0.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjk0Yzk5NGIyN2ZjZTQwNWVhODU0NjA5MmYyYWE0ZDJlL3RhYmxlcmFuZ2U6OTRjOTk0YjI3ZmNlNDA1ZWE4NTQ2MDkyZjJhYTRkMmVfNC04LTEtMS03NTE0MA_a206c8e7-7ecb-4da1-a811-8518f6f71494">373.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in prior years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29cfc0f0c2944f219a39cbd064853d72_D20220101-20220331" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjk0Yzk5NGIyN2ZjZTQwNWVhODU0NjA5MmYyYWE0ZDJlL3RhYmxlcmFuZ2U6OTRjOTk0YjI3ZmNlNDA1ZWE4NTQ2MDkyZjJhYTRkMmVfNS0yLTEtMS03NTE0MA_7fdfa4c9-037c-44cb-b974-80251aa78ec4">58.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f9240206d2e4fdfa0bf34f005ce7fdc_D20220101-20220331" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjk0Yzk5NGIyN2ZjZTQwNWVhODU0NjA5MmYyYWE0ZDJlL3RhYmxlcmFuZ2U6OTRjOTk0YjI3ZmNlNDA1ZWE4NTQ2MDkyZjJhYTRkMmVfNS00LTEtMS03NTE0MA_49feda2e-595f-47d0-9751-0182d5ad3ef2">314.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0962864d41e04b9897a3e8d3c6267a4e_D20220101-20220331" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjk0Yzk5NGIyN2ZjZTQwNWVhODU0NjA5MmYyYWE0ZDJlL3RhYmxlcmFuZ2U6OTRjOTk0YjI3ZmNlNDA1ZWE4NTQ2MDkyZjJhYTRkMmVfNS02LTEtMS03NTE0MA_2404d193-6ae4-4f46-acdc-6e55d59d6420">6.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjk0Yzk5NGIyN2ZjZTQwNWVhODU0NjA5MmYyYWE0ZDJlL3RhYmxlcmFuZ2U6OTRjOTk0YjI3ZmNlNDA1ZWE4NTQ2MDkyZjJhYTRkMmVfNS04LTEtMS03NTE0MA_509a0a7d-215d-458d-b4fe-f0bb639f70e7">379.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06abbb84d032422fb1a3f75785252f65_I20220331" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjk0Yzk5NGIyN2ZjZTQwNWVhODU0NjA5MmYyYWE0ZDJlL3RhYmxlcmFuZ2U6OTRjOTk0YjI3ZmNlNDA1ZWE4NTQ2MDkyZjJhYTRkMmVfNi0yLTEtMS03NTE0MA_6cc5b693-209a-4629-b499-b134a014a51e">142.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc6e75dd023146aeb4a6678f69c4242c_I20220331" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjk0Yzk5NGIyN2ZjZTQwNWVhODU0NjA5MmYyYWE0ZDJlL3RhYmxlcmFuZ2U6OTRjOTk0YjI3ZmNlNDA1ZWE4NTQ2MDkyZjJhYTRkMmVfNi00LTEtMS03NTE0MA_ba73fdef-3e45-4bf8-b67f-606e7f84e4ee">792.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia76f9cf51eab4d948a5698ec20d971c9_I20220331" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjk0Yzk5NGIyN2ZjZTQwNWVhODU0NjA5MmYyYWE0ZDJlL3RhYmxlcmFuZ2U6OTRjOTk0YjI3ZmNlNDA1ZWE4NTQ2MDkyZjJhYTRkMmVfNi02LTEtMS03NTE0MA_b513b16a-063f-4e2f-8e7b-535645c58a7b">32.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjk0Yzk5NGIyN2ZjZTQwNWVhODU0NjA5MmYyYWE0ZDJlL3RhYmxlcmFuZ2U6OTRjOTk0YjI3ZmNlNDA1ZWE4NTQ2MDkyZjJhYTRkMmVfNi04LTEtMS03NTE0MA_3ac355fb-972c-45f7-9d42-d904ecd70ee5">968.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RleHRyZWdpb246YTIyMjQwMjQ3OTQ4NGY5ZTg3OTE5ZmYwNTMwYWFmYjhfMjAzNw_1da6d036-2a49-4a87-9e4a-af2d08aa5d84" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.400%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reduction of accounts receivable</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id33287c4ca8e4b7c9960bc9a3c2091e4_I20220331" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjA1OTkyMTkzNTliODQ3ODQ4MGI2NWNiYTFhZGUxMWRkL3RhYmxlcmFuZ2U6MDU5OTIxOTM1OWI4NDc4NDgwYjY1Y2JhMWFkZTExZGRfMS0yLTEtMS03NTE0MA_1cd35601-e37c-4903-a958-2014d1810892">136.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaac99eb6afb34c03b2e78fd08137df46_I20211231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjA1OTkyMTkzNTliODQ3ODQ4MGI2NWNiYTFhZGUxMWRkL3RhYmxlcmFuZ2U6MDU5OTIxOTM1OWI4NDc4NDgwYjY1Y2JhMWFkZTExZGRfMS00LTEtMS03NTE0MA_54ed180b-cd05-4316-b71d-ffb0058f6de0">133.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Component of accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bdcfb675756479fa2aa02a4f8a3a6ce_I20220331" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjA1OTkyMTkzNTliODQ3ODQ4MGI2NWNiYTFhZGUxMWRkL3RhYmxlcmFuZ2U6MDU5OTIxOTM1OWI4NDc4NDgwYjY1Y2JhMWFkZTExZGRfMi0yLTEtMS03NTE0MA_2f2b96cb-0138-4e84-8b4f-4487a0ff00a5">831.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d7e46af1def46ae846f93734361fcc5_I20211231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjA1OTkyMTkzNTliODQ3ODQ4MGI2NWNiYTFhZGUxMWRkL3RhYmxlcmFuZ2U6MDU5OTIxOTM1OWI4NDc4NDgwYjY1Y2JhMWFkZTExZGRfMi00LTEtMS03NTE0MA_6203e8ed-01e8-473b-ac8b-2461654103e5">802.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue-related reserves</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjA1OTkyMTkzNTliODQ3ODQ4MGI2NWNiYTFhZGUxMWRkL3RhYmxlcmFuZ2U6MDU5OTIxOTM1OWI4NDc4NDgwYjY1Y2JhMWFkZTExZGRfMy0yLTEtMS03NTE0MA_d28e6c10-3e37-4986-8254-2fcff1a338b4">968.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjA1OTkyMTkzNTliODQ3ODQ4MGI2NWNiYTFhZGUxMWRkL3RhYmxlcmFuZ2U6MDU5OTIxOTM1OWI4NDc4NDgwYjY1Y2JhMWFkZTExZGRfMy00LTEtMS03NTE0MA_64bb30b5-70bf-48f6-8058-e610fc0db8a5">935.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue from Anti-CD20 Therapeutic Programs</span></div><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RleHRyZWdpb246YTIyMjQwMjQ3OTQ4NGY5ZTg3OTE5ZmYwNTMwYWFmYjhfMjA2NA_03aa0596-4092-4d7f-933e-a37640c1ef63" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from anti-CD20 therapeutic programs is summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddf807d85db941d0a2233de6ebb901c4_D20220101-20220331" decimals="-5" name="biib:ShareOfCoPromotionProfits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjRjOGM3NDdhNmE4MjQ2ODRiZGJkYTAwYmEzMzUyNWFiL3RhYmxlcmFuZ2U6NGM4Yzc0N2E2YTgyNDY4NGJkYmRhMDBiYTMzNTI1YWJfMi0yLTEtMS03NTE0MA_7e92ddc4-467f-436d-a266-b729eba89b90">143.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a4a7cbdeb574c34acd8f0fd4451328e_D20210101-20210331" decimals="-5" name="biib:ShareOfCoPromotionProfits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjRjOGM3NDdhNmE4MjQ2ODRiZGJkYTAwYmEzMzUyNWFiL3RhYmxlcmFuZ2U6NGM4Yzc0N2E2YTgyNDY4NGJkYmRhMDBiYTMzNTI1YWJfMi00LTEtMS03NTE0MA_d04ebf87-7bdd-48d0-9e5c-ec4542038df5">174.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OCREVUS and other revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddf807d85db941d0a2233de6ebb901c4_D20220101-20220331" decimals="-5" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjRjOGM3NDdhNmE4MjQ2ODRiZGJkYTAwYmEzMzUyNWFiL3RhYmxlcmFuZ2U6NGM4Yzc0N2E2YTgyNDY4NGJkYmRhMDBiYTMzNTI1YWJfMy0yLTEtMS03NTE0MA_f94cada1-a071-4dcf-bf2e-ea8d0cd4936b">256.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a4a7cbdeb574c34acd8f0fd4451328e_D20210101-20210331" decimals="-5" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjRjOGM3NDdhNmE4MjQ2ODRiZGJkYTAwYmEzMzUyNWFiL3RhYmxlcmFuZ2U6NGM4Yzc0N2E2YTgyNDY4NGJkYmRhMDBiYTMzNTI1YWJfMy00LTEtMS03NTE0MA_3300019c-aefd-4b5c-9221-44687b5e043d">214.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5e84907dfd54cd09fdf7dc476b17545_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjRjOGM3NDdhNmE4MjQ2ODRiZGJkYTAwYmEzMzUyNWFiL3RhYmxlcmFuZ2U6NGM4Yzc0N2E2YTgyNDY4NGJkYmRhMDBiYTMzNTI1YWJfNC0yLTEtMS03NTE0MA_a3e3c348-9721-4f10-80b2-bdc63c1368d0">399.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6b11452af4d4ae0bf50278351f22899_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjRjOGM3NDdhNmE4MjQ2ODRiZGJkYTAwYmEzMzUyNWFiL3RhYmxlcmFuZ2U6NGM4Yzc0N2E2YTgyNDY4NGJkYmRhMDBiYTMzNTI1YWJfNC00LTEtMS03NTE0MA_67c2e6e2-3bdc-49e1-8907-3a3fb6c610dc">389.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt;padding-right:2.25pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our consolidated financial statements included in our 2021 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Revenue</span></div><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="biib:OtherrevenuesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RleHRyZWdpb246YTIyMjQwMjQ3OTQ4NGY5ZTg3OTE5ZmYwNTMwYWFmYjhfMjA2MQ_9dad7099-0ba0-4a60-be5f-2294df024e7a" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from collaborative and other relationships:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue earned under our technical development agreement, manufacturing services agreements and royalty revenue on biosimilar products with Samsung Bioepis</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35f562ab50824cc2bc7a3c789fec1b1c_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmJjYzA4ZmEwMzA2YzQ5Yjc5NzEzYjNlYjljMDY4MmY0L3RhYmxlcmFuZ2U6YmNjMDhmYTAzMDZjNDliNzk3MTNiM2ViOWMwNjgyZjRfMy0yLTEtMS03NTE0MA_7fa16384-6e14-4414-8e15-37a6bfa463be">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9173e074bac74af1b3732b3d6a272a0e_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmJjYzA4ZmEwMzA2YzQ5Yjc5NzEzYjNlYjljMDY4MmY0L3RhYmxlcmFuZ2U6YmNjMDhmYTAzMDZjNDliNzk3MTNiM2ViOWMwNjgyZjRfMy00LTEtMS03NTE0MA_7e0f02fa-8652-4395-8de9-e0123a2c7745">3.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other royalty and corporate revenue:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6985304f226c46fca0470a43faf8887c_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmJjYzA4ZmEwMzA2YzQ5Yjc5NzEzYjNlYjljMDY4MmY0L3RhYmxlcmFuZ2U6YmNjMDhmYTAzMDZjNDliNzk3MTNiM2ViOWMwNjgyZjRfNi0yLTEtMS03NTE0MA_6c2eb642-0d21-4731-a6a2-bb1eafbf87dc">10.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a84089481564844bfa9bc6d09008d08_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmJjYzA4ZmEwMzA2YzQ5Yjc5NzEzYjNlYjljMDY4MmY0L3RhYmxlcmFuZ2U6YmNjMDhmYTAzMDZjNDliNzk3MTNiM2ViOWMwNjgyZjRfNi00LTEtMS03NTE0MA_a673b9f9-f433-4829-aa26-e3d4cc990b87">6.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fc4bd215e8a4eda8144b5304af45e97_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmJjYzA4ZmEwMzA2YzQ5Yjc5NzEzYjNlYjljMDY4MmY0L3RhYmxlcmFuZ2U6YmNjMDhmYTAzMDZjNDliNzk3MTNiM2ViOWMwNjgyZjRfNy0yLTEtMS03NTE0MA_be0d46cb-a692-4cc0-bb29-1efeaf8054b1">47.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf64235b712a458e82807e9c3b0ae91f_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmJjYzA4ZmEwMzA2YzQ5Yjc5NzEzYjNlYjljMDY4MmY0L3RhYmxlcmFuZ2U6YmNjMDhmYTAzMDZjNDliNzk3MTNiM2ViOWMwNjgyZjRfNy00LTEtMS03NTE0MA_40165e94-3bcc-40ba-9a48-1e46d44466fe">83.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36b52f54c6e84045a18f6f934ed61b63_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmJjYzA4ZmEwMzA2YzQ5Yjc5NzEzYjNlYjljMDY4MmY0L3RhYmxlcmFuZ2U6YmNjMDhmYTAzMDZjNDliNzk3MTNiM2ViOWMwNjgyZjRfOC0yLTEtMS03NTE0MA_d828b7c0-3823-4681-b4b8-93cd14911cec">66.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee301b6f981549919f1dd915c03e2623_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmJjYzA4ZmEwMzA2YzQ5Yjc5NzEzYjNlYjljMDY4MmY0L3RhYmxlcmFuZ2U6YmNjMDhmYTAzMDZjNDliNzk3MTNiM2ViOWMwNjgyZjRfOC00LTEtMS03NTE0MA_a6bccb6d-a9c1-4977-8882-6409c74a70fc">93.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive royalties from net sales on products related to patents that we have out-licensed and we record other corporate revenue primarily from amounts earned under contract manufacturing agreements.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="ie9658fba2baf4e3799b1175f69eaed46_58"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;INVENTORY </span></div><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81OC9mcmFnOjlhNDVlZTBiNzM1NjRhN2NhM2NiN2U3OTQ3YWQ0YmE5L3RleHRyZWdpb246OWE0NWVlMGI3MzU2NGE3Y2EzY2I3ZTc5NDdhZDRiYTlfNzA_18868e42-e646-49fd-bd0d-9968f57780e5" escape="true"><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81OC9mcmFnOjlhNDVlZTBiNzM1NjRhN2NhM2NiN2U3OTQ3YWQ0YmE5L3RleHRyZWdpb246OWE0NWVlMGI3MzU2NGE3Y2EzY2I3ZTc5NDdhZDRiYTlfNzk_95b265ed-99c1-4ba3-ae96-02396d0d5a0a" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81OC9mcmFnOjlhNDVlZTBiNzM1NjRhN2NhM2NiN2U3OTQ3YWQ0YmE5L3RhYmxlOjIyYjc2Njg1MGY2ZTQ3Y2FiODY4MDIyZDdiOTMxNGZjL3RhYmxlcmFuZ2U6MjJiNzY2ODUwZjZlNDdjYWI4NjgwMjJkN2I5MzE0ZmNfMS0yLTEtMS03NTE0MA_5596ef5b-1073-43b9-8db8-b998b492063c">354.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81OC9mcmFnOjlhNDVlZTBiNzM1NjRhN2NhM2NiN2U3OTQ3YWQ0YmE5L3RhYmxlOjIyYjc2Njg1MGY2ZTQ3Y2FiODY4MDIyZDdiOTMxNGZjL3RhYmxlcmFuZ2U6MjJiNzY2ODUwZjZlNDdjYWI4NjgwMjJkN2I5MzE0ZmNfMS00LTEtMS03NTE0MA_c199d70e-78fe-4695-9775-72048555e6c4">349.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81OC9mcmFnOjlhNDVlZTBiNzM1NjRhN2NhM2NiN2U3OTQ3YWQ0YmE5L3RhYmxlOjIyYjc2Njg1MGY2ZTQ3Y2FiODY4MDIyZDdiOTMxNGZjL3RhYmxlcmFuZ2U6MjJiNzY2ODUwZjZlNDdjYWI4NjgwMjJkN2I5MzE0ZmNfMi0yLTEtMS03NTE0MA_a8b08220-4ebe-4f7b-ab9a-4d62e5c19ef1">655.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81OC9mcmFnOjlhNDVlZTBiNzM1NjRhN2NhM2NiN2U3OTQ3YWQ0YmE5L3RhYmxlOjIyYjc2Njg1MGY2ZTQ3Y2FiODY4MDIyZDdiOTMxNGZjL3RhYmxlcmFuZ2U6MjJiNzY2ODUwZjZlNDdjYWI4NjgwMjJkN2I5MzE0ZmNfMi00LTEtMS03NTE0MA_951f4969-4778-46c8-a245-30cfcc43a9a2">814.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81OC9mcmFnOjlhNDVlZTBiNzM1NjRhN2NhM2NiN2U3OTQ3YWQ0YmE5L3RhYmxlOjIyYjc2Njg1MGY2ZTQ3Y2FiODY4MDIyZDdiOTMxNGZjL3RhYmxlcmFuZ2U6MjJiNzY2ODUwZjZlNDdjYWI4NjgwMjJkN2I5MzE0ZmNfMy0yLTEtMS03NTE0MA_a6e92b14-3ca5-4d06-8d19-c61ce81b6b01">205.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81OC9mcmFnOjlhNDVlZTBiNzM1NjRhN2NhM2NiN2U3OTQ3YWQ0YmE5L3RhYmxlOjIyYjc2Njg1MGY2ZTQ3Y2FiODY4MDIyZDdiOTMxNGZjL3RhYmxlcmFuZ2U6MjJiNzY2ODUwZjZlNDdjYWI4NjgwMjJkN2I5MzE0ZmNfMy00LTEtMS03NTE0MA_c94c797b-a669-421c-a8d1-39503af3db83">187.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="biib:Inventorynetcurrentandnoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81OC9mcmFnOjlhNDVlZTBiNzM1NjRhN2NhM2NiN2U3OTQ3YWQ0YmE5L3RhYmxlOjIyYjc2Njg1MGY2ZTQ3Y2FiODY4MDIyZDdiOTMxNGZjL3RhYmxlcmFuZ2U6MjJiNzY2ODUwZjZlNDdjYWI4NjgwMjJkN2I5MzE0ZmNfNC0yLTEtMS03NTE0MA_8cdf75d1-04a2-445d-ad2d-9825e117cc66">1,215.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="biib:Inventorynetcurrentandnoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81OC9mcmFnOjlhNDVlZTBiNzM1NjRhN2NhM2NiN2U3OTQ3YWQ0YmE5L3RhYmxlOjIyYjc2Njg1MGY2ZTQ3Y2FiODY4MDIyZDdiOTMxNGZjL3RhYmxlcmFuZ2U6MjJiNzY2ODUwZjZlNDdjYWI4NjgwMjJkN2I5MzE0ZmNfNC00LTEtMS03NTE0MA_a75d198e-3df7-4935-9b55-80a8667ea4aa">1,351.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2022 the Centers for Medicare and Medicaid Services (CMS) released the final National Coverage Decision (NCD) for the class of anti-amyloid treatments in Alzheimer&#8217;s disease, including ADUHELM. The final NCD  confirmed coverage with evidence development, in which patients with Medicare can only access treatment if they are part of an approved clinical trial. We expect that this decision will reduce future demand for ADUHELM to a minimal level. During the first quarter of 2022 we wrote-off approximately $<ix:nonFraction unitRef="usd" contextRef="i722a1d8416ce4b6b9e7ebbb4433afb51_D20220101-20220331" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81OC9mcmFnOjlhNDVlZTBiNzM1NjRhN2NhM2NiN2U3OTQ3YWQ0YmE5L3RleHRyZWdpb246OWE0NWVlMGI3MzU2NGE3Y2EzY2I3ZTc5NDdhZDRiYTlfMTA5OTUxMTYzMDE4OQ_df37636d-e606-404a-a319-039e00e327fe">275.0</ix:nonFraction>&#160;million of inventory related to ADUHELM, as a result of this CMS decision, which was recognized in cost of sales within our condensed consolidated statements of income. We have recognized approximately $<ix:nonFraction unitRef="usd" contextRef="i9a8520df9645495bbf150a3c973688bb_D20220101-20220331" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81OC9mcmFnOjlhNDVlZTBiNzM1NjRhN2NhM2NiN2U3OTQ3YWQ0YmE5L3RleHRyZWdpb246OWE0NWVlMGI3MzU2NGE3Y2EzY2I3ZTc5NDdhZDRiYTlfMTA5OTUxMTYzNDM3MA_4a33a482-a18a-4a2b-b09d-dd46551efe17">136.0</ix:nonFraction>&#160;million related to Eisai's <ix:nonFraction unitRef="number" contextRef="i8a12e5f049a6452f9e97a9998e1ce4b6_D20220101-20220331" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81OC9mcmFnOjlhNDVlZTBiNzM1NjRhN2NhM2NiN2U3OTQ3YWQ0YmE5L3RleHRyZWdpb246OWE0NWVlMGI3MzU2NGE3Y2EzY2I3ZTc5NDdhZDRiYTlfMTA5OTUxMTYzNDM0NA_05cf3daf-ff6a-4232-a16a-6ff1e749730b">45.0</ix:nonFraction>% share of these charges in collaboration profit (loss) sharing within our condensed consolidated statements of income. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the fourth quarter of 2021 we wrote-off approximately $<ix:nonFraction unitRef="usd" contextRef="i20495f1f0a824d538aee78626f0d54b7_D20211001-20211231" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81OC9mcmFnOjlhNDVlZTBiNzM1NjRhN2NhM2NiN2U3OTQ3YWQ0YmE5L3RleHRyZWdpb246OWE0NWVlMGI3MzU2NGE3Y2EzY2I3ZTc5NDdhZDRiYTlfMTA5OTUxMTYzNTA5OQ_f50ad61d-ea33-443a-943a-4a23dd0581c6">120.0</ix:nonFraction>&#160;million of inventory in excess of forecasted demand related to ADUHELM, which was recognized in cost of sales within our condensed consolidated statements of income. We have recognized approximately $<ix:nonFraction unitRef="usd" contextRef="i2a241cb8f282478689ee6d7bba151c98_D20211001-20211231" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81OC9mcmFnOjlhNDVlZTBiNzM1NjRhN2NhM2NiN2U3OTQ3YWQ0YmE5L3RleHRyZWdpb246OWE0NWVlMGI3MzU2NGE3Y2EzY2I3ZTc5NDdhZDRiYTlfNTQ5NzU1ODE0NjAzMw_8df9b84f-320e-40c4-b576-0b3eaf6cf257">59.0</ix:nonFraction>&#160;million related to Eisai's <ix:nonFraction unitRef="number" contextRef="i8a12e5f049a6452f9e97a9998e1ce4b6_D20220101-20220331" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81OC9mcmFnOjlhNDVlZTBiNzM1NjRhN2NhM2NiN2U3OTQ3YWQ0YmE5L3RleHRyZWdpb246OWE0NWVlMGI3MzU2NGE3Y2EzY2I3ZTc5NDdhZDRiYTlfNTQ5NzU1ODE0NjAyNg_05cf3daf-ff6a-4232-a16a-6ff1e749730b">45.0</ix:nonFraction>% share of these charges in collaboration profit (loss) sharing within our condensed consolidated statements of income during the fourth quarter of 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of March 31, 2022, our total ADUHELM inventory was de minimis. As of December 31, 2021, we had approximately $<ix:nonFraction unitRef="usd" contextRef="idee35b744e58496a91eb6fe7628d49eb_I20211231" decimals="-5" name="biib:InventoryNetCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81OC9mcmFnOjlhNDVlZTBiNzM1NjRhN2NhM2NiN2U3OTQ3YWQ0YmE5L3RleHRyZWdpb246OWE0NWVlMGI3MzU2NGE3Y2EzY2I3ZTc5NDdhZDRiYTlfMTA5OTUxMTYzMTY4Nw_d94f5cef-b1ca-40da-a516-0e01a02f8de0">223.0</ix:nonFraction>&#160;million of ADUHELM inventory. For additional information please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 16, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, to these condensed consolidated financial statements.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="ie9658fba2baf4e3799b1175f69eaed46_61"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;INTANGIBLE ASSETS AND GOODWILL </span></div><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RleHRyZWdpb246ODY4NzYyZjk4NDAwNDdhMGI0MzEyMTg3MzUwNTg1NTZfNDY3Mw_a1572208-07cb-44ac-ac01-65c306255965" continuedAt="i0f116fed29764d5b878f8c0df75728ed" escape="true"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="biib:IntangibleAssetsExcludingGoodwillTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RleHRyZWdpb246ODY4NzYyZjk4NDAwNDdhMGI0MzEyMTg3MzUwNTg1NTZfNDY0MA_75a96891-957b-4a63-82e1-9d01b667334b" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.257%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.972%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.972%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.669%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completed technology</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4-28 years</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6011e1fbb7ec4eafa87167881be73a90_I20220331" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOmMyNWFjMDg3ZTEzNTRkOWE4ZjkxNjIzZTYyMjM3MTA5L3RhYmxlcmFuZ2U6YzI1YWMwODdlMTM1NGQ5YThmOTE2MjNlNjIyMzcxMDlfMi00LTEtMS03NTE0MA_8880b5a7-781d-45cf-96da-c8c02843d5f0">7,413.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6011e1fbb7ec4eafa87167881be73a90_I20220331" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOmMyNWFjMDg3ZTEzNTRkOWE4ZjkxNjIzZTYyMjM3MTA5L3RhYmxlcmFuZ2U6YzI1YWMwODdlMTM1NGQ5YThmOTE2MjNlNjIyMzcxMDlfMi02LTEtMS03NTE0MA_68ba5d2d-074d-4c6e-b7b1-a16c28ad063c">5,455.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6011e1fbb7ec4eafa87167881be73a90_I20220331" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOmMyNWFjMDg3ZTEzNTRkOWE4ZjkxNjIzZTYyMjM3MTA5L3RhYmxlcmFuZ2U6YzI1YWMwODdlMTM1NGQ5YThmOTE2MjNlNjIyMzcxMDlfMi04LTEtMS03NTE0MA_e75c9cd1-2ffb-4b27-baa1-2eb79fb438c3">1,957.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96046c4bfde14c4a9405390c5dd1681e_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOmMyNWFjMDg3ZTEzNTRkOWE4ZjkxNjIzZTYyMjM3MTA5L3RhYmxlcmFuZ2U6YzI1YWMwODdlMTM1NGQ5YThmOTE2MjNlNjIyMzcxMDlfMi0xMC0xLTEtNzUxNDA_dc7888e1-e75f-4915-88cc-9df9f00d7533">7,413.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96046c4bfde14c4a9405390c5dd1681e_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOmMyNWFjMDg3ZTEzNTRkOWE4ZjkxNjIzZTYyMjM3MTA5L3RhYmxlcmFuZ2U6YzI1YWMwODdlMTM1NGQ5YThmOTE2MjNlNjIyMzcxMDlfMi0xMi0xLTEtNzUxNDA_74ea66ad-fc22-4f4a-bd44-a968f96af08a">5,388.5</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96046c4bfde14c4a9405390c5dd1681e_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOmMyNWFjMDg3ZTEzNTRkOWE4ZjkxNjIzZTYyMjM3MTA5L3RhYmxlcmFuZ2U6YzI1YWMwODdlMTM1NGQ5YThmOTE2MjNlNjIyMzcxMDlfMi0xNC0xLTEtNzUxNDA_65661db9-9c76-4b38-869b-f7f673e564af">2,024.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite until commercialization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c9e43d132c24282b7716b0c5a1f9cfc_I20220331" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOmMyNWFjMDg3ZTEzNTRkOWE4ZjkxNjIzZTYyMjM3MTA5L3RhYmxlcmFuZ2U6YzI1YWMwODdlMTM1NGQ5YThmOTE2MjNlNjIyMzcxMDlfMy00LTEtMS03NTE0MA_2e10aa90-a529-4e2e-a1f3-636b46cf8403">129.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c9e43d132c24282b7716b0c5a1f9cfc_I20220331" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOmMyNWFjMDg3ZTEzNTRkOWE4ZjkxNjIzZTYyMjM3MTA5L3RhYmxlcmFuZ2U6YzI1YWMwODdlMTM1NGQ5YThmOTE2MjNlNjIyMzcxMDlfMy02LTEtMS03NTE0MA_05fda5bf-032d-4415-a569-1499172fcee8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c9e43d132c24282b7716b0c5a1f9cfc_I20220331" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOmMyNWFjMDg3ZTEzNTRkOWE4ZjkxNjIzZTYyMjM3MTA5L3RhYmxlcmFuZ2U6YzI1YWMwODdlMTM1NGQ5YThmOTE2MjNlNjIyMzcxMDlfMy04LTEtMS03NTE0MA_fe6389d8-5d99-4cf4-ae0f-5af94a3ba3f0">129.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fb812dd0c044aa5a8506c4bc6e9c90a_I20211231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOmMyNWFjMDg3ZTEzNTRkOWE4ZjkxNjIzZTYyMjM3MTA5L3RhYmxlcmFuZ2U6YzI1YWMwODdlMTM1NGQ5YThmOTE2MjNlNjIyMzcxMDlfMy0xMC0xLTEtNzUxNDA_219f8242-199c-4e61-8d2a-2336b13ae7bd">132.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fb812dd0c044aa5a8506c4bc6e9c90a_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOmMyNWFjMDg3ZTEzNTRkOWE4ZjkxNjIzZTYyMjM3MTA5L3RhYmxlcmFuZ2U6YzI1YWMwODdlMTM1NGQ5YThmOTE2MjNlNjIyMzcxMDlfMy0xMi0xLTEtNzUxNDA_67b060bb-36aa-44b7-abd9-e5306bf97729">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fb812dd0c044aa5a8506c4bc6e9c90a_I20211231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOmMyNWFjMDg3ZTEzNTRkOWE4ZjkxNjIzZTYyMjM3MTA5L3RhYmxlcmFuZ2U6YzI1YWMwODdlMTM1NGQ5YThmOTE2MjNlNjIyMzcxMDlfMy0xNC0xLTEtNzUxNDA_9c2fd82e-9735-4a75-b8c8-8f070c2cf861">132.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks&#160;and trade names</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5c719f9e5e4e2d9b3c6b1da3536e36_I20220331" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOmMyNWFjMDg3ZTEzNTRkOWE4ZjkxNjIzZTYyMjM3MTA5L3RhYmxlcmFuZ2U6YzI1YWMwODdlMTM1NGQ5YThmOTE2MjNlNjIyMzcxMDlfNC00LTEtMS03NTE0MA_8c9cf1aa-0b12-48cf-90e4-484ae2dba747">64.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5c719f9e5e4e2d9b3c6b1da3536e36_I20220331" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOmMyNWFjMDg3ZTEzNTRkOWE4ZjkxNjIzZTYyMjM3MTA5L3RhYmxlcmFuZ2U6YzI1YWMwODdlMTM1NGQ5YThmOTE2MjNlNjIyMzcxMDlfNC02LTEtMS03NTE0MA_073ac49e-4b5c-48e0-8672-a19c59ae1bde">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5c719f9e5e4e2d9b3c6b1da3536e36_I20220331" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOmMyNWFjMDg3ZTEzNTRkOWE4ZjkxNjIzZTYyMjM3MTA5L3RhYmxlcmFuZ2U6YzI1YWMwODdlMTM1NGQ5YThmOTE2MjNlNjIyMzcxMDlfNC04LTEtMS03NTE0MA_6fee93e0-4c8c-41d0-874d-628c77c14223">64.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c35d264b82c493ba58144b8a17842a9_I20211231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOmMyNWFjMDg3ZTEzNTRkOWE4ZjkxNjIzZTYyMjM3MTA5L3RhYmxlcmFuZ2U6YzI1YWMwODdlMTM1NGQ5YThmOTE2MjNlNjIyMzcxMDlfNC0xMC0xLTEtNzUxNDA_f81a6e3a-3d64-4aec-9c84-60c1698e90a6">64.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c35d264b82c493ba58144b8a17842a9_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOmMyNWFjMDg3ZTEzNTRkOWE4ZjkxNjIzZTYyMjM3MTA5L3RhYmxlcmFuZ2U6YzI1YWMwODdlMTM1NGQ5YThmOTE2MjNlNjIyMzcxMDlfNC0xMi0xLTEtNzUxNDA_1904ef61-fe3d-478d-9c6b-5849a1e50be2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c35d264b82c493ba58144b8a17842a9_I20211231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOmMyNWFjMDg3ZTEzNTRkOWE4ZjkxNjIzZTYyMjM3MTA5L3RhYmxlcmFuZ2U6YzI1YWMwODdlMTM1NGQ5YThmOTE2MjNlNjIyMzcxMDlfNC0xNC0xLTEtNzUxNDA_2c8e56dc-f084-4165-8a19-7cb2e5873e86">64.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOmMyNWFjMDg3ZTEzNTRkOWE4ZjkxNjIzZTYyMjM3MTA5L3RhYmxlcmFuZ2U6YzI1YWMwODdlMTM1NGQ5YThmOTE2MjNlNjIyMzcxMDlfNS00LTEtMS03NTE0MA_bf3668be-8580-44ef-b2cf-19496e7f7682">7,606.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOmMyNWFjMDg3ZTEzNTRkOWE4ZjkxNjIzZTYyMjM3MTA5L3RhYmxlcmFuZ2U6YzI1YWMwODdlMTM1NGQ5YThmOTE2MjNlNjIyMzcxMDlfNS02LTEtMS03NTE0MA_1e2a8abf-bbd4-49a6-bd8c-20ea7a7e39ed">5,455.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOmMyNWFjMDg3ZTEzNTRkOWE4ZjkxNjIzZTYyMjM3MTA5L3RhYmxlcmFuZ2U6YzI1YWMwODdlMTM1NGQ5YThmOTE2MjNlNjIyMzcxMDlfNS04LTEtMS03NTE0MA_d8218f1a-36b0-4272-8853-870411b260fb">2,150.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOmMyNWFjMDg3ZTEzNTRkOWE4ZjkxNjIzZTYyMjM3MTA5L3RhYmxlcmFuZ2U6YzI1YWMwODdlMTM1NGQ5YThmOTE2MjNlNjIyMzcxMDlfNS0xMC0xLTEtNzUxNDA_deff1f95-637c-443d-9db2-97edea8723eb">7,609.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOmMyNWFjMDg3ZTEzNTRkOWE4ZjkxNjIzZTYyMjM3MTA5L3RhYmxlcmFuZ2U6YzI1YWMwODdlMTM1NGQ5YThmOTE2MjNlNjIyMzcxMDlfNS0xMi0xLTEtNzUxNDA_edb69a54-d0f4-4872-9b66-7c2ecf6f11e2">5,388.5</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOmMyNWFjMDg3ZTEzNTRkOWE4ZjkxNjIzZTYyMjM3MTA5L3RhYmxlcmFuZ2U6YzI1YWMwODdlMTM1NGQ5YThmOTE2MjNlNjIyMzcxMDlfNS0xNC0xLTEtNzUxNDA_ad31bd98-dc2a-4080-ad2e-57de755fe2d5">2,221.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization and Impairments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, amortization and impairment of acquired intangible assets totaled $<ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RleHRyZWdpb246ODY4NzYyZjk4NDAwNDdhMGI0MzEyMTg3MzUwNTg1NTZfMjE5OTAyMzI2MTQzNA_35824f57-87e7-4005-a133-6ebc714e8bff">66.9</ix:nonFraction> million, compared to $<ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RleHRyZWdpb246ODY4NzYyZjk4NDAwNDdhMGI0MzEyMTg3MzUwNTg1NTZfMjE5OTAyMzI2MTQ2Ng_8514b729-4696-4885-a867-5953ecef18ed">98.1</ix:nonFraction> million in the prior year comparative period. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended March 31, 2022, we had </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">no</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> impairment charges.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, amortization and impairment of acquired intangible assets reflects the impact of a $<ix:nonFraction unitRef="usd" contextRef="i46b4be49d678422682879c3bf61b0688_D20220101-20220331" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RleHRyZWdpb246ODY4NzYyZjk4NDAwNDdhMGI0MzEyMTg3MzUwNTg1NTZfODcw_53e19f77-e9e9-4758-a505-0cb61c6736bc">44.3</ix:nonFraction>&#160;million impairment charge related to vixotrigine (BIIB074) for the potential treatment of trigeminal neuralgia (TGN). </span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Completed Technology</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Completed technology primarily relates to our acquisition of all remaining rights to TYSABRI as well as other amounts related to our other marketed products and programs acquired through business combinations.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IPR&amp;D Related to Business Combinations</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In-process research and development (IPR&amp;D) represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. Included in IPR&amp;D balances are adjustments related to foreign currency exchange rate fluctuations. We review amounts capitalized as acquired IPR&amp;D for impairment annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable. The carrying value associated with our IPR&amp;D assets as of March 31, 2022, relates to the IPR&amp;D programs we acquired in connection with our acquisition of Convergence Pharmaceuticals Holdings Ltd. (Convergence). </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vixotrigine</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the periods since we acquired vixotrigine, there have been numerous delays in the initiation of Phase 3 studies for the potential treatment of TGN and for the potential treatment of diabetic painful neuropathy (DPN), another form of neuropathic pain. We have engaged with the FDA regarding the design of the Phase 3 studies of vixotrigine for the potential treatment of TGN and DPN and are now performing an additional clinical trial of vixotrigine, which is expected to be completed by the end of 2022.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance of this additional clinical trial delayed the initiation of the Phase 3 studies of vixotrigine for the potential treatment of TGN, and, as a result, we recognized an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i46b4be49d678422682879c3bf61b0688_D20220101-20220331" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RleHRyZWdpb246ODY4NzYyZjk4NDAwNDdhMGI0MzEyMTg3MzUwNTg1NTZfMjgyMQ_53e19f77-e9e9-4758-a505-0cb61c6736bc">44.3</ix:nonFraction>&#160;million related to vixotrigine for the potential treatment of TGN during the fi</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rst quarter of 2021. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, the carrying value associated with the remaining IPR&amp;D asset for DPN </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was $<ix:nonFraction unitRef="usd" contextRef="i6c345c953cb94d34804e7d2a988c33be_I20220331" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RleHRyZWdpb246ODY4NzYyZjk4NDAwNDdhMGI0MzEyMTg3MzUwNTg1NTZfMzAxMQ_c5910725-89d2-41a5-8800-9ba9768bd866">129.1</ix:nonFraction>&#160;million a</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd the fair value of this asset was not significantly in excess of its carrying value. Upon the completion of the additional clinical trial we will reevaluate the carrying value of the program.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i0f116fed29764d5b878f8c0df75728ed" continuedAt="ib3530abff7f1436db1a76444b2cc749f"><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estimated Future Amortization of Intangible Assets</span></div><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RleHRyZWdpb246ODY4NzYyZjk4NDAwNDdhMGI0MzEyMTg3MzUwNTg1NTZfNDYyOQ_48e3bb80-f5e6-47ac-87d6-a6a3e9e46d81" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022 (remaining nine months)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOjkyMTA1OWExNWU5MjRkMjU4ZTRkMWZiMWJhZmZlMDhiL3RhYmxlcmFuZ2U6OTIxMDU5YTE1ZTkyNGQyNThlNGQxZmIxYmFmZmUwOGJfMS0yLTEtMS03NTE0MA_018dff18-1e2e-4254-93c4-c054001b5654">200.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOjkyMTA1OWExNWU5MjRkMjU4ZTRkMWZiMWJhZmZlMDhiL3RhYmxlcmFuZ2U6OTIxMDU5YTE1ZTkyNGQyNThlNGQxZmIxYmFmZmUwOGJfMi0yLTEtMS03NTE0MA_b0c728bf-4766-4ea7-a734-122aa515923b">210.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOjkyMTA1OWExNWU5MjRkMjU4ZTRkMWZiMWJhZmZlMDhiL3RhYmxlcmFuZ2U6OTIxMDU5YTE1ZTkyNGQyNThlNGQxZmIxYmFmZmUwOGJfMy0yLTEtMS03NTE0MA_d3c31d2a-3b19-4598-9e56-a30080bac7c9">195.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOjkyMTA1OWExNWU5MjRkMjU4ZTRkMWZiMWJhZmZlMDhiL3RhYmxlcmFuZ2U6OTIxMDU5YTE1ZTkyNGQyNThlNGQxZmIxYmFmZmUwOGJfNC0yLTEtMS03NTE0MA_5ad7c384-3f82-4bff-b16c-afd48ea6013e">195.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOjkyMTA1OWExNWU5MjRkMjU4ZTRkMWZiMWJhZmZlMDhiL3RhYmxlcmFuZ2U6OTIxMDU5YTE1ZTkyNGQyNThlNGQxZmIxYmFmZmUwOGJfNS0yLTEtMS03NTE0MA_c84702fd-1ea9-4605-87f8-b735bf0106ff">180.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOjkyMTA1OWExNWU5MjRkMjU4ZTRkMWZiMWJhZmZlMDhiL3RhYmxlcmFuZ2U6OTIxMDU5YTE1ZTkyNGQyNThlNGQxZmIxYmFmZmUwOGJfNi0yLTEtMS03NTE0MA_1276d175-bf66-4e08-a7a5-a47edc45d813">165.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RleHRyZWdpb246ODY4NzYyZjk4NDAwNDdhMGI0MzEyMTg3MzUwNTg1NTZfNDY1Ng_e212d4e0-1e55-464f-9678-27e0b003e635" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOjUzZDA1YjZlNGFiNjRmZmNiMjg1ZjRkYjQyMjJiOWNhL3RhYmxlcmFuZ2U6NTNkMDViNmU0YWI2NGZmY2IyODVmNGRiNDIyMmI5Y2FfMS0yLTEtMS03NTE0MA_54f46cd6-dfd4-409b-a3a4-43343e84b85f">5,761.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOjUzZDA1YjZlNGFiNjRmZmNiMjg1ZjRkYjQyMjJiOWNhL3RhYmxlcmFuZ2U6NTNkMDViNmU0YWI2NGZmY2IyODVmNGRiNDIyMmI5Y2FfMy0yLTEtMS03NTE0MA_db80dd2e-de28-4796-b3fd-e28286ea6646">3.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOjUzZDA1YjZlNGFiNjRmZmNiMjg1ZjRkYjQyMjJiOWNhL3RhYmxlcmFuZ2U6NTNkMDViNmU0YWI2NGZmY2IyODVmNGRiNDIyMmI5Y2FfNC0yLTEtMS03NTE0MA_0aa6514d-b5ad-4dba-a7a5-27e8e35f0673">5,758.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;text-indent:24.75pt"><ix:continuation id="ib3530abff7f1436db1a76444b2cc749f" continuedAt="i53cdb950812f429f94e4baf0c3ded567"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, we had</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="INF" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RleHRyZWdpb246ODY4NzYyZjk4NDAwNDdhMGI0MzEyMTg3MzUwNTg1NTZfNDQ5MQ_6f05ec49-3a43-4820-8b2f-bc682623c43a">no</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ac</span></ix:continuation><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i53cdb950812f429f94e4baf0c3ded567">cumulated impairment losses related to goodwill. Other includes adjustments related to foreign currency exchange rate fluctuations.</ix:continuation> </span></div><div id="ie9658fba2baf4e3799b1175f69eaed46_67"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;FAIR VALUE MEASUREMENTS </span></div><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RleHRyZWdpb246ZmY0MDI4MzgxMGFkNDY5OWFjMzU4M2JmY2Y4NzkwMTNfNDg5NQ_a4efc4dc-87e2-46de-9dbe-0619036a8815" continuedAt="i442127d663284930b376240733272cd1" escape="true"><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RleHRyZWdpb246ZmY0MDI4MzgxMGFkNDY5OWFjMzU4M2JmY2Y4NzkwMTNfNDg5Ng_0a42ce77-77af-4cf2-a3a8-f4b72bb01f37" continuedAt="i07853b44408648f085974d9e6f8a921e" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.796%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia69f061a62954ac7af98aa5c677f4971_I20220331" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfMy0yLTEtMS03NTE0MA_43d4b96d-6622-4de8-9771-0eee8b7ae82c">1,283.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64a5ad19dcce4cf8b7c43a569fe0c245_I20220331" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfMy00LTEtMS03NTE0MA_b32bff68-18d3-460b-ac88-62e75d673060">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42f910d9635f4c0480b7fb380b5fe276_I20220331" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfMy02LTEtMS03NTE0MA_7b058479-1b7f-4966-b998-69646150be44">1,283.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3396020533494d35b8c27ddcd8a5252e_I20220331" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfMy04LTEtMS03NTE0MA_f3454b38-b7c1-4572-8837-eb5db0a67599">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb9349b48fb4c629485bfe7b5880e8c_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfNS0yLTEtMS03NTE0MA_6b3d8e5c-f51e-4b47-b1fb-5d99af83a5eb">1,579.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2a85ce0b81243eba23da6278ed1f57e_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfNS00LTEtMS03NTE0MA_e4458948-47a7-4b34-9a09-139045e84889">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e9c1bab79f40279289b0b3dcc2c161_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfNS02LTEtMS03NTE0MA_c451a9c8-dbfb-4fc7-a095-98e7505ba7be">1,579.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec22cc68ef57484183e4ae80b280d372_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfNS04LTEtMS03NTE0MA_2deead9b-de75-4370-8e56-20a5d5492778">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1f4d496ec7641838d1ecec434c28f66_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfNi0yLTEtMS03NTE0MA_6acb22c2-fbcf-42c7-96fb-f97b5bb92f01">1,252.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c661d66c6224d4a81bd51c24ea79d40_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfNi00LTEtMS03NTE0MA_51b068d7-cee6-47ee-a8eb-0e001a0e7821">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac84ce7144dd4bcc82d4253f927d2752_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfNi02LTEtMS03NTE0MA_6615b28b-2f60-44f7-8a68-5145776e912f">1,252.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if398ac5e39c747a6af59aeb27650b335_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfNi04LTEtMS03NTE0MA_592d774f-921f-4cee-90bd-dad27b11b44d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09eff9f500604711ab6a499956c8d5f3_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfNy0yLTEtMS03NTE0MA_98dbbc43-51d3-417e-a957-e692257ed04b">171.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ccde35ecf6c42b486ba8b193205887c_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfNy00LTEtMS03NTE0MA_859e55b0-d113-4511-b515-725be89af23b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i289d8737ebbf49019c8cd089b87cc769_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfNy02LTEtMS03NTE0MA_2de3ad26-6e5a-47b9-9047-31d1f1371f75">171.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f9738b4665048cfa86018d909055f8e_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfNy04LTEtMS03NTE0MA_1726ff4d-4e4a-4a32-89c1-91afd957b5a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia69f061a62954ac7af98aa5c677f4971_I20220331" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfOC0yLTEtMS03NTE0MA_15790787-5faa-414e-b934-b96c8fb40999">860.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64a5ad19dcce4cf8b7c43a569fe0c245_I20220331" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfOC00LTEtMS03NTE0MA_868c9c12-838f-40dd-8bf3-30c9e5596fb0">607.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42f910d9635f4c0480b7fb380b5fe276_I20220331" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfOC02LTEtMS03NTE0MA_ea284378-26ec-4fbf-b6d6-65b82393e638">253.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3396020533494d35b8c27ddcd8a5252e_I20220331" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfOC04LTEtMS03NTE0MA_d8da7e9e-f415-43ef-af1f-30b5b895a5f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia69f061a62954ac7af98aa5c677f4971_I20220331" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfOS0yLTEtMS03NTE0MA_b29fce95-40f1-44d8-8e3a-982339e32ee6">97.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64a5ad19dcce4cf8b7c43a569fe0c245_I20220331" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfOS00LTEtMS03NTE0MA_fe30e444-bae9-4bb9-ba01-a68a9511995e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42f910d9635f4c0480b7fb380b5fe276_I20220331" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfOS02LTEtMS03NTE0MA_38eaac85-ff20-4947-b10a-0fa077f3c96e">97.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3396020533494d35b8c27ddcd8a5252e_I20220331" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfOS04LTEtMS03NTE0MA_01034bb3-0b92-450c-8283-58afdb30ee48">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia69f061a62954ac7af98aa5c677f4971_I20220331" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfMTAtMi0xLTEtNzUxNDA_bffe4ffa-6809-46ec-ac3c-a9bbc769e900">35.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64a5ad19dcce4cf8b7c43a569fe0c245_I20220331" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfMTAtNC0xLTEtNzUxNDA_30dfd5da-df64-4b07-92c1-b6359c8085cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42f910d9635f4c0480b7fb380b5fe276_I20220331" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfMTAtNi0xLTEtNzUxNDA_f1d9a41b-e569-4053-9a22-b7b7c2592899">35.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3396020533494d35b8c27ddcd8a5252e_I20220331" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfMTAtOC0xLTEtNzUxNDA_e9ec2bac-ee87-4e29-a5d0-78cf90eaebd8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia69f061a62954ac7af98aa5c677f4971_I20220331" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfMTEtMi0xLTEtNzUxNDA_e354d4bd-f291-4efb-856e-e480fffff770">5,281.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64a5ad19dcce4cf8b7c43a569fe0c245_I20220331" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfMTEtNC0xLTEtNzUxNDA_c28bae9b-9881-4b36-9564-079b0b5fad37">607.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42f910d9635f4c0480b7fb380b5fe276_I20220331" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfMTEtNi0xLTEtNzUxNDA_7be127fc-578a-47d2-adca-802334779954">4,674.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3396020533494d35b8c27ddcd8a5252e_I20220331" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfMTEtOC0xLTEtNzUxNDA_d0708041-f85d-412e-8866-ca731a811d22">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia69f061a62954ac7af98aa5c677f4971_I20220331" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfMTMtMi0xLTEtNzUxNDA_120b410f-7e11-40cb-bee3-1b80cf33fa99">12.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64a5ad19dcce4cf8b7c43a569fe0c245_I20220331" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfMTMtNC0xLTEtNzUxNDA_55bbf9db-d355-4c04-afe5-8311e82c835c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42f910d9635f4c0480b7fb380b5fe276_I20220331" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfMTMtNi0xLTEtNzUxNDA_cc88cab2-9210-4a82-a6fa-e58c584456dc">12.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3396020533494d35b8c27ddcd8a5252e_I20220331" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfMTMtOC0xLTEtNzUxNDA_603f1807-8019-4453-b2ba-c755fba5f23c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia69f061a62954ac7af98aa5c677f4971_I20220331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfMTQtMi0xLTEtNzUxNDA_2f76279d-86ac-42ac-b10d-f26669c0785f">202.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64a5ad19dcce4cf8b7c43a569fe0c245_I20220331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfMTQtNC0xLTEtNzUxNDA_199e3496-9e1f-4d0e-bb6c-b6ae33492815">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42f910d9635f4c0480b7fb380b5fe276_I20220331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfMTQtNi0xLTEtNzUxNDA_ef56686e-1f87-43be-ab50-0d5894f91de6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3396020533494d35b8c27ddcd8a5252e_I20220331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfMTQtOC0xLTEtNzUxNDA_2e4cf290-1970-4fc4-8077-92d6909aa016">202.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia69f061a62954ac7af98aa5c677f4971_I20220331" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfMTUtMi0xLTEtNzUxNDA_940699e9-2db1-4972-a2c5-d0d13989a6a3">214.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64a5ad19dcce4cf8b7c43a569fe0c245_I20220331" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfMTUtNC0xLTEtNzUxNDA_877584b3-d954-428e-be83-9a12757ca83b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42f910d9635f4c0480b7fb380b5fe276_I20220331" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfMTUtNi0xLTEtNzUxNDA_1d88cd2c-b24b-4db3-ae7d-dbd2f86e534e">12.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3396020533494d35b8c27ddcd8a5252e_I20220331" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfMTUtOC0xLTEtNzUxNDA_37247464-b035-4331-b00f-d69b61b44f7b">202.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i442127d663284930b376240733272cd1" continuedAt="i8dc127ca052949259b124f0855f9a099"><div><ix:continuation id="i07853b44408648f085974d9e6f8a921e"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.796%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i264ccf816a664702a7ba8ff1332adb5a_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfMy0yLTEtMS03NTE0MA_14bd4658-8b41-474c-8548-0d4e2b4758df">1,632.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie241349e66f143e1b0f96548fcc184b5_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfMy00LTEtMS03NTE0MA_ea5deb0d-7065-4a8d-846c-f3b685fa70e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5576a00f6d4d15946a9368e3767e64_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfMy02LTEtMS03NTE0MA_af0bb7c9-16af-4209-9de5-2734e19b9463">1,632.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i421472e2622c437d8bf685a39d6aecc3_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfMy04LTEtMS03NTE0MA_0e0d2b4f-28b2-49bf-87dc-a91f558bac47">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cec5ba41ae343fba33cd31f8de35a45_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfNS0yLTEtMS03NTE0MA_c53078f7-0516-485e-b72c-f60587273ba4">1,108.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied9fbb6e460240998c2c685327f742f9_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfNS00LTEtMS03NTE0MA_3394d51c-e3a2-4b75-82f4-4907ce98b167">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if386e194b1a943d8871f1a74fa3cf259_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfNS02LTEtMS03NTE0MA_dc42fb10-a8d5-4743-86a2-043b2d5c7d9c">1,108.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91224f4cdc6744fbae4bcd98dc85a3a0_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfNS04LTEtMS03NTE0MA_52de75bd-017f-4390-8fdd-5db16be8fc4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id787117c37b84ec99ac24ed6b36b3e3f_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfNi0yLTEtMS03NTE0MA_819d5b11-cff3-4edf-9e63-2aa7152f984b">1,192.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3422e6ed664422993d44483803e8115_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfNi00LTEtMS03NTE0MA_3dfc33e2-8b5c-49c1-a519-1f937a06a20d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a7eda1ce0584e48809dc53d22b2b031_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfNi02LTEtMS03NTE0MA_bbb42c9e-cc50-4196-acb4-cf8a31bfdf49">1,192.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec70156770664cf39f79a786ae051946_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfNi04LTEtMS03NTE0MA_4abd1c40-efeb-4f76-9025-120d25c129fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia81961b9f3eb48868302e49901fb6144_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfNy0yLTEtMS03NTE0MA_ba509dcc-4ae4-443a-b7a9-ed240258bc19">132.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i239a26613bda429395a6a963a2cde2c7_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfNy00LTEtMS03NTE0MA_4b8a5a61-687f-4ab3-bc07-37936ef3d51a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib469728d72fa415a9631ce58a0a2133d_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfNy02LTEtMS03NTE0MA_03137d00-fe02-4269-8c80-172301278c74">132.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99b3022f714c46afa3ad4d95b9e0cc1c_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfNy04LTEtMS03NTE0MA_d4dd2142-548d-4157-badc-dc2c2eb7695f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i264ccf816a664702a7ba8ff1332adb5a_I20211231" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfOC0yLTEtMS03NTE0MA_1b32636f-fb8e-4ad9-8a4b-4f8384403e6a">1,048.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie241349e66f143e1b0f96548fcc184b5_I20211231" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfOC00LTEtMS03NTE0MA_9d25824c-fd9a-4566-afa8-549fbf500eac">181.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5576a00f6d4d15946a9368e3767e64_I20211231" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfOC02LTEtMS03NTE0MA_419e7da8-1449-4dc8-9181-90ad1d681f69">866.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i421472e2622c437d8bf685a39d6aecc3_I20211231" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfOC04LTEtMS03NTE0MA_1c7e8d28-ca88-42a2-bed7-7c0eee3e5161">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i264ccf816a664702a7ba8ff1332adb5a_I20211231" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfOS0yLTEtMS03NTE0MA_4370b6f4-babd-4105-b7b7-e6b520b54ed9">80.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie241349e66f143e1b0f96548fcc184b5_I20211231" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfOS00LTEtMS03NTE0MA_2c76c490-5d05-4f25-9e8d-296ad825ac4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5576a00f6d4d15946a9368e3767e64_I20211231" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfOS02LTEtMS03NTE0MA_923d5297-f22c-4233-abae-53b21dc54933">80.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i421472e2622c437d8bf685a39d6aecc3_I20211231" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfOS04LTEtMS03NTE0MA_93c00767-5dee-4172-9f17-6f3e758bf213">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i264ccf816a664702a7ba8ff1332adb5a_I20211231" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfMTAtMi0xLTEtNzUxNDA_5e9717ac-f8fe-4848-8dcb-686466b41dba">33.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie241349e66f143e1b0f96548fcc184b5_I20211231" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfMTAtNC0xLTEtNzUxNDA_c5fc832f-3219-4e2b-ab2d-39a4cb23ec72">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5576a00f6d4d15946a9368e3767e64_I20211231" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfMTAtNi0xLTEtNzUxNDA_fab91967-57fe-486b-88e8-5eae6406517b">33.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i421472e2622c437d8bf685a39d6aecc3_I20211231" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfMTAtOC0xLTEtNzUxNDA_2b02f1de-be8e-4707-b837-6ff7066bb134">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i264ccf816a664702a7ba8ff1332adb5a_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfMTEtMi0xLTEtNzUxNDA_7363918e-b52e-48d5-937c-69967b517398">5,228.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie241349e66f143e1b0f96548fcc184b5_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfMTEtNC0xLTEtNzUxNDA_6c9282c0-0fea-4e1e-a221-13d9f5994466">181.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5576a00f6d4d15946a9368e3767e64_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfMTEtNi0xLTEtNzUxNDA_d9832cca-b657-4107-bb63-eb0f510f8403">5,046.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i421472e2622c437d8bf685a39d6aecc3_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfMTEtOC0xLTEtNzUxNDA_1d4ad76d-47d0-48e9-90ee-aba5a459cd26">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i264ccf816a664702a7ba8ff1332adb5a_I20211231" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfMTMtMi0xLTEtNzUxNDA_94b9abc8-6a75-4507-a66e-54801c7eeac0">10.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie241349e66f143e1b0f96548fcc184b5_I20211231" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfMTMtNC0xLTEtNzUxNDA_9eeecdff-ccda-4b08-a2ed-04c464c411d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5576a00f6d4d15946a9368e3767e64_I20211231" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfMTMtNi0xLTEtNzUxNDA_4f7a7b15-f0fe-4453-8030-41a0ca4a06fa">10.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i421472e2622c437d8bf685a39d6aecc3_I20211231" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfMTMtOC0xLTEtNzUxNDA_42792936-0a28-43c2-a6e6-39fadd3a53c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i264ccf816a664702a7ba8ff1332adb5a_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfMTQtMi0xLTEtNzUxNDA_d5952c64-02b7-410f-a4f4-5f7257ee911a">209.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie241349e66f143e1b0f96548fcc184b5_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfMTQtNC0xLTEtNzUxNDA_f8497f34-74e2-4e08-ba24-72de26ee9349">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5576a00f6d4d15946a9368e3767e64_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfMTQtNi0xLTEtNzUxNDA_5914ab19-e8a8-4ebc-9a1b-1c3da9464dda">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i421472e2622c437d8bf685a39d6aecc3_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfMTQtOC0xLTEtNzUxNDA_fcf5477c-8384-45f6-897e-a41a74d6d908">209.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i264ccf816a664702a7ba8ff1332adb5a_I20211231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfMTUtMi0xLTEtNzUxNDA_fd45a669-a587-4fdc-a0eb-10f3391d468d">219.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie241349e66f143e1b0f96548fcc184b5_I20211231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfMTUtNC0xLTEtNzUxNDA_58d6a93c-d71e-4b19-b573-73bc9d52f921">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5576a00f6d4d15946a9368e3767e64_I20211231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfMTUtNi0xLTEtNzUxNDA_f6bfff59-4461-4742-be94-45303d93e2b8">10.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i421472e2622c437d8bf685a39d6aecc3_I20211231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfMTUtOC0xLTEtNzUxNDA_c4320e93-e8a2-4b54-99df-48121e10dd5e">209.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been <ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="INF" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RleHRyZWdpb246ZmY0MDI4MzgxMGFkNDY5OWFjMzU4M2JmY2Y4NzkwMTNfMjgy_05c1abea-a748-4fe0-9b1c-805a48dbd6ca"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="INF" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RleHRyZWdpb246ZmY0MDI4MzgxMGFkNDY5OWFjMzU4M2JmY2Y4NzkwMTNfMjgy_ded37167-7d51-4253-a28b-f12abc614620">no</ix:nonFraction></ix:nonFraction> material impairments of our assets measured and carried at fair value as of March 31, 2022 and December 31, 2021. In addition, there have been no changes in valuation techniques as of March 31, 2022 and December 31, 2021. The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities was determined through third-party pricing services. The fair value of Level 2 instruments classified as marketable equity securities represents our investments in the common stock of Sangamo Therapeutics, Inc. (Sangamo) and Sage Therapeutics, Inc. (Sage) and are valued using an option pricing valuation model as the investments are each subject to certain holding period restrictions. The holding period restrictions for our investment in the common stock of Denali Therapeutics Inc. (Denali) and a portion of our Sangamo investment expired during the first quarter of 2022 and the second quarter of 2021, respectively. The fair value of our Denali investment and this portion of our Sangamo investment were Level 1 measurements as of March 31, 2022. For additional information on our investments in Sangamo, Denali and Sage common stock, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7, Financial Instruments,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies - Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2021 Form 10-K. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the significant unobservable inputs in the fair value measurement of our contingent consideration obligations as of March 31, 2022 and December 31, 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:24.266%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.773%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.020%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Input(s)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td rowspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td rowspan="2" style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia69f061a62954ac7af98aa5c677f4971_I20220331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOmM0MjZmMzZkZmQ5MjRkNDlhM2NlMzBmNGIxY2FhYTJlL3RhYmxlcmFuZ2U6YzQyNmYzNmRmZDkyNGQ0OWEzY2UzMGY0YjFjYWFhMmVfMy0yLTEtMS03NTE0MA_2f76279d-86ac-42ac-b10d-f26669c0785f">202.0</ix:nonFraction>&#160;</span></td><td rowspan="2" style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4a551835cbc34cf1af2a3029ace704ab_I20220331" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOmM0MjZmMzZkZmQ5MjRkNDlhM2NlMzBmNGIxY2FhYTJlL3RhYmxlcmFuZ2U6YzQyNmYzNmRmZDkyNGQ0OWEzY2UzMGY0YjFjYWFhMmVfMy04LTEtMS03NTE0MA_92f52db6-585a-4279-b6ea-3ce23e9bee5b">2.89</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2985054f44d640bd846c15c69370c8e1_I20220331" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOmM0MjZmMzZkZmQ5MjRkNDlhM2NlMzBmNGIxY2FhYTJlL3RhYmxlcmFuZ2U6YzQyNmYzNmRmZDkyNGQ0OWEzY2UzMGY0YjFjYWFhMmVfMy0xMC0xLTEtNzUxNDA_e47cad10-4c08-4bbc-8c9b-aecce7651b59">2.89</ix:nonFraction>%</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected timing of achievement of development milestones</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023 to 2027</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Input(s)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td rowspan="2" style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td rowspan="2" style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i264ccf816a664702a7ba8ff1332adb5a_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOmM0MjZmMzZkZmQ5MjRkNDlhM2NlMzBmNGIxY2FhYTJlL3RhYmxlcmFuZ2U6YzQyNmYzNmRmZDkyNGQ0OWEzY2UzMGY0YjFjYWFhMmVfOS0yLTEtMS03NTE0MA_d5952c64-02b7-410f-a4f4-5f7257ee911a">209.1</ix:nonFraction>&#160;</span></td><td rowspan="2" style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i939e4f82661e4da6ab148f59a8ec8270_I20211231" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOmM0MjZmMzZkZmQ5MjRkNDlhM2NlMzBmNGIxY2FhYTJlL3RhYmxlcmFuZ2U6YzQyNmYzNmRmZDkyNGQ0OWEzY2UzMGY0YjFjYWFhMmVfOS04LTEtMS03NTE0MA_e7d7f9c3-0e23-4a3f-b6f6-422e56627f6b">1.30</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i708bc707f83a45a6b58bb6226275def9_I20211231" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOmM0MjZmMzZkZmQ5MjRkNDlhM2NlMzBmNGIxY2FhYTJlL3RhYmxlcmFuZ2U6YzQyNmYzNmRmZDkyNGQ0OWEzY2UzMGY0YjFjYWFhMmVfOS0xMC0xLTEtNzUxNDA_16d0bdf2-c257-4abb-bf35-8d93aca71ce0">1.30</ix:nonFraction>%</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected timing of achievement of development milestones</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023 to 2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i8dc127ca052949259b124f0855f9a099"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average discount rate was calculated based on the relative fair value of our contingent consideration obligations. In addition, we apply various probabilities of technological and regulatory success, ranging from <ix:nonFraction unitRef="number" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="3" name="biib:TechnologicalAndRegulatorySuccessProbability" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RleHRyZWdpb246ZmY0MDI4MzgxMGFkNDY5OWFjMzU4M2JmY2Y4NzkwMTNfMjA5Mg_c2f9371e-4cf5-4e1f-838b-372459ef001c">10.9</ix:nonFraction>% to certain probability as of March 31, 2022, to the valuation models to estimate the fair values of our contingent consideration obligations.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Instruments</span></div><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RleHRyZWdpb246ZmY0MDI4MzgxMGFkNDY5OWFjMzU4M2JmY2Y4NzkwMTNfNDkxNQ_84b73552-db30-4823-b152-de921229e378" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:42.091%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.625% Senior Notes due September 15, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6518b6b1ff547bda3f65b2aff26f52a_I20220331" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfMy0yLTEtMS03NTE0MA_6623b696-de61-431a-9af5-df7a00b77e41">1,008.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6518b6b1ff547bda3f65b2aff26f52a_I20220331" decimals="-5" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfMy00LTEtMS03NTE0MA_2103e848-dbff-43d1-bd6c-aebe4bcfda84">999.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief5ba800372a46ebb499feb08bd01f68_I20211231" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfMy02LTEtMS03NTE0MA_c762e12d-782d-484a-8f90-e30a3bad482b">1,020.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief5ba800372a46ebb499feb08bd01f68_I20211231" decimals="-5" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfMy04LTEtMS03NTE0MA_6cd6831c-8ccb-4630-b7cb-0ec8e13b3c4a">999.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.050% Senior Notes due September 15, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59761a7057b84b83b94391f9934d130e_I20220331" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfNC0yLTEtMS03NTE0MA_09fa1a83-9d4a-49c7-a662-6e9031e169f0">1,797.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59761a7057b84b83b94391f9934d130e_I20220331" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfNC00LTEtMS03NTE0MA_b1800657-fd33-433b-88fe-f744b38a8b58">1,743.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0eb428de5f74817b5197dce23437c27_I20211231" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfNC02LTEtMS03NTE0MA_da26df59-c2e9-4c14-9078-fbee3dfb864c">1,895.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0eb428de5f74817b5197dce23437c27_I20211231" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfNC04LTEtMS03NTE0MA_aac8b47a-9a08-4505-840d-b913158e4358">1,742.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.250% Senior Notes due May 1, 2030</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6dd011d88b4ac782dc7a1775ddccb8_I20220331" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfNS0yLTEtMS03NTE0MA_64d81b1d-98a0-42bb-8d1c-049552f0a055">1,341.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6dd011d88b4ac782dc7a1775ddccb8_I20220331" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfNS00LTEtMS03NTE0MA_0e6bebc5-e4b3-41e7-8d13-e6092ae6c7bc">1,492.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id66b49914ec440e8ade962aeaba44c27_I20211231" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfNS02LTEtMS03NTE0MA_b6161273-e87f-422e-9552-975574e88c42">1,475.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id66b49914ec440e8ade962aeaba44c27_I20211231" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfNS04LTEtMS03NTE0MA_78472c5c-744a-4992-81ed-9c1ca725d019">1,492.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.200% Senior Notes due September 15, 2045</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53483a1cc9e941e09201232721818ef2_I20220331" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfNi0yLTEtMS03NTE0MA_8c7b34b2-e78f-4d60-8318-d8f1d790f92b">1,240.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53483a1cc9e941e09201232721818ef2_I20220331" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfNi00LTEtMS03NTE0MA_191655b7-446e-47f7-81f8-0ceb27b8a15e">1,100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bed4b676403412ba1adb6018bde8953_I20211231" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfNi02LTEtMS03NTE0MA_3e40bab0-2e62-48ca-9a7e-4c56a40b5aae">1,463.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bed4b676403412ba1adb6018bde8953_I20211231" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfNi04LTEtMS03NTE0MA_878135d0-a68c-4e86-9777-951f840bb5b5">1,099.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.150% Senior Notes due May 1, 2050</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6864de98b5c49cab9140ebeace06324_I20220331" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfNy0yLTEtMS03NTE0MA_721d6ab6-b8e1-4b7a-9be3-704012f2c6cc">1,225.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6864de98b5c49cab9140ebeace06324_I20220331" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfNy00LTEtMS03NTE0MA_6f06e62d-4a24-4ea0-a774-a95dd4fc7683">1,473.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e6a4a2c46af47cd94c9fdc6dd993664_I20211231" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfNy02LTEtMS03NTE0MA_a2010bcc-4446-4319-8897-06e1bbd28bd7">1,457.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e6a4a2c46af47cd94c9fdc6dd993664_I20211231" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfNy04LTEtMS03NTE0MA_5ac5e8d5-1fa1-4819-9ca3-45846399936e">1,473.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.250% Senior Notes due February 15, 2051</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f6d74e47a314e6c9c9ceec4cbe4c782_I20220331" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfOC0yLTEtMS03NTE0MA_039ef08d-b566-4f8a-bc25-a835774de367">581.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f6d74e47a314e6c9c9ceec4cbe4c782_I20220331" decimals="-5" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfOC00LTEtMS03NTE0MA_2ecd6a67-cafe-4c50-be28-55000c8d233d">466.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec2168b953d46088128b4f2e3774ed2_I20211231" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfOC02LTEtMS03NTE0MA_a8d2d491-164d-46fe-ab0e-382835d3306c">692.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec2168b953d46088128b4f2e3774ed2_I20211231" decimals="-5" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfOC04LTEtMS03NTE0MA_14bf7e91-5888-42b9-b04e-162a3ebc4ba8">466.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfOS0yLTEtMS03NTE0MA_55fd020e-d05a-4e4a-9305-56f8df17d31a">7,195.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfOS00LTEtMS03NTE0MA_e949de00-6d7a-40f2-81ad-0f19b6067a9d">7,275.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfOS02LTEtMS03NTE0MA_eae27cae-4a4a-486b-9b9b-3aa5c457cc39">8,004.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfOS04LTEtMS03NTE0MA_ec78d7b3-e749-485e-b3c6-c8525b603fff">7,273.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. For additional information related to our Senior Notes, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 12,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2021 Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Obligations</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisitions of Convergence and Biogen International Neuroscience GmbH, we agreed to make additional payments based upon the achievement of certain milestone events. <ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RleHRyZWdpb246ZmY0MDI4MzgxMGFkNDY5OWFjMzU4M2JmY2Y4NzkwMTNfNDkwNA_ad10538f-26e1-44f9-b013-c717e5f6981d" continuedAt="ic6cbe0a260b74d67844c250d9721b24a" escape="true">The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:</ix:nonNumeric></span></div><div><ix:continuation id="ic6cbe0a260b74d67844c250d9721b24a"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, beginning of period</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i264ccf816a664702a7ba8ff1332adb5a_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjRiNjFhMjBkYzdkNzRmN2JhODAwMmI1MzgxY2MzNGEzL3RhYmxlcmFuZ2U6NGI2MWEyMGRjN2Q3NGY3YmE4MDAyYjUzODFjYzM0YTNfMi0yLTEtMS03NTE0MA_04ac20e3-953f-4668-ae14-9656eaa3d7aa">209.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief3a3f71bf3549c59cbe89249ff122bd_I20201231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjRiNjFhMjBkYzdkNzRmN2JhODAwMmI1MzgxY2MzNGEzL3RhYmxlcmFuZ2U6NGI2MWEyMGRjN2Q3NGY3YmE4MDAyYjUzODFjYzM0YTNfMi00LTEtMS03NTE0MA_b5a77246-f39a-431a-8e4a-82474e365cdf">259.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in fair value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjRiNjFhMjBkYzdkNzRmN2JhODAwMmI1MzgxY2MzNGEzL3RhYmxlcmFuZ2U6NGI2MWEyMGRjN2Q3NGY3YmE4MDAyYjUzODFjYzM0YTNfMy0yLTEtMS03NTE0MA_f0806090-8db0-4b8e-8e2e-a4616edb32b1">7.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjRiNjFhMjBkYzdkNzRmN2JhODAwMmI1MzgxY2MzNGEzL3RhYmxlcmFuZ2U6NGI2MWEyMGRjN2Q3NGY3YmE4MDAyYjUzODFjYzM0YTNfMy00LTEtMS03NTE0MA_5ff1c09a-2d2b-4f86-8c47-84ecbdc3d19b">33.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, end of period</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia69f061a62954ac7af98aa5c677f4971_I20220331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjRiNjFhMjBkYzdkNzRmN2JhODAwMmI1MzgxY2MzNGEzL3RhYmxlcmFuZ2U6NGI2MWEyMGRjN2Q3NGY3YmE4MDAyYjUzODFjYzM0YTNfNS0yLTEtMS03NTE0MA_84fd7349-fce2-484c-881f-09b4733aebc0">202.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6c7df5e15646bebd2254ac4e7a08fa_I20210331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjRiNjFhMjBkYzdkNzRmN2JhODAwMmI1MzgxY2MzNGEzL3RhYmxlcmFuZ2U6NGI2MWEyMGRjN2Q3NGY3YmE4MDAyYjUzODFjYzM0YTNfNS00LTEtMS03NTE0MA_2fa45222-e1e4-4c5d-bfd4-c59f51bc3672">226.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022 and December 31, 2021, approximately</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RleHRyZWdpb246ZmY0MDI4MzgxMGFkNDY5OWFjMzU4M2JmY2Y4NzkwMTNfMzg2Mg_e8717eb9-3fab-4877-8f55-b371fb9868e6">202.0</ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $<ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RleHRyZWdpb246ZmY0MDI4MzgxMGFkNDY5OWFjMzU4M2JmY2Y4NzkwMTNfMzg2OQ_ac9c678a-e4b9-4c34-a6ae-d77186f3dab2">209.1</ix:nonFraction> million, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our condensed consolidated balance sheets with any remaining balances reflected as a </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">component of accrued expense and other.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, changes in the fair value of our contingent consideration obligations were primarily due to an increase in discount rates used to revalue these obligations and delays in the expected timing of the achievement of certain remaining developmental milestones related to our vixotrigine programs.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, changes in the fair value of our contingent consideration obligations were primarily due to delays in the expected timing of the achievement of certain remaining developmental milestones related to our vixotrigine programs.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="ie9658fba2baf4e3799b1175f69eaed46_73"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;FINANCIAL INSTRUMENTS </span></div><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RleHRyZWdpb246NTYzMmJhNmE4ZDFkNDU1YmFmMTU2NGVjOTY4YjJmMzdfNDkxOQ_7fbe1d4c-d5bd-45dc-87d3-cf7784db7b8a" continuedAt="ib870a14ef7634113bee734eb076531d2" escape="true"><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RleHRyZWdpb246NTYzMmJhNmE4ZDFkNDU1YmFmMTU2NGVjOTY4YjJmMzdfNDkzNA_57bf3d85-03f3-4e2b-a44b-edcfbaf0fb47" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1a0391f5d734ca4b2c1b7de94fd8721_I20220331" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjA2NmMxOTY2MzQzNzQ4NzRiNDYzNTg0ODM3ODM5NGU2L3RhYmxlcmFuZ2U6MDY2YzE5NjYzNDM3NDg3NGI0NjM1ODQ4Mzc4Mzk0ZTZfMS0yLTEtMS03NTE0MA_7132be67-090b-4c5d-a0ad-c774bf2a9259">278.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c2efbd4b9c74a8da864a279a9e91498_I20211231" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjA2NmMxOTY2MzQzNzQ4NzRiNDYzNTg0ODM3ODM5NGU2L3RhYmxlcmFuZ2U6MDY2YzE5NjYzNDM3NDg3NGI0NjM1ODQ4Mzc4Mzk0ZTZfMS00LTEtMS03NTE0MA_c3d70c5f-ef67-4e92-bf45-46e969e83c3a">247.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Overnight reverse repurchase agreements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieed6ef51023543d0bb40d96a559c5941_I20220331" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjA2NmMxOTY2MzQzNzQ4NzRiNDYzNTg0ODM3ODM5NGU2L3RhYmxlcmFuZ2U6MDY2YzE5NjYzNDM3NDg3NGI0NjM1ODQ4Mzc4Mzk0ZTZfMi0yLTEtMS03NTE0MA_1df19e27-6bcc-4de5-9054-6d521158c671">13.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c8bc783a7334b3d8875f060ac7bb1a2_I20211231" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjA2NmMxOTY2MzQzNzQ4NzRiNDYzNTg0ODM3ODM5NGU2L3RhYmxlcmFuZ2U6MDY2YzE5NjYzNDM3NDg3NGI0NjM1ODQ4Mzc4Mzk0ZTZfMi00LTEtMS03NTE0MA_e9d3c001-27c4-496a-b11c-4172ddf4bcbf">200.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i185e162f6d4545b68e3749067e1070d6_I20220331" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjA2NmMxOTY2MzQzNzQ4NzRiNDYzNTg0ODM3ODM5NGU2L3RhYmxlcmFuZ2U6MDY2YzE5NjYzNDM3NDg3NGI0NjM1ODQ4Mzc4Mzk0ZTZfMy0yLTEtMS03NTE0MA_12b1dc06-642e-4b3f-b706-67f425472384">585.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1e2bbc4c00345d494de8e8b436b2968_I20211231" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjA2NmMxOTY2MzQzNzQ4NzRiNDYzNTg0ODM3ODM5NGU2L3RhYmxlcmFuZ2U6MDY2YzE5NjYzNDM3NDg3NGI0NjM1ODQ4Mzc4Mzk0ZTZfMy00LTEtMS03NTE0MA_f0e13d50-7f32-4491-9a85-f281b8795f97">901.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bf885a6fb7c456e9521985a665b058e_I20220331" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjA2NmMxOTY2MzQzNzQ4NzRiNDYzNTg0ODM3ODM5NGU2L3RhYmxlcmFuZ2U6MDY2YzE5NjYzNDM3NDg3NGI0NjM1ODQ4Mzc4Mzk0ZTZfNC0yLTEtMS03NTE0MA_f0ba5617-0985-41fb-8003-9c1db675b0b9">406.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11d469fdaeea46ac984f86f25cf7aefd_I20211231" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjA2NmMxOTY2MzQzNzQ4NzRiNDYzNTg0ODM3ODM5NGU2L3RhYmxlcmFuZ2U6MDY2YzE5NjYzNDM3NDg3NGI0NjM1ODQ4Mzc4Mzk0ZTZfNC00LTEtMS03NTE0MA_e7e41ef7-1cc6-48d9-9988-03fe9a30981e">283.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjA2NmMxOTY2MzQzNzQ4NzRiNDYzNTg0ODM3ODM5NGU2L3RhYmxlcmFuZ2U6MDY2YzE5NjYzNDM3NDg3NGI0NjM1ODQ4Mzc4Mzk0ZTZfNS0yLTEtMS03NTE0MA_e618e560-0571-473e-94ce-a9536baab4bc">1,283.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjA2NmMxOTY2MzQzNzQ4NzRiNDYzNTg0ODM3ODM5NGU2L3RhYmxlcmFuZ2U6MDY2YzE5NjYzNDM3NDg3NGI0NjM1ODQ4Mzc4Mzk0ZTZfNS00LTEtMS03NTE0MA_d9e5b0ae-2591-4adc-b52e-07435343c9b4">1,632.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and short-term debt securities approximate fair value due to their short-term maturities. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketable equity securities gains (losses) are recorded in other income (expense), net in our condensed consolidated statements of income. <ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RleHRyZWdpb246NTYzMmJhNmE4ZDFkNDU1YmFmMTU2NGVjOTY4YjJmMzdfNDkyNA_c79cbf31-3e57-43ed-824b-6f660b3d849d" continuedAt="ifa18d9cd444f42b2bfd07c9f802f0e3c" escape="true">The following tables summarize our marketable debt and equity securities, classified as available-for-sale:</ix:nonNumeric></span></div><div><ix:continuation id="ifa18d9cd444f42b2bfd07c9f802f0e3c" continuedAt="i1edc1a7ad7734473ac6f3342f46c99f1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i154d489ea3c6499a8e77ce72f6e567a2_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfNC0yLTEtMS03NTE0MA_f5443610-1346-4318-9932-d4c4ca259809">1,126.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i154d489ea3c6499a8e77ce72f6e567a2_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfNC00LTEtMS03NTE0MA_700e87b1-8a5c-4595-bfe6-061f9ddf920d">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i154d489ea3c6499a8e77ce72f6e567a2_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfNC02LTEtMS03NTE0MA_674af1c5-8bbe-400d-b277-96b0c08cd7e4">2.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i154d489ea3c6499a8e77ce72f6e567a2_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfNC04LTEtMS03NTE0MA_8e82077b-ed4a-454e-94af-cba515eb64f7">1,124.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd8430987f44ff08faf10d31756ef75_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfNS0yLTEtMS03NTE0MA_e9a4aa30-2ebb-4e37-8aef-e32ebd7b93ea">460.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd8430987f44ff08faf10d31756ef75_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfNS00LTEtMS03NTE0MA_4d9cf59e-0234-45c7-b2a2-2106d3bff7db">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabd8430987f44ff08faf10d31756ef75_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfNS02LTEtMS03NTE0MA_d69b734d-fa55-45f5-acbb-58008ac637ea">5.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd8430987f44ff08faf10d31756ef75_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfNS04LTEtMS03NTE0MA_19cd3d39-d995-4b27-9ec8-3821749416d6">454.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf11806fefce4b389ac4b64510af48f2_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfNy0yLTEtMS03NTE0MA_9da8f849-fecb-40bd-88b8-cccde3ea6bbf">878.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf11806fefce4b389ac4b64510af48f2_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfNy00LTEtMS03NTE0MA_fac81ed8-f696-4b86-a846-7834b0f1ca42">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf11806fefce4b389ac4b64510af48f2_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfNy02LTEtMS03NTE0MA_cee0142e-6150-4f2a-9598-2abd78a9bc34">2.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf11806fefce4b389ac4b64510af48f2_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfNy04LTEtMS03NTE0MA_2ce09a25-dad5-4db9-a1d4-2daacfe90a1d">877.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie09432231a464e39a944c6a44cd6b69c_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfOC0yLTEtMS03NTE0MA_a9c6b7b7-bb3e-43fd-a5e6-56a8c7fe7f82">379.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie09432231a464e39a944c6a44cd6b69c_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfOC00LTEtMS03NTE0MA_a982bb42-be10-4f46-88f7-0cd115a084e1">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie09432231a464e39a944c6a44cd6b69c_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfOC02LTEtMS03NTE0MA_26ea3104-7ca3-4fba-b27e-0d4e4b57e579">3.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie09432231a464e39a944c6a44cd6b69c_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfOC04LTEtMS03NTE0MA_0bf87e6c-6489-4d6c-9231-6e3f41e6009e">375.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96ee067d94d34ad18d8184a7addb8ae6_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfMTAtMi0xLTEtNzUxNDA_7e09e259-a963-499d-852d-ca90907f6283">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96ee067d94d34ad18d8184a7addb8ae6_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfMTAtNC0xLTEtNzUxNDA_c446c2ed-c44c-477b-9a49-5558f00cbb72">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96ee067d94d34ad18d8184a7addb8ae6_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfMTAtNi0xLTEtNzUxNDA_8a69d706-5bf8-4aa5-b713-b4af553768de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96ee067d94d34ad18d8184a7addb8ae6_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfMTAtOC0xLTEtNzUxNDA_c7fdcc46-218c-4fc6-b997-013b890f64a1">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cd3f693083d457bbe88209270fd1b39_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfMTEtMi0xLTEtNzUxNDA_6d66c31e-1963-49ca-abca-c780c4b857bb">173.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cd3f693083d457bbe88209270fd1b39_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfMTEtNC0xLTEtNzUxNDA_4b6b7e30-4216-4aec-972d-9fa1d2ddcbab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cd3f693083d457bbe88209270fd1b39_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfMTEtNi0xLTEtNzUxNDA_296bc1aa-e493-4070-9ef4-feb15b4207f3">2.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cd3f693083d457bbe88209270fd1b39_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfMTEtOC0xLTEtNzUxNDA_265b04e8-4de9-4c21-bbfd-5c993aae8425">171.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfMTItMi0xLTEtNzUxNDA_cbff79b6-887b-44bf-8b2f-e01357dcbcac">3,019.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfMTItNC0xLTEtNzUxNDA_0bdc1be1-006b-4752-b331-814482f2d22e">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfMTItNi0xLTEtNzUxNDA_2cb50029-fa4e-42c6-892b-ae4a14abfda6">16.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfMTItOC0xLTEtNzUxNDA_889e54ba-0535-4d90-bed8-4037b2cc5277">3,004.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d92b30f82ea4eed911cc841fff8bf84_I20220331" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfMTUtMi0xLTEtNzUxNDA_c80c9b1b-8850-4bd2-bbd1-af1633e1e5e3">33.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d92b30f82ea4eed911cc841fff8bf84_I20220331" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfMTUtNC0xLTEtNzUxNDA_c171ecc0-bbcb-41f5-b0d7-868fe52b8631">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d92b30f82ea4eed911cc841fff8bf84_I20220331" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfMTUtNi0xLTEtNzUxNDA_d1b8416a-45ce-4fe7-8f49-523e3e4c524f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d92b30f82ea4eed911cc841fff8bf84_I20220331" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfMTUtOC0xLTEtNzUxNDA_5b1cf6f8-8ec2-4daa-9409-9052b287cde4">33.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3b43bd6e13a4a9c9403015c85ba502f_I20220331" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfMTYtMi0xLTEtNzUxNDA_46d62430-75dc-4cb9-a928-338579f45d01">1,133.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3b43bd6e13a4a9c9403015c85ba502f_I20220331" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfMTYtNC0xLTEtNzUxNDA_b6211fe0-597d-44af-ae3b-5c4310dec64c">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3b43bd6e13a4a9c9403015c85ba502f_I20220331" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfMTYtNi0xLTEtNzUxNDA_c9153dfe-c59f-4e82-b2ae-aa41ed12cbb7">311.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3b43bd6e13a4a9c9403015c85ba502f_I20220331" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfMTYtOC0xLTEtNzUxNDA_bbe9a9bc-b57e-47f7-8c65-aaad103a7a34">826.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfMTctMi0xLTEtNzUxNDA_6b17208d-385f-49fe-b27f-e3ad5c22e44f">1,167.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfMTctNC0xLTEtNzUxNDA_7f2e13f1-5131-4dd8-a976-32eaf2358270">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfMTctNi0xLTEtNzUxNDA_9d650054-413f-4aa2-b586-9562b4f94ae2">311.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfMTctOC0xLTEtNzUxNDA_cac40bab-7675-4d98-b08a-10f80bd6b5c6">860.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="ib870a14ef7634113bee734eb076531d2" continuedAt="i63a72ade777a4345b671f1a9d6dce135"><div><ix:continuation id="i1edc1a7ad7734473ac6f3342f46c99f1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4c19e0ddd2b4245bded3c176e7644d5_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfNC0yLTEtMS03NTE0MA_70cc922a-ed53-4821-bd8e-15ee4c4259d7">723.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4c19e0ddd2b4245bded3c176e7644d5_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfNC00LTEtMS03NTE0MA_30b6b30a-2c47-41c1-9e1d-a2b1d364bf10">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4c19e0ddd2b4245bded3c176e7644d5_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfNC02LTEtMS03NTE0MA_160a8844-986e-4c5c-afaf-95006b05d18b">0.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4c19e0ddd2b4245bded3c176e7644d5_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfNC04LTEtMS03NTE0MA_7880e81d-5d38-449f-b590-40c9a2362098">723.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7202374646d4a99bbde3c93490e6ecd_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfNS0yLTEtMS03NTE0MA_ed8c05b5-b866-46be-affe-a3184a5a392a">385.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7202374646d4a99bbde3c93490e6ecd_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfNS00LTEtMS03NTE0MA_c11028f2-7306-427c-82f4-7f26847bf822">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7202374646d4a99bbde3c93490e6ecd_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfNS02LTEtMS03NTE0MA_f88a1a8a-54f1-4649-ae5a-93cb70bd691b">0.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7202374646d4a99bbde3c93490e6ecd_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfNS04LTEtMS03NTE0MA_bc1b1dd7-759d-41cb-9f3e-12994e02ba77">384.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd0e0d8d79a54c8e9e1b178519ddc273_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfNy0yLTEtMS03NTE0MA_46dade40-b455-471a-adc8-33b2ede82248">817.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd0e0d8d79a54c8e9e1b178519ddc273_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfNy00LTEtMS03NTE0MA_2e65aaa8-ee5c-4337-aeeb-c29ca80c8381">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd0e0d8d79a54c8e9e1b178519ddc273_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfNy02LTEtMS03NTE0MA_d7da48fc-bac7-4beb-8871-73dfdeae1830">0.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd0e0d8d79a54c8e9e1b178519ddc273_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfNy04LTEtMS03NTE0MA_bc388dc5-e737-4f52-bc07-60bc3e6e7e69">816.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib018ee899f4e4ac48084e28043d8cddf_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfOC0yLTEtMS03NTE0MA_af784bde-4a8a-4423-a8ff-8beede11fee7">377.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib018ee899f4e4ac48084e28043d8cddf_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfOC00LTEtMS03NTE0MA_2388bcbe-cb9c-48e6-acbd-db1f7357d7e5">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib018ee899f4e4ac48084e28043d8cddf_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfOC02LTEtMS03NTE0MA_7db62285-78bc-4569-8f9c-17fefd10bd99">1.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib018ee899f4e4ac48084e28043d8cddf_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfOC04LTEtMS03NTE0MA_df5cf0e5-1631-42d6-b013-5c651ffa586f">376.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d2052cb740a446b8e69b4604e07264e_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfMTAtMi0xLTEtNzUxNDA_d6476403-0168-4572-b73d-5e5995fdfa56">1.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d2052cb740a446b8e69b4604e07264e_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfMTAtNC0xLTEtNzUxNDA_55115496-77eb-4511-b901-2b3c1d66a1bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d2052cb740a446b8e69b4604e07264e_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfMTAtNi0xLTEtNzUxNDA_ddb9405a-26dd-4c77-ae16-f32b4f38ef35">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d2052cb740a446b8e69b4604e07264e_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfMTAtOC0xLTEtNzUxNDA_0418f578-5275-40d8-9411-a8695df8cf30">1.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e32269d553441f28cfce5965c1b73f6_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfMTEtMi0xLTEtNzUxNDA_3a3bc388-f650-4bde-8d9b-3b7b69ef44ed">131.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e32269d553441f28cfce5965c1b73f6_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfMTEtNC0xLTEtNzUxNDA_169e7b2e-fe12-4e9e-8346-13d0e666e2de">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e32269d553441f28cfce5965c1b73f6_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfMTEtNi0xLTEtNzUxNDA_86d5b1aa-3385-4073-a8dd-65b2fc7c9b5d">0.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e32269d553441f28cfce5965c1b73f6_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfMTEtOC0xLTEtNzUxNDA_349c0552-6da1-4ad1-b6b6-8a1bd8789057">131.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfMTItMi0xLTEtNzUxNDA_a103a534-606c-463f-87f6-5af4e13e9827">2,435.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfMTItNC0xLTEtNzUxNDA_7b0cde6b-7c3f-497a-94a1-a91ab7e2009b">0.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfMTItNi0xLTEtNzUxNDA_a6bc9266-e8fd-4b43-a12a-15bb80496371">3.2</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfMTItOC0xLTEtNzUxNDA_47f6d57c-141b-40fa-8eb7-fe06e3c97a23">2,433.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4753836c14c24f67acbeca373ca2d5d4_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfMTUtMi0xLTEtNzUxNDA_78186751-3e5e-408e-84cf-d27b6f6894a6">33.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4753836c14c24f67acbeca373ca2d5d4_I20211231" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfMTUtNC0xLTEtNzUxNDA_f5ba22dc-8205-41dc-9171-6bf3508fb90f">9.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4753836c14c24f67acbeca373ca2d5d4_I20211231" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfMTUtNi0xLTEtNzUxNDA_b1f84b21-a12a-4b95-9475-548d9891673b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4753836c14c24f67acbeca373ca2d5d4_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfMTUtOC0xLTEtNzUxNDA_a5f274b3-3b8a-4487-a831-87eb61dc1424">43.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i441022c1a0eb4576a80a097476642f3d_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfMTYtMi0xLTEtNzUxNDA_4a3f112d-b9ad-4c0f-a439-2bc132ae22f4">1,133.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i441022c1a0eb4576a80a097476642f3d_I20211231" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfMTYtNC0xLTEtNzUxNDA_49f93c17-28ee-4da7-8804-092b4da33d1b">151.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i441022c1a0eb4576a80a097476642f3d_I20211231" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfMTYtNi0xLTEtNzUxNDA_4d198ae9-87cd-4a4f-b4d3-be3072c2bc67">279.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i441022c1a0eb4576a80a097476642f3d_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfMTYtOC0xLTEtNzUxNDA_e55f6364-4be3-47bd-9af8-1f18109ed377">1,004.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfMTctMi0xLTEtNzUxNDA_6e4f1624-bb0c-4849-b366-f31e2d93e4b3">1,167.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfMTctNC0xLTEtNzUxNDA_9eb5f849-4e2e-48bb-8011-02a9dd55c0d9">160.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfMTctNi0xLTEtNzUxNDA_4e7a07a3-77c9-41a8-8a63-da3369017a65">279.4</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfMTctOC0xLTEtNzUxNDA_6f91b020-d50a-4cb6-8c0e-2206553b2ba1">1,048.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Contractual Maturities: Available-for-Sale Debt Securities</span></div><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RleHRyZWdpb246NTYzMmJhNmE4ZDFkNDU1YmFmMTU2NGVjOTY4YjJmMzdfNDkzNw_39f401c8-48fe-44e5-80b3-6b2a2055c3dd" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:41.924%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.413%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmUxZGZiZTdiNTVlNDQyOWRhNzFjNDZmNjVlMzdlN2I5L3RhYmxlcmFuZ2U6ZTFkZmJlN2I1NWU0NDI5ZGE3MWM0NmY2NWUzN2U3YjlfMi0yLTEtMS03NTE0MA_fbb38f1d-6824-49e9-ad1c-3664fcbaa4a3">2,002.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmUxZGZiZTdiNTVlNDQyOWRhNzFjNDZmNjVlMzdlN2I5L3RhYmxlcmFuZ2U6ZTFkZmJlN2I1NWU0NDI5ZGE3MWM0NmY2NWUzN2U3YjlfMi00LTEtMS03NTE0MA_926b0068-20a7-4484-805a-3d9b150bad59">2,006.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmUxZGZiZTdiNTVlNDQyOWRhNzFjNDZmNjVlMzdlN2I5L3RhYmxlcmFuZ2U6ZTFkZmJlN2I1NWU0NDI5ZGE3MWM0NmY2NWUzN2U3YjlfMi02LTEtMS03NTE0MA_1779927e-7791-422a-8583-592e8c8b04a6">1,541.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmUxZGZiZTdiNTVlNDQyOWRhNzFjNDZmNjVlMzdlN2I5L3RhYmxlcmFuZ2U6ZTFkZmJlN2I1NWU0NDI5ZGE3MWM0NmY2NWUzN2U3YjlfMi04LTEtMS03NTE0MA_965f7f0d-74a6-4a77-9887-8b58b13e280e">1,541.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmUxZGZiZTdiNTVlNDQyOWRhNzFjNDZmNjVlMzdlN2I5L3RhYmxlcmFuZ2U6ZTFkZmJlN2I1NWU0NDI5ZGE3MWM0NmY2NWUzN2U3YjlfMy0yLTEtMS03NTE0MA_3fc54cfc-1f80-49a7-a333-1204ea9dcf7f">982.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmUxZGZiZTdiNTVlNDQyOWRhNzFjNDZmNjVlMzdlN2I5L3RhYmxlcmFuZ2U6ZTFkZmJlN2I1NWU0NDI5ZGE3MWM0NmY2NWUzN2U3YjlfMy00LTEtMS03NTE0MA_ae4908f2-d52b-46cc-b37e-1d11ad90faa0">993.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmUxZGZiZTdiNTVlNDQyOWRhNzFjNDZmNjVlMzdlN2I5L3RhYmxlcmFuZ2U6ZTFkZmJlN2I1NWU0NDI5ZGE3MWM0NmY2NWUzN2U3YjlfMy02LTEtMS03NTE0MA_5670c6fb-e9d5-4fb7-93ee-2085a3230ffa">868.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmUxZGZiZTdiNTVlNDQyOWRhNzFjNDZmNjVlMzdlN2I5L3RhYmxlcmFuZ2U6ZTFkZmJlN2I1NWU0NDI5ZGE3MWM0NmY2NWUzN2U3YjlfMy04LTEtMS03NTE0MA_1c206c2b-09b3-4a8f-b0a5-c4e793338506">870.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after five years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmUxZGZiZTdiNTVlNDQyOWRhNzFjNDZmNjVlMzdlN2I5L3RhYmxlcmFuZ2U6ZTFkZmJlN2I1NWU0NDI5ZGE3MWM0NmY2NWUzN2U3YjlfNC0yLTEtMS03NTE0MA_ae8a814e-67e4-4ffe-8bf3-e0037553c5b1">18.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmUxZGZiZTdiNTVlNDQyOWRhNzFjNDZmNjVlMzdlN2I5L3RhYmxlcmFuZ2U6ZTFkZmJlN2I1NWU0NDI5ZGE3MWM0NmY2NWUzN2U3YjlfNC00LTEtMS03NTE0MA_d6f1658f-ff9c-4d8a-8ecc-11d191d48cff">19.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmUxZGZiZTdiNTVlNDQyOWRhNzFjNDZmNjVlMzdlN2I5L3RhYmxlcmFuZ2U6ZTFkZmJlN2I1NWU0NDI5ZGE3MWM0NmY2NWUzN2U3YjlfNC02LTEtMS03NTE0MA_30a4102f-6962-48f3-b690-68a0c8b79800">23.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmUxZGZiZTdiNTVlNDQyOWRhNzFjNDZmNjVlMzdlN2I5L3RhYmxlcmFuZ2U6ZTFkZmJlN2I1NWU0NDI5ZGE3MWM0NmY2NWUzN2U3YjlfNC04LTEtMS03NTE0MA_845c034c-126b-48c7-a9eb-51efc4db7ab2">24.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmUxZGZiZTdiNTVlNDQyOWRhNzFjNDZmNjVlMzdlN2I5L3RhYmxlcmFuZ2U6ZTFkZmJlN2I1NWU0NDI5ZGE3MWM0NmY2NWUzN2U3YjlfNS0yLTEtMS03NTE0MA_da88f0ae-5d4a-4124-9ae7-c42ebc4678fa">3,004.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmUxZGZiZTdiNTVlNDQyOWRhNzFjNDZmNjVlMzdlN2I5L3RhYmxlcmFuZ2U6ZTFkZmJlN2I1NWU0NDI5ZGE3MWM0NmY2NWUzN2U3YjlfNS00LTEtMS03NTE0MA_1909d69b-3944-4a83-b7fb-f72f6a1f9515">3,019.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmUxZGZiZTdiNTVlNDQyOWRhNzFjNDZmNjVlMzdlN2I5L3RhYmxlcmFuZ2U6ZTFkZmJlN2I1NWU0NDI5ZGE3MWM0NmY2NWUzN2U3YjlfNS02LTEtMS03NTE0MA_82e3c898-32ec-451e-81aa-0a3365e98936">2,433.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmUxZGZiZTdiNTVlNDQyOWRhNzFjNDZmNjVlMzdlN2I5L3RhYmxlcmFuZ2U6ZTFkZmJlN2I1NWU0NDI5ZGE3MWM0NmY2NWUzN2U3YjlfNS04LTEtMS03NTE0MA_73f0a9d8-6483-4bbc-813e-95153e95e472">2,435.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The average maturity of our marketable debt securities available-for-sale as of March 31, 2022 and December 31, 2021, was approximately <ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="biib:AverageMaturityOfMarketableSecurities" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RleHRyZWdpb246NTYzMmJhNmE4ZDFkNDU1YmFmMTU2NGVjOTY4YjJmMzdfMTAyMw_46707cf7-a575-4a41-a85c-758aff2c58c8"><ix:nonNumeric contextRef="iaf0a6c3fc8694a58a8f2838a236b6959_D20210101-20211231" name="biib:AverageMaturityOfMarketableSecurities" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RleHRyZWdpb246NTYzMmJhNmE4ZDFkNDU1YmFmMTU2NGVjOTY4YjJmMzdfMTAyMw_dfa8c8e1-210b-4258-83cb-684bcd85d710">10</ix:nonNumeric></ix:nonNumeric> months.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Proceeds from Marketable Debt Securities</span></div><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="us-gaap:RealizedGainLossOnInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RleHRyZWdpb246NTYzMmJhNmE4ZDFkNDU1YmFmMTU2NGVjOTY4YjJmMzdfNDk0OA_3a5a49be-eeef-4059-b24b-be4cd01a1019" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from maturities and sales</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjNjMTI4NzJlY2U2YjQwNTVhNDFiMzUwN2RkNDRjNDQ1L3RhYmxlcmFuZ2U6M2MxMjg3MmVjZTZiNDA1NWE0MWIzNTA3ZGQ0NGM0NDVfMi0yLTEtMS03NTE0MA_5e134050-ce75-4181-a218-2a624ebacc15">543.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjNjMTI4NzJlY2U2YjQwNTVhNDFiMzUwN2RkNDRjNDQ1L3RhYmxlcmFuZ2U6M2MxMjg3MmVjZTZiNDA1NWE0MWIzNTA3ZGQ0NGM0NDVfMi00LTEtMS03NTE0MA_fa02abca-8b5a-4ef7-b426-22c6dee1ae94">819.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjNjMTI4NzJlY2U2YjQwNTVhNDFiMzUwN2RkNDRjNDQ1L3RhYmxlcmFuZ2U6M2MxMjg3MmVjZTZiNDA1NWE0MWIzNTA3ZGQ0NGM0NDVfMy0yLTEtMS03NTE0MA_468e1b42-6706-475f-b035-64e590d63e03">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjNjMTI4NzJlY2U2YjQwNTVhNDFiMzUwN2RkNDRjNDQ1L3RhYmxlcmFuZ2U6M2MxMjg3MmVjZTZiNDA1NWE0MWIzNTA3ZGQ0NGM0NDVfMy00LTEtMS03NTE0MA_14f60ba8-9079-4491-8437-9e3066610567">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjNjMTI4NzJlY2U2YjQwNTVhNDFiMzUwN2RkNDRjNDQ1L3RhYmxlcmFuZ2U6M2MxMjg3MmVjZTZiNDA1NWE0MWIzNTA3ZGQ0NGM0NDVfNC0yLTEtMS03NTE0MA_66ddcb20-1510-4350-a061-e466fd680831">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjNjMTI4NzJlY2U2YjQwNTVhNDFiMzUwN2RkNDRjNDQ1L3RhYmxlcmFuZ2U6M2MxMjg3MmVjZTZiNDA1NWE0MWIzNTA3ZGQ0NGM0NDVfNC00LTEtMS03NTE0MA_6a79f16f-01bb-4421-a83f-14c1eae2213e">0.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized losses for the three months ended</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2022 and 2021, primarily relate to sales of corporate bonds, agency mortgage-backed securities and other asset-backed securities.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i63a72ade777a4345b671f1a9d6dce135"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strategic Investments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022 and December 31, 2021, our strategic investment portfolio was comprised of investments totaling $<ix:nonFraction unitRef="usd" contextRef="i3803e965a1724d08a4f85f6e2e7521f4_I20220331" decimals="-5" name="biib:StrategicInvestmentPortfolio" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RleHRyZWdpb246NTYzMmJhNmE4ZDFkNDU1YmFmMTU2NGVjOTY4YjJmMzdfMTMzOQ_f6a662b2-dfe5-496e-b2bf-418aadf5806b">919.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7fc3a5a6750b4a08b8ea8136ff17e32f_I20211231" decimals="-5" name="biib:StrategicInvestmentPortfolio" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RleHRyZWdpb246NTYzMmJhNmE4ZDFkNDU1YmFmMTU2NGVjOTY4YjJmMzdfMTM0Ng_d995ff3e-4987-44b5-99dd-081e8646f573">1,110.3</ix:nonFraction> million, respectively, which are included in other current assets and investments and other assets in our condensed consolidated balance sheets. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6, Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in our strategic investment portfolio for the three months ended March 31, 2022, was primarily due to decreases in the fair value of our investments in Denali, Sage and Sangamo common stock.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our investments in Denali, Ionis Pharmaceuticals, Inc. (Ionis), Sage and Sangamo common stock, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2021 Form 10-K.</span></div></ix:continuation><div id="ie9658fba2baf4e3799b1175f69eaed46_79"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;DERIVATIVE INSTRUMENTS </span></div><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfNjk2MA_ac5f7b98-8129-4aea-bda7-d2a0623c07b7" continuedAt="ie50e64bb602842198a58d735a5aa462e" escape="true"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Forward Contracts - Hedging Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the global nature of our operations, portions of our revenue and operating expense are recorded in currencies other than the U.S.&#160;dollar. The value of revenue and operating expense measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes, we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenue and operating expense.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency forward contracts in effect as of March 31, 2022 and December 31, 2021, had durations of <ix:nonNumeric contextRef="i272a8c61f3584e998890821513df00d8_D20220101-20220331" name="us-gaap:DerivativeRemainingMaturity1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfNjIz_1d0c20f6-ca74-4a90-b35f-2fbc1ad4f016">1</ix:nonNumeric> to </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i406fa505aaae46879e51842eed75d4ce_D20220101-20220331" name="us-gaap:DerivativeRemainingMaturity1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfNjI5_92631d7e-f2d7-4f5c-8eaa-c1d22ede45c0">18</ix:nonNumeric> months</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and <ix:nonNumeric contextRef="i249928d43b8e4fa299b055c1da71dd67_D20210101-20210630" name="us-gaap:DerivativeRemainingMaturity1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfNjM2_7dc59cf4-eba5-435f-b6e9-ed0f3504f826">1</ix:nonNumeric> to <ix:nonNumeric contextRef="i3bd066a82d6840d8b01775d5dad75db4_D20210101-20210630" name="us-gaap:DerivativeRemainingMaturity1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfNjQy_cd0f6328-3e0d-4ef7-b0ea-86d73214ac5c">15</ix:nonNumeric> months, respectively. These contracts have been designated as cash flow hedges and unrealized gains or losses on the portion of these foreign currency forward contracts that are included in the effectiveness test are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the table below). Realized gains and losses of such contracts are recognized in revenue when the sale of product in the currency being hedged is recognized and in operating expense when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from accumulated other comprehensive income (loss) and fair value changes of excluded portions in the same line item in our condensed consolidated statements of income that has been impacted by the hedged item.</span></div><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfNjk2OQ_92d6111e-fc75-4a40-8c0e-73d004cf9171" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional amount of foreign currency forward contracts that were entered into to hedge forecasted revenue and operating expense is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id58fea331b54435bbde5915e58d7c5a1_I20220331" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjQwM2Q1NzdiMThhZTRmODZhZDQwNDVmMGIxNzIxNWE0L3RhYmxlcmFuZ2U6NDAzZDU3N2IxOGFlNGY4NmFkNDA0NWYwYjE3MjE1YTRfMi0yLTEtMS03NTE0MA_1329c9e0-b0ad-4820-a299-129ce27b9e47">1,631.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bbc3b1e9fdb469cb4328efd19cda789_I20211231" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjQwM2Q1NzdiMThhZTRmODZhZDQwNDVmMGIxNzIxNWE0L3RhYmxlcmFuZ2U6NDAzZDU3N2IxOGFlNGY4NmFkNDA0NWYwYjE3MjE1YTRfMi00LTEtMS03NTE0MA_43ff5cac-d4df-419e-a7ac-b29d1f2eb3e7">1,828.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">British pound</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39a50582990a42dcb07d38607ad68af5_I20220331" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjQwM2Q1NzdiMThhZTRmODZhZDQwNDVmMGIxNzIxNWE0L3RhYmxlcmFuZ2U6NDAzZDU3N2IxOGFlNGY4NmFkNDA0NWYwYjE3MjE1YTRfMy0yLTEtMS03NTE0MA_7d9a5fd1-a5f1-4308-8e70-421ff9f1550f">126.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i240c4ec54c41471f939a44ea69015b0a_I20211231" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjQwM2Q1NzdiMThhZTRmODZhZDQwNDVmMGIxNzIxNWE0L3RhYmxlcmFuZ2U6NDAzZDU3N2IxOGFlNGY4NmFkNDA0NWYwYjE3MjE1YTRfMy00LTEtMS03NTE0MA_357a8f3f-7f07-4b27-9c47-17de38a35229">166.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Swiss franc</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28837dfd41bf48e4a23a28d077a47405_I20220331" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjQwM2Q1NzdiMThhZTRmODZhZDQwNDVmMGIxNzIxNWE0L3RhYmxlcmFuZ2U6NDAzZDU3N2IxOGFlNGY4NmFkNDA0NWYwYjE3MjE1YTRfNC0yLTEtMS03NTE0MA_aa943e42-2983-4db4-8e4b-54d2976e5d1c">128.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0736edb3bf194531887102c104754d6b_I20211231" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjQwM2Q1NzdiMThhZTRmODZhZDQwNDVmMGIxNzIxNWE0L3RhYmxlcmFuZ2U6NDAzZDU3N2IxOGFlNGY4NmFkNDA0NWYwYjE3MjE1YTRfNC00LTEtMS03NTE0MA_b9847e6d-bdd4-48c5-86c9-dd351ba9c537">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Japanese yen</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i598f0b3c24fe484495f6ccb41c9c3f69_I20220331" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjQwM2Q1NzdiMThhZTRmODZhZDQwNDVmMGIxNzIxNWE0L3RhYmxlcmFuZ2U6NDAzZDU3N2IxOGFlNGY4NmFkNDA0NWYwYjE3MjE1YTRfNS0yLTEtMS03NTE0MA_c31c653b-3bfa-4344-9a9b-8195aa31cde8">55.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e3ec7e46b3849eab9fbf5b26dbd2c8c_I20211231" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjQwM2Q1NzdiMThhZTRmODZhZDQwNDVmMGIxNzIxNWE0L3RhYmxlcmFuZ2U6NDAzZDU3N2IxOGFlNGY4NmFkNDA0NWYwYjE3MjE1YTRfNS00LTEtMS03NTE0MA_0ab8a0f7-b9ae-4226-bba8-74c6fbaddb15">72.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canadian dollar</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i694ddc9c46354d1e860c687aa876734c_I20220331" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjQwM2Q1NzdiMThhZTRmODZhZDQwNDVmMGIxNzIxNWE0L3RhYmxlcmFuZ2U6NDAzZDU3N2IxOGFlNGY4NmFkNDA0NWYwYjE3MjE1YTRfNi0yLTEtMS03NTE0MA_4ec0f4b6-228d-4588-96e9-4f5bfb696bff">44.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac85fcf21047427c834103ba4c06b629_I20211231" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjQwM2Q1NzdiMThhZTRmODZhZDQwNDVmMGIxNzIxNWE0L3RhYmxlcmFuZ2U6NDAzZDU3N2IxOGFlNGY4NmFkNDA0NWYwYjE3MjE1YTRfNi00LTEtMS03NTE0MA_42196576-faff-41d4-b8a8-1c32748146a7">59.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total foreign currency forward contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id06b33f7f9d2442c99ed5a3715b1fb03_I20220331" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjQwM2Q1NzdiMThhZTRmODZhZDQwNDVmMGIxNzIxNWE0L3RhYmxlcmFuZ2U6NDAzZDU3N2IxOGFlNGY4NmFkNDA0NWYwYjE3MjE1YTRfNy0yLTEtMS03NTE0MA_a8e14a7e-9094-463f-9ff9-e0948ca49be5">1,986.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic777b57bc84141bcbc813beba9a72c17_I20211231" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjQwM2Q1NzdiMThhZTRmODZhZDQwNDVmMGIxNzIxNWE0L3RhYmxlcmFuZ2U6NDAzZDU3N2IxOGFlNGY4NmFkNDA0NWYwYjE3MjE1YTRfNy00LTEtMS03NTE0MA_62a0deaf-c801-4c62-92be-f6adee58fe95">2,126.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="biib:DerivativeInstrumentsUnrealizedGainLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfNjU5NzA2OTc3NzgyNQ_68f56211-2714-4a5d-9ded-f8876c1eaa8f" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59dedd55a80f4d2a830844b533c8f387_D20220101-20220331" decimals="-5" name="biib:UnrealizedGainOnDerivatives" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjAzNGQxZTg3MGU2MDQyMTFhNmJmYjNkOTY1Njk5ZmY1L3RhYmxlcmFuZ2U6MDM0ZDFlODcwZTYwNDIxMWE2YmZiM2Q5NjU2OTlmZjVfMi0yLTEtMS0xMDUwNjE_47618693-40c5-4078-938f-6f84ec419f26">76.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c177fb43a1c4b4e8e78a519ab0c6de9_D20210101-20210331" decimals="-5" name="biib:UnrealizedGainOnDerivatives" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjAzNGQxZTg3MGU2MDQyMTFhNmJmYjNkOTY1Njk5ZmY1L3RhYmxlcmFuZ2U6MDM0ZDFlODcwZTYwNDIxMWE2YmZiM2Q5NjU2OTlmZjVfMi00LTEtMS0xMDUwNjM_7f4a8436-8444-4d2f-9a68-f466f70732f3">60.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized (losses)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i59dedd55a80f4d2a830844b533c8f387_D20220101-20220331" decimals="-5" name="biib:UnrealizedLossOnDerivatives" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjAzNGQxZTg3MGU2MDQyMTFhNmJmYjNkOTY1Njk5ZmY1L3RhYmxlcmFuZ2U6MDM0ZDFlODcwZTYwNDIxMWE2YmZiM2Q5NjU2OTlmZjVfMy0yLTEtMS0xMDUwNjE_6bb1535d-0be6-42ce-8a03-7c5d6ecb7c8d">4.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c177fb43a1c4b4e8e78a519ab0c6de9_D20210101-20210331" decimals="-5" name="biib:UnrealizedLossOnDerivatives" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjAzNGQxZTg3MGU2MDQyMTFhNmJmYjNkOTY1Njk5ZmY1L3RhYmxlcmFuZ2U6MDM0ZDFlODcwZTYwNDIxMWE2YmZiM2Q5NjU2OTlmZjVfMy00LTEtMS0xMDUwNjM_ea7b8aec-345e-4529-8de5-26e54db27045">7.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized gains (losses)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59dedd55a80f4d2a830844b533c8f387_D20220101-20220331" decimals="-5" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjAzNGQxZTg3MGU2MDQyMTFhNmJmYjNkOTY1Njk5ZmY1L3RhYmxlcmFuZ2U6MDM0ZDFlODcwZTYwNDIxMWE2YmZiM2Q5NjU2OTlmZjVfNC0yLTEtMS04NDQxOA_73c23b64-d473-49d1-918f-cd5ca701c6c4">72.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c177fb43a1c4b4e8e78a519ab0c6de9_D20210101-20210331" decimals="-5" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjAzNGQxZTg3MGU2MDQyMTFhNmJmYjNkOTY1Njk5ZmY1L3RhYmxlcmFuZ2U6MDM0ZDFlODcwZTYwNDIxMWE2YmZiM2Q5NjU2OTlmZjVfNC00LTEtMS0xMDUwNjM_7888ec6d-d92b-4b76-ac6a-1168651a325d">53.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the net unrealized gains of $<ix:nonFraction unitRef="usd" contextRef="i59dedd55a80f4d2a830844b533c8f387_D20220101-20220331" decimals="-5" name="us-gaap:UnrealizedGainLossOnDerivatives" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfMTMxOTQxMzk1NDQ0Njc_8d91d1b0-b850-4483-a16b-446afadb3736">72.1</ix:nonFraction>&#160;million to be settled over the next <ix:nonNumeric contextRef="i406fa505aaae46879e51842eed75d4ce_D20220101-20220331" name="us-gaap:DerivativeRemainingMaturity1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfMjA1NQ_74856495-19ca-4005-aa59-5c404b459232">18</ix:nonNumeric> months, of which $<ix:nonFraction unitRef="usd" contextRef="i317559ce8f9e4b26a225b70d06a61b25_I20220331" decimals="-5" name="biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfMjA2OA_74516da5-6e52-4185-bd9f-89ce8883a77d">72.0</ix:nonFraction> million of these net unrealized gains are expected to be settled over the next <ix:nonNumeric contextRef="ibfad3eb157664139a953f3e9ba192977_D20220101-20220331" name="us-gaap:DerivativeRemainingMaturity1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfMjEzMg_540aaf11-64c2-48c0-8136-0835fd7d1338">12</ix:nonNumeric> months, with any amounts in </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="ie50e64bb602842198a58d735a5aa462e" continuedAt="i50b0edacabf64747bd474ec408d9c804"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accumulated other comprehensive income (loss) to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of March 31, 2022 and December 31, 2021, credit risk did not materially change the fair value of our foreign currency forward contracts.</span></div><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfNjk2OA_2257e678-cfab-4b5d-8b54-f98d428c3c35" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:22.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.154%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Operating Income (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i930b3a82003f4bec8f1d94de444724dc_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOmQ3ODc0ZjM5ZjY1ZTRmYTJiMGFhY2Q1ODhmZjIxYWVlL3RhYmxlcmFuZ2U6ZDc4NzRmMzlmNjVlNGZhMmIwYWFjZDU4OGZmMjFhZWVfMy0yLTEtMS03NTE0MA_3a65614b-cd9b-4881-ad64-7fbe88d4e157">20.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b9c2fab12ac4d2bb51603b6415c4055_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOmQ3ODc0ZjM5ZjY1ZTRmYTJiMGFhY2Q1ODhmZjIxYWVlL3RhYmxlcmFuZ2U6ZDc4NzRmMzlmNjVlNGZhMmIwYWFjZDU4OGZmMjFhZWVfMy00LTEtMS03NTE0MA_5e1782ae-55d6-4456-ba97-6d11fdfc11b8">23.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i355096b3d6354bf5a1914fc120d6d527_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOmQ3ODc0ZjM5ZjY1ZTRmYTJiMGFhY2Q1ODhmZjIxYWVlL3RhYmxlcmFuZ2U6ZDc4NzRmMzlmNjVlNGZhMmIwYWFjZDU4OGZmMjFhZWVfMy04LTEtMS03NTE0MA_cc25a29b-bcc9-4cb7-9e4c-282417fcb507">6.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2469406df0d54a489bd5f64e3dea3d36_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOmQ3ODc0ZjM5ZjY1ZTRmYTJiMGFhY2Q1ODhmZjIxYWVlL3RhYmxlcmFuZ2U6ZDc4NzRmMzlmNjVlNGZhMmIwYWFjZDU4OGZmMjFhZWVfMy0xMC0xLTEtNzUxNDA_bcca13ed-f10b-465e-9d3d-ec4401d5b506">3.0</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabceb3a0623e41c4a664ac8948832356_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOmQ3ODc0ZjM5ZjY1ZTRmYTJiMGFhY2Q1ODhmZjIxYWVlL3RhYmxlcmFuZ2U6ZDc4NzRmMzlmNjVlNGZhMmIwYWFjZDU4OGZmMjFhZWVfNC0yLTEtMS03NTE0MA_cfae4bcb-06f8-4776-814e-9a4da3f6be8e">0.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ea5c7e3d1434a96a8496e2352fabe5b_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOmQ3ODc0ZjM5ZjY1ZTRmYTJiMGFhY2Q1ODhmZjIxYWVlL3RhYmxlcmFuZ2U6ZDc4NzRmMzlmNjVlNGZhMmIwYWFjZDU4OGZmMjFhZWVfNC00LTEtMS03NTE0MA_9dc8f1a4-268e-4955-8d32-a8979761796b">0.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8992ee77c09249988dad3a68bcc5843f_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOmQ3ODc0ZjM5ZjY1ZTRmYTJiMGFhY2Q1ODhmZjIxYWVlL3RhYmxlcmFuZ2U6ZDc4NzRmMzlmNjVlNGZhMmIwYWFjZDU4OGZmMjFhZWVfNC04LTEtMS03NTE0MA_cb1129ad-8a44-4766-8767-a5a8919d08c7">0.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62cbd491b5784eedb300e49ae6efc87a_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOmQ3ODc0ZjM5ZjY1ZTRmYTJiMGFhY2Q1ODhmZjIxYWVlL3RhYmxlcmFuZ2U6ZDc4NzRmMzlmNjVlNGZhMmIwYWFjZDU4OGZmMjFhZWVfNC0xMC0xLTEtNzUxNDA_1e13420d-1117-4070-a080-9fb4cbcbc6f7">0.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Investment Hedges - Hedging Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately <ix:nonFraction unitRef="number" contextRef="i2b7ac531239c4d9aac8a7b0c71f6fdf5_I20180531" decimals="3" name="biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfMjE5OTAyMzI2NjQyMA_3af745c8-8944-4ffb-b23a-3d18d76c0d55">5.0</ix:nonFraction>% to approximately <ix:nonFraction unitRef="number" contextRef="ia5fabf9c71294456a0158d60a5f483a4_I20220331" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfNDA2NQ_0952b3aa-e388-47ac-91cb-321e4a6f024f">49.9</ix:nonFraction>%. The share purchase transaction was completed in November 2018 and, upon closing, we paid <ix:nonFraction unitRef="krw" contextRef="i76b1491614cc49378a38f3c27aafce95_D20181101-20181130" decimals="-8" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfMjE5OTAyMzI2NDQ3OQ_a4b7ab0b-46d6-41ce-af0e-b9b52fedc146">759.5</ix:nonFraction> billion South Korean won ($<ix:nonFraction unitRef="usd" contextRef="i76b1491614cc49378a38f3c27aafce95_D20181101-20181130" decimals="-5" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfMjE5OTAyMzI2NDQ5NQ_c3a7f988-7e5a-4879-a634-e5f881d90aea">676.6</ix:nonFraction> million) to Samsung BioLogics. Our investment in the equity of Samsung Bioepis is exposed to the currency fluctuations in the South Korean won. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to mitigate the currency fluctuations between the U.S. dollar and South Korean won, we have entered into foreign currency forward contracts. Foreign currency forward contracts in effect as of March 31, 2022, had a remaining duration of <ix:nonNumeric contextRef="ifb6cf45b64754d4b88c6cd9ba8980d50_D20220101-20220331" name="us-gaap:DerivativeTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfNDU1Mg_ab35018e-421d-40db-856a-6ab49683c2aa">seven months</ix:nonNumeric>. These contracts have been designated as net investment hedges. We recognize changes in the spot exchange rate in accumulated other comprehensive income (loss). The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of $<ix:nonFraction unitRef="usd" contextRef="ifb6cf45b64754d4b88c6cd9ba8980d50_D20220101-20220331" decimals="-5" name="us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfNDkwNQ_7cd2f09e-c0bf-4116-8ddd-486281cfdaf1">20.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0df6dbddbff746298274ecd0b63baf47_D20210101-20210930" decimals="-5" name="us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfNDkyNg_ed69c8a4-c7a1-4117-9560-4f8f5b15aca6">10.6</ix:nonFraction> million as of March 31, 2022 and December 31, 2021, respectively. We exclude fair value changes related to the forward rate from our hedging relationship and will amortize the forward points in other income (expense), net in our condensed consolidated statements of income over the term of the contract. The pre-tax portion of the fair value of the forward points that were included in accumulated other comprehensive income (loss) in total equity reflected net losses of $<ix:nonFraction unitRef="usd" contextRef="ib51e9913c2884e49a66dce4cf9163f6d_I20220331" decimals="-5" name="us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfNTM2MQ_d7499e49-1ae8-4ad0-a2de-0d4521c868a6">2.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5062e91336b74ad5ab0ffa4f2982b8e3_I20211231" decimals="-5" name="us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfNTM2OA_8ad3b881-f278-40ba-b7dc-a54d0fb02d06">3.6</ix:nonFraction> million as of March 31, 2022 and December 31, 2021, respectively. In conjunction with the closing of our sale of equity in Samsung Bioepis to Samsung BioLogics, which occurred in April 2022, we concurrently closed our foreign currency forward contracts.</span></div><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfNjk1MQ_cd119b7c-3d83-4c18-845b-4c5bfb85e5e8" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of our net investment hedge in our condensed consolidated financial statements:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:18.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.202%"></td><td style="width:0.1%"></td></tr><tr><td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) <br/>(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Net Income <br/>(Amounts Excluded from Effectiveness Testing) (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb6cf45b64754d4b88c6cd9ba8980d50_D20220101-20220331" decimals="-5" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjlkZDJhNjk4OTIyZTQ2YjJiYmI3ZDRkZWU4ZmM1Y2I1L3RhYmxlcmFuZ2U6OWRkMmE2OTg5MjJlNDZiMmJiYjdkNGRlZThmYzVjYjVfMy0yLTEtMS03NTE0MA_0c301916-e909-4c89-b5c7-f967fe88a8b8">10.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1d439a992034e5a880d6b7d7d1fd8ff_D20210101-20210331" decimals="-5" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjlkZDJhNjk4OTIyZTQ2YjJiYmI3ZDRkZWU4ZmM1Y2I1L3RhYmxlcmFuZ2U6OWRkMmE2OTg5MjJlNDZiMmJiYjdkNGRlZThmYzVjYjVfMy00LTEtMS03NTE0MA_ca04fe11-20ff-4c30-a57a-f29757557248">23.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb6cf45b64754d4b88c6cd9ba8980d50_D20220101-20220331" decimals="-5" sign="-" name="biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjlkZDJhNjk4OTIyZTQ2YjJiYmI3ZDRkZWU4ZmM1Y2I1L3RhYmxlcmFuZ2U6OWRkMmE2OTg5MjJlNDZiMmJiYjdkNGRlZThmYzVjYjVfMy04LTEtMS03NTE0MA_fc184ed2-e37c-4402-a7be-df896ce19e97">3.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1d439a992034e5a880d6b7d7d1fd8ff_D20210101-20210331" decimals="-5" sign="-" name="biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjlkZDJhNjk4OTIyZTQ2YjJiYmI3ZDRkZWU4ZmM1Y2I1L3RhYmxlcmFuZ2U6OWRkMmE2OTg5MjJlNDZiMmJiYjdkNGRlZThmYzVjYjVfMy0xMC0xLTEtNzUxNDA_73f92e86-1777-409b-a6fb-783a32e272e6">1.4</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04123d710b8e48c89a62fd25aa7cc3dc_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjlkZDJhNjk4OTIyZTQ2YjJiYmI3ZDRkZWU4ZmM1Y2I1L3RhYmxlcmFuZ2U6OWRkMmE2OTg5MjJlNDZiMmJiYjdkNGRlZThmYzVjYjVfMy0xNC0xLTEtNzUxNDA_bcefbb36-9433-4013-ae33-d36a90b67a64">1.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49647cb8da844b74bee321a532e55b36_D20210101-20210331" decimals="-5" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjlkZDJhNjk4OTIyZTQ2YjJiYmI3ZDRkZWU4ZmM1Y2I1L3RhYmxlcmFuZ2U6OWRkMmE2OTg5MjJlNDZiMmJiYjdkNGRlZThmYzVjYjVfMy0xNi0xLTEtNzUxNDA_8999cafd-10e9-4d50-a442-5460fe0d2e1e">0.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Forward Contracts - Other Derivative Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate notional amount of these outstanding foreign currency forward contracts was $<ix:nonFraction unitRef="usd" contextRef="i9f94fcf078da46ef9117103ab626567e_I20220331" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfNjA4Nw_fc88f027-f2b0-4bce-bacf-494236f37d40">1,333.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1d28240f464f4a5c8cc87e17a9a57d40_I20211231" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfNjA5NA_eec8b929-89e1-4313-ae46-1b02cf0ac407">1,268.0</ix:nonFraction> million as of March 31, 2022 and December 31, 2021, respectively. Net losses of $<ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfNjE0Mg_efbde012-2cdb-4eba-abbc-0b57b2b399c5">12.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfMjE5OTAyMzI2NDU1MA_f200f3b1-601e-44d8-8ca2-3a2bd2983396">17.4</ix:nonFraction> million related to these contracts were recorded as a component of other income (expense), net for the three months ended March 31, 2022 and 2021, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i50b0edacabf64747bd474ec408d9c804"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Derivative Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset.</span></div><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfNjk1Mw_e794306c-2a8b-4071-b58b-6a0900531c27" escape="true"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:28.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Cash Flow Hedging Instruments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife02cc8b68b74e45a4550426f8f6e028_I20220331" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjMwNGUzYWI5ZDhmZDQ3YWI5MDQ5YTMwMDJkN2UzNWEwL3RhYmxlcmFuZ2U6MzA0ZTNhYjlkOGZkNDdhYjkwNDlhMzAwMmQ3ZTM1YTBfMi00LTEtMS03NTE0MA_091fe025-d90d-4098-87e2-7fa96c4aabae">79.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55597e78171f481ea55329770d91ef68_I20211231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjMwNGUzYWI5ZDhmZDQ3YWI5MDQ5YTMwMDJkN2UzNWEwL3RhYmxlcmFuZ2U6MzA0ZTNhYjlkOGZkNDdhYjkwNDlhMzAwMmQ3ZTM1YTBfMi02LTEtMS03NTE0MA_6e6f3bb8-a6df-4859-845e-a5fc9e1cdfff">66.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f169aefbf5349eb87fe05cb8688fca5_I20220331" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjMwNGUzYWI5ZDhmZDQ3YWI5MDQ5YTMwMDJkN2UzNWEwL3RhYmxlcmFuZ2U6MzA0ZTNhYjlkOGZkNDdhYjkwNDlhMzAwMmQ3ZTM1YTBfMy00LTEtMS03NTE0MA_7793cdb6-fa1d-45c1-b9ef-c1c2e24b62d3">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb5afc172aec4efebd6f1b568ac8ba97_I20211231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjMwNGUzYWI5ZDhmZDQ3YWI5MDQ5YTMwMDJkN2UzNWEwL3RhYmxlcmFuZ2U6MzA0ZTNhYjlkOGZkNDdhYjkwNDlhMzAwMmQ3ZTM1YTBfMy02LTEtMS03NTE0MA_f66dd465-7adc-42b8-804d-e801c24263ff">5.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadd2bb0a22624c17a5f24102ad78024e_I20220331" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjMwNGUzYWI5ZDhmZDQ3YWI5MDQ5YTMwMDJkN2UzNWEwL3RhYmxlcmFuZ2U6MzA0ZTNhYjlkOGZkNDdhYjkwNDlhMzAwMmQ3ZTM1YTBfNC00LTEtMS03NTE0MA_750df7c7-17ec-406c-8755-42f5123ee4c9">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ca7b68a94cf428e9116acf90742cf4c_I20211231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjMwNGUzYWI5ZDhmZDQ3YWI5MDQ5YTMwMDJkN2UzNWEwL3RhYmxlcmFuZ2U6MzA0ZTNhYjlkOGZkNDdhYjkwNDlhMzAwMmQ3ZTM1YTBfNC02LTEtMS03NTE0MA_82df4ca1-a704-4741-8c1a-e48d752fadcb">6.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a575848d988444ca4869d5a47cae38a_I20220331" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjMwNGUzYWI5ZDhmZDQ3YWI5MDQ5YTMwMDJkN2UzNWEwL3RhYmxlcmFuZ2U6MzA0ZTNhYjlkOGZkNDdhYjkwNDlhMzAwMmQ3ZTM1YTBfNS00LTEtMS03NTE0MA_3b5de5a5-15bd-47d6-bc34-3a20d630316b">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib79aa8e4e7624556b3ddeed5fa194e23_I20211231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjMwNGUzYWI5ZDhmZDQ3YWI5MDQ5YTMwMDJkN2UzNWEwL3RhYmxlcmFuZ2U6MzA0ZTNhYjlkOGZkNDdhYjkwNDlhMzAwMmQ3ZTM1YTBfNS02LTEtMS03NTE0MA_53c9ab48-b674-41a8-9653-a378517f7630">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Instruments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i493a11d6c18c49269d42f6e6982e8f44_I20220331" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjMwNGUzYWI5ZDhmZDQ3YWI5MDQ5YTMwMDJkN2UzNWEwL3RhYmxlcmFuZ2U6MzA0ZTNhYjlkOGZkNDdhYjkwNDlhMzAwMmQ3ZTM1YTBfOC00LTEtMS03NTE0MA_070cb9d9-4f5c-4f66-b169-54b562e77c17">10.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i639c896977df489fbc54f9088f6147de_I20211231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjMwNGUzYWI5ZDhmZDQ3YWI5MDQ5YTMwMDJkN2UzNWEwL3RhYmxlcmFuZ2U6MzA0ZTNhYjlkOGZkNDdhYjkwNDlhMzAwMmQ3ZTM1YTBfOC02LTEtMS03NTE0MA_a5b4408f-c275-4fdd-8273-4e57a43a0e6a">4.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other Derivative Instruments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0a4f26886de44beaaa9fd8add3e3cd9_I20220331" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjMwNGUzYWI5ZDhmZDQ3YWI5MDQ5YTMwMDJkN2UzNWEwL3RhYmxlcmFuZ2U6MzA0ZTNhYjlkOGZkNDdhYjkwNDlhMzAwMmQ3ZTM1YTBfMTYtNC0xLTEtNzUxNDA_c92c7d9b-bd8f-48ee-898b-474a3c5ed358">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46e754dc01c0498393cd6a5acbb81bc2_I20211231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjMwNGUzYWI5ZDhmZDQ3YWI5MDQ5YTMwMDJkN2UzNWEwL3RhYmxlcmFuZ2U6MzA0ZTNhYjlkOGZkNDdhYjkwNDlhMzAwMmQ3ZTM1YTBfMTYtNi0xLTEtNzUxNDA_ed258236-ffb7-42b8-bf34-9000cacaffa4">5.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52be7c4aa2b64ac78381cc2d75fa44bd_I20220331" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjMwNGUzYWI5ZDhmZDQ3YWI5MDQ5YTMwMDJkN2UzNWEwL3RhYmxlcmFuZ2U6MzA0ZTNhYjlkOGZkNDdhYjkwNDlhMzAwMmQ3ZTM1YTBfMTctNC0xLTEtNzUxNDA_0e947e1f-8780-4f33-b621-b16274f4d104">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91d51f7faa640ed87d6899c2a544613_I20211231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjMwNGUzYWI5ZDhmZDQ3YWI5MDQ5YTMwMDJkN2UzNWEwL3RhYmxlcmFuZ2U6MzA0ZTNhYjlkOGZkNDdhYjkwNDlhMzAwMmQ3ZTM1YTBfMTctNi0xLTEtNzUxNDA_758f060e-03ab-4a97-b459-19a9325c6b33">4.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ie9658fba2baf4e3799b1175f69eaed46_85"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;PROPERTY, PLANT AND EQUIPMENT </span></div><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl84NS9mcmFnOmI1NDczMDk0NjVlNjQxZDg4NWM1YmEwMzZjNDhkODlhL3RleHRyZWdpb246YjU0NzMwOTQ2NWU2NDFkODg1YzViYTAzNmM0OGQ4OWFfMTIwMw_f250b035-f7d7-4507-b8ce-14bb5cf8761b" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was $<ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl84NS9mcmFnOmI1NDczMDk0NjVlNjQxZDg4NWM1YmEwMzZjNDhkODlhL3RleHRyZWdpb246YjU0NzMwOTQ2NWU2NDFkODg1YzViYTAzNmM0OGQ4OWFfMTcx_100944c1-d97b-443e-847a-aa02406a9c92">2,082.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl84NS9mcmFnOmI1NDczMDk0NjVlNjQxZDg4NWM1YmEwMzZjNDhkODlhL3RleHRyZWdpb246YjU0NzMwOTQ2NWU2NDFkODg1YzViYTAzNmM0OGQ4OWFfMTc4_c8c73942-39ba-4d56-b238-9235fcca6918">2,006.6</ix:nonFraction> million as of March 31, 2022 and December 31, 2021, respectively. For the three months ended March 31, 2022, depreciation expense totaled $<ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl84NS9mcmFnOmI1NDczMDk0NjVlNjQxZDg4NWM1YmEwMzZjNDhkODlhL3RleHRyZWdpb246YjU0NzMwOTQ2NWU2NDFkODg1YzViYTAzNmM0OGQ4OWFfMjc2_d93b0bf2-eb7c-4d8a-96cb-bf19b10be2e2">76.3</ix:nonFraction> million compared to $<ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl84NS9mcmFnOmI1NDczMDk0NjVlNjQxZDg4NWM1YmEwMzZjNDhkODlhL3RleHRyZWdpb246YjU0NzMwOTQ2NWU2NDFkODg1YzViYTAzNmM0OGQ4OWFfMzEz_ec7bd608-37a6-43fa-9ae0-8c72e12f4e63">48.8</ix:nonFraction> million in the prior year comparative period.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Solothurn, Switzerland Manufacturing Facility</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to support our future growth and drug development pipeline, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. Upon completion, this facility will include <ix:nonFraction unitRef="sqft" contextRef="i6f64e07d384c415c831dd4b33c3b6b7f_D20220101-20220331" decimals="INF" name="biib:NumberOfSquareFeet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl84NS9mcmFnOmI1NDczMDk0NjVlNjQxZDg4NWM1YmEwMzZjNDhkODlhL3RleHRyZWdpb246YjU0NzMwOTQ2NWU2NDFkODg1YzViYTAzNmM0OGQ4OWFfNjI2_17bf9b78-b96c-494f-aa14-448af7b00e33">393,000</ix:nonFraction> square feet related to a large-scale biologics manufacturing facility, <ix:nonFraction unitRef="sqft" contextRef="i099a9481f0f445269310c0321517d33c_D20220101-20220331" decimals="INF" name="biib:NumberOfSquareFeet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl84NS9mcmFnOmI1NDczMDk0NjVlNjQxZDg4NWM1YmEwMzZjNDhkODlhL3RleHRyZWdpb246YjU0NzMwOTQ2NWU2NDFkODg1YzViYTAzNmM0OGQ4OWFfNzAw_798a7fcc-0110-4fb8-b797-275db855d0d7">290,000</ix:nonFraction> square feet of warehouse, utilities and support space and <ix:nonFraction unitRef="sqft" contextRef="ieed6363c4f674d66a54d0dc0c55f0f52_D20220101-20220331" decimals="INF" name="biib:NumberOfSquareFeet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl84NS9mcmFnOmI1NDczMDk0NjVlNjQxZDg4NWM1YmEwMzZjNDhkODlhL3RleHRyZWdpb246YjU0NzMwOTQ2NWU2NDFkODg1YzViYTAzNmM0OGQ4OWFfNzYx_4ed22dab-091a-436a-8f35-85cdcbf1c20f">51,000</ix:nonFraction> square feet of administrative space. As of March 31, 2022 and December 31, 2021, we had approximately $<ix:nonFraction unitRef="usd" contextRef="i3e94ec2413a34ad39baef4a302252a4a_I20220331" decimals="-5" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl84NS9mcmFnOmI1NDczMDk0NjVlNjQxZDg4NWM1YmEwMzZjNDhkODlhL3RleHRyZWdpb246YjU0NzMwOTQ2NWU2NDFkODg1YzViYTAzNmM0OGQ4OWFfODM5_b3bfdecb-3cc1-4e55-aa7c-1b35a97e8889">682.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie078509e1f7d4077a083b848308445a3_I20211231" decimals="-6" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl84NS9mcmFnOmI1NDczMDk0NjVlNjQxZDg4NWM1YmEwMzZjNDhkODlhL3RleHRyZWdpb246YjU0NzMwOTQ2NWU2NDFkODg1YzViYTAzNmM0OGQ4OWFfODQ2_3a99950e-d261-49cf-a47a-e89a2e679c9a">677.0</ix:nonFraction> million, respectively, capitalized as construction in progress related to this facility. In the second quarter of 2021, a portion of the facility received a Good Manufacturing Practice multi-product license from the Swiss Agency for Therapeutic Products, resulting in approximately $<ix:nonFraction unitRef="usd" contextRef="i3e94ec2413a34ad39baef4a302252a4a_I20220331" decimals="-8" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl84NS9mcmFnOmI1NDczMDk0NjVlNjQxZDg4NWM1YmEwMzZjNDhkODlhL3RleHRyZWdpb246YjU0NzMwOTQ2NWU2NDFkODg1YzViYTAzNmM0OGQ4OWFfMTEyMw_0f4119c7-8bc3-4b9d-a20e-fce55f4f1370">1.2</ix:nonFraction>&#160;billion of fixed assets being placed in service during the second quarter of 2021. In April 2022 the FDA approved the Prior Approval Supplement for the Solothurn facility for ADUHELM. We estimate the remainder of the facility will be operational during the first half of 2023.</span></div></ix:nonNumeric><div id="ie9658fba2baf4e3799b1175f69eaed46_88"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.</span><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INDEBTEDNESS</span><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl84OC9mcmFnOjA1ZmRmODU1OWJiZTQwODM4N2RiZmUxZjJkNzcyMjA5L3RleHRyZWdpb246MDVmZGY4NTU5YmJlNDA4Mzg3ZGJmZTFmMmQ3NzIyMDlfMzU2Ng_a755fd17-777c-43bb-9f06-24cadf4d0c51" continuedAt="i9ae6e678b12947078f82596b171a53cd" escape="true"><div style="margin-top:6pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exchange Offer</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021 we completed our Exchange Offer of our tendered 2045 Senior Notes for our 2051 Senior Notes and cash, and an offer to purchase our tendered 2045 Senior Notes for cash. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An aggregate principal amount of approximately $<ix:nonFraction unitRef="usd" contextRef="id425e7508d5f4fcf9ccfcc07674b63de_D20210201-20210228" decimals="-5" name="biib:LongTermDebtExchangedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl84OC9mcmFnOjA1ZmRmODU1OWJiZTQwODM4N2RiZmUxZjJkNzcyMjA5L3RleHRyZWdpb246MDVmZGY4NTU5YmJlNDA4Mzg3ZGJmZTFmMmQ3NzIyMDlfMjYx_8c9e4c52-23ae-474a-a1f8-8996b71597ed">624.6</ix:nonFraction>&#160;million of our 2045 Senior Notes was exchanged for an aggregate principal amount of approximately $<ix:nonFraction unitRef="usd" contextRef="ie3968065f0a74bfead74be1f343078f9_D20210201-20210228" decimals="-5" name="biib:LongTermDebtExchangedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl84OC9mcmFnOjA1ZmRmODU1OWJiZTQwODM4N2RiZmUxZjJkNzcyMjA5L3RleHRyZWdpb246MDVmZGY4NTU5YmJlNDA4Mzg3ZGJmZTFmMmQ3NzIyMDlfMzU0_89100470-eb17-4863-a884-6388ed14ff16">700.7</ix:nonFraction>&#160;million of our 2051 Senior Notes and aggregate cash payments of approximately $<ix:nonFraction unitRef="usd" contextRef="id164d47b16824f0c874ceeea51fbbcbc_D20210201-20210228" decimals="-5" name="us-gaap:RepaymentsOfSeniorDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl84OC9mcmFnOjA1ZmRmODU1OWJiZTQwODM4N2RiZmUxZjJkNzcyMjA5L3RleHRyZWdpb246MDVmZGY4NTU5YmJlNDA4Mzg3ZGJmZTFmMmQ3NzIyMDlfNDI3_1ee51db3-4b36-4f61-8a0f-59cddc0c1cef">151.8</ix:nonFraction>&#160;million. Our Exchange Offer has been accounted for as a debt modification; as such, the cash component has been reflected as additional debt discount and is amortized as an adjustment to interest expense over the term of our 2051 Senior Notes.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we redeemed an aggregate principal amount of approximately $<ix:nonFraction unitRef="usd" contextRef="id425e7508d5f4fcf9ccfcc07674b63de_D20210201-20210228" decimals="-5" name="biib:DebtInstrumentRedemptionAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl84OC9mcmFnOjA1ZmRmODU1OWJiZTQwODM4N2RiZmUxZjJkNzcyMjA5L3RleHRyZWdpb246MDVmZGY4NTU5YmJlNDA4Mzg3ZGJmZTFmMmQ3NzIyMDlfNzM4_e3d1a2f7-be95-47e6-9610-2d7c5103454e">8.9</ix:nonFraction>&#160;million of our 2045 Senior Notes for aggregate cash payments of approximately $<ix:nonFraction unitRef="usd" contextRef="id425e7508d5f4fcf9ccfcc07674b63de_D20210201-20210228" decimals="-5" name="us-gaap:RepaymentsOfSeniorDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl84OC9mcmFnOjA1ZmRmODU1OWJiZTQwODM4N2RiZmUxZjJkNzcyMjA5L3RleHRyZWdpb246MDVmZGY4NTU5YmJlNDA4Mzg3ZGJmZTFmMmQ3NzIyMDlfODEx_480be16f-1fa0-435a-8051-644eb252cac5">12.1</ix:nonFraction>&#160;million, excluding accrued and unpaid interest. The redemption has been accounted for as a debt extinguishment; as such, we recognized a pre-tax charge of </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i9ae6e678b12947078f82596b171a53cd"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="if242145ab9704eacb41a099fd01ce221_D20220101-20220331" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl84OC9mcmFnOjA1ZmRmODU1OWJiZTQwODM4N2RiZmUxZjJkNzcyMjA5L3RleHRyZWdpb246MDVmZGY4NTU5YmJlNDA4Mzg3ZGJmZTFmMmQ3NzIyMDlfOTYx_1fcc8c44-a120-42b0-9a57-65a83c90012e">3.2</ix:nonFraction>&#160;million upon the extinguishment of such 2045 Senior Notes. This charge, which was recognized in interest expense in other income (expense), net in our condensed consolidated statements of income for the three months ended March 31, 2021, reflects the payment of an early call premium and the write-off of the remaining unamortized original debt issuance costs and discount balances associated with such 2045 Senior Notes.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon settlement, we also made aggregate cash payments of approximately $<ix:nonFraction unitRef="usd" contextRef="if242145ab9704eacb41a099fd01ce221_D20220101-20220331" decimals="-5" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl84OC9mcmFnOjA1ZmRmODU1OWJiZTQwODM4N2RiZmUxZjJkNzcyMjA5L3RleHRyZWdpb246MDVmZGY4NTU5YmJlNDA4Mzg3ZGJmZTFmMmQ3NzIyMDlfMTQyNw_763c10aa-64a9-4bf6-adc8-5807cc92bffc">13.8</ix:nonFraction>&#160;million to settle all accrued and unpaid interest from the last interest payment date on our 2045 Senior Notes that were exchanged or redeemed. We incurred approximately $<ix:nonFraction unitRef="usd" contextRef="if242145ab9704eacb41a099fd01ce221_D20220101-20220331" decimals="-5" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl84OC9mcmFnOjA1ZmRmODU1OWJiZTQwODM4N2RiZmUxZjJkNzcyMjA5L3RleHRyZWdpb246MDVmZGY4NTU5YmJlNDA4Mzg3ZGJmZTFmMmQ3NzIyMDlfMTU5Mg_3e483d7b-1e22-498e-b3b5-8effed6bd05d">6.1</ix:nonFraction>&#160;million of costs associated with our Exchange Offer, which was recognized in interest expense in other income (expense), net in our condensed consolidated statements of income for the three months ended March 31, 2021.</span></div></ix:continuation><div id="ie9658fba2baf4e3799b1175f69eaed46_97"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;EQUITY </span></div><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RleHRyZWdpb246ZWE2MjIzNjgyOGJkNDBlMzkyZWFmMGM3ODBjOTk4MzlfMTgwNA_721ecbfa-665a-4670-b640-29b63b1383f5" continuedAt="i5605230b12ca48d3a69f8351014c222c" escape="true"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchases</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 our Board of Directors authorized a program to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="i927398c21f2c4253b9e5fc9aa1970ccb_I20201031" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RleHRyZWdpb246ZWE2MjIzNjgyOGJkNDBlMzkyZWFmMGM3ODBjOTk4MzlfMTEx_02d312d2-f814-4c4c-81d4-4435c19e433f">5.0</ix:nonFraction> billion of our common stock (2020 Share Repurchase Program). Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired. Under our 2020 Share Repurchase Program, we repurchased and retired approximately <ix:nonFraction unitRef="shares" contextRef="i8035064229a94dc1909b26988c0c3fc7_D20210101-20210331" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RleHRyZWdpb246ZWE2MjIzNjgyOGJkNDBlMzkyZWFmMGM3ODBjOTk4MzlfMjE5OTAyMzI1NzM5Mg_cb4694b6-7fc3-4cf7-8f21-fe0639dfe2e8">2.2</ix:nonFraction> million shares of our common stock at a cost of approximately $<ix:nonFraction unitRef="usd" contextRef="i8035064229a94dc1909b26988c0c3fc7_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RleHRyZWdpb246ZWE2MjIzNjgyOGJkNDBlMzkyZWFmMGM3ODBjOTk4MzlfMjE5OTAyMzI1NzQwMg_0e4a0b63-a411-4f1e-bdd0-ffa9255e56e0">600.0</ix:nonFraction> million during the three months ended March 31, 2021. There were no share repurchases of our common stock during the three months ended March 31, 2022. Approximately $<ix:nonFraction unitRef="usd" contextRef="i8aed478a3bb84a26a97e98654c7ce707_I20220331" decimals="-8" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RleHRyZWdpb246ZWE2MjIzNjgyOGJkNDBlMzkyZWFmMGM3ODBjOTk4MzlfNTM2_aa35c789-8110-400c-97a7-8ce3f5ece43f">2.8</ix:nonFraction> billion remained available under our 2020 Share Repurchase Program as of March 31, 2022.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income (Loss)</span></div><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RleHRyZWdpb246ZWE2MjIzNjgyOGJkNDBlMzkyZWFmMGM3ODBjOTk4MzlfMTc5Ng_947fbb7d-cf5b-4e03-8c3b-7d86be263e17" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.696%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.859%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses) on Net Investment Hedge, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia823c01230e94f078e3bd77c94d36863_I20211231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfMS0yLTEtMS03NTE0MA_ab6749e4-28c3-4014-8f1b-c459945357b7">2.2</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89079b4dcd7340cc8676a18916e07cce_I20211231" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfMS00LTEtMS03NTE0MA_796a9792-1606-4d75-94e2-1fcd3d7f5eb5">53.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1ba18679af24668b4316adb5b46bbeb_I20211231" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfMS02LTEtMS03NTE0MA_f9efcd74-bbf9-4fb3-a784-c2f48086330f">25.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic535854c80b1412f924435f8c91f63b8_I20211231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfMS04LTEtMS03NTE0MA_0a5886ce-e958-4187-af35-b20ffa2a8a17">44.8</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib29fa61175a74b01bcdc01a071bd7d48_I20211231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfMS0xMC0xLTEtNzUxNDA_34a64969-a98d-412a-8c14-362024cf654d">139.0</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfMS0xMi0xLTEtNzUxNDA_a384e6e0-571e-47fb-a1c2-b454ef7219f2">106.7</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e87abb1f9db4300857139f5ddaa4d14_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfMi0yLTEtMS03NTE0MA_f3fac3d8-18ec-45d3-96ea-8a7669232291">10.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc0ec6584c7c4d459947e00620f435cd_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfMi00LTEtMS03NTE0MA_a352c8d7-b75b-4c24-b5d4-88efbe20b448">34.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0f10b22c834ba396c8b4c6a3188b23_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfMi02LTEtMS03NTE0MA_5003f3f0-6003-4667-ae8d-4ca6b9022a00">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5838303fd7294f56a6ba30fc62e8ecac_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfMi04LTEtMS03NTE0MA_600bf9bb-be0c-4a79-bcc1-6a4b2a412435">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b54fa2358e34e17ae6d8739b9b3339b_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfMi0xMC0xLTEtNzUxNDA_2bcf48a2-075c-4af7-80ec-7ef4ba847474">21.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfMi0xMi0xLTEtNzUxNDA_00863554-908b-407e-9312-3af3ded2aa49">8.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e87abb1f9db4300857139f5ddaa4d14_D20220101-20220331" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfMy0yLTEtMS03NTE0MA_47253f8a-5be7-4bf9-b4be-6d125d739e4c">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc0ec6584c7c4d459947e00620f435cd_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfMy00LTEtMS03NTE0MA_6ed84316-8fb6-47b5-a57c-030c51b37b3c">18.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0f10b22c834ba396c8b4c6a3188b23_D20220101-20220331" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfMy02LTEtMS03NTE0MA_d29dd85f-e0f4-4d47-813a-396bd3b84176">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5838303fd7294f56a6ba30fc62e8ecac_D20220101-20220331" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfMy04LTEtMS03NTE0MA_e0f3a938-d96a-4346-baad-ece32dc79e51">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b54fa2358e34e17ae6d8739b9b3339b_D20220101-20220331" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfMy0xMC0xLTEtNzUxNDA_738cd259-6cf5-4a9c-a461-51a923c74bb0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfMy0xMi0xLTEtNzUxNDA_7c90ee49-555f-4359-a446-8b6a1de0b14c">16.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e87abb1f9db4300857139f5ddaa4d14_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfNC0yLTEtMS03NTE0MA_fe42be91-0f56-4d3f-93c0-399948e3d737">9.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc0ec6584c7c4d459947e00620f435cd_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfNC00LTEtMS03NTE0MA_a18a1867-33e8-422a-add8-f4d7c46ee5a3">15.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0f10b22c834ba396c8b4c6a3188b23_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfNC02LTEtMS03NTE0MA_1b6cc1be-7c27-45a0-9dac-6113adcd5d39">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5838303fd7294f56a6ba30fc62e8ecac_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfNC04LTEtMS03NTE0MA_cc4a133a-0753-4440-997f-0ac2e2ab935f">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b54fa2358e34e17ae6d8739b9b3339b_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfNC0xMC0xLTEtNzUxNDA_151e655a-46f3-4b2e-917f-09e50cbdbb0d">21.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfNC0xMi0xLTEtNzUxNDA_dd40b563-ee21-4b5f-a2b1-a9c8844df5a5">8.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b84e664424c4f9c9c3be2725156b218_I20220331" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfNS0yLTEtMS03NTE0MA_e38a5852-f066-43a8-8569-28ed6c1061c8">11.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i405ecf1b53c842e8ab96a5daf031a812_I20220331" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfNS00LTEtMS03NTE0MA_2eb5b6fb-14c6-4d2f-aa13-be9b252029e9">69.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac817d516214d4294329c0c3985e64a_I20220331" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfNS02LTEtMS03NTE0MA_8c0e4d5f-3c3a-4b44-ae8e-a7c32fc68948">31.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie992e5401cf74a7eb8a5100825da7530_I20220331" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfNS04LTEtMS03NTE0MA_150fd91e-b1af-4ab0-b766-67f005d21a10">43.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9dc7e3bd5af43b9ae44d024af7d45ee_I20220331" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfNS0xMC0xLTEtNzUxNDA_74a5c93d-ff50-4912-95d4-5cbabd8dffc5">160.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfNS0xMi0xLTEtNzUxNDA_519023d8-cb42-48af-820c-44b6bf0e6f36">115.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.696%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.859%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses) on Net Investment Hedge, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b8f47e6df9047dc9800a3ef46b3a47a_I20201231" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfMS0yLTEtMS03NTE0MA_0f9ef1ed-f181-4fff-afdd-7dfb13a38a14">1.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c403b59149b4448b3ab41d54ea6da30_I20201231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfMS00LTEtMS03NTE0MA_c6b0a468-f5d7-4d63-954b-fa0d2b8495e7">179.0</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07e5a2d28d8644f0a7750374306253d1_I20201231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfMS02LTEtMS03NTE0MA_2a3d63ae-9b39-487f-b032-46fcdcb5a5e9">8.5</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic788e2af1c2a42bdad2a187fa0f3f0f9_I20201231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfMS04LTEtMS03NTE0MA_92331b64-c9ec-4e02-a542-fb833fc14ab0">66.3</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9905d8e67a1c49bba25ddc2283754bd9_I20201231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfMS0xMC0xLTEtNzUxNDA_11f7d9ae-a1c6-497f-98a7-c277e5fd7ceb">46.6</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8f47af926b14294931310a85ceac0ce_I20201231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfMS0xMi0xLTEtNzUxNDA_d9bbd22a-3946-4ee9-9c32-5b23d27de2e5">299.0</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56c6c6dbd77141ebb3ba11ea6d1906c2_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfMi0yLTEtMS03NTE0MA_f2a5ed10-de46-4d35-a48d-d089a39d2c45">1.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21cbbb23fa0942b0b38de55781a30060_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfMi00LTEtMS03NTE0MA_22d26899-2045-43b6-9f3d-155712e27fe0">128.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76808577ee454761a0b2fc6e21960006_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfMi02LTEtMS03NTE0MA_aca03bea-bc37-456f-a2d2-f5121fd31760">22.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6abbeadb96ac4f689ba74b0475350c98_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfMi04LTEtMS03NTE0MA_a96a376d-2743-4aaf-8c1d-95cb7f6e06a6">2.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf39efdb65104bcb856efd226f4e02aa_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfMi0xMC0xLTEtNzUxNDA_3725a310-2b6d-4e26-b696-f00cae92e65b">48.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfMi0xMi0xLTEtNzUxNDA_d51716b3-6d6e-47dc-a9f7-9928eb4c4795">103.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56c6c6dbd77141ebb3ba11ea6d1906c2_D20210101-20210331" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfMy0yLTEtMS03NTE0MA_b52c1fbd-d614-46ff-8bde-bf1034a99fa2">0.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21cbbb23fa0942b0b38de55781a30060_D20210101-20210331" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfMy00LTEtMS03NTE0MA_dd28e6ab-b924-4bf3-b7eb-9ef6044eb4f1">21.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76808577ee454761a0b2fc6e21960006_D20210101-20210331" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfMy02LTEtMS03NTE0MA_02f348e2-b569-4856-bf2d-eae508cce7b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6abbeadb96ac4f689ba74b0475350c98_D20210101-20210331" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfMy04LTEtMS03NTE0MA_715d7057-b043-4a28-9da4-38ab7d938ba2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf39efdb65104bcb856efd226f4e02aa_D20210101-20210331" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfMy0xMC0xLTEtNzUxNDA_20442a7d-fef0-48df-9bbf-8f48688c09aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfMy0xMi0xLTEtNzUxNDA_f1ae373a-59af-4b29-9518-8c57a6c11ec4">21.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56c6c6dbd77141ebb3ba11ea6d1906c2_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfNC0yLTEtMS03NTE0MA_18aa45dd-cd82-40ae-8cb4-b9a10a7aafde">0.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21cbbb23fa0942b0b38de55781a30060_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfNC00LTEtMS03NTE0MA_ff0d86b4-e744-488f-b5a6-2d6349a3922e">149.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76808577ee454761a0b2fc6e21960006_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfNC02LTEtMS03NTE0MA_59abcbd3-b272-44b6-81f8-850dcd8ce26d">22.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6abbeadb96ac4f689ba74b0475350c98_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfNC04LTEtMS03NTE0MA_17b6ca38-491d-4849-b1bd-811ae3a9cf4d">2.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf39efdb65104bcb856efd226f4e02aa_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfNC0xMC0xLTEtNzUxNDA_8f24ced6-2559-43ac-b6f3-f18545f5a431">48.5</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfNC0xMi0xLTEtNzUxNDA_5766aa41-d324-4abf-891f-f85b853e6f99">124.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd3f194d4161459fa9fc9aaed46498ea_I20210331" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfNS0yLTEtMS03NTE0MA_8bfd775b-e23c-4465-bffd-5b6f89d5dfff">0.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70ab7808a4b842c9925eda0753188c9f_I20210331" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfNS00LTEtMS03NTE0MA_31c44d89-1a9c-41f9-a3fb-67b18cb04706">29.4</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8c8dc8cb4ac4de98e44bab2c31b1282_I20210331" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfNS02LTEtMS03NTE0MA_0d38c4c5-6ee3-483c-bfce-dfd9610ea034">13.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4e7315860ff46c0acb88d0816fd6daf_I20210331" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfNS04LTEtMS03NTE0MA_ae547820-903d-4b60-8d4d-e59b87a0d93d">64.3</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52bad0c11e3144e899c81a5bb55aabb2_I20210331" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfNS0xMC0xLTEtNzUxNDA_7b689544-0969-4cd0-8d87-47ec2ffe9eec">95.1</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8239e2124c804a2ea880e06ae55914e8_I20210331" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfNS0xMi0xLTEtNzUxNDA_8193a3ca-614f-4442-a4ca-25d2cff30b47">174.3</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i5605230b12ca48d3a69f8351014c222c"><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RleHRyZWdpb246ZWE2MjIzNjgyOGJkNDBlMzkyZWFmMGM3ODBjOTk4MzlfMTc5Mg_5a64af82-8ef9-430b-8029-d8ebadd3d13c" escape="true"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts reclassified from accumulated other comprehensive income (loss):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:18pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts Reclassified from Accumulated Other Comprehensive Income (Loss)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on securities available for sale</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54a289067eb44a92a43277cf25c506fe_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmUwYjczNGJlYjBmNTRhYTc5NDMyOGI2ZjRjOGIwZjk2L3RhYmxlcmFuZ2U6ZTBiNzM0YmViMGY1NGFhNzk0MzI4YjZmNGM4YjBmOTZfMy0zLTEtMS03NTE0MA_4dba1bcf-6f82-4b11-a4d1-f31e13cdf7cb">0.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaaff40b00b8a475aa7213303ae060f69_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmUwYjczNGJlYjBmNTRhYTc5NDMyOGI2ZjRjOGIwZjk2L3RhYmxlcmFuZ2U6ZTBiNzM0YmViMGY1NGFhNzk0MzI4YjZmNGM4YjBmOTZfMy01LTEtMS03NTE0MA_7f8f363e-0942-4280-9569-8a9ee0fd5186">0.5</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54a289067eb44a92a43277cf25c506fe_D20220101-20220331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmUwYjczNGJlYjBmNTRhYTc5NDMyOGI2ZjRjOGIwZjk2L3RhYmxlcmFuZ2U6ZTBiNzM0YmViMGY1NGFhNzk0MzI4YjZmNGM4YjBmOTZfNC0zLTEtMS03NTE0MA_7504d899-916c-4a2a-8c02-c16b0bacc7f4">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaff40b00b8a475aa7213303ae060f69_D20210101-20210331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmUwYjczNGJlYjBmNTRhYTc5NDMyOGI2ZjRjOGIwZjk2L3RhYmxlcmFuZ2U6ZTBiNzM0YmViMGY1NGFhNzk0MzI4YjZmNGM4YjBmOTZfNC01LTEtMS03NTE0MA_54c6bf91-f5df-440a-8550-06974e59cd25">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on cash flow hedges</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82e69258ff2a411eb0af8d55689ed83c_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmUwYjczNGJlYjBmNTRhYTc5NDMyOGI2ZjRjOGIwZjk2L3RhYmxlcmFuZ2U6ZTBiNzM0YmViMGY1NGFhNzk0MzI4YjZmNGM4YjBmOTZfNi0zLTEtMS03NTE0MA_f314ea47-ddca-4cb9-b05e-a0355653ec71">20.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia89aa06c882742e4a448659b8c11481c_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmUwYjczNGJlYjBmNTRhYTc5NDMyOGI2ZjRjOGIwZjk2L3RhYmxlcmFuZ2U6ZTBiNzM0YmViMGY1NGFhNzk0MzI4YjZmNGM4YjBmOTZfNi01LTEtMS03NTE0MA_027a6f46-5219-45d7-8c41-da07dcbf7ceb">23.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82e69258ff2a411eb0af8d55689ed83c_D20220101-20220331" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmUwYjczNGJlYjBmNTRhYTc5NDMyOGI2ZjRjOGIwZjk2L3RhYmxlcmFuZ2U6ZTBiNzM0YmViMGY1NGFhNzk0MzI4YjZmNGM4YjBmOTZfNy0zLTEtMS03NTE0MA_0bcccae9-b6af-46b4-bc8e-04eb8aed4ae6">0.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia89aa06c882742e4a448659b8c11481c_D20210101-20210331" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmUwYjczNGJlYjBmNTRhYTc5NDMyOGI2ZjRjOGIwZjk2L3RhYmxlcmFuZ2U6ZTBiNzM0YmViMGY1NGFhNzk0MzI4YjZmNGM4YjBmOTZfNy01LTEtMS03NTE0MA_1cbea698-6d2f-4a1e-91ff-4e20c92d2823">0.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82e69258ff2a411eb0af8d55689ed83c_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmUwYjczNGJlYjBmNTRhYTc5NDMyOGI2ZjRjOGIwZjk2L3RhYmxlcmFuZ2U6ZTBiNzM0YmViMGY1NGFhNzk0MzI4YjZmNGM4YjBmOTZfOC0zLTEtMS03NTE0MA_afea7d44-c9cd-4a52-bb18-45ec6051bb25">0.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia89aa06c882742e4a448659b8c11481c_D20210101-20210331" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmUwYjczNGJlYjBmNTRhYTc5NDMyOGI2ZjRjOGIwZjk2L3RhYmxlcmFuZ2U6ZTBiNzM0YmViMGY1NGFhNzk0MzI4YjZmNGM4YjBmOTZfOC01LTEtMS03NTE0MA_c7517061-aa29-403e-86f5-888b82f5877c">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82e69258ff2a411eb0af8d55689ed83c_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmUwYjczNGJlYjBmNTRhYTc5NDMyOGI2ZjRjOGIwZjk2L3RhYmxlcmFuZ2U6ZTBiNzM0YmViMGY1NGFhNzk0MzI4YjZmNGM4YjBmOTZfOS0zLTEtMS03NTE0MA_300d9495-61ba-4fd3-83b6-e4cbb634d8a6">2.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia89aa06c882742e4a448659b8c11481c_D20210101-20210331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmUwYjczNGJlYjBmNTRhYTc5NDMyOGI2ZjRjOGIwZjk2L3RhYmxlcmFuZ2U6ZTBiNzM0YmViMGY1NGFhNzk0MzI4YjZmNGM4YjBmOTZfOS01LTEtMS03NTE0MA_0c94ee58-d438-4b7d-a79c-e8b2de16f2b1">2.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53aa42306e12421f90d4b595dc6b62f5_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmUwYjczNGJlYjBmNTRhYTc5NDMyOGI2ZjRjOGIwZjk2L3RhYmxlcmFuZ2U6ZTBiNzM0YmViMGY1NGFhNzk0MzI4YjZmNGM4YjBmOTZfMTEtMy0xLTEtNzUxNDA_ce669462-67fc-4d69-8c36-21669ddcb1ef">1.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9477047c7de34040997c009eedbe4518_D20210101-20210331" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmUwYjczNGJlYjBmNTRhYTc5NDMyOGI2ZjRjOGIwZjk2L3RhYmxlcmFuZ2U6ZTBiNzM0YmViMGY1NGFhNzk0MzI4YjZmNGM4YjBmOTZfMTEtNS0xLTEtNzUxNDA_9e93cc37-00aa-4356-a927-78a466d43965">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4e4d15b86ad443eb9d3edf6dee5f7b5_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmUwYjczNGJlYjBmNTRhYTc5NDMyOGI2ZjRjOGIwZjk2L3RhYmxlcmFuZ2U6ZTBiNzM0YmViMGY1NGFhNzk0MzI4YjZmNGM4YjBmOTZfMTQtMy0xLTEtNzUxNDA_2deb5dac-0844-40bd-bb61-f6734a418c27">16.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie709fcb90ef24b93b760d2540d00088a_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmUwYjczNGJlYjBmNTRhYTc5NDMyOGI2ZjRjOGIwZjk2L3RhYmxlcmFuZ2U6ZTBiNzM0YmViMGY1NGFhNzk0MzI4YjZmNGM4YjBmOTZfMTQtNS0xLTEtNzUxNDA_928d4580-d9bf-47a6-a89c-63d518f4e5a1">21.4</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ie9658fba2baf4e3799b1175f69eaed46_100"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;EARNINGS PER SHARE </span></div><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDAvZnJhZzo4ZmU4Njg2OTllZTk0YjhhODViNWFiM2YwMDY2MzU2NC90ZXh0cmVnaW9uOjhmZTg2ODY5OWVlOTRiOGE4NWI1YWIzZjAwNjYzNTY0XzI2MA_1d327ce6-6a54-46e9-b807-d91c5e374156" escape="true"><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDAvZnJhZzo4ZmU4Njg2OTllZTk0YjhhODViNWFiM2YwMDY2MzU2NC90ZXh0cmVnaW9uOjhmZTg2ODY5OWVlOTRiOGE4NWI1YWIzZjAwNjYzNTY0XzI2Nw_12aa6e13-201c-4bea-ba1d-f089b2536e31" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDAvZnJhZzo4ZmU4Njg2OTllZTk0YjhhODViNWFiM2YwMDY2MzU2NC90YWJsZTo5OGQ5ODNmNDZjNjQ0NTU5YTU1ZjkyMTU4NGIzZGNhZS90YWJsZXJhbmdlOjk4ZDk4M2Y0NmM2NDQ1NTlhNTVmOTIxNTg0YjNkY2FlXzMtMi0xLTEtNzUxNDA_6c52809a-f550-4c58-a5cd-ee28cf287ec2">303.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDAvZnJhZzo4ZmU4Njg2OTllZTk0YjhhODViNWFiM2YwMDY2MzU2NC90YWJsZTo5OGQ5ODNmNDZjNjQ0NTU5YTU1ZjkyMTU4NGIzZGNhZS90YWJsZXJhbmdlOjk4ZDk4M2Y0NmM2NDQ1NTlhNTVmOTIxNTg0YjNkY2FlXzMtNC0xLTEtNzUxNDA_7807fd1e-f962-4718-aadb-c9d7552c82cb">410.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDAvZnJhZzo4ZmU4Njg2OTllZTk0YjhhODViNWFiM2YwMDY2MzU2NC90YWJsZTo5OGQ5ODNmNDZjNjQ0NTU5YTU1ZjkyMTU4NGIzZGNhZS90YWJsZXJhbmdlOjk4ZDk4M2Y0NmM2NDQ1NTlhNTVmOTIxNTg0YjNkY2FlXzUtMi0xLTEtNzUxNDA_fd6f7d5c-d2a1-4999-8d2e-d7762cb1fd14">147.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDAvZnJhZzo4ZmU4Njg2OTllZTk0YjhhODViNWFiM2YwMDY2MzU2NC90YWJsZTo5OGQ5ODNmNDZjNjQ0NTU5YTU1ZjkyMTU4NGIzZGNhZS90YWJsZXJhbmdlOjk4ZDk4M2Y0NmM2NDQ1NTlhNTVmOTIxNTg0YjNkY2FlXzUtNC0xLTEtNzUxNDA_4d9c2bf2-0fd4-48d9-aae5-555bcccc37a0">151.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i810555191bc946a183d59137a3d60baf_D20220101-20220331" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDAvZnJhZzo4ZmU4Njg2OTllZTk0YjhhODViNWFiM2YwMDY2MzU2NC90YWJsZTo5OGQ5ODNmNDZjNjQ0NTU5YTU1ZjkyMTU4NGIzZGNhZS90YWJsZXJhbmdlOjk4ZDk4M2Y0NmM2NDQ1NTlhNTVmOTIxNTg0YjNkY2FlXzgtMi0xLTEtNzUxNDA_7bdd1223-776e-47f5-9c91-5950cf436c6c">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i091a772781f844e0996d9dd61c0fbb5f_D20210101-20210331" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDAvZnJhZzo4ZmU4Njg2OTllZTk0YjhhODViNWFiM2YwMDY2MzU2NC90YWJsZTo5OGQ5ODNmNDZjNjQ0NTU5YTU1ZjkyMTU4NGIzZGNhZS90YWJsZXJhbmdlOjk4ZDk4M2Y0NmM2NDQ1NTlhNTVmOTIxNTg0YjNkY2FlXzgtNC0xLTEtNzUxNDA_1f8d1392-be57-4940-ae74-bfb8de55ad58">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i39e928655ba643399618f0c17b2b0812_D20220101-20220331" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDAvZnJhZzo4ZmU4Njg2OTllZTk0YjhhODViNWFiM2YwMDY2MzU2NC90YWJsZTo5OGQ5ODNmNDZjNjQ0NTU5YTU1ZjkyMTU4NGIzZGNhZS90YWJsZXJhbmdlOjk4ZDk4M2Y0NmM2NDQ1NTlhNTVmOTIxNTg0YjNkY2FlXzktMi0xLTEtNzUxNDA_1b0ca4b6-9687-4d0a-8312-a162f991867b">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic6d836e623c94a73a4c74c493f93fee4_D20210101-20210331" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDAvZnJhZzo4ZmU4Njg2OTllZTk0YjhhODViNWFiM2YwMDY2MzU2NC90YWJsZTo5OGQ5ODNmNDZjNjQ0NTU5YTU1ZjkyMTU4NGIzZGNhZS90YWJsZXJhbmdlOjk4ZDk4M2Y0NmM2NDQ1NTlhNTVmOTIxNTg0YjNkY2FlXzktNC0xLTEtNzUxNDA_45dc2017-f7f7-4528-9fcc-1faa72416d6f">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iddfb71709ed840e98b85ca08ce7bdeaf_D20220101-20220331" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDAvZnJhZzo4ZmU4Njg2OTllZTk0YjhhODViNWFiM2YwMDY2MzU2NC90YWJsZTo5OGQ5ODNmNDZjNjQ0NTU5YTU1ZjkyMTU4NGIzZGNhZS90YWJsZXJhbmdlOjk4ZDk4M2Y0NmM2NDQ1NTlhNTVmOTIxNTg0YjNkY2FlXzEwLTItMS0xLTc1MTQw_b6034148-7120-4d27-811d-2c990f47a56f">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9afd12c183494d549b839596293da75e_D20210101-20210331" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDAvZnJhZzo4ZmU4Njg2OTllZTk0YjhhODViNWFiM2YwMDY2MzU2NC90YWJsZTo5OGQ5ODNmNDZjNjQ0NTU5YTU1ZjkyMTU4NGIzZGNhZS90YWJsZXJhbmdlOjk4ZDk4M2Y0NmM2NDQ1NTlhNTVmOTIxNTg0YjNkY2FlXzEwLTQtMS0xLTc1MTQw_42c13a62-49ca-454c-a342-d1122e7f6332">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dilutive potential common shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDAvZnJhZzo4ZmU4Njg2OTllZTk0YjhhODViNWFiM2YwMDY2MzU2NC90YWJsZTo5OGQ5ODNmNDZjNjQ0NTU5YTU1ZjkyMTU4NGIzZGNhZS90YWJsZXJhbmdlOjk4ZDk4M2Y0NmM2NDQ1NTlhNTVmOTIxNTg0YjNkY2FlXzExLTItMS0xLTc1MTQw_28d788b6-413b-474f-8867-bbd393f2cf7d">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDAvZnJhZzo4ZmU4Njg2OTllZTk0YjhhODViNWFiM2YwMDY2MzU2NC90YWJsZTo5OGQ5ODNmNDZjNjQ0NTU5YTU1ZjkyMTU4NGIzZGNhZS90YWJsZXJhbmdlOjk4ZDk4M2Y0NmM2NDQ1NTlhNTVmOTIxNTg0YjNkY2FlXzExLTQtMS0xLTc1MTQw_df26a7fb-e229-4668-b9d7-b3cc6f4ef6d3">0.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used in calculating diluted earnings per share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDAvZnJhZzo4ZmU4Njg2OTllZTk0YjhhODViNWFiM2YwMDY2MzU2NC90YWJsZTo5OGQ5ODNmNDZjNjQ0NTU5YTU1ZjkyMTU4NGIzZGNhZS90YWJsZXJhbmdlOjk4ZDk4M2Y0NmM2NDQ1NTlhNTVmOTIxNTg0YjNkY2FlXzEyLTItMS0xLTc1MTQw_f4b581b2-fb79-4501-bc1d-b9dab6daea06">147.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDAvZnJhZzo4ZmU4Njg2OTllZTk0YjhhODViNWFiM2YwMDY2MzU2NC90YWJsZTo5OGQ5ODNmNDZjNjQ0NTU5YTU1ZjkyMTU4NGIzZGNhZS90YWJsZXJhbmdlOjk4ZDk4M2Y0NmM2NDQ1NTlhNTVmOTIxNTg0YjNkY2FlXzEyLTQtMS0xLTc1MTQw_3d8ae53f-3039-4572-88d0-b89bb6709322">152.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.</span></div></ix:nonNumeric><div id="ie9658fba2baf4e3799b1175f69eaed46_103"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;SHARE-BASED PAYMENTS </span></div><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90ZXh0cmVnaW9uOmVjODkxNDU2ZmZkMjQyNjViNTk3Y2IyNzIxYjY5NDAwXzY0Mg_c052d51a-393d-4cec-890f-b34edd1b1a38" continuedAt="ic9c7dfd5b3a942068979ae4f2ea97854" escape="true"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based Compensation Expense</span></div><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90ZXh0cmVnaW9uOmVjODkxNDU2ZmZkMjQyNjViNTk3Y2IyNzIxYjY5NDAwXzY0NQ_44099aa2-52b6-4dbf-8a6a-e0bbe791059d" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida7d6be5a5da461dbf5390a92f2c5e9d_D20220101-20220331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTo3MmJhNDExYWRmOTQ0ZGI1YjMxYzg1M2U4YjVmYjVkZS90YWJsZXJhbmdlOjcyYmE0MTFhZGY5NDRkYjViMzFjODUzZThiNWZiNWRlXzItMi0xLTEtNzUxNDA_800f2e24-c402-4051-b685-692d9f33db8b">25.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0163dd5e3d654e748b422f150d2d5a9c_D20210101-20210331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTo3MmJhNDExYWRmOTQ0ZGI1YjMxYzg1M2U4YjVmYjVkZS90YWJsZXJhbmdlOjcyYmE0MTFhZGY5NDRkYjViMzFjODUzZThiNWZiNWRlXzItNC0xLTEtNzUxNDA_930ccf61-ed0d-442d-9e33-cad89240dc6d">33.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4eff7cd113a74d2e910753e991374627_D20220101-20220331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTo3MmJhNDExYWRmOTQ0ZGI1YjMxYzg1M2U4YjVmYjVkZS90YWJsZXJhbmdlOjcyYmE0MTFhZGY5NDRkYjViMzFjODUzZThiNWZiNWRlXzMtMi0xLTEtNzUxNDA_12cdea00-80ac-459c-91fd-2c6457e196f4">46.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i286ad499ff5d462799e0f941ef3e205f_D20210101-20210331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTo3MmJhNDExYWRmOTQ0ZGI1YjMxYzg1M2U4YjVmYjVkZS90YWJsZXJhbmdlOjcyYmE0MTFhZGY5NDRkYjViMzFjODUzZThiNWZiNWRlXzMtNC0xLTEtNzUxNDA_02d4971e-f5e3-4663-9c3c-9871bc9963d2">44.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTo3MmJhNDExYWRmOTQ0ZGI1YjMxYzg1M2U4YjVmYjVkZS90YWJsZXJhbmdlOjcyYmE0MTFhZGY5NDRkYjViMzFjODUzZThiNWZiNWRlXzQtMi0xLTEtNzUxNDA_b4684005-92d5-4be9-b36d-99309574833b">71.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTo3MmJhNDExYWRmOTQ0ZGI1YjMxYzg1M2U4YjVmYjVkZS90YWJsZXJhbmdlOjcyYmE0MTFhZGY5NDRkYjViMzFjODUzZThiNWZiNWRlXzQtNC0xLTEtNzUxNDA_624596a2-6cfc-41e9-9b37-a9c2f45c2275">78.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTo3MmJhNDExYWRmOTQ0ZGI1YjMxYzg1M2U4YjVmYjVkZS90YWJsZXJhbmdlOjcyYmE0MTFhZGY5NDRkYjViMzFjODUzZThiNWZiNWRlXzUtMi0xLTEtNzUxNDA_82c8baea-3255-40aa-b047-8a61b913cd6f">2.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTo3MmJhNDExYWRmOTQ0ZGI1YjMxYzg1M2U4YjVmYjVkZS90YWJsZXJhbmdlOjcyYmE0MTFhZGY5NDRkYjViMzFjODUzZThiNWZiNWRlXzUtNC0xLTEtNzUxNDA_a339e818-118a-4790-a906-4c1d45ba0320">2.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTo3MmJhNDExYWRmOTQ0ZGI1YjMxYzg1M2U4YjVmYjVkZS90YWJsZXJhbmdlOjcyYmE0MTFhZGY5NDRkYjViMzFjODUzZThiNWZiNWRlXzYtMi0xLTEtNzUxNDA_f3abc44a-11a8-4bb0-998f-e858967fe46a">69.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTo3MmJhNDExYWRmOTQ0ZGI1YjMxYzg1M2U4YjVmYjVkZS90YWJsZXJhbmdlOjcyYmE0MTFhZGY5NDRkYjViMzFjODUzZThiNWZiNWRlXzYtNC0xLTEtNzUxNDA_76bfa8c9-297a-41e8-876c-ecab2358a1ec">75.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax effect</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTo3MmJhNDExYWRmOTQ0ZGI1YjMxYzg1M2U4YjVmYjVkZS90YWJsZXJhbmdlOjcyYmE0MTFhZGY5NDRkYjViMzFjODUzZThiNWZiNWRlXzctMi0xLTEtNzUxNDA_3b9fc1f1-ee98-43ea-8d64-dabcb2beee10">12.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTo3MmJhNDExYWRmOTQ0ZGI1YjMxYzg1M2U4YjVmYjVkZS90YWJsZXJhbmdlOjcyYmE0MTFhZGY5NDRkYjViMzFjODUzZThiNWZiNWRlXzctNC0xLTEtNzUxNDA_00978f65-f230-4656-99e9-4c7a396d4eb9">14.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib96d4930fa9c4ea4920b41bc8432568c_D20220101-20220331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTo3MmJhNDExYWRmOTQ0ZGI1YjMxYzg1M2U4YjVmYjVkZS90YWJsZXJhbmdlOjcyYmE0MTFhZGY5NDRkYjViMzFjODUzZThiNWZiNWRlXzgtMi0xLTEtNzUxNDA_08c5002d-f842-42c7-a62e-5ff974ffcda7">56.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa0242e914b24b17a8a259457c37203f_D20210101-20210331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTo3MmJhNDExYWRmOTQ0ZGI1YjMxYzg1M2U4YjVmYjVkZS90YWJsZXJhbmdlOjcyYmE0MTFhZGY5NDRkYjViMzFjODUzZThiNWZiNWRlXzgtNC0xLTEtNzUxNDA_1b98c42e-23e5-4ef8-84b0-a4fd10814935">61.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="ic9c7dfd5b3a942068979ae4f2ea97854"><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90ZXh0cmVnaW9uOmVjODkxNDU2ZmZkMjQyNjViNTk3Y2IyNzIxYjY5NDAwXzY2NQ_2f70ebfb-4367-4f37-8c50-40eba4f9a2f5" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7e00bf0cede4201ac36bccc9be5e5fd_D20220101-20220331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTpmOGRkY2UzOGRjZTA0YWRjYjk5YjQ5MWI3OGM1Y2EwMy90YWJsZXJhbmdlOmY4ZGRjZTM4ZGNlMDRhZGNiOTliNDkxYjc4YzVjYTAzXzItMi0xLTEtNzUxNDA_254016de-e4dc-4616-bbd4-c08f760866ea">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i650e185cf72a422c97cc333e4de95e3e_D20210101-20210331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTpmOGRkY2UzOGRjZTA0YWRjYjk5YjQ5MWI3OGM1Y2EwMy90YWJsZXJhbmdlOmY4ZGRjZTM4ZGNlMDRhZGNiOTliNDkxYjc4YzVjYTAzXzItNC0xLTEtNzUxNDA_e9a7bde9-088e-44c6-a37c-b928c79de50d">16.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie511e6e4286f476b8bf2a94aa1d42b95_D20220101-20220331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTpmOGRkY2UzOGRjZTA0YWRjYjk5YjQ5MWI3OGM1Y2EwMy90YWJsZXJhbmdlOmY4ZGRjZTM4ZGNlMDRhZGNiOTliNDkxYjc4YzVjYTAzXzMtMi0xLTEtNzUxNDA_a33fdd58-1d88-4fe8-b9ab-e7adccaa3444">51.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dc6984b1c814916847de41632ad1d34_D20210101-20210331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTpmOGRkY2UzOGRjZTA0YWRjYjk5YjQ5MWI3OGM1Y2EwMy90YWJsZXJhbmdlOmY4ZGRjZTM4ZGNlMDRhZGNiOTliNDkxYjc4YzVjYTAzXzMtNC0xLTEtNzUxNDA_a20c8dd3-b5b5-424e-987b-fd2ee09140bb">42.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e2fa4eb32484e43801f3346334b0be3_D20220101-20220331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTpmOGRkY2UzOGRjZTA0YWRjYjk5YjQ5MWI3OGM1Y2EwMy90YWJsZXJhbmdlOmY4ZGRjZTM4ZGNlMDRhZGNiOTliNDkxYjc4YzVjYTAzXzYtMi0xLTEtNzUxNDA_01da5769-4768-400a-9056-0561553e9de1">8.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7c53ba95781468ab194b339910b54ea_D20210101-20210331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTpmOGRkY2UzOGRjZTA0YWRjYjk5YjQ5MWI3OGM1Y2EwMy90YWJsZXJhbmdlOmY4ZGRjZTM4ZGNlMDRhZGNiOTliNDkxYjc4YzVjYTAzXzYtNC0xLTEtNzUxNDA_a2f04942-3483-4812-9c3b-479466e6fa0e">6.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in cash</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadfc29fbc15b47a0bb4c9a7e11d2d1f6_D20220101-20220331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTpmOGRkY2UzOGRjZTA0YWRjYjk5YjQ5MWI3OGM1Y2EwMy90YWJsZXJhbmdlOmY4ZGRjZTM4ZGNlMDRhZGNiOTliNDkxYjc4YzVjYTAzXzctMi0xLTEtNzUxNDA_963e97d1-ac40-4e2d-9732-f0038e2b496b">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b5373d736be447fa8c13cecb1075da6_D20210101-20210331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTpmOGRkY2UzOGRjZTA0YWRjYjk5YjQ5MWI3OGM1Y2EwMy90YWJsZXJhbmdlOmY4ZGRjZTM4ZGNlMDRhZGNiOTliNDkxYjc4YzVjYTAzXzctNC0xLTEtNzUxNDA_77b1a78a-01cb-41c4-9374-14fe35ab262c">6.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fecd952a0f246f4bc6ae41add94430d_D20220101-20220331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTpmOGRkY2UzOGRjZTA0YWRjYjk5YjQ5MWI3OGM1Y2EwMy90YWJsZXJhbmdlOmY4ZGRjZTM4ZGNlMDRhZGNiOTliNDkxYjc4YzVjYTAzXzgtMi0xLTEtNzUxNDA_72f2b29e-8339-49d1-b35a-24efa8182b74">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11b85385e04c4d72bb460d8796578ce0_D20210101-20210331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTpmOGRkY2UzOGRjZTA0YWRjYjk5YjQ5MWI3OGM1Y2EwMy90YWJsZXJhbmdlOmY4ZGRjZTM4ZGNlMDRhZGNiOTliNDkxYjc4YzVjYTAzXzgtNC0xLTEtNzUxNDA_79cd1407-d92c-48dc-898d-1d5b22dbf364">6.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTpmOGRkY2UzOGRjZTA0YWRjYjk5YjQ5MWI3OGM1Y2EwMy90YWJsZXJhbmdlOmY4ZGRjZTM4ZGNlMDRhZGNiOTliNDkxYjc4YzVjYTAzXzEwLTItMS0xLTc1MTQw_d2cc5cd7-6847-48a1-afd2-5a7a35ab47f6">71.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTpmOGRkY2UzOGRjZTA0YWRjYjk5YjQ5MWI3OGM1Y2EwMy90YWJsZXJhbmdlOmY4ZGRjZTM4ZGNlMDRhZGNiOTliNDkxYjc4YzVjYTAzXzEwLTQtMS0xLTc1MTQw_bcb4f965-74d8-40a7-8426-70fa89e7731d">78.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTpmOGRkY2UzOGRjZTA0YWRjYjk5YjQ5MWI3OGM1Y2EwMy90YWJsZXJhbmdlOmY4ZGRjZTM4ZGNlMDRhZGNiOTliNDkxYjc4YzVjYTAzXzExLTItMS0xLTc1MTQw_c13011b0-e1b7-4456-9e6c-0276040edbf7">2.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTpmOGRkY2UzOGRjZTA0YWRjYjk5YjQ5MWI3OGM1Y2EwMy90YWJsZXJhbmdlOmY4ZGRjZTM4ZGNlMDRhZGNiOTliNDkxYjc4YzVjYTAzXzExLTQtMS0xLTc1MTQw_135937b1-8fd6-46db-9029-1309618daa79">2.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTpmOGRkY2UzOGRjZTA0YWRjYjk5YjQ5MWI3OGM1Y2EwMy90YWJsZXJhbmdlOmY4ZGRjZTM4ZGNlMDRhZGNiOTliNDkxYjc4YzVjYTAzXzEyLTItMS0xLTc1MTQw_4b2a25ed-28bd-4232-aeb1-70292e6811ce">69.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTpmOGRkY2UzOGRjZTA0YWRjYjk5YjQ5MWI3OGM1Y2EwMy90YWJsZXJhbmdlOmY4ZGRjZTM4ZGNlMDRhZGNiOTliNDkxYjc4YzVjYTAzXzEyLTQtMS0xLTc1MTQw_39b64aa9-821b-48b6-8ebc-5e75d3ba97c1">75.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of our obligations associated with our performance stock units settled in cash at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recognized each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.</span></div></ix:continuation><div id="ie9658fba2baf4e3799b1175f69eaed46_106"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;INCOME TAXES</span></div><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90ZXh0cmVnaW9uOjVlODA0YWZjNTczZjRmMTA5NDdlMjczYzY4ZTAwMmY4XzU0NTg_5a0f3146-8d23-4fae-956e-12f308661970" continuedAt="ibc7c81c094414605a77228168ee51bfe" escape="true"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tax Rate</span></div><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90ZXh0cmVnaW9uOjVlODA0YWZjNTczZjRmMTA5NDdlMjczYzY4ZTAwMmY4XzU0NzU_e9ff538f-656e-4845-9cb6-2b509040d193" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Statutory rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90YWJsZTphOTJiYmJjZjFmNzE0Y2E0YWY5Yjc0ZDRmODQ1ZThjOC90YWJsZXJhbmdlOmE5MmJiYmNmMWY3MTRjYTRhZjliNzRkNGY4NDVlOGM4XzItMS0xLTEtNzUxNDA_ea67009b-3f41-4f31-96da-a7d1370b69bd">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90YWJsZTphOTJiYmJjZjFmNzE0Y2E0YWY5Yjc0ZDRmODQ1ZThjOC90YWJsZXJhbmdlOmE5MmJiYmNmMWY3MTRjYTRhZjliNzRkNGY4NDVlOGM4XzItMy0xLTEtNzUxNDA_ad18f569-efe3-4e75-a648-81e8080836bb">21.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90YWJsZTphOTJiYmJjZjFmNzE0Y2E0YWY5Yjc0ZDRmODQ1ZThjOC90YWJsZXJhbmdlOmE5MmJiYmNmMWY3MTRjYTRhZjliNzRkNGY4NDVlOGM4XzMtMS0xLTEtNzUxNDA_a1efd00c-f079-46f9-bbfb-8597b64f88bb">0.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90YWJsZTphOTJiYmJjZjFmNzE0Y2E0YWY5Yjc0ZDRmODQ1ZThjOC90YWJsZXJhbmdlOmE5MmJiYmNmMWY3MTRjYTRhZjliNzRkNGY4NDVlOGM4XzMtMy0xLTEtNzUxNDA_5b292d10-0b6f-491c-9d90-1d33e12157cc">0.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes on foreign earnings</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90YWJsZTphOTJiYmJjZjFmNzE0Y2E0YWY5Yjc0ZDRmODQ1ZThjOC90YWJsZXJhbmdlOmE5MmJiYmNmMWY3MTRjYTRhZjliNzRkNGY4NDVlOGM4XzQtMS0xLTEtNzUxNDA_26f79ce4-91ed-4003-937e-f4b80d472339">10.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90YWJsZTphOTJiYmJjZjFmNzE0Y2E0YWY5Yjc0ZDRmODQ1ZThjOC90YWJsZXJhbmdlOmE5MmJiYmNmMWY3MTRjYTRhZjliNzRkNGY4NDVlOGM4XzQtMy0xLTEtNzUxNDA_697b5e85-a982-4e33-9877-71381a3268a6">10.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90YWJsZTphOTJiYmJjZjFmNzE0Y2E0YWY5Yjc0ZDRmODQ1ZThjOC90YWJsZXJhbmdlOmE5MmJiYmNmMWY3MTRjYTRhZjliNzRkNGY4NDVlOGM4XzUtMS0xLTEtNzUxNDA_02b91cf7-37a1-4bbd-b671-3eb9de5148db">2.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90YWJsZTphOTJiYmJjZjFmNzE0Y2E0YWY5Yjc0ZDRmODQ1ZThjOC90YWJsZXJhbmdlOmE5MmJiYmNmMWY3MTRjYTRhZjliNzRkNGY4NDVlOGM4XzUtMy0xLTEtNzUxNDA_5227ca58-6ee4-4e76-b192-8af275ae7e39">3.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90YWJsZTphOTJiYmJjZjFmNzE0Y2E0YWY5Yjc0ZDRmODQ1ZThjOC90YWJsZXJhbmdlOmE5MmJiYmNmMWY3MTRjYTRhZjliNzRkNGY4NDVlOGM4XzYtMS0xLTEtNzUxNDA_f577b567-2ccb-48a3-9a54-0022f0757fc1">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90YWJsZTphOTJiYmJjZjFmNzE0Y2E0YWY5Yjc0ZDRmODQ1ZThjOC90YWJsZXJhbmdlOmE5MmJiYmNmMWY3MTRjYTRhZjliNzRkNGY4NDVlOGM4XzYtMy0xLTEtNzUxNDA_88d0ea06-c6a2-4b9c-b8fe-46f1e3237c4a">0.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GILTI</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="3" name="biib:EffectiveTaxRateReconciliationGILTItax" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90YWJsZTphOTJiYmJjZjFmNzE0Y2E0YWY5Yjc0ZDRmODQ1ZThjOC90YWJsZXJhbmdlOmE5MmJiYmNmMWY3MTRjYTRhZjliNzRkNGY4NDVlOGM4XzEwLTEtMS0xLTc1MTQw_319a502e-c937-457c-a736-53758477d709">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="3" name="biib:EffectiveTaxRateReconciliationGILTItax" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90YWJsZTphOTJiYmJjZjFmNzE0Y2E0YWY5Yjc0ZDRmODQ1ZThjOC90YWJsZXJhbmdlOmE5MmJiYmNmMWY3MTRjYTRhZjliNzRkNGY4NDVlOGM4XzEwLTMtMS0xLTc1MTQw_429543ab-4326-41cb-a9b2-39369e7db33e">0.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Neurimmune tax impacts</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="3" name="biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90YWJsZTphOTJiYmJjZjFmNzE0Y2E0YWY5Yjc0ZDRmODQ1ZThjOC90YWJsZXJhbmdlOmE5MmJiYmNmMWY3MTRjYTRhZjliNzRkNGY4NDVlOGM4XzEzLTEtMS0xLTc1MTQw_3c97118b-5a87-4132-860e-4b646db528a2">24.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="3" sign="-" name="biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90YWJsZTphOTJiYmJjZjFmNzE0Y2E0YWY5Yjc0ZDRmODQ1ZThjOC90YWJsZXJhbmdlOmE5MmJiYmNmMWY3MTRjYTRhZjliNzRkNGY4NDVlOGM4XzEzLTMtMS0xLTc1MTQw_c3233040-c1f6-4cd6-b4fe-11b1ff5d64f9">0.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90YWJsZTphOTJiYmJjZjFmNzE0Y2E0YWY5Yjc0ZDRmODQ1ZThjOC90YWJsZXJhbmdlOmE5MmJiYmNmMWY3MTRjYTRhZjliNzRkNGY4NDVlOGM4XzE1LTEtMS0xLTc1MTQw_21732c6e-4d99-4a6e-b73a-4b796015f9a0">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90YWJsZTphOTJiYmJjZjFmNzE0Y2E0YWY5Yjc0ZDRmODQ1ZThjOC90YWJsZXJhbmdlOmE5MmJiYmNmMWY3MTRjYTRhZjliNzRkNGY4NDVlOGM4XzE1LTMtMS0xLTc1MTQw_a97d0fd7-8787-49f0-8724-1fc8702d7a3c">1.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90YWJsZTphOTJiYmJjZjFmNzE0Y2E0YWY5Yjc0ZDRmODQ1ZThjOC90YWJsZXJhbmdlOmE5MmJiYmNmMWY3MTRjYTRhZjliNzRkNGY4NDVlOGM4XzE2LTEtMS0xLTc1MTQw_0f802476-0803-4a25-b73e-fd9a3275acd6">36.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90YWJsZTphOTJiYmJjZjFmNzE0Y2E0YWY5Yjc0ZDRmODQ1ZThjOC90YWJsZXJhbmdlOmE5MmJiYmNmMWY3MTRjYTRhZjliNzRkNGY4NDVlOGM4XzE2LTMtMS0xLTc1MTQw_d8c32e1d-9e46-4b05-b45a-9bcfadb07654">9.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt"><span style="color:#00823b;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Tax Rate</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021 we recorded a net deferred tax asset in Switzerland of approximately $<ix:nonFraction unitRef="usd" contextRef="i350f52cf56ca419f9abcc85ddabdf66a_I20210630" decimals="-5" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90ZXh0cmVnaW9uOjVlODA0YWZjNTczZjRmMTA5NDdlMjczYzY4ZTAwMmY4XzEwOTk1MTE2NDE5MDY_5a1e626e-1911-40d4-bd13-9d2536359647"><ix:nonFraction unitRef="usd" contextRef="i350f52cf56ca419f9abcc85ddabdf66a_I20210630" decimals="-5" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90ZXh0cmVnaW9uOjVlODA0YWZjNTczZjRmMTA5NDdlMjczYzY4ZTAwMmY4XzEwOTk1MTE2NDE5MDY_a6fd5756-faf6-433e-abf0-882ac35e6c15">490.0</ix:nonFraction></ix:nonFraction>&#160;million on Neurimmune SubOne AG's (Neurimmune) tax basis in ADUHELM, the realization of which is dependent on future sales of ADUHELM. During the fourth quarter of 2021, due to reduced future expected revenue associated with ADUHELM, we recorded a valuation allowance of approximately $<ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90ZXh0cmVnaW9uOjVlODA0YWZjNTczZjRmMTA5NDdlMjczYzY4ZTAwMmY4XzEwOTk1MTE2NDE5MzE_f162b270-dd9d-4e6d-a19a-875190f5c2ca">390.0</ix:nonFraction>&#160;million. During the first quarter of 2022, upon issuance of the final NCD related to ADUHELM, we recorded an additional valuation allowance of approximately $<ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90ZXh0cmVnaW9uOjVlODA0YWZjNTczZjRmMTA5NDdlMjczYzY4ZTAwMmY4XzEwOTk1MTE2NDE5NTE_66d041a0-5993-465d-9d7e-ea7cbebc52ff">85.0</ix:nonFraction>&#160;million to reduce the net value of this deferred tax asset to zero. These adjustments to our deferred tax assets and their valuation allowances are each recorded with an equal and offsetting amount assigned to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income, resulting in a zero net impact to net income attributable to Biogen Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, compared to the same period in 2021, the increase in our effective tax rate was primarily due to a deferred tax expense related to a valuation allowance, as discussed above, and the non-cash tax effects of changes in the value of our equity investments. The tax effects of this change in value of our equity investments were recorded discretely, since changes in value of equity investments cannot be forecasted.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="ibc7c81c094414605a77228168ee51bfe"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For additional information on our collaboration arrangement with Neurimmune, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 17, Investments in Variable Interest Entities</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tax Basis in Samsung Bioepis</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022 and December 31, 2021, the carrying value of our investment in Samsung Bioepis totaled <ix:nonFraction unitRef="krw" contextRef="ia5fabf9c71294456a0158d60a5f483a4_I20220331" decimals="-8" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90ZXh0cmVnaW9uOjVlODA0YWZjNTczZjRmMTA5NDdlMjczYzY4ZTAwMmY4XzEwOTk1MTE2NDM2MDA_42b8f7c7-8367-40a5-a788-0ce0ca5abd0f">709.4</ix:nonFraction> billion South Korean won ($<ix:nonFraction unitRef="usd" contextRef="ia5fabf9c71294456a0158d60a5f483a4_I20220331" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90ZXh0cmVnaW9uOjVlODA0YWZjNTczZjRmMTA5NDdlMjczYzY4ZTAwMmY4XzEwOTk1MTE2NDM2MjI_242c97d3-6430-48e6-9d3f-2fbb9fe5f8cc">586.4</ix:nonFraction> million) and <ix:nonFraction unitRef="krw" contextRef="i9fcfddd14c424cd095a98f9df64e862f_I20211231" decimals="-8" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90ZXh0cmVnaW9uOjVlODA0YWZjNTczZjRmMTA5NDdlMjczYzY4ZTAwMmY4XzEwOTk1MTE2NDM2MzE_87266759-74dd-482d-9478-742073642902">713.3</ix:nonFraction> billion South Korean won ($<ix:nonFraction unitRef="usd" contextRef="i9fcfddd14c424cd095a98f9df64e862f_I20211231" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90ZXh0cmVnaW9uOjVlODA0YWZjNTczZjRmMTA5NDdlMjczYzY4ZTAwMmY4XzEwOTk1MTE2NDM2NTM_36c5f1d6-739a-424b-9e0f-fa7c3dd89332">599.9</ix:nonFraction> million), respectively, which is classified as a component of investments and other assets in our condensed consolidated balance sheets. As of March 31, 2022, we have not recorded deferred taxes of approximately $<ix:nonFraction unitRef="usd" contextRef="ia5fabf9c71294456a0158d60a5f483a4_I20220331" decimals="-5" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90ZXh0cmVnaW9uOjVlODA0YWZjNTczZjRmMTA5NDdlMjczYzY4ZTAwMmY4XzEwOTk1MTE2NDM4MDI_b2b4f694-0031-4164-948a-2417b0fb8fc4">70.0</ix:nonFraction>&#160;million on our tax over book basis related to this joint venture.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting for Uncertainty in Income Taxes</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2017 or state, local or non-U.S. income tax examinations for years before 2012.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration matters and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate that it is reasonably possible that our gross unrecognized tax benefits, exclusive of interest, could decrease by up to approximately $<ix:nonFraction unitRef="usd" contextRef="i8cc3940c5a604d08b1a0524870f97a03_I20230331" decimals="-5" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90ZXh0cmVnaW9uOjVlODA0YWZjNTczZjRmMTA5NDdlMjczYzY4ZTAwMmY4XzUzMzY_39cafb40-e73a-46de-bf5f-32ab01436dc4">500.0</ix:nonFraction> million, including approximately $<ix:nonFraction unitRef="usd" contextRef="i8cc3940c5a604d08b1a0524870f97a03_I20230331" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90ZXh0cmVnaW9uOjVlODA0YWZjNTczZjRmMTA5NDdlMjczYzY4ZTAwMmY4XzIxOTkwMjMyNjYzNjY_1ca40358-2691-4ec9-ad6b-22f4cea909c8">455.0</ix:nonFraction>&#160;million related to the unrecognized tax benefits related to Neurimmune's tax basis in ADUHELM in the next 12 months as a result of various audit closures, settlements and expiration of the statute of limitations.</span></div></ix:continuation><div id="ie9658fba2baf4e3799b1175f69eaed46_112"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.&#160;&#160;&#160;&#160;OTHER CONSOLIDATED FINANCIAL STATEMENT DETAIL </span></div><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90ZXh0cmVnaW9uOmUyMTU0MTI5NTg1ZDRlYzg5Y2ExMzlkNTVmNDk5NTA1XzE4MTc_cc9c5eaa-fee8-4f24-8c3f-61ed76d81cf9" continuedAt="i4fa397a1d42b4b4fa5704a3b209370f8" escape="true"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90ZXh0cmVnaW9uOmUyMTU0MTI5NTg1ZDRlYzg5Y2ExMzlkNTVmNDk5NTA1XzE3ODg_6349b01d-b205-4a0c-bb13-277a1277d403" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other income (expense), net, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTpmZDE4NGFhMWNmZDc0NWU2ODRhYjYyMTJmZTdlMWI3MC90YWJsZXJhbmdlOmZkMTg0YWExY2ZkNzQ1ZTY4NGFiNjIxMmZlN2UxYjcwXzItMi0xLTEtNzUxNDA_6e84a208-5600-457d-8c88-4ff5cf67929f">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTpmZDE4NGFhMWNmZDc0NWU2ODRhYjYyMTJmZTdlMWI3MC90YWJsZXJhbmdlOmZkMTg0YWExY2ZkNzQ1ZTY4NGFiNjIxMmZlN2UxYjcwXzItNC0xLTEtNzUxNDA_af3ff6e1-f64c-449b-8d5a-f34b1b8e9ba7">2.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTpmZDE4NGFhMWNmZDc0NWU2ODRhYjYyMTJmZTdlMWI3MC90YWJsZXJhbmdlOmZkMTg0YWExY2ZkNzQ1ZTY4NGFiNjIxMmZlN2UxYjcwXzMtMi0xLTEtNzUxNDA_6b02d887-a339-488e-9177-2416d9f35c22">66.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTpmZDE4NGFhMWNmZDc0NWU2ODRhYjYyMTJmZTdlMWI3MC90YWJsZXJhbmdlOmZkMTg0YWExY2ZkNzQ1ZTY4NGFiNjIxMmZlN2UxYjcwXzMtNC0xLTEtNzUxNDA_19e49ae5-6d3f-41c9-a3c7-9616831e96d1">64.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on investments, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:RealizedInvestmentGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTpmZDE4NGFhMWNmZDc0NWU2ODRhYjYyMTJmZTdlMWI3MC90YWJsZXJhbmdlOmZkMTg0YWExY2ZkNzQ1ZTY4NGFiNjIxMmZlN2UxYjcwXzQtMi0xLTEtNzUxNDA_0b8a95e1-14cf-4c51-9dab-f330b145d5ea">191.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:RealizedInvestmentGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTpmZDE4NGFhMWNmZDc0NWU2ODRhYjYyMTJmZTdlMWI3MC90YWJsZXJhbmdlOmZkMTg0YWExY2ZkNzQ1ZTY4NGFiNjIxMmZlN2UxYjcwXzQtNC0xLTEtNzUxNDA_12017785-9560-43d5-b12c-24ece7eb7739">436.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange gains (losses), net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTpmZDE4NGFhMWNmZDc0NWU2ODRhYjYyMTJmZTdlMWI3MC90YWJsZXJhbmdlOmZkMTg0YWExY2ZkNzQ1ZTY4NGFiNjIxMmZlN2UxYjcwXzUtMi0xLTEtNzUxNDA_6c6e7036-3e51-42e2-8bed-1ba68f4cafcd">8.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTpmZDE4NGFhMWNmZDc0NWU2ODRhYjYyMTJmZTdlMWI3MC90YWJsZXJhbmdlOmZkMTg0YWExY2ZkNzQ1ZTY4NGFiNjIxMmZlN2UxYjcwXzUtNC0xLTEtNzUxNDA_5503d5f8-3a7a-43ca-b356-53c08412381f">8.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTpmZDE4NGFhMWNmZDc0NWU2ODRhYjYyMTJmZTdlMWI3MC90YWJsZXJhbmdlOmZkMTg0YWExY2ZkNzQ1ZTY4NGFiNjIxMmZlN2UxYjcwXzYtMi0xLTEtNzUxNDA_c8a1c556-84ce-4bac-8c42-2879597c498d">0.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTpmZDE4NGFhMWNmZDc0NWU2ODRhYjYyMTJmZTdlMWI3MC90YWJsZXJhbmdlOmZkMTg0YWExY2ZkNzQ1ZTY4NGFiNjIxMmZlN2UxYjcwXzYtNC0xLTEtNzUxNDA_ab03901e-f71e-4117-a0d0-beafe90c340c">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTpmZDE4NGFhMWNmZDc0NWU2ODRhYjYyMTJmZTdlMWI3MC90YWJsZXJhbmdlOmZkMTg0YWExY2ZkNzQ1ZTY4NGFiNjIxMmZlN2UxYjcwXzctMi0xLTEtNzUxNDA_6c34fb6b-3aa8-451f-9ad9-e5f9ab94e55a">263.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTpmZDE4NGFhMWNmZDc0NWU2ODRhYjYyMTJmZTdlMWI3MC90YWJsZXJhbmdlOmZkMTg0YWExY2ZkNzQ1ZTY4NGFiNjIxMmZlN2UxYjcwXzctNC0xLTEtNzUxNDA_966b9cc7-663e-4cfa-acd1-26d806133b83">506.9</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains (losses) on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.</span></div><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="us-gaap:GainLossOnInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90ZXh0cmVnaW9uOmUyMTU0MTI5NTg1ZDRlYzg5Y2ExMzlkNTVmNDk5NTA1XzE3Nzg_ab7af4a1-a2e9-4474-b5e9-78d93053a40a" continuedAt="i6920a75f479844c7a81c6132aa22dcc5" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our gains (losses) on investments, net that relates to our equity securities held as of March 31, 2022 and 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net gains (losses) recognized during the period on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTpiZDI0YjdhYjkyMjc0YzlmYWY0YjBiMjE2ZGZhN2VhYy90YWJsZXJhbmdlOmJkMjRiN2FiOTIyNzRjOWZhZjRiMGIyMTZkZmE3ZWFjXzItMi0xLTEtNzUxNDA_dbf18ecd-d417-4035-855f-6bcfe45ca8af">190.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTpiZDI0YjdhYjkyMjc0YzlmYWY0YjBiMjE2ZGZhN2VhYy90YWJsZXJhbmdlOmJkMjRiN2FiOTIyNzRjOWZhZjRiMGIyMTZkZmE3ZWFjXzItNC0xLTEtNzUxNDA_18379e3a-3ea0-46f8-a2ee-7854eeb8d26a">436.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net gains (losses) realized during the period on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTpiZDI0YjdhYjkyMjc0YzlmYWY0YjBiMjE2ZGZhN2VhYy90YWJsZXJhbmdlOmJkMjRiN2FiOTIyNzRjOWZhZjRiMGIyMTZkZmE3ZWFjXzMtMi0xLTEtNzUxNDA_edc69e89-6f31-49dd-9a3b-2d7104695689">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTpiZDI0YjdhYjkyMjc0YzlmYWY0YjBiMjE2ZGZhN2VhYy90YWJsZXJhbmdlOmJkMjRiN2FiOTIyNzRjOWZhZjRiMGIyMTZkZmE3ZWFjXzMtNC0xLTEtNzUxNDA_6c207532-0bce-4a8c-9a70-8b1e5c6fea0f">6.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains (losses) recognized during the period on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTpiZDI0YjdhYjkyMjc0YzlmYWY0YjBiMjE2ZGZhN2VhYy90YWJsZXJhbmdlOmJkMjRiN2FiOTIyNzRjOWZhZjRiMGIyMTZkZmE3ZWFjXzQtMi0xLTEtNzUxNDA_8d94cf97-4173-46e7-85fd-9a2b6d7b1d64">190.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTpiZDI0YjdhYjkyMjc0YzlmYWY0YjBiMjE2ZGZhN2VhYy90YWJsZXJhbmdlOmJkMjRiN2FiOTIyNzRjOWZhZjRiMGIyMTZkZmE3ZWFjXzQtNC0xLTEtNzUxNDA_a8ba648a-09e4-4f7a-8239-087ff5e65964">442.3</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i4fa397a1d42b4b4fa5704a3b209370f8"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6920a75f479844c7a81c6132aa22dcc5">The net unrealized losses recognized during the three months ended March 31, 2022, primarily reflect decreases in the aggregate fair value of our investments in Denali, Sage and Sangamo common stock of approximately $<ix:nonFraction unitRef="usd" contextRef="i20649c5c9db8492a84683240d40b1cc8_D20220101-20220331" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90ZXh0cmVnaW9uOmUyMTU0MTI5NTg1ZDRlYzg5Y2ExMzlkNTVmNDk5NTA1XzIxOTkwMjMyNTc2NDg_7b3dd0f1-9a52-4727-9a29-9bde5bc25387">205.5</ix:nonFraction>&#160;million.</ix:continuation></span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expense and Other</span></div><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90ZXh0cmVnaW9uOmUyMTU0MTI5NTg1ZDRlYzg5Y2ExMzlkNTVmNDk5NTA1XzE3ODA_3b6a39c5-f547-48c1-916a-6cad83ab09b7" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expense and other consists of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue-related reserves for discounts and allowances</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bdcfb675756479fa2aa02a4f8a3a6ce_I20220331" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTplY2Q2ZTFmYmY3M2U0ODdiYmE0YmU5NDFhYjQyNjg1MC90YWJsZXJhbmdlOmVjZDZlMWZiZjczZTQ4N2JiYTRiZTk0MWFiNDI2ODUwXzEtMi0xLTEtNzUxNDA_06bf2ee8-bdd7-4e4a-b3e2-9ca1430b2276">831.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d7e46af1def46ae846f93734361fcc5_I20211231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTplY2Q2ZTFmYmY3M2U0ODdiYmE0YmU5NDFhYjQyNjg1MC90YWJsZXJhbmdlOmVjZDZlMWZiZjczZTQ4N2JiYTRiZTk0MWFiNDI2ODUwXzEtNC0xLTEtNzUxNDA_255c09a8-884f-4cd0-ade3-a392b701ca44">802.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="biib:Collaborationexpensesaccrual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTplY2Q2ZTFmYmY3M2U0ODdiYmE0YmU5NDFhYjQyNjg1MC90YWJsZXJhbmdlOmVjZDZlMWZiZjczZTQ4N2JiYTRiZTk0MWFiNDI2ODUwXzItMi0xLTEtNzUxNDA_c911af61-6742-4740-b303-9e775bc829a0">266.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="biib:Collaborationexpensesaccrual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTplY2Q2ZTFmYmY3M2U0ODdiYmE0YmU5NDFhYjQyNjg1MC90YWJsZXJhbmdlOmVjZDZlMWZiZjczZTQ4N2JiYTRiZTk0MWFiNDI2ODUwXzItNC0xLTEtNzUxNDA_dcba1e65-e5c9-4108-bb7e-420a6799afd6">324.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties and licensing fees</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:AccruedRoyaltiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTplY2Q2ZTFmYmY3M2U0ODdiYmE0YmU5NDFhYjQyNjg1MC90YWJsZXJhbmdlOmVjZDZlMWZiZjczZTQ4N2JiYTRiZTk0MWFiNDI2ODUwXzMtMi0xLTEtMTAyMTUz_250db3fb-5396-458a-a35a-41c613b1ee31">216.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:AccruedRoyaltiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTplY2Q2ZTFmYmY3M2U0ODdiYmE0YmU5NDFhYjQyNjg1MC90YWJsZXJhbmdlOmVjZDZlMWZiZjczZTQ4N2JiYTRiZTk0MWFiNDI2ODUwXzMtNC0xLTEtMTAyMTUz_42337be6-0972-45e2-b6b7-10e5f39ee7aa">234.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTplY2Q2ZTFmYmY3M2U0ODdiYmE0YmU5NDFhYjQyNjg1MC90YWJsZXJhbmdlOmVjZDZlMWZiZjczZTQ4N2JiYTRiZTk0MWFiNDI2ODUwXzMtMi0xLTEtNzUxNDA_4f8509bf-2266-4f2e-bbad-028d2cb82dd7">206.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTplY2Q2ZTFmYmY3M2U0ODdiYmE0YmU5NDFhYjQyNjg1MC90YWJsZXJhbmdlOmVjZDZlMWZiZjczZTQ4N2JiYTRiZTk0MWFiNDI2ODUwXzMtNC0xLTEtNzUxNDA_93aa8493-8ea8-47d0-af98-d65251f55219">345.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTplY2Q2ZTFmYmY3M2U0ODdiYmE0YmU5NDFhYjQyNjg1MC90YWJsZXJhbmdlOmVjZDZlMWZiZjczZTQ4N2JiYTRiZTk0MWFiNDI2ODUwXzctMi0xLTEtNzUxNDA_750e20ef-e1da-45c2-8c8e-ae71f3703baf">711.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTplY2Q2ZTFmYmY3M2U0ODdiYmE0YmU5NDFhYjQyNjg1MC90YWJsZXJhbmdlOmVjZDZlMWZiZjczZTQ4N2JiYTRiZTk0MWFiNDI2ODUwXzctNC0xLTEtNzUxNDA_c1950049-faf2-4ae1-a954-9f7dc0e2ac8b">828.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTplY2Q2ZTFmYmY3M2U0ODdiYmE0YmU5NDFhYjQyNjg1MC90YWJsZXJhbmdlOmVjZDZlMWZiZjczZTQ4N2JiYTRiZTk0MWFiNDI2ODUwXzgtMi0xLTEtNzUxNDA_6ecf8ad0-fe22-4999-b7f4-69b2c0c1f216">2,231.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTplY2Q2ZTFmYmY3M2U0ODdiYmE0YmU5NDFhYjQyNjg1MC90YWJsZXJhbmdlOmVjZDZlMWZiZjczZTQ4N2JiYTRiZTk0MWFiNDI2ODUwXzgtNC0xLTEtNzUxNDA_1bbaad9e-54f5-4ce1-a000-f6d7e8d19a0b">2,535.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Long-term Liabilities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities were $<ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90ZXh0cmVnaW9uOmUyMTU0MTI5NTg1ZDRlYzg5Y2ExMzlkNTVmNDk5NTA1XzE2NjU_ae9b79e7-c50a-4224-bacb-005459810b00">1,287.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90ZXh0cmVnaW9uOmUyMTU0MTI5NTg1ZDRlYzg5Y2ExMzlkNTVmNDk5NTA1XzE2NzI_2b393ea2-2d62-4e7f-b365-49ddd66c9824">1,320.5</ix:nonFraction> million as of March 31, 2022 and December 31, 2021, respectively, and included accrued income taxes totaling $<ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90ZXh0cmVnaW9uOmUyMTU0MTI5NTg1ZDRlYzg5Y2ExMzlkNTVmNDk5NTA1XzE3NDk_d680cbe1-88f9-4d61-996a-8e74f4184ea6">640.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90ZXh0cmVnaW9uOmUyMTU0MTI5NTg1ZDRlYzg5Y2ExMzlkNTVmNDk5NTA1XzE3NTY_0f9310db-f2f1-45bf-b3f4-2f302f691e30">664.5</ix:nonFraction> million, respectively.</span></div></ix:continuation><div id="ie9658fba2baf4e3799b1175f69eaed46_115"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">16.&#160;&#160;&#160;&#160;COLLABORATIVE AND OTHER RELATIONSHIPS </span></div><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzIwMTEw_61ac2d7d-c64b-49c1-8038-aa17ed122a50" continuedAt="i8593b394c7244196a5c070cf69acb25d" escape="true"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Eisai Co., Ltd.</span></div><div style="margin-top:5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lecanemab Collaboration</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with Eisai Co., Ltd. (Eisai) to jointly develop and commercialize lecanemab (BAN2401), an anti-amyloid antibody, and elenbecestat, the oral BACE (base amyloid cleaving enzyme) inhibitor, two Eisai product candidates for the potential treatment of Alzheimer's disease (the Lecanemab Collaboration). In September 2019 we and Eisai discontinued the global Phase 3 studies of elenbecestat in early Alzheimer's disease.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eisai serves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product, and Eisai having final decision-making authority. All costs, including research, development, sales and marketing expense, are shared equally between us and Eisai. If lecanemab receives marketing approval, we and Eisai will co-promote lecanemab and share profits equally. In March 2022 we extended our supply agreement related to lecanemab from <ix:nonNumeric contextRef="i7720f6aec35b4d8da3f83be28c73da37_D20210101-20211231" name="biib:CollaborationAgreementTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzEwOTk1MTE2NjUwMDY_61223c0e-c4c4-44c8-9d3d-3862a8f2040c">five years</ix:nonNumeric> to <ix:nonNumeric contextRef="i8a12e5f049a6452f9e97a9998e1ce4b6_D20220101-20220331" name="biib:CollaborationAgreementTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzEwOTk1MTE2NjUwMTQ_2e8c3d93-6ea1-45c8-91a0-3e0de1576f4d">ten years</ix:nonNumeric>, and we will manufacture the lecanemab drug substance in our Solothurn manufacturing facility.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Lecanemab Collaboration also provided Eisai with an option to jointly develop and commercialize ADUHELM (aducanumab) (ADUHELM Option). In October 2017 Eisai exercised its ADUHELM Option and we entered into a new collaboration agreement for the joint development and commercialization of ADUHELM (aducanumab) (the ADUHELM Collaboration Agreement).</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development and sales and marketing expense related to the Lecanemab Collaboration is as follows:</span></div><div><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzIwMDk0_901075db-d9d0-4855-8754-b238dd3fb482" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.523%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total development expense incurred by the collaboration related to the advancement of lecanemab and elenbecestat</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic53a168048b7491ea87c3962591ce459_D20220101-20220331" decimals="-5" name="biib:ExpenseIncurredByCollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTo0MDkzYzgzZjkwNGU0YmZmOGViYmMwM2QzMTMyMDU1MS90YWJsZXJhbmdlOjQwOTNjODNmOTA0ZTRiZmY4ZWJiYzAzZDMxMzIwNTUxXzItMi0xLTEtNzUxNDA_3023fb82-99e0-4032-9b4f-14b8efe26bdd">77.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic988722c1187407388795922a811a006_D20210101-20210331" decimals="-5" name="biib:ExpenseIncurredByCollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTo0MDkzYzgzZjkwNGU0YmZmOGViYmMwM2QzMTMyMDU1MS90YWJsZXJhbmdlOjQwOTNjODNmOTA0ZTRiZmY4ZWJiYzAzZDMxMzIwNTUxXzItNC0xLTEtNzUxNDA_f7ceb55a-3763-473c-aae9-1c0889b7a7e0">55.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of lecanemab and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic53a168048b7491ea87c3962591ce459_D20220101-20220331" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTo0MDkzYzgzZjkwNGU0YmZmOGViYmMwM2QzMTMyMDU1MS90YWJsZXJhbmdlOjQwOTNjODNmOTA0ZTRiZmY4ZWJiYzAzZDMxMzIwNTUxXzMtMi0xLTEtNzUxNDA_e114e398-61ba-4f90-ab02-84ad1fc577ab">38.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic988722c1187407388795922a811a006_D20210101-20210331" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTo0MDkzYzgzZjkwNGU0YmZmOGViYmMwM2QzMTMyMDU1MS90YWJsZXJhbmdlOjQwOTNjODNmOTA0ZTRiZmY4ZWJiYzAzZDMxMzIwNTUxXzMtNC0xLTEtNzUxNDA_c36c33d5-2868-4c10-83aa-50115b555821">27.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total sales and marketing expense incurred by the Lecanemab Collaboration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5eb97d60723b4bd0984e9c72d9e41857_D20220101-20220331" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTo0MDkzYzgzZjkwNGU0YmZmOGViYmMwM2QzMTMyMDU1MS90YWJsZXJhbmdlOjQwOTNjODNmOTA0ZTRiZmY4ZWJiYzAzZDMxMzIwNTUxXzQtMi0xLTEtNzUxNDA_20731138-5d68-4187-89d8-4c6e6c8a1585">15.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfdf8192d59c42ea96f70ac07a430dab_D20210101-20210331" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTo0MDkzYzgzZjkwNGU0YmZmOGViYmMwM2QzMTMyMDU1MS90YWJsZXJhbmdlOjQwOTNjODNmOTA0ZTRiZmY4ZWJiYzAzZDMxMzIwNTUxXzQtNC0xLTEtODE5MzA_be641104-176e-4080-b236-f95dc8999e3c">5.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of lecanemab and elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5eb97d60723b4bd0984e9c72d9e41857_D20220101-20220331" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTo0MDkzYzgzZjkwNGU0YmZmOGViYmMwM2QzMTMyMDU1MS90YWJsZXJhbmdlOjQwOTNjODNmOTA0ZTRiZmY4ZWJiYzAzZDMxMzIwNTUxXzUtMi0xLTEtNzUxNDA_3734ce90-73b0-4f96-91a5-f9a3b22a0dfd">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfdf8192d59c42ea96f70ac07a430dab_D20210101-20210331" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTo0MDkzYzgzZjkwNGU0YmZmOGViYmMwM2QzMTMyMDU1MS90YWJsZXJhbmdlOjQwOTNjODNmOTA0ZTRiZmY4ZWJiYzAzZDMxMzIwNTUxXzUtNC0xLTEtODE5MzA_acbac4a3-26cd-4bb5-940a-2d62708fcab9">2.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our Lecanemab Collaboration, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2021 Form 10-K.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i8593b394c7244196a5c070cf69acb25d" continuedAt="i91493b19985440ee9d1891dc630ee7f3"><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ADUHELM Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our initial ADUHELM Collaboration Agreement, we would lead the ongoing development of ADUHELM, and we and Eisai would co-promote ADUHELM with a region-based profit split. Beginning January 1, 2019, Eisai was reimbursing us for&#160;<ix:nonFraction unitRef="number" contextRef="i8a12e5f049a6452f9e97a9998e1ce4b6_D20220101-20220331" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzI0NDQ_05cf3daf-ff6a-4232-a16a-6ff1e749730b">45.0</ix:nonFraction>%&#160;of development costs incurred by the collaboration for the advancement of ADUHELM (ADUHELM development expense). </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 ADUHELM was granted accelerated approval by the FDA for the treatment of Alzheimer's disease and had its first commercial sale. As a result of the launch of ADUHELM in the U.S., we made a $<ix:nonFraction unitRef="usd" contextRef="ica3cdddcf72b46f8b05a616e0b059254_D20210601-20210630" decimals="-5" name="biib:AdditionalMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzM5NjM_dccfd1b1-f695-4163-9720-2d4130fcf448">100.0</ix:nonFraction>&#160;million milestone payment to Neurimmune. During the second quarter of 2021 we recognized net profit-sharing income of $<ix:nonFraction unitRef="usd" contextRef="i20e19171955440b582851c5ac5d45b30_D20210101-20210331" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzQwNzA_6cfa1de8-eeb2-4b32-b090-bb112aa7a6a4">45.0</ix:nonFraction>&#160;million to reflect Eisai's <ix:nonFraction unitRef="number" contextRef="i8a12e5f049a6452f9e97a9998e1ce4b6_D20220101-20220331" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzQwOTI_05cf3daf-ff6a-4232-a16a-6ff1e749730b">45.0</ix:nonFraction>% share of the $<ix:nonFraction unitRef="usd" contextRef="ica3cdddcf72b46f8b05a616e0b059254_D20210601-20210630" decimals="-5" name="biib:AdditionalMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzQxMDg_dccfd1b1-f695-4163-9720-2d4130fcf448">100.0</ix:nonFraction>&#160;million milestone payment, which was recorded in collaboration profit (loss) sharing in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022 we amended our ADUHELM Collaboration Agreement with Eisai. Effective March 2022 we have sole decision making and commercialization rights worldwide on ADUHELM and beginning January 1, 2023, Eisai will receive a tiered royalty based on net sales of ADUHELM, rather than sharing global profits and losses. Eisai's share of development, commercialization and manufacturing expense is limited to $<ix:nonFraction unitRef="usd" contextRef="i4afdc1a2dcdf424eabd0653274b690c7_D20220101-20221231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzEwOTk1MTE2NjYzMDQ_389955b6-bcc7-4d0e-a090-f9459a2d8f65">335.0</ix:nonFraction>&#160;million for the period from January 1, 2022 to December 31, 2022. Once the tiered royalty model commences on January 1, 2023, Eisai will not participate in ADUHELM&#8217;s economics beyond these royalties.</span></div><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="biib:SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzIwMTEy_b55bfee7-441f-4e36-b93c-18c24c733f48" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development expense, sales and marketing expense and milestone payments related to the ADUHELM Collaboration Agreement is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.523%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total ADUHELM development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90093effd3884afba4d3e630d74c241a_D20220101-20220331" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTpkNzFmMDhhYzM3OTg0NzFhYjBjYTExZjIwZDc1ZmViMC90YWJsZXJhbmdlOmQ3MWYwOGFjMzc5ODQ3MWFiMGNhMTFmMjBkNzVmZWIwXzItMi0xLTEtNzUxNDA_4632e2f3-bdb4-49a5-91fe-82fb8c5525c4">44.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95c7cf13e2f1475ea47f58a3f48df9e2_D20210101-20210331" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTpkNzFmMDhhYzM3OTg0NzFhYjBjYTExZjIwZDc1ZmViMC90YWJsZXJhbmdlOmQ3MWYwOGFjMzc5ODQ3MWFiMGNhMTFmMjBkNzVmZWIwXzItNC0xLTEtNzUxNDA_ead91645-9579-4cad-b160-6554556e83f3">47.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of ADUHELM development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90093effd3884afba4d3e630d74c241a_D20220101-20220331" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTpkNzFmMDhhYzM3OTg0NzFhYjBjYTExZjIwZDc1ZmViMC90YWJsZXJhbmdlOmQ3MWYwOGFjMzc5ODQ3MWFiMGNhMTFmMjBkNzVmZWIwXzMtMi0xLTEtNzUxNDA_3c8fbbd8-2bcb-49cc-ac61-562580e535d4">24.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95c7cf13e2f1475ea47f58a3f48df9e2_D20210101-20210331" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTpkNzFmMDhhYzM3OTg0NzFhYjBjYTExZjIwZDc1ZmViMC90YWJsZXJhbmdlOmQ3MWYwOGFjMzc5ODQ3MWFiMGNhMTFmMjBkNzVmZWIwXzMtNC0xLTEtNzUxNDA_31624ac6-2ee2-48f8-9565-32eae78baae6">25.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total ADUHELM sales and marketing expense incurred by the ADUHELM Collaboration Agreement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i534d34ae3d78433f9a80a80261d8c791_D20220101-20220331" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTpkNzFmMDhhYzM3OTg0NzFhYjBjYTExZjIwZDc1ZmViMC90YWJsZXJhbmdlOmQ3MWYwOGFjMzc5ODQ3MWFiMGNhMTFmMjBkNzVmZWIwXzQtMi0xLTEtNzUxNDA_7dbecd71-f1ff-43fa-a7c7-8fdc1e5a9d98">95.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i535bbd28d8064cd99845c7aad7ef40b6_D20210101-20210331" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTpkNzFmMDhhYzM3OTg0NzFhYjBjYTExZjIwZDc1ZmViMC90YWJsZXJhbmdlOmQ3MWYwOGFjMzc5ODQ3MWFiMGNhMTFmMjBkNzVmZWIwXzQtNC0xLTEtNzUxNDA_e0a0fb8d-98e8-4c81-b214-5a30aed4fe59">111.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of ADUHELM sales and marketing expense reflected in selling, general and administrative expense and collaboration profit (loss) sharing in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i534d34ae3d78433f9a80a80261d8c791_D20220101-20220331" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTpkNzFmMDhhYzM3OTg0NzFhYjBjYTExZjIwZDc1ZmViMC90YWJsZXJhbmdlOmQ3MWYwOGFjMzc5ODQ3MWFiMGNhMTFmMjBkNzVmZWIwXzUtMi0xLTEtNzUxNDA_51385a97-a259-44c5-a8a0-17fc36938b49">50.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i535bbd28d8064cd99845c7aad7ef40b6_D20210101-20210331" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTpkNzFmMDhhYzM3OTg0NzFhYjBjYTExZjIwZDc1ZmViMC90YWJsZXJhbmdlOmQ3MWYwOGFjMzc5ODQ3MWFiMGNhMTFmMjBkNzVmZWIwXzUtNC0xLTEtNzUxNDA_7eb62fa0-03d6-42d1-884c-e2ae772ca7a0">60.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">o-promotion Profits and Losses</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S. we recognize revenue on sales to third parties as a component of product revenue, net in our condensed consolidated statements of income. We also record the related cost of revenue and sales and marketing expense in our condensed consolidated statements of income as these costs are incurred. Payments made to and received from Eisai for its <ix:nonFraction unitRef="number" contextRef="i8a12e5f049a6452f9e97a9998e1ce4b6_D20220101-20220331" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzQ3OTY_05cf3daf-ff6a-4232-a16a-6ff1e749730b">45.0</ix:nonFraction>% share of the co-promotion profits or losses in the U.S. are recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. For the three months ended March 31, 2022, we recognized a net reduction to our operating expense of </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i8a12e5f049a6452f9e97a9998e1ce4b6_D20220101-20220331" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzUwMzI_9ad781aa-deba-43a7-9a80-f0cf4a57a16e">181.7</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to reflect Eisai's <ix:nonFraction unitRef="number" contextRef="i140fc83df9b443f8947b6e9c5a831662_D20210101-20210331" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzUwNzY_adec97ed-40df-4fea-8402-228ea0e15490">45.0</ix:nonFraction>% share of net collaboration losses in the U.S.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2022 we recorded approximately $<ix:nonFraction unitRef="usd" contextRef="i722a1d8416ce4b6b9e7ebbb4433afb51_D20220101-20220331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzIxOTkwMjMyOTQ4Nzk_93da7398-8194-4a20-87bb-0a10fd68a3dd">275.0</ix:nonFraction>&#160;million of gross charges associated with inventory and purchase commitments in excess of forecasted demand related to ADUHELM, as well as approximately $<ix:nonFraction unitRef="usd" contextRef="i8a12e5f049a6452f9e97a9998e1ce4b6_D20220101-20220331" decimals="-5" name="biib:CostOfGoodsSoldCapacityCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzEwOTk1MTE2NzI2MDQ_97b8d295-1432-4a71-94c6-4067faa38a4a">45.0</ix:nonFraction>&#160;million of gross idle capacity charges, which were recognized in cost of sales within our condensed consolidated statements of income. We have recognized approximately $<ix:nonFraction unitRef="usd" contextRef="i11a20f8ab31748a3a765230d484a950c_D20220101-20220331" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzEwOTk1MTE2NzcyODQ_ebfcb53e-3e77-4cfc-b25b-959829a17d04">160.0</ix:nonFraction>&#160;million related to Eisai's <ix:nonFraction unitRef="number" contextRef="i8a12e5f049a6452f9e97a9998e1ce4b6_D20220101-20220331" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzEwOTk1MTE2NjY5OTg_05cf3daf-ff6a-4232-a16a-6ff1e749730b">45.0</ix:nonFraction>% share of these charges in collaboration profit (loss) sharing within our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts receivable from Eisai related to the agreements discussed above were </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i30f95d1127004fdb916215bc0644001f_I20220331" decimals="-5" name="us-gaap:DueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzIxOTkwMjMyODI4MDc_dd0a5a40-69b9-4bc1-88dc-bd8adc50c55b">402.7</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $<ix:nonFraction unitRef="usd" contextRef="i4e6c000a5c1747719d713bf44ab5594d_I20211231" decimals="-5" name="us-gaap:DueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzIxOTkwMjMyODI4MjY_34ac071a-d581-48b2-8590-751c9ebbdf4c">285.4</ix:nonFraction>&#160;million as of March 31, 2022 and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively. Amounts payable to Eisai related to the agreements discussed above were </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i30f95d1127004fdb916215bc0644001f_I20220331" decimals="-5" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzIxOTkwMjMyODI5Mzc_35cd03e0-5f85-4a7f-bc7a-7261264c444c">36.5</ix:nonFraction>&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $<ix:nonFraction unitRef="usd" contextRef="i4e6c000a5c1747719d713bf44ab5594d_I20211231" decimals="-5" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzIxOTkwMjMyODI5MjA_299ca192-1067-469d-a4c8-dfc801b6704e">46.5</ix:nonFraction>&#160;million as of March 31, 2022 and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021, respectively</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the ADUHELM Collaboration Agreement, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2021 Form 10-K.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i91493b19985440ee9d1891dc630ee7f3" continuedAt="ia861f26347294a199d2a38bb9dd5c1ae"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">UCB</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with UCB to jointly develop and commercialize dapirolizumab pegol, an anti-CD40L pegylated Fab, for the potential treatment of systemic lupus erythematosus and other future agreed indications. Either we or UCB may propose development of dapirolizumab pegol in additional indications. If the parties do not agree to add an indication as an agreed indication to the collaboration, we or UCB may, at the sole expense of the applicable party, pursue development in such excluded indication(s), subject to an opt-in right of the non-pursuing party after proof of clinical activity. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All costs incurred for agreed indications, including research, development, sales and marketing expense, are shared equally between us and UCB. Upon marketing approval, we and UCB will co-promote dapirolizumab pegol and share profits equally.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development expense related to the UCB collaboration agreement is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.523%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total UCB collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i385de3e6fdd648569c6459df74a3f24c_D20220101-20220331" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZToyMmYyNTNkYTNlNWI0ZWY1ODEzMWJjYWIwZDczMDEzZS90YWJsZXJhbmdlOjIyZjI1M2RhM2U1YjRlZjU4MTMxYmNhYjBkNzMwMTNlXzItMi0xLTEtNzUxNDA_93659a77-c37a-432d-a486-ac39454e5c66">17.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81ff85ba433e49f3bf5366754bf14dfd_D20210101-20210331" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZToyMmYyNTNkYTNlNWI0ZWY1ODEzMWJjYWIwZDczMDEzZS90YWJsZXJhbmdlOjIyZjI1M2RhM2U1YjRlZjU4MTMxYmNhYjBkNzMwMTNlXzItNC0xLTEtNzUxNDA_17569137-bbfc-4642-a628-1887d82f3318">16.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of UCB development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i385de3e6fdd648569c6459df74a3f24c_D20220101-20220331" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZToyMmYyNTNkYTNlNWI0ZWY1ODEzMWJjYWIwZDczMDEzZS90YWJsZXJhbmdlOjIyZjI1M2RhM2U1YjRlZjU4MTMxYmNhYjBkNzMwMTNlXzMtMi0xLTEtNzUxNDA_54f54254-5fdb-4807-ad7d-ca281f1c0562">8.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81ff85ba433e49f3bf5366754bf14dfd_D20210101-20210331" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZToyMmYyNTNkYTNlNWI0ZWY1ODEzMWJjYWIwZDczMDEzZS90YWJsZXJhbmdlOjIyZjI1M2RhM2U1YjRlZjU4MTMxYmNhYjBkNzMwMTNlXzMtNC0xLTEtNzUxNDA_a5e25a1e-a8a5-4a7a-abb5-d0033762d9b9">8.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:7pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sage Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2020 we entered into a global collaboration and license agreement with Sage to jointly develop and commercialize BIIB125 (zuranolone) for the potential treatment of major depressive disorder and postpartum depression and BIIB124 (SAGE-324) for the potential treatment of essential tremor with potential in other neurological conditions such as epilepsy.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under this collaboration, both companies will share equal responsibility and costs for development as well as profits and losses for commercialization in the U.S. Outside of the U.S., we are responsible for development and commercialization, excluding Japan, Taiwan and South Korea, with respect to zuranolone and may pay Sage potential tiered royalties in the high teens to low twenties.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development and sales and marketing expense related to this collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.523%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sage collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f28921d58149e88f70f267093af3ed_D20220101-20220331" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTo0NGE3YWYyZGZlOWM0MGRhYTFmNWU2YTJiZWU0MGIyMS90YWJsZXJhbmdlOjQ0YTdhZjJkZmU5YzQwZGFhMWY1ZTZhMmJlZTQwYjIxXzItMi0xLTEtNzUxNDA_abf1c9c1-ae19-451b-a13a-829403d93023">38.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84748af08d094521ad62103f37c3ba5e_D20210101-20210331" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTo0NGE3YWYyZGZlOWM0MGRhYTFmNWU2YTJiZWU0MGIyMS90YWJsZXJhbmdlOjQ0YTdhZjJkZmU5YzQwZGFhMWY1ZTZhMmJlZTQwYjIxXzItNC0xLTEtNzUxNDA_c3b13feb-edf9-41e6-ae7d-2005fd8181c3">39.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Sage development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f28921d58149e88f70f267093af3ed_D20220101-20220331" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTo0NGE3YWYyZGZlOWM0MGRhYTFmNWU2YTJiZWU0MGIyMS90YWJsZXJhbmdlOjQ0YTdhZjJkZmU5YzQwZGFhMWY1ZTZhMmJlZTQwYjIxXzMtMi0xLTEtNzUxNDA_ebf29024-0809-4577-945d-d750ed9fa3f4">19.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84748af08d094521ad62103f37c3ba5e_D20210101-20210331" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTo0NGE3YWYyZGZlOWM0MGRhYTFmNWU2YTJiZWU0MGIyMS90YWJsZXJhbmdlOjQ0YTdhZjJkZmU5YzQwZGFhMWY1ZTZhMmJlZTQwYjIxXzMtNC0xLTEtNzUxNDA_6a067ebb-9a72-4bfc-8599-b7ffffb2dccc">19.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sage sales and marketing expense incurred by the collaboration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9f8dc7db02f46a382226b3a06689770_D20220101-20220331" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTo0NGE3YWYyZGZlOWM0MGRhYTFmNWU2YTJiZWU0MGIyMS90YWJsZXJhbmdlOjQ0YTdhZjJkZmU5YzQwZGFhMWY1ZTZhMmJlZTQwYjIxXzQtMi0xLTEtNzUxNDA_4a611faa-568a-4dcf-9d16-3250e23969e3">18.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccef06de5f364c6e864a306f6c4d2222_D20210101-20210331" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTo0NGE3YWYyZGZlOWM0MGRhYTFmNWU2YTJiZWU0MGIyMS90YWJsZXJhbmdlOjQ0YTdhZjJkZmU5YzQwZGFhMWY1ZTZhMmJlZTQwYjIxXzQtNC0xLTEtNzUxNDA_d09af062-fc4a-4751-ab73-cef26cf6d8da">5.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Sage sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9f8dc7db02f46a382226b3a06689770_D20220101-20220331" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTo0NGE3YWYyZGZlOWM0MGRhYTFmNWU2YTJiZWU0MGIyMS90YWJsZXJhbmdlOjQ0YTdhZjJkZmU5YzQwZGFhMWY1ZTZhMmJlZTQwYjIxXzUtMi0xLTEtNzUxNDA_7f712296-aaee-464c-bf44-329d938c48a7">9.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccef06de5f364c6e864a306f6c4d2222_D20210101-20210331" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTo0NGE3YWYyZGZlOWM0MGRhYTFmNWU2YTJiZWU0MGIyMS90YWJsZXJhbmdlOjQ0YTdhZjJkZmU5YzQwZGFhMWY1ZTZhMmJlZTQwYjIxXzUtNC0xLTEtNzUxNDA_723555b3-e34e-4c8c-9009-6cf4253e7a1c">2.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Denali Therapeutics Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020 we entered into a collaboration and license agreement with Denali to co-develop and co-commercialize Denali's small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson's disease. Under this collaboration, both companies share responsibility and costs for global development based on specified percentages as well as profits and losses for commercialization in the U.S. and China. Outside the U.S. and China we are responsible for commercialization and may pay Denali potential tiered royalties.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the LRRK2 program, we also have an exclusive option to license two preclinical programs from Denali&#8217;s Transport Vehicle platform, including its Antibody Transport Vehicle (ATV): ATV enabled anti-amyloid beta program and a second program utilizing its Transport Vehicle technology. Further, we have the right of first negotiation on two additional ATV enabled therapeutics for indications within specific neurodegenerative diseases, should Denali decide to seek a collaboration for such programs.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="ia861f26347294a199d2a38bb9dd5c1ae" continuedAt="i2fab3c6b75af4a37a892b4b4ac280ba0"><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="biib:SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzIwMTE3_ad0f28d4-f089-4965-84b4-6b1a89f35cab" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development expense related to this collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.523%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Denali collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22e581ce75fe402f95badbea9059a2fd_D20220101-20220331" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTowZGM3M2UzMDczNjc0NWM4YjBhOTAwMzhjYjNhOGY4OS90YWJsZXJhbmdlOjBkYzczZTMwNzM2NzQ1YzhiMGE5MDAzOGNiM2E4Zjg5XzItMi0xLTEtNzUxNDA_c706b096-4bf0-47eb-a1ac-09d16e976f96">14.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0323b821ee4490ab9cd6f46708b92d2_D20210101-20210331" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTowZGM3M2UzMDczNjc0NWM4YjBhOTAwMzhjYjNhOGY4OS90YWJsZXJhbmdlOjBkYzczZTMwNzM2NzQ1YzhiMGE5MDAzOGNiM2E4Zjg5XzItNC0xLTEtNzUxNDA_a17b2649-3ec9-4d82-8284-175dd214e175">15.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Denali development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22e581ce75fe402f95badbea9059a2fd_D20220101-20220331" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTowZGM3M2UzMDczNjc0NWM4YjBhOTAwMzhjYjNhOGY4OS90YWJsZXJhbmdlOjBkYzczZTMwNzM2NzQ1YzhiMGE5MDAzOGNiM2E4Zjg5XzMtMi0xLTEtNzUxNDA_2c5ebbdf-396b-4463-b3b6-1cdf7d081c70">8.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0323b821ee4490ab9cd6f46708b92d2_D20210101-20210331" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTowZGM3M2UzMDczNjc0NWM4YjBhOTAwMzhjYjNhOGY4OS90YWJsZXJhbmdlOjBkYzczZTMwNzM2NzQ1YzhiMGE5MDAzOGNiM2E4Zjg5XzMtNC0xLTEtNzUxNDA_95a5065f-e5c4-4f2d-a474-5fce93c65ced">9.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sangamo Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020 we entered into a collaboration and license agreement with Sangamo to develop and commercialize ST-501 for tauopathies, including Alzheimer's disease; ST-502 for synucleinopathies, including Parkinson&#8217;s disease; a third neuromuscular disease target; and up to nine additional neurological disease targets to be identified and selected within a <ix:nonNumeric contextRef="i7cab4c6e22304f01a6e538f0a28da4a6_D20220101-20220331" name="biib:Termofcollaborationagreement" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzIwMTE4_e86061f5-2ad9-4318-9e56-c9b91d3d8bfe">five-year</ix:nonNumeric> period. The companies are leveraging Sangamo&#8217;s proprietary zinc finger protein technology delivered via adeno-associated virus to modulate the expression of key genes involved in neurological diseases. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this collaboration, we may pay Sangamo tiered royalties on potential net sales of any products developed under this collaboration in the high single digit to sub-teen percentages.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development expense related to this collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.523%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sangamo collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2f3b87f1c704bfeaa184c005c15f509_D20220101-20220331" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTo4NDBmYjNmNzdkYWY0ZjNjYjk1ZjczMWExYzQ2NjJhZi90YWJsZXJhbmdlOjg0MGZiM2Y3N2RhZjRmM2NiOTVmNzMxYTFjNDY2MmFmXzItMi0xLTEtODU2MTk_322ad19d-004a-4ecf-9f03-a51a579fd22e">8.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1980e9c4bcf04c69813dff866529db3b_D20210101-20211231" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTo4NDBmYjNmNzdkYWY0ZjNjYjk1ZjczMWExYzQ2NjJhZi90YWJsZXJhbmdlOjg0MGZiM2Y3N2RhZjRmM2NiOTVmNzMxYTFjNDY2MmFmXzItNC0xLTEtODU2MTk_5206a14c-15f0-4ff4-b27b-1784c3838b4a">4.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Sangamo development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2f3b87f1c704bfeaa184c005c15f509_D20220101-20220331" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTo4NDBmYjNmNzdkYWY0ZjNjYjk1ZjczMWExYzQ2NjJhZi90YWJsZXJhbmdlOjg0MGZiM2Y3N2RhZjRmM2NiOTVmNzMxYTFjNDY2MmFmXzMtMi0xLTEtODU2MTk_24f8f214-96b6-4a12-8583-705921db05bd">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1980e9c4bcf04c69813dff866529db3b_D20210101-20211231" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTo4NDBmYjNmNzdkYWY0ZjNjYjk1ZjczMWExYzQ2NjJhZi90YWJsZXJhbmdlOjg0MGZiM2Y3N2RhZjRmM2NiOTVmNzMxYTFjNDY2MmFmXzMtNC0xLTEtODU2MTk_d41fa814-d182-4175-a27b-995775ffd869">4.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">InnoCare Pharma Limited</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2021 we entered into a collaboration and license agreement with InnoCare Pharma Limited (InnoCare) for orelabrutinib, an oral small molecule Bruton&#8217;s tyrosine kinase inhibitor for the potential treatment of MS. Orelabrutinib is currently being studied in a multi-country, placebo-controlled Phase 2 trial in relapsing-remitting MS. Under the terms of the collaboration, we have exclusive rights to orelabrutinib in the field of MS worldwide and certain autoimmune diseases outside of China (including Hong Kong, Macau and Taiwan), while InnoCare retains ex</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">clusive worldwide rights to orelabrutinib in the field of oncology and certain autoimmune diseases in China (including Hong Kong, Macau and Taiwan). </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#0a0a0a;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the closing of this transaction in August 2021 we made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i416b5c2161cb4be49401dc463e803f6e_D20210801-20210831" decimals="-5" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzEyOTAy_466b79c8-d665-4c11-bf4a-97c8e3f394c3">125.0</ix:nonFraction>&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">that was recorded as research and development expense in our condensed consolidated statements of income. </span><span style="background-color:#ffffff;color:#0a0a0a;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We may also pay InnoCare up to approximately $<ix:nonFraction unitRef="usd" contextRef="i416b5c2161cb4be49401dc463e803f6e_D20210801-20210831" decimals="-5" name="biib:ContingentMilestonePaymentsMadeToCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzEzMDA1_4c3b2732-2d67-40db-b917-2dad4b9872f0">812.5</ix:nonFraction>&#160;million in potential development milestones and potential commercial payments should this collaboration achieve certain development, commercial milestones and sales thresholds. In addition, we may pay InnoCare tiered royalties on potential net sales of any products developed under this collaboration in the low to high teen percentages.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Research and Discovery Arrangements</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, we recorded </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i871bd576e8054a32a94dd16a50cc8f38_D20220101-20220331" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzEzNjE0_c09e7284-7322-418e-a3e6-bc50db883288">19.5</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as research and development expense in our condensed consolidated statements of income related to other research and discovery related arrangements, compared to less than </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i69f6f1c65f31482a9985575399db62f4_D20210101-20210331" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzEzODAw_350fafba-47de-4d28-bc7c-4be35f6abdff">1.0</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the prior year comparative period.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Samsung Bioepis Co., Ltd.</span></div><div style="margin-top:5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Joint Venture Agreement</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. As of March 31, 2022, our ownership percentage was approximately <ix:nonFraction unitRef="number" contextRef="ia5fabf9c71294456a0158d60a5f483a4_I20220331" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzE0NDYw_0952b3aa-e388-47ac-91cb-321e4a6f024f">49.9</ix:nonFraction>%.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i2fab3c6b75af4a37a892b4b4ac280ba0" continuedAt="i24642973011748aaab293a2cc70cb268"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in (income) loss of investee, net of tax in our condensed consolidated statements of income. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon investment, the equity method of accounting requires us to identify and allocate differences between the fair value of our investment and the carrying value of our interest in the underlying net assets of the investee. These basis differences are amortized over their economic life. The total basis difference was approximately $<ix:nonFraction unitRef="usd" contextRef="i17a7835e9c634cd3898253b27970e1ae_I20181107" decimals="-5" name="us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzE1NDc1_8f3f1be1-d7b3-447d-ab51-2f9211baf253">675.0</ix:nonFraction> million and relates to inventory, developed technology, IPR&amp;D and deferred tax balances. The basis differences related to inventory were amortized, net of tax, over their estimated useful lives of <ix:nonNumeric contextRef="i3777c8eb44d147d2bc71177545a1a119_D20220101-20220331" name="biib:Equitymethodinvestmentbasisdifferenceamortizationperiod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzE1NjY3_4261d8ea-715a-40ce-94a9-5b41b2c47133">1.5</ix:nonNumeric> years, and the basis differences related to developed technology and IPR&amp;D for marketed products will be amortized, net of tax, over their estimated useful lives of <ix:nonNumeric contextRef="i81aebf0e69b74044934ae698e82a35a4_D20220101-20220331" name="biib:Equitymethodinvestmentbasisdifferenceamortizationperiod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzE1ODM1_d3c5cd01-c15c-496e-9973-ab6c025263e5">15</ix:nonNumeric> years.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, we recognized net losses on our investment of $<ix:nonFraction unitRef="usd" contextRef="id6783744f49842d8974c9aa1108f7b92_D20220101-20220331" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzE2MzQy_5fbb7013-3aa7-43db-a58f-65b10610df91">3.3</ix:nonFraction> million, reflecting our share of Samsung Bioepis' operating profits, net of tax totaling $<ix:nonFraction unitRef="usd" contextRef="id6783744f49842d8974c9aa1108f7b92_D20220101-20220331" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzEwOTk1MTE2NjI0NjM_dbc08def-9ad8-48b6-8a27-24461609946b">4.0</ix:nonFraction>&#160;million offset by amortization of basis differences totaling $<ix:nonFraction unitRef="usd" contextRef="id6783744f49842d8974c9aa1108f7b92_D20220101-20220331" decimals="-5" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzEwOTk1MTE2NjI0Nzc_3039608b-e6a2-4327-8ae8-cfca1e0be7bb">7.3</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, we recognized net losses on our investment of $<ix:nonFraction unitRef="usd" contextRef="idb43218ef58b4c47acc0ed3d32fc1c8a_D20210101-20210331" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzE2NTIx_1afc735c-f367-4705-9a52-3b7795286c88">18.2</ix:nonFraction> million, reflecting our share of Samsung Bioepis' operating losses, net of tax totaling $<ix:nonFraction unitRef="usd" contextRef="idb43218ef58b4c47acc0ed3d32fc1c8a_D20210101-20210331" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzEwOTk1MTE2NjI3OTg_8fe17270-8c7a-4c0d-bb88-aa0e80a4f45e">11.0</ix:nonFraction>&#160;million and amortization of basis differences totaling $<ix:nonFraction unitRef="usd" contextRef="idb43218ef58b4c47acc0ed3d32fc1c8a_D20210101-20210331" decimals="-5" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzEwOTk1MTE2NjI4MTU_686221a2-af77-47f1-851a-5ec154b5684a">7.2</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022 and December 31, 2021, the carrying value of our investment in Samsung Bioepis totaled <ix:nonFraction unitRef="krw" contextRef="ia5fabf9c71294456a0158d60a5f483a4_I20220331" decimals="-8" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzE2NzQw_42b8f7c7-8367-40a5-a788-0ce0ca5abd0f">709.4</ix:nonFraction> billion South Korean won ($<ix:nonFraction unitRef="usd" contextRef="ia5fabf9c71294456a0158d60a5f483a4_I20220331" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzE2NzYx_242c97d3-6430-48e6-9d3f-2fbb9fe5f8cc">586.4</ix:nonFraction> million) and <ix:nonFraction unitRef="krw" contextRef="i9fcfddd14c424cd095a98f9df64e862f_I20211231" decimals="-8" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzE2NzY5_87266759-74dd-482d-9478-742073642902">713.3</ix:nonFraction> billion South Korean won ($<ix:nonFraction unitRef="usd" contextRef="i9fcfddd14c424cd095a98f9df64e862f_I20211231" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzE2Nzkw_36c5f1d6-739a-424b-9e0f-fa7c3dd89332">599.9</ix:nonFraction> million), respectively, which is classified as a component of investments and other assets in our condensed consolidated balance sheets.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022 we entered into an agreement to sell to Samsung BioLogics our equity in Samsung Bioepis, which was completed on April 20, 2022. Under the terms of the transaction, we received approximately $<ix:nonFraction unitRef="usd" contextRef="i54ef960b3f344a6284182d87fe3863d1_D20220101-20220131" decimals="-8" name="us-gaap:ProceedsFromDivestitureOfInterestInJointVenture" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzEwOTk1MTE2NjExNzU_fce74663-058b-43f8-bf9e-f72ace1396b5">1.0</ix:nonFraction>&#160;billion in cash at closing and will receive approximately $<ix:nonFraction unitRef="usd" contextRef="i9a34f5e20a214f4fb6abb8675f411f59_I20220131" decimals="-8" name="biib:PayablesToDivestitureOfInterestInJointVenture" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzEwOTk1MTE2NjExODk_0a15c1c7-1dde-49d3-8593-4c152ba1480f">1.3</ix:nonFraction>&#160;billion to be deferred over two payments of $<ix:nonFraction unitRef="usd" contextRef="ice9f6a67517e4256bcc4feff2a07a95c_I20220131" decimals="-5" name="biib:PayablesToDivestitureOfInterestInJointVenture" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzEwOTk1MTE2NjEyMDM_d3527318-ce7f-4266-9f36-82648329f8a3">812.5</ix:nonFraction>&#160;million due at the first anniversary and $<ix:nonFraction unitRef="usd" contextRef="ifbc3564cb9f74c5e96af956bdb92ace9_I20220131" decimals="-5" name="biib:PayablesToDivestitureOfInterestInJointVenture" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzEwOTk1MTE2NjEyMTk_eafa605f-1217-427f-b0c8-b50618a96d07">437.5</ix:nonFraction>&#160;million due at the second anniversary of the closing of the transaction. We are also eligible to receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="i54ef960b3f344a6284182d87fe3863d1_D20220101-20220131" decimals="-5" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzEwOTk1MTE2NjEyMzU_99895d95-1041-4fda-82d0-8c3a5f51e837">50.0</ix:nonFraction>&#160;million upon the achievement of certain commercial milestones.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 Development and Commercialization Agreement</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize two potential ophthalmology biosimilar products, BYOOVIZ (ranibizumab-nuna), a proposed ranibizumab biosimilar referencing LUCENTIS, and SB15, a proposed aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. Samsung Bioepis will be responsible for development and will supply both products to us at a pre-specified gross margin.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this transaction, we made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i8140a335ecc449f6bb7f8e4660aac8ea_D20200101-20200331" decimals="-5" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzE3NTU0_361043e1-e17c-4a9c-a0ff-a9ec14e679b8">100.0</ix:nonFraction> million to Samsung Bioepis in January 2020, of which $<ix:nonFraction unitRef="usd" contextRef="i8140a335ecc449f6bb7f8e4660aac8ea_D20200101-20200331" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzE3NjAy_0973ed1b-1a60-4075-8ca3-f9db8d7e873b">63.0</ix:nonFraction> million was recorded as research and development expense in our condensed consolidated statements of income in 2019 and $<ix:nonFraction unitRef="usd" contextRef="i8c93649201d542fd82a365350912101f_I20200131" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzE3NjY2_66be4540-57fe-4c67-a05d-dd53062232f6">37.0</ix:nonFraction> million was recorded as intangible assets, net in our condensed consolidated balance sheets in 2019. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2021 we accrued $<ix:nonFraction unitRef="usd" contextRef="ib0074296436b4840ada078b60b901e66_D20220101-20220331" decimals="-5" name="biib:AccruedMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzE3OTUz_87dcbfd0-339f-4cdd-a808-ff9a6c3e0e27">15.0</ix:nonFraction>&#160;million in milestone payments related to the approval of BYOOVIZ in the U.S., the E.U. and the U.K., that were capitalized within intangible assets, net in our condensed consolidated balance sheets. We may also pay Samsung Bioepis up to approximately $<ix:nonFraction unitRef="usd" contextRef="ib0074296436b4840ada078b60b901e66_D20220101-20220331" decimals="-5" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzE4MTA3_6b667a39-203f-4a51-855e-53fe9b6b1236">180.0</ix:nonFraction> million in additional development, regulatory and sales-based milestones.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also acquired an option to extend the term of our 2013 c</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ommercial agreement for BENEPALI, IMRALDI and FLIXABI by an additional <ix:nonNumeric contextRef="ib0074296436b4840ada078b60b901e66_D20220101-20220331" name="biib:CollaborationAgreementTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzE4MzA2_c4222ced-8565-48ea-9d5b-820d3ece4302">five years</ix:nonNumeric>, subject to payment of an option exercise fee of $<ix:nonFraction unitRef="usd" contextRef="ib0074296436b4840ada078b60b901e66_D20220101-20220331" decimals="-5" name="biib:ContractOptionExerciseFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzE4MzU4_4a36a6f3-eb35-49b5-9e10-f8b0b75ddea7">60.0</ix:nonFraction> million, and obtained an option to acquire exclusive rights to commercialize these products in China.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2013 Commercial Agreement</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We reflect revenue on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenue, net in our condensed consolidated statements of income and record the related cost of revenue and sales and marketing expense in our condensed consolidated statements of income to their respective line items when these costs are incurred. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We share <ix:nonFraction unitRef="number" contextRef="ib0074296436b4840ada078b60b901e66_D20220101-20220331" decimals="INF" name="biib:EquityMethodInvestmentsExpectedProfitShare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzEwOTk1MTE2NDg0Nzk_7323f3fd-6ae4-4ecc-972e-8ed6e5c77f82">50.0</ix:nonFraction>% of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. For the three months ended March 31, 2022, we recognized net profit-sharing expense of $<ix:nonFraction unitRef="usd" contextRef="id6783744f49842d8974c9aa1108f7b92_D20220101-20220331" decimals="-5" name="biib:Collaborationprofitlosssharing" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzE5MDk0_40eaca52-c94d-46a7-9d77-15ee9f716d38">64.4</ix:nonFraction>&#160;million to reflect Samsung </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i24642973011748aaab293a2cc70cb268" continuedAt="idcd93eb6534149aea421d95bea0e505a"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bioepis' <ix:nonFraction unitRef="number" contextRef="ib0074296436b4840ada078b60b901e66_D20220101-20220331" decimals="INF" name="biib:EquityMethodInvestmentsExpectedProfitShare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzEwOTk1MTE2NDg0ODM_7323f3fd-6ae4-4ecc-972e-8ed6e5c77f82">50.0</ix:nonFraction>% sharing of the net collaboration profits, compared to a net profit-sharing expense of $<ix:nonFraction unitRef="usd" contextRef="idb43218ef58b4c47acc0ed3d32fc1c8a_D20210101-20210331" decimals="-5" name="biib:Collaborationprofitlosssharing" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzE5MjM2_f28b7aea-0a13-4e30-982c-5944704dffe7">68.5</ix:nonFraction> million in the prior year comparative period. </span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Services</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Simultaneous with the formation of Samsung Bioepis, we also entered into a technical development services agreement, a manufacturing agreement and a license agreement with Samsung Bioepis. Revenue related to these services is reflected in revenue from collaborative and other relationships as a component of other revenue in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts receivable from Samsung Bioepis related to the agreements discussed above were $<ix:nonFraction unitRef="usd" contextRef="ia9e98bb878a84e13ac251a6b98a15e94_I20220331" decimals="-5" name="us-gaap:DueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzEwOTk1MTE2NjIxNjA_4982cf4f-ec93-4f6e-ac42-783dc5dce201">5.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i33310cbd0d8e4927a25d422f87b6a6e3_I20211231" decimals="-5" name="us-gaap:DueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzEwOTk1MTE2NjIxNzc_e8abf0d0-5f05-49a8-9e84-95f332f40a88">4.1</ix:nonFraction>&#160;million as of March 31, 2022 and December 31, 2021, respectively. Amounts payable to Samsung Bioepis related to the agreements discussed above were $<ix:nonFraction unitRef="usd" contextRef="ia9e98bb878a84e13ac251a6b98a15e94_I20220331" decimals="-5" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzE5Nzcz_2bb4d91e-d8dd-40e1-ba81-c8774bee23d5">102.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i33310cbd0d8e4927a25d422f87b6a6e3_I20211231" decimals="-5" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzE5Nzgw_be707371-8450-46c0-ac00-c237c0bc43c5">148.7</ix:nonFraction>&#160;million as of March 31, 2022 and December 31, 2021, respectively.</span></div></ix:continuation><div style="margin-top:6pt;text-indent:24.75pt"><ix:continuation id="idcd93eb6534149aea421d95bea0e505a" continuedAt="id9fd6bc43e684abca9b319418525a3b8"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis and our other significant collaboration arrangements, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships,</span></ix:continuation><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id9fd6bc43e684abca9b319418525a3b8"> to our consolidated financial statements included in our 2021 Form 10-K.</ix:continuation> </span></div><div id="ie9658fba2baf4e3799b1175f69eaed46_121"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">17.&#160;&#160;&#160;&#160;INVESTMENTS IN VARIABLE INTEREST ENTITIES </span></div><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="us-gaap:VariableInterestEntityDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMjEvZnJhZzowNWVkOTJlYWFjOTk0NmVjYTBlMDM3NWQxMDRhZDFjMy90ZXh0cmVnaW9uOjA1ZWQ5MmVhYWM5OTQ2ZWNhMGUwMzc1ZDEwNGFkMWMzXzY1Njc_3cd8d8b2-e595-448c-bc13-e6633037a114" continuedAt="ia080d0039e4f4c5483c71e10e908afc5" escape="true"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidated Variable Interest Entities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neurimmune SubOne AG</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration and license agreement with Neurimmune for the development and commercialization of antibodies for the potential treatment of Alzheimer's disease, including ADUHELM (as amended, the Neurimmune Agreement). We are responsible for the development, manufacturing and commercialization of all collaboration products. The Neurimmune Agreement is effective for the longer of the duration of certain patents relating to a licensed product or <ix:nonNumeric contextRef="i5e6825d4d7fc4c049bc35822d827b16a_D20220101-20220331" name="biib:CollaborationAgreementTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMjEvZnJhZzowNWVkOTJlYWFjOTk0NmVjYTBlMDM3NWQxMDRhZDFjMy90ZXh0cmVnaW9uOjA1ZWQ5MmVhYWM5OTQ2ZWNhMGUwMzc1ZDEwNGFkMWMzXzc0Mg_713c9e9b-be48-4893-a734-6a6536d0fd6c">12</ix:nonNumeric> years from the first commercial sale of a licensed product.  </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#8217;s economic performance and we are required to fund <ix:nonFraction unitRef="number" contextRef="i5e6825d4d7fc4c049bc35822d827b16a_D20220101-20220331" decimals="INF" name="biib:ResearchAndDevelopmentCostsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMjEvZnJhZzowNWVkOTJlYWFjOTk0NmVjYTBlMDM3NWQxMDRhZDFjMy90ZXh0cmVnaW9uOjA1ZWQ5MmVhYWM5OTQ2ZWNhMGUwMzc1ZDEwNGFkMWMzXzEwODU_9b76dfae-b24e-4e3b-8178-f56308da58db">100.0</ix:nonFraction>% of the research and development costs incurred in support of the collaboration. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 ADUHELM was granted accelerated approval by the FDA. Under the terms of the Neurimmune Agreement, we were required to pay Neurimmune a milestone payment of $<ix:nonFraction unitRef="usd" contextRef="ie40c7dd8da0c4c3d8730bcde07b49856_I20210630" decimals="-5" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMjEvZnJhZzowNWVkOTJlYWFjOTk0NmVjYTBlMDM3NWQxMDRhZDFjMy90ZXh0cmVnaW9uOjA1ZWQ5MmVhYWM5OTQ2ZWNhMGUwMzc1ZDEwNGFkMWMzXzMwNDE_710abec4-304c-4b61-a323-9da980121c51">100.0</ix:nonFraction>&#160;million related to the launch of ADUHELM in the U.S. During the second quarter of 2021 we made this $<ix:nonFraction unitRef="usd" contextRef="ie40c7dd8da0c4c3d8730bcde07b49856_I20210630" decimals="-5" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMjEvZnJhZzowNWVkOTJlYWFjOTk0NmVjYTBlMDM3NWQxMDRhZDFjMy90ZXh0cmVnaW9uOjA1ZWQ5MmVhYWM5OTQ2ZWNhMGUwMzc1ZDEwNGFkMWMzXzMxMzY_710abec4-304c-4b61-a323-9da980121c51">100.0</ix:nonFraction>&#160;million payment, which was recognized as a charge to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income. In addition, during the second quarter of 2021 we recognized net profit-sharing income of $<ix:nonFraction unitRef="usd" contextRef="i08f827f32a3b446c825d77324ed50eb7_D20210401-20210630" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMjEvZnJhZzowNWVkOTJlYWFjOTk0NmVjYTBlMDM3NWQxMDRhZDFjMy90ZXh0cmVnaW9uOjA1ZWQ5MmVhYWM5OTQ2ZWNhMGUwMzc1ZDEwNGFkMWMzXzMzOTc_7bd43a88-806c-4e5d-8106-57876d218e1f">45.0</ix:nonFraction>&#160;million to reflect Eisai's </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i8a12e5f049a6452f9e97a9998e1ce4b6_D20220101-20220331" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMjEvZnJhZzowNWVkOTJlYWFjOTk0NmVjYTBlMDM3NWQxMDRhZDFjMy90ZXh0cmVnaW9uOjA1ZWQ5MmVhYWM5OTQ2ZWNhMGUwMzc1ZDEwNGFkMWMzXzEwOTk1MTE2Mzk1NzE_05cf3daf-ff6a-4232-a16a-6ff1e749730b">45.0</ix:nonFraction>%</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> share of the $<ix:nonFraction unitRef="usd" contextRef="ie40c7dd8da0c4c3d8730bcde07b49856_I20210630" decimals="-5" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMjEvZnJhZzowNWVkOTJlYWFjOTk0NmVjYTBlMDM3NWQxMDRhZDFjMy90ZXh0cmVnaW9uOjA1ZWQ5MmVhYWM5OTQ2ZWNhMGUwMzc1ZDEwNGFkMWMzXzM0MzU_710abec4-304c-4b61-a323-9da980121c51">100.0</ix:nonFraction>&#160;million milestone payment, which was recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if aducanumab receives regulatory approval in the jurisdictions where we have submitted filings, we may pay additional milestones to Neurimmune, including $<ix:nonFraction unitRef="usd" contextRef="i22cd2c200d674e7185cf096a998f436a_D20210601-20210630" decimals="-5" name="biib:AdditionalMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMjEvZnJhZzowNWVkOTJlYWFjOTk0NmVjYTBlMDM3NWQxMDRhZDFjMy90ZXh0cmVnaW9uOjA1ZWQ5MmVhYWM5OTQ2ZWNhMGUwMzc1ZDEwNGFkMWMzXzIxOTkwMjMyNjgyMDk_0296fd27-8656-4ab7-abcf-eecd851ad69e">50.0</ix:nonFraction>&#160;million  if launched in Japan. Milestones payable to Neurimmune are shared expenses under the ADUHELM Collaboration Agreement.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs for which we reimburse Neurimmune are reflected in research and development expense in our condensed consolidated statements of income. During the three months ended March 31, 2022 and 2021, amounts reimbursed were immaterial.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021 we recorded a net deferred tax asset in Switzerland of approximately $<ix:nonFraction unitRef="usd" contextRef="i350f52cf56ca419f9abcc85ddabdf66a_I20210630" decimals="-5" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMjEvZnJhZzowNWVkOTJlYWFjOTk0NmVjYTBlMDM3NWQxMDRhZDFjMy90ZXh0cmVnaW9uOjA1ZWQ5MmVhYWM5OTQ2ZWNhMGUwMzc1ZDEwNGFkMWMzXzEwOTk1MTE2NDE3MTI_5a1e626e-1911-40d4-bd13-9d2536359647"><ix:nonFraction unitRef="usd" contextRef="i350f52cf56ca419f9abcc85ddabdf66a_I20210630" decimals="-5" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMjEvZnJhZzowNWVkOTJlYWFjOTk0NmVjYTBlMDM3NWQxMDRhZDFjMy90ZXh0cmVnaW9uOjA1ZWQ5MmVhYWM5OTQ2ZWNhMGUwMzc1ZDEwNGFkMWMzXzEwOTk1MTE2NDE3MTI_a6fd5756-faf6-433e-abf0-882ac35e6c15">490.0</ix:nonFraction></ix:nonFraction>&#160;million on Neurimmune's tax basis in ADUHELM, the realization of which is dependent on future sales of ADUHELM. During the fourth quarter of 2021, due to reduced future expected revenue associated with ADUHELM, we recorded a valuation allowance of approximately $<ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMjEvZnJhZzowNWVkOTJlYWFjOTk0NmVjYTBlMDM3NWQxMDRhZDFjMy90ZXh0cmVnaW9uOjA1ZWQ5MmVhYWM5OTQ2ZWNhMGUwMzc1ZDEwNGFkMWMzXzEwOTk1MTE2NDE3NjM_f162b270-dd9d-4e6d-a19a-875190f5c2ca">390.0</ix:nonFraction>&#160;million. During the first quarter of 2022, upon issuance of the final NCD related to ADUHELM, we recorded an additional valuation allowance of approximately $<ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMjEvZnJhZzowNWVkOTJlYWFjOTk0NmVjYTBlMDM3NWQxMDRhZDFjMy90ZXh0cmVnaW9uOjA1ZWQ5MmVhYWM5OTQ2ZWNhMGUwMzc1ZDEwNGFkMWMzXzEwOTk1MTE2NDE3NzI_66d041a0-5993-465d-9d7e-ea7cbebc52ff">85.0</ix:nonFraction>&#160;million to reduce the net value of this deferred tax asset to zero. These adjustments to our deferred tax assets and their valuation allowances are each recorded with an equal and offsetting amount assigned to net income (loss) </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="ia080d0039e4f4c5483c71e10e908afc5"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income, resulting in a zero net impact to net income attributable to Biogen Inc.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding the impact of the Neurimmune deferred tax asset, the assets and liabilities of Neurimmune are not significant to our condensed consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than contractually required amounts.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unconsolidated Variable Interest Entities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relationships with various variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022 and December 31, 2021, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled $<ix:nonFraction unitRef="usd" contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331" decimals="-5" name="biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMjEvZnJhZzowNWVkOTJlYWFjOTk0NmVjYTBlMDM3NWQxMDRhZDFjMy90ZXh0cmVnaW9uOjA1ZWQ5MmVhYWM5OTQ2ZWNhMGUwMzc1ZDEwNGFkMWMzXzU3Mzg_97299af9-07c2-4930-b813-4fbc60ddee66">24.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231" decimals="-5" name="biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMjEvZnJhZzowNWVkOTJlYWFjOTk0NmVjYTBlMDM3NWQxMDRhZDFjMy90ZXh0cmVnaW9uOjA1ZWQ5MmVhYWM5OTQ2ZWNhMGUwMzc1ZDEwNGFkMWMzXzU3NDU_8bf55fc6-d429-44c5-a65c-294d01c05a73">24.6</ix:nonFraction> million, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previous contractually required amounts. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our investments in Neurimmune and other variable interest entities, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Investments in Variable Interest Entities,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2021 Form 10-K.</span></div></ix:continuation><div id="ie9658fba2baf4e3799b1175f69eaed46_127"></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">18.&#160;&#160;&#160;&#160;LITIGATION </span></div><ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMjcvZnJhZzoxMjZjMDFjOTg5YjU0Y2UyOWEwNTc0NDBmMzc3MDczNi90ZXh0cmVnaW9uOjEyNmMwMWM5ODliNTRjZTI5YTA1NzQ0MGYzNzcwNzM2XzExOTU0_e08af882-dcdd-442c-8916-db4609bfef0d" continuedAt="i0b51554d9fd043d1bf9ed0ecb220eb63" escape="true"><div style="margin-top:6pt;padding-left:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2021 Form 10-K.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#8217; legal theories; and (v) the parties' settlement positions. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i0b51554d9fd043d1bf9ed0ecb220eb63" continuedAt="i17280ba7cd9d4c09a57a7a14198d730c"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss Contingencies </span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ADUHELM Securities Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and certain current and former officers are named as defendants in actions filed by shareholders on November 13, 2020 and February 7, 2022, and pending in the U.S. District Court for the District of Massachusetts. The actions allege violations of federal securities laws under 15 U.S.C &#167;78j(b) and &#167;78t(a) and 17 C.F.R. &#167;240.10b-5 and seek declarations of the actions as class actions and monetary relief. We have filed a motion to dismiss the action filed on November 13, 2020, which is pending. An estimate of the possible loss or range of loss in these actions cannot be made at this time.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Action</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We and members of the Board of Directors are named as defendants in an action filed by a shareholder on February 9, 2022, in the U.S. District Court for the District of Massachusetts. The action alleges violations of federal securities laws under 15 U.S.C. &#167;78n(a) and 17 C.F.R. &#167;240 14.a-9, breaches of fiduciary duties and waste of corporate assets, and seeks declaratory and injunctive relief, monetary relief to Biogen, and attorneys&#8217; fees and costs to the plaintiff. An estimate of the possible loss or range of loss cannot be made at this time.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IMRALDI Patent Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018 Fresenius Kabi Deutschland GmbH (Fresenius Kabi) commenced proceedings for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris (the French proceeding) and in November 2018 against Biogen GmbH in the D&#252;sseldorf Regional Court (the German proceeding), alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis that Biogen has commercialized in Europe, infringes national counterparts of European Patent No. 3 148 510 (the EP '510 Patent, expiring in May 2035). In May 2020 the European Patent Office (EPO) held the EP '510 Patent invalid. Fresenius Kabi has appealed to the EPO's Technical Boards of Appeal, a hearing has been set for June 2022, and the German and French proceedings have been stayed pending the decision on appeal.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020 Fresenius Kabi commenced proceedings in Denmark's Maritime and Commercial High Court alleging that IMRALDI infringes the Danish counterpart of European Patent No. 3 145 488 (the EP '488 Patent, expiring in May 2035) and a Danish utility model. In September 2021 the Court ruled that the patent and utility model are invalid and not infringed. Fresenius Kabi has appealed to the High Court of Eastern Denmark and the appeal is pending. The EPO has scheduled a hearing on the validity of the EP '488 Patent for October 2022.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020 the Danish Patent Board of Appeal revoked the Danish utility models that Fresenius Kabi had asserted against Biogen and Fresenius Kabi has appealed to the Danish Maritime and Commercial High Court. No hearing has been scheduled.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019 Gedeon Richter Nyrt commenced proceedings for damages and injunctive relief against Biogen GmbH in the D&#252;sseldorf Regional Court alleging infringement of the German counterpart of European Patent No. 3 212 667, which expires in October 2035. The case has been stayed pending proceedings in the EPO seeking to invalidate the patent. In November 2020 Gedeon Richter Nyrt commenced additional proceedings against Biogen GmbH in the D&#252;sseldorf Regional Court alleging infringement of a German utility model. In October 2021 Biogen filed cancellation proceedings in respect of the German utility model and the infringement proceedings have been stayed pending the outcome of the cancellation proceedings.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An estimate of the possible loss or range of loss in the IMRALDI patent litigation described above cannot be made at this time.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Qui Tam Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2015 a qui tam action filed by Michael Bawduniak on behalf of the U.S. and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts and seeks damages of $<ix:nonFraction unitRef="usd" contextRef="i179745ea816f45eeb6066bd1ea79e129_I20210715" decimals="-5" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMjcvZnJhZzoxMjZjMDFjOTg5YjU0Y2UyOWEwNTc0NDBmMzc3MDczNi90ZXh0cmVnaW9uOjEyNmMwMWM5ODliNTRjZTI5YTA1NzQ0MGYzNzcwNzM2XzQ2NTE_1b7b0dfc-4a0f-4d9e-89d2-62d8c2f1ab54">981.1</ix:nonFraction>&#160;million plus statutory trebling of damages, civil penalties, attorneys&#8217; fees and costs. The U.S. has not made an intervention decision. A trial is scheduled for the third quarter of 2022. An estimate of the possible loss cannot be made at this time.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i17280ba7cd9d4c09a57a7a14198d730c" continuedAt="ie7c9a14b66d84a2b8f7ff431b213bd21"><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dispute with Former Convergence Shareholders</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November and December 2019 Shareholder Representative Services LLC, on behalf of the former shareholders of Convergence, sent us correspondence asserting claims of $<ix:nonFraction unitRef="usd" contextRef="if8f47af926b14294931310a85ceac0ce_I20201231" decimals="-5" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMjcvZnJhZzoxMjZjMDFjOTg5YjU0Y2UyOWEwNTc0NDBmMzc3MDczNi90ZXh0cmVnaW9uOjEyNmMwMWM5ODliNTRjZTI5YTA1NzQ0MGYzNzcwNzM2XzUwODQ_69b2e76f-0ea6-487d-bbf0-cad0245a0c40">200.0</ix:nonFraction> million for alleged breach of the contract under which we acquired Convergence. We dispute the claims.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ERISA Class Action Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020 the U.S. District Court for the District of Massachusetts consolidated two cases filed against us in July and August 2020 by participants in the Biogen 401(k) Savings Plan alleging breach of fiduciary duty under ERISA. Plaintiffs seek a declaration of the action as a class action and monetary and other relief. An estimate of the possible loss or range of loss cannot be made at this time.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Humana Patient Assistance Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021 Humana Inc. (Humana) filed suit against us in the U.S. District Court for the District of Massachusetts alleging damages related to our providing MS patients with free medications and making charitable contributions to non-profit organizations that assist MS patients. Humana alleges violation of the federal RICO Act and state laws and seeks statutory treble damages, attorneys' fees and costs. We filed a motion to dismiss, which is pending. An estimate of the possible loss cannot be made at this time.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Investigations</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. House of Representatives Committees on Oversight and Reform and Energy and Commerce and the Office of Inspector General of the U.S. Department of Health and Human Services have announced investigations relating to ADUHELM. In addition, the Company has received a civil investigative demand from the Federal Trade Commission and a subpoena from the Securities and Exchange Commission seeking information relating to ADUHELM, including healthcare sites, ADUHELM&#8217;s approval and ADUHELM&#8217;s marketing.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TECFIDERA Patent Matters</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017 to 2020 we filed patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act (the Delaware Actions), against Accord Healthcare Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Cipla Limited, Graviti Pharmaceuticals Pvt. Ltd., Hetero USA, Inc., Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Prinston Pharmaceutical Inc., Sandoz Inc., Shilpa Medicare Limited, Slayback Pharma LLC, Sun Pharmaceutical Industries, Ltd., Sun Pharmaceutical Industries, Inc., Sun Pharma Global FZE, Torrent Pharmaceuticals Ltd., TWi Pharmaceuticals, Inc., Windlas Healthcare Pvt. Ltd. and Zydus Pharmaceuticals (USA) Inc. (collectively, the Delaware Defendants) in the U.S. District Court for the District of Delaware (the Delaware Court) and against Mylan (the West Virginia Action) in the U.S. District Court for the Northern District of West Virginia (the West Virginia Court).</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2021 the Federal Circuit affirmed the West Virginia Court judgment that the asserted claims of our U.S. Patent No. 8,399,514 (the '514 Patent) are invalid for lack of written description.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Delaware Court entered judgment for the Delaware Defendants on the grounds that the judgment of the West Virginia Court applies to the Delaware Actions under principles of collateral estoppel. The appeals in the Delaware Actions are stayed.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2018 Mylan Pharmaceuticals, Inc. (Mylan) also filed a petition with the U.S. Patent Trial and Appeal Board (PTAB) for </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">inter partes</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> review of the '514 Patent. In November 2021 the Federal Circuit ruled that the PTAB decision upholding the patentability of the &#8216;514 patent was moot, but in April 2022 the Federal Circuit vacated that ruling and stayed the appeal pending any final action by the United States Supreme Court in the West Virginia Action.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TYSABRI Patent Revocation Matters</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017 Swiss Pharma International AG, affiliated with the Polpharma Group, filed an action in the Commercial Court of Rome to invalidate the Italian counterpart of the European Patent No. 1 485 127 (the EP '127 Patent) which covers administration of natalizumab (TYSABRI) to treat MS and expires in February 2023. A hearing has been set for June 2022.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="ie7c9a14b66d84a2b8f7ff431b213bd21"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020 Polpharma Biologics S.A., also affiliated with the Polpharma Group, brought an action in the Polish Patent Office to revoke our Polish Patent No. 215263, which corresponds to the EP '127 Patent and expires in February 2023. The action was suspended by the Polish Patent Office in April 2021 pending examination of our amended patent claims.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 Polpharma Biologics S.A., Sandoz B.V. and Sandoz AG filed an action in the District Court of the Hague, Netherlands to invalidate the Dutch counterpart of our European Patent 2 676 967 (the EP '967 Patent), which expires in 2027 and covers methods of treatment using natalizumab (TYSABRI) and pre-treatment testing of patients. A hearing has been set for September 2022. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021 the EPO revoked the EP &#8216;967 Patent. We have appealed to the EPO&#8217;s Technical Boards of Appeal. A hearing date has not been set.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021 Polpharma Biologics S.A., Sandoz AG, Sandoz Limited and Sandoz GmbH filed an action in the English High Court to revoke the U.K. counterpart of the EP &#8216;967 Patent and seeking a declaration that the patent would not be infringed by the marketing of Polpharma&#8217;s proposed natalizumab biosimilar. A hearing has been set for November 2022.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Annulment Proceedings in General Court of the European Union relating to TECFIDERA</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical Works Polpharma SA (Polpharma) and Mylan Ireland Ltd. (Mylan Ireland) each filed actions in the General Court of the European Union (Polpharma in October 2018 and Mylan Ireland in November 2020) to annul the European Medicines Agency's (EMA) decision not to validate their applications to market generic versions of TECFIDERA on the grounds that TECFIDERA benefits from regulatory data protection. On May 5, 2021, the European General Court annulled the EMA's non-validation decision with respect to Polpharma. We have appealed the decision to the European Court of Justice and the appeal is pending. The case brought by Mylan Ireland has been stayed.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Liability and Other Legal Proceedings</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><div id="ie9658fba2baf4e3799b1175f69eaed46_130"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">19.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMzAvZnJhZzoyYjY1ODZkMDU2YzQ0NzU3YjE5OTAxNjAwNDVhYzhmMy90ZXh0cmVnaW9uOjJiNjU4NmQwNTZjNDQ3NTdiMTk5MDE2MDA0NWFjOGYzXzQ2_acda27b8-5aa4-47bf-a5cf-11967ec34d6a" continuedAt="i3c81ede8338640c183b5424e51aa4624" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="i3c81ede8338640c183b5424e51aa4624">On May 3, 2022, Biogen Inc. (the "Company") announced that it had begun a search for a new Chief Executive Officer ("CEO"). The Company has agreed with its current CEO, Michel Vounatsos, that he will continue to serve as CEO during the interim period. Mr. Vounatsos will remain on the Board of Directors of Biogen until he steps down from his CEO position.</ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><div id="ie9658fba2baf4e3799b1175f69eaed46_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM&#160;2.&#160;&#160;&#160;&#160;MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion should be read in conjunction with our unaudited condensed consolidated financial statements (condensed consolidated financial statements) and the accompanying notes beginning on page&#160;5 of this quarterly report on Form&#160;10-Q and our audited consolidated financial statements and the accompanying notes included in our Annual Report on Form&#160;10-K for the year ended December 31, 2021 (2021 Form&#160;10-K).</span></div><div id="ie9658fba2baf4e3799b1175f69eaed46_136"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Executive Summary</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Introduction</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. We have a leading portfolio of medicines to treat multiple sclerosis (MS), have introduced the first approved treatment for spinal muscular atrophy (SMA) and are providing the first and only approved treatment to address a defining pathology of Alzheimer's disease. We also commercialize biosimilars of advanced biologics and focus on advancing our pipeline in neuroscience and specialized immunology. Lastly, we are focused on accelerating our efforts in digital health to support our commercial and pipeline programs while also creating opportunities for potential digital therapeutics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS and relapsing MS (RMS); and other potential anti-CD20 therapies, including mosunetuzumab, pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2021 Form 10-K.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through our collaboration with Samsung Bioepis Co., Ltd. (Samsung Bioepis) we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe. We have also secured the exclusive rights to commercialize BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS, which was approved in the United States (U.S.), the European Union (E.U.) and the United Kingdom (U.K.) during the third quarter of 2021. For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to ensure an uninterrupted supply of medicines to patients around the world. To that end, we continually review our manufacturing capacity, capabilities, processes and facilities. In order to support our future growth and drug development pipeline, we are expanding our large molecule production capacity by building a large-scale biologics manufacturing facility in Solothurn, Switzerland. In the second quarter of 2021 a portion of the facility received a Good Manufacturing Practice (GMP) multi-product license from the Swiss Agency for Therapeutic Products (SWISSMEDIC). In April 2022 the U.S. Food and Drug Administration (FDA) approved the Prior Approval Supplement for the Solothurn facility for ADUHELM. We estimate the remainder of the facility will be operational during the first half of 2023. We believe that the Solothurn facility will support our anticipated near-term needs for the manufacturing of biologic assets. In addition, we believe that the Solothurn facility may provide us with the ability to further expand if we need additional large scale manufacturing capacity to support future clinical and commercial manufacturing requirements. If we are unable to fully utilize our manufacturing facilities, due to lower than forecasted demand for our products, we will incur excess capacity charges which will have a negative effect on our financial condition and results of operations.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue depends upon continued sales of our products as well as the financial rights we have in our anti-CD20 therapeutic programs, and, unless we develop, acquire rights to and/or commercialize new products and technologies, we will be substantially dependent on sales from our products and our </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial rights in our anti-CD20 therapeutic programs for many years.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the longer term, our revenue growth will depend upon the successful clinical development, regulatory approval and launch of new commercial products as well as additional indications for our existing products, our ability to obtain and maintain patents and other rights related to our marketed products, assets originating from our research and development efforts and/or successful execution of external business development opportunities.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Environment</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biopharmaceutical industry and the markets in which we operate are intensely competitive. Many of our competitors are working to develop or have commercialized products similar to those we market or are developing and have considerable experience in undertaking clinical trials and in obtaining regulatory approval to market pharmaceutical products. In addition, the commercialization of certain of our own approved products, products of our collaborators and pipeline product candidates may negatively impact future sales of our existing products.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products and revenue streams continue to face increasing competition in many markets from generic versions, prodrugs and biosimilars of existing products as well as products approved under abbreviated regulatory pathways. Such products are likely to be sold at substantially lower prices than branded products. Accordingly, the introduction of such products as well as other lower-priced competing products may significantly reduce both the price that we are able to charge for our products and the volume of products we sell, which will negatively impact our revenue. In addition, in some markets, when a generic or biosimilar version of one of our products is commercialized, it may be automatically substituted for our product and significantly reduce our revenue in a short period of time.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of our products depend, to a significant extent, on the availability and extent of adequate coverage, pricing and reimbursement from government health administration authorities, private health insurers and other organizations. When a new pharmaceutical product is approved, the availability of government and private reimbursement for that product may be uncertain, as is the pricing and amount for which that product will be reimbursed.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug prices are under significant scrutiny in the markets in which our products are prescribed. We expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to obtain or maintain adequate coverage, pricing or reimbursement for our products </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">could have an adverse effect on our business, reputation, revenue and results of operations, could curtail or eliminate our ability to adequately fund research and development programs for the discovery and commercialization of new products and/or could cause a decline or volatility in our stock price.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the impact of competition, pricing actions and other measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, our sales and operations could also be affected by other risks of doing business internationally, including the impact of public health epidemics, such as the COVID-19 pandemic, on employees, the global economy and the delivery of healthcare treatments, geopolitical events, foreign currency exchange fluctuations, changes in intellectual property legal protections and changes in trade regulations and procedures.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a detailed discussion on our business environment, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in our 2021 Form 10-K. For additional information on our competition and pricing risks that could negatively impact our product sales, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in this report.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ADUHELM (aducanumab)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 the FDA granted accelerated approval of ADUHELM, which we are collaborating on with Eisai Co., Ltd. (Eisai), based on reduction in amyloid beta plaques observed in patients treated with ADUHELM. As part of the accelerated approval, we are required to conduct a confirmatory trial to verify the clinical benefit of ADUHELM in patients with Alzheimer&#8217;s disease. The FDA may withdraw approval if, among other things, the confirmatory trial fails to verify clinical benefit of ADUHELM, ADUHELM's benefit-risk is no longer positive or we fail to comply with the conditions of the accelerated approval.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. ADUHELM product label states that treatment with ADUHELM should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population which was studied in clinical trials.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2022 the Centers for Medicare and Medicaid Services (CMS) released a proposed National Coverage Determination (NCD) decision memorandum, stating the proposed NCD would cover FDA approved monoclonal antibodies that target amyloid for the treatment of Alzheimer's disease for people with Medicare only if they are enrolled in qualifying clinical trials.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2022 CMS released the final NCD for the class of anti-amyloid treatments in Alzheimer&#8217;s disease, including ADUHELM. The final NCD confirmed coverage with evidence development, in which </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">patients with Medicare can only access treatment if they are part of an approved clinical trial. We expect that this decision will reduce future demand for ADUHELM to a minimal level. During the first quarter of 2022 we wrote-off approximately $275.0&#160;million of gross charges associated with inventory and purchase commitments related to ADUHELM and recognized approximately $45.0&#160;million of gross idle capacity charges, as a result of this CMS decision, which were recognized in cost of sales within our condensed consolidated statements of income. We have recognized approximately $160.0&#160;million related to Eisai's 45.0% share of these charges in collaboration profit (loss) sharing within our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, as a result of the final NCD we will substantially eliminate our commercial infrastructure supporting ADUHELM, retaining minimal resources to manage patient access programs, including a continued free drug program for patients currently on treatment in the U.S. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We expect to continue funding certain regulatory and research and development activities for ADUHELM, including the continuation of the EMBARK re-dosing study and the initiation of the Phase 4 post-marketing requirement study, ENVISION. Additional actions regarding ADUHELM may be informed by upcoming data readouts expected for this class of antibodies, as well as further engagement with the FDA and CMS.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2022 we amended our ADUHELM Collaboration Agreement with Eisai. Effective March 2022 we have sole decision making and commercialization rights worldwide on ADUHELM and beginning January 1, 2023, Eisai will receive a tiered royalty based on net sales of ADUHELM, rather than sharing global profits and losses. Eisai's share of development, commercialization and manufacturing expense is limited to $335.0&#160;million for the period from January 1, 2022 to December 31, 2022. Once the tiered royalty model commences on January 1, 2023, Eisai will not participate in ADUHELM&#8217;s economics beyond these royalties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rest of World</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 the European Medicines Agency (EMA) accepted for review the Marketing Authorization Application (MAA) for aducanumab and in December 2020 the Ministry of Health, Labor and Welfare accepted for review the Japanese New Drug Application (NDA) for aducanumab.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021 the Committee for Medicinal Products for Human Use (CHMP) of the EMA adopted a negative opinion on the MAA for aducanumab in Europe. We sought re-examination of the opinion by the CHMP. In April 2022 we announced our decision to withdraw our MAA for aducanumab in Europe.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not receive regulatory approval or are unable to successfully commercialize aducanumab in </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other jurisdictions, our financial condition, business and operations may be adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TECFIDERA</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020 U.S. federal courts in West Virginia and Delaware entered judgments in favor of the defendants in patent infringement proceedings relating to TECFIDERA Orange-Book listed patents. We appealed both decisions. In late 2021 the U.S. Court of Appeals for the Federal Circuit (Federal Circuit) affirmed the judgment of the West Virginia federal court. The appeals in the actions in Delaware are stayed.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multiple TECFIDERA generic entrants are now in the U.S. market and have deeply discounted prices compared to TECFIDERA. The generic competition for TECFIDERA has significantly reduced our TECFIDERA revenue and is expected to continue to have a substantial and increasing negative impact on our U.S. TECFIDERA revenue in the future.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2021 the European General Court annulled the EMA's decision not to validate applications for approval of TECFIDERA generics on the basis that the EMA conducted the wrong assessment when determining TECFIDERA's entitlement to regulatory data and marketing protection. Our Company, the EMA and the European Commission (EC) have each appealed the General Court&#8217;s decision as wrongly decided and the appeal is pending.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021 the CHMP of the EMA issued an ad hoc opinion referencing the General Court&#8217;s decision which concluded that "the totality of the available data cannot establish that [monoethyl fumarate] exerts a clinically relevant therapeutic contribution within FUMADERM." The EC will decide TECFIDERA&#8217;s entitlement to regulatory data and market protection. If data and market protection is not upheld, we could face generic competition in the E.U. as early as the first half of 2022, which would have an adverse impact on our TECFIDERA sales in the E.U. and our results of operations.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Litigation,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report and the discussion under </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Results of Operations - Product Revenue - Multiple Sclerosis (MS) - Fumarate</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Update Regarding COVID-19 and Other Disruptions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to present a substantial public health and economic challenge around the world. The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including sales, expense, reserves and allowances, the supply chain, manufacturing, clinical trials, research and development costs and employee-related costs, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are monitoring the demand for our products, including the duration and degree to which we may see delays in starting new patients on a product due to hospitals diverting the resources that are necessary to administer certain of our products to care for COVID-19 patients, including products, such as TYSABRI and SPINRAZA, that are administered in a physician's office or hospital setting. We may also see reduced demand for immunosuppressant therapies during the COVID-19 pandemic.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we are currently continuing the clinical trials we have underway in sites across the globe, COVID-19 precautions have impacted the timeline for some of our clinical trials and these precautions may, directly or indirectly, have a further impact on timing in the future. To help mitigate the impact of the COVID-19 pandemic to our clinical trials, we are pursuing innovative approaches such as remote monitoring, remote patient visits and supporting home infusions. These alternative measures have resulted in an immaterial increase to the cost of the clinical trials underway.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Conflict in Ukraine</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ongoing geopolitical tensions related to Russia's invasion of Ukraine have resulted in global business disruptions and economic volatility, including sanctions and other restrictions levied on the government and businesses in Russia. Although we do not have affiliates or employees, in either Russia or Ukraine, we do provide various therapies to patients in Russia through a distributor and are currently involved in clinical trials with sites in Ukraine and Russia. The timing and costs of these trials may be impacted as a result of the conflict. For example, the development of orelabrutinib, an oral small molecule Bruton&#8217;s tyrosine kinase inhibitor for the potential treatment of MS, that we are developing with </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">InnoCare has been delayed and will require the establishment of new clinical sites in other geographies.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impact of the conflict on our operations and financial performance remains uncertain and will depend on future developments, including the severity and duration of the conflict, its impact on regional and global economic conditions and whether the conflict spreads or has effects on countries outside Ukraine and Russia. Revenue generated from sales in these regions represented less than 2.0% of total product revenue for the three months ended March 31, 2022 and the year ended December 31, 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to monitor the ongoing conflict between Russia and Ukraine and assess any potential impacts on our business, supply chain, partners or customers, as well as any factors that could have an adverse effect on our results of operations.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors such as the COVID-19 pandemic, adverse weather events, geopolitical events, labor or raw material shortages and other supply chain disruptions could result in product shortages or other difficulties and delays or increased costs in manufacturing our products.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the various risks posed by the COVID-19 pandemic and Russia's invasion of Ukraine, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">included in this report.</span></div><div id="ie9658fba2baf4e3799b1175f69eaed46_139"></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Highlights</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted earnings per share attributable to Biogen Inc. was $2.06 for the three months ended March 31, 2022, representing a decrease of 23.4% compared to $2.69 in the same period in 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described below under </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Results of Operations</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our net income and diluted earnings per share attributable to Biogen Inc. for the three months ended March 31, 2022, compared to the three months ended March 31, 2021, reflects the following:</span></div><div style="margin-top:5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Total revenue was $2,531.8 million for the first quarter of 2022, representing a $162.2 million, or 6.0%, decrease compared to $2,694.0 million in the same period in 2021.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Product revenue, net totaled $2,066.3 million for the first quarter of 2022, representing a $145.4 million, or 6.6%, decrease compared to $2,211.7 million in the same period in 2021. This decrease was primarily due to an $88.8 million, or 6.0%, decrease in MS product revenue and a $48.0 million, or 9.2%, decrease in SPINRAZA product revenue.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.59pt">The decrease in MS product revenue was primarily due to a decrease in </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt;padding-left:72pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rest of world Interferon demand due to increasing competition from our other MS products as well as other treatments for MS, including biosimilars. The decrease was also due to a decrease in U.S. TECFIDERA demand as a result of multiple TECFIDERA generic entrants in the U.S. market.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.59pt">The decrease in SPINRAZA revenue was primarily due to a decrease in demand as a result of increased competition in certain established markets, particularly Germany, and the timing of shipments, as well as the unfavorable impact of foreign currency exchange.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Revenue from anti-CD20 therapeutic programs totaled $399.4 million for the first quarter of 2022, representing a $10.4 million, or 2.7%, increase compared to $389.0 million in the same period in 2021. T</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hi</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s increase wa</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s primarily due to a </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$43.0&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.5%</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increase</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in royalty revenue on sales of OCREVUS, partially offset by a</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $31.0&#160;million, or 19.5%, decrease </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in RITUXAN revenue. Sales of RITUXAN have been a</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dversely affected by the onset of biosimilars competition.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Other revenue totaled $66.1 million for the first quarter of 2022, representing a $27.2 million, or 29.2% decrease from $93.3 million in the same period in 2021.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expense</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Total cost and expense was $1,921.1 million for the first quarter of 2022, representing a $201.0 million, or 11.7%, increase compared to $1,720.1 million in the same period in 2021.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.59pt">This increase was primarily due to a $275.8 million, or 57.7%, increase in cost of sales, driven by approximately $275.0&#160;million of gross charges associated with inventory and purchase commitments in excess of forecasted demand related to ADUHELM, as well as approximately $45.0&#160;million of gross idle capacity charges.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">The increase in cost and expense for the first quarter of 2022 also reflects an increase in selling, general and administrative expense due to ADUHELM commercialization expense of approximately $80.0&#160;million and </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;padding-left:72pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">restructuring charges of approximately $38.1 million related to our 2022 cost saving initiatives.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described below under </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Condition, Liquidity and Capital Resources:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">We generated $161.8 million of net cash flow from operations for the three months ended March 31, 2022.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Cash, cash equivalents and marketable securities totaled approximately $4,753.3 million as of March 31, 2022.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">There were no share repurchases of our common stock during the first quarter of 2022 under a program authorized by our Board of Directors in October 2020 to repurchase up to $5.0 billion of our common stock (2020 Share Repurchase Program). Approximately $2.8 billion remained available under our 2020 Share Repurchase Program as of March 31, 2022.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborative and Other Relationships</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaborative and other relationships discussed below, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17, Investments in Variable Interest Entities</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Samsung Bioepis - Biogen's Joint Venture with Samsung BioLogics</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022 we entered into an agreement to sell to Samsung BioLogics our equity in Samsung Bioepis, which was completed on April 20, 2022. Under the terms of the transaction, we received approximately $1.0&#160;billion in cash at closing and will receive approximately $1.3&#160;billion to be deferred over two payments of $812.5&#160;million due at the first anniversary and $437.5&#160;million due at the second anniversary of the closing of the transaction. We are also eligible to receive up to an additional $50.0&#160;million upon the achievement of certain commercial milestones.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the transaction and our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Eisai Collaboration Agreements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">ADUHELM Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022 we amended our ADUHELM Collaboration Agreement with Eisai. Effective March 2022 we have sole decision making and commercialization rights worldwide on ADUHELM and beginning January 1, 2023, Eisai will receive a tiered </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">royalty based on net sales of ADUHELM, rather than sharing global profits and losses. Eisai's share of development, commercialization and manufacturing expense is limited to $335.0&#160;million for the period from January 1, 2022 to December 31, 2022. Once the tiered royalty model commences on January 1, 2023, Eisai will not participate in ADUHELM&#8217;s economics beyond these royalties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Lecanemab Collaboration</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In March 2022 we extended our supply agreement related to lecanemab from 5 years to 10 years, and we will manufacture the lecanemab drug substance in our Solothurn manufacturing facility.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 16, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Key Developments</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Cost Saving Initiatives</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021 and May 2022 we announced our plans to implement a series of cost-reduction measures during 2022. These savings are expected to be achieved through a number of initiatives, including reductions to our workforce, primarily within our global Alzheimer's infrastructure, the consolidation of certain real estate locations and operating efficiency gains across our selling, general and administrative and research and development functions.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under these initiatives, we expect to incur restructuring charges ranging from approximately $100.0&#160;million to $150.0&#160;million. These amounts are primarily related to severance and are expected to be substantially incurred and paid by the end of 2022.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For additional information on our 2022 cost saving initiatives, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 2, Restructuring, Business Transformation and Other Cost Saving Initiatives, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">to our condensed consolidated financial statements included in this report.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><div id="ie9658fba2baf4e3799b1175f69eaed46_142"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="margin-top:13pt"><span style="color:#0a2299;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:3pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.703%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenue, net:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">875.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">899.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,191.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,311.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(120.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,066.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,211.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(145.4)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.6)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">399.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">389.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,531.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,694.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(162.2)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div id="ie9658fba2baf4e3799b1175f69eaed46_145"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product Revenue</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"></div></div><div style="margin-top:3pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.703%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis (MS):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fumarate</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">537.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">552.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interferon</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">309.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(90.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">520.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">503.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: MS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,394.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,483.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(88.8)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">472.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">520.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(48.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alzheimer's disease:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ADUHELM</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilars</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">194.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.8)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FUMADERM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,066.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,211.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(145.4)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.6)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Fumarate includes TECFIDERA and VUMERITY. VUMERITY became commercially available in the E.U. during the fourth quarter of 2021.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Interferon includes AVONEX and PLEGRIDY.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> In June 2021 the FDA granted accelerated approval of ADUHELM, which became commercially available in the U.S. during the second quarter of 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">- Eisai Co., Ltd. - ADUHELM Collaboration Agreement</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">nm</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Not meaningful</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Multiple Sclerosis (MS)</span></div><div style="margin-top:6pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fumarate</span></div><div><img src="biib-20220331_g2.jpg" alt="biib-20220331_g2.jpg" style="height:549px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fumarate revenue includes sales from TECFIDERA and VUMERITY. During the fourth quarter of 2021 VUMERITY was approved for the treatment of relapsing-remitting MS (RRMS) in the E.U., Switzerland and the U.K.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, compared to the same period in 2021, the 2.7% increase in U.S. Fumarate revenue was primarily due to a favorable adjustment of prior year estimates on Medicaid-related sales of VUMERITY. The increase was also due to an increase in VUMERITY sales volumes in the U.S., partially offset by a decrease in TECFIDERA demand as a result of multiple TECFIDERA generic entrants in the U.S. market.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, compared to the same period in 2021, the 6.7% decrease in rest of world Fumarate revenue was primarily due to TECFIDERA pricing reductions in certain European countries.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020 U.S. federal courts in West Virginia and Delaware entered judgments in favor of the defendants in patent infringement proceedings relating to TECFIDERA Orange-Book listed patents. We appealed both decisions. In late 2021 the Federal Circuit affirmed the judgment of the West Virginia federal court. The appeals in the actions in Delaware are stayed.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multiple TECFIDERA generic entrants are now in the U.S. market and have deeply discounted prices compared to TECFIDERA. The generic competition for TECFIDERA has significantly reduced our TECFIDERA revenue and is expected to continue to have a substantial and increasing negative impact on our U.S. TECFIDERA revenue in the future.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2021 the European General Court annulled the EMA's decision not to validate applications for approval of TECFIDERA generics on the basis that the EMA conducted the wrong assessment when determining TECFIDERA's entitlement to regulatory data and marketing protection. Our Company, the EMA and the EC have each appealed the General Court&#8217;s decision as wrongly decided and the appeal is pending.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021 the CHMP of the EMA issued an ad hoc opinion referencing the General Court&#8217;s decision which concluded that "the totality of the available data cannot establish that [monoethyl fumarate] exerts a clinically relevant therapeutic contribution within FUMADERM." The EC will decide TECFIDERA&#8217;s entitlement to regulatory data and market protection. If data and market protection is not upheld, we could face generic competition in the E.U. as early as the first half of 2022, which would have an adverse impact on our TECFIDERA sales in the E.U. and our results of operations.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Litigation,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that TECFIDERA revenue will continue to decline in 2022, compared to 2021, as a result of increasing generic competition.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect an increase in VUMERITY sales volumes in 2022, compared to 2021, mostly due to demand growth, including the continued launch of VUMERITY in the E.U.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interferon</span></div><div><img src="biib-20220331_g3.jpg" alt="biib-20220331_g3.jpg" style="height:525px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, compared to the same period in 2021, the 24.6% decrease in U.S. Interferon revenue was primarily due to a decrease in Interferon sales volumes of 14.6% and a decrease in pricing of 10.0%. The net decline in sales volumes reflects the continued decline of the Interferon market as patients transition to other higher efficacy and oral MS therapies.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, compared to the same period in 2021, the 19.8% decrease in rest of world Interferon revenue was primarily due to a decrease in Interferon sales volumes resulting from the continued decline of the Interferon market.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that Interferon revenue will continue to decline in both the U.S. and rest of world markets in 2022, compared to 2021, as a result of increasing competition from other MS products, including biosimilars, and further pricing reductions in certain European markets.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TYSABRI</span></div><div><img src="biib-20220331_g4.jpg" alt="biib-20220331_g4.jpg" style="height:333px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, compared to the same period in 2021, the 4.1% increase in U.S. TYSABRI revenue was primarily due to price increases, partially offset by a decrease in sales volumes.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, compared to the same period in 2021, the 2.7% increase in rest of world TYSABRI revenue was primarily due to favorable volume impacts, partially offset by a decrease in pricing.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate TYSABRI revenue to be relatively flat on a global basis in 2022, compared to 2021, despite increasing competition from additional treatments for MS. We expect to continue to face price reductions in certain European markets.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Spinal Muscular Atrophy</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SPINRAZA</span></div><div><img src="biib-20220331_g5.jpg" alt="biib-20220331_g5.jpg" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, compared to the same period in 2021, the 9.8% increase in U.S. SPINRAZA revenue was primarily due to an increase in sales volumes resulting from favorable channel dynamics.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, compared to the same period in 2021, the 16.8% decrease in rest of world SPINRAZA revenue was primarily due to a decrease in sales volumes of 10.0% resulting from increased competition in certain established markets, particularly Germany, and the timing of shipments, as well as the unfavorable impact of foreign currency exchange. The decrease was partially offset by sales volume growth in certain Asian markets.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face competition from a gene therapy product and an oral product. In 2022 we expect that SPINRAZA revenue will be subject to increased competition likely resulting in continued patient discontinuations and a lower rate of new patient starts combined with the impact of loading dose dynamics as patients transition to dosing once every four months and lower prices in certain rest of world countries.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Ionis Pharmaceuticals, Inc. (Ionis), please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2021 Form 10-K. </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Alzheimer's Disease</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ADUHELM</span></div><div style="margin-top:6pt"><img src="biib-20220331_g6.jpg" alt="biib-20220331_g6.jpg" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In June 2021 the FDA granted accelerated approval of ADUHELM, which became commercially available in the U.S. during the second quarter of 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2022 the CMS released the final NCD for the class of anti-amyloid treatments in Alzheimer&#8217;s disease, including ADUHELM. The final NCD confirmed coverage with evidence development, in which patients with Medicare can only access treatment if they are part of an approved clinical trial. We expect that this decision will reduce future demand for ADUHELM to a minimal level.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, as a result of the final NCD we will substantially eliminate our commercial infrastructure supporting ADUHELM, retaining minimal resources to manage patient access programs, including a continued free drug program for patients currently on treatment in the U.S.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:107%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Note 16, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:107%">to</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:107%">our condensed consolidated financial statements included in this report.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biosimilars</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BENEPALI, IMRALDI and FLIXABI</span></div><div><img src="biib-20220331_g7.jpg" alt="biib-20220331_g7.jpg" style="height:333px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, compared to the same period in 2021, the 5.3% decrease in biosimilar revenue was primarily due to a decrease in pricing in certain markets and unfavorable foreign currency impact, partially offset by an increase in sales volumes.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2021 BYOOVIZ, a biosimilar referencing LUCENTIS, was approved in the U.S., the E.U. and the U.K.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate a slight decline in revenue from our biosimilars business in 2022, compared to 2021, despite the launch of BYOOVIZ in the U.S. and an anticipated modest increase in sales volumes in 2022, as we continue to face price reductions in certain markets.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div id="ie9658fba2baf4e3799b1175f69eaed46_148"></div><div style="margin-top:6pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Revenue from Anti-CD20 Therapeutic Programs</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genentech (Roche Group)</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share of RITUXAN, including RITUXAN HYCELA, and GAZYVA collaboration operating profits in the U.S. and other revenue from anti-CD20 therapeutic programs are summarized in the table below. For purposes of this discussion, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div><img src="biib-20220331_g8.jpg" alt="biib-20220331_g8.jpg" style="height:346px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Biogen&#8217;s Share of Pre-tax Profits in the U.S. for RITUXAN and GAZYVA</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of amounts comprising our share of pre-tax profits in the U.S. for RITUXAN and GAZYVA:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.371%"><tr><td style="width:1.0%"></td><td style="width:52.064%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.735%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.737%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">455.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">551.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax profits in the U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">395.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">477.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of pre-tax profits</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, compared to the same period in 2021, the decrease i</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n U.S.&#160;product revenue, net was primarily due to a decrease in sales volumes of RITUXAN in the U.S. of 30.4%, primarily due to the onset of competition from multiple biosimilar products and</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a decrease in GAZYVA sales volumes of 3.6%.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, compared to the same pe</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">riod in 2021, the decrease in collaboration costs and expense was primarily due </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to lower cost of sales, selling and marketing expense and distribution costs related to RITUXAN.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of several other anti-CD20 molecules, including biosimilar products, that have been approved and are competing with RITUXAN and GAZYVA in the oncology and other markets. In November 2019, January 2020 and January 2021 biosimilar products referencing RITUXAN were launched in the U.S. and are being offered at lower prices. This competition has had a significant adverse impact on the pre-tax profits of our collaboration arrangements with Genentech, as the sales of RITUXAN have decreased substantially compared to prior periods. We expect that biosimilar competition will continue to increase as these products capture additional market share and that this will have a significant adverse impact on our co-promotion profits in the U.S. in future years.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Revenue from Anti-CD20 Therapeutic Programs</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue from anti-CD20 therapeutic programs consists of royalty revenue on sales of OCREVUS and our share of pre-tax co-promotion profits from RITUXAN in Canada. </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended March 31, 2022, compared to the same period in 2021, the increase in other revenue from anti-CD20 therapeutic programs was primarily due to sales growth of OCREVUS. Royalty revenue recognized on sales of OCREVUS for the three months ended March 31, 2022, totaled $252.3 million compared to $209.3&#160;million in the prior year comparative period.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OCREVUS royalty revenue is based on our estimates from third party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenue will be adjusted for in the period in which they become known, which is generally expected to be the following quarter.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Genentech, including information regarding the pre-tax profit-sharing formula and its impact on future revenue from anti-CD20 therapeutic programs, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note&#160;18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2021 Form 10-K.</span></div><div id="ie9658fba2baf4e3799b1175f69eaed46_151"></div></div></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Revenue</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue is summarized as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.556%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from collaborative and other relationships</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other royalty and corporate revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(35.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29.2)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27.2)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue from Collaborative and Other Relationships</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from collaborative and other relationships primarily includes royalty revenue on biosimilar products from Samsung Bioepis.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaborative arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Royalty and Corporate Revenue</span></div><div><img src="biib-20220331_g9.jpg" alt="biib-20220331_g9.jpg" style="height:300px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive royalties from net sales on products related to patents that we have out-licensed and we record other corporate revenue primarily from amounts earned under contract manufacturing agreements.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, compared to the same period in 2021, the decrease in other royalty and corporate revenue was primarily due to lower contract manufacturing revenue related to timing of batch releases.</span></div><div id="ie9658fba2baf4e3799b1175f69eaed46_154"></div><div style="margin-top:6pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Reserves for Discounts and Allowances</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recorded net of reserves established for applicable discounts and allowances, including those associated with the implementation of pricing actions in certain international markets where we operate.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). These estimates reflect our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for discounts, contractual adjustments and returns that reduced gross product revenue are summarized as follows:</span></div><div><img src="biib-20220331_g10.jpg" alt="biib-20220331_g10.jpg" style="height:400px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, reserves for discounts and allowances as a percentage of gross product revenue was 27.0% compared to 29.0% in the prior year comparative period. </span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Discounts</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discounts include trade term discounts and wholesaler incentives.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, compared to the same period in 2021, the decrease in discounts was primarily driven by a decrease in gross sales.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Adjustments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual adjustments primarily relate to Medicaid and managed care rebates in the U.S., pharmacy rebates, co-payment (copay) assistance, Veterans Administration, 340B discounts, specialty pharmacy program fees and other government rebates or applicable allowances.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, compared to the same period in 2021, the decrease in contractual adjustments was primarily driven by lower TECFIDERA sales in the U.S., resulting in lower pharmacy rebates, co-pay assistance and managed care rebates, as well as lower Medicaid rebates in the </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. driven by a favorable change in estimates for VUMERITY.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Returns</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product return reserves are established for returns made by wholesalers. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Provisions for product returns are recognized in the period the related revenue is recognized, resulting in a reduction to product sales.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, compared to the same period in 2021, return reserves were relatively consistent.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our revenue reserves, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Revenue,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div id="ie9658fba2baf4e3799b1175f69eaed46_157"></div></div></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cost and Expense</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of total cost and expense is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.338%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales, excluding amortization and impairment of acquired intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">753.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">478.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">275.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">551.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">514.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">634.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">595.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and impairment of acquired intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration profit (loss) sharing</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(117.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(271.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(185.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain) loss on fair value remeasurement of contingent consideration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(79.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,921.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,720.1&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">201.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">nm</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Not meaningful</span></div><div id="ie9658fba2baf4e3799b1175f69eaed46_160"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales, Excluding Amortization and Impairment of Acquired Intangible Assets</span></div><div><img src="biib-20220331_g11.jpg" alt="biib-20220331_g11.jpg" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Cost of Sales</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, compared to the same period in 2021, the increase in product cost of sales was primarily due to the write-off of ADUHELM inventory and idle capacity charges.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2022 we recorded approximately $275.0&#160;million of gross charges associated with inventory and purchase commitments in excess of forecasted demand related to ADUHELM, as well as approximately $45.0&#160;million of gross idle capacity charges, which were recognized in cost of sales within our condensed consolidated statements of income. We have recognized approximately $160.0&#160;million related to Eisai's 45.0% share of these charges in collaboration profit (loss) sharing within our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, compared to the same period in 2021, royalty cost of sales remained flat.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><div id="ie9658fba2baf4e3799b1175f69eaed46_163"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div><img src="biib-20220331_g12.jpg" alt="biib-20220331_g12.jpg" style="height:366px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div><img src="biib-20220331_g13.jpg" alt="biib-20220331_g13.jpg" style="height:766px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant amount of our research and development costs consists of indirect costs incurred in support of overall research and development activities and non-specific programs, including activities that benefit multiple programs, such as </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">management costs, as well as depreciation, information technology and facility-based expenses. These costs are considered other research and development costs in the table above and are not allocated to a specific program or stage.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense incurred in support of our marketed products includes costs associated with product lifecycle management activities including, if applicable, costs associated with the development of new indications for existing products. Late stage programs are programs in Phase 3 development or in registration stage. Early stage programs are programs in Phase 1 or Phase 2 development. Research and discovery represents costs incurred to support our discovery research and translational science efforts. Costs are reflected in the development stage based upon the program status when incurred. Therefore, the same program could be reflected in different development stages in the same year. For several of our programs, the research and development activities are part of our collaborative and other relationships. Our costs reflect our share of the total costs incurred.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, compared to the same period in 2021, the increase in research and development expense was primarily due to milestone payments, an increase in spending related to lecanemab, the advancement of BIIB059 (anti-BDCA2) for the potential treatment of systemic lupus erytheatosus (SLE), the development of mosunetuzumab, a late-stage bispecific antibody in development for B-cell non-Hodgkin's lymphoma and other therapeutic areas, the development of BIIB124 (SAGE-324) for the potential treatment of essential tremor, which we are developing in collaboration with Sage Therapeutics, Inc. (Sage), the development of BIIB122 (DNL151) for the potential treatment of Parkinson's disease, which we are developing in collaboration with Denali Therapeutics Inc. (Denali), and the development of BIIB135 (orelabrutinib) for the potential treatment of MS.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021 we recorded upfront payments related to our new collaborations as part of research and development expense. Excluding upfront payments, we expect our core research and development expense in 2022 to be consistent with 2021 as we continue to invest in our pipeline. We intend to continue committing significant resources to targeted research and development opportunities where there is a significant unmet need and where a drug candidate has the potential to be highly differentiated.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Early Stage Programs</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, compared to the same period in 2021, the decrease in spending related to our early stage programs was primarily due to a decrease in costs associated with:</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the discontinuation of BIIB054 (cinpanemab) in Parkinson's disease;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the discontinuation of gosuranemab (BIIB092) in Alzheimer's disease;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the discontinuation of BIIB112 (cotoretigene toliparvovec) in X-linked retinitis pigmentosa; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the advancement of BIIB059 for the potential treatment of SLE into late stage.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These decreases were partially offset by an increase in costs associated with:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">an increase in spending in the development of BIIB124 for the potential treatment of essential tremor;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">an increase in spending in the development of BIIB122 for the potential treatment of Parkinson's disease; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">an increase in spending in the development of BIIB135 for the potential treatment of MS.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Late Stage Programs</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, compared to the same period in 2021, the decrease in spending associated with our late stage programs was primarily due to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the advancement of ADUHELM from late stage to marketed upon the accelerated approval of ADUHELM in the U.S.; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the discontinuation of BIIB111 (timrepigene emparvovec) in choroideremia.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These decreases were partially offset by an increase in costs associated with:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the advancement of BIIB059 for the potential treatment of SLE into late stage;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">an increase in spending related to lecanemab; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">an increase in spending related to mosunetuzumab, a late-stage bispecific antibody in development for B-cell non-Hodgkin's lymphoma and other therapeutic areas.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketed Programs</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, compared to the same period in 2021, the increase in spending associated with our marketed programs was primarily due to an increase in costs associated with:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the advancement of ADUHELM from late stage to marketed upon the accelerated approval of ADUHELM in the U.S.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019 Eisai initiated a global Phase 3 trial for the development of lecanemab in early Alzheimer's disease. Under our collaboration arrangement, Eisai serves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product, and Eisai having final decision-making authority. All costs, including research, development, sales and marketing expense, are shared equally between us and Eisai.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our condensed consolidated financial statements included in this report.</span></div><div id="ie9658fba2baf4e3799b1175f69eaed46_166"></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative</span></div><div><img src="biib-20220331_g14.jpg" alt="biib-20220331_g14.jpg" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, compared to the same period in 2021, the 6.7% increase in selling, general and administrative expense was primarily due to gross ADUHELM commercialization expense of approximately $80.0&#160;million, partially offset by cost-reduction measures realized during the first quarter of 2022.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As a result of the final NCD we will substantially eliminate our commercial infrastructure supporting ADUHELM, retaining minimal resources to manage patient access programs, including a continued free drug program for patients currently on treatment in the U.S.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the second quarter of 2021 reimbursement from Eisai for its share of U.S. ADUHELM selling, general and administrative expense is recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income.</span></div><div id="ie9658fba2baf4e3799b1175f69eaed46_169"></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amortization and Impairment of Acquired Intangible Assets</span></div><div><img src="biib-20220331_g15.jpg" alt="biib-20220331_g15.jpg" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amortization expense is based on the economic consumption and impairment of intangible assets. Our most significant amortizable intangible assets are related to our TYSABRI, AVONEX, SPINRAZA, VUMERITY and TECFIDERA (rest of world) products and other programs acquired through business combinations. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, compared to the same period in March 31, 2021, the decrease in amortization and impairment of acquired intangible assets was primarily related to a $44.3&#160;million impairment charge recorded during the first quarter of 2021 related to vixotrigine (BIIB074) for the potential treatment of trigeminal neuralgia (TGN). </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended March 31, 2022, we had </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">no</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> impairment charges.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We monitor events and expectations regarding product performance. If new information indicates that the assumptions underlying our most recent analysis are substantially different than those utilized in our current estimates, our analysis would be updated and may result in a significant change in the anticipated lifetime revenue of the relevant products. The occurrence of an adverse event could substantially increase the amount of amortization expense related to our acquired intangible assets as compared to previous periods or our current expectations, which may result in a significant negative impact on our future results of operations.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IPR&amp;D Related to Business Combinations</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. We review amounts capitalized as acquired IPR&amp;D for impairment annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, the value of our acquired IPR&amp;D assets is dependent upon several variables, including estimates of future revenue and the effects of competition, our ability to secure sufficient pricing in a competitive market, our ability to confirm safety and efficacy based on data from clinical trials and regulatory feedback, the level of anticipated development costs and the probability and timing of successfully advancing a particular research program from one clinical trial phase to the next. We are continually reevaluating our estimates concerning these and other variables, including our life cycle management strategies, research and development priorities and development risk, changes in program and portfolio economics and related impact of foreign currency exchange rates and economic trends and evaluating industry and company data regarding the productivity of clinical research and the development process. Changes in our estimates may result in a significant change to our valuation of our IPR&amp;D assets.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vixotrigine</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the periods since we acquired vixotrigine, there have been numerous delays in the initiation of Phase 3 studies for the potential treatment of TGN and for the potential treatment of diabetic painful neuropathy (DPN), another form of neuropathic pain. We have engaged with the FDA regarding the design of the Phase 3 studies of vixotrigine for the potential treatment of TGN and DPN and are now performing an additional clinical trial of vixotrigine, which is expected to be completed by the end of 2022.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance of this additional clinical trial delayed the initiation of the Phase 3 studies of vixotrigine for the potential treatment of TGN, and, as a result, we recognized an impairment charge of $44.3&#160;million related to vixotrigine for the potential treatment of TGN during the fi</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rst quarter of 2021. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, the carrying value associated with the remaining IPR&amp;D asset for DPN </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was $129.1&#160;million a</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd the fair value of this asset was not significantly in excess of its carrying value. Upon the completion of the additional clinical trial we will reevaluate the carrying value of the program.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the amortization and impairment of our acquired intangible assets, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 5, Intangible Assets and Goodwill,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report. </span></div><div id="ie9658fba2baf4e3799b1175f69eaed46_172"></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Profit (Loss) Sharing</span></div><div><img src="biib-20220331_g16.jpg" alt="biib-20220331_g16.jpg" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration profit (loss) sharing primarily includes Samsung Bioepis' 50.0% share of the profit or loss related to our biosimilars commercial agreement with Samsung Bioepis and, beginning in the second quarter of 2021, Eisai's 45.0% share of income and expense in the U.S. related to the ADUHELM Collaboration Agreement.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, we recognized net profit-sharing expense of $64.4 million to reflect Samsung Bioepis' 50.0% sharing of the net collaboration profits compared to a net profit-sharing expense of $68.5 million in the prior year comparative period. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, we recognized a net reduction to our operating expense of </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$181.7&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to reflect Eisai's 45.0% share of net collaboration losses in the U.S.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis and Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report. </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><div id="ie9658fba2baf4e3799b1175f69eaed46_178"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Gain) Loss on Fair Value Remeasurement of Contingent Consideration</span></div><div><img src="biib-20220331_g17.jpg" alt="biib-20220331_g17.jpg" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration payable for certain of our business combinations includes future payments that are contingent upon the occurrence of a particular event or events. We record an obligation for such contingent consideration payments at fair value on the acquisition date. We then revalue our contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations, other than changes due to payments, are recognized as a (gain) loss on fair value remeasurement of contingent consideration in our condensed consolidated statements of income. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, changes</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the fair value of our contingent consideration obligations were primarily due to an increase in discount rates used to revalue these obligations and delays in the expected timing of the achievement of certain remaining developmental milestones related to our vixotrigine programs.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div id="ie9658fba2baf4e3799b1175f69eaed46_2076"></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring Charges</span></div><div><img src="biib-20220331_g18.jpg" alt="biib-20220331_g18.jpg" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Cost Saving Initiatives</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021 and May 2022 we announced our plans to implement a series of cost-reduction measures during 2022. These savings are expected to be achieved through a number of initiatives, including reductions to our workforce, primarily within our global Alzheimer's infrastructure, the consolidation of certain real estate locations and operating efficiency gains across our selling, general and administrative and research and development functions.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under these initiatives, we expect to incur restructuring charges ranging from approximately $<ix:nonFraction unitRef="usd" contextRef="i8c3728b044d743d0b57e33fc6e523b46_D20220101-20221231" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMDc2L2ZyYWc6NWYwMzJkZjM4N2ZkNDI3MDlhNzVkMmVjN2Q2NTc1N2MvdGV4dHJlZ2lvbjo1ZjAzMmRmMzg3ZmQ0MjcwOWE3NWQyZWM3ZDY1NzU3Y18xMDk5NTExNjMzNjI1_7757f36e-1765-477c-9ac4-fd5bc273bada">100.0</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="i4afdc1a2dcdf424eabd0653274b690c7_D20220101-20221231" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMDc2L2ZyYWc6NWYwMzJkZjM4N2ZkNDI3MDlhNzVkMmVjN2Q2NTc1N2MvdGV4dHJlZ2lvbjo1ZjAzMmRmMzg3ZmQ0MjcwOWE3NWQyZWM3ZDY1NzU3Y18xMDk5NTExNjMzNjMy_5d273450-c405-446c-829b-c2ef58f66cc6">150.0</ix:nonFraction>&#160;million. These amounts are primarily related to severance and are expected to be substantially incurred and paid by the end of 2022.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, we recognized $<ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMDc2L2ZyYWc6NWYwMzJkZjM4N2ZkNDI3MDlhNzVkMmVjN2Q2NTc1N2MvdGV4dHJlZ2lvbjo1ZjAzMmRmMzg3ZmQ0MjcwOWE3NWQyZWM3ZDY1NzU3Y18xMDk5NTExNjMzNTEy_2c710b30-fdbd-439d-92d1-0718cace4812">27.7</ix:nonFraction>&#160;million of employee related costs, primarily related to severance. These costs were recorded in restructuring charges in our condensed consolidated statements of income. Our restructuring reserve is included in accrued expense and other in our condensed consolidated balance sheets.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following an evaluation of our current capacity needs, in March 2022 we ceased using a patient services office space in Durham, North Carolina. We are marketing the space for sublease. Our decision to cease using the facility resulted in the immediate expense of certain leasehold improvements and other assets at this facility, which we do not believe can be adequately recovered in a sublease. As a result, for the three months ended March 31, 2022, we recognized approximately $<ix:nonFraction unitRef="usd" contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331" decimals="-5" name="us-gaap:RestructuringReserveAcceleratedDepreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMDc2L2ZyYWc6NWYwMzJkZjM4N2ZkNDI3MDlhNzVkMmVjN2Q2NTc1N2MvdGV4dHJlZ2lvbjo1ZjAzMmRmMzg3ZmQ0MjcwOWE3NWQyZWM3ZDY1NzU3Y18xMDk5NTExNjMzNTk4_12834c9a-8f35-46a1-964e-850e14779284">10.4</ix:nonFraction>&#160;million of accelerated depreciation expense, which was recorded in </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">restructuring charges in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the charges and spending related to our 2022 cost saving initiatives for the three months ended March 31, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.685%"><tr><td style="width:1.0%"></td><td style="width:53.474%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.061%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.351%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.061%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Workforce Reduction</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of<br/>December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4b04ecc1818447ebb524096be801f20_I20211231" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMDc2L2ZyYWc6NWYwMzJkZjM4N2ZkNDI3MDlhNzVkMmVjN2Q2NTc1N2MvdGFibGU6NWUzMDEyNDYwNWM2NGFjZjg4M2YzYTUxOGQ1ZDg0M2UvdGFibGVyYW5nZTo1ZTMwMTI0NjA1YzY0YWNmODgzZjNhNTE4ZDVkODQzZV8xLTItMS0xLTkxMzcy_163b9aaf-593d-4b96-802b-420f17dabc39">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i929ddd179174497bb90c576f4da728fd_D20220101-20220331" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMDc2L2ZyYWc6NWYwMzJkZjM4N2ZkNDI3MDlhNzVkMmVjN2Q2NTc1N2MvdGFibGU6NWUzMDEyNDYwNWM2NGFjZjg4M2YzYTUxOGQ1ZDg0M2UvdGFibGVyYW5nZTo1ZTMwMTI0NjA1YzY0YWNmODgzZjNhNTE4ZDVkODQzZV8yLTItMS0xLTkxMzcy_5514dae4-7ecc-4239-a5ae-5686ec7fe363">27.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i929ddd179174497bb90c576f4da728fd_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMDc2L2ZyYWc6NWYwMzJkZjM4N2ZkNDI3MDlhNzVkMmVjN2Q2NTc1N2MvdGFibGU6NWUzMDEyNDYwNWM2NGFjZjg4M2YzYTUxOGQ1ZDg0M2UvdGFibGVyYW5nZTo1ZTMwMTI0NjA1YzY0YWNmODgzZjNhNTE4ZDVkODQzZV8zLTItMS0xLTkxMzcy_4e784a52-630c-4700-8b5f-dcf2dbbe50a3">6.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of<br/>March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div id="ie9658fba2baf4e3799b1175f69eaed46_184"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><div><img src="biib-20220331_g19.jpg" alt="biib-20220331_g19.jpg" style="height:266px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, compared to the same period in 2021, the change in other income (expense), net primarily reflects net unrealized losses on our holdings in equity securities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, net unrealized losses and realized gains on our holdings in equity securities were approximately $190.9 million and $0.2 million, respectively, compared to net unrealized losses and realized gains of approximately $442.3 million and $6.2 million, respectively, in the prior year comparative period. The net unrealized losses recognized during the three months ended March 31, 2022, primarily reflect decreases in the aggregate fair value of our investments in Denali, Sage and Sangamo Therapeutics, Inc. (Sangamo) common stock of approximately $205.5&#160;million.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div id="ie9658fba2baf4e3799b1175f69eaed46_187"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Income Tax Provision</span></div><div><img src="biib-20220331_g20.jpg" alt="biib-20220331_g20.jpg" style="height:300px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate fluctuates from year to year due to the global nature of our operations. The factors that most significantly impact our effective tax rate include changes in tax laws, variability in the allocation of our taxable earnings among multiple jurisdictions, the amount and characterization of our research and development expense, the levels of certain deductions and credits, acquisitions and licensing transactions.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021 we recorded a net deferred tax asset in Switzerland of approximately $490.0&#160;million on Neurimmune SubOne AG's (Neurimmune) tax basis in ADUHELM, the realization of which is dependent on future sales of ADUHELM. During the fourth quarter of 2021, due to reduced future expected revenue associated with ADUHELM, we recorded a valuation allowance of approximately $390.0&#160;million.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2022, upon issuance of the final NCD related to ADUHELM, we recorded an additional valuation allowance of approximately $85.0&#160;million to reduce the net value of this deferred tax asset to zero. These adjustments to our deferred tax assets and their valuation allowances are each recorded with an equal and offsetting amount assigned to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income, resulting in a zero net impact to net income attributable to Biogen Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, compared to the same period in 2021, the increase in our effective tax rate was primarily due to a deferred tax expense related to a valuation allowance, as discussed above, and the non-cash tax effects of changes in the value of our equity investments. The tax effects of this change in value of our equity </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investments were recorded discretely, since changes in value of equity investments cannot be forecasted.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For additional information on our collaboration arrangement with Neurimmune, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 17, Investments in Variable Interest Entities</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For additional information on our income taxes please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 14, Income Taxes,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> to our condensed consolidated financial statements included in this report.</span></div><div id="ie9658fba2baf4e3799b1175f69eaed46_190"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Equity in (Income) Loss of Investee, Net of Tax</span></div><div><img src="biib-20220331_g21.jpg" alt="biib-20220331_g21.jpg" style="height:266px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. As of March 31, 2022, our ownership percentage was approximately 49.9%.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in (income) loss of investee, net of tax in our condensed consolidated statements of income. We recognize amortization on certain basis differences resulting from our November 2018 investment.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, we recognized net losses on our investment of $3.3 million, reflecting our share of Samsung Bioepis' operating profits, net of tax totaling $4.0&#160;million offset by amortization of basis differences totaling $7.3&#160;million.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, we recognized net losses on our investment of $18.2 </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million, reflecting our share of Samsung Bioepis' operating losses, net of tax totaling $11.0&#160;million and amortization of basis differences totaling $7.2&#160;million.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div id="ie9658fba2baf4e3799b1175f69eaed46_193"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Noncontrolling Interests, Net of Tax</span></div><div><img src="biib-20220331_g22.jpg" alt="biib-20220331_g22.jpg" style="height:250px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the financial results of our variable interest entity, Neurimmune, as we determined that we are the primary beneficiary.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, compared to the same period in 2021, the change in net income (loss) attributable to noncontrolling interests, net of tax, was primarily due to a valuation allowance related to a prior year deferred tax benefit associated with the accelerated approval of ADUHELM by the FDA in the U.S. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2022 we recorded a valuation allowance of approximately $85.0&#160;million related to this deferred tax asset. There is an equal and offsetting amount assigned to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income, resulting in a zero net impact to net income attributable to Biogen Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration agreement with Neurimmune, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17, Investments in Variable Interest Entities,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><div id="ie9658fba2baf4e3799b1175f69eaed46_196"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="margin-top:14pt"><span style="color:#0a2299;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial condition is summarized as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:54.686%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.181%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.774%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change&#160;%</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,749.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,261.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities &#8212; current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,002.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,541.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities &#8212; non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,001.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">892.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cash, cash equivalents and marketable securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,753.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,694.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Borrowings:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of notes payable</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">999.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">999.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notes payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,275.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,274.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total borrowings</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,275.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,273.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Working capital:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,915.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,856.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,946.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,298.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total working capital</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,969.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,558.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div id="ie9658fba2baf4e3799b1175f69eaed46_199"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, certain significant cash flows were as follows:</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$161.8 million in net cash flow provided by operating activities; and</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$57.9 million used for purchases of property, plant and equipment.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have historically financed and expect to continue to fund our operating and capital expenditures primarily through cash flow earned through our operations as well as our existing cash resources. We believe generic competition for TECFIDERA in the U.S. will continue to reduce our cash flow from operations in 2022 and will have a significant adverse impact on our future cash flow from operations. Additionally, in 2022 we will repay or refinance $1.0&#160;billion related to our 3.625% Senior Notes due September 15, 2022.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2021 we announced our plans to build a new gene therapy manufacturing facility in RTP, North Carolina to support our gene therapy pipeline across multiple therapeutic areas. The new facility is expected to be operational by the end of 2023, with an estimated total investment of approximately $200.0&#160;million. Construction for this new facility began during the fourth quarter of 2021.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe that our existing funds, when combined with cash generated from operations and our access to additional financing resources, if needed, are sufficient to satisfy our operating, working capital, strategic alliance, milestone payment, capital expenditure and debt service requirements for the foreseeable future. In addition, we may choose to opportunistically return cash to shareholders and pursue other business initiatives, including acquisition and licensing activities. We may, from time to time, </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">also seek additional funding through a combination of new collaborative agreements, strategic alliances and additional equity and debt financings or from other sources should we identify a significant new opportunity</span><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For additional information on certain risks that could negatively impact our financial position or future results of operations, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Item 1A.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Risk Factors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> included in this report.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Marketable Securities</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until required for another use in our business, we typically invest our cash reserves in bank deposits, certificates of deposit, commercial paper, corporate notes, U.S.&#160;and foreign government instruments, overnight reverse repurchase agreements and other interest-bearing marketable debt instruments in accordance with our investment policy. It is our policy to mitigate credit risk in our cash reserves and marketable securities by maintaining a well-diversified portfolio that limits the amount of exposure as to institution, maturity and investment type.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, we had cash, cash equivalents and marketable securities totaling approximately $4.8 billion compared to approximately $4.7 billion as of December 31, 2021. The change in cash, cash equivalents and marketable securities at March 31, 2022, from December 31, 2021, was primarily due to net cash flow provided by operating activities, partially offset by cash used for capital expenditures.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments and other assets in our condensed consolidated balance sheets as of March 31, 2022 and December 31, 2021, include the carrying value of our investment in Samsung Bioepis of $586.4 million </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $599.9 million, respectively. In January 2022 we entered into an agreement to sell to Samsung BioLogics our equity in Samsung Bioepis, which was completed on April 20, 2022. Under the terms of the transaction, we received approximately $1.0&#160;billion in cash at closing and will receive approximately $1.3&#160;billion to be deferred over two payments of $812.5&#160;million due at the first anniversary and $437.5&#160;million due at the second anniversary of the closing of the transaction. We are also eligible to receive up to an additional $50.0&#160;million upon the achievement of certain commercial milestones.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value of our significant common stock investments in the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.805%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.088%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.293%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sangamo</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">138.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Denali</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">428.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">550.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sage</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">184.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">231.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ionis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">106.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">857.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,043.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis, Sangamo, Denali and Sage, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our condensed consolidated financial statements included in this report</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Ionis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2021 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Borrowings</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021 we completed our Exchange Offer, consisting of the following:</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$624.6&#160;million aggregate principal amount of our 2045 Senior Notes was exchanged for $700.7&#160;million aggregate principal amount of our 2051 Senior Notes and approximately $151.8&#160;million of aggregate cash payments; and</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$8.9&#160;million aggregate principal amount of our 2045 Senior Notes was redeemed for approximately $12.1&#160;million of aggregate cash payments, excluding accrued and unpaid interest.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020 we issued senior unsecured notes for an aggregate principal amount of $3.0 billion (2020 Senior Notes), consisting of the following:</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$1.5 billion aggregate principal amount of 2.25% Senior Notes due May 1, 2030; and</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$1.5 billion aggregate principal amount of 3.15% Senior Notes due May 1, 2050.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of our currently outstanding senior unsecured notes issued in 2015 (2015 Senior Notes):</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$1.0 billion aggregate principal amount of 3.625% Senior Notes due September 15, 2022;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$1.75 billion aggregate principal amount of 4.05% Senior Notes due September 15, 2025; and</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$1.12 billion aggregate principal amount of 5.20% Senior Notes due September 15,&#160;2045.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2020 Senior Notes and our 2015 Senior Notes were issued at a discount, which are amortized as additional interest expense over the period from issuance through maturity.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a summary of the fair and carrying values of our outstanding borrowings as of March 31, 2022 and December 31, 2021, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6, Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facility</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020 we entered into a $1.0 billion, five-year senior unsecured revolving credit facility under which we are permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility include a financial covenant that requires us not to exceed a maximum consolidated leverage ratio. As of March 31, 2022 and December 31, 2021, we had no outstanding borrowings and were in compliance with all covenants under this facility.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Working Capital</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Working capital is defined as current assets less current liabilities. Working capital was $4.0 billion and $3.6 billion as of March 31, 2022 and December 31, 2021, respectively. The change in working capital reflects an increase in total current assets of approximately $59.4 million and a decrease in total current liabilities of approximately $351.6 million.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in total current assets was primarily driven by an increase in our product accounts receivable and other receivable balances, partially offset by the write-off of inventory related to ADUHELM.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in current liabilities was primarily due to a reduction in accounts payable and accrued expense and other, which was primarily related to a decrease in the accrual for employee compensation, as well as approximately $66.0&#160;million of upfront and milestone payments made in 2022, which were </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accrued as of December 31, 2021, partially offset by an increase in income taxes payable. </span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchase Programs</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (2020 Share Repurchase Program). Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">retired. Under our 2020 Share Repurchase Program, we repurchased and retired approximately 2.2 million shares of our common stock at a cost of approximately $600.0 million during the three months ended March 31, 2021. There were no share repurchases of our common stock during the three months ended March 31, 2022. Approximately $2.8 billion remained available under our 2020 Share Repurchase Program as of March 31, 2022.</span></div><div id="ie9658fba2baf4e3799b1175f69eaed46_202"></div></div></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flow</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flow activity:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash flow provided by (used in) operating activities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">161.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">769.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(79.0)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash flow provided by (used in) investing activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(648.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(64.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">901.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash flow provided by (used in) financing activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(785.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(97.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flow from operating activities represents the cash receipts and disbursements related to all of our activities other than investing and financing activities. We expect cash provided from operating activities will continue to be our primary source of funds to finance operating needs and capital expenditures for the foreseeable future.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flow is derived by adjusting our net income for:</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">non-cash operating items such as depreciation and amortization, impairment charges, unrealized gain (loss) on strategic investments, acquired IPR&amp;D and share-based compensation;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in operating assets and liabilities, which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in results of operations;&#160;and</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in the fair value of contingent payments associated with our acquisitions of businesses and payments related to collaborations.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, compared to the same period in 2021, the decrease in net cash flow provided by operating activities was primarily due to lower net income as well as timing of payments, which includes approximately $69.0&#160;million of upfront and milestone payments made in 2022.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, compared to the same period in 2021, the increase in net cash flow used in investing activities was primarily due to an increase in net purchases of marketable securities in the current period.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, compared to the same period in 2021, the decrease in net cash flow used in financing activities was primarily due to no share repurchase activity in 2022 compared to approximately $600.0&#160;million of shares repurchased in the prior year comparative period. Additionally, we executed our Exchange Offer in the first quarter of 2021, which resulted in net cash outflows of $169.3&#160;million.</span></div><div id="ie9658fba2baf4e3799b1175f69eaed46_205"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Contractual Obligations and Off-Balance Sheet Arrangements</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contractual obligations primarily consist of our obligations under non-cancellable operating leases, long-term debt obligations and defined benefit and other purchase obligations, excluding amounts related to uncertain tax positions, funding commitments, contingent development, regulatory and commercial milestone payments, contingent payments and contingent consideration related to our business combinations, as described below.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in our contractual obligations since December 31, 2021.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty Payments</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TYSABRI</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated to make contingent payments of 18.0% on annual worldwide net sales of TYSABRI up to $2.0 billion and 25.0% on annual worldwide net sales of TYSABRI that exceed $2.0 billion. Royalty payments are recognized as cost of sales in our condensed consolidated statements of income.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SPINRAZA</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make royalty payments on annual worldwide net sales of SPINRAZA using a tiered royalty rate between 11.0% and 15.0%, which are recognized as cost of sales in our condensed consolidated statements of income.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VUMERITY</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019 the FDA approved VUMERITY for the treatment of RMS. During the fourth quarter of 2021 VUMERITY was approved for the treatment of RRMS in the E.U., Switzerland and the U.K. Under our agreement with Alkermes Pharma Ireland Limited, a subsidiary of Alkermes plc (Alkermes), we make royalty payments to Alkermes on worldwide net sales of VUMERITY using a royalty rate of 15.0%, which are recorded as cost of sales in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019 we entered into a new supply agreement and amended our license and collaboration agreement with Alkermes. We have elected to initiate a technology transfer and, following a transition period, to manufacture VUMERITY or have VUMERITY manufactured by a third party we have engaged in exchange for paying an increased royalty rate to Alkermes on any portion of future worldwide net sales of VUMERITY that is manufactured by us or our designee. For additional information on our collaboration arrangement with Alkermes, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2021 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration related to Business Combinations</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Convergence Pharmaceuticals Holdings Ltd. we agreed to make additional payments based upon the achievement of certain milestone events.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized the contingent consideration liabilities associated with this acquisition at their fair value on the acquisition date and revalue these obligations each reporting period. We may pay up to approximately $400.0 million in remaining milestones related to this acquisition.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Development, Regulatory and Commercial Milestone Payments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our development plans as of March 31, 2022, we could trigger potential future milestone payments to third parties of up to approximately $9.2 billion, including approximately $1.9 billion in development milestones, approximately $900.0 million in regulatory milestones and approximately $6.4 billion in commercial milestones, as part of our various collaborations, including licensing and </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development programs. Payments under these agreements generally become due and payable upon achievement of certain development, regulatory or commercial milestones. Because the achievement of these milestones was not considered probable as of March 31, 2022, such contingencies have not been recorded in our financial statements. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory or commercial milestones.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If certain clinical and commercial milestones are met, we may pay up to $49.8&#160;million in milestones in 2022 under our current agreements. Additionally, if aducanumab receives regulatory approval in the jurisdictions where we have submitted filings, we may pay additional milestones to Neurimmune, including $50.0&#160;million if launched in Japan. Milestones payable to Neurimmune are shared expenses under the ADUHELM Collaboration Agreement.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangement with Neurimmune, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17, Investments in Variable Interest Entities,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Funding Commitments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, we have several ongoing clinical studies in various clinical trial stages. Our most significant clinical trial expenditures are to contract research organizations (CROs). The contracts with CROs are generally cancellable, with notice, at our option. We recorded accrued expense of approximately $26.9 million in our condensed consolidated balance sheet for expenditures incurred by CROs as of March 31, 2022. We have approximately $881.4 million in cancellable future commitments based on existing CRO contracts as of March 31, 2022.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the sale of our Hiller&#248;d, Denmark manufacturing operations to FUJIFILM Corporation (FUJIFILM), we provided FUJIFILM with certain minimum batch production commitment guarantees. There is a risk that the minimum contractual batch production commitments will not be met. Based upon current estimates we do not expect to incur an adverse commitment obligation associated with such guarantees. We developed this estimate using a probability-weighted estimate of future manufacturing activity and may further adjust this estimate based upon changes in business conditions, which may </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">result in the increase or reduction of this adverse commitment obligation in subsequent periods.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Divestitures</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2021 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tax Related Obligations</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We exclude liabilities pertaining to uncertain tax positions from our summary of contractual obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of March 31, 2022, we have approximately $105.6 million of liabilities associated with uncertain tax positions.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022 and December 31, 2021, we have accrued income tax liabilities of approximately $633.0&#160;million under a one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings (the Transition Toll Tax). Of the amounts accrued as of March 31, 2022, approximately $72.7&#160;million is expected to be paid within one year. The Transition Toll Tax will be paid in installments over an eight-year period, which started in 2018, and will not accrue interest.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Off-Balance Sheet Arrangements</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any relationships with entities often referred to as structured finance or special purpose entities that were established for the purpose of facilitating off-balance sheet arrangements. As such, we are not exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in such relationships. We consolidate variable interest entities if we are the primary beneficiary.</span></div><div id="ie9658fba2baf4e3799b1175f69eaed46_208"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">New Accounting Standards</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of new accounting standards please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div id="ie9658fba2baf4e3799b1175f69eaed46_211"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S., requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of our critical accounting estimates, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Part&#160;II,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2021 Form&#160;10-K. There have been no material changes to our critical accounting estimates since our 2021 Form&#160;10-K.</span></div><div id="ie9658fba2baf4e3799b1175f69eaed46_214"></div><div style="margin-top:14pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to certain risks that may affect our results of operations, cash flow and fair values of assets and liabilities, including volatility in foreign currency exchange rates, interest rate movements and equity price exposure as well as changes in economic conditions in the markets in which we operate as a result of the COVID-19 pandemic and Russia's invasion of Ukraine. We manage the impact of foreign currency exchange rates and interest rates through various financial instruments, including derivative instruments such as foreign currency forward contracts, interest rate lock contracts and interest rate swap contracts. We do not enter into financial instruments for trading or speculative purposes. The counterparties to these contracts are major financial institutions, and there is no significant concentration of exposure with any one counterparty.  </span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Risk</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations are subject to foreign currency exchange rate fluctuations due to the global nature of our operations. As a result, our consolidated financial position, results of operations and cash flow can be affected by market fluctuations in foreign currency exchange rates, primarily with respect to the Euro, British pound sterling, Canadian dollar, Swiss franc, Japanese yen and South Korean won.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the financial results of our global activities are reported in U.S. dollars, the functional currency for most of our foreign subsidiaries is their respective local currency. Fluctuations in the foreign currency exchange rates of the countries in which we do business will affect our operating results, often in ways that are difficult to predict. In particular, as the U.S. dollar strengthens versus other currencies, the value of the non-U.S. revenue will decline when reported in U.S. dollars. The impact to net income as a result of a strengthening U.S. dollar will be partially mitigated by the value of non-U.S. expense, which will also decline when reported in U.S. dollars. As the U.S. dollar weakens versus other currencies, the value of </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the non-U.S. revenue and expense will increase when reported in U.S. dollars.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established revenue and operating expense hedging and balance sheet risk management programs to protect against volatility of future foreign currency cash flow and changes in fair value caused by volatility in foreign currency exchange rates.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2018 the International Practices Task Force of the Center for Audit Quality categorized Argentina as a country with a projected three-year cumulative inflation rate greater than 100.0%, which indicated that Argentina's economy is highly inflationary. This categorization did not have a material impact on our results of operations or financial position as of March 31, 2022, and is not expected to have a material impact on our results of operations or financial position in the future.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue and Operating Expense Hedging Program</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our foreign currency hedging program is designed to mitigate, over time, a portion of the impact resulting from volatility in exchange rate changes on revenue and operating expense. We use foreign currency forward contracts to manage foreign currency risk, with the majority of our forward contracts used to hedge certain forecasted revenue and operating expense transactions denominated in foreign currencies in the next 18 months. We do not engage in currency speculation. For a more detailed disclosure of our revenue and operating expense hedging program, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8, Derivative Instruments,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to mitigate the impact of foreign currency exchange rate changes on revenue and net income diminishes as significant foreign currency exchange rate fluctuations are sustained over extended periods of time. In particular, devaluation or significant deterioration of foreign currency exchange rates are difficult to mitigate and likely to negatively impact earnings. The cash flow from these contracts are reported as operating activities in our condensed consolidated statements of cash flow.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Balance Sheet Risk Management Hedging Program</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also use forward contracts to mitigate the foreign currency exposure related to certain balance sheet items. The primary objective of our balance sheet risk management program is to mitigate the exposure of foreign currency denominated net monetary assets and liabilities of foreign affiliates. In these instances, we principally utilize currency forward contracts. We have not elected hedge accounting for the balance sheet related items. The cash flow from these contracts are reported as operating activities in our condensed consolidated statements of cash flow.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following quantitative information includes the impact of currency movements on forward contracts used in our revenue, operating expense and balance sheet hedging programs. As of March 31, 2022 and December 31, 2021, a hypothetical adverse 10.0% movement in foreign currency exchange rates compared to the U.S. dollar across all maturities would result in a hypothetical decrease in the fair value of forward contracts of approximately $298.5 million and $333.1 million, respectively. The estimated fair value change was determined by measuring the impact of the hypothetical exchange rate movement on outstanding forward contracts. Our use of this methodology to quantify the market risk of such instruments is subject to assumptions and actual impact could be significantly different. The quantitative information about market risk is limited because it does not take into account all foreign currency operating transactions. </span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Investment Hedge Program</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net investment hedging program is designed to mitigate currency fluctuations between the U.S. dollar and the South Korean won as a result of our approximately 49.9% ownership interest in Samsung Bioepis. We entered into foreign currency forward contracts to hedge changes in the spot rate over the next seven months. As of March 31, 2022 and December 31, 2021, a hypothetical adverse 10.0% movement would result in a hypothetical decrease in fair value of approximately $58.0 million and $58.7 million, respectively. The estimated fair value was determined by measuring the impact of the hypothetical spot rate movement on outstanding forward contracts. In conjunction with the closing of our sale of equity in Samsung Bioepis to Samsung BioLogics, which occurred in April 2022, we concurrently closed our foreign currency forward contracts.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment portfolio includes cash equivalents and short-term investments. The fair value of our marketable securities is subject to change as a result of potential changes in market interest rates. The potential change in fair value for interest rate sensitive instruments has been assessed on a hypothetical 100 basis point adverse movement across all maturities. As of March 31, 2022 and December 31, 2021, we estimate that such hypothetical 100 basis point adverse movement would result in a hypothetical loss in fair value of approximately $19.8 million and $14.3 million, respectively, to our interest rate sensitive instruments. The fair values of our investments were determined using third-party pricing services or other market observable data.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Risk</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentrations of credit risk include cash and cash equivalents, investments, derivatives and accounts receivable. We attempt to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments. We have established guidelines related to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. Our investment portfolio is maintained in accordance with our investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. We minimize credit risk resulting from derivative instruments by choosing only highly rated financial institutions as counterparties.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We operate in certain countries where weakness in economic conditions, including the effects of the COVID-19 pandemic and Russia's invasion of Ukraine, can result in extended collection periods. We continue to monitor these conditions, including the volatility associated with international economies and the relevant financial markets, and assess their possible impact on our business. To date, we have not experienced any significant losses with respect to the collection of our accounts receivable.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our allowance for doubtful accounts was adequate as of March 31, 2022 and December 31, 2021.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Price Risk</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies. While we are holding such securities, we are subject to equity price risk, and this may increase the volatility of our income in future periods due to changes in the fair value of equity investments. We may sell such equity securities based on our business considerations, which may include limiting our price risk.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Changes in the fair value of these equity securities are impacted by the volatility of the stock market and changes in general economic conditions, among other factors. The potential change in fair value for equity price sensitive instruments has been assessed on a hypothetical 10.0% adverse movement. As of March 31, 2022 and December 31, 2021, a hypothetical adverse 10.0% movement would result in a hypothetical decrease in fair value of approximately $86.0&#160;million and $104.8&#160;million, respectively.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div id="ie9658fba2baf4e3799b1175f69eaed46_217"></div><div style="margin-top:12pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 4. &#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:8pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures and Internal Control over Financial Reporting</span></div><div style="margin-top:8pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Controls and Procedures</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules&#160;13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended), as of March 31, 2022. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are effective in ensuring that:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized and reported within the time periods specified in the U.S. Securities and Exchange Commission&#8217;s rules and forms; and </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-top:8pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting during the quarter ended March 31, 2022, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><div id="ie9658fba2baf4e3799b1175f69eaed46_220"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="margin-top:14pt;text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART&#160;II OTHER INFORMATION</span></div><div id="ie9658fba2baf4e3799b1175f69eaed46_223"></div><div style="margin-top:14pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM&#160;1.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of legal proceedings as of March 31, 2022, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Litigation,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report, which is incorporated into this item by reference.</span></div><div id="ie9658fba2baf4e3799b1175f69eaed46_226"></div><div style="margin-top:6pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM&#160;1A.&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="margin-top:6pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are substantially dependent on revenue from our products. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue depends upon continued sales of our products as well as the financial rights we have in our anti-CD20 therapeutic programs. A significant portion of our revenue is concentrated on sales of our products in increasingly competitive markets and in markets affected directly and indirectly by the COVID-19 pandemic. Any of the following negative developments relating to any of our products or any of our anti-CD20 therapeutic programs may adversely affect our revenue and results of operations or could cause a decline in our stock price: </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the introduction, greater acceptance or more favorable reimbursement of competing products, including new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">safety or efficacy issues;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limitations and additional pressures on product pricing or price increases, including those resulting from governmental or regulatory requirements; increased competition, including from generic or biosimilar versions of our products; or changes in, or implementation of, reimbursement policies and practices of payors and other third-parties;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">adverse legal, administrative, regulatory or legislative developments;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to maintain a positive reputation among patients, healthcare providers and others, which may be impacted by our pricing and reimbursement decisions; or</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the inability or reluctance of patients to receive a diagnosis, prescription or administration of our products or a decision to prescribe and administer competitive therapies as a direct or indirect result of the COVID-19 pandemic.</span></div><div style="margin-top:6pt;padding-left:4.5pt;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 the FDA granted accelerated approval of ADUHELM in the U.S. In addition to risks associated with new products and the other factors described in these Risk Factors, our ability to successfully commercialize ADUHELM may be adversely affected due to:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the lack of readiness of healthcare providers to initiate treatment as well as our ability to successfully identify eligible patients based on the information included in ADUHELM&#8217;s label;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">concern regarding the accelerated approval of ADUHELM and its data;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to obtain and maintain reimbursement for ADUHELM;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the impact of the final NCD by CMS for the class of anti-amyloid treatments in Alzheimer's disease, including ADUHELM;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the lack of market acceptance of ADUHELM;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the effectiveness of our commercial strategy for marketing ADUHELM;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the approval of other new products for the same or similar indications; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to maintain a positive reputation among patients, healthcare providers and others in the Alzheimer&#8217;s disease community, which may be impacted by pricing and reimbursement decisions relating to ADUHELM.</span></div><div style="margin-top:6pt;padding-left:4.5pt;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accelerated approval, we will conduct a confirmatory trial to verify the clinical benefit of ADUHELM in patients with Alzheimer's disease. The FDA may withdraw approval if, among other things, the confirmatory trial fails to verify clinical benefit, ADUHELM's benefit-risk is no longer positive or we fail to comply with the conditions of the accelerated approval.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our long-term success depends upon the successful development of new products and additional indications for our existing products.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term success will depend upon the successful development of new products from our research and development activities or our licenses or acquisitions from third-parties, including our commercialization agreements with Samsung Bioepis, as well as additional indications for our existing products.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Product development is very expensive and involves a high degree of uncertainty and risk and may not be successful. Only a small number of research and development programs result in the commercialization of a product. It is difficult to predict the success and the time and cost of product development of novel approaches for the treatment of diseases. The development of novel approaches for the treatment of diseases, including development efforts in new modalities such as those based on the antisense oligonucleotide platform and gene therapy, may present additional challenges and risks, including obtaining approval from regulatory authorities that have limited experience with the development of such therapies. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Clinical trial data are subject to differing interpretations and even if we view data as sufficient to support the safety, effectiveness and/or approval of an investigational therapy, regulatory authorities may disagree and may require additional data, limit the scope of the approval or deny approval altogether. Furthermore, the approval of a product candidate by one regulatory agency does not mean that other regulatory agencies will also approve such product candidate.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Success in preclinical work or early stage clinical trials does not ensure that later stage or larger scale clinical trials will be successful. Clinical trials may indicate that our product candidates lack efficacy, have harmful side effects, result in unexpected adverse events or raise other concerns that may significantly reduce the likelihood of regulatory approval. This may result in terminated programs, significant restrictions on use and safety warnings in an approved label, adverse placement within the treatment paradigm or significant reduction in the commercial potential of the product candidate.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we could successfully develop new products or indications, we may make a strategic decision to discontinue development of a product candidate or indication if, for example, we believe commercialization will be difficult relative to the standard of care or we prefer to pursue other opportunities in our pipeline. </span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of new products or products with additional indications may not meet investor expectations.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to compete effectively, our business and market position would suffer.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biopharmaceutical industry and the markets in which we operate are intensely competitive. We compete in the marketing and sale of our products, the development of new products and processes, the acquisition of rights to new products with commercial potential and the hiring and retention of personnel. We compete with biotechnology and pharmaceutical companies that have a greater number of products on the market and in the product pipeline, substantially greater financial, marketing, research and development and other resources and other technological or competitive advantages. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products continue to face increasing competition from the introduction of new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways. Some of these products are likely to be sold at substantially lower prices than our branded products. The introduction of such products as well as other lower-priced competing products has reduced, and may in the future, significantly reduce both the price that we are able to charge for our products and the volume of products we sell, which will negatively impact our revenue. For instance, demand and price for TECFIDERA declined significantly as a result of multiple TECFIDERA generic entrants entering the U.S. market in 2020. In addition, in some markets, when a generic or biosimilar version of one of our products is commercialized, it may be automatically substituted for our product and significantly reduce our revenue in a short period of time.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to compete, maintain and grow our business may also be adversely affected due to a number of factors, including:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the introduction of other products, including products that may be more efficacious, safer, less expensive or more convenient alternatives to our products, including our own products and products of our collaborators;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the off-label use by physicians of therapies indicated for other conditions to treat patients; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">patient dynamics, including the size of the patient population and our ability to identify, attract and maintain new and current patients to our therapies;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the reluctance of physicians to prescribe, and patients to use, our products without additional data on the efficacy and safety of such products;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">damage to physician and patient confidence in any of our products, generic or biosimilars of our products or any other product from the same class as one of our products, or to our sales and reputation as a result of label changes, pricing and reimbursement decisions or adverse experiences or events that may occur with patients treated with our products or generic or biosimilars of our products;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">inability to obtain appropriate pricing and reimbursement for our products compared to our competitors in key international markets; or</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to obtain and maintain patent, data or market exclusivity for our products.</span></div><div style="margin-top:6pt;padding-left:4.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business may be adversely affected if we do not successfully execute or realize the anticipated benefits of our strategic and growth initiatives.</span></div><div style="margin-top:6pt;padding-left:4.5pt;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The successful execution of our strategic and growth initiatives may depend upon internal development projects, commercial initiatives and external opportunities, which may include the acquisition and in-licensing of products, technologies and companies or the entry into strategic alliances and collaborations. </span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe we have a number of promising programs in our pipeline, failure or delay of internal development projects to advance or difficulties in executing on our commercial initiatives could impact our current and future growth, resulting in additional reliance on external development opportunities for growth. </span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supporting the further development of our existing products and potential new products in our pipeline will require significant capital expenditures and management resources, including investments in research and development, sales and marketing, manufacturing capabilities and other areas of our business. We have made, and may continue to make, significant operating and capital expenditures for potential new products prior to regulatory approval with no assurance that such investment will be recouped, which may adversely affect our financial condition, business and operations.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability of high quality, fairly valued external product development is limited and the opportunity for their acquisition is highly competitive. As such, we are not certain that we will be able to identify suitable candidates for acquisition or if we will be able to reach agreement.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may fail to initiate or complete transactions for many reasons, including failure to obtain regulatory or other approvals as well as disputes or litigation. Furthermore, we may not be able to achieve the full strategic and financial benefits expected to result from transactions, or the benefits may be delayed or not occur at all. We may also face additional costs or liabilities in completed transactions that were not contemplated prior to completion.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any failure in the execution of a transaction, in the integration of an acquired asset or business or in achieving expected synergies could result in slower growth, higher than expected costs, the recording of asset impairment charges and other actions which could adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Sales of our products depend, to a significant extent, on adequate coverage, pricing and reimbursement from third-party payors, which are subject to increasing and intense pressure from political, social, competitive and other sources. Our inability to obtain and maintain adequate coverage, or a reduction in pricing or reimbursement, could have an adverse effect on our business, reputation, revenue and results of operations.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of our products depend, to a significant extent, on adequate coverage, pricing and reimbursement from third-party payors. When a new pharmaceutical product is approved, the availability of government and private reimbursement for that product may be uncertain, as is the pricing and amount for which that product will be reimbursed. </span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pricing and reimbursement for our products may be adversely affected by a number of factors, including:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in, and implementation of, federal, state or foreign government regulations or private third-party payors&#8217; reimbursement policies; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">pressure by employers on private health insurance plans to reduce costs;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">consolidation and increasing assertiveness of payors seeking price discounts or rebates in connection with the placement of our products on their formularies and, in some cases, the imposition of restrictions on access or coverage of particular drugs or pricing determined based on perceived value;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to receive reimbursement for our products or our ability to receive comparable reimbursement to that of competing products; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our value-based contracting program pursuant to which we aim to tie the pricing of our products to their clinical values by either aligning price to patient outcomes or adjusting price for patients who discontinue therapy for any reason, including efficacy or tolerability concerns.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to set the price for our products varies significantly from country to country and, as a result, so can the price of our products. Certain countries set prices by reference to the prices in other countries where our products are marketed. Our inability to obtain and maintain adequate prices in a particular country may not only limit the revenue from our products within that country but may also adversely affect our ability to secure acceptable prices in existing and potential new markets, which may limit market growth. This may create the opportunity for third-party cross-border trade or influence our decision to sell or not to sell a product, thus adversely affecting our geographic expansion plans and revenue.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug prices are under significant scrutiny in the markets in which our products are prescribed. We expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis. Competition from current and future competitors may negatively impact our ability to maintain pricing and our market share. New products marketed by our competitors could cause our revenue to decrease due to potential price reductions and lower sales volumes. Additionally, the introduction of generic or biosimilar versions of our products, follow-on products, prodrugs or products approved under abbreviated regulatory pathways may significantly reduce the price that we are able to charge for our products and the volume of products we sell.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many payors continue to adopt benefit plan changes that shift a greater portion of prescription costs to patients, including more limited benefit plan designs, higher patient co-pay or co-insurance obligations and limitations on patients' use of commercial manufacturer co-pay payment assistance programs (including through co-pay accumulator adjustment or maximization programs). Significant consolidation in the health insurance industry has resulted in a few large insurers and pharmacy benefit managers exerting greater pressure in pricing and usage negotiations with drug manufacturers, significantly increasing discounts and rebates required of manufacturers and limiting patient access and usage. Further consolidation among insurers, pharmacy benefit managers and other payors would increase the negotiating leverage such entities have over us and other drug manufacturers. Additional discounts, rebates, coverage or plan changes, restrictions or exclusions as described above could have a material adverse effect on sales of our affected products.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our failure to obtain or maintain adequate coverage, pricing or reimbursement for our products could have an adverse effect on our business, reputation, revenue and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on relationships with collaborators, joint venture partners and other third-parties for revenue, and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates, which are outside of our full control.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on a number of collaborative, joint venture and other third-party relationships for revenue and the development, regulatory approval, commercialization and marketing of certain of our products and product candidates. We also outsource certain aspects of our regulatory affairs and clinical development relating to our products and product candidates to third-parties. Reliance on third-parties subjects us to a number of risks, including:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">we may be unable to control the resources our collaborators, joint venture partners or third-parties devote to our programs, products or product candidates;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">disputes may arise under an agreement, including with respect to the achievement and payment of milestones, payment of development or commercial costs, ownership of rights to technology developed, and the underlying agreement may fail to provide us with significant protection or may fail to be effectively enforced if the collaborators, joint ventures partners or third-parties fail to perform; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the interests of our collaborators, joint venture partners or third-parties may not always be aligned with our interests, and such parties may not pursue regulatory approvals or market a product in the same manner or to the same extent that we would, which could adversely affect our revenue, or may adopt tax strategies that could have an adverse effect on our business, results of operations or financial condition; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">third-party relationships require the parties to cooperate, and failure to do so effectively could adversely affect product sales or the clinical development or regulatory approvals of product candidates under joint control, could result in termination of the research, development or commercialization of product candidates or could result in litigation or arbitration;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">any failure on the part of our collaborators, joint venture partners or third-parties to comply with applicable laws, including tax laws, regulatory requirements and/or applicable contractual obligations or to fulfill any </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:40.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">responsibilities they may have to protect and enforce any intellectual property rights underlying our products could have an adverse effect on our revenue as well as involve us in possible legal proceedings; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">any improper conduct or actions on the part of our collaborators, joint venture partners or third-parties could subject us to civil or criminal investigations and monetary and injunctive penalties, impact the accuracy and timing of our financial reporting and/or adversely impact our ability to conduct business, our operating results and our reputation.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain officers and affiliates of our former joint venture partner, Samsung BioLogics, are currently subject to ongoing criminal proceedings that may impact its operations and business or divert the attention of the Samsung Bioepis management team from its ongoing operations.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given these risks, there is considerable uncertainty regarding the success of our current and future collaborative efforts. If these efforts fail, our product development or commercialization of new products could be delayed, revenue from products could decline and/or we may not realize the anticipated benefits of these arrangements.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our results of operations may be adversely affected by current and potential future healthcare reforms.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of health care. Legislative and regulatory proposals, enactments to reform health care insurance programs and increasing pressure from social sources could significantly influence the manner in which our products are prescribed and purchased. For example, provisions of the Patient Protection and Affordable Care Act (PPACA) have resulted in changes in the way health care is paid for by both governmental and private insurers, including increased rebates owed by manufacturers under the Medicaid Drug Rebate Program, annual fees and taxes on manufacturers of certain branded prescription drugs, the requirement that manufacturers participate in a discount program for certain outpatient drugs under Medicare Part D and the expansion of the number of hospitals eligible for discounts under Section 340B of the Public Health Service Act. These changes have had and are expected to continue to have a significant impact on our business. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may face uncertainties as a result of efforts to repeal, substantially modify or invalidate some or all of the provisions of the PPACA. There is no assurance that the PPACA, as currently enacted or as amended in the future, will not adversely affect our business and financial results, and we cannot predict how future federal or state legislative or administrative changes relating to healthcare reform will affect our business.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is increasing public attention on the costs of prescription drugs and we expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis. For example, two committees of the U.S. House of Representatives are investigating the approval and price of ADUHELM. In addition, there have been, and are expected to continue to be, legislative proposals to address prescription drug pricing. Some of these proposals could have significant effects on our business, including an executive order issued in September 2020 to test a &#8220;most favored nation&#8221; model for Part B and Part D drugs that tie reimbursement rates to international drug pricing metrics. These actions and the uncertainty about the future of the PPACA and healthcare laws may put downward pressure on pharmaceutical pricing and increase our regulatory burdens and operating costs. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is also significant economic pressure on state budgets, including as a result of the COVID-19 pandemic, that may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for our drugs. In recent years, some states have considered legislation and ballot initiatives that would control the prices of drugs, including laws to allow importation of pharmaceutical products from lower cost jurisdictions outside the U.S. and laws intended to impose price controls on state drug purchases. State Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates and requiring prior authorization by the state program for use of any drug for which supplemental rebates are not being paid. Government efforts to reduce Medicaid expense may lead to increased use of managed care organizations by Medicaid programs. This may result in managed care organizations influencing prescription decisions for a larger segment of the population and a corresponding limitation on prices and reimbursement for our products. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the E.U. and some other international markets, the government provides health care at low cost to consumers and regulates pharmaceutical prices, patient eligibility or reimbursement levels to control costs for the government-sponsored health care system. Many countries have announced or implemented measures, and may in the future implement new or additional measures, to reduce health care costs to limit the overall level of government expenditures. These measures vary by country and may include, among other things, patient access restrictions, suspensions on price increases, prospective and possible retroactive price reductions and other recoupments and increased mandatory discounts or rebates, recoveries of past price increases and greater importation of drugs from </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">lower-cost countries. These measures have negatively impacted our revenue and may continue to adversely affect our revenue and results of operations in the future.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success in commercializing biosimilars is subject to risks and uncertainties inherent in the development, manufacture and commercialization of biosimilars. If we are unsuccessful in such activities, our business may be adversely affected.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development, manufacture and commercialization of biosimilar products require specialized expertise and are very costly and subject to complex regulation. Our success in commercializing biosimilars is subject to a number of risks, including:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Reliance on Third-Parties.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are dependent, in part, on the efforts of Samsung Bioepis, collaboration partners and other third-parties over whom we have limited or no control in the development and manufacturing of biosimilars products. If these third-parties fail to perform successfully, our biosimilar product development or commercialization of biosimilar products could be delayed, revenue from biosimilar products could decline and/or we may not realize the anticipated benefits of these arrangements;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Regulatory Compliance.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Biosimilar products may face regulatory hurdles or delays due to the evolving and uncertain regulatory and commercial pathway of biosimilars products in certain jurisdictions; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Intellectual Property and Regulatory Challenges.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Biosimilar products may face extensive patent clearances, patent infringement litigation, injunctions or regulatory challenges, which could prevent the commercial launch of a product or delay it for many years or result in imposition of monetary damages, penalties or other civil sanctions and damage our reputation; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Failure to Gain Market and Patient Acceptance.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Market success of biosimilar products will be adversely affected if patients, physicians and/or payors do not accept biosimilar products as safe and efficacious products offering a more competitive price or other benefit over existing therapies; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Ability to Provide Adequate Supply.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Manufacturing biosimilars is complex. If we encounter any manufacturing or supply chain difficulties we may be unable to meet higher than anticipated demand. We are dependent on a third-party for the manufacture of our biosimilar products and such third-party may not perform its obligations in a timely and cost-effective manner or in compliance with applicable regulations and may be unable or unwilling to increase production capacity commensurate with demand for our existing or future biosimilar products; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Competitive Challenges.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Biosimilar products face significant competition, including from innovator products and biosimilar products offered by other companies that may receive greater acceptance or more favorable reimbursement. Local tendering processes may restrict biosimilar products from being marketed and sold in some jurisdictions. The number of competitors in a jurisdiction, the timing of approval and the ability to market biosimilar products successfully in a timely and cost-effective manner are additional factors that may impact our success and/or the success of Samsung Bioepis in this business area.</span></div><div style="margin-top:6pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Risks Related to Intellectual Property</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain and maintain adequate protection for our data, intellectual property and other proprietary rights, our business may be harmed. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success, including our long-term viability and growth, depends, in part, on our ability to obtain and defend patent and other intellectual property rights, including certain regulatory forms of exclusivity, that are important to the commercialization of our products and product candidates. Patent protection and/or regulatory exclusivity in the U.S. and other important markets remains uncertain and depends, in part, upon decisions of the patent offices, courts, administrative bodies and lawmakers in these countries. We may fail to obtain or preserve patent and other intellectual property rights, including certain regulatory forms of exclusivity, or the protection we obtain may not be of sufficient breadth and degree to protect our commercial interests in all countries where we conduct business, which could result in financial, business or reputational harm to us or could cause a decline or volatility in our stock price. In addition, settlements of such proceedings often result in reducing the period of patent and other protections, resulting in a reduction in revenue from affected products.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In many markets, including the U.S., manufacturers may be allowed to rely on the safety and efficacy data of the innovator's product and do not need to conduct clinical trials before marketing a competing version of a product after there is no longer patent or regulatory exclusivity. In such cases, manufacturers often charge significantly lower prices and a major portion of the company's revenue may be reduced in a short period of time. In addition, manufacturers of generics and biosimilars may choose to launch or attempt to launch their products before the expiration of our patent or other intellectual property protections.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our products may be determined to infringe patents or other intellectual property rights held by third-parties. Legal proceedings, administrative challenges or other types of proceedings are and may in the future be necessary to determine the validity, scope or non-infringement of certain patent rights claimed by third-parties to be pertinent to the manufacture, use or sale of our products.&#160;Such proceedings are unpredictable and are often protracted and expensive. Negative outcomes of such proceedings could hinder or prevent us from manufacturing and marketing our products, require us to seek a license for the infringed product or technology or result in the assessment of significant monetary damages against us that may exceed amounts, if any, accrued in our financial statements. A failure to obtain necessary licenses for an infringed product or technology could prevent us from manufacturing or selling our products. Furthermore, payments under any licenses that we are able to obtain would reduce our profits from the covered products and services. Any of these circumstances could result in financial, business or reputational harm to us or could cause a decline or volatility in our stock price.</span></div><div style="margin-top:6pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Risks Related to Development, Clinical Testing and Regulation of Our Products and Product Candidates</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Successful preclinical work or early stage clinical trials does not ensure success in later stage trials, regulatory approval or commercial viability of a product.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Positive results in a clinical trial may not be replicated in subsequent or confirmatory trials. Additionally, success in preclinical work or early stage clinical trials does not ensure that later stage or larger scale clinical trials will be successful or that regulatory approval will be obtained. Even if later stage clinical trials are successful, regulatory authorities may delay or decline approval of our product candidates. Regulatory authorities may disagree with our view of the data, require additional studies or disagree with our trial design or endpoints. Regulatory authorities may also fail to approve the facilities or processes used to manufacture a product candidate, our dosing or delivery methods or companion devices. Regulatory authorities may grant marketing approval that is more restricted than anticipated, including limiting indications to narrow patient populations and the imposition of safety monitoring, educational requirements, requiring confirmatory trials and risk evaluation and mitigation strategies. For example, as part of the accelerated approval, we will conduct a confirmatory trial to verify the clinical benefit of ADUHELM in patients with Alzheimer's disease. The occurrence of any of these events could result in significant costs and expense, have an adverse effect on our business, financial condition and results of operations and/or cause our stock price to decline or experience periods of volatility.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical trials and the development of biopharmaceutical products is a lengthy and complex process. If we fail to adequately manage our clinical activities, our clinical trials or potential regulatory approvals may be delayed or denied.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conducting clinical trials is a complex, time-consuming and expensive process. Our ability to complete clinical trials in a timely fashion depends on a number of key factors, including protocol design, regulatory and institutional review board approval, patient enrollment rates and compliance with current Good Clinical Practices. If we or our third-party clinical trial providers or third-party CROs do not successfully carry out these clinical activities, our clinical trials or the potential regulatory approval of a product candidate may be delayed or denied.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have opened clinical trial sites and are enrolling patients in a number of countries where our experience is limited. In most cases, we use the services of third-parties to carry out our clinical trial related activities and rely on such parties to accurately report their results. Our reliance on third-parties for these activities may impact our ability to control the timing, conduct, expense and quality of our clinical trials. One CRO has responsibility for a substantial portion of our activities and reporting related to our clinical trials and if such CRO does not adequately perform, many of our trials may be affected. We may need to replace our CROs, which may result in the delay of the affected trials or otherwise adversely affect our efforts to obtain regulatory approvals and commercialize our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adverse safety events or restrictions on use and safety warnings for our products can negatively affect our business, product sales and stock price.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse safety events involving our marketed products, generic or biosimilar versions of our marketed products or products from the same class as one of our products may have a negative impact on our business. Discovery of safety issues with our products could create product liability and could cause additional regulatory scrutiny and requirements for additional labeling or safety monitoring, withdrawal of products from the market and/or the imposition of fines or criminal penalties. Adverse safety events may also damage physician, patient and/or investor confidence in our products and our reputation. Any of these could result in adverse impacts on our results of operations. </span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities are making greater amounts of stand-alone safety information directly available to the public through periodic safety update reports, patient registries and other reporting requirements. The reporting of adverse safety events involving our products or products similar to ours and public rumors about such events may </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increase claims against us and may also cause our product sales to decline or our stock price to experience periods of volatility.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restrictions on use or safety warnings that may be required to be included in the label of our products may significantly reduce expected revenue for those products and require significant expense and management time.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The illegal distribution and sale by third-parties of counterfeit or unfit versions of our products or stolen products could have a negative impact on our reputation and business.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-parties might illegally distribute and sell counterfeit or unfit versions of our products, which do not meet our rigorous manufacturing, distribution and testing standards. A patient who receives a counterfeit or unfit drug may be at risk for a number of dangerous health consequences. Our reputation and business could suffer harm as a result of counterfeit or unfit drugs sold under our brand name. Inventory that is stolen from warehouses, plants or while in-transit, and that is subsequently improperly stored and sold through unauthorized channels, could adversely impact patient safety, our reputation and our business.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The increasing use of social media platforms presents new risks and challenges.</span></div><div style="margin-top:4pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Social media is increasingly being used to communicate about our products and the diseases our therapies are designed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear and create uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients may use social media channels to comment on the effectiveness of a product or to report an alleged adverse event. When such disclosures occur, there is a risk that we fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend the company or the public's legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our products. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on social media. We may also encounter criticism on social media regarding our company, management, product candidates or products. The immediacy of social media precludes us from having real-time control over postings made regarding us via social media, whether matters of fact or opinion. Our reputation could be damaged by negative publicity or if adverse information concerning us is posted on social media platforms or similar mediums, which we may not be able to reverse. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face restrictive regulatory actions or incur other harm to our business.</span></div><div style="margin-top:6pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Operations</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A breakdown or breach of our technology systems could subject us to liability or interrupt the operation of our business.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are increasingly dependent upon technology systems and data to operate our business. The COVID-19 pandemic has caused us to modify our business practices in ways that heighten this dependence, including changing the requirement that most of our office-based employees in the U.S. and our other key markets work from the office, with a number of our employees now working in hybrid or full-remote positions. As a result, we are increasingly dependent upon our technology systems to operate our business and our ability to effectively manage our business depends on the security, reliability and adequacy of our technology systems and data, which includes use of cloud technologies, including Software as a Service (SaaS), Platform as a Service (PaaS) and Infrastructure as a Service (IaaS). Breakdowns, invasions, corruptions, destructions and/or breaches of our technology systems or those of our business partners, including our cloud technologies, and/or unauthorized access to our data and information could subject us to liability, negatively impact our business operations, and/or require replacement of technology and/or ransom payments. Our technology systems, including our cloud technologies, continue to increase in multitude and complexity, increasing our vulnerability when breakdowns, malicious intrusions and random attacks occur.&#160;Data privacy or security breaches also pose a risk that sensitive data, including intellectual property, trade secrets or personal information belonging to us, patients, customers or other business partners, may be exposed to unauthorized persons or to the public.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cyber-attacks are increasing in their frequency, sophistication and intensity, and are becoming increasingly difficult to detect, when they impact vendors, customers or companies, including vendors, suppliers and other companies in our supply chain. They are often carried out by motivated, well-resourced, skilled and persistent actors, including nation states, organized crime groups, &#8220;hacktivists&#8221; and employees or contractors acting with careless or malicious intent. Geopolitical instability, including that related to Russia's invasion of Ukraine may increase cyber-attacks. Cyber-attacks include deployment of harmful malware and key loggers, ransomware, a denial-of-service attack, a malicious website, the use of social engineering and other means to affect the confidentiality, integrity and availability of our technology systems and data. Cyber-attacks also include manufacturing, hardware or software supply chain attacks, which could cause a delay in the manufacturing of products or products produced for contract </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturing or lead to a data privacy or security breach. Our key business partners face similar risks and any security breach of their systems could adversely affect our security posture. In addition, our increased use of cloud technologies heightens these and other operational risks, and any failure by cloud or other technology service providers to adequately safeguard their systems and prevent cyber-attacks could disrupt our operations and result in misappropriation, corruption or loss of confidential or propriety information. Regulators are considering new cyber security regulations. For example, the SEC has proposed amendments to its disclosure rules regarding cyber security risk management, strategy, governance and incident reporting by public companies. These proposed regulations may impact the manner in which we operate. Failure to comply with new laws may result in governmental enforcement actions, litigation, fines and penalties or adverse publicity and could cause our customers to lose trust in us, which could have a material adverse effect on our business and results of operations.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we continue to build and improve our systems and infrastructure, including our business continuity plans, there can be no assurance that our efforts will prevent breakdowns or breaches in our systems that could adversely affect our business and operations and/or result in the loss of critical or sensitive information, which could result in financial, legal, operational or reputational harm to us, loss of competitive advantage or loss of consumer confidence. Our liability insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyber-attacks and other related breaches.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulators are imposing new data privacy and security requirements, including new and greater monetary fines for privacy violations. For example, the E.U.&#8217;s General Data Protection Regulation established regulations regarding the handling of personal data, and provides an enforcement authority and imposes large penalties for noncompliance. New U.S. data privacy and security laws, such as the California Consumer Privacy Act (CCPA), and others that may be passed, similarly introduce requirements with respect to personal information, and non-compliance with the CCPA may result in liability through private actions (subject to statutorily defined damages in the event of certain data breaches) and enforcement. Failure to comply with these current and future laws, policies, industry standards or legal obligations or any security incident resulting in the unauthorized access to, or acquisition, release or transfer of personal information may result in governmental enforcement actions, litigation, fines and penalties or adverse publicity and could cause our customers to lose trust in us, which could have a material adverse effect on our business and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management and other personnel changes may disrupt our operations, and we may have difficulty retaining personnel or attracting and retaining qualified replacements on a timely basis for the management and other personnel who may leave the Company.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in management, other personnel and our overall retention rate may disrupt our business, and any such disruption could adversely affect our operations, programs, growth, financial condition or results of operations. New members of management may have different perspectives on programs and opportunities for our business, which may cause us to focus on new opportunities or reduce or change emphasis on our existing programs.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success is dependent upon our ability to attract and retain qualified management and key personnel in a highly competitive environment. Qualified individuals are in high demand, and we may incur significant costs to attract or retain them. We may face difficulty in attracting and retaining talent for a number of reasons, including management changes, the underperformance or discontinuation of one or more marketed or late stage programs, recruitment by competitors or changes in the overall labor market. In addition, changes in our organizational structure or in our flexible working arrangements could impact employees' productivity and morale as well as our ability to attract, retain and motivate employees. We cannot ensure that we will be able to hire or retain the personnel necessary for our operations or that the loss of any personnel will not have a material impact on our financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with the extensive legal and regulatory requirements affecting the health care industry, we could face increased costs, penalties and a loss of business.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our activities, and the activities of our collaborators, distributors and other third-party providers, are subject to extensive government regulation and oversight in the U.S.&#160;and in foreign jurisdictions, and are subject to change and evolving interpretations, which could require us to incur substantial costs associated with compliance or to alter one or more of our business practices. The FDA and comparable foreign agencies directly regulate many of our most critical business activities, including the conduct of preclinical and clinical studies, product manufacturing, advertising and promotion, product distribution, adverse event reporting, product risk management and our compliance with good practice quality guidelines and regulations. Our interactions  with physicians and other health care providers that prescribe or purchase our products are also subject to government regulation designed to prevent fraud and abuse in the sale and use of products and place significant restrictions on the marketing practices of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">health care companies. Health care companies are facing heightened scrutiny of their relationships with health care providers and have been the target of lawsuits and investigations alleging violations of government regulation, including claims asserting submission of incorrect pricing information, impermissible off-label promotion of pharmaceutical products, payments intended to influence the referral of health care business, submission of false claims for government reimbursement, antitrust violations or violations related to environmental matters. There is also enhanced scrutiny of company-sponsored patient assistance programs, including insurance premium and co-pay assistance programs and donations to third-party charities that provide such assistance. The U.S. government has challenged some of our donations to third-party charities that provide patient assistance. If we, or our vendors or donation recipients, are found to fail to comply with relevant laws, regulations or government guidance in the operation of these programs, we could be subject to significant fines or penalties. Risks relating to compliance with laws and regulations may be heightened as we continue to expand our global operations and enter new therapeutic areas with different patient populations, which may have different product distribution methods, marketing programs or patient assistance programs from those we currently utilize or support. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conditions and regulations governing the health care industry are subject to change, with possible retroactive effect, including:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or judicial decisions, related to health care availability, pricing or marketing practices, compliance with employment practices, method of delivery, payment for health care products and services, compliance with health information and data privacy and security laws and regulations, tracking and reporting payments and other transfers of value made to physicians and teaching hospitals, extensive anti-bribery and anti-corruption prohibitions, product serialization and labeling requirements and used product take-back requirements; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in the FDA and foreign regulatory approval processes or perspectives that may delay or prevent the approval of new products and result in lost market opportunity; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">government shutdowns or relocations may result in delays to the review and approval process, slowing the time necessary for new drug candidates to be reviewed and/or approved, which may adversely affect our business;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">requirements that provide for increased transparency of clinical trial results and quality data, such as the EMA's clinical transparency policy, which could impact our ability to protect trade secrets and competitively-sensitive information contained in approval applications or could be misinterpreted leading to reputational damage, misperception or legal action, which could harm our business; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in FDA and foreign regulations that may require additional safety monitoring, labeling changes, restrictions on product distribution or use or other measures after the introduction of our products to market, which could increase our costs of doing business, adversely affect the future permitted uses of approved products or otherwise adversely affect the market for our products.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violations of governmental regulation may be punishable by criminal and civil sanctions, including fines and civil monetary penalties and exclusion from participation in government programs, including Medicare and Medicaid, as well as against executives overseeing our business. We could also be required to repay amounts we received from government payors or pay additional rebates and interest if we are found to have miscalculated the pricing information we submitted to the government. In addition, legal proceedings and investigations are inherently unpredictable, and large judgments or settlements sometimes occur. While we believe that we have appropriate compliance controls, policies and procedures in place to comply with the laws or regulations of the jurisdictions in which we operate, there is a risk that acts committed by our employees, agents, distributors, collaborators or third-party providers might violate such laws or regulations. Whether or not we have complied with the law, an investigation or litigation related to alleged unlawful conduct could increase our expense, damage our reputation, divert management time and attention and adversely affect our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our sales and operations are subject to the risks of doing business internationally.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are increasing our presence in international markets, subjecting us to many risks that could adversely affect our business and revenue. There is no guarantee that our efforts and strategies to expand sales in international markets will succeed. Emerging market countries may be especially vulnerable to periods of global and local political, legal, regulatory and financial instability and may have a higher incidence of corruption and fraudulent business practices. Certain countries may require local clinical trial data as part of the drug registration process in addition to global clinical trials, which can add to overall drug development and registration timelines. We may also be required to increase our reliance on third-party agents and unfamiliar operations and arrangements previously utilized by companies we collaborate with or acquire in emerging markets.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our sales and operations are subject to the risks of doing business internationally, including:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the impact of public health epidemics, such as the COVID-19 pandemic, on the global economy and the delivery of healthcare treatments;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">less favorable intellectual property or other applicable laws; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the inability to obtain necessary foreign regulatory approvals of products in a timely manner; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limitations and additional pressures on our ability to obtain and maintain product pricing or receive price increases, including those resulting from governmental or regulatory requirements;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">increased cost of goods due to factors such as inflation and supply chain disruptions;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">additional complexity in manufacturing internationally;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">delays in clinical trials relating to geopolitical instability related to Russia's invasion of Ukraine;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the inability to successfully complete subsequent or confirmatory clinical trials in countries where our experience is limited;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">longer payment and reimbursement cycles and uncertainties regarding the collectability of accounts receivable; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">fluctuations in foreign currency exchange rates that may adversely impact our revenue, net income and value of certain of our investments; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the imposition of governmental controls; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">diverse data privacy and protection requirements;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">increasingly complex standards for complying with foreign laws and regulations that may differ substantially from country to country and may conflict with corresponding U.S. laws and regulations; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the far-reaching anti-bribery and anti-corruption legislation in the United Kingdom (U.K.), including the U.K. Bribery Act 2010, and elsewhere and escalation of investigations and prosecutions pursuant to such laws;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">compliance with complex import and export control laws;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in tax laws; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the imposition of tariffs or embargoes and other trade restrictions.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, our international operations are subject to regulation under U.S. law. For example, the U.S. Foreign Corrupt Practices Act (FCPA) prohibits U.S. companies and their representatives from paying, offering to pay, promising to pay or authorizing the payment of anything of value to any foreign government official, government staff member, political party or political candidate for the purpose of obtaining or retaining business or to otherwise obtain favorable treatment or influence a person working in an official capacity. In many countries, the health care professionals we regularly interact with may meet the FCPA's definition of a foreign government official. Failure to comply with domestic or foreign laws could result in various adverse consequences, including possible delay in approval or refusal to approve a product, recalls, seizures or withdrawal of an approved product from the market, disruption in the supply or availability of our products or suspension of export or import privileges, the imposition of civil or criminal sanctions, the prosecution of executives overseeing our international operations and damage to our reputation. Any significant impairment of our ability to sell products outside of the U.S. could adversely impact our business and financial results. In addition, while we believe that we have appropriate compliance controls, policies and procedures in place to comply with the FCPA, there is a risk that acts committed by our employees, agents, distributors, collaborators or third-party providers might violate the FCPA and we might be held responsible. If our employees, agents, distributors, collaborators or third-party providers are found to have engaged in such practices, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">we could suffer severe penalties and may be subject to other liabilities, which could negatively affect our business, operating results and financial condition.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are building a large-scale biologics manufacturing facility, which will result in the incurrence of significant investment with no assurance that such investment will be recouped.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to support our future growth and drug development pipeline, we are expanding our large molecule production capacity by building a large-scale biologics manufacturing facility in Solothurn, Switzerland with no assurance that the additional capacity will be required or this investment will be recouped.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to fully utilize our manufacturing facilities, our business may be harmed. Charges resulting from excess capacity may continue to occur and would have a negative effect on our financial condition and results of operations.</span></div><div style="margin-top:4pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Solothurn facility was approved by the FDA for aducanumab, there can be no assurance that the regulatory authorities will approve the Solothurn facility for the manufacturing of other products or product candidates. If we do not receive the necessary regulatory approvals of the Solothurn facility or if our future growth and drug development plans increase, we may not have sufficient large-scale manufacturing capacity to meet our long-term manufacturing requirements.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing issues could substantially increase our costs, limit supply of our products and/or reduce our revenue.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of manufacturing our products is complex, highly regulated and subject to numerous risks, including:</span></div><div style="padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:12pt">Risks of Reliance on Third-Parties and Single Source Providers.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> We rely on third-party suppliers and manufacturers for many aspects of our manufacturing process for our products and product candidates. In some cases, due to the unique manner in which our products are manufactured, we rely on single source providers of raw materials and manufacturing supplies. These third-parties are independent entities subject to their own unique operational and financial risks that are outside of our control. These third-parties may not perform their obligations in a timely and cost-effective manner or in compliance with applicable regulations, and they may be unable or unwilling to increase production capacity commensurate with demand for our existing or future products. Finding alternative providers could take a significant amount of time and involve significant expense due to the specialized nature of the services and the need to obtain regulatory approval of any significant changes to our suppliers or manufacturing methods. We cannot be certain that we could reach agreement with alternative providers or that the FDA or other regulatory authorities would approve our use of such alternatives. Furthermore, factors such as the COVID-19 pandemic, weather events, labor or raw material shortages and other supply chain disruptions could result in difficulties and delays in manufacturing our products, which could have an adverse impact on our results in operations or result in product shortages.</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:12pt">Global Bulk Supply Risks. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We rely on our manufacturing facilities for the production of drug substance for our large molecule products and product candidates. Our global bulk supply of these products and product candidates depends on the uninterrupted and efficient operation of these facilities, which could be adversely affected by equipment failures, labor or raw material shortages, public health epidemics, natural disasters, power failures, cyber-attacks and many other factors.</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Risks Relating to Compliance with current GMP (cGMP).</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We and our third-party providers are generally required to maintain compliance with cGMP and other stringent requirements and are subject to inspections by the FDA and other regulatory authorities to confirm compliance. Any delay, interruption or other issues that arise in the manufacture, fill-finish, packaging or storage of our products as a result of a failure of our facilities or operations or those of third-parties to receive regulatory approval or pass any regulatory agency inspection could significantly impair our ability to develop and commercialize our products. Significant noncompliance could also result in the imposition of monetary penalties or other civil or criminal sanctions and damage our reputation.</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Risk of Product Loss.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The manufacturing process for our products is extremely susceptible to product loss due to contamination, oxidation, equipment failure or improper installation or operation of equipment or vendor or operator error. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our products or manufacturing facilities, we may need to close our manufacturing facilities for an extended period of time to investigate and remediate the contaminant.</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Risk Relating to Government Actions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We and/or our third-party providers may be required by the U.S. federal government to manufacture medical supplies needed to treat COVID-19 patients under the Defense Production Act or other acts or orders of government entities, which may result in delays in the manufacturing and supply of our products.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any adverse developments affecting our manufacturing operations or the operations of our third-party suppliers and manufacturers may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls or other interruptions in the commercial supply of our products. We may also have to take inventory write-offs and incur other charges and expense for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Such developments could increase our manufacturing costs, cause us to lose revenue or market share as patients and physicians turn to competing therapeutics, diminish our profitability or damage our reputation. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, although we have business continuity plans to reduce the potential for manufacturing disruptions or delays and reduce the severity of a disruptive event, there is no guarantee that these plans will be adequate, which could adversely affect our business and operations.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The ongoing COVID-19 pandemic may, directly or indirectly, adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business has and could continue to be adversely affected, directly or indirectly, by the ongoing COVID-19 pandemic. National, state and local governments have implemented and may continue to implement safety precautions. These measures may disrupt normal business operations and may have significant negative impacts on businesses and financial markets worldwide.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor our operations and applicable government recommendations, and we have made modifications to our normal operations because of the COVID-19 pandemic, including limiting travel and working from home. Customer-facing professionals interactions in healthcare settings have changed as a result of the COVID-19 pandemic. This limits our ability to market our products and educate physicians, which, in turn, could have an adverse effect on our ability to compete in the marketing and sales of our products.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in flexible working arrangements could impact employee retention, employees' productivity and morale, strain our technology resources and introduce operational risks. Additionally, the risk of cyber-attacks or other privacy or data security incidents may be heightened as a result of our moving increasingly towards a remote working environment, which may be less secure and more susceptible to hacking attacks.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic could affect the health and availability of our workforce as well as those of the third-parties we rely on. Furthermore, delays and disruptions experienced by our collaborators, joint venture partners or other third-parties due to the COVID-19 pandemic could adversely impact the ability of such parties to fulfill their obligations, which could affect product sales or the clinical development or regulatory approvals of product candidates under joint control.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our ability to continue our existing clinical trials or to initiate new clinical trials has been and may continue to be adversely affected, directly or indirectly, by the COVID-19 pandemic. Restrictions on travel and/or transport of clinical materials as well as diversion of hospital staff and resources to COVID-19 infected patients could disrupt trial operations and recruitment, possibly resulting in a slowdown in enrollment and/or deviations from or disruptions in key clinical trial activities, such as clinical trial site monitoring. These challenges may lead to difficulties in meeting protocol-specified procedures. We may need to make certain adjustments to the operation of clinical trials in an effort to minimize risks to trial data integrity during the COVID-19 pandemic. In addition, the impact of the COVID-19 pandemic on the operations of the FDA and other health authorities may delay potential approvals of our product candidates.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the COVID-19 pandemic, legislation has been enacted aimed at providing emergency assistance and health care for individuals, families and businesses and broadly supporting the U.S. economy. Additional state and federal healthcare reform measures may be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products or additional pricing pressures and have a financial impact on our business that we cannot predict.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While it is not possible at this time to estimate the entirety of the impact that the COVID-19 pandemic will continue to have on our business, operations, employees, customers, suppliers or collaboration partners, continued spread of COVID-19, measures taken by governments, actions taken to protect employees and the broad impact of the pandemic on all business activities may materially and adversely affect our business, supply chain and distribution systems, results of operations and financial condition.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Holding Our Common Stock</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operating results are subject to significant fluctuations.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quarterly revenue, expense and net income (loss) have fluctuated in the past and are likely to fluctuate significantly in the future due to the risks described in these </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as the timing of charges and expense that we may take. We have recorded, or may be required to record, charges that include:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the cost of restructurings or other initiatives to streamline our operations and reallocate resources; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">impairments with respect to investments, fixed assets and long-lived assets, including in-process research and development (IPR&amp;D) and other intangible assets; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">inventory write-downs for failed quality specifications, recurring charges for excess or obsolete inventory and charges for inventory write-downs relating to product suspensions, expirations or recalls; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in the fair value of contingent consideration or our equity investments;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">bad debt expense and increased bad debt reserves;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">outcomes of litigation and other legal or administrative proceedings, regulatory matters and tax matters;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">payments in connection with acquisitions, divestitures and other business development activities and under license and collaboration agreements;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">failure to meet certain contractual commitments; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the impact of public health epidemics, such as the COVID-19 pandemic, on employees, the global economy and the delivery of healthcare treatments.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue and certain assets and liabilities are also subject to foreign currency exchange rate fluctuations due to the global nature of our operations. Our efforts to mitigate the impact of fluctuating currency exchange rates may not be successful. As a result, currency fluctuations among our reporting currency, the U.S.&#160;dollar, and other currencies in which we do business will affect our operating results, often in unpredictable ways. Our net income may also fluctuate due to the impact of charges we may be required to take with respect to foreign currency hedge transactions. In particular, we may incur higher than expected charges from early termination of a hedge relationship.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results during any one period do not necessarily suggest the anticipated results of future periods.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our investments in properties may not be fully realized.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own or lease real estate primarily consisting of buildings that contain research laboratories, office space and manufacturing operations. We may decide to consolidate or co-locate certain aspects of our business operations or dispose of one or more of our properties, some of which may be located in markets that are experiencing high vacancy rates and decreasing property values. If we determine that the fair value of any of our owned properties is lower than their book value, we may not realize the full investment in these properties and incur significant impairment charges or additional depreciation when the expected useful lives of certain assets have been shortened due to the anticipated closing of facilities. If we decide to fully or partially vacate a property, we may incur significant cost, including facility closing costs, employee separation and retention expense, lease termination fees, rent expense in excess of sublease income and impairment of leasehold improvements and accelerated depreciation of assets. Any of these events may have an adverse impact on our results of operations.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our investment portfolio is subject to market, interest and credit risk that may reduce its value.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a portfolio of marketable securities for investment of our cash as well as investments in equity securities of certain biotechnology companies. Changes in the value of our investment portfolio could adversely affect our earnings. The value of our investments may decline due to, among other things, increases in interest rates, downgrades of the bonds and other securities in our portfolio, negative company-specific news, biotechnology market sentiment, instability in the global financial markets that reduces the liquidity of securities in our portfolio, declines in the value of collateral underlying the securities in our portfolio and other factors. Each of these events may cause us to record charges to reduce the carrying value of our investment portfolio or sell investments for less than our acquisition cost. Although we attempt to mitigate these risks through diversification of our investments and continuous monitoring of our portfolio's overall risk profile, the value of our investments may nevertheless decline.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There can be no assurance that we will continue to repurchase shares or that we will repurchase shares at favorable prices.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time our Board of Directors authorizes share repurchase programs. The amount and timing of share repurchases are subject to capital availability and our determination that share repurchases are in the best interest of our shareholders and are in compliance with all respective laws and our applicable agreements. Our ability to repurchase shares will depend upon, among other factors, our cash balances and potential future capital requirements for strategic transactions, our results of operations, our financial condition and other factors beyond our control that we may deem relevant. A reduction in repurchases under, or the completion of, our share repurchase programs could have a negative effect on our stock price. We can provide no assurance that we will repurchase shares at favorable prices, if at all.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to access the capital and credit markets on terms that are favorable to us.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek access to the capital and credit markets to supplement our existing funds and cash generated from operations for working capital, capital expenditure and debt service requirements and other business initiatives. The capital and credit markets are experiencing, and have in the past experienced, extreme volatility and disruption, which leads to uncertainty and liquidity issues for both borrowers and investors. In the event of adverse market conditions, we may be unable to obtain capital or credit market financing on favorable terms. Changes in credit ratings issued by nationally recognized credit rating agencies could also adversely affect our cost of financing and the market price of our securities.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our indebtedness could adversely affect our business and limit our ability to plan for or respond to changes in our business. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our indebtedness, together with our significant contingent liabilities, including milestone and royalty payment obligations, could have important consequences to our business; for example, such obligations could: </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">increase our vulnerability to general adverse economic and industry conditions;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limit our ability to access capital markets and incur additional debt in the future;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">require us to dedicate a substantial portion of our cash flow from operations to payments on our indebtedness, thereby reducing the availability of our cash flow for other purposes, including business development, research and development and mergers and acquisitions;&#160;and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate, thereby placing us at a disadvantage compared to our competitors that have less debt.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Some of our collaboration agreements contain change in control provisions that may discourage a third-party from attempting to acquire us.</span></div><div style="margin-top:6pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our collaboration agreements include change in control provisions that could reduce the potential acquisition price an acquirer is willing to pay or discourage a takeover attempt that could be viewed as beneficial to shareholders. Upon a change in control, some of these provisions could trigger reduced milestone, profit or royalty payments to us or give our collaboration partner rights to terminate our collaboration agreement, acquire operational control or force the purchase or sale of the programs that are the subject of the collaboration.</span></div><div style="margin-top:6pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our effective tax rate fluctuates, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a global biopharmaceutical company, we are subject to taxation in numerous countries, states and other jurisdictions. As a result, our effective tax rate is derived from a combination of applicable tax rates, including withholding taxes, in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of such places. Our effective tax rate may be different than experienced in the past or our current expectations due to many factors, including changes in the mix of our profitability from country to country, the results of examinations and audits of our tax filings (including those related to the impact of the Tax Cuts and Jobs Act of 2017), adjustments to the value of our uncertain tax positions, interpretations by tax authorities or other bodies with jurisdiction, the result of tax cases, changes in accounting for income taxes and changes in tax laws and regulations either prospectively or retrospectively. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to secure or sustain acceptable arrangements with tax authorities and future changes in the tax laws, among other things, may result in tax obligations in excess of amounts accrued in our financial statements.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The enactment of some or all of the recommendations set forth or that may be forthcoming in the Organization for Economic Cooperation and Development&#8217;s project on &#8220;Base Erosion and Profit Shifting&#8221; (BEPS) by tax authorities </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and economic blocs in the countries in which we operate, could unfavorably impact our effective tax rate. These initiatives focus on common international principles for the entitlement to taxation of global corporate profits and minimum global tax rates.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business involves environmental risks, which include the cost of compliance and the risk of contamination or injury.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business and the business of several of our strategic partners involve the controlled use of hazardous materials, chemicals, biologics and radioactive compounds. Although we believe that our safety procedures for handling and disposing of such materials comply with state, federal and foreign standards, there will always be the risk of accidental contamination or injury. If we were to become liable for an accident, or if we were to suffer an extended facility shutdown, we could incur significant costs, damages and penalties that could harm our business. Manufacturing of our products and product candidates also requires permits from government agencies for water supply and wastewater discharge. If we do not obtain appropriate permits, including permits for sufficient quantities of water and wastewater, we could incur significant costs and limits on our manufacturing volumes that could harm our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><div id="ie9658fba2baf4e3799b1175f69eaed46_229"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="margin-top:14pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM&#160;2.&#160;&#160;&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:6pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our common stock repurchase activity under our 2020 Share Repurchase Program during the first quarter of 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:21.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.726%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number&#160;of<br/>Shares&#160;Purchased<br/>(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average&#160;Price<br/>Paid&#160;per&#160;Share<br/>($)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number&#160;of<br/>Shares&#160;Purchased<br/>as&#160;Part&#160;of&#160;Publicly<br/>Announced Programs<br/>(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate Dollar Value<br/>of Shares That May Yet Be Purchased Under<br/>Our Programs<br/>($ in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,800.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">February 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,800.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,800.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">There were no share repurchases during the first quarter of 2022.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (2020 Share Repurchase Program). Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired. Under our 2020 Share Repurchase Program, we repurchased and retired approximately 2.2 million shares of our common stock at a cost of approximately $600.0 million during the three months ended March 31, 2021. There were no share repurchases of our common stock during the three months ended March 31, 2022. Approximately $2.8 billion remained available under our 2020 Share Repurchase Program as of March 31, 2022.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><div id="ie9658fba2baf4e3799b1175f69eaed46_232"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:14pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM&#160;6.&#160;&#160;&#160;&#160;EXHIBITS</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits listed below are filed or furnished as part of this Quarterly Report on Form&#160;10-Q.</span></div><div id="ie9658fba2baf4e3799b1175f69eaed46_235"></div><div style="-sec-extract:summary;margin-top:14pt;text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT&#160;INDEX&#160;</span></div><div style="margin-top:19pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:15.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.024%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.232%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Number</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Description of Exhibit</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="biib-2022331xex311.htm">Certification of the Chief Executive Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="biib-2022331xex312.htm">Certification of the Chief Financial Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1++</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="biib-2022331xex321.htm">Certification Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000875045/000087504522000013/exhibit101letteragreement.htm">Letter regarding employment arrangement of Michel Vounatsos dated May 2, 2022. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed on May 3, 2022.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2*+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit102biogeninc2006non.htm">Biogen Inc. 2006 Non-Employee Directors Equity Plan, as amended.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101++</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following materials from Biogen Inc.&#8217;s Quarterly Report on Form&#160;10-Q for the quarter ended March 31, 2022, formatted in iXBRL (Inline Extensible Business Reporting Language): (i)&#160;the Condensed Consolidated Statements of Income, (ii)&#160;the Condensed Consolidated Statements of Comprehensive Income, (iii) the Condensed Consolidated Balance Sheets, (iv)&#160;the Condensed Consolidated Statements of Cash Flow, (v) the Condensed Consolidated Statements of Equity and (vi)&#160;Notes to Condensed Consolidated Financial Statements.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104++</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page from this Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, formatted in Inline XBRL.</span></div></td></tr></table></div><div style="padding-left:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Management contract or compensatory plan or arrangement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;Filed herewith </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">++&#160;&#160;&#160;&#160;Furnished herewith</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><div id="ie9658fba2baf4e3799b1175f69eaed46_238"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie9658fba2baf4e3799b1175f69eaed46_7">Table of Contents</a></span></div></div><div style="margin-top:14pt;text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:5pt;padding-left:297pt;text-indent:-13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.590%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BIOGEN INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Michael R. McDonnell</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael R. McDonnell</span></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(principal financial officer)</span></td></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May&#160;3, 2022 </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>2
<FILENAME>exhibit102biogeninc2006non.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i732207ab26c048d881dc503d8bbe6954_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 10.2</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BIOGEN INC.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2006 NON-EMPLOYEE DIRECTORS EQUITY PLAN</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(Approved by stockholders on May 25, 2006&#59; as amended through March 27, 2015 and approved by stockholders on June 10, 2015&#59; and as amended on April 6, 2022)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Purpose&#59; Establishment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Biogen Inc. 2006 Non-Employee Directors Equity Plan is intended to encourage ownership of shares of Common Stock by Non-Employee Directors of the Company and its Affiliates, and to provide an additional incentive to those directors to promote the success of the Company and its Affiliates. The Plan has been adopted and approved by the Board of Directors, and became effective on the Effective Date. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Definitions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As used in the Plan, the following definitions apply to the terms indicated below&#58; </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a) &#8220;Affiliate&#8221; shall have the meaning set forth in Rule 12b-2 under Section 12 of the Exchange Act. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b) &#8220;Agreement&#8221; shall mean either the written or electronic agreement between the Company and a Participant or a written or electronic notice from the Company to a Participant evidencing an Award. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c) &#8220;Award&#8221; shall mean any Option, Restricted Stock, Restricted Stock Unit, Dividend Equivalent Rights, Stock Appreciation Right or Other Award granted pursuant to the terms of the Plan. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d) &#8220;Beneficial Owner&#8221; shall have the meaning set forth in Section 13(d) of the Exchange Act. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e) &#8220;Board of Directors&#8221; or &#8220;Board&#8221; shall mean the Board of Directors of the Company. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f) &#8220;Certificate&#8221; shall mean either a physical paper stock certificate or electronic book entry or other electronic form of account entry evidencing the ownership of shares of Restricted Stock or shares of Common Stock acquired upon exercise, vesting or settlement, as the case may be, of Awards other than Restricted Stock. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g) &#8220;Code&#8221; shall mean the Internal Revenue Code of 1986, as amended from time to time, and any regulations promulgated thereunder. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h) &#8220;Committee&#8221; shall mean the committee appointed to administer the Plan pursuant to Section 3. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i) &#8220;Company&#8221; shall mean Biogen Inc., a Delaware corporation. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j) &#8220;Common Stock&#8221; shall mean the common stock of the Company, par value $0.0005 per share. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(k) &#8220;Continuing Director&#8221; shall mean, as of any date of determination, any member of the Board who (a) was a member of the Board on the Effective Date or (b) becomes a member of the Board subsequent to the Effective Date and was appointed, nominated for election or elected to the Board with the approval of a majority of the Continuing Directors who were members of the Board at the time of such appointment, nomination or election, provided that a director whose </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122942834_1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">initial assumption of office is in connection with an actual or threatened election contest will not be considered a Continuing Director unless and until (i) such director has served on the Board for at least two years and (ii) the most recent reelection of such director has been approved by a majority of the Continuing Directors in office at the time of such approval.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(l) A &#8220;Corporate Change in Control&#8221; shall be deemed to have occurred upon the first of the following events&#58; </font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">an event in which any Person, is or becomes the Beneficial Owner, together with all Affiliates and associates (as such terms are used in Rule 12b-2 of the General Rules and Regulations under the Exchange Act) of such Person, directly or indirectly, of securities of the Company representing 50% or more of the combined voting power of the Company&#8217;s then outstanding securities&#59;</font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">the consummation of the merger or consolidation of the Company with any other company, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity) more than 50%  of the combined voting power of the voting securities of the Company or such surviving entity outstanding immediately after such merger&#59; or</font></div><div style="padding-left:54pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">at any time the Continuing Directors do not constitute a majority of the Board (or, if applicable, the board of directors of a successor to the Company).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, in any case where the occurrence of a Corporate Change in Control could affect the vesting of or payment under an Award subject to the requirements of Section 409A of the Code, to the extent required to comply with Section 409A of the Code, the term &#8220;Corporate Change in Control&#8221; shall mean an occurrence that both (i) satisfies the requirements set forth above in this definition and (ii) is a &#8220;change in control event&#8221; as that term is defined in the regulations under Section 409A of the Code.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (m) A &#8220;Corporate Transaction&#8221; shall be deemed to have occurred upon the first of the following events&#58; (i)&#160;a consolidation, merger or similar transaction or series of related transactions, including a sale or other disposition of stock, in which the Company (or an Affiliate) is not the surviving corporation or which results in the acquisition of all or substantially all of the then outstanding Common Stock by a single person or entity or by a group of persons and&#47;or entities acting in concert&#59; (ii)&#160;a sale or transfer of all or substantially all of the Company&#8217;s assets&#59; or (iii)&#160;a dissolution or liquidation of the Company. Where a Corporate Transaction involves a tender offer that is reasonably expected to be followed by a merger described in clause&#160;(i) as determined by the Committee, the Corporate Transaction shall be deemed to have occurred upon consummation of the tender offer.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, in any case where the occurrence of a Corporate Transaction could affect the vesting of or payment under an Award subject to the requirements of Section 409A of the Code, to the extent required to comply with Section 409A of the Code, the term &#8220;Corporate Transaction&#8221; shall mean an occurrence that both (i) satisfies the requirements set forth above in this definition and (ii) is a &#8220;change in control event&#8221; as that term is defined in the regulations under Section 409A of the Code.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;-2-</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122942834_1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(n) A &#8220;Disability&#8221; shall exist for purposes of the Plan if a Participant is entitled to receive benefits under the applicable long-term disability program of the Company or an Affiliate of the Company, or, if no such program is in effect with respect to such Participant, if the Participant has become totally and permanently disabled within the meaning of Section 22(e)(3) of the Code. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(o) &#8220;Dividend Equivalent Rights&#8221; shall mean a right, granted in connection with an Award, to receive dividends (which may or may not be made subject to restrictions or forfeiture conditions, as determined by the Committee) upon the payment of a dividend with respect to the Common Stock underlying the Award, which dividends will be held in escrow until all restrictions or conditions to the vesting of the Common Stock underlying the Award have lapsed.  Any escrowed dividends may, in the Committee&#8217;s discretion, be reinvested or deemed reinvested in Common Stock as of the dividend payment date. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (p) &#8220;Effective Date&#8221; shall mean May 25, 2006, the date that the Company's stockholders approved the Plan. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (q) &#8220;Exchange Act&#8221; shall mean the Securities Exchange Act of 1934, as amended from time to time. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (r) &#8220;Fair Market Value&#8221; of the Common Stock shall be calculated as follows&#58; (i) if the Common Stock is listed on a national securities exchange and sale prices are regularly reported for the Common Stock, then the Fair Market Value shall be the closing selling price for the Common Stock reported on the applicable composite tape or other comparable reporting system on the applicable date, or if the applicable date is not a trading day, on the most recent trading day immediately prior to the applicable date&#59; or (ii) if closing selling prices are not regularly reported for the Common Stock as described in clause (i) above, but bid and asked prices for the Common Stock are regularly reported, then the Fair Market Value shall be the arithmetic mean between the closing or last bid and asked prices for the Common Stock on the applicable date or, if the applicable date is not a trading day, on the most recent trading day immediately prior to the applicable date&#59; or (iii) if prices are not regularly reported for the Common Stock as described in clauses (i) or (ii) above, then the Fair Market Value shall be such value as the Committee in good faith determines. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (s) &#8220;For Cause&#8221; shall mean any act of&#58; (i) fraud or intentional misrepresentation, or (ii) embezzlement, misappropriation or conversion of assets or opportunities of the Company or any Affiliate. The determination of the Committee as to the existence of circumstances warranting a termination For Cause shall be conclusive. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (t) &#8220;Non-Employee Director&#8221; has the meaning set forth in Section 5. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (u) &#8220;Nonqualified Stock Option&#8221; shall mean an Option that is not an &#8220;incentive stock option&#8221; within the meaning of Section 422 of the Code, or any successor provision. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (v) &#8220;Option&#8221; shall mean an option to purchase shares of Common Stock granted pursuant to Section 7. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (w) &#8220;Other Award&#8221; shall mean an Award granted pursuant to Section 10. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (x) &#8220;Participant&#8221; shall mean a Non-Employee Director to whom an Award is granted pursuant to the Plan. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (y) &#8220;Person&#8221; shall have the meaning given in Section 3(a)(9) of the Exchange Act, as modified and used in Sections 13(d) and 14(d) thereof, except that such term shall not include&#58; (i) the Company or any of its Affiliates, (ii) a trustee or other fiduciary holding securities under an </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;-3-</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122942834_1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">employee benefits plan of the Company or any of its Affiliates, (iii) an underwriter temporarily holding securities pursuant to an offering of such securities or (iv) a corporation or other business entity owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company. (z) &#8220;Plan&#8221; shall mean the Biogen Inc. 2006 Non-Employee Directors Equity Plan (formerly the Biogen Idec Inc. 2006 Non-Employee Directors Equity Plan), as amended from time to time.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (aa) &#8220;Restricted Stock&#8221; shall mean a share of Common Stock which is granted pursuant to the terms of Section 8 and which may not be in any manner transferred or disposed of (such restrictions being known as the &#8220;Transfer Restrictions&#8221;) prior to the applicable Vesting Date. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (bb) &#8220;Restricted Stock Unit&#8221; means a unit granted pursuant to Section 8 that represents the right to receive the Fair Market Value of one share of Common Stock, which is payable in cash or Common Stock, as specified in the applicable Agreement, and which may or may not be subject to forfeiture restrictions. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (cc) &#8220;Retirement&#8221; as to any Participant shall mean such person's leaving the Board under the following circumstances&#58; (i) as of the annual stockholders meeting that occurs in the year in which the Participant reaches age 75, or (ii) upon the completion of such person's current term provided he or she has provided the Board with at least six months prior written notice of retirement, but not including a Participant's termination For Cause, as determined by the Committee. Notwithstanding the foregoing, a Participant elected to the Board other than at an annual stockholders meeting shall not be eligible for Retirement pursuant to clause (ii) of this Section 2(cc) until the completion of a term for which such Participant is elected to serve by the stockholders at an annual stockholders meeting. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (dd) &#8220;Rule 16b-3&#8221; shall mean Rule 16b-3 promulgated under the Exchange Act, as amended from time to time. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (ee) &#8220;Stock Appreciation Right&#8221; shall mean the right to receive an amount equal to the excess of the Fair Market Value of a share of Common Stock (as determined on the date of exercise) over&#58; (i) if the Stock Appreciation Right is not related to an Option, the Fair Market Value of a share of Common Stock on the date the Stock Appreciation Right was granted, or (ii) if the Stock Appreciation Right is related to an Option, the exercise price of the related Option, subject to such further terms and conditions as are provided under Section 9. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (ff) &#8220;Transaction&#8221; has the meaning set forth in Section 4(c).  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (gg) &#8220;Vesting Date&#8221; shall mean the date established by the Committee on which an Award shall vest. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 3.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Administration of the Plan.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Plan shall be administered by the Board of Directors, or by a committee of the Board which shall consist of two or more persons each of whom, unless otherwise determined by the Board, is (a) a &#8220;non-employee director&#8221; within the meaning of Rule 16b-3 and (b) an &#8220;independent director&#8221; as defined in Nasdaq Stock Market Rules. References in the Plan to the &#8220;Committee&#8221; shall mean the Board or any such committee. The Committee shall have the authority in its sole and absolute discretion, subject to and not inconsistent with the express provisions of the Plan, to administer the Plan and to exercise all the powers and authorities either specifically granted to it under the Plan or necessary or advisable in the administration of the Plan, including, without limitation&#58; (1) the authority to grant Awards, (2) to determine the type and number of Awards to be granted, the number of shares of Common Stock to which an Award may relate and the terms, conditions and restrictions relating to any Award, (3) to determine whether, to what extent, and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;-4-</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122942834_1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">under what circumstances an Award may be settled, cancelled, forfeited, exchanged, or surrendered, (4) to construe and interpret the Plan and any Award, (5) to prescribe, amend and rescind rules and regulations relating to the Plan, (6) to determine the terms and provisions of Agreements, and (7) to make all other determinations deemed necessary or advisable for the administration of the Plan. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Committee may, in its sole and absolute discretion, without amendment to the Plan, waive or amend the operation of Plan provisions respecting exercise after termination of Board service and, except as otherwise provided herein, adjust any of the terms of any Award. The Committee may also (a) accelerate the date on which any Award granted under the Plan becomes exercisable or (b) accelerate the Vesting Date or waive or adjust any condition imposed hereunder with respect to the vesting or exercisability of an Award, provided that the Committee determines that such acceleration, waiver or other adjustment is necessary or desirable in light of extraordinary circumstances. Notwithstanding the foregoing, no Award outstanding under the Plan may be repriced, regranted through cancellation or otherwise amended to reduce the exercise price applicable thereto (other than with respect to adjustments made in connection with a Transaction or other change in the Company's capitalization) without the approval of the Company's stockholders. In addition, no Award shall provide a &#8220;reload&#8221; feature pursuant to which the Participant would receive an automatic grant of additional Awards to replace the shares of Common Stock surrendered to exercise an Award, and no Option shall be exercisable prior to the applicable Vesting Date for shares of Common Stock subject to repurchase by the Company, upon a termination of Board service prior to such Vesting Date, for the exercise price paid by the Participant. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 4.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Stock Subject to the Plan.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Shares Available for Awards.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Subject to the provisions of Sections 4(b), 4(c) and 4(d) hereof, the maximum number of shares of Common Stock reserved for issuance under the Plan shall be 1,600,000 shares. Such shares may be authorized but unissued Common Stock or authorized and issued Common Stock held in the Company's treasury.  The grant of any Award other than an Option or a Stock Appreciation Right shall, for purposes of this Section 4(a), reduce the number of shares of Common Stock available for issuance under the Plan by one and one-half (1.5) shares of Common Stock for each such share actually subject to the Award. The grant of an Option or a Stock Appreciation Right shall be deemed, for purposes of this Section 4(a), as an Award of one share of Common Stock for each such share actually subject to the Award. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Adjustment for Change in Capitalization.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  In the event that any dividend or other distribution is declared (whether in the form of cash, Common Stock, or other property), or there occurs any recapitalization, reclassification, stock split, reverse stock split, reorganization, merger, consolidation, spin-off, combination, repurchase, or share exchange, or other similar corporate transaction or event, then, unless otherwise determined by the Committee in its sole and absolute discretion with respect to dividends or distributions of cash or other non-stock property, (1) the number and kind of shares of stock which may thereafter be issued in connection with Awards, (2) the number and kind of shares of stock or other property issued or issuable in connection with outstanding Awards, (3) the exercise price, grant price or purchase price relating to any outstanding Awards, and (4) the limits on Awards under Section 6(b) shall be equitably adjusted as necessary to prevent the dilution or enlargement of the rights of Participants. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (c) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Adjustment for Change or Exchange of Shares for Other Consideration.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  In the event that outstanding shares of Common Stock shall be changed into or exchanged for any other class or series of capital stock or cash, securities or other property pursuant to a recapitalization, reclassification, reorganization, merger, consolidation, spin-off, combination, repurchase, or share exchange, or other similar corporate transaction or event (&#8220;Transaction&#8221;), then, unless </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;-5-</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122942834_1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">otherwise determined by the Committee in its sole and absolute discretion, (1) each outstanding Option shall thereafter become exercisable for the number and&#47;or kind of capital stock, and&#47;or the amount of cash, securities or other property so distributed, into which the shares of Common Stock subject to the Option would have been changed or exchanged had the Option been exercised in full prior to such Transaction, provided that, if necessary, the provisions of the Option shall be appropriately adjusted so as to be applicable to any shares of capital stock, cash, securities or other property thereafter issuable or deliverable upon exercise of the Option, and (2) each outstanding Award that is not an Option and that is not automatically changed in connection with the Transaction shall represent the number and&#47;or kind of capital stock, and&#47;or the amount of cash, securities or other property so distributed, into which the shares of Common Stock covered by the outstanding Award would have been changed or exchanged had they been held by a stockholder of the Company. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (d) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Reuse of Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Any shares subject to an Award that remain unissued upon the cancellation, surrender, exchange or termination of such Award for any reason whatsoever shall again become available for Awards in an amount determined in accordance with the share counting formulas set forth in Section 4(a), except that the exercise of a Stock Appreciation Right shall not be deemed to result in unissued shares, even if fewer shares are issued than the number of shares in which the Award was denominated.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 5.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Eligibility.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The persons who shall be eligible to receive Awards pursuant to the Plan shall be limited to&#58; (i) those individuals who are first elected as non-employee Board members after the Effective Date, whether by the Company's stockholders or by the Board, and (ii) those individuals who continue to serve as non-employee Board members after such Effective Date, whether or not they commenced Board service prior to such Effective Date. In no event, however, shall any non-employee Board member be eligible to participate in the Plan unless such individual is an &#8220;independent director&#8221; as defined in Nasdaq Stock Market Rules. Each non-employee Board member eligible to participate in the Plan pursuant to the foregoing criteria shall be designated an eligible &#8220;Non-Employee Director&#8221; for purposes of the Plan. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 6.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Awards Under the Plan&#59; Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">General.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Committee may grant Options, shares of Restricted Stock, Restricted Stock Units, Stock Appreciation Rights and Other Awards pursuant to Section 6(b), in such amounts and with such terms and conditions as the Committee shall determine, subject to the provisions of the Plan, and may provide for Dividend Equivalent Rights with respect to any Award. Each Award granted under the Plan shall be evidenced by an Agreement which shall contain such provisions as the Committee may in its sole discretion deem necessary or desirable, which are not in conflict with the terms of the Plan. By accepting an Award, a Participant thereby agrees that the Award shall be subject to all of the terms and provisions of the Plan and the applicable Agreement. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Awards.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Awards shall be granted as specified below.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;(i) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Initial Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each individual who is first elected as a Non-Employee Director, whether by the Company's stockholders or by the Board, on or after the Effective Date, may be granted, on the date of such initial election, one or more Awards (defined as the &#8220;Initial Grant&#8221;), the amount and type of which shall be determined by the Committee consistent with the provisions of the Plan, provided that the number of shares of Common Stock subject to such Initial Grant shall not exceed 35,000 shares in the aggregate (calculated as described in subsection (iv) below). Initial Grants shall vest ratably in equal annual installments on each of the first three anniversaries of the date of grant. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;-6-</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122942834_1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;(ii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Annual Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  On the date of each annual stockholders meeting, commencing with the 2006 annual meeting, each individual who is at the time serving as a Non-Employee Director shall be granted one or more Awards (defined as the &#8220;Annual Grant&#8221;), the amount and type of which shall be determined by the Committee consistent with the provisions of the Plan, provided that the number of shares of Common Stock subject to such Annual Grant shall not exceed 17,500 shares in the aggregate (calculated as described in subsection (iv) below). An individual elected as a Non-Employee Director other than at an annual meeting of stockholders shall receive, on the date of such election, a pro rata portion of the Annual Grant made at the preceding annual stockholders meeting based on the number of days from the date of election to the next annual meeting of stockholders, divided by 365. Unless otherwise determined by the Committee, all outstanding and future Annual Grants shall fully vest on the earlier of (i) the next annual meeting of stockholders following the date of grant or (ii) first anniversary of the date of grant or over such longer period and in such increments as the Committee may otherwise determine. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;(iii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Non-Executive Chairman Grants.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Upon election as Non-Executive Chairman of the Board of Directors on or after the Effective Date, a Non-Employee Director may be granted, on the date of such election, one or more Awards (defined as the &#8220;Supplemental Initial Grant&#8221;), the amount and type of which shall be determined by the Committee consistent with the provisions of the Plan, provided that the number of shares of Common Stock subject to such an individual's Initial Grant and Supplemental Initial Grant shall not exceed 50,000 shares in the aggregate (calculated as described in subsection (iv) below). On the date of each annual stockholders meeting commencing with the 2006 annual meeting, any Non-Employee Director then serving as Non-Executive Chairman of the Board of Directors shall be granted one or more Awards (defined as the &#8220;Supplemental Annual Grant&#8221;), the amount and type of which shall be determined by the Committee consistent with the provisions of the Plan, provided that the number of shares of Common Stock subject to such an individual's Annual Grant and Supplemental Annual Grant shall not exceed 30,000 shares in the aggregate (calculated as described in subsection (iv) below). A Non-Employee Director elected as Non-Executive Chairman of the Board other than at an annual meeting of stockholders shall receive, on the date of such election, a pro rata portion of the Supplemental Annual Grant. Supplemental Initial Grants shall vest ratably in equal annual installments on each of the first three anniversaries of the date of grant, and Supplemental Annual Grants shall fully vest on the first anniversary of the date of grant. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;(iv) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Share Equivalents.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  For purposes of applying the limits on the number of shares of Common Stock which may be subject to Awards made pursuant to Initial Grants, Supplemental Initial Grants, Annual Grants and Supplemental Annual Grants under this Section 6(b)&#58; (A) the grant of any Award other than an Option or a Stock Appreciation Right shall be treated as an Award of one and one-half (1.5) shares of Common Stock for each such share actually subject to the Award, and (B) the grant of an Option or a Stock Appreciation Right shall be treated as an Award of one share of Common Stock for each such share actually subject to the Award. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 7.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Options. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Identification of Options.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Each Option shall be a Nonqualified Stock Option and shall state the number of shares of the Common Stock to which it pertains. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Exercise Price.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Each Agreement with respect to an Option shall set forth the amount (the &#8220;option exercise price&#8221;) payable by the Participant to the Company upon exercise of the Option. The option exercise price per share shall be equal to the Fair Market Value of the Common Stock on the date of grant. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (c) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Term and Exercise of Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;-7-</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122942834_1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;(i) Each Option shall become exercisable at the time or times determined by the Committee as set forth in the applicable Agreement, consistent with the provisions of the Plan. The expiration date of each Option shall be ten (10) years from the date of the grant thereof, or at such earlier time as the Committee shall expressly state in the applicable Agreement. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;(ii) An Option shall be exercised by delivering notice as specified in the Agreement on the form of notice provided by the Company. The option exercise price shall be payable upon the exercise of the Option. It shall be payable in one of the following forms&#58; (A) in United States dollars in cash or by check, (B) if permitted by the Committee, in shares of Common Stock that have been held by the Participant (or a permitted transferee of such person) for at least six months and having a Fair Market Value as of the date of exercise equal to the aggregate option exercise price, (C) at the discretion of the Committee, in accordance with a cashless exercise program established with a securities brokerage firm, or (D) at the discretion of the Committee, by any combination of (A), (B) and (C) above, or (E) by such other method as the Committee may, in its discretion, permit. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;(iii) Certificates for shares of Common Stock purchased upon the exercise of an Option shall be issued in the name of or for the account of the Participant, or other person entitled to receive such shares, and delivered to the Participant or such other person as soon as practicable following the effective date on which the Option is exercised. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (iv) Notwithstanding anything to the contrary in this Plan, on the last day on which an Option is exercisable in accordance with the Plan and the terms of the Award, if the exercise price of the Option is less than the Fair Market Value of the Common Stock on that day, the stock option will be deemed to have been exercised on a net share settlement basis at the close of business on that day. As promptly as practicable thereafter, the Company will deliver to the Participant the number of shares underlying the Option less the number of shares having a Fair Market Value on the date of the deemed exercise equal to the aggregate exercise price for the Option. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (d) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Effect of Termination of Board Service.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;(i) Except as may otherwise be determined by the Committee (A) in the event that the Participant&#8217;s Board service shall terminate on account of the Retirement, death or Disability of the Participant, each Option granted to such Participant that is outstanding as of the date of such termination shall become fully vested and exercisable, and (B) in the event that the Participant&#8217;s Board service shall terminate for any reason other than Retirement, death or Disability, each Option that is not exercisable as of the date of such termination shall be cancelled at the time of such termination.   </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;(ii) In the event that the Participant&#8217;s Board service shall terminate for any reason other than For Cause, each Option granted to such Participant, to the extent that it is or becomes exercisable at the time of such termination, shall remain exercisable by the Participant (or, in the event of the Participant&#8217;s death while such Option is still outstanding, by the Participant&#8217;s legal representatives, heirs or legatees) for the three-year period following such termination (or for such other period as may be provided by the Committee), but in no event following the expiration of its term. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;(iii) In the event of the termination of the Participant&#8217;s Board service For Cause, each outstanding Option granted (including any portion of the Option that is then exercisable) to such Participant shall be cancelled as of the commencement of business on the date of such termination. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 8.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Restricted Stock&#59; Restricted Stock Units.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;-8-</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122942834_1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Price.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  At the time of the grant of shares of Restricted Stock, the Committee shall determine the price, if any, to be paid by the Participant for each share of Restricted Stock subject to the Award. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Vesting Date.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Provided that all conditions to the vesting of a share of Restricted Stock imposed pursuant to Section 6(b) are satisfied, and except as provided in Section 8(g), upon the occurrence of the Vesting Date with respect to a share of Restricted Stock, such share shall vest and the Transfer Restrictions shall lapse. Provided that all conditions to the vesting of a Restricted Stock Unit imposed pursuant to Section 6(b) are satisfied, and except as provided in Section 8(g), upon the occurrence of the Vesting Date with respect to a Restricted Stock Unit, such Restricted Stock Unit shall vest and become non-forfeitable&#59; provided, however, that the payment with respect to such Restricted Stock Unit shall be made in a manner that complies with the requirements of Section 409A of the Code.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (c) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Dividends.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Any dividends paid on shares of Restricted Stock will be held in escrow until all restrictions or conditions to the vesting of such shares have lapsed.  Any escrowed dividends may, in the Committee&#8217;s discretion, be reinvested or deemed reinvested in Common Stock as of the dividend payment date. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (d) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Issuance of Certificates.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Following the date of grant with respect to shares of Restricted Stock, or the settlement of a Restricted Stock Unit payable in Common Stock, the Company shall cause to be issued a Certificate, registered in the name of or for the account of the Participant to whom such shares were granted, evidencing such shares. In the case of an Award of Restricted Stock, each such Certificate shall bear the following legend or substantially similar restrictive account legend&#58;  &#8220;The transferability of this Certificate and the shares of stock represented hereby are subject to the restrictions, terms and conditions (including forfeiture provisions and restrictions against transfer) contained in or imposed pursuant to the Biogen Inc. 2006 Non-Employee Directors Equity Plan.&#8221;  Such legend shall not be removed until such shares vest pursuant to the terms hereof.  Each Certificate issued pursuant to this Section 8(d) in connection with a grant of Restricted Stock shall be held by the Company or its designee prior to the applicable Vesting Date, unless the Committee determines otherwise. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (e) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Consequences of Vesting of Restricted Stock.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Upon the vesting of a share of Restricted Stock pursuant to the terms hereof, the Transfer Restrictions shall lapse with respect to such share. Following the date on which a share of Restricted Stock vests, the Company shall cause to be delivered to the Participant to whom such shares were granted (or a permitted transferee of such person), a Certificate evidencing such share, free of the legend set forth in Section 8(d). </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (f) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Settlement of Restricted Stock Units.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The settlement of Restricted Stock Units may occur or commence when all vesting conditions applicable to the Restricted Stock Units have been satisfied, or it may be deferred in accordance with such terms and conditions as the Committee may specify, subject to compliance with Section 409A of the Code. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (g) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Effect of Termination of Board Service.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  In the event that the Participant's Board service shall terminate for any reason other than (i) Retirement, (ii) death or (iii) Disability, each unvested grant of Restricted Stock or Restricted Stock Units shall be forfeited at the time of such termination (except as may be otherwise determined by the Committee). In the event that the Participant's Board service shall terminate on account of Retirement, death or Disability of the Participant, each grant of Restricted Stock and Restricted Stock Units that is outstanding as of the date of Retirement, death or Disability shall become fully vested. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 9.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Stock Appreciation Rights.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;-9-</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122942834_1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (a) A Stock Appreciation Right may be granted in connection with an Option, either at the time of grant or at any time thereafter during the term of the Option, or may be granted unrelated to an Option. At the time of grant of a Stock Appreciation Right, the Committee may impose such restrictions or conditions to the exercisability of the Stock Appreciation Right as it, in its absolute discretion, deems appropriate. The term of a Stock Appreciation Right granted without relationship to an Option shall not exceed ten years from the date of grant. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (b) A Stock Appreciation Right related to an Option shall require the holder, upon exercise, to surrender such Option with respect to the number of shares as to which such Stock Appreciation Right is exercised, in order to receive payment of any amount computed pursuant to Section 9(d). Such Option will, to the extent surrendered, then cease to be exercisable. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (c) Subject to Section 9(d)(i), and to such rules and restrictions as the Committee may impose, a Stock Appreciation Right granted in connection with an Option will be exercisable at such time or times, and only to the extent that a related Option is exercisable, and will not be transferable except to the extent that such related Option may be transferable. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (d) Subject to Section 9(f), the exercise of a Stock Appreciation Right related to an Option will entitle the holder to receive payment of an amount determined by multiplying&#58; </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;(i) the excess of the Fair Market Value of a share of Common Stock on the date of exercise of such Stock Appreciation Right over the exercise price of the related Option, by </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;(ii) the number of shares as to which such Stock Appreciation Right is exercised. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (e) The maximum number of shares underlying a Stock Appreciation Right granted without relationship to an Option shall be set forth in the applicable Award Agreement. A Stock Appreciation Right granted without relationship to an Option will entitle the holder to receive payment, subject to Section 9(f), of an amount determined by multiplying&#58; </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;(i) the excess of the Fair Market Value of a share of Common Stock on the date of exercise of such Stock Appreciation Right over the Fair Market Value of a share of Common Stock on the date the Stock Appreciation Right was granted or such greater amount as may be set forth in the applicable Agreement, by </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;(ii) the number of shares as to which such Stock Appreciation Right is exercised. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (f) Notwithstanding subsections (d) and (e) above, the Committee may place a limitation on the amount payable upon exercise of a Stock Appreciation Right. Any such limitation must be determined as of the date of grant and noted in the applicable Award Agreement. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (g) Payment of the amount determined under subsections (d) and (e) above may be made solely in whole shares of Common Stock valued at their Fair Market Value on the date of exercise of the Stock Appreciation Right or alternatively, in the sole discretion of the Committee, solely in cash or a combination of cash and shares of Common Stock. If the Committee decides that payment of the amount determined under subsections (d) and (e) above may be made shares of Common Stock, and the amount payable results in a fractional share, payment for the fractional share will be made in cash. The payment with respect to any Stock Appreciation Right shall be made in a manner that complies with the requirements of Section 409A of the Code. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (h) Other than with respect to an adjustment described in Section 4(b) or 4(c), in no event shall the exercise price with respect to a Stock Appreciation Right be reduced following the grant of such Stock Appreciation Right, nor shall the Stock Appreciation Right be cancelled in exchange for a replacement Stock Appreciation Right with a lower exercise price. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;-10-</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122942834_1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (i) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Effect of Termination of Board Service.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;(i) In the event that the Participant's Board service shall terminate on account of the Retirement of the Participant, each Stock Appreciation Right granted to such Participant that is outstanding as of the date of such termination shall become fully exercisable and shall remain exercisable for the three year period following such termination (or for such other period as may be provided by the Committee), but in no event following the expiration of its term. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;(ii) In the event that the Participant's Board service shall terminate on account of the death of the Participant, each Stock Appreciation Right granted to such Participant that is outstanding as of the date of death shall become fully exercisable and shall remain exercisable by the Participant's legal representatives, heirs or legatees for the one year period following the date of death (or for such other period as may be provided by the Committee), but in no event following the expiration of its term. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;(iii) In the event that the Participant's Board service shall terminate on account of the Disability of the Participant, each Stock Appreciation Right granted to such Participant that is outstanding as of the date of such termination shall become fully vested and shall remain exercisable by the Participant (or such Participant's legal representatives) for the one year period following such termination (or for such other period as may be provided by the Committee), but in no event following the expiration of its term. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;(iv) In the event of the termination of a Participant's Board service For Cause, each outstanding Stock Appreciation Right granted (including any portion of the Stock Appreciation Right that is then exercisable) to such Participant shall be cancelled at the commencement of business on the date of such termination.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v) In the event that the Participant's Board service shall terminate for any reason other than (A) Retirement, (B) death, (C) Disability or (D) For Cause, each Stock Appreciation Right granted to such Participant, to the extent that it is exercisable at the time of such termination, shall remain exercisable for the six month period following such termination (or for such other period as may be provided by the Committee), but in no event following the expiration of its term. Each Stock Appreciation Right that remains unexercisable as of the date of such a termination shall be cancelled at the time of such termination (except as may be otherwise determined by the Committee). </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;(vi) In the event of the Participant's death within six months following the Participant's termination of Board service other than For Cause, each Stock Appreciation Right granted to such Participant that is vested and outstanding as of the date of death shall remain exercisable by the Participant's legal representatives, heirs or legatees for the one year period following the date of death (or for such other period as may be provided by the Committee), but in no event following the expiration of its term. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 10.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Other Awards.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">General.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Other Awards valued in whole or in part by reference to, or otherwise based on, Common Stock may be granted either alone or in addition to other Awards under the Plan. Subject to the provisions of Section 6(b), the Committee shall have sole and complete authority to determine the number of shares of Common Stock to be granted pursuant to such Other Awards and all other terms and conditions of such Other Awards. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Payment of Non-Employee Directors' Fees in Securities.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  In addition to the Awards authorized under Section 6(b), and only to the extent permitted by the Committee, a Non-Employee Director may elect to receive his or her annual retainer payments and&#47;or meeting fees </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;-11-</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122942834_1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from the Company in the form of Awards under the Plan by completing the procedures prescribed by the Committee. Such Awards shall be issued under the Plan. The terms and the number of Awards to be granted to Non-Employee Directors in lieu of annual retainers and&#47;or meeting fees under this Section 10 shall be determined by the Committee. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 11.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Effect of a Corporate Transaction.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Options and Stock Appreciation Rights. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> In the event of a Corporate Transaction, the Committee shall, prior to the effective date of the Corporate Transaction, as to each outstanding Option and Stock Appreciation Right under the Plan, take one or more of the following actions&#58; (i) make appropriate provisions for the Options and Stock Appreciation Rights to be assumed by the successor corporation or its parent or be replaced with a comparable option or stock appreciation right to purchase shares of the capital stock of the successor corporation or its parent&#59; (ii) upon reasonable prior written notice to the Participants provide that all Options and Stock Appreciation Rights must be exercised prior to a specified date and, to the extent unexercised as of such specified date, such Options and Stock Appreciation Rights will terminate (all Options and Stock Appreciation Rights having been made fully exercisable as set forth below in this Section 11)&#59; or (iii) terminate all Options and Stock Appreciation Rights in exchange for, in the case of Options, a cash payment equal to the excess of the then aggregate Fair Market Value of the shares subject to such Options over the aggregate exercise prices thereof, or in the case of Stock Appreciation Rights, the amount otherwise payable on exercise of such Stock Appreciation Rights pursuant to Section 9 (all Options and Stock Appreciation Rights having been made fully exercisable as set forth below in this Section 11). Without limiting the generality of Sections 4(b) and 4(c) hereof, each outstanding Option and Stock Appreciation Right under the Plan which is assumed in connection with a Corporate Transaction, or is otherwise to continue in effect, shall be appropriately adjusted, immediately after such Corporate Transaction, to apply and pertain to the number and class of securities which would have been issued, in consummation of such Corporate Transaction, to an actual holder of the same number of shares of the Common Stock as are subject to such Option or Stock Appreciation Right immediately prior to such Corporate Transaction. Appropriate adjustments shall also be made to the option exercise price payable per share pursuant to the Option, provided the aggregate option exercise price payable for such securities pursuant to the Option shall remain the same, and the basis for calculating the amount payable on exercise of the Stock Appreciation Right pursuant to Section 9. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Awards other than Options and Stock Appreciation Rights.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  In the event of a Corporate Transaction, the Committee shall, prior to the effective date of the Corporate Transaction, as to each outstanding Award (other than an Option or Stock Appreciation Right) under the Plan take one or more of the following actions&#58; (i) make appropriate provisions for the Awards to be assumed by the successor corporation or its parent, or be replaced with a comparable award with respect to the successor corporation or its parent&#59; (ii) provide that such Awards shall be fully vested and settled prior to such Corporate Transaction&#59; or (iii) terminate all such Awards in exchange for a cash payment equal to the then aggregate Fair Market Value of the shares of Common Stock and cash payments subject to such Award (all Awards having been made fully vested as set forth below in this Section 11). </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (c) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Involuntary Termination.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If at any time within two years of the effective date of a Corporate Transaction there is an Involuntary Termination with respect to a Participant's continued service as a Non-Employee Director of the successor corporation or its parent, each then outstanding Award assumed or replaced under this Section 11 and held by such Participant (or a permitted transferee of such person) shall, upon the occurrence of such Involuntary Termination, automatically accelerate so that each such Award shall become fully vested or exercisable, as applicable, immediately prior to such Involuntary Termination. Upon the occurrence of an Involuntary Termination with respect to a Participant, any outstanding Option or Stock </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;-12-</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122942834_1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Appreciation Right held by such Participant (and a permitted transferee of such person) shall be exercisable within one year of the Involuntary Termination or, if earlier, within the originally prescribed term of the Option or Stock Appreciation Right. An &#8220;Involuntary Termination&#8221; as to a Participant shall mean the termination of the Participant's Board service other than (1) because of termination For Cause, (2) on account of the Participant's voluntary resignation or (3) on account of the Participant's choosing not to seek reelection&#59; provided, however, that for purposes of the Plan, a termination of Board service, at the request of the Board, where such termination is in connection with a reduction of the number of members of the Board (and not in connection with a replacement of the terminating member) shall be treated as an Involuntary Termination. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (d) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Other Adjustments.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The class and number of securities available for issuance under the Plan on both an aggregate and per Participant or per grant basis shall be appropriately adjusted by the Committee to reflect the effect of the Corporate Transaction upon the Company's capital structure. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (e) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Termination of Plan&#59; Cash Out of Awards.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  In the event the Company terminates the Plan or elects to cash out Awards in accordance with clauses (ii) or (iii) of paragraph (a) or clause (iii) of paragraph (b) of this Section 11, then the exercisability and vesting of each affected Award outstanding under the Plan shall be automatically accelerated so that each such Award shall, immediately prior to such Corporate Transaction, become fully vested and may be exercised prior to such Corporate Transaction for all or any portion of such Award. The Committee shall, in its discretion, determine the timing and mechanics required to implement the foregoing Plan provision. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (f) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Special Rule Regarding Determination of Termination for Cause.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Following the occurrence of a Corporate Transaction, the determination of whether circumstances warrant a termination For Cause shall be made in good faith by the Committee, provided that such determination shall not be presumed to be correct or given deference in any subsequent litigation, arbitration or other proceeding with respect to the existence of circumstances warranting a termination For Cause. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 12.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Acceleration Upon Corporate Change in Control.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Unless otherwise determined by the Committee at the time of grant and set forth in the applicable Award Agreement, in the event of a Corporate Change in Control, the exercisability or vesting of each Award outstanding under the Plan shall be automatically accelerated so that each such Award shall, immediately prior to such Corporate Change in Control, become fully vested and&#47;or exercisable for the full number of shares of the Common Stock purchasable or cash payable under an Award to the extent not previously exercised, and may be exercised for all or any portion of such shares or cash within the originally prescribed term of such Award and in the case of RSUs and other awards shall be immediately settled. The Committee shall, in its discretion, determine the timing and mechanics required to implement the foregoing Plan provision. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 13.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Rights as a Stockholder. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> No person shall have any rights as a stockholder with respect to any shares of Common Stock covered by or relating to any Award until the date of issuance of a Certificate with respect to such shares. Except as otherwise expressly provided in Section 4(b) or 4(c), no adjustment to any Award shall be made for dividends or other rights for which the record date occurs prior to the date of issuance of such Certificate. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 14.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">No Right to Continued Board Service&#59; No Right to Award.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;-13-</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122942834_1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Nothing contained in the Plan or any Agreement shall confer upon any Participant any right with respect to the continuation of service as a member of the Board or interfere in any way with the right of the Company or its stockholders to remove any individual from the Board at any time in accordance with the provisions of applicable law. No person shall have any claim or right to receive an Award hereunder. The Committee's granting of an Award to a Participant at any time shall neither require the Committee to grant any other Award to such Participant or other person at any time or preclude the Committee from making subsequent grants to such Participant or any other person. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 15.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Matters.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (a) Notwithstanding anything herein to the contrary, the Company shall not be obligated to cause to be issued or delivered any Certificates evidencing shares of Common Stock pursuant to the Plan unless and until the Company is advised by its counsel that the issuance and delivery of such Certificates is in compliance with all applicable laws, regulations of governmental authority and the requirements of any securities exchange on which shares of Common Stock are traded. The Committee may require, as a condition of the issuance and delivery of Certificates evidencing shares of Common Stock pursuant to the terms hereof, that the recipient of such shares make such agreements and representations, and that such Certificates bear such legends, as the Committee, in its sole discretion, deems necessary or desirable. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (b) The transfer of any shares of Common Stock hereunder shall be effective only at such time as counsel to the Company shall have determined that the issuance and delivery of such shares is in compliance with all applicable laws, regulations of governmental authority and the requirements of any securities exchange on which shares of Common Stock are traded. The Committee may, in its sole discretion, defer the effectiveness of any transfer of shares of Common Stock hereunder in order to allow the issuance of such shares to be made pursuant to registration or an exemption from registration or other methods for compliance available under federal or state securities laws. The Committee shall inform the Participant (or a permitted transferee of such person) in writing of its decision to defer the effectiveness of a transfer. During the period of such deferral in connection with the exercise of an Option, the Participant (or a permitted transferee of such person) may, by written notice, withdraw such exercise and obtain the refund of any amount paid with respect thereto, subject to compliance with the requirements of Section 409A of the Code. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 16.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Notification of Election Under Section 83(b) of the Code.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> If any Participant shall, in connection with the acquisition of shares of Common Stock under the Plan, make the election permitted under Section 83(b) of the Code, such Participant shall notify the Company of such election within 10 days of filing notice of the election with the Internal Revenue Service. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 17.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amendment or Termination of the Plan.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Board of Directors may, at any time, suspend or terminate the Plan or revise or amend it in any respect whatsoever&#59; provided, however, that stockholder approval shall be required for any such amendment if and to the extent the Board of Directors determines that such approval is appropriate or necessary for purposes of satisfying any applicable law or the requirements of any securities exchange upon which the securities of the Company trade. Nothing herein shall restrict the Committee's ability to exercise its discretionary authority pursuant to Section 3, which discretion may be exercised without amendment to the Plan. No amendment or termination of the Plan may, without the consent of the affected Participant, reduce the Participant's rights under any outstanding Award. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;-14-</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122942834_1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 18.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Transferability. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Committee may direct that any Certificate evidencing shares issued pursuant to the Plan shall bear a legend setting forth such restrictions on transferability as may apply to such shares. Awards granted under the Plan shall not be transferable by a Participant other than&#58; (i) by will or by the laws of descent and distribution, (ii) pursuant to a qualified domestic relations order, as defined by the Code or Title 1 of the Employee Retirement Income Security Act or the rules thereunder or (iii) as otherwise determined by the Committee in its sole and absolute discretion. The designation of a beneficiary of an Award by a Participant shall not be deemed a transfer prohibited by this Section 18. Except as provided pursuant to this Section 18, an Award shall be exercisable during a Participant's lifetime only by the Participant (or by his or her legal representative) and shall not be assigned, pledged, or hypothecated in any way (whether by operation of law or otherwise) and shall not be subject to execution, attachment or similar process. Any attempted transfer, assignment, pledge, hypothecation, or other disposition of any Award contrary to the provisions of this Section 18, or the levy of any attachment or similar process upon an Award, shall be null and void. Upon the death of a Participant, outstanding Awards granted to such Participant may be exercised only by the designated beneficiary, executor or administrator of the Participant's estate, or by a person who shall have acquired the right to such exercise by will or by the laws of descent and distribution (or by a permitted transferee of such person). No transfer of an Award by will or the laws of descent and distribution, or as otherwise permitted by this Section 18, shall be effective to bind the Company unless the Committee shall have been furnished with&#58; (a) written notice thereof and with such evidence as the Committee may deem necessary to establish the validity of the transfer, and (b) an agreement by the transferee to comply with all the terms and conditions of the Award that are or would have been applicable to the Participant and to be bound by the acknowledgments made by the Participant in connection with the grant of the Award. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 19.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Dissolution or Liquidation of the Company.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Immediately prior to the dissolution or liquidation of the Company, other than in connection with transactions to which Section 11 is applicable, all Awards granted hereunder shall terminate and become null and void&#59; provided, however, that if the rights hereunder of a Participant or one who acquired an Award by will or by the laws of descent and distribution, or as otherwise permitted pursuant to Section 18, have not otherwise terminated and expired, the Participant or such person shall have the right immediately prior to such termination to exercise any Award granted hereunder to the extent that the right to exercise such Award has vested as of the date immediately prior to such dissolution or liquidation. Awards of Restricted Stock and Restricted Stock Units that have not vested as of the date of such dissolution or liquidation shall be forfeited immediately prior to such dissolution or liquidation. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 20.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Effective Date and Term of Plan.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Plan shall be subject to the requisite approval of the stockholders of the Company. In the absence of such approval, any Awards shall be null and void. Unless the Plan is extended or earlier terminated by the Board of Directors, the right to grant Awards under the Plan shall terminate on the later of (i) the tenth anniversary of the Effective Date (i.e., May 25, 2016) and (ii) if the stockholders approve the amendment to the term of the Plan at the Company&#8217;s 2015 annual meeting of stockholders, June 10, 2025. Awards outstanding at Plan termination shall remain in effect according to their terms and the provisions of the Plan and the applicable Award Agreement. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 21.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Applicable Law.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;-15-</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122942834_1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Plan shall be construed and enforced in accordance with the laws of the State of Delaware, without reference to its principles of conflicts of law. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 22.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Participant Rights.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> No Participant shall have any claim to be granted any Award under the Plan, and there is no obligation for uniformity of treatment for Participants. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 23.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Unfunded Status of Awards. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Plan is intended to constitute an &#8220;unfunded&#8221; plan for incentive and deferred compensation purposes. With respect to any payments not yet made to a Participant pursuant to an Award, nothing contained in the Plan or any Agreement shall give any such Participant any rights that are greater than those of a general, unsecured creditor of the Company. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 24.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">No Fractional Shares. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> No fractional shares of Common Stock shall be issued or delivered pursuant to the Plan. The Committee shall determine whether cash, other Awards, or other property shall be issued or paid in lieu of such fractional shares, or whether such fractional shares or any rights thereto shall be forfeited or otherwise eliminated. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 25.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Beneficiary. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> A Participant may file with the Committee a written designation of a beneficiary on such form as may be prescribed by the Committee and may, from time to time, amend or revoke such designation. If no designated beneficiary survives the Participant, the executor or administrator of the Participant's estate shall be deemed to be the Participant's beneficiary. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 26.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Interpretation&#59; Limitation on Liability&#59; Special Rules.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">  Awards under the Plan are intended either to be exempt from the rules of Section 409A of the Code or to satisfy those rules, and shall be construed accordingly. Granted Awards may be modified at any time, in the Committee&#8217;s discretion, so as to increase the likelihood of exemption from or compliance with the rules of Section 409A.  In the event that a Participant is prohibited from executing market trades by reason of the application of the federal securities laws or for any other reason determined by the Committee, the Committee may extend the exercise period of an Award to the extent permitted by Section 409A. To the extent required by Section 409A of the Code, references to a termination of Board service shall be construed to require a &#8220;separation from service&#8221; under Section 409A of the Code.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b) Notwithstanding anything to the contrary in the Plan, neither the Company nor the Committee, nor any person acting on behalf of the Company or the Committee, will be liable to any Participant or to the estate or beneficiary of any Participant or to any other holder of a Stock Award by reason of any acceleration of income, or any additional tax (including any interest and penalties), by reason of the failure of an Award to satisfy the requirements of Section 409A or by reason of Section 4999 of the Code, or as otherwise asserted with respect to the Award.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)  Subject to Section 16 of the Exchange Act, to the extent the Committee deems it necessary, appropriate or desirable to comply with foreign law or practices, and to further the purpose of the Plan, the Committee may, without amending the Plan, establish special rules applicable to Awards granted to Participants who are foreign nationals or are employed outside the United States, or both, including rules that differ from those set forth in the Plan, and grant Awards (or amend existing Awards) in accordance with those rules. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;-16-</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122942834_1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 27.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Severability. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> If any provision of the Plan is held to be invalid or unenforceable, the other provisions of the Plan shall not be affected but shall be applied as if the invalid or unenforceable provision had not been included in the Plan. </font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;-17-</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122942834_1</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>biib-2022331xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="id232e9db5fb942beb32faf635d2222bc_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michel Vounatsos, certify that&#58;</font></div><div style="margin-top:9pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">I have reviewed this quarterly report of Biogen Inc.&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#8211;15(f) and 15d&#8211;15(f)) for the registrant and have&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.23pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 3, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michel Vounatsos</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michel Vounatsos</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>biib-2022331xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="if6a82e1341a34a808aa4c19904c40158_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michael R. McDonnell, certify that&#58;</font></div><div style="margin-top:9pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">I have reviewed this quarterly report of Biogen Inc.&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#8211;15(f) and 15d&#8211;15(f)) for the registrant and have&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.23pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 3, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michael R. McDonnell</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael R. McDonnell</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>biib-2022331xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i0731e39008b84ee29640b1e647e4b6fb_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a)&#160;and (b)&#160;of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Biogen Inc., a Delaware corporation (the &#8220;Company&#8221;), does hereby certify, to such officer&#8217;s knowledge, that&#58;</font></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 (the &#8220;Form 10-Q&#8221;) of the Company fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:9pt;text-indent:24.75pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 3, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michel Vounatsos</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michel Vounatsos</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;principal executive officer&#93;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 3, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;Michael R. McDonnell</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael R. McDonnell</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;principal financial officer&#93;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>biib-20220331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:c574431f-8208-4dea-bcfe-8d8f5f068522,g:425f524b-de43-4dfe-85cc-ae50a1579d49-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:biib="http://www.biogenidec.com/20220331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.biogenidec.com/20220331">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.biogenidec.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofIncomeUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited">
        <link:definition>1001002 - Statement - Condensed Consolidated Statements of Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited">
        <link:definition>1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1">
        <link:definition>1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>1003004 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>1004005 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementofEquityStatement" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement">
        <link:definition>1006007 - Statement - Condensed Consolidated Statement of Equity Statement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>2403401 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringBusinessTransformationandOtherCostSavingInitiatives" roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiatives">
        <link:definition>2104102 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringBusinessTransformationandOtherCostSavingInitiativesTables" roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables">
        <link:definition>2305301 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails" roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails">
        <link:definition>2406402 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails" roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails">
        <link:definition>2407403 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Restructuring Reserve Roll Forward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.biogenidec.com/role/Revenues">
        <link:definition>2108103 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.biogenidec.com/role/RevenuesTables">
        <link:definition>2309302 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesbyproductDetails" roleURI="http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails">
        <link:definition>2410404 - Disclosure - Revenues - Revenues by product (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesReservesforDiscountsandAllowancesDetails1" roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1">
        <link:definition>2411405 - Disclosure - Revenues Reserves for Discounts and Allowances (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesReservesforDiscountsandAllowancesDetails2" roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2">
        <link:definition>2412406 - Disclosure - Revenues- Reserves for Discounts and Allowances (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" roleURI="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails">
        <link:definition>2413407 - Disclosure - Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesOtherRevenuesDetails" roleURI="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails">
        <link:definition>2414408 - Disclosure - Revenues - Other Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesNarrativeDetails" roleURI="http://www.biogenidec.com/role/RevenuesNarrativeDetails">
        <link:definition>2415409 - Disclosure - Revenues - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.biogenidec.com/role/Inventory">
        <link:definition>2116104 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.biogenidec.com/role/InventoryTables">
        <link:definition>2317303 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryComponentsofInventoryDetails" roleURI="http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails">
        <link:definition>2418410 - Disclosure - Inventory - Components of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryNarrativeDetails" roleURI="http://www.biogenidec.com/role/InventoryNarrativeDetails">
        <link:definition>2419411 - Disclosure - Inventory - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwill" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwill">
        <link:definition>2120105 - Disclosure - Intangible Assets and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillTables" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables">
        <link:definition>2321304 - Disclosure - Intangible Assets and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillDetails" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails">
        <link:definition>2422412 - Disclosure - Intangible Assets and Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillDetails1" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1">
        <link:definition>2423413 - Disclosure - Intangible Assets and Goodwill (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.biogenidec.com/role/FairValueMeasurements">
        <link:definition>2124106 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables">
        <link:definition>2325305 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails">
        <link:definition>2426414 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetailsTextual" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual">
        <link:definition>2427415 - Disclosure - Fair Value Measurements (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails">
        <link:definition>2428416 - Disclosure - Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNonrecurringAssetsDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsNonrecurringAssetsDetails">
        <link:definition>2429417 - Disclosure - Fair Value Measurements - Nonrecurring Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails1" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1">
        <link:definition>2430418 - Disclosure - Fair Value Measurements (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails2" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2">
        <link:definition>2431419 - Disclosure - Fair Value Measurements (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.biogenidec.com/role/FinancialInstruments">
        <link:definition>2132107 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables">
        <link:definition>2333306 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails">
        <link:definition>2434420 - Disclosure - Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails1" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1">
        <link:definition>2435421 - Disclosure - Financial Instruments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails2" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2">
        <link:definition>2436422 - Disclosure - Financial Instruments (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails3" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3">
        <link:definition>2437423 - Disclosure - Financial Instruments (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetailsTextual" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual">
        <link:definition>2438424 - Disclosure - Financial Instruments (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFinancialInstrumentsDetailsTextual2" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2">
        <link:definition>2439425 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstruments" roleURI="http://www.biogenidec.com/role/DerivativeInstruments">
        <link:definition>2140108 - Disclosure - Derivative Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsTables" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables">
        <link:definition>2341307 - Disclosure - Derivative Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsDetails" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails">
        <link:definition>2442426 - Disclosure - Derivative Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipment" roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipment">
        <link:definition>2143109 - Disclosure - Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentDetails" roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails">
        <link:definition>2444427 - Disclosure - Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Indebtedness" roleURI="http://www.biogenidec.com/role/Indebtedness">
        <link:definition>2145110 - Disclosure - Indebtedness</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndebtednessDetails" roleURI="http://www.biogenidec.com/role/IndebtednessDetails">
        <link:definition>2446428 - Disclosure - Indebtedness (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.biogenidec.com/role/Equity">
        <link:definition>2147111 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossTables" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables">
        <link:definition>2348308 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareRepurchasesDetails" roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails">
        <link:definition>2449429 - Disclosure - Share Repurchases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>2450430 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>2451431 - Disclosure - Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShare" roleURI="http://www.biogenidec.com/role/EarningsperShare">
        <link:definition>2152112 - Disclosure - Earnings per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShareTables" roleURI="http://www.biogenidec.com/role/EarningsperShareTables">
        <link:definition>2353309 - Disclosure - Earnings per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShareDetails" roleURI="http://www.biogenidec.com/role/EarningsperShareDetails">
        <link:definition>2454432 - Disclosure - Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedPayments" roleURI="http://www.biogenidec.com/role/SharebasedPayments">
        <link:definition>2155113 - Disclosure - Share-based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsTables" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables">
        <link:definition>2356310 - Disclosure - Share-Based Payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails">
        <link:definition>2457433 - Disclosure - Share-Based Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails1" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1">
        <link:definition>2458434 - Disclosure - Share-Based Payments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.biogenidec.com/role/IncomeTaxes">
        <link:definition>2159114 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.biogenidec.com/role/IncomeTaxesTables">
        <link:definition>2360311 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetailsTextual" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual">
        <link:definition>2461435 - Disclosure - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails">
        <link:definition>2462436 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetail" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail">
        <link:definition>2163115 - Disclosure - Other Consolidated Financial Statement Detail</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailTables" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables">
        <link:definition>2364312 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailDetails" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails">
        <link:definition>2465437 - Disclosure - Other Consolidated Financial Statement Detail (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailsTextual" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual">
        <link:definition>2466438 - Disclosure - Other Consolidated Financial Statement (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationships" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationships">
        <link:definition>2167116 - Disclosure - Collaborative and Other Relationships</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsTables" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables">
        <link:definition>2368313 - Disclosure - Collaborative and Other Relationships (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsCollaborationsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails">
        <link:definition>2469439 - Disclosure - Collaborative and Other Relationships - Collaborations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails">
        <link:definition>2470440 - Disclosure - Collaborative and Other Relationships - Equity Method Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinVariableInterestEntities" roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities">
        <link:definition>2171117 - Disclosure - Investments in Variable Interest Entities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinVariableInterestEntitiesDetails" roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails">
        <link:definition>2472441 - Disclosure - Investments in Variable Interest Entities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Litigation" roleURI="http://www.biogenidec.com/role/Litigation">
        <link:definition>2173118 - Disclosure - Litigation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LitigationDetails" roleURI="http://www.biogenidec.com/role/LitigationDetails">
        <link:definition>2474442 - Disclosure - Litigation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.biogenidec.com/role/SubsequentEvents">
        <link:definition>2175119 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="biib_RegulatoryMilestonesMember" abstract="true" name="RegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_NumberOfWholesalers" abstract="false" name="NumberOfWholesalers" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="biib_DistributorTwoMember" abstract="true" name="DistributorTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_FutureContingentMilestoneTypesAxis" abstract="true" name="FutureContingentMilestoneTypesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" abstract="false" name="AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" abstract="false" name="AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_StrategicInvestmentsMember" abstract="true" name="StrategicInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_AdditionalMilestonePayment" abstract="false" name="AdditionalMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_RocheGroupGenentechMember" abstract="true" name="RocheGroupGenentechMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" abstract="false" name="EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" abstract="false" name="EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_Collaborationexpensesaccrual" abstract="false" name="Collaborationexpensesaccrual" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_EquitySecuritiesNonCurrentMember" abstract="true" name="EquitySecuritiesNonCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_FacilityLocationDomain" abstract="true" name="FacilityLocationDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_PlanAssetsForDeferredCompensationFairValueDisclosure" abstract="false" name="PlanAssetsForDeferredCompensationFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ExpenseIncurredByCollaboration" abstract="false" name="ExpenseIncurredByCollaboration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ResearchanddevelopmentassetDomain" abstract="true" name="ResearchanddevelopmentassetDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_UnrealizedLossOnDerivatives" abstract="false" name="UnrealizedLossOnDerivatives" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_InterferonMember" abstract="true" name="InterferonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" abstract="false" name="AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ZINBRYTAMember" abstract="true" name="ZINBRYTAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_MSProductRevenuesMember" abstract="true" name="MSProductRevenuesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_GovernmentSecuritiesCurrentMember" abstract="true" name="GovernmentSecuritiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" abstract="false" name="IncomeLossFromEquityMethodInvestmentsNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" abstract="false" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_A2.25SeniorNotesdueMay12030Member" abstract="true" name="A2.25SeniorNotesdueMay12030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" abstract="true" name="MortgageAndOtherAssetBackedSecuritiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_OtherrevenuesfromantiCD20therapeuticprograms" abstract="false" name="OtherrevenuesfromantiCD20therapeuticprograms" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_SageTherapeuticsIncMember" abstract="true" name="SageTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_BusinessOverviewPolicyTextBlock" abstract="false" name="BusinessOverviewPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" abstract="false" name="CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_InventoryNetCurrentAndNoncurrent" abstract="false" name="InventoryNetCurrentAndNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_OtherresearchanddiscoveryMember" abstract="true" name="OtherresearchanddiscoveryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_WarehouseUtilitiesAndSupportSpaceMember" abstract="true" name="WarehouseUtilitiesAndSupportSpaceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" abstract="false" name="UpfrontAndMilestonePaymentsMadeToCollaborativePartner" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_TechnologicalAndRegulatorySuccessProbability" abstract="false" name="TechnologicalAndRegulatorySuccessProbability" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" abstract="false" name="SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" abstract="true" name="SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_ContractOptionExerciseFee" abstract="false" name="ContractOptionExerciseFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_SPINRAZAMember" abstract="true" name="SPINRAZAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_ResearchanddevelopmentassetAxis" abstract="true" name="ResearchanddevelopmentassetAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_LongTermDebtExchangedAmount" abstract="false" name="LongTermDebtExchangedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_Revenuesfromanticd20therapeuticprogramsMember" abstract="true" name="Revenuesfromanticd20therapeuticprogramsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_CollaborationAgreementTerm" abstract="false" name="CollaborationAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_EquityMethodInvestmentsExpectedProfitShare" abstract="false" name="EquityMethodInvestmentsExpectedProfitShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" abstract="false" name="SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="biib_InterestInSubsidiary" abstract="false" name="InterestInSubsidiary" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_A3.15SeniorNotesdueMay12050Member" abstract="true" name="A3.15SeniorNotesdueMay12050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_EffectiveTaxRateReconciliationGILTItax" abstract="false" name="EffectiveTaxRateReconciliationGILTItax" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_CorporateDebtSecuritiesNonCurrentMember" abstract="true" name="CorporateDebtSecuritiesNonCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_PaymentDueAtFirstAnniversaryMember" abstract="true" name="PaymentDueAtFirstAnniversaryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_A3250SeniorNotesDueFebruary152051Member" abstract="true" name="A3250SeniorNotesDueFebruary152051Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" abstract="false" name="EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_PayablesToDivestitureOfInterestInJointVenture" abstract="false" name="PayablesToDivestitureOfInterestInJointVenture" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_InnoCarePharmaLimitedInnoCareAgreementMember" abstract="true" name="InnoCarePharmaLimitedInnoCareAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_StrategicInvestmentPortfolio" abstract="false" name="StrategicInvestmentPortfolio" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_CentersForMedicareAndMedicaidServiceMember" abstract="true" name="CentersForMedicareAndMedicaidServiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_IonisSangamoDenaliAndSageMember" abstract="true" name="IonisSangamoDenaliAndSageMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" abstract="false" name="EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="biib_SangamoTherapeuticsInc.AgreementMember" abstract="true" name="SangamoTherapeuticsInc.AgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" abstract="false" name="PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_EquitySecuritiesCurrentMember" abstract="true" name="EquitySecuritiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_ReserveforCashDiscountsMember" abstract="true" name="ReserveforCashDiscountsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_PerformanceStockUnitsSettledinStockMember" abstract="true" name="PerformanceStockUnitsSettledinStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_OutLicensedPatentsMember" abstract="true" name="OutLicensedPatentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_FumarateMember" abstract="true" name="FumarateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_FutureContingentMilestoneTypesDomain" abstract="true" name="FutureContingentMilestoneTypesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" abstract="true" name="ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_CashflowsoperatingexpensesMember" abstract="true" name="CashflowsoperatingexpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_Expensereflectedwithinstatementsofincome" abstract="false" name="Expensereflectedwithinstatementsofincome" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_UCBPharmaS.A.Member" abstract="true" name="UCBPharmaS.A.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_BasicAndDilutedEarningsPerShareAbstract" abstract="true" name="BasicAndDilutedEarningsPerShareAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_EntityWidePercentageOfRevenueFromMajorDistributors" abstract="false" name="EntityWidePercentageOfRevenueFromMajorDistributors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_InvestmentsInVariableInterestEntitiesAbstract" abstract="true" name="InvestmentsInVariableInterestEntitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_CostOfGoodsSoldCapacityCharges" abstract="false" name="CostOfGoodsSoldCapacityCharges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ContingentMilestonePaymentsMadeToCollaborativePartner" abstract="false" name="ContingentMilestonePaymentsMadeToCollaborativePartner" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_PerformanceStockUnitsSettledinCashMember" abstract="true" name="PerformanceStockUnitsSettledinCashMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_OtherrevenuesAbstract" abstract="true" name="OtherrevenuesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_FacilityTypeDomain" abstract="true" name="FacilityTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" abstract="true" name="SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" abstract="false" name="EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_IntangibleAssetsExcludingGoodwillTableTextBlock" abstract="false" name="IntangibleAssetsExcludingGoodwillTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="biib_Expenseincurredbythecollaboration" abstract="false" name="Expenseincurredbythecollaboration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" abstract="false" name="AmortizationAndImpairmentOfAcquiredIntangibleAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_GovernmentSecuritiesNonCurrentMember" abstract="true" name="GovernmentSecuritiesNonCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_ShareOfCoPromotionProfits" abstract="false" name="ShareOfCoPromotionProfits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_DebtInstrumentRedemptionAmount" abstract="false" name="DebtInstrumentRedemptionAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" abstract="false" name="UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_TGNMember" abstract="true" name="TGNMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" abstract="true" name="SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_ResearchAndDevelopmentCostsPercentage" abstract="false" name="ResearchAndDevelopmentCostsPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_BENEPALIMember" abstract="true" name="BENEPALIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_VixotrigineMember" abstract="true" name="VixotrigineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_MarketStockUnitsMember" abstract="true" name="MarketStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_TimeVestedRestrictedStockUnitsMember" abstract="true" name="TimeVestedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_NumberOfSquareFeet" abstract="false" name="NumberOfSquareFeet" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="biib_ContractualAdjustmentsMember" abstract="true" name="ContractualAdjustmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_WorkforceReductionMember" abstract="true" name="WorkforceReductionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" abstract="false" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_A2020ShareRepurchaseProgramMember" abstract="true" name="A2020ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_NeurimmuneMember" abstract="true" name="NeurimmuneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_DuefromantiCD20therapeuticprograms" abstract="false" name="DuefromantiCD20therapeuticprograms" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_SamsungBiosimilarAgreementMember" abstract="true" name="SamsungBiosimilarAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_CashflowsrevenueMember" abstract="true" name="CashflowsrevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_BiologicsManufacturingMember" abstract="true" name="BiologicsManufacturingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_DenaliTherapeuticsIncMember" abstract="true" name="DenaliTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_FAMPYRAMember" abstract="true" name="FAMPYRAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" abstract="false" name="SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="biib_OtherrevenuesTableTextBlock" abstract="false" name="OtherrevenuesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="biib_FacilityTypeAxis" abstract="true" name="FacilityTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_Collaborationprofitlosssharing" abstract="false" name="Collaborationprofitlosssharing" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ADUHELMMember" abstract="true" name="ADUHELMMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_NoncontrollingInterestIncreaseDecreaseOther" abstract="false" name="NoncontrollingInterestIncreaseDecreaseOther" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_OthercorporaterevenuesMember" abstract="true" name="OthercorporaterevenuesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" abstract="false" name="ShareBasedCompensationExpenseIncludedInCostsAndExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" abstract="false" name="AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" abstract="false" name="SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="biib_EisaiMember" abstract="true" name="EisaiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_IMRALDIMember" abstract="true" name="IMRALDIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" abstract="true" name="MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_FacilityLocationAxis" abstract="true" name="FacilityLocationAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_DerivativeMaturityAxis" abstract="true" name="DerivativeMaturityAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_TysabriProductMember" abstract="true" name="TysabriProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_DistributorOneMember" abstract="true" name="DistributorOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_Termofcollaborationagreement" abstract="false" name="Termofcollaborationagreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" abstract="false" name="PercentageoffuturedevelopmentcostsrelatedtoEisai" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" abstract="false" name="Equitymethodinvestmentbasisdifferenceamortizationperiod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" abstract="false" name="InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock" abstract="false" name="DerivativeInstrumentsUnrealizedGainLossTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" abstract="true" name="SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_CorporateDebtSecuritiesCurrentMember" abstract="true" name="CorporateDebtSecuritiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_FUMADERMMember" abstract="true" name="FUMADERMMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" abstract="false" name="RevenuesfromantiCD20therapeuticprogramsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="biib_SolothurnSwitzerlandMember" abstract="true" name="SolothurnSwitzerlandMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_DerivativeMaturityDomain" abstract="true" name="DerivativeMaturityDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_AccruedMilestonePayments" abstract="false" name="AccruedMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_FLIXABIMember" abstract="true" name="FLIXABIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_PaymentDueAtSecondAnniversaryMember" abstract="true" name="PaymentDueAtSecondAnniversaryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_UnrealizedGainOnDerivatives" abstract="false" name="UnrealizedGainOnDerivatives" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_E2609andBAN2401Member" abstract="true" name="E2609andBAN2401Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_BiosimilarsMember" abstract="true" name="BiosimilarsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" abstract="false" name="Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ShorttermderivativeMember" abstract="true" name="ShorttermderivativeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_AverageMaturityOfMarketableSecurities" abstract="false" name="AverageMaturityOfMarketableSecurities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_AdministrativeSpaceMember" abstract="true" name="AdministrativeSpaceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_Inventorynetcurrentandnoncurrent" abstract="false" name="Inventorynetcurrentandnoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>biib-20220331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:c574431f-8208-4dea-bcfe-8d8f5f068522,g:425f524b-de43-4dfe-85cc-ae50a1579d49-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="simple" xlink:href="biib-20220331.xsd#CondensedConsolidatedStatementsofIncomeUnaudited"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_134cfdce-b079-4273-97f5-4f4eefd97f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_dcd4ad27-c420-422e-b9ea-b64041356c64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_134cfdce-b079-4273-97f5-4f4eefd97f3e" xlink:to="loc_us-gaap_Revenues_dcd4ad27-c420-422e-b9ea-b64041356c64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_d1bab457-2d35-45cc-ae4b-2e11b2cba795" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_134cfdce-b079-4273-97f5-4f4eefd97f3e" xlink:to="loc_us-gaap_CostsAndExpenses_d1bab457-2d35-45cc-ae4b-2e11b2cba795" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9a796acd-5b68-41a9-b46a-e6ad962551da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_afba06a4-5f61-45b9-ad50-274ad1272cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_9a796acd-5b68-41a9-b46a-e6ad962551da" xlink:to="loc_us-gaap_ProfitLoss_afba06a4-5f61-45b9-ad50-274ad1272cd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0114aea0-803b-4b06-9f27-23f0bc0c47ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_9a796acd-5b68-41a9-b46a-e6ad962551da" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0114aea0-803b-4b06-9f27-23f0bc0c47ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_6a29cda9-10e6-4633-bc44-902d3b6dc3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_48b95a31-a95f-4621-8b3f-f1a252f16472" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_6a29cda9-10e6-4633-bc44-902d3b6dc3bc" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_48b95a31-a95f-4621-8b3f-f1a252f16472" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_c7315428-9c2e-4f0c-8360-86599415a125" xlink:href="biib-20220331.xsd#biib_Collaborationprofitlosssharing"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_6a29cda9-10e6-4633-bc44-902d3b6dc3bc" xlink:to="loc_biib_Collaborationprofitlosssharing_c7315428-9c2e-4f0c-8360-86599415a125" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_9882c2d0-dec2-423f-8d64-98c8034eb822" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_6a29cda9-10e6-4633-bc44-902d3b6dc3bc" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_9882c2d0-dec2-423f-8d64-98c8034eb822" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_abe63313-5efc-400c-9b7f-dc41c37ddad8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_6a29cda9-10e6-4633-bc44-902d3b6dc3bc" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_abe63313-5efc-400c-9b7f-dc41c37ddad8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_a1e3f8bd-6264-475d-a9a1-91ee361c16ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_6a29cda9-10e6-4633-bc44-902d3b6dc3bc" xlink:to="loc_us-gaap_RestructuringCharges_a1e3f8bd-6264-475d-a9a1-91ee361c16ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_3ba97fcf-99f3-4125-982d-ffe1ea696009" xlink:href="biib-20220331.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_6a29cda9-10e6-4633-bc44-902d3b6dc3bc" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_3ba97fcf-99f3-4125-982d-ffe1ea696009" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_732ad4ba-c6f1-4e99-9773-e1b14fc854d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_6a29cda9-10e6-4633-bc44-902d3b6dc3bc" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_732ad4ba-c6f1-4e99-9773-e1b14fc854d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_68c871ff-0ac9-424e-8fc7-b9b93e55223a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b3eb331e-f10c-4a2e-9b60-76ce03dcd261" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_68c871ff-0ac9-424e-8fc7-b9b93e55223a" xlink:to="loc_us-gaap_OperatingIncomeLoss_b3eb331e-f10c-4a2e-9b60-76ce03dcd261" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_f8e96c0a-2e64-4854-8fc7-771055e29302" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_68c871ff-0ac9-424e-8fc7-b9b93e55223a" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_f8e96c0a-2e64-4854-8fc7-771055e29302" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4e920504-d1af-491c-85ab-83acf75e0035" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_543b01cd-fd3d-4e1a-8881-42fc494ac824" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_4e920504-d1af-491c-85ab-83acf75e0035" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_543b01cd-fd3d-4e1a-8881-42fc494ac824" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_befc34fb-8a81-4500-8277-d6245d64f864" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_4e920504-d1af-491c-85ab-83acf75e0035" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_befc34fb-8a81-4500-8277-d6245d64f864" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_c2258480-7b3c-4aa7-a01c-046133dcafc6" xlink:href="biib-20220331.xsd#biib_IncomeLossFromEquityMethodInvestmentsNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_4e920504-d1af-491c-85ab-83acf75e0035" xlink:to="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_c2258480-7b3c-4aa7-a01c-046133dcafc6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="simple" xlink:href="biib-20220331.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_95ab1b67-e38c-429d-b79b-0b78957a35ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_caf6972c-e5e8-4d81-a427-3790a59ad4d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_95ab1b67-e38c-429d-b79b-0b78957a35ab" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_caf6972c-e5e8-4d81-a427-3790a59ad4d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_408f3820-d4b9-4893-b7b3-1393a7ee93cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_95ab1b67-e38c-429d-b79b-0b78957a35ab" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_408f3820-d4b9-4893-b7b3-1393a7ee93cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_d52887b5-2844-4eef-9b8e-9f9cc470b971" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_95ab1b67-e38c-429d-b79b-0b78957a35ab" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_d52887b5-2844-4eef-9b8e-9f9cc470b971" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_762c7cca-e458-4e56-b924-4853a5206cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_95ab1b67-e38c-429d-b79b-0b78957a35ab" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_762c7cca-e458-4e56-b924-4853a5206cb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_4ec89b3c-5294-4e91-85ad-1ddc4375a97c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_95ab1b67-e38c-429d-b79b-0b78957a35ab" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_4ec89b3c-5294-4e91-85ad-1ddc4375a97c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_e32e2eab-7230-4c99-b662-8e2532229e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_780d05ce-c57a-411c-9904-ebf569705f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_e32e2eab-7230-4c99-b662-8e2532229e9c" xlink:to="loc_us-gaap_NetIncomeLoss_780d05ce-c57a-411c-9904-ebf569705f8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6a4657d0-0f8e-4ab9-b131-223c5f999ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_e32e2eab-7230-4c99-b662-8e2532229e9c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6a4657d0-0f8e-4ab9-b131-223c5f999ed7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" xlink:type="simple" xlink:href="biib-20220331.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_437cb301-6d5d-47f4-af71-e95e71fd6db5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_6022e1c2-8a31-424a-a217-f64abb05efdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_437cb301-6d5d-47f4-af71-e95e71fd6db5" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_6022e1c2-8a31-424a-a217-f64abb05efdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_b1b69d00-9ea5-43a2-a148-04580809f30b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_437cb301-6d5d-47f4-af71-e95e71fd6db5" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_b1b69d00-9ea5-43a2-a148-04580809f30b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="biib-20220331.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f7dab30c-5375-46d5-8764-c62268930c49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c5e7a3be-6cbd-4a98-b037-207ada21a510" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f7dab30c-5375-46d5-8764-c62268930c49" xlink:to="loc_us-gaap_AssetsCurrent_c5e7a3be-6cbd-4a98-b037-207ada21a510" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_bda58a81-3c9c-44e4-974e-ada287b6f48e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f7dab30c-5375-46d5-8764-c62268930c49" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_bda58a81-3c9c-44e4-974e-ada287b6f48e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_74dcaf46-2520-49ad-a409-e62e874510ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f7dab30c-5375-46d5-8764-c62268930c49" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_74dcaf46-2520-49ad-a409-e62e874510ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_a60220b3-711d-4904-98ca-9b0c9a157a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f7dab30c-5375-46d5-8764-c62268930c49" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_a60220b3-711d-4904-98ca-9b0c9a157a4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_effab5c6-8ddb-48d5-ae26-68710203a859" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f7dab30c-5375-46d5-8764-c62268930c49" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_effab5c6-8ddb-48d5-ae26-68710203a859" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b31155a4-f4d9-4f0a-b262-45d5cfc5edd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f7dab30c-5375-46d5-8764-c62268930c49" xlink:to="loc_us-gaap_Goodwill_b31155a4-f4d9-4f0a-b262-45d5cfc5edd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_a0cfb94e-8409-47c6-977e-ac01adb9be00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f7dab30c-5375-46d5-8764-c62268930c49" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_a0cfb94e-8409-47c6-977e-ac01adb9be00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_a5b7695c-bda8-4579-bc21-34d976b6c8fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f7dab30c-5375-46d5-8764-c62268930c49" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_a5b7695c-bda8-4579-bc21-34d976b6c8fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f132e07b-2639-4509-8f36-a4e255cb004a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_bf1db888-b94c-42e0-8645-d298e141f2e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f132e07b-2639-4509-8f36-a4e255cb004a" xlink:to="loc_us-gaap_AccountsPayableCurrent_bf1db888-b94c-42e0-8645-d298e141f2e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_51842de8-6b48-47c0-afff-b8be3d5b9bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f132e07b-2639-4509-8f36-a4e255cb004a" xlink:to="loc_us-gaap_TaxesPayableCurrent_51842de8-6b48-47c0-afff-b8be3d5b9bf4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_2fdd6321-2fcd-495b-96a2-1336e53e1545" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f132e07b-2639-4509-8f36-a4e255cb004a" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_2fdd6321-2fcd-495b-96a2-1336e53e1545" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_f9eded95-0183-479e-aeef-35b2afb9a8cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f132e07b-2639-4509-8f36-a4e255cb004a" xlink:to="loc_us-gaap_NotesPayableCurrent_f9eded95-0183-479e-aeef-35b2afb9a8cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_1f48ef0f-9488-49d0-aceb-c5895b6a83fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5930f37f-2634-48fd-8c4c-70d6c4c937fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1f48ef0f-9488-49d0-aceb-c5895b6a83fc" xlink:to="loc_us-gaap_LiabilitiesCurrent_5930f37f-2634-48fd-8c4c-70d6c4c937fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_29dfb06c-61ea-4e62-9b8c-39da40f7a547" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1f48ef0f-9488-49d0-aceb-c5895b6a83fc" xlink:to="loc_us-gaap_LongTermDebt_29dfb06c-61ea-4e62-9b8c-39da40f7a547" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_1edd36e1-e595-49fa-9d89-40f629e362b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1f48ef0f-9488-49d0-aceb-c5895b6a83fc" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_1edd36e1-e595-49fa-9d89-40f629e362b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_16efc92b-494c-46d8-bf0a-47f313cdfa12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1f48ef0f-9488-49d0-aceb-c5895b6a83fc" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_16efc92b-494c-46d8-bf0a-47f313cdfa12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_a1735ad7-9cb3-40f0-a6bf-8476ea4b44e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1f48ef0f-9488-49d0-aceb-c5895b6a83fc" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_a1735ad7-9cb3-40f0-a6bf-8476ea4b44e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5d3a1e9c-385e-42f4-acf5-0ee6dd14c410" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_96f78e97-abf0-4334-89e7-7f37916f4173" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5d3a1e9c-385e-42f4-acf5-0ee6dd14c410" xlink:to="loc_us-gaap_StockholdersEquity_96f78e97-abf0-4334-89e7-7f37916f4173" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_57d96654-bcfd-408f-91a2-3af44237b3cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5d3a1e9c-385e-42f4-acf5-0ee6dd14c410" xlink:to="loc_us-gaap_MinorityInterest_57d96654-bcfd-408f-91a2-3af44237b3cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_99e29e3d-0e8c-4b6d-82f1-2b4a77d199e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_2c765389-c92d-4373-a3ae-120d606e5644" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_99e29e3d-0e8c-4b6d-82f1-2b4a77d199e8" xlink:to="loc_us-gaap_PreferredStockValue_2c765389-c92d-4373-a3ae-120d606e5644" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_32ed3e64-1e43-4367-9658-36fd9cb7b74e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_99e29e3d-0e8c-4b6d-82f1-2b4a77d199e8" xlink:to="loc_us-gaap_CommonStockValue_32ed3e64-1e43-4367-9658-36fd9cb7b74e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_3726ada0-4abe-44c3-9ff6-b790c948aa62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_99e29e3d-0e8c-4b6d-82f1-2b4a77d199e8" xlink:to="loc_us-gaap_AdditionalPaidInCapital_3726ada0-4abe-44c3-9ff6-b790c948aa62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8ecf0eb2-ffcd-4134-9517-e869b67a8f88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_99e29e3d-0e8c-4b6d-82f1-2b4a77d199e8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8ecf0eb2-ffcd-4134-9517-e869b67a8f88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2b7dacf0-f871-4a17-b847-fc4c5289e059" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_99e29e3d-0e8c-4b6d-82f1-2b4a77d199e8" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2b7dacf0-f871-4a17-b847-fc4c5289e059" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_efd9d4e1-9cc6-4e0b-90c7-4455d44aa1fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_99e29e3d-0e8c-4b6d-82f1-2b4a77d199e8" xlink:to="loc_us-gaap_TreasuryStockValue_efd9d4e1-9cc6-4e0b-90c7-4455d44aa1fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_dab44170-2f34-4591-9246-558f23f83037" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_eeac416f-0d54-4eac-aeac-fd14ed6272f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dab44170-2f34-4591-9246-558f23f83037" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_eeac416f-0d54-4eac-aeac-fd14ed6272f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e0988ccf-24e6-4900-bfbb-5ed996c98c15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dab44170-2f34-4591-9246-558f23f83037" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e0988ccf-24e6-4900-bfbb-5ed996c98c15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_2d108f53-6856-4f58-b0dc-fe46736cc630" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dab44170-2f34-4591-9246-558f23f83037" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_2d108f53-6856-4f58-b0dc-fe46736cc630" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DuefromantiCD20therapeuticprograms_e785f739-d7e9-4051-b385-8dd2e7f0c612" xlink:href="biib-20220331.xsd#biib_DuefromantiCD20therapeuticprograms"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dab44170-2f34-4591-9246-558f23f83037" xlink:to="loc_biib_DuefromantiCD20therapeuticprograms_e785f739-d7e9-4051-b385-8dd2e7f0c612" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_4b6a5a11-cbed-45e6-a10d-df8835586a43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dab44170-2f34-4591-9246-558f23f83037" xlink:to="loc_us-gaap_InventoryNet_4b6a5a11-cbed-45e6-a10d-df8835586a43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_0941fde8-8f38-4c3f-8488-df38f329b6d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dab44170-2f34-4591-9246-558f23f83037" xlink:to="loc_us-gaap_OtherAssetsCurrent_0941fde8-8f38-4c3f-8488-df38f329b6d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f3ee6458-1ca7-48ac-996d-00d1ad5f3f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1990a4f1-b07d-4240-abf8-0e620aaa0d60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f3ee6458-1ca7-48ac-996d-00d1ad5f3f6d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1990a4f1-b07d-4240-abf8-0e620aaa0d60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_2639eb90-1610-4272-96f4-9384239abf01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f3ee6458-1ca7-48ac-996d-00d1ad5f3f6d" xlink:to="loc_us-gaap_Liabilities_2639eb90-1610-4272-96f4-9384239abf01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_07c35f8f-2880-4f16-888a-84f274de45dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f3ee6458-1ca7-48ac-996d-00d1ad5f3f6d" xlink:to="loc_us-gaap_CommitmentsAndContingencies_07c35f8f-2880-4f16-888a-84f274de45dd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="biib-20220331.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b26cb072-b877-4f15-b36b-b40111a6cdfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_29e939b7-3f00-41ad-a959-24a5f93069e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b26cb072-b877-4f15-b36b-b40111a6cdfe" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_29e939b7-3f00-41ad-a959-24a5f93069e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_30b3a9d5-b31d-4641-b255-1451dbdf9875" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b26cb072-b877-4f15-b36b-b40111a6cdfe" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_30b3a9d5-b31d-4641-b255-1451dbdf9875" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8afffbde-5998-4a6e-b3d8-6c56c5c32523" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b26cb072-b877-4f15-b36b-b40111a6cdfe" xlink:to="loc_us-gaap_ProfitLoss_8afffbde-5998-4a6e-b3d8-6c56c5c32523" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_4a94132f-5bbd-487f-a205-dcc26cf2f9b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b26cb072-b877-4f15-b36b-b40111a6cdfe" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_4a94132f-5bbd-487f-a205-dcc26cf2f9b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_5e3ca7fd-bd89-4383-bf03-47f370b15981" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b26cb072-b877-4f15-b36b-b40111a6cdfe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_5e3ca7fd-bd89-4383-bf03-47f370b15981" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_1c7097a2-737e-471f-a769-f4c27f434cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b26cb072-b877-4f15-b36b-b40111a6cdfe" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_1c7097a2-737e-471f-a769-f4c27f434cf2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_603e7c01-cf2f-4660-88e8-8bf9fb5dca24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b26cb072-b877-4f15-b36b-b40111a6cdfe" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_603e7c01-cf2f-4660-88e8-8bf9fb5dca24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b41242e2-5928-4fe3-bd21-e37c76b84b57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b26cb072-b877-4f15-b36b-b40111a6cdfe" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b41242e2-5928-4fe3-bd21-e37c76b84b57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_1f8cb7c4-7a70-4c4b-a6ae-8ad0432feb21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b26cb072-b877-4f15-b36b-b40111a6cdfe" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_1f8cb7c4-7a70-4c4b-a6ae-8ad0432feb21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_3e4965fa-5105-4874-943a-dab10866785d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b26cb072-b877-4f15-b36b-b40111a6cdfe" xlink:to="loc_us-gaap_InventoryWriteDown_3e4965fa-5105-4874-943a-dab10866785d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b698b2b5-4378-4688-a77a-05da4542c737" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b26cb072-b877-4f15-b36b-b40111a6cdfe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b698b2b5-4378-4688-a77a-05da4542c737" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_2f8f2f26-9a85-42cb-b631-4c973e82d7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b26cb072-b877-4f15-b36b-b40111a6cdfe" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_2f8f2f26-9a85-42cb-b631-4c973e82d7ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_831d8b61-9817-4f46-b809-0dd35f02f284" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b26cb072-b877-4f15-b36b-b40111a6cdfe" xlink:to="loc_us-gaap_ShareBasedCompensation_831d8b61-9817-4f46-b809-0dd35f02f284" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_a936c303-e5d0-4790-9ef3-829328d65189" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b26cb072-b877-4f15-b36b-b40111a6cdfe" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_a936c303-e5d0-4790-9ef3-829328d65189" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_49c0a04b-2c44-42ec-9f32-106112152f46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b26cb072-b877-4f15-b36b-b40111a6cdfe" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_49c0a04b-2c44-42ec-9f32-106112152f46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_b99066a8-71bb-46f4-817a-c9d4e419a8d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b26cb072-b877-4f15-b36b-b40111a6cdfe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_b99066a8-71bb-46f4-817a-c9d4e419a8d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2a87a87e-255c-4926-8490-042b29c1c1fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_af83df52-f800-490b-966b-865b2b39a8a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2a87a87e-255c-4926-8490-042b29c1c1fd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_af83df52-f800-490b-966b-865b2b39a8a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f5d60d80-2faa-4ed2-8f5d-3bdc90f876f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2a87a87e-255c-4926-8490-042b29c1c1fd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f5d60d80-2faa-4ed2-8f5d-3bdc90f876f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_74731a1b-c28a-4aa0-a5bc-136db3211245" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2a87a87e-255c-4926-8490-042b29c1c1fd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_74731a1b-c28a-4aa0-a5bc-136db3211245" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_334d289f-e5f8-444c-9780-d1a0511a18bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_b8b79837-1a1d-43ed-af27-bf570703ca64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_334d289f-e5f8-444c-9780-d1a0511a18bf" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_b8b79837-1a1d-43ed-af27-bf570703ca64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_e52c1c8d-1cb3-48a0-a3c3-29cea2fdadb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_334d289f-e5f8-444c-9780-d1a0511a18bf" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_e52c1c8d-1cb3-48a0-a3c3-29cea2fdadb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_db278161-c7d6-4994-9b5f-2d3add075728" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_334d289f-e5f8-444c-9780-d1a0511a18bf" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_db278161-c7d6-4994-9b5f-2d3add075728" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_abb23e72-12b5-4734-97f4-024837b23f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_334d289f-e5f8-444c-9780-d1a0511a18bf" xlink:to="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_abb23e72-12b5-4734-97f4-024837b23f9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_4de04a85-e046-4ab1-abc8-efce5db890ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_334d289f-e5f8-444c-9780-d1a0511a18bf" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_4de04a85-e046-4ab1-abc8-efce5db890ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_caec6dbf-a961-475d-9646-10b841d4db64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e7d54236-e77d-47a3-bd04-201d0e8eddae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_caec6dbf-a961-475d-9646-10b841d4db64" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e7d54236-e77d-47a3-bd04-201d0e8eddae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_13faa6cf-823d-4e52-aebb-377213318a01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_caec6dbf-a961-475d-9646-10b841d4db64" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_13faa6cf-823d-4e52-aebb-377213318a01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_20a9821a-4874-4541-bee8-e8f9d2c2a03b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_caec6dbf-a961-475d-9646-10b841d4db64" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_20a9821a-4874-4541-bee8-e8f9d2c2a03b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_a6a76ada-bfd6-4be9-9791-30050c135cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_caec6dbf-a961-475d-9646-10b841d4db64" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_a6a76ada-bfd6-4be9-9791-30050c135cc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_ead0df15-b9c9-4fb8-9f29-45abd995d069" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_caec6dbf-a961-475d-9646-10b841d4db64" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_ead0df15-b9c9-4fb8-9f29-45abd995d069" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_dd448cfa-9ca3-4055-886c-ad468d656c02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_caec6dbf-a961-475d-9646-10b841d4db64" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_dd448cfa-9ca3-4055-886c-ad468d656c02" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_4705b123-1b95-4cfe-a71b-e4edca55f24c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfCoPromotionProfits_541b002c-fe49-4065-9e60-fd306aafb950" xlink:href="biib-20220331.xsd#biib_ShareOfCoPromotionProfits"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_4705b123-1b95-4cfe-a71b-e4edca55f24c" xlink:to="loc_biib_ShareOfCoPromotionProfits_541b002c-fe49-4065-9e60-fd306aafb950" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#InventoryComponentsofInventoryDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_9b4eb8ec-e017-4f14-b65f-f66a3865e2f1" xlink:href="biib-20220331.xsd#biib_Inventorynetcurrentandnoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_ddb276f2-dd7d-45bc-8e26-8f075a889aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_9b4eb8ec-e017-4f14-b65f-f66a3865e2f1" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_ddb276f2-dd7d-45bc-8e26-8f075a889aaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_6c650684-772c-4ebc-95a0-e2dfb4906f20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_9b4eb8ec-e017-4f14-b65f-f66a3865e2f1" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_6c650684-772c-4ebc-95a0-e2dfb4906f20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_52210d74-d9fb-4425-94ae-bab16f036e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_9b4eb8ec-e017-4f14-b65f-f66a3865e2f1" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_52210d74-d9fb-4425-94ae-bab16f036e6a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#IntangibleAssetsandGoodwillDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e5d96837-06ce-4a42-8dcb-54b4ab7676d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_cc3fd63a-4fe2-44fe-98ff-cb177d79f361" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e5d96837-06ce-4a42-8dcb-54b4ab7676d3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_cc3fd63a-4fe2-44fe-98ff-cb177d79f361" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_eca75fb6-a514-48c6-aa5c-a940f058b6dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e5d96837-06ce-4a42-8dcb-54b4ab7676d3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_eca75fb6-a514-48c6-aa5c-a940f058b6dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9ed9f9c4-1759-4193-9390-33110c07faa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ff96f806-88b7-4535-9788-8981e7d0fd2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9ed9f9c4-1759-4193-9390-33110c07faa9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ff96f806-88b7-4535-9788-8981e7d0fd2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_d67f9fc2-2b65-4269-97ed-fdc4c27f2397" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9ed9f9c4-1759-4193-9390-33110c07faa9" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_d67f9fc2-2b65-4269-97ed-fdc4c27f2397" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#FairValueMeasurementsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_6ae1c925-2ca0-4c3e-ba63-ece58aecb79e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a8084355-a8ea-4679-82c3-a38796ef6948" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_6ae1c925-2ca0-4c3e-ba63-ece58aecb79e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a8084355-a8ea-4679-82c3-a38796ef6948" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_03737e70-ddd6-4d13-ba60-c0d19b79932c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_6ae1c925-2ca0-4c3e-ba63-ece58aecb79e" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_03737e70-ddd6-4d13-ba60-c0d19b79932c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="simple" xlink:href="biib-20220331.xsd#FinancialInstrumentsDetails1"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_aafaab0d-dbdd-4a04-acdd-4dd548b7ee00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bbdb2c0a-5d9d-4baf-a592-87660bc5d1d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_aafaab0d-dbdd-4a04-acdd-4dd548b7ee00" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bbdb2c0a-5d9d-4baf-a592-87660bc5d1d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_15aa107b-10ae-4fc0-a28f-6317e0cbdd23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_aafaab0d-dbdd-4a04-acdd-4dd548b7ee00" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_15aa107b-10ae-4fc0-a28f-6317e0cbdd23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_24db3152-de32-4c0e-9474-2a70f7051b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_aafaab0d-dbdd-4a04-acdd-4dd548b7ee00" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_24db3152-de32-4c0e-9474-2a70f7051b1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_bb61246c-e2b3-42eb-97be-059d6ffc3211" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_17bea35d-8603-4414-8fde-4970b068219f" xlink:href="biib-20220331.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost_bb61246c-e2b3-42eb-97be-059d6ffc3211" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_17bea35d-8603-4414-8fde-4970b068219f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_85c968e8-3c25-47ae-9ae5-50a8824c5024" xlink:href="biib-20220331.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost_bb61246c-e2b3-42eb-97be-059d6ffc3211" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_85c968e8-3c25-47ae-9ae5-50a8824c5024" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_1f7b3869-cc4e-4ecd-9e56-a27d9ca4860e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost_bb61246c-e2b3-42eb-97be-059d6ffc3211" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_1f7b3869-cc4e-4ecd-9e56-a27d9ca4860e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="simple" xlink:href="biib-20220331.xsd#FinancialInstrumentsDetails2"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_038241ab-a8c2-4a94-ae67-b1d99d454f97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_0b78c475-2a5d-4a3c-a864-1f0816a67ebc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_038241ab-a8c2-4a94-ae67-b1d99d454f97" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_0b78c475-2a5d-4a3c-a864-1f0816a67ebc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_5815e855-c3bc-49aa-ae09-6d0c5602d14d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_038241ab-a8c2-4a94-ae67-b1d99d454f97" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_5815e855-c3bc-49aa-ae09-6d0c5602d14d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_8a9a1148-3281-4828-a175-a45b58411d11" xlink:href="biib-20220331.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_038241ab-a8c2-4a94-ae67-b1d99d454f97" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_8a9a1148-3281-4828-a175-a45b58411d11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_74834569-cb45-40b6-bc25-186d5bd54a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_2cc854ee-0a12-4f4e-95b9-53196731eebb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_74834569-cb45-40b6-bc25-186d5bd54a9c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_2cc854ee-0a12-4f4e-95b9-53196731eebb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_4f1d9f6e-8a30-4da9-9364-aaa5454f9b03" xlink:href="biib-20220331.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_74834569-cb45-40b6-bc25-186d5bd54a9c" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_4f1d9f6e-8a30-4da9-9364-aaa5454f9b03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_bf842bc3-8651-4f22-ae3e-b84374234cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_74834569-cb45-40b6-bc25-186d5bd54a9c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_bf842bc3-8651-4f22-ae3e-b84374234cc6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#EarningsperShareDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e8771abe-be34-4f5b-95fe-f8bb6d93d260" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_ec20beca-71dc-411d-a79e-2b939f5aa6b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e8771abe-be34-4f5b-95fe-f8bb6d93d260" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_ec20beca-71dc-411d-a79e-2b939f5aa6b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4e6fe618-6956-4026-ae61-fedaa6235a19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e9a7d811-8071-48f6-8110-c947cbd62812" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4e6fe618-6956-4026-ae61-fedaa6235a19" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e9a7d811-8071-48f6-8110-c947cbd62812" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_a2ffa442-b6c4-4c5b-a9e1-29f0cf08955b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4e6fe618-6956-4026-ae61-fedaa6235a19" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_a2ffa442-b6c4-4c5b-a9e1-29f0cf08955b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#ShareBasedPaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_50ee5e0e-1746-4e67-a4bc-6ab8d3dffac3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_5918fc37-a4d9-46cd-88bd-c8eeac43b9b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_50ee5e0e-1746-4e67-a4bc-6ab8d3dffac3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_5918fc37-a4d9-46cd-88bd-c8eeac43b9b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_8fe6c6cd-ae90-49fb-a6d7-cbb40845edd7" xlink:href="biib-20220331.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_50ee5e0e-1746-4e67-a4bc-6ab8d3dffac3" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_8fe6c6cd-ae90-49fb-a6d7-cbb40845edd7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#IncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_952e0503-76ed-4b52-98cd-b13cb0a74e64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_eb447086-34a5-4295-b2c7-87669146f32e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_952e0503-76ed-4b52-98cd-b13cb0a74e64" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_eb447086-34a5-4295-b2c7-87669146f32e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_2492ae8b-681c-46e2-8b08-46d3d378fc3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_952e0503-76ed-4b52-98cd-b13cb0a74e64" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_2492ae8b-681c-46e2-8b08-46d3d378fc3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationGILTItax_9ef0a298-7e08-4094-aa4e-b5af138e3236" xlink:href="biib-20220331.xsd#biib_EffectiveTaxRateReconciliationGILTItax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_952e0503-76ed-4b52-98cd-b13cb0a74e64" xlink:to="loc_biib_EffectiveTaxRateReconciliationGILTItax_9ef0a298-7e08-4094-aa4e-b5af138e3236" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts_c9ae6d95-99d9-4356-bc4a-2ce80329d467" xlink:href="biib-20220331.xsd#biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_952e0503-76ed-4b52-98cd-b13cb0a74e64" xlink:to="loc_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts_c9ae6d95-99d9-4356-bc4a-2ce80329d467" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_0e09feb8-07bf-479c-9a3f-cc0f0b5f62e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_952e0503-76ed-4b52-98cd-b13cb0a74e64" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_0e09feb8-07bf-479c-9a3f-cc0f0b5f62e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_781d7e26-cc2b-4ed6-9703-e81ba51e730e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_952e0503-76ed-4b52-98cd-b13cb0a74e64" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_781d7e26-cc2b-4ed6-9703-e81ba51e730e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_601865d1-84c3-499d-a941-dc9b8bc596d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_952e0503-76ed-4b52-98cd-b13cb0a74e64" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_601865d1-84c3-499d-a941-dc9b8bc596d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_b505ecc4-004e-42dc-a5de-e033652fac42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_952e0503-76ed-4b52-98cd-b13cb0a74e64" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_b505ecc4-004e-42dc-a5de-e033652fac42" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#OtherConsolidatedFinancialStatementDetailDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_d5105e8a-6369-4cf4-b4ff-5b9aea2c302d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_267943b4-1f34-46e9-ac4d-840dec3f3ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_d5105e8a-6369-4cf4-b4ff-5b9aea2c302d" xlink:to="loc_us-gaap_InvestmentIncomeInterest_267943b4-1f34-46e9-ac4d-840dec3f3ef2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_9661b0e1-f5b2-4ade-a310-ecc90a3fd9c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_d5105e8a-6369-4cf4-b4ff-5b9aea2c302d" xlink:to="loc_us-gaap_InterestExpense_9661b0e1-f5b2-4ade-a310-ecc90a3fd9c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_bca630d8-5a9a-41bc-800d-9be904154788" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_d5105e8a-6369-4cf4-b4ff-5b9aea2c302d" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_bca630d8-5a9a-41bc-800d-9be904154788" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_cbcd2629-c8a7-41cd-953f-6ddd22472032" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_d5105e8a-6369-4cf4-b4ff-5b9aea2c302d" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_cbcd2629-c8a7-41cd-953f-6ddd22472032" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_cb0dcddc-8f5f-4b02-a6a1-380146b0e775" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_d5105e8a-6369-4cf4-b4ff-5b9aea2c302d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_cb0dcddc-8f5f-4b02-a6a1-380146b0e775" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_d1e1c6b0-8f96-4a25-831b-8e557e27a58b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_4f67446b-0a64-4b31-a25a-af951bbe3223" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_d1e1c6b0-8f96-4a25-831b-8e557e27a58b" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_4f67446b-0a64-4b31-a25a-af951bbe3223" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_d0092030-3835-4ef3-a0f5-180ca6354e26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_d1e1c6b0-8f96-4a25-831b-8e557e27a58b" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_d0092030-3835-4ef3-a0f5-180ca6354e26" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>biib-20220331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:c574431f-8208-4dea-bcfe-8d8f5f068522,g:425f524b-de43-4dfe-85cc-ae50a1579d49-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="simple" xlink:href="biib-20220331.xsd#CondensedConsolidatedStatementsofIncomeUnaudited"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="extended" id="i17c33ad5b83042598cabf5e5caecab9f_CondensedConsolidatedStatementsofIncomeUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_bbe904bb-8cf6-4c09-b896-d9ca075178fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_8ecf7bcc-9753-45f0-a37f-c0f95b27defc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bbe904bb-8cf6-4c09-b896-d9ca075178fb" xlink:to="loc_us-gaap_Revenues_8ecf7bcc-9753-45f0-a37f-c0f95b27defc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_d111c932-8917-41c7-a9c5-9f20f0587716" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bbe904bb-8cf6-4c09-b896-d9ca075178fb" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_d111c932-8917-41c7-a9c5-9f20f0587716" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_f8b11b67-20f9-43fb-9eb1-7291f25f790d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d111c932-8917-41c7-a9c5-9f20f0587716" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_f8b11b67-20f9-43fb-9eb1-7291f25f790d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0e92b850-cdef-48c0-91ab-ede19fc082e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d111c932-8917-41c7-a9c5-9f20f0587716" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0e92b850-cdef-48c0-91ab-ede19fc082e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0e62cd71-46e8-4d67-a633-9286571a7a57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d111c932-8917-41c7-a9c5-9f20f0587716" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0e62cd71-46e8-4d67-a633-9286571a7a57" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_44a20ed0-82bb-45a1-8222-0ff1f1b991a7" xlink:href="biib-20220331.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d111c932-8917-41c7-a9c5-9f20f0587716" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_44a20ed0-82bb-45a1-8222-0ff1f1b991a7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_91a27af4-374c-4765-b82e-868eebf28e92" xlink:href="biib-20220331.xsd#biib_Collaborationprofitlosssharing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d111c932-8917-41c7-a9c5-9f20f0587716" xlink:to="loc_biib_Collaborationprofitlosssharing_91a27af4-374c-4765-b82e-868eebf28e92" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_876f3e36-4739-42f4-8695-975f718bb50e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d111c932-8917-41c7-a9c5-9f20f0587716" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_876f3e36-4739-42f4-8695-975f718bb50e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_eff1a2c2-950a-45ae-a2aa-65ac149d5e40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d111c932-8917-41c7-a9c5-9f20f0587716" xlink:to="loc_us-gaap_RestructuringCharges_eff1a2c2-950a-45ae-a2aa-65ac149d5e40" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_ae8bb097-5bd4-4df6-86f6-93ec74f68ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d111c932-8917-41c7-a9c5-9f20f0587716" xlink:to="loc_us-gaap_CostsAndExpenses_ae8bb097-5bd4-4df6-86f6-93ec74f68ce6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_185299d9-8324-4664-8b38-aba4a42ab38d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bbe904bb-8cf6-4c09-b896-d9ca075178fb" xlink:to="loc_us-gaap_OperatingIncomeLoss_185299d9-8324-4664-8b38-aba4a42ab38d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9143b0da-7329-490e-b560-5e812350dd10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bbe904bb-8cf6-4c09-b896-d9ca075178fb" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_9143b0da-7329-490e-b560-5e812350dd10" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_4eb56d15-0e3d-46f3-bc97-17ea1868ffb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bbe904bb-8cf6-4c09-b896-d9ca075178fb" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_4eb56d15-0e3d-46f3-bc97-17ea1868ffb1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_04b0f032-568f-4f0f-ac86-9f87a6c71398" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bbe904bb-8cf6-4c09-b896-d9ca075178fb" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_04b0f032-568f-4f0f-ac86-9f87a6c71398" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_10e857e2-b485-4fce-8c46-433b335921ee" xlink:href="biib-20220331.xsd#biib_IncomeLossFromEquityMethodInvestmentsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bbe904bb-8cf6-4c09-b896-d9ca075178fb" xlink:to="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_10e857e2-b485-4fce-8c46-433b335921ee" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a79bc0be-7110-4422-af65-9e570083c59f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bbe904bb-8cf6-4c09-b896-d9ca075178fb" xlink:to="loc_us-gaap_ProfitLoss_a79bc0be-7110-4422-af65-9e570083c59f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1b79a804-d7e6-4d81-a8f6-8c0233389abf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bbe904bb-8cf6-4c09-b896-d9ca075178fb" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1b79a804-d7e6-4d81-a8f6-8c0233389abf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ed2fff9f-496b-43f2-8f58-6118fb3f348a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bbe904bb-8cf6-4c09-b896-d9ca075178fb" xlink:to="loc_us-gaap_NetIncomeLoss_ed2fff9f-496b-43f2-8f58-6118fb3f348a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_53a6146b-2a35-4a3d-97e8-d9f26375f964" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bbe904bb-8cf6-4c09-b896-d9ca075178fb" xlink:to="loc_us-gaap_EarningsPerShareAbstract_53a6146b-2a35-4a3d-97e8-d9f26375f964" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_29494366-6794-4b80-bef1-0fdb7068b111" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_53a6146b-2a35-4a3d-97e8-d9f26375f964" xlink:to="loc_us-gaap_EarningsPerShareBasic_29494366-6794-4b80-bef1-0fdb7068b111" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_489c0b22-a787-4c0a-9bfc-1c014c96afc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_53a6146b-2a35-4a3d-97e8-d9f26375f964" xlink:to="loc_us-gaap_EarningsPerShareDiluted_489c0b22-a787-4c0a-9bfc-1c014c96afc9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0167f782-c17d-44b2-b132-b7767f796749" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bbe904bb-8cf6-4c09-b896-d9ca075178fb" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0167f782-c17d-44b2-b132-b7767f796749" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e199cce5-0726-427a-ad24-8dc232407dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0167f782-c17d-44b2-b132-b7767f796749" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e199cce5-0726-427a-ad24-8dc232407dc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f959e952-f703-45bf-9a51-cf6e77edc4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0167f782-c17d-44b2-b132-b7767f796749" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f959e952-f703-45bf-9a51-cf6e77edc4ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_184707dd-946d-48e8-93eb-fc57e543f17d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_bbe904bb-8cf6-4c09-b896-d9ca075178fb" xlink:to="loc_us-gaap_StatementTable_184707dd-946d-48e8-93eb-fc57e543f17d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d5702c3e-a50a-4537-a9eb-fb55b408858e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_184707dd-946d-48e8-93eb-fc57e543f17d" xlink:to="loc_srt_ProductOrServiceAxis_d5702c3e-a50a-4537-a9eb-fb55b408858e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d5702c3e-a50a-4537-a9eb-fb55b408858e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d5702c3e-a50a-4537-a9eb-fb55b408858e" xlink:to="loc_srt_ProductsAndServicesDomain_d5702c3e-a50a-4537-a9eb-fb55b408858e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3ddf752b-c0ce-4477-8581-0ba67366ee1b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d5702c3e-a50a-4537-a9eb-fb55b408858e" xlink:to="loc_srt_ProductsAndServicesDomain_3ddf752b-c0ce-4477-8581-0ba67366ee1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_4329ec7b-a07c-4b79-a7f8-7447e8a30dda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3ddf752b-c0ce-4477-8581-0ba67366ee1b" xlink:to="loc_us-gaap_ProductMember_4329ec7b-a07c-4b79-a7f8-7447e8a30dda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_3d525ec4-36b9-4623-bfc2-cdbf395b6749" xlink:href="biib-20220331.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3ddf752b-c0ce-4477-8581-0ba67366ee1b" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_3d525ec4-36b9-4623-bfc2-cdbf395b6749" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_ceffbfda-a41d-4116-9d53-9c6ecd97ae49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3ddf752b-c0ce-4477-8581-0ba67366ee1b" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_ceffbfda-a41d-4116-9d53-9c6ecd97ae49" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement" xlink:type="simple" xlink:href="biib-20220331.xsd#CondensedConsolidatedStatementofEquityStatement"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement" xlink:type="extended" id="ida94b57263ea4d85b2621227227e586a_CondensedConsolidatedStatementofEquityStatement">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_35ce0307-a798-48c9-b677-04881ed2455b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_720dfe77-3855-4b15-96c7-c6add2e9be8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_35ce0307-a798-48c9-b677-04881ed2455b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_720dfe77-3855-4b15-96c7-c6add2e9be8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_935f898c-8af0-4e1a-8d27-151822495b62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_35ce0307-a798-48c9-b677-04881ed2455b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_935f898c-8af0-4e1a-8d27-151822495b62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_34f1e584-52b1-49dc-9ab6-32605afbe65e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_35ce0307-a798-48c9-b677-04881ed2455b" xlink:to="loc_us-gaap_ProfitLoss_34f1e584-52b1-49dc-9ab6-32605afbe65e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_13f78ac6-2afe-4dac-9aed-4113b03aba77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_35ce0307-a798-48c9-b677-04881ed2455b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_13f78ac6-2afe-4dac-9aed-4113b03aba77" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NoncontrollingInterestIncreaseDecreaseOther_378591b6-bf02-4f58-af9d-6800bca66360" xlink:href="biib-20220331.xsd#biib_NoncontrollingInterestIncreaseDecreaseOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_35ce0307-a798-48c9-b677-04881ed2455b" xlink:to="loc_biib_NoncontrollingInterestIncreaseDecreaseOther_378591b6-bf02-4f58-af9d-6800bca66360" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_2f8106b3-508a-4d1b-864c-192a435ae9f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_35ce0307-a798-48c9-b677-04881ed2455b" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_2f8106b3-508a-4d1b-864c-192a435ae9f7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_afd8765d-6aed-4c3a-87e4-22adc9003dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_35ce0307-a798-48c9-b677-04881ed2455b" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_afd8765d-6aed-4c3a-87e4-22adc9003dc8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_2e952cc4-1650-4bb3-88b2-a54a10fd6236" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_35ce0307-a798-48c9-b677-04881ed2455b" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_2e952cc4-1650-4bb3-88b2-a54a10fd6236" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_81ce6aa5-6042-4851-9f56-59e1bfe628cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_35ce0307-a798-48c9-b677-04881ed2455b" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_81ce6aa5-6042-4851-9f56-59e1bfe628cb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_22ba6ff8-978a-4b2f-b3d2-df8d08c78a32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_35ce0307-a798-48c9-b677-04881ed2455b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_22ba6ff8-978a-4b2f-b3d2-df8d08c78a32" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_a87fe139-c1eb-4bc8-98f9-8c0e5971e8ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_35ce0307-a798-48c9-b677-04881ed2455b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_a87fe139-c1eb-4bc8-98f9-8c0e5971e8ce" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_de9ce6ee-7ecd-4e54-8460-82f6efe24958" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_35ce0307-a798-48c9-b677-04881ed2455b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_de9ce6ee-7ecd-4e54-8460-82f6efe24958" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_cd8a0a31-faed-4d24-9fdb-45a9e821c486" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_35ce0307-a798-48c9-b677-04881ed2455b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_cd8a0a31-faed-4d24-9fdb-45a9e821c486" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_289ed509-e884-43ad-af1e-2e36d5d1def6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_35ce0307-a798-48c9-b677-04881ed2455b" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_289ed509-e884-43ad-af1e-2e36d5d1def6" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_f07d6a7b-0744-47b4-a950-4396c4da9ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_35ce0307-a798-48c9-b677-04881ed2455b" xlink:to="loc_us-gaap_StockholdersEquityOther_f07d6a7b-0744-47b4-a950-4396c4da9ec9" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b8a45164-f189-485c-ae83-3939f57446a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d24b964a-3032-4872-91f5-a7b7d9445447" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_33b6d105-5125-4506-bda4-20df0b0e41b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_35ce0307-a798-48c9-b677-04881ed2455b" xlink:to="loc_us-gaap_StatementTable_33b6d105-5125-4506-bda4-20df0b0e41b1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_4daa18a6-4cc3-4127-aa38-b98aa271f87e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_33b6d105-5125-4506-bda4-20df0b0e41b1" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_4daa18a6-4cc3-4127-aa38-b98aa271f87e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_4daa18a6-4cc3-4127-aa38-b98aa271f87e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_4daa18a6-4cc3-4127-aa38-b98aa271f87e" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_4daa18a6-4cc3-4127-aa38-b98aa271f87e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_9d24c010-767c-4fd7-bd63-a29b0b62b099" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_4daa18a6-4cc3-4127-aa38-b98aa271f87e" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_9d24c010-767c-4fd7-bd63-a29b0b62b099" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2020ShareRepurchaseProgramMember_35c3253b-b1ef-41ae-add1-3b4b66e87c87" xlink:href="biib-20220331.xsd#biib_A2020ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_9d24c010-767c-4fd7-bd63-a29b0b62b099" xlink:to="loc_biib_A2020ShareRepurchaseProgramMember_35c3253b-b1ef-41ae-add1-3b4b66e87c87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a8b8a484-a653-46c0-b037-a28a1f710e72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_33b6d105-5125-4506-bda4-20df0b0e41b1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a8b8a484-a653-46c0-b037-a28a1f710e72" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a8b8a484-a653-46c0-b037-a28a1f710e72_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a8b8a484-a653-46c0-b037-a28a1f710e72" xlink:to="loc_us-gaap_EquityComponentDomain_a8b8a484-a653-46c0-b037-a28a1f710e72_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1a2d5a17-e573-47f1-ba6c-08dae72c488a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a8b8a484-a653-46c0-b037-a28a1f710e72" xlink:to="loc_us-gaap_EquityComponentDomain_1a2d5a17-e573-47f1-ba6c-08dae72c488a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_e2059ea4-2bf1-412c-bb74-297aa1e3e810" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1a2d5a17-e573-47f1-ba6c-08dae72c488a" xlink:to="loc_us-gaap_PreferredStockMember_e2059ea4-2bf1-412c-bb74-297aa1e3e810" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9ec6aea7-3389-4f4b-bf26-3f1d60bbcb06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1a2d5a17-e573-47f1-ba6c-08dae72c488a" xlink:to="loc_us-gaap_CommonStockMember_9ec6aea7-3389-4f4b-bf26-3f1d60bbcb06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_defecd12-2fa5-4532-8c18-32e2046de9bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1a2d5a17-e573-47f1-ba6c-08dae72c488a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_defecd12-2fa5-4532-8c18-32e2046de9bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_929e08b6-767d-42e8-997b-e2eb11c9d2b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1a2d5a17-e573-47f1-ba6c-08dae72c488a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_929e08b6-767d-42e8-997b-e2eb11c9d2b0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_32dcea53-0c1e-48bc-a46e-f441985394c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1a2d5a17-e573-47f1-ba6c-08dae72c488a" xlink:to="loc_us-gaap_RetainedEarningsMember_32dcea53-0c1e-48bc-a46e-f441985394c6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_45692c8c-376a-4e75-8dfa-fee29b3d52d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1a2d5a17-e573-47f1-ba6c-08dae72c488a" xlink:to="loc_us-gaap_TreasuryStockMember_45692c8c-376a-4e75-8dfa-fee29b3d52d2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_1af934e9-d77b-4b48-94e8-f6a4241e2bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1a2d5a17-e573-47f1-ba6c-08dae72c488a" xlink:to="loc_us-gaap_ParentMember_1af934e9-d77b-4b48-94e8-f6a4241e2bf0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_c87e52d6-e5e7-4c82-9108-a70bd1369de4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1a2d5a17-e573-47f1-ba6c-08dae72c488a" xlink:to="loc_us-gaap_NoncontrollingInterestMember_c87e52d6-e5e7-4c82-9108-a70bd1369de4" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails" xlink:type="extended" id="ied506ae721734a8582c441a455f28854_RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_883457be-c502-41b1-b3e3-76bd3d058246" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_542d2fc5-dfc1-4e71-9ea2-a214274c0be8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_883457be-c502-41b1-b3e3-76bd3d058246" xlink:to="loc_us-gaap_RestructuringCharges_542d2fc5-dfc1-4e71-9ea2-a214274c0be8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_ffaa295c-e6a5-49d3-9624-595ec9a754b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_883457be-c502-41b1-b3e3-76bd3d058246" xlink:to="loc_us-gaap_SeveranceCosts1_ffaa295c-e6a5-49d3-9624-595ec9a754b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_17f96436-604b-489e-9086-0f5ef9af6155" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_883457be-c502-41b1-b3e3-76bd3d058246" xlink:to="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_17f96436-604b-489e-9086-0f5ef9af6155" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2558aff2-4b2f-4812-b03f-aef45129e176" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_883457be-c502-41b1-b3e3-76bd3d058246" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2558aff2-4b2f-4812-b03f-aef45129e176" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9b22d935-35c6-4b20-8d5c-651f18e55e9e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2558aff2-4b2f-4812-b03f-aef45129e176" xlink:to="loc_srt_RangeAxis_9b22d935-35c6-4b20-8d5c-651f18e55e9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9b22d935-35c6-4b20-8d5c-651f18e55e9e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9b22d935-35c6-4b20-8d5c-651f18e55e9e" xlink:to="loc_srt_RangeMember_9b22d935-35c6-4b20-8d5c-651f18e55e9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_18c92473-4728-49e8-87e7-6f293c400ca9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9b22d935-35c6-4b20-8d5c-651f18e55e9e" xlink:to="loc_srt_RangeMember_18c92473-4728-49e8-87e7-6f293c400ca9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_36c5f05d-ace8-40a4-9329-835d554472c0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_18c92473-4728-49e8-87e7-6f293c400ca9" xlink:to="loc_srt_MinimumMember_36c5f05d-ace8-40a4-9329-835d554472c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8ef960f8-75cc-4105-aa35-7be072d354a4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_18c92473-4728-49e8-87e7-6f293c400ca9" xlink:to="loc_srt_MaximumMember_8ef960f8-75cc-4105-aa35-7be072d354a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_c5dc0d58-288a-4140-a063-3f5729e18f02" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2558aff2-4b2f-4812-b03f-aef45129e176" xlink:to="loc_srt_StatementScenarioAxis_c5dc0d58-288a-4140-a063-3f5729e18f02" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_c5dc0d58-288a-4140-a063-3f5729e18f02_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_c5dc0d58-288a-4140-a063-3f5729e18f02" xlink:to="loc_srt_ScenarioUnspecifiedDomain_c5dc0d58-288a-4140-a063-3f5729e18f02_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_8281f728-25d9-4f61-9947-dd07911cfdd0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_c5dc0d58-288a-4140-a063-3f5729e18f02" xlink:to="loc_srt_ScenarioUnspecifiedDomain_8281f728-25d9-4f61-9947-dd07911cfdd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_ce652f7c-1661-4cf7-a487-d5d8d7ed17ab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_8281f728-25d9-4f61-9947-dd07911cfdd0" xlink:to="loc_srt_ScenarioForecastMember_ce652f7c-1661-4cf7-a487-d5d8d7ed17ab" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails" xlink:type="extended" id="i11d1cef85c5c41bfa686ea05ec84893d_RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_dd90172f-06f5-4fe0-96de-04470bd79edd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_7f6051e7-300c-44c3-973d-0fd1a1a0b919" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_dd90172f-06f5-4fe0-96de-04470bd79edd" xlink:to="loc_us-gaap_RestructuringReserve_7f6051e7-300c-44c3-973d-0fd1a1a0b919" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_f3bd870f-239c-4ab5-b252-74a789dd387d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_dd90172f-06f5-4fe0-96de-04470bd79edd" xlink:to="loc_us-gaap_RestructuringCharges_f3bd870f-239c-4ab5-b252-74a789dd387d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_8889c180-2c2b-4979-b500-980307b1075b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_dd90172f-06f5-4fe0-96de-04470bd79edd" xlink:to="loc_us-gaap_PaymentsForRestructuring_8889c180-2c2b-4979-b500-980307b1075b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_2f4b1c08-3863-45eb-9971-3e0a70438a67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_68a9a9f0-f569-4abb-ba3a-3383c508784e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_dd90172f-06f5-4fe0-96de-04470bd79edd" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_68a9a9f0-f569-4abb-ba3a-3383c508784e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_58860efe-f576-46ca-9efb-3d0547229531" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_68a9a9f0-f569-4abb-ba3a-3383c508784e" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_58860efe-f576-46ca-9efb-3d0547229531" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_58860efe-f576-46ca-9efb-3d0547229531_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_58860efe-f576-46ca-9efb-3d0547229531" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_58860efe-f576-46ca-9efb-3d0547229531_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_8e6c987d-7fd9-46f8-b6a3-9598b05e9a93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_58860efe-f576-46ca-9efb-3d0547229531" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_8e6c987d-7fd9-46f8-b6a3-9598b05e9a93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WorkforceReductionMember_7625b14d-2b61-404b-a0eb-93de064922b3" xlink:href="biib-20220331.xsd#biib_WorkforceReductionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_8e6c987d-7fd9-46f8-b6a3-9598b05e9a93" xlink:to="loc_biib_WorkforceReductionMember_7625b14d-2b61-404b-a0eb-93de064922b3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#RevenuesRevenuesbyproductDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails" xlink:type="extended" id="ic1cd58d53e96401e9b479f55ff0ad9f0_RevenuesRevenuesbyproductDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_4f09d128-b6df-40a8-9bc4-2587151a0b16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_65267ef6-296f-4c4c-8ff4-1707a20a16d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4f09d128-b6df-40a8-9bc4-2587151a0b16" xlink:to="loc_us-gaap_Revenues_65267ef6-296f-4c4c-8ff4-1707a20a16d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_24f2dd19-e297-4791-8f31-ace018ff9ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4f09d128-b6df-40a8-9bc4-2587151a0b16" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_24f2dd19-e297-4791-8f31-ace018ff9ec0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_83cdb1fe-3d9c-4f56-b7c4-26530a6885af" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_24f2dd19-e297-4791-8f31-ace018ff9ec0" xlink:to="loc_srt_ProductOrServiceAxis_83cdb1fe-3d9c-4f56-b7c4-26530a6885af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_83cdb1fe-3d9c-4f56-b7c4-26530a6885af_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_83cdb1fe-3d9c-4f56-b7c4-26530a6885af" xlink:to="loc_srt_ProductsAndServicesDomain_83cdb1fe-3d9c-4f56-b7c4-26530a6885af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_651b9153-2b49-4d1d-a7ce-e91ad9004ead" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_83cdb1fe-3d9c-4f56-b7c4-26530a6885af" xlink:to="loc_srt_ProductsAndServicesDomain_651b9153-2b49-4d1d-a7ce-e91ad9004ead" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumarateMember_d5798bda-d7ff-4916-a079-9c0c73d31621" xlink:href="biib-20220331.xsd#biib_FumarateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_651b9153-2b49-4d1d-a7ce-e91ad9004ead" xlink:to="loc_biib_FumarateMember_d5798bda-d7ff-4916-a079-9c0c73d31621" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterferonMember_b759ae10-9495-45c2-ae16-f9fe549afcd8" xlink:href="biib-20220331.xsd#biib_InterferonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_651b9153-2b49-4d1d-a7ce-e91ad9004ead" xlink:to="loc_biib_InterferonMember_b759ae10-9495-45c2-ae16-f9fe549afcd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TysabriProductMember_8ac592b0-ee5c-404c-9ea6-28d753b7666b" xlink:href="biib-20220331.xsd#biib_TysabriProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_651b9153-2b49-4d1d-a7ce-e91ad9004ead" xlink:to="loc_biib_TysabriProductMember_8ac592b0-ee5c-404c-9ea6-28d753b7666b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FAMPYRAMember_0c9820f7-3754-4e72-ae82-73049ca34ecd" xlink:href="biib-20220331.xsd#biib_FAMPYRAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_651b9153-2b49-4d1d-a7ce-e91ad9004ead" xlink:to="loc_biib_FAMPYRAMember_0c9820f7-3754-4e72-ae82-73049ca34ecd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MSProductRevenuesMember_9bdf295d-142a-4285-b706-3a38090214b2" xlink:href="biib-20220331.xsd#biib_MSProductRevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_651b9153-2b49-4d1d-a7ce-e91ad9004ead" xlink:to="loc_biib_MSProductRevenuesMember_9bdf295d-142a-4285-b706-3a38090214b2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SPINRAZAMember_0b855d7b-2155-4f64-b608-9f787ca8818d" xlink:href="biib-20220331.xsd#biib_SPINRAZAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_651b9153-2b49-4d1d-a7ce-e91ad9004ead" xlink:to="loc_biib_SPINRAZAMember_0b855d7b-2155-4f64-b608-9f787ca8818d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_7a1456d0-e354-497f-84a8-ebf83699ed38" xlink:href="biib-20220331.xsd#biib_ADUHELMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_651b9153-2b49-4d1d-a7ce-e91ad9004ead" xlink:to="loc_biib_ADUHELMMember_7a1456d0-e354-497f-84a8-ebf83699ed38" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BENEPALIMember_26e2b679-9d2d-4607-9e88-998c9ffd2fb5" xlink:href="biib-20220331.xsd#biib_BENEPALIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_651b9153-2b49-4d1d-a7ce-e91ad9004ead" xlink:to="loc_biib_BENEPALIMember_26e2b679-9d2d-4607-9e88-998c9ffd2fb5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IMRALDIMember_58e4a3df-1ccc-4171-8728-3335598d0afe" xlink:href="biib-20220331.xsd#biib_IMRALDIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_651b9153-2b49-4d1d-a7ce-e91ad9004ead" xlink:to="loc_biib_IMRALDIMember_58e4a3df-1ccc-4171-8728-3335598d0afe" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FLIXABIMember_caf4b6a2-8047-42e4-b4e8-75abf38018e9" xlink:href="biib-20220331.xsd#biib_FLIXABIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_651b9153-2b49-4d1d-a7ce-e91ad9004ead" xlink:to="loc_biib_FLIXABIMember_caf4b6a2-8047-42e4-b4e8-75abf38018e9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiosimilarsMember_b0dffaa6-3eaa-4b98-ab93-339214d91687" xlink:href="biib-20220331.xsd#biib_BiosimilarsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_651b9153-2b49-4d1d-a7ce-e91ad9004ead" xlink:to="loc_biib_BiosimilarsMember_b0dffaa6-3eaa-4b98-ab93-339214d91687" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FUMADERMMember_b365ef37-523d-4547-bc66-981b3f81cf11" xlink:href="biib-20220331.xsd#biib_FUMADERMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_651b9153-2b49-4d1d-a7ce-e91ad9004ead" xlink:to="loc_biib_FUMADERMMember_b365ef37-523d-4547-bc66-981b3f81cf11" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_0dcadf82-4e7b-478a-a0cd-900835475455" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_651b9153-2b49-4d1d-a7ce-e91ad9004ead" xlink:to="loc_us-gaap_ProductMember_0dcadf82-4e7b-478a-a0cd-900835475455" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_9227cb1f-1dcf-4fbe-bb41-1d819522bf35" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_24f2dd19-e297-4791-8f31-ace018ff9ec0" xlink:to="loc_srt_StatementGeographicalAxis_9227cb1f-1dcf-4fbe-bb41-1d819522bf35" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9227cb1f-1dcf-4fbe-bb41-1d819522bf35_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_9227cb1f-1dcf-4fbe-bb41-1d819522bf35" xlink:to="loc_srt_SegmentGeographicalDomain_9227cb1f-1dcf-4fbe-bb41-1d819522bf35_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a618a071-c3cc-42e1-85dc-c6c28a8f6366" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_9227cb1f-1dcf-4fbe-bb41-1d819522bf35" xlink:to="loc_srt_SegmentGeographicalDomain_a618a071-c3cc-42e1-85dc-c6c28a8f6366" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_965d6714-3880-4c2d-96ec-2baf3aa52478" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_a618a071-c3cc-42e1-85dc-c6c28a8f6366" xlink:to="loc_country_US_965d6714-3880-4c2d-96ec-2baf3aa52478" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_60583efb-96f5-42c1-955b-e3be6f7664e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_a618a071-c3cc-42e1-85dc-c6c28a8f6366" xlink:to="loc_us-gaap_NonUsMember_60583efb-96f5-42c1-955b-e3be6f7664e9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1" xlink:type="simple" xlink:href="biib-20220331.xsd#RevenuesReservesforDiscountsandAllowancesDetails1"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1" xlink:type="extended" id="i0cd300d9b28b41e09eab693dcd587c36_RevenuesReservesforDiscountsandAllowancesDetails1">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_8150506f-9ae6-473e-bdb2-42fc59df75e0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_9d8cb4c1-6790-4493-b76e-7bb2ab819b39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_8150506f-9ae6-473e-bdb2-42fc59df75e0" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_9d8cb4c1-6790-4493-b76e-7bb2ab819b39" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_afa6d289-effd-47cc-be90-7ae7a6082ceb" xlink:href="biib-20220331.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_8150506f-9ae6-473e-bdb2-42fc59df75e0" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_afa6d289-effd-47cc-be90-7ae7a6082ceb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_e26167c2-d3a8-4df8-ad30-b8e575c2c8c0" xlink:href="biib-20220331.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_8150506f-9ae6-473e-bdb2-42fc59df75e0" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_e26167c2-d3a8-4df8-ad30-b8e575c2c8c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_c793416b-d227-4f50-9da5-49966ec5f784" xlink:href="biib-20220331.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_8150506f-9ae6-473e-bdb2-42fc59df75e0" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_c793416b-d227-4f50-9da5-49966ec5f784" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_7ba6b28c-eb19-436e-82d1-cf80df58d343" xlink:href="biib-20220331.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_8150506f-9ae6-473e-bdb2-42fc59df75e0" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_7ba6b28c-eb19-436e-82d1-cf80df58d343" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_af537c12-7c44-46ab-9f89-5e72f43389ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_eb87cbd1-18fe-4695-ae36-73071b61f899" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_8150506f-9ae6-473e-bdb2-42fc59df75e0" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_eb87cbd1-18fe-4695-ae36-73071b61f899" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_baf38519-4530-4c08-8e0b-27bcdb21ef81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_eb87cbd1-18fe-4695-ae36-73071b61f899" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_baf38519-4530-4c08-8e0b-27bcdb21ef81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_baf38519-4530-4c08-8e0b-27bcdb21ef81_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_baf38519-4530-4c08-8e0b-27bcdb21ef81" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_baf38519-4530-4c08-8e0b-27bcdb21ef81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_8674c3a7-8a8f-49bc-bcee-6ad91e7f8ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_baf38519-4530-4c08-8e0b-27bcdb21ef81" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_8674c3a7-8a8f-49bc-bcee-6ad91e7f8ec4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReserveforCashDiscountsMember_28fddbc5-11d4-48b1-b8d2-8eaa12e8266f" xlink:href="biib-20220331.xsd#biib_ReserveforCashDiscountsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8674c3a7-8a8f-49bc-bcee-6ad91e7f8ec4" xlink:to="loc_biib_ReserveforCashDiscountsMember_28fddbc5-11d4-48b1-b8d2-8eaa12e8266f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractualAdjustmentsMember_fad14e1a-f97e-44a1-82d1-f1d46e0d2096" xlink:href="biib-20220331.xsd#biib_ContractualAdjustmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8674c3a7-8a8f-49bc-bcee-6ad91e7f8ec4" xlink:to="loc_biib_ContractualAdjustmentsMember_fad14e1a-f97e-44a1-82d1-f1d46e0d2096" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_4263d6ef-2aab-4bcb-b295-b036ae600836" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8674c3a7-8a8f-49bc-bcee-6ad91e7f8ec4" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_4263d6ef-2aab-4bcb-b295-b036ae600836" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2" xlink:type="simple" xlink:href="biib-20220331.xsd#RevenuesReservesforDiscountsandAllowancesDetails2"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2" xlink:type="extended" id="i235cb5033f11426db7e750a2bc6c4924_RevenuesReservesforDiscountsandAllowancesDetails2">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_53c86e8c-2ca0-48a4-a876-2e47428aa927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_7500ed0d-1e2e-48e4-aafd-71106386f530" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_53c86e8c-2ca0-48a4-a876-2e47428aa927" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_7500ed0d-1e2e-48e4-aafd-71106386f530" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_037c6c95-1cb9-4738-af93-3a87d63bb720" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_53c86e8c-2ca0-48a4-a876-2e47428aa927" xlink:to="loc_us-gaap_StatementTable_037c6c95-1cb9-4738-af93-3a87d63bb720" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_c7c3c5d7-c572-4094-917a-302449593e6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_037c6c95-1cb9-4738-af93-3a87d63bb720" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_c7c3c5d7-c572-4094-917a-302449593e6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_c7c3c5d7-c572-4094-917a-302449593e6c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c7c3c5d7-c572-4094-917a-302449593e6c" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_c7c3c5d7-c572-4094-917a-302449593e6c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e51d9b2c-af7e-4c9e-bf65-fdd5bd5c8b44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c7c3c5d7-c572-4094-917a-302449593e6c" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e51d9b2c-af7e-4c9e-bf65-fdd5bd5c8b44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_da802b13-2acf-4a7f-894c-35042a85b13d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e51d9b2c-af7e-4c9e-bf65-fdd5bd5c8b44" xlink:to="loc_us-gaap_AccountsReceivableMember_da802b13-2acf-4a7f-894c-35042a85b13d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_35976d2e-b59c-49d7-adad-62ed65a9632e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e51d9b2c-af7e-4c9e-bf65-fdd5bd5c8b44" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_35976d2e-b59c-49d7-adad-62ed65a9632e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="extended" id="i98b015ffaf9e44c3ac8fe150c4e039da_RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_477c1a83-895c-4b1b-8f8e-e4313fcc9383" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfCoPromotionProfits_35bd4f3b-798a-43e3-8683-d8ed9e86bbaf" xlink:href="biib-20220331.xsd#biib_ShareOfCoPromotionProfits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_477c1a83-895c-4b1b-8f8e-e4313fcc9383" xlink:to="loc_biib_ShareOfCoPromotionProfits_35bd4f3b-798a-43e3-8683-d8ed9e86bbaf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_a0cd1202-1403-4848-ae10-ecb8bcdd5b38" xlink:href="biib-20220331.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_477c1a83-895c-4b1b-8f8e-e4313fcc9383" xlink:to="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_a0cd1202-1403-4848-ae10-ecb8bcdd5b38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_07e2c818-8ba1-42e6-ba66-36af130f8a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_477c1a83-895c-4b1b-8f8e-e4313fcc9383" xlink:to="loc_us-gaap_Revenues_07e2c818-8ba1-42e6-ba66-36af130f8a1f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_08c3224f-2682-4dfb-9029-59cb0c70c1b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_477c1a83-895c-4b1b-8f8e-e4313fcc9383" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_08c3224f-2682-4dfb-9029-59cb0c70c1b8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_bc90fe7e-3045-4587-a1c9-ebeb3fd08ac4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_08c3224f-2682-4dfb-9029-59cb0c70c1b8" xlink:to="loc_srt_ProductOrServiceAxis_bc90fe7e-3045-4587-a1c9-ebeb3fd08ac4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bc90fe7e-3045-4587-a1c9-ebeb3fd08ac4_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_bc90fe7e-3045-4587-a1c9-ebeb3fd08ac4" xlink:to="loc_srt_ProductsAndServicesDomain_bc90fe7e-3045-4587-a1c9-ebeb3fd08ac4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a619d0fe-e019-4758-ae57-380bb85a4650" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_bc90fe7e-3045-4587-a1c9-ebeb3fd08ac4" xlink:to="loc_srt_ProductsAndServicesDomain_a619d0fe-e019-4758-ae57-380bb85a4650" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_3e42d8d3-7ada-4473-b3a5-a957393eb142" xlink:href="biib-20220331.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a619d0fe-e019-4758-ae57-380bb85a4650" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_3e42d8d3-7ada-4473-b3a5-a957393eb142" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_6d18675f-eceb-4839-8e1d-16c988349344" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_08c3224f-2682-4dfb-9029-59cb0c70c1b8" xlink:to="loc_srt_MajorCustomersAxis_6d18675f-eceb-4839-8e1d-16c988349344" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_6d18675f-eceb-4839-8e1d-16c988349344_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_6d18675f-eceb-4839-8e1d-16c988349344" xlink:to="loc_srt_NameOfMajorCustomerDomain_6d18675f-eceb-4839-8e1d-16c988349344_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_0d549c47-a3df-4ed5-95c8-526c03dd1cfd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_6d18675f-eceb-4839-8e1d-16c988349344" xlink:to="loc_srt_NameOfMajorCustomerDomain_0d549c47-a3df-4ed5-95c8-526c03dd1cfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RocheGroupGenentechMember_ea7510f0-ba52-4021-b111-ad77aef5dbbe" xlink:href="biib-20220331.xsd#biib_RocheGroupGenentechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_0d549c47-a3df-4ed5-95c8-526c03dd1cfd" xlink:to="loc_biib_RocheGroupGenentechMember_ea7510f0-ba52-4021-b111-ad77aef5dbbe" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#RevenuesOtherRevenuesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:type="extended" id="i00a907de07d24fb2862e4c6ead719a82_RevenuesOtherRevenuesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_6a4807e4-2f04-4647-a3b9-168c03690906" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f66e42fc-e94d-444f-84f2-1232c9dae0bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6a4807e4-2f04-4647-a3b9-168c03690906" xlink:to="loc_us-gaap_Revenues_f66e42fc-e94d-444f-84f2-1232c9dae0bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_09aea55e-c24b-48b2-9775-70a44bc656da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6a4807e4-2f04-4647-a3b9-168c03690906" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_09aea55e-c24b-48b2-9775-70a44bc656da" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_effe119a-966c-4a80-921a-ff0eae0fa5d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_09aea55e-c24b-48b2-9775-70a44bc656da" xlink:to="loc_us-gaap_TypeOfArrangementAxis_effe119a-966c-4a80-921a-ff0eae0fa5d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_effe119a-966c-4a80-921a-ff0eae0fa5d5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_effe119a-966c-4a80-921a-ff0eae0fa5d5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_effe119a-966c-4a80-921a-ff0eae0fa5d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c3c8f42c-7c8d-4d27-a2f7-b34291dcd1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_effe119a-966c-4a80-921a-ff0eae0fa5d5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c3c8f42c-7c8d-4d27-a2f7-b34291dcd1d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_54d396fb-4d42-44e5-a47b-2bc99a1e3931" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c3c8f42c-7c8d-4d27-a2f7-b34291dcd1d3" xlink:to="loc_us-gaap_CollaborativeArrangementMember_54d396fb-4d42-44e5-a47b-2bc99a1e3931" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ea9a1f58-cb7c-4c71-a52a-f5bf6c4839f4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_09aea55e-c24b-48b2-9775-70a44bc656da" xlink:to="loc_srt_ProductOrServiceAxis_ea9a1f58-cb7c-4c71-a52a-f5bf6c4839f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ea9a1f58-cb7c-4c71-a52a-f5bf6c4839f4_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ea9a1f58-cb7c-4c71-a52a-f5bf6c4839f4" xlink:to="loc_srt_ProductsAndServicesDomain_ea9a1f58-cb7c-4c71-a52a-f5bf6c4839f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e64bc3a3-c958-4f72-8409-9eef7091e2b6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ea9a1f58-cb7c-4c71-a52a-f5bf6c4839f4" xlink:to="loc_srt_ProductsAndServicesDomain_e64bc3a3-c958-4f72-8409-9eef7091e2b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_5bd7b253-e79c-4d52-8e6f-8703668e82ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e64bc3a3-c958-4f72-8409-9eef7091e2b6" xlink:to="loc_us-gaap_RoyaltyMember_5bd7b253-e79c-4d52-8e6f-8703668e82ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OthercorporaterevenuesMember_c5aca094-b021-44d5-84e7-8d563d221ac7" xlink:href="biib-20220331.xsd#biib_OthercorporaterevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e64bc3a3-c958-4f72-8409-9eef7091e2b6" xlink:to="loc_biib_OthercorporaterevenuesMember_c5aca094-b021-44d5-84e7-8d563d221ac7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_3becc52f-a10d-48b9-b39a-b0433292d178" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e64bc3a3-c958-4f72-8409-9eef7091e2b6" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_3becc52f-a10d-48b9-b39a-b0433292d178" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_abc8d871-d3af-4eba-a267-19850356b5f2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_09aea55e-c24b-48b2-9775-70a44bc656da" xlink:to="loc_srt_MajorCustomersAxis_abc8d871-d3af-4eba-a267-19850356b5f2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_abc8d871-d3af-4eba-a267-19850356b5f2_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_abc8d871-d3af-4eba-a267-19850356b5f2" xlink:to="loc_srt_NameOfMajorCustomerDomain_abc8d871-d3af-4eba-a267-19850356b5f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_f68c4e49-be2a-451b-bb60-dab81153888b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_abc8d871-d3af-4eba-a267-19850356b5f2" xlink:to="loc_srt_NameOfMajorCustomerDomain_f68c4e49-be2a-451b-bb60-dab81153888b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_0e825491-128c-47af-add4-0a13781542a5" xlink:href="biib-20220331.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_f68c4e49-be2a-451b-bb60-dab81153888b" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_0e825491-128c-47af-add4-0a13781542a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ZINBRYTAMember_43296cbf-ff93-4fd5-aaf3-8488f34977a3" xlink:href="biib-20220331.xsd#biib_ZINBRYTAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_f68c4e49-be2a-451b-bb60-dab81153888b" xlink:to="loc_biib_ZINBRYTAMember_43296cbf-ff93-4fd5-aaf3-8488f34977a3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesNarrativeDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#RevenuesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesNarrativeDetails" xlink:type="extended" id="i55c724e29c87448db14d7af897ad69a8_RevenuesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_5ee32246-3259-413c-ad9b-ab42151adacc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_90f7bde8-a842-49cc-9718-86904c512feb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5ee32246-3259-413c-ad9b-ab42151adacc" xlink:to="loc_us-gaap_Revenues_90f7bde8-a842-49cc-9718-86904c512feb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_447ef24e-67ff-49dc-bdf5-b217acd201d3" xlink:href="biib-20220331.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5ee32246-3259-413c-ad9b-ab42151adacc" xlink:to="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_447ef24e-67ff-49dc-bdf5-b217acd201d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfWholesalers_fae94bc1-0aca-4228-855b-4c9f7d2b6ee2" xlink:href="biib-20220331.xsd#biib_NumberOfWholesalers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5ee32246-3259-413c-ad9b-ab42151adacc" xlink:to="loc_biib_NumberOfWholesalers_fae94bc1-0aca-4228-855b-4c9f7d2b6ee2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_835b90fe-196d-4c67-ac8d-62cc1744f9fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5ee32246-3259-413c-ad9b-ab42151adacc" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_835b90fe-196d-4c67-ac8d-62cc1744f9fd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fc6cc4cb-80df-4203-9a82-7dd2b4864839" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_835b90fe-196d-4c67-ac8d-62cc1744f9fd" xlink:to="loc_srt_ProductOrServiceAxis_fc6cc4cb-80df-4203-9a82-7dd2b4864839" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fc6cc4cb-80df-4203-9a82-7dd2b4864839_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_fc6cc4cb-80df-4203-9a82-7dd2b4864839" xlink:to="loc_srt_ProductsAndServicesDomain_fc6cc4cb-80df-4203-9a82-7dd2b4864839_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2da15d77-661f-44a3-be9f-c3989bf2503f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_fc6cc4cb-80df-4203-9a82-7dd2b4864839" xlink:to="loc_srt_ProductsAndServicesDomain_2da15d77-661f-44a3-be9f-c3989bf2503f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OthercorporaterevenuesMember_7d5c2deb-a973-4921-a4db-793be7ba0b12" xlink:href="biib-20220331.xsd#biib_OthercorporaterevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2da15d77-661f-44a3-be9f-c3989bf2503f" xlink:to="loc_biib_OthercorporaterevenuesMember_7d5c2deb-a973-4921-a4db-793be7ba0b12" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_441cd6e8-d552-472d-a26c-94a7e96d1bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2da15d77-661f-44a3-be9f-c3989bf2503f" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_441cd6e8-d552-472d-a26c-94a7e96d1bb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_7101282e-b7ee-485f-a338-ae71035fb6ee" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_835b90fe-196d-4c67-ac8d-62cc1744f9fd" xlink:to="loc_srt_MajorCustomersAxis_7101282e-b7ee-485f-a338-ae71035fb6ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_7101282e-b7ee-485f-a338-ae71035fb6ee_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_7101282e-b7ee-485f-a338-ae71035fb6ee" xlink:to="loc_srt_NameOfMajorCustomerDomain_7101282e-b7ee-485f-a338-ae71035fb6ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_0d878043-f8a3-4559-8b2f-7ff966133466" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_7101282e-b7ee-485f-a338-ae71035fb6ee" xlink:to="loc_srt_NameOfMajorCustomerDomain_0d878043-f8a3-4559-8b2f-7ff966133466" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorOneMember_a07031cc-bb8c-4599-bbf9-88ff14be88de" xlink:href="biib-20220331.xsd#biib_DistributorOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_0d878043-f8a3-4559-8b2f-7ff966133466" xlink:to="loc_biib_DistributorOneMember_a07031cc-bb8c-4599-bbf9-88ff14be88de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorTwoMember_af1eb086-c957-4bae-bfe8-e20f825293f4" xlink:href="biib-20220331.xsd#biib_DistributorTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_0d878043-f8a3-4559-8b2f-7ff966133466" xlink:to="loc_biib_DistributorTwoMember_af1eb086-c957-4bae-bfe8-e20f825293f4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryNarrativeDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#InventoryNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InventoryNarrativeDetails" xlink:type="extended" id="i215561c4f79a408594c5cc146a277596_InventoryNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_b0bfdc22-341a-43d7-a0d5-876f5a20bc7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_ea2cb098-135b-4b29-b097-c30df0c6583e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_b0bfdc22-341a-43d7-a0d5-876f5a20bc7a" xlink:to="loc_us-gaap_InventoryWriteDown_ea2cb098-135b-4b29-b097-c30df0c6583e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5e5273f4-1985-49b6-ae5d-a6ed84fef871" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_b0bfdc22-341a-43d7-a0d5-876f5a20bc7a" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5e5273f4-1985-49b6-ae5d-a6ed84fef871" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_361b3872-5e42-4aad-8ccd-68f257d81e7f" xlink:href="biib-20220331.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_b0bfdc22-341a-43d7-a0d5-876f5a20bc7a" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_361b3872-5e42-4aad-8ccd-68f257d81e7f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InventoryNetCurrentAndNoncurrent_97af5aaa-27b2-4cd1-b798-15bd9393cca5" xlink:href="biib-20220331.xsd#biib_InventoryNetCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_b0bfdc22-341a-43d7-a0d5-876f5a20bc7a" xlink:to="loc_biib_InventoryNetCurrentAndNoncurrent_97af5aaa-27b2-4cd1-b798-15bd9393cca5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_429b8229-20c1-49a4-bd89-31210c1c2da1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_b0bfdc22-341a-43d7-a0d5-876f5a20bc7a" xlink:to="loc_us-gaap_InventoryCurrentTable_429b8229-20c1-49a4-bd89-31210c1c2da1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_50dec1de-06ce-4152-ab16-a2926a63f927" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_429b8229-20c1-49a4-bd89-31210c1c2da1" xlink:to="loc_srt_ProductOrServiceAxis_50dec1de-06ce-4152-ab16-a2926a63f927" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_50dec1de-06ce-4152-ab16-a2926a63f927_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_50dec1de-06ce-4152-ab16-a2926a63f927" xlink:to="loc_srt_ProductsAndServicesDomain_50dec1de-06ce-4152-ab16-a2926a63f927_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_08b902aa-bc8a-48d2-aa3a-9a5aed5986ed" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_50dec1de-06ce-4152-ab16-a2926a63f927" xlink:to="loc_srt_ProductsAndServicesDomain_08b902aa-bc8a-48d2-aa3a-9a5aed5986ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_76e1e014-7e19-4b08-be2f-3f4777f0e367" xlink:href="biib-20220331.xsd#biib_ADUHELMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_08b902aa-bc8a-48d2-aa3a-9a5aed5986ed" xlink:to="loc_biib_ADUHELMMember_76e1e014-7e19-4b08-be2f-3f4777f0e367" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f8cfce26-2cc2-4508-93f7-a695b5d92d62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_429b8229-20c1-49a4-bd89-31210c1c2da1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f8cfce26-2cc2-4508-93f7-a695b5d92d62" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f8cfce26-2cc2-4508-93f7-a695b5d92d62_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f8cfce26-2cc2-4508-93f7-a695b5d92d62" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f8cfce26-2cc2-4508-93f7-a695b5d92d62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a9fdbaf4-51f5-4aa7-9fab-376c00d64bae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f8cfce26-2cc2-4508-93f7-a695b5d92d62" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a9fdbaf4-51f5-4aa7-9fab-376c00d64bae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_688df941-3cc0-47c9-90b9-6d563d82e368" xlink:href="biib-20220331.xsd#biib_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a9fdbaf4-51f5-4aa7-9fab-376c00d64bae" xlink:to="loc_biib_EisaiMember_688df941-3cc0-47c9-90b9-6d563d82e368" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_baa56de9-ce13-4118-82d1-db9dc4ca4d26" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_429b8229-20c1-49a4-bd89-31210c1c2da1" xlink:to="loc_srt_CounterpartyNameAxis_baa56de9-ce13-4118-82d1-db9dc4ca4d26" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_baa56de9-ce13-4118-82d1-db9dc4ca4d26_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_baa56de9-ce13-4118-82d1-db9dc4ca4d26" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_baa56de9-ce13-4118-82d1-db9dc4ca4d26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4a704c76-0169-4ba5-9cfd-a6c3dc97a58d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_baa56de9-ce13-4118-82d1-db9dc4ca4d26" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4a704c76-0169-4ba5-9cfd-a6c3dc97a58d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CentersForMedicareAndMedicaidServiceMember_aa5de7f7-234d-4dc3-97fb-55d26150ef57" xlink:href="biib-20220331.xsd#biib_CentersForMedicareAndMedicaidServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4a704c76-0169-4ba5-9cfd-a6c3dc97a58d" xlink:to="loc_biib_CentersForMedicareAndMedicaidServiceMember_aa5de7f7-234d-4dc3-97fb-55d26150ef57" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#IntangibleAssetsandGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="extended" id="i71d8db7542c74a698c238e2e564b08e5_IntangibleAssetsandGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2f78f5f2-c950-415f-98de-b611a4229950" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_ba8131a9-31e3-41fa-b6b4-5b7d45e80c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2f78f5f2-c950-415f-98de-b611a4229950" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_ba8131a9-31e3-41fa-b6b4-5b7d45e80c7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_101ff643-9171-4bee-8bd9-1c4a43c22151" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_ba8131a9-31e3-41fa-b6b4-5b7d45e80c7e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_101ff643-9171-4bee-8bd9-1c4a43c22151" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_43826931-7ba4-4bf7-a1eb-a7e3a22b75ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_ba8131a9-31e3-41fa-b6b4-5b7d45e80c7e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_43826931-7ba4-4bf7-a1eb-a7e3a22b75ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_09b6ebbd-a044-4676-804f-e7cceb3b11b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_ba8131a9-31e3-41fa-b6b4-5b7d45e80c7e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_09b6ebbd-a044-4676-804f-e7cceb3b11b2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7aaab4b1-cb6b-435c-8ab9-72f121015fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_ba8131a9-31e3-41fa-b6b4-5b7d45e80c7e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7aaab4b1-cb6b-435c-8ab9-72f121015fb4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_1e75f51f-36e8-47c9-8a79-d713b72fd140" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_ba8131a9-31e3-41fa-b6b4-5b7d45e80c7e" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_1e75f51f-36e8-47c9-8a79-d713b72fd140" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5421b97f-adb7-4c55-9f3d-ebbbf6ce5077" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_ba8131a9-31e3-41fa-b6b4-5b7d45e80c7e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5421b97f-adb7-4c55-9f3d-ebbbf6ce5077" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_805dc206-cac4-4ec8-9674-996fe37e4298" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_ba8131a9-31e3-41fa-b6b4-5b7d45e80c7e" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_805dc206-cac4-4ec8-9674-996fe37e4298" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_d9d150a1-3a4c-4cec-a80c-9b3b13747cf6" xlink:href="biib-20220331.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2f78f5f2-c950-415f-98de-b611a4229950" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_d9d150a1-3a4c-4cec-a80c-9b3b13747cf6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_564483a1-13c2-4e1d-80a7-f9622ec72f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2f78f5f2-c950-415f-98de-b611a4229950" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_564483a1-13c2-4e1d-80a7-f9622ec72f6a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_5c383acb-4930-4734-bb9f-7668f6c36b60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2f78f5f2-c950-415f-98de-b611a4229950" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_5c383acb-4930-4734-bb9f-7668f6c36b60" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_47aeb672-b441-4746-bb5e-f360f5e34d01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2f78f5f2-c950-415f-98de-b611a4229950" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_47aeb672-b441-4746-bb5e-f360f5e34d01" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_55508aa9-b6f1-4a5a-aece-4b4a0ba4074d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2f78f5f2-c950-415f-98de-b611a4229950" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_55508aa9-b6f1-4a5a-aece-4b4a0ba4074d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_c2628aae-3358-47e0-ad6e-8237a3ca01f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2f78f5f2-c950-415f-98de-b611a4229950" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_c2628aae-3358-47e0-ad6e-8237a3ca01f9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_a8c8b2a8-75d0-493a-bbd9-67726ed34ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2f78f5f2-c950-415f-98de-b611a4229950" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_a8c8b2a8-75d0-493a-bbd9-67726ed34ec3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_65b15d4e-b695-4c12-91ab-1b5179a860ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2f78f5f2-c950-415f-98de-b611a4229950" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_65b15d4e-b695-4c12-91ab-1b5179a860ff" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_d3944e83-8416-4341-962e-f467e08aba33" xlink:href="biib-20220331.xsd#biib_ResearchanddevelopmentassetAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_65b15d4e-b695-4c12-91ab-1b5179a860ff" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_d3944e83-8416-4341-962e-f467e08aba33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_d3944e83-8416-4341-962e-f467e08aba33_default" xlink:href="biib-20220331.xsd#biib_ResearchanddevelopmentassetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_d3944e83-8416-4341-962e-f467e08aba33" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_d3944e83-8416-4341-962e-f467e08aba33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_ba4032a7-3bdb-4c65-bb16-f069295bd728" xlink:href="biib-20220331.xsd#biib_ResearchanddevelopmentassetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_d3944e83-8416-4341-962e-f467e08aba33" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_ba4032a7-3bdb-4c65-bb16-f069295bd728" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_VixotrigineMember_6613efee-f40d-45a3-8db0-d5a694db831e" xlink:href="biib-20220331.xsd#biib_VixotrigineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_ba4032a7-3bdb-4c65-bb16-f069295bd728" xlink:to="loc_biib_VixotrigineMember_6613efee-f40d-45a3-8db0-d5a694db831e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TGNMember_f7b6d78f-952c-476e-b543-309dfdf2d840" xlink:href="biib-20220331.xsd#biib_TGNMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_ba4032a7-3bdb-4c65-bb16-f069295bd728" xlink:to="loc_biib_TGNMember_f7b6d78f-952c-476e-b543-309dfdf2d840" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_58429d90-7201-4b7f-b708-87f3c0c700e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_65b15d4e-b695-4c12-91ab-1b5179a860ff" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_58429d90-7201-4b7f-b708-87f3c0c700e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_58429d90-7201-4b7f-b708-87f3c0c700e9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_58429d90-7201-4b7f-b708-87f3c0c700e9" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_58429d90-7201-4b7f-b708-87f3c0c700e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_560d8a64-cd5a-4956-9c45-9a35e65f49b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_58429d90-7201-4b7f-b708-87f3c0c700e9" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_560d8a64-cd5a-4956-9c45-9a35e65f49b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_fa73bc68-d6c1-4b0a-9289-77899c2cf893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_560d8a64-cd5a-4956-9c45-9a35e65f49b0" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_fa73bc68-d6c1-4b0a-9289-77899c2cf893" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_03fdee23-f210-4fa8-890e-b452d57950e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_560d8a64-cd5a-4956-9c45-9a35e65f49b0" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_03fdee23-f210-4fa8-890e-b452d57950e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cd345392-6b26-4117-a87e-1c58f66f321a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_65b15d4e-b695-4c12-91ab-1b5179a860ff" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cd345392-6b26-4117-a87e-1c58f66f321a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cd345392-6b26-4117-a87e-1c58f66f321a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cd345392-6b26-4117-a87e-1c58f66f321a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cd345392-6b26-4117-a87e-1c58f66f321a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_59e7b3bc-3bd6-4611-b478-341cada185bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cd345392-6b26-4117-a87e-1c58f66f321a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_59e7b3bc-3bd6-4611-b478-341cada185bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OutLicensedPatentsMember_fc8f19da-c3d3-4480-967e-f6b57b9d689e" xlink:href="biib-20220331.xsd#biib_OutLicensedPatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_59e7b3bc-3bd6-4611-b478-341cada185bf" xlink:to="loc_biib_OutLicensedPatentsMember_fc8f19da-c3d3-4480-967e-f6b57b9d689e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_13bad91a-4dc3-4f4a-bf00-39ea24330556" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_59e7b3bc-3bd6-4611-b478-341cada185bf" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_13bad91a-4dc3-4f4a-bf00-39ea24330556" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1370cb04-f78a-466b-8841-4cf66d53ce00" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_65b15d4e-b695-4c12-91ab-1b5179a860ff" xlink:to="loc_srt_RangeAxis_1370cb04-f78a-466b-8841-4cf66d53ce00" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1370cb04-f78a-466b-8841-4cf66d53ce00_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1370cb04-f78a-466b-8841-4cf66d53ce00" xlink:to="loc_srt_RangeMember_1370cb04-f78a-466b-8841-4cf66d53ce00_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7b65147b-53d6-4611-a4e4-41e58a95a98b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1370cb04-f78a-466b-8841-4cf66d53ce00" xlink:to="loc_srt_RangeMember_7b65147b-53d6-4611-a4e4-41e58a95a98b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6460c320-7521-4787-a2d2-28f56853a1d2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7b65147b-53d6-4611-a4e4-41e58a95a98b" xlink:to="loc_srt_MinimumMember_6460c320-7521-4787-a2d2-28f56853a1d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_baf4cbb1-7bcc-465f-8e61-c90b86a0b706" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7b65147b-53d6-4611-a4e4-41e58a95a98b" xlink:to="loc_srt_MaximumMember_baf4cbb1-7bcc-465f-8e61-c90b86a0b706" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended" id="ib1634ae863584b329cec6c62fe7c9765_FairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42eaa6ce-b71c-4286-8bb9-86b50085d192" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_deac2c66-e6da-41fe-a83d-7a036f827e76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42eaa6ce-b71c-4286-8bb9-86b50085d192" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_deac2c66-e6da-41fe-a83d-7a036f827e76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_122a4487-bc0d-4e64-a754-b37e5c0c2ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_deac2c66-e6da-41fe-a83d-7a036f827e76" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_122a4487-bc0d-4e64-a754-b37e5c0c2ec1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5eba2bb7-af54-4a1a-bf9b-c9a54e16cec7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_122a4487-bc0d-4e64-a754-b37e5c0c2ec1" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5eba2bb7-af54-4a1a-bf9b-c9a54e16cec7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f665c6a7-9b80-4544-9b6e-21300c252123" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_122a4487-bc0d-4e64-a754-b37e5c0c2ec1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f665c6a7-9b80-4544-9b6e-21300c252123" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_643b809d-1244-43c8-8ca2-df7de6ef1039" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_122a4487-bc0d-4e64-a754-b37e5c0c2ec1" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_643b809d-1244-43c8-8ca2-df7de6ef1039" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_c1b3e0ab-b467-4be6-a8dd-1e393ec0c8df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_122a4487-bc0d-4e64-a754-b37e5c0c2ec1" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_c1b3e0ab-b467-4be6-a8dd-1e393ec0c8df" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_581e054d-b923-4006-ac05-0a325bb22f69" xlink:href="biib-20220331.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_122a4487-bc0d-4e64-a754-b37e5c0c2ec1" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_581e054d-b923-4006-ac05-0a325bb22f69" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_aa2827a9-71b4-48f4-bb5e-f02ce1676789" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_122a4487-bc0d-4e64-a754-b37e5c0c2ec1" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_aa2827a9-71b4-48f4-bb5e-f02ce1676789" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_14896d28-1dff-4e91-8d75-4df82454ee98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_deac2c66-e6da-41fe-a83d-7a036f827e76" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_14896d28-1dff-4e91-8d75-4df82454ee98" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_967e6db9-1838-43f8-973d-a74fd215aed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_14896d28-1dff-4e91-8d75-4df82454ee98" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_967e6db9-1838-43f8-973d-a74fd215aed4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2b1878eb-b5a5-4b72-971f-6adbf49966a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_14896d28-1dff-4e91-8d75-4df82454ee98" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2b1878eb-b5a5-4b72-971f-6adbf49966a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_15e55c48-ef25-4fd1-b107-3826c614c7f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_14896d28-1dff-4e91-8d75-4df82454ee98" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_15e55c48-ef25-4fd1-b107-3826c614c7f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_758f4cb5-e036-4c80-91b6-89148082c429" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42eaa6ce-b71c-4286-8bb9-86b50085d192" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_758f4cb5-e036-4c80-91b6-89148082c429" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_212dfd47-b47b-4f75-bb42-7bd5893a5835" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_758f4cb5-e036-4c80-91b6-89148082c429" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_212dfd47-b47b-4f75-bb42-7bd5893a5835" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_212dfd47-b47b-4f75-bb42-7bd5893a5835_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_212dfd47-b47b-4f75-bb42-7bd5893a5835" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_212dfd47-b47b-4f75-bb42-7bd5893a5835_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_65bd5e7f-b796-41dc-8404-6ca55edc6f61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_212dfd47-b47b-4f75-bb42-7bd5893a5835" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_65bd5e7f-b796-41dc-8404-6ca55edc6f61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_25176269-e961-4849-9854-9ccf2f980d09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_65bd5e7f-b796-41dc-8404-6ca55edc6f61" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_25176269-e961-4849-9854-9ccf2f980d09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_c91d0b34-7583-461f-b85d-1e89f11fb4bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_65bd5e7f-b796-41dc-8404-6ca55edc6f61" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_c91d0b34-7583-461f-b85d-1e89f11fb4bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_03a1055e-d842-4f87-a501-d22969c9d77b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_65bd5e7f-b796-41dc-8404-6ca55edc6f61" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_03a1055e-d842-4f87-a501-d22969c9d77b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f71aadb8-578f-4daf-9b1e-22707b483cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_758f4cb5-e036-4c80-91b6-89148082c429" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f71aadb8-578f-4daf-9b1e-22707b483cfe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_f71aadb8-578f-4daf-9b1e-22707b483cfe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f71aadb8-578f-4daf-9b1e-22707b483cfe" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_f71aadb8-578f-4daf-9b1e-22707b483cfe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_b5ed3d4a-cea8-485e-b78e-71ba27546105" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f71aadb8-578f-4daf-9b1e-22707b483cfe" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_b5ed3d4a-cea8-485e-b78e-71ba27546105" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_5b0ea085-e04d-4503-a498-cb7b66876bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_b5ed3d4a-cea8-485e-b78e-71ba27546105" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_5b0ea085-e04d-4503-a498-cb7b66876bc3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_42acba19-4f35-47ff-8528-fb3fc00ac3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_758f4cb5-e036-4c80-91b6-89148082c429" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_42acba19-4f35-47ff-8528-fb3fc00ac3c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_42acba19-4f35-47ff-8528-fb3fc00ac3c9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_42acba19-4f35-47ff-8528-fb3fc00ac3c9" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_42acba19-4f35-47ff-8528-fb3fc00ac3c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a3642954-b692-4617-a4ac-9c05934cca07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_42acba19-4f35-47ff-8528-fb3fc00ac3c9" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a3642954-b692-4617-a4ac-9c05934cca07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_07af2ba7-813b-449a-98e8-ef83a5bcc332" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a3642954-b692-4617-a4ac-9c05934cca07" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_07af2ba7-813b-449a-98e8-ef83a5bcc332" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_1a2b0b01-ef7f-4144-bdf1-9f72b6e871ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a3642954-b692-4617-a4ac-9c05934cca07" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_1a2b0b01-ef7f-4144-bdf1-9f72b6e871ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_41e63f27-d865-4fc2-bb96-19874c128947" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a3642954-b692-4617-a4ac-9c05934cca07" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_41e63f27-d865-4fc2-bb96-19874c128947" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="simple" xlink:href="biib-20220331.xsd#FairValueMeasurementsDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended" id="ie63c35b512ae45209be834eca7e3a357_FairValueMeasurementsDetailsTextual">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_ad20be2c-f7ab-43b8-a0c4-5eee87e7aca1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_19360e79-a722-4f5e-ac60-9ccf78c5a97d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_ad20be2c-f7ab-43b8-a0c4-5eee87e7aca1" xlink:to="loc_us-gaap_AssetImpairmentCharges_19360e79-a722-4f5e-ac60-9ccf78c5a97d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e8cbc7a1-417b-42e4-bdaf-6c02d4486df9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_ad20be2c-f7ab-43b8-a0c4-5eee87e7aca1" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e8cbc7a1-417b-42e4-bdaf-6c02d4486df9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_e4163639-9803-4281-ac25-ec60ab0b58fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_ad20be2c-f7ab-43b8-a0c4-5eee87e7aca1" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_e4163639-9803-4281-ac25-ec60ab0b58fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TechnologicalAndRegulatorySuccessProbability_6c0d7e33-3cbc-4b6c-a4ca-0afdc22fdcc7" xlink:href="biib-20220331.xsd#biib_TechnologicalAndRegulatorySuccessProbability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_ad20be2c-f7ab-43b8-a0c4-5eee87e7aca1" xlink:to="loc_biib_TechnologicalAndRegulatorySuccessProbability_6c0d7e33-3cbc-4b6c-a4ca-0afdc22fdcc7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_81e2e408-78ce-40ea-9329-e2520ff91f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_ad20be2c-f7ab-43b8-a0c4-5eee87e7aca1" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_81e2e408-78ce-40ea-9329-e2520ff91f0b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_0a16affb-d885-455d-bf0d-28db37ed1279" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_81e2e408-78ce-40ea-9329-e2520ff91f0b" xlink:to="loc_us-gaap_DebtInstrumentAxis_0a16affb-d885-455d-bf0d-28db37ed1279" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0a16affb-d885-455d-bf0d-28db37ed1279_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_0a16affb-d885-455d-bf0d-28db37ed1279" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0a16affb-d885-455d-bf0d-28db37ed1279_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_81db7d96-bc87-4521-a33e-d73e6a2d6b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_0a16affb-d885-455d-bf0d-28db37ed1279" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_81db7d96-bc87-4521-a33e-d73e6a2d6b2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_bc40581f-1b5a-490d-844d-4dad42fffe50" xlink:href="biib-20220331.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_81db7d96-bc87-4521-a33e-d73e6a2d6b2a" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_bc40581f-1b5a-490d-844d-4dad42fffe50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_5622c601-95bd-474d-bb96-91a186fbbae8" xlink:href="biib-20220331.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_81db7d96-bc87-4521-a33e-d73e6a2d6b2a" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_5622c601-95bd-474d-bb96-91a186fbbae8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_ae5ae3ea-698a-4f42-99af-231997457043" xlink:href="biib-20220331.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_81db7d96-bc87-4521-a33e-d73e6a2d6b2a" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_ae5ae3ea-698a-4f42-99af-231997457043" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:type="extended" id="if59308f10166478a9ab447eee0bc18a4_FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1a10c028-eb47-4036-ac62-7a98e0446a56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_02306d75-d4f4-43a0-a0f6-21864fc5ada5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1a10c028-eb47-4036-ac62-7a98e0446a56" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_02306d75-d4f4-43a0-a0f6-21864fc5ada5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_d0449374-263d-4a98-8c12-67aac0208c97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1a10c028-eb47-4036-ac62-7a98e0446a56" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_d0449374-263d-4a98-8c12-67aac0208c97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c5c9adcc-db61-46a7-9695-c7e9a61118e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1a10c028-eb47-4036-ac62-7a98e0446a56" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c5c9adcc-db61-46a7-9695-c7e9a61118e8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f866f751-a886-4f8f-91a0-f6f911eccae7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c5c9adcc-db61-46a7-9695-c7e9a61118e8" xlink:to="loc_srt_RangeAxis_f866f751-a886-4f8f-91a0-f6f911eccae7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f866f751-a886-4f8f-91a0-f6f911eccae7_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f866f751-a886-4f8f-91a0-f6f911eccae7" xlink:to="loc_srt_RangeMember_f866f751-a886-4f8f-91a0-f6f911eccae7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6bf5d048-76d7-4280-ab29-fe0691414762" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f866f751-a886-4f8f-91a0-f6f911eccae7" xlink:to="loc_srt_RangeMember_6bf5d048-76d7-4280-ab29-fe0691414762" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_79329f22-6267-4c51-bd9c-bb5d2bdc3cf6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6bf5d048-76d7-4280-ab29-fe0691414762" xlink:to="loc_srt_WeightedAverageMember_79329f22-6267-4c51-bd9c-bb5d2bdc3cf6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_0ee2b65d-1ed3-4729-a805-d98d8562be81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c5c9adcc-db61-46a7-9695-c7e9a61118e8" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_0ee2b65d-1ed3-4729-a805-d98d8562be81" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_0ee2b65d-1ed3-4729-a805-d98d8562be81_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_0ee2b65d-1ed3-4729-a805-d98d8562be81" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_0ee2b65d-1ed3-4729-a805-d98d8562be81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_aa4908fe-cff5-4e43-ba11-018f6bac4708" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_0ee2b65d-1ed3-4729-a805-d98d8562be81" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_aa4908fe-cff5-4e43-ba11-018f6bac4708" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_970ed2e7-9391-40d4-b01b-48a63ab33cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_aa4908fe-cff5-4e43-ba11-018f6bac4708" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_970ed2e7-9391-40d4-b01b-48a63ab33cd4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="simple" xlink:href="biib-20220331.xsd#FairValueMeasurementsDetails1"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended" id="i782fd61ca199425bab66eda17a831209_FairValueMeasurementsDetails1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0a87a471-6d8e-44ab-ad7f-86f1df006d45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_b257aa91-7e72-4354-af92-5215542a35c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0a87a471-6d8e-44ab-ad7f-86f1df006d45" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_b257aa91-7e72-4354-af92-5215542a35c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_1f37af7d-ef79-452c-8eea-4c271899cdf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0a87a471-6d8e-44ab-ad7f-86f1df006d45" xlink:to="loc_us-gaap_NotesPayable_1f37af7d-ef79-452c-8eea-4c271899cdf7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_cbc4ef1a-df98-4435-8a4c-cccaf490da75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0a87a471-6d8e-44ab-ad7f-86f1df006d45" xlink:to="loc_us-gaap_DebtInstrumentFairValue_cbc4ef1a-df98-4435-8a4c-cccaf490da75" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_fb5abe1f-c4b8-4d98-bf13-1924c03b9a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0a87a471-6d8e-44ab-ad7f-86f1df006d45" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_fb5abe1f-c4b8-4d98-bf13-1924c03b9a5d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LongTermDebtExchangedAmount_9f00b766-3e62-4ebf-8f50-7ad6dbd2033d" xlink:href="biib-20220331.xsd#biib_LongTermDebtExchangedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0a87a471-6d8e-44ab-ad7f-86f1df006d45" xlink:to="loc_biib_LongTermDebtExchangedAmount_9f00b766-3e62-4ebf-8f50-7ad6dbd2033d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_4e4bc873-b689-4f2e-9ba4-629e99b00b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0a87a471-6d8e-44ab-ad7f-86f1df006d45" xlink:to="loc_us-gaap_DebtInstrumentTable_4e4bc873-b689-4f2e-9ba4-629e99b00b0b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_bd85cb93-a7b6-4363-b960-14dfa4977468" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4e4bc873-b689-4f2e-9ba4-629e99b00b0b" xlink:to="loc_us-gaap_DebtInstrumentAxis_bd85cb93-a7b6-4363-b960-14dfa4977468" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bd85cb93-a7b6-4363-b960-14dfa4977468_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_bd85cb93-a7b6-4363-b960-14dfa4977468" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bd85cb93-a7b6-4363-b960-14dfa4977468_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_742be7ab-5dab-48e7-a6ca-3faf46943610" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_bd85cb93-a7b6-4363-b960-14dfa4977468" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_742be7ab-5dab-48e7-a6ca-3faf46943610" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_df7728fc-7b3b-44de-be79-cf0e62b6fe9d" xlink:href="biib-20220331.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_742be7ab-5dab-48e7-a6ca-3faf46943610" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_df7728fc-7b3b-44de-be79-cf0e62b6fe9d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_35b00977-8214-4d91-a2f4-d4fe986b86bc" xlink:href="biib-20220331.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_742be7ab-5dab-48e7-a6ca-3faf46943610" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_35b00977-8214-4d91-a2f4-d4fe986b86bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.25SeniorNotesdueMay12030Member_b0cee811-d9bb-4916-b7a0-f95e215f13a1" xlink:href="biib-20220331.xsd#biib_A2.25SeniorNotesdueMay12030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_742be7ab-5dab-48e7-a6ca-3faf46943610" xlink:to="loc_biib_A2.25SeniorNotesdueMay12030Member_b0cee811-d9bb-4916-b7a0-f95e215f13a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_10e13de0-2340-4aa5-b8bc-5b485f6af4ba" xlink:href="biib-20220331.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_742be7ab-5dab-48e7-a6ca-3faf46943610" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_10e13de0-2340-4aa5-b8bc-5b485f6af4ba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3.15SeniorNotesdueMay12050Member_3b0eae0c-29c4-4fad-b538-491cc23e7a11" xlink:href="biib-20220331.xsd#biib_A3.15SeniorNotesdueMay12050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_742be7ab-5dab-48e7-a6ca-3faf46943610" xlink:to="loc_biib_A3.15SeniorNotesdueMay12050Member_3b0eae0c-29c4-4fad-b538-491cc23e7a11" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3250SeniorNotesDueFebruary152051Member_cfe6b8a0-b763-4d6e-bff8-cc28e245092f" xlink:href="biib-20220331.xsd#biib_A3250SeniorNotesDueFebruary152051Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_742be7ab-5dab-48e7-a6ca-3faf46943610" xlink:to="loc_biib_A3250SeniorNotesDueFebruary152051Member_cfe6b8a0-b763-4d6e-bff8-cc28e245092f" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="simple" xlink:href="biib-20220331.xsd#FairValueMeasurementsDetails2"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended" id="i7ff16970dce74421b6d2399d39e415a8_FairValueMeasurementsDetails2">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_d34cff7d-9dbc-4ff2-b187-1367d0d79144" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_077fda16-bef3-4860-98b1-2245f7ed9b05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_d34cff7d-9dbc-4ff2-b187-1367d0d79144" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_077fda16-bef3-4860-98b1-2245f7ed9b05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_0f459ef2-a9bb-4099-b4f7-897d5d79edb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_d34cff7d-9dbc-4ff2-b187-1367d0d79144" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_0f459ef2-a9bb-4099-b4f7-897d5d79edb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8157a318-a900-4d53-822c-0461b19f4ead" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_e1b997d3-5dd5-47fd-a6d4-c0e7960a5d56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_d34cff7d-9dbc-4ff2-b187-1367d0d79144" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_e1b997d3-5dd5-47fd-a6d4-c0e7960a5d56" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_37461c17-8f48-456f-bfe7-6fd16bfc5a8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_e1b997d3-5dd5-47fd-a6d4-c0e7960a5d56" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_37461c17-8f48-456f-bfe7-6fd16bfc5a8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_37461c17-8f48-456f-bfe7-6fd16bfc5a8f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_37461c17-8f48-456f-bfe7-6fd16bfc5a8f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_37461c17-8f48-456f-bfe7-6fd16bfc5a8f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3e756339-49be-405d-89c6-57dfacf8b74f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_37461c17-8f48-456f-bfe7-6fd16bfc5a8f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3e756339-49be-405d-89c6-57dfacf8b74f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_b527513c-2754-4ba6-b27e-aa3e41051c46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_3e756339-49be-405d-89c6-57dfacf8b74f" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_b527513c-2754-4ba6-b27e-aa3e41051c46" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#FinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended" id="iddfe6d27989345ffae63a4e07e2dbcfe_FinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_4479fc93-5b2b-435b-8a53-8bcc46bd75cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_58774848-9b82-4cfd-863e-216e9ade5b93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_4479fc93-5b2b-435b-8a53-8bcc46bd75cd" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_58774848-9b82-4cfd-863e-216e9ade5b93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_45a84bb0-8d7c-440a-934d-6631a7666ace" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_58774848-9b82-4cfd-863e-216e9ade5b93" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_45a84bb0-8d7c-440a-934d-6631a7666ace" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_0c6f9cfe-aff8-42cf-abfb-d3bc52a190e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_4479fc93-5b2b-435b-8a53-8bcc46bd75cd" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_0c6f9cfe-aff8-42cf-abfb-d3bc52a190e2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_0522c505-c7fe-4176-a50d-a2dc47f773ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_0c6f9cfe-aff8-42cf-abfb-d3bc52a190e2" xlink:to="loc_us-gaap_InvestmentTypeAxis_0522c505-c7fe-4176-a50d-a2dc47f773ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_0522c505-c7fe-4176-a50d-a2dc47f773ce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_0522c505-c7fe-4176-a50d-a2dc47f773ce" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_0522c505-c7fe-4176-a50d-a2dc47f773ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_2b46ef3f-2d84-492d-adbd-b65c468b1bff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_0522c505-c7fe-4176-a50d-a2dc47f773ce" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_2b46ef3f-2d84-492d-adbd-b65c468b1bff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_3a916f40-5ef9-42e8-b71d-b665a3d49139" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2b46ef3f-2d84-492d-adbd-b65c468b1bff" xlink:to="loc_us-gaap_CommercialPaperMember_3a916f40-5ef9-42e8-b71d-b665a3d49139" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_f849e0f7-0b08-4086-ab7a-388c2efd3ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepurchaseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2b46ef3f-2d84-492d-adbd-b65c468b1bff" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_f849e0f7-0b08-4086-ab7a-388c2efd3ebe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_52cd41d5-8bdd-44b0-91de-aa636aaae9bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2b46ef3f-2d84-492d-adbd-b65c468b1bff" xlink:to="loc_us-gaap_MoneyMarketFundsMember_52cd41d5-8bdd-44b0-91de-aa636aaae9bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_554acc84-5bf3-4d64-bc47-f4ade5139df8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2b46ef3f-2d84-492d-adbd-b65c468b1bff" xlink:to="loc_us-gaap_DebtSecuritiesMember_554acc84-5bf3-4d64-bc47-f4ade5139df8" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="simple" xlink:href="biib-20220331.xsd#FinancialInstrumentsDetails1"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended" id="i59c45d86327d4d5294010dd3a8a7bedb_FinancialInstrumentsDetails1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_13f6b84f-f5f5-4009-8ed9-877dbe4715d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0b70a1ff-8133-409f-be14-bf76e777a62e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_13f6b84f-f5f5-4009-8ed9-877dbe4715d2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0b70a1ff-8133-409f-be14-bf76e777a62e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_628f1b49-fb78-4016-8e10-8e19005413cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0b70a1ff-8133-409f-be14-bf76e777a62e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_628f1b49-fb78-4016-8e10-8e19005413cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4f45d8f0-2cd2-4433-af5e-e09f2371b194" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0b70a1ff-8133-409f-be14-bf76e777a62e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4f45d8f0-2cd2-4433-af5e-e09f2371b194" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9be084d5-0c44-4863-8654-072a1893bf2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0b70a1ff-8133-409f-be14-bf76e777a62e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9be084d5-0c44-4863-8654-072a1893bf2e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2ca30f0b-daee-4279-9ffd-9774fd4bf4d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0b70a1ff-8133-409f-be14-bf76e777a62e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2ca30f0b-daee-4279-9ffd-9774fd4bf4d4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_e015b69f-005f-4bb2-b400-1798c748ed03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_13f6b84f-f5f5-4009-8ed9-877dbe4715d2" xlink:to="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_e015b69f-005f-4bb2-b400-1798c748ed03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_9d68a3bc-4c3a-4275-896f-bbeff0690995" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_e015b69f-005f-4bb2-b400-1798c748ed03" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_9d68a3bc-4c3a-4275-896f-bbeff0690995" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_b0bc9d61-7240-42e5-b3db-5c036de807f5" xlink:href="biib-20220331.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_e015b69f-005f-4bb2-b400-1798c748ed03" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_b0bc9d61-7240-42e5-b3db-5c036de807f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_27994361-3826-4796-b9b6-4c1affd83ceb" xlink:href="biib-20220331.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_e015b69f-005f-4bb2-b400-1798c748ed03" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_27994361-3826-4796-b9b6-4c1affd83ceb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_f62129ae-acc5-4219-a01f-f24360cdaeaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_e015b69f-005f-4bb2-b400-1798c748ed03" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_f62129ae-acc5-4219-a01f-f24360cdaeaa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_4bc7182e-dbe8-437e-bc74-1fd040a34f6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_13f6b84f-f5f5-4009-8ed9-877dbe4715d2" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_4bc7182e-dbe8-437e-bc74-1fd040a34f6f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_f24af806-5113-41af-9250-3181795e3d94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_4bc7182e-dbe8-437e-bc74-1fd040a34f6f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_f24af806-5113-41af-9250-3181795e3d94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f24af806-5113-41af-9250-3181795e3d94_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f24af806-5113-41af-9250-3181795e3d94" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f24af806-5113-41af-9250-3181795e3d94_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2bae1c19-890d-4d2a-b804-dc55ab57d1a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f24af806-5113-41af-9250-3181795e3d94" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2bae1c19-890d-4d2a-b804-dc55ab57d1a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_13ab2b4a-0b58-4e03-82f8-87353e075619" xlink:href="biib-20220331.xsd#biib_CorporateDebtSecuritiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2bae1c19-890d-4d2a-b804-dc55ab57d1a1" xlink:to="loc_biib_CorporateDebtSecuritiesCurrentMember_13ab2b4a-0b58-4e03-82f8-87353e075619" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_f21994d6-ac9e-4f04-bb54-bf362130a2b2" xlink:href="biib-20220331.xsd#biib_CorporateDebtSecuritiesNonCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2bae1c19-890d-4d2a-b804-dc55ab57d1a1" xlink:to="loc_biib_CorporateDebtSecuritiesNonCurrentMember_f21994d6-ac9e-4f04-bb54-bf362130a2b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_a1173c29-54ea-45c3-9cc0-525d7a6b41c1" xlink:href="biib-20220331.xsd#biib_GovernmentSecuritiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2bae1c19-890d-4d2a-b804-dc55ab57d1a1" xlink:to="loc_biib_GovernmentSecuritiesCurrentMember_a1173c29-54ea-45c3-9cc0-525d7a6b41c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_22dc5f6a-e493-4fb8-aa5f-d5d22aa0cce6" xlink:href="biib-20220331.xsd#biib_GovernmentSecuritiesNonCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2bae1c19-890d-4d2a-b804-dc55ab57d1a1" xlink:to="loc_biib_GovernmentSecuritiesNonCurrentMember_22dc5f6a-e493-4fb8-aa5f-d5d22aa0cce6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_55bf0013-9a1f-4e78-ab2c-641b291fdc7f" xlink:href="biib-20220331.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2bae1c19-890d-4d2a-b804-dc55ab57d1a1" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_55bf0013-9a1f-4e78-ab2c-641b291fdc7f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_b1290bc7-a509-467e-932f-6105c29b737d" xlink:href="biib-20220331.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2bae1c19-890d-4d2a-b804-dc55ab57d1a1" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_b1290bc7-a509-467e-932f-6105c29b737d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesCurrentMember_8d2bb90f-499b-48cc-99e5-3dd2eb0cc58e" xlink:href="biib-20220331.xsd#biib_EquitySecuritiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2bae1c19-890d-4d2a-b804-dc55ab57d1a1" xlink:to="loc_biib_EquitySecuritiesCurrentMember_8d2bb90f-499b-48cc-99e5-3dd2eb0cc58e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesNonCurrentMember_17c4cd3d-e6cd-4ac3-b990-f9724dce4119" xlink:href="biib-20220331.xsd#biib_EquitySecuritiesNonCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2bae1c19-890d-4d2a-b804-dc55ab57d1a1" xlink:to="loc_biib_EquitySecuritiesNonCurrentMember_17c4cd3d-e6cd-4ac3-b990-f9724dce4119" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" xlink:href="biib-20220331.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended" id="i0e3ca680c33544d78a76893263966cb5_FinancialInstrumentsFinancialInstrumentsDetailsTextual2">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_896e0f22-fe42-4dc5-b2f3-32d503a9be40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentPortfolio_29784210-7ec0-4ac1-86c9-e4c2086b33d9" xlink:href="biib-20220331.xsd#biib_StrategicInvestmentPortfolio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_896e0f22-fe42-4dc5-b2f3-32d503a9be40" xlink:to="loc_biib_StrategicInvestmentPortfolio_29784210-7ec0-4ac1-86c9-e4c2086b33d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a7610f76-d2d6-40c1-8b61-d3ca614118d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_896e0f22-fe42-4dc5-b2f3-32d503a9be40" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a7610f76-d2d6-40c1-8b61-d3ca614118d1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_e1efac9e-64f7-4b0a-bd66-625fa265965a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a7610f76-d2d6-40c1-8b61-d3ca614118d1" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_e1efac9e-64f7-4b0a-bd66-625fa265965a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e1efac9e-64f7-4b0a-bd66-625fa265965a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e1efac9e-64f7-4b0a-bd66-625fa265965a" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e1efac9e-64f7-4b0a-bd66-625fa265965a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_72a6f16d-9faf-4519-a9e8-4b6000a43089" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e1efac9e-64f7-4b0a-bd66-625fa265965a" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_72a6f16d-9faf-4519-a9e8-4b6000a43089" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_cccd002b-ba52-4733-a736-f8a7c36367dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_72a6f16d-9faf-4519-a9e8-4b6000a43089" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_cccd002b-ba52-4733-a736-f8a7c36367dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_618ac2fb-484f-47b6-970e-f8bd63df3dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a7610f76-d2d6-40c1-8b61-d3ca614118d1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_618ac2fb-484f-47b6-970e-f8bd63df3dbc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_618ac2fb-484f-47b6-970e-f8bd63df3dbc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_618ac2fb-484f-47b6-970e-f8bd63df3dbc" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_618ac2fb-484f-47b6-970e-f8bd63df3dbc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4b0911e5-12bd-4b03-a137-94c35be81b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_618ac2fb-484f-47b6-970e-f8bd63df3dbc" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4b0911e5-12bd-4b03-a137-94c35be81b8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentsMember_d85f4078-9559-4d0e-9154-e4ae3353f378" xlink:href="biib-20220331.xsd#biib_StrategicInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4b0911e5-12bd-4b03-a137-94c35be81b8b" xlink:to="loc_biib_StrategicInvestmentsMember_d85f4078-9559-4d0e-9154-e4ae3353f378" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#DerivativeInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended" id="i26a7f5e49eb34d00bf34dba2fd2832d2_DerivativeInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_0eac2f1e-c5c4-4a1c-869d-c0e7e518c1f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_aa99c071-63c0-4124-86c9-24959048a94d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0eac2f1e-c5c4-4a1c-869d-c0e7e518c1f1" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_aa99c071-63c0-4124-86c9-24959048a94d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_2d4566b2-de1a-4a5c-aff8-ac95913fb002" xlink:href="biib-20220331.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0eac2f1e-c5c4-4a1c-869d-c0e7e518c1f1" xlink:to="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_2d4566b2-de1a-4a5c-aff8-ac95913fb002" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_ed4954d5-b382-4176-95ba-23ecfa83cf67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0eac2f1e-c5c4-4a1c-869d-c0e7e518c1f1" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_ed4954d5-b382-4176-95ba-23ecfa83cf67" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_fc768945-b693-48dd-8961-d90ec473d520" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0eac2f1e-c5c4-4a1c-869d-c0e7e518c1f1" xlink:to="loc_us-gaap_DerivativeNotionalAmount_fc768945-b693-48dd-8961-d90ec473d520" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_71db31db-701b-4ae1-9777-5888d89dde0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0eac2f1e-c5c4-4a1c-869d-c0e7e518c1f1" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_71db31db-701b-4ae1-9777-5888d89dde0c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_6a415c27-9392-4c45-b13f-1675df63f415" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0eac2f1e-c5c4-4a1c-869d-c0e7e518c1f1" xlink:to="loc_us-gaap_DerivativeTermOfContract_6a415c27-9392-4c45-b13f-1675df63f415" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_0012c310-d057-47d6-aecb-89fc5c6c2304" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0eac2f1e-c5c4-4a1c-869d-c0e7e518c1f1" xlink:to="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_0012c310-d057-47d6-aecb-89fc5c6c2304" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_36eb119f-4b95-4c34-8812-c84fd292d23e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0eac2f1e-c5c4-4a1c-869d-c0e7e518c1f1" xlink:to="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_36eb119f-4b95-4c34-8812-c84fd292d23e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_0714dac6-8706-4460-bd77-33797b35e96c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0eac2f1e-c5c4-4a1c-869d-c0e7e518c1f1" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_0714dac6-8706-4460-bd77-33797b35e96c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_93eeae32-87d6-4958-a43a-ee6ea410ec5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0eac2f1e-c5c4-4a1c-869d-c0e7e518c1f1" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_93eeae32-87d6-4958-a43a-ee6ea410ec5d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_6250b605-7aee-4b69-bf04-cab109955840" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0eac2f1e-c5c4-4a1c-869d-c0e7e518c1f1" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_6250b605-7aee-4b69-bf04-cab109955840" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_4a0187d5-19f2-46fb-8843-b38ff0cb9316" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0eac2f1e-c5c4-4a1c-869d-c0e7e518c1f1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_4a0187d5-19f2-46fb-8843-b38ff0cb9316" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_ccd7b36c-dbcb-42f5-a460-e20442f57bfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0eac2f1e-c5c4-4a1c-869d-c0e7e518c1f1" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_ccd7b36c-dbcb-42f5-a460-e20442f57bfe" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_c29d8f16-c69c-4534-89cb-62527452980c" xlink:href="biib-20220331.xsd#biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0eac2f1e-c5c4-4a1c-869d-c0e7e518c1f1" xlink:to="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_c29d8f16-c69c-4534-89cb-62527452980c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_09c912c0-1f01-462d-8fe7-cb41c8af1306" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0eac2f1e-c5c4-4a1c-869d-c0e7e518c1f1" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_09c912c0-1f01-462d-8fe7-cb41c8af1306" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGainOnDerivatives_fedc9772-4023-43eb-b3de-8d8d843bade0" xlink:href="biib-20220331.xsd#biib_UnrealizedGainOnDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0eac2f1e-c5c4-4a1c-869d-c0e7e518c1f1" xlink:to="loc_biib_UnrealizedGainOnDerivatives_fedc9772-4023-43eb-b3de-8d8d843bade0" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedLossOnDerivatives_fc46f82b-9f02-4272-ae65-fe0924dc5907" xlink:href="biib-20220331.xsd#biib_UnrealizedLossOnDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0eac2f1e-c5c4-4a1c-869d-c0e7e518c1f1" xlink:to="loc_biib_UnrealizedLossOnDerivatives_fc46f82b-9f02-4272-ae65-fe0924dc5907" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_ff4fb926-8efe-4979-922c-f4471229f196" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0eac2f1e-c5c4-4a1c-869d-c0e7e518c1f1" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_ff4fb926-8efe-4979-922c-f4471229f196" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_2598720d-9918-4adf-a582-85e50c648841" xlink:href="biib-20220331.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0eac2f1e-c5c4-4a1c-869d-c0e7e518c1f1" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_2598720d-9918-4adf-a582-85e50c648841" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_3bf1ad78-de48-465d-8dbf-19d7c9ad9c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0eac2f1e-c5c4-4a1c-869d-c0e7e518c1f1" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_3bf1ad78-de48-465d-8dbf-19d7c9ad9c4c" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1ec735f4-f2e8-4f80-a7f7-9f4f7ddfb815" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0eac2f1e-c5c4-4a1c-869d-c0e7e518c1f1" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1ec735f4-f2e8-4f80-a7f7-9f4f7ddfb815" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityAxis_04d2147f-ae15-4035-b493-8cee857149b5" xlink:href="biib-20220331.xsd#biib_DerivativeMaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1ec735f4-f2e8-4f80-a7f7-9f4f7ddfb815" xlink:to="loc_biib_DerivativeMaturityAxis_04d2147f-ae15-4035-b493-8cee857149b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityDomain_04d2147f-ae15-4035-b493-8cee857149b5_default" xlink:href="biib-20220331.xsd#biib_DerivativeMaturityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_DerivativeMaturityAxis_04d2147f-ae15-4035-b493-8cee857149b5" xlink:to="loc_biib_DerivativeMaturityDomain_04d2147f-ae15-4035-b493-8cee857149b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityDomain_0168e6bd-9439-4dc3-a71d-54a8a4c66007" xlink:href="biib-20220331.xsd#biib_DerivativeMaturityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_DerivativeMaturityAxis_04d2147f-ae15-4035-b493-8cee857149b5" xlink:to="loc_biib_DerivativeMaturityDomain_0168e6bd-9439-4dc3-a71d-54a8a4c66007" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShorttermderivativeMember_97feaab5-2425-4bca-bad1-aebaa5251886" xlink:href="biib-20220331.xsd#biib_ShorttermderivativeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeMaturityDomain_0168e6bd-9439-4dc3-a71d-54a8a4c66007" xlink:to="loc_biib_ShorttermderivativeMember_97feaab5-2425-4bca-bad1-aebaa5251886" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6b4ae5df-db55-4419-8316-8e81dac63200" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1ec735f4-f2e8-4f80-a7f7-9f4f7ddfb815" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6b4ae5df-db55-4419-8316-8e81dac63200" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_6b4ae5df-db55-4419-8316-8e81dac63200_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6b4ae5df-db55-4419-8316-8e81dac63200" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_6b4ae5df-db55-4419-8316-8e81dac63200_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_f3aa1094-1e43-4cd6-a914-df83fad7648d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6b4ae5df-db55-4419-8316-8e81dac63200" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_f3aa1094-1e43-4cd6-a914-df83fad7648d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_385cfc7f-062a-4299-a363-250151bcdc2d" xlink:href="biib-20220331.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f3aa1094-1e43-4cd6-a914-df83fad7648d" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_385cfc7f-062a-4299-a363-250151bcdc2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_347c9402-f27a-47b9-840b-725c57d479e9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1ec735f4-f2e8-4f80-a7f7-9f4f7ddfb815" xlink:to="loc_srt_CurrencyAxis_347c9402-f27a-47b9-840b-725c57d479e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_347c9402-f27a-47b9-840b-725c57d479e9_default" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_347c9402-f27a-47b9-840b-725c57d479e9" xlink:to="loc_currency_AllCurrenciesDomain_347c9402-f27a-47b9-840b-725c57d479e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_67ae9da1-0b5e-408b-b06c-b7f1598011f9" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_347c9402-f27a-47b9-840b-725c57d479e9" xlink:to="loc_currency_AllCurrenciesDomain_67ae9da1-0b5e-408b-b06c-b7f1598011f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_2218d38f-a232-4f9a-9a09-dafe40c3f5ba" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_EUR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_67ae9da1-0b5e-408b-b06c-b7f1598011f9" xlink:to="loc_currency_EUR_2218d38f-a232-4f9a-9a09-dafe40c3f5ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP_71aa4fcf-ac09-49fc-8ed0-4bbf553740b6" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_GBP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_67ae9da1-0b5e-408b-b06c-b7f1598011f9" xlink:to="loc_currency_GBP_71aa4fcf-ac09-49fc-8ed0-4bbf553740b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF_3f5c0c77-ed7f-45e6-9d01-7fef123225e7" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_CHF"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_67ae9da1-0b5e-408b-b06c-b7f1598011f9" xlink:to="loc_currency_CHF_3f5c0c77-ed7f-45e6-9d01-7fef123225e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_JPY_a5310e58-183a-4394-8ce9-984b43077566" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_JPY"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_67ae9da1-0b5e-408b-b06c-b7f1598011f9" xlink:to="loc_currency_JPY_a5310e58-183a-4394-8ce9-984b43077566" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CAD_750a2479-2d49-4c8a-9ec7-d592f6debf2f" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_CAD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_67ae9da1-0b5e-408b-b06c-b7f1598011f9" xlink:to="loc_currency_CAD_750a2479-2d49-4c8a-9ec7-d592f6debf2f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_dfe3a7d3-d8e0-4be4-bf7d-1ba2efef12d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1ec735f4-f2e8-4f80-a7f7-9f4f7ddfb815" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_dfe3a7d3-d8e0-4be4-bf7d-1ba2efef12d8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_dfe3a7d3-d8e0-4be4-bf7d-1ba2efef12d8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_dfe3a7d3-d8e0-4be4-bf7d-1ba2efef12d8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_dfe3a7d3-d8e0-4be4-bf7d-1ba2efef12d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9c614c19-ba7d-445e-966a-7e2c89c046f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_dfe3a7d3-d8e0-4be4-bf7d-1ba2efef12d8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9c614c19-ba7d-445e-966a-7e2c89c046f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_ccc4ac9c-d4cc-44b1-992c-2f3de9aeaf09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9c614c19-ba7d-445e-966a-7e2c89c046f8" xlink:to="loc_us-gaap_SalesMember_ccc4ac9c-d4cc-44b1-992c-2f3de9aeaf09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember_44f380e2-478d-4acf-af7b-0d5b2ddec72a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9c614c19-ba7d-445e-966a-7e2c89c046f8" xlink:to="loc_us-gaap_OperatingExpenseMember_44f380e2-478d-4acf-af7b-0d5b2ddec72a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_68d63c38-8c4c-44c4-b7ee-7fc023f14264" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9c614c19-ba7d-445e-966a-7e2c89c046f8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_68d63c38-8c4c-44c4-b7ee-7fc023f14264" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_da2075cc-38df-4bd6-bdda-c4f87467551c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1ec735f4-f2e8-4f80-a7f7-9f4f7ddfb815" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_da2075cc-38df-4bd6-bdda-c4f87467551c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_da2075cc-38df-4bd6-bdda-c4f87467551c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_da2075cc-38df-4bd6-bdda-c4f87467551c" xlink:to="loc_us-gaap_HedgingRelationshipDomain_da2075cc-38df-4bd6-bdda-c4f87467551c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_46986b0b-1a2c-4a0a-b122-1152154d14c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_da2075cc-38df-4bd6-bdda-c4f87467551c" xlink:to="loc_us-gaap_HedgingRelationshipDomain_46986b0b-1a2c-4a0a-b122-1152154d14c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_1d76bcf4-60c9-49df-a84e-361487a7b2c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_46986b0b-1a2c-4a0a-b122-1152154d14c5" xlink:to="loc_us-gaap_CashFlowHedgingMember_1d76bcf4-60c9-49df-a84e-361487a7b2c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsrevenueMember_ec12fec0-cabd-40f1-b530-f6a9ccd735c0" xlink:href="biib-20220331.xsd#biib_CashflowsrevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_46986b0b-1a2c-4a0a-b122-1152154d14c5" xlink:to="loc_biib_CashflowsrevenueMember_ec12fec0-cabd-40f1-b530-f6a9ccd735c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsoperatingexpensesMember_cd6bd3c1-a48b-4ed6-a3fc-51e41f2e83c5" xlink:href="biib-20220331.xsd#biib_CashflowsoperatingexpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_46986b0b-1a2c-4a0a-b122-1152154d14c5" xlink:to="loc_biib_CashflowsoperatingexpensesMember_cd6bd3c1-a48b-4ed6-a3fc-51e41f2e83c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_f9b58b2e-a44d-4272-9d22-fd1980fe3815" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_46986b0b-1a2c-4a0a-b122-1152154d14c5" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_f9b58b2e-a44d-4272-9d22-fd1980fe3815" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_b9b5c4fb-16d4-4c00-949a-47f824fc48c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1ec735f4-f2e8-4f80-a7f7-9f4f7ddfb815" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_b9b5c4fb-16d4-4c00-949a-47f824fc48c3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b9b5c4fb-16d4-4c00-949a-47f824fc48c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b9b5c4fb-16d4-4c00-949a-47f824fc48c3" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b9b5c4fb-16d4-4c00-949a-47f824fc48c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_fcb43cc4-28b2-455b-b291-ba806ce4642c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b9b5c4fb-16d4-4c00-949a-47f824fc48c3" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_fcb43cc4-28b2-455b-b291-ba806ce4642c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_1186f501-c3d0-40af-969d-9f54a63ecc03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fcb43cc4-28b2-455b-b291-ba806ce4642c" xlink:to="loc_us-gaap_ForeignExchangeContractMember_1186f501-c3d0-40af-969d-9f54a63ecc03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_3ab0a53e-25e3-41fa-9c27-dc3eba37f622" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fcb43cc4-28b2-455b-b291-ba806ce4642c" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_3ab0a53e-25e3-41fa-9c27-dc3eba37f622" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_f84270a1-0e54-439d-b8e6-72c17247f3e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1ec735f4-f2e8-4f80-a7f7-9f4f7ddfb815" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_f84270a1-0e54-439d-b8e6-72c17247f3e6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f84270a1-0e54-439d-b8e6-72c17247f3e6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f84270a1-0e54-439d-b8e6-72c17247f3e6" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f84270a1-0e54-439d-b8e6-72c17247f3e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5ce960d3-5df9-4aaa-a046-18595a5d7fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f84270a1-0e54-439d-b8e6-72c17247f3e6" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5ce960d3-5df9-4aaa-a046-18595a5d7fe0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_77da6695-d18f-4981-977a-18cc0965ecc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5ce960d3-5df9-4aaa-a046-18595a5d7fe0" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_77da6695-d18f-4981-977a-18cc0965ecc8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_1ec969ce-2367-42aa-ab14-bc147274dc74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5ce960d3-5df9-4aaa-a046-18595a5d7fe0" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_1ec969ce-2367-42aa-ab14-bc147274dc74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_9d1953a1-0f1d-4163-9099-a77bada429c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5ce960d3-5df9-4aaa-a046-18595a5d7fe0" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_9d1953a1-0f1d-4163-9099-a77bada429c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_899ae316-94be-414a-ad72-cde3bb398901" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5ce960d3-5df9-4aaa-a046-18595a5d7fe0" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_899ae316-94be-414a-ad72-cde3bb398901" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_b809b83c-83c0-48e0-b98b-a6d6b2bb4725" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1ec735f4-f2e8-4f80-a7f7-9f4f7ddfb815" xlink:to="loc_us-gaap_HedgingDesignationAxis_b809b83c-83c0-48e0-b98b-a6d6b2bb4725" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_b809b83c-83c0-48e0-b98b-a6d6b2bb4725_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_b809b83c-83c0-48e0-b98b-a6d6b2bb4725" xlink:to="loc_us-gaap_HedgingDesignationDomain_b809b83c-83c0-48e0-b98b-a6d6b2bb4725_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_de43e38e-5731-4013-891d-22baa38dabf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_b809b83c-83c0-48e0-b98b-a6d6b2bb4725" xlink:to="loc_us-gaap_HedgingDesignationDomain_de43e38e-5731-4013-891d-22baa38dabf7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_195c70b1-699d-4bbd-94e6-9f9bfeb2a3d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_de43e38e-5731-4013-891d-22baa38dabf7" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_195c70b1-699d-4bbd-94e6-9f9bfeb2a3d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_3d175d51-08ca-438f-ba57-ad95379c96f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_de43e38e-5731-4013-891d-22baa38dabf7" xlink:to="loc_us-gaap_NondesignatedMember_3d175d51-08ca-438f-ba57-ad95379c96f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_29db2e11-5d5c-4a79-a2a0-5062ff93a9ab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1ec735f4-f2e8-4f80-a7f7-9f4f7ddfb815" xlink:to="loc_srt_RangeAxis_29db2e11-5d5c-4a79-a2a0-5062ff93a9ab" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_29db2e11-5d5c-4a79-a2a0-5062ff93a9ab_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_29db2e11-5d5c-4a79-a2a0-5062ff93a9ab" xlink:to="loc_srt_RangeMember_29db2e11-5d5c-4a79-a2a0-5062ff93a9ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_aba501dd-53d3-4052-8e3d-1ee7734dca0c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_29db2e11-5d5c-4a79-a2a0-5062ff93a9ab" xlink:to="loc_srt_RangeMember_aba501dd-53d3-4052-8e3d-1ee7734dca0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2e866d0d-6979-40da-8216-7ede5d3da46c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_aba501dd-53d3-4052-8e3d-1ee7734dca0c" xlink:to="loc_srt_MinimumMember_2e866d0d-6979-40da-8216-7ede5d3da46c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bc19c13d-d217-4da1-970b-11e4500fe8d6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_aba501dd-53d3-4052-8e3d-1ee7734dca0c" xlink:to="loc_srt_MaximumMember_bc19c13d-d217-4da1-970b-11e4500fe8d6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#PropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="extended" id="i38ce12f97f1e4f0d826e8e241142a449_PropertyPlantandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_20d54828-a830-425d-95dd-18adaf99b485" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_220c24f6-b8c2-419f-b522-60fa43ba1f84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_20d54828-a830-425d-95dd-18adaf99b485" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_220c24f6-b8c2-419f-b522-60fa43ba1f84" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_c6e39dd4-be29-43f3-b6ae-77736abeacbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_20d54828-a830-425d-95dd-18adaf99b485" xlink:to="loc_us-gaap_Depreciation_c6e39dd4-be29-43f3-b6ae-77736abeacbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfSquareFeet_e1d7bead-a884-44e9-9654-c93ffbfccc67" xlink:href="biib-20220331.xsd#biib_NumberOfSquareFeet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_20d54828-a830-425d-95dd-18adaf99b485" xlink:to="loc_biib_NumberOfSquareFeet_e1d7bead-a884-44e9-9654-c93ffbfccc67" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_c87cda7c-ad3f-4541-9643-85746e68a2ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_20d54828-a830-425d-95dd-18adaf99b485" xlink:to="loc_us-gaap_ConstructionInProgressGross_c87cda7c-ad3f-4541-9643-85746e68a2ae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_c0bd248d-19de-4fd8-a181-9b10ea228434" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_20d54828-a830-425d-95dd-18adaf99b485" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_c0bd248d-19de-4fd8-a181-9b10ea228434" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2403413b-be66-4711-b81a-e50f2ef6cc0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_20d54828-a830-425d-95dd-18adaf99b485" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2403413b-be66-4711-b81a-e50f2ef6cc0d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationAxis_2e1891b8-d61f-4d2b-8abc-564ebc69a2eb" xlink:href="biib-20220331.xsd#biib_FacilityLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2403413b-be66-4711-b81a-e50f2ef6cc0d" xlink:to="loc_biib_FacilityLocationAxis_2e1891b8-d61f-4d2b-8abc-564ebc69a2eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationDomain_2e1891b8-d61f-4d2b-8abc-564ebc69a2eb_default" xlink:href="biib-20220331.xsd#biib_FacilityLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityLocationAxis_2e1891b8-d61f-4d2b-8abc-564ebc69a2eb" xlink:to="loc_biib_FacilityLocationDomain_2e1891b8-d61f-4d2b-8abc-564ebc69a2eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationDomain_fb91394c-f729-4c79-8790-09d580490cdd" xlink:href="biib-20220331.xsd#biib_FacilityLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityLocationAxis_2e1891b8-d61f-4d2b-8abc-564ebc69a2eb" xlink:to="loc_biib_FacilityLocationDomain_fb91394c-f729-4c79-8790-09d580490cdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SolothurnSwitzerlandMember_e934d0f0-1e6a-43f8-b926-56074adbccbd" xlink:href="biib-20220331.xsd#biib_SolothurnSwitzerlandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityLocationDomain_fb91394c-f729-4c79-8790-09d580490cdd" xlink:to="loc_biib_SolothurnSwitzerlandMember_e934d0f0-1e6a-43f8-b926-56074adbccbd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeAxis_eedcbda0-3b87-4544-96f0-5eb3a2940315" xlink:href="biib-20220331.xsd#biib_FacilityTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2403413b-be66-4711-b81a-e50f2ef6cc0d" xlink:to="loc_biib_FacilityTypeAxis_eedcbda0-3b87-4544-96f0-5eb3a2940315" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeDomain_eedcbda0-3b87-4544-96f0-5eb3a2940315_default" xlink:href="biib-20220331.xsd#biib_FacilityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityTypeAxis_eedcbda0-3b87-4544-96f0-5eb3a2940315" xlink:to="loc_biib_FacilityTypeDomain_eedcbda0-3b87-4544-96f0-5eb3a2940315_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeDomain_5337ac8b-aae6-49ac-92b4-22486f91ad6a" xlink:href="biib-20220331.xsd#biib_FacilityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityTypeAxis_eedcbda0-3b87-4544-96f0-5eb3a2940315" xlink:to="loc_biib_FacilityTypeDomain_5337ac8b-aae6-49ac-92b4-22486f91ad6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiologicsManufacturingMember_6ed5c32d-7d1e-44d8-afbe-8f477bde64d7" xlink:href="biib-20220331.xsd#biib_BiologicsManufacturingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityTypeDomain_5337ac8b-aae6-49ac-92b4-22486f91ad6a" xlink:to="loc_biib_BiologicsManufacturingMember_6ed5c32d-7d1e-44d8-afbe-8f477bde64d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WarehouseUtilitiesAndSupportSpaceMember_6d54bdee-d5dd-48ba-a3b9-f58fb2136b98" xlink:href="biib-20220331.xsd#biib_WarehouseUtilitiesAndSupportSpaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityTypeDomain_5337ac8b-aae6-49ac-92b4-22486f91ad6a" xlink:to="loc_biib_WarehouseUtilitiesAndSupportSpaceMember_6d54bdee-d5dd-48ba-a3b9-f58fb2136b98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdministrativeSpaceMember_52794670-b23f-4de1-a354-8f16ed7d99ce" xlink:href="biib-20220331.xsd#biib_AdministrativeSpaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityTypeDomain_5337ac8b-aae6-49ac-92b4-22486f91ad6a" xlink:to="loc_biib_AdministrativeSpaceMember_52794670-b23f-4de1-a354-8f16ed7d99ce" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#IndebtednessDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="extended" id="i3586c7d44bb548a9813b481763cd4789_IndebtednessDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a3f5ca94-8f20-40d4-97bf-3e5b4cf0c279" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_670c1623-5850-49ff-9503-0016a8490dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a3f5ca94-8f20-40d4-97bf-3e5b4cf0c279" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_670c1623-5850-49ff-9503-0016a8490dcd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DebtInstrumentRedemptionAmount_597fbfdc-484c-4966-b210-1dabc2e37de8" xlink:href="biib-20220331.xsd#biib_DebtInstrumentRedemptionAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a3f5ca94-8f20-40d4-97bf-3e5b4cf0c279" xlink:to="loc_biib_DebtInstrumentRedemptionAmount_597fbfdc-484c-4966-b210-1dabc2e37de8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LongTermDebtExchangedAmount_9fbc8d95-bf9d-4ab3-9ce8-dbfe2431425d" xlink:href="biib-20220331.xsd#biib_LongTermDebtExchangedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a3f5ca94-8f20-40d4-97bf-3e5b4cf0c279" xlink:to="loc_biib_LongTermDebtExchangedAmount_9fbc8d95-bf9d-4ab3-9ce8-dbfe2431425d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4d0cdf4d-5629-4c75-882f-091cb8d8a9c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a3f5ca94-8f20-40d4-97bf-3e5b4cf0c279" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4d0cdf4d-5629-4c75-882f-091cb8d8a9c5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_796dbba3-c5e7-4fea-9e93-2712ee17ebff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a3f5ca94-8f20-40d4-97bf-3e5b4cf0c279" xlink:to="loc_us-gaap_RepaymentsOfDebt_796dbba3-c5e7-4fea-9e93-2712ee17ebff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_6de1e6cc-1ea4-485c-acb8-7f95ee65fe36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a3f5ca94-8f20-40d4-97bf-3e5b4cf0c279" xlink:to="loc_us-gaap_InterestExpense_6de1e6cc-1ea4-485c-acb8-7f95ee65fe36" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_46282ab4-2eb8-4364-b787-61df8a3fb7d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a3f5ca94-8f20-40d4-97bf-3e5b4cf0c279" xlink:to="loc_us-gaap_DebtInstrumentTable_46282ab4-2eb8-4364-b787-61df8a3fb7d8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b3d08360-0b0c-42c0-8290-c9f7545a162b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_46282ab4-2eb8-4364-b787-61df8a3fb7d8" xlink:to="loc_us-gaap_DebtInstrumentAxis_b3d08360-0b0c-42c0-8290-c9f7545a162b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b3d08360-0b0c-42c0-8290-c9f7545a162b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_b3d08360-0b0c-42c0-8290-c9f7545a162b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b3d08360-0b0c-42c0-8290-c9f7545a162b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d269a8c3-4f54-4571-80a4-f38520ad7ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_b3d08360-0b0c-42c0-8290-c9f7545a162b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d269a8c3-4f54-4571-80a4-f38520ad7ee5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_80c7da0f-956b-4b21-9bc6-b4ff555c56d9" xlink:href="biib-20220331.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d269a8c3-4f54-4571-80a4-f38520ad7ee5" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_80c7da0f-956b-4b21-9bc6-b4ff555c56d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3250SeniorNotesDueFebruary152051Member_4015a1b2-5c26-4aa0-819e-d0db2e84eab1" xlink:href="biib-20220331.xsd#biib_A3250SeniorNotesDueFebruary152051Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d269a8c3-4f54-4571-80a4-f38520ad7ee5" xlink:to="loc_biib_A3250SeniorNotesDueFebruary152051Member_4015a1b2-5c26-4aa0-819e-d0db2e84eab1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#ShareRepurchasesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="extended" id="i439935e82d2d40a5bcea0b1157749ff1_ShareRepurchasesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_7c0fb94a-ad3b-462c-9fff-b4057ccc3069" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_c7714aeb-ec28-4f12-af29-2364b393280c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7c0fb94a-ad3b-462c-9fff-b4057ccc3069" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_c7714aeb-ec28-4f12-af29-2364b393280c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_292a1d76-1bc0-47ec-8f9d-ca2a99445701" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7c0fb94a-ad3b-462c-9fff-b4057ccc3069" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_292a1d76-1bc0-47ec-8f9d-ca2a99445701" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d0198b5b-e440-4e8d-a8ce-355dbd26805e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7c0fb94a-ad3b-462c-9fff-b4057ccc3069" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d0198b5b-e440-4e8d-a8ce-355dbd26805e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_ffe92c07-fd71-4728-ad13-cf0d3ea98e09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7c0fb94a-ad3b-462c-9fff-b4057ccc3069" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_ffe92c07-fd71-4728-ad13-cf0d3ea98e09" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_10e10ceb-0f59-4e09-b671-48dfb11f0c55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_7c0fb94a-ad3b-462c-9fff-b4057ccc3069" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_10e10ceb-0f59-4e09-b671-48dfb11f0c55" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_0e7fe89f-055e-4a3c-ac77-aa8b98362a66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_10e10ceb-0f59-4e09-b671-48dfb11f0c55" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_0e7fe89f-055e-4a3c-ac77-aa8b98362a66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_0e7fe89f-055e-4a3c-ac77-aa8b98362a66_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_0e7fe89f-055e-4a3c-ac77-aa8b98362a66" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_0e7fe89f-055e-4a3c-ac77-aa8b98362a66_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_a762554e-4e92-4fc9-9c8a-d07a500374f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_0e7fe89f-055e-4a3c-ac77-aa8b98362a66" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_a762554e-4e92-4fc9-9c8a-d07a500374f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2020ShareRepurchaseProgramMember_f71692d2-5b36-454f-9160-2bf333d70127" xlink:href="biib-20220331.xsd#biib_A2020ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_a762554e-4e92-4fc9-9c8a-d07a500374f7" xlink:to="loc_biib_A2020ShareRepurchaseProgramMember_f71692d2-5b36-454f-9160-2bf333d70127" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#AccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" id="i9066d5b7b7b14f94a182a51aa05acb82_AccumulatedOtherComprehensiveIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1ab367f2-a8c7-45cb-b35e-9032be860225" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_464fe35b-c335-4960-bee6-0c4bc3267f85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1ab367f2-a8c7-45cb-b35e-9032be860225" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_464fe35b-c335-4960-bee6-0c4bc3267f85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8713c404-afdc-4ace-9a33-6d15f1cdc6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8bfd8e96-5bce-4ab8-8d38-16e729c28af9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1ab367f2-a8c7-45cb-b35e-9032be860225" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8bfd8e96-5bce-4ab8-8d38-16e729c28af9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_c135b650-0927-4acc-92cd-60ef766c45d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1ab367f2-a8c7-45cb-b35e-9032be860225" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_c135b650-0927-4acc-92cd-60ef766c45d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5e9b09d5-89db-421b-a64e-1bb6ac80a0d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1ab367f2-a8c7-45cb-b35e-9032be860225" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5e9b09d5-89db-421b-a64e-1bb6ac80a0d6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b46ca415-30a2-4371-8518-7d40ac4a6589" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_39a9f235-2c2e-4204-9d90-c5a8da5da04b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1ab367f2-a8c7-45cb-b35e-9032be860225" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_39a9f235-2c2e-4204-9d90-c5a8da5da04b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_6bc25427-a975-4ee7-b737-70c930205e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1ab367f2-a8c7-45cb-b35e-9032be860225" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_6bc25427-a975-4ee7-b737-70c930205e1f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_975a2098-9ccd-4617-a583-b07c98eb2704" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_6bc25427-a975-4ee7-b737-70c930205e1f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_975a2098-9ccd-4617-a583-b07c98eb2704" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_975a2098-9ccd-4617-a583-b07c98eb2704_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_975a2098-9ccd-4617-a583-b07c98eb2704" xlink:to="loc_us-gaap_EquityComponentDomain_975a2098-9ccd-4617-a583-b07c98eb2704_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2fa803cf-229b-44e8-aefe-12545fc6606f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_975a2098-9ccd-4617-a583-b07c98eb2704" xlink:to="loc_us-gaap_EquityComponentDomain_2fa803cf-229b-44e8-aefe-12545fc6606f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_c33197e8-c1ed-478f-9358-cd2e326de668" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2fa803cf-229b-44e8-aefe-12545fc6606f" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_c33197e8-c1ed-478f-9358-cd2e326de668" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_eaefe4a5-0055-4e68-9a5e-3a7dca4c18dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2fa803cf-229b-44e8-aefe-12545fc6606f" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_eaefe4a5-0055-4e68-9a5e-3a7dca4c18dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_7789a95a-9588-4f29-9986-a588a6646c51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2fa803cf-229b-44e8-aefe-12545fc6606f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_7789a95a-9588-4f29-9986-a588a6646c51" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_b7d3252c-7d99-4945-b804-a45075bfad26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2fa803cf-229b-44e8-aefe-12545fc6606f" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_b7d3252c-7d99-4945-b804-a45075bfad26" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_dd809f26-eb66-4ebf-a3ff-58b731a8a0a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2fa803cf-229b-44e8-aefe-12545fc6606f" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_dd809f26-eb66-4ebf-a3ff-58b731a8a0a8" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" id="i439c91596b18425cb3812409ee4b6d14_ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_33c5c9ff-d5c9-46e6-a302-b5b3a5b5fcb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_550ac514-9f3a-4ec3-a5c2-e7b4287e0cfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_33c5c9ff-d5c9-46e6-a302-b5b3a5b5fcb7" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_550ac514-9f3a-4ec3-a5c2-e7b4287e0cfc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f79ec281-3382-41e1-97f6-50d819c90481" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_33c5c9ff-d5c9-46e6-a302-b5b3a5b5fcb7" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f79ec281-3382-41e1-97f6-50d819c90481" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_b338febd-fa0f-4098-9b7d-97cbb3d8c568" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_33c5c9ff-d5c9-46e6-a302-b5b3a5b5fcb7" xlink:to="loc_us-gaap_Revenues_b338febd-fa0f-4098-9b7d-97cbb3d8c568" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_55d959d8-2ce8-44b1-a491-89a94a94ef02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_33c5c9ff-d5c9-46e6-a302-b5b3a5b5fcb7" xlink:to="loc_us-gaap_OperatingExpenses_55d959d8-2ce8-44b1-a491-89a94a94ef02" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e1255b90-b89f-4f32-84fc-57d3234942a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_33c5c9ff-d5c9-46e6-a302-b5b3a5b5fcb7" xlink:to="loc_us-gaap_NetIncomeLoss_e1255b90-b89f-4f32-84fc-57d3234942a8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_bb8f8b30-607d-4369-9120-0d8524316a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_33c5c9ff-d5c9-46e6-a302-b5b3a5b5fcb7" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_bb8f8b30-607d-4369-9120-0d8524316a4b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_315f8434-59bd-457b-bbd3-79fabdd3e765" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_bb8f8b30-607d-4369-9120-0d8524316a4b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_315f8434-59bd-457b-bbd3-79fabdd3e765" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_315f8434-59bd-457b-bbd3-79fabdd3e765_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_315f8434-59bd-457b-bbd3-79fabdd3e765" xlink:to="loc_us-gaap_EquityComponentDomain_315f8434-59bd-457b-bbd3-79fabdd3e765_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f4ea72a7-529d-424f-ad78-a1e41d659e47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_315f8434-59bd-457b-bbd3-79fabdd3e765" xlink:to="loc_us-gaap_EquityComponentDomain_f4ea72a7-529d-424f-ad78-a1e41d659e47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_0c54d29d-5d9b-410d-8b4a-51309e5ba302" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f4ea72a7-529d-424f-ad78-a1e41d659e47" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_0c54d29d-5d9b-410d-8b4a-51309e5ba302" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_d70e4df8-7c20-4d04-a2da-092035701491" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f4ea72a7-529d-424f-ad78-a1e41d659e47" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_d70e4df8-7c20-4d04-a2da-092035701491" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_b79bc330-ab07-43c8-b88f-ad9dac468760" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f4ea72a7-529d-424f-ad78-a1e41d659e47" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_b79bc330-ab07-43c8-b88f-ad9dac468760" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_ddea83e7-74ca-4121-a88b-079ae9b8e7fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_bb8f8b30-607d-4369-9120-0d8524316a4b" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_ddea83e7-74ca-4121-a88b-079ae9b8e7fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_ddea83e7-74ca-4121-a88b-079ae9b8e7fa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_ddea83e7-74ca-4121-a88b-079ae9b8e7fa" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_ddea83e7-74ca-4121-a88b-079ae9b8e7fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_91032093-8802-434f-b97d-d0015ed5c290" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_ddea83e7-74ca-4121-a88b-079ae9b8e7fa" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_91032093-8802-434f-b97d-d0015ed5c290" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_191dd198-e3ba-47b9-9899-8c701d3f0443" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_91032093-8802-434f-b97d-d0015ed5c290" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_191dd198-e3ba-47b9-9899-8c701d3f0443" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#EarningsperShareDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="extended" id="i2ed42b537937450492d3cce2843f8209_EarningsperShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d752351c-8463-43a2-984d-41b83eb6fc76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_d2432d76-4152-4c05-bb04-5e3c41378d24" xlink:href="biib-20220331.xsd#biib_BasicAndDilutedEarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d752351c-8463-43a2-984d-41b83eb6fc76" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_d2432d76-4152-4c05-bb04-5e3c41378d24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_cd2b45c9-6974-4510-a5e6-4a1d6fdf06ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_d2432d76-4152-4c05-bb04-5e3c41378d24" xlink:to="loc_us-gaap_NetIncomeLossAbstract_cd2b45c9-6974-4510-a5e6-4a1d6fdf06ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_79307d15-bc3f-435e-9d0b-ecb7f0fb911a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_cd2b45c9-6974-4510-a5e6-4a1d6fdf06ad" xlink:to="loc_us-gaap_NetIncomeLoss_79307d15-bc3f-435e-9d0b-ecb7f0fb911a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_74a1b9a8-6cda-4bcd-b012-87f505affddf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_d2432d76-4152-4c05-bb04-5e3c41378d24" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_74a1b9a8-6cda-4bcd-b012-87f505affddf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_deb35423-4e8c-4435-9a7c-ea8376a58479" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_74a1b9a8-6cda-4bcd-b012-87f505affddf" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_deb35423-4e8c-4435-9a7c-ea8376a58479" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_95b7c1b0-e869-46d5-a977-2572a630540c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_74a1b9a8-6cda-4bcd-b012-87f505affddf" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_95b7c1b0-e869-46d5-a977-2572a630540c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_909efb4e-823a-45cf-93c2-7ea6ce12753f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_95b7c1b0-e869-46d5-a977-2572a630540c" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_909efb4e-823a-45cf-93c2-7ea6ce12753f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_c2878fe2-5b02-4c3b-9f41-162dd3b4b4fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_95b7c1b0-e869-46d5-a977-2572a630540c" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_c2878fe2-5b02-4c3b-9f41-162dd3b4b4fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_82c44e68-039a-45fa-b4a9-30b824854e38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_74a1b9a8-6cda-4bcd-b012-87f505affddf" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_82c44e68-039a-45fa-b4a9-30b824854e38" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a57d2bc2-2421-4525-9f55-e8d7258b3207" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d752351c-8463-43a2-984d-41b83eb6fc76" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a57d2bc2-2421-4525-9f55-e8d7258b3207" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ecc555f6-3959-4398-946f-ea988936ba74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a57d2bc2-2421-4525-9f55-e8d7258b3207" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ecc555f6-3959-4398-946f-ea988936ba74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ecc555f6-3959-4398-946f-ea988936ba74_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ecc555f6-3959-4398-946f-ea988936ba74" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ecc555f6-3959-4398-946f-ea988936ba74_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6956e831-5109-4e20-bf4d-56288cd0b875" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ecc555f6-3959-4398-946f-ea988936ba74" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6956e831-5109-4e20-bf4d-56288cd0b875" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_a20decfe-d156-4421-a01f-347fcd4d7479" xlink:href="biib-20220331.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6956e831-5109-4e20-bf4d-56288cd0b875" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_a20decfe-d156-4421-a01f-347fcd4d7479" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_ba76a378-20d0-47dc-836f-d73f8884c480" xlink:href="biib-20220331.xsd#biib_MarketStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6956e831-5109-4e20-bf4d-56288cd0b875" xlink:to="loc_biib_MarketStockUnitsMember_ba76a378-20d0-47dc-836f-d73f8884c480" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_05313ff2-06f1-4851-9454-9b474d205350" xlink:href="biib-20220331.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6956e831-5109-4e20-bf4d-56288cd0b875" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_05313ff2-06f1-4851-9454-9b474d205350" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#ShareBasedPaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended" id="i12d229c1e8a84007b258bc28142dc3c7_ShareBasedPaymentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c3a2681d-5baa-4acd-8923-22aa40f5d860" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_feaee58b-25ec-43bc-8bb6-d68ed8aea573" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c3a2681d-5baa-4acd-8923-22aa40f5d860" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_feaee58b-25ec-43bc-8bb6-d68ed8aea573" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a5f1a09a-0bc0-4ce1-bbf9-0440f59bbc0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_feaee58b-25ec-43bc-8bb6-d68ed8aea573" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a5f1a09a-0bc0-4ce1-bbf9-0440f59bbc0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_36b00769-7ebe-46d0-8b44-3adf5d762e82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_feaee58b-25ec-43bc-8bb6-d68ed8aea573" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_36b00769-7ebe-46d0-8b44-3adf5d762e82" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_482ca445-9ac2-4ff1-b806-5ff5cb299a37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_feaee58b-25ec-43bc-8bb6-d68ed8aea573" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_482ca445-9ac2-4ff1-b806-5ff5cb299a37" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_16da0448-0b67-400d-b534-eb6184976168" xlink:href="biib-20220331.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_feaee58b-25ec-43bc-8bb6-d68ed8aea573" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_16da0448-0b67-400d-b534-eb6184976168" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_5e435a59-a6c8-4d77-93c2-888c1f8dd6cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_feaee58b-25ec-43bc-8bb6-d68ed8aea573" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_5e435a59-a6c8-4d77-93c2-888c1f8dd6cd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c376a45d-2027-4a37-9f44-5d6d9fa842e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c3a2681d-5baa-4acd-8923-22aa40f5d860" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c376a45d-2027-4a37-9f44-5d6d9fa842e2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_43d8091d-6864-4228-a29a-5606110b69b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c376a45d-2027-4a37-9f44-5d6d9fa842e2" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_43d8091d-6864-4228-a29a-5606110b69b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_43d8091d-6864-4228-a29a-5606110b69b4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_43d8091d-6864-4228-a29a-5606110b69b4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_43d8091d-6864-4228-a29a-5606110b69b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6e42b39c-e60b-4436-8ae5-9f0b6275f7d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_43d8091d-6864-4228-a29a-5606110b69b4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6e42b39c-e60b-4436-8ae5-9f0b6275f7d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ea88abc5-0fca-4a1b-8551-be95339afd66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6e42b39c-e60b-4436-8ae5-9f0b6275f7d7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ea88abc5-0fca-4a1b-8551-be95339afd66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6ecfb7c0-65be-4ddc-8a08-1fbae5b25d50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6e42b39c-e60b-4436-8ae5-9f0b6275f7d7" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6ecfb7c0-65be-4ddc-8a08-1fbae5b25d50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_3185936b-eae0-43fd-96a7-ccd2569ba676" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6e42b39c-e60b-4436-8ae5-9f0b6275f7d7" xlink:to="loc_us-gaap_ParentMember_3185936b-eae0-43fd-96a7-ccd2569ba676" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="simple" xlink:href="biib-20220331.xsd#ShareBasedPaymentsDetails1"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended" id="if5010d67ca604d0b8993dc2f09d43a18_ShareBasedPaymentsDetails1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3a6fc156-6bb7-4ac3-ad9b-725256610472" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_59f0247a-bc1c-4f18-a99b-30df946d57d1" xlink:href="biib-20220331.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3a6fc156-6bb7-4ac3-ad9b-725256610472" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_59f0247a-bc1c-4f18-a99b-30df946d57d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_c00256b5-b226-4621-af7d-95013587c5fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_59f0247a-bc1c-4f18-a99b-30df946d57d1" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_c00256b5-b226-4621-af7d-95013587c5fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_a3fc0a1d-ad50-4508-aa72-6b3804428318" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_59f0247a-bc1c-4f18-a99b-30df946d57d1" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_a3fc0a1d-ad50-4508-aa72-6b3804428318" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_5814beff-2af8-45ee-89ec-634a616737a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_59f0247a-bc1c-4f18-a99b-30df946d57d1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_5814beff-2af8-45ee-89ec-634a616737a2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_f8d08f5d-d93b-4aee-ae04-d188a525a684" xlink:href="biib-20220331.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_59f0247a-bc1c-4f18-a99b-30df946d57d1" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_f8d08f5d-d93b-4aee-ae04-d188a525a684" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4480210b-1753-41ff-8228-31cb964a72a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3a6fc156-6bb7-4ac3-ad9b-725256610472" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4480210b-1753-41ff-8228-31cb964a72a7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_856ccfed-44f2-40a5-8d51-b22863234a91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4480210b-1753-41ff-8228-31cb964a72a7" xlink:to="loc_us-gaap_AwardTypeAxis_856ccfed-44f2-40a5-8d51-b22863234a91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_856ccfed-44f2-40a5-8d51-b22863234a91_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_856ccfed-44f2-40a5-8d51-b22863234a91" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_856ccfed-44f2-40a5-8d51-b22863234a91_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a9343bbd-4769-4606-9352-f000b7a4eda0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_856ccfed-44f2-40a5-8d51-b22863234a91" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a9343bbd-4769-4606-9352-f000b7a4eda0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_6dc6067d-5ac4-4bf3-9961-85af221f4404" xlink:href="biib-20220331.xsd#biib_MarketStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a9343bbd-4769-4606-9352-f000b7a4eda0" xlink:to="loc_biib_MarketStockUnitsMember_6dc6067d-5ac4-4bf3-9961-85af221f4404" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_b0a06e88-20c8-4d43-86f6-058a9b8ecfd8" xlink:href="biib-20220331.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a9343bbd-4769-4606-9352-f000b7a4eda0" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_b0a06e88-20c8-4d43-86f6-058a9b8ecfd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_1b5ffa4d-e4e8-4007-aed3-a5779570d4bc" xlink:href="biib-20220331.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a9343bbd-4769-4606-9352-f000b7a4eda0" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_1b5ffa4d-e4e8-4007-aed3-a5779570d4bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_b4aa20d4-0dd9-429f-9db3-2b291e3aa5d9" xlink:href="biib-20220331.xsd#biib_PerformanceStockUnitsSettledinCashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a9343bbd-4769-4606-9352-f000b7a4eda0" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_b4aa20d4-0dd9-429f-9db3-2b291e3aa5d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_21cb0557-3a53-4272-a331-db3b844379a5" xlink:href="biib-20220331.xsd#biib_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a9343bbd-4769-4606-9352-f000b7a4eda0" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_21cb0557-3a53-4272-a331-db3b844379a5" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="biib-20220331.xsd#IncomeTaxesDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended" id="i4d9609c553894f89a1fccb4ee93396d5_IncomeTaxesDetailsTextual">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_e4fba51a-447c-4166-b00f-c53c3a024c56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_2d9e1f22-3124-44fa-962b-37dc4803bff2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_e4fba51a-447c-4166-b00f-c53c3a024c56" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_2d9e1f22-3124-44fa-962b-37dc4803bff2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5b6def43-c224-4d0a-bcf3-79dc3ccc022f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_e4fba51a-447c-4166-b00f-c53c3a024c56" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5b6def43-c224-4d0a-bcf3-79dc3ccc022f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_ba314a00-733e-43ba-b94d-a53fff286026" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_e4fba51a-447c-4166-b00f-c53c3a024c56" xlink:to="loc_us-gaap_EquityMethodInvestments_ba314a00-733e-43ba-b94d-a53fff286026" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_f7c78a33-5309-4cd8-a466-007135315773" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_e4fba51a-447c-4166-b00f-c53c3a024c56" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_f7c78a33-5309-4cd8-a466-007135315773" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_26fffc01-b192-46b1-906d-44a6ed23443a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_e4fba51a-447c-4166-b00f-c53c3a024c56" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_26fffc01-b192-46b1-906d-44a6ed23443a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_85e9f359-86bf-49e6-99a0-18642472769b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_26fffc01-b192-46b1-906d-44a6ed23443a" xlink:to="loc_srt_StatementScenarioAxis_85e9f359-86bf-49e6-99a0-18642472769b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_85e9f359-86bf-49e6-99a0-18642472769b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_85e9f359-86bf-49e6-99a0-18642472769b" xlink:to="loc_srt_ScenarioUnspecifiedDomain_85e9f359-86bf-49e6-99a0-18642472769b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_f350bd0b-ddab-43e3-a3ad-1929485ff206" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_85e9f359-86bf-49e6-99a0-18642472769b" xlink:to="loc_srt_ScenarioUnspecifiedDomain_f350bd0b-ddab-43e3-a3ad-1929485ff206" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_05a60432-c32d-43a1-ba4b-ad10f25b0093" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_f350bd0b-ddab-43e3-a3ad-1929485ff206" xlink:to="loc_srt_ScenarioForecastMember_05a60432-c32d-43a1-ba4b-ad10f25b0093" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ab833f99-1a88-401f-9479-f14bee0ddd79" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_26fffc01-b192-46b1-906d-44a6ed23443a" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ab833f99-1a88-401f-9479-f14bee0ddd79" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_ab833f99-1a88-401f-9479-f14bee0ddd79_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ab833f99-1a88-401f-9479-f14bee0ddd79" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_ab833f99-1a88-401f-9479-f14bee0ddd79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_f540139a-5ee5-4044-9967-ac8000720a35" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ab833f99-1a88-401f-9479-f14bee0ddd79" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_f540139a-5ee5-4044-9967-ac8000720a35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_03896ddb-eef7-4645-91f6-1d0d9c05a32c" xlink:href="biib-20220331.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f540139a-5ee5-4044-9967-ac8000720a35" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_03896ddb-eef7-4645-91f6-1d0d9c05a32c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#OtherConsolidatedFinancialStatementDetailDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended" id="i60855506ec0442078c548ffaa0f40cd9_OtherConsolidatedFinancialStatementDetailDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_dd96e6ee-d698-481d-9623-5aa5373b6906" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract_22a15c70-1c0d-4015-8678-0e59cfc76122" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dd96e6ee-d698-481d-9623-5aa5373b6906" xlink:to="loc_us-gaap_InterestIncomeExpenseNetAbstract_22a15c70-1c0d-4015-8678-0e59cfc76122" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_e7fb7dd9-043c-40db-85c3-f6a36ec62425" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_22a15c70-1c0d-4015-8678-0e59cfc76122" xlink:to="loc_us-gaap_InvestmentIncomeInterest_e7fb7dd9-043c-40db-85c3-f6a36ec62425" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_68b3b622-a12f-4392-8a79-7a6b4d19ad54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_22a15c70-1c0d-4015-8678-0e59cfc76122" xlink:to="loc_us-gaap_InterestExpense_68b3b622-a12f-4392-8a79-7a6b4d19ad54" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_3d6c62da-9689-455f-9406-e75ea87532ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_22a15c70-1c0d-4015-8678-0e59cfc76122" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_3d6c62da-9689-455f-9406-e75ea87532ee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_92d8efd9-8d24-4009-adb1-67cf7bfb7154" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_22a15c70-1c0d-4015-8678-0e59cfc76122" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_92d8efd9-8d24-4009-adb1-67cf7bfb7154" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_a47caa0d-ab8a-4ec5-81b6-2a0b8e1e64be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_22a15c70-1c0d-4015-8678-0e59cfc76122" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_a47caa0d-ab8a-4ec5-81b6-2a0b8e1e64be" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_927bc273-bdc7-462d-af71-7694d47594ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_22a15c70-1c0d-4015-8678-0e59cfc76122" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_927bc273-bdc7-462d-af71-7694d47594ce" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_21ceae2a-bae1-4fe2-a74d-3fdeccc17f88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dd96e6ee-d698-481d-9623-5aa5373b6906" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_21ceae2a-bae1-4fe2-a74d-3fdeccc17f88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_4ac3d1b2-b55f-428f-b6f8-a8467f754df8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_21ceae2a-bae1-4fe2-a74d-3fdeccc17f88" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_4ac3d1b2-b55f-428f-b6f8-a8467f754df8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_cfc5f873-0def-4468-9216-3870f30d315e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_21ceae2a-bae1-4fe2-a74d-3fdeccc17f88" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_cfc5f873-0def-4468-9216-3870f30d315e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_97487a08-dfc9-41f5-887e-94ee9f183832" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_21ceae2a-bae1-4fe2-a74d-3fdeccc17f88" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_97487a08-dfc9-41f5-887e-94ee9f183832" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_eccfdee9-0f5b-4562-b17f-f1be12f1c40e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dd96e6ee-d698-481d-9623-5aa5373b6906" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_eccfdee9-0f5b-4562-b17f-f1be12f1c40e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_e6443883-67f5-40a3-8eb0-38dd6e04f0b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_eccfdee9-0f5b-4562-b17f-f1be12f1c40e" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_e6443883-67f5-40a3-8eb0-38dd6e04f0b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c5c182f0-73f3-4961-b36a-15b7b5f3c4cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_eccfdee9-0f5b-4562-b17f-f1be12f1c40e" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c5c182f0-73f3-4961-b36a-15b7b5f3c4cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_4a94cc74-c20d-4191-8e00-01e668785322" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_eccfdee9-0f5b-4562-b17f-f1be12f1c40e" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_4a94cc74-c20d-4191-8e00-01e668785322" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationexpensesaccrual_6cdc531c-2510-467c-a471-a3e544f5ddab" xlink:href="biib-20220331.xsd#biib_Collaborationexpensesaccrual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_eccfdee9-0f5b-4562-b17f-f1be12f1c40e" xlink:to="loc_biib_Collaborationexpensesaccrual_6cdc531c-2510-467c-a471-a3e544f5ddab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0c12b158-bef7-42b6-8a3d-fe5e31e8e079" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_eccfdee9-0f5b-4562-b17f-f1be12f1c40e" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0c12b158-bef7-42b6-8a3d-fe5e31e8e079" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_ae92c127-70f6-42bc-ace5-268c202c4dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_eccfdee9-0f5b-4562-b17f-f1be12f1c40e" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_ae92c127-70f6-42bc-ace5-268c202c4dd9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_666763c9-b890-41a5-9678-20801b13349d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_dd96e6ee-d698-481d-9623-5aa5373b6906" xlink:to="loc_us-gaap_StatementTable_666763c9-b890-41a5-9678-20801b13349d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_986261c2-baf9-4cf9-abb6-7ad34a3f18ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_666763c9-b890-41a5-9678-20801b13349d" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_986261c2-baf9-4cf9-abb6-7ad34a3f18ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_986261c2-baf9-4cf9-abb6-7ad34a3f18ae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_986261c2-baf9-4cf9-abb6-7ad34a3f18ae" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_986261c2-baf9-4cf9-abb6-7ad34a3f18ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_67db7b70-f751-4fe1-8c09-638a5e019570" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_986261c2-baf9-4cf9-abb6-7ad34a3f18ae" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_67db7b70-f751-4fe1-8c09-638a5e019570" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_5849a3c2-1c68-4d9e-9804-3897f4cac55e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_67db7b70-f751-4fe1-8c09-638a5e019570" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_5849a3c2-1c68-4d9e-9804-3897f4cac55e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_214cda25-20ea-4299-a929-62dc3b9d1ea0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_666763c9-b890-41a5-9678-20801b13349d" xlink:to="loc_dei_LegalEntityAxis_214cda25-20ea-4299-a929-62dc3b9d1ea0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_214cda25-20ea-4299-a929-62dc3b9d1ea0_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_214cda25-20ea-4299-a929-62dc3b9d1ea0" xlink:to="loc_dei_EntityDomain_214cda25-20ea-4299-a929-62dc3b9d1ea0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_7c448928-ea2c-4743-a713-97b04afcf3fa" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_214cda25-20ea-4299-a929-62dc3b9d1ea0" xlink:to="loc_dei_EntityDomain_7c448928-ea2c-4743-a713-97b04afcf3fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisSangamoDenaliAndSageMember_3d7e50af-6151-45ce-a136-3d1af26a02a5" xlink:href="biib-20220331.xsd#biib_IonisSangamoDenaliAndSageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_7c448928-ea2c-4743-a713-97b04afcf3fa" xlink:to="loc_biib_IonisSangamoDenaliAndSageMember_3d7e50af-6151-45ce-a136-3d1af26a02a5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" xlink:href="biib-20220331.xsd#OtherConsolidatedFinancialStatementDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended" id="i2b77b6bb1b294ac89c874eeb94a21f11_OtherConsolidatedFinancialStatementDetailsTextual">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_aa9af5f8-0221-4188-b12b-eef2db4d1b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_1a3cc504-ebd6-4a1b-9dd9-00bc61bb53b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_aa9af5f8-0221-4188-b12b-eef2db4d1b7e" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_1a3cc504-ebd6-4a1b-9dd9-00bc61bb53b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_a572580b-0c50-44b3-920e-2f263220f43e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_aa9af5f8-0221-4188-b12b-eef2db4d1b7e" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_a572580b-0c50-44b3-920e-2f263220f43e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_2ffaf865-1e68-4104-b6e2-c3f31f85ba64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_aa9af5f8-0221-4188-b12b-eef2db4d1b7e" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_2ffaf865-1e68-4104-b6e2-c3f31f85ba64" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_7cdd7a9c-da32-4ff1-ba66-3f702b5f86c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_aa9af5f8-0221-4188-b12b-eef2db4d1b7e" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_7cdd7a9c-da32-4ff1-ba66-3f702b5f86c5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_04a07a34-ecac-47be-8d94-7ffb12933be8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_aa9af5f8-0221-4188-b12b-eef2db4d1b7e" xlink:to="loc_us-gaap_StatementTable_04a07a34-ecac-47be-8d94-7ffb12933be8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_2279c40d-797a-4c79-b608-da2f43d8a0b9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_04a07a34-ecac-47be-8d94-7ffb12933be8" xlink:to="loc_dei_LegalEntityAxis_2279c40d-797a-4c79-b608-da2f43d8a0b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2279c40d-797a-4c79-b608-da2f43d8a0b9_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2279c40d-797a-4c79-b608-da2f43d8a0b9" xlink:to="loc_dei_EntityDomain_2279c40d-797a-4c79-b608-da2f43d8a0b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b77dfc26-2859-4321-babf-bdca759af2f1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2279c40d-797a-4c79-b608-da2f43d8a0b9" xlink:to="loc_dei_EntityDomain_b77dfc26-2859-4321-babf-bdca759af2f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisSangamoDenaliAndSageMember_d0130dca-f8ad-4257-b486-c510dc4597a5" xlink:href="biib-20220331.xsd#biib_IonisSangamoDenaliAndSageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b77dfc26-2859-4321-babf-bdca759af2f1" xlink:to="loc_biib_IonisSangamoDenaliAndSageMember_d0130dca-f8ad-4257-b486-c510dc4597a5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#CollaborativeandOtherRelationshipsCollaborationsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails" xlink:type="extended" id="i6409117d075f4c2ba1b5a0425a6c13bb_CollaborativeandOtherRelationshipsCollaborationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63b94ba1-f7ca-4987-b373-39fcf291fec0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpenseIncurredByCollaboration_f3d108bf-0424-40b5-8372-623f8ca07469" xlink:href="biib-20220331.xsd#biib_ExpenseIncurredByCollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63b94ba1-f7ca-4987-b373-39fcf291fec0" xlink:to="loc_biib_ExpenseIncurredByCollaboration_f3d108bf-0424-40b5-8372-623f8ca07469" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_ccccd986-3057-4409-b02a-7e84b607827e" xlink:href="biib-20220331.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63b94ba1-f7ca-4987-b373-39fcf291fec0" xlink:to="loc_biib_Expenseincurredbythecollaboration_ccccd986-3057-4409-b02a-7e84b607827e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_ce35af90-8059-4f40-bc75-5b83b9fcfe86" xlink:href="biib-20220331.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63b94ba1-f7ca-4987-b373-39fcf291fec0" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_ce35af90-8059-4f40-bc75-5b83b9fcfe86" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_56f0a51b-8a65-4169-b1ee-accb0df8c400" xlink:href="biib-20220331.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63b94ba1-f7ca-4987-b373-39fcf291fec0" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_56f0a51b-8a65-4169-b1ee-accb0df8c400" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_49a2bba3-b16e-456c-9813-75fcf8f0383e" xlink:href="biib-20220331.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63b94ba1-f7ca-4987-b373-39fcf291fec0" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_49a2bba3-b16e-456c-9813-75fcf8f0383e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationAgreementTerm_47754542-69c1-45b2-81f2-9a263b393805" xlink:href="biib-20220331.xsd#biib_CollaborationAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63b94ba1-f7ca-4987-b373-39fcf291fec0" xlink:to="loc_biib_CollaborationAgreementTerm_47754542-69c1-45b2-81f2-9a263b393805" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e8a273b6-0391-4969-815d-6201e58d9c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63b94ba1-f7ca-4987-b373-39fcf291fec0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e8a273b6-0391-4969-815d-6201e58d9c5f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Termofcollaborationagreement_1eef6b7f-20f4-4ab6-94c8-30f22e35bb90" xlink:href="biib-20220331.xsd#biib_Termofcollaborationagreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63b94ba1-f7ca-4987-b373-39fcf291fec0" xlink:to="loc_biib_Termofcollaborationagreement_1eef6b7f-20f4-4ab6-94c8-30f22e35bb90" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContingentMilestonePaymentsMadeToCollaborativePartner_f1c10218-1673-465b-ad18-aa29201e35ef" xlink:href="biib-20220331.xsd#biib_ContingentMilestonePaymentsMadeToCollaborativePartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63b94ba1-f7ca-4987-b373-39fcf291fec0" xlink:to="loc_biib_ContingentMilestonePaymentsMadeToCollaborativePartner_f1c10218-1673-465b-ad18-aa29201e35ef" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment_c68f9643-0ee0-4560-bf94-9ece5522f983" xlink:href="biib-20220331.xsd#biib_AdditionalMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63b94ba1-f7ca-4987-b373-39fcf291fec0" xlink:to="loc_biib_AdditionalMilestonePayment_c68f9643-0ee0-4560-bf94-9ece5522f983" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_58d413ca-ebec-4de2-8894-1e5ee2263c88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63b94ba1-f7ca-4987-b373-39fcf291fec0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_58d413ca-ebec-4de2-8894-1e5ee2263c88" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_e58f84ba-8d85-42d4-b0d9-15d60d3ac9f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63b94ba1-f7ca-4987-b373-39fcf291fec0" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_e58f84ba-8d85-42d4-b0d9-15d60d3ac9f1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CostOfGoodsSoldCapacityCharges_9609b7f8-4895-46ff-930d-bfa09285677b" xlink:href="biib-20220331.xsd#biib_CostOfGoodsSoldCapacityCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63b94ba1-f7ca-4987-b373-39fcf291fec0" xlink:to="loc_biib_CostOfGoodsSoldCapacityCharges_9609b7f8-4895-46ff-930d-bfa09285677b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_6a564342-552f-4900-98d1-11838c8d3e96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63b94ba1-f7ca-4987-b373-39fcf291fec0" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_6a564342-552f-4900-98d1-11838c8d3e96" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_a0a1fd32-dafe-4b53-978b-f14ef01da0c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63b94ba1-f7ca-4987-b373-39fcf291fec0" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_a0a1fd32-dafe-4b53-978b-f14ef01da0c2" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_767c601e-897e-4a00-9156-e9cb144116c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63b94ba1-f7ca-4987-b373-39fcf291fec0" xlink:to="loc_us-gaap_AdjustmentForAmortization_767c601e-897e-4a00-9156-e9cb144116c0" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedParties_aba756c3-18c8-4daa-83ee-236548506936" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63b94ba1-f7ca-4987-b373-39fcf291fec0" xlink:to="loc_us-gaap_DueFromRelatedParties_aba756c3-18c8-4daa-83ee-236548506936" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_a7a07724-d8a4-454a-bc4b-1d620c4e159a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63b94ba1-f7ca-4987-b373-39fcf291fec0" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_a7a07724-d8a4-454a-bc4b-1d620c4e159a" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_51a3f0ff-86a8-4b8c-a6b6-df20a95d3a65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63b94ba1-f7ca-4987-b373-39fcf291fec0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_51a3f0ff-86a8-4b8c-a6b6-df20a95d3a65" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c7161a18-5024-4a6c-8463-2954aee815a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_51a3f0ff-86a8-4b8c-a6b6-df20a95d3a65" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c7161a18-5024-4a6c-8463-2954aee815a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c7161a18-5024-4a6c-8463-2954aee815a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c7161a18-5024-4a6c-8463-2954aee815a9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c7161a18-5024-4a6c-8463-2954aee815a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b58a74c9-c549-49f9-8ae0-41cbfb317bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c7161a18-5024-4a6c-8463-2954aee815a9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b58a74c9-c549-49f9-8ae0-41cbfb317bc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1dec8c8e-81fc-47c0-92fb-3cd40eb5dfe8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b58a74c9-c549-49f9-8ae0-41cbfb317bc4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1dec8c8e-81fc-47c0-92fb-3cd40eb5dfe8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_42560054-b002-48a3-8431-21dbbf75a72f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b58a74c9-c549-49f9-8ae0-41cbfb317bc4" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_42560054-b002-48a3-8431-21dbbf75a72f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_fd853147-fedb-4311-b8fb-5c1fd54965c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_51a3f0ff-86a8-4b8c-a6b6-df20a95d3a65" xlink:to="loc_us-gaap_TypeOfArrangementAxis_fd853147-fedb-4311-b8fb-5c1fd54965c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fd853147-fedb-4311-b8fb-5c1fd54965c8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fd853147-fedb-4311-b8fb-5c1fd54965c8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fd853147-fedb-4311-b8fb-5c1fd54965c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6567381-dbe7-4d5c-b68a-e78e7ce2717a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fd853147-fedb-4311-b8fb-5c1fd54965c8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6567381-dbe7-4d5c-b68a-e78e7ce2717a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_5c163d2f-bf83-4d83-9f8d-82a3c3378c93" xlink:href="biib-20220331.xsd#biib_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6567381-dbe7-4d5c-b68a-e78e7ce2717a" xlink:to="loc_biib_EisaiMember_5c163d2f-bf83-4d83-9f8d-82a3c3378c93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_8d8c370d-cd87-4893-9262-e4441b5d79ce" xlink:href="biib-20220331.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6567381-dbe7-4d5c-b68a-e78e7ce2717a" xlink:to="loc_biib_DenaliTherapeuticsIncMember_8d8c370d-cd87-4893-9262-e4441b5d79ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_133d7d26-308d-4b17-a3dc-e9a65c7e10fc" xlink:href="biib-20220331.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_2393570e-ba23-41c6-b340-e9e54deff53f" xlink:href="biib-20220331.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6567381-dbe7-4d5c-b68a-e78e7ce2717a" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_2393570e-ba23-41c6-b340-e9e54deff53f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember_3f840bf0-3f6c-4077-af45-e5157c4a38b3" xlink:href="biib-20220331.xsd#biib_SageTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6567381-dbe7-4d5c-b68a-e78e7ce2717a" xlink:to="loc_biib_SageTherapeuticsIncMember_3f840bf0-3f6c-4077-af45-e5157c4a38b3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UCBPharmaS.A.Member_550e077a-c811-4cb9-8ec2-9ba0658176e4" xlink:href="biib-20220331.xsd#biib_UCBPharmaS.A.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6567381-dbe7-4d5c-b68a-e78e7ce2717a" xlink:to="loc_biib_UCBPharmaS.A.Member_550e077a-c811-4cb9-8ec2-9ba0658176e4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoTherapeuticsInc.AgreementMember_6e82675e-1d39-4b18-b5af-3a26c9a9e65d" xlink:href="biib-20220331.xsd#biib_SangamoTherapeuticsInc.AgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6567381-dbe7-4d5c-b68a-e78e7ce2717a" xlink:to="loc_biib_SangamoTherapeuticsInc.AgreementMember_6e82675e-1d39-4b18-b5af-3a26c9a9e65d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherresearchanddiscoveryMember_4f074646-b87c-4f3e-8dfc-2f311e140e9e" xlink:href="biib-20220331.xsd#biib_OtherresearchanddiscoveryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6567381-dbe7-4d5c-b68a-e78e7ce2717a" xlink:to="loc_biib_OtherresearchanddiscoveryMember_4f074646-b87c-4f3e-8dfc-2f311e140e9e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InnoCarePharmaLimitedInnoCareAgreementMember_32c00f96-9c80-43a4-9939-7dbcf9fa6434" xlink:href="biib-20220331.xsd#biib_InnoCarePharmaLimitedInnoCareAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6567381-dbe7-4d5c-b68a-e78e7ce2717a" xlink:to="loc_biib_InnoCarePharmaLimitedInnoCareAgreementMember_32c00f96-9c80-43a4-9939-7dbcf9fa6434" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_199bc63f-7eb8-4fc2-a0bc-78a10290fef7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_51a3f0ff-86a8-4b8c-a6b6-df20a95d3a65" xlink:to="loc_srt_ProductOrServiceAxis_199bc63f-7eb8-4fc2-a0bc-78a10290fef7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_199bc63f-7eb8-4fc2-a0bc-78a10290fef7_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_199bc63f-7eb8-4fc2-a0bc-78a10290fef7" xlink:to="loc_srt_ProductsAndServicesDomain_199bc63f-7eb8-4fc2-a0bc-78a10290fef7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_54368295-e17b-47f4-9441-2cf11966eb53" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_199bc63f-7eb8-4fc2-a0bc-78a10290fef7" xlink:to="loc_srt_ProductsAndServicesDomain_54368295-e17b-47f4-9441-2cf11966eb53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_E2609andBAN2401Member_eeb18212-1e1e-4298-845c-59222b3c8aa5" xlink:href="biib-20220331.xsd#biib_E2609andBAN2401Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_54368295-e17b-47f4-9441-2cf11966eb53" xlink:to="loc_biib_E2609andBAN2401Member_eeb18212-1e1e-4298-845c-59222b3c8aa5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_c7e83bb1-c693-467f-9f62-2ca04442dc58" xlink:href="biib-20220331.xsd#biib_ADUHELMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_54368295-e17b-47f4-9441-2cf11966eb53" xlink:to="loc_biib_ADUHELMMember_c7e83bb1-c693-467f-9f62-2ca04442dc58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3ceb9989-616a-47ce-ba15-d0c8bc0d1f4d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_51a3f0ff-86a8-4b8c-a6b6-df20a95d3a65" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3ceb9989-616a-47ce-ba15-d0c8bc0d1f4d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_3ceb9989-616a-47ce-ba15-d0c8bc0d1f4d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3ceb9989-616a-47ce-ba15-d0c8bc0d1f4d" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_3ceb9989-616a-47ce-ba15-d0c8bc0d1f4d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_085bc3df-7548-4ee3-9fb2-dc257cf1be9e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3ceb9989-616a-47ce-ba15-d0c8bc0d1f4d" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_085bc3df-7548-4ee3-9fb2-dc257cf1be9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_9fa9aeb8-0a2f-411e-a208-f67665dc9ee1" xlink:href="biib-20220331.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_085bc3df-7548-4ee3-9fb2-dc257cf1be9e" xlink:to="loc_biib_DenaliTherapeuticsIncMember_9fa9aeb8-0a2f-411e-a208-f67665dc9ee1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoTherapeuticsInc.AgreementMember_2d6784fa-6eb0-4887-bbff-afd34b770e8c" xlink:href="biib-20220331.xsd#biib_SangamoTherapeuticsInc.AgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_085bc3df-7548-4ee3-9fb2-dc257cf1be9e" xlink:to="loc_biib_SangamoTherapeuticsInc.AgreementMember_2d6784fa-6eb0-4887-bbff-afd34b770e8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_88257ba1-0e70-4a28-bf0e-9023068f3b58" xlink:href="biib-20220331.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_085bc3df-7548-4ee3-9fb2-dc257cf1be9e" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_88257ba1-0e70-4a28-bf0e-9023068f3b58" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_86821177-22b6-4b6f-ad84-0b7437bf3e52" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_51a3f0ff-86a8-4b8c-a6b6-df20a95d3a65" xlink:to="loc_srt_RangeAxis_86821177-22b6-4b6f-ad84-0b7437bf3e52" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_86821177-22b6-4b6f-ad84-0b7437bf3e52_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_86821177-22b6-4b6f-ad84-0b7437bf3e52" xlink:to="loc_srt_RangeMember_86821177-22b6-4b6f-ad84-0b7437bf3e52_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2df8ef7c-225b-4fe5-9ca7-3993085277b0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_86821177-22b6-4b6f-ad84-0b7437bf3e52" xlink:to="loc_srt_RangeMember_2df8ef7c-225b-4fe5-9ca7-3993085277b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c2e3f15b-b9e2-4823-b281-6fcfb3034ad9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2df8ef7c-225b-4fe5-9ca7-3993085277b0" xlink:to="loc_srt_MaximumMember_c2e3f15b-b9e2-4823-b281-6fcfb3034ad9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_8e6e045c-fa1d-4004-bdf7-353667a9bc21" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_51a3f0ff-86a8-4b8c-a6b6-df20a95d3a65" xlink:to="loc_srt_StatementScenarioAxis_8e6e045c-fa1d-4004-bdf7-353667a9bc21" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_8e6e045c-fa1d-4004-bdf7-353667a9bc21_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_8e6e045c-fa1d-4004-bdf7-353667a9bc21" xlink:to="loc_srt_ScenarioUnspecifiedDomain_8e6e045c-fa1d-4004-bdf7-353667a9bc21_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_65af413e-681b-4c08-a9b8-302e89e61b01" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_8e6e045c-fa1d-4004-bdf7-353667a9bc21" xlink:to="loc_srt_ScenarioUnspecifiedDomain_65af413e-681b-4c08-a9b8-302e89e61b01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_196ac21a-8cae-4123-8f36-3724931ab702" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_65af413e-681b-4c08-a9b8-302e89e61b01" xlink:to="loc_srt_ScenarioForecastMember_196ac21a-8cae-4123-8f36-3724931ab702" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="extended" id="ia7443457b0ad43f2aa9db4d96b76d848_CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2bcaf592-ff8d-46b4-969f-ae7efe494014" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_db347ba4-81f4-49e2-8ee6-af2f838aa2fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2bcaf592-ff8d-46b4-969f-ae7efe494014" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_db347ba4-81f4-49e2-8ee6-af2f838aa2fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_8fc19ae7-7af1-47a5-9313-d90596978756" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2bcaf592-ff8d-46b4-969f-ae7efe494014" xlink:to="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_8fc19ae7-7af1-47a5-9313-d90596978756" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_e7759d83-32ed-4ff3-82cf-95dde287dae7" xlink:href="biib-20220331.xsd#biib_Equitymethodinvestmentbasisdifferenceamortizationperiod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2bcaf592-ff8d-46b4-969f-ae7efe494014" xlink:to="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_e7759d83-32ed-4ff3-82cf-95dde287dae7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_c30f6cb1-1f70-4da8-9d21-84e5a8de5386" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2bcaf592-ff8d-46b4-969f-ae7efe494014" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_c30f6cb1-1f70-4da8-9d21-84e5a8de5386" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_81cd29c4-c2d3-4c37-aa31-b23a1b56b66a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2bcaf592-ff8d-46b4-969f-ae7efe494014" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_81cd29c4-c2d3-4c37-aa31-b23a1b56b66a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_119fb189-0b3b-4598-833f-dc0cb8bda4c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfInterestInJointVenture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2bcaf592-ff8d-46b4-969f-ae7efe494014" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_119fb189-0b3b-4598-833f-dc0cb8bda4c5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_ca507693-30bf-409a-b972-54b00e2089c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2bcaf592-ff8d-46b4-969f-ae7efe494014" xlink:to="loc_us-gaap_EquityMethodInvestments_ca507693-30bf-409a-b972-54b00e2089c8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PayablesToDivestitureOfInterestInJointVenture_69363e69-3ea0-4478-97ba-244a59d70012" xlink:href="biib-20220331.xsd#biib_PayablesToDivestitureOfInterestInJointVenture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2bcaf592-ff8d-46b4-969f-ae7efe494014" xlink:to="loc_biib_PayablesToDivestitureOfInterestInJointVenture_69363e69-3ea0-4478-97ba-244a59d70012" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare_dbee44f5-ee60-45f0-9117-83a231ada69e" xlink:href="biib-20220331.xsd#biib_EquityMethodInvestmentsExpectedProfitShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2bcaf592-ff8d-46b4-969f-ae7efe494014" xlink:to="loc_biib_EquityMethodInvestmentsExpectedProfitShare_dbee44f5-ee60-45f0-9117-83a231ada69e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_6cf9740d-f701-4eb3-be67-f1d22e5f8a7f" xlink:href="biib-20220331.xsd#biib_Collaborationprofitlosssharing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2bcaf592-ff8d-46b4-969f-ae7efe494014" xlink:to="loc_biib_Collaborationprofitlosssharing_6cf9740d-f701-4eb3-be67-f1d22e5f8a7f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_23a3132d-b4be-484e-954e-0f214acd3b00" xlink:href="biib-20220331.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2bcaf592-ff8d-46b4-969f-ae7efe494014" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_23a3132d-b4be-484e-954e-0f214acd3b00" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b16972c0-975e-4d00-a72a-dc827771a83b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2bcaf592-ff8d-46b4-969f-ae7efe494014" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b16972c0-975e-4d00-a72a-dc827771a83b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_24c783f1-784f-405e-92f6-22c67b31f924" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2bcaf592-ff8d-46b4-969f-ae7efe494014" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_24c783f1-784f-405e-92f6-22c67b31f924" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccruedMilestonePayments_3e6fabe5-0174-4a1e-8016-d5a1cbbde04b" xlink:href="biib-20220331.xsd#biib_AccruedMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2bcaf592-ff8d-46b4-969f-ae7efe494014" xlink:to="loc_biib_AccruedMilestonePayments_3e6fabe5-0174-4a1e-8016-d5a1cbbde04b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_c253331d-c2fc-4788-a44e-f15c1b4f70cd" xlink:href="biib-20220331.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2bcaf592-ff8d-46b4-969f-ae7efe494014" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_c253331d-c2fc-4788-a44e-f15c1b4f70cd" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractOptionExerciseFee_014d815a-7b43-45a7-9140-9d660aa592a1" xlink:href="biib-20220331.xsd#biib_ContractOptionExerciseFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2bcaf592-ff8d-46b4-969f-ae7efe494014" xlink:to="loc_biib_ContractOptionExerciseFee_014d815a-7b43-45a7-9140-9d660aa592a1" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_0cdfff9f-43ca-4652-8905-4b8f699c771a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2bcaf592-ff8d-46b4-969f-ae7efe494014" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_0cdfff9f-43ca-4652-8905-4b8f699c771a" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5d96b9af-2f14-4366-a3d1-6dcfe9e9a654" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2bcaf592-ff8d-46b4-969f-ae7efe494014" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5d96b9af-2f14-4366-a3d1-6dcfe9e9a654" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_92593066-0cc3-4ad5-b3ab-580fcf60f8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5d96b9af-2f14-4366-a3d1-6dcfe9e9a654" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_92593066-0cc3-4ad5-b3ab-580fcf60f8e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_92593066-0cc3-4ad5-b3ab-580fcf60f8e4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_92593066-0cc3-4ad5-b3ab-580fcf60f8e4" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_92593066-0cc3-4ad5-b3ab-580fcf60f8e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5af33a89-5229-4be2-bf3e-ea4b5edf0ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_92593066-0cc3-4ad5-b3ab-580fcf60f8e4" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5af33a89-5229-4be2-bf3e-ea4b5edf0ee5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_dcbb7e5f-9bab-4434-b817-5c2a94d7c33d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5af33a89-5229-4be2-bf3e-ea4b5edf0ee5" xlink:to="loc_us-gaap_InventoriesMember_dcbb7e5f-9bab-4434-b817-5c2a94d7c33d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_e7672c1e-9742-481e-a96e-cc7fba1e55f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5af33a89-5229-4be2-bf3e-ea4b5edf0ee5" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_e7672c1e-9742-481e-a96e-cc7fba1e55f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f3f101f9-5189-408c-b5ed-5bdfa0769070" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5d96b9af-2f14-4366-a3d1-6dcfe9e9a654" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f3f101f9-5189-408c-b5ed-5bdfa0769070" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f3f101f9-5189-408c-b5ed-5bdfa0769070_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f3f101f9-5189-408c-b5ed-5bdfa0769070" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f3f101f9-5189-408c-b5ed-5bdfa0769070_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_28408e40-dc92-4a13-8516-6a584549fac2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f3f101f9-5189-408c-b5ed-5bdfa0769070" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_28408e40-dc92-4a13-8516-6a584549fac2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_ea865eda-b25f-49f2-bf9d-4f2d2f10b855" xlink:href="biib-20220331.xsd#biib_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_28408e40-dc92-4a13-8516-6a584549fac2" xlink:to="loc_biib_EisaiMember_ea865eda-b25f-49f2-bf9d-4f2d2f10b855" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_a6185e93-0356-460f-841d-51f688354f43" xlink:href="biib-20220331.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_28408e40-dc92-4a13-8516-6a584549fac2" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_a6185e93-0356-460f-841d-51f688354f43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6342efba-1717-4be1-894b-766486dc47b8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5d96b9af-2f14-4366-a3d1-6dcfe9e9a654" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6342efba-1717-4be1-894b-766486dc47b8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_6342efba-1717-4be1-894b-766486dc47b8_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6342efba-1717-4be1-894b-766486dc47b8" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_6342efba-1717-4be1-894b-766486dc47b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_113c0590-1ac3-4bd4-af84-834b111e30e8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6342efba-1717-4be1-894b-766486dc47b8" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_113c0590-1ac3-4bd4-af84-834b111e30e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_7b837dd8-522e-4068-8cc6-35f3e395a2e2" xlink:href="biib-20220331.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_113c0590-1ac3-4bd4-af84-834b111e30e8" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_7b837dd8-522e-4068-8cc6-35f3e395a2e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0f32e4c4-43d9-4943-b8c4-81da47424631" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5d96b9af-2f14-4366-a3d1-6dcfe9e9a654" xlink:to="loc_srt_ProductOrServiceAxis_0f32e4c4-43d9-4943-b8c4-81da47424631" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0f32e4c4-43d9-4943-b8c4-81da47424631_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0f32e4c4-43d9-4943-b8c4-81da47424631" xlink:to="loc_srt_ProductsAndServicesDomain_0f32e4c4-43d9-4943-b8c4-81da47424631_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_87d689e3-323f-439b-9bf0-ef42e1e7e3b6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0f32e4c4-43d9-4943-b8c4-81da47424631" xlink:to="loc_srt_ProductsAndServicesDomain_87d689e3-323f-439b-9bf0-ef42e1e7e3b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_e8a5eaf7-0a2b-456e-9761-0f70b9dd2f54" xlink:href="biib-20220331.xsd#biib_ADUHELMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_87d689e3-323f-439b-9bf0-ef42e1e7e3b6" xlink:to="loc_biib_ADUHELMMember_e8a5eaf7-0a2b-456e-9761-0f70b9dd2f54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_18802e2f-0477-4b9f-93ff-39d59768c933" xlink:href="biib-20220331.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5d96b9af-2f14-4366-a3d1-6dcfe9e9a654" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_18802e2f-0477-4b9f-93ff-39d59768c933" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_18802e2f-0477-4b9f-93ff-39d59768c933_default" xlink:href="biib-20220331.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_18802e2f-0477-4b9f-93ff-39d59768c933" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_18802e2f-0477-4b9f-93ff-39d59768c933_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_97e06a79-2e35-47d2-87a9-97db4b7633f5" xlink:href="biib-20220331.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_18802e2f-0477-4b9f-93ff-39d59768c933" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_97e06a79-2e35-47d2-87a9-97db4b7633f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentDueAtFirstAnniversaryMember_30955cfd-ba06-4bbe-897b-c14d9fefd1e9" xlink:href="biib-20220331.xsd#biib_PaymentDueAtFirstAnniversaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_97e06a79-2e35-47d2-87a9-97db4b7633f5" xlink:to="loc_biib_PaymentDueAtFirstAnniversaryMember_30955cfd-ba06-4bbe-897b-c14d9fefd1e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentDueAtSecondAnniversaryMember_429e3266-f1bc-4f9a-9a62-3216d586c7fd" xlink:href="biib-20220331.xsd#biib_PaymentDueAtSecondAnniversaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_97e06a79-2e35-47d2-87a9-97db4b7633f5" xlink:to="loc_biib_PaymentDueAtSecondAnniversaryMember_429e3266-f1bc-4f9a-9a62-3216d586c7fd" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#InvestmentsinVariableInterestEntitiesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="extended" id="i13774094bddb468cb06a9bb2abc729f1_InvestmentsinVariableInterestEntitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_058f36dc-96b0-4e5b-a4a6-d88263bfd577" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationAgreementTerm_3b393615-ab9e-4910-a6db-4f932984ea26" xlink:href="biib-20220331.xsd#biib_CollaborationAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_058f36dc-96b0-4e5b-a4a6-d88263bfd577" xlink:to="loc_biib_CollaborationAgreementTerm_3b393615-ab9e-4910-a6db-4f932984ea26" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentCostsPercentage_09a31c1e-01f8-4c40-95a1-4518c336ee57" xlink:href="biib-20220331.xsd#biib_ResearchAndDevelopmentCostsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_058f36dc-96b0-4e5b-a4a6-d88263bfd577" xlink:to="loc_biib_ResearchAndDevelopmentCostsPercentage_09a31c1e-01f8-4c40-95a1-4518c336ee57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_e43c523b-8bed-4b59-9b98-6f4eaf4179e0" xlink:href="biib-20220331.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_058f36dc-96b0-4e5b-a4a6-d88263bfd577" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_e43c523b-8bed-4b59-9b98-6f4eaf4179e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_75e81eda-2b46-4959-afbd-d47812db1d89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_058f36dc-96b0-4e5b-a4a6-d88263bfd577" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_75e81eda-2b46-4959-afbd-d47812db1d89" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_5d906546-e194-4a6e-8c90-c495b172d45c" xlink:href="biib-20220331.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_058f36dc-96b0-4e5b-a4a6-d88263bfd577" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_5d906546-e194-4a6e-8c90-c495b172d45c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment_e99f7b5c-fd4c-45bc-86a9-bcab3589732f" xlink:href="biib-20220331.xsd#biib_AdditionalMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_058f36dc-96b0-4e5b-a4a6-d88263bfd577" xlink:to="loc_biib_AdditionalMilestonePayment_e99f7b5c-fd4c-45bc-86a9-bcab3589732f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_57cabbcd-ec18-4f4d-b70c-5854781f2e23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_058f36dc-96b0-4e5b-a4a6-d88263bfd577" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_57cabbcd-ec18-4f4d-b70c-5854781f2e23" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_ea5f6601-c60f-478b-928d-6ddd175a8cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_058f36dc-96b0-4e5b-a4a6-d88263bfd577" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_ea5f6601-c60f-478b-928d-6ddd175a8cd4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_9bee3af4-01d3-47b1-acc4-de3f6d71fb98" xlink:href="biib-20220331.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_058f36dc-96b0-4e5b-a4a6-d88263bfd577" xlink:to="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_9bee3af4-01d3-47b1-acc4-de3f6d71fb98" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_504e858e-2dc3-4e17-a47a-34cacba17ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_058f36dc-96b0-4e5b-a4a6-d88263bfd577" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_504e858e-2dc3-4e17-a47a-34cacba17ec5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_cdbe744f-7c4a-4949-9aa8-7225d3943887" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_504e858e-2dc3-4e17-a47a-34cacba17ec5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_cdbe744f-7c4a-4949-9aa8-7225d3943887" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cdbe744f-7c4a-4949-9aa8-7225d3943887_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_cdbe744f-7c4a-4949-9aa8-7225d3943887" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cdbe744f-7c4a-4949-9aa8-7225d3943887_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_012a9fb1-293c-4896-ac44-d5bab465b7c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_cdbe744f-7c4a-4949-9aa8-7225d3943887" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_012a9fb1-293c-4896-ac44-d5bab465b7c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_31aea951-9ba3-4c3b-8793-7b2c767777dc" xlink:href="biib-20220331.xsd#biib_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_012a9fb1-293c-4896-ac44-d5bab465b7c9" xlink:to="loc_biib_EisaiMember_31aea951-9ba3-4c3b-8793-7b2c767777dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_f21c78b2-e7c9-4e0e-88bf-a5e31b4f3445" xlink:href="biib-20220331.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_504e858e-2dc3-4e17-a47a-34cacba17ec5" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_f21c78b2-e7c9-4e0e-88bf-a5e31b4f3445" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_f21c78b2-e7c9-4e0e-88bf-a5e31b4f3445_default" xlink:href="biib-20220331.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_f21c78b2-e7c9-4e0e-88bf-a5e31b4f3445" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_f21c78b2-e7c9-4e0e-88bf-a5e31b4f3445_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_d8af50b3-0830-4403-9a8c-3d73bef0b976" xlink:href="biib-20220331.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_f21c78b2-e7c9-4e0e-88bf-a5e31b4f3445" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_d8af50b3-0830-4403-9a8c-3d73bef0b976" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RegulatoryMilestonesMember_fd52f6b1-b001-4feb-a910-0b1f422c4352" xlink:href="biib-20220331.xsd#biib_RegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_d8af50b3-0830-4403-9a8c-3d73bef0b976" xlink:to="loc_biib_RegulatoryMilestonesMember_fd52f6b1-b001-4feb-a910-0b1f422c4352" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_17419de1-253d-4ca4-838d-d4d6a2850d5d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_504e858e-2dc3-4e17-a47a-34cacba17ec5" xlink:to="loc_srt_ConsolidatedEntitiesAxis_17419de1-253d-4ca4-838d-d4d6a2850d5d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_17419de1-253d-4ca4-838d-d4d6a2850d5d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_17419de1-253d-4ca4-838d-d4d6a2850d5d" xlink:to="loc_srt_ConsolidatedEntitiesDomain_17419de1-253d-4ca4-838d-d4d6a2850d5d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_5d907c7a-808f-4348-a8e0-dc4aabf6d6f8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_17419de1-253d-4ca4-838d-d4d6a2850d5d" xlink:to="loc_srt_ConsolidatedEntitiesDomain_5d907c7a-808f-4348-a8e0-dc4aabf6d6f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NeurimmuneMember_41242b3e-9a39-460e-9912-ab3d1ada6a0b" xlink:href="biib-20220331.xsd#biib_NeurimmuneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_5d907c7a-808f-4348-a8e0-dc4aabf6d6f8" xlink:to="loc_biib_NeurimmuneMember_41242b3e-9a39-460e-9912-ab3d1ada6a0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9f4f2c50-c6d1-49e6-b750-4fd2cafb22f7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_504e858e-2dc3-4e17-a47a-34cacba17ec5" xlink:to="loc_srt_ProductOrServiceAxis_9f4f2c50-c6d1-49e6-b750-4fd2cafb22f7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9f4f2c50-c6d1-49e6-b750-4fd2cafb22f7_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9f4f2c50-c6d1-49e6-b750-4fd2cafb22f7" xlink:to="loc_srt_ProductsAndServicesDomain_9f4f2c50-c6d1-49e6-b750-4fd2cafb22f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9bc112c7-f27f-4506-b619-1eb2322a858f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9f4f2c50-c6d1-49e6-b750-4fd2cafb22f7" xlink:to="loc_srt_ProductsAndServicesDomain_9bc112c7-f27f-4506-b619-1eb2322a858f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_5375bb9a-2983-4cc1-b920-1190edf5b36a" xlink:href="biib-20220331.xsd#biib_ADUHELMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9bc112c7-f27f-4506-b619-1eb2322a858f" xlink:to="loc_biib_ADUHELMMember_5375bb9a-2983-4cc1-b920-1190edf5b36a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_1c196c0e-c880-45ec-b14a-4b447120f3ac" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_504e858e-2dc3-4e17-a47a-34cacba17ec5" xlink:to="loc_srt_StatementGeographicalAxis_1c196c0e-c880-45ec-b14a-4b447120f3ac" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1c196c0e-c880-45ec-b14a-4b447120f3ac_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_1c196c0e-c880-45ec-b14a-4b447120f3ac" xlink:to="loc_srt_SegmentGeographicalDomain_1c196c0e-c880-45ec-b14a-4b447120f3ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7fcf7080-7457-4df5-9085-15dd4412a2dd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_1c196c0e-c880-45ec-b14a-4b447120f3ac" xlink:to="loc_srt_SegmentGeographicalDomain_7fcf7080-7457-4df5-9085-15dd4412a2dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_2350debe-334d-419a-8b12-551dcf0b19e5" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7fcf7080-7457-4df5-9085-15dd4412a2dd" xlink:to="loc_country_JP_2350debe-334d-419a-8b12-551dcf0b19e5" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>biib-20220331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:c574431f-8208-4dea-bcfe-8d8f5f068522,g:425f524b-de43-4dfe-85cc-ae50a1579d49-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_biib_Expenseincurredbythecollaboration_eb5e61f5-8f00-4133-951d-c54e8c171f66_terseLabel_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:label id="lab_biib_Expenseincurredbythecollaboration_label_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:label id="lab_biib_Expenseincurredbythecollaboration_documentation_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration" xlink:href="biib-20220331.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Expenseincurredbythecollaboration" xlink:to="lab_biib_Expenseincurredbythecollaboration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_c9ff0f24-9f01-492a-b3cb-ba3bedcc2585_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_716bc7aa-7b28-4811-b40e-dc8cdff79a8f_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_6d2e27f1-241c-4b65-87b3-12e837b6a966_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_62aa0ccf-04b8-4bae-a8b0-446ae877ca73_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on securities available for sale</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_3e24bba4-c0ab-4fc2-b98a-2ea898d3516d_verboseLabel_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_label_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Excluding Goodwill [Table Text Block]</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_documentation_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets excluding goodwill.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:href="biib-20220331.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:to="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_06be66fb-d957-407f-ba32-44a0747dfed9_verboseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_5a933c77-e259-4bf0-b87f-76b7545028c8_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TechnologicalAndRegulatorySuccessProbability_be664d5a-ca36-4e67-8005-2a0c1e1c36f4_terseLabel_en-US" xlink:label="lab_biib_TechnologicalAndRegulatorySuccessProbability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technological and Regulatory Success, Probability</link:label>
    <link:label id="lab_biib_TechnologicalAndRegulatorySuccessProbability_label_en-US" xlink:label="lab_biib_TechnologicalAndRegulatorySuccessProbability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technological and Regulatory Success, Probability</link:label>
    <link:label id="lab_biib_TechnologicalAndRegulatorySuccessProbability_documentation_en-US" xlink:label="lab_biib_TechnologicalAndRegulatorySuccessProbability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technological and Regulatory Success, Probability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TechnologicalAndRegulatorySuccessProbability" xlink:href="biib-20220331.xsd#biib_TechnologicalAndRegulatorySuccessProbability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TechnologicalAndRegulatorySuccessProbability" xlink:to="lab_biib_TechnologicalAndRegulatorySuccessProbability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_74090728-f60c-48ce-9b94-2f991489a5ab_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks and Trade Names</link:label>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks and Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:to="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_017da49b-21fb-4efe-b118-275cde5929c3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_0c5fa8ef-906b-4dca-9d16-5a3b4240506c_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_a5b942ff-513d-4291-acfc-17712ed48770_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_bb48fe42-2782-4212-a0f1-c1a10412d500_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_c868f322-b71a-4850-875f-585e119e758d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_da657f36-f066-4c0b-afb5-20ed478e03b4_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency forward contracts that were entered into to hedge forecasted revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_2dd99332-da72-42a8-ae2c-a529881f3504_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_fc143b81-6a43-4f4d-a18e-8e72c60494c3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration expense</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ZINBRYTAMember_7ea5e89b-11f8-4f1b-9bb1-b1a735ed5f35_terseLabel_en-US" xlink:label="lab_biib_ZINBRYTAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZINBRYTA</link:label>
    <link:label id="lab_biib_ZINBRYTAMember_label_en-US" xlink:label="lab_biib_ZINBRYTAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZINBRYTA [Member]</link:label>
    <link:label id="lab_biib_ZINBRYTAMember_documentation_en-US" xlink:label="lab_biib_ZINBRYTAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZINBRYTA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ZINBRYTAMember" xlink:href="biib-20220331.xsd#biib_ZINBRYTAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ZINBRYTAMember" xlink:to="lab_biib_ZINBRYTAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_b062df7b-fc54-4a72-94ec-095839291174_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_8c01961a-5a3c-4ba2-863e-e1b739c4f656_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_a8d7a7ea-a746-4aca-a20e-dacc207932d2_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_429174c1-6fcd-4a83-9d83-e4397e74bff9_negatedLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments/Returns Relating To Sales in Prior Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Prior Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to prior year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:href="biib-20220331.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_af0d038f-65f6-4c45-8379-2f15c6e257dd_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_8b133104-7297-4e59-b15c-af73c33ce4e0_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_04696d7b-4a10-43b5-9b89-d1e6fedb7aaa_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_9c5d2bbb-64ff-4dc3-bb3b-def71f91be5d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_a5968591-e4c6-4311-87be-fb7212a9ce58_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DenaliTherapeuticsIncMember_c83663c7-14fa-40b1-9c58-756a5f6b4cc0_terseLabel_en-US" xlink:label="lab_biib_DenaliTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denali Therapeutics</link:label>
    <link:label id="lab_biib_DenaliTherapeuticsIncMember_label_en-US" xlink:label="lab_biib_DenaliTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denali Therapeutics Inc [Member]</link:label>
    <link:label id="lab_biib_DenaliTherapeuticsIncMember_documentation_en-US" xlink:label="lab_biib_DenaliTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denali Therapeutics Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember" xlink:href="biib-20220331.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DenaliTherapeuticsIncMember" xlink:to="lab_biib_DenaliTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_51b6ed22-1aeb-465c-960b-6aebe4917574_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments and other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d98de9a0-4d4d-40f6-9590-620bbd28499b_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NoncontrollingInterestIncreaseDecreaseOther_577d562f-9410-4762-b7f7-88c4b2eb86fc_terseLabel_en-US" xlink:label="lab_biib_NoncontrollingInterestIncreaseDecreaseOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital contribution from noncontrolling interest</link:label>
    <link:label id="lab_biib_NoncontrollingInterestIncreaseDecreaseOther_label_en-US" xlink:label="lab_biib_NoncontrollingInterestIncreaseDecreaseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase (Decrease) Other</link:label>
    <link:label id="lab_biib_NoncontrollingInterestIncreaseDecreaseOther_documentation_en-US" xlink:label="lab_biib_NoncontrollingInterestIncreaseDecreaseOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase (Decrease) Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NoncontrollingInterestIncreaseDecreaseOther" xlink:href="biib-20220331.xsd#biib_NoncontrollingInterestIncreaseDecreaseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NoncontrollingInterestIncreaseDecreaseOther" xlink:to="lab_biib_NoncontrollingInterestIncreaseDecreaseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_06b26cf9-35cb-41e9-8ad0-d032454a604e_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_a161fab7-8924-47ee-a355-e777e0975695_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the sales of strategic investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SPINRAZAMember_edc0f30e-b966-4fe1-8ede-784da6666349_terseLabel_en-US" xlink:label="lab_biib_SPINRAZAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINRAZA</link:label>
    <link:label id="lab_biib_SPINRAZAMember_label_en-US" xlink:label="lab_biib_SPINRAZAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINRAZA [Member]</link:label>
    <link:label id="lab_biib_SPINRAZAMember_documentation_en-US" xlink:label="lab_biib_SPINRAZAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINRAZA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SPINRAZAMember" xlink:href="biib-20220331.xsd#biib_SPINRAZAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SPINRAZAMember" xlink:to="lab_biib_SPINRAZAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoriesMember_33c99bee-fc40-41b1-879f-71846b068f3c_terseLabel_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoriesMember_label_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoriesMember" xlink:to="lab_us-gaap_InventoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_950440b4-53ba-440f-94d2-6bbe383a61b0_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_e6263bbf-1cfa-4ca9-99a4-681597ea33f2_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TysabriProductMember_183767f9-96e5-461f-97ab-906b473da485_terseLabel_en-US" xlink:label="lab_biib_TysabriProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TYSABRI</link:label>
    <link:label id="lab_biib_TysabriProductMember_label_en-US" xlink:label="lab_biib_TysabriProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:label id="lab_biib_TysabriProductMember_documentation_en-US" xlink:label="lab_biib_TysabriProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TysabriProductMember" xlink:href="biib-20220331.xsd#biib_TysabriProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TysabriProductMember" xlink:to="lab_biib_TysabriProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_73cf612e-b91f-4c45-bdd9-e8820f95fc07_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_31b27044-db3b-4b23-b5f6-2a273de152f3_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on fair value remeasurement of contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_5742c539-947e-4f32-99b5-4a0f74d1f02a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_5f2a818c-83e9-42c8-83eb-9824bdc552ce_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration impairment</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_5fdd527a-6629-4fc1-81d0-074e5d426d79_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Contracts, Liability, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:to="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_e69070d6-b386-492d-8703-1d7c768cd20c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable debt and equity securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CentersForMedicareAndMedicaidServiceMember_2efa2290-b1c7-4b4f-8066-0bb2a39f2fa6_terseLabel_en-US" xlink:label="lab_biib_CentersForMedicareAndMedicaidServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Centers for Medicare and Medicaid Service</link:label>
    <link:label id="lab_biib_CentersForMedicareAndMedicaidServiceMember_label_en-US" xlink:label="lab_biib_CentersForMedicareAndMedicaidServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Centers for Medicare and Medicaid Service [Member]</link:label>
    <link:label id="lab_biib_CentersForMedicareAndMedicaidServiceMember_documentation_en-US" xlink:label="lab_biib_CentersForMedicareAndMedicaidServiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Centers for Medicare and Medicaid Service</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CentersForMedicareAndMedicaidServiceMember" xlink:href="biib-20220331.xsd#biib_CentersForMedicareAndMedicaidServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CentersForMedicareAndMedicaidServiceMember" xlink:to="lab_biib_CentersForMedicareAndMedicaidServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_ba93322c-dc3e-4ad2-826f-e7113da3dfe3_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_e6118db3-2961-4420-886c-270e63c920ce_terseLabel_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</link:label>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_label_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Of Co Promotion Profits</link:label>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_documentation_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of co promotion profits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfCoPromotionProfits" xlink:href="biib-20220331.xsd#biib_ShareOfCoPromotionProfits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareOfCoPromotionProfits" xlink:to="lab_biib_ShareOfCoPromotionProfits" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_3168b54e-0f41-479c-a27f-1dcb69ace390_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0c1bdaf9-2987-491f-a696-32a3bed542e3_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_d244e5ac-0f73-4bf0-ace5-91bb0c8cfe04_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_e75c2020-d592-4d94-94b5-1d451ec84ddf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_27224f25-3188-4176-90d8-37e15e32d806_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount remaining under 2019 Share Repurchase Program</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ResearchanddevelopmentassetDomain_7ede37a3-a8ea-4343-9330-fc5a7cbff271_terseLabel_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development asset [Domain]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetDomain_label_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development asset [Domain]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetDomain_documentation_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Research and development asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetDomain" xlink:href="biib-20220331.xsd#biib_ResearchanddevelopmentassetDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResearchanddevelopmentassetDomain" xlink:to="lab_biib_ResearchanddevelopmentassetDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_41279a15-c407-4991-96e8-77af2548e0cb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember" xlink:to="lab_us-gaap_OtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_fc0598fc-1e5e-4244-a724-cfa6c111dce5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_0f2e56ca-ae5b-4b76-b194-1b6d3c6af528_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_55fb1280-5968-4642-b6aa-26070da2fa7b_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_b9c5c01a-a5da-4618-b467-36d5ed04d28f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InnoCarePharmaLimitedInnoCareAgreementMember_61289787-26e0-4458-81fc-f69067bae92b_terseLabel_en-US" xlink:label="lab_biib_InnoCarePharmaLimitedInnoCareAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">InnoCare Pharma Limited (InnoCare) Agreement</link:label>
    <link:label id="lab_biib_InnoCarePharmaLimitedInnoCareAgreementMember_label_en-US" xlink:label="lab_biib_InnoCarePharmaLimitedInnoCareAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">InnoCare Pharma Limited (InnoCare) Agreement [Member]</link:label>
    <link:label id="lab_biib_InnoCarePharmaLimitedInnoCareAgreementMember_documentation_en-US" xlink:label="lab_biib_InnoCarePharmaLimitedInnoCareAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">InnoCare Pharma Limited (InnoCare) Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InnoCarePharmaLimitedInnoCareAgreementMember" xlink:href="biib-20220331.xsd#biib_InnoCarePharmaLimitedInnoCareAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InnoCarePharmaLimitedInnoCareAgreementMember" xlink:to="lab_biib_InnoCarePharmaLimitedInnoCareAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_043f9633-4999-45f8-853e-ac4df85f62c9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_cd257021-9984-488f-a955-4a7dd0fd733b_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e28f4a62-3a10-498b-b37b-f1089db73fec_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_3e2b6dd0-62f6-42de-b448-83a54149b19d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ContractualAdjustmentsMember_eb2b8989-5d0c-4d40-871c-8912bac933cd_terseLabel_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual adjustments</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_label_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Adjustments [Member]</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_documentation_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual adjustments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractualAdjustmentsMember" xlink:href="biib-20220331.xsd#biib_ContractualAdjustmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContractualAdjustmentsMember" xlink:to="lab_biib_ContractualAdjustmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_3cc0c1ff-4fe1-4f91-bd00-933142a1bc4d_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_ca984d84-8298-4fb2-86e5-549407911dc9_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_2105a10a-16cb-48f3-84e0-ae50a7b65b0a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on net investment hedge</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_c56d6c37-16f3-42b6-967d-947c43b7d640_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated impairment losses related to goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OutLicensedPatentsMember_9a782689-9505-43e9-8bf5-96c3a49be211_terseLabel_en-US" xlink:label="lab_biib_OutLicensedPatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Completed technology</link:label>
    <link:label id="lab_biib_OutLicensedPatentsMember_label_en-US" xlink:label="lab_biib_OutLicensedPatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Out Licensed Patents [Member]</link:label>
    <link:label id="lab_biib_OutLicensedPatentsMember_documentation_en-US" xlink:label="lab_biib_OutLicensedPatentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Out-licensed patents.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OutLicensedPatentsMember" xlink:href="biib-20220331.xsd#biib_OutLicensedPatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OutLicensedPatentsMember" xlink:to="lab_biib_OutLicensedPatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DistributorTwoMember_7cd15693-9742-40e9-9d60-945e060fc148_terseLabel_en-US" xlink:label="lab_biib_DistributorTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor Two</link:label>
    <link:label id="lab_biib_DistributorTwoMember_label_en-US" xlink:label="lab_biib_DistributorTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor Two [Member]</link:label>
    <link:label id="lab_biib_DistributorTwoMember_documentation_en-US" xlink:label="lab_biib_DistributorTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorTwoMember" xlink:href="biib-20220331.xsd#biib_DistributorTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorTwoMember" xlink:to="lab_biib_DistributorTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_1ac902ef-74c7-44f2-9efc-e5da090a7b3b_negatedLabel_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments Relating To Prior Years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_label_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Product Revenue Reserves Relating To Sales In Prior Years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_documentation_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to product revenue reserves relating to sales in prior years.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:href="biib-20220331.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:to="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_e258ae7b-c5ea-450f-b8e7-0eefed3c2bec_terseLabel_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of stake in entity</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_label_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_documentation_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:href="biib-20220331.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:to="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_a15f0e75-17ea-42a4-8d69-987b6d08b36d_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_b891a8ee-b4dc-4ac0-8abf-bb4dfe5f7d05_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of contractual maturities: available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_06a5a80b-aacf-4be6-866f-04edd5e9d24b_terseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in unrecognized tax benefits is reasonably possible</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5599b709-6380-43e7-b86e-56a9af9a0e42_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_7dbed33b-677a-4b8a-8a47-dbb7a181e64c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_2b39ed23-ec4f-4891-9da3-3eb6ff74e237_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_80aef2f7-8bd7-4898-8c9a-26c1375e12b9_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value $0.001 per share</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CurrencyAxis_699c66f9-8eda-43fa-9440-bd5c1832db0b_terseLabel_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_srt_CurrencyAxis_label_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis" xlink:to="lab_srt_CurrencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MarketStockUnitsMember_9a054088-bb32-447b-bb58-0e71c47bc27b_verboseLabel_en-US" xlink:label="lab_biib_MarketStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market stock units</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_label_en-US" xlink:label="lab_biib_MarketStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Stock Units [Member]</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_documentation_en-US" xlink:label="lab_biib_MarketStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market stock units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember" xlink:href="biib-20220331.xsd#biib_MarketStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MarketStockUnitsMember" xlink:to="lab_biib_MarketStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_c9c6b869-3632-4fc2-8452-643790b070a2_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_8b7e8d48-655a-4c45-b51b-60930e451787_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.625% Senior Notes due 2022</link:label>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_label_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_documentation_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:href="biib-20220331.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:to="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_7cdc125c-a170-4dea-9fda-831ba5b4aa56_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_bd98cc1a-51b7-48de-af3b-c07e147aa718_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_44b4b228-6a35-4556-9fb1-898069a44c16_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instruments, fair value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_8255b8f8-0f83-4765-8f0b-803e72f46933_verboseLabel_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and other asset backed securities Current</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_label_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage And Other Asset Backed Securities Current [Member]</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_documentation_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and other asset backed securities Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:href="biib-20220331.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:to="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_9c1b7157-fb12-4498-8d6b-a56ece429171_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesMember" xlink:to="lab_us-gaap_DebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_12d11c12-d234-412c-b54d-cbf716c010e1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts_e8e59744-b676-4625-ba04-35148da1202c_terseLabel_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neurimmune tax impacts</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts_label_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, NuerImmune Tax Impacts</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts_documentation_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, NuerImmune Tax Impacts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" xlink:href="biib-20220331.xsd#biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" xlink:to="lab_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_20f8ab8e-6f20-4370-8e60-ba6f4f18abb0_terseLabel_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense included in total costs and expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_label_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Expense Included In Costs And Expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_documentation_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation expense included in costs and expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:href="biib-20220331.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:to="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_a3ea12f5-9afa-435f-afd6-15b7b5621b30_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_75a78259-0087-42b5-b0c2-5d32144ac6c5_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_9ef80ded-065f-4e66-bf4d-64bf9db35052_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_c94cfd08-0641-405d-800b-20f4e20e1fd4_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IMRALDIMember_66fb129e-3d64-4955-98b8-bf54b475e40a_terseLabel_en-US" xlink:label="lab_biib_IMRALDIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMRALDI</link:label>
    <link:label id="lab_biib_IMRALDIMember_label_en-US" xlink:label="lab_biib_IMRALDIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMRALDI [Member]</link:label>
    <link:label id="lab_biib_IMRALDIMember_documentation_en-US" xlink:label="lab_biib_IMRALDIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMRALDI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IMRALDIMember" xlink:href="biib-20220331.xsd#biib_IMRALDIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IMRALDIMember" xlink:to="lab_biib_IMRALDIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0b7377a7-d182-4bbf-8f72-4f4982c8d0e4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_0238eaab-5364-480d-a01c-80d35b1d40e0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_8ee99d6a-b7a8-4f70-90a8-c2e98735f1d0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized share-based compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Amount Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2a137734-deff-4711-8d6f-8d842aa759ab_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_f802461a-566e-4ca2-9487-9479ee71768c_terseLabel_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenues from major distributors</link:label>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_label_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Wide Percentage Of Revenue From Major Distributors</link:label>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_documentation_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity wide percentage of revenue from major distributors.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:href="biib-20220331.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:to="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_6fd1abf5-26b4-4254-982f-0dd4e62ef523_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNetAbstract_21efa83e-778c-4d9f-86ae-8ef11547fbd9_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income (Expense), Net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNetAbstract_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract" xlink:to="lab_us-gaap_InterestIncomeExpenseNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenseMember_afad8fdd-08ac-49e7-bfd3-e3c5c5b28a0f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expense</link:label>
    <link:label id="lab_us-gaap_OperatingExpenseMember_label_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenseMember" xlink:to="lab_us-gaap_OperatingExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d49a96c4-3834-4415-8467-53f7e0f7cd3f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_44cdcda3-7bfa-434c-97eb-2a077dd1da08_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_fc9e2793-b003-4851-9038-d9641a388e39_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_f650bfe6-1577-43d3-a63a-f407e992e509_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net gains (losses) realized during the period on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_c2b2846a-e2f5-4ed5-afe8-2254806ba2d3_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gains (losses) realized during the period on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_f6886a20-5526-45a1-b3e6-096e4312c866_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_db9767be-73c7-4dc7-8836-a344a5474899_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on pension benefit obligation, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_b44640c8-d813-4386-a445-49b622964efe_terseLabel_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Variable Interest Entities [Abstract]</link:label>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_label_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Variable Interest Entities [Abstract]</link:label>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_documentation_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments In Variable Interest Entities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:href="biib-20220331.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:to="lab_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_e5ca1e9c-5d77-4c59-b127-cc6174930bca_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_cccf0474-41e0-4dbe-92be-c09ea1bad165_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherresearchanddiscoveryMember_b9724b9c-2056-41a4-aafd-bbf79f438fed_terseLabel_en-US" xlink:label="lab_biib_OtherresearchanddiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other research and discovery</link:label>
    <link:label id="lab_biib_OtherresearchanddiscoveryMember_label_en-US" xlink:label="lab_biib_OtherresearchanddiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other research and discovery [Member]</link:label>
    <link:label id="lab_biib_OtherresearchanddiscoveryMember_documentation_en-US" xlink:label="lab_biib_OtherresearchanddiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other research and discovery [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherresearchanddiscoveryMember" xlink:href="biib-20220331.xsd#biib_OtherresearchanddiscoveryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherresearchanddiscoveryMember" xlink:to="lab_biib_OtherresearchanddiscoveryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_b905405f-9a63-4f63-a044-114c714580c8_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_eb55d6f6-dc8a-45fb-8b3d-a375e3b35b48_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_2a84ec10-1bc1-48c5-aeca-f97fe3c58f5e_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues by product</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueFromRelatedParties_8ddc8d36-7948-4c37-849f-400730e5d584_terseLabel_en-US" xlink:label="lab_us-gaap_DueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from Related Parties</link:label>
    <link:label id="lab_us-gaap_DueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_DueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromRelatedParties" xlink:to="lab_us-gaap_DueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_bd64407d-164a-45c6-b07e-7445d38d0359_verboseLabel_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan assets for deferred compensation</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_label_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Assets For Deferred Compensation Fair Value Disclosure</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_documentation_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair values as of the balance sheet date of all assets of deferred compensation plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:href="biib-20220331.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:to="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_bf1181d5-b112-4071-8719-923142abcaea_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Derivatives</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationGILTItax_0d91372d-7e6f-4954-9e53-e06e2edddfa0_terseLabel_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationGILTItax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GILTI</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationGILTItax_label_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationGILTItax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, GILTI tax</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationGILTItax_documentation_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationGILTItax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, GILTI tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationGILTItax" xlink:href="biib-20220331.xsd#biib_EffectiveTaxRateReconciliationGILTItax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveTaxRateReconciliationGILTItax" xlink:to="lab_biib_EffectiveTaxRateReconciliationGILTItax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_69ec26b2-02b8-43d6-8be8-f0a3a86431ea_terseLabel_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Provisions Relating To Sales In Current Year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_label_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Provisions To Product Revenue Reserves Relating To Sales In Current Year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_documentation_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current provisions to product revenue reserves relating to sales in current year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:href="biib-20220331.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:to="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FumarateMember_fee50c97-df5a-4523-ab4d-8212295a04b6_terseLabel_en-US" xlink:label="lab_biib_FumarateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fumarate</link:label>
    <link:label id="lab_biib_FumarateMember_label_en-US" xlink:label="lab_biib_FumarateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fumarate [Member]</link:label>
    <link:label id="lab_biib_FumarateMember_documentation_en-US" xlink:label="lab_biib_FumarateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fumarate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumarateMember" xlink:href="biib-20220331.xsd#biib_FumarateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FumarateMember" xlink:to="lab_biib_FumarateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_e9198689-4a74-4c4a-a6ce-9690c15f79cd_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_db6dfc4b-9104-4d78-bc62-6c98a6c2728a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_08e4dc71-bbb5-4f40-aee0-47ac981c34e4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative asset, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_3b113a47-69c8-471b-90ad-2725999233b4_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, at Carrying Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A3.15SeniorNotesdueMay12050Member_d7f6ae74-ed1d-4332-b9fd-f879a7cd4eba_terseLabel_en-US" xlink:label="lab_biib_A3.15SeniorNotesdueMay12050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.150% Senior Notes due May 1, 2050</link:label>
    <link:label id="lab_biib_A3.15SeniorNotesdueMay12050Member_label_en-US" xlink:label="lab_biib_A3.15SeniorNotesdueMay12050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.15% Senior Notes due May 1, 2050 [Member]</link:label>
    <link:label id="lab_biib_A3.15SeniorNotesdueMay12050Member_documentation_en-US" xlink:label="lab_biib_A3.15SeniorNotesdueMay12050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.15% Senior Notes due May 1, 2050 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3.15SeniorNotesdueMay12050Member" xlink:href="biib-20220331.xsd#biib_A3.15SeniorNotesdueMay12050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A3.15SeniorNotesdueMay12050Member" xlink:to="lab_biib_A3.15SeniorNotesdueMay12050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_0cdd3c26-ae51-45d1-888b-d3ee04196a7f_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_1b0fb2f3-15e4-4a28-9db2-090d8ad22559_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the effect of derivatives designated as net investment hedging instruments on our consolidated statement of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ReserveforCashDiscountsMember_78551184-ce1c-4472-933c-ac2758b2afad_terseLabel_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounts</link:label>
    <link:label id="lab_biib_ReserveforCashDiscountsMember_label_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for Cash Discounts [Member]</link:label>
    <link:label id="lab_biib_ReserveforCashDiscountsMember_documentation_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for Cash Discounts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReserveforCashDiscountsMember" xlink:href="biib-20220331.xsd#biib_ReserveforCashDiscountsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReserveforCashDiscountsMember" xlink:to="lab_biib_ReserveforCashDiscountsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_5c68c8a1-c0df-4ff8-9ced-a10e106deb70_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on investments in equity securities</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:to="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NumberOfWholesalers_e28fc452-5dc7-4232-a5d5-4a52478c09ea_terseLabel_en-US" xlink:label="lab_biib_NumberOfWholesalers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of wholesalers</link:label>
    <link:label id="lab_biib_NumberOfWholesalers_label_en-US" xlink:label="lab_biib_NumberOfWholesalers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Wholesalers</link:label>
    <link:label id="lab_biib_NumberOfWholesalers_documentation_en-US" xlink:label="lab_biib_NumberOfWholesalers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Wholesalers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfWholesalers" xlink:href="biib-20220331.xsd#biib_NumberOfWholesalers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfWholesalers" xlink:to="lab_biib_NumberOfWholesalers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_28bbe0ca-8da4-4f3b-9947-4aaf6469d962_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_3ef33649-a973-4440-9b53-5b864ca20a61_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.050% Senior Notes due 2025</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_label_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_documentation_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:href="biib-20220331.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:to="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_8ee0933d-fe88-4075-8d90-e13261647bb8_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_74fad11b-91ff-4d69-8e22-2d4e5e7379be_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_199b3ce5-6c13-4b48-86ce-00495803bfa9_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_dcea8c62-6e2a-4fe4-a494-daebb68438cf_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_72faba1e-75ad-431d-815c-4ab769c5ce82_terseLabel_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Expected Profit Share</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_label_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Expected Profit Share</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_documentation_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Expected Profit Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare" xlink:href="biib-20220331.xsd#biib_EquityMethodInvestmentsExpectedProfitShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquityMethodInvestmentsExpectedProfitShare" xlink:to="lab_biib_EquityMethodInvestmentsExpectedProfitShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_64046b34-f720-42df-ad1f-356932ed0b87_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_ef6cec0c-5274-4153-a855-f65714c99ef5_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_55751564-81cd-438e-ae41-278114528619_terseLabel_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments made to collaborative partner</link:label>
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_label_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront And Milestone Payments Made To Collaborative Partner</link:label>
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_documentation_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total upfront and milestone payments made to collaborative partner.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:href="biib-20220331.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:to="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_c9626387-773b-48ff-b122-0d2033fd604c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_5fcdc5fb-50db-4b00-adbf-cd6a1096f26d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_58039b77-5d0c-4ac4-bb12-87e3295f34d6_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_1e1200e7-a646-41e6-b4be-a3219600e39b_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4a7a3205-6d86-4ffa-a3a8-0510d3f5208c_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_e1809837-d98b-408d-8b31-00936bb54b76_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on cash flow hedges, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_1e1d916a-56ab-4dae-88b5-09b754f9685a_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_19fc47b1-fd4d-43b7-a758-a339de0616fa_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities and sales</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_87f3fbab-efee-4592-8c43-5c106e4565bc_verboseLabel_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_label_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_documentation_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:href="biib-20220331.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:to="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_194bec7e-0ffa-4e32-95b3-9c9903c1ffaa_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IonisSangamoDenaliAndSageMember_16cd1b2e-d828-4c89-a670-7540dcc31325_terseLabel_en-US" xlink:label="lab_biib_IonisSangamoDenaliAndSageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ionis, Sangamo, Denali and Sage</link:label>
    <link:label id="lab_biib_IonisSangamoDenaliAndSageMember_label_en-US" xlink:label="lab_biib_IonisSangamoDenaliAndSageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ionis, Sangamo, Denali and Sage [Member]</link:label>
    <link:label id="lab_biib_IonisSangamoDenaliAndSageMember_documentation_en-US" xlink:label="lab_biib_IonisSangamoDenaliAndSageMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ionis, Sangamo, Denali and Sage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisSangamoDenaliAndSageMember" xlink:href="biib-20220331.xsd#biib_IonisSangamoDenaliAndSageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IonisSangamoDenaliAndSageMember" xlink:to="lab_biib_IonisSangamoDenaliAndSageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_db9c0a5a-be62-430f-a48c-037a1a0b8315_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_e742bd47-c01d-4568-86ad-b0c8bd3830a4_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f39271f1-7fe4-4844-a627-f1e2d33ca5e3_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_7abb7ecc-e0b3-4805-9dc7-b09df3fa9bbe_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_84c48d66-c369-401b-b469-6e3e84c1287f_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Contract, Asset, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:to="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_36fe6a3c-fb91-4e64-9a19-7ecdc2b13ef8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_00f32ef7-7de0-4bd3-89bb-bd2899aedf13_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_d734f865-747d-48fd-9d5d-4e12c3a3aa54_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_41942988-3c2d-45c7-9f6e-c7416b975cbc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_26685a4b-c75f-4589-8be9-127de1b94551_totalLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gains (losses) recognized during the period on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_656f4a9a-6150-482e-991e-77ce4b102f9d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_4e1c4593-a668-478f-bf7b-1a566cfc9d8f_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of stake in entity maximum</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_9801f92c-fca4-4a52-a5a4-83e5e7686c81_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_9ca1f20b-e0b8-4a2f-a75d-5d15376e2ecf_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization expense, 2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_4eba1cb7-4510-49e4-a613-b263977f663b_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Consolidated Financial Statement Detail</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ccb80422-43d7-42db-a4bf-7b3b7fde1fd2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under stock award plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_01345daf-a095-48ab-b2b6-c7aa2a3d0d3d_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_eb8a7311-2b1e-43e0-bd25-7954692dfa1e_verboseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FUMADERMMember_3ce17336-7a9c-465c-8202-9641232b26d4_terseLabel_en-US" xlink:label="lab_biib_FUMADERMMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FUMADERM</link:label>
    <link:label id="lab_biib_FUMADERMMember_label_en-US" xlink:label="lab_biib_FUMADERMMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FUMADERM [Member]</link:label>
    <link:label id="lab_biib_FUMADERMMember_documentation_en-US" xlink:label="lab_biib_FUMADERMMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FUMADERM [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FUMADERMMember" xlink:href="biib-20220331.xsd#biib_FUMADERMMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FUMADERMMember" xlink:to="lab_biib_FUMADERMMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_237e0078-30cd-4ab2-bbef-0d1a625f8ae8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized gains</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_fac3a798-96d9-430f-95b8-1139ae718e99_terseLabel_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on net investment hedges, net of tax</link:label>
    <link:label id="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives used in Net Investment Hedge, Net of Tax, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:to="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_38b8b7ef-4d13-4448-9277-7c8d82f4aa35_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other changes in operating assets and liabilities, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FacilityLocationDomain_d34a1157-5a25-4117-a6ea-7a71c7102a84_terseLabel_en-US" xlink:label="lab_biib_FacilityLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Location [Domain]</link:label>
    <link:label id="lab_biib_FacilityLocationDomain_label_en-US" xlink:label="lab_biib_FacilityLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Location [Domain]</link:label>
    <link:label id="lab_biib_FacilityLocationDomain_documentation_en-US" xlink:label="lab_biib_FacilityLocationDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationDomain" xlink:href="biib-20220331.xsd#biib_FacilityLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityLocationDomain" xlink:to="lab_biib_FacilityLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BiologicsManufacturingMember_4ccf5af6-7340-4592-9b4e-28de32da50d0_terseLabel_en-US" xlink:label="lab_biib_BiologicsManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biologics Manufacturing</link:label>
    <link:label id="lab_biib_BiologicsManufacturingMember_label_en-US" xlink:label="lab_biib_BiologicsManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biologics Manufacturing [Member]</link:label>
    <link:label id="lab_biib_BiologicsManufacturingMember_documentation_en-US" xlink:label="lab_biib_BiologicsManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biologics Manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiologicsManufacturingMember" xlink:href="biib-20220331.xsd#biib_BiologicsManufacturingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiologicsManufacturingMember" xlink:to="lab_biib_BiologicsManufacturingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_7b1bc8a7-8b46-4b04-a725-e6e5ac9c7db2_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_d321b8fb-963c-495c-b567-b76e0e73b1be_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_640c63c2-5201-49dc-a209-fc5244566ea3_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5b1d27da-794c-4c61-8478-6285870de821_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income tax expense and equity in loss of investee, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_0688cf20-dafa-4c45-bbe8-8ffd4b1c72ae_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_946adbe7-9693-4355-a554-f7761e21fad4_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5de75a2d-2d8c-4092-8122-5a404687f016_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_1b4d09e7-d690-4920-af57-9dc37fd63e66_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_0acca945-baf2-4870-86be-2d7d18422c46_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e24281f7-1a81-4e7a-a755-d4e71bf87993_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_19780c11-470d-45f7-9325-02641c010caf_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_9c741df0-afd1-4b9f-8085-168a8e131251_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring reserve, beginning</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_852ecbb2-55e9-4627-a7af-fda6c911ae2e_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring reserve, ending</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_57d173f2-6a34-4285-88ec-c28d22a945c4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_9c83f69f-bb2f-4d1d-9764-c059c3a5d5c9_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_c1c093c1-470e-4483-8143-0f41a199c554_terseLabel_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_label_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_documentation_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:href="biib-20220331.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:to="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_89875dbc-f9a9-4d90-b122-55b012b55cb5_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_c588102d-1046-4795-a2fb-345676345702_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indebtedness</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FacilityTypeDomain_0ad023e5-4d4a-4d94-9e1a-e96038130745_terseLabel_en-US" xlink:label="lab_biib_FacilityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type [Domain]</link:label>
    <link:label id="lab_biib_FacilityTypeDomain_label_en-US" xlink:label="lab_biib_FacilityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type [Domain]</link:label>
    <link:label id="lab_biib_FacilityTypeDomain_documentation_en-US" xlink:label="lab_biib_FacilityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeDomain" xlink:href="biib-20220331.xsd#biib_FacilityTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityTypeDomain" xlink:to="lab_biib_FacilityTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_71280056-1741-48e4-86b3-8fc8339cdcfb_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payments</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BENEPALIMember_7ff6e41c-798a-4935-9c56-3f9333e76d80_terseLabel_en-US" xlink:label="lab_biib_BENEPALIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BENEPALI</link:label>
    <link:label id="lab_biib_BENEPALIMember_label_en-US" xlink:label="lab_biib_BENEPALIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BENEPALI [Member]</link:label>
    <link:label id="lab_biib_BENEPALIMember_documentation_en-US" xlink:label="lab_biib_BENEPALIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BENEPALI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BENEPALIMember" xlink:href="biib-20220331.xsd#biib_BENEPALIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BENEPALIMember" xlink:to="lab_biib_BENEPALIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_18872ef1-07a8-455d-8ce5-dd6b28a2f6d8_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_6130ec68-ff67-4b25-a0ee-226660e7d7d7_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_9f511acf-004c-441f-8d40-a9d6288a0367_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of basis differences</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Difference Between Carrying Amount and Underlying Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:to="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_0cebef0b-6179-43ea-a2ea-fb663b4de2e5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_d0dc0fd4-99cb-420e-b537-e14d79fedf95_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_97a8138a-0497-4420-a828-ddfbb96bddb7_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_ccb5e399-bb44-44e2-b3ab-cb1ec26c3c44_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_b0ef100b-bd8f-4e6d-b01e-c8784581003b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract" xlink:to="lab_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_df378011-6f52-467a-aab7-c7f4b0c6661a_totalLabel_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_label_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net current and noncurrent</link:label>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_documentation_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net current and noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent" xlink:href="biib-20220331.xsd#biib_Inventorynetcurrentandnoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent" xlink:to="lab_biib_Inventorynetcurrentandnoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_b8287710-81ed-4442-b8d6-6b85d033b5f1_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_bc259b7b-8d6d-4ff6-91e4-92f1bbe751ee_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange gains (losses), net</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_30458a51-0413-40bb-b221-485ad1124a5e_terseLabel_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="biib-20220331.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_0e7e05f3-7c44-46c7-9ea9-79db9da9eb89_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value $0.0005 per share</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_StrategicInvestmentsMember_977a97fc-0c87-414a-88b8-ca088ec3b0a1_terseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Investments</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_label_en-US" xlink:label="lab_biib_StrategicInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Investments [Member]</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentsMember" xlink:href="biib-20220331.xsd#biib_StrategicInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentsMember" xlink:to="lab_biib_StrategicInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_bc54ee4a-f545-4675-9010-a2562c13ce62_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_34760e75-1584-439d-8f18-86288dca5e78_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_650d50cf-29d7-413d-9803-520d09b46fda_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_4165b330-59d9-4d67-b29d-bb428bf7b56a_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNetAbstract_fee8d156-03af-4718-932c-2690f0764588_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNetAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetAbstract" xlink:to="lab_us-gaap_InventoryNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_6f38ad2e-39d2-4772-b340-dd3eff447c47_terseLabel_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total reserves included in consolidated balance sheets</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Product Revenue Reserves Included In Consolidated Balance Sheets [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of total product revenue reserves included in consolidated balance sheets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:href="biib-20220331.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:to="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InventoryNetCurrentAndNoncurrent_1f9e242d-42f1-4c20-a9e4-5ececc77aed3_terseLabel_en-US" xlink:label="lab_biib_InventoryNetCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_biib_InventoryNetCurrentAndNoncurrent_label_en-US" xlink:label="lab_biib_InventoryNetCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net Current and Noncurrent</link:label>
    <link:label id="lab_biib_InventoryNetCurrentAndNoncurrent_documentation_en-US" xlink:label="lab_biib_InventoryNetCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net Current and Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InventoryNetCurrentAndNoncurrent" xlink:href="biib-20220331.xsd#biib_InventoryNetCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InventoryNetCurrentAndNoncurrent" xlink:to="lab_biib_InventoryNetCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_e84f5e1f-ef59-4cea-b958-3fc6a6a69fec_verboseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_659e1410-2d3d-4434-8190-ecb42e582a05_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_4804751d-fbfb-40a5-9052-c0b3f973a253_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments, contingencies and guarantees</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_aca0ff32-be55-43b1-a970-231487431122_terseLabel_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Contingent Milestone Types [Domain]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_label_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Contingent Milestone Types [Domain]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_documentation_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Future Contingent Milestone Types [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain" xlink:href="biib-20220331.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain" xlink:to="lab_biib_FutureContingentMilestoneTypesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5dc49706-da7e-4a67-be69-4bfd16495824_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_747d616f-8873-437d-ac82-b8469f479d66_periodStartLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss), net of tax beginning balance</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9830dbac-f6f8-4aa7-8f1b-bc46903da985_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, January 1, 2018</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7f335d08-3325-4f86-ba4f-bee1e0ca608b_periodEndLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss), net of tax ending balance</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_a3129527-682b-4444-81e9-8459bca09162_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_462ab6a4-ddf2-46cb-ae11-0d4a70cef7dd_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued income taxes</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_3364cf7b-6080-468e-9ca5-7df19fb27438_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess and obsolescence charges related to inventory</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ContractOptionExerciseFee_9f3c182f-dbdf-4723-a0dd-c269e9d0546a_terseLabel_en-US" xlink:label="lab_biib_ContractOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Option Exercise Fee</link:label>
    <link:label id="lab_biib_ContractOptionExerciseFee_label_en-US" xlink:label="lab_biib_ContractOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Option Exercise Fee</link:label>
    <link:label id="lab_biib_ContractOptionExerciseFee_documentation_en-US" xlink:label="lab_biib_ContractOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Option Exercise Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractOptionExerciseFee" xlink:href="biib-20220331.xsd#biib_ContractOptionExerciseFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContractOptionExerciseFee" xlink:to="lab_biib_ContractOptionExerciseFee" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PayablesToDivestitureOfInterestInJointVenture_07f34f4c-9e82-49e4-8d32-491e6d90663c_terseLabel_en-US" xlink:label="lab_biib_PayablesToDivestitureOfInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables To Divestiture Of Interest In Joint Venture</link:label>
    <link:label id="lab_biib_PayablesToDivestitureOfInterestInJointVenture_label_en-US" xlink:label="lab_biib_PayablesToDivestitureOfInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables To Divestiture Of Interest In Joint Venture</link:label>
    <link:label id="lab_biib_PayablesToDivestitureOfInterestInJointVenture_documentation_en-US" xlink:label="lab_biib_PayablesToDivestitureOfInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables To Divestiture Of Interest In Joint Venture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PayablesToDivestitureOfInterestInJointVenture" xlink:href="biib-20220331.xsd#biib_PayablesToDivestitureOfInterestInJointVenture"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PayablesToDivestitureOfInterestInJointVenture" xlink:to="lab_biib_PayablesToDivestitureOfInterestInJointVenture" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_e1a18815-32d9-4b64-af21-3c66d854fe44_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock_bd695ddc-2bb7-4e0f-a095-55da1831f78c_terseLabel_en-US" xlink:label="lab_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Unrealized Gain (Loss)</link:label>
    <link:label id="lab_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock_label_en-US" xlink:label="lab_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Unrealized Gain (Loss) [Table Text Block]</link:label>
    <link:label id="lab_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock_documentation_en-US" xlink:label="lab_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock" xlink:href="biib-20220331.xsd#biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock" xlink:to="lab_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_dfd682e7-6d40-41ed-b001-e8a8535dea03_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_6065c8ec-3474-444b-945a-492d1ef7c9bc_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_bac3490f-96ce-4bbf-a4b6-1de492ab76bf_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_19ea2b0d-4ab9-40b7-8a32-016b2af06f1d_verboseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock units</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_e773c586-213c-4591-82cd-f940c474afe2_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cost and expense</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_97f11d57-6d00-4a62-9a16-8d7abffd84b9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), before reclassifications, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_8b6b151e-ef71-4a5b-9d96-56527ade1866_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_GBP_825c764b-8fe1-42b4-b788-c1acb67f747c_terseLabel_en-US" xlink:label="lab_currency_GBP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">British pound</link:label>
    <link:label id="lab_currency_GBP_label_en-US" xlink:label="lab_currency_GBP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom, Pounds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_GBP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_GBP" xlink:to="lab_currency_GBP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_3bfc9351-4b7b-4837-9eb5-a17f707627b9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_b45c16dd-7b75-4b64-bc58-b98a6637e2a5_terseLabel_en-US" xlink:label="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment basis difference amortization period</link:label>
    <link:label id="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_label_en-US" xlink:label="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment basis difference amortization period</link:label>
    <link:label id="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_documentation_en-US" xlink:label="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment basis difference amortization period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:href="biib-20220331.xsd#biib_Equitymethodinvestmentbasisdifferenceamortizationperiod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:to="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_edfac360-3b6b-41f0-81b5-fcafa80e9047_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PaymentDueAtFirstAnniversaryMember_531b34aa-4029-4e7b-8c6b-ddf358894159_terseLabel_en-US" xlink:label="lab_biib_PaymentDueAtFirstAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Due At First Anniversary</link:label>
    <link:label id="lab_biib_PaymentDueAtFirstAnniversaryMember_label_en-US" xlink:label="lab_biib_PaymentDueAtFirstAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Due At First Anniversary [Member]</link:label>
    <link:label id="lab_biib_PaymentDueAtFirstAnniversaryMember_documentation_en-US" xlink:label="lab_biib_PaymentDueAtFirstAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Due At First Anniversary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentDueAtFirstAnniversaryMember" xlink:href="biib-20220331.xsd#biib_PaymentDueAtFirstAnniversaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentDueAtFirstAnniversaryMember" xlink:to="lab_biib_PaymentDueAtFirstAnniversaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AdministrativeSpaceMember_8b6b6a2e-d435-440d-aafc-30118dfc8dc8_terseLabel_en-US" xlink:label="lab_biib_AdministrativeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Administrative Space</link:label>
    <link:label id="lab_biib_AdministrativeSpaceMember_label_en-US" xlink:label="lab_biib_AdministrativeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Administrative Space [Member]</link:label>
    <link:label id="lab_biib_AdministrativeSpaceMember_documentation_en-US" xlink:label="lab_biib_AdministrativeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Administrative Space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdministrativeSpaceMember" xlink:href="biib-20220331.xsd#biib_AdministrativeSpaceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdministrativeSpaceMember" xlink:to="lab_biib_AdministrativeSpaceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_efddce5d-92ad-4cb6-ac05-5a87bb37cd28_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on strategic investments</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:to="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_72927cef-d0bc-4ee8-88d1-a44cf8be1c39_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_23432376-b507-4655-a281-2dfd43c36c29_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_677364dc-aeb8-4d8f-a243-0ef78bed798d_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DerivativeMaturityAxis_7ac9f385-1ca7-4b08-880d-6ed9a6d0aca4_terseLabel_en-US" xlink:label="lab_biib_DerivativeMaturityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Maturity [Axis]</link:label>
    <link:label id="lab_biib_DerivativeMaturityAxis_label_en-US" xlink:label="lab_biib_DerivativeMaturityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Maturity [Axis]</link:label>
    <link:label id="lab_biib_DerivativeMaturityAxis_documentation_en-US" xlink:label="lab_biib_DerivativeMaturityAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Maturity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityAxis" xlink:href="biib-20220331.xsd#biib_DerivativeMaturityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DerivativeMaturityAxis" xlink:to="lab_biib_DerivativeMaturityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_9e8e10c5-2071-4b12-a096-1fa1e8652887_negatedTerseLabel_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="biib-20220331.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_71249152-df21-47ee-a1cd-c15d0f6d2e0f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_a86d9d58-5bf5-4990-b28c-ce744da2e679_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NumberOfSquareFeet_4c06a2bd-64f7-4a4f-85fa-500f44aa9787_terseLabel_en-US" xlink:label="lab_biib_NumberOfSquareFeet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of square feet</link:label>
    <link:label id="lab_biib_NumberOfSquareFeet_label_en-US" xlink:label="lab_biib_NumberOfSquareFeet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Square Feet</link:label>
    <link:label id="lab_biib_NumberOfSquareFeet_documentation_en-US" xlink:label="lab_biib_NumberOfSquareFeet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Square Feet</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfSquareFeet" xlink:href="biib-20220331.xsd#biib_NumberOfSquareFeet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfSquareFeet" xlink:to="lab_biib_NumberOfSquareFeet" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_89e3115b-fedf-4dc9-a5be-7085c9b103ef_terseLabel_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance stock units settled in stock</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_label_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Units Settled in Stock [Member]</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_documentation_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Units Settled in Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember" xlink:href="biib-20220331.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockMember" xlink:to="lab_biib_PerformanceStockUnitsSettledinStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_61054186-1cee-4b23-ba92-50f0066fc075_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_0d97ee78-cc30-4ebf-92aa-0cc94184d9bb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_11af0c47-b458-400f-8163-e7b9d1339462_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_6e571011-f0f3-472c-9b03-08317a1004c7_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credits and net operating loss utilization</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InterferonMember_21f74a76-43a7-4b04-8a95-06e8e4fa826a_terseLabel_en-US" xlink:label="lab_biib_InterferonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interferon</link:label>
    <link:label id="lab_biib_InterferonMember_label_en-US" xlink:label="lab_biib_InterferonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interferon [Member]</link:label>
    <link:label id="lab_biib_InterferonMember_documentation_en-US" xlink:label="lab_biib_InterferonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interferon</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterferonMember" xlink:href="biib-20220331.xsd#biib_InterferonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InterferonMember" xlink:to="lab_biib_InterferonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_55343b75-5dac-47a7-8717-a7dbf792b5fd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_6aaf55b4-94be-42ea-8d7b-a16498e5ac3f_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_76792507-c16c-4d02-bb66-ae39a611c0c0_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_dcaba60e-b734-4640-8a4e-98f587661f6c_verboseLabel_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities Non-current</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_label_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities Non Current [Member]</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_documentation_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities Non Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:href="biib-20220331.xsd#biib_CorporateDebtSecuritiesNonCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:to="lab_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_c045d8df-fa11-4e75-8b2d-67803a63a341_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_51a2bd2d-cab6-43af-9104-441b029f013e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_a30b11e2-01c1-4738-a7f0-a7ab39697883_terseLabel_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Samsung Bioepis</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_label_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Samsung Biosimilar Agreement [Member]</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_documentation_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Samsung bio-similar agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember" xlink:href="biib-20220331.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SamsungBiosimilarAgreementMember" xlink:to="lab_biib_SamsungBiosimilarAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_1da06a6b-51ee-4f1c-9f38-c89ec8bc786c_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4949bcb1-d67b-4cb4-bd3d-1481bf713496_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_f83c77f3-b6bc-4b60-a3a5-dbe0432f1329_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) recognized in net income, excluded component</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_CAD_2b9e66d0-2f6f-49d4-a2f6-ba3fd40f87b6_verboseLabel_en-US" xlink:label="lab_currency_CAD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canadian dollar</link:label>
    <link:label id="lab_currency_CAD_label_en-US" xlink:label="lab_currency_CAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada, Dollars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CAD" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_CAD"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CAD" xlink:to="lab_currency_CAD" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ResearchAndDevelopmentCostsPercentage_19ca8963-6b06-41d2-9035-36fea7bba59a_terseLabel_en-US" xlink:label="lab_biib_ResearchAndDevelopmentCostsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development costs, percentage</link:label>
    <link:label id="lab_biib_ResearchAndDevelopmentCostsPercentage_label_en-US" xlink:label="lab_biib_ResearchAndDevelopmentCostsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs, Percentage</link:label>
    <link:label id="lab_biib_ResearchAndDevelopmentCostsPercentage_documentation_en-US" xlink:label="lab_biib_ResearchAndDevelopmentCostsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentCostsPercentage" xlink:href="biib-20220331.xsd#biib_ResearchAndDevelopmentCostsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResearchAndDevelopmentCostsPercentage" xlink:to="lab_biib_ResearchAndDevelopmentCostsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ShorttermderivativeMember_97b822ea-67b2-4087-8f55-088e548c86ea_terseLabel_en-US" xlink:label="lab_biib_ShorttermderivativeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term derivative</link:label>
    <link:label id="lab_biib_ShorttermderivativeMember_label_en-US" xlink:label="lab_biib_ShorttermderivativeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term derivative [Member]</link:label>
    <link:label id="lab_biib_ShorttermderivativeMember_documentation_en-US" xlink:label="lab_biib_ShorttermderivativeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term derivative [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShorttermderivativeMember" xlink:href="biib-20220331.xsd#biib_ShorttermderivativeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShorttermderivativeMember" xlink:to="lab_biib_ShorttermderivativeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_07b5bd68-cfce-4da9-b2d9-6bf5e9840a33_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_ae31f68a-b290-4591-99a4-2ad1cb7f6f75_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years, estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6572ff45-adbf-4220-b539-1e9b4c30af25_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_1ec54ec2-c2fe-42a3-af95-2650fc288ae4_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative and Other Relationships</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_cd55a3cc-7a28-4b7a-b31f-98c6510b0a86_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization expense, 2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_bb9e46f9-abe3-4e6a-bd21-c33364f334f4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_0b43f373-a163-47e0-9d2f-77ba7460021b_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_7449308b-7559-414d-b783-5b6ec72973c0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under stock option and stock purchase plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Treasury Stock Reissued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_a4bb3cf5-e21b-44f3-a347-d68e8b4f2454_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_3b804e46-fe6e-4d0f-a503-d5300eb1d2b1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_9578f63a-b52d-4e28-a0d3-630cd5ba607e_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_1b199d00-3a27-49c7-b4cf-5347f1120f6f_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, Business Transformation and Other Cost Saving Initiatives</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_cbaa3f9f-b242-4703-80ed-a1f148e274f8_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_b22c83bb-2867-4e16-b91f-d1eb708dbfa6_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_628fe0a9-9eb5-4673-bf37-ca2461e9eecc_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of borrowings and premiums paid on debt exchange</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_UnrealizedGainOnDerivatives_21f59456-60c0-42b3-9fcb-68fdfa2ba047_terseLabel_en-US" xlink:label="lab_biib_UnrealizedGainOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain on Derivatives</link:label>
    <link:label id="lab_biib_UnrealizedGainOnDerivatives_label_en-US" xlink:label="lab_biib_UnrealizedGainOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain on Derivatives</link:label>
    <link:label id="lab_biib_UnrealizedGainOnDerivatives_documentation_en-US" xlink:label="lab_biib_UnrealizedGainOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain on Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGainOnDerivatives" xlink:href="biib-20220331.xsd#biib_UnrealizedGainOnDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UnrealizedGainOnDerivatives" xlink:to="lab_biib_UnrealizedGainOnDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DebtInstrumentRedemptionAmount_22861c79-f575-4180-8a89-23f916bbee75_terseLabel_en-US" xlink:label="lab_biib_DebtInstrumentRedemptionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Amount</link:label>
    <link:label id="lab_biib_DebtInstrumentRedemptionAmount_label_en-US" xlink:label="lab_biib_DebtInstrumentRedemptionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Amount</link:label>
    <link:label id="lab_biib_DebtInstrumentRedemptionAmount_documentation_en-US" xlink:label="lab_biib_DebtInstrumentRedemptionAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DebtInstrumentRedemptionAmount" xlink:href="biib-20220331.xsd#biib_DebtInstrumentRedemptionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DebtInstrumentRedemptionAmount" xlink:to="lab_biib_DebtInstrumentRedemptionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ContingentMilestonePaymentsMadeToCollaborativePartner_7e951c5f-0090-4ff7-b3d3-112f3b3a7187_terseLabel_en-US" xlink:label="lab_biib_ContingentMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent additional milestone payment</link:label>
    <link:label id="lab_biib_ContingentMilestonePaymentsMadeToCollaborativePartner_label_en-US" xlink:label="lab_biib_ContingentMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Milestone Payments Made To Collaborative Partner</link:label>
    <link:label id="lab_biib_ContingentMilestonePaymentsMadeToCollaborativePartner_documentation_en-US" xlink:label="lab_biib_ContingentMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Milestone Payments Made To Collaborative Partner</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContingentMilestonePaymentsMadeToCollaborativePartner" xlink:href="biib-20220331.xsd#biib_ContingentMilestonePaymentsMadeToCollaborativePartner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContingentMilestonePaymentsMadeToCollaborativePartner" xlink:to="lab_biib_ContingentMilestonePaymentsMadeToCollaborativePartner" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_4c76dd83-0114-4445-9741-e6b56db1dfee_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_1c4f8c5e-323c-41ae-af7c-c1a58b237712_verboseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on interest rate swap</link:label>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_label_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Derivative Instruments, Net, Pretax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_5c01445c-5e8e-4d9f-b3fe-ba65a05f4531_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expense and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_47676d11-38e1-485f-b49c-27a8f886e3e6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5bda0a6e-ff6a-4ea6-86cb-da64478438e4_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_863f1247-7a47-4d16-9ca6-753cb2e46699_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairment charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_fb03e72e-459d-4c95-852c-d5c0c3d282a1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_d8d3b657-6414-439f-9d5d-431e34f9b4b5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_cbe0c0bd-8673-4306-9891-c6381081e237_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_03f99989-b2c2-483f-b8e0-601af9c24193_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b352ba47-0173-484a-936c-097868900d89_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_032e39d6-0aec-4a64-855b-5862dc002afc_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expense and other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_1bc3d63e-78dc-4492-912a-49c35dcaece3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expense and other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InterestInSubsidiary_dd517548-441f-4748-90e4-a40463c81eb1_verboseLabel_en-US" xlink:label="lab_biib_InterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest in subsidiary (less than given percentage)</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_label_en-US" xlink:label="lab_biib_InterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest In Subsidiary</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_documentation_en-US" xlink:label="lab_biib_InterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest in subsidiary.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterestInSubsidiary" xlink:href="biib-20220331.xsd#biib_InterestInSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InterestInSubsidiary" xlink:to="lab_biib_InterestInSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_b3d394af-1b62-48ca-8a45-39aedfb05d56_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_1c08404b-91cf-4a1f-b5b1-dd88aa003944_verboseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_f48d40a6-38f6-4abc-aa21-931df0ad2cb3_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_06d8be9f-7ab3-4731-b788-a93550cdb4be_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NeurimmuneMember_1fbd7ade-449d-4749-9891-9d3663c5f726_terseLabel_en-US" xlink:label="lab_biib_NeurimmuneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neurimmune</link:label>
    <link:label id="lab_biib_NeurimmuneMember_label_en-US" xlink:label="lab_biib_NeurimmuneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neurimmune [Member]</link:label>
    <link:label id="lab_biib_NeurimmuneMember_documentation_en-US" xlink:label="lab_biib_NeurimmuneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neurimmune.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NeurimmuneMember" xlink:href="biib-20220331.xsd#biib_NeurimmuneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NeurimmuneMember" xlink:to="lab_biib_NeurimmuneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_4a15fda4-d495-46d7-9df1-0700663cb4c3_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_c7ad3e66-28af-46a1-97bd-5c2f12d2998d_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_602e37bc-212d-41a8-9472-512e7d17ac53_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_E2609andBAN2401Member_5a408ba8-85e4-4cec-8e40-130a5e870fa1_terseLabel_en-US" xlink:label="lab_biib_E2609andBAN2401Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BAN2401 and Elenbecestat</link:label>
    <link:label id="lab_biib_E2609andBAN2401Member_label_en-US" xlink:label="lab_biib_E2609andBAN2401Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">E2609 and BAN2401 [Member]</link:label>
    <link:label id="lab_biib_E2609andBAN2401Member_documentation_en-US" xlink:label="lab_biib_E2609andBAN2401Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">E2609 and BAN2401 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_E2609andBAN2401Member" xlink:href="biib-20220331.xsd#biib_E2609andBAN2401Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_E2609andBAN2401Member" xlink:to="lab_biib_E2609andBAN2401Member" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_86541f18-779d-4036-b194-2bbfb250d483_terseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_339bd58b-b432-4990-ba42-dc897a1a4bff_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_0c7e2455-4f20-4b58-9036-4c4b57cfc9a1_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_f4ec3f9f-73b0-478c-b12d-0179a64b5aa0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization expense, 2020</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_32edb5d0-84a7-4319-b13e-4ff8beb79616_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_7e800c3b-f5c2-4682-aba1-ff886a84de6e_terseLabel_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of share based compensation expense associated with different programs [Abstract]</link:label>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_label_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of share based compensation expense associated with different programs [Abstract]</link:label>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_documentation_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of share-based compensation expense associated with different programs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:href="biib-20220331.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:to="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_41b997ce-8bb9-4187-b05a-a3e435e03dbd_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_eaf5e26c-86d2-49dd-acc4-13f8cb5d1bc6_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Biogen Inc. shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_99c67364-72e8-4663-95e9-2f6ccad04e9f_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_b5ce475b-2e65-4c63-86f1-3952016c50ee_verboseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8e22565a-baf5-4f56-b0fd-ba923617dc42_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_50699466-c374-415b-bbea-5c1f48c905d7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_8fdbfecc-4fef-4570-8169-75d42bd81629_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_f1eaef62-a0c2-4ffb-9916-41ed868afd4b_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Senior Debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Senior Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:to="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Collaborationexpensesaccrual_4e7510d1-0abe-4518-9c40-505b5a3d232a_terseLabel_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration expense</link:label>
    <link:label id="lab_biib_Collaborationexpensesaccrual_label_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:label id="lab_biib_Collaborationexpensesaccrual_documentation_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationexpensesaccrual" xlink:href="biib-20220331.xsd#biib_Collaborationexpensesaccrual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Collaborationexpensesaccrual" xlink:to="lab_biib_Collaborationexpensesaccrual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_59a1ffb1-b239-42ba-8671-6e926fd7e8de_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_28c17574-c99f-4291-9d7e-048e08525cca_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of treasury stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_98343d4b-2a25-4b5e-90fc-4e6ea9aace1f_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_d27fe3bf-2f0d-4933-9932-ccc9f3210765_terseLabel_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_label_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues [Table Text Block]</link:label>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_documentation_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesTableTextBlock" xlink:href="biib-20220331.xsd#biib_OtherrevenuesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesTableTextBlock" xlink:to="lab_biib_OtherrevenuesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_a8527a1c-19fd-4400-8144-f5bb0abd02da_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen Idec Inc. shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_75049a93-e90c-4e7a-95ad-5679213cce86_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DerivativeMaturityDomain_384feff6-d0f2-484f-a135-1f871743f7af_terseLabel_en-US" xlink:label="lab_biib_DerivativeMaturityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Maturity [Domain]</link:label>
    <link:label id="lab_biib_DerivativeMaturityDomain_label_en-US" xlink:label="lab_biib_DerivativeMaturityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Maturity [Domain]</link:label>
    <link:label id="lab_biib_DerivativeMaturityDomain_documentation_en-US" xlink:label="lab_biib_DerivativeMaturityDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Derivative Maturity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityDomain" xlink:href="biib-20220331.xsd#biib_DerivativeMaturityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DerivativeMaturityDomain" xlink:to="lab_biib_DerivativeMaturityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableCurrent_2c42d165-47b4-4bec-9317-b42ef77b5bc9_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of notes payable</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent" xlink:to="lab_us-gaap_NotesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_a7d44a9f-0feb-4a0e-a858-bd1cc81e976d_terseLabel_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_label_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_documentation_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis" xlink:href="biib-20220331.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis" xlink:to="lab_biib_FutureContingentMilestoneTypesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_e05fa05b-798f-4e74-ab65-a13c638a31c6_verboseLabel_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EmployeeStockPurchasePlanMember" xlink:href="biib-20220331.xsd#biib_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EmployeeStockPurchasePlanMember" xlink:to="lab_biib_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_e93a14ce-4a45-44c5-ba97-96ab6db32cbd_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_38335125-6f68-4282-b5f2-12ae70dda8b8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_d9b7964e-b194-4ea2-ba20-ecb3b3e4b6f5_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember" xlink:to="lab_us-gaap_AccruedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_37d1a1a5-1ec6-4d64-b297-6dd3c787ce89_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_65d12cc0-59d0-4261-bbdb-b0e738919093_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Information about Litigation Matters [Abstract]</link:label>
    <link:label id="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_label_en-US" xlink:label="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Information about Litigation Matters [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:to="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_7f6f7c72-d8bb-414f-98a5-63e02d4b809b_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_24b61624-ea91-460e-be38-62242bffa4c4_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_06f4f141-0f4c-4d00-bf4a-5f0e64b7a53c_terseLabel_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Analysis of change In reserves</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_label_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Analysis Of Amount Of And Change In Product Revenue Reserves [Table Text Block]</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_documentation_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Analysis of amount of and change in product revenue reserves.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:href="biib-20220331.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:to="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_7a592bfa-2d2a-4683-b9d1-7616ba80e5d0_negatedLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax effect</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_675bb730-a9c0-42f2-b241-8b8cbab53e0b_verboseLabel_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from marketable debt securities</link:label>
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:to="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_6f45bf39-d176-4823-a75a-9e79a638e4da_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_dabdbf08-0659-4adb-af91-e5c2aab3a56c_negatedTerseLabel_en-US" xlink:label="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in (income) loss of investee, net of tax</link:label>
    <link:label id="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_label_en-US" xlink:label="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments, Net of Tax</link:label>
    <link:label id="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_documentation_en-US" xlink:label="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:href="biib-20220331.xsd#biib_IncomeLossFromEquityMethodInvestmentsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:to="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_99929f85-6c4c-4ce4-944b-cdbb005d567a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A2.25SeniorNotesdueMay12030Member_cce0cc97-5d95-450e-b294-4c8eca519b6f_terseLabel_en-US" xlink:label="lab_biib_A2.25SeniorNotesdueMay12030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.250% Senior Notes due May 1, 2030</link:label>
    <link:label id="lab_biib_A2.25SeniorNotesdueMay12030Member_label_en-US" xlink:label="lab_biib_A2.25SeniorNotesdueMay12030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Senior Notes due May 1, 2030 [Member]</link:label>
    <link:label id="lab_biib_A2.25SeniorNotesdueMay12030Member_documentation_en-US" xlink:label="lab_biib_A2.25SeniorNotesdueMay12030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Senior Notes due May 1, 2030 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.25SeniorNotesdueMay12030Member" xlink:href="biib-20220331.xsd#biib_A2.25SeniorNotesdueMay12030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2.25SeniorNotesdueMay12030Member" xlink:to="lab_biib_A2.25SeniorNotesdueMay12030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_b5b2fe8c-28ff-4a19-ab2a-24d0aeb827fe_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_ae0d19e7-d355-4c22-8531-aaf25eb373e8_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_e8798e43-0761-4176-b764-c3153eba2185_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Termofcollaborationagreement_ec4a6a17-8303-4151-848f-6eaf8b5bde75_terseLabel_en-US" xlink:label="lab_biib_Termofcollaborationagreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of collaboration agreement</link:label>
    <link:label id="lab_biib_Termofcollaborationagreement_label_en-US" xlink:label="lab_biib_Termofcollaborationagreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of collaboration agreement</link:label>
    <link:label id="lab_biib_Termofcollaborationagreement_documentation_en-US" xlink:label="lab_biib_Termofcollaborationagreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of collaboration agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Termofcollaborationagreement" xlink:href="biib-20220331.xsd#biib_Termofcollaborationagreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Termofcollaborationagreement" xlink:to="lab_biib_Termofcollaborationagreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_7c904678-f311-4d1b-ba97-457826e16b3d_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the effect of cash flow derivatives designated as hedging instruments on the condensed consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_9a10cbc3-cd4b-4e95-95d6-867b1e9de70b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_dc7642fc-b9f6-4983-9d01-87f902660d79_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Samsung Bioepis</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_9ac8ab04-ab6c-4e81-a8fc-d069d7925d79_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_UCBPharmaS.A.Member_cb9a8e3a-731a-4f80-945d-dd6c1c9f6e59_terseLabel_en-US" xlink:label="lab_biib_UCBPharmaS.A.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UCB Pharma S.A. [Member]</link:label>
    <link:label id="lab_biib_UCBPharmaS.A.Member_label_en-US" xlink:label="lab_biib_UCBPharmaS.A.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UCB Pharma S.A. [Member]</link:label>
    <link:label id="lab_biib_UCBPharmaS.A.Member_documentation_en-US" xlink:label="lab_biib_UCBPharmaS.A.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UCB Pharma S.A. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UCBPharmaS.A.Member" xlink:href="biib-20220331.xsd#biib_UCBPharmaS.A.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UCBPharmaS.A.Member" xlink:to="lab_biib_UCBPharmaS.A.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_5098c25f-79d1-4858-8e96-fb4aa5474e59_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_e94cf812-4747-440f-a21c-a16ca1f1cfe9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_d7fcc723-a723-4c3a-a011-0da935bcd69d_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_68dae72f-7b01-4217-82a7-bc62b39deeb6_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_16160771-666a-443b-8a2e-1e1d3723ccab_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid research and development expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_00dfbfa4-0e8b-4602-8c28-9218779fe879_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_b86b76d1-793d-463d-90b9-edfe696ec5f4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_75fc0ecd-bc08-49a4-9942-5137a591169a_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable, fair value</link:label>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableFairValueDisclosure" xlink:to="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_afe1c83d-af67-4312-820c-089f5f7addcf_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost and Net</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_c60608b5-8930-467e-aa94-37bbef281d95_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_d90b1b11-65ed-4c8a-982e-4e23ad57ed22_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining duration of Net Investment Hedges</link:label>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_label_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTermOfContract" xlink:to="lab_us-gaap_DerivativeTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e2ba834d-fba7-444b-a00e-d78634e28694_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_49ea49ed-28bf-4ee2-aa00-d3eda36f8087_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_becd7e6d-06c9-4f8b-9a05-c8739b067e80_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e24f7eb4-e668-4222-8526-0331efcd6a94_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_7d7abec3-9826-4265-98d5-5b2a40421d58_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (benefit) expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_5fd0da1f-fbe5-4ef6-951e-3ef0a6d6d5c9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BiosimilarsMember_1bc1205a-e410-4448-903c-32cddb7fdd67_terseLabel_en-US" xlink:label="lab_biib_BiosimilarsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biosimilars</link:label>
    <link:label id="lab_biib_BiosimilarsMember_label_en-US" xlink:label="lab_biib_BiosimilarsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biosimilars [Member]</link:label>
    <link:label id="lab_biib_BiosimilarsMember_documentation_en-US" xlink:label="lab_biib_BiosimilarsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biosimilars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiosimilarsMember" xlink:href="biib-20220331.xsd#biib_BiosimilarsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiosimilarsMember" xlink:to="lab_biib_BiosimilarsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_b35972dd-e33e-429e-b955-4696fd9dce40_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_22a1b0f1-275f-4255-8151-c57750630de1_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_5d67a785-d3c4-48c4-8123-213ca8456833_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_6eb29599-cdd9-46e0-a8e7-c77e4a5e3408_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_4559a900-e771-4e17-b9c1-1c50075aa071_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_6c92efed-1f9a-4b1b-a77a-cb4ac77aefef_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_a244df43-fed5-4cdd-a8b9-c56f51360f13_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7aa5db78-a2fe-4f5b-81b0-fe3a5f1e8faa_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_3fe7b608-e0ab-42ac-b1c3-d8ab41b6ea69_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_f33cb76c-a657-41f5-824a-65e0369dec90_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_7e00f6c5-4508-4bea-8e34-ca6ce1697e4b_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsToMinorityShareholders_d69e8b6c-1a55-495e-8cc7-868b2880f3c1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (distribution) contribution to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsToMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments to) Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:to="lab_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_c77ac9c9-26e8-40ec-b96b-520595492772_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction of accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_3dfd15b8-d19c-46a5-bcc8-e6025ee0872a_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_ad8014bb-496b-4090-8af4-49fc2e46bb18_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_c4d4ac22-f117-4041-8742-eb2d4f3e0e41_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_UnrealizedLossOnDerivatives_de938e96-9949-44e2-8632-5d9420a38c92_negatedTerseLabel_en-US" xlink:label="lab_biib_UnrealizedLossOnDerivatives" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Loss on Derivatives</link:label>
    <link:label id="lab_biib_UnrealizedLossOnDerivatives_label_en-US" xlink:label="lab_biib_UnrealizedLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Loss on Derivatives</link:label>
    <link:label id="lab_biib_UnrealizedLossOnDerivatives_documentation_en-US" xlink:label="lab_biib_UnrealizedLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Loss on Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedLossOnDerivatives" xlink:href="biib-20220331.xsd#biib_UnrealizedLossOnDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UnrealizedLossOnDerivatives" xlink:to="lab_biib_UnrealizedLossOnDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_fd3a82a3-bdac-4fef-8ef1-b4ccfb7ec074_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a6ae9d09-9e00-493c-bd74-ff9861adcc28_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_0a33780f-bdf1-4da4-b05c-8677aeeb6d2b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_6a56e62c-675e-4956-8cba-c09a65461bf1_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:to="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_LongTermDebtExchangedAmount_7d24fe87-2bd3-4948-9439-b7aafb03d50d_terseLabel_en-US" xlink:label="lab_biib_LongTermDebtExchangedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt, Exchanged, Amount</link:label>
    <link:label id="lab_biib_LongTermDebtExchangedAmount_label_en-US" xlink:label="lab_biib_LongTermDebtExchangedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt, Exchanged, Amount</link:label>
    <link:label id="lab_biib_LongTermDebtExchangedAmount_documentation_en-US" xlink:label="lab_biib_LongTermDebtExchangedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt, Exchanged, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LongTermDebtExchangedAmount" xlink:href="biib-20220331.xsd#biib_LongTermDebtExchangedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_LongTermDebtExchangedAmount" xlink:to="lab_biib_LongTermDebtExchangedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_d9f57a12-f28d-4ba7-afc0-f1325202e57c_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_71613852-845e-4643-9e8d-beb12d2df46c_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties_c560ac28-de93-420b-91da-3ae578453798_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Due from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:to="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_de1d4462-6eda-424c-a2f9-4a052e181302_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_761ace35-efc2-4752-801b-31ef9493e912_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_a5635351-331c-40e8-b85f-711e5e774090_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_b37834bb-3a51-49d6-9e51-979fbe2c8b06_verboseLabel_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government securities Current</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_label_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Current [Member]</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_documentation_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government securities Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember" xlink:href="biib-20220331.xsd#biib_GovernmentSecuritiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GovernmentSecuritiesCurrentMember" xlink:to="lab_biib_GovernmentSecuritiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_4130c129-6592-4aba-afcd-77745db9ebb5_terseLabel_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_label_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs [Table Text Block]</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_documentation_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:href="biib-20220331.xsd#biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:to="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_7d38857a-4463-4685-997b-d454ba7dc3f9_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on net investment hedges in AOCI</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:to="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_561a40db-186d-4366-a8e5-3613e32feee8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CollaborationAgreementTerm_cd329308-8b43-4924-9182-465aa728cdcf_terseLabel_en-US" xlink:label="lab_biib_CollaborationAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement term</link:label>
    <link:label id="lab_biib_CollaborationAgreementTerm_label_en-US" xlink:label="lab_biib_CollaborationAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement Term</link:label>
    <link:label id="lab_biib_CollaborationAgreementTerm_documentation_en-US" xlink:label="lab_biib_CollaborationAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationAgreementTerm" xlink:href="biib-20220331.xsd#biib_CollaborationAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CollaborationAgreementTerm" xlink:to="lab_biib_CollaborationAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_cca672a1-55f9-4b88-b9b3-72955154b860_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_b786b159-2b61-47a0-a0f0-a243ac45fc59_terseLabel_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Aducanumab Collaboration</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Aducanumab Collaboration [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:href="biib-20220331.xsd#biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:to="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_29846e12-182c-4929-807f-1ec70bae5c94_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_46a3a1c9-561e-4ef1-9e9c-90c4dab71ef5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RocheGroupGenentechMember_0c564328-3219-4483-aebf-642a0ffb12dc_terseLabel_en-US" xlink:label="lab_biib_RocheGroupGenentechMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genentech</link:label>
    <link:label id="lab_biib_RocheGroupGenentechMember_label_en-US" xlink:label="lab_biib_RocheGroupGenentechMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche Group Genentech Member</link:label>
    <link:label id="lab_biib_RocheGroupGenentechMember_documentation_en-US" xlink:label="lab_biib_RocheGroupGenentechMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche group Genentech.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RocheGroupGenentechMember" xlink:href="biib-20220331.xsd#biib_RocheGroupGenentechMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RocheGroupGenentechMember" xlink:to="lab_biib_RocheGroupGenentechMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_5a21e3aa-c722-49f1-8255-345ebe95d5e6_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.200% Senior Notes due 2045</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_label_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_documentation_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:href="biib-20220331.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:to="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_d1cd520c-72f2-45ad-b10a-b9a6769b3d08_terseLabel_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future milestone payments commitment to third party</link:label>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_label_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Milestone Payments Commitment To Third Party Approximately</link:label>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_documentation_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future milestone payments commitment to third party approximately.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:href="biib-20220331.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:to="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_d628c23b-308e-4975-a2bf-a3e54e4ec9ef_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_1f7c2ae2-7327-49ea-b49b-f65229cb33ae_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_eaadfe18-1bbd-40d3-ba5f-a276aec0d147_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SolothurnSwitzerlandMember_9b2369db-5e72-46a4-b4f6-d6e773139ca4_terseLabel_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Solothurn, Switzerland</link:label>
    <link:label id="lab_biib_SolothurnSwitzerlandMember_label_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Solothurn, Switzerland [Member]</link:label>
    <link:label id="lab_biib_SolothurnSwitzerlandMember_documentation_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Solothurn, Switzerland [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SolothurnSwitzerlandMember" xlink:href="biib-20220331.xsd#biib_SolothurnSwitzerlandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SolothurnSwitzerlandMember" xlink:to="lab_biib_SolothurnSwitzerlandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_4168d768-cd43-4400-bd62-c088bdacac81_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Contractual Maturities: Available-for-Sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Debt Maturities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_ce56648b-d196-48b7-8e2f-fce438e6883d_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of share-based compensation expense associated with each of our share-based compensating programs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FacilityTypeAxis_22c0c44a-61e9-44e2-a1af-c6a7deb94c76_terseLabel_en-US" xlink:label="lab_biib_FacilityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type [Axis]</link:label>
    <link:label id="lab_biib_FacilityTypeAxis_label_en-US" xlink:label="lab_biib_FacilityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type [Axis]</link:label>
    <link:label id="lab_biib_FacilityTypeAxis_documentation_en-US" xlink:label="lab_biib_FacilityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeAxis" xlink:href="biib-20220331.xsd#biib_FacilityTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityTypeAxis" xlink:to="lab_biib_FacilityTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4a866d7d-d6f5-4151-afdb-e2567b1b3460_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c75d8d6c-de45-4b69-b104-a337b9a63404_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cbd7516e-7424-4125-ac00-479ddd6b8052_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_JPY_fa5d271d-82cb-4fa7-83a4-d4e712ebf31f_terseLabel_en-US" xlink:label="lab_currency_JPY" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan, Yen</link:label>
    <link:label id="lab_currency_JPY_label_en-US" xlink:label="lab_currency_JPY" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan, Yen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_JPY" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_JPY"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_JPY" xlink:to="lab_currency_JPY" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_e9dfb9f0-8a8b-427b-bf1f-726e86ea54a0_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of fair and carrying value of debt instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_71d8dbf4-e840-4792-8af7-f752891ba4d4_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_d7f132c2-8a3f-4af4-9a6e-bdaf3d2c9ac4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of common stock pursuant to Share Repurchase Progams, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_label_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Retired, Cost Method, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:to="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_c50a6a78-b61c-4221-a0c4-acf6bbf23998_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangible assets, gross</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_29c3c93e-d5f6-4278-ba0b-2edafe20fc50_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_ba086e5f-667c-435f-a0aa-76a6a136896b_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_WorkforceReductionMember_76a5bfa3-542b-468b-8805-519fbc2f4097_terseLabel_en-US" xlink:label="lab_biib_WorkforceReductionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workforce Reduction</link:label>
    <link:label id="lab_biib_WorkforceReductionMember_label_en-US" xlink:label="lab_biib_WorkforceReductionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workforce Reduction [Member]</link:label>
    <link:label id="lab_biib_WorkforceReductionMember_documentation_en-US" xlink:label="lab_biib_WorkforceReductionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workforce Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WorkforceReductionMember" xlink:href="biib-20220331.xsd#biib_WorkforceReductionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_WorkforceReductionMember" xlink:to="lab_biib_WorkforceReductionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_775d7d17-a86f-49bb-9cc0-b50121b17772_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses and Other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_56552ffe-25d1-4b0c-92b7-51b2385b0d99_verboseLabel_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government securities Non-current</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_label_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Non-current [Member]</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_documentation_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Non Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember" xlink:href="biib-20220331.xsd#biib_GovernmentSecuritiesNonCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GovernmentSecuritiesNonCurrentMember" xlink:to="lab_biib_GovernmentSecuritiesNonCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherrevenuesAbstract_33573cda-11f0-4a88-ba83-c1d9ea7945d2_terseLabel_en-US" xlink:label="lab_biib_OtherrevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues [Abstract]</link:label>
    <link:label id="lab_biib_OtherrevenuesAbstract_label_en-US" xlink:label="lab_biib_OtherrevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues [Abstract]</link:label>
    <link:label id="lab_biib_OtherrevenuesAbstract_documentation_en-US" xlink:label="lab_biib_OtherrevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesAbstract" xlink:href="biib-20220331.xsd#biib_OtherrevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesAbstract" xlink:to="lab_biib_OtherrevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_d03e78b8-df8d-4667-a446-d440f2b21b04_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_a0a453e3-e3b3-420f-b01b-4dccd0d52f40_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, unrecognized tax benefit</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_VixotrigineMember_43394f2d-7eb3-45ae-afa6-3a2a7bb55679_terseLabel_en-US" xlink:label="lab_biib_VixotrigineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vixotrigine</link:label>
    <link:label id="lab_biib_VixotrigineMember_label_en-US" xlink:label="lab_biib_VixotrigineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vixotrigine [Member]</link:label>
    <link:label id="lab_biib_VixotrigineMember_documentation_en-US" xlink:label="lab_biib_VixotrigineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vixotrigine</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_VixotrigineMember" xlink:href="biib-20220331.xsd#biib_VixotrigineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_VixotrigineMember" xlink:to="lab_biib_VixotrigineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_11eab155-5489-4a7b-b244-bdf24016e21b_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_732e88ca-5fe4-4ab6-a389-42c118ba42f8_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3fe32b46-20d4-49c2-bdc9-1614cd6cf1d3_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated life, (in years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_df2a4224-2ae3-4a65-ab5b-3ca02df13f37_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_120843f7-9b88-4229-9a81-7e82e167cf61_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Collaborationprofitlosssharing_1e3b844c-2baa-4d30-ad11-da1986c1cdc6_terseLabel_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:label id="lab_biib_Collaborationprofitlosssharing_label_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:label id="lab_biib_Collaborationprofitlosssharing_documentation_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing" xlink:href="biib-20220331.xsd#biib_Collaborationprofitlosssharing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Collaborationprofitlosssharing" xlink:to="lab_biib_Collaborationprofitlosssharing" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_d8a8d457-b796-47eb-8f14-adc2153cdfd1_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_91b822b2-4bfa-4915-9393-b02669b81d9e_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_83ebcd07-08b4-494f-9a94-1e916c066073_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_81e06eb9-96d2-425d-bc8a-d5552179f8a2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9f83a1d0-fb55-4c0c-b1be-099abb2e0197_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4cff2044-4661-4dc5-805f-e47785f3a97a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_bb18b09d-f29a-49a0-ab8c-151bd450b4ce_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense included in condensed consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_fdf9bb1c-e7b4-48a1-b91f-d7a3b290fea2_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_07c5eafc-faf3-4315-bced-367c4c6bd931_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_65302358-7f1f-4da3-a0b4-72f03bb61330_terseLabel_en-US" xlink:label="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative qualifying as net investment hedge, excluded component</link:label>
    <link:label id="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_label_en-US" xlink:label="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Derivative Qualifying as Hedge, Excluded Component, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:to="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_82dfff4f-18fd-4add-8e69-e48a598d93b0_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_cfc97cc0-df8c-4ef1-bdad-513a77bde3cb_terseLabel_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on investments, net</link:label>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_label_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Investment Gains (Losses)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:to="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_cde5507a-3657-49df-8770-923058e0c645_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_8e6e085c-9a63-4e00-b792-742267f75c54_terseLabel_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance stock units settled in cash</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_label_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Units Settled in Cash [Member]</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_documentation_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Units Settled in Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember" xlink:href="biib-20220331.xsd#biib_PerformanceStockUnitsSettledinCashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceStockUnitsSettledinCashMember" xlink:to="lab_biib_PerformanceStockUnitsSettledinCashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PaymentDueAtSecondAnniversaryMember_aa272c56-2524-4975-ae79-cce1919a4451_terseLabel_en-US" xlink:label="lab_biib_PaymentDueAtSecondAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Due At Second Anniversary</link:label>
    <link:label id="lab_biib_PaymentDueAtSecondAnniversaryMember_label_en-US" xlink:label="lab_biib_PaymentDueAtSecondAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Due At Second Anniversary [Member]</link:label>
    <link:label id="lab_biib_PaymentDueAtSecondAnniversaryMember_documentation_en-US" xlink:label="lab_biib_PaymentDueAtSecondAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Due At Second Anniversary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentDueAtSecondAnniversaryMember" xlink:href="biib-20220331.xsd#biib_PaymentDueAtSecondAnniversaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentDueAtSecondAnniversaryMember" xlink:to="lab_biib_PaymentDueAtSecondAnniversaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_9e7f377e-e90d-455d-92e4-f4d046a9027e_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_2bb400df-1f5d-44c7-a971-d9dfc155a6a6_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_2a9d6e97-968b-44dc-987d-866f82d05a70_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_40df6c9b-dade-4844-aab9-7e0af21db7e4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_fdb3a7f0-da3e-42be-90d4-f1e117a82ccb_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_0ebb1eec-e36c-4346-af3d-82d9ccb87e43_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_2c558c12-4c64-46ba-92ca-a1bab6a14785_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior notes interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_1d836d6a-3d15-4704-b99b-6bd58a487846_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OthercorporaterevenuesMember_98f05208-ec2d-4612-8944-df27f7605167_terseLabel_en-US" xlink:label="lab_biib_OthercorporaterevenuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other corporate revenues</link:label>
    <link:label id="lab_biib_OthercorporaterevenuesMember_label_en-US" xlink:label="lab_biib_OthercorporaterevenuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other corporate revenues [Member]</link:label>
    <link:label id="lab_biib_OthercorporaterevenuesMember_documentation_en-US" xlink:label="lab_biib_OthercorporaterevenuesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other corporate revenues [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OthercorporaterevenuesMember" xlink:href="biib-20220331.xsd#biib_OthercorporaterevenuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OthercorporaterevenuesMember" xlink:to="lab_biib_OthercorporaterevenuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b881af67-d604-4830-b337-0e9abfd11ddb_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net&#160;income (loss) attributable to noncontrolling interests, net&#160;of&#160;tax</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_026295e6-dbd8-45b1-8a9b-9ac7b919d2cb_verboseLabel_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time-vested restricted stock units</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Vested Restricted Stock Units [Member]</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time vested restricted stock units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember" xlink:href="biib-20220331.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TimeVestedRestrictedStockUnitsMember" xlink:to="lab_biib_TimeVestedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_7de93bac-fabe-4736-be4c-8e61c3f7e91a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_6f8af958-4362-43cd-864c-aea4dcec23b1_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, beginning of period</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_b4327193-4543-4b1c-8c09-f021461fb28e_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, end of period</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CashflowsrevenueMember_79144715-444c-4177-ad63-f2f21b9c43d5_terseLabel_en-US" xlink:label="lab_biib_CashflowsrevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, revenue</link:label>
    <link:label id="lab_biib_CashflowsrevenueMember_label_en-US" xlink:label="lab_biib_CashflowsrevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, revenue [Member]</link:label>
    <link:label id="lab_biib_CashflowsrevenueMember_documentation_en-US" xlink:label="lab_biib_CashflowsrevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsrevenueMember" xlink:href="biib-20220331.xsd#biib_CashflowsrevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashflowsrevenueMember" xlink:to="lab_biib_CashflowsrevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCost_e03cd589-b914-458d-bb14-c26da6468082_totalLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCost_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_d3e58ead-8377-4de4-ae54-c556dc1ffbb6_terseLabel_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_label_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_documentation_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome" xlink:href="biib-20220331.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Expensereflectedwithinstatementsofincome" xlink:to="lab_biib_Expensereflectedwithinstatementsofincome" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_7f2967ea-8be3-4a46-9ff0-ad1d625f173b_terseLabel_en-US" xlink:label="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:label id="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_label_en-US" xlink:label="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:label id="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_documentation_en-US" xlink:label="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:href="biib-20220331.xsd#biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:to="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_99899c0a-4b58-4ee9-99e8-e14502db6150_terseLabel_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overnight reverse repurchase agreements</link:label>
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_label_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepurchaseAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepurchaseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepurchaseAgreementsMember" xlink:to="lab_us-gaap_RepurchaseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_7525172b-7e0c-49bf-b34f-e6f417a19194_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of significant accounting policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_AllCurrenciesDomain_fc07c40b-1da1-4366-a67d-3f9ff762a246_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain" xlink:to="lab_currency_AllCurrenciesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_76ba4011-c239-4fbe-8198-b8fb664eeb8e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_8401b0c5-553f-45a0-94c3-0c4412ea0855_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash flow provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_12b416d7-0f6a-45b5-a28b-af72cb92db18_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_324a1344-aeda-46e3-a93a-acec33949f4c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_4fe9ba48-80fa-4981-8038-1331fc196490_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_39509ff8-4748-416f-9d93-155ccff25302_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_07715a2e-6e31-4f24-b291-34ff9ba92e02_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5a107ba2-2d88-4ceb-90b1-100b4050becd_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d474fbf7-dbd4-4e3d-a4b4-642e9c41cee7_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of common shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_e75ddd03-ed2b-4e20-99b0-134f230224d3_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A2020ShareRepurchaseProgramMember_21d0ab3c-13c2-41bb-a4e4-19d9c17065e2_terseLabel_en-US" xlink:label="lab_biib_A2020ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Share Repurchase Program</link:label>
    <link:label id="lab_biib_A2020ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_biib_A2020ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_A2020ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_biib_A2020ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Share Repurchase Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2020ShareRepurchaseProgramMember" xlink:href="biib-20220331.xsd#biib_A2020ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2020ShareRepurchaseProgramMember" xlink:to="lab_biib_A2020ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_f64ce2f1-3301-48c9-b125-c59fbb6a42e0_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive potential common shares</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_77e0e9ed-1ddb-4830-8ade-1cffcbccaf0e_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_c252b626-1bb8-4523-8331-6c6601742f5b_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_15f44103-d377-4be2-aa59-a444ed2e4f0a_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember" xlink:to="lab_us-gaap_NetInvestmentHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_dbacef52-18a1-4616-a3f8-58335bd78f36_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesMember_9041c0f4-dd7a-45be-820c-f24d3f123bf0_terseLabel_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesMember_label_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember" xlink:to="lab_us-gaap_SalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_12ff47b3-f839-4e13-9f39-1ff2fa6016ae_verboseLabel_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and other asset backed securities Non-current</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_label_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage And Other Asset Backed Securities Non Current [Member]</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_documentation_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage And Other Asset Backed Securities Non Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:href="biib-20220331.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:to="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_CHF_4e7e14df-7082-4ef8-81cd-506d97fb97b3_terseLabel_en-US" xlink:label="lab_currency_CHF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swiss franc</link:label>
    <link:label id="lab_currency_CHF_label_en-US" xlink:label="lab_currency_CHF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Switzerland, Francs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_CHF"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CHF" xlink:to="lab_currency_CHF" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_6e8c1b40-2e29-45e5-98ae-c5ff817f02ec_negatedLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments/Returns Relating To Sales in Current Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Current Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to current year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:href="biib-20220331.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_cdf69e03-f14f-4158-a42b-04bbbd2f0883_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under stock option and stock purchase plans, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Treasury Stock Reissued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SangamoTherapeuticsInc.AgreementMember_ff56ea87-20d2-4f9d-8243-ed85eb343edc_terseLabel_en-US" xlink:label="lab_biib_SangamoTherapeuticsInc.AgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo Therapeutics, Inc. Agreement</link:label>
    <link:label id="lab_biib_SangamoTherapeuticsInc.AgreementMember_label_en-US" xlink:label="lab_biib_SangamoTherapeuticsInc.AgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo Therapeutics, Inc. Agreement [Member]</link:label>
    <link:label id="lab_biib_SangamoTherapeuticsInc.AgreementMember_documentation_en-US" xlink:label="lab_biib_SangamoTherapeuticsInc.AgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo Therapeutics, Inc. Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoTherapeuticsInc.AgreementMember" xlink:href="biib-20220331.xsd#biib_SangamoTherapeuticsInc.AgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SangamoTherapeuticsInc.AgreementMember" xlink:to="lab_biib_SangamoTherapeuticsInc.AgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_b15451aa-e0c2-4f2b-8620-ff436c38b019_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest of World</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_840f1b72-8f05-4855-8f88-f149eb40dc15_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9440acb3-f69d-4549-8ca4-1b304e59ffd5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_9f7b0d73-aec5-4139-931e-5215215c8edf_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_15e13d64-5647-430b-9346-d3fefb02e941_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_da9381e4-ff3f-46ae-924d-5848915fe249_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss) attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_ddca54bd-dd3d-45b0-b326-fd13369bf835_verboseLabel_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain/Loss on fair value of foreign currency forward contracts</link:label>
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_label_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Losses) on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_documentation_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:href="biib-20220331.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:to="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_dcfc80ff-471f-48e0-a58a-08073a3427ae_terseLabel_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_label_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_documentation_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:href="biib-20220331.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:to="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_201c5931-b524-4c0e-9a59-8a607352755a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash flow provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_e26978d5-72de-4289-8c3a-b37827813e90_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_06a820f7-66e6-4d90-9ccd-38a002f2ec33_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares used in calculating:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_WarehouseUtilitiesAndSupportSpaceMember_36e56b4c-ee74-410d-b595-c3871b2ad797_terseLabel_en-US" xlink:label="lab_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warehouse, Utilities and Support Space</link:label>
    <link:label id="lab_biib_WarehouseUtilitiesAndSupportSpaceMember_label_en-US" xlink:label="lab_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warehouse, Utilities and Support Space [Member]</link:label>
    <link:label id="lab_biib_WarehouseUtilitiesAndSupportSpaceMember_documentation_en-US" xlink:label="lab_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warehouse, Utilities and Support Space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:href="biib-20220331.xsd#biib_WarehouseUtilitiesAndSupportSpaceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:to="lab_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_284d0493-8fd0-4294-a2f3-51b7e0c7526b_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_18c6fa4f-457c-45b6-aa37-81ff855fe804_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_cb0daf27-6a58-45f9-a99f-9b2ec00d0f9f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_f7e129b2-809b-4f2b-80fc-d855b6fdf93a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_1619bd22-ccc4-4781-9031-aa4d6fe58141_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A3250SeniorNotesDueFebruary152051Member_33a353ce-1f3c-47fb-90c7-68c4e8b0838e_terseLabel_en-US" xlink:label="lab_biib_A3250SeniorNotesDueFebruary152051Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.250% Senior Notes, Due February 15, 2051</link:label>
    <link:label id="lab_biib_A3250SeniorNotesDueFebruary152051Member_label_en-US" xlink:label="lab_biib_A3250SeniorNotesDueFebruary152051Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.250% Senior Notes, Due February 15, 2051 [Member]</link:label>
    <link:label id="lab_biib_A3250SeniorNotesDueFebruary152051Member_documentation_en-US" xlink:label="lab_biib_A3250SeniorNotesDueFebruary152051Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.250% Senior Notes, Due February 15, 2051</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3250SeniorNotesDueFebruary152051Member" xlink:href="biib-20220331.xsd#biib_A3250SeniorNotesDueFebruary152051Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A3250SeniorNotesDueFebruary152051Member" xlink:to="lab_biib_A3250SeniorNotesDueFebruary152051Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayable_f98e3812-1c80-4366-a881-456744993719_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable, carrying value</link:label>
    <link:label id="lab_us-gaap_NotesPayable_label_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable" xlink:to="lab_us-gaap_NotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_21601ca4-6e24-4b7c-a1c1-ea7fadf0cf01_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3254d9d4-10cc-483e-a9ec-38dbcdbe5d55_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_421378dd-8a5d-4c80-b0e8-48da58c28acc_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_3416aa1c-7f0c-4e25-936e-85244fa231da_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_2f4f2db1-7a1c-40fd-a62e-2e1289e1205f_terseLabel_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, operating expenses</link:label>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_label_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, operating expenses [Member]</link:label>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_documentation_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, operating expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsoperatingexpensesMember" xlink:href="biib-20220331.xsd#biib_CashflowsoperatingexpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashflowsoperatingexpensesMember" xlink:to="lab_biib_CashflowsoperatingexpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_ee822f4a-7c48-4c09-be46-ea079b40de5c_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_80937c68-89cf-4b58-8f8d-3428fa5e5952_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_fb1bc5a8-e162-4dc9-9b70-88bfcfd101cc_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_2a801e38-621e-4a32-afe8-b248e818ba0c_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent</link:label>
    <link:label id="lab_us-gaap_ParentMember_5c7d6006-0eda-458b-98e4-b3e3cd090fde_verboseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total share-based compensation expense, net of tax</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_2e48915d-7e3f-428c-8654-fd06ce42b463_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_22567116-c4fc-47b7-8520-bde90ea93bf7_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_8727286c-b2dc-4528-bae3-0b30c501c0d2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization expense, 2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_7e8f851b-5f68-4235-9f20-b0401aaa9090_totalLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_68416423-3f1c-4fd6-8914-973393b9ec1f_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_1f86a11f-3150-467a-9562-b7481c7de110_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Expense included in consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ca83d275-84df-4271-8f9c-9aff78490b22_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_1ea160c2-9ef7-4985-a9a8-f70a88836f15_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization expense, 2019 (remaining three months)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_5227e0e3-c8f5-4200-9c27-d7950a5b206b_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_86ed5cf4-d6fb-47f3-8791-5e899d549d93_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties and licensing fees</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_0af917a6-09eb-4808-beb8-678c78f0b651_verboseLabel_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years, estimated fair value</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_label_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities Debt Maturities After Five Years Fair Value</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_documentation_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:href="biib-20220331.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:to="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_22511b9f-42ef-4ac9-aa9c-73105bf65768_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance, shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_1596e00a-27f5-4ffb-9795-488ceaf9df48_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance, shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9ad2a4ad-e71c-445e-93ce-4bba3b37ab81_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_dd016a3d-f93c-463f-bc9b-7dc0a7a15843_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales, excluding amortization and impairment of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_c7fadf46-da2f-43df-b61b-6ac2f9cba3b4_verboseLabel_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average maturity of marketable securities, months</link:label>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average Maturity Of Marketable Securities</link:label>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_documentation_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average remaining time to maturity of marketable debt securities, available-for-sale securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AverageMaturityOfMarketableSecurities" xlink:href="biib-20220331.xsd#biib_AverageMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AverageMaturityOfMarketableSecurities" xlink:to="lab_biib_AverageMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_06333067-1504-46e3-878b-5232afb390cd_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_3e9d6e17-ad6a-4a9f-aae0-d6742dc7b38a_verboseLabel_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities Current</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_label_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities Current [Member]</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_documentation_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember" xlink:href="biib-20220331.xsd#biib_CorporateDebtSecuritiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CorporateDebtSecuritiesCurrentMember" xlink:to="lab_biib_CorporateDebtSecuritiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_6aa4f35c-f1b1-42a7-a0fa-e1b1361c4457_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from divestiture of Hiller&#248;d, Denmark manufacturing operations</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquitySecuritiesCurrentMember_79095bce-96d6-461e-a0e5-19b2ccaa935c_terseLabel_en-US" xlink:label="lab_biib_EquitySecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Current</link:label>
    <link:label id="lab_biib_EquitySecuritiesCurrentMember_label_en-US" xlink:label="lab_biib_EquitySecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Current [Member]</link:label>
    <link:label id="lab_biib_EquitySecuritiesCurrentMember_documentation_en-US" xlink:label="lab_biib_EquitySecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesCurrentMember" xlink:href="biib-20220331.xsd#biib_EquitySecuritiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquitySecuritiesCurrentMember" xlink:to="lab_biib_EquitySecuritiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_8482f45c-d424-495b-a1e4-75d7d3553b25_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_229a0fda-f7de-404e-bdba-a989e32e34ad_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_900988ce-7edf-41c7-a40a-9424dda60f70_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on securities available for sale, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_b8241d62-6985-45e8-a354-3cc0a240de09_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_da42ef8e-eace-41c6-85d7-7ffdba285960_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_0ac90719-f2a9-493f-8aed-b3fd0c592e98_verboseLabel_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overview</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_label_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Overview [Policy Text Block]</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_documentation_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Describes an overview of the company and its operations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock" xlink:href="biib-20220331.xsd#biib_BusinessOverviewPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessOverviewPolicyTextBlock" xlink:to="lab_biib_BusinessOverviewPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_b8136ddb-041b-4d74-8534-f5a68b39c5c9_terseLabel_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to BAN2401 and Elenbecestat Collaboration</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to E2609 and BAN2401 Collaboration [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:href="biib-20220331.xsd#biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:to="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_ee919600-5dae-4759-b432-9d66f3420c43_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_c0de8e75-7510-4cbc-8089-678a46d300b4_terseLabel_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns</link:label>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_label_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Returns and Allowances [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesReturnsAndAllowancesMember" xlink:to="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_86e78d12-1b2a-4f55-9dff-efa510d78d7d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_9409616c-a2fc-42d1-a73f-a2c898c38931_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_83035905-8105-4eb5-8990-855bbc99bf67_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AdditionalMilestonePayment_866af084-a55f-476d-9433-6928682c1a33_terseLabel_en-US" xlink:label="lab_biib_AdditionalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional milestone payment</link:label>
    <link:label id="lab_biib_AdditionalMilestonePayment_label_en-US" xlink:label="lab_biib_AdditionalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Milestone Payment</link:label>
    <link:label id="lab_biib_AdditionalMilestonePayment_documentation_en-US" xlink:label="lab_biib_AdditionalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional milestone payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment" xlink:href="biib-20220331.xsd#biib_AdditionalMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdditionalMilestonePayment" xlink:to="lab_biib_AdditionalMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_6180a8fc-a098-4435-b78b-afaec4f667d5_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in one year or less, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ADUHELMMember_6c24df2d-6eb4-4fdb-9f8e-1e3edf4e13f7_terseLabel_en-US" xlink:label="lab_biib_ADUHELMMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADUHELM</link:label>
    <link:label id="lab_biib_ADUHELMMember_label_en-US" xlink:label="lab_biib_ADUHELMMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADUHELM [Member]</link:label>
    <link:label id="lab_biib_ADUHELMMember_documentation_en-US" xlink:label="lab_biib_ADUHELMMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADUHELM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember" xlink:href="biib-20220331.xsd#biib_ADUHELMMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ADUHELMMember" xlink:to="lab_biib_ADUHELMMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_d3970215-22a3-4496-ac13-26f4711959bf_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_f1c9b403-4c1c-4e7b-9bae-81445506b87b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_3f60d8fc-db20-45f2-a388-4c083e3a565b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_0de483a4-e4de-4ca1-a39e-31071ad73ed8_verboseLabel_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years, amortized cost</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_label_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities Debt Maturities After Five Years Amortized Cost</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_documentation_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:href="biib-20220331.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:to="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TGNMember_bf02f079-1882-4968-b4f0-c9260bed0aaf_terseLabel_en-US" xlink:label="lab_biib_TGNMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TGN</link:label>
    <link:label id="lab_biib_TGNMember_label_en-US" xlink:label="lab_biib_TGNMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TGN [Member]</link:label>
    <link:label id="lab_biib_TGNMember_documentation_en-US" xlink:label="lab_biib_TGNMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TGN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TGNMember" xlink:href="biib-20220331.xsd#biib_TGNMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TGNMember" xlink:to="lab_biib_TGNMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AccruedMilestonePayments_aeb1f831-c063-4dd0-aef9-845cd53b5ab6_terseLabel_en-US" xlink:label="lab_biib_AccruedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued milestone payments</link:label>
    <link:label id="lab_biib_AccruedMilestonePayments_label_en-US" xlink:label="lab_biib_AccruedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Milestone Payments</link:label>
    <link:label id="lab_biib_AccruedMilestonePayments_documentation_en-US" xlink:label="lab_biib_AccruedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccruedMilestonePayments" xlink:href="biib-20220331.xsd#biib_AccruedMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AccruedMilestonePayments" xlink:to="lab_biib_AccruedMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_799d172a-9b17-4e50-a121-847edcd13e13_terseLabel_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense Incurred By Collaboration</link:label>
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_label_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense Incurred By Collaboration</link:label>
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_documentation_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total expense incurred by collaboration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpenseIncurredByCollaboration" xlink:href="biib-20220331.xsd#biib_ExpenseIncurredByCollaboration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ExpenseIncurredByCollaboration" xlink:to="lab_biib_ExpenseIncurredByCollaboration" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RegulatoryMilestonesMember_e3190fda-f8ab-49b8-86ae-acb284e8f643_terseLabel_en-US" xlink:label="lab_biib_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones</link:label>
    <link:label id="lab_biib_RegulatoryMilestonesMember_label_en-US" xlink:label="lab_biib_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:label id="lab_biib_RegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_biib_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RegulatoryMilestonesMember" xlink:href="biib-20220331.xsd#biib_RegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RegulatoryMilestonesMember" xlink:to="lab_biib_RegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_8fa3a74b-205e-4206-826a-28edb1f9afda_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_2e0699bd-92b3-4803-a021-a6a63d906653_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated future amortization for acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_38c1bf42-d2d3-406e-8a1a-d30e62892106_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock, at cost, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_503fdef5-64a6-48dd-a8b8-caf729d7f138_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock, at cost, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7693dd14-6895-489f-87d7-689d8be1a4b7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_dc9f042d-d669-4ba2-8d4a-aa3fe2c37c60_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_2ac1ef17-9079-49f5-b2db-5dc290b09d93_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of borrowings and premiums paid on debt exchange</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_f26603d3-2172-4cff-811c-6ab81e9fe5a1_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_3b356508-b65b-48d9-81c8-c5049f039002_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_254980ae-a42d-4d10-a3b2-49413c302f84_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_cf9e9674-3f54-44a2-927c-3f6792231d50_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_e1c9aa40-6e5d-4086-9ffe-ac7136012b0e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets placed into service</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_fcf674c6-bdd2-411b-9a0f-3cc6daca5ebf_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) recognized during the period on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_640312d4-f4df-4283-9b73-afe136452cf8_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gains recognized on the increase in fair value of equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_1189e3cc-3868-4744-a921-532be20cff79_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_abf4fa04-bf60-43fc-8470-5ac373ae6607_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_1645f1e2-a848-42f0-ab2a-3f5de6d99708_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_us-gaap_Revenues_4e2cbecb-874e-4f16-9776-42fe77b33c13_netLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_c2e85325-7175-4e6f-a7de-ede4c7ccd4cd_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts reclassified from accumulated other comprehensive income, net of tax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_0f1a552e-1a30-45a7-90f7-a25950700f94_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Component of accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_7ad419aa-ad0a-4d9f-803b-0f0074782e65_terseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee related costs</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_40b94edb-3e97-4b40-a9a1-851bcceeedfa_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange contract</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_0e65cad5-972b-4533-a99b-c64e91f89a6d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Interest in Joint Venture</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Interest in Joint Venture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfInterestInJointVenture"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_4afe4e40-f13c-45e6-863e-ae8f0d82bba1_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_ba87a4cf-577c-4c6e-9fdf-b3ca0e874f9f_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_200ccd7a-f7f6-4899-a14d-691e6446784a_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_3c1e2c0c-ee35-44dd-8265-8595961fe550_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation related to share-based payments</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_cda78dd4-265b-409b-99b5-593d51650a41_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_86d1cb89-7d39-4553-a58f-7ebdeb0f21f3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_f14541e1-4246-4b27-933c-ec0588639f7b_verboseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic investment portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_label_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Investment Portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic investment portfolio.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentPortfolio" xlink:href="biib-20220331.xsd#biib_StrategicInvestmentPortfolio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentPortfolio" xlink:to="lab_biib_StrategicInvestmentPortfolio" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FLIXABIMember_5f07f3b5-01b0-4cb1-9e48-3acdc5b98205_terseLabel_en-US" xlink:label="lab_biib_FLIXABIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FLIXABI</link:label>
    <link:label id="lab_biib_FLIXABIMember_label_en-US" xlink:label="lab_biib_FLIXABIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FLIXABI [Member]</link:label>
    <link:label id="lab_biib_FLIXABIMember_documentation_en-US" xlink:label="lab_biib_FLIXABIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FLIXABI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FLIXABIMember" xlink:href="biib-20220331.xsd#biib_FLIXABIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FLIXABIMember" xlink:to="lab_biib_FLIXABIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_d6cf18a7-66a8-40e5-bcbd-7c58aad3c0b1_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c9655e01-5c06-4c63-9afc-b5f9a9e5a23f_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_3a8090f0-9ed8-486e-895d-3a77883b0d89_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DuefromantiCD20therapeuticprograms_493706b7-3115-4535-bb97-616e0841b847_verboseLabel_en-US" xlink:label="lab_biib_DuefromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_DuefromantiCD20therapeuticprograms_label_en-US" xlink:label="lab_biib_DuefromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_DuefromantiCD20therapeuticprograms_documentation_en-US" xlink:label="lab_biib_DuefromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable from anti-CD20 therapeutic programs for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DuefromantiCD20therapeuticprograms" xlink:href="biib-20220331.xsd#biib_DuefromantiCD20therapeuticprograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DuefromantiCD20therapeuticprograms" xlink:to="lab_biib_DuefromantiCD20therapeuticprograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_337315a5-5383-40ac-97c8-afe57c973daa_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_93da6e72-a5e3-4ee1-8dfc-f746160c88ab_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_8000add9-93b7-46d1-9517-c1b1a8533879_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_74239d0a-846d-4636-afca-02cda1fef6fb_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_db73fd46-c260-426e-a164-ac852c876172_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type Categorization [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_a757505b-5f8b-447c-8015-d2fac2ab4494_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_c4d078d3-0cda-4b85-9f81-6d5b79448d0d_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales and maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ddbcc56f-0017-452b-ab22-d7e58baf68e6_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b5603b7e-9510-4acc-bb43-1a78d0611ac9_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a0435425-a7d4-43ce-b5d1-44df64cfa4bd_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FacilityLocationAxis_2f68d317-403a-49f1-9ced-14d99814ab77_terseLabel_en-US" xlink:label="lab_biib_FacilityLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Location [Axis]</link:label>
    <link:label id="lab_biib_FacilityLocationAxis_label_en-US" xlink:label="lab_biib_FacilityLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Location [Axis]</link:label>
    <link:label id="lab_biib_FacilityLocationAxis_documentation_en-US" xlink:label="lab_biib_FacilityLocationAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationAxis" xlink:href="biib-20220331.xsd#biib_FacilityLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityLocationAxis" xlink:to="lab_biib_FacilityLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_43c1ac45-95cf-435e-88c9-31e8d88e2a9c_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_aad2830d-7de4-49ad-8355-bee10f5c0abb_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_18f909d3-d9a7-43d4-bb5f-659b5a93e144_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_13c01db5-62dc-4f20-b152-e0ecb7dc20b6_verboseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:to="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_9a7bbc41-9c3c-40a5-a4b2-ec933e60dd0e_verboseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_4ed6af5b-a591-41a7-a0e8-4d4cfea3b00f_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7c91e660-8bc6-4c77-8a85-598eb85b1076_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_aa84e4ec-f589-4ef6-a2c6-43dae923177e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_bde0bbd5-2ac6-4642-976e-da02a841b225_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_acdc8dce-8e3f-4f3c-b31f-54e12ec6aeaf_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_82034609-92cf-452e-891b-180731c49249_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_c6f07a03-60b7-44ea-9acc-b8d8cf9ae7fa_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_191ac94c-02f5-4372-b07e-617eda48f05d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under award plan, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6abb5d76-1a7f-46cc-b55d-2835a7fcb168_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ea745ed6-c4bc-4e20-964b-ea4409a67a44_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in calculating diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8a5a1ec5-bb8f-4cd4-8df6-9f9a2c4a78dd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_381a6eb1-4426-4363-8821-27ecd6952d5b_terseLabel_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated additional payments upon achievement of development and commercial milestones</link:label>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_label_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Additional Payments Upon Achievement Of Development And Commercial Milestones</link:label>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_documentation_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated additional payments upon achievement of development and commercial milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:href="biib-20220331.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:to="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_58a72d47-ab77-4839-8cf1-3f902e05ad65_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_label_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentForAmortization" xlink:to="lab_us-gaap_AdjustmentForAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_ae3ebb2c-c758-4185-a3bf-82ce6da7f925_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SageTherapeuticsIncMember_75cdf89a-52a5-4dd0-a889-d87985bc6761_terseLabel_en-US" xlink:label="lab_biib_SageTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sage Therapeutics Inc.</link:label>
    <link:label id="lab_biib_SageTherapeuticsIncMember_label_en-US" xlink:label="lab_biib_SageTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sage Therapeutics Inc. [Member]</link:label>
    <link:label id="lab_biib_SageTherapeuticsIncMember_documentation_en-US" xlink:label="lab_biib_SageTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sage Therapeutics Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember" xlink:href="biib-20220331.xsd#biib_SageTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SageTherapeuticsIncMember" xlink:to="lab_biib_SageTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_3b26b0aa-a7c4-448b-aad8-4e784f61982d_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_a4e83976-cb51-4bbf-9c7e-72abe91d7f02_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_14b43b39-d9c9-40f3-8320-47e0a66f0d30_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on cash flow hedges</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_7de2682d-1b98-48c9-a216-0829bdcaaef0_terseLabel_en-US" xlink:label="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and impairment of acquired intangible assets</link:label>
    <link:label id="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_label_en-US" xlink:label="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and Impairment of Acquired Intangible Assets</link:label>
    <link:label id="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_documentation_en-US" xlink:label="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and Impairment of Acquired Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:href="biib-20220331.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:to="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_c46f557b-41a0-40d1-b2db-0e1c4f2dd867_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased intangible assets</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation and Amortization, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_18082cfa-18c4-4944-b6ed-df9fad03f6c2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization expense, 2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MSProductRevenuesMember_384dd177-d6af-4d74-a0be-b43e6876e1c2_terseLabel_en-US" xlink:label="lab_biib_MSProductRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MS Product Revenues</link:label>
    <link:label id="lab_biib_MSProductRevenuesMember_label_en-US" xlink:label="lab_biib_MSProductRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MS Product Revenues [Member]</link:label>
    <link:label id="lab_biib_MSProductRevenuesMember_documentation_en-US" xlink:label="lab_biib_MSProductRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MS Product Revenues [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MSProductRevenuesMember" xlink:href="biib-20220331.xsd#biib_MSProductRevenuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MSProductRevenuesMember" xlink:to="lab_biib_MSProductRevenuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_8d894135-31cf-4ed0-984d-1321e69a335d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_42508c05-9175-43ef-a5dd-ecf201dbb9e4_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire additional investment in equity method investment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_fc271636-9586-48f9-9389-b542df921a2f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_5d0ad5e3-a73d-4924-9501-73df402a71cd_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bea63033-f3bd-4f6a-ae45-ca0e21b296c6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ResearchanddevelopmentassetAxis_fe450b15-4670-4a31-8fb8-00466c58f5ab_terseLabel_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development asset [Axis]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetAxis_label_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development asset [Axis]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetAxis_documentation_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetAxis" xlink:href="biib-20220331.xsd#biib_ResearchanddevelopmentassetAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResearchanddevelopmentassetAxis" xlink:to="lab_biib_ResearchanddevelopmentassetAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_d06b4bfc-cb54-454e-8c42-eaef73d6d067_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_d58b756f-8b1f-4d40-a379-75102386e69a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_a45ac880-1175-47f6-9a61-c21abe854281_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash flow provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueAbstract_d409cf0c-d304-42f2-98ae-bf23f9f25ea4_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract" xlink:to="lab_us-gaap_DisaggregationOfRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5c25b191-261e-44d2-8add-ee8f6135046c_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities, net:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f8138d63-f79c-42fb-b445-432665494d9d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_565121e0-4c81-4371-aec2-fa4992ef1a4e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_4ecf770e-59c7-4ec4-a38b-a51a18a28680_verboseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_f64e2349-fac7-44cd-9a26-a9116df2faa5_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_784f8eb5-0085-46f6-aee9-fff7431bf050_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_64b021bb-5b0c-41d8-8c74-b47dc1201724_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments related to issuance of stock for share-based compensation arrangements, net</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_b4154e3c-0901-4dfc-b1d3-af7dc17b9bba_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated depreciation expense</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Accelerated Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:to="lab_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_ae2b3da7-856a-4934-9656-a55bb2db2fcc_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on foreign currency derivative instruments not designated as hedging instruments</link:label>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_label_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:to="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_EUR_e4d0a583-cb22-4a90-94c2-80adc46f4c53_verboseLabel_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro</link:label>
    <link:label id="lab_currency_EUR_label_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_EUR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR" xlink:to="lab_currency_EUR" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FAMPYRAMember_5be60254-a0c8-4479-826a-1ed139f2ffa1_terseLabel_en-US" xlink:label="lab_biib_FAMPYRAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAMPYRA</link:label>
    <link:label id="lab_biib_FAMPYRAMember_label_en-US" xlink:label="lab_biib_FAMPYRAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAMPYRA [Member]</link:label>
    <link:label id="lab_biib_FAMPYRAMember_documentation_en-US" xlink:label="lab_biib_FAMPYRAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAMPYRA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FAMPYRAMember" xlink:href="biib-20220331.xsd#biib_FAMPYRAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FAMPYRAMember" xlink:to="lab_biib_FAMPYRAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeForwardMember_fa79097e-43c7-4ef3-ad80-e5e81ba2e754_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeForwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Forward</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeForwardMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeForwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Forward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeForwardMember" xlink:to="lab_us-gaap_ForeignExchangeForwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_69c4566d-d63c-4a6f-87d8-044c27c74a28_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_36146cf9-81d9-4a50-990d-76902ff98bad_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_89378cb2-44fa-4b91-8f99-29913d0268fa_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EisaiMember_8f4e9331-4cd7-4cdc-bd67-d63d6bc7a806_terseLabel_en-US" xlink:label="lab_biib_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eisai</link:label>
    <link:label id="lab_biib_EisaiMember_label_en-US" xlink:label="lab_biib_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eisai [Member]</link:label>
    <link:label id="lab_biib_EisaiMember_documentation_en-US" xlink:label="lab_biib_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eisai [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember" xlink:href="biib-20220331.xsd#biib_EisaiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EisaiMember" xlink:to="lab_biib_EisaiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_2af89eb3-5f84-4327-a1f3-5ec5af920c95_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_07bcadfe-345f-4559-a3c8-63c8b1751d4a_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_1f6f9da6-bcc4-49ce-9696-9fb10aca4bbd_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_778eea82-28d3-4e80-bcab-4c7bd3f9008d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DistributorOneMember_f8f46712-cf5d-4ade-b3e4-d6cb8936269c_terseLabel_en-US" xlink:label="lab_biib_DistributorOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor One</link:label>
    <link:label id="lab_biib_DistributorOneMember_label_en-US" xlink:label="lab_biib_DistributorOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor One [Member]</link:label>
    <link:label id="lab_biib_DistributorOneMember_documentation_en-US" xlink:label="lab_biib_DistributorOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorOneMember" xlink:href="biib-20220331.xsd#biib_DistributorOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorOneMember" xlink:to="lab_biib_DistributorOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_3b52467e-b14b-4b72-bd14-402be0aa77b4_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and other asset backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_cebadfe2-290b-4319-b543-8f920a377ffb_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_809813a8-a049-4648-89d6-e25470a4c689_verboseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_42d0a403-52c2-4277-9b24-8f20df1252d2_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_4cc6dd63-2aab-46f2-b17d-4caba666f2bd_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_17521d47-a7ff-4f2c-85fd-13469a01b461_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of durations of foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_label_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Remaining Maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeRemainingMaturity1" xlink:to="lab_us-gaap_DerivativeRemainingMaturity1" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_9af45e01-9066-4a15-ad7b-188013608ecb_verboseLabel_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_label_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic And Diluted Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_documentation_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted earnings per share.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:href="biib-20220331.xsd#biib_BasicAndDilutedEarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:to="lab_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock_a52c8954-f760-4a33-9937-a6e3f554f1f9_terseLabel_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Denali Therapeutics Collaboration</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Denali Therapeutics Collaboration [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Denali Therapeutics Collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:href="biib-20220331.xsd#biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:to="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_39a66e15-3d8d-4a60-9662-8eeb5415d0f0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_e41af502-b782-48ad-a510-f81da999cb74_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_f6e32e7b-39ab-4a3f-b332-59515a09c3b9_netLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_9566f335-9a2b-404e-ad02-8c6c5b9308c4_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, beginning of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_b3368a62-3bc9-42c9-bde0-14d94e8efc09_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, end of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_37c88f3b-30d4-41a4-b1d5-fb1e3c340157_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_a300e2fe-2d29-4ffc-a40c-381becaafeb5_verboseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_353ae63c-226a-4535-876a-b6f739d2f188_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes on foreign earnings</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_9d953a70-9742-455c-a593-545519cc048d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_efd12800-e208-4f71-95da-42e7c6166a1f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_5d1d43db-6d1b-4b6a-8c76-f0171fe5102f_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Reserves</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_badfb32f-b14f-4f4c-a713-9c889c45f0f7_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue-related reserves for discounts and allowances</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_281c6cde-fed1-4745-8f84-abc620c05b39_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_5ab9b2ab-50d4-4789-995e-8c6123f440d3_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_e788c880-a09b-42d3-a90e-f0f007beb6e4_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d832b5eb-41ba-4700-bcee-857e488fb599_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash flow from operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CostOfGoodsSoldCapacityCharges_b705c2d1-bd42-48a1-8733-dab7a12c6cf5_terseLabel_en-US" xlink:label="lab_biib_CostOfGoodsSoldCapacityCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods Sold, Capacity Charges</link:label>
    <link:label id="lab_biib_CostOfGoodsSoldCapacityCharges_label_en-US" xlink:label="lab_biib_CostOfGoodsSoldCapacityCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods Sold, Capacity Charges</link:label>
    <link:label id="lab_biib_CostOfGoodsSoldCapacityCharges_documentation_en-US" xlink:label="lab_biib_CostOfGoodsSoldCapacityCharges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods Sold, Capacity Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CostOfGoodsSoldCapacityCharges" xlink:href="biib-20220331.xsd#biib_CostOfGoodsSoldCapacityCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CostOfGoodsSoldCapacityCharges" xlink:to="lab_biib_CostOfGoodsSoldCapacityCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquitySecuritiesNonCurrentMember_c6fbe589-00fc-4e73-866f-dbc78ed842fe_terseLabel_en-US" xlink:label="lab_biib_EquitySecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Non-Current</link:label>
    <link:label id="lab_biib_EquitySecuritiesNonCurrentMember_label_en-US" xlink:label="lab_biib_EquitySecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Non-Current [Member]</link:label>
    <link:label id="lab_biib_EquitySecuritiesNonCurrentMember_documentation_en-US" xlink:label="lab_biib_EquitySecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Non-Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesNonCurrentMember" xlink:href="biib-20220331.xsd#biib_EquitySecuritiesNonCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquitySecuritiesNonCurrentMember" xlink:to="lab_biib_EquitySecuritiesNonCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_d01a7fbf-fb60-4d3a-86c3-eec5179743ea_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_4a05c520-410c-473f-b681-03c1c0c15b48_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of fair value and presentation of derivatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_8150d98b-7ca6-4fc7-a9c4-ff50cc6a21a3_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in one year or less, estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_3ce4754a-ebc7-461f-95e2-8bd353fbe7af_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss recorded on Samsung Bioepis joint venture</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments, Net of Dividends or Distributions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_a472f5ed-807d-48a6-ad9a-6b3600f8d1f9_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfunded status of postretirement benefit plans</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_a1675a4b-ca6d-4d89-87a4-5e484aeed09d_terseLabel_en-US" xlink:label="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on net investment hedge, excluded component</link:label>
    <link:label id="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_label_en-US" xlink:label="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)</link:label>
    <link:label id="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_documentation_en-US" xlink:label="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:href="biib-20220331.xsd#biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:to="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_e27b8f74-c73c-48c9-b62b-f2d1f4e2db4f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_64ddafd6-3198-4b12-9f5c-84c8584b6f19_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_56f257e0-247d-466c-b0a6-e2797c37a217_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_09027e68-20eb-4171-84cb-286716dba118_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_144aa042-1741-4afc-abd5-6f03209d56fc_terseLabel_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_label_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from anti-cd20 therapeutic programs [Member]</link:label>
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_documentation_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from anti-cd20 therapeutic programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:href="biib-20220331.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:to="lab_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>biib-20220331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:c574431f-8208-4dea-bcfe-8d8f5f068522,g:425f524b-de43-4dfe-85cc-ae50a1579d49-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biogenidec.com/role/CoverPage" xlink:type="simple" xlink:href="biib-20220331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_ba399701-2fab-4722-b3e0-85c266e2b089" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_a1b3062d-9400-4317-a0db-50ac57fb6265" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba399701-2fab-4722-b3e0-85c266e2b089" xlink:to="loc_dei_DocumentType_a1b3062d-9400-4317-a0db-50ac57fb6265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_d656dee2-c2eb-4d2d-a0d8-1b8c052cca41" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba399701-2fab-4722-b3e0-85c266e2b089" xlink:to="loc_dei_DocumentQuarterlyReport_d656dee2-c2eb-4d2d-a0d8-1b8c052cca41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_d75bf895-63f6-4591-992c-ec703cf38ab6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba399701-2fab-4722-b3e0-85c266e2b089" xlink:to="loc_dei_DocumentPeriodEndDate_d75bf895-63f6-4591-992c-ec703cf38ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_555b82b5-a96b-49c8-a530-032a9ad12bf0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba399701-2fab-4722-b3e0-85c266e2b089" xlink:to="loc_dei_DocumentTransitionReport_555b82b5-a96b-49c8-a530-032a9ad12bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_14e66668-3c35-4226-b328-3f91fa597992" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba399701-2fab-4722-b3e0-85c266e2b089" xlink:to="loc_dei_EntityFileNumber_14e66668-3c35-4226-b328-3f91fa597992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_9b2bc421-c612-41ac-9f91-59e39a7a8086" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba399701-2fab-4722-b3e0-85c266e2b089" xlink:to="loc_dei_EntityRegistrantName_9b2bc421-c612-41ac-9f91-59e39a7a8086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_ffd24115-3bd6-4840-a1b9-a2bf6cda6f6e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba399701-2fab-4722-b3e0-85c266e2b089" xlink:to="loc_dei_EntityCentralIndexKey_ffd24115-3bd6-4840-a1b9-a2bf6cda6f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_6cf71bc1-ad9a-4331-8848-998a22ac5416" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba399701-2fab-4722-b3e0-85c266e2b089" xlink:to="loc_dei_CurrentFiscalYearEndDate_6cf71bc1-ad9a-4331-8848-998a22ac5416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_f212e42c-c370-438a-96af-fa8ef19d2903" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba399701-2fab-4722-b3e0-85c266e2b089" xlink:to="loc_dei_DocumentFiscalYearFocus_f212e42c-c370-438a-96af-fa8ef19d2903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_5cc0fd98-bb63-41c3-9699-5d09d0f69975" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba399701-2fab-4722-b3e0-85c266e2b089" xlink:to="loc_dei_DocumentFiscalPeriodFocus_5cc0fd98-bb63-41c3-9699-5d09d0f69975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_dbb42b5b-8a3d-438c-904e-cd81e8880a22" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba399701-2fab-4722-b3e0-85c266e2b089" xlink:to="loc_dei_AmendmentFlag_dbb42b5b-8a3d-438c-904e-cd81e8880a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_ba837382-b834-4fe0-a069-697796ff02fc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba399701-2fab-4722-b3e0-85c266e2b089" xlink:to="loc_dei_EntityIncorporationStateCountryCode_ba837382-b834-4fe0-a069-697796ff02fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_8f00d4ed-8fd6-42df-86de-a27720b690bd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba399701-2fab-4722-b3e0-85c266e2b089" xlink:to="loc_dei_EntityTaxIdentificationNumber_8f00d4ed-8fd6-42df-86de-a27720b690bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_5e5ae1e5-88cc-4f68-b8a1-fae28c6dcaa2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba399701-2fab-4722-b3e0-85c266e2b089" xlink:to="loc_dei_EntityAddressAddressLine1_5e5ae1e5-88cc-4f68-b8a1-fae28c6dcaa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_3a5a510b-56f5-4fb1-93e5-7a83f59847d7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba399701-2fab-4722-b3e0-85c266e2b089" xlink:to="loc_dei_EntityAddressCityOrTown_3a5a510b-56f5-4fb1-93e5-7a83f59847d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_a02afff8-2651-4beb-a5f0-8640a758088a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba399701-2fab-4722-b3e0-85c266e2b089" xlink:to="loc_dei_EntityAddressStateOrProvince_a02afff8-2651-4beb-a5f0-8640a758088a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_ed4dcb77-1109-49ee-85f4-c5c416125e10" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba399701-2fab-4722-b3e0-85c266e2b089" xlink:to="loc_dei_EntityAddressPostalZipCode_ed4dcb77-1109-49ee-85f4-c5c416125e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_b22fc61e-de1d-4724-af34-18c959b1c931" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba399701-2fab-4722-b3e0-85c266e2b089" xlink:to="loc_dei_CityAreaCode_b22fc61e-de1d-4724-af34-18c959b1c931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_d867f312-9a7f-4eae-8419-3d8c944a33dc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba399701-2fab-4722-b3e0-85c266e2b089" xlink:to="loc_dei_LocalPhoneNumber_d867f312-9a7f-4eae-8419-3d8c944a33dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_bb3514cb-5392-4d57-b81d-522fc0461411" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba399701-2fab-4722-b3e0-85c266e2b089" xlink:to="loc_dei_Security12bTitle_bb3514cb-5392-4d57-b81d-522fc0461411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_fb9c5e44-f54f-4b6e-b77a-a2716a5c882b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba399701-2fab-4722-b3e0-85c266e2b089" xlink:to="loc_dei_TradingSymbol_fb9c5e44-f54f-4b6e-b77a-a2716a5c882b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_dd5dcc04-0d63-4139-914e-0e2801fde071" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba399701-2fab-4722-b3e0-85c266e2b089" xlink:to="loc_dei_SecurityExchangeName_dd5dcc04-0d63-4139-914e-0e2801fde071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_739cb89c-1d46-4883-af04-f790f6529493" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba399701-2fab-4722-b3e0-85c266e2b089" xlink:to="loc_dei_EntityCurrentReportingStatus_739cb89c-1d46-4883-af04-f790f6529493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_a08df165-0a9b-41d0-ab7e-be53594ef926" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba399701-2fab-4722-b3e0-85c266e2b089" xlink:to="loc_dei_EntityInteractiveDataCurrent_a08df165-0a9b-41d0-ab7e-be53594ef926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_45942636-cc3a-4e4c-afa7-58997a6d2a79" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba399701-2fab-4722-b3e0-85c266e2b089" xlink:to="loc_dei_EntityFilerCategory_45942636-cc3a-4e4c-afa7-58997a6d2a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_5f71e898-c2ef-434b-b7af-1ec042eb5601" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba399701-2fab-4722-b3e0-85c266e2b089" xlink:to="loc_dei_EntitySmallBusiness_5f71e898-c2ef-434b-b7af-1ec042eb5601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_52d5585f-92b6-42af-9618-718cefedbe69" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba399701-2fab-4722-b3e0-85c266e2b089" xlink:to="loc_dei_EntityEmergingGrowthCompany_52d5585f-92b6-42af-9618-718cefedbe69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_e27d0b8e-08ad-41bf-9dd6-abb5f8038b5f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba399701-2fab-4722-b3e0-85c266e2b089" xlink:to="loc_dei_EntityShellCompany_e27d0b8e-08ad-41bf-9dd6-abb5f8038b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_be441b4b-b9f5-44f3-afcd-92ed3ac8fbf1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba399701-2fab-4722-b3e0-85c266e2b089" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_be441b4b-b9f5-44f3-afcd-92ed3ac8fbf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="simple" xlink:href="biib-20220331.xsd#CondensedConsolidatedStatementsofIncomeUnaudited"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_6164875e-1741-4c74-b803-24957a555ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_184707dd-946d-48e8-93eb-fc57e543f17d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6164875e-1741-4c74-b803-24957a555ef2" xlink:to="loc_us-gaap_StatementTable_184707dd-946d-48e8-93eb-fc57e543f17d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d5702c3e-a50a-4537-a9eb-fb55b408858e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_184707dd-946d-48e8-93eb-fc57e543f17d" xlink:to="loc_srt_ProductOrServiceAxis_d5702c3e-a50a-4537-a9eb-fb55b408858e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3ddf752b-c0ce-4477-8581-0ba67366ee1b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d5702c3e-a50a-4537-a9eb-fb55b408858e" xlink:to="loc_srt_ProductsAndServicesDomain_3ddf752b-c0ce-4477-8581-0ba67366ee1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_4329ec7b-a07c-4b79-a7f8-7447e8a30dda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3ddf752b-c0ce-4477-8581-0ba67366ee1b" xlink:to="loc_us-gaap_ProductMember_4329ec7b-a07c-4b79-a7f8-7447e8a30dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_3d525ec4-36b9-4623-bfc2-cdbf395b6749" xlink:href="biib-20220331.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3ddf752b-c0ce-4477-8581-0ba67366ee1b" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_3d525ec4-36b9-4623-bfc2-cdbf395b6749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_ceffbfda-a41d-4116-9d53-9c6ecd97ae49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3ddf752b-c0ce-4477-8581-0ba67366ee1b" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_ceffbfda-a41d-4116-9d53-9c6ecd97ae49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_bbe904bb-8cf6-4c09-b896-d9ca075178fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_184707dd-946d-48e8-93eb-fc57e543f17d" xlink:to="loc_us-gaap_StatementLineItems_bbe904bb-8cf6-4c09-b896-d9ca075178fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_8ecf7bcc-9753-45f0-a37f-c0f95b27defc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bbe904bb-8cf6-4c09-b896-d9ca075178fb" xlink:to="loc_us-gaap_Revenues_8ecf7bcc-9753-45f0-a37f-c0f95b27defc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_d111c932-8917-41c7-a9c5-9f20f0587716" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bbe904bb-8cf6-4c09-b896-d9ca075178fb" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_d111c932-8917-41c7-a9c5-9f20f0587716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_f8b11b67-20f9-43fb-9eb1-7291f25f790d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d111c932-8917-41c7-a9c5-9f20f0587716" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_f8b11b67-20f9-43fb-9eb1-7291f25f790d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0e92b850-cdef-48c0-91ab-ede19fc082e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d111c932-8917-41c7-a9c5-9f20f0587716" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0e92b850-cdef-48c0-91ab-ede19fc082e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0e62cd71-46e8-4d67-a633-9286571a7a57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d111c932-8917-41c7-a9c5-9f20f0587716" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0e62cd71-46e8-4d67-a633-9286571a7a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_44a20ed0-82bb-45a1-8222-0ff1f1b991a7" xlink:href="biib-20220331.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d111c932-8917-41c7-a9c5-9f20f0587716" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_44a20ed0-82bb-45a1-8222-0ff1f1b991a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_91a27af4-374c-4765-b82e-868eebf28e92" xlink:href="biib-20220331.xsd#biib_Collaborationprofitlosssharing"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d111c932-8917-41c7-a9c5-9f20f0587716" xlink:to="loc_biib_Collaborationprofitlosssharing_91a27af4-374c-4765-b82e-868eebf28e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_876f3e36-4739-42f4-8695-975f718bb50e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d111c932-8917-41c7-a9c5-9f20f0587716" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_876f3e36-4739-42f4-8695-975f718bb50e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_eff1a2c2-950a-45ae-a2aa-65ac149d5e40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d111c932-8917-41c7-a9c5-9f20f0587716" xlink:to="loc_us-gaap_RestructuringCharges_eff1a2c2-950a-45ae-a2aa-65ac149d5e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_ae8bb097-5bd4-4df6-86f6-93ec74f68ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d111c932-8917-41c7-a9c5-9f20f0587716" xlink:to="loc_us-gaap_CostsAndExpenses_ae8bb097-5bd4-4df6-86f6-93ec74f68ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_185299d9-8324-4664-8b38-aba4a42ab38d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bbe904bb-8cf6-4c09-b896-d9ca075178fb" xlink:to="loc_us-gaap_OperatingIncomeLoss_185299d9-8324-4664-8b38-aba4a42ab38d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9143b0da-7329-490e-b560-5e812350dd10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bbe904bb-8cf6-4c09-b896-d9ca075178fb" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_9143b0da-7329-490e-b560-5e812350dd10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_4eb56d15-0e3d-46f3-bc97-17ea1868ffb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bbe904bb-8cf6-4c09-b896-d9ca075178fb" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_4eb56d15-0e3d-46f3-bc97-17ea1868ffb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_04b0f032-568f-4f0f-ac86-9f87a6c71398" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bbe904bb-8cf6-4c09-b896-d9ca075178fb" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_04b0f032-568f-4f0f-ac86-9f87a6c71398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_10e857e2-b485-4fce-8c46-433b335921ee" xlink:href="biib-20220331.xsd#biib_IncomeLossFromEquityMethodInvestmentsNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bbe904bb-8cf6-4c09-b896-d9ca075178fb" xlink:to="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_10e857e2-b485-4fce-8c46-433b335921ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a79bc0be-7110-4422-af65-9e570083c59f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bbe904bb-8cf6-4c09-b896-d9ca075178fb" xlink:to="loc_us-gaap_ProfitLoss_a79bc0be-7110-4422-af65-9e570083c59f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1b79a804-d7e6-4d81-a8f6-8c0233389abf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bbe904bb-8cf6-4c09-b896-d9ca075178fb" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1b79a804-d7e6-4d81-a8f6-8c0233389abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ed2fff9f-496b-43f2-8f58-6118fb3f348a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bbe904bb-8cf6-4c09-b896-d9ca075178fb" xlink:to="loc_us-gaap_NetIncomeLoss_ed2fff9f-496b-43f2-8f58-6118fb3f348a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_53a6146b-2a35-4a3d-97e8-d9f26375f964" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bbe904bb-8cf6-4c09-b896-d9ca075178fb" xlink:to="loc_us-gaap_EarningsPerShareAbstract_53a6146b-2a35-4a3d-97e8-d9f26375f964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_29494366-6794-4b80-bef1-0fdb7068b111" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_53a6146b-2a35-4a3d-97e8-d9f26375f964" xlink:to="loc_us-gaap_EarningsPerShareBasic_29494366-6794-4b80-bef1-0fdb7068b111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_489c0b22-a787-4c0a-9bfc-1c014c96afc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_53a6146b-2a35-4a3d-97e8-d9f26375f964" xlink:to="loc_us-gaap_EarningsPerShareDiluted_489c0b22-a787-4c0a-9bfc-1c014c96afc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0167f782-c17d-44b2-b132-b7767f796749" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bbe904bb-8cf6-4c09-b896-d9ca075178fb" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0167f782-c17d-44b2-b132-b7767f796749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e199cce5-0726-427a-ad24-8dc232407dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0167f782-c17d-44b2-b132-b7767f796749" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e199cce5-0726-427a-ad24-8dc232407dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f959e952-f703-45bf-9a51-cf6e77edc4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0167f782-c17d-44b2-b132-b7767f796749" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f959e952-f703-45bf-9a51-cf6e77edc4ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="simple" xlink:href="biib-20220331.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f7da2a7c-a6c6-4647-a36d-628f887b5e22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f062edeb-13a3-440c-acc6-ee5cb9e4b440" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f7da2a7c-a6c6-4647-a36d-628f887b5e22" xlink:to="loc_us-gaap_NetIncomeLoss_f062edeb-13a3-440c-acc6-ee5cb9e4b440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_f034715d-dcda-42e2-91d1-65e177cf87a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f7da2a7c-a6c6-4647-a36d-628f887b5e22" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_f034715d-dcda-42e2-91d1-65e177cf87a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_2b260be3-432a-4eec-9612-0080a73e512e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_f034715d-dcda-42e2-91d1-65e177cf87a4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_2b260be3-432a-4eec-9612-0080a73e512e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_33f0a171-4214-4b73-a4e0-ef93c78cc1f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_f034715d-dcda-42e2-91d1-65e177cf87a4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_33f0a171-4214-4b73-a4e0-ef93c78cc1f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_115bae73-ad96-49e0-82ad-5f6bd32432c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_f034715d-dcda-42e2-91d1-65e177cf87a4" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_115bae73-ad96-49e0-82ad-5f6bd32432c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_cd9054eb-7f15-4125-a109-0d360121659f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_f034715d-dcda-42e2-91d1-65e177cf87a4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_cd9054eb-7f15-4125-a109-0d360121659f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_5bf01f6a-8744-4229-a1d7-cadc47bb2d16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_f034715d-dcda-42e2-91d1-65e177cf87a4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_5bf01f6a-8744-4229-a1d7-cadc47bb2d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f80bb12b-3c20-4bf6-a552-9450b4e46ece" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_f034715d-dcda-42e2-91d1-65e177cf87a4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f80bb12b-3c20-4bf6-a552-9450b4e46ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_b2446a91-656b-446f-897a-b7a8cfd6964b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_f034715d-dcda-42e2-91d1-65e177cf87a4" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_b2446a91-656b-446f-897a-b7a8cfd6964b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_76f006a3-8d09-4e66-b864-346e6e3865bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_f034715d-dcda-42e2-91d1-65e177cf87a4" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_76f006a3-8d09-4e66-b864-346e6e3865bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_684f4d0b-108e-4947-aba0-2baef9763d01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_f034715d-dcda-42e2-91d1-65e177cf87a4" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_684f4d0b-108e-4947-aba0-2baef9763d01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" xlink:type="simple" xlink:href="biib-20220331.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="biib-20220331.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_edad7b35-9443-4fbf-ab14-0955fb9e9cac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_1b04a146-7053-48d6-bae7-3785ef62056a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_edad7b35-9443-4fbf-ab14-0955fb9e9cac" xlink:to="loc_us-gaap_AssetsAbstract_1b04a146-7053-48d6-bae7-3785ef62056a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_69e857c5-9076-4b49-b72c-b591a6db3362" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1b04a146-7053-48d6-bae7-3785ef62056a" xlink:to="loc_us-gaap_AssetsCurrentAbstract_69e857c5-9076-4b49-b72c-b591a6db3362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d6f35d96-e0a4-459a-aa93-795ceef38ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_69e857c5-9076-4b49-b72c-b591a6db3362" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d6f35d96-e0a4-459a-aa93-795ceef38ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_60c395d6-3b72-4f73-be39-37ce46e1add6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_69e857c5-9076-4b49-b72c-b591a6db3362" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_60c395d6-3b72-4f73-be39-37ce46e1add6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_aa4940cd-1e9b-4ce1-bb8b-2dea9403a07f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_69e857c5-9076-4b49-b72c-b591a6db3362" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_aa4940cd-1e9b-4ce1-bb8b-2dea9403a07f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DuefromantiCD20therapeuticprograms_74e63d26-ed96-447d-b074-1f9f152e321a" xlink:href="biib-20220331.xsd#biib_DuefromantiCD20therapeuticprograms"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_69e857c5-9076-4b49-b72c-b591a6db3362" xlink:to="loc_biib_DuefromantiCD20therapeuticprograms_74e63d26-ed96-447d-b074-1f9f152e321a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_29c750b0-95ca-4c41-a576-f9e8821a28b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_69e857c5-9076-4b49-b72c-b591a6db3362" xlink:to="loc_us-gaap_InventoryNet_29c750b0-95ca-4c41-a576-f9e8821a28b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_5695659a-8eec-46f0-90db-9eac43bd2f34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_69e857c5-9076-4b49-b72c-b591a6db3362" xlink:to="loc_us-gaap_OtherAssetsCurrent_5695659a-8eec-46f0-90db-9eac43bd2f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5757c4d1-72f6-4fd0-b9d3-a0877f5788b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_69e857c5-9076-4b49-b72c-b591a6db3362" xlink:to="loc_us-gaap_AssetsCurrent_5757c4d1-72f6-4fd0-b9d3-a0877f5788b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_fd204480-ce3e-4dc3-87b0-874028bd8e02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1b04a146-7053-48d6-bae7-3785ef62056a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_fd204480-ce3e-4dc3-87b0-874028bd8e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3193b72e-a54d-432c-b4b2-7fe7384572e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1b04a146-7053-48d6-bae7-3785ef62056a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3193b72e-a54d-432c-b4b2-7fe7384572e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ff69356a-ce6f-412b-a932-10285d0f8840" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1b04a146-7053-48d6-bae7-3785ef62056a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ff69356a-ce6f-412b-a932-10285d0f8840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8fbe2b22-fe0c-458b-aada-2ce1825c3d94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1b04a146-7053-48d6-bae7-3785ef62056a" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8fbe2b22-fe0c-458b-aada-2ce1825c3d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d536c345-35b0-4908-a1eb-ff0e3e1d377d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1b04a146-7053-48d6-bae7-3785ef62056a" xlink:to="loc_us-gaap_Goodwill_d536c345-35b0-4908-a1eb-ff0e3e1d377d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_aff2806b-2cff-4715-8294-ea3eca86fede" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1b04a146-7053-48d6-bae7-3785ef62056a" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_aff2806b-2cff-4715-8294-ea3eca86fede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_c5e7bda8-f5c7-4b69-bd76-3af2fa524862" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1b04a146-7053-48d6-bae7-3785ef62056a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_c5e7bda8-f5c7-4b69-bd76-3af2fa524862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b5ab5bd9-9f77-4292-bb93-9ee05577c062" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1b04a146-7053-48d6-bae7-3785ef62056a" xlink:to="loc_us-gaap_Assets_b5ab5bd9-9f77-4292-bb93-9ee05577c062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_cdd581d3-1da4-40b3-b96e-442054006d85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_edad7b35-9443-4fbf-ab14-0955fb9e9cac" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_cdd581d3-1da4-40b3-b96e-442054006d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_7ea1bb17-2224-40a4-bd35-737c5f415770" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_cdd581d3-1da4-40b3-b96e-442054006d85" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_7ea1bb17-2224-40a4-bd35-737c5f415770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_4bf8f017-09cb-488f-8d53-d07a5ff085ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7ea1bb17-2224-40a4-bd35-737c5f415770" xlink:to="loc_us-gaap_NotesPayableCurrent_4bf8f017-09cb-488f-8d53-d07a5ff085ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_35e1c476-f39b-482a-80aa-3758de785692" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7ea1bb17-2224-40a4-bd35-737c5f415770" xlink:to="loc_us-gaap_TaxesPayableCurrent_35e1c476-f39b-482a-80aa-3758de785692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_f45429d2-4808-49c9-be0b-1fd4ef857c65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7ea1bb17-2224-40a4-bd35-737c5f415770" xlink:to="loc_us-gaap_AccountsPayableCurrent_f45429d2-4808-49c9-be0b-1fd4ef857c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_deb0be3c-b471-4d8f-88fd-5aa491b69cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7ea1bb17-2224-40a4-bd35-737c5f415770" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_deb0be3c-b471-4d8f-88fd-5aa491b69cf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_974e0ad9-8de5-458d-8ceb-b91b54b96fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7ea1bb17-2224-40a4-bd35-737c5f415770" xlink:to="loc_us-gaap_LiabilitiesCurrent_974e0ad9-8de5-458d-8ceb-b91b54b96fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_34be30f1-6964-4953-bab4-4570e03111f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_cdd581d3-1da4-40b3-b96e-442054006d85" xlink:to="loc_us-gaap_LongTermDebt_34be30f1-6964-4953-bab4-4570e03111f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_5a3ac0c1-1a46-4700-9b0e-a7318a794d73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_cdd581d3-1da4-40b3-b96e-442054006d85" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_5a3ac0c1-1a46-4700-9b0e-a7318a794d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_56501aa6-9b7d-4a81-8c33-0e5b42562243" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_cdd581d3-1da4-40b3-b96e-442054006d85" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_56501aa6-9b7d-4a81-8c33-0e5b42562243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_4562e47a-16fd-40de-b9c5-f6a65d65b438" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_cdd581d3-1da4-40b3-b96e-442054006d85" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_4562e47a-16fd-40de-b9c5-f6a65d65b438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7a99bd35-263c-4b8d-aa48-0aab783a1b26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_cdd581d3-1da4-40b3-b96e-442054006d85" xlink:to="loc_us-gaap_Liabilities_7a99bd35-263c-4b8d-aa48-0aab783a1b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_3c86e549-d57e-45df-a9a5-50de16560bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_cdd581d3-1da4-40b3-b96e-442054006d85" xlink:to="loc_us-gaap_CommitmentsAndContingencies_3c86e549-d57e-45df-a9a5-50de16560bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a4b92627-773d-4352-b5d5-7b2595e5f24e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_cdd581d3-1da4-40b3-b96e-442054006d85" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a4b92627-773d-4352-b5d5-7b2595e5f24e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_a79d0405-dd06-436b-8191-8ab442b57f00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a4b92627-773d-4352-b5d5-7b2595e5f24e" xlink:to="loc_us-gaap_StockholdersEquityAbstract_a79d0405-dd06-436b-8191-8ab442b57f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_3288fd54-3434-4057-b6d4-006aa2ab289f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a79d0405-dd06-436b-8191-8ab442b57f00" xlink:to="loc_us-gaap_PreferredStockValue_3288fd54-3434-4057-b6d4-006aa2ab289f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_40fd6618-a26d-4acb-aabc-3644ae7e3f02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a79d0405-dd06-436b-8191-8ab442b57f00" xlink:to="loc_us-gaap_CommonStockValue_40fd6618-a26d-4acb-aabc-3644ae7e3f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_09415719-1678-491a-a928-b46f46b407cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a79d0405-dd06-436b-8191-8ab442b57f00" xlink:to="loc_us-gaap_AdditionalPaidInCapital_09415719-1678-491a-a928-b46f46b407cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2f29c188-fc4f-4bf4-9428-418fb4dcb824" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a79d0405-dd06-436b-8191-8ab442b57f00" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2f29c188-fc4f-4bf4-9428-418fb4dcb824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4de6f185-b602-4406-8215-0819c5f12cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a79d0405-dd06-436b-8191-8ab442b57f00" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4de6f185-b602-4406-8215-0819c5f12cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_8ab9f2af-6e8d-4278-ba06-301da34e9b57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a79d0405-dd06-436b-8191-8ab442b57f00" xlink:to="loc_us-gaap_TreasuryStockValue_8ab9f2af-6e8d-4278-ba06-301da34e9b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_995e57f9-e0ac-4b0e-9f45-f1a57fd9d5f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a79d0405-dd06-436b-8191-8ab442b57f00" xlink:to="loc_us-gaap_StockholdersEquity_995e57f9-e0ac-4b0e-9f45-f1a57fd9d5f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_523f5626-cb42-4fbe-b809-882ec5c0f662" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a4b92627-773d-4352-b5d5-7b2595e5f24e" xlink:to="loc_us-gaap_MinorityInterest_523f5626-cb42-4fbe-b809-882ec5c0f662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c7f88913-d4cc-4608-a92f-033c9da3f2d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a4b92627-773d-4352-b5d5-7b2595e5f24e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c7f88913-d4cc-4608-a92f-033c9da3f2d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_95dba9a8-b7cf-48e8-8f32-6d4384e5c276" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_cdd581d3-1da4-40b3-b96e-442054006d85" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_95dba9a8-b7cf-48e8-8f32-6d4384e5c276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="biib-20220331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2b7820d2-05ff-4bf1-a5a1-c5fd43b1f638" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_68b54e6b-3fac-4ac3-8d89-e3d074e8109d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2b7820d2-05ff-4bf1-a5a1-c5fd43b1f638" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_68b54e6b-3fac-4ac3-8d89-e3d074e8109d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_96f42469-4d43-46bd-9b3f-2570086844b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2b7820d2-05ff-4bf1-a5a1-c5fd43b1f638" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_96f42469-4d43-46bd-9b3f-2570086844b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="biib-20220331.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_5ca80443-1511-4e84-a18b-88c7749721d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3fe3f3c8-67de-4d95-8208-4b7097abc6e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5ca80443-1511-4e84-a18b-88c7749721d0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3fe3f3c8-67de-4d95-8208-4b7097abc6e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8ab7365b-10f6-4be7-827e-c1a2b1ead139" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3fe3f3c8-67de-4d95-8208-4b7097abc6e8" xlink:to="loc_us-gaap_ProfitLoss_8ab7365b-10f6-4be7-827e-c1a2b1ead139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7de10ebe-2f7c-49e2-8202-0999d92fb6eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3fe3f3c8-67de-4d95-8208-4b7097abc6e8" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7de10ebe-2f7c-49e2-8202-0999d92fb6eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_3fb3a437-3363-4940-b4ae-04254037f628" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7de10ebe-2f7c-49e2-8202-0999d92fb6eb" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_3fb3a437-3363-4940-b4ae-04254037f628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_3c364fa3-39c5-4104-a601-a953fbf0f0b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7de10ebe-2f7c-49e2-8202-0999d92fb6eb" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_3c364fa3-39c5-4104-a601-a953fbf0f0b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_26940d26-c307-4cef-a9ad-386a3892ba66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7de10ebe-2f7c-49e2-8202-0999d92fb6eb" xlink:to="loc_us-gaap_InventoryWriteDown_26940d26-c307-4cef-a9ad-386a3892ba66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_e5234ca7-669f-4927-9139-e3cf872ca3e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7de10ebe-2f7c-49e2-8202-0999d92fb6eb" xlink:to="loc_us-gaap_ShareBasedCompensation_e5234ca7-669f-4927-9139-e3cf872ca3e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_10d27b8f-2b15-4ea4-82aa-11ae9226a708" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7de10ebe-2f7c-49e2-8202-0999d92fb6eb" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_10d27b8f-2b15-4ea4-82aa-11ae9226a708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b9766176-b344-43c0-9a16-7b9c6fbf815a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7de10ebe-2f7c-49e2-8202-0999d92fb6eb" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b9766176-b344-43c0-9a16-7b9c6fbf815a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_9abaab0c-2fe9-4488-8f1d-c9f4b7f16a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7de10ebe-2f7c-49e2-8202-0999d92fb6eb" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_9abaab0c-2fe9-4488-8f1d-c9f4b7f16a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a6cf9ef5-a9c3-4210-a881-a93c19a57415" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7de10ebe-2f7c-49e2-8202-0999d92fb6eb" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a6cf9ef5-a9c3-4210-a881-a93c19a57415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_e51d1505-114c-45e7-9bb3-d438de06a231" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7de10ebe-2f7c-49e2-8202-0999d92fb6eb" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_e51d1505-114c-45e7-9bb3-d438de06a231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b267fdbb-3951-447b-ab44-69051029a902" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7de10ebe-2f7c-49e2-8202-0999d92fb6eb" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b267fdbb-3951-447b-ab44-69051029a902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9dd49d5a-33ce-4128-a18b-e6dfdc69a8e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b267fdbb-3951-447b-ab44-69051029a902" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9dd49d5a-33ce-4128-a18b-e6dfdc69a8e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_8510391b-b4e1-45dc-bffa-2c94de4bcb04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b267fdbb-3951-447b-ab44-69051029a902" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_8510391b-b4e1-45dc-bffa-2c94de4bcb04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_2a9f6bc5-3452-448a-909e-8d62114767b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b267fdbb-3951-447b-ab44-69051029a902" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_2a9f6bc5-3452-448a-909e-8d62114767b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_3c795caf-5df6-4933-9a8a-bc61e070c513" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b267fdbb-3951-447b-ab44-69051029a902" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_3c795caf-5df6-4933-9a8a-bc61e070c513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_9509324a-29c5-4f71-b9db-a86d6ad19af2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b267fdbb-3951-447b-ab44-69051029a902" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_9509324a-29c5-4f71-b9db-a86d6ad19af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_2e73fdf2-ca9d-4791-bb6b-2cc955256542" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b267fdbb-3951-447b-ab44-69051029a902" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_2e73fdf2-ca9d-4791-bb6b-2cc955256542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a70e9770-cfc0-4ce4-8d83-3d9d6daabd56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7de10ebe-2f7c-49e2-8202-0999d92fb6eb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a70e9770-cfc0-4ce4-8d83-3d9d6daabd56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c56c6afa-cb05-4df3-adc0-904aaaa58802" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5ca80443-1511-4e84-a18b-88c7749721d0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c56c6afa-cb05-4df3-adc0-904aaaa58802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_76a87d0c-7548-43f1-8f0c-7bad87b7fc92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c56c6afa-cb05-4df3-adc0-904aaaa58802" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_76a87d0c-7548-43f1-8f0c-7bad87b7fc92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_9e59f1c7-8494-41c3-93f3-432069c85c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c56c6afa-cb05-4df3-adc0-904aaaa58802" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_9e59f1c7-8494-41c3-93f3-432069c85c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_d7b0f02c-9b62-495c-a5f6-db519a65e33b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c56c6afa-cb05-4df3-adc0-904aaaa58802" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_d7b0f02c-9b62-495c-a5f6-db519a65e33b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_027ea308-bf13-4c98-8881-854aaedfdfa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c56c6afa-cb05-4df3-adc0-904aaaa58802" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_027ea308-bf13-4c98-8881-854aaedfdfa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_0a14a2ad-850b-4751-b701-f1d4bb90a8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c56c6afa-cb05-4df3-adc0-904aaaa58802" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_0a14a2ad-850b-4751-b701-f1d4bb90a8b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_58f914fd-b427-45d2-bccb-029ae8bef47b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c56c6afa-cb05-4df3-adc0-904aaaa58802" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_58f914fd-b427-45d2-bccb-029ae8bef47b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_89dac36e-8e63-41bb-bba9-4fe01be24329" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c56c6afa-cb05-4df3-adc0-904aaaa58802" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_89dac36e-8e63-41bb-bba9-4fe01be24329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_abaad55a-c186-4855-9407-743c1d2ea1bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5ca80443-1511-4e84-a18b-88c7749721d0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_abaad55a-c186-4855-9407-743c1d2ea1bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_4cbc495e-0bf5-4827-8ab2-43c85e9f726d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_abaad55a-c186-4855-9407-743c1d2ea1bf" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_4cbc495e-0bf5-4827-8ab2-43c85e9f726d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_04685b32-05da-430d-bd01-74ed02b572e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_abaad55a-c186-4855-9407-743c1d2ea1bf" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_04685b32-05da-430d-bd01-74ed02b572e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_bd1ae78b-fec8-47b5-8edf-02723b3dbd5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_abaad55a-c186-4855-9407-743c1d2ea1bf" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_bd1ae78b-fec8-47b5-8edf-02723b3dbd5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_97e488ab-882a-45d2-bb8d-d3b9493113af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_abaad55a-c186-4855-9407-743c1d2ea1bf" xlink:to="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_97e488ab-882a-45d2-bb8d-d3b9493113af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_4b986fe9-9eb3-499c-b5b1-0f8d83a97bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_abaad55a-c186-4855-9407-743c1d2ea1bf" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_4b986fe9-9eb3-499c-b5b1-0f8d83a97bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_50948726-cbbb-4e5a-b9ff-22da68329dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_abaad55a-c186-4855-9407-743c1d2ea1bf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_50948726-cbbb-4e5a-b9ff-22da68329dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_97a59752-08d3-4bf2-8c19-d13fec88240b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5ca80443-1511-4e84-a18b-88c7749721d0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_97a59752-08d3-4bf2-8c19-d13fec88240b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_06c170c6-83b6-49bb-ab37-6aeafcfb6ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5ca80443-1511-4e84-a18b-88c7749721d0" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_06c170c6-83b6-49bb-ab37-6aeafcfb6ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_764e2335-59d8-48bb-820d-2b6021fb0c33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5ca80443-1511-4e84-a18b-88c7749721d0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_764e2335-59d8-48bb-820d-2b6021fb0c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_84afb4dd-155c-45d4-b186-b3e69679a492" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5ca80443-1511-4e84-a18b-88c7749721d0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_84afb4dd-155c-45d4-b186-b3e69679a492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement" xlink:type="simple" xlink:href="biib-20220331.xsd#CondensedConsolidatedStatementofEquityStatement"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_9d3b0a3d-0ab0-41c8-acc2-3223c7a55584" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_33b6d105-5125-4506-bda4-20df0b0e41b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_9d3b0a3d-0ab0-41c8-acc2-3223c7a55584" xlink:to="loc_us-gaap_StatementTable_33b6d105-5125-4506-bda4-20df0b0e41b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_4daa18a6-4cc3-4127-aa38-b98aa271f87e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_33b6d105-5125-4506-bda4-20df0b0e41b1" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_4daa18a6-4cc3-4127-aa38-b98aa271f87e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_9d24c010-767c-4fd7-bd63-a29b0b62b099" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_4daa18a6-4cc3-4127-aa38-b98aa271f87e" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_9d24c010-767c-4fd7-bd63-a29b0b62b099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2020ShareRepurchaseProgramMember_35c3253b-b1ef-41ae-add1-3b4b66e87c87" xlink:href="biib-20220331.xsd#biib_A2020ShareRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_9d24c010-767c-4fd7-bd63-a29b0b62b099" xlink:to="loc_biib_A2020ShareRepurchaseProgramMember_35c3253b-b1ef-41ae-add1-3b4b66e87c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a8b8a484-a653-46c0-b037-a28a1f710e72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_33b6d105-5125-4506-bda4-20df0b0e41b1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a8b8a484-a653-46c0-b037-a28a1f710e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1a2d5a17-e573-47f1-ba6c-08dae72c488a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a8b8a484-a653-46c0-b037-a28a1f710e72" xlink:to="loc_us-gaap_EquityComponentDomain_1a2d5a17-e573-47f1-ba6c-08dae72c488a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_e2059ea4-2bf1-412c-bb74-297aa1e3e810" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1a2d5a17-e573-47f1-ba6c-08dae72c488a" xlink:to="loc_us-gaap_PreferredStockMember_e2059ea4-2bf1-412c-bb74-297aa1e3e810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9ec6aea7-3389-4f4b-bf26-3f1d60bbcb06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1a2d5a17-e573-47f1-ba6c-08dae72c488a" xlink:to="loc_us-gaap_CommonStockMember_9ec6aea7-3389-4f4b-bf26-3f1d60bbcb06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_defecd12-2fa5-4532-8c18-32e2046de9bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1a2d5a17-e573-47f1-ba6c-08dae72c488a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_defecd12-2fa5-4532-8c18-32e2046de9bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_929e08b6-767d-42e8-997b-e2eb11c9d2b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1a2d5a17-e573-47f1-ba6c-08dae72c488a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_929e08b6-767d-42e8-997b-e2eb11c9d2b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_32dcea53-0c1e-48bc-a46e-f441985394c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1a2d5a17-e573-47f1-ba6c-08dae72c488a" xlink:to="loc_us-gaap_RetainedEarningsMember_32dcea53-0c1e-48bc-a46e-f441985394c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_45692c8c-376a-4e75-8dfa-fee29b3d52d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1a2d5a17-e573-47f1-ba6c-08dae72c488a" xlink:to="loc_us-gaap_TreasuryStockMember_45692c8c-376a-4e75-8dfa-fee29b3d52d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_1af934e9-d77b-4b48-94e8-f6a4241e2bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1a2d5a17-e573-47f1-ba6c-08dae72c488a" xlink:to="loc_us-gaap_ParentMember_1af934e9-d77b-4b48-94e8-f6a4241e2bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_c87e52d6-e5e7-4c82-9108-a70bd1369de4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1a2d5a17-e573-47f1-ba6c-08dae72c488a" xlink:to="loc_us-gaap_NoncontrollingInterestMember_c87e52d6-e5e7-4c82-9108-a70bd1369de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_35ce0307-a798-48c9-b677-04881ed2455b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_33b6d105-5125-4506-bda4-20df0b0e41b1" xlink:to="loc_us-gaap_StatementLineItems_35ce0307-a798-48c9-b677-04881ed2455b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_720dfe77-3855-4b15-96c7-c6add2e9be8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_35ce0307-a798-48c9-b677-04881ed2455b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_720dfe77-3855-4b15-96c7-c6add2e9be8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_935f898c-8af0-4e1a-8d27-151822495b62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_35ce0307-a798-48c9-b677-04881ed2455b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_935f898c-8af0-4e1a-8d27-151822495b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_34f1e584-52b1-49dc-9ab6-32605afbe65e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_35ce0307-a798-48c9-b677-04881ed2455b" xlink:to="loc_us-gaap_ProfitLoss_34f1e584-52b1-49dc-9ab6-32605afbe65e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_13f78ac6-2afe-4dac-9aed-4113b03aba77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_35ce0307-a798-48c9-b677-04881ed2455b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_13f78ac6-2afe-4dac-9aed-4113b03aba77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NoncontrollingInterestIncreaseDecreaseOther_378591b6-bf02-4f58-af9d-6800bca66360" xlink:href="biib-20220331.xsd#biib_NoncontrollingInterestIncreaseDecreaseOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_35ce0307-a798-48c9-b677-04881ed2455b" xlink:to="loc_biib_NoncontrollingInterestIncreaseDecreaseOther_378591b6-bf02-4f58-af9d-6800bca66360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_2f8106b3-508a-4d1b-864c-192a435ae9f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_35ce0307-a798-48c9-b677-04881ed2455b" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_2f8106b3-508a-4d1b-864c-192a435ae9f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_afd8765d-6aed-4c3a-87e4-22adc9003dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_35ce0307-a798-48c9-b677-04881ed2455b" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_afd8765d-6aed-4c3a-87e4-22adc9003dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_2e952cc4-1650-4bb3-88b2-a54a10fd6236" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_35ce0307-a798-48c9-b677-04881ed2455b" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_2e952cc4-1650-4bb3-88b2-a54a10fd6236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_81ce6aa5-6042-4851-9f56-59e1bfe628cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_35ce0307-a798-48c9-b677-04881ed2455b" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_81ce6aa5-6042-4851-9f56-59e1bfe628cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_22ba6ff8-978a-4b2f-b3d2-df8d08c78a32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_35ce0307-a798-48c9-b677-04881ed2455b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_22ba6ff8-978a-4b2f-b3d2-df8d08c78a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_a87fe139-c1eb-4bc8-98f9-8c0e5971e8ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_35ce0307-a798-48c9-b677-04881ed2455b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_a87fe139-c1eb-4bc8-98f9-8c0e5971e8ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_de9ce6ee-7ecd-4e54-8460-82f6efe24958" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_35ce0307-a798-48c9-b677-04881ed2455b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_de9ce6ee-7ecd-4e54-8460-82f6efe24958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_cd8a0a31-faed-4d24-9fdb-45a9e821c486" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_35ce0307-a798-48c9-b677-04881ed2455b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_cd8a0a31-faed-4d24-9fdb-45a9e821c486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_289ed509-e884-43ad-af1e-2e36d5d1def6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_35ce0307-a798-48c9-b677-04881ed2455b" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_289ed509-e884-43ad-af1e-2e36d5d1def6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_f07d6a7b-0744-47b4-a950-4396c4da9ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_35ce0307-a798-48c9-b677-04881ed2455b" xlink:to="loc_us-gaap_StockholdersEquityOther_f07d6a7b-0744-47b4-a950-4396c4da9ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b8a45164-f189-485c-ae83-3939f57446a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_35ce0307-a798-48c9-b677-04881ed2455b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b8a45164-f189-485c-ae83-3939f57446a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d24b964a-3032-4872-91f5-a7b7d9445447" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_35ce0307-a798-48c9-b677-04881ed2455b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d24b964a-3032-4872-91f5-a7b7d9445447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="biib-20220331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a2e15ef2-f5f8-403b-b5be-97c7db907720" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_7dabf536-95e7-4ff6-b54a-2df4ad574426" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a2e15ef2-f5f8-403b-b5be-97c7db907720" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_7dabf536-95e7-4ff6-b54a-2df4ad574426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="biib-20220331.xsd#SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5000128b-40ab-42ec-8069-9d0059f9859e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock_160671b1-5662-475f-8678-0fd7334c8149" xlink:href="biib-20220331.xsd#biib_BusinessOverviewPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5000128b-40ab-42ec-8069-9d0059f9859e" xlink:to="loc_biib_BusinessOverviewPolicyTextBlock_160671b1-5662-475f-8678-0fd7334c8149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_86c31969-d6bf-4858-8551-2e27bf7b09ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5000128b-40ab-42ec-8069-9d0059f9859e" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_86c31969-d6bf-4858-8551-2e27bf7b09ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_e6c9ac97-a9fc-46a4-a2c9-040f4f883b85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5000128b-40ab-42ec-8069-9d0059f9859e" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_e6c9ac97-a9fc-46a4-a2c9-040f4f883b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_4fb690b9-1bcd-45a5-a523-a9e334685641" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5000128b-40ab-42ec-8069-9d0059f9859e" xlink:to="loc_us-gaap_UseOfEstimates_4fb690b9-1bcd-45a5-a523-a9e334685641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_77e931de-640b-4ae2-9cd2-7bf9643d9e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5000128b-40ab-42ec-8069-9d0059f9859e" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_77e931de-640b-4ae2-9cd2-7bf9643d9e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c3db30d4-db61-415f-bd2e-1bfda7b2b907" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_e4d1f26b-27e0-4508-94cd-495603bdc5a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3db30d4-db61-415f-bd2e-1bfda7b2b907" xlink:to="loc_us-gaap_NumberOfReportableSegments_e4d1f26b-27e0-4508-94cd-495603bdc5a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterestInSubsidiary_9afa27eb-9400-4fb6-b82e-f38ed85d2e9b" xlink:href="biib-20220331.xsd#biib_InterestInSubsidiary"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3db30d4-db61-415f-bd2e-1bfda7b2b907" xlink:to="loc_biib_InterestInSubsidiary_9afa27eb-9400-4fb6-b82e-f38ed85d2e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiatives" xlink:type="simple" xlink:href="biib-20220331.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiatives"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiatives" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_692ff28f-bfb4-4e52-bf9a-568b58b801f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_82bfb983-0856-4153-9888-eb1e57e0aba5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_692ff28f-bfb4-4e52-bf9a-568b58b801f6" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_82bfb983-0856-4153-9888-eb1e57e0aba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables" xlink:type="simple" xlink:href="biib-20220331.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5c51e438-756c-4a30-88e8-feb18270eda2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_1765951f-6711-4584-8710-81bf1e584912" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5c51e438-756c-4a30-88e8-feb18270eda2" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_1765951f-6711-4584-8710-81bf1e584912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_260f2699-1f88-4182-923d-7e98b6945241" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2558aff2-4b2f-4812-b03f-aef45129e176" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_260f2699-1f88-4182-923d-7e98b6945241" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2558aff2-4b2f-4812-b03f-aef45129e176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9b22d935-35c6-4b20-8d5c-651f18e55e9e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2558aff2-4b2f-4812-b03f-aef45129e176" xlink:to="loc_srt_RangeAxis_9b22d935-35c6-4b20-8d5c-651f18e55e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_18c92473-4728-49e8-87e7-6f293c400ca9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9b22d935-35c6-4b20-8d5c-651f18e55e9e" xlink:to="loc_srt_RangeMember_18c92473-4728-49e8-87e7-6f293c400ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_36c5f05d-ace8-40a4-9329-835d554472c0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_18c92473-4728-49e8-87e7-6f293c400ca9" xlink:to="loc_srt_MinimumMember_36c5f05d-ace8-40a4-9329-835d554472c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8ef960f8-75cc-4105-aa35-7be072d354a4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_18c92473-4728-49e8-87e7-6f293c400ca9" xlink:to="loc_srt_MaximumMember_8ef960f8-75cc-4105-aa35-7be072d354a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_c5dc0d58-288a-4140-a063-3f5729e18f02" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2558aff2-4b2f-4812-b03f-aef45129e176" xlink:to="loc_srt_StatementScenarioAxis_c5dc0d58-288a-4140-a063-3f5729e18f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_8281f728-25d9-4f61-9947-dd07911cfdd0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_c5dc0d58-288a-4140-a063-3f5729e18f02" xlink:to="loc_srt_ScenarioUnspecifiedDomain_8281f728-25d9-4f61-9947-dd07911cfdd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_ce652f7c-1661-4cf7-a487-d5d8d7ed17ab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_8281f728-25d9-4f61-9947-dd07911cfdd0" xlink:to="loc_srt_ScenarioForecastMember_ce652f7c-1661-4cf7-a487-d5d8d7ed17ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_883457be-c502-41b1-b3e3-76bd3d058246" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2558aff2-4b2f-4812-b03f-aef45129e176" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_883457be-c502-41b1-b3e3-76bd3d058246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_542d2fc5-dfc1-4e71-9ea2-a214274c0be8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_883457be-c502-41b1-b3e3-76bd3d058246" xlink:to="loc_us-gaap_RestructuringCharges_542d2fc5-dfc1-4e71-9ea2-a214274c0be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_ffaa295c-e6a5-49d3-9624-595ec9a754b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_883457be-c502-41b1-b3e3-76bd3d058246" xlink:to="loc_us-gaap_SeveranceCosts1_ffaa295c-e6a5-49d3-9624-595ec9a754b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_17f96436-604b-489e-9086-0f5ef9af6155" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_883457be-c502-41b1-b3e3-76bd3d058246" xlink:to="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_17f96436-604b-489e-9086-0f5ef9af6155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3a53da1c-4807-43cd-8b97-367d376be384" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_68a9a9f0-f569-4abb-ba3a-3383c508784e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3a53da1c-4807-43cd-8b97-367d376be384" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_68a9a9f0-f569-4abb-ba3a-3383c508784e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_58860efe-f576-46ca-9efb-3d0547229531" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_68a9a9f0-f569-4abb-ba3a-3383c508784e" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_58860efe-f576-46ca-9efb-3d0547229531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_8e6c987d-7fd9-46f8-b6a3-9598b05e9a93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_58860efe-f576-46ca-9efb-3d0547229531" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_8e6c987d-7fd9-46f8-b6a3-9598b05e9a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WorkforceReductionMember_7625b14d-2b61-404b-a0eb-93de064922b3" xlink:href="biib-20220331.xsd#biib_WorkforceReductionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_8e6c987d-7fd9-46f8-b6a3-9598b05e9a93" xlink:to="loc_biib_WorkforceReductionMember_7625b14d-2b61-404b-a0eb-93de064922b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_dd90172f-06f5-4fe0-96de-04470bd79edd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_68a9a9f0-f569-4abb-ba3a-3383c508784e" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_dd90172f-06f5-4fe0-96de-04470bd79edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_7f6051e7-300c-44c3-973d-0fd1a1a0b919" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_dd90172f-06f5-4fe0-96de-04470bd79edd" xlink:to="loc_us-gaap_RestructuringReserve_7f6051e7-300c-44c3-973d-0fd1a1a0b919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_f3bd870f-239c-4ab5-b252-74a789dd387d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_dd90172f-06f5-4fe0-96de-04470bd79edd" xlink:to="loc_us-gaap_RestructuringCharges_f3bd870f-239c-4ab5-b252-74a789dd387d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_8889c180-2c2b-4979-b500-980307b1075b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_dd90172f-06f5-4fe0-96de-04470bd79edd" xlink:to="loc_us-gaap_PaymentsForRestructuring_8889c180-2c2b-4979-b500-980307b1075b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_2f4b1c08-3863-45eb-9971-3e0a70438a67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_dd90172f-06f5-4fe0-96de-04470bd79edd" xlink:to="loc_us-gaap_RestructuringReserve_2f4b1c08-3863-45eb-9971-3e0a70438a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Revenues" xlink:type="simple" xlink:href="biib-20220331.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_fc0b833e-1eec-4e9a-946d-5854101a30ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_f1c1dd8d-1855-46e3-a4d6-633daa2bde93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_fc0b833e-1eec-4e9a-946d-5854101a30ed" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_f1c1dd8d-1855-46e3-a4d6-633daa2bde93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesTables" xlink:type="simple" xlink:href="biib-20220331.xsd#RevenuesTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e0f2fe8c-2686-49d6-9880-876ef31bf769" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_e9c229b1-5815-4437-b2d6-71a86adb6a63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e0f2fe8c-2686-49d6-9880-876ef31bf769" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_e9c229b1-5815-4437-b2d6-71a86adb6a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_11bc0fa1-3cae-4b6d-b840-237ac0cf83d3" xlink:href="biib-20220331.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e0f2fe8c-2686-49d6-9880-876ef31bf769" xlink:to="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_11bc0fa1-3cae-4b6d-b840-237ac0cf83d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_fb1a1ccb-f7c9-47fb-a4c1-0600d984b37d" xlink:href="biib-20220331.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e0f2fe8c-2686-49d6-9880-876ef31bf769" xlink:to="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_fb1a1ccb-f7c9-47fb-a4c1-0600d984b37d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_8316a127-8322-4d56-9495-64714f6e77ca" xlink:href="biib-20220331.xsd#biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e0f2fe8c-2686-49d6-9880-876ef31bf769" xlink:to="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_8316a127-8322-4d56-9495-64714f6e77ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesTableTextBlock_94d9f069-f448-4f1b-bb97-b353c61f07e0" xlink:href="biib-20220331.xsd#biib_OtherrevenuesTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e0f2fe8c-2686-49d6-9880-876ef31bf769" xlink:to="loc_biib_OtherrevenuesTableTextBlock_94d9f069-f448-4f1b-bb97-b353c61f07e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#RevenuesRevenuesbyproductDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract_6f46fbde-7cf2-43a7-8829-78ae40beb15a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_24f2dd19-e297-4791-8f31-ace018ff9ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract_6f46fbde-7cf2-43a7-8829-78ae40beb15a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_24f2dd19-e297-4791-8f31-ace018ff9ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_83cdb1fe-3d9c-4f56-b7c4-26530a6885af" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_24f2dd19-e297-4791-8f31-ace018ff9ec0" xlink:to="loc_srt_ProductOrServiceAxis_83cdb1fe-3d9c-4f56-b7c4-26530a6885af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_651b9153-2b49-4d1d-a7ce-e91ad9004ead" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_83cdb1fe-3d9c-4f56-b7c4-26530a6885af" xlink:to="loc_srt_ProductsAndServicesDomain_651b9153-2b49-4d1d-a7ce-e91ad9004ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumarateMember_d5798bda-d7ff-4916-a079-9c0c73d31621" xlink:href="biib-20220331.xsd#biib_FumarateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_651b9153-2b49-4d1d-a7ce-e91ad9004ead" xlink:to="loc_biib_FumarateMember_d5798bda-d7ff-4916-a079-9c0c73d31621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterferonMember_b759ae10-9495-45c2-ae16-f9fe549afcd8" xlink:href="biib-20220331.xsd#biib_InterferonMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_651b9153-2b49-4d1d-a7ce-e91ad9004ead" xlink:to="loc_biib_InterferonMember_b759ae10-9495-45c2-ae16-f9fe549afcd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TysabriProductMember_8ac592b0-ee5c-404c-9ea6-28d753b7666b" xlink:href="biib-20220331.xsd#biib_TysabriProductMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_651b9153-2b49-4d1d-a7ce-e91ad9004ead" xlink:to="loc_biib_TysabriProductMember_8ac592b0-ee5c-404c-9ea6-28d753b7666b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FAMPYRAMember_0c9820f7-3754-4e72-ae82-73049ca34ecd" xlink:href="biib-20220331.xsd#biib_FAMPYRAMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_651b9153-2b49-4d1d-a7ce-e91ad9004ead" xlink:to="loc_biib_FAMPYRAMember_0c9820f7-3754-4e72-ae82-73049ca34ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MSProductRevenuesMember_9bdf295d-142a-4285-b706-3a38090214b2" xlink:href="biib-20220331.xsd#biib_MSProductRevenuesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_651b9153-2b49-4d1d-a7ce-e91ad9004ead" xlink:to="loc_biib_MSProductRevenuesMember_9bdf295d-142a-4285-b706-3a38090214b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SPINRAZAMember_0b855d7b-2155-4f64-b608-9f787ca8818d" xlink:href="biib-20220331.xsd#biib_SPINRAZAMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_651b9153-2b49-4d1d-a7ce-e91ad9004ead" xlink:to="loc_biib_SPINRAZAMember_0b855d7b-2155-4f64-b608-9f787ca8818d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_7a1456d0-e354-497f-84a8-ebf83699ed38" xlink:href="biib-20220331.xsd#biib_ADUHELMMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_651b9153-2b49-4d1d-a7ce-e91ad9004ead" xlink:to="loc_biib_ADUHELMMember_7a1456d0-e354-497f-84a8-ebf83699ed38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BENEPALIMember_26e2b679-9d2d-4607-9e88-998c9ffd2fb5" xlink:href="biib-20220331.xsd#biib_BENEPALIMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_651b9153-2b49-4d1d-a7ce-e91ad9004ead" xlink:to="loc_biib_BENEPALIMember_26e2b679-9d2d-4607-9e88-998c9ffd2fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IMRALDIMember_58e4a3df-1ccc-4171-8728-3335598d0afe" xlink:href="biib-20220331.xsd#biib_IMRALDIMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_651b9153-2b49-4d1d-a7ce-e91ad9004ead" xlink:to="loc_biib_IMRALDIMember_58e4a3df-1ccc-4171-8728-3335598d0afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FLIXABIMember_caf4b6a2-8047-42e4-b4e8-75abf38018e9" xlink:href="biib-20220331.xsd#biib_FLIXABIMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_651b9153-2b49-4d1d-a7ce-e91ad9004ead" xlink:to="loc_biib_FLIXABIMember_caf4b6a2-8047-42e4-b4e8-75abf38018e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiosimilarsMember_b0dffaa6-3eaa-4b98-ab93-339214d91687" xlink:href="biib-20220331.xsd#biib_BiosimilarsMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_651b9153-2b49-4d1d-a7ce-e91ad9004ead" xlink:to="loc_biib_BiosimilarsMember_b0dffaa6-3eaa-4b98-ab93-339214d91687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FUMADERMMember_b365ef37-523d-4547-bc66-981b3f81cf11" xlink:href="biib-20220331.xsd#biib_FUMADERMMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_651b9153-2b49-4d1d-a7ce-e91ad9004ead" xlink:to="loc_biib_FUMADERMMember_b365ef37-523d-4547-bc66-981b3f81cf11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_0dcadf82-4e7b-478a-a0cd-900835475455" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_651b9153-2b49-4d1d-a7ce-e91ad9004ead" xlink:to="loc_us-gaap_ProductMember_0dcadf82-4e7b-478a-a0cd-900835475455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_9227cb1f-1dcf-4fbe-bb41-1d819522bf35" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_24f2dd19-e297-4791-8f31-ace018ff9ec0" xlink:to="loc_srt_StatementGeographicalAxis_9227cb1f-1dcf-4fbe-bb41-1d819522bf35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a618a071-c3cc-42e1-85dc-c6c28a8f6366" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_9227cb1f-1dcf-4fbe-bb41-1d819522bf35" xlink:to="loc_srt_SegmentGeographicalDomain_a618a071-c3cc-42e1-85dc-c6c28a8f6366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_965d6714-3880-4c2d-96ec-2baf3aa52478" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_a618a071-c3cc-42e1-85dc-c6c28a8f6366" xlink:to="loc_country_US_965d6714-3880-4c2d-96ec-2baf3aa52478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_60583efb-96f5-42c1-955b-e3be6f7664e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_a618a071-c3cc-42e1-85dc-c6c28a8f6366" xlink:to="loc_us-gaap_NonUsMember_60583efb-96f5-42c1-955b-e3be6f7664e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_4f09d128-b6df-40a8-9bc4-2587151a0b16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_24f2dd19-e297-4791-8f31-ace018ff9ec0" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_4f09d128-b6df-40a8-9bc4-2587151a0b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_65267ef6-296f-4c4c-8ff4-1707a20a16d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4f09d128-b6df-40a8-9bc4-2587151a0b16" xlink:to="loc_us-gaap_Revenues_65267ef6-296f-4c4c-8ff4-1707a20a16d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1" xlink:type="simple" xlink:href="biib-20220331.xsd#RevenuesReservesforDiscountsandAllowancesDetails1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_57a3c27a-2526-44da-8a6f-78f24a6f51a6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_eb87cbd1-18fe-4695-ae36-73071b61f899" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_57a3c27a-2526-44da-8a6f-78f24a6f51a6" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_eb87cbd1-18fe-4695-ae36-73071b61f899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_baf38519-4530-4c08-8e0b-27bcdb21ef81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_eb87cbd1-18fe-4695-ae36-73071b61f899" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_baf38519-4530-4c08-8e0b-27bcdb21ef81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_8674c3a7-8a8f-49bc-bcee-6ad91e7f8ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_baf38519-4530-4c08-8e0b-27bcdb21ef81" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_8674c3a7-8a8f-49bc-bcee-6ad91e7f8ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReserveforCashDiscountsMember_28fddbc5-11d4-48b1-b8d2-8eaa12e8266f" xlink:href="biib-20220331.xsd#biib_ReserveforCashDiscountsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8674c3a7-8a8f-49bc-bcee-6ad91e7f8ec4" xlink:to="loc_biib_ReserveforCashDiscountsMember_28fddbc5-11d4-48b1-b8d2-8eaa12e8266f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractualAdjustmentsMember_fad14e1a-f97e-44a1-82d1-f1d46e0d2096" xlink:href="biib-20220331.xsd#biib_ContractualAdjustmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8674c3a7-8a8f-49bc-bcee-6ad91e7f8ec4" xlink:to="loc_biib_ContractualAdjustmentsMember_fad14e1a-f97e-44a1-82d1-f1d46e0d2096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_4263d6ef-2aab-4bcb-b295-b036ae600836" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8674c3a7-8a8f-49bc-bcee-6ad91e7f8ec4" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_4263d6ef-2aab-4bcb-b295-b036ae600836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_8150506f-9ae6-473e-bdb2-42fc59df75e0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_eb87cbd1-18fe-4695-ae36-73071b61f899" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_8150506f-9ae6-473e-bdb2-42fc59df75e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_9d8cb4c1-6790-4493-b76e-7bb2ab819b39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_8150506f-9ae6-473e-bdb2-42fc59df75e0" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_9d8cb4c1-6790-4493-b76e-7bb2ab819b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_afa6d289-effd-47cc-be90-7ae7a6082ceb" xlink:href="biib-20220331.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_8150506f-9ae6-473e-bdb2-42fc59df75e0" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_afa6d289-effd-47cc-be90-7ae7a6082ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_e26167c2-d3a8-4df8-ad30-b8e575c2c8c0" xlink:href="biib-20220331.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_8150506f-9ae6-473e-bdb2-42fc59df75e0" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_e26167c2-d3a8-4df8-ad30-b8e575c2c8c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_c793416b-d227-4f50-9da5-49966ec5f784" xlink:href="biib-20220331.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_8150506f-9ae6-473e-bdb2-42fc59df75e0" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_c793416b-d227-4f50-9da5-49966ec5f784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_7ba6b28c-eb19-436e-82d1-cf80df58d343" xlink:href="biib-20220331.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_8150506f-9ae6-473e-bdb2-42fc59df75e0" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_7ba6b28c-eb19-436e-82d1-cf80df58d343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_af537c12-7c44-46ab-9f89-5e72f43389ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_8150506f-9ae6-473e-bdb2-42fc59df75e0" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_af537c12-7c44-46ab-9f89-5e72f43389ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2" xlink:type="simple" xlink:href="biib-20220331.xsd#RevenuesReservesforDiscountsandAllowancesDetails2"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_69a54f4f-b02a-4d10-ad00-4f3c6680b53e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_037c6c95-1cb9-4738-af93-3a87d63bb720" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_69a54f4f-b02a-4d10-ad00-4f3c6680b53e" xlink:to="loc_us-gaap_StatementTable_037c6c95-1cb9-4738-af93-3a87d63bb720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_c7c3c5d7-c572-4094-917a-302449593e6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_037c6c95-1cb9-4738-af93-3a87d63bb720" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_c7c3c5d7-c572-4094-917a-302449593e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e51d9b2c-af7e-4c9e-bf65-fdd5bd5c8b44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c7c3c5d7-c572-4094-917a-302449593e6c" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e51d9b2c-af7e-4c9e-bf65-fdd5bd5c8b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_da802b13-2acf-4a7f-894c-35042a85b13d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e51d9b2c-af7e-4c9e-bf65-fdd5bd5c8b44" xlink:to="loc_us-gaap_AccountsReceivableMember_da802b13-2acf-4a7f-894c-35042a85b13d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_35976d2e-b59c-49d7-adad-62ed65a9632e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e51d9b2c-af7e-4c9e-bf65-fdd5bd5c8b44" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_35976d2e-b59c-49d7-adad-62ed65a9632e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_53c86e8c-2ca0-48a4-a876-2e47428aa927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_037c6c95-1cb9-4738-af93-3a87d63bb720" xlink:to="loc_us-gaap_StatementLineItems_53c86e8c-2ca0-48a4-a876-2e47428aa927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_7500ed0d-1e2e-48e4-aafd-71106386f530" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_53c86e8c-2ca0-48a4-a876-2e47428aa927" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_7500ed0d-1e2e-48e4-aafd-71106386f530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9ea87775-2bdf-4cb8-9f18-2377d8f761d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_08c3224f-2682-4dfb-9029-59cb0c70c1b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9ea87775-2bdf-4cb8-9f18-2377d8f761d1" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_08c3224f-2682-4dfb-9029-59cb0c70c1b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_bc90fe7e-3045-4587-a1c9-ebeb3fd08ac4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_08c3224f-2682-4dfb-9029-59cb0c70c1b8" xlink:to="loc_srt_ProductOrServiceAxis_bc90fe7e-3045-4587-a1c9-ebeb3fd08ac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a619d0fe-e019-4758-ae57-380bb85a4650" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_bc90fe7e-3045-4587-a1c9-ebeb3fd08ac4" xlink:to="loc_srt_ProductsAndServicesDomain_a619d0fe-e019-4758-ae57-380bb85a4650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_3e42d8d3-7ada-4473-b3a5-a957393eb142" xlink:href="biib-20220331.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a619d0fe-e019-4758-ae57-380bb85a4650" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_3e42d8d3-7ada-4473-b3a5-a957393eb142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_6d18675f-eceb-4839-8e1d-16c988349344" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_08c3224f-2682-4dfb-9029-59cb0c70c1b8" xlink:to="loc_srt_MajorCustomersAxis_6d18675f-eceb-4839-8e1d-16c988349344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_0d549c47-a3df-4ed5-95c8-526c03dd1cfd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_6d18675f-eceb-4839-8e1d-16c988349344" xlink:to="loc_srt_NameOfMajorCustomerDomain_0d549c47-a3df-4ed5-95c8-526c03dd1cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RocheGroupGenentechMember_ea7510f0-ba52-4021-b111-ad77aef5dbbe" xlink:href="biib-20220331.xsd#biib_RocheGroupGenentechMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_0d549c47-a3df-4ed5-95c8-526c03dd1cfd" xlink:to="loc_biib_RocheGroupGenentechMember_ea7510f0-ba52-4021-b111-ad77aef5dbbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_477c1a83-895c-4b1b-8f8e-e4313fcc9383" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_08c3224f-2682-4dfb-9029-59cb0c70c1b8" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_477c1a83-895c-4b1b-8f8e-e4313fcc9383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfCoPromotionProfits_35bd4f3b-798a-43e3-8683-d8ed9e86bbaf" xlink:href="biib-20220331.xsd#biib_ShareOfCoPromotionProfits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_477c1a83-895c-4b1b-8f8e-e4313fcc9383" xlink:to="loc_biib_ShareOfCoPromotionProfits_35bd4f3b-798a-43e3-8683-d8ed9e86bbaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_a0cd1202-1403-4848-ae10-ecb8bcdd5b38" xlink:href="biib-20220331.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_477c1a83-895c-4b1b-8f8e-e4313fcc9383" xlink:to="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_a0cd1202-1403-4848-ae10-ecb8bcdd5b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_07e2c818-8ba1-42e6-ba66-36af130f8a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_477c1a83-895c-4b1b-8f8e-e4313fcc9383" xlink:to="loc_us-gaap_Revenues_07e2c818-8ba1-42e6-ba66-36af130f8a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#RevenuesOtherRevenuesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesAbstract_01349ed0-2fcf-4b09-912a-01f6c0b842c5" xlink:href="biib-20220331.xsd#biib_OtherrevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_09aea55e-c24b-48b2-9775-70a44bc656da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_OtherrevenuesAbstract_01349ed0-2fcf-4b09-912a-01f6c0b842c5" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_09aea55e-c24b-48b2-9775-70a44bc656da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_effe119a-966c-4a80-921a-ff0eae0fa5d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_09aea55e-c24b-48b2-9775-70a44bc656da" xlink:to="loc_us-gaap_TypeOfArrangementAxis_effe119a-966c-4a80-921a-ff0eae0fa5d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c3c8f42c-7c8d-4d27-a2f7-b34291dcd1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_effe119a-966c-4a80-921a-ff0eae0fa5d5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c3c8f42c-7c8d-4d27-a2f7-b34291dcd1d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_54d396fb-4d42-44e5-a47b-2bc99a1e3931" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c3c8f42c-7c8d-4d27-a2f7-b34291dcd1d3" xlink:to="loc_us-gaap_CollaborativeArrangementMember_54d396fb-4d42-44e5-a47b-2bc99a1e3931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ea9a1f58-cb7c-4c71-a52a-f5bf6c4839f4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_09aea55e-c24b-48b2-9775-70a44bc656da" xlink:to="loc_srt_ProductOrServiceAxis_ea9a1f58-cb7c-4c71-a52a-f5bf6c4839f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e64bc3a3-c958-4f72-8409-9eef7091e2b6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ea9a1f58-cb7c-4c71-a52a-f5bf6c4839f4" xlink:to="loc_srt_ProductsAndServicesDomain_e64bc3a3-c958-4f72-8409-9eef7091e2b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_5bd7b253-e79c-4d52-8e6f-8703668e82ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e64bc3a3-c958-4f72-8409-9eef7091e2b6" xlink:to="loc_us-gaap_RoyaltyMember_5bd7b253-e79c-4d52-8e6f-8703668e82ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OthercorporaterevenuesMember_c5aca094-b021-44d5-84e7-8d563d221ac7" xlink:href="biib-20220331.xsd#biib_OthercorporaterevenuesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e64bc3a3-c958-4f72-8409-9eef7091e2b6" xlink:to="loc_biib_OthercorporaterevenuesMember_c5aca094-b021-44d5-84e7-8d563d221ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_3becc52f-a10d-48b9-b39a-b0433292d178" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e64bc3a3-c958-4f72-8409-9eef7091e2b6" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_3becc52f-a10d-48b9-b39a-b0433292d178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_abc8d871-d3af-4eba-a267-19850356b5f2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_09aea55e-c24b-48b2-9775-70a44bc656da" xlink:to="loc_srt_MajorCustomersAxis_abc8d871-d3af-4eba-a267-19850356b5f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_f68c4e49-be2a-451b-bb60-dab81153888b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_abc8d871-d3af-4eba-a267-19850356b5f2" xlink:to="loc_srt_NameOfMajorCustomerDomain_f68c4e49-be2a-451b-bb60-dab81153888b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_0e825491-128c-47af-add4-0a13781542a5" xlink:href="biib-20220331.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_f68c4e49-be2a-451b-bb60-dab81153888b" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_0e825491-128c-47af-add4-0a13781542a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ZINBRYTAMember_43296cbf-ff93-4fd5-aaf3-8488f34977a3" xlink:href="biib-20220331.xsd#biib_ZINBRYTAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_f68c4e49-be2a-451b-bb60-dab81153888b" xlink:to="loc_biib_ZINBRYTAMember_43296cbf-ff93-4fd5-aaf3-8488f34977a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_6a4807e4-2f04-4647-a3b9-168c03690906" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_09aea55e-c24b-48b2-9775-70a44bc656da" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_6a4807e4-2f04-4647-a3b9-168c03690906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f66e42fc-e94d-444f-84f2-1232c9dae0bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6a4807e4-2f04-4647-a3b9-168c03690906" xlink:to="loc_us-gaap_Revenues_f66e42fc-e94d-444f-84f2-1232c9dae0bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesNarrativeDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#RevenuesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_250df212-1799-4b98-bb6c-cc2d18d399e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_835b90fe-196d-4c67-ac8d-62cc1744f9fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_250df212-1799-4b98-bb6c-cc2d18d399e1" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_835b90fe-196d-4c67-ac8d-62cc1744f9fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fc6cc4cb-80df-4203-9a82-7dd2b4864839" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_835b90fe-196d-4c67-ac8d-62cc1744f9fd" xlink:to="loc_srt_ProductOrServiceAxis_fc6cc4cb-80df-4203-9a82-7dd2b4864839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2da15d77-661f-44a3-be9f-c3989bf2503f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_fc6cc4cb-80df-4203-9a82-7dd2b4864839" xlink:to="loc_srt_ProductsAndServicesDomain_2da15d77-661f-44a3-be9f-c3989bf2503f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OthercorporaterevenuesMember_7d5c2deb-a973-4921-a4db-793be7ba0b12" xlink:href="biib-20220331.xsd#biib_OthercorporaterevenuesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2da15d77-661f-44a3-be9f-c3989bf2503f" xlink:to="loc_biib_OthercorporaterevenuesMember_7d5c2deb-a973-4921-a4db-793be7ba0b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_441cd6e8-d552-472d-a26c-94a7e96d1bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2da15d77-661f-44a3-be9f-c3989bf2503f" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_441cd6e8-d552-472d-a26c-94a7e96d1bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_7101282e-b7ee-485f-a338-ae71035fb6ee" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_835b90fe-196d-4c67-ac8d-62cc1744f9fd" xlink:to="loc_srt_MajorCustomersAxis_7101282e-b7ee-485f-a338-ae71035fb6ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_0d878043-f8a3-4559-8b2f-7ff966133466" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_7101282e-b7ee-485f-a338-ae71035fb6ee" xlink:to="loc_srt_NameOfMajorCustomerDomain_0d878043-f8a3-4559-8b2f-7ff966133466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorOneMember_a07031cc-bb8c-4599-bbf9-88ff14be88de" xlink:href="biib-20220331.xsd#biib_DistributorOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_0d878043-f8a3-4559-8b2f-7ff966133466" xlink:to="loc_biib_DistributorOneMember_a07031cc-bb8c-4599-bbf9-88ff14be88de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorTwoMember_af1eb086-c957-4bae-bfe8-e20f825293f4" xlink:href="biib-20220331.xsd#biib_DistributorTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_0d878043-f8a3-4559-8b2f-7ff966133466" xlink:to="loc_biib_DistributorTwoMember_af1eb086-c957-4bae-bfe8-e20f825293f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_5ee32246-3259-413c-ad9b-ab42151adacc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_835b90fe-196d-4c67-ac8d-62cc1744f9fd" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_5ee32246-3259-413c-ad9b-ab42151adacc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_90f7bde8-a842-49cc-9718-86904c512feb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5ee32246-3259-413c-ad9b-ab42151adacc" xlink:to="loc_us-gaap_Revenues_90f7bde8-a842-49cc-9718-86904c512feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_447ef24e-67ff-49dc-bdf5-b217acd201d3" xlink:href="biib-20220331.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5ee32246-3259-413c-ad9b-ab42151adacc" xlink:to="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_447ef24e-67ff-49dc-bdf5-b217acd201d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfWholesalers_fae94bc1-0aca-4228-855b-4c9f7d2b6ee2" xlink:href="biib-20220331.xsd#biib_NumberOfWholesalers"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5ee32246-3259-413c-ad9b-ab42151adacc" xlink:to="loc_biib_NumberOfWholesalers_fae94bc1-0aca-4228-855b-4c9f7d2b6ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:type="simple" xlink:href="biib-20220331.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_98fa2ad6-9537-497f-b425-98a1380134d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_1c8245c6-2149-4ed0-8ee9-b68887de4093" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_98fa2ad6-9537-497f-b425-98a1380134d5" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_1c8245c6-2149-4ed0-8ee9-b68887de4093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:type="simple" xlink:href="biib-20220331.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_bb0a60b1-ae21-4aa6-b243-982b70f2c9d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_124337c7-592c-445b-b6f2-32395efa9da9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_bb0a60b1-ae21-4aa6-b243-982b70f2c9d0" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_124337c7-592c-445b-b6f2-32395efa9da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#InventoryComponentsofInventoryDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_c9e76472-b8a1-4d6e-ac67-2b98979b7114" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetAbstract_e08d96c3-c84b-4ba6-a260-94ef1cfecc98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_c9e76472-b8a1-4d6e-ac67-2b98979b7114" xlink:to="loc_us-gaap_InventoryNetAbstract_e08d96c3-c84b-4ba6-a260-94ef1cfecc98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_c48ac74e-ff2c-40bc-a4b0-4e95e6ca8ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_e08d96c3-c84b-4ba6-a260-94ef1cfecc98" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_c48ac74e-ff2c-40bc-a4b0-4e95e6ca8ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_dd4a3fb5-ebeb-4fb1-9c13-48ba10153fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_e08d96c3-c84b-4ba6-a260-94ef1cfecc98" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_dd4a3fb5-ebeb-4fb1-9c13-48ba10153fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_65ffcf9a-a376-4388-a8cf-8f3ebf1846a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_e08d96c3-c84b-4ba6-a260-94ef1cfecc98" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_65ffcf9a-a376-4388-a8cf-8f3ebf1846a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_ac1d7ba0-5fd6-4278-ab6c-4ad735b68808" xlink:href="biib-20220331.xsd#biib_Inventorynetcurrentandnoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_e08d96c3-c84b-4ba6-a260-94ef1cfecc98" xlink:to="loc_biib_Inventorynetcurrentandnoncurrent_ac1d7ba0-5fd6-4278-ab6c-4ad735b68808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryNarrativeDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#InventoryNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_ecc57875-98ca-4816-9012-1f6d8993ccce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_429b8229-20c1-49a4-bd89-31210c1c2da1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_ecc57875-98ca-4816-9012-1f6d8993ccce" xlink:to="loc_us-gaap_InventoryCurrentTable_429b8229-20c1-49a4-bd89-31210c1c2da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_50dec1de-06ce-4152-ab16-a2926a63f927" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_429b8229-20c1-49a4-bd89-31210c1c2da1" xlink:to="loc_srt_ProductOrServiceAxis_50dec1de-06ce-4152-ab16-a2926a63f927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_08b902aa-bc8a-48d2-aa3a-9a5aed5986ed" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_50dec1de-06ce-4152-ab16-a2926a63f927" xlink:to="loc_srt_ProductsAndServicesDomain_08b902aa-bc8a-48d2-aa3a-9a5aed5986ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_76e1e014-7e19-4b08-be2f-3f4777f0e367" xlink:href="biib-20220331.xsd#biib_ADUHELMMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_08b902aa-bc8a-48d2-aa3a-9a5aed5986ed" xlink:to="loc_biib_ADUHELMMember_76e1e014-7e19-4b08-be2f-3f4777f0e367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f8cfce26-2cc2-4508-93f7-a695b5d92d62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_429b8229-20c1-49a4-bd89-31210c1c2da1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f8cfce26-2cc2-4508-93f7-a695b5d92d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a9fdbaf4-51f5-4aa7-9fab-376c00d64bae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f8cfce26-2cc2-4508-93f7-a695b5d92d62" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a9fdbaf4-51f5-4aa7-9fab-376c00d64bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_688df941-3cc0-47c9-90b9-6d563d82e368" xlink:href="biib-20220331.xsd#biib_EisaiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a9fdbaf4-51f5-4aa7-9fab-376c00d64bae" xlink:to="loc_biib_EisaiMember_688df941-3cc0-47c9-90b9-6d563d82e368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_baa56de9-ce13-4118-82d1-db9dc4ca4d26" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_429b8229-20c1-49a4-bd89-31210c1c2da1" xlink:to="loc_srt_CounterpartyNameAxis_baa56de9-ce13-4118-82d1-db9dc4ca4d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4a704c76-0169-4ba5-9cfd-a6c3dc97a58d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_baa56de9-ce13-4118-82d1-db9dc4ca4d26" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4a704c76-0169-4ba5-9cfd-a6c3dc97a58d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CentersForMedicareAndMedicaidServiceMember_aa5de7f7-234d-4dc3-97fb-55d26150ef57" xlink:href="biib-20220331.xsd#biib_CentersForMedicareAndMedicaidServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4a704c76-0169-4ba5-9cfd-a6c3dc97a58d" xlink:to="loc_biib_CentersForMedicareAndMedicaidServiceMember_aa5de7f7-234d-4dc3-97fb-55d26150ef57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_b0bfdc22-341a-43d7-a0d5-876f5a20bc7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_429b8229-20c1-49a4-bd89-31210c1c2da1" xlink:to="loc_us-gaap_InventoryLineItems_b0bfdc22-341a-43d7-a0d5-876f5a20bc7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_ea2cb098-135b-4b29-b097-c30df0c6583e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_b0bfdc22-341a-43d7-a0d5-876f5a20bc7a" xlink:to="loc_us-gaap_InventoryWriteDown_ea2cb098-135b-4b29-b097-c30df0c6583e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5e5273f4-1985-49b6-ae5d-a6ed84fef871" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_b0bfdc22-341a-43d7-a0d5-876f5a20bc7a" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5e5273f4-1985-49b6-ae5d-a6ed84fef871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_361b3872-5e42-4aad-8ccd-68f257d81e7f" xlink:href="biib-20220331.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_b0bfdc22-341a-43d7-a0d5-876f5a20bc7a" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_361b3872-5e42-4aad-8ccd-68f257d81e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InventoryNetCurrentAndNoncurrent_97af5aaa-27b2-4cd1-b798-15bd9393cca5" xlink:href="biib-20220331.xsd#biib_InventoryNetCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_b0bfdc22-341a-43d7-a0d5-876f5a20bc7a" xlink:to="loc_biib_InventoryNetCurrentAndNoncurrent_97af5aaa-27b2-4cd1-b798-15bd9393cca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwill" xlink:type="simple" xlink:href="biib-20220331.xsd#IntangibleAssetsandGoodwill"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7a8ef21f-a882-4e4b-8473-fb6bcf42a28a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_90c6699e-7353-4667-a127-e223e61cc214" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7a8ef21f-a882-4e4b-8473-fb6bcf42a28a" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_90c6699e-7353-4667-a127-e223e61cc214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables" xlink:type="simple" xlink:href="biib-20220331.xsd#IntangibleAssetsandGoodwillTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_dfd9fa22-6c6d-47fe-a4e5-169c01bba00d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_c0464f74-0882-40c0-8f7a-668631d729ae" xlink:href="biib-20220331.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_dfd9fa22-6c6d-47fe-a4e5-169c01bba00d" xlink:to="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_c0464f74-0882-40c0-8f7a-668631d729ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_19a3be22-f774-48e6-8347-80a394eba030" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_dfd9fa22-6c6d-47fe-a4e5-169c01bba00d" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_19a3be22-f774-48e6-8347-80a394eba030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_d486ec5b-015e-4bdc-84f2-e5e6352933c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_dfd9fa22-6c6d-47fe-a4e5-169c01bba00d" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_d486ec5b-015e-4bdc-84f2-e5e6352933c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#IntangibleAssetsandGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e3bf84fe-434d-45c8-b452-3fbf709645f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_65b15d4e-b695-4c12-91ab-1b5179a860ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e3bf84fe-434d-45c8-b452-3fbf709645f9" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_65b15d4e-b695-4c12-91ab-1b5179a860ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_d3944e83-8416-4341-962e-f467e08aba33" xlink:href="biib-20220331.xsd#biib_ResearchanddevelopmentassetAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_65b15d4e-b695-4c12-91ab-1b5179a860ff" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_d3944e83-8416-4341-962e-f467e08aba33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_ba4032a7-3bdb-4c65-bb16-f069295bd728" xlink:href="biib-20220331.xsd#biib_ResearchanddevelopmentassetDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_d3944e83-8416-4341-962e-f467e08aba33" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_ba4032a7-3bdb-4c65-bb16-f069295bd728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_VixotrigineMember_6613efee-f40d-45a3-8db0-d5a694db831e" xlink:href="biib-20220331.xsd#biib_VixotrigineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_ba4032a7-3bdb-4c65-bb16-f069295bd728" xlink:to="loc_biib_VixotrigineMember_6613efee-f40d-45a3-8db0-d5a694db831e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TGNMember_f7b6d78f-952c-476e-b543-309dfdf2d840" xlink:href="biib-20220331.xsd#biib_TGNMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_ba4032a7-3bdb-4c65-bb16-f069295bd728" xlink:to="loc_biib_TGNMember_f7b6d78f-952c-476e-b543-309dfdf2d840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_58429d90-7201-4b7f-b708-87f3c0c700e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_65b15d4e-b695-4c12-91ab-1b5179a860ff" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_58429d90-7201-4b7f-b708-87f3c0c700e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_560d8a64-cd5a-4956-9c45-9a35e65f49b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_58429d90-7201-4b7f-b708-87f3c0c700e9" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_560d8a64-cd5a-4956-9c45-9a35e65f49b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_fa73bc68-d6c1-4b0a-9289-77899c2cf893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_560d8a64-cd5a-4956-9c45-9a35e65f49b0" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_fa73bc68-d6c1-4b0a-9289-77899c2cf893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_03fdee23-f210-4fa8-890e-b452d57950e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_560d8a64-cd5a-4956-9c45-9a35e65f49b0" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_03fdee23-f210-4fa8-890e-b452d57950e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cd345392-6b26-4117-a87e-1c58f66f321a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_65b15d4e-b695-4c12-91ab-1b5179a860ff" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cd345392-6b26-4117-a87e-1c58f66f321a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_59e7b3bc-3bd6-4611-b478-341cada185bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cd345392-6b26-4117-a87e-1c58f66f321a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_59e7b3bc-3bd6-4611-b478-341cada185bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OutLicensedPatentsMember_fc8f19da-c3d3-4480-967e-f6b57b9d689e" xlink:href="biib-20220331.xsd#biib_OutLicensedPatentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_59e7b3bc-3bd6-4611-b478-341cada185bf" xlink:to="loc_biib_OutLicensedPatentsMember_fc8f19da-c3d3-4480-967e-f6b57b9d689e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_13bad91a-4dc3-4f4a-bf00-39ea24330556" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_59e7b3bc-3bd6-4611-b478-341cada185bf" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_13bad91a-4dc3-4f4a-bf00-39ea24330556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1370cb04-f78a-466b-8841-4cf66d53ce00" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_65b15d4e-b695-4c12-91ab-1b5179a860ff" xlink:to="loc_srt_RangeAxis_1370cb04-f78a-466b-8841-4cf66d53ce00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7b65147b-53d6-4611-a4e4-41e58a95a98b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1370cb04-f78a-466b-8841-4cf66d53ce00" xlink:to="loc_srt_RangeMember_7b65147b-53d6-4611-a4e4-41e58a95a98b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6460c320-7521-4787-a2d2-28f56853a1d2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7b65147b-53d6-4611-a4e4-41e58a95a98b" xlink:to="loc_srt_MinimumMember_6460c320-7521-4787-a2d2-28f56853a1d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_baf4cbb1-7bcc-465f-8e61-c90b86a0b706" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7b65147b-53d6-4611-a4e4-41e58a95a98b" xlink:to="loc_srt_MaximumMember_baf4cbb1-7bcc-465f-8e61-c90b86a0b706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2f78f5f2-c950-415f-98de-b611a4229950" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_65b15d4e-b695-4c12-91ab-1b5179a860ff" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2f78f5f2-c950-415f-98de-b611a4229950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_ba8131a9-31e3-41fa-b6b4-5b7d45e80c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2f78f5f2-c950-415f-98de-b611a4229950" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_ba8131a9-31e3-41fa-b6b4-5b7d45e80c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_101ff643-9171-4bee-8bd9-1c4a43c22151" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_ba8131a9-31e3-41fa-b6b4-5b7d45e80c7e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_101ff643-9171-4bee-8bd9-1c4a43c22151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_43826931-7ba4-4bf7-a1eb-a7e3a22b75ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_ba8131a9-31e3-41fa-b6b4-5b7d45e80c7e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_43826931-7ba4-4bf7-a1eb-a7e3a22b75ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_09b6ebbd-a044-4676-804f-e7cceb3b11b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_ba8131a9-31e3-41fa-b6b4-5b7d45e80c7e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_09b6ebbd-a044-4676-804f-e7cceb3b11b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7aaab4b1-cb6b-435c-8ab9-72f121015fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_ba8131a9-31e3-41fa-b6b4-5b7d45e80c7e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7aaab4b1-cb6b-435c-8ab9-72f121015fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_1e75f51f-36e8-47c9-8a79-d713b72fd140" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_ba8131a9-31e3-41fa-b6b4-5b7d45e80c7e" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_1e75f51f-36e8-47c9-8a79-d713b72fd140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5421b97f-adb7-4c55-9f3d-ebbbf6ce5077" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_ba8131a9-31e3-41fa-b6b4-5b7d45e80c7e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5421b97f-adb7-4c55-9f3d-ebbbf6ce5077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_805dc206-cac4-4ec8-9674-996fe37e4298" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_ba8131a9-31e3-41fa-b6b4-5b7d45e80c7e" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_805dc206-cac4-4ec8-9674-996fe37e4298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_d9d150a1-3a4c-4cec-a80c-9b3b13747cf6" xlink:href="biib-20220331.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2f78f5f2-c950-415f-98de-b611a4229950" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_d9d150a1-3a4c-4cec-a80c-9b3b13747cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_564483a1-13c2-4e1d-80a7-f9622ec72f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2f78f5f2-c950-415f-98de-b611a4229950" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_564483a1-13c2-4e1d-80a7-f9622ec72f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_5c383acb-4930-4734-bb9f-7668f6c36b60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2f78f5f2-c950-415f-98de-b611a4229950" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_5c383acb-4930-4734-bb9f-7668f6c36b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_47aeb672-b441-4746-bb5e-f360f5e34d01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2f78f5f2-c950-415f-98de-b611a4229950" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_47aeb672-b441-4746-bb5e-f360f5e34d01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_55508aa9-b6f1-4a5a-aece-4b4a0ba4074d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2f78f5f2-c950-415f-98de-b611a4229950" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_55508aa9-b6f1-4a5a-aece-4b4a0ba4074d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_c2628aae-3358-47e0-ad6e-8237a3ca01f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2f78f5f2-c950-415f-98de-b611a4229950" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_c2628aae-3358-47e0-ad6e-8237a3ca01f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_a8c8b2a8-75d0-493a-bbd9-67726ed34ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2f78f5f2-c950-415f-98de-b611a4229950" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_a8c8b2a8-75d0-493a-bbd9-67726ed34ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1" xlink:type="simple" xlink:href="biib-20220331.xsd#IntangibleAssetsandGoodwillDetails1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_05fefd90-4d08-4ced-a6ab-9ca8ea6bb13d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_f38c8bbb-d884-499e-b02d-7e116d1ff8b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_05fefd90-4d08-4ced-a6ab-9ca8ea6bb13d" xlink:to="loc_us-gaap_GoodwillRollForward_f38c8bbb-d884-499e-b02d-7e116d1ff8b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_bfe5a1ff-45ba-4395-acf9-f2b5ea8ac801" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_f38c8bbb-d884-499e-b02d-7e116d1ff8b2" xlink:to="loc_us-gaap_Goodwill_bfe5a1ff-45ba-4395-acf9-f2b5ea8ac801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_6a32b458-c47b-4fa4-86ac-d2003c61f44a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_f38c8bbb-d884-499e-b02d-7e116d1ff8b2" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_6a32b458-c47b-4fa4-86ac-d2003c61f44a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_5cf01583-8293-4a79-955c-ca85d624ab6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_f38c8bbb-d884-499e-b02d-7e116d1ff8b2" xlink:to="loc_us-gaap_Goodwill_5cf01583-8293-4a79-955c-ca85d624ab6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_3ca7d5ee-50e5-4754-b0e6-9af79be8537a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_05fefd90-4d08-4ced-a6ab-9ca8ea6bb13d" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_3ca7d5ee-50e5-4754-b0e6-9af79be8537a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_9184a297-924e-4f7f-b816-06e45432c3a7" xlink:href="biib-20220331.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_05fefd90-4d08-4ced-a6ab-9ca8ea6bb13d" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_9184a297-924e-4f7f-b816-06e45432c3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_666d6552-a4f4-4a64-9e8c-de051fd199a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_05fefd90-4d08-4ced-a6ab-9ca8ea6bb13d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_666d6552-a4f4-4a64-9e8c-de051fd199a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="biib-20220331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_531a74c2-b5d9-4d24-a17d-3982d43037e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_b3415c28-8161-4477-9ddc-5b2a6de2e467" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_531a74c2-b5d9-4d24-a17d-3982d43037e9" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_b3415c28-8161-4477-9ddc-5b2a6de2e467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="biib-20220331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4b31f43f-a1dd-41da-9a58-e2d281b69b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1e3daa4f-d96f-4b17-86ef-c68e68c36ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4b31f43f-a1dd-41da-9a58-e2d281b69b4a" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1e3daa4f-d96f-4b17-86ef-c68e68c36ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_bbb9945d-9f11-4e4c-9f4b-5e3dd8d45515" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4b31f43f-a1dd-41da-9a58-e2d281b69b4a" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_bbb9945d-9f11-4e4c-9f4b-5e3dd8d45515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_48168508-0633-47b8-993e-8c4172df436f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4b31f43f-a1dd-41da-9a58-e2d281b69b4a" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_48168508-0633-47b8-993e-8c4172df436f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_51690542-fe0f-46b3-9372-80b913b2eec6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_758f4cb5-e036-4c80-91b6-89148082c429" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_51690542-fe0f-46b3-9372-80b913b2eec6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_758f4cb5-e036-4c80-91b6-89148082c429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_212dfd47-b47b-4f75-bb42-7bd5893a5835" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_758f4cb5-e036-4c80-91b6-89148082c429" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_212dfd47-b47b-4f75-bb42-7bd5893a5835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_65bd5e7f-b796-41dc-8404-6ca55edc6f61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_212dfd47-b47b-4f75-bb42-7bd5893a5835" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_65bd5e7f-b796-41dc-8404-6ca55edc6f61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_25176269-e961-4849-9854-9ccf2f980d09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_65bd5e7f-b796-41dc-8404-6ca55edc6f61" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_25176269-e961-4849-9854-9ccf2f980d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_c91d0b34-7583-461f-b85d-1e89f11fb4bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_65bd5e7f-b796-41dc-8404-6ca55edc6f61" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_c91d0b34-7583-461f-b85d-1e89f11fb4bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_03a1055e-d842-4f87-a501-d22969c9d77b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_65bd5e7f-b796-41dc-8404-6ca55edc6f61" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_03a1055e-d842-4f87-a501-d22969c9d77b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f71aadb8-578f-4daf-9b1e-22707b483cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_758f4cb5-e036-4c80-91b6-89148082c429" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f71aadb8-578f-4daf-9b1e-22707b483cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_b5ed3d4a-cea8-485e-b78e-71ba27546105" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f71aadb8-578f-4daf-9b1e-22707b483cfe" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_b5ed3d4a-cea8-485e-b78e-71ba27546105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_5b0ea085-e04d-4503-a498-cb7b66876bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_b5ed3d4a-cea8-485e-b78e-71ba27546105" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_5b0ea085-e04d-4503-a498-cb7b66876bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_42acba19-4f35-47ff-8528-fb3fc00ac3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_758f4cb5-e036-4c80-91b6-89148082c429" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_42acba19-4f35-47ff-8528-fb3fc00ac3c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a3642954-b692-4617-a4ac-9c05934cca07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_42acba19-4f35-47ff-8528-fb3fc00ac3c9" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a3642954-b692-4617-a4ac-9c05934cca07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_07af2ba7-813b-449a-98e8-ef83a5bcc332" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a3642954-b692-4617-a4ac-9c05934cca07" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_07af2ba7-813b-449a-98e8-ef83a5bcc332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_1a2b0b01-ef7f-4144-bdf1-9f72b6e871ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a3642954-b692-4617-a4ac-9c05934cca07" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_1a2b0b01-ef7f-4144-bdf1-9f72b6e871ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_41e63f27-d865-4fc2-bb96-19874c128947" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a3642954-b692-4617-a4ac-9c05934cca07" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_41e63f27-d865-4fc2-bb96-19874c128947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42eaa6ce-b71c-4286-8bb9-86b50085d192" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_758f4cb5-e036-4c80-91b6-89148082c429" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42eaa6ce-b71c-4286-8bb9-86b50085d192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_deac2c66-e6da-41fe-a83d-7a036f827e76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42eaa6ce-b71c-4286-8bb9-86b50085d192" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_deac2c66-e6da-41fe-a83d-7a036f827e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_122a4487-bc0d-4e64-a754-b37e5c0c2ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_deac2c66-e6da-41fe-a83d-7a036f827e76" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_122a4487-bc0d-4e64-a754-b37e5c0c2ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5eba2bb7-af54-4a1a-bf9b-c9a54e16cec7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_122a4487-bc0d-4e64-a754-b37e5c0c2ec1" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5eba2bb7-af54-4a1a-bf9b-c9a54e16cec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f665c6a7-9b80-4544-9b6e-21300c252123" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_122a4487-bc0d-4e64-a754-b37e5c0c2ec1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f665c6a7-9b80-4544-9b6e-21300c252123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_643b809d-1244-43c8-8ca2-df7de6ef1039" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_122a4487-bc0d-4e64-a754-b37e5c0c2ec1" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_643b809d-1244-43c8-8ca2-df7de6ef1039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_c1b3e0ab-b467-4be6-a8dd-1e393ec0c8df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_122a4487-bc0d-4e64-a754-b37e5c0c2ec1" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_c1b3e0ab-b467-4be6-a8dd-1e393ec0c8df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_581e054d-b923-4006-ac05-0a325bb22f69" xlink:href="biib-20220331.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_122a4487-bc0d-4e64-a754-b37e5c0c2ec1" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_581e054d-b923-4006-ac05-0a325bb22f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_aa2827a9-71b4-48f4-bb5e-f02ce1676789" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_122a4487-bc0d-4e64-a754-b37e5c0c2ec1" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_aa2827a9-71b4-48f4-bb5e-f02ce1676789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_14896d28-1dff-4e91-8d75-4df82454ee98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_deac2c66-e6da-41fe-a83d-7a036f827e76" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_14896d28-1dff-4e91-8d75-4df82454ee98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_967e6db9-1838-43f8-973d-a74fd215aed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_14896d28-1dff-4e91-8d75-4df82454ee98" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_967e6db9-1838-43f8-973d-a74fd215aed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2b1878eb-b5a5-4b72-971f-6adbf49966a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_14896d28-1dff-4e91-8d75-4df82454ee98" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2b1878eb-b5a5-4b72-971f-6adbf49966a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_15e55c48-ef25-4fd1-b107-3826c614c7f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_14896d28-1dff-4e91-8d75-4df82454ee98" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_15e55c48-ef25-4fd1-b107-3826c614c7f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="simple" xlink:href="biib-20220331.xsd#FairValueMeasurementsDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6db75dfa-ae41-4160-bd6e-da10f038984b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_81e2e408-78ce-40ea-9329-e2520ff91f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6db75dfa-ae41-4160-bd6e-da10f038984b" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_81e2e408-78ce-40ea-9329-e2520ff91f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_0a16affb-d885-455d-bf0d-28db37ed1279" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_81e2e408-78ce-40ea-9329-e2520ff91f0b" xlink:to="loc_us-gaap_DebtInstrumentAxis_0a16affb-d885-455d-bf0d-28db37ed1279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_81db7d96-bc87-4521-a33e-d73e6a2d6b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_0a16affb-d885-455d-bf0d-28db37ed1279" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_81db7d96-bc87-4521-a33e-d73e6a2d6b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_bc40581f-1b5a-490d-844d-4dad42fffe50" xlink:href="biib-20220331.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_81db7d96-bc87-4521-a33e-d73e6a2d6b2a" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_bc40581f-1b5a-490d-844d-4dad42fffe50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_5622c601-95bd-474d-bb96-91a186fbbae8" xlink:href="biib-20220331.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_81db7d96-bc87-4521-a33e-d73e6a2d6b2a" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_5622c601-95bd-474d-bb96-91a186fbbae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_ae5ae3ea-698a-4f42-99af-231997457043" xlink:href="biib-20220331.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_81db7d96-bc87-4521-a33e-d73e6a2d6b2a" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_ae5ae3ea-698a-4f42-99af-231997457043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_ad20be2c-f7ab-43b8-a0c4-5eee87e7aca1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_81e2e408-78ce-40ea-9329-e2520ff91f0b" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_ad20be2c-f7ab-43b8-a0c4-5eee87e7aca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_19360e79-a722-4f5e-ac60-9ccf78c5a97d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_ad20be2c-f7ab-43b8-a0c4-5eee87e7aca1" xlink:to="loc_us-gaap_AssetImpairmentCharges_19360e79-a722-4f5e-ac60-9ccf78c5a97d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e8cbc7a1-417b-42e4-bdaf-6c02d4486df9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_ad20be2c-f7ab-43b8-a0c4-5eee87e7aca1" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e8cbc7a1-417b-42e4-bdaf-6c02d4486df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_e4163639-9803-4281-ac25-ec60ab0b58fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_ad20be2c-f7ab-43b8-a0c4-5eee87e7aca1" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_e4163639-9803-4281-ac25-ec60ab0b58fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TechnologicalAndRegulatorySuccessProbability_6c0d7e33-3cbc-4b6c-a4ca-0afdc22fdcc7" xlink:href="biib-20220331.xsd#biib_TechnologicalAndRegulatorySuccessProbability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_ad20be2c-f7ab-43b8-a0c4-5eee87e7aca1" xlink:to="loc_biib_TechnologicalAndRegulatorySuccessProbability_6c0d7e33-3cbc-4b6c-a4ca-0afdc22fdcc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b81ba51b-cad3-4661-be46-6b3b9dc25c18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c5c9adcc-db61-46a7-9695-c7e9a61118e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b81ba51b-cad3-4661-be46-6b3b9dc25c18" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c5c9adcc-db61-46a7-9695-c7e9a61118e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f866f751-a886-4f8f-91a0-f6f911eccae7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c5c9adcc-db61-46a7-9695-c7e9a61118e8" xlink:to="loc_srt_RangeAxis_f866f751-a886-4f8f-91a0-f6f911eccae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6bf5d048-76d7-4280-ab29-fe0691414762" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f866f751-a886-4f8f-91a0-f6f911eccae7" xlink:to="loc_srt_RangeMember_6bf5d048-76d7-4280-ab29-fe0691414762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_79329f22-6267-4c51-bd9c-bb5d2bdc3cf6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6bf5d048-76d7-4280-ab29-fe0691414762" xlink:to="loc_srt_WeightedAverageMember_79329f22-6267-4c51-bd9c-bb5d2bdc3cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_0ee2b65d-1ed3-4729-a805-d98d8562be81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c5c9adcc-db61-46a7-9695-c7e9a61118e8" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_0ee2b65d-1ed3-4729-a805-d98d8562be81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_aa4908fe-cff5-4e43-ba11-018f6bac4708" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_0ee2b65d-1ed3-4729-a805-d98d8562be81" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_aa4908fe-cff5-4e43-ba11-018f6bac4708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_970ed2e7-9391-40d4-b01b-48a63ab33cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_aa4908fe-cff5-4e43-ba11-018f6bac4708" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_970ed2e7-9391-40d4-b01b-48a63ab33cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1a10c028-eb47-4036-ac62-7a98e0446a56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c5c9adcc-db61-46a7-9695-c7e9a61118e8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1a10c028-eb47-4036-ac62-7a98e0446a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_02306d75-d4f4-43a0-a0f6-21864fc5ada5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1a10c028-eb47-4036-ac62-7a98e0446a56" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_02306d75-d4f4-43a0-a0f6-21864fc5ada5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_d0449374-263d-4a98-8c12-67aac0208c97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1a10c028-eb47-4036-ac62-7a98e0446a56" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_d0449374-263d-4a98-8c12-67aac0208c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsNonrecurringAssetsDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#FairValueMeasurementsNonrecurringAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsNonrecurringAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7752627b-0a3f-4524-a6ee-fe6e8d880986" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_b0b22b68-2975-4e5b-889e-8430c36b72c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7752627b-0a3f-4524-a6ee-fe6e8d880986" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_b0b22b68-2975-4e5b-889e-8430c36b72c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="simple" xlink:href="biib-20220331.xsd#FairValueMeasurementsDetails1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c26137e3-d7e2-453b-91f3-540e65ba62e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_4e4bc873-b689-4f2e-9ba4-629e99b00b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c26137e3-d7e2-453b-91f3-540e65ba62e2" xlink:to="loc_us-gaap_DebtInstrumentTable_4e4bc873-b689-4f2e-9ba4-629e99b00b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_bd85cb93-a7b6-4363-b960-14dfa4977468" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4e4bc873-b689-4f2e-9ba4-629e99b00b0b" xlink:to="loc_us-gaap_DebtInstrumentAxis_bd85cb93-a7b6-4363-b960-14dfa4977468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_742be7ab-5dab-48e7-a6ca-3faf46943610" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_bd85cb93-a7b6-4363-b960-14dfa4977468" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_742be7ab-5dab-48e7-a6ca-3faf46943610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_df7728fc-7b3b-44de-be79-cf0e62b6fe9d" xlink:href="biib-20220331.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_742be7ab-5dab-48e7-a6ca-3faf46943610" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_df7728fc-7b3b-44de-be79-cf0e62b6fe9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_35b00977-8214-4d91-a2f4-d4fe986b86bc" xlink:href="biib-20220331.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_742be7ab-5dab-48e7-a6ca-3faf46943610" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_35b00977-8214-4d91-a2f4-d4fe986b86bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.25SeniorNotesdueMay12030Member_b0cee811-d9bb-4916-b7a0-f95e215f13a1" xlink:href="biib-20220331.xsd#biib_A2.25SeniorNotesdueMay12030Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_742be7ab-5dab-48e7-a6ca-3faf46943610" xlink:to="loc_biib_A2.25SeniorNotesdueMay12030Member_b0cee811-d9bb-4916-b7a0-f95e215f13a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_10e13de0-2340-4aa5-b8bc-5b485f6af4ba" xlink:href="biib-20220331.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_742be7ab-5dab-48e7-a6ca-3faf46943610" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_10e13de0-2340-4aa5-b8bc-5b485f6af4ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3.15SeniorNotesdueMay12050Member_3b0eae0c-29c4-4fad-b538-491cc23e7a11" xlink:href="biib-20220331.xsd#biib_A3.15SeniorNotesdueMay12050Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_742be7ab-5dab-48e7-a6ca-3faf46943610" xlink:to="loc_biib_A3.15SeniorNotesdueMay12050Member_3b0eae0c-29c4-4fad-b538-491cc23e7a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3250SeniorNotesDueFebruary152051Member_cfe6b8a0-b763-4d6e-bff8-cc28e245092f" xlink:href="biib-20220331.xsd#biib_A3250SeniorNotesDueFebruary152051Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_742be7ab-5dab-48e7-a6ca-3faf46943610" xlink:to="loc_biib_A3250SeniorNotesDueFebruary152051Member_cfe6b8a0-b763-4d6e-bff8-cc28e245092f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0a87a471-6d8e-44ab-ad7f-86f1df006d45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4e4bc873-b689-4f2e-9ba4-629e99b00b0b" xlink:to="loc_us-gaap_DebtInstrumentLineItems_0a87a471-6d8e-44ab-ad7f-86f1df006d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_b257aa91-7e72-4354-af92-5215542a35c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0a87a471-6d8e-44ab-ad7f-86f1df006d45" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_b257aa91-7e72-4354-af92-5215542a35c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_1f37af7d-ef79-452c-8eea-4c271899cdf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0a87a471-6d8e-44ab-ad7f-86f1df006d45" xlink:to="loc_us-gaap_NotesPayable_1f37af7d-ef79-452c-8eea-4c271899cdf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_cbc4ef1a-df98-4435-8a4c-cccaf490da75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0a87a471-6d8e-44ab-ad7f-86f1df006d45" xlink:to="loc_us-gaap_DebtInstrumentFairValue_cbc4ef1a-df98-4435-8a4c-cccaf490da75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_fb5abe1f-c4b8-4d98-bf13-1924c03b9a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0a87a471-6d8e-44ab-ad7f-86f1df006d45" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_fb5abe1f-c4b8-4d98-bf13-1924c03b9a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LongTermDebtExchangedAmount_9f00b766-3e62-4ebf-8f50-7ad6dbd2033d" xlink:href="biib-20220331.xsd#biib_LongTermDebtExchangedAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0a87a471-6d8e-44ab-ad7f-86f1df006d45" xlink:to="loc_biib_LongTermDebtExchangedAmount_9f00b766-3e62-4ebf-8f50-7ad6dbd2033d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="simple" xlink:href="biib-20220331.xsd#FairValueMeasurementsDetails2"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e75a3bdc-f8f5-4fd9-9bb5-e29b5c047628" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_e1b997d3-5dd5-47fd-a6d4-c0e7960a5d56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e75a3bdc-f8f5-4fd9-9bb5-e29b5c047628" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_e1b997d3-5dd5-47fd-a6d4-c0e7960a5d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_37461c17-8f48-456f-bfe7-6fd16bfc5a8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_e1b997d3-5dd5-47fd-a6d4-c0e7960a5d56" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_37461c17-8f48-456f-bfe7-6fd16bfc5a8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3e756339-49be-405d-89c6-57dfacf8b74f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_37461c17-8f48-456f-bfe7-6fd16bfc5a8f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3e756339-49be-405d-89c6-57dfacf8b74f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_b527513c-2754-4ba6-b27e-aa3e41051c46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_3e756339-49be-405d-89c6-57dfacf8b74f" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_b527513c-2754-4ba6-b27e-aa3e41051c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_d34cff7d-9dbc-4ff2-b187-1367d0d79144" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_e1b997d3-5dd5-47fd-a6d4-c0e7960a5d56" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_d34cff7d-9dbc-4ff2-b187-1367d0d79144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_077fda16-bef3-4860-98b1-2245f7ed9b05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_d34cff7d-9dbc-4ff2-b187-1367d0d79144" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_077fda16-bef3-4860-98b1-2245f7ed9b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_0f459ef2-a9bb-4099-b4f7-897d5d79edb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_d34cff7d-9dbc-4ff2-b187-1367d0d79144" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_0f459ef2-a9bb-4099-b4f7-897d5d79edb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8157a318-a900-4d53-822c-0461b19f4ead" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_d34cff7d-9dbc-4ff2-b187-1367d0d79144" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8157a318-a900-4d53-822c-0461b19f4ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="simple" xlink:href="biib-20220331.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6a4ebe84-3b0e-4196-9300-dd8b9484fe26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_b3ff37d2-64c4-4f3f-a0a4-7c35a439bc72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6a4ebe84-3b0e-4196-9300-dd8b9484fe26" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_b3ff37d2-64c4-4f3f-a0a4-7c35a439bc72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="biib-20220331.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0d838761-3b40-46aa-8ebb-7b6a52b31537" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_b0df1dbc-ea13-4046-8243-42899e0a85a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0d838761-3b40-46aa-8ebb-7b6a52b31537" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_b0df1dbc-ea13-4046-8243-42899e0a85a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_65dc27e8-fded-40d7-b0a9-7dfdb1f144f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0d838761-3b40-46aa-8ebb-7b6a52b31537" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_65dc27e8-fded-40d7-b0a9-7dfdb1f144f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_7b737484-c6ee-41ed-878a-7055b9a3be5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0d838761-3b40-46aa-8ebb-7b6a52b31537" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_7b737484-c6ee-41ed-878a-7055b9a3be5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_6396e1d9-0a0a-4518-9d6c-ab84ca2e32bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0d838761-3b40-46aa-8ebb-7b6a52b31537" xlink:to="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_6396e1d9-0a0a-4518-9d6c-ab84ca2e32bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#FinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_fd664ee4-4bd8-497b-9a45-7cb54c96521e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_0c6f9cfe-aff8-42cf-abfb-d3bc52a190e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_fd664ee4-4bd8-497b-9a45-7cb54c96521e" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_0c6f9cfe-aff8-42cf-abfb-d3bc52a190e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_0522c505-c7fe-4176-a50d-a2dc47f773ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_0c6f9cfe-aff8-42cf-abfb-d3bc52a190e2" xlink:to="loc_us-gaap_InvestmentTypeAxis_0522c505-c7fe-4176-a50d-a2dc47f773ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_2b46ef3f-2d84-492d-adbd-b65c468b1bff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_0522c505-c7fe-4176-a50d-a2dc47f773ce" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_2b46ef3f-2d84-492d-adbd-b65c468b1bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_3a916f40-5ef9-42e8-b71d-b665a3d49139" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2b46ef3f-2d84-492d-adbd-b65c468b1bff" xlink:to="loc_us-gaap_CommercialPaperMember_3a916f40-5ef9-42e8-b71d-b665a3d49139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_f849e0f7-0b08-4086-ab7a-388c2efd3ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepurchaseAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2b46ef3f-2d84-492d-adbd-b65c468b1bff" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_f849e0f7-0b08-4086-ab7a-388c2efd3ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_52cd41d5-8bdd-44b0-91de-aa636aaae9bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2b46ef3f-2d84-492d-adbd-b65c468b1bff" xlink:to="loc_us-gaap_MoneyMarketFundsMember_52cd41d5-8bdd-44b0-91de-aa636aaae9bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_554acc84-5bf3-4d64-bc47-f4ade5139df8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2b46ef3f-2d84-492d-adbd-b65c468b1bff" xlink:to="loc_us-gaap_DebtSecuritiesMember_554acc84-5bf3-4d64-bc47-f4ade5139df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_4479fc93-5b2b-435b-8a53-8bcc46bd75cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_0c6f9cfe-aff8-42cf-abfb-d3bc52a190e2" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_4479fc93-5b2b-435b-8a53-8bcc46bd75cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_58774848-9b82-4cfd-863e-216e9ade5b93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_4479fc93-5b2b-435b-8a53-8bcc46bd75cd" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_58774848-9b82-4cfd-863e-216e9ade5b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_45a84bb0-8d7c-440a-934d-6631a7666ace" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_58774848-9b82-4cfd-863e-216e9ade5b93" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_45a84bb0-8d7c-440a-934d-6631a7666ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="simple" xlink:href="biib-20220331.xsd#FinancialInstrumentsDetails1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a7308068-6185-423d-a321-9ba9c6cc018a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_4bc7182e-dbe8-437e-bc74-1fd040a34f6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a7308068-6185-423d-a321-9ba9c6cc018a" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_4bc7182e-dbe8-437e-bc74-1fd040a34f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_f24af806-5113-41af-9250-3181795e3d94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_4bc7182e-dbe8-437e-bc74-1fd040a34f6f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_f24af806-5113-41af-9250-3181795e3d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2bae1c19-890d-4d2a-b804-dc55ab57d1a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f24af806-5113-41af-9250-3181795e3d94" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2bae1c19-890d-4d2a-b804-dc55ab57d1a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_13ab2b4a-0b58-4e03-82f8-87353e075619" xlink:href="biib-20220331.xsd#biib_CorporateDebtSecuritiesCurrentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2bae1c19-890d-4d2a-b804-dc55ab57d1a1" xlink:to="loc_biib_CorporateDebtSecuritiesCurrentMember_13ab2b4a-0b58-4e03-82f8-87353e075619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_f21994d6-ac9e-4f04-bb54-bf362130a2b2" xlink:href="biib-20220331.xsd#biib_CorporateDebtSecuritiesNonCurrentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2bae1c19-890d-4d2a-b804-dc55ab57d1a1" xlink:to="loc_biib_CorporateDebtSecuritiesNonCurrentMember_f21994d6-ac9e-4f04-bb54-bf362130a2b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_a1173c29-54ea-45c3-9cc0-525d7a6b41c1" xlink:href="biib-20220331.xsd#biib_GovernmentSecuritiesCurrentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2bae1c19-890d-4d2a-b804-dc55ab57d1a1" xlink:to="loc_biib_GovernmentSecuritiesCurrentMember_a1173c29-54ea-45c3-9cc0-525d7a6b41c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_22dc5f6a-e493-4fb8-aa5f-d5d22aa0cce6" xlink:href="biib-20220331.xsd#biib_GovernmentSecuritiesNonCurrentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2bae1c19-890d-4d2a-b804-dc55ab57d1a1" xlink:to="loc_biib_GovernmentSecuritiesNonCurrentMember_22dc5f6a-e493-4fb8-aa5f-d5d22aa0cce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_55bf0013-9a1f-4e78-ab2c-641b291fdc7f" xlink:href="biib-20220331.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2bae1c19-890d-4d2a-b804-dc55ab57d1a1" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_55bf0013-9a1f-4e78-ab2c-641b291fdc7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_b1290bc7-a509-467e-932f-6105c29b737d" xlink:href="biib-20220331.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2bae1c19-890d-4d2a-b804-dc55ab57d1a1" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_b1290bc7-a509-467e-932f-6105c29b737d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesCurrentMember_8d2bb90f-499b-48cc-99e5-3dd2eb0cc58e" xlink:href="biib-20220331.xsd#biib_EquitySecuritiesCurrentMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2bae1c19-890d-4d2a-b804-dc55ab57d1a1" xlink:to="loc_biib_EquitySecuritiesCurrentMember_8d2bb90f-499b-48cc-99e5-3dd2eb0cc58e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesNonCurrentMember_17c4cd3d-e6cd-4ac3-b990-f9724dce4119" xlink:href="biib-20220331.xsd#biib_EquitySecuritiesNonCurrentMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2bae1c19-890d-4d2a-b804-dc55ab57d1a1" xlink:to="loc_biib_EquitySecuritiesNonCurrentMember_17c4cd3d-e6cd-4ac3-b990-f9724dce4119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_13f6b84f-f5f5-4009-8ed9-877dbe4715d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_4bc7182e-dbe8-437e-bc74-1fd040a34f6f" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_13f6b84f-f5f5-4009-8ed9-877dbe4715d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0b70a1ff-8133-409f-be14-bf76e777a62e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_13f6b84f-f5f5-4009-8ed9-877dbe4715d2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0b70a1ff-8133-409f-be14-bf76e777a62e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_628f1b49-fb78-4016-8e10-8e19005413cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0b70a1ff-8133-409f-be14-bf76e777a62e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_628f1b49-fb78-4016-8e10-8e19005413cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4f45d8f0-2cd2-4433-af5e-e09f2371b194" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0b70a1ff-8133-409f-be14-bf76e777a62e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4f45d8f0-2cd2-4433-af5e-e09f2371b194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9be084d5-0c44-4863-8654-072a1893bf2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0b70a1ff-8133-409f-be14-bf76e777a62e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9be084d5-0c44-4863-8654-072a1893bf2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2ca30f0b-daee-4279-9ffd-9774fd4bf4d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0b70a1ff-8133-409f-be14-bf76e777a62e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2ca30f0b-daee-4279-9ffd-9774fd4bf4d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_e015b69f-005f-4bb2-b400-1798c748ed03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_13f6b84f-f5f5-4009-8ed9-877dbe4715d2" xlink:to="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_e015b69f-005f-4bb2-b400-1798c748ed03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_9d68a3bc-4c3a-4275-896f-bbeff0690995" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_e015b69f-005f-4bb2-b400-1798c748ed03" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_9d68a3bc-4c3a-4275-896f-bbeff0690995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_b0bc9d61-7240-42e5-b3db-5c036de807f5" xlink:href="biib-20220331.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_e015b69f-005f-4bb2-b400-1798c748ed03" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_b0bc9d61-7240-42e5-b3db-5c036de807f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_27994361-3826-4796-b9b6-4c1affd83ceb" xlink:href="biib-20220331.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_e015b69f-005f-4bb2-b400-1798c748ed03" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_27994361-3826-4796-b9b6-4c1affd83ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_f62129ae-acc5-4219-a01f-f24360cdaeaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_e015b69f-005f-4bb2-b400-1798c748ed03" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_f62129ae-acc5-4219-a01f-f24360cdaeaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="simple" xlink:href="biib-20220331.xsd#FinancialInstrumentsDetails2"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ed4b5330-b593-49fa-83a6-13f8631af147" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_3505ac7a-a1bf-41d0-8833-ca386b97e80d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ed4b5330-b593-49fa-83a6-13f8631af147" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_3505ac7a-a1bf-41d0-8833-ca386b97e80d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_6d159f36-0bb2-4fec-abf5-c880e370f675" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_3505ac7a-a1bf-41d0-8833-ca386b97e80d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_6d159f36-0bb2-4fec-abf5-c880e370f675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_282e9fef-22b3-4abf-8225-a40724397a52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_3505ac7a-a1bf-41d0-8833-ca386b97e80d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_282e9fef-22b3-4abf-8225-a40724397a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_86259dbf-d534-445e-882c-90fa3a9a25a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_3505ac7a-a1bf-41d0-8833-ca386b97e80d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_86259dbf-d534-445e-882c-90fa3a9a25a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_d6f940a3-eba2-4675-a71b-192da73ab9a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_3505ac7a-a1bf-41d0-8833-ca386b97e80d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_d6f940a3-eba2-4675-a71b-192da73ab9a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_9122bdcb-f4f1-428e-a541-66f708d185e5" xlink:href="biib-20220331.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_3505ac7a-a1bf-41d0-8833-ca386b97e80d" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_9122bdcb-f4f1-428e-a541-66f708d185e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_c4bdb427-69f3-45b9-a68a-9e70bb9cb8cb" xlink:href="biib-20220331.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_3505ac7a-a1bf-41d0-8833-ca386b97e80d" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_c4bdb427-69f3-45b9-a68a-9e70bb9cb8cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9be5a655-e8fc-47ae-8c86-17eea4f80284" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_3505ac7a-a1bf-41d0-8833-ca386b97e80d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9be5a655-e8fc-47ae-8c86-17eea4f80284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f24b5563-c2e8-4ab2-b191-fc677e11d609" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_3505ac7a-a1bf-41d0-8833-ca386b97e80d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f24b5563-c2e8-4ab2-b191-fc677e11d609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="simple" xlink:href="biib-20220331.xsd#FinancialInstrumentsDetails3"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_df36e152-abe5-4922-949a-f97b19c4d4b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_1d6d2159-6882-4ff0-bcb7-52f4b091feca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_df36e152-abe5-4922-949a-f97b19c4d4b0" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_1d6d2159-6882-4ff0-bcb7-52f4b091feca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_1f6fadae-50aa-452f-8c88-24866bcb70da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_df36e152-abe5-4922-949a-f97b19c4d4b0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_1f6fadae-50aa-452f-8c88-24866bcb70da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_25c87616-f0ea-4285-a7d0-93980db18c57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_df36e152-abe5-4922-949a-f97b19c4d4b0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_25c87616-f0ea-4285-a7d0-93980db18c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="simple" xlink:href="biib-20220331.xsd#FinancialInstrumentsDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7d25066f-58d3-4714-8085-2ded630fd5d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AverageMaturityOfMarketableSecurities_7d509a8d-cef5-43b9-bfc3-c3e95f54fb46" xlink:href="biib-20220331.xsd#biib_AverageMaturityOfMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7d25066f-58d3-4714-8085-2ded630fd5d3" xlink:to="loc_biib_AverageMaturityOfMarketableSecurities_7d509a8d-cef5-43b9-bfc3-c3e95f54fb46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" xlink:href="biib-20220331.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_cc802f4f-51d1-4775-8ed5-cb3512b757bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a7610f76-d2d6-40c1-8b61-d3ca614118d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_cc802f4f-51d1-4775-8ed5-cb3512b757bc" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a7610f76-d2d6-40c1-8b61-d3ca614118d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_e1efac9e-64f7-4b0a-bd66-625fa265965a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a7610f76-d2d6-40c1-8b61-d3ca614118d1" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_e1efac9e-64f7-4b0a-bd66-625fa265965a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_72a6f16d-9faf-4519-a9e8-4b6000a43089" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e1efac9e-64f7-4b0a-bd66-625fa265965a" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_72a6f16d-9faf-4519-a9e8-4b6000a43089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_cccd002b-ba52-4733-a736-f8a7c36367dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_72a6f16d-9faf-4519-a9e8-4b6000a43089" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_cccd002b-ba52-4733-a736-f8a7c36367dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_618ac2fb-484f-47b6-970e-f8bd63df3dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a7610f76-d2d6-40c1-8b61-d3ca614118d1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_618ac2fb-484f-47b6-970e-f8bd63df3dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4b0911e5-12bd-4b03-a137-94c35be81b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_618ac2fb-484f-47b6-970e-f8bd63df3dbc" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4b0911e5-12bd-4b03-a137-94c35be81b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentsMember_d85f4078-9559-4d0e-9154-e4ae3353f378" xlink:href="biib-20220331.xsd#biib_StrategicInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4b0911e5-12bd-4b03-a137-94c35be81b8b" xlink:to="loc_biib_StrategicInvestmentsMember_d85f4078-9559-4d0e-9154-e4ae3353f378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_896e0f22-fe42-4dc5-b2f3-32d503a9be40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a7610f76-d2d6-40c1-8b61-d3ca614118d1" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_896e0f22-fe42-4dc5-b2f3-32d503a9be40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentPortfolio_29784210-7ec0-4ac1-86c9-e4c2086b33d9" xlink:href="biib-20220331.xsd#biib_StrategicInvestmentPortfolio"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_896e0f22-fe42-4dc5-b2f3-32d503a9be40" xlink:to="loc_biib_StrategicInvestmentPortfolio_29784210-7ec0-4ac1-86c9-e4c2086b33d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="simple" xlink:href="biib-20220331.xsd#DerivativeInstruments"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_37f9b53c-c79b-4a85-bd54-a500bc221e64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_2e245103-68c7-4d61-b6d3-615988f23b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_37f9b53c-c79b-4a85-bd54-a500bc221e64" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_2e245103-68c7-4d61-b6d3-615988f23b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="simple" xlink:href="biib-20220331.xsd#DerivativeInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ce865411-04d2-4f37-ba4a-7feeea6b606a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_fcecc45e-707a-4257-b3f9-3596fd15b331" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ce865411-04d2-4f37-ba4a-7feeea6b606a" xlink:to="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_fcecc45e-707a-4257-b3f9-3596fd15b331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_7cd26cd9-6b83-4dd7-8d81-c0732a84b3c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ce865411-04d2-4f37-ba4a-7feeea6b606a" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_7cd26cd9-6b83-4dd7-8d81-c0732a84b3c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_63830e86-59bc-4ae4-b655-a0378d0f7e74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ce865411-04d2-4f37-ba4a-7feeea6b606a" xlink:to="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_63830e86-59bc-4ae4-b655-a0378d0f7e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_b9e8477f-faf1-4d4d-9016-f48a38c97752" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ce865411-04d2-4f37-ba4a-7feeea6b606a" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_b9e8477f-faf1-4d4d-9016-f48a38c97752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock_58b01b42-3642-403b-8358-1367bf29ca28" xlink:href="biib-20220331.xsd#biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ce865411-04d2-4f37-ba4a-7feeea6b606a" xlink:to="loc_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock_58b01b42-3642-403b-8358-1367bf29ca28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#DerivativeInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_62395dd2-fee8-4a85-9970-9d1f519cbbbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1ec735f4-f2e8-4f80-a7f7-9f4f7ddfb815" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_62395dd2-fee8-4a85-9970-9d1f519cbbbe" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1ec735f4-f2e8-4f80-a7f7-9f4f7ddfb815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityAxis_04d2147f-ae15-4035-b493-8cee857149b5" xlink:href="biib-20220331.xsd#biib_DerivativeMaturityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1ec735f4-f2e8-4f80-a7f7-9f4f7ddfb815" xlink:to="loc_biib_DerivativeMaturityAxis_04d2147f-ae15-4035-b493-8cee857149b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityDomain_0168e6bd-9439-4dc3-a71d-54a8a4c66007" xlink:href="biib-20220331.xsd#biib_DerivativeMaturityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeMaturityAxis_04d2147f-ae15-4035-b493-8cee857149b5" xlink:to="loc_biib_DerivativeMaturityDomain_0168e6bd-9439-4dc3-a71d-54a8a4c66007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShorttermderivativeMember_97feaab5-2425-4bca-bad1-aebaa5251886" xlink:href="biib-20220331.xsd#biib_ShorttermderivativeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeMaturityDomain_0168e6bd-9439-4dc3-a71d-54a8a4c66007" xlink:to="loc_biib_ShorttermderivativeMember_97feaab5-2425-4bca-bad1-aebaa5251886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6b4ae5df-db55-4419-8316-8e81dac63200" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1ec735f4-f2e8-4f80-a7f7-9f4f7ddfb815" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6b4ae5df-db55-4419-8316-8e81dac63200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_f3aa1094-1e43-4cd6-a914-df83fad7648d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6b4ae5df-db55-4419-8316-8e81dac63200" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_f3aa1094-1e43-4cd6-a914-df83fad7648d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_385cfc7f-062a-4299-a363-250151bcdc2d" xlink:href="biib-20220331.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f3aa1094-1e43-4cd6-a914-df83fad7648d" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_385cfc7f-062a-4299-a363-250151bcdc2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_347c9402-f27a-47b9-840b-725c57d479e9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1ec735f4-f2e8-4f80-a7f7-9f4f7ddfb815" xlink:to="loc_srt_CurrencyAxis_347c9402-f27a-47b9-840b-725c57d479e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_67ae9da1-0b5e-408b-b06c-b7f1598011f9" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_347c9402-f27a-47b9-840b-725c57d479e9" xlink:to="loc_currency_AllCurrenciesDomain_67ae9da1-0b5e-408b-b06c-b7f1598011f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_2218d38f-a232-4f9a-9a09-dafe40c3f5ba" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_EUR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_67ae9da1-0b5e-408b-b06c-b7f1598011f9" xlink:to="loc_currency_EUR_2218d38f-a232-4f9a-9a09-dafe40c3f5ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP_71aa4fcf-ac09-49fc-8ed0-4bbf553740b6" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_GBP"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_67ae9da1-0b5e-408b-b06c-b7f1598011f9" xlink:to="loc_currency_GBP_71aa4fcf-ac09-49fc-8ed0-4bbf553740b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF_3f5c0c77-ed7f-45e6-9d01-7fef123225e7" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_CHF"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_67ae9da1-0b5e-408b-b06c-b7f1598011f9" xlink:to="loc_currency_CHF_3f5c0c77-ed7f-45e6-9d01-7fef123225e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_JPY_a5310e58-183a-4394-8ce9-984b43077566" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_JPY"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_67ae9da1-0b5e-408b-b06c-b7f1598011f9" xlink:to="loc_currency_JPY_a5310e58-183a-4394-8ce9-984b43077566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CAD_750a2479-2d49-4c8a-9ec7-d592f6debf2f" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_CAD"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_67ae9da1-0b5e-408b-b06c-b7f1598011f9" xlink:to="loc_currency_CAD_750a2479-2d49-4c8a-9ec7-d592f6debf2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_dfe3a7d3-d8e0-4be4-bf7d-1ba2efef12d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1ec735f4-f2e8-4f80-a7f7-9f4f7ddfb815" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_dfe3a7d3-d8e0-4be4-bf7d-1ba2efef12d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9c614c19-ba7d-445e-966a-7e2c89c046f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_dfe3a7d3-d8e0-4be4-bf7d-1ba2efef12d8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9c614c19-ba7d-445e-966a-7e2c89c046f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_ccc4ac9c-d4cc-44b1-992c-2f3de9aeaf09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9c614c19-ba7d-445e-966a-7e2c89c046f8" xlink:to="loc_us-gaap_SalesMember_ccc4ac9c-d4cc-44b1-992c-2f3de9aeaf09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember_44f380e2-478d-4acf-af7b-0d5b2ddec72a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9c614c19-ba7d-445e-966a-7e2c89c046f8" xlink:to="loc_us-gaap_OperatingExpenseMember_44f380e2-478d-4acf-af7b-0d5b2ddec72a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_68d63c38-8c4c-44c4-b7ee-7fc023f14264" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9c614c19-ba7d-445e-966a-7e2c89c046f8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_68d63c38-8c4c-44c4-b7ee-7fc023f14264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_da2075cc-38df-4bd6-bdda-c4f87467551c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1ec735f4-f2e8-4f80-a7f7-9f4f7ddfb815" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_da2075cc-38df-4bd6-bdda-c4f87467551c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_46986b0b-1a2c-4a0a-b122-1152154d14c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_da2075cc-38df-4bd6-bdda-c4f87467551c" xlink:to="loc_us-gaap_HedgingRelationshipDomain_46986b0b-1a2c-4a0a-b122-1152154d14c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_1d76bcf4-60c9-49df-a84e-361487a7b2c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_46986b0b-1a2c-4a0a-b122-1152154d14c5" xlink:to="loc_us-gaap_CashFlowHedgingMember_1d76bcf4-60c9-49df-a84e-361487a7b2c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsrevenueMember_ec12fec0-cabd-40f1-b530-f6a9ccd735c0" xlink:href="biib-20220331.xsd#biib_CashflowsrevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_46986b0b-1a2c-4a0a-b122-1152154d14c5" xlink:to="loc_biib_CashflowsrevenueMember_ec12fec0-cabd-40f1-b530-f6a9ccd735c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsoperatingexpensesMember_cd6bd3c1-a48b-4ed6-a3fc-51e41f2e83c5" xlink:href="biib-20220331.xsd#biib_CashflowsoperatingexpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_46986b0b-1a2c-4a0a-b122-1152154d14c5" xlink:to="loc_biib_CashflowsoperatingexpensesMember_cd6bd3c1-a48b-4ed6-a3fc-51e41f2e83c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_f9b58b2e-a44d-4272-9d22-fd1980fe3815" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_46986b0b-1a2c-4a0a-b122-1152154d14c5" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_f9b58b2e-a44d-4272-9d22-fd1980fe3815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_b9b5c4fb-16d4-4c00-949a-47f824fc48c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1ec735f4-f2e8-4f80-a7f7-9f4f7ddfb815" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_b9b5c4fb-16d4-4c00-949a-47f824fc48c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_fcb43cc4-28b2-455b-b291-ba806ce4642c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b9b5c4fb-16d4-4c00-949a-47f824fc48c3" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_fcb43cc4-28b2-455b-b291-ba806ce4642c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_1186f501-c3d0-40af-969d-9f54a63ecc03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fcb43cc4-28b2-455b-b291-ba806ce4642c" xlink:to="loc_us-gaap_ForeignExchangeContractMember_1186f501-c3d0-40af-969d-9f54a63ecc03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_3ab0a53e-25e3-41fa-9c27-dc3eba37f622" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fcb43cc4-28b2-455b-b291-ba806ce4642c" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_3ab0a53e-25e3-41fa-9c27-dc3eba37f622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_f84270a1-0e54-439d-b8e6-72c17247f3e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1ec735f4-f2e8-4f80-a7f7-9f4f7ddfb815" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_f84270a1-0e54-439d-b8e6-72c17247f3e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5ce960d3-5df9-4aaa-a046-18595a5d7fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f84270a1-0e54-439d-b8e6-72c17247f3e6" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5ce960d3-5df9-4aaa-a046-18595a5d7fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_77da6695-d18f-4981-977a-18cc0965ecc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5ce960d3-5df9-4aaa-a046-18595a5d7fe0" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_77da6695-d18f-4981-977a-18cc0965ecc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_1ec969ce-2367-42aa-ab14-bc147274dc74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5ce960d3-5df9-4aaa-a046-18595a5d7fe0" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_1ec969ce-2367-42aa-ab14-bc147274dc74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_9d1953a1-0f1d-4163-9099-a77bada429c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5ce960d3-5df9-4aaa-a046-18595a5d7fe0" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_9d1953a1-0f1d-4163-9099-a77bada429c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_899ae316-94be-414a-ad72-cde3bb398901" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5ce960d3-5df9-4aaa-a046-18595a5d7fe0" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_899ae316-94be-414a-ad72-cde3bb398901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_b809b83c-83c0-48e0-b98b-a6d6b2bb4725" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1ec735f4-f2e8-4f80-a7f7-9f4f7ddfb815" xlink:to="loc_us-gaap_HedgingDesignationAxis_b809b83c-83c0-48e0-b98b-a6d6b2bb4725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_de43e38e-5731-4013-891d-22baa38dabf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_b809b83c-83c0-48e0-b98b-a6d6b2bb4725" xlink:to="loc_us-gaap_HedgingDesignationDomain_de43e38e-5731-4013-891d-22baa38dabf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_195c70b1-699d-4bbd-94e6-9f9bfeb2a3d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_de43e38e-5731-4013-891d-22baa38dabf7" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_195c70b1-699d-4bbd-94e6-9f9bfeb2a3d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_3d175d51-08ca-438f-ba57-ad95379c96f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_de43e38e-5731-4013-891d-22baa38dabf7" xlink:to="loc_us-gaap_NondesignatedMember_3d175d51-08ca-438f-ba57-ad95379c96f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_29db2e11-5d5c-4a79-a2a0-5062ff93a9ab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1ec735f4-f2e8-4f80-a7f7-9f4f7ddfb815" xlink:to="loc_srt_RangeAxis_29db2e11-5d5c-4a79-a2a0-5062ff93a9ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_aba501dd-53d3-4052-8e3d-1ee7734dca0c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_29db2e11-5d5c-4a79-a2a0-5062ff93a9ab" xlink:to="loc_srt_RangeMember_aba501dd-53d3-4052-8e3d-1ee7734dca0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2e866d0d-6979-40da-8216-7ede5d3da46c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_aba501dd-53d3-4052-8e3d-1ee7734dca0c" xlink:to="loc_srt_MinimumMember_2e866d0d-6979-40da-8216-7ede5d3da46c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bc19c13d-d217-4da1-970b-11e4500fe8d6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_aba501dd-53d3-4052-8e3d-1ee7734dca0c" xlink:to="loc_srt_MaximumMember_bc19c13d-d217-4da1-970b-11e4500fe8d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_0eac2f1e-c5c4-4a1c-869d-c0e7e518c1f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1ec735f4-f2e8-4f80-a7f7-9f4f7ddfb815" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_0eac2f1e-c5c4-4a1c-869d-c0e7e518c1f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_aa99c071-63c0-4124-86c9-24959048a94d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0eac2f1e-c5c4-4a1c-869d-c0e7e518c1f1" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_aa99c071-63c0-4124-86c9-24959048a94d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_2d4566b2-de1a-4a5c-aff8-ac95913fb002" xlink:href="biib-20220331.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0eac2f1e-c5c4-4a1c-869d-c0e7e518c1f1" xlink:to="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_2d4566b2-de1a-4a5c-aff8-ac95913fb002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_ed4954d5-b382-4176-95ba-23ecfa83cf67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0eac2f1e-c5c4-4a1c-869d-c0e7e518c1f1" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_ed4954d5-b382-4176-95ba-23ecfa83cf67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_fc768945-b693-48dd-8961-d90ec473d520" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0eac2f1e-c5c4-4a1c-869d-c0e7e518c1f1" xlink:to="loc_us-gaap_DerivativeNotionalAmount_fc768945-b693-48dd-8961-d90ec473d520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_71db31db-701b-4ae1-9777-5888d89dde0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0eac2f1e-c5c4-4a1c-869d-c0e7e518c1f1" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_71db31db-701b-4ae1-9777-5888d89dde0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_6a415c27-9392-4c45-b13f-1675df63f415" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0eac2f1e-c5c4-4a1c-869d-c0e7e518c1f1" xlink:to="loc_us-gaap_DerivativeTermOfContract_6a415c27-9392-4c45-b13f-1675df63f415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_0012c310-d057-47d6-aecb-89fc5c6c2304" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0eac2f1e-c5c4-4a1c-869d-c0e7e518c1f1" xlink:to="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_0012c310-d057-47d6-aecb-89fc5c6c2304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_36eb119f-4b95-4c34-8812-c84fd292d23e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0eac2f1e-c5c4-4a1c-869d-c0e7e518c1f1" xlink:to="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_36eb119f-4b95-4c34-8812-c84fd292d23e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_0714dac6-8706-4460-bd77-33797b35e96c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0eac2f1e-c5c4-4a1c-869d-c0e7e518c1f1" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_0714dac6-8706-4460-bd77-33797b35e96c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_93eeae32-87d6-4958-a43a-ee6ea410ec5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0eac2f1e-c5c4-4a1c-869d-c0e7e518c1f1" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_93eeae32-87d6-4958-a43a-ee6ea410ec5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_6250b605-7aee-4b69-bf04-cab109955840" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0eac2f1e-c5c4-4a1c-869d-c0e7e518c1f1" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_6250b605-7aee-4b69-bf04-cab109955840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_4a0187d5-19f2-46fb-8843-b38ff0cb9316" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0eac2f1e-c5c4-4a1c-869d-c0e7e518c1f1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_4a0187d5-19f2-46fb-8843-b38ff0cb9316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_ccd7b36c-dbcb-42f5-a460-e20442f57bfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0eac2f1e-c5c4-4a1c-869d-c0e7e518c1f1" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_ccd7b36c-dbcb-42f5-a460-e20442f57bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_c29d8f16-c69c-4534-89cb-62527452980c" xlink:href="biib-20220331.xsd#biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0eac2f1e-c5c4-4a1c-869d-c0e7e518c1f1" xlink:to="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_c29d8f16-c69c-4534-89cb-62527452980c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_09c912c0-1f01-462d-8fe7-cb41c8af1306" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0eac2f1e-c5c4-4a1c-869d-c0e7e518c1f1" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_09c912c0-1f01-462d-8fe7-cb41c8af1306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGainOnDerivatives_fedc9772-4023-43eb-b3de-8d8d843bade0" xlink:href="biib-20220331.xsd#biib_UnrealizedGainOnDerivatives"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0eac2f1e-c5c4-4a1c-869d-c0e7e518c1f1" xlink:to="loc_biib_UnrealizedGainOnDerivatives_fedc9772-4023-43eb-b3de-8d8d843bade0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedLossOnDerivatives_fc46f82b-9f02-4272-ae65-fe0924dc5907" xlink:href="biib-20220331.xsd#biib_UnrealizedLossOnDerivatives"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0eac2f1e-c5c4-4a1c-869d-c0e7e518c1f1" xlink:to="loc_biib_UnrealizedLossOnDerivatives_fc46f82b-9f02-4272-ae65-fe0924dc5907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_ff4fb926-8efe-4979-922c-f4471229f196" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0eac2f1e-c5c4-4a1c-869d-c0e7e518c1f1" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_ff4fb926-8efe-4979-922c-f4471229f196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_2598720d-9918-4adf-a582-85e50c648841" xlink:href="biib-20220331.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0eac2f1e-c5c4-4a1c-869d-c0e7e518c1f1" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_2598720d-9918-4adf-a582-85e50c648841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_3bf1ad78-de48-465d-8dbf-19d7c9ad9c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0eac2f1e-c5c4-4a1c-869d-c0e7e518c1f1" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_3bf1ad78-de48-465d-8dbf-19d7c9ad9c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipment" xlink:type="simple" xlink:href="biib-20220331.xsd#PropertyPlantandEquipment"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_65354941-10c7-4609-b002-b9b1c5af7a89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_52a3e84e-0bcb-4507-bf6a-b1af3f7e810f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_65354941-10c7-4609-b002-b9b1c5af7a89" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_52a3e84e-0bcb-4507-bf6a-b1af3f7e810f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#PropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c43a165d-10cc-4765-92e3-8f58815936ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2403413b-be66-4711-b81a-e50f2ef6cc0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c43a165d-10cc-4765-92e3-8f58815936ad" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2403413b-be66-4711-b81a-e50f2ef6cc0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationAxis_2e1891b8-d61f-4d2b-8abc-564ebc69a2eb" xlink:href="biib-20220331.xsd#biib_FacilityLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2403413b-be66-4711-b81a-e50f2ef6cc0d" xlink:to="loc_biib_FacilityLocationAxis_2e1891b8-d61f-4d2b-8abc-564ebc69a2eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationDomain_fb91394c-f729-4c79-8790-09d580490cdd" xlink:href="biib-20220331.xsd#biib_FacilityLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationAxis_2e1891b8-d61f-4d2b-8abc-564ebc69a2eb" xlink:to="loc_biib_FacilityLocationDomain_fb91394c-f729-4c79-8790-09d580490cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SolothurnSwitzerlandMember_e934d0f0-1e6a-43f8-b926-56074adbccbd" xlink:href="biib-20220331.xsd#biib_SolothurnSwitzerlandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationDomain_fb91394c-f729-4c79-8790-09d580490cdd" xlink:to="loc_biib_SolothurnSwitzerlandMember_e934d0f0-1e6a-43f8-b926-56074adbccbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeAxis_eedcbda0-3b87-4544-96f0-5eb3a2940315" xlink:href="biib-20220331.xsd#biib_FacilityTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2403413b-be66-4711-b81a-e50f2ef6cc0d" xlink:to="loc_biib_FacilityTypeAxis_eedcbda0-3b87-4544-96f0-5eb3a2940315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeDomain_5337ac8b-aae6-49ac-92b4-22486f91ad6a" xlink:href="biib-20220331.xsd#biib_FacilityTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityTypeAxis_eedcbda0-3b87-4544-96f0-5eb3a2940315" xlink:to="loc_biib_FacilityTypeDomain_5337ac8b-aae6-49ac-92b4-22486f91ad6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiologicsManufacturingMember_6ed5c32d-7d1e-44d8-afbe-8f477bde64d7" xlink:href="biib-20220331.xsd#biib_BiologicsManufacturingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityTypeDomain_5337ac8b-aae6-49ac-92b4-22486f91ad6a" xlink:to="loc_biib_BiologicsManufacturingMember_6ed5c32d-7d1e-44d8-afbe-8f477bde64d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WarehouseUtilitiesAndSupportSpaceMember_6d54bdee-d5dd-48ba-a3b9-f58fb2136b98" xlink:href="biib-20220331.xsd#biib_WarehouseUtilitiesAndSupportSpaceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityTypeDomain_5337ac8b-aae6-49ac-92b4-22486f91ad6a" xlink:to="loc_biib_WarehouseUtilitiesAndSupportSpaceMember_6d54bdee-d5dd-48ba-a3b9-f58fb2136b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdministrativeSpaceMember_52794670-b23f-4de1-a354-8f16ed7d99ce" xlink:href="biib-20220331.xsd#biib_AdministrativeSpaceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityTypeDomain_5337ac8b-aae6-49ac-92b4-22486f91ad6a" xlink:to="loc_biib_AdministrativeSpaceMember_52794670-b23f-4de1-a354-8f16ed7d99ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_20d54828-a830-425d-95dd-18adaf99b485" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2403413b-be66-4711-b81a-e50f2ef6cc0d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_20d54828-a830-425d-95dd-18adaf99b485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_220c24f6-b8c2-419f-b522-60fa43ba1f84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_20d54828-a830-425d-95dd-18adaf99b485" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_220c24f6-b8c2-419f-b522-60fa43ba1f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_c6e39dd4-be29-43f3-b6ae-77736abeacbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_20d54828-a830-425d-95dd-18adaf99b485" xlink:to="loc_us-gaap_Depreciation_c6e39dd4-be29-43f3-b6ae-77736abeacbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfSquareFeet_e1d7bead-a884-44e9-9654-c93ffbfccc67" xlink:href="biib-20220331.xsd#biib_NumberOfSquareFeet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_20d54828-a830-425d-95dd-18adaf99b485" xlink:to="loc_biib_NumberOfSquareFeet_e1d7bead-a884-44e9-9654-c93ffbfccc67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_c87cda7c-ad3f-4541-9643-85746e68a2ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_20d54828-a830-425d-95dd-18adaf99b485" xlink:to="loc_us-gaap_ConstructionInProgressGross_c87cda7c-ad3f-4541-9643-85746e68a2ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_c0bd248d-19de-4fd8-a181-9b10ea228434" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_20d54828-a830-425d-95dd-18adaf99b485" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_c0bd248d-19de-4fd8-a181-9b10ea228434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Indebtedness" xlink:type="simple" xlink:href="biib-20220331.xsd#Indebtedness"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Indebtedness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_418021ae-4cb7-48f1-940b-b8d867ae03e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_152dc3b1-9ed1-4511-8f79-bd8de147fee7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_418021ae-4cb7-48f1-940b-b8d867ae03e4" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_152dc3b1-9ed1-4511-8f79-bd8de147fee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#IndebtednessDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_399274b6-6894-47ea-87f8-f1a75e43b59a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_46282ab4-2eb8-4364-b787-61df8a3fb7d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_399274b6-6894-47ea-87f8-f1a75e43b59a" xlink:to="loc_us-gaap_DebtInstrumentTable_46282ab4-2eb8-4364-b787-61df8a3fb7d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b3d08360-0b0c-42c0-8290-c9f7545a162b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_46282ab4-2eb8-4364-b787-61df8a3fb7d8" xlink:to="loc_us-gaap_DebtInstrumentAxis_b3d08360-0b0c-42c0-8290-c9f7545a162b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d269a8c3-4f54-4571-80a4-f38520ad7ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_b3d08360-0b0c-42c0-8290-c9f7545a162b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d269a8c3-4f54-4571-80a4-f38520ad7ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_80c7da0f-956b-4b21-9bc6-b4ff555c56d9" xlink:href="biib-20220331.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d269a8c3-4f54-4571-80a4-f38520ad7ee5" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_80c7da0f-956b-4b21-9bc6-b4ff555c56d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3250SeniorNotesDueFebruary152051Member_4015a1b2-5c26-4aa0-819e-d0db2e84eab1" xlink:href="biib-20220331.xsd#biib_A3250SeniorNotesDueFebruary152051Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d269a8c3-4f54-4571-80a4-f38520ad7ee5" xlink:to="loc_biib_A3250SeniorNotesDueFebruary152051Member_4015a1b2-5c26-4aa0-819e-d0db2e84eab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a3f5ca94-8f20-40d4-97bf-3e5b4cf0c279" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_46282ab4-2eb8-4364-b787-61df8a3fb7d8" xlink:to="loc_us-gaap_DebtInstrumentLineItems_a3f5ca94-8f20-40d4-97bf-3e5b4cf0c279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_670c1623-5850-49ff-9503-0016a8490dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a3f5ca94-8f20-40d4-97bf-3e5b4cf0c279" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_670c1623-5850-49ff-9503-0016a8490dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DebtInstrumentRedemptionAmount_597fbfdc-484c-4966-b210-1dabc2e37de8" xlink:href="biib-20220331.xsd#biib_DebtInstrumentRedemptionAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a3f5ca94-8f20-40d4-97bf-3e5b4cf0c279" xlink:to="loc_biib_DebtInstrumentRedemptionAmount_597fbfdc-484c-4966-b210-1dabc2e37de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LongTermDebtExchangedAmount_9fbc8d95-bf9d-4ab3-9ce8-dbfe2431425d" xlink:href="biib-20220331.xsd#biib_LongTermDebtExchangedAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a3f5ca94-8f20-40d4-97bf-3e5b4cf0c279" xlink:to="loc_biib_LongTermDebtExchangedAmount_9fbc8d95-bf9d-4ab3-9ce8-dbfe2431425d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4d0cdf4d-5629-4c75-882f-091cb8d8a9c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a3f5ca94-8f20-40d4-97bf-3e5b4cf0c279" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4d0cdf4d-5629-4c75-882f-091cb8d8a9c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_796dbba3-c5e7-4fea-9e93-2712ee17ebff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a3f5ca94-8f20-40d4-97bf-3e5b4cf0c279" xlink:to="loc_us-gaap_RepaymentsOfDebt_796dbba3-c5e7-4fea-9e93-2712ee17ebff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_6de1e6cc-1ea4-485c-acb8-7f95ee65fe36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a3f5ca94-8f20-40d4-97bf-3e5b4cf0c279" xlink:to="loc_us-gaap_InterestExpense_6de1e6cc-1ea4-485c-acb8-7f95ee65fe36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:type="simple" xlink:href="biib-20220331.xsd#Equity"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_b05385c1-ccee-4ea0-8ad4-90db26329cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_dc4791bd-5448-4c23-9b47-f944f12e3a33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b05385c1-ccee-4ea0-8ad4-90db26329cf4" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_dc4791bd-5448-4c23-9b47-f944f12e3a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" xlink:href="biib-20220331.xsd#AccumulatedOtherComprehensiveIncomeLossTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_9222deac-c86a-4f97-ba03-7d7e3aa2314e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_dca4c64a-e33e-446f-aa93-a251ca4ab212" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9222deac-c86a-4f97-ba03-7d7e3aa2314e" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_dca4c64a-e33e-446f-aa93-a251ca4ab212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_deba62d7-34ed-4007-8de0-1e5aa71784b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9222deac-c86a-4f97-ba03-7d7e3aa2314e" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_deba62d7-34ed-4007-8de0-1e5aa71784b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#ShareRepurchasesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_dbae7096-b38e-4a8e-a3da-2f8c0378c45c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_10e10ceb-0f59-4e09-b671-48dfb11f0c55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_dbae7096-b38e-4a8e-a3da-2f8c0378c45c" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_10e10ceb-0f59-4e09-b671-48dfb11f0c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_0e7fe89f-055e-4a3c-ac77-aa8b98362a66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_10e10ceb-0f59-4e09-b671-48dfb11f0c55" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_0e7fe89f-055e-4a3c-ac77-aa8b98362a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_a762554e-4e92-4fc9-9c8a-d07a500374f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_0e7fe89f-055e-4a3c-ac77-aa8b98362a66" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_a762554e-4e92-4fc9-9c8a-d07a500374f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2020ShareRepurchaseProgramMember_f71692d2-5b36-454f-9160-2bf333d70127" xlink:href="biib-20220331.xsd#biib_A2020ShareRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_a762554e-4e92-4fc9-9c8a-d07a500374f7" xlink:to="loc_biib_A2020ShareRepurchaseProgramMember_f71692d2-5b36-454f-9160-2bf333d70127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_7c0fb94a-ad3b-462c-9fff-b4057ccc3069" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_10e10ceb-0f59-4e09-b671-48dfb11f0c55" xlink:to="loc_us-gaap_ClassOfStockLineItems_7c0fb94a-ad3b-462c-9fff-b4057ccc3069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_c7714aeb-ec28-4f12-af29-2364b393280c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7c0fb94a-ad3b-462c-9fff-b4057ccc3069" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_c7714aeb-ec28-4f12-af29-2364b393280c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_292a1d76-1bc0-47ec-8f9d-ca2a99445701" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7c0fb94a-ad3b-462c-9fff-b4057ccc3069" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_292a1d76-1bc0-47ec-8f9d-ca2a99445701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d0198b5b-e440-4e8d-a8ce-355dbd26805e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7c0fb94a-ad3b-462c-9fff-b4057ccc3069" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d0198b5b-e440-4e8d-a8ce-355dbd26805e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_ffe92c07-fd71-4728-ad13-cf0d3ea98e09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7c0fb94a-ad3b-462c-9fff-b4057ccc3069" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_ffe92c07-fd71-4728-ad13-cf0d3ea98e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#AccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_16fe7c38-715c-4adc-888d-bc788d942770" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_6bc25427-a975-4ee7-b737-70c930205e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_16fe7c38-715c-4adc-888d-bc788d942770" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_6bc25427-a975-4ee7-b737-70c930205e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_975a2098-9ccd-4617-a583-b07c98eb2704" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_6bc25427-a975-4ee7-b737-70c930205e1f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_975a2098-9ccd-4617-a583-b07c98eb2704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2fa803cf-229b-44e8-aefe-12545fc6606f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_975a2098-9ccd-4617-a583-b07c98eb2704" xlink:to="loc_us-gaap_EquityComponentDomain_2fa803cf-229b-44e8-aefe-12545fc6606f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_c33197e8-c1ed-478f-9358-cd2e326de668" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2fa803cf-229b-44e8-aefe-12545fc6606f" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_c33197e8-c1ed-478f-9358-cd2e326de668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_eaefe4a5-0055-4e68-9a5e-3a7dca4c18dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2fa803cf-229b-44e8-aefe-12545fc6606f" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_eaefe4a5-0055-4e68-9a5e-3a7dca4c18dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_7789a95a-9588-4f29-9986-a588a6646c51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2fa803cf-229b-44e8-aefe-12545fc6606f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_7789a95a-9588-4f29-9986-a588a6646c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_b7d3252c-7d99-4945-b804-a45075bfad26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2fa803cf-229b-44e8-aefe-12545fc6606f" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_b7d3252c-7d99-4945-b804-a45075bfad26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_dd809f26-eb66-4ebf-a3ff-58b731a8a0a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2fa803cf-229b-44e8-aefe-12545fc6606f" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_dd809f26-eb66-4ebf-a3ff-58b731a8a0a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1ab367f2-a8c7-45cb-b35e-9032be860225" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_6bc25427-a975-4ee7-b737-70c930205e1f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1ab367f2-a8c7-45cb-b35e-9032be860225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_464fe35b-c335-4960-bee6-0c4bc3267f85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1ab367f2-a8c7-45cb-b35e-9032be860225" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_464fe35b-c335-4960-bee6-0c4bc3267f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8713c404-afdc-4ace-9a33-6d15f1cdc6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1ab367f2-a8c7-45cb-b35e-9032be860225" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8713c404-afdc-4ace-9a33-6d15f1cdc6a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8bfd8e96-5bce-4ab8-8d38-16e729c28af9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1ab367f2-a8c7-45cb-b35e-9032be860225" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8bfd8e96-5bce-4ab8-8d38-16e729c28af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_c135b650-0927-4acc-92cd-60ef766c45d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1ab367f2-a8c7-45cb-b35e-9032be860225" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_c135b650-0927-4acc-92cd-60ef766c45d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5e9b09d5-89db-421b-a64e-1bb6ac80a0d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1ab367f2-a8c7-45cb-b35e-9032be860225" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5e9b09d5-89db-421b-a64e-1bb6ac80a0d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b46ca415-30a2-4371-8518-7d40ac4a6589" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1ab367f2-a8c7-45cb-b35e-9032be860225" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b46ca415-30a2-4371-8518-7d40ac4a6589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_39a9f235-2c2e-4204-9d90-c5a8da5da04b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1ab367f2-a8c7-45cb-b35e-9032be860225" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_39a9f235-2c2e-4204-9d90-c5a8da5da04b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_b5ed7db7-987d-4211-acf9-0dd104fd2203" xlink:href="biib-20220331.xsd#biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_bb8f8b30-607d-4369-9120-0d8524316a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_b5ed7db7-987d-4211-acf9-0dd104fd2203" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_bb8f8b30-607d-4369-9120-0d8524316a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_315f8434-59bd-457b-bbd3-79fabdd3e765" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_bb8f8b30-607d-4369-9120-0d8524316a4b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_315f8434-59bd-457b-bbd3-79fabdd3e765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f4ea72a7-529d-424f-ad78-a1e41d659e47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_315f8434-59bd-457b-bbd3-79fabdd3e765" xlink:to="loc_us-gaap_EquityComponentDomain_f4ea72a7-529d-424f-ad78-a1e41d659e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_0c54d29d-5d9b-410d-8b4a-51309e5ba302" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f4ea72a7-529d-424f-ad78-a1e41d659e47" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_0c54d29d-5d9b-410d-8b4a-51309e5ba302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_d70e4df8-7c20-4d04-a2da-092035701491" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f4ea72a7-529d-424f-ad78-a1e41d659e47" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_d70e4df8-7c20-4d04-a2da-092035701491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_b79bc330-ab07-43c8-b88f-ad9dac468760" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f4ea72a7-529d-424f-ad78-a1e41d659e47" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_b79bc330-ab07-43c8-b88f-ad9dac468760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_ddea83e7-74ca-4121-a88b-079ae9b8e7fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_bb8f8b30-607d-4369-9120-0d8524316a4b" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_ddea83e7-74ca-4121-a88b-079ae9b8e7fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_91032093-8802-434f-b97d-d0015ed5c290" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_ddea83e7-74ca-4121-a88b-079ae9b8e7fa" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_91032093-8802-434f-b97d-d0015ed5c290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_191dd198-e3ba-47b9-9899-8c701d3f0443" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_91032093-8802-434f-b97d-d0015ed5c290" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_191dd198-e3ba-47b9-9899-8c701d3f0443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_33c5c9ff-d5c9-46e6-a302-b5b3a5b5fcb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_bb8f8b30-607d-4369-9120-0d8524316a4b" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_33c5c9ff-d5c9-46e6-a302-b5b3a5b5fcb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_550ac514-9f3a-4ec3-a5c2-e7b4287e0cfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_33c5c9ff-d5c9-46e6-a302-b5b3a5b5fcb7" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_550ac514-9f3a-4ec3-a5c2-e7b4287e0cfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f79ec281-3382-41e1-97f6-50d819c90481" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_33c5c9ff-d5c9-46e6-a302-b5b3a5b5fcb7" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f79ec281-3382-41e1-97f6-50d819c90481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_b338febd-fa0f-4098-9b7d-97cbb3d8c568" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_33c5c9ff-d5c9-46e6-a302-b5b3a5b5fcb7" xlink:to="loc_us-gaap_Revenues_b338febd-fa0f-4098-9b7d-97cbb3d8c568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_55d959d8-2ce8-44b1-a491-89a94a94ef02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_33c5c9ff-d5c9-46e6-a302-b5b3a5b5fcb7" xlink:to="loc_us-gaap_OperatingExpenses_55d959d8-2ce8-44b1-a491-89a94a94ef02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e1255b90-b89f-4f32-84fc-57d3234942a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_33c5c9ff-d5c9-46e6-a302-b5b3a5b5fcb7" xlink:to="loc_us-gaap_NetIncomeLoss_e1255b90-b89f-4f32-84fc-57d3234942a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShare" xlink:type="simple" xlink:href="biib-20220331.xsd#EarningsperShare"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1c9b81d8-96c0-4a13-90a1-a2d3e8c3a858" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_158bbca1-c53b-46d6-821f-99f2380eb312" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1c9b81d8-96c0-4a13-90a1-a2d3e8c3a858" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_158bbca1-c53b-46d6-821f-99f2380eb312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareTables" xlink:type="simple" xlink:href="biib-20220331.xsd#EarningsperShareTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5ca2fe1f-22f2-4592-a34f-d0b476c19553" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_d59cccce-cf7a-4cd8-af9a-eeaef038a1d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5ca2fe1f-22f2-4592-a34f-d0b476c19553" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_d59cccce-cf7a-4cd8-af9a-eeaef038a1d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#EarningsperShareDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0fbe29bd-f98a-423a-84e5-c95b55e9be8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a57d2bc2-2421-4525-9f55-e8d7258b3207" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0fbe29bd-f98a-423a-84e5-c95b55e9be8a" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a57d2bc2-2421-4525-9f55-e8d7258b3207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ecc555f6-3959-4398-946f-ea988936ba74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a57d2bc2-2421-4525-9f55-e8d7258b3207" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ecc555f6-3959-4398-946f-ea988936ba74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6956e831-5109-4e20-bf4d-56288cd0b875" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ecc555f6-3959-4398-946f-ea988936ba74" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6956e831-5109-4e20-bf4d-56288cd0b875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_a20decfe-d156-4421-a01f-347fcd4d7479" xlink:href="biib-20220331.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6956e831-5109-4e20-bf4d-56288cd0b875" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_a20decfe-d156-4421-a01f-347fcd4d7479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_ba76a378-20d0-47dc-836f-d73f8884c480" xlink:href="biib-20220331.xsd#biib_MarketStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6956e831-5109-4e20-bf4d-56288cd0b875" xlink:to="loc_biib_MarketStockUnitsMember_ba76a378-20d0-47dc-836f-d73f8884c480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_05313ff2-06f1-4851-9454-9b474d205350" xlink:href="biib-20220331.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6956e831-5109-4e20-bf4d-56288cd0b875" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_05313ff2-06f1-4851-9454-9b474d205350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d752351c-8463-43a2-984d-41b83eb6fc76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a57d2bc2-2421-4525-9f55-e8d7258b3207" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d752351c-8463-43a2-984d-41b83eb6fc76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_d2432d76-4152-4c05-bb04-5e3c41378d24" xlink:href="biib-20220331.xsd#biib_BasicAndDilutedEarningsPerShareAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d752351c-8463-43a2-984d-41b83eb6fc76" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_d2432d76-4152-4c05-bb04-5e3c41378d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_cd2b45c9-6974-4510-a5e6-4a1d6fdf06ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_d2432d76-4152-4c05-bb04-5e3c41378d24" xlink:to="loc_us-gaap_NetIncomeLossAbstract_cd2b45c9-6974-4510-a5e6-4a1d6fdf06ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_79307d15-bc3f-435e-9d0b-ecb7f0fb911a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_cd2b45c9-6974-4510-a5e6-4a1d6fdf06ad" xlink:to="loc_us-gaap_NetIncomeLoss_79307d15-bc3f-435e-9d0b-ecb7f0fb911a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_74a1b9a8-6cda-4bcd-b012-87f505affddf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_d2432d76-4152-4c05-bb04-5e3c41378d24" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_74a1b9a8-6cda-4bcd-b012-87f505affddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_deb35423-4e8c-4435-9a7c-ea8376a58479" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_74a1b9a8-6cda-4bcd-b012-87f505affddf" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_deb35423-4e8c-4435-9a7c-ea8376a58479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_95b7c1b0-e869-46d5-a977-2572a630540c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_74a1b9a8-6cda-4bcd-b012-87f505affddf" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_95b7c1b0-e869-46d5-a977-2572a630540c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_909efb4e-823a-45cf-93c2-7ea6ce12753f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_95b7c1b0-e869-46d5-a977-2572a630540c" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_909efb4e-823a-45cf-93c2-7ea6ce12753f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_c2878fe2-5b02-4c3b-9f41-162dd3b4b4fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_95b7c1b0-e869-46d5-a977-2572a630540c" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_c2878fe2-5b02-4c3b-9f41-162dd3b4b4fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_82c44e68-039a-45fa-b4a9-30b824854e38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_74a1b9a8-6cda-4bcd-b012-87f505affddf" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_82c44e68-039a-45fa-b4a9-30b824854e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SharebasedPayments" xlink:type="simple" xlink:href="biib-20220331.xsd#SharebasedPayments"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SharebasedPayments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2e560d44-3678-4c82-9119-fdd36a98865f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a3476a83-9893-4da4-b6c2-804e62345d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2e560d44-3678-4c82-9119-fdd36a98865f" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a3476a83-9893-4da4-b6c2-804e62345d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="simple" xlink:href="biib-20220331.xsd#ShareBasedPaymentsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b8fa1beb-ac48-4b87-8912-f8279b5af2f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_d2b59b94-d91a-4a54-aa86-2039d8514c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b8fa1beb-ac48-4b87-8912-f8279b5af2f7" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_d2b59b94-d91a-4a54-aa86-2039d8514c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_9f433872-32ac-4bb1-8d98-e188136b058f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b8fa1beb-ac48-4b87-8912-f8279b5af2f7" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_9f433872-32ac-4bb1-8d98-e188136b058f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#ShareBasedPaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2b9cfa0d-7c05-4961-9596-1704c3591efb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c376a45d-2027-4a37-9f44-5d6d9fa842e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2b9cfa0d-7c05-4961-9596-1704c3591efb" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c376a45d-2027-4a37-9f44-5d6d9fa842e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_43d8091d-6864-4228-a29a-5606110b69b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c376a45d-2027-4a37-9f44-5d6d9fa842e2" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_43d8091d-6864-4228-a29a-5606110b69b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6e42b39c-e60b-4436-8ae5-9f0b6275f7d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_43d8091d-6864-4228-a29a-5606110b69b4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6e42b39c-e60b-4436-8ae5-9f0b6275f7d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ea88abc5-0fca-4a1b-8551-be95339afd66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6e42b39c-e60b-4436-8ae5-9f0b6275f7d7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ea88abc5-0fca-4a1b-8551-be95339afd66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6ecfb7c0-65be-4ddc-8a08-1fbae5b25d50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6e42b39c-e60b-4436-8ae5-9f0b6275f7d7" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6ecfb7c0-65be-4ddc-8a08-1fbae5b25d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_3185936b-eae0-43fd-96a7-ccd2569ba676" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6e42b39c-e60b-4436-8ae5-9f0b6275f7d7" xlink:to="loc_us-gaap_ParentMember_3185936b-eae0-43fd-96a7-ccd2569ba676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c3a2681d-5baa-4acd-8923-22aa40f5d860" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c376a45d-2027-4a37-9f44-5d6d9fa842e2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c3a2681d-5baa-4acd-8923-22aa40f5d860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_feaee58b-25ec-43bc-8bb6-d68ed8aea573" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c3a2681d-5baa-4acd-8923-22aa40f5d860" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_feaee58b-25ec-43bc-8bb6-d68ed8aea573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a5f1a09a-0bc0-4ce1-bbf9-0440f59bbc0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_feaee58b-25ec-43bc-8bb6-d68ed8aea573" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a5f1a09a-0bc0-4ce1-bbf9-0440f59bbc0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_36b00769-7ebe-46d0-8b44-3adf5d762e82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_feaee58b-25ec-43bc-8bb6-d68ed8aea573" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_36b00769-7ebe-46d0-8b44-3adf5d762e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_482ca445-9ac2-4ff1-b806-5ff5cb299a37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_feaee58b-25ec-43bc-8bb6-d68ed8aea573" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_482ca445-9ac2-4ff1-b806-5ff5cb299a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_16da0448-0b67-400d-b534-eb6184976168" xlink:href="biib-20220331.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_feaee58b-25ec-43bc-8bb6-d68ed8aea573" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_16da0448-0b67-400d-b534-eb6184976168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_5e435a59-a6c8-4d77-93c2-888c1f8dd6cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_feaee58b-25ec-43bc-8bb6-d68ed8aea573" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_5e435a59-a6c8-4d77-93c2-888c1f8dd6cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="simple" xlink:href="biib-20220331.xsd#ShareBasedPaymentsDetails1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dc42fa6d-25fc-4d86-91ce-762e26cf2da0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4480210b-1753-41ff-8228-31cb964a72a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dc42fa6d-25fc-4d86-91ce-762e26cf2da0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4480210b-1753-41ff-8228-31cb964a72a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_856ccfed-44f2-40a5-8d51-b22863234a91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4480210b-1753-41ff-8228-31cb964a72a7" xlink:to="loc_us-gaap_AwardTypeAxis_856ccfed-44f2-40a5-8d51-b22863234a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a9343bbd-4769-4606-9352-f000b7a4eda0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_856ccfed-44f2-40a5-8d51-b22863234a91" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a9343bbd-4769-4606-9352-f000b7a4eda0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_6dc6067d-5ac4-4bf3-9961-85af221f4404" xlink:href="biib-20220331.xsd#biib_MarketStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a9343bbd-4769-4606-9352-f000b7a4eda0" xlink:to="loc_biib_MarketStockUnitsMember_6dc6067d-5ac4-4bf3-9961-85af221f4404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_b0a06e88-20c8-4d43-86f6-058a9b8ecfd8" xlink:href="biib-20220331.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a9343bbd-4769-4606-9352-f000b7a4eda0" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_b0a06e88-20c8-4d43-86f6-058a9b8ecfd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_1b5ffa4d-e4e8-4007-aed3-a5779570d4bc" xlink:href="biib-20220331.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a9343bbd-4769-4606-9352-f000b7a4eda0" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_1b5ffa4d-e4e8-4007-aed3-a5779570d4bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_b4aa20d4-0dd9-429f-9db3-2b291e3aa5d9" xlink:href="biib-20220331.xsd#biib_PerformanceStockUnitsSettledinCashMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a9343bbd-4769-4606-9352-f000b7a4eda0" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_b4aa20d4-0dd9-429f-9db3-2b291e3aa5d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_21cb0557-3a53-4272-a331-db3b844379a5" xlink:href="biib-20220331.xsd#biib_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a9343bbd-4769-4606-9352-f000b7a4eda0" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_21cb0557-3a53-4272-a331-db3b844379a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3a6fc156-6bb7-4ac3-ad9b-725256610472" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4480210b-1753-41ff-8228-31cb964a72a7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3a6fc156-6bb7-4ac3-ad9b-725256610472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_59f0247a-bc1c-4f18-a99b-30df946d57d1" xlink:href="biib-20220331.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3a6fc156-6bb7-4ac3-ad9b-725256610472" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_59f0247a-bc1c-4f18-a99b-30df946d57d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_c00256b5-b226-4621-af7d-95013587c5fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_59f0247a-bc1c-4f18-a99b-30df946d57d1" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_c00256b5-b226-4621-af7d-95013587c5fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_a3fc0a1d-ad50-4508-aa72-6b3804428318" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_59f0247a-bc1c-4f18-a99b-30df946d57d1" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_a3fc0a1d-ad50-4508-aa72-6b3804428318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_5814beff-2af8-45ee-89ec-634a616737a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_59f0247a-bc1c-4f18-a99b-30df946d57d1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_5814beff-2af8-45ee-89ec-634a616737a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_f8d08f5d-d93b-4aee-ae04-d188a525a684" xlink:href="biib-20220331.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_59f0247a-bc1c-4f18-a99b-30df946d57d1" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_f8d08f5d-d93b-4aee-ae04-d188a525a684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="simple" xlink:href="biib-20220331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0e6735b5-5038-4e63-a776-dd6ac998ce29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_443f6f1b-568f-48fb-ac59-9656ac14867d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0e6735b5-5038-4e63-a776-dd6ac998ce29" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_443f6f1b-568f-48fb-ac59-9656ac14867d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="biib-20220331.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2bc27e49-aea7-4b69-9d89-d02f33ba741a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_303cb734-6f53-4ea4-822b-f5ce39c94504" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2bc27e49-aea7-4b69-9d89-d02f33ba741a" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_303cb734-6f53-4ea4-822b-f5ce39c94504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="biib-20220331.xsd#IncomeTaxesDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_5d27c18c-117b-44b4-8578-afd8a923ae4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_26fffc01-b192-46b1-906d-44a6ed23443a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5d27c18c-117b-44b4-8578-afd8a923ae4c" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_26fffc01-b192-46b1-906d-44a6ed23443a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_85e9f359-86bf-49e6-99a0-18642472769b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_26fffc01-b192-46b1-906d-44a6ed23443a" xlink:to="loc_srt_StatementScenarioAxis_85e9f359-86bf-49e6-99a0-18642472769b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_f350bd0b-ddab-43e3-a3ad-1929485ff206" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_85e9f359-86bf-49e6-99a0-18642472769b" xlink:to="loc_srt_ScenarioUnspecifiedDomain_f350bd0b-ddab-43e3-a3ad-1929485ff206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_05a60432-c32d-43a1-ba4b-ad10f25b0093" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_f350bd0b-ddab-43e3-a3ad-1929485ff206" xlink:to="loc_srt_ScenarioForecastMember_05a60432-c32d-43a1-ba4b-ad10f25b0093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ab833f99-1a88-401f-9479-f14bee0ddd79" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_26fffc01-b192-46b1-906d-44a6ed23443a" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ab833f99-1a88-401f-9479-f14bee0ddd79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_f540139a-5ee5-4044-9967-ac8000720a35" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ab833f99-1a88-401f-9479-f14bee0ddd79" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_f540139a-5ee5-4044-9967-ac8000720a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_03896ddb-eef7-4645-91f6-1d0d9c05a32c" xlink:href="biib-20220331.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f540139a-5ee5-4044-9967-ac8000720a35" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_03896ddb-eef7-4645-91f6-1d0d9c05a32c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_e4fba51a-447c-4166-b00f-c53c3a024c56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_26fffc01-b192-46b1-906d-44a6ed23443a" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_e4fba51a-447c-4166-b00f-c53c3a024c56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_2d9e1f22-3124-44fa-962b-37dc4803bff2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_e4fba51a-447c-4166-b00f-c53c3a024c56" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_2d9e1f22-3124-44fa-962b-37dc4803bff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5b6def43-c224-4d0a-bcf3-79dc3ccc022f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_e4fba51a-447c-4166-b00f-c53c3a024c56" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5b6def43-c224-4d0a-bcf3-79dc3ccc022f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_ba314a00-733e-43ba-b94d-a53fff286026" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_e4fba51a-447c-4166-b00f-c53c3a024c56" xlink:to="loc_us-gaap_EquityMethodInvestments_ba314a00-733e-43ba-b94d-a53fff286026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_f7c78a33-5309-4cd8-a466-007135315773" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_e4fba51a-447c-4166-b00f-c53c3a024c56" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_f7c78a33-5309-4cd8-a466-007135315773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_356417f2-b20a-4a98-8379-8007ef07acba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ed46a074-4747-4a38-975f-83ef4717ee81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_356417f2-b20a-4a98-8379-8007ef07acba" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ed46a074-4747-4a38-975f-83ef4717ee81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_3d0c0cbc-6e2b-42ed-b415-40189e3ed137" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ed46a074-4747-4a38-975f-83ef4717ee81" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_3d0c0cbc-6e2b-42ed-b415-40189e3ed137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_ab9f7719-2484-407d-aebf-350def0a1183" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ed46a074-4747-4a38-975f-83ef4717ee81" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_ab9f7719-2484-407d-aebf-350def0a1183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_c70a607b-ef9e-42f8-b688-ae7b8616770c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ed46a074-4747-4a38-975f-83ef4717ee81" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_c70a607b-ef9e-42f8-b688-ae7b8616770c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_740841b6-e198-4ae8-a75a-9f29cbca8dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ed46a074-4747-4a38-975f-83ef4717ee81" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_740841b6-e198-4ae8-a75a-9f29cbca8dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_00b9660d-91c6-4811-9fcd-af4e4dd8d1f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ed46a074-4747-4a38-975f-83ef4717ee81" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_00b9660d-91c6-4811-9fcd-af4e4dd8d1f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationGILTItax_f5ad12b5-0531-4bc9-a912-69b6d6522d37" xlink:href="biib-20220331.xsd#biib_EffectiveTaxRateReconciliationGILTItax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ed46a074-4747-4a38-975f-83ef4717ee81" xlink:to="loc_biib_EffectiveTaxRateReconciliationGILTItax_f5ad12b5-0531-4bc9-a912-69b6d6522d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts_43a8cf74-4593-4a1e-99aa-07b7f2995c12" xlink:href="biib-20220331.xsd#biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ed46a074-4747-4a38-975f-83ef4717ee81" xlink:to="loc_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts_43a8cf74-4593-4a1e-99aa-07b7f2995c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_34ad7b7e-9afd-4fd5-b39e-932cc44bfdf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ed46a074-4747-4a38-975f-83ef4717ee81" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_34ad7b7e-9afd-4fd5-b39e-932cc44bfdf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ecaf6495-3e54-4a4f-99e2-4aef76278353" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ed46a074-4747-4a38-975f-83ef4717ee81" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ecaf6495-3e54-4a4f-99e2-4aef76278353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="simple" xlink:href="biib-20220331.xsd#OtherConsolidatedFinancialStatementDetail"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b1d9acfd-8034-4234-b5c4-1311ba756e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_62814ba9-7a27-4751-8a8e-b010c9dafec3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b1d9acfd-8034-4234-b5c4-1311ba756e4f" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_62814ba9-7a27-4751-8a8e-b010c9dafec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" xlink:href="biib-20220331.xsd#OtherConsolidatedFinancialStatementDetailTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a7d02d1f-08ca-4595-9919-0830fde0da7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_a7f1055b-60a3-4ef7-9cc8-3dd4b3131ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a7d02d1f-08ca-4595-9919-0830fde0da7a" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_a7f1055b-60a3-4ef7-9cc8-3dd4b3131ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock_2043008c-a747-4d8b-8f45-d8a06e4e2de6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a7d02d1f-08ca-4595-9919-0830fde0da7a" xlink:to="loc_us-gaap_GainLossOnInvestmentsTextBlock_2043008c-a747-4d8b-8f45-d8a06e4e2de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_e4831c92-e9bd-45f3-b329-ac8d7a0e3d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a7d02d1f-08ca-4595-9919-0830fde0da7a" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_e4831c92-e9bd-45f3-b329-ac8d7a0e3d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#OtherConsolidatedFinancialStatementDetailDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aa4b2a8c-a536-408e-9ee8-e21d333aa595" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_666763c9-b890-41a5-9678-20801b13349d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aa4b2a8c-a536-408e-9ee8-e21d333aa595" xlink:to="loc_us-gaap_StatementTable_666763c9-b890-41a5-9678-20801b13349d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_986261c2-baf9-4cf9-abb6-7ad34a3f18ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_666763c9-b890-41a5-9678-20801b13349d" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_986261c2-baf9-4cf9-abb6-7ad34a3f18ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_67db7b70-f751-4fe1-8c09-638a5e019570" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_986261c2-baf9-4cf9-abb6-7ad34a3f18ae" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_67db7b70-f751-4fe1-8c09-638a5e019570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_5849a3c2-1c68-4d9e-9804-3897f4cac55e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_67db7b70-f751-4fe1-8c09-638a5e019570" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_5849a3c2-1c68-4d9e-9804-3897f4cac55e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_214cda25-20ea-4299-a929-62dc3b9d1ea0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_666763c9-b890-41a5-9678-20801b13349d" xlink:to="loc_dei_LegalEntityAxis_214cda25-20ea-4299-a929-62dc3b9d1ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_7c448928-ea2c-4743-a713-97b04afcf3fa" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_214cda25-20ea-4299-a929-62dc3b9d1ea0" xlink:to="loc_dei_EntityDomain_7c448928-ea2c-4743-a713-97b04afcf3fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisSangamoDenaliAndSageMember_3d7e50af-6151-45ce-a136-3d1af26a02a5" xlink:href="biib-20220331.xsd#biib_IonisSangamoDenaliAndSageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_7c448928-ea2c-4743-a713-97b04afcf3fa" xlink:to="loc_biib_IonisSangamoDenaliAndSageMember_3d7e50af-6151-45ce-a136-3d1af26a02a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_dd96e6ee-d698-481d-9623-5aa5373b6906" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_666763c9-b890-41a5-9678-20801b13349d" xlink:to="loc_us-gaap_StatementLineItems_dd96e6ee-d698-481d-9623-5aa5373b6906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract_22a15c70-1c0d-4015-8678-0e59cfc76122" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dd96e6ee-d698-481d-9623-5aa5373b6906" xlink:to="loc_us-gaap_InterestIncomeExpenseNetAbstract_22a15c70-1c0d-4015-8678-0e59cfc76122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_e7fb7dd9-043c-40db-85c3-f6a36ec62425" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_22a15c70-1c0d-4015-8678-0e59cfc76122" xlink:to="loc_us-gaap_InvestmentIncomeInterest_e7fb7dd9-043c-40db-85c3-f6a36ec62425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_68b3b622-a12f-4392-8a79-7a6b4d19ad54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_22a15c70-1c0d-4015-8678-0e59cfc76122" xlink:to="loc_us-gaap_InterestExpense_68b3b622-a12f-4392-8a79-7a6b4d19ad54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_3d6c62da-9689-455f-9406-e75ea87532ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_22a15c70-1c0d-4015-8678-0e59cfc76122" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_3d6c62da-9689-455f-9406-e75ea87532ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_92d8efd9-8d24-4009-adb1-67cf7bfb7154" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_22a15c70-1c0d-4015-8678-0e59cfc76122" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_92d8efd9-8d24-4009-adb1-67cf7bfb7154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_a47caa0d-ab8a-4ec5-81b6-2a0b8e1e64be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_22a15c70-1c0d-4015-8678-0e59cfc76122" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_a47caa0d-ab8a-4ec5-81b6-2a0b8e1e64be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_927bc273-bdc7-462d-af71-7694d47594ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_22a15c70-1c0d-4015-8678-0e59cfc76122" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_927bc273-bdc7-462d-af71-7694d47594ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_21ceae2a-bae1-4fe2-a74d-3fdeccc17f88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dd96e6ee-d698-481d-9623-5aa5373b6906" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_21ceae2a-bae1-4fe2-a74d-3fdeccc17f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_4ac3d1b2-b55f-428f-b6f8-a8467f754df8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_21ceae2a-bae1-4fe2-a74d-3fdeccc17f88" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_4ac3d1b2-b55f-428f-b6f8-a8467f754df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_cfc5f873-0def-4468-9216-3870f30d315e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_21ceae2a-bae1-4fe2-a74d-3fdeccc17f88" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_cfc5f873-0def-4468-9216-3870f30d315e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_97487a08-dfc9-41f5-887e-94ee9f183832" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_21ceae2a-bae1-4fe2-a74d-3fdeccc17f88" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_97487a08-dfc9-41f5-887e-94ee9f183832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_eccfdee9-0f5b-4562-b17f-f1be12f1c40e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dd96e6ee-d698-481d-9623-5aa5373b6906" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_eccfdee9-0f5b-4562-b17f-f1be12f1c40e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_e6443883-67f5-40a3-8eb0-38dd6e04f0b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_eccfdee9-0f5b-4562-b17f-f1be12f1c40e" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_e6443883-67f5-40a3-8eb0-38dd6e04f0b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c5c182f0-73f3-4961-b36a-15b7b5f3c4cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_eccfdee9-0f5b-4562-b17f-f1be12f1c40e" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c5c182f0-73f3-4961-b36a-15b7b5f3c4cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_4a94cc74-c20d-4191-8e00-01e668785322" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_eccfdee9-0f5b-4562-b17f-f1be12f1c40e" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_4a94cc74-c20d-4191-8e00-01e668785322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationexpensesaccrual_6cdc531c-2510-467c-a471-a3e544f5ddab" xlink:href="biib-20220331.xsd#biib_Collaborationexpensesaccrual"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_eccfdee9-0f5b-4562-b17f-f1be12f1c40e" xlink:to="loc_biib_Collaborationexpensesaccrual_6cdc531c-2510-467c-a471-a3e544f5ddab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0c12b158-bef7-42b6-8a3d-fe5e31e8e079" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_eccfdee9-0f5b-4562-b17f-f1be12f1c40e" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0c12b158-bef7-42b6-8a3d-fe5e31e8e079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_ae92c127-70f6-42bc-ace5-268c202c4dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_eccfdee9-0f5b-4562-b17f-f1be12f1c40e" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_ae92c127-70f6-42bc-ace5-268c202c4dd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" xlink:href="biib-20220331.xsd#OtherConsolidatedFinancialStatementDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e51d89d2-e4e4-4a70-93ff-9b716bf2a29f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_04a07a34-ecac-47be-8d94-7ffb12933be8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e51d89d2-e4e4-4a70-93ff-9b716bf2a29f" xlink:to="loc_us-gaap_StatementTable_04a07a34-ecac-47be-8d94-7ffb12933be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_2279c40d-797a-4c79-b608-da2f43d8a0b9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_04a07a34-ecac-47be-8d94-7ffb12933be8" xlink:to="loc_dei_LegalEntityAxis_2279c40d-797a-4c79-b608-da2f43d8a0b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b77dfc26-2859-4321-babf-bdca759af2f1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2279c40d-797a-4c79-b608-da2f43d8a0b9" xlink:to="loc_dei_EntityDomain_b77dfc26-2859-4321-babf-bdca759af2f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisSangamoDenaliAndSageMember_d0130dca-f8ad-4257-b486-c510dc4597a5" xlink:href="biib-20220331.xsd#biib_IonisSangamoDenaliAndSageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b77dfc26-2859-4321-babf-bdca759af2f1" xlink:to="loc_biib_IonisSangamoDenaliAndSageMember_d0130dca-f8ad-4257-b486-c510dc4597a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_aa9af5f8-0221-4188-b12b-eef2db4d1b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_04a07a34-ecac-47be-8d94-7ffb12933be8" xlink:to="loc_us-gaap_StatementLineItems_aa9af5f8-0221-4188-b12b-eef2db4d1b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_1a3cc504-ebd6-4a1b-9dd9-00bc61bb53b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_aa9af5f8-0221-4188-b12b-eef2db4d1b7e" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_1a3cc504-ebd6-4a1b-9dd9-00bc61bb53b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_a572580b-0c50-44b3-920e-2f263220f43e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_aa9af5f8-0221-4188-b12b-eef2db4d1b7e" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_a572580b-0c50-44b3-920e-2f263220f43e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_2ffaf865-1e68-4104-b6e2-c3f31f85ba64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_aa9af5f8-0221-4188-b12b-eef2db4d1b7e" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_2ffaf865-1e68-4104-b6e2-c3f31f85ba64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_7cdd7a9c-da32-4ff1-ba66-3f702b5f86c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_aa9af5f8-0221-4188-b12b-eef2db4d1b7e" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_7cdd7a9c-da32-4ff1-ba66-3f702b5f86c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationships" xlink:type="simple" xlink:href="biib-20220331.xsd#CollaborativeandOtherRelationships"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationships" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_48da0520-632c-4a09-8ced-a7299e3ccbf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_613f2a7e-88c1-47dc-a617-7fda86035727" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_48da0520-632c-4a09-8ced-a7299e3ccbf9" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_613f2a7e-88c1-47dc-a617-7fda86035727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables" xlink:type="simple" xlink:href="biib-20220331.xsd#CollaborativeandOtherRelationshipsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_20f09ef4-174a-4192-958a-baca8d2c4df6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_1c256ed5-33a5-4e8b-9e83-ec983f2086c9" xlink:href="biib-20220331.xsd#biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_20f09ef4-174a-4192-958a-baca8d2c4df6" xlink:to="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_1c256ed5-33a5-4e8b-9e83-ec983f2086c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_e02e04fa-c934-440f-b498-8263f4a7f09f" xlink:href="biib-20220331.xsd#biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_20f09ef4-174a-4192-958a-baca8d2c4df6" xlink:to="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_e02e04fa-c934-440f-b498-8263f4a7f09f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock_23c9b3d9-e132-40c9-a9ad-713651496c0e" xlink:href="biib-20220331.xsd#biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_20f09ef4-174a-4192-958a-baca8d2c4df6" xlink:to="loc_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock_23c9b3d9-e132-40c9-a9ad-713651496c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#CollaborativeandOtherRelationshipsCollaborationsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3f29a724-a542-461a-acab-53ccdae04136" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_51a3f0ff-86a8-4b8c-a6b6-df20a95d3a65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3f29a724-a542-461a-acab-53ccdae04136" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_51a3f0ff-86a8-4b8c-a6b6-df20a95d3a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c7161a18-5024-4a6c-8463-2954aee815a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_51a3f0ff-86a8-4b8c-a6b6-df20a95d3a65" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c7161a18-5024-4a6c-8463-2954aee815a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b58a74c9-c549-49f9-8ae0-41cbfb317bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c7161a18-5024-4a6c-8463-2954aee815a9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b58a74c9-c549-49f9-8ae0-41cbfb317bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1dec8c8e-81fc-47c0-92fb-3cd40eb5dfe8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b58a74c9-c549-49f9-8ae0-41cbfb317bc4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1dec8c8e-81fc-47c0-92fb-3cd40eb5dfe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_42560054-b002-48a3-8431-21dbbf75a72f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b58a74c9-c549-49f9-8ae0-41cbfb317bc4" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_42560054-b002-48a3-8431-21dbbf75a72f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_fd853147-fedb-4311-b8fb-5c1fd54965c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_51a3f0ff-86a8-4b8c-a6b6-df20a95d3a65" xlink:to="loc_us-gaap_TypeOfArrangementAxis_fd853147-fedb-4311-b8fb-5c1fd54965c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6567381-dbe7-4d5c-b68a-e78e7ce2717a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fd853147-fedb-4311-b8fb-5c1fd54965c8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6567381-dbe7-4d5c-b68a-e78e7ce2717a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_5c163d2f-bf83-4d83-9f8d-82a3c3378c93" xlink:href="biib-20220331.xsd#biib_EisaiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6567381-dbe7-4d5c-b68a-e78e7ce2717a" xlink:to="loc_biib_EisaiMember_5c163d2f-bf83-4d83-9f8d-82a3c3378c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_8d8c370d-cd87-4893-9262-e4441b5d79ce" xlink:href="biib-20220331.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6567381-dbe7-4d5c-b68a-e78e7ce2717a" xlink:to="loc_biib_DenaliTherapeuticsIncMember_8d8c370d-cd87-4893-9262-e4441b5d79ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_133d7d26-308d-4b17-a3dc-e9a65c7e10fc" xlink:href="biib-20220331.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_2393570e-ba23-41c6-b340-e9e54deff53f" xlink:href="biib-20220331.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6567381-dbe7-4d5c-b68a-e78e7ce2717a" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_2393570e-ba23-41c6-b340-e9e54deff53f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember_3f840bf0-3f6c-4077-af45-e5157c4a38b3" xlink:href="biib-20220331.xsd#biib_SageTherapeuticsIncMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6567381-dbe7-4d5c-b68a-e78e7ce2717a" xlink:to="loc_biib_SageTherapeuticsIncMember_3f840bf0-3f6c-4077-af45-e5157c4a38b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UCBPharmaS.A.Member_550e077a-c811-4cb9-8ec2-9ba0658176e4" xlink:href="biib-20220331.xsd#biib_UCBPharmaS.A.Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6567381-dbe7-4d5c-b68a-e78e7ce2717a" xlink:to="loc_biib_UCBPharmaS.A.Member_550e077a-c811-4cb9-8ec2-9ba0658176e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoTherapeuticsInc.AgreementMember_6e82675e-1d39-4b18-b5af-3a26c9a9e65d" xlink:href="biib-20220331.xsd#biib_SangamoTherapeuticsInc.AgreementMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6567381-dbe7-4d5c-b68a-e78e7ce2717a" xlink:to="loc_biib_SangamoTherapeuticsInc.AgreementMember_6e82675e-1d39-4b18-b5af-3a26c9a9e65d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherresearchanddiscoveryMember_4f074646-b87c-4f3e-8dfc-2f311e140e9e" xlink:href="biib-20220331.xsd#biib_OtherresearchanddiscoveryMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6567381-dbe7-4d5c-b68a-e78e7ce2717a" xlink:to="loc_biib_OtherresearchanddiscoveryMember_4f074646-b87c-4f3e-8dfc-2f311e140e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InnoCarePharmaLimitedInnoCareAgreementMember_32c00f96-9c80-43a4-9939-7dbcf9fa6434" xlink:href="biib-20220331.xsd#biib_InnoCarePharmaLimitedInnoCareAgreementMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6567381-dbe7-4d5c-b68a-e78e7ce2717a" xlink:to="loc_biib_InnoCarePharmaLimitedInnoCareAgreementMember_32c00f96-9c80-43a4-9939-7dbcf9fa6434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_199bc63f-7eb8-4fc2-a0bc-78a10290fef7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_51a3f0ff-86a8-4b8c-a6b6-df20a95d3a65" xlink:to="loc_srt_ProductOrServiceAxis_199bc63f-7eb8-4fc2-a0bc-78a10290fef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_54368295-e17b-47f4-9441-2cf11966eb53" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_199bc63f-7eb8-4fc2-a0bc-78a10290fef7" xlink:to="loc_srt_ProductsAndServicesDomain_54368295-e17b-47f4-9441-2cf11966eb53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_E2609andBAN2401Member_eeb18212-1e1e-4298-845c-59222b3c8aa5" xlink:href="biib-20220331.xsd#biib_E2609andBAN2401Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_54368295-e17b-47f4-9441-2cf11966eb53" xlink:to="loc_biib_E2609andBAN2401Member_eeb18212-1e1e-4298-845c-59222b3c8aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_c7e83bb1-c693-467f-9f62-2ca04442dc58" xlink:href="biib-20220331.xsd#biib_ADUHELMMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_54368295-e17b-47f4-9441-2cf11966eb53" xlink:to="loc_biib_ADUHELMMember_c7e83bb1-c693-467f-9f62-2ca04442dc58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3ceb9989-616a-47ce-ba15-d0c8bc0d1f4d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_51a3f0ff-86a8-4b8c-a6b6-df20a95d3a65" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3ceb9989-616a-47ce-ba15-d0c8bc0d1f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_085bc3df-7548-4ee3-9fb2-dc257cf1be9e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3ceb9989-616a-47ce-ba15-d0c8bc0d1f4d" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_085bc3df-7548-4ee3-9fb2-dc257cf1be9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_9fa9aeb8-0a2f-411e-a208-f67665dc9ee1" xlink:href="biib-20220331.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_085bc3df-7548-4ee3-9fb2-dc257cf1be9e" xlink:to="loc_biib_DenaliTherapeuticsIncMember_9fa9aeb8-0a2f-411e-a208-f67665dc9ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoTherapeuticsInc.AgreementMember_2d6784fa-6eb0-4887-bbff-afd34b770e8c" xlink:href="biib-20220331.xsd#biib_SangamoTherapeuticsInc.AgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_085bc3df-7548-4ee3-9fb2-dc257cf1be9e" xlink:to="loc_biib_SangamoTherapeuticsInc.AgreementMember_2d6784fa-6eb0-4887-bbff-afd34b770e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_88257ba1-0e70-4a28-bf0e-9023068f3b58" xlink:href="biib-20220331.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_085bc3df-7548-4ee3-9fb2-dc257cf1be9e" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_88257ba1-0e70-4a28-bf0e-9023068f3b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_86821177-22b6-4b6f-ad84-0b7437bf3e52" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_51a3f0ff-86a8-4b8c-a6b6-df20a95d3a65" xlink:to="loc_srt_RangeAxis_86821177-22b6-4b6f-ad84-0b7437bf3e52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2df8ef7c-225b-4fe5-9ca7-3993085277b0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_86821177-22b6-4b6f-ad84-0b7437bf3e52" xlink:to="loc_srt_RangeMember_2df8ef7c-225b-4fe5-9ca7-3993085277b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c2e3f15b-b9e2-4823-b281-6fcfb3034ad9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2df8ef7c-225b-4fe5-9ca7-3993085277b0" xlink:to="loc_srt_MaximumMember_c2e3f15b-b9e2-4823-b281-6fcfb3034ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_8e6e045c-fa1d-4004-bdf7-353667a9bc21" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_51a3f0ff-86a8-4b8c-a6b6-df20a95d3a65" xlink:to="loc_srt_StatementScenarioAxis_8e6e045c-fa1d-4004-bdf7-353667a9bc21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_65af413e-681b-4c08-a9b8-302e89e61b01" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_8e6e045c-fa1d-4004-bdf7-353667a9bc21" xlink:to="loc_srt_ScenarioUnspecifiedDomain_65af413e-681b-4c08-a9b8-302e89e61b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_196ac21a-8cae-4123-8f36-3724931ab702" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_65af413e-681b-4c08-a9b8-302e89e61b01" xlink:to="loc_srt_ScenarioForecastMember_196ac21a-8cae-4123-8f36-3724931ab702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63b94ba1-f7ca-4987-b373-39fcf291fec0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_51a3f0ff-86a8-4b8c-a6b6-df20a95d3a65" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63b94ba1-f7ca-4987-b373-39fcf291fec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpenseIncurredByCollaboration_f3d108bf-0424-40b5-8372-623f8ca07469" xlink:href="biib-20220331.xsd#biib_ExpenseIncurredByCollaboration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63b94ba1-f7ca-4987-b373-39fcf291fec0" xlink:to="loc_biib_ExpenseIncurredByCollaboration_f3d108bf-0424-40b5-8372-623f8ca07469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_ccccd986-3057-4409-b02a-7e84b607827e" xlink:href="biib-20220331.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63b94ba1-f7ca-4987-b373-39fcf291fec0" xlink:to="loc_biib_Expenseincurredbythecollaboration_ccccd986-3057-4409-b02a-7e84b607827e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_ce35af90-8059-4f40-bc75-5b83b9fcfe86" xlink:href="biib-20220331.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63b94ba1-f7ca-4987-b373-39fcf291fec0" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_ce35af90-8059-4f40-bc75-5b83b9fcfe86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_56f0a51b-8a65-4169-b1ee-accb0df8c400" xlink:href="biib-20220331.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63b94ba1-f7ca-4987-b373-39fcf291fec0" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_56f0a51b-8a65-4169-b1ee-accb0df8c400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_49a2bba3-b16e-456c-9813-75fcf8f0383e" xlink:href="biib-20220331.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63b94ba1-f7ca-4987-b373-39fcf291fec0" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_49a2bba3-b16e-456c-9813-75fcf8f0383e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationAgreementTerm_47754542-69c1-45b2-81f2-9a263b393805" xlink:href="biib-20220331.xsd#biib_CollaborationAgreementTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63b94ba1-f7ca-4987-b373-39fcf291fec0" xlink:to="loc_biib_CollaborationAgreementTerm_47754542-69c1-45b2-81f2-9a263b393805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e8a273b6-0391-4969-815d-6201e58d9c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63b94ba1-f7ca-4987-b373-39fcf291fec0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e8a273b6-0391-4969-815d-6201e58d9c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Termofcollaborationagreement_1eef6b7f-20f4-4ab6-94c8-30f22e35bb90" xlink:href="biib-20220331.xsd#biib_Termofcollaborationagreement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63b94ba1-f7ca-4987-b373-39fcf291fec0" xlink:to="loc_biib_Termofcollaborationagreement_1eef6b7f-20f4-4ab6-94c8-30f22e35bb90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContingentMilestonePaymentsMadeToCollaborativePartner_f1c10218-1673-465b-ad18-aa29201e35ef" xlink:href="biib-20220331.xsd#biib_ContingentMilestonePaymentsMadeToCollaborativePartner"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63b94ba1-f7ca-4987-b373-39fcf291fec0" xlink:to="loc_biib_ContingentMilestonePaymentsMadeToCollaborativePartner_f1c10218-1673-465b-ad18-aa29201e35ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment_c68f9643-0ee0-4560-bf94-9ece5522f983" xlink:href="biib-20220331.xsd#biib_AdditionalMilestonePayment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63b94ba1-f7ca-4987-b373-39fcf291fec0" xlink:to="loc_biib_AdditionalMilestonePayment_c68f9643-0ee0-4560-bf94-9ece5522f983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_58d413ca-ebec-4de2-8894-1e5ee2263c88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63b94ba1-f7ca-4987-b373-39fcf291fec0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_58d413ca-ebec-4de2-8894-1e5ee2263c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_e58f84ba-8d85-42d4-b0d9-15d60d3ac9f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63b94ba1-f7ca-4987-b373-39fcf291fec0" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_e58f84ba-8d85-42d4-b0d9-15d60d3ac9f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CostOfGoodsSoldCapacityCharges_9609b7f8-4895-46ff-930d-bfa09285677b" xlink:href="biib-20220331.xsd#biib_CostOfGoodsSoldCapacityCharges"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63b94ba1-f7ca-4987-b373-39fcf291fec0" xlink:to="loc_biib_CostOfGoodsSoldCapacityCharges_9609b7f8-4895-46ff-930d-bfa09285677b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_6a564342-552f-4900-98d1-11838c8d3e96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63b94ba1-f7ca-4987-b373-39fcf291fec0" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_6a564342-552f-4900-98d1-11838c8d3e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_a0a1fd32-dafe-4b53-978b-f14ef01da0c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63b94ba1-f7ca-4987-b373-39fcf291fec0" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_a0a1fd32-dafe-4b53-978b-f14ef01da0c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_767c601e-897e-4a00-9156-e9cb144116c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63b94ba1-f7ca-4987-b373-39fcf291fec0" xlink:to="loc_us-gaap_AdjustmentForAmortization_767c601e-897e-4a00-9156-e9cb144116c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedParties_aba756c3-18c8-4daa-83ee-236548506936" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedParties"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63b94ba1-f7ca-4987-b373-39fcf291fec0" xlink:to="loc_us-gaap_DueFromRelatedParties_aba756c3-18c8-4daa-83ee-236548506936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_a7a07724-d8a4-454a-bc4b-1d620c4e159a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_63b94ba1-f7ca-4987-b373-39fcf291fec0" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_a7a07724-d8a4-454a-bc4b-1d620c4e159a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8b19b477-a422-4a4e-865d-9fb286214439" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5d96b9af-2f14-4366-a3d1-6dcfe9e9a654" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8b19b477-a422-4a4e-865d-9fb286214439" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5d96b9af-2f14-4366-a3d1-6dcfe9e9a654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_92593066-0cc3-4ad5-b3ab-580fcf60f8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5d96b9af-2f14-4366-a3d1-6dcfe9e9a654" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_92593066-0cc3-4ad5-b3ab-580fcf60f8e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5af33a89-5229-4be2-bf3e-ea4b5edf0ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_92593066-0cc3-4ad5-b3ab-580fcf60f8e4" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5af33a89-5229-4be2-bf3e-ea4b5edf0ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_dcbb7e5f-9bab-4434-b817-5c2a94d7c33d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5af33a89-5229-4be2-bf3e-ea4b5edf0ee5" xlink:to="loc_us-gaap_InventoriesMember_dcbb7e5f-9bab-4434-b817-5c2a94d7c33d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_e7672c1e-9742-481e-a96e-cc7fba1e55f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5af33a89-5229-4be2-bf3e-ea4b5edf0ee5" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_e7672c1e-9742-481e-a96e-cc7fba1e55f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f3f101f9-5189-408c-b5ed-5bdfa0769070" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5d96b9af-2f14-4366-a3d1-6dcfe9e9a654" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f3f101f9-5189-408c-b5ed-5bdfa0769070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_28408e40-dc92-4a13-8516-6a584549fac2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f3f101f9-5189-408c-b5ed-5bdfa0769070" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_28408e40-dc92-4a13-8516-6a584549fac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_ea865eda-b25f-49f2-bf9d-4f2d2f10b855" xlink:href="biib-20220331.xsd#biib_EisaiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_28408e40-dc92-4a13-8516-6a584549fac2" xlink:to="loc_biib_EisaiMember_ea865eda-b25f-49f2-bf9d-4f2d2f10b855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_a6185e93-0356-460f-841d-51f688354f43" xlink:href="biib-20220331.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_28408e40-dc92-4a13-8516-6a584549fac2" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_a6185e93-0356-460f-841d-51f688354f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6342efba-1717-4be1-894b-766486dc47b8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5d96b9af-2f14-4366-a3d1-6dcfe9e9a654" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6342efba-1717-4be1-894b-766486dc47b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_113c0590-1ac3-4bd4-af84-834b111e30e8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6342efba-1717-4be1-894b-766486dc47b8" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_113c0590-1ac3-4bd4-af84-834b111e30e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_7b837dd8-522e-4068-8cc6-35f3e395a2e2" xlink:href="biib-20220331.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_113c0590-1ac3-4bd4-af84-834b111e30e8" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_7b837dd8-522e-4068-8cc6-35f3e395a2e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0f32e4c4-43d9-4943-b8c4-81da47424631" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5d96b9af-2f14-4366-a3d1-6dcfe9e9a654" xlink:to="loc_srt_ProductOrServiceAxis_0f32e4c4-43d9-4943-b8c4-81da47424631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_87d689e3-323f-439b-9bf0-ef42e1e7e3b6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0f32e4c4-43d9-4943-b8c4-81da47424631" xlink:to="loc_srt_ProductsAndServicesDomain_87d689e3-323f-439b-9bf0-ef42e1e7e3b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_e8a5eaf7-0a2b-456e-9761-0f70b9dd2f54" xlink:href="biib-20220331.xsd#biib_ADUHELMMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_87d689e3-323f-439b-9bf0-ef42e1e7e3b6" xlink:to="loc_biib_ADUHELMMember_e8a5eaf7-0a2b-456e-9761-0f70b9dd2f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_18802e2f-0477-4b9f-93ff-39d59768c933" xlink:href="biib-20220331.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5d96b9af-2f14-4366-a3d1-6dcfe9e9a654" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_18802e2f-0477-4b9f-93ff-39d59768c933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_97e06a79-2e35-47d2-87a9-97db4b7633f5" xlink:href="biib-20220331.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_18802e2f-0477-4b9f-93ff-39d59768c933" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_97e06a79-2e35-47d2-87a9-97db4b7633f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentDueAtFirstAnniversaryMember_30955cfd-ba06-4bbe-897b-c14d9fefd1e9" xlink:href="biib-20220331.xsd#biib_PaymentDueAtFirstAnniversaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_97e06a79-2e35-47d2-87a9-97db4b7633f5" xlink:to="loc_biib_PaymentDueAtFirstAnniversaryMember_30955cfd-ba06-4bbe-897b-c14d9fefd1e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentDueAtSecondAnniversaryMember_429e3266-f1bc-4f9a-9a62-3216d586c7fd" xlink:href="biib-20220331.xsd#biib_PaymentDueAtSecondAnniversaryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_97e06a79-2e35-47d2-87a9-97db4b7633f5" xlink:to="loc_biib_PaymentDueAtSecondAnniversaryMember_429e3266-f1bc-4f9a-9a62-3216d586c7fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2bcaf592-ff8d-46b4-969f-ae7efe494014" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5d96b9af-2f14-4366-a3d1-6dcfe9e9a654" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2bcaf592-ff8d-46b4-969f-ae7efe494014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_db347ba4-81f4-49e2-8ee6-af2f838aa2fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2bcaf592-ff8d-46b4-969f-ae7efe494014" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_db347ba4-81f4-49e2-8ee6-af2f838aa2fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_8fc19ae7-7af1-47a5-9313-d90596978756" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2bcaf592-ff8d-46b4-969f-ae7efe494014" xlink:to="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_8fc19ae7-7af1-47a5-9313-d90596978756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_e7759d83-32ed-4ff3-82cf-95dde287dae7" xlink:href="biib-20220331.xsd#biib_Equitymethodinvestmentbasisdifferenceamortizationperiod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2bcaf592-ff8d-46b4-969f-ae7efe494014" xlink:to="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_e7759d83-32ed-4ff3-82cf-95dde287dae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_c30f6cb1-1f70-4da8-9d21-84e5a8de5386" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2bcaf592-ff8d-46b4-969f-ae7efe494014" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_c30f6cb1-1f70-4da8-9d21-84e5a8de5386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_81cd29c4-c2d3-4c37-aa31-b23a1b56b66a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2bcaf592-ff8d-46b4-969f-ae7efe494014" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_81cd29c4-c2d3-4c37-aa31-b23a1b56b66a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_119fb189-0b3b-4598-833f-dc0cb8bda4c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfInterestInJointVenture"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2bcaf592-ff8d-46b4-969f-ae7efe494014" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_119fb189-0b3b-4598-833f-dc0cb8bda4c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_ca507693-30bf-409a-b972-54b00e2089c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2bcaf592-ff8d-46b4-969f-ae7efe494014" xlink:to="loc_us-gaap_EquityMethodInvestments_ca507693-30bf-409a-b972-54b00e2089c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PayablesToDivestitureOfInterestInJointVenture_69363e69-3ea0-4478-97ba-244a59d70012" xlink:href="biib-20220331.xsd#biib_PayablesToDivestitureOfInterestInJointVenture"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2bcaf592-ff8d-46b4-969f-ae7efe494014" xlink:to="loc_biib_PayablesToDivestitureOfInterestInJointVenture_69363e69-3ea0-4478-97ba-244a59d70012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare_dbee44f5-ee60-45f0-9117-83a231ada69e" xlink:href="biib-20220331.xsd#biib_EquityMethodInvestmentsExpectedProfitShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2bcaf592-ff8d-46b4-969f-ae7efe494014" xlink:to="loc_biib_EquityMethodInvestmentsExpectedProfitShare_dbee44f5-ee60-45f0-9117-83a231ada69e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_6cf9740d-f701-4eb3-be67-f1d22e5f8a7f" xlink:href="biib-20220331.xsd#biib_Collaborationprofitlosssharing"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2bcaf592-ff8d-46b4-969f-ae7efe494014" xlink:to="loc_biib_Collaborationprofitlosssharing_6cf9740d-f701-4eb3-be67-f1d22e5f8a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_23a3132d-b4be-484e-954e-0f214acd3b00" xlink:href="biib-20220331.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2bcaf592-ff8d-46b4-969f-ae7efe494014" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_23a3132d-b4be-484e-954e-0f214acd3b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b16972c0-975e-4d00-a72a-dc827771a83b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2bcaf592-ff8d-46b4-969f-ae7efe494014" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b16972c0-975e-4d00-a72a-dc827771a83b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_24c783f1-784f-405e-92f6-22c67b31f924" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2bcaf592-ff8d-46b4-969f-ae7efe494014" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_24c783f1-784f-405e-92f6-22c67b31f924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccruedMilestonePayments_3e6fabe5-0174-4a1e-8016-d5a1cbbde04b" xlink:href="biib-20220331.xsd#biib_AccruedMilestonePayments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2bcaf592-ff8d-46b4-969f-ae7efe494014" xlink:to="loc_biib_AccruedMilestonePayments_3e6fabe5-0174-4a1e-8016-d5a1cbbde04b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_c253331d-c2fc-4788-a44e-f15c1b4f70cd" xlink:href="biib-20220331.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2bcaf592-ff8d-46b4-969f-ae7efe494014" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_c253331d-c2fc-4788-a44e-f15c1b4f70cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractOptionExerciseFee_014d815a-7b43-45a7-9140-9d660aa592a1" xlink:href="biib-20220331.xsd#biib_ContractOptionExerciseFee"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2bcaf592-ff8d-46b4-969f-ae7efe494014" xlink:to="loc_biib_ContractOptionExerciseFee_014d815a-7b43-45a7-9140-9d660aa592a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_0cdfff9f-43ca-4652-8905-4b8f699c771a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2bcaf592-ff8d-46b4-969f-ae7efe494014" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_0cdfff9f-43ca-4652-8905-4b8f699c771a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities" xlink:type="simple" xlink:href="biib-20220331.xsd#InvestmentsinVariableInterestEntities"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_bb407c2e-3b7d-4038-abec-c53e8a6a3236" xlink:href="biib-20220331.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_8898b185-17f5-48c8-a117-74165c7584c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_bb407c2e-3b7d-4038-abec-c53e8a6a3236" xlink:to="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_8898b185-17f5-48c8-a117-74165c7584c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#InvestmentsinVariableInterestEntitiesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_689dda55-b993-415b-b495-908ec6386262" xlink:href="biib-20220331.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_504e858e-2dc3-4e17-a47a-34cacba17ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_689dda55-b993-415b-b495-908ec6386262" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_504e858e-2dc3-4e17-a47a-34cacba17ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_cdbe744f-7c4a-4949-9aa8-7225d3943887" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_504e858e-2dc3-4e17-a47a-34cacba17ec5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_cdbe744f-7c4a-4949-9aa8-7225d3943887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_012a9fb1-293c-4896-ac44-d5bab465b7c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_cdbe744f-7c4a-4949-9aa8-7225d3943887" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_012a9fb1-293c-4896-ac44-d5bab465b7c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_31aea951-9ba3-4c3b-8793-7b2c767777dc" xlink:href="biib-20220331.xsd#biib_EisaiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_012a9fb1-293c-4896-ac44-d5bab465b7c9" xlink:to="loc_biib_EisaiMember_31aea951-9ba3-4c3b-8793-7b2c767777dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_f21c78b2-e7c9-4e0e-88bf-a5e31b4f3445" xlink:href="biib-20220331.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_504e858e-2dc3-4e17-a47a-34cacba17ec5" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_f21c78b2-e7c9-4e0e-88bf-a5e31b4f3445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_d8af50b3-0830-4403-9a8c-3d73bef0b976" xlink:href="biib-20220331.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_f21c78b2-e7c9-4e0e-88bf-a5e31b4f3445" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_d8af50b3-0830-4403-9a8c-3d73bef0b976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RegulatoryMilestonesMember_fd52f6b1-b001-4feb-a910-0b1f422c4352" xlink:href="biib-20220331.xsd#biib_RegulatoryMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_d8af50b3-0830-4403-9a8c-3d73bef0b976" xlink:to="loc_biib_RegulatoryMilestonesMember_fd52f6b1-b001-4feb-a910-0b1f422c4352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_17419de1-253d-4ca4-838d-d4d6a2850d5d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_504e858e-2dc3-4e17-a47a-34cacba17ec5" xlink:to="loc_srt_ConsolidatedEntitiesAxis_17419de1-253d-4ca4-838d-d4d6a2850d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_5d907c7a-808f-4348-a8e0-dc4aabf6d6f8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_17419de1-253d-4ca4-838d-d4d6a2850d5d" xlink:to="loc_srt_ConsolidatedEntitiesDomain_5d907c7a-808f-4348-a8e0-dc4aabf6d6f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NeurimmuneMember_41242b3e-9a39-460e-9912-ab3d1ada6a0b" xlink:href="biib-20220331.xsd#biib_NeurimmuneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_5d907c7a-808f-4348-a8e0-dc4aabf6d6f8" xlink:to="loc_biib_NeurimmuneMember_41242b3e-9a39-460e-9912-ab3d1ada6a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9f4f2c50-c6d1-49e6-b750-4fd2cafb22f7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_504e858e-2dc3-4e17-a47a-34cacba17ec5" xlink:to="loc_srt_ProductOrServiceAxis_9f4f2c50-c6d1-49e6-b750-4fd2cafb22f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9bc112c7-f27f-4506-b619-1eb2322a858f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9f4f2c50-c6d1-49e6-b750-4fd2cafb22f7" xlink:to="loc_srt_ProductsAndServicesDomain_9bc112c7-f27f-4506-b619-1eb2322a858f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_5375bb9a-2983-4cc1-b920-1190edf5b36a" xlink:href="biib-20220331.xsd#biib_ADUHELMMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9bc112c7-f27f-4506-b619-1eb2322a858f" xlink:to="loc_biib_ADUHELMMember_5375bb9a-2983-4cc1-b920-1190edf5b36a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_1c196c0e-c880-45ec-b14a-4b447120f3ac" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_504e858e-2dc3-4e17-a47a-34cacba17ec5" xlink:to="loc_srt_StatementGeographicalAxis_1c196c0e-c880-45ec-b14a-4b447120f3ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7fcf7080-7457-4df5-9085-15dd4412a2dd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_1c196c0e-c880-45ec-b14a-4b447120f3ac" xlink:to="loc_srt_SegmentGeographicalDomain_7fcf7080-7457-4df5-9085-15dd4412a2dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_2350debe-334d-419a-8b12-551dcf0b19e5" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7fcf7080-7457-4df5-9085-15dd4412a2dd" xlink:to="loc_country_JP_2350debe-334d-419a-8b12-551dcf0b19e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_058f36dc-96b0-4e5b-a4a6-d88263bfd577" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_504e858e-2dc3-4e17-a47a-34cacba17ec5" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_058f36dc-96b0-4e5b-a4a6-d88263bfd577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationAgreementTerm_3b393615-ab9e-4910-a6db-4f932984ea26" xlink:href="biib-20220331.xsd#biib_CollaborationAgreementTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_058f36dc-96b0-4e5b-a4a6-d88263bfd577" xlink:to="loc_biib_CollaborationAgreementTerm_3b393615-ab9e-4910-a6db-4f932984ea26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentCostsPercentage_09a31c1e-01f8-4c40-95a1-4518c336ee57" xlink:href="biib-20220331.xsd#biib_ResearchAndDevelopmentCostsPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_058f36dc-96b0-4e5b-a4a6-d88263bfd577" xlink:to="loc_biib_ResearchAndDevelopmentCostsPercentage_09a31c1e-01f8-4c40-95a1-4518c336ee57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_e43c523b-8bed-4b59-9b98-6f4eaf4179e0" xlink:href="biib-20220331.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_058f36dc-96b0-4e5b-a4a6-d88263bfd577" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_e43c523b-8bed-4b59-9b98-6f4eaf4179e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_75e81eda-2b46-4959-afbd-d47812db1d89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_058f36dc-96b0-4e5b-a4a6-d88263bfd577" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_75e81eda-2b46-4959-afbd-d47812db1d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_5d906546-e194-4a6e-8c90-c495b172d45c" xlink:href="biib-20220331.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_058f36dc-96b0-4e5b-a4a6-d88263bfd577" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_5d906546-e194-4a6e-8c90-c495b172d45c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment_e99f7b5c-fd4c-45bc-86a9-bcab3589732f" xlink:href="biib-20220331.xsd#biib_AdditionalMilestonePayment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_058f36dc-96b0-4e5b-a4a6-d88263bfd577" xlink:to="loc_biib_AdditionalMilestonePayment_e99f7b5c-fd4c-45bc-86a9-bcab3589732f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_57cabbcd-ec18-4f4d-b70c-5854781f2e23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_058f36dc-96b0-4e5b-a4a6-d88263bfd577" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_57cabbcd-ec18-4f4d-b70c-5854781f2e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_ea5f6601-c60f-478b-928d-6ddd175a8cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_058f36dc-96b0-4e5b-a4a6-d88263bfd577" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_ea5f6601-c60f-478b-928d-6ddd175a8cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_9bee3af4-01d3-47b1-acc4-de3f6d71fb98" xlink:href="biib-20220331.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_058f36dc-96b0-4e5b-a4a6-d88263bfd577" xlink:to="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_9bee3af4-01d3-47b1-acc4-de3f6d71fb98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:type="simple" xlink:href="biib-20220331.xsd#Litigation"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_6928fd69-e2a4-4c39-ab80-d725d4a221c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_34545ac3-219f-463b-a3c8-f91dacffe934" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_6928fd69-e2a4-4c39-ab80-d725d4a221c4" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_34545ac3-219f-463b-a3c8-f91dacffe934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationDetails" xlink:type="simple" xlink:href="biib-20220331.xsd#LitigationDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/LitigationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_bc7b89f8-6819-4c5a-99de-8e3e7f3f3a64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_b72c1d83-b0f9-41a6-9758-3ce87670c47e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_bc7b89f8-6819-4c5a-99de-8e3e7f3f3a64" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_b72c1d83-b0f9-41a6-9758-3ce87670c47e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SubsequentEvents" xlink:type="simple" xlink:href="biib-20220331.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_9546ab7b-a677-440a-b803-ea9d9aa8f878" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_6d359c45-3791-4871-bf5a-f727a53292d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_9546ab7b-a677-440a-b803-ea9d9aa8f878" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_6d359c45-3791-4871-bf5a-f727a53292d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>biib-20220331_g1.jpg
<TEXT>
begin 644 biib-20220331_g1.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M4D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0
M86-S<$U31E0     245#('-21T(                  /;6  $     TRU(
M4" @
M       18W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP
M=    @0    4<EA96@   A@    49UA96@   BP    48EA96@   D     4
M9&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0
M   D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P
M!#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG
M:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M    $G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV
M-BTR+C$
M             %A96B        #S40 !     1;,6%E:(
M      !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:
M6%E:(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
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M"58 4    %<?YVUE87,          0                        */
M G-I9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M
M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H
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M# P,# P,_\  $0@!(@-H P$B  (1 0,1 ?_$ !\   $% 0$! 0$!
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M5AT8'D&OVK@O.98W!>RJN\Z=D_-='^C]+]3VJ=^6S)****^R- HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MFCV):***_3"3Y1_X+6?\H]O%7_7[I_\ Z5Q5^(-?M]_P6L_Y1[>*O^OW3_\
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M8?#Z;PYXRTF.^MV!:VND 6[T^3_GI#)@E&X&>H8<,""17X/?M9?LSZU^R/\
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M#^IV>L:/J"E[:\M)1+#. Q4E6'!PP(^H-<>,CCE!?6E/EO\ :YK7^?4ZL)+
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MDAAC2&*,;51!A5'L*DK]3R;):6 IZ:S>[_1=E^9E*5PHHHKVR0HHHH ^4?\
M@M9_RCV\5?\ 7[I__I7%7X@U^WW_  6L_P"4>WBK_K]T_P#]*XJ_$&OW[PO_
M .13/_KY+_TF)^%^)/\ R-8_X%^<@HHHK]&/S\_>3_@D]_RCU^&G_7E<?^E<
M]?1%?.__  2>_P"4>OPT_P"O*X_]*YZ^B*_E#/?^1EB/^OD__2F?U!D?_(NP
M_P#@A_Z2@HHHKRCU HHHH *_/;_@X8UR"#X#^ =-9O\ 2KO7Y;F,>J16[*WZ
MS)^=?H37XJ_\%J/VH[7]H#]J9="T>Y6ZT+X?POIB2(VY)KQF!NG4^@*QQ^YA
M)R017VWA_@:F(SFG4BO=IWDW\FE][:_$^-X[QL*&43A+>=HI?--_<D_P/CVB
MBBOZ./Y]"OWP_P""7?A*3P7^P'\,;.2/RFFTHWX7&,K<S27"GKW$H/X]NE?A
MK\%_A7J7QP^+/AWPCI*EM0\17\5C$<9$>]@&<_[*KEB>P4U_1IX0\+6?@7PG
MI>B:;'Y.GZ/:16-K'_<BB0(@_!5%?DOBICHJA0PG5MR^25E]]W]Q^I^&.#DZ
MU;%O9)1^;=W]UE]YI5\[_P#!6'_E'K\2_P#KRM__ $K@KZ(KYW_X*P_\H]?B
M7_UY6_\ Z5P5^5Y#_P C/#_]?(?^E(_3<[_Y%V(_P3_])9^#=%%%?U<?R^%?
MO)_P2>_Y1Z_#3_KRN/\ TKGK\&Z_>3_@D]_RCU^&G_7E<?\ I7/7YEXI_P#(
MMI?]?%_Z3(_1O#/_ )&-3_ __2HGT11117X0?MP51\1>(]/\(:#=ZIJM]:Z;
MINGQ-/<W5S*(H;>-1DLS,0%4#N:9XK\5:;X&\,W^LZQ>V^FZ5I<#W-W=3OLC
MMXD!+.Q[  &OQ-_X*2_\%+-;_;-\7S:-HLUYI'PYTV4BTL-Q1]493Q<7('4\
M JAR$'JV2?IN&>&<1G%?DA[L(_%+MY+NWV^\^=XCXDH930YY^].7PQ[^;[)=
MSZ'_ &V_^"Z\[75WX=^"\*1PIF*3Q/?6^YG/K:P., ?[<H.<GY!@,?SK^(?Q
M-\1_%GQ)-K'BC7-5\0:I-]^ZU"Z>XDQZ L3A1V P .F*PZ*_H/)^'L#EE/DP
ML+/K)ZR?J_T6GD?@N;9]C<RJ<^*G==(K2*]%^N_F%%%%>V>.%%%% %K1-<OO
M#.K6^H:;>76GWUJXD@N;:5HIH6'1E92"I]P:^Y/V-/\ @N%XS^%%W9Z+\3EF
M\;>&\B/^T1@:M9KD<EN%N !GA\.<_?XQ7PC17EYIDN#S&E[+%P4NSZKT>Z/2
MRW.,7@*GM<+-Q?5='ZK9G](GPA^,GAGX]> [/Q-X1UBSUS1;X?N[BW;[K#&4
M=3\R.,\JP##N*ZBOY^_V)/VW_%7[$OQ.CUC19'OM$O&5-7T:20K;ZC%Z]]DJ
M\[9 ,@\'*EE/[G_L_P#Q[\-_M,?"K3/&'A2]^V:3J:?=8 36L@^_#*N3MD0\
M$9QT()!!/\_<5\)5LGJ<\?>I2VEV\I>?Y_>E^[<+\54<VI\LO=JQWCW\UY?E
M]S?:T445\@?6!3)95@B:21E1$!9F8X"@=233Z_+?_@L[_P %'[R]U_4/@YX'
MU!K>PLP8/%-_ V'NI>]DC#HBCB3!^9B4. KA_:R'(Z^:XM86AIU;Z)=_\EU9
MX^>9U0RS"O$UM>B75OM_F^B.J_;O_P""X=OX/O[WPK\&Q::E?0DQ7'B:X02V
ML3#@BUC/$I!_Y:/\G'"N"&K\U?BC\8O%7QM\32:QXN\0:MXBU*0G]_?7+2E
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M,<7SN?QZ#]:]8HKUL)P=@Z;O6;F_N7W+7\2>=F/X9\#:9X23_0[95DQ@RO\
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MQ]@,U^D?_!/#_@BI>IK&G^-/C):10V]NXN+/PLQ$C3,.5:\(RH4<'R@23T?
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M^?X*RZ'\RYSFM7,<7+%5>NR[+HOE^=V%%%?6W_!);]@:+]L#XMW&M>)+=Y/
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MP_:XT_\ 8Q_9YU3Q9.L5SJTQ^PZ+9N3B[O'!*9QSL0!G;I\J$9!(KV:OQ/\
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M_P#E^!_-'XM\(ZKX!\2WNC:WI]YI.K:;*8;JTNXC%- XZJRMR#_C6?7[;_\
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M=O'%OXB\&ZY?:'JEN1EX'_=SK_<EC.5D0_W7!'Y U^;Y]X<X;%MUL+-QJ/\
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M#V(!K^<WXI?#V^^$OQ+\0>%]2&-0\.ZC/IMQQ@,\4C(2/8[<CV(K^DZOP_\
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MFOY)S'"_5L75P_\ )*4?N;1_4V7XGZQA:>(_FBG]Z3/P;_X*O_\ *0GXE_\
M7[;_ /I)!7SO7T1_P5?_ .4A/Q+_ .OVW_\ 22"OG>OZBR'_ )%F'_Z]P_\
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M4E_:6(U?\2?_ *4S^GLDIQ>78?3[$/\ TE&7_P (3HO_ $"-+_\  5/\*/\
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M^(F1QQ>7O%P7OTM?6/5?+?Y/N?>< YU+"X]863]RKIZ2Z/Y[?-=C];J^=_\
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M['Q__/B?_@,O\CPNBO=/^'9WQZ_Z)?XG_P"_2?\ Q5'_  [.^/7_ $2_Q/\
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M M]_Z M?M57\^^)G_(W7^"/YL_=O#C_D4O\ QR_)!1117YZ??!1110 4444
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MMG.8I+AWCQ[!2 /85Q-?UU@5-8:FJGQ<JOZVU/Y5QKB\1-PVYG;TOH%>S?\
M!.OQC-X%_;G^%=] TBO-XBM=..WKMNG^S-^!64Y]L]>E>,UZ!^R38R:G^U7\
M,K:$A9;CQ9I42$G #&\B Y^IK/,X*>$JPELXR3^YE9;-PQ=*<=U*+_%']%E?
M._\ P5A_Y1Z_$O\ Z\K?_P!*X*^B*^=_^"L/_*/7XE_]>5O_ .E<%?R_D/\
MR,\/_P!?(?\ I2/Z4SO_ )%V(_P3_P#26?@W1117]7'\OA7[R?\ !)[_ )1Z
M_#3_ *\KC_TKGK\&Z_>3_@D]_P H]?AI_P!>5Q_Z5SU^9>*?_(MI?]?%_P"D
MR/T;PS_Y&-3_  /_ -*B?1%?SR_MP>&&\'?MC_%'3V4JL7BC4'C!SGRWN'=/
M_'66OZ&J_$W_ (+=?#!_A_\ MWZMJ2Q[;;Q?IEIJT6!\N0GV9Q]=UN6/^^/4
M5\IX78I0S&I1?VH:>J:_1L^H\2L.YY?3K+[,OP:?ZI'R+1117[P?B)],_P#!
M'KQ*OAK_ (*&^ 3)M$5\;VS8GJ"]E.$QR.2X4=^"?:OW3K^<?]G#XG'X+_'_
M ,%^+-S+'X>UJTOIL?QQ)*ID7_@2;A^-?T:6]Q'>01S0R)+%*H='1MRNIY!!
M'4&OPWQ4PSCCJ.(Z2A;YQ;?_ +<C]I\,L0I8*K0ZQE?Y227_ +:R2BBBORT_
M2PHHHH *_'O_ (. /$":C^U[X=T^,JW]F^%8/,]0[W5RV#_P'8?^!5^PE?@W
M_P %6_B@OQ5_;U^(%U#)OM=)NTT:$9SM^RQK#(!_VU64_C7Z)X9X=U,V=7I"
M#?WM+]6? >(V(4,K5/K*27W7?^1\[T445_0!^%%K0M&F\1:Y9Z?;C=/?3I;Q
M#&<L[!1^I%?TN65G'IUE#;PKMAMT6.-<D[5 P!GKTK\ ?^"=OPU;XL?MO?#/
M2%C,D::W#J$RXX,5KFY<'V*Q$?C7] E?B?BMB%*OA\.OLJ3^]I+_ -)9^Q>&
M.':H5Z_=Q7W)O_VY&5XV\:Z3\.?".I:]KE];Z9H^DV[W5Y=3MB."-1DD_P"
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M4>OPT_Z\KC_TKGK\R\4_^1;2_P"OB_\ 29'Z-X9_\C&I_@?_ *5$^B*^ O\
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M'Y?C'A]YM@'2I_Q(OFCZ]5\U^-CZ3A//EE>.52I\$M)>G1_)_A<_H2HKSO\
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M\!?:W_ :_G-UG1[KP]K%UI]["]O>6,SV\\3_ 'HI$8JRGW!!'X5_3)7XO_\
M!;/]E5O@?^T^_C#3[<KX?^(N^_RH^6&_7'VE#_OEEER>IE?'W37Z9X7YM&EB
M:F7U'\>L?5;KYK7Y'YSXE96ZF'ACH+X-)>CV?R>GS/C.BBBOW _&3]3?^" ?
M[3-MJ/@GQ%\*M0N8X]0TVX;6=(5VPT\$@59XU]=CA7QU_>L>@X_1^OYM/A-\
M5-=^"/Q'T?Q9X;OGT_6]#N%N;:9>0"."K#HR,I*LIX96(/!K]Q/V!_\ @H;X
M4_;<\#1"*6VT?QM8Q ZIH;R?.I'!F@SS)"3SD9*9PW8M^%>(7"]6AB99G05Z
M<]96^S+JWY/>_>_D?MG 7$E*MAXY=7=IQTC?[2[+S6UNUO,^AZ***_,#]("B
MBN7^,'QF\,? /P'>>)O%VL6>BZ-8KF2:=L%V[(B_>=V[*H))Z"KITYU)*%--
MMZ)+5LBI4C"+G-V2W;V1YQ_P4*_:BM_V2_V7/$7B1;E(=<NHCINAQG[TM[*I
M"$#TC :0].(R.I%?BOX._;H^,G@(*NE_$_QQ#'']V*75YKB%>O1)&91U/;T]
M!75?\%#?V[M6_;D^+::@89M,\*:('M]#TUVRT2,1NFEQQYTF%SCA0JJ,X+-X
M!7]#\'\)T\#@.7&04JD]9)I.W9?+KYMGX'Q9Q14QN.YL)-QA#2+3:OW?SZ>2
M1]5>#O\ @M+^T%X5=?M'BO3]<BCQB/4-'MB"/0M$B.<^[9Y^E>K>!O\ @X'^
M)44L-OJ_@7P?K4C,L:BQ-S:22DX ZO*-Q/H,9/ K\_Z^JO\ @D!^RQ-^T=^U
MIIFI7EL9/#7@1DUK4'9,QR3*V;: ]LM(NXJ>"D4@KJSK(<BH86IBL1AX)13>
MBY;]E[MM6]$<V3YYG5?$PPM"O)N32U?-ZO6^B6I^VGAR]N]2\/:?<7]HMA?7
M%M')<6JR>8+:0J"\8? W;6)&<#..@Z5>HHK^;).[N?T/'169^#?_  5?_P"4
MA/Q+_P"OVW_])(*^=Z^B/^"K_P#RD)^)?_7[;_\ I)!7SO7]6Y#_ ,BS#_\
M7N'_ *2C^8,[_P"1C7_QS_\ 2F%?='_!OQ_R>7XF_P"Q+NO_ $NL*^%Z^Z/^
M#?C_ )/+\3?]B7=?^EUA7G\8_P#(EQ'^']4=W"?_ ".,/_B/V$HHHK^83^D@
MHHHH *_"[_@L;_RD>^(W_<,_]-=I7[HU^%W_  6-_P"4CWQ&_P"X9_Z:[2OT
MKPM_Y&M3_KV__2H'YWXF?\BNG_U\7_I,SYDHHHK]Z/P\^PO^"&O_ "?KI_\
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MU6V$5W=IS;Z;&<%K>WSR>0-TAY; P%'!^KJ_ >.>+EF4_J>$?[J+U?\ ,_\
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MU=;+JG<^KZ***^=/H HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\.>'4;@KIFFPV:G\(U%1B/%7"I?N:$F_-I?ES%4/#'$M_OJ\4O)-_G8_$O\
M9Y_X),?&K]H*YMY1X7F\):/*P+ZCX@#62A3SE82/.?(Y!";3Q\PSFOTH_8N_
MX)%_#O\ 92N+76]27_A-O&5N1(FI7\(6WLG'>W@R54CC#N68$9!7.*^L**^$
MSKCK,\QBZ5_9P?2/7U>[_!/L?;9/P3EV DJMN>:ZRZ>BV7XOS"BBBOC3ZX*X
M7]I'X\Z/^S+\$?$/C?7&W66AVQE6%6P]U,2%BA7_ &G<JN>@SD\ UW5?G/\
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M47!RW<_-%?TV5^)G_!9[]F;2/V>?VL5O/#]K#8:-XTL!JRVD*;(K6XWM',J
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MBA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *@O["'5+&
M:UNH8[BWN8VBEBD4,DB,,%2#P002,5/11KN@W/Q+_P""G/\ P3/U?]D7QG>>
M)O#=I<:A\-=4G+P3(I=M$=VXMINX0$X20\$$*3N^]\CU_3%JVDVFNZ9<6-]:
MV][97D30SP3QB2*=&&&1E;(92"00>"#BO@G]J_\ X(/>$_B/>W&L?##5E\%Z
MC,2[:5=J\^F2,?[C#,D.3Z;U'0*HK]HX7\1J7LXX;-7:2T4]T_\ %;5/SV?6
MQ^/\2>']55'B,L5T]7#9K_#?1KRW72Y^2=%>[?&S_@FA\;/@/-.VK> ]6U"P
M@R?M^CI_:-L5'\9,661>/^6BJ?SKPNXMY+2=HI8WCDC;:R.NUE/<$5^I87'8
M?$QY\/-37=-/\C\UQ6#KX>7)B(.+\TU^8VBBBNHY0HHHH **** "BO0O@_\
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M2/IY^?X+J4445\&?<!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
?!1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>biib-20220331_g10.jpg
<TEXT>
begin 644 biib-20220331_g10.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@#
M( )Z P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#5H=3N+F>(30"62XEC<$AU""0;1M0)7VS10 5X]^WW^QGX _X*#_ +(/C?\
M8]^)VMWVF:/XTT^&&34],"F>SG@N8KJWG4-PVR>")BIQN"E<C.1[#10!\:^*
MO^"='[:'QS_8M^+W['G[77_!1NQ^(*?$7PO!HWASQ-;_  9MM(F\/A3)Y\TT
M5O?D:@TH,/&Z *8F(SO('J7[0W[$O_"^O^"<^N_L _\ "S?[*_MKX9Q^$?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5;_Q->:1=&TU+7F9KZ]TH7LZZ=/.S$EV:T$!5R2738Q)+$G\Z?C=_P %H_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M /&:/JE#_H(A]U3_ .0#Z_BO^@2I]]+_ .6'WI17P7_PVU^TA_T4#_RE6?\
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M_P#!1[_DF^@?]AQO_1+U]%5\Z_\ !1[_ ))OH'_8<;_T2] 'Q[1110 4444
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MS:R7%M',T7//RER.>>* .LHHHH **** "BBB@ HHHH *]O\ ^"?_ /R7P_\
M8#N?_0HZ\0KV_P#X)_\ _)?#_P!@.Y_]"CH ^W:*** "BBB@ HHHH **** "
MBBB@ HHHH **** /"_\ @GO_ ,D3U;_L>]9_]*37NE>%_P#!/?\ Y(GJW_8]
MZS_Z4FO=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^=?^"CW_)-] _[#C?^
MB7KZ*KYU_P""CW_)-] _[#C?^B7H ^/:*** "BBB@ HHHH **** "BBB@ KQ
MS]JC]EGX;?M,:SX7N+[XE:SX/\=>$Y+F_P#!GB3PMJD<&I6:R*D=QM1PPE@<
M>6LBE<$8&1N.?8Z\^^.O[*O[/W[2ZZ:WQM^&EIK<^C-(VDWQN)K>ZL_,V[_*
MG@=)4#;5R P!VCTH ^/_ -A?XQ_M*? /Q[\$?V?/'_Q/TGQWX/\ BKHFLR:-
M;C18[/5?#36*239D:([;B!\%=[@-N)Y&S#[D7BK]LOP1^VA\0OCYXJ_8'\3^
M.95GD\/?#J_T[Q3IUO::=H$4A.^))9-XENG FD9@#C8@P 17M/[$'["'PA_9
M.\&6&K6GPWTJ'QU+I[6VM^(DNYKR>13(S>6DUPS,D9&S*)M4E1D'&:]\H ^$
M?^"%GQ&^(FL_ O5O NL?!+4=,T*W\2:Q?0>+9M3@>"XNGO!OLA$I\P.FYLN1
MM.PXZBOI+]IS]HNS\!?LC?$+X\?!K4='\47'AGP]?36ILKI+NV%S$AR)?+8@
MB,G<Z9!PI!QG-==\%/@1\*?V=?!C_#[X.>%?['T=]1N+YK3[=/<9N)WWROOG
M=V^9N<9P.P%5OA'^SC\%?@7X!O\ X7?##P+#8>']4OKJ\U'2[FZFO([B6Y_U
MY;[0\A*OT*9VXX  H ^#G_X)U_ N/_@G3_PTX/C1JW]O+X._X3H71N;;_A&S
MJ?D?;/)_LCROL7D>;^Z\ORMWX\5]P?L??%CQ'\=?V6O 'QA\7Z+%I^I^(_"M
MG?7UK;QE(A(\8):-3]U&^\HYPK 9/6O,A_P2+_8+%[_R2.__ +*^V_;/^$8/
MBW4O[)\[=NW?8_M'E8W<[,;>V,<5]'Z=IUAI&GP:3I5C#:VMK"L-M;6\02.*
M-0 J*HX50   . !0!-1110 4444 %%%% !1110 5[?\ \$__ /DOA_[ =S_Z
M%'7B%>W_ /!/_P#Y+X?^P'<_^A1T ?;M%%% !1110 4444 %%%% !1110 44
M44 %%%% 'A?_  3W_P"2)ZM_V/>L_P#I2:]TKPO_ ()[_P#)$]6_['O6?_2D
MU[I0 4444 %%%% !1110 4444 %%%% ".Z1H9)'"JHRS,< #UKX'\9?\'#G[
M GAS]J#3_AIHGQ:EUWX?P>$]=N?$_CKPYX"UW5+6SU6SO=,@ABBN;2UDAGMO
M+NKLRSQ^9'&Z0!I$\P!_MOXI^ K/XJ?#'Q'\,-1U*YLK?Q)H-YI<]Y9MB:!+
MB%XFD0]F4.2/<"OQV^%M[_P4M_X(Y_&_X5?"+X@_L@^&?C=X7^$GP \:V.AZ
MM\(_$PT[4[OPN-9\.SW6ISV%['B2\@:.U1K:%R9C=.X<^4Q< _4KX]?'KXVZ
M9^SYI'QH_8B_9YL/C5J&NFRNM+T.?QU#X<BN-,N(C*+Q;JY@E'"F,B,H&82=
M1M(KXY^,W_!97_@I%^S;\2OA;\-?V@/^".6CZ#=?%SQ]:>%/"JV/[2ECJ,TE
MU,PWRF&WTIF$42'>[G"J"N6&17W+^RU^T7\*_P!KC]G?P?\ M*?!&]FG\*^,
MM#AU'1C<V_DRQ1L,&*1 2$DC8-&R@D!D(!(P3\._#C_C8)_P<'>*OBA)_IG@
M#]C?P7_PC7A]C\T,OC/6$+7TR9X+0VJM;N,922&-NXR >X_M]_\ !2/QI^S'
M\</AS^QU^S-^S;/\6/C+\4;>]O=#\.3>(X]'T[3=-M%S/?WMY)')L0?-M14)
M<QN,JVP/B_LK_P#!3'XY>(OVSV_X)[?MW_LEV_PK^)&H^$)/$W@O4?#OC%-=
MT3Q+I\4GESB*80PR6\T9#$Q2*25C9B5R@?Q7_@JVGCSXM?\ !5W]G_X(_L*/
M'X<_:6\.>"]5\4?\+&UJ[7^Q-'\'32M:7%M?61@E;4O/F21(XT,+128?S &)
M7$_9[TWX^_ K_@NKX2TO_@J/XDTOX@_$GXC_  MU73O@#X[\%*+#0]*LK+-W
MJFGMI;1>9#=N@:4W33SAHV6,;<D* ?0W[3W_  4[^+^E?M4ZC^PM_P $^?V2
M7^-/Q+\,Z1:ZG\1+K4/%D.AZ%X/M[D;K:.[NY(Y#)<RI\ZV\:[MC;P3M<+[9
M^QO\5_VK_BU\.M2U/]L3]E2S^$OBG3M=>RM](TWQQ;Z_:ZG:""&1;Z&>&-/+
M5GDDC\J10ZF DY#*:_*[_@G7^S?^UO\ M8_\%%?VZ_#&D_ME>+?@YX6T7]H.
M]FU.\^'EG9IK^O3O)<1Z?%)>7<4WDV=M:P*RQH@,ANFRV$&/L;_@D7^TY^T[
MK?QY_:+_ ."=W[7/Q0C^(/BC]GGQ-HT>E?$;^S(K.XUW1M6M)+JS%U%"!&+F
M)(L.R@;MX!W%6=@#Z[^/'QM^'/[-GP7\4_'_ .+NN#3?#'@[0KG5]<O=FYH[
M>",R/M4<NY VJ@Y9B%')%? LW_!;G]L/X>?!KP_^W;^T5_P3"N_"?[-OB*YL
MI&\76OQ$AOO$.AZ3>2)'::O>Z4ENH$$GF1,8TE+QK*,[L#=VG_!S;_PD'_#C
MCXZ_\(WYGG_8M#\[ROO?9_[?TWS_ ,/*WY_V<UUG_!5@_#__ (<8?&,P?9O[
M!_X4#=_V1C'E_P#(/'V/;V^_Y.WWQ0!]?Z9J>G:WIMOK.CWT5U:7<"36MS!(
M'CFC=0RNK#@J0001U!J>O$/^"9?_  D'_#MW]GW_ (2SS/[4_P"%(>%/[2\[
M[_VC^Q[7S-WONSGWKV^@ HHHH **** "BBB@ HHHH **** "BBB@ KYU_P""
MCW_)-] _[#C?^B7KZ*KYU_X*/?\ )-] _P"PXW_HEZ /CVBBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KV_\
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M*2M:565&?-%+YI-?<TT8UZ$,33Y)MI>4I1?WQ:?XF1_PVU^TA_T4#_RE6?\
M\9H_X;:_:0_Z*!_Y2K/_ .,UY/173_:%?^6'_@NG_P#(G%_9.%_FJ?\ @VK_
M /)GK'_#;7[2'_10/_*59_\ QFC_ (;:_:0_Z*!_Y2K/_P",UY/11_:%?^6'
M_@NG_P#(A_9.%_FJ?^#:O_R9ZQ_PVU^TA_T4#_RE6?\ \9H_X;:_:0_Z*!_Y
M2K/_ .,UY/11_:%?^6'_ (+I_P#R(?V3A?YJG_@VK_\ )GK'_#;7[2'_ $4#
M_P I5G_\9H_X;:_:0_Z*!_Y2K/\ ^,UY/11_:%?^6'_@NG_\B']DX7^:I_X-
MJ_\ R9ZQ_P -M?M(?]% _P#*59__ !FC_AMK]I#_ **!_P"4JS_^,UY/11_:
M%?\ EA_X+I__ "(?V3A?YJG_ (-J_P#R9ZQ_PVU^TA_T4#_RE6?_ ,9H_P"&
MVOVD/^B@?^4JS_\ C->3T4?VA7_EA_X+I_\ R(?V3A?YJG_@VK_\F>L?\-M?
MM(?]% _\I5G_ /&:/^&VOVD/^B@?^4JS_P#C->3T4?VA7_EA_P""Z?\ \B']
MDX7^:I_X-J__ "9ZQ_PVU^TA_P!% _\ *59__&:/^&VOVD/^B@?^4JS_ /C-
M>3T4?VA7_EA_X+I__(A_9.%_FJ?^#:O_ ,F>L?\ #;7[2'_10/\ RE6?_P 9
MH_X;:_:0_P"B@?\ E*L__C->3T4?VA7_ )8?^"Z?_P B']DX7^:I_P"#:O\
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M_HE*^/:^PO\ @G#_ ,DWU_\ [#B_^B4H ^BJ*** "BBB@ KYU_X*/?\ )-]
M_P"PXW_HEZ^BJ^=?^"CW_)-] _[#C?\ HEZ /CVBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KV__ ()__P#)
M?#_V [G_ -"CKQ"O;_\ @G__ ,E\/_8#N?\ T*.@#[=HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH \+_X)[_\D3U;_L>]9_\ 2DU[I7A?_!/?_DB>K?\
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M;_L>]9_]*37NE !7Q%_P4 _Y+X/^P';?^A25]NU\1?\ !0#_ )+X/^P';?\
MH4E 'B%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !7V%_P3A_Y)OK_P#V'%_]$I7Q[7V%_P $X?\ DF^O_P#8
M<7_T2E 'T51110 4444 %?.O_!1[_DF^@?\ 8<;_ -$O7T57SK_P4>_Y)OH'
M_8<;_P!$O0!\>T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %>W_\ !/\ _P"2^'_L!W/_ *%'7B%>W_\ !/\
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M-<R3&WM+>)888S)*S.^U$4;G9F.,DDDFMFBB@#PO_@GO_P D3U;_ +'O6?\
MTI->Z5X7_P $]_\ DB>K?]CWK/\ Z4FO=* "OB+_ (* ?\E\'_8#MO\ T*2O
MMVOB+_@H!_R7P?\ 8#MO_0I* /$**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "OL+_@G#_P DWU__ +#B_P#H
ME*^/:^PO^"</_)-]?_[#B_\ HE* /HJBBB@ HHHH *^=?^"CW_)-] _[#C?^
MB7KZ*KYU_P""CW_)-] _[#C?^B7H ^/:*** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O;_ /@G_P#\E\/_ & [
MG_T*.O$*]O\ ^"?_ /R7P_\ 8#N?_0HZ /MVBBB@ HHHH **** "BBB@ HHH
MH _-KQ7\.OVS_P#@I7_P4+^/OP?;_@H)\0_@9\/O@?J6A:/X>\)_"H6]EJ6K
M27NEQWSZG=W<B,[1.SLD: %"(R!M9'+^S?LN?\$L_BS^SC\=M"^,WB;_ (*K
M_M'_ !)L=&^U>?X*\>^+8+K2=1\ZUE@'GQ) I;RVE$J8(Q)$A[8KP?\ X*>_
ML3_L]^ _VL[_ /;X^-O_  6V\>_LXZIXFTVVTK2-,TCQ58:8CV=M#$K6D*,O
MG7D7FA[@QL)%22X=@%W5UG_!,CX+^$OB#\6M-_:"^"7_  7K^)/[1&@^&&G7
M6_!%[XJTZ]L93/:S0Q"\AA02Q%6<3)N"Y>%3R : /T+HHHH \+_X)[_\D3U;
M_L>]9_\ 2DU[I7A?_!/?_DB>K?\ 8]ZS_P"E)KW2@ KXB_X* ?\ )?!_V [;
M_P!"DK[=KXB_X* ?\E\'_8#MO_0I* /$**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OL+_@G#_R3?7_^PXO_
M *)2OCVOL+_@G#_R3?7_ /L.+_Z)2@#Z*HHHH **** "OG7_ (*/?\DWT#_L
M.-_Z)>OHJOG7_@H]_P DWT#_ +#C?^B7H ^/:*** "BBB@ HHHH **** "BB
MB@ HKY?^)'_!5?\ 9D\$_&O2_AQI/C5]9TJ&34H/%^KZ)X9U+48]-N+=(RD:
M2VL+QR8+/YFS?L &[;FO8?%GQA\3ZS\"[;XQ_LQ> ;;XC3ZK:6MYH&EOKRZ3
M'J%M,R'S?/GC;R\1L7PR9.-O!- '?T5\9_&__@HU^VG^SOI>B:M\4O\ @G#I
M]HOB/Q':Z%HD-M\:K2XFN[^X+>5"D<5BS$G:W.,#'-?8E_JECHVE3ZSKE[!9
MVUI;M/>7$\P6*!%4L[LS8 4 $DG' S0!8HKYG_8T_P""C=G^V+\<?&7PLT7X
M-WN@Z1X>TN#5-!\0W^J;I-;L)Y62"Y^S&%3;I(@$BY=B493@9KI/C3\9/VY]
M#^(VH>%?@+^QOHWB'0;&.%H/%.O?$2"Q74&:)'=(K98GD38S%-SD E21Q0![
MI17B_P"QU^U\/VHK/Q5X;\5_#"^\$>-_ >LC2_&7A.^O4NOL<S*6CDBN(P%F
MB<*Q5P!G:>"-K-Z;\3/&7_"NOAOX@^(/]F_;/["T.[U'[)YWE^?Y$+R^7OPV
MW=MQG!QG.#TH VZ*^2OA%^W%^WA\;OA[H7Q6\"?\$VM-GT#Q#8Q7FG7DGQML
MXV:!^0YC>R# X[$ U]:T %%%% !1110 4444 %>W_P#!/_\ Y+X?^P'<_P#H
M4=>(5[?_ ,$__P#DOA_[ =S_ .A1T ?;M%%% !1110 4444 %%%% !117E_[
M6G[2>I_LL?#2T^(VE?LZ_$;XG276O6VFGP_\,- 74M0A68/FZ>(R)B"/9\[Y
MXW+P<T ? ?@VS_8*U/\ X+=_M'K_ ,%-(_ \OQ!AB\-CX'P?%O[,=.'A4Z8A
M<Z0M]^X,OVW[5YVS,@??MP/-H\86?[!FF?\ !;W]G%?^"9:>!XO'\T'B4?'*
M#X2?9AIQ\+#3',9U=;']P)OMWV;R=^)"^S=D>57<_P#!3W]H7]F_QW\7M0_9
MY_:8_P""$WQZ_:!L_"3P'2?&_AOX-6^KZ9)Y]M#._P!AOFN$E 4R"*0+M'F0
MLISM!I?^"8'[0O[.'@?XO:?^SM^S1_P0H^/7[/MEXM:X;5O&_B7X-V^D:9']
MGMIKA/MU\MP\K!C&8H@VX>9,BC&XF@#]$J*** /"_P#@GO\ \D3U;_L>]9_]
M*37NE>%_\$]_^2)ZM_V/>L_^E)KW2@ KXB_X* ?\E\'_ & [;_T*2OMVOB+_
M (* ?\E\'_8#MO\ T*2@#Q"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ K["_X)P_\DWU_P#[#B_^B4KX]K["
M_P""</\ R3?7_P#L.+_Z)2@#Z*HHHH **** "OG7_@H]_P DWT#_ +#C?^B7
MKZ*KYU_X*/?\DWT#_L.-_P"B7H ^/:*** "BBB@ HHHH **** "F7$*W$#V[
M.RB1"I9&P1D8R#V-/J.Z@^TVTEL)GC\R,KYD389<C&0>Q% 'YR^$O G[9O\
MP3O\;?#'X/Z9\$M$^*WAOPG%XHD\(S^%M:%AJ]]93M'/.US#.A1KB/>"%C8^
M9D*"2,G[D_9J^/\ \/OVHO@CH/QT^%XN4T;7;=W@M[V 1SV\D<CQ2PR*"0'2
M1'4X)!QD$@@GYI^(7[)_[:D/QM^'OAC3?V[M>O;!-.UR&V\3W?PZLIM0TF$P
MVX*27*,L<DLJX597C# H6&XGCZ9_9Q^ '@/]EWX+:%\"OAJMT=(T&W=(9KZ8
M23W$DDC2RS2L  7>1W<X  +8     /G3Q?\ \97_ /!6/0_!2?Z1X4_9X\.?
MVQJH',<GB+45 MHVQP3' %E4]5>-QZU0_P""GG[47PHL/B5X0_8D^*WQ0A\&
M>%_%5E_;GQ(UVY:5#/H<<S(FF0&-2WF74T3(Y&-D*/UWXKW#]D+]D_\ X9AL
M_&NJZ_X^_P"$K\3>/O&EWXA\0^(#I7V/S&E(\NW2+S9=L<2Y"C>?OMP!P/5-
M2\->'-9G%SK&@65W(J;5DN;5)&"Y)QE@>,D_G0!^??[*7[7W[)>H_P#!5KXA
M7O@/XJ:-_8GBWP?X<T'P2+.WD2&\N8D2/[+"NP;=N H!  QQ7V1^TCX3_:A\
M6:)IUO\ LP?%SP]X2OXIY&U.X\0^'CJ"3QE0$5%#KL(;))YSZ5S_ ,/OV-/#
M_@+]L'QI^U;!KUG,GBS0M.TZV\.IH21C37M5 \Y9O,.XOC.!&F/4UD_%'X&?
MMY7_ ,0M7\0_!3]M[2M&T#5)A)9^'=?^'%O?'2?D52(;@3(TBE@6 D!QN(Z4
M >=?\$NI;WP?\3?C;\%OC%I\L_QCTCQ/9:C\1?%(OUGM_$"7=N9+*>W"Q1"W
MB6+($&S]V''S$DJOU3\2O!R_$7X<Z_\ #Y]0-H-=T2[T\W8BWF$30M'OVY&[
M&[.,C..HKS+]D/\ 8\M_V9)?%?C;Q9\3]2\=>/?'NHPWOC/QEJEI';->O"A2
M&**",E8(8U9@J G&[&=H55L_#3]GSXW>!?@!XA^%6M?M7:SK7BC5;Z^N-(\>
M7FDAKC21,088UAFFE658<<!F"L"1@4 ?-_Q/_90_:B_X)_?LR7'Q7_9U_;A\
M3ZM#\,]!^UR>#/%^F6DND7VG6R[I;=$1 \!\L,0P9F) &Y2=P^R/@G\2K7XS
M?!KPE\8+'3VM(?%?AFPUB*U=LM"MS;I,$)[D!\9]J^;?'_["7[:?[0GAS_A4
MO[2O[?4.I>!;F1!K^G>$_A[;Z7?:U"K!O)DN!,XA5B!D(I!Z$$&OJOPOX:T+
MP7X:T[P=X7TV.STS2;&&STZSBSM@@B0)'&,]E50!]* +U%%% !1110 4444
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MI->Z4 %?$7_!0#_DO@_[ =M_Z%)7V[7Q%_P4 _Y+X/\ L!VW_H4E 'B%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7V%_P $X?\ DF^O_P#8<7_T2E?'M?87_!.'_DF^O_\ 8<7_ -$I0!]%
M4444 %%%% !7SK_P4>_Y)OH'_8<;_P!$O7T57SK_ ,%'O^2;Z!_V'&_]$O0!
M\>T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MPO\ X)[_ /)$]6_['O6?_2DU[I0 5\1?\% /^2^#_L!VW_H4E?;M?$7_  4
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M5?%;?:+CQ'?A0$TJVFMT,$(8JI=9)0S_ "!5+;0WZ"T %%%% !1110 4444
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MGJW_ &/>L_\ I2:]TH *^(O^"@'_ "7P?]@.V_\ 0I*^W:^(O^"@'_)?!_V
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MP]_;ZUSX _#CX':EHNB:=HG@?PS9SZOKUU>:9%?O?W-S<@M%%^]V1HGRNJ]
MRLS^O?LN?\$WOVL/@)\=M"^+/Q+_ ."MWQ@^)VB:3]J^V^!_%.GV$=AJ7FVL
ML*>:T2!QY;R),N#]Z)<\9KR_]I__ ()H^+_C7^VYXC_;8^"O_!9;Q'\)=1U[
M2++2QH7A.RTMH([.V@1%AF9I1]L7SO.G7SU<Q-<R!"H)SW'[(_[&_P"T]\*?
MVA/#_C[XB?\ !;/QA\7='L/M?VSX>:IH>CPP:MOM)HTW/;GS1Y3NLXV]3" >
M": /M>BBB@#PO_@GO_R1/5O^Q[UG_P!*37NE?/7[!>L7]A\'-6@MM N+E?\
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^PO^"</_)-]?_[#B_\
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M@ HHHH **** "OL+_@G#_P DWU__ +#B_P#HE*^/:^PO^"</_)-]?_[#B_\
MHE* /HJBBB@ HHHH *^=?^"CW_)-] _[#C?^B7KZ*KYU_P""CW_)-] _[#C?
M^B7H ^/:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "O;_ /@G_P#\E\/_ & [G_T*.O$*]O\ ^"?_ /R7P_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KV_\
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M?\DWT#_L.-_Z)>@#X]HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *]O\ ^"?_ /R7P_\ 8#N?_0HZ\0KV_P#X
M)_\ _)?#_P!@.Y_]"CH ^W:*** "BBB@ HHHH **** "BBB@ HHHH **** /
M"_\ @GO_ ,D3U;_L>]9_]*37NE>%_P#!/?\ Y(GJW_8]ZS_Z4FO=* "OB+_@
MH!_R7P?]@.V_]"DK[=KXB_X* ?\ )?!_V [;_P!"DH \0HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^PO\
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MVYR?S6NC"<3_ %K%0H^QMS.U^;_[4#UVBBBOK "BBB@ HHHH **** "BBB@
MHHHH **** /"_P#@GO\ \D3U;_L>]9_]*37NE>%_\$]_^2)ZM_V/>L_^E)KW
M2@ KP+]I'X6^!/&'Q&_M?Q%H7VBX_L^)/,^U2I\H+8&%8#N:]]KR+XV?\CI_
MVYQ_S:O!XCK5J&7<U.3B[K5.W?L!Y!_PH3X3?]"I_P"3T_\ \<H_X4)\)O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MVYQ_S:O7:\B^-G_(Z?\ ;G'_ #:OG.*/^19_V\OU Y"BBBOSH HHHH ****
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M% !77_!/_D=/^W.3^:UR%=?\$_\ D=/^W.3^:UZ.4?\ (SH_XD!Z[1117ZN
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M4NO ^F_LYZ/I,5WI\.T&RBF@N2;53&NP,BG8,8'%?7=%%16KSKRO*WR27Y)
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M_A;'_P"-4?\ #D+]DW_HHWQ3_P#"V/\ \:K[&HH ^.?^'(7[)O\ T4;XI_\
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M_P#&J^QJ* /CG_AR%^R;_P!%&^*?_A;'_P"-4?\ #D+]DW_HHWQ3_P#"V/\
M\:K[&HH ^.?^'(7[)O\ T4;XI_\ A;'_ .-4?\.0OV3?^BC?%/\ \+8__&J^
MQJ* /CG_ (<A?LF_]%&^*?\ X6Q_^-4?\.0OV3?^BC?%/_PMC_\ &J^QJ* /
MCG_AR%^R;_T4;XI_^%L?_C5>8_';_@DU^SE\/?B1\-/"VA^/?B,]MXJ\3O8:
MDUUXO9W2(0EP8R(QM;(ZD&OT4KS[XQ_!G4_B;X]\ >+['6H+6/P=XA?4;F&:
M-BUPIB*;%(Z')SS0!\]?\.0OV3?^BC?%/_PMC_\ &J/^'(7[)O\ T4;XI_\
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M;+1?%WB#P%K.G:'>W!. BW]S:I"HX/SNRI@9W8KV#]D[]@_PQ^S2WQQM-?\
M%5OXRT[XW?%[6/'&IZ5J>A(D%FE_;6T#Z<Z-)(MR@6WY=@H82$%!CGYZ_P"#
M@7XM^"-=_9"G_P"":WP^\!VWCCXQ?'V*+0OAO\/K6)'>V19D:369^"+6UM%C
M:03M@!XQCY4D9 #[&_:)_:;^ ?[)?PGO/CG^T=\4M+\)>$K"2*.ZUS5)&$*O
M(VV-!L#,S,3@*H)/:N*_8F_X*0?L7?\ !1?1/$/B3]C3XT+XSL?"M_%9:]<)
MH&H6"VT\BLZ*/MMO"9 55CN3<O'7D5U?P9_9^T7P5^S/X!_9^^*4&G^,&\&^
M$](TRYO-7L4N$O+JRM8H?M>V4'#EXRX8\@GUKXQ_X(Q0Q6__  4 _;^@@B5$
M3X\6"HB+@*!8N  !T% 'Z)T444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^
M:?PN^ W_  4&_P"".7QN^)6C?LE_LICX^_L]_$OQE=>+M'\-:%XNLM*U_P "
MZI=;?M5LJ7S+'=V;,J; C;D"Y;!W&3]+** /R>_8T\8?$O\ X+3?\%/8_P!I
M?]I;PQ8?"_1OV0]8O=.\._ "_P!1:X\11^(+N)5.L:I^[C18 B*;?RMZEX?E
M<@.9?8/^"Z=E_P %'/V@_P!GSQU^PQ^R-_P3GG^(OA[Q_P""H89OB8OQ9T32
M4TR\:Z+/;G3[YXY9MB0QMO#JI\_ .4-?;EI\&O@_I_Q1NOCA8?"GPU!XUOM.
M73[WQ?#H5NNJ7%HI4BW>[">:\0*)A"Q4;5XX%=+0!\O_ /!,+XC?MOZ[\)[?
MX3?MB_L"3_!=? WA?1M+T'4IOB?I/B$>(FC@:&=Q'IY)M-GDQ-B0G=Y^%)V,
M:^H*** /E#_@L=K/_!3&#]D6;P?_ ,$K?A7'X@^(7B755TW4=6'B'3]/N/#V
MEO%*9KVV:_GAB:XW+'$AW$H92X4E01X#_P $S[O_ (* ?L8^$_!?[*G@_P#X
M(*:GX*\&W?B&V_X3CXB:G^TMX:U6_DDN)D6^UV^6%1-?SA2TK(F&81K'&% 1
M1^EM% 'YE?\ !<3X8?\ !5+]J#XQ>#OV=O@7^Q;J?Q'_ &:X+2#5/B=IWAKX
MLZ/X9OO&5V)9"ND3SWDPF@LD\N%Y!'$?.\P@.I52GT?^P-\<OVX/%GB!/@U\
M>?\ @DE'^SQX"\/>% OAO5+/XO:%KEL)89((8--BLM.4/ ODM(X?[BBWV]76
MOJ:B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ KX+_;<_8X_;!^"_P"WWI'_  5?_P""='@K1_&_B2Z\'#PC\7?A
M#K.NQZ7_ ,)9I22B6WN;.\E!B@O8F5%S+A2D2@=75_O2B@#\=?VU_P!J?]K'
M_@K!\<?"G_!%WXO_ +.E[^ROH?Q%MHM>\9ZOX_\ $=O=ZIXJT>RN4FETO1/L
MBM;O<,\2L^Z4L$1B4"@K)^CO[3WCW]HC]E?X)>&]._8=_8<;XQ75A=6VD)X-
MLOB#I_AM=*TN.V<)<"XU#*2*ABAB$0^<^8&Z*:](\>_!KX/_ !4U/0]:^*'P
MI\->)+SPSJ(U#PW=Z]H5O>2Z3=@J1<6S2HQ@E!52'0JWRCG@5TM 'Y=_\$+O
M"/\ P53_ &.=&C_92_:0_P""7=QX<\)>)/B'X@\2:Q\3O^%S^'[Q-&2\#W$4
M)T^UDDFN/WJ1P[D8?ZW>5 4BOU$HHH Y#]H#Q)\7O!_P.\7>*O@!\.K;Q?XY
MT_P[>3^$/"]YJ,=G#JFI+$QM[=YI&1(D>3:"S,H )^8=1^3_ .P7X?\ ^"S_
M .RKX[\8?M-_';_@B-JWQ9^.WQ#NG_X2SXGZG^TCX3L_)L ^8-*TZUWR"PLH
ME"?NE<EV4,Q(6-4_8^B@#R/XF_&7]J7PK^R/:?&7X=?L:3>*OBG-HNEW5U\&
M4^(&GV3V]Y.8!>6?]JS#[*YM1),?-'RS>1\GWUK\^?\ @G-9_P#!8O\ 9O\
MVR?C-\4/B1_P1WNK;P]^T'\6-.UO5M2'Q\\-/_PB%EM%O-(T<4CO?>6CM+M1
M8V;9M R0:_6*B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]^WAX>^'7_!37Q9X+U72;_X=2Z[K]A\-/#=[)KL5SH5Q+9PR175F\4 LX?\
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MEW]M[_MGVRX>'[+]E\D>7LV[O,\UMV<;1UH ]^HKP'PM^W*/$O\ P4J\6?\
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M !4BNK7X32?#KX@0>);G4M<C"&'0[E!! D%Q,TL2+-O\D,^2Q19)(^V^$O\
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M_;,^(-SX.^)OA3X[^*+NQ\'7&A7D]_XCLK^\^T6-QIL4,3&\%P'Q&L>6/RG
M5E)\S_9-^,?[6/@W_@W#_:7^-/[*_AW7M#^)@^,GBN\ALM/M_-U/189M9M?[
M1:-5S^_M[1[I@RG*-%N4Y45^UEQH.AW>JPZ[=:-:2WULI6WO)+=6EB4YR%<C
M*@Y/0]ZMT ?S@?\ !6M_^").O?\ !,OQ%KO["GQ#\?\ QF^*]UI^DW>H^+=0
M^)'BC5IM$LS?VOVC4=:AN;D64#2%A;+')$K&>Z0HGR%E_3O_ (*(LS?\%@O^
M"=3,Q).L_$0DD]?^*:BK[XTGP_H.@^=_8>B6=E]HE,EQ]DMDC\US_$VT#<?<
M\U<H *_#?P#\4O\ @G3\6OB7\<;K_@N'\=_B-<?&O0/B[K.GZ'\(YO&_B735
MM-&64#2K?0M-TB>$7:S1D;&7S&E9PY/SAV_<BJD_A_0;K5X=?N=$LY+^W0I!
M>O;(9HU.<A7(W <G@'N: /PC_97_ &8/BC^U9_P;#_M*? 7X)?#+5++Q*?C5
MKNH:1X%NII+J]C_L[5].OWTQB[-)/.([9X@"S/)*!RQ//MG_  51_P""W?[#
MG[67_!'CXD>!/V?O%LWB7XA>,_A])#??#:STBX.I>&0NQK^744,86TCLU67,
MCD([HBQEMZFOU[JI9:#H>FWUSJFG:-:6]S>$&[N(;=4DG(Z%V RV,GKZT ?F
M!^V9_P B-_P2\_[*_P"#O_3 U:OQQ_:0^$'_  3G_P""^NO_ !X_;"\5#P7\
M/OB[^SWIVD^%/'.IVLO]F-JVGZC(TVGR3(K"*7R6$HW87:RC.6 /T#^T#^P;
M^T'^U/\ M_?#3XZ_%OXU^&+;X/?!KQ$/$O@?P/HOAZ;^U]0UDV/D"6^O))3&
M(HY7ED18H\E<*W)W+]5:QH>B^(;,Z=K^CVM];E@Q@O+=94W#H=K C(H _+_]
MA#]JOX??M8?\' WQE^./PKL=5D\&_P##,FD0>&M=OM+FM5U^TBU7+7UM',JR
M-;M*9HXW*@2"'>N496/S7^T%\7/^"0?PE^$GC/\ :2_X)!?\%2OB+\(_B?<_
M:M4\,?!7P1JVH2Z=KWB)\M'83^&;ZV<J9IR(B J1Q;R0I1=M?NZJJJA54  8
M  Z51_X1;PQ_;?\ PDW_  CEA_:07 U#[&GGXQC'F8W=..M 'Y@_\% _BSX_
M^%/Q(_X)U?\ !0C]M;PM=^%=-\&'5'^-VHV>CW$]OX6U;5_#4$16=(5D>*(7
M:S1Y((7;@GUU?^"EO[2GP(_:]UK]@SXY_LY?$6Q\6^$=3_;&T>/3];L$D$4T
MD$5[%( )%5LK(C+R.J\5^G%% 'P#_P %B8T?]M?]@X.@./VBI",CTTV4_P Q
M2_\ !5?C_@I[^P 1U_X6GXGY_P"X)7W[10!^)'Q:^"_[-W[*/_!63]H*7_@I
M#^TE\:/@WX4^,6NV'BCX4?$;P1\1=7T'P_K0^R^7=Z?=S6)\M+NW<803$'RP
M3E0T>_Z9_P""=O@;_@ESJ?B+XZ_&/]@K]IGXA?%OQ1%\/HM'\;>,/&'BW5=<
MM_L[)=26UO#>WR!9V0PR$B)W$:LN=N\9_1;5=(TG7;%]+UO3+>\MI,>9;W4"
MR1M@Y&58$'GFG:?IVGZ191Z;I5A#:V\*[8K>WB"(@] H  % 'PE_P0%1%_X(
M)?!Y50 'P)JY( [F_OB:^)-(\#>-O&W_  9U_#6Z\#>$M2UR?P[>V&NW^GZ1
M:-<7)LK3QC++<2)&@+-Y<0:1L=$1B> :_<ZB@#X6_:"_X*1_\$3?VY/V)?&[
M?&?XSZ3XY^#::AIFD>/)8=%U7;I,]V[263S"*%;BV826Y82J 8F0%BN,U\H?
MLT_&WP+\(/\ @H;\#O@E_P $B?\ @I?\2?C_ .!?%>KW4/Q7^&7BK7Y/$^E>
M$_#Z6Y*W\-_+"K::(WP$B,A,C[5Y#;&_9=T21#'(@96&&5AD$>E4M$\,^&_#
M,4D'AOP_8Z>DK[Y4L;1(@[>I"@9/O0!>HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH X[X@_'WX2_"O6HO#WCSQ9]@O)K5;B.'[!/+F(LRALQQL.J,
M,9SQ]*PO^&R/V;_^BC?^4B\_^,UX5_P4%_Y+-IG_ &+$/_I1<UX57V^7<-8'
M%X*G6G*5Y*^C5OR/S+-^-,TR_,ZN'IP@XQ=E=2O\[27Y'W5_PV1^S?\ ]%&_
M\I%Y_P#&:]$T36=-\1Z+:>(=&N?.L[^UCN+2;8R[XG4,K88 C((." :_-&OT
M1^"?_)&?"/\ V+%A_P"D\=>=GN387*Z4)4G)W=M;?HD>QPMQ)CL\Q%2%>,4H
MI-<J:Z^;9T]%%%?,GVH4444 %%?F5XE\>_\ !3+]K7_@L5^T+^Q]\!?^"DM_
M\'/!/PJ\,^%=1T;3;'X3>']=,KZAI\<DP,E[!YH_>!WY=OOX   %>B?\$OOV
MP/VP[_\ ;6^//_!,O]M[XAZ#\0O$_P '+71M6T/XG:!X>CTDZWIVHVZS*EW9
MQ$Q03H)(N(\ Y<?,%5V /O&BOF?]IW_@KQ^PE^R9\6)_@/\ $GXFZOJGC:RL
MDO=7\+>!_!VI:_>:5:NH99KM=/@E%J"I5@)"K%65@I4@UR_[8O\ P5:^!/A+
M_@E/XW_X*"_LK_&*Q\06;>%-07P#KFGZ#=ZA"=;6WE^SPW5O'$9+8+,@$OVA
M8EB_Y:%!S0!]@45\??L"?\%>OV9_VI/V<M&\4>(/B#K1\7>'_@[:^+_B=+<?
M#+7M.L;3R;.!]1E@GN+)(+A5ED8JEO)*SK\T8=06KZ%\"?M,_!'XE_LXV7[6
MW@GQM]M^'NH^%CXCL_$']FW,?F:8(3.9_(DC6<?NU+;#&'XQMSQ0!WE%>'>)
M?^"DG[%/@W]F+P=^V5XI^-T-C\-/'U]I]GX4\4W&AWZQW<M\Q6U#1>1YT"N5
M.7F1%0#+E1S7#^$?^"TG_!._QMX.^('Q/T'XOZN_@_X::,FJ^)?&,G@75UTV
M2S:80":SE^R_Z>GF$#=;B0$$,"5(:@#ZIHKX]U+_ (+S_P#!+;2OB'IO@*\_
M:,G6WU358M+MO%__  B.J?\ "/+?R<+:OJIMOLJ2 \/F3;&P97*%6 ]>_;"_
M;[_96_80T30]6_:3^(\FEW/BF^>R\+:%I>C7>IZGK-PBAG2VL[.*6:78&4LP
M7:F]=S#<N0#V2BO#_P!C[_@H?^S'^W)>^(=#^!>L>)$UCPI%:2^(="\6>"-3
MT2\LH[DRBWD,=];Q>8KF"7!C+ ;#G&1GW"@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*7P^UN#4/A_HG]D>#=;\,^.-6TB^TRQP@,"SV=S&TBD1IGS=YXSG/- 'G?[
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6BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>biib-20220331_g11.jpg
<TEXT>
begin 644 biib-20220331_g11.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#5H=3N+F>(30"62XEC<$AU""0;1M0)7VS10 5X]^WW^QGX _X*#_ +(/C?\
M8]^)VMWVF:/XTT^&&34],"F>SG@N8KJWG4-PVR>")BIQN"E<C.1[#10!\:^*
MO^"='[:'QS_8M^+W['G[77_!1NQ^(*?$7PO!HWASQ-;_  9MM(F\/A3)Y\TT
M5O?D:@TH,/&Z *8F(SO('J7[0W[$O_"^O^"<^N_L _\ "S?[*_MKX9Q^$?\
MA+?[%\_R=MJD'VK[+YR;L[-WE^:.N-W>O>** /D[]IK_ ()6Z#^T%^S_ /!W
MP3X<^.NL>!_B?\!;:R?X8?%W0-,B>XTV[ALXK68R6<KE)[6X2)?-MF?#!54N
M0#N=\$OV9_\ @JU9?%;P]XH_:7_X*6^%M<\*:%<^;J/A/P3\%[?2Y/$(",JK
M<W<UW.\"[BKE8%7<5QD+D'ZKN[NTL+66_O[F."""-I)IIG"I&@&2S$\  #))
MK/\ !?C?P7\1_"]GXW^'GB_2]>T748S)I^KZ+J$=U:W*!BI:.6)F1QD$9!/(
M([4 :E?.G[=W[ ?_  VQ\1O@-X__ .%L_P#",_\ "DOB_8>.?LG]@_;?[:^S
M C['N\^+[-NS_K<28_N&OHNH[N\M+"UDO;^ZC@AB0M+-,X544=22> * /(?^
M"@7[)O\ PW5^QG\0?V1O^$__ .$6_P"$[T(Z;_PD']E?;OL.9$?S/(\V+S?N
M8V^8O7K63^U)^Q+_ ,-*?\$\/$7[!/\ PLW^Q?[?^'\/AC_A*_[%^T^1LBCC
M^T?9?.3=GR\[/-'7&[BO:]"\2>'?%%F=0\,Z]9:C;ARAGL;I)D##J-R$C/M5
MV@#Y?^*O_!-S_A9OC7]EKQA_PN;[#_PS3J)NOL__  COF_\ "1_\2M;#;N^T
M+]C^[YF<3==N/XJ[7]OS]ACX7_\ !0?]G^3X&_$G7-6T*YL=:M-=\(>+?#TX
MBU'PYK5HQ:UU"V8@@2(692#U21P"I(8>UT4 ?&7@C]D7_@L8FM:)HGQ2_P""
MMGAB]\-:3J%O)J=UX?\ @):6>LZ];1R*S03327DD-J95!5I(8MPW';@X(VOV
MP_\ @FOX\^*O[3.C_MU_L:?M.W'P<^,NF^&SX=U?5I?#46LZ1XGT?S?.2SU"
MQDDCWE).4G1U=!C[VU-GUG5#3O%/AG5]2N-'TGQ'875W9G%W:V]XCR0'_;52
M2OXT >$_LF_ 7_@H!X%^).H?$3]LC]NS1_B'8SZ*]CI?@CPG\,(-!TVQG::)
MS>M,;B>XN)=L90*SJBB5\*2<U[CXY\-?\)IX)UCP=]M^S?VMI5Q9_:?+W^5Y
ML;)OVY&[&[.,C..HK4Z=:IZ+XAT#Q);/>>'=<L[^&.4QR2V5RDJJXZJ2I(!&
M1Q0!\]?L3?\ !-KX6?LP?\$\_!/_  3U^,J^'_BYH'A*UFBNI_$_@Z#['J;-
M?S7B2-8SO<(I1I0!EWY0,""<";]JG]@"U_:4_:D_9U_:0L?B;'X<@^ 'B'5=
M3A\.Q>'Q.FLI>6<=L(5E$\8M!&(]P(27.<87&:]_USQ%X?\ #-F-0\2:[9Z?
M;EP@GOKI(D+'HNYR!D^E6H9H;F%+BWF62.10T<B,"K*1D$$=10!\=_M(_P#!
M-#XW7/[8FH_M\?L!?M8V_P )OB#XJ\/6NB_$?2]?\&IKNA^*[>U&VTGF@\Z&
M2&ZA3"+,CG*($PH9R_2?L"?\$XM1_9-\6?$?]H3XX_'N]^*OQG^+MS;2>.?'
MUYHL>G0+;6T1CM;"RLXW=;:VA5B,;R7(4L?E4+])WGBGPSIVKP>']0\16$%_
M=#-M937B+-,.GRH3N;\!5^@#P/\ X)@_L/\ _#M_]A?P+^Q;_P +/_X3/_A"
MH]17_A)?[%_L[[9]JU*ZO?\ CW\Z;R]OVG9_K&SLW<9VCQOX>?\ !$WP!HO_
M  1??_@CE\3/C;?Z]I,EM?!O'.F:&NGSK<2ZY+K-O,ELTTX7R9VB4J9#Y@B/
M*;\+]P44 ?&GB_\ X)S?MH?'C]BKXO?L=_M=_P#!1NP^( ^(WAJWTCPYXGMO
M@S;:1-X?"M(9YIHK>_*W[2YAXW0!#$Q&=Y ]3_:/_8E_X:"_X)TZ]^P'_P +
M-_LC^V_AO'X3_P"$L_L7[1Y.RW2'[3]E\Y-V=F[R_-'7&[O7O%% 'R]\5OV2
M?VZM'\"?#/PQ^QE^WEI7@/\ X0/P;;Z#K>E>)?A?!K.G>)3###%'<L#<QS6;
MJ(V($<C B3#9P#5']BS_ ()U_%/X,?M0>,?VZOVMOVF(?BA\6O%_A6U\+QWF
MC>$8]#TG1=$@G\];.WMEEE>1FFP[2R2%C@  <D_5]8_A#X@^ ?B"-3/@+QOH
M^MC1=7GTK63I&IQ7/V"_AQYUI-Y;'RITW+NB;#KN&0,T <[^U%\%?^&D_P!F
M;XB_LZ?\)+_8O_"?>!-7\.?VQ]C^T_8/MUE+:^?Y6]/-V>;OV;UW;<;ESD?$
M'P-_X)/_ /!7_P#9P^#OAGX"_!__ (+PV.E^%O"&C0:5H&G/^RMHMP;:TA0)
M&ADEOV=\* -S,2>Y-?HS5#1_%'AGQ#-<6_A_Q%87TEH^RZ2SNTE,+>CA2=I]
MC0!\R_'3_@G=\4/VE?!_[.%O\:OVJTUCQ7\"OBMI'CG7O%4?@2*V7Q=<64<Z
M-"+6&Y6/3_,\[.Y3*$V?<;/'5_MV_L-_\-KZK\$]3_X6A_PC/_"G?CIH?Q&V
M?V)]M_M?^SEN%^P9\Z+[/YGG_P"N_>;=O^K;/'ODTT5O$UQ<2JD:*6=W; 4#
MDDD]!5?1]<T7Q%8KJGA_6+6^MG)"W%G<++&2.H#*2* /DG]JC_@FU\:_$G[7
M\/[?/["'[5%K\)_B3J'A>/PYX[M-=\(+KFB^*M.B??;FXM_.A>*XA/"S(^2B
MJG W;J'[%/\ P2B^(?[,O[=OC/\ X*!_&+]LC4/B=XR^(7P^A\/^*8KSPC%I
MT(NH[N.59[417#K;VR0PPP):[&(\LR-,[.U?8.N>*/#7AB.*;Q+XBL=.2>39
M"U]=I")&_NJ7(R?85>!# ,IR#T(H ^$=%_X)8_M@?LG>/O%UY_P3*_;PTGX?
M> /&WB*YUZ^^%WCWX;)K^GZ+J5R=UQ-ILR75O+;Q.PW?9CNC4Y(/.*]0\7?\
M$[?$O[2_[!?C#]BW]O\ _:4O_BO>^-I))=1\:6/ABUT)].D#Q2VALK6 ND(M
MI88Y$W,Y<@^86#$'Z>HH _-/]H__ ((K_P#!07]N#]ER]_8__;#_ ."MB:WX
M3M;:W71;G0_A##:7>I7,$B&WN=8<7V;P1JI;R8VA#S%)7=S&%;]'?"VB?\(U
MX8T[PY]I\_\ L^PAMO.V;?,\M N[&3C.,XR:OT4 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5;_Q->:1=&TU+7F9KZ]TH7LZZ=/.S$EV:T$!5R2738Q)+$G\Z?C=_P %H_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(Z6CW@C;R%G:,%Q$9-H8J"P7..:_*_\ :=^*?_!4#X[_ +5^@_"'Q9_P2?\
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M+X?\1?VIH?BO1Q-Y+W-G,41XW23@PN"V$<DKM*CO?VP_VI?VY/V>OB9IEG\
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M>)K[P+X=U$75EX>@BA:.TLFN!A)I\._F2(=C?*02<T 6_P#@X-^$7QH^.?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \+_ .">
M_P#R1/5O^Q[UG_TI->Z5X7_P3W_Y(GJW_8]ZS_Z4FO=* "BBO%_CQ^U[_P *
M2\=#P5_PKW^T_P#0H[C[3_:WD_>+#;M\INFWKGO73A<'B,;5]G1C>6^Z7YV.
M+'YA@\LH>VQ,N6-[7LWJ_1-GM%%?,?\ P\;_ .J.?^7#_P#<]'_#QO\ ZHY_
MY</_ -SUZ7^KF<_\^O\ R:/^9XW^N/#G_/\ _P#)9_\ R)].45\Q_P##QO\
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MCPY_S_\ _)9__(GTY17S'_P\;_ZHY_Y</_W/1_P\;_ZHY_Y</_W/1_JYG/\
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MBBB@ KZV_P"">7_).]=_[#0_]$I7R37UM_P3R_Y)WKO_ &&A_P"B4KP.)O\
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MT5]E;M>)XG#U*E6BZD5&4%&+2GRQY9*2B[Q4M;.[L]7?O;B_V<_^4P_[1?\
M8_\ Q[?\(7X5_M?9T^U_9AY6[_:\K./:MW]NG]HSQ=XKU.;]@C]E*VAU?XH^
M,M*>'6KUB39^#=(F79+J%XXSL<HY$47WF9E;!RBR=K^RQ^Q[=?LW^%_&.JZE
M\5[OQ/\ $3X@ZB^I>+?'M[ID<37%V(RD CME)2."$,=D6X@;F&0" OA/P/\
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M &/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XUL44 8_V+QO\ ]!NR_P#
M8_XT?8O&_P#T&[+_ ,!C_C6Q10!C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\
MP&/^-;%% &/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XUL44 8_V+QO\
M]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C6Q10!C_8O&_P#T&[+_ ,!C_C1]B\;_
M /0;LO\ P&/^-;%% &/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XUL44
M8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C6Q10!C_8O&_P#T&[+_ ,!C
M_C1]B\;_ /0;LO\ P&/^-;%% &/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P#
M8_XUL44 8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C6Q10!C_8O&_P#T
M&[+_ ,!C_C1]B\;_ /0;LO\ P&/^-;%% &/]B\;_ /0;LO\ P&/^-'V+QO\
M]!NR_P# 8_XUL44 8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C6Q10!E
MV=IXM2Z1[[5K5X@W[Q$MR"1[&M2BB@ HHHH **** "BBB@ HHHH **** /"_
M^">__)$]6_['O6?_ $I->Z5X7_P3W_Y(GJW_ &/>L_\ I2:]TH *^+_V\?\
MDN@_[ MO_P"A25]H5\7_ +>/_)=!_P!@6W_]"DKZ3A7_ )&G_;K_ $/C.._^
M1'_V_']3Q>BBBOT@_&@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ KZV_X)Y?\D[UW_L-#_P!$I7R37UM_P3R_Y)WK
MO_8:'_HE*\#B;_D42]5^9]9P3_R4$/27Y'T%1117YD?M@4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'A?\ P3W_ .2)
MZM_V/>L_^E)KW2O"_P#@GO\ \D3U;_L>]9_]*37NE !7Q?\ MX_\ET'_ &!;
M?_T*2OM"OB_]O'_DN@_[ MO_ .A25])PK_R-/^W7^A\9QW_R(_\ M^/ZGB]%
M%%?I!^-!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !7UM_P3R_Y)WKO_8:'_HE*^2:^MO^">7_ "3O7?\ L-#_ -$I
M7@<3?\BB7JOS/K."?^2@AZ2_(^@J***_,C]L"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \+_X)[_\ )$]6_P"Q[UG_
M -*37NE>%_\ !/?_ )(GJW_8]ZS_ .E)KW2@ KXO_;Q_Y+H/^P+;_P#H4E?:
M%?%_[>/_ "70?]@6W_\ 0I*^DX5_Y&G_ &Z_T/C.._\ D1_]OQ_4\7HHHK](
M/QH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *^MO^">7_ "3O7?\ L-#_ -$I7R37UM_P3R_Y)WKO_8:'_HE*\#B;
M_D42]5^9]9P3_P E!#TE^1]!4445^9'[8%%%% !1110 4444 %%%% !1110
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M^*'_ $+'_D[!_P#%T?\ "D?BA_T+'_D[!_\ %U] T4?\19XC_P"?5+_P&?\
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M (4C\4/^A8_\G8/_ (NC_A2/Q0_Z%C_R=@_^+KZ!HH_XBSQ'_P ^J7_@,_\
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MA?".D>#_ !-J][90:/XX\/>)X);$IO>YTC5K74X(FWJ1Y;RVB(^.=C-@@X(
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M;Q%XCT3PK;ZIK_BK6KNQCO9(XS<$+9VT,<T:;EPS-D_.&Q&?"+Q+_P %$O\
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MU?\ #9'[-_\ T4;_ ,I%Y_\ &:/^&R/V;_\ HHW_ )2+S_XS7PK11_JEEO\
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M2^ W_(!O?^OP?^@"O>X:_P"1M'T?Y =U1117Z4 4444 %?/O_!0W_DG>A?\
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MKR6J2MIM9O>QY;\)O^"H7[%_QD^(>F_"SPU\2[VPUO7&QH%MXD\-7VF+JIZ
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MFO=*\+_X)[_\D3U;_L>]9_\ 2DU[I0 5Y%\;/^1T_P"W./\ FU>NUY%\;/\
MD=/^W./^;5\YQ1_R+/\ MY?J!R%%%%?G0!1110 4444 %%%% !1110 4444
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M0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7J7P&_Y -[_P!?@_\ 0!7EM>C_  6US2-*T6\BU&_CA9KH%0YZC:*]
M[AK_ )&T?1_D!Z+16;_PF/AC_H-0?]]4?\)CX8_Z#4'_ 'U7Z4!I45F_\)CX
M8_Z#4'_?5'_"8^&/^@U!_P!]4 :5?/O_  4-_P"2=Z%_V&C_ .B7KW#_ (3'
MPQ_T&H/^^J\$_;]US2-5^'^AQ:=?QS,NLDL$/0>4]>OD7_(WI>OZ,^?XJ_Y)
M_$>B_-'RI1117ZJ?@X4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXJ_Y)_$>B_-'R31117ZJ?@X4444 %%%% !1110 4444 %%%% !1110 4444
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MY^HO>0Z7/=6T\FI:;!,[,3'!-&B[=QP26.6D9CM_\%0_^4C/[#?_ &4O7_\
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M ,P_L7)O^@:G_P" 1_R.4_X4C\+_ /H6/_)V?_XNC_A2/PO_ .A8_P#)V?\
M^+KJZ*/]9>(_^@RK_P"#)_YA_8N3?] U/_P"/^1RG_"D?A?_ -"Q_P"3L_\
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MD?A?_P!"Q_Y.S_\ Q='_  I'X7_]"Q_Y.S__ !==711_K+Q'_P!!E7_P9/\
MS#^Q<F_Z!J?_ (!'_(Y3_A2/PO\ ^A8_\G9__BZ/^%(_"_\ Z%C_ ,G9_P#X
MNNKHH_UEXC_Z#*O_ (,G_F']BY-_T#4__ (_Y'*?\*1^%_\ T+'_ ).S_P#Q
M='_"D?A?_P!"Q_Y.S_\ Q==711_K+Q'_ -!E7_P9/_,/[%R;_H&I_P#@$?\
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MBBOU< HHHH **** "BBB@ HHHH **** "BBB@#PO_@GO_P D3U;_ +'O6?\
MTI->Z5X7_P $]_\ DB>K?]CWK/\ Z4FO=* "O(OC9_R.G_;G'_-J]=KR+XV?
M\CI_VYQ_S:OG.*/^19_V\OU Y"BBBOSH HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ KU+X#?\@&]_Z_!_Z *\MKU+
MX#?\@&]_Z_!_Z *][AK_ )&T?1_D!W5%%%?I0!1110 5POQY_P"0#9?]?A_]
M -=U7"_'G_D V7_7X?\ T UY.>_\BFKZ?J@/+:***_+0"BBB@ HHHH ****
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>I? ;_D
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M7C!0@URJVLD]/_ 5W ****XP"BBB@ HHHH *Z_X)_P#(Z?\ ;G)_-:Y"NO\
M@G_R.G_;G)_-:]'*/^1G1_Q(#UVBBBOU< HHHH **** "BBB@ HHHH ****
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M?J@/+:***_+0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?^@"O+:]2^ W_(!O?^OP?^@"O>X:_P"1M'T?Y =U1117Z4 4444 %<+\>?\
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M-<7_ ,.0OV3?^BC?%/\ \+8__&J /L:O(OC9_P CI_VYQ_S:O%O^'(7[)O\
MT4;XI_\ A;'_ .-4?\.0OV3?^BC?%/\ \+8__&J\[-,O_M+"^QYN75.]K[?-
M =U17"_\.0OV3?\ HHWQ3_\ "V/_ ,:H_P"'(7[)O_11OBG_ .%L?_C5?.?Z
MH?\ 3_\ \E_^V [JBN%_X<A?LF_]%&^*?_A;'_XU1_PY"_9-_P"BC?%/_P +
M8_\ QJC_ %0_Z?\ _DO_ -L!W5%<+_PY"_9-_P"BC?%/_P +8_\ QJC_ (<A
M?LF_]%&^*?\ X6Q_^-4?ZH?]/_\ R7_[8#NJ*X7_ (<A?LF_]%&^*?\ X6Q_
M^-4?\.0OV3?^BC?%/_PMC_\ &J/]4/\ I_\ ^2__ &P'=45PO_#D+]DW_HHW
MQ3_\+8__ !JC_AR%^R;_ -%&^*?_ (6Q_P#C5'^J'_3_ /\ )?\ [8#NJ*X7
M_AR%^R;_ -%&^*?_ (6Q_P#C5'_#D+]DW_HHWQ3_ /"V/_QJC_5#_I__ .2_
M_; =U17"_P##D+]DW_HHWQ3_ /"V/_QJO,?"W_!)K]G+5_VKO%7P=NO'OQ&&
ME:/X8L;^UE3Q>PG:65V#!G\O!7C@8&*/]4/^G_\ Y+_]L!]$45PO_#D+]DW_
M **-\4__  MC_P#&J/\ AR%^R;_T4;XI_P#A;'_XU1_JA_T__P#)?_M@.ZHK
MA?\ AR%^R;_T4;XI_P#A;'_XU1_PY"_9-_Z*-\4__"V/_P :H_U0_P"G_P#Y
M+_\ ; =U17"_\.0OV3?^BC?%/_PMC_\ &J/^'(7[)O\ T4;XI_\ A;'_ .-4
M?ZH?]/\ _P E_P#M@.ZHKA?^'(7[)O\ T4;XI_\ A;'_ .-4?\.0OV3?^BC?
M%/\ \+8__&J/]4/^G_\ Y+_]L!W5%<+_ ,.0OV3?^BC?%/\ \+8__&J/^'(7
M[)O_ $4;XI_^%L?_ (U1_JA_T_\ _)?_ +8#NJ*X7_AR%^R;_P!%&^*?_A;'
M_P"-4?\ #D+]DW_HHWQ3_P#"V/\ \:H_U0_Z?_\ DO\ ]L!W5>I? ;_D WO_
M %^#_P! %?.?_#D+]DW_ **-\4__  MC_P#&J/\ AR%^R;_T4;XI_P#A;'_X
MU7?EO#W]G8M5_:\UKZ<MM_FP/L:BOCG_ (<A?LF_]%&^*?\ X6Q_^-4?\.0O
MV3?^BC?%/_PMC_\ &J^E ^QJ*^.?^'(7[)O_ $4;XI_^%L?_ (U1_P .0OV3
M?^BC?%/_ ,+8_P#QJ@#[&KA?CS_R ;+_ *_#_P"@&OG/_AR%^R;_ -%&^*?_
M (6Q_P#C5'_#D+]DW_HHWQ3_ /"V/_QJN3'87Z[A)T+VYNN_^0'=45PO_#D+
M]DW_ **-\4__  MC_P#&J/\ AR%^R;_T4;XI_P#A;'_XU7RW^J'_ $__ /)?
M_M@.ZHKA?^'(7[)O_11OBG_X6Q_^-4?\.0OV3?\ HHWQ3_\ "V/_ ,:H_P!4
M/^G_ /Y+_P#; =U17"_\.0OV3?\ HHWQ3_\ "V/_ ,:H_P"'(7[)O_11OBG_
M .%L?_C5'^J'_3__ ,E_^V [JBN%_P"'(7[)O_11OBG_ .%L?_C5'_#D+]DW
M_HHWQ3_\+8__ !JC_5#_ *?_ /DO_P!L!W5%<+_PY"_9-_Z*-\4__"V/_P :
MH_X<A?LF_P#11OBG_P"%L?\ XU1_JA_T_P#_ "7_ .V [JBN%_X<A?LF_P#1
M1OBG_P"%L?\ XU1_PY"_9-_Z*-\4_P#PMC_\:H_U0_Z?_P#DO_VP'=45PO\
MPY"_9-_Z*-\4_P#PMC_\:KS'X[?\$FOV<OA[\2/AIX6T/Q[\1GMO%7B=[#4F
MNO%[.Z1"$N#&1&-K9'4@T?ZH?]/_ /R7_P"V ^B**X7_ (<A?LF_]%&^*?\
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M+&]?49YKZDH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!^CW-U]ET\W:R37.H7&,^3;6T"//<R8Y*QHQ Y.!S0!ZK17RK^S;_P %I?\
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M0;;X8Z3?J'@T^]U6.&[N-2BC/ N )'A\S&<%.<HFW],*^"_VW/V./VP?@O\
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ML)YKQ HF$+%1M7C@5TM%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!S7CWX-?!_P"*
MFIZ'K7Q0^%/AKQ)>>&=1&H>&[O7M"M[R72;L%2+BV:5&,$H*J0Z%6^4<\"NE
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB,=K%97'BWXB:YJ-QIL%O<17$,%G-+>%[.,2PQLRPE/,"!7WK\M ''?MI?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
-HH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>biib-20220331_g12.jpg
<TEXT>
begin 644 biib-20220331_g12.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#5H=3N+F>(30"62XEC<$AU""0;1M0)7VS10 5X]^WW^QGX _X*#_ +(/C?\
M8]^)VMWVF:/XTT^&&34],"F>SG@N8KJWG4-PVR>")BIQN"E<C.1[#10!\:^*
MO^"='[:'QS_8M^+W['G[77_!1NQ^(*?$7PO!HWASQ-;_  9MM(F\/A3)Y\TT
M5O?D:@TH,/&Z *8F(SO('J7[0W[$O_"^O^"<^N_L _\ "S?[*_MKX9Q^$?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5;_Q->:1=&TU+7F9KZ]TH7LZZ=/.S$EV:T$!5R2738Q)+$G\Z?C=_P %H_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM:IXH\279MM&T^X^%WB6R2>4(S[3/=:='#'\JL<NZCC&<D4 ?65%>"?MH?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% 'A?_  3W_P"2)ZM_V/>L_P#I2:]T
MKPO_ ()[_P#)$]6_['O6?_2DU[I0 4444 %%%% !1110 4444 %%%% &!\5K
M7Q[>_"[Q)9?"N^@M?%$V@7B>&[FZ ,45^8'%N[Y!&T2["<@\ U_/=^SEH?\
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M*7_D_P#_ &NC_6')_P#G[_Y++_(#T:BO.?\ A?\ _P!2E_Y/_P#VNC_A?_\
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MX7__ -2E_P"3_P#]KH_UAR?_ )^_^2R_R ]&HKSG_A?_ /U*7_D__P#:Z/\
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M/ GP5%]<P:AH=A\UM>>(K>&6*V$$*IP\LB/Y:*3E AKZX^*6J_L??$7]MO\
M91\<_$&]\6V7BZ\\/>(]2^!NDI"D>C222Z1$;X7*HK8NTL),Q*7"A1*4R0U
M'U?1110!X7_P3W_Y(GJW_8]ZS_Z4FO=*\+_X)[_\D3U;_L>]9_\ 2DU[I0 5
MY%\;/^1T_P"W./\ FU>NUY%\;/\ D=/^W./^;5\YQ1_R+/\ MY?J!R%%%%?G
M0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7J7P&_Y -[_P!?@_\ 0!7EM>I? ;_D WO_ %^#_P! %>]PU_R-H^C_
M " [JBBBOTH HHHH **** "BBB@ HHHH **** "BBB@ K\BO^"V_QR_X(M?&
MW5$^'W[6WPZT_2OB;X7^+WA/2-;O_%O@+4=-U.[\.+XBL5U*2TU*&%3=6;:>
M;ME,,S,$+%55R*_76N'^/WP)\._M"^$=(\'^)M7O;*#1_''A[Q/!+8E-[W.D
M:M:ZG!$V]2/+>6T1'QSL9L$'! !\+_\ !$7QAXE^#/[._P"T#\2+S4_B1=?L
MV>&/&5[J?P$G^(-I>S:NWANVLO-NC;1W2BZDL]Z'[,KC<V'XW%JR?V]O^"[_
M /P25^//[#GQ!^$'PH^,<'Q;\3_$3P;J&@>%/AGX?\*ZA<:GJ^HW5N\5O$;:
M2W5H2LCHY9PK+L)0,X53^FU4+;PKX8LM9E\16?ARPBU"<$37T5FBS2 XR&<#
M<>@ZGM0!\J_L3Z[9?\$P_P#@CC\,-5_;T\9'PQ%\-?AKI</C:^NX)KLZ07,<
M4=LRVZ2.YB,T5O\ (K %./E&:^!_^":O_!9K_@FCX3_X*S_MA?$CQ!^T_:6V
MB?&SQ;X%A^&%\?#>J,-<>WTZXM9@JK:EH=LTT:?OA'G=D9 )'[8T4 ?"G[8/
M_!-?]O#XL?\ !06U_;M_9=_;D\*>";G2O "^%_#^C>+/AF-=72(GF,MY-;%[
MA$BDG81AY GF%$";MORU\N?\$?\ X2?\% =)_P""VW[7?_"??M?>%M7/AS7/
M!/\ PN3[+\.H[?\ X3$2Z+??8!:8F/\ 9OD#A]N_S>^*_8ZB@#QSX+?MQ_!?
MX\_M4_%W]C[P1:ZVGBSX*'1QXQDOK%([1_[3MFN;;[/()&:3"(=VY4P>!GK7
MX^_%G_@M-_P3@_X*@_M<W6E_MS?M40> OV9/A?KZ2>&OA7<^'M5N+OXG:K"V
M4U+5OLEK(D>G1,,Q63-ND8;I5'W1^\M% 'F_[)W[4O[.?[9'P0TOXZ_LI^.[
M?Q'X(O99K32]3M-,N+.-C;R&&2-8KB*-U",A7E ..,BO2*** "BBB@ HHHH
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MOC9_R.G_ &YQ_P VKYSBC_D6?]O+]0.0HHHK\Z **** "BBB@ HHHH ****
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M  MKX??]#!_Y*2__ !%>+44?ZV9C_)#[G_\ ) >T_P#"VOA]_P!#!_Y*2_\
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M'S#YW_X*L_M+_P#!0/XI1?M=?$SX"_MA:W\)/ 7[*UOI&EZ/X?\ !NF0"_\
M%&K7%K:W=W=7EW(IEA@B2Z")'%@.%W'!!W>@?#WX ?MA?L _\%1_@19_&O\
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M.<4?\BS_ +>7Z@<A1117YT 4444 %%%% !1110 4444 %%%% !1110 4444
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M1110 4444 %%%% !1110 4444 %%%% !7J7P&_Y -[_U^#_T 5Y;7J7P&_Y
M-[_U^#_T 5[W#7_(VCZ/\@.ZHHHK]* **** "N%^//\ R ;+_K\/_H!KNJX7
MX\_\@&R_Z_#_ .@&O)SW_D4U?3]4!Y;1117Y: 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5U_P $_P#D=/\ MSD_
MFM<A77_!/_D=/^W.3^:UZ.4?\C.C_B0'KM%%%?JX!1110 4444 %%%% !111
M0!^4>K_L[_\ !.WXP?\ !8_]HBR_X*O77@KQ#XFD@\.O\%-,^(WB2--.A\-G
M38Q/#8P2RK$+A;SS6FC8>:/,255"3%W^J?V9OV)O^",7PB^-VB?$/]D_X1?!
M/2_B!I_VG^P+[PC>6;ZC%YEM+%/Y0CD+'-N\P; ^X6SQFOEC_@KGXO\ ^"+?
MPZ_:-\;:Y\9O^"9&L?M!?%K2?"T/B;XJW?@OPPUV/#>E0VBK!=:O>//'#:@V
MMNNQ/F<I&I*@,I;V+X)?LV?\$?/V0_VJ_P!G[5_A#^POIW@GX@?%W1=5OOAI
MXMTK3 8;&6+23/=6<TIN"T<[V5Q,% C97"R ,"* /OBBBB@#PO\ X)[_ /)$
M]6_['O6?_2DU[I7A?_!/?_DB>K?]CWK/_I2:]TH *\B^-G_(Z?\ ;G'_ #:O
M7:\B^-G_ ".G_;G'_-J^<XH_Y%G_ &\OU Y"BBBOSH HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KU+X#?\@&]_Z_
M!_Z *\MKU+X#?\@&]_Z_!_Z *][AK_D;1]'^0'=4445^E %%%% !7"_'G_D
MV7_7X?\ T UW5<+\>?\ D V7_7X?_0#7DY[_ ,BFKZ?J@/+:***_+0"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N
MO^"?_(Z?]N<G\UKD*Z_X)_\ (Z?]N<G\UKT<H_Y&='_$@/7:***_5P"BBB@
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M[<X_YM7KM>1?&S_D=/\ MSC_ )M7SG%'_(L_[>7Z@<A1117YT 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5ZE\!O
M^0#>_P#7X/\ T 5Y;7J7P&_Y -[_ -?@_P#0!7O<-?\ (VCZ/\@.ZHHHK]*
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M.<4?\BS_ +>7Z@<A1117YT 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_(L_[>7Z@<A1117YT 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5ZE\!O^0#>_P#7X/\ T 5Y;7J7P&_Y -[_ -?@
M_P#0!7O<-?\ (VCZ/\@.ZHHHK]* **** "N%^//_ " ;+_K\/_H!KNJX7X\_
M\@&R_P"OP_\ H!KR<]_Y%-7T_5 >6T445^6@%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %=?\$_\ D=/^W.3^:UR%
M=?\ !/\ Y'3_ +<Y/YK7HY1_R,Z/^) >NT445^K@%%%% !1110 4444 %%%%
M 'P!^VQ_P3A_8L_X*>_M%?$[PO\ "[]I[Q[\-OC!X>\)V7A?XS7?PVNYK>#5
MM(U&U>2UT_5XI8OLM^#;L[*J/YJ(R!R%$8%O]D7]@']D?_@G9^UCX&NOCK^U
MA\0?BM\=O'OAR_\ #_PNUOXH7<UTMGIEA;I/=V&EI%%]FL0( KLK/YCJ)-GR
MF4'B?'G[1'C?_@C[_P % _CE\5/CG^S5\1/%_P &/CSJ>D>)=#^(GPY\-OK#
M>'M4M=,AL+K3]2AC(>*-A;I+%(.,-M 8[S&G@7]H+QO_ ,%@_P#@H/\  OXM
M? []FCXA>$/@S\!-2UCQ)K7Q$^(_AM]';Q#J=UILMC:Z?IL,A+RQKY[2RR'C
M"[2%.PR 'Z5T444 >%_\$]_^2)ZM_P!CWK/_ *4FO=*\+_X)[_\ )$]6_P"Q
M[UG_ -*37NE !7D7QL_Y'3_MSC_FU>NUY%\;/^1T_P"W./\ FU?.<4?\BS_M
MY?J!R%%%%?G0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU3QY^S]<WR7.EW>^SE:#5_#R[BUFWVDVOFQQ_N'A=L%=D24 ?;5%%% 'A?\
MP3W_ .2)ZM_V/>L_^E)KW2O"_P#@GO\ \D3U;_L>]9_]*37NE !7D7QL_P"1
MT_[<X_YM7KM>1?&S_D=/^W./^;5\YQ1_R+/^WE^H'(4445^= %%%% !1110
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M_P#0#7=5POQY_P"0#9?]?A_] ->3GO\ R*:OI^J \MHHHK\M **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Z_X)_\
MCI_VYR?S6N0KK_@G_P CI_VYR?S6O1RC_D9T?\2 ]=HHHK]7 **** "BBB@
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M=" :NT44 >%_\$]_^2)ZM_V/>L_^E)KW2O"_^">__)$]6_['O6?_ $I->Z4
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M>?\ D V7_7X?_0#7DY[_ ,BFKZ?J@/+:***_+0"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "NO^"?_(Z?]N<G\UKD
M*Z_X)_\ (Z?]N<G\UKT<H_Y&='_$@/7:***_5P"BBB@ HHHH **** "BBB@#
M\ZOV^?VH/V=4_:\UO]G#]G3_ ((ZZ1^U5\;=-TNRU'XA3#P_H]G::%%-"OV.
M/4=8O[>4)/) B-'$P/[H+@\;0O[ G[3_ .SJ_P"UYHG[./[1'_!'?2/V5?C=
MJ.E7NH_#Z7_A']'O+378H86%['IVL6%O&'G2!W,D0 _=%LGG::?Q&\:?M:?\
M$I_V]/C3\=]#_84\?_'3X0?'C4=)U]=3^$%@FI>(?#>K6NGQ6$UG/8%E>X@<
M0K+'(I58PQ7+$D ^''C+]K/_ (*K_MZ_!;X]:[^PKX_^!?PA^ ^H:MKW]I?%
M^Q33?$/B35KO3Y;"&T@L S/;P1B9I9)&++(%"Y4@ @'Z04444 >%_P#!/?\
MY(GJW_8]ZS_Z4FO=*\+_ .">_P#R1/5O^Q[UG_TI->Z4 %>1?&S_ )'3_MSC
M_FU>NUY%\;/^1T_[<X_YM7SG%'_(L_[>7Z@<A1117YT 4444 %%%% !1110
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MGN\W+?FG&'Q<LK6YK[.]K>9]H45^+]%?TY_Q*%_U.O\ RV_^^#\#_P")EO\
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M'F4E3ERN/+*_->UK:WV/E_\ X>%_M@?]%>_\H&G_ /R/1_P\+_; _P"BO?\
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MR;M:VM]C\K:*]H_X=Z?M@?\ 1(?_ "OZ?_\ )%'_  [T_; _Z)#_ .5_3_\
MY(K_ $Q_XB1X=_\ 0XPO_A11_P#DS^"_]1>-O^A7B/\ P14_^1/%Z_3C_@GI
M_P F?^$/^XA_Z<+FOB__ (=Z?M@?]$A_\K^G_P#R17W5^QO\//&'PJ_9O\.>
M ?'VD?8-6L/MGVNT^T1R^7OO)Y%^:-F4Y1U/!/7!YR*_G?Z3'%O"N?<!X;#Y
M9CZ%>HL3"3C3JTYR452K)R:C)M)-I7VNTNI^V^ O#?$63\85ZV/P=6C!T))2
MG3G!-^TI.R<DE>R;MO9/L>G4445_#9_6P4444 %%%% !1110 4444 %=?\$_
M^1T_[<Y/YK7(5U_P3_Y'3_MSD_FM>CE'_(SH_P") >NT445^K@%%%% !1110
M 4444 %%%% ' _&W]JS]EW]FA+23]H[]I+P#\/UU $V#>-O&-EI0N<<'R_M4
MJ;\>V:YWX6_\%"?V!?CCX[L?A;\%/VX?@_XP\3ZIYO\ 9GASPM\2]*U"_N_+
MB>:3RK>"X>239%')(VU3M5&8X )K\^KW1?\ @E5HG_!9K]I*U_X*MZ_\&-<\
M5ZZGANY^%TGQ?U'3+S3K#0ETJ))-/CBO6:"QNEN-TABD"2RI<131AED8U]9?
MLS>'O^"%=C\;M$NOV-]#_9,A^)"?:?\ A')/AE;>&%UP9MI1<?9C8CS_ /CV
M\_?L_P"67F;OEW4 ?6=%%% 'A?\ P3W_ .2)ZM_V/>L_^E)KW2O"_P#@GO\
M\D3U;_L>]9_]*37NE !7D7QL_P"1T_[<X_YM7KM>1?&S_D=/^W./^;5\YQ1_
MR+/^WE^H'(4445^= %%%% !1110 4444 %5]7TV/6=)NM(EN)H4NK=X6EMWV
MR(&4J64]F&<@]C5BJFO:WIGAG0[WQ)K=SY-EI]I)<W<VPMLBC4L[84$G !.
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M_LW:\UII-Q?W*1VGB'QZ4V2W&YR%>/3(Y#"AX_TJ>0J3Y0QV_P#P4)^+NO\
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M]-K:NU[=0/N:BLOP/X=O?"/@S2?"NI>)[_6[G3=-@MKG6=493<W\B(%:>4J
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M0RD$$$<$&OAK_@CW_P G*?MI?]G)W_\ Z)%?4'QA_8^_9W^/?[/D'[+'Q6\
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M&!%306\%K"MO;0I'&@PD<:@*H] !TI]% !1110!X7_P3W_Y(GJW_ &/>L_\
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MKNJX7X\_\@&R_P"OP_\ H!KR<]_Y%-7T_5 >6T445^6@%%%% !1110 4444
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M[_T<Q\+/_"0NO_BZ/^&2O^"GO_1S'PL_\)"Z_P#BZ^SZ*/[-R[_GS#_P%?Y
M?&'_  R5_P %/?\ HYCX6?\ A(77_P 71_PR5_P4]_Z.8^%G_A(77_Q=?9]%
M']FY=_SYA_X"O\@/C#_ADK_@I[_T<Q\+/_"0NO\ XNC_ (9*_P""GO\ T<Q\
M+/\ PD+K_P"+K[/HH_LW+O\ GS#_ ,!7^0'QA_PR5_P4]_Z.8^%G_A(77_Q=
M'_#)7_!3W_HYCX6?^$A=?_%U]GT4?V;EW_/F'_@*_P @/C#_ (9*_P""GO\
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M'PL_\)"Z_P#BZ/\ ADK_ (*>_P#1S'PL_P#"0NO_ (NOL^BN7^S<N_Y\P_\
M 5_D!\8?\,E?\%/?^CF/A9_X2%U_\71_PR5_P4]_Z.8^%G_A(77_ ,77V?11
M_9N7?\^8?^ K_(#XP_X9*_X*>_\ 1S'PL_\ "0NO_BZ/^&2O^"GO_1S'PL_\
M)"Z_^+K[/HH_LW+O^?,/_ 5_D!\8?\,E?\%/?^CF/A9_X2%U_P#%T?\ #)7_
M  4]_P"CF/A9_P"$A=?_ !=?9]%']FY=_P ^8?\ @*_R ^,/^&2O^"GO_1S'
MPL_\)"Z_^+H_X9*_X*>_]',?"S_PD+K_ .+K[/HH_LW+O^?,/_ 5_D!\8?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%))(D2-+*X55!+,QP /4TM?F)^U'X:U+_@K-_P %D]<_X)N?%7Q;K-G\ O@3
M\/=/\1?$3P=HNJS67_"::[J/ER6EK>RP,DC6<=O(K^6K#YXV_OJ4 /TMT+Q/
MX;\46[W?AGQ#8ZC%')LDEL+M)E5O[I*$@'VJ]7Y3?\%2/^"8WP1_X)F_LVZI
M_P %+_\ @E9X3'P?^)7P>-MJ^HV'AW4+E=)\6Z,MQ&MWIVHVC2&.:/RG>0,
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M HHHH **** "BBB@ HHHH *_)/\ X)V?M2?"[_@A+X@^(?\ P35_X*&ZG=>
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M8_'G6K'2_$GBO_A"];BB%Q<S1Q6F@:7YUBB6EA'(T4:Y*"0JKOM542/]?J*
M/S _X+P?\%H-#_9*^)'AK_@G=\._C=;?"SQ;\0-+2^\7_&/5])NKNW\$:#*\
ML9GM(+:.26YU"7R94B"J%C.UF920\?J/_!&#]JO_ ((WW/@V/]AC_@F%\=8?
M%.H^']%G\1>(C<:%J<.H:LWG00W6K7MS=VL2W%Q)-/"&.<@,JHJQH OW=10
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5^8G[4GB35/^"3/_  62US_@I-\4O"&LWOP"^.OP]T_P[\1O&&AZ3->_
M\(7KFG^7':7=Y% KR"SDMXU3S%4_/(W=%$GZ=TCHDBE'4,K#!!&010!^4O\
MP5&_X*>? _\ X*;?LYZG_P $R?\ @E7XN7XO_$SXPK;Z7J-]X>L+DZ5X2T0W
M,37FI:C=/&L<48C5H@H);,H.,[%?[3^*G[3/[&O_  2!_9+^'>B?M/?&=/"?
M@_0M.TSP7H&KW>D7ET;J:VL"L2%+2*5E)AM7;)&T;<9R1F;XD_\ !-7]G/QQ
M^U;X'_;5\(R:WX!^(?@B"2R_MCP%<6]DFOZ9(P9]-U.%X)([NV)R0,*Z%MR.
MK!2OT%0!^.__  ;)_P#!3']AX_":X_8H'QVM_P#A9_C+XQ^+-6\->%?[$O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MPU\'-4M=1^&F@^(9/%WPSUS45MKS3M:T9)3=Z5+<+'(JG?& )1&WR2(Q0'*
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M1U>*X4!9%)P!@U[[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 <7\=?^11MO^PDG_HN2O)Z]_UWP[H_B:T6PUNS\^))!(J>8RX8
M C.5(/0FLG_A4OP^_P"A?_\ )N7_ .+KY+.,AQF88UUJ<HI62U;OIZ)@>+5Z
MQ\"O^11N?^PD_P#Z+CK1_P"%2_#[_H7_ /R;E_\ BZUM"\.Z/X9M&L-$L_(B
M>0R,GF,V6( SEB3T HR?(<9E^-5:I*+5FM&[Z^J0%VBBBOK0"BBB@#\RO^"W
MOPE^&7QU_P""F'[ ?PE^,G@32_$WAG6_''C*'5]"UJS6XM;R,:99N%DC8$,
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MNF%E:)$)#ZMM R>>]/OO#^@ZI?6VIZGHEG<7-FVZTN)[9'> \<HQ&5/ Z>E
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MI=O4B)L G /[G:=ING:/91Z;I&GP6MM$,16]M$$1!UP%4 "IZ /R)_X*Z?\
M!23]DK_@K-^PK%_P3R_X)Y_$)/B=\3?CIKFA6>G:#I&E7/F^&[2#4[6]N=0U
M,/&HLHX5M]K^80P+[L%58C?_ ."A/[1_@;]C'_@OU^S[\6_BO9:E+X0TO]GK
M6K+Q3XBM=.ENSH5I)>F,:E.D2LX@6;R4ED (C29G;Y5-?J7I_AWP_I-[<ZEI
M6AV=M<7C[KR>WM41YVR3EV !8Y)Y/J:^>/'O[$7C+Q=_P53\!_M^6_C#2X]
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M.FP7=M* );>ZA62-P#D95@0>0#1INEZ9HUE'INCZ=!:6T0Q%;VT*QH@Z\*H
M% 'PA_P;#HB?\$,O@4$4 &V\0$X'<^(M3KY=_P""<FL_\$[K7_@V%^"'A/\
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MDN)7Y*QQ*S$ D# ) !Z/17Y<_M>_\%@/A=^T!\9/V5_!/['?QX\6>']4U/\
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MD,=Q-/8VUN\]FD3@JS7"1@," 2>*]U^ '[5/[/?[47P$TS]I_P"!7Q4TS7O
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MNM/I&MVNN>&+_2+O3[Y(8IF@EM[Z&*0,(YXFW!2I#C#'G'JE !1110 4444
M%%%% !1110 4444 %%%% !7S[K'Q%_X*10ZO=0Z)^SE\/I[)+EUM)IO%\BO)
M$&.QF&W@E<$CM7T%17I9=F%+ 2DYX>G6O;XU)VMVY9QWZWN>9F675<PC%0Q-
M2C:_\-P5[]^:$]NEK'SK_P +*_X*:_\ 1M'PY_\ "SD_^)H_X65_P4U_Z-H^
M'/\ X6<G_P 37T517J_ZQ83_ *%V'^ZK_P#+3R?]6\7_ -#+$??2_P#E)\&?
M\%#/&_[=&L?L?>+].^,?P.\%Z/X;D_L_^T=1TGQ,]Q<0XU"V,>R,J V9 BGT
M#$]J_,:OVA_X*R?\H_O'_P#W"O\ TZV=?B]7]5^!N-IX[A*O4A1A22KR5H<U
MG^[I:^]*3OK;>VBT/Y)\>L#4P'&%"G.O.JW0B^:?+=?O*JLN6,5;2^U[MZA7
MVC_P2%\2_M-^'O\ A87_  SG\-/#GB+SO[)_MG_A(-9:T^SX^V^5Y>T'?NS+
MGTVKZU\75^BW_! ?_FK'_<!_]R-?1>+&)AA. ,95E3C42]G[L[\KO5@M>5Q>
MFZLUJOD?-^$6&GC/$/!48U94V_:>]"W,K4:CTYE):[.Z>C?74^C/^%E?\%-?
M^C:/AS_X6<G_ ,31_P +*_X*:_\ 1M'PY_\ "SD_^)KZ*HK^,O\ 6+"?]"[#
M_=5_^6G]M?ZMXO\ Z&6(^^E_\I/G7_A97_!37_HVCX<_^%G)_P#$U] Z/+J<
MVD6LVMVT<%Z]LC7<,+[DCE*C>JGN V0#5FBO-S',J./C%0PU.E:_P*>OKS3E
MMTM8]/+<LK9?*3GBJE:]OXC@[6[<L(;];W/RY_X+T?"K7/C=_P %#_V#/A5X
M:^+WB7P%?:SXU\8PV_B_P?<1Q:EIA&FV3^9 \B.JL0I4Y4\,:XCQ/^S7KW_!
M*;_@K7\#_P!IO]L7X[^+OC]X$^(3S> O!_Q)^*>IR3:C\,/$-TC>0(Q&RVGD
M7RF2)I/)5T"R,64*?-_3CXM?LG?L_P#QS^+OP[^._P 4_ /]J>*_A1J%[>^
M-5_M6[@_LN>[B2&X?RH94CGWQHJXF5PN,J 233OVI?V4?V?OVU?@QJ/[/G[3
MGPZA\4>$=4N+>>[TN2^N+5Q+!,LT4D<]M)'-"ZN@.Z-U)&5)*LP/E'K'YL?M
M367[86I?\')\=E\"/B#\+O#OB1_V:(!\-+CXO>';W4;.>V_M&0ZBFG+:W,!2
M]W!RY!+FW5QC;FO=_@9^P9_P4$_X>:>$OV^/VM_CW\%[F[T?X>:GX2O=*^&7
MA/4=,N=:L)G6>)9S=W4WFK#<!)!TVY/J*^BOVL/^">O[(G[;W@?0_ G[3'PF
M7Q%'X7E$WAC6#J]W;:MI$P51YMOJ$$J74;'8A8^9^\**7W$"N?\ V5?^"6'[
M&7['/Q.NOC=\(?!?B&Z\:7>DR:7+XK\7^.]6UR]6Q=XW:W1K^YE6)"T49.Q5
M)V#).!0!\=Z?\$/^"G__  1!_9L\5>(?V1O'/P?^-'[.G@A=9\80^$O&L5UH
M_B;3])DDFU&YBMM1MS);7;*'E<23KN?^%1\L=<#^W_\ '/XP?M6?MU?\$\/V
MBO@+JO@[PAI/Q \"ZSKWPZ;XPZ-<7VC67B"\TZVFC@N(K::'=>"&1$MVWX\[
M!CR37UG%_P &]/\ P2O@5=%@^#/BE?# N1<-X#/Q5\0MH#N&#_-8-?&)DW -
MY9&SMMQQ7T/^T/\ L5?LJ?M6_ R+]FKX^_ W0O$'@BU2!=-T%K<VZ::8$V0O
M:/ 4DM'C3**\+(RJ2H(!((!\A^)/V!?^"HGQN_;#^ _[2_[5?[1OP"C3X.^,
M9]0L7\ >"=5T_4[ZUNK9H+S3Q-=7DRF.6+JF!R@/0&G^"OVA?^"C?_!1+]IG
MXZ^!/V2OVCOA[\#/ WP5^(TO@J2ZU3X;'Q/KNNZE;PQM<7<L<MY;0V]L2P6(
M@,S!6R3MX]E_9^_X(V_L'_LW_%[1/CSX,\$^+-7\6^&!(/"^K>,_B3K>M?V.
M)(7A?[/%>7<D49,<CINV%@&(!&33?CU_P1@_X)Z?M'_&_6/VA?B'\(]7M?$W
MB:"*'QA/X6\<:MHT'B..-0J+?P6-S%'<_+\I++EAPQ/% 'PK_P $HM<U&]_8
M$_X*.:'/\7-+\<P67Q,\>N/%.@Z)'INGZM<OH0%Q>6UK%))'!',\>\*CLN""
M"0<U]>_\$6/ :?#[_@AW\&]+^"VAVUAJM_\ "--4LUAB51-JMU"]PTS]F9IY
M,DG^0KVOX._\$[_V,OV?OAQ\0/A#\%O@98^&_#'Q0EN)/&VAZ9J-VEO>F>T6
MSD6-3,?LB&W58PEOY2J!E0IYKT#X(_!;X9_LY?"+PY\"/@SX:_L;PIX2TB'3
M/#^E?;)KC[):1*%CC\V=WDDP !N=F8]R: /B?_@V-_X5H/\ @D!X!7P=Y/\
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M8WC$Z>?$,.F7MRT%R;&W^S6VV&65XX=L60?+5-Y)9]S$M0!^<O\ P2+^&?\
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M[<4G_!0[_@G'^T/X!T7Q]<> (/!WC#P1\4] GO=%U6SAN6NX'\^S<7-E(&<
MA 0P"GCG=M^$?^"$?_!,?PQ]CN]3^!FK^)-2TW5-/O\ 2]<\7?$#6M2O[![&
M83VL4%Q-=EX8$E"N8$(CD*KYBOM7'5_M/?\ !)?]BG]K7XO/\?\ XG>$O%.G
M^-IM,ATZ[\2^#?B)K&AW%U:1;O+AE%C=1QR*NYL%E+<]: ,7_@F!^WY\6OVP
M;WXK_!;]I3X,:1X,^*/P3\81>'O&T'A;66O]'U!Y8/.AN;25U#JK*&S$^63"
M[CEBJ_5U>7_LF_L9_LT_L._#27X2_LP?"ZV\,Z/=:C)J.I%;J:ZNM1O9 !)=
M75S</)-<RL% +R.QP !@  >H4 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%?*W_  5.\>S?#?P%X:\3ZY_P5)TO
M]E[PPM[<Q:[J\VA:7=W^ONRQF&VM'U .(F0+*[>5%([!A]T*2?EG_@EC_P %
M1[WQO_P48N/V$]%_X*)V'[4/@/Q%\/+GQ%X8\<3^%H=+UCP]J-K.B3:9=&WA
MACNHI(7,RS;-X*[> .0#]3Z**_)[_@G1JW_!7;_@J;\&/'/Q.\6?\%*]0^%N
ME^%OB=XA\.^#)O"?PXT2XO-5:UNF"7%\9;<(;>$.D"0Q+&\ABD>61B4P ?K#
M17YA>%O^"VGQF^"O_!(WXW?M&_M+>%=#U?XT_L\_$;4?AEX@@LE-OINO^((;
MNWM;6_"*5\NW<744LBJ4!$,VSRPRJOB7Q=_X*$_&#]FCX!W'[7?A;_@XM^#_
M ,7?B3X=M(]8\0_ U%\-)H'B")2K7.DZ?]E(O8I%0LL,RNTDK1KN4>8< '[5
M45^;W[??[<O[;/B[]I[]A_X8?\$^OBOIOA+3/VEO#OBF_P!9_P"$B\-6NHQ1
M6<>CZ?>V]ZRR+YAELX;BXN$BCEB2:5$24M&2*N?M7_%G]NW_ ()^_"[X<_L?
M?#O]K6X^+GQQ_:*^+S:-X,^(GQ$\*V-M!X2TT6D+7MP;2R1(KA;<1M+&A7EK
MEL[A&$8 _16BOF#]F?\ 8W_;G^"'Q7TCQK\5?^"J'BOXJ>'OLTZ>*?"/BCX<
MZ+:0WTS0L(IK6>SBCEL@DI5_+S(K+E3V:OA;1_\ @J%=?MW?%GXE^,/$G_!;
MKP+^RCX(\)>.-0\-?#OP'9R>'VUO5XK)A&=:U%]5WN(YI-WEV\:HNQ<$DC>P
M!^Q%%?E=\*_^"MG[0OQ+_P""0'[4_P 3=,^.?A7Q#\5OV=Y]9T;3/BUX(L;2
M?2_$R0P)/8:W#;L);96EC<AX0&C#QM@ ':M'XS:I_P %E/ ?_!-6V_X*O7?_
M  49@M_%6@_#K3_&M[\';?X<Z7_PCESIHMXIY[*>;R_M+W+P,SR3HZ+YI9(D
MB38R@'Z8?$WX^_!OX,^(?"?A3XH_$+3]$U'QUKRZ+X1M+UR'U34&0N+>+ .7
M*JQP<=*Z^OR5_P""P,/Q@_:@^*W[ /QP^%G[2&L^ K'Q_P#$;1I="TJT\-Z9
M??V%J-UITUVNJ*]U YGE6*58?)DW0$)NV;B37U[\;_!_[0W[/7[$VHV_Q<_X
M*ZQ>$M4L]?2[U;X[^-? 7AZW>QTUL+]ABM5C@L1(S *DKH[YD("N=HH ^K:*
M_'/]GK_@K+9_";]O[X._ WX5_P#!8"V_:J\$_%?Q-)X9\3^'->\(6EGJWAF\
MDB9K34;6\L[:!9H6F58GB<,%4Y7);<GT1\6?BW^VE^WG_P %.OB1^PK^S#^U
M->?!/X?_  "\,:'=_$/Q/X=\.66H:SKVLZQ UU:6D37L<D5O;1VZ%F95+%U9
M3D,-@!^@E%?GE^PE^T'_ ,%!] _X*]?%+]@C]KS]H:P\<^$_ OP9T[7/"^KV
MOA2QTR35C/?*HU"Y$$89+@([V\B(X@)M_,2-"^!\W_"7_@J+JG_!0VS\2?M(
M>*?^"\O@#]EC0IO$6H6?PN^%=@OAR74+>PMIFA@U'6?[4+32RW!0R?9AY<8C
MVE6P^: /V=HKY%_X(L_M[^,/^"@'[)>K^+_B9KWAO6_%GP]^(FK^!?$_B?P=
M(K:1XAN; Q-'JEGM)7R;BWN()1M.TEF*X4A1%_P5[_;)^/G[-_@WX7_ ?]D:
M72K3XK_'CXEV?@SPEK^NV8N;3P]%(K27>J/">)S!& 5C(()?)#!=C 'U_7SU
M^V#_ ,%+?@+^QM\0_#GP5\1^#?B#XZ\?^*]-GU+1? 'PK\%7&NZO)80L$EO'
MAAP(H YV[W9<D-C.UB/E?XY^.?\ @H5_P2*^*GP<^*GQD_;KU/X]_"7XB_$G
M3? OQ$TGQ?X,TS3K[0KO4=ZV^K6,UA&A$*R(=]O)O 7"KDOOC\\^*W[./[7/
MB_\ X.5-0\-^!O\ @HIXG\*:KJ'[)UWKFC>(+/X>>'[N31]&?Q9Y::!'#<VC
MQ2PHY$HNI%:Y)7:9"I(H _5OP)XJ7QUX(T;QNOA[5=(&LZ5;WPTG7;(VU]9>
M=$LGD7$)),4R;MKH2=K*1VK%^&GQ]^#?QC\3>+?!OPP^(6GZUJG@36_['\7V
M5DY+Z5?;!)]GER!A]K \9X-=1IEM>6>F6]G?ZBUW<10(DUV\:HTSA0"Y50%4
MDY. ,#/%?D+_ ,$F?V7?VT=9_;#_ &M(_#W_  4X\6:.WAO]H*.'Q?)!\,_#
M<Q\7S+:0N\\XELR+0NG[LK;>6H'S !N: /V!JIX@U[1_"N@WOB?Q#J$=II^F
MVDMU?74IPD,,:EW=O8*"3]*_/.U^*'[=/_!3S]N?XV_!_P#9\_; U#X%?"'X
M!Z[;^%9+_P *>%]/O]9\5>(3!YMT\DM]'(MM;VY(0(BYDW D\_)A?##]H?\
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MV2X2,L23&)DD"Y).W&>:_6&@ HK\X/V@?C3_ ,%)?CA_P6C\3?\ !/#]FO\
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M7D:R11K).SM$6!F9R#P"!Q0!]U45^*_PL_X*#_%W]J'X$1?M:>,?^#BOX/\
MP9^(GB*P?5_"WP/M3X9DT3P[&V7MM+U)KPM>3RLFQ9I&9'B:1@JGRP#^DO\
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7 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>biib-20220331_g13.jpg
<TEXT>
begin 644 biib-20220331_g13.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#5H=3N+F>(30"62XEC<$AU""0;1M0)7VS10 5X]^WW^QGX _X*#_ +(/C?\
M8]^)VMWVF:/XTT^&&34],"F>SG@N8KJWG4-PVR>")BIQN"E<C.1[#10!\:^*
MO^"='[:'QS_8M^+W['G[77_!1NQ^(*?$7PO!HWASQ-;_  9MM(F\/A3)Y\TT
M5O?D:@TH,/&Z *8F(SO('J7[0W[$O_"^O^"<^N_L _\ "S?[*_MKX9Q^$?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5;_Q->:1=&TU+7F9KZ]TH7LZZ=/.S$EV:T$!5R2738Q)+$G\Z?C=_P %H_\
M@G1_P4Z_:^OO!W[;_P"U/%\/OV8OA;X@5M'^&5QH&JSWGQ2U:!\K?:I]DMI%
MBTR)U!CM&8/(P#2*/NI^RW[(_P"U3^S9^V3\$-.^-O[)?CNU\1>")YIK'3-1
MLM+N+.(-;MY3Q+%<11.H0KM'R <<<4 7_P!I;XA?&OX7_"*_\6_L\?  _$[Q
M;'<6\.E^$#XGM]&2Y\R54>22\N%9(8XT+2-\K,0FU59B!7R[X?\ ^"EW[9/P
M._:$^'7P;_X*-?L,Z)\/O#_Q:\2IX:\%_$'P/\25UZQAUV6-Y+;3;V)[6"6%
MYA&ZI*NY2PQC&YEJ_P#!P1\6/BY\(/V.?"&M>"O'GB_PCX'U#XR>'M.^.7C/
MP&94U70?!4KS?VA=02PJ9(/F%NAE0%@)-N"&(K\X_P!KJQ_X)%P_M)?LDW7_
M  3(NO$OC?5XOVM/ A\:_$9/B!XDUS2M/C>])ALII-1NY+47MPRM*JQKYJ)9
MRYV*X# 'Z:_M;_\ !5CXI? C_@H1I/\ P3A^!W[%NH?$SQEXG^$*^,O#=];>
M,8M.MA/_ &E/:/;WIEMV6TMHX;:6=KK>[%O+A2!GD4UK?L4_\%&?C7\6_P!K
M/Q?^P/\ MG_LMVOPK^*WAOP?!XNTB'1/%RZUI7B+0)+G[*UY;S^3$R&.X*Q-
M&ZYSDY&"!YU>(C?\'25F64$K^P7(5)'0_P#"9X_K3_$7'_!SWX<([_L0WN?_
M  JUH N:9_P54_;!_:-^*WC^#_@GG_P3[LOB;\-OAAXHN?#FN>-_$'Q,AT*3
MQ#JMKC[9;:1 ]M*LHB)"B:5TBD9@ RCFN1_X-KOB1IWQC^#7[4/Q=T?1=2TV
MT\5?MJ^.=8M=.UFU\B\M8[F+39EBGCR?+E4.%=<G:P(SQ7FW_!*K]O7]ES_@
MD_\ "+XA?\$\OV^OB./AWX_^'7Q.U^\TZVUK3+EG\8:3?7LEU9:CIWEQL;WS
MA(4$<>Z3* %<G%>B?\&S_C#4OB%\"_VF_'VL^";[PS>:Y^VAXWU"[\-ZI!Y5
MSI4DT.FR-:3)_!)$6,;+V9"* /M?]K;]DWX2_ML?!:\_9]^.9UJ3PMJ=[;3Z
MM8Z'KD^G27T<,HD^SR30,L@A<J ZJREEXR*_,#_@J-^P'^QY_P $V_'O[-_C
MK_@F!\.?^%:_'_7OC5I&B>%-&\'ZO=EO$NCLQ.I0WT$DKB:T2/RS+*X^4. S
M;6./T3_X*4?M]?#+_@F?^R!XG_:W^*>AW^K6NB+%;Z9HNFC$NI7\[^7;V^\@
MK$K.1ND8$(@8@,<(WY@_\$V?^"J/_!*$?&:?]O\ _P""@'[?V@^*_P!I3QW;
MI8:;IEGX-UU]*^'>ERMB+0M*#6153\^)[D$F1F<!V#223 'TW_P5KM+G]L7_
M (*-_LR_\$I?%FM:A;_##QC:Z[XU^+FDZ=J$MLWB&RTV#-EITKQ,K_9WN%?S
M4##<"C##1J:Y7Q7\ ?A5_P $A?\ @L/^SC9_L9^&O^$+^&G[2%OKWA3XC?#_
M $N[E_LMM2L;2.YT[4H8'9EBN"[B)F7 \M6XS(Y/5?\ !6RZNOV.O^"C/[,W
M_!5OQ7H>HW/PP\&VNN^"_B[JVFZ?+<MX>L=2@Q9:C*D2L_V=+AG\UPIV@(HR
MTBBN4\4?'_X5_P#!7W_@L-^SEJ'[&7B,^,_AG^S?;Z_XK^(WQ TVSF&EKJ=]
M:1VVG:;#/(JK+<!T$K*N1Y;-SF-P #Z0^+__  1"_P""9WQ_^,_BW]HO]I7X
M"'Q_XG\5R^9?:AXO\1WTT.GPK$L8@M(5F2*UC4)D%%#Y));ICQ3_ (-R=0U6
MW\ _'[X>_#'QMK/B/X!^$/CEJ6C_  "U?6M0DNQ_942@3P6D\A+364<FP1/D
MJ2TA!SNKPG_@K]_P61_9Y^+7[86J_P#!)[QY^U5/\$/A3X?"I\>OB#'I5_-J
MOB%65';P[I2VEO,T"2(X6>ZD"@J75=R@K/\ H#_P3%_:[_X)M?M&?!=_A9_P
M3+\<Z3J7@OX86UII3Z5HV@WUA#I:2+(T*8O((FD9_+E9G&YF;<SL6;) /@K]
MJK_@G!^S3^Q%_P %C_V(_B/\'H?%-]XF\>_$WQ0WBGQ#XM\87NJW-XL6G))%
M&!/(8XD1IY<"-%^]@Y &/V+K\4_^"IO_  6/_P"";/B;_@J#^R3XGT/]INUG
ML?@A\3/%2?%*<>'-47^PBUG%:J&#6H,^9HI$_<B3[N>A!/ZY_LV?M)_!/]KW
MX*:'^T5^SIXYC\2^#/$B3MHNMQ64]NMR(;B2WD(CN(XY%VRPR+\RC.W(R""0
M#N:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@".[M+6_M9+*^MHYH94*2PRH&5U(P00>"#Z5'I>E:7HEC'I>BZ;;VEM$#
MY5O:PK'&F3DX50 .23^-6** "F75K;7MM)9WMO'-#*A26*5 RNI&""#P01VI
M]% %71]#T7P]9#3= TBUL;96++;V=NL2 GJ=J@"K5%% !45_86.J6<FG:G90
MW-O,A6:">,.CJ>Q4\$?6I:* *NCZ%HGAVR&F^']'M;&V#%A;V=NL2 GJ=J@#
M-6J** "O.OV8_P!EKX/_ +(WP_O_ (=?!K1KBWM-6\3ZGXBUJ[OKDSW6HZG?
MW+W%S<SRGF1V9]H)Z(B*.%%>BT4 %%%% !531] T+P[;O:>']%M+&)Y#(\5G
M;+$K.>K$* ">!S[5;HH **** "BBB@!LL44\303QJZ.I5T<9# ]01W%5](T3
M1?#]D--T#2+6QME8LMO9VZQ(">IVJ .:M44 %%%% %2]T'0]2OK;5-1T:TN+
MFS8FSN)K=7D@)ZE&(RN<#IZ5;HHH **** &RQ13Q-!/&KHZE71UR&!Z@CN*@
MTC1=&\/V*Z9H.DVUE;*25M[2!8D!)R2%4 <U9HH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **\2_8(U34]7^#6J
MW.K:C/=2+XWUA%DN)F=@HN2 N6)X Z#M7MM !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% 'A?_  3W_P"2)ZM_V/>L_P#I2:]TKPO_ ()[_P#)$]6_['O6?_2DU[I0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!X7_ ,$]_P#DB>K?]CWK/_I2:]TKPO\
MX)[_ /)$]6_['O6?_2DU[I0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X7_P3W_Y
M(GJW_8]ZS_Z4FO=*\+_X)[_\D3U;_L>]9_\ 2DU[I0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!X7_P3W_Y(GJW_ &/>L_\ I2:]TKPO_@GO_P D3U;_ +'O6?\
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M]G;X&0_M >,/ =A9:5XET6#QA;Z&;BV*3R7,]G<7HV$13-&D<3A2\0Q\IZ>
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU6TG6-(U_3HM8T+5+:]M)UW075I.LD<@SC*LI(/((X]* /J__AY;_P!45_\
M+C_^YJ/^'EO_ %17_P N/_[FKY9HH ^IO^'EO_5%?_+C_P#N:C_AY;_U17_R
MX_\ [FKY0FUC2+;4(M(N-4MH[N92T-J\ZB20#NJDY(X/2K- 'U-_P\M_ZHK_
M .7'_P#<U'_#RW_JBO\ Y<?_ -S5\LT4 ?4W_#RW_JBO_EQ__<U'_#RW_JBO
M_EQ__<U?+-% 'U-_P\M_ZHK_ .7'_P#<U'_#RW_JBO\ Y<?_ -S5\LT4 ?4W
M_#RW_JBO_EQ__<U'_#RW_JBO_EQ__<U?+-% 'U-_P\M_ZHK_ .7'_P#<U'_#
MRW_JBO\ Y<?_ -S5\LT4 ?4W_#RW_JBO_EQ__<U>P_LX?'[_ (:"\-ZAXA_X
M1/\ LC[#?"W\G[?]HW_(&W9\M,=<8P:_/BOL+_@G#_R3?7_^PXO_ *)2@#Z*
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#PO\ X)[_ /)$]6_['O6?_2DU[I7A?_!/?_DB>K?]CWK/_I2:]TH
M*^(O^"@'_)?!_P!@.V_]"DK[=KXB_P""@'_)?!_V [;_ -"DH \0HHHH ***
M* "BBB@ HHHH **** /F3]O3]H?XF?#SXM?"3]GWP)\5M-^'-G\2=1U--7^(
MNIV$%Q_9R6D$<B6T*W'[@33M)L5I 0"!M#$XJI_P31^%OQQ\,?!_PIXRUW]I
M^]\2^$+[0)Q!X1U'PS91FTG-P=DT5Y J2% %?,;A@=^01C![K]LKXJ_LC>$]
M'TSX>?MD>$([[PUKXFE@O=7\)S:CID$T.P 2RQQ2"VE(D)1FV\*^&!%?%?\
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MJB@#YL_X4#\6_P#H4_\ R?M__CE'_"@?BW_T*?\ Y/V__P <KZ3HH ^;/^%
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M;F0*2=F\KEMN3],T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!X7_P3W_Y(GJW_8]ZS_Z4FO=*\+_X)[_\D3U;_L>]9_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]/\
M@5_R KW_ *^Q_P"@BO,*]/\ @5_R KW_ *^Q_P"@B@#N:*** "BBB@ KAOCK
M_P @*R_Z^S_Z":[FN&^.O_("LO\ K[/_ *": /,**** "BBB@ HHHH ****
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M6_Y'/_MTD_F*Y*NM^"W_ ".?_;I)_,4 >MT444 %%%% !1110 4444 %%%%
M!1110 4444 >%_\ !/?_ )(GJW_8]ZS_ .E)KW2O"_\ @GO_ ,D3U;_L>]9_
M]*37NE !7DGQI_Y'/_MTC_F:];KR3XT_\CG_ -ND?\S0!R5%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7I_P
M*_Y 5[_U]C_T$5YA7I_P*_Y 5[_U]C_T$4 =S1110 4444 %<-\=?^0%9?\
M7V?_ $$UW-<-\=?^0%9?]?9_]!- 'F%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !76_!;_D<_P#MTD_F*Y*N
MM^"W_(Y_]NDG\Q0!ZW1110 4444 %%%% !1110 4444 %%%% !1110!X7_P3
MW_Y(GJW_ &/>L_\ I2:]TKPO_@GO_P D3U;_ +'O6?\ TI->Z4 %>2?&G_D<
M_P#MTC_F:];KR3XT_P#(Y_\ ;I'_ #- ')4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>G_ K_D!7O\ U]C_
M -!%>85Z?\"O^0%>_P#7V/\ T$4 =S1110 4444 %<-\=?\ D!67_7V?_037
M<UPWQU_Y 5E_U]G_ -!- 'F%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !76_!;_D<_\ MTD_F*Y*NM^"W_(Y
M_P#;I)_,4 >MT444 %%%% !1110 4444 %%%% !1110 4444 >%_\$]_^2)Z
MM_V/>L_^E)KW2O"_^">__)$]6_['O6?_ $I->Z4 %>2?&G_D<_\ MTC_ )FO
M6Z\D^-/_ ".?_;I'_,T <E1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5Z?\  K_D!7O_ %]C_P!!%>85Z?\
M K_D!7O_ %]C_P!!% '<T444 %%%% !7#?'7_D!67_7V?_037<UPWQU_Y 5E
M_P!?9_\ 030!YA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5UOP6_P"1S_[=)/YBN2KK?@M_R.?_ &Z2?S%
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M]@^+]*6]LHKZ()/ =S))#( 2 \<B/&V"5RAP2,&N,_X* ?MP>'_V$/@WIGQ
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MFN&^.O\ R K+_K[/_H)H \PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MGX6ZW_P5ZTU?#]["UM=Z_8?!*RMM=>U9=K(LJ7(CBE*DCSD4,"=XP0*^V:*
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M KW_ *^Q_P"@B@#N:*** "BBB@ KAOCK_P @*R_Z^S_Z":[FN&^.O_("LO\
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M>&]'N=4U>\?I!:V\32RO^"(Q_"@#X#_9N\;_ /!1#3?^"OS?L?>+?^"A%_\
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M* "BBB@ KK?@M_R.?_;I)_,5R5=;\%O^1S_[=)/YB@#UNBBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#PO_@GO_P D3U;_ +'O6?\ TI->Z5X7_P $]_\
MDB>K?]CWK/\ Z4FO=* "O)/C3_R.?_;I'_,UZW7DGQI_Y'/_ +=(_P"9H Y*
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ KT_X%?\@*]_Z^Q_Z"*\PKT_X%?\@*]_Z^Q_Z"* .YHHHH ****
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M\@*]_P"OL?\ H(KS"O3_ (%?\@*]_P"OL?\ H(H [FBBB@ HHHH *X;XZ_\
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MBB@ HHHH **** "BBB@ HHHH **** "O3_@5_P @*]_Z^Q_Z"*\PKT_X%?\
M("O?^OL?^@B@#N:*** "BBB@ KAOCK_R K+_ *^S_P"@FNYKAOCK_P @*R_Z
M^S_Z": /,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "NM^"W_(Y_]NDG\Q7)5UOP6_Y'/_MTD_F* /6Z***
M"BBB@ HHHH **** "BBB@ HHHH **** /"_^">__ "1/5O\ L>]9_P#2DU[I
M7A?_  3W_P"2)ZM_V/>L_P#I2:]TH *\D^-/_(Y_]ND?\S7K=>2?&G_D<_\
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MHHH **** "BBB@ HHHH \+_X)[_\D3U;_L>]9_\ 2DU[I7A?_!/?_DB>K?\
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M5_O1I1S3VM50Y+7\_P#@'W!1117[2>L%%%% !1110 4444 %>9?M9?'GQ_\
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M /L.-_Z)>OBO$7_DBL9_A7_I43DQW^Z3/CNBBBOXX/E@HHHH **** "BBB@
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M_L.-_P"B7KXKQ%_Y(K&?X5_Z5$Y,=_NDSX[HHHK^.#Y8**** "BBB@ HHHH
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MVT ?K-1110!X7_P3W_Y(GJW_ &/>L_\ I2:]TKPO_@GO_P D3U;_ +'O6?\
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MP'J>D:C\#?@-I?C[2Y8YEUVP?Q5'I=_;R93RGA:=##*F/,#*S(<[2#UKY/\
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M_8F_X)YMX&\ >&]'\7?%*!KK58]"-VL-A)>W5UYCVZR/)$H1(V(SO4%E)'!
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^Q/\
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M ()M_P#!-GXP^/\ 4+@[(O&7Q$T7_A$?"=GGCS9;ZZ+2S;/O-#%$9& PO)%
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M$O7KY%_R-Z7K^C/G^*O^2?Q'HOS1\DT445^JGX.%%%% !1110 4444 %%%%
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M7/./M+<U[?\ \)CX8_Z#4'_?5 &E7Q?^WC_R70?]@6W_ /0I*^OO^$Q\,?\
M0:@_[ZKX[_;CU"RU/XVBYL+E98_[&MQN7IG<]?2<*_\ (T_[=?Z'QG'?_(C_
M .WX_J>.T445^D'XT%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %?6W_!/+_DG>N_]AH?^B4KY)KZK_8"US2-*^'^N
M1:C?QPLVL@J'/4>4E>!Q-_R*)>J_,^LX)_Y*"'I+\CZ-HK-_X3'PQ_T&H/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5];?\ !/+_ ))WKO\
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MHHK\E/W\**** "BBB@ HHHH **** "BBB@ HHHH \+_X)[_\D3U;_L>]9_\
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M_P#)I_\ R1Y3_P ,Q_\ 4[_^4W_[91_PS'_U._\ Y3?_ +97JU%'_$1.,?\
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MCKS<X_Y%=;_"SV>'O^1YA_\ &OS/M"BBBOR4_?PHHHH **** "BBB@ HHHH
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M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5[1^P=_R70_\
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M_P"0/GZBOH'_ (4C\+_^A8_\G9__ (NC_A2/PO\ ^A8_\G9__BZ/^(L\.?\
M/JK_ . P_P#E@?\ $/\ .?\ GY3^^7_R!\_5[1^P=_R70_\ 8%N/_0HZV?\
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MU+X#?\@&]_Z_!_Z *][AK_D;1]'^0'=4445^E %%%% !7"_'G_D V7_7X?\
MT UW5<+\>?\ D V7_7X?_0#7DY[_ ,BFKZ?J@/+:***_+0"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "NO^"?_(Z?
M]N<G\UKD*Z_X)_\ (Z?]N<G\UKT<H_Y&='_$@/7:***_5P"BBB@ HHHH ***
M* "BBB@ HHHH **** /"_P#@GO\ \D3U;_L>]9_]*37NE>%_\$]_^2)ZM_V/
M>L_^E)KW2@ KR+XV?\CI_P!N<?\ -J]=KR+XV?\ (Z?]N<?\VKYSBC_D6?\
M;R_4#D****_.@"BBB@ HHHH **** "BBB@ HJI9:_H6I:G>Z+IVM6EQ>::T:
MZC:0W*O+:EUWH)%!RA92&&X#(.1Q5NC8 HHJMJNLZ1H5F=0US5;:SMPP4SW<
MZQH">@W,0*-P+-%-CDCFC6:&171U!5E.00>A!JKJ_B#0?#\<<NO:W9V*ROLB
M:\N4B#M_=&XC)]J+,"Y10"",@Y!Z&B@ HHHH **** "BBB@ HHHH *]2^ W_
M " ;W_K\'_H KRVO4O@-_P @&]_Z_!_Z *][AK_D;1]'^0'=4445^E %%%%
M!7"_'G_D V7_ %^'_P! -=U7"_'G_D V7_7X?_0#7DY[_P BFKZ?J@/+:***
M_+0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "NO\ @G_R.G_;G)_-:Y"NO^"?_(Z?]N<G\UKT<H_Y&='_ !(#UVBB
MBOU< HHHH **** "BBB@ HHHH **** "BBB@#PO_ ()[_P#)$]6_['O6?_2D
MU[I7A?\ P3W_ .2)ZM_V/>L_^E)KW2@ KR+XV?\ (Z?]N<?\VKUVO(OC9_R.
MG_;G'_-J^<XH_P"19_V\OU Y"BBBOSH HHHH **** "BBB@ KY]_X*F_M4_$
M+]BK]@[Q]^TC\*O#]KJ/B#0+2TCTU;^!Y+:V>YO(+4W4R)\S1PK,92!U\O!P
M"37T%7 _M.?%WX9_ _X*ZQ\0?C+X4U36?"L2Q6NOV6E>&I=7;[+/(L#O):1(
M[RP*)-TF$;$88[2!BML/95X7CS*ZT[Z[?,#XE_8F^#?[5_CG]I;XB_$GP%_P
M59D\60VNN>%KKQ+J-EX"T.ZTCQ;;-IL,LD48@0-:#R]T,<D,I91AF\Q@<_6_
M[7_[#?P+_;DT'1?"'Q_/B.YT71KR6X.CZ)XGNM-@ORZA2ES]F='E0 <#<,$D
M]Z_'[XQP_L(Z_P#&'XD>)O\ @D<-8T[XYR>+O#'_  I.R^$>GZE90;&BMSJ2
MWML$2VAL@?/,HG5 ",?<WJ?V*_:G_;9_9H_8;\"Z3X__ &M/BK;>$].U>_&G
MV=Z=+N[I)KORFD,:K;12,HVHYRP P.N:];'4\1"M3G2NI-:)149*R71;[Z>C
M70#YD_X-PM,L=%_X)JVVC:9!Y5M:?$3Q)#;Q[BVQ$OW51DDDX ')YKE_!OP.
M^&?_  5)_P""HWQ_E_:T\/?\)=X!^!#:1X5^'W@C4KF7^SH;VYMGFU"_DA1E
M62?>NQ68'Y& ZQH1QG_!NG^W]^R)+\"-)_8QC^,4!^)FN>.?$NH:5X7_ +)O
M=\]L99[P2";R?)7_ $>-Y,-(#\N,;L"NS\(?''X9_P#!+3_@J+\?U_:T\0'P
MCX ^.YT?Q5\/_&^H6LITZ6^MK9X;^PDF166.?>V]5;'R*#UD0':O3Q%/'XGE
M34VFX[W?O*[7ROMTN!M_\$YM<@_8O_:__::_8 M];U";X9_#>QTKQI\.;&^O
M)+E]$TV]M#->6$;R,6\B.4*(T+''S$DER:^.?V<?CS_P3;_:K\%ZQ^V?_P %
M.O /C?XQ>.O%%_>WNMPZ-X7UC6-"^%NA^?*EG8,UIB"U'DQB=C\TN)59L$L6
M^Q/^"=?A]/VU/VM_VG/V_+31]1M?AK\2]/TOP5\-]0OK*2WDUK3;*S:&\U"-
M)0K>1)*5,;$#/S X*$5Y7_P2Z_;._9%_X)2_L=ZY^P_^VYXGB\"?$7X=>)M:
M_M[0[_19S+XIAFN9)+:^L@L9%XDT!BB3!)(B&<+@UJFTZCBI.I^[ORNTOA][
M6S?Q6YO/<#]#/V/+#]G+3/V9/!EG^R+J=K>?#5='5O!TUEJ$UU%]C9F8*))V
M:4[6+*5D.]"I5L%2!:_:C_:1^'7[(_P&\1_M _%*ZD72O#]EYBVELNZXO[EB
M$@LX%_CFFE9(D7NSC.!DCXV_X)=^*[O_ ()M?\$:)?CU^U+X(UWP]HEAJFJ^
M)XO"<-D&O](TJ]U#_1K<0NR!6(D$NPE2!+R V17IW[</[*/QG_X*&:5\#?C;
M^S=^T/IO@>R\(WW_  F%EIGBGP@-6MM0NY[:%M/N);?SD02VJM.RY+ /-D<J
M#7DSPU..-:J2]SF:YGUMKNKZOOKO<#Y1_98^#_QG\#?\%S?AM\7_ -IK49)/
MB9\5/@EK?B?Q?I8G+6^@;[CRK72+<=!':VT4,1/)>02L2=P-?K37Y!>./@I_
MP4OL/^"V/PN\+>*_VW_!^H>.I?@[J5U8>*X/A='#;6^EK>.)K-K7SR'D<AB)
M=V5SC!Q7Z^UKFSYI4I<R=X]+VW=MTM.B] "BBBO) **** "BBB@ KU+X#?\
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MW_5@"J^J:1I.N6AT_6M,M[R!B"T%U LB$CH<,"*L44@$CC2)%BB0*J@!548
M'H*K7NAZ+J5Y;ZAJ.CVMQ<6C;K6>>W5WA/!RC$94\#IZ5:HH **** "BBB@
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M_P CI_VYQ_S:O7:\B^-G_(Z?]N<?\VKYSBC_ )%G_;R_4#D****_.@"BBB@
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]2^ W_ " ;W_K\'_H
MKRVO4O@-_P @&]_Z_!_Z *][AK_D;1]'^0'=4445^E %%%% !7"_'G_D V7_
M %^'_P! -=U7"_'G_D V7_7X?_0#7DY[_P BFKZ?J@/+:***_+0"BBB@ HHH
MH **** "BBB@ HJI=Z_H5AJUIH%]K5I#?:@LC6%E+<JLUR(P#(8T)RX4,I;
M.-PSC-6Z "BBB@ HHJ*]OK+3;22_U&\BMX(EW2S3R!$0>I)X H EHJ#3=3TW
M6;)-2TC4(+JWE&8KBVE61''LRD@U/0 450M?%/AF]U>7P_9>([":_A!,UC%>
M(TT8!QED!W#\15^AIH HHHH **** "BBB@ KK_@G_P CI_VYR?S6N0KK_@G_
M ,CI_P!N<G\UKT<H_P"1G1_Q(#UVBBBOU< HHHH **** "BBB@ HHHH ****
M "BBB@#PO_@GO_R1/5O^Q[UG_P!*37NE>%_\$]_^2)ZM_P!CWK/_ *4FO=*
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M^H[VY%E9RWA@DE\J)G\J%-SO@9PH[D]A0!^1/[-/Q9_:U_X*7?%3X0_'Y/\
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M%%?@_11_Q+O_ -3/_P H_P#W4/\ B*7_ %"?^5/_ +0_>"BOP?HH_P")=_\
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M_P"(I?\ 4)_Y4_\ M#]X**_!^BC_ (EW_P"IG_Y1_P#NH?\ $4O^H3_RI_\
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M3XQHHHK^@C\'"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "OUI_P"#>G_DWKQW_P!CFG_I)%7Y+5^M/_!O3_R;UX[_
M .QS3_TDBKX;Q%_Y):I_BA_Z4C[3P_\ ^2FI_P"&7Y,_0.BBBOYT/Z "BBB@
M KA?CS_R ;+_ *_#_P"@&NZKA?CS_P @&R_Z_#_Z :\G/?\ D4U?3]4!Y;11
M17Y: 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5U_P3_Y'3_MSD_FM<A77_!/_D=/^W.3^:UZ.4?\C.C_ (D!Z[11
M17ZN 4444 %%%% !1110 4444 %%%% !1110!X7_ ,$]_P#DB>K?]CWK/_I2
M:]TKPO\ X)[_ /)$]6_['O6?_2DU[I0 5^,/_!=[_D^<?]B9I_\ Z'/7[/5^
M,/\ P7>_Y/G'_8F:?_Z'/7Z%X9_\E)_VY+\T?!^(W_)._P#;\?U/C&BBBOZ"
M/P<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *_6G_ (-Z?^3>O'?_ &.:?^DD5?DM7ZT_\&]/_)O7CO\ ['-/_22*
MOAO$7_DEJG^*'_I2/M/#_P#Y*:G_ (9?DS] Z***_G0_H **** "N%^//_(!
MLO\ K\/_ * :[JN%^//_ " ;+_K\/_H!KR<]_P"135]/U0'EM%%%?EH!1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M77_!/_D=/^W.3^:UR%=?\$_^1T_[<Y/YK7HY1_R,Z/\ B0'KM%%%?JX!1110
M 4444 %%%% !1110 4444 %%%% 'A?\ P3W_ .2)ZM_V/>L_^E)KW2O"_P#@
MGO\ \D3U;_L>]9_]*37NE !7XP_\%WO^3YQ_V)FG_P#H<]?L]7XP_P#!=[_D
M^<?]B9I__H<]?H7AG_R4G_;DOS1\'XC?\D[_ -OQ_4^,:***_H(_!PHHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K]
M:?\ @WI_Y-Z\=_\ 8YI_Z215^2U?K3_P;T_\F]>._P#L<T_])(J^&\1?^26J
M?XH?^E(^T\/_ /DIJ?\ AE^3/T#HHHK^=#^@ HHHH *X7X\_\@&R_P"OP_\
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MASU^A>&?_)2?]N2_-'P?B-_R3O\ V_']3XQHHHK^@C\'"BBB@ HHHH ****
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MW[/_ ,7_ -H;Q!<^&OA#X,FU:XLK4W6H3&>*"WLX!UEFGF9(HE]W89[9KO\
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MQR_[*?[,.L?M/>-=3TC_ (2ZR\->'_#>B3ZSXM\4:C$TD.EV$.-\FQ2#*YR
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MW_!"'_D^<_\ 8F:A_P"AP5\8U]G?\$(?^3YS_P!B9J'_ *'!7SW%G_)-8O\
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M.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P!*37NE !7XP_\ !=[_ )/G'_8F:?\ ^ASU^SU?C#_P7>_Y/G'_ &)FG_\
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M'_\ 0^?"S\]8_P#BJ/\ AP3^T?\ ]#Y\+/SUC_XJC_B*7#__ #ZJ_P#@,/\
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MAR:/^(I</_\ /JK_ . P_P#DP_XAIGO_ #\I??+_ .0/B6BOT+_X<$_M'_\
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBDDD2)&EE<*J@EF8X 'J:
M%HJCH7B?PWXHMWN_#/B&QU&*.39)+87:3*K?W24) /M5Z@ KR#]H_P "^+O%
MGQ8^$FM^'-!GN[30_&$EUJT\(!6UA,#*';GIGBO7Z* "BBJ%OXI\,W>MR^&K
M3Q%82ZC FZ?3X[Q&GC7U9 =P'N10!?HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *_)3_ ()U?LM_"S_@NQK_ ,0_^"E?_!0W2KGX@>%Y_B'JGA[X
M'_#+4]3N%T/PWH5DXA%U]FB=$ENYV+"1W!YCW ?,HC_6NOR3_P""=G[4GPM_
MX(2^(/B'_P $U?\ @H;J=UX \*P_$/5/$/P.^)VI:7</H?B/0[UQ,+7[3$CK
M#=PL&,B.1S(5!X4R &QXX^#GA_\ X(>_\%-_@%%^R#>:CHGP)_:2\4W'@OQO
M\)Y=4GN=,TG7G5#8:GIZ3.YMGDD?;(JG;LC8 ?,OEZ/_  <F?\$X/V:?B?\
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M]W4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW7_"?AVS^SZ?I?QO\66EC;^8S^5#'=(B+N8EFPJ@9))..2:_1^OQW_X-D_\
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M  C1U,;0VI6]H8=]M<N 0YCE5'W?,AVIM]ZHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M1T212CJ&5A@@C((I:* /GWXD_P#!-7]G/QQ^U;X'_;5\(R:WX!^(?@B"2R_M
MCP%<6]DFOZ9(P9]-U.%X)([NV)R0,*Z%MR.K!2OT%110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445S'QL^(W_
M  I[X->+OBY_8W]H_P#"+>&+_5_[/^T>3]J^S6\DWE>9M;9NV;=VUL9S@XQ5
MTZ<ZU14X*[;LO5D5*D*5-SD]$KOT1T]%?F3_ ,1&7_5G7_F0O_O?1_Q$9?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MP?\ #%RBZCK4@FF#7$TC!EL;&/#-+>2C8BHQ <J5K[-NHHH/^"7\D$,81$^
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MR3"VA2^O$V.RS*7VQ.^Q2Q(&\9PO^">7_!77]E?]FW_@F5X8_8Y^,!O])_:
M^%_A1_ ]_P# 6;0[AM?U76[5&M[>WMK=8R)UN<1.)5)C42EG90K$ 'M/_!L9
M_P H-/@3_P!>>O?^I#J=>G?\%5/^"F=C_P $O_AW\./B/J7P,U3Q]!X]^*FG
M^#9-,T/4O)O;;[5!<S>?;Q&&3[7+FWV);DQ!VD'[U,<^8_\ !L9_R@T^!/\
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M\.6%W<VIS;7%U9I(\)SGY68$KSSQ5^BB@ HHHH **** "BBB@ HHHH ****
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MIT>>ZT;5/%,$D;QS)XALKEQ*\MS&9"LP$6UL/F/- '[8T444 %%%% !1110
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MBJSK @+<@%>&'W[10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MNJ6'CWX4:YJRVMYI&NZ<Z)=:9+<K#(%(WHRRB(Y1U)16W(H!]I45\:_LL?\
M!1K]JK]H?2-+_::\>?L267PT_9UOO!4_B*3X@^*/B#%)JRV<=F;D7O\ 9L<
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M1@SQ12!CSMR1@_8M !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ9>PW-O,@:&>"0.CJ>X8<$?2H=9U[0_#EG_:/B'6;2PM]X3S[VX6)-QZ#<Q
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,RIJ.G:H(M5G:ZCDA.X.Z-('0$.N2:]8_P""B7[-FK:!_P %.O&/[4G[</\
MP31\<_M4?!/6/!6CV'PV3P-"FMS> I8(W&HQ-HC3QF4W$Q6<SJ"54!5+$LJ_
M3_P^_9,_X+"IXI\/67QB_P""L/A?4/#&B:K:W&KCPS\!K2QU7Q';12H[VT\\
MEY+%:"55*N\$6X!VVX.".A_: _9P_P""I>L?&_Q!\0/V6O\ @HUX5\-^$-=^
MS&R\!>-?@Y#JR:"\=K##(]M>17<$L@E>-IBDH8*TC '% 'Q=^U)^V;^RK\ O
M^"!GC?XB_P#!%J/4/!NE:SX^@\+26>FP75MJ7A'5K^\MXM1B%O>2![.Z6)R$
M561$>>.2-AD,?&OCA^R7\//#_P"SPD/[ ?\ P0U_:F^&OQW\+F#4? /QFEAT
MX:G_ &O%(KM/J%RNKR/=1SCS%F1HW0B5MJ#  _0[X4?\$6/@AI?[#GQ5_8Y_
M:/\ B'JWQ(O/CGXMU#Q9\5/&LEE#IMQ>Z]=20R_;;.WBWQV7DR6\$D4?[Q5=
M"3N5BM8OAS]A?_@LQX8\*VWP=TW_ (+)Z*WAJQA6UL_%=[\!K2Y\4?9%7:B2
M3RWIMY)@N%-P\+,Q&]@6)% '(_\ !1_QQ^RK\:=<^ OP4_:E_P"">GB3X_\
MQUU;P9<^(-!^#FBW:06NBI-%:KJ%YJ#7-U#9Q1)-$((Y)_,*L'5 N]B?%O\
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M_$'Q;HMII7Q)TK6_!\>NZ#XNAM%V6DUQ;F:%X+F&/Y%FC?.Q0H"[I"X!Y?\
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M+CRG5 WEQP@=L5^BG["?[+W_  Q3^Q[\._V3_P#A.?\ A)O^$!\,6^D?V_\
MV9]B^W>4#^]\CS9?*SG[OF-CU-?FK\?/AC^R?_P5E_X+_?"#Q+^S'\0;'QIX
M;^%G@R/Q#\>-:\*ZHEUHEY+87SR:!I\TD1,4UT+MY6=&+'R%(Q^[8  ^\?\
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M10 450NO%7ABQUF'PY>^(["'4;A=UO82WB+-*/54)W,.#T%7Z "BD9E12[L
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MH>K2Z7K:Z3J<5R=/OHL&2UG$;'RIDW+NC;#+N&0,UL4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5G>+_ /D4M4_[!T__ *+:M&L[Q?\ \BEJG_8.G_\ 1;4
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M(/?M^?LG^,?V)?A1^P98?%(6GQD\$_#;[#XJ^'.JZ1>6>I:;-9+Y=P)$FB4
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M+:'X!\8'4)XYO#_AWQ0-8M5MPP\J5;GRX\EE/*E1@BOC[XM:-8Z/_P '&7P
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M[]FGQ+X-\2?\%'/^">.E?#;X:>./$MGH(\:>$OBI#X@D\*7]XXCM(]5@6UA
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MK^N:S\5KVYA86VL7>CW)T_PJ8BV00D<J2 '/F(C$<4 ?I'^UK_P4>^)7P/\
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M\<:;X"L/$VF:O/XZCTS35@GD9)I+YY+9OLL,/[L!D,TDTDR(L:C<Z\7\,/\
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MFG?L-ZKXCU+X8ZM^T1X=U'0M0\6?:S>7K2^(V$\["\CCFV22K(ZEU!965NC
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M?V<1^7Y)$WD^?N$9WE]@+U[/^U9_P5.'P_L_@/X1_8T^#47Q?\;?M*6MW?\
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M0 51M_"_AFTUF7Q%:^';"+4)AB:_CM$6:0<<,X&X]!U/:KU% !1110 4444
M4-%\+^&?#AE;P]X=L+ SMNG-E:)%YA]6V@9ZGK1JGA;PQK=[!J6M>'+"\N+4
MYM;BZLTD>$YSE68$KSSQ5^B@ JA9>%_#.FZI/KFG>';"WO;DDW-Y!:(DLN3D
M[G RV3ZFK]% %36= T'Q%;K9^(-$M+Z)) Z17ELLJJPZ, P(!Y/-6^G2BB@
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M_P#VCH>C7=M>0W/A+Q(VH6D%[$UO=.7M9Q%=.IB_U86?<@VN"?;_ -MCX+?
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M]L=&\;Z0+2;4-/V^=9S1RQSP3H&X8QSQ1/M/#;=IQFO6:* /S6_:._X(O_\
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>BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>biib-20220331_g14.jpg
<TEXT>
begin 644 biib-20220331_g14.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#5H=3N+F>(30"62XEC<$AU""0;1M0)7VS10 5X]^WW^QGX _X*#_ +(/C?\
M8]^)VMWVF:/XTT^&&34],"F>SG@N8KJWG4-PVR>")BIQN"E<C.1[#10!\:^*
MO^"='[:'QS_8M^+W['G[77_!1NQ^(*?$7PO!HWASQ-;_  9MM(F\/A3)Y\TT
M5O?D:@TH,/&Z *8F(SO('J7[0W[$O_"^O^"<^N_L _\ "S?[*_MKX9Q^$?\
MA+?[%\_R=MJD'VK[+YR;L[-WE^:.N-W>O>** /D[]IK_ ()6Z#^T%^S_ /!W
MP3X<^.NL>!_B?\!;:R?X8?%W0-,B>XTV[ALXK68R6<KE)[6X2)?-MF?#!54N
M0#N=\$OV9_\ @JU9?%;P]XH_:7_X*6^%M<\*:%<^;J/A/P3\%[?2Y/$(",JK
M<W<UW.\"[BKE8%7<5QD+D'ZKN[NTL+66_O[F."""-I)IIG"I&@&2S$\  #))
MK/\ !?C?P7\1_"]GXW^'GB_2]>T748S)I^KZ+J$=U:W*!BI:.6)F1QD$9!/(
M([4 :E?.G[=W[ ?_  VQ\1O@-X__ .%L_P#",_\ "DOB_8>.?LG]@_;?[:^S
M C['N\^+[-NS_K<28_N&OHNH[N\M+"UDO;^ZC@AB0M+-,X544=22> * /(?^
M"@7[)O\ PW5^QG\0?V1O^$__ .$6_P"$[T(Z;_PD']E?;OL.9$?S/(\V+S?N
M8V^8O7K63^U)^Q+_ ,-*?\$\/$7[!/\ PLW^Q?[?^'\/AC_A*_[%^T^1LBCC
M^T?9?.3=GR\[/-'7&[BO:]"\2>'?%%F=0\,Z]9:C;ARAGL;I)D##J-R$C/M5
MV@#Y?^*O_!-S_A9OC7]EKQA_PN;[#_PS3J)NOL__  COF_\ "1_\2M;#;N^T
M+]C^[YF<3==N/XJ[7]OS]ACX7_\ !0?]G^3X&_$G7-6T*YL=:M-=\(>+?#TX
MBU'PYK5HQ:UU"V8@@2(692#U21P"I(8>UT4 ?&7@C]D7_@L8FM:)HGQ2_P""
MMGAB]\-:3J%O)J=UX?\ @):6>LZ];1R*S03327DD-J95!5I(8MPW';@X(VOV
MP_\ @FOX\^*O[3.C_MU_L:?M.W'P<^,NF^&SX=U?5I?#46LZ1XGT?S?.2SU"
MQDDCWE).4G1U=!C[VU-GUG5#3O%/AG5]2N-'TGQ'875W9G%W:V]XCR0'_;52
M2OXT >$_LF_ 7_@H!X%^).H?$3]LC]NS1_B'8SZ*]CI?@CPG\,(-!TVQG::)
MS>M,;B>XN)=L90*SJBB5\*2<U[CXY\-?\)IX)UCP=]M^S?VMI5Q9_:?+W^5Y
ML;)OVY&[&[.,C..HK4Z=:IZ+XAT#Q);/>>'=<L[^&.4QR2V5RDJJXZJ2I(!&
M1Q0!\]?L3?\ !-KX6?LP?\$\_!/_  3U^,J^'_BYH'A*UFBNI_$_@Z#['J;-
M?S7B2-8SO<(I1I0!EWY0,""<";]JG]@"U_:4_:D_9U_:0L?B;'X<@^ 'B'5=
M3A\.Q>'Q.FLI>6<=L(5E$\8M!&(]P(27.<87&:]_USQ%X?\ #-F-0\2:[9Z?
M;EP@GOKI(D+'HNYR!D^E6H9H;F%+BWF62.10T<B,"K*1D$$=10!\=_M(_P#!
M-#XW7/[8FH_M\?L!?M8V_P )OB#XJ\/6NB_$?2]?\&IKNA^*[>U&VTGF@\Z&
M2&ZA3"+,CG*($PH9R_2?L"?\$XM1_9-\6?$?]H3XX_'N]^*OQG^+MS;2>.?'
MUYHL>G0+;6T1CM;"RLXW=;:VA5B,;R7(4L?E4+])WGBGPSIVKP>']0\16$%_
M=#-M937B+-,.GRH3N;\!5^@#P/\ X)@_L/\ _#M_]A?P+^Q;_P +/_X3/_A"
MH]17_A)?[%_L[[9]JU*ZO?\ CW\Z;R]OVG9_K&SLW<9VCQOX>?\ !$WP!HO_
M  1??_@CE\3/C;?Z]I,EM?!O'.F:&NGSK<2ZY+K-O,ELTTX7R9VB4J9#Y@B/
M*;\+]P44 ?&GB_\ X)S?MH?'C]BKXO?L=_M=_P#!1NP^( ^(WAJWTCPYXGMO
M@S;:1-X?"M(9YIHK>_*W[2YAXW0!#$Q&=Y ]3_:/_8E_X:"_X)TZ]^P'_P +
M-_LC^V_AO'X3_P"$L_L7[1Y.RW2'[3]E\Y-V=F[R_-'7&[O7O%% 'R]\5OV2
M?VZM'\"?#/PQ^QE^WEI7@/\ X0/P;;Z#K>E>)?A?!K.G>)3###%'<L#<QS6;
MJ(V($<C B3#9P#5']BS_ ()U_%/X,?M0>,?VZOVMOVF(?BA\6O%_A6U\+QWF
MC>$8]#TG1=$@G\];.WMEEE>1FFP[2R2%C@  <D_5]8_A#X@^ ?B"-3/@+QOH
M^MC1=7GTK63I&IQ7/V"_AQYUI-Y;'RITW+NB;#KN&0,T <[^U%\%?^&D_P!F
M;XB_LZ?\)+_8O_"?>!-7\.?VQ]C^T_8/MUE+:^?Y6]/-V>;OV;UW;<;ESD?$
M'P-_X)/_ /!7_P#9P^#OAGX"_!__ (+PV.E^%O"&C0:5H&G/^RMHMP;:TA0)
M&ADEOV=\* -S,2>Y-?HS5#1_%'AGQ#-<6_A_Q%87TEH^RZ2SNTE,+>CA2=I]
MC0!\R_'3_@G=\4/VE?!_[.%O\:OVJTUCQ7\"OBMI'CG7O%4?@2*V7Q=<64<Z
M-"+6&Y6/3_,\[.Y3*$V?<;/'5_MV_L-_\-KZK\$]3_X6A_PC/_"G?CIH?Q&V
M?V)]M_M?^SEN%^P9\Z+[/YGG_P"N_>;=O^K;/'ODTT5O$UQ<2JD:*6=W; 4#
MDDD]!5?1]<T7Q%8KJGA_6+6^MG)"W%G<++&2.H#*2* /DG]JC_@FU\:_$G[7
M\/[?/["'[5%K\)_B3J'A>/PYX[M-=\(+KFB^*M.B??;FXM_.A>*XA/"S(^2B
MJG W;J'[%/\ P2B^(?[,O[=OC/\ X*!_&+]LC4/B=XR^(7P^A\/^*8KSPC%I
MT(NH[N.59[417#K;VR0PPP):[&(\LR-,[.U?8.N>*/#7AB.*;Q+XBL=.2>39
M"U]=I")&_NJ7(R?85>!# ,IR#T(H ^$=%_X)8_M@?LG>/O%UY_P3*_;PTGX?
M> /&WB*YUZ^^%WCWX;)K^GZ+J5R=UQ-ILR75O+;Q.PW?9CNC4Y(/.*]0\7?\
M$[?$O[2_[!?C#]BW]O\ _:4O_BO>^-I))=1\:6/ABUT)].D#Q2VALK6 ND(M
MI88Y$W,Y<@^86#$'Z>HH _-/]H__ ((K_P#!07]N#]ER]_8__;#_ ."MB:WX
M3M;:W71;G0_A##:7>I7,$B&WN=8<7V;P1JI;R8VA#S%)7=S&%;]'?"VB?\(U
MX8T[PY]I\_\ L^PAMO.V;?,\M N[&3C.,XR:OT4 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5;_Q->:1=&TU+7F9KZ]TH7LZZ=/.S$EV:T$!5R2738Q)+$G\Z?C=_P %H_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **\2_8(U34]7^#6J
MW.K:C/=2+XWUA%DN)F=@HN2 N6)X Z#M7MM !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% 'A?_  3W_P"2)ZM_V/>L_P#I2:]TKPO_ ()[_P#)$]6_['O6?_2DU[I0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!X7_ ,$]_P#DB>K?]CWK/_I2:]TKPO\
MX)[_ /)$]6_['O6?_2DU[I0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P 17.44?VEF/_/Z?_@3_P P.C_X6U\0?^A@_P#)2+_XBC_A;7Q!_P"A@_\
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M7A4A)8KFQ.^UV."?).X,"03Q6I^T-^R3^VW\9_BSJGBGX??\%,?$/PW\)/%
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M^%M?$'_H8/\ R4B_^(H_ULR[^2?W+_Y(#U'_ (275_\ H4+W_OI:/^$EU?\
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M#"Q'5D+%#[J:WQ&$E0CS<RDKV=KZ-=-4OO6C [6BBBN0 HHHH **** "NO\
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M^135]/U0'EM%%%?EH!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !77_!/_ )'3_MSD_FM<A77_  3_ .1T_P"W.3^:
MUZ.4?\C.C_B0'KM%%%?JX!1110 4444 %%%% !1110 4444 %%%% 'A?_!/?
M_DB>K?\ 8]ZS_P"E)KW2O"_^">__ "1/5O\ L>]9_P#2DU[I0 5Y%\;/^1T_
M[<X_YM7KM>1?&S_D=/\ MSC_ )M7SG%'_(L_[>7Z@<A1117YT 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5ZE\!O
M^0#>_P#7X/\ T 5Y;7J7P&_Y -[_ -?@_P#0!7O<-?\ (VCZ/\@.ZHHHK]*
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M_D4U?3]4!Y;1117Y: 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M50JG)P ?4/AKPUX=\&>'-/\ !_A#0;+2M)TJRBL]+TO3K5(+>SMHD"1PQ1H
ML<:(JJJJ %    %7:** /"_^">__ "1/5O\ L>]9_P#2DU[I7A?_  3W_P"2
M)ZM_V/>L_P#I2:]TH *\B^-G_(Z?]N<?\VKUVO(OC9_R.G_;G'_-J^<XH_Y%
MG_;R_4#D****_.@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "O4O@-_R ;W_K\'_H KRVO4O@-_R ;W_K\'_H KWN
M&O\ D;1]'^0'=4445^E %%%% !7"_'G_ ) -E_U^'_T UW5<+\>?^0#9?]?A
M_P#0#7DY[_R*:OI^J \MHHHK\M **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *Z_X)_P#(Z?\ ;G)_-:Y"NO\ @G_R
M.G_;G)_-:]'*/^1G1_Q(#UVBBBOU< HHHH **** "BBB@ HHHH _+_Q)^PWX
M&_X*8_\ !4S]H3X=?\% _BGX]FTSX>IX>_X5%\+='\;7>CZ;_85SIZ/+K,<=
MLZ-=.]Z)X7E!(C>,QMG$:K] _LN?\$,O^">W['7QVT+]H[X'>#O&%IXI\.?:
MO[+N-5^(VK7\"_:+66UDW07%P\;YBGD W*<$AA@@&OEO_@LC\!/^"!O@3]J]
M/C;^W]\1?'Q^+WC"W@N-*\+^!?$^LW&H^1%;QVJ2P65AN%I&R6P&X^6LCHY!
M9@V-'_@CU\+O^"&WQ._:6@^)W["7QH^)MQ\3O %O<W%QX)^(7C+7(KNVAGMI
M+22633]08+<1A+DC>F]8W>,DJQ7(!^J5%%% 'A?_  3W_P"2)ZM_V/>L_P#I
M2:]TKPO_ ()[_P#)$]6_['O6?_2DU[I0 5Y%\;/^1T_[<X_YM7KM>1?&S_D=
M/^W./^;5\YQ1_P BS_MY?J!R%%%%?G0!1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !7J7P&_Y -[_U^#_T 5Y;7J7P
M&_Y -[_U^#_T 5[W#7_(VCZ/\@.ZHHHK]* **** "N%^//\ R ;+_K\/_H!K
MNJX7X\_\@&R_Z_#_ .@&O)SW_D4U?3]4!Y;1117Y: 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5U_P $_P#D=/\
MMSD_FM<A77_!/_D=/^W.3^:UZ.4?\C.C_B0'KM%%%?JX!1110 4444 %%%%
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M-FC:<FJ%K:*25FT^[@=HC'.\L0W9W"+>.&%+^QA\?_\ @J)?_%W0/A-\9?\
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M<G\UKD*Z_P""?_(Z?]N<G\UKT<H_Y&='_$@/7:***_5P"BBB@ HHHH ****
M"HKNQLM0B$%_9Q3H&#!)HPP!'0X/>I:* /AG]I3_ (*D_$:P_:F\7_LJ_L._
M\$S?$W[0OBGX>1V7_"QM8MO$6G:#I6CW%U L\%H+R]5A<3^259D4#:#C)(8+
MM_LH_M?_ /!1;XI?'W0/ GQW_P"")]Y\(_"E]]J_M7XA2_&/0]572=EK-)%F
MUM8EEE\V5(X/E/R^=N/RJ:^>?%W[2G[6/P7_ ."M7QY\-?\ !*+]B6\^-EI?
M1:)=?'VRU_Q/9>'M,TCQ*NGQI:OIVH7$G[QY+$0"X@,3XDC5E9<OGZ2_9<_:
MR_X*Z?$SX[:%X(_:?_X)*:/\,? U[]J_MSQQ:_'G2]:DTW9:RR0XLX(EDF\R
M=(H?E(VB4N>%- 'U_1110!X7_P $]_\ DB>K?]CWK/\ Z4FO=*\+_P"">_\
MR1/5O^Q[UG_TI->Z4 %>1?&S_D=/^W./^;5Z[7D7QL_Y'3_MSC_FU?.<4?\
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M_P"&@#]-J*** /"_^">__)$]6_['O6?_ $I->Z5X7_P3W_Y(GJW_ &/>L_\
MI2:]TH *\B^-G_(Z?]N<?\VKUVO(OC9_R.G_ &YQ_P VKYSBC_D6?]O+]0.0
MHHHK\Z **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *]2^ W_(!O?\ K\'_ * *\MKU+X#?\@&]_P"OP?\ H KWN&O^
M1M'T?Y =U1117Z4 4444 %<+\>?^0#9?]?A_] -=U7"_'G_D V7_ %^'_P!
M->3GO_(IJ^GZH#RVBBBORT HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]2^
MW_(!O?\ K\'_ * *\MKU+X#?\@&]_P"OP?\ H KWN&O^1M'T?Y =U1117Z4
M4444 %<+\>?^0#9?]?A_] -=U7"_'G_D V7_ %^'_P! ->3GO_(IJ^GZH#RV
MBBBORT HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KK_@G_P CI_VYR?S6N0KK_@G_ ,CI_P!N<G\UKT<H_P"1G1_Q
M(#UVBBBOU< HHHH **** "BBB@ HHHH **** "BBB@#PO_@GO_R1/5O^Q[UG
M_P!*37NE>%_\$]_^2)ZM_P!CWK/_ *4FO=* "O(OC9_R.G_;G'_-J]=KR+XV
M?\CI_P!N<?\ -J^<XH_Y%G_;R_4#D****_.@"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O4O@-_R ;W_ *_!_P"@
M"O+:]2^ W_(!O?\ K\'_ * *][AK_D;1]'^0'=4445^E %%%% !7"_'G_D V
M7_7X?_0#7=5POQY_Y -E_P!?A_\ 0#7DY[_R*:OI^J \MHHHK\M **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Z_X
M)_\ (Z?]N<G\UKD*Z_X)_P#(Z?\ ;G)_-:]'*/\ D9T?\2 ]=HHHK]7 ****
M "BBB@ HHHH **** "BBB@ HHHH \+_X)[_\D3U;_L>]9_\ 2DU[I7A?_!/?
M_DB>K?\ 8]ZS_P"E)KW2@ KR+XV?\CI_VYQ_S:O7:\B^-G_(Z?\ ;G'_ #:O
MG.*/^19_V\OU Y"BBBOSH HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ KU+X#?\@&]_P"OP?\ H KRVO4O@-_R ;W_
M *_!_P"@"O>X:_Y&T?1_D!W5%%%?I0!1110 5POQY_Y -E_U^'_T UW5<+\>
M?^0#9?\ 7X?_ $ UY.>_\BFKZ?J@/+:***_+0"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "NO^"?_ ".G_;G)_-:Y
M"NO^"?\ R.G_ &YR?S6O1RC_ )&='_$@/7:***_5P"BBB@ HHHH **** "BB
MB@ HHHH **** /"_^">__)$]6_['O6?_ $I->Z5X7_P3W_Y(GJW_ &/>L_\
MI2:]TH *\B^-G_(Z?]N<?\VKUVO(OC9_R.G_ &YQ_P VKYSBC_D6?]O+]0.0
MHHHK\Z **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *]2^ W_(!O?\ K\'_ * *\MKU+X#?\@&]_P"OP?\ H KWN&O^
M1M'T?Y =U1117Z4 4444 %<+\>?^0#9?]?A_] -=U7"_'G_D V7_ %^'_P!
M->3GO_(IJ^GZH#RVBBBORT HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KU+X#?\@&]_P"OP?\
MH KRVO4O@-_R ;W_ *_!_P"@"O>X:_Y&T?1_D!W5%%%?I0!1110 5POQY_Y
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MKYSBC_D6?]O+]0.0HHHK\Z **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *]2^ W_(!O?\ K\'_ * *\MKU+X#?\@&]
M_P"OP?\ H KWN&O^1M'T?Y =U1117Z4 4444 %<+\>?^0#9?]?A_] -=U7"_
M'G_D V7_ %^'_P! ->3GO_(IJ^GZH#RVBBBORT HHHH **** "BBB@ HHHH
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M_D;1]'^0'=4445^E %%%% !7"_'G_D V7_7X?_0#7=5POQY_Y -E_P!?A_\
M0#7DY[_R*:OI^J \MHHHK\M **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *Z_X)_\ (Z?]N<G\UKD*Z_X)_P#(Z?\
M;G)_-:]'*/\ D9T?\2 ]=HHHK]7 **** "BBB@ HHHH **** "BBB@ HHHH
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MS<Q_Y\S_ / 7_D![317BW_#Q3]BC_HX31?\ OW/_ /&Z/^'BG[%'_1PFB_\
M?N?_ .-T?V;F/_/F?_@+_P @/::*\6_X>*?L4?\ 1PFB_P#?N?\ ^-T?\/%/
MV*/^CA-%_P"_<_\ \;H_LW,?^?,__ 7_ ) >TT5XM_P\4_8H_P"CA-%_[]S_
M /QNC_AXI^Q1_P!'":+_ -^Y_P#XW1_9N8_\^9_^ O\ R ]IHKQ;_AXI^Q1_
MT<)HO_?N?_XW31_P48_8G,AC'[0>CY R3Y-QC\_+Q1_9N8_\^9_^ O\ R ]K
MHKQ;_AXI^Q1_T<)HO_?N?_XW1_P\4_8H_P"CA-%_[]S_ /QNC^S<Q_Y\S_\
M 7_D![317BW_  \4_8H_Z.$T7_OW/_\ &Z/^'BG[%'_1PFB_]^Y__C=']FYC
M_P ^9_\ @+_R ]IHKQ;_ (>*?L4?]'":+_W[G_\ C='_  \4_8H_Z.$T7_OW
M/_\ &Z/[-S'_ )\S_P# 7_D![317BW_#Q3]BC_HX31?^_<__ ,;H_P"'BG[%
M'_1PFB_]^Y__ (W1_9N8_P#/F?\ X"_\@/::*\6_X>*?L4?]'":+_P!^Y_\
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MG1_T=)HO_@!>?_&:/^'MW_!.C_HZ31?_   O/_C- 'T97"_'G_D V7_7X?\
MT UY;_P]N_X)T?\ 1TFB_P#@!>?_ !FN3^+7_!4C]@/Q/I%K:Z'^TMHL[QW)
M9U^RW2X&TC/S1"O,SFG4JY94A!-MK9:O= =917BW_#Q3]BC_ *.$T7_OW/\
M_&Z/^'BG[%'_ $<)HO\ W[G_ /C=?F_]FYC_ ,^9_P#@+_R ]IHKQ;_AXI^Q
M1_T<)HO_ '[G_P#C='_#Q3]BC_HX31?^_<__ ,;H_LW,?^?,_P#P%_Y >TT5
MXM_P\4_8H_Z.$T7_ +]S_P#QNC_AXI^Q1_T<)HO_ '[G_P#C=']FYC_SYG_X
M"_\ (#VFBO%O^'BG[%'_ $<)HO\ W[G_ /C='_#Q3]BC_HX31?\ OW/_ /&Z
M/[-S'_GS/_P%_P"0'M-%>+?\/%/V*/\ HX31?^_<_P#\;H_X>*?L4?\ 1PFB
M_P#?N?\ ^-T?V;F/_/F?_@+_ ,@/::*\6_X>*?L4?]'":+_W[G_^-T?\/%/V
M*/\ HX31?^_<_P#\;H_LW,?^?,__  %_Y >TT5XM_P /%/V*/^CA-%_[]S__
M !NFO_P48_8G1E4_M!Z/\QP,0W!_/$?%']FYC_SYG_X"_P#(#VNBO%O^'BG[
M%'_1PFB_]^Y__C='_#Q3]BC_ *.$T7_OW/\ _&Z/[-S'_GS/_P !?^0'M-%>
M+?\ #Q3]BC_HX31?^_<__P ;H_X>*?L4?]'":+_W[G_^-T?V;F/_ #YG_P"
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M %Y_\9H_X>W?\$Z/^CI-%_\  "\_^,U^F ?1E%>%> /^"F'["WQ2\:Z9\._
M/[1.DZEK6LW:6NF6$5I=*T\S'"H"\04$GU(KW6@ HHHH **** "BBB@ HHHH
M **** .7\5?!#X+>.M7;Q!XV^$/A?6+]T5'OM5\/VUQ,RJ,*"\B%B .@SQ6=
M_P ,O_LT_P#1O'@7_P )*S_^-5W-% '#?\,O_LT_]&\>!?\ PDK/_P"-4?\
M#+_[-/\ T;QX%_\ "2L__C5=S10!PW_#+_[-/_1O'@7_ ,)*S_\ C5'_  R_
M^S3_ -&\>!?_  DK/_XU7<T4 <-_PR_^S3_T;QX%_P#"2L__ (U1_P ,O_LT
M_P#1O'@7_P )*S_^-5W-% '#?\,O_LT_]&\>!?\ PDK/_P"-4?\ #+_[-/\
MT;QX%_\ "2L__C5=S10!PW_#+_[-/_1O'@7_ ,)*S_\ C5'_  R_^S3_ -&\
M>!?_  DK/_XU7<T4 <-_PR_^S3_T;QX%_P#"2L__ (U1_P ,O_LT_P#1O'@7
M_P )*S_^-5W-% '#?\,O_LT_]&\>!?\ PDK/_P"-4?\ #+_[-/\ T;QX%_\
M"2L__C5=S10!PW_#+_[-/_1O'@7_ ,)*S_\ C5>*^!_V?_@-<?MU^.?#EQ\$
MO",FGVW@K3);>P?PW:F&*1G;<ZH8]JL>Y R:^HZYO3/A3X1TCXHZI\8+.&<:
MUJ^FP6-Z[3DQF&(DH G8Y/7O0!E?\,O_ +-/_1O'@7_PDK/_ .-4?\,O_LT_
M]&\>!?\ PDK/_P"-5W-% '#?\,O_ +-/_1O'@7_PDK/_ .-4?\,O_LT_]&\>
M!?\ PDK/_P"-5W-% '#?\,O_ +-/_1O'@7_PDK/_ .-4?\,O_LT_]&\>!?\
MPDK/_P"-5W-% '#?\,O_ +-/_1O'@7_PDK/_ .-4?\,O_LT_]&\>!?\ PDK/
M_P"-5W-% '#?\,O_ +-/_1O'@7_PDK/_ .-4?\,O_LT_]&\>!?\ PDK/_P"-
M5W-% '#?\,O_ +-/_1O'@7_PDK/_ .-4?\,O_LT_]&\>!?\ PDK/_P"-5W-%
M '#?\,O_ +-/_1O'@7_PDK/_ .-4?\,O_LT_]&\>!?\ PDK/_P"-5W-% '#?
M\,O_ +-/_1O'@7_PDK/_ .-4?\,O_LT_]&\>!?\ PDK/_P"-5W-% '#?\,O_
M +-/_1O'@7_PDK/_ .-4?\,O_LT_]&\>!?\ PDK/_P"-5W-% '#?\,O_ +-/
M_1O'@7_PDK/_ .-4?\,O_LT_]&\>!?\ PDK/_P"-5W-% '#?\,O_ +-/_1O'
M@7_PDK/_ .-4?\,O_LT_]&\>!?\ PDK/_P"-5W-% '#?\,O_ +-/_1O'@7_P
MDK/_ .-4?\,O_LT_]&\>!?\ PDK/_P"-5W-% '#?\,O_ +-/_1O'@7_PDK/_
M .-4?\,O_LT_]&\>!?\ PDK/_P"-5W-% '#?\,O_ +-/_1O'@7_PDK/_ .-4
M?\,O_LT_]&\>!?\ PDK/_P"-5W-% '#?\,O_ +-/_1O'@7_PDK/_ .-4?\,O
M_LT_]&\>!?\ PDK/_P"-5W-% '#?\,O_ +-/_1O'@7_PDK/_ .-4?\,O_LT_
M]&\>!?\ PDK/_P"-5W-% '#?\,O_ +-/_1O'@7_PDK/_ .-5XK^T_P#L_P#P
M&T?XP_!JQTGX)>$;6"_\:RQ7T-MX;M42XC^SL=D@6,!USS@Y%?4=<WXW^%/A
M'X@^(O#GBCQ'#.UWX6U)K[23#.459BA0EA_$,'I0!E?\,O\ [-/_ $;QX%_\
M)*S_ /C5'_#+_P"S3_T;QX%_\)*S_P#C5=S10!PW_#+_ .S3_P!&\>!?_"2L
M_P#XU1_PR_\ LT_]&\>!?_"2L_\ XU7<T4 <-_PR_P#LT_\ 1O'@7_PDK/\
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M'X3V/AHZ##:I)&X+VUQ,UWYB& 9D(*^1G)+FOHZBB@#Y:_X*Z?\ !//XH?\
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M5M=33XC>.K'Q)\5='/[..F0_\)*8& DA64W\GV'S(=\>^%1LW[@I(%?H]10
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
..4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>biib-20220331_g15.jpg
<TEXT>
begin 644 biib-20220331_g15.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#5H=3N+F>(30"62XEC<$AU""0;1M0)7VS10 5X]^WW^QGX _X*#_ +(/C?\
M8]^)VMWVF:/XTT^&&34],"F>SG@N8KJWG4-PVR>")BIQN"E<C.1[#10!\:^*
MO^"='[:'QS_8M^+W['G[77_!1NQ^(*?$7PO!HWASQ-;_  9MM(F\/A3)Y\TT
M5O?D:@TH,/&Z *8F(SO('J7[0W[$O_"^O^"<^N_L _\ "S?[*_MKX9Q^$?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5;_Q->:1=&TU+7F9KZ]TH7LZZ=/.S$EV:T$!5R2738Q)+$G\Z?C=_P %H_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **\2_8(U34]7^#6J
MW.K:C/=2+XWUA%DN)F=@HN2 N6)X Z#M7MM !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU\0?^A@_\E(O_B*/^%M?$'_H8/\ R4B_^(KG**/[2S'_ )_3_P# G_F!T?\
MPMKX@_\ 0P?^2D7_ ,11_P +:^(/_0P?^2D7_P 17.44?VEF/_/Z?_@3_P P
M.C_X6U\0?^A@_P#)2+_XBC_A;7Q!_P"A@_\ )2+_ .(KG**/[2S'_G]/_P "
M?^8'1_\ "VOB#_T,'_DI%_\ $4?\+:^(/_0P?^2D7_Q%<Y11_:68_P#/Z?\
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M^TLQ_P"?T_\ P)_Y@='_ ,+:^(/_ $,'_DI%_P#$4?\ "VOB#_T,'_DI%_\
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M_P CI_VYR?S6N0KK_@G_ ,CI_P!N<G\UKT<H_P"1G1_Q(#UVBBBOU< HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5POQY_Y -E_U^'_T UW5<+\>?^0#9?\ 7X?_ $ UY.>_\BFKZ?J@/+:***_+
M0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M117ZN 4444 %%%% !1110 4444 %%%% !1110!X7_P $]_\ DB>K?]CWK/\
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M/U0'EM%%%?EH!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !77_  3_ .1T_P"W.3^:UR%=?\$_^1T_[<Y/YK7HY1_R
M,Z/^) >NT445^K@%%%% !1110 4444 %%%% 'Y?^)/V&_ W_  4Q_P""IG[0
MGPZ_X*!_%/Q[-IGP]3P]_P *B^%NC^-KO1]-_L*YT]'EUF..V=&NG>]$\+R@
MD1O&8VSB-5^@?V7/^"&7_!/;]CKX[:%^T=\#O!WC"T\4^'/M7]EW&J_$;5K^
M!?M%K+:R;H+BX>-\Q3R ;E."0PP0#7RW_P %D?@)_P $#? G[5Z?&W]O[XB^
M/C\7O&%O!<:5X7\"^)]9N-1\B*WCM4E@LK#<+2-DM@-Q\M9'1R"S!L:/_!'K
MX7?\$-OB=^TM!\3OV$OC1\3;CXG> +>YN+CP3\0O&6N17=M#/;26DDLFGZ@P
M6XC"7)&]-ZQN\9)5BN0#]4J*** /"_\ @GO_ ,D3U;_L>]9_]*37NE>%_P#!
M/?\ Y(GJW_8]ZS_Z4FO=* "O(OC9_P CI_VYQ_S:O7:\B^-G_(Z?]N<?\VKY
MSBC_ )%G_;R_4#D****_.@"BBB@ HHHH **** "BBB@#R#]ISXE_MA?#'6-"
MU7]FS]F/1OB?HLT-PGB73)/&T6BZG:RYC,$ENURAMYD(\T.CO&P.P@XR*^'?
M^"<O[-G[2G[2GQ1_9P_:O^(7P.T7X;^$?@KX8U^'3=5_X2*"^UKQE)J*RVZQ
M.MLNVVM(-TC!9'9BQ;"@2$K^H-9O@_P=X5^'_AJT\'>"/#UII6E6$92RT^Q@
M$<,*DEB%4< 9)/XUVT<9[&A*$8J[TOK>S33ZVV=MOQL!\5_$?X*_M3_L2?\
M!0?Q_P#MK?LQ_LVR?%OP?\:=!TNW\>>%]&\0VFGZMHVJZ<AA@NX1=LD<\$D3
M$,BL'#LS' 4;MK]@G]F/]HKQ+^U+\8O^"@/[8?PSL?!.K_%#2M.\/^'/AO#J
M\6H2Z3HMI'M)O)X<Q233,%8JA(3# ]=J_9E%$L;4E2<>57:46];M*UEO;HM;
M7LO4#\Y?V8?#?_!1;_@E=\)=8_8F^$7[",_QB\-:1KNIW/PE\;Z3XZTZPMS9
MWEP]Q';ZI%=.DL,D4DK;Y$!5P<+]W<?3OV2_V7_VL_\ @G5_P2[OO WPG\,:
M%\0OCA)<7OB&XT22]6WTV]UB]NQ)+;K++)"%CCB.W<70,T9(QN"U]F44ZF/G
M5O>*U:E+?WFN^OF[VMOZ >1?&7XH?M-^!?V;](\=^"/V58OB'XVGMK$>)_A_
M9>*;33O+$D/^F"&>X+PR>4Y("%CY@R QX)^4] _9N_:=_;O_ &@_AKKOQG_8
MPTK]GWX,_"?QC'XR3PJVL6%WJGB[Q% A6SDDCL!Y5O! 6<G>2T@) R&S'^A-
M%9TL4Z,7R15W?76ZOVUMZ:7 ****Y0"BBB@ HHHH **** "O4O@-_P @&]_Z
M_!_Z *\MKU+X#?\ (!O?^OP?^@"O>X:_Y&T?1_D!W5%%%?I0!1110 5POQY_
MY -E_P!?A_\ 0#7=5POQY_Y -E_U^'_T UY.>_\ (IJ^GZH#RVBBBORT HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M KK_ ()_\CI_VYR?S6N0KK_@G_R.G_;G)_-:]'*/^1G1_P 2 ]=HHHK]7 **
M** "BBB@ HHHH ***\O_ &M/B5^TW\*_AI:>(_V4/V:+7XK>)9=>MK:[\-W?
MC.VT)8+%P_G7?VBX5D8QX3]T!N;?P>* /@K3_P!K+]E[_@F#_P %?_VBO%W_
M  4.+^#+GXR2:!J'PF^+FL:'/<:?J&C6VEP6T^CI=11O]D>"XB=GC.U7W(['
M_5;B]_:P_9?_ ."GO_!8+]G7QE_P3Q,GC.X^#3>(+_XM?%O1]#GM]/L-'NM+
MFMK?1WNI8T^UO-<R(Z1C<J;7=3_K=ON7[9OQ_P#^"HMC\7/$'PG^#G_!&;PI
M\9OAM:R6K:-XI\0?&S1M.35"UM%)*S:?=P.T1CG>6(;L[A%O'#"E_8P^/_\
MP5$O_B[H'PF^,O\ P1H\*_!CX;73W;:QXI\/_&O1]172V6UEDB*Z?:0(TIEG
M2&$[<;1+O.0IH ^TJ*** /"_^">__)$]6_['O6?_ $I->Z5X7_P3W_Y(GJW_
M &/>L_\ I2:]TH *\B^-G_(Z?]N<?\VKUVO(OC9_R.G_ &YQ_P VKYSBC_D6
M?]O+]0.0HHHK\Z **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *]2^ W_(!O?\ K\'_ * *\MKU+X#?\@&]_P"OP?\
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M+:]2^ W_ " ;W_K\'_H KWN&O^1M'T?Y =U1117Z4 4444 %<+\>?^0#9?\
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M@&R_Z_#_ .@&O)SW_D4U?3]4!Y;1117Y: 4444 %%%% !1110 4444 %%%%
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M117ZN 4444 %%%% !1110 4444 %%%% !1110!X7_P $]_\ DB>K?]CWK/\
MZ4FO=*\+_P"">_\ R1/5O^Q[UG_TI->Z4 %>1?&S_D=/^W./^;5Z[7D7QL_Y
M'3_MSC_FU?.<4?\ (L_[>7Z@<A1117YT 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 5ZE\!O^0#>_]?@_] %>6UZE
M\!O^0#>_]?@_] %>]PU_R-H^C_(#NJ***_2@"BBB@ KA?CS_ ,@&R_Z_#_Z
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M!KR<]_Y%-7T_5 >6T445^6@%%%% !1110 4444 %%%% !1110 4444 %%%%
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M117ZN 4444 %%%% !1110 4444 %%%% !1110!X7_P $]_\ DB>K?]CWK/\
MZ4FO=*\+_P"">_\ R1/5O^Q[UG_TI->Z4 %>1?&S_D=/^W./^;5Z[7D7QL_Y
M'3_MSC_FU?.<4?\ (L_[>7Z@<A1117YT 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 5ZE\!O^0#>_]?@_] %>6UZE
M\!O^0#>_]?@_] %>]PU_R-H^C_(#NJ***_2@"BBB@ KA?CS_ ,@&R_Z_#_Z
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M!KR<]_Y%-7T_5 >6T445^6@%%%% !1110 4444 %%%% !1110 4444 %%%%
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M117ZN 4444 %%%% !1110 4444 %%%% !1110!X7_P $]_\ DB>K?]CWK/\
MZ4FO=*\+_P"">_\ R1/5O^Q[UG_TI->Z4 %>1?&S_D=/^W./^;5Z[7D7QL_Y
M'3_MSC_FU?.<4?\ (L_[>7Z@<A1117YT 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 5ZE\!O^0#>_]?@_] %>6UZE
M\!O^0#>_]?@_] %>]PU_R-H^C_(#NJ***_2@"BBB@ KA?CS_ ,@&R_Z_#_Z
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M!KR<]_Y%-7T_5 >6T445^6@%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %=?\ !/\ Y'3_ +<Y/YK7(5U_P3_Y'3_M
MSD_FM>CE'_(SH_XD!Z[1117ZN 4444 %%%% !1110 4444 %%%% !1110!X7
M_P $]_\ DB>K?]CWK/\ Z4FO=*^/O@=^V/\ LT?L=Z#K'P:_:7^*]EX2\3IX
MHU#4'T?4+:=Y5MKB8R0R'RHV #H0P&<X(XYKM?\ A[=_P3H_Z.DT7_P O/\
MXS0!]&5Y%\;/^1T_[<X_YM7(?\/;O^"='_1TFB_^ %Y_\9KSCXH_\%,OV$_$
M?B?^T=&_:/T6:'[,B[_L]RO()R,-$#WKP>(Z-:OEW+3BY.ZT2OW[ >CT5XM_
MP\4_8H_Z.$T7_OW/_P#&Z/\ AXI^Q1_T<)HO_?N?_P"-U\%_9N8_\^9_^ O_
M " ]IHKQ;_AXI^Q1_P!'":+_ -^Y_P#XW1_P\4_8H_Z.$T7_ +]S_P#QNC^S
M<Q_Y\S_\!?\ D![317BW_#Q3]BC_ *.$T7_OW/\ _&Z/^'BG[%'_ $<)HO\
MW[G_ /C=']FYC_SYG_X"_P#(#VFBO%O^'BG[%'_1PFB_]^Y__C='_#Q3]BC_
M *.$T7_OW/\ _&Z/[-S'_GS/_P !?^0'M-%>+?\ #Q3]BC_HX31?^_<__P ;
MH_X>*?L4?]'":+_W[G_^-T?V;F/_ #YG_P" O_(#VFBO%O\ AXI^Q1_T<)HO
M_?N?_P"-T?\ #Q3]BC_HX31?^_<__P ;H_LW,?\ GS/_ ,!?^0'M-%>+?\/%
M/V*/^CA-%_[]S_\ QNFC_@HQ^Q.9#&/V@]'R!DGR;C'Y^7BC^S<Q_P"?,_\
MP%_Y >UT5XM_P\4_8H_Z.$T7_OW/_P#&Z/\ AXI^Q1_T<)HO_?N?_P"-T?V;
MF/\ SYG_ . O_(#VFBO%O^'BG[%'_1PFB_\ ?N?_ .-T?\/%/V*/^CA-%_[]
MS_\ QNC^S<Q_Y\S_ / 7_D![317BW_#Q3]BC_HX31?\ OW/_ /&Z/^'BG[%'
M_1PFB_\ ?N?_ .-T?V;F/_/F?_@+_P @/::*\6_X>*?L4?\ 1PFB_P#?N?\
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MUU_P3_Y'3_MSD_FM?,__  \4_8H_Z.$T7_OW/_\ &ZZ+X7?\%,OV$_#GB?\
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MX\"_^$E9_P#QJC_AE_\ 9I_Z-X\"_P#A)6?_ ,:KN:* .&_X9?\ V:?^C>/
MO_A)6?\ \:H_X9?_ &:?^C>/ O\ X25G_P#&J[FB@#AO^&7_ -FG_HWCP+_X
M25G_ /&J/^&7_P!FG_HWCP+_ .$E9_\ QJNYHH X;_AE_P#9I_Z-X\"_^$E9
M_P#QJC_AE_\ 9I_Z-X\"_P#A)6?_ ,:KN:* .&_X9?\ V:?^C>/ O_A)6?\
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M^&7_ -FG_HWCP+_X25G_ /&J[FB@#AO^&7_V:?\ HWCP+_X25G_\:H_X9?\
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MCXX_V#_:O_"&>#]3UW^R_M7D?;/LEK)<>3YFU_+W^7MW[6VYSM.,5C_L<_\
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M]\9+7X,_L5_\$Z1\2[=M AU+5/'_ (G^(EMH&BV$DDTT8M%#Q2374P$(=A&
M$66,D\UC_L"?\%,O&'[37QW\>?L8?M1?LR7OP>^-?PZTZVU75?"K>((M7L-5
MTF<A8]1L;V)$$L>YD#*5!0R*NYF#A/:OVNOVN?@/^PY\!=;_ &COVC/&<>C>
M&]$B&2%WW%]<-D16EM%D&>XE8;4C'7DDA59A\O?\$LOV;?VA/B-^T5\1/^"N
M_P"V7X,?P?XW^+FAVFA^ _AK(V9_!_A"!Q+!!>-@9O9W6.>5/^6;#&%+-%&
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MCP59MI_PD^)$6@>5X$'AF< ,=(\F)8K2_;S'2:*9C-L<@%_WS5[9_P %3_\
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MX9-I?--"Z7GVJTN)'D"QI-'Y) 4^?NSE #]*T4 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?*W[?'_!,2R_:U^*
M7@[]JOX&?'O6?@W\<_A[;2VGA;XF:#ID-^LMA(6,FGZA93%8[ZU+.["-F7:S
ML0<,P/U310!^1GQ\_8W_ ."C/Q5_;S^#GPE_X*P^-M=^._[.\]X-0LT^#GP_
M^P:1:>)H''V;_A);.%9IVL2K<2&3R0Q^<(@E)_17]LGX/?M8_&?X=:;X;_8^
M_;'@^"?B"UUI+G4/$DWPXL_$PO+(0RHUH+:[EC2+,C12>:"6'E;<88D>O44
M? '_  3)_P""1O[</_!.;Q/8:"?^"JEOXR^&!\2:IKOB7X=?\*(L-.?5[R]C
MDWN-0^W33V^)VCFVH"I\K8  QK[_ *** .0_: \!>/?BI\#O%WPT^%GQ8N?
MGB37_#MYI^B>-+/3Q=3:'<S1,D=XD)=!(\;,'"[UY4?,.M?GE^R=_P $1/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
5HH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>biib-20220331_g16.jpg
<TEXT>
begin 644 biib-20220331_g16.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#5H=3N+F>(30"62XEC<$AU""0;1M0)7VS10 5X]^WW^QGX _X*#_ +(/C?\
M8]^)VMWVF:/XTT^&&34],"F>SG@N8KJWG4-PVR>")BIQN"E<C.1[#10!\:^*
MO^"='[:'QS_8M^+W['G[77_!1NQ^(*?$7PO!HWASQ-;_  9MM(F\/A3)Y\TT
M5O?D:@TH,/&Z *8F(SO('J7[0W[$O_"^O^"<^N_L _\ "S?[*_MKX9Q^$?\
MA+?[%\_R=MJD'VK[+YR;L[-WE^:.N-W>O>** /D[]IK_ ()6Z#^T%^S_ /!W
MP3X<^.NL>!_B?\!;:R?X8?%W0-,B>XTV[ALXK68R6<KE)[6X2)?-MF?#!54N
M0#N=\$OV9_\ @JU9?%;P]XH_:7_X*6^%M<\*:%<^;J/A/P3\%[?2Y/$(",JK
M<W<UW.\"[BKE8%7<5QD+D'ZKN[NTL+66_O[F."""-I)IIG"I&@&2S$\  #))
MK/\ !?C?P7\1_"]GXW^'GB_2]>T748S)I^KZ+J$=U:W*!BI:.6)F1QD$9!/(
M([4 :E?.G[=W[ ?_  VQ\1O@-X__ .%L_P#",_\ "DOB_8>.?LG]@_;?[:^S
M C['N\^+[-NS_K<28_N&OHNH[N\M+"UDO;^ZC@AB0M+-,X544=22> * /(?^
M"@7[)O\ PW5^QG\0?V1O^$__ .$6_P"$[T(Z;_PD']E?;OL.9$?S/(\V+S?N
M8V^8O7K63^U)^Q+_ ,-*?\$\/$7[!/\ PLW^Q?[?^'\/AC_A*_[%^T^1LBCC
M^T?9?.3=GR\[/-'7&[BO:]"\2>'?%%F=0\,Z]9:C;ARAGL;I)D##J-R$C/M5
MV@#Y?^*O_!-S_A9OC7]EKQA_PN;[#_PS3J)NOL__  COF_\ "1_\2M;#;N^T
M+]C^[YF<3==N/XJ[7]OS]ACX7_\ !0?]G^3X&_$G7-6T*YL=:M-=\(>+?#TX
MBU'PYK5HQ:UU"V8@@2(692#U21P"I(8>UT4 ?&7@C]D7_@L8FM:)HGQ2_P""
MMGAB]\-:3J%O)J=UX?\ @):6>LZ];1R*S03327DD-J95!5I(8MPW';@X(VOV
MP_\ @FOX\^*O[3.C_MU_L:?M.W'P<^,NF^&SX=U?5I?#46LZ1XGT?S?.2SU"
MQDDCWE).4G1U=!C[VU-GUG5#3O%/AG5]2N-'TGQ'875W9G%W:V]XCR0'_;52
M2OXT >$_LF_ 7_@H!X%^).H?$3]LC]NS1_B'8SZ*]CI?@CPG\,(-!TVQG::)
MS>M,;B>XN)=L90*SJBB5\*2<U[CXY\-?\)IX)UCP=]M^S?VMI5Q9_:?+W^5Y
ML;)OVY&[&[.,C..HK4Z=:IZ+XAT#Q);/>>'=<L[^&.4QR2V5RDJJXZJ2I(!&
M1Q0!\]?L3?\ !-KX6?LP?\$\_!/_  3U^,J^'_BYH'A*UFBNI_$_@Z#['J;-
M?S7B2-8SO<(I1I0!EWY0,""<";]JG]@"U_:4_:D_9U_:0L?B;'X<@^ 'B'5=
M3A\.Q>'Q.FLI>6<=L(5E$\8M!&(]P(27.<87&:]_USQ%X?\ #-F-0\2:[9Z?
M;EP@GOKI(D+'HNYR!D^E6H9H;F%+BWF62.10T<B,"K*1D$$=10!\=_M(_P#!
M-#XW7/[8FH_M\?L!?M8V_P )OB#XJ\/6NB_$?2]?\&IKNA^*[>U&VTGF@\Z&
M2&ZA3"+,CG*($PH9R_2?L"?\$XM1_9-\6?$?]H3XX_'N]^*OQG^+MS;2>.?'
MUYHL>G0+;6T1CM;"RLXW=;:VA5B,;R7(4L?E4+])WGBGPSIVKP>']0\16$%_
M=#-M937B+-,.GRH3N;\!5^@#P/\ X)@_L/\ _#M_]A?P+^Q;_P +/_X3/_A"
MH]17_A)?[%_L[[9]JU*ZO?\ CW\Z;R]OVG9_K&SLW<9VCQOX>?\ !$WP!HO_
M  1??_@CE\3/C;?Z]I,EM?!O'.F:&NGSK<2ZY+K-O,ELTTX7R9VB4J9#Y@B/
M*;\+]P44 ?&GB_\ X)S?MH?'C]BKXO?L=_M=_P#!1NP^( ^(WAJWTCPYXGMO
M@S;:1-X?"M(9YIHK>_*W[2YAXW0!#$Q&=Y ]3_:/_8E_X:"_X)TZ]^P'_P +
M-_LC^V_AO'X3_P"$L_L7[1Y.RW2'[3]E\Y-V=F[R_-'7&[O7O%% 'R]\5OV2
M?VZM'\"?#/PQ^QE^WEI7@/\ X0/P;;Z#K>E>)?A?!K.G>)3###%'<L#<QS6;
MJ(V($<C B3#9P#5']BS_ ()U_%/X,?M0>,?VZOVMOVF(?BA\6O%_A6U\+QWF
MC>$8]#TG1=$@G\];.WMEEE>1FFP[2R2%C@  <D_5]8_A#X@^ ?B"-3/@+QOH
M^MC1=7GTK63I&IQ7/V"_AQYUI-Y;'RITW+NB;#KN&0,T <[^U%\%?^&D_P!F
M;XB_LZ?\)+_8O_"?>!-7\.?VQ]C^T_8/MUE+:^?Y6]/-V>;OV;UW;<;ESD?$
M'P-_X)/_ /!7_P#9P^#OAGX"_!__ (+PV.E^%O"&C0:5H&G/^RMHMP;:TA0)
M&ADEOV=\* -S,2>Y-?HS5#1_%'AGQ#-<6_A_Q%87TEH^RZ2SNTE,+>CA2=I]
MC0!\R_'3_@G=\4/VE?!_[.%O\:OVJTUCQ7\"OBMI'CG7O%4?@2*V7Q=<64<Z
M-"+6&Y6/3_,\[.Y3*$V?<;/'5_MV_L-_\-KZK\$]3_X6A_PC/_"G?CIH?Q&V
M?V)]M_M?^SEN%^P9\Z+[/YGG_P"N_>;=O^K;/'ODTT5O$UQ<2JD:*6=W; 4#
MDDD]!5?1]<T7Q%8KJGA_6+6^MG)"W%G<++&2.H#*2* /DG]JC_@FU\:_$G[7
M\/[?/["'[5%K\)_B3J'A>/PYX[M-=\(+KFB^*M.B??;FXM_.A>*XA/"S(^2B
MJG W;J'[%/\ P2B^(?[,O[=OC/\ X*!_&+]LC4/B=XR^(7P^A\/^*8KSPC%I
MT(NH[N.59[417#K;VR0PPP):[&(\LR-,[.U?8.N>*/#7AB.*;Q+XBL=.2>39
M"U]=I")&_NJ7(R?85>!# ,IR#T(H ^$=%_X)8_M@?LG>/O%UY_P3*_;PTGX?
M> /&WB*YUZ^^%WCWX;)K^GZ+J5R=UQ-ILR75O+;Q.PW?9CNC4Y(/.*]0\7?\
M$[?$O[2_[!?C#]BW]O\ _:4O_BO>^-I))=1\:6/ABUT)].D#Q2VALK6 ND(M
MI88Y$W,Y<@^86#$'Z>HH _-/]H__ ((K_P#!07]N#]ER]_8__;#_ ."MB:WX
M3M;:W71;G0_A##:7>I7,$B&WN=8<7V;P1JI;R8VA#S%)7=S&%;]'?"VB?\(U
MX8T[PY]I\_\ L^PAMO.V;?,\M N[&3C.,XR:OT4 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5;_Q->:1=&TU+7F9KZ]TH7LZZ=/.S$EV:T$!5R2738Q)+$G\Z?C=_P %H_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **\2_8(U34]7^#6J
MW.K:C/=2+XWUA%DN)F=@HN2 N6)X Z#M7MM !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% 'A?_  3W_P"2)ZM_V/>L_P#I2:]TKPO_ ()[_P#)$]6_['O6?_2DU[I0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!X7_ ,$]_P#DB>K?]CWK/_I2:]TKPO\
MX)[_ /)$]6_['O6?_2DU[I0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X7_P3W_Y
M(GJW_8]ZS_Z4FO=*^>OV"[;Q)+\'-6;2=2MXHO\ A.-9RLL)8Y^TMSFO;?L7
MC?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#
M8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\
M@,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_
M (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_
M .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-
M_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -B
MBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P"
MQ_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\
M@,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\
MZ#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_
M .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**
MQ_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'
M_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P"
MQ_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H
M-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\
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MW*2&)O1@I.T^QH N455UC7=$\/6GV_7]8M;&#<%\^\N%B3<>@RQ S4\$\%U
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M !1110 4444 %%%% 'A?_!/?_DB>K?\ 8]ZS_P"E)KW2O"_^">__ "1/5O\
ML>]9_P#2DU[I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7"_'G_D V7_ %^'
M_P! -=U7"_'G_D V7_7X?_0#7DY[_P BFKZ?J@/+:***_+0"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "NO\ @G_R
M.G_;G)_-:Y"NO^"?_(Z?]N<G\UKT<H_Y&='_ !(#UVBBBOU< HHHH **** "
MBBB@ HHKA_VB?VE?@-^R5\*M0^-W[27Q4TCP=X6TS:+K5]9N=B&1L[(HU +S
M2M@A8HU9W(PJDT =Q17Y^ZI_P6Y^.'Q)<ZG^Q5_P1V_:&^)GA\\VGBS7M*B\
M+6&I)GB:T-]F2:,C.&,:'(QBM#PE_P %W/!/@/5[?0O^"A/[$OQI_9N2ZG6&
M'Q;XY\+->^&#*S;4C;5;/?'$Q)&3(B(H.2X'- 'WE15/P_X@T#Q;H%CXJ\*Z
MY9ZGI>IV<5WINI:?<I-;W=O(@>.:*1"5D1E(964D$$$$@U<H \+_ .">_P#R
M1/5O^Q[UG_TI->Z5X7_P3W_Y(GJW_8]ZS_Z4FO=* "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *X7X\_\ (!LO^OP_^@&NZKA?CS_R ;+_ *_#_P"@&O)SW_D4
MU?3]4!Y;1117Y: 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5U_P3_P"1T_[<Y/YK7(5U_P $_P#D=/\ MSD_FM>C
ME'_(SH_XD!Z[1117ZN 4444 %%%% !1110 5E>*? O@GQR-/7QKX/TO6!I.I
M1ZCI8U33X[C['>1AECN(O,4^7*H=P'7# ,<'DUJT4 >&>"?V\_AAXM^)_P ?
M?!-_HE_I.B_L\M9)XN\77SH;2Y>72QJ=P(54E\6\#()"P&6;"Y S7SI^QQ_P
M6>UW]K[XJ^!_A=^T!_P3U\3_  Q\!?'G2M2F^"/C+Q+XALM3M?&-O;V[7$D-
MU:1H&T]I;0/+&DAD650=I8$,>6_;6_X)8_\ !1GQW\5/CQX2_8S^/GPNT'X3
M?M3+8#XJ#QG8Z@VN>')$L8]/OGTH6X,-P+FUB 99V7#.54H/GKWGXM_L&>,]
M=_:#_9(B^&$FBV'PK_9VDU*YU.WO+V0:C.Z:&VEZ7!;QK$8V1?,=I69TX50J
MG)P ?4/AKPUX=\&>'-/\'^$-!LM*TG2K**STO2].M4@M[.VB0)'#%&@"QQHB
MJJJH 4    5=HHH \+_X)[_\D3U;_L>]9_\ 2DU[I7A?_!/?_DB>K?\ 8]ZS
M_P"E)KW2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N%^//\ R ;+_K\/_H!K
MNJX7X\_\@&R_Z_#_ .@&O)SW_D4U?3]4!Y;1117Y: 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5U_P $_P#D=/\
MMSD_FM<A77_!/_D=/^W.3^:UZ.4?\C.C_B0'KM%%%?JX!1110 4444 %%%%
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MFUZY11_:68_\_I_^!/\ S \C_P"&&OV<?^@)XG_\.-KG_P FT?\ ##7[./\
MT!/$_P#X<;7/_DVO7**/[2S'_G]/_P "?^8'D?\ PPU^SC_T!/$__AQM<_\
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M_P .)=T?\.>OV8?^B@_%/_PXEW7U910!\I_\.>OV8?\ HH/Q3_\ #B7==/\
M"_\ X)M?!SX.:I<ZSX"^)GQ#AN+NW\F=M1\3B_4IN#<+=12*IR!RH![9Q7T+
M145*=.K!PFDT^CU0'F'_  R_IW_17/%O_?.F_P#R'1_PR_IW_17/%O\ WSIO
M_P AUZ?17+_9N7?\^8?^ K_(#S#_ (9?T[_HKGBW_OG3?_D.C_AE_3O^BN>+
M?^^=-_\ D.O3Z*/[-R[_ )\P_P# 5_D!YA_PR_IW_17/%O\ WSIO_P AT?\
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M&^.3QNP>XXKVZBJA@,#3DI1I137517^0'RG_ ,.>OV8?^B@_%/\ \.)=T?\
M#GK]F'_HH/Q3_P##B7=?5E%=8'SG\+/^"87[/WPA^(>D?$SPSXU^(EQ?Z-=B
MYM8=4\<7-Q;NX!&)(VX=>>AKZ,HHH **** "BBB@ HHKR_\ :T^)7[3?PK^&
MEIXC_90_9HM?BMXEEUZVMKOPW=^,[;0E@L7#^==_:+A61C'A/W0&YM_!XH ^
M"M/_ &LOV7O^"8/_  5__:*\7?\ !0XOX,N?C))H&H?";XN:QH<]QI^H:-;:
M7!;3Z.EU%&_V1X+B)V>,[5?<CL?]5N+W]K#]E_\ X*>_\%@OV=?&7_!/$R>,
M[CX--X@O_BU\6]'T.>WT^PT>ZTN:VM]'>ZEC3[6\US(CI&-RIM=U/^MV^Y?M
MF_'_ /X*BV/Q<\0?"?X.?\$9O"GQF^&UK):MHWBGQ!\;-&TY-4+6T4DK-I]W
M [1&.=Y8ANSN$6\<,*7]C#X__P#!42_^+N@?";XR_P#!&CPK\&/AM=/=MK'B
MGP_\:]'U%=+9;662(KI]I C2F6=(83MQM$N\Y"F@#[2HHHH \+_X)[_\D3U;
M_L>]9_\ 2DU[I7A?_!/?_DB>K?\ 8]ZS_P"E)KW2@ KR+XV?\CI_VYQ_S:O7
M:\B^-G_(Z?\ ;G'_ #:OG.*/^19_V\OU Y"BBBOSH HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KU+X#?\@&]_P"O
MP?\ H KRVO4O@-_R ;W_ *_!_P"@"O>X:_Y&T?1_D!W5%%%?I0!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2^ W_(!O?^OP?^@"O>X:_P"1M'T?Y =U1117Z4 4444 %%%% !1110 4444
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7J7P&_Y
M-[_U^#_T 5Y;7H?P<U:]T_1KN.UT.>Z#70)>(C"_*..:][AK_D;1]'^0'I-%
M8_\ PDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2U^E ;%%8_\ PDNK_P#0H7O_
M 'TM'_"2ZO\ ]"A>_P#?2T ;%%8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2T
M ;%%8_\ PDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2T ;%%8__"2ZO_T*%[_W
MTM'_  DNK_\ 0H7O_?2T ;%%8_\ PDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?
M2T ;%%8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2T ;%%8_\ PDNK_P#0H7O_
M 'TM'_"2ZO\ ]"A>_P#?2T ;%%8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2T
M ;%%8_\ PDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2T ;%%8__"2ZO_T*%[_W
MTM'_  DNK_\ 0H7O_?2T ;%%8_\ PDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?
M2T ;%%8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2T ;%%8_\ PDNK_P#0H7O_
M 'TM'_"2ZO\ ]"A>_P#?2T ;%%8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2T
M ;%%8_\ PDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2T ;%%8__"2ZO_T*%[_W
MTM'_  DNK_\ 0H7O_?2T ;%%8_\ PDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?
M2T ;%%9=GKVI7-TD$WAFZA5FPTKLN%]S6I0 4444 %%%% !1110!^;OQ3\"_
M\%BOV9?^"D/QA^-G[!_[&/P\\7?#+XF)HUSJT/BCXCQ6,VHZK:Z;#;MJ$*8#
M6;$ V\D;"191;1RKL9FW>Q_LN?'_ /X+,>-OCMH7AC]J[_@GW\-_!'@"Z^U?
MV_XHT#XKIJ=W9;;65X/+MA&#)OG6&,\_*LC-_#7U_10 4444 >%_\$]_^2)Z
MM_V/>L_^E)KW2O"_^">__)$]6_['O6?_ $I->Z4 %>1?&S_D=/\ MSC_ )M7
MKM>1?&S_ )'3_MSC_FU?.<4?\BS_ +>7Z@<A1117YT 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5ZE\!O^0#>_\
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M8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\ OT* *?\ PF/AC_H-0?\
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M'_OT* *?_"8^&/\ H-0?]]4?\)CX8_Z#4'_?57/[.T__ )\8?^_0H_L[3_\
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MO"_^">__ "1/5O\ L>]9_P#2DU[I0 5Y%\;/^1T_[<X_YM7KM>1?&S_D=/\
MMSC_ )M7SG%'_(L_[>7Z@<A1117YT 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5ZE\!O^0#>_P#7X/\ T 5Y;7J7
MP&_Y -[_ -?@_P#0!7O<-?\ (VCZ/\@.ZHHHK]* **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MMSFO;?L7C?\ Z#=E_P" Q_QKR/\ X)[_ /)$]6_['O6?_2DU[I0!C_8O&_\
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M%N N]OW<H>,YY4TZ]?!U,<JNKC=-II)Z=-WN!Y[_ ,$N?V3Y/V+?V%?A_P#
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MST'PKHEKI6CVN<F.VMXEBC!.!EMJC)[G)[UT-<>*K+$8F=5?:;?WL HHHK
MHHHH *]#^#EOX@FT:[.CZA!"@NAO$L18D[17GE>I? ;_ ) -[_U^#_T 5[W#
M7_(VCZ/\@.B^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &MBBOTH#'^Q>-_\
MH-V7_@,?\:/L7C?_ *#=E_X#'_&MBB@#'^Q>-_\ H-V7_@,?\:/L7C?_ *#=
ME_X#'_&MBB@#'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&MBB@#'^Q>-_\
MH-V7_@,?\:/L7C?_ *#=E_X#'_&MBB@#'^Q>-_\ H-V7_@,?\:/L7C?_ *#=
ME_X#'_&MBB@#'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&MBB@#'^Q>-_\
MH-V7_@,?\:/L7C?_ *#=E_X#'_&MBB@#'^Q>-_\ H-V7_@,?\:/L7C?_ *#=
ME_X#'_&MBB@#'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&MBB@#'^Q>-_\
MH-V7_@,?\:/L7C?_ *#=E_X#'_&MBB@#'^Q>-_\ H-V7_@,?\:/L7C?_ *#=
ME_X#'_&MBB@#'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&MBB@#'^Q>-_\
MH-V7_@,?\:/L7C?_ *#=E_X#'_&MBB@#'^Q>-_\ H-V7_@,?\:/L7C?_ *#=
ME_X#'_&MBB@#'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&MBB@#'^Q>-_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#PO\ X)[_ /)$]6_['O6?_2DU[I7A?_!/?_DB>K?]CWK/_I2:]TH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/^R/_P!%ZT'_ +_/_P#$T?\ #<_[(_\ T7K0?^_S_P#Q- 'J/]G:?_SXP_\
M?H4?V=I__/C#_P!^A7EW_#<_[(__ $7K0?\ O\__ ,31_P -S_LC_P#1>M!_
M[_/_ /$T >H_V=I__/C#_P!^A1_9VG_\^,/_ 'Z%>7?\-S_LC_\ 1>M!_P"_
MS_\ Q-'_  W/^R/_ -%ZT'_O\_\ \30!ZC_9VG_\^,/_ 'Z%']G:?_SXP_\
M?H5Y=_PW/^R/_P!%ZT'_ +_/_P#$T?\ #<_[(_\ T7K0?^_S_P#Q- 'J/]G:
M?_SXP_\ ?H4?V=I__/C#_P!^A7EW_#<_[(__ $7K0?\ O\__ ,31_P -S_LC
M_P#1>M!_[_/_ /$T >H_V=I__/C#_P!^A1_9VG_\^,/_ 'Z%>7?\-S_LC_\
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M?^_S_P#Q- 'J/]G:?_SXP_\ ?H4?V=I__/C#_P!^A7EW_#<_[(__ $7K0?\
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M?&'_ +]"C^SM/_Y\8?\ OT*\N_X;G_9'_P"B]:#_ -_G_P#B:/\ AN?]D?\
MZ+UH/_?Y_P#XF@#U'^SM/_Y\8?\ OT*/[.T__GQA_P"_0KR[_AN?]D?_ *+U
MH/\ W^?_ .)H_P"&Y_V1_P#HO6@_]_G_ /B: /4?[.T__GQA_P"_0H_L[3_^
M?&'_ +]"O+O^&Y_V1_\ HO6@_P#?Y_\ XFC_ (;G_9'_ .B]:#_W^?\ ^)H
M]1_L[3_^?&'_ +]"C^SM/_Y\8?\ OT*\N_X;G_9'_P"B]:#_ -_G_P#B:/\
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M:O@'XA^-#Z]:Z==>&/#7A&>*WGU*VO%1XKCS+@A8HA&ZNS-T4]*\K_X)=_\
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M1_;)_9/\+7O@7]J#]OF#XU:-:Z3ING>"[*'X3V/AHZ##:I)&X+VUQ,UWYB&
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M$_\ !52W\9?# ^)-4UWQ+\.O^%$6&G/J]Y>QR;W&H?;II[?$[1S;4!4^5L
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>biib-20220331_g17.jpg
<TEXT>
begin 644 biib-20220331_g17.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#5H=3N+F>(30"62XEC<$AU""0;1M0)7VS10 5X]^WW^QGX _X*#_ +(/C?\
M8]^)VMWVF:/XTT^&&34],"F>SG@N8KJWG4-PVR>")BIQN"E<C.1[#10!\:^*
MO^"='[:'QS_8M^+W['G[77_!1NQ^(*?$7PO!HWASQ-;_  9MM(F\/A3)Y\TT
M5O?D:@TH,/&Z *8F(SO('J7[0W[$O_"^O^"<^N_L _\ "S?[*_MKX9Q^$?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5;_Q->:1=&TU+7F9KZ]TH7LZZ=/.S$EV:T$!5R2738Q)+$G\Z?C=_P %H_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\
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M^^J/^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\
M0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ% %/\
MX3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^JN?V=I__/C#_P!^A1_9VG_\^,/_ 'Z%
M %/_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJKG]G:?\ \^,/_?H4?V=I_P#SXP_]
M^A0!3_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,
M/_?H4 4_^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?
M_P ^,/\ WZ% %/\ X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^JN?V=I__/C#_P!^
MA1_9VG_\^,/_ 'Z% %/_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJKG]G:?\ \^,/
M_?H4?V=I_P#SXP_]^A0!3_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZJY_9VG_P#/
MC#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?
M_P ^,/\ WZ%']G:?_P ^,/\ WZ% %/\ X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^
M^JN?V=I__/C#_P!^A1_9VG_\^,/_ 'Z% %/_ (3'PQ_T&H/^^J/^$Q\,?]!J
M#_OJKG]G:?\ \^,/_?H4?V=I_P#SXP_]^A0!3_X3'PQ_T&H/^^J/^$Q\,?\
M0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 5K;Q1X?O)UM;758GD<X1%/
M)-7ZB2QLHV#QV<2L.A6, BI: "BBB@ HHHH **** "BBB@ HHHH \+_X)[_\
MD3U;_L>]9_\ 2DU[I7A?_!/?_DB>K?\ 8]ZS_P"E)KW2@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#PO_@GO_P D3U;_ +'O6?\ TI->Z5X7_P $]_\ DB>K?]CW
MK/\ Z4FO=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** /"_\ @GO_ ,D3U;_L>]9_
M]*37NE>%_P#!/?\ Y(GJW_8]ZS_Z4FO=* "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)=7_ .A0O?\ OI:/^$EU?_H4+W_OI:V** ,?_A)=7_Z%"]_[Z6C_ (275_\
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M^$EU?_H4+W_OI:V** ,?_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI:V** ,?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/"_^">__ "1/5O\ L>]9_P#2DU[I7A?_  3W_P"2)ZM_V/>L_P#I2:]TH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH \+_P"">_\ R1/5O^Q[UG_TI->Z5X7_ ,$]
M_P#DB>K?]CWK/_I2:]TH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^&/V?/^"?GP
M5_:6\)ZM\2/'OBOQO9W_ /PEFJVGD^'_ !;/96^Q+IR#Y:<;OF.3WXKN_P#A
MSU^S#_T4'XI_^'$NZ[C_ ()[_P#)$]6_['O6?_2DU[I0!\I_\.>OV8?^B@_%
M/_PXEW7+^+_^"<O[-G@'5_[!A?QKJ2^4LGVG4?B+JWF<Y^7]S<1K@8_NYYZU
M]J5Y%\;/^1T_[<X_YM7@\1UJU#+N:G)Q=UJG;OV ^=/^&&OV<?\ H">)_P#P
MXVN?_)M'_##7[./_ $!/$_\ X<;7/_DVO7**^"_M+,?^?T__  )_Y@>1_P##
M#7[./_0$\3_^'&US_P"3:/\ AAK]G'_H">)__#C:Y_\ )M>N44?VEF/_ #^G
M_P"!/_,#R/\ X8:_9Q_Z GB?_P .-KG_ ,FT?\,-?LX_] 3Q/_X<;7/_ )-K
MURBC^TLQ_P"?T_\ P)_Y@>1_\,-?LX_] 3Q/_P"'&US_ .3:/^&&OV<?^@)X
MG_\ #C:Y_P#)M>N44?VEF/\ S^G_ .!/_,#R/_AAK]G'_H">)_\ PXVN?_)M
M'_##7[./_0$\3_\ AQM<_P#DVO7**/[2S'_G]/\ \"?^8'D?_##7[./_ $!/
M$_\ X<;7/_DVC_AAK]G'_H">)_\ PXVN?_)M>N44?VEF/_/Z?_@3_P P/(_^
M&&OV<?\ H">)_P#PXVN?_)M'_##7[./_ $!/$_\ X<;7/_DVO7**/[2S'_G]
M/_P)_P"8'D?_  PU^SC_ - 3Q/\ ^'&US_Y-H_X8:_9Q_P"@)XG_ /#C:Y_\
MFUZY11_:68_\_I_^!/\ S \C_P"&&OV<?^@)XG_\.-KG_P FT?\ ##7[./\
MT!/$_P#X<;7/_DVO7**/[2S'_G]/_P "?^8'D?\ PPU^SC_T!/$__AQM<_\
MDVC_ (8:_9Q_Z GB?_PXVN?_ ";7KE%']I9C_P _I_\ @3_S \C_ .&&OV<?
M^@)XG_\ #C:Y_P#)M'_##7[./_0$\3_^'&US_P"3:]<HH_M+,?\ G]/_ ,"?
M^8'D?_##7[./_0$\3_\ AQM<_P#DVC_AAK]G'_H">)__  XVN?\ R;7KE%']
MI9C_ ,_I_P#@3_S \C_X8:_9Q_Z GB?_ ,.-KG_R;1_PPU^SC_T!/$__ (<;
M7/\ Y-KURBC^TLQ_Y_3_ / G_F!Y'_PPU^SC_P! 3Q/_ .'&US_Y-KH_!?\
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MN?\ R;7KE%?F_P#:68_\_I_^!/\ S \C_P"&&OV<?^@)XG_\.-KG_P FT?\
M##7[./\ T!/$_P#X<;7/_DVO7**/[2S'_G]/_P "?^8'D?\ PPU^SC_T!/$_
M_AQM<_\ DVC_ (8:_9Q_Z GB?_PXVN?_ ";7KE%']I9C_P _I_\ @3_S \C_
M .&&OV<?^@)XG_\ #C:Y_P#)M'_##7[./_0$\3_^'&US_P"3:]<HH_M+,?\
MG]/_ ,"?^8'D?_##7[./_0$\3_\ AQM<_P#DVC_AAK]G'_H">)__  XVN?\
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MC_T!/$__ (<;7/\ Y-H_X8:_9Q_Z GB?_P .-KG_ ,FUZY11_:68_P#/Z?\
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M#Q;H%CXJ\*ZY9ZGI>IV<5WINI:?<I-;W=O(@>.:*1"5D1E(964D$$$$@U<H
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MW*&&(7*3"Y^7RT^;S=QQR3DY]P_X5+\0?^A?_P#)N+_XNC_A4OQ!_P"A?_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "N%^//_(!LO^OP_P#H!KNJX7X\_P#(!LO^
MOP_^@&O)SW_D4U?3]4!Y;1117Y: 4444 %%%% !1110 4444 %%%% !1110
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MK^BBB@#PO_@GO_R1/5O^Q[UG_P!*37NE>%_\$]_^2)ZM_P!CWK/_ *4FO=*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *X7X\_P#(!LO^OP_^@&NZKA?CS_R
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M2W.:]M^Q>-_^@W9?^ Q_QH V**Q_L7C?_H-V7_@,?\:/L7C?_H-V7_@,?\:
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M$]6_['O6?_2DU[I7A?\ P3W_ .2)ZM_V/>L_^E)KW2@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7"_'G_ ) -E_U^'_T UW5<+\>?^0#9?]?A_P#0#7DY[_R*:OI^J \M
MHHHK\M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\)CX8_Z#4'_?5'_"8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\ OT*
M*?\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]5<_L[3_ /GQA_[]"C^SM/\ ^?&'
M_OT* *?_  F/AC_H-0?]]4?\)CX8_P"@U!_WU5S^SM/_ .?&'_OT*/[.T_\
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MSE%='_PJ7X@_]"__ .3<7_Q='_"I?B#_ -"__P"3<7_Q=']FYC_SYG_X"_\
M(#RSP/\ !K0O GQ1\;_%;3M4NYKSQU<V$^HV\Q7RK<VEHML@CP <%5!.XGGI
M@<51_:>_9M^&?[7'P/USX _%NVNSHVN11[KK3;@0W=C/%(LL%U;RE6\N:*5$
MD1L$!E&01D'V'_A4OQ!_Z%__ ,FXO_BZ/^%2_$'_ *%__P FXO\ XNK6!S13
M4U2G=6M[KZ;= ./L]#@3P]!X=UBYDU9([1(+B?4DC=[O:H!>4*JH6;&3A0N2
M< #BI-*T;2-"M!8:)I5M9P!BP@M8%C0$]3A0!76?\*E^(/\ T+__ )-Q?_%T
M?\*E^(/_ $+_ /Y-Q?\ Q=3_ &=F7_/F?_@+_P @.0UCP]H'B&%+?7]#L[Z.
M-MT:7ELDH4^H# X-6HHHH(EAAC5$10J(HP% Z #L*Z7_ (5+\0?^A?\ _)N+
M_P"+H_X5+\0?^A?_ /)N+_XNE_9N9?\ /F?_ ("_\@.<JG/X=\/W6JQZ[<Z%
M9R7T(Q%>/:H94'/ <C(ZGOWKK_\ A4OQ!_Z%_P#\FXO_ (NC_A4OQ!_Z%_\
M\FXO_BZ/[-S)?\N9_P#@+_R \;_:A_9M\#?M;_!G4?@)\3M8UFV\.:U<6S:W
M;Z)>);R7]O#.DS6DCE&(@E,820)M9D+*& 8UWEA86.E6,.EZ99Q6UM;1+%;V
M\$81(D4 *JJ.%    '  KJ/^%2_$'_H7_P#R;B_^+H_X5+\0?^A?_P#)N+_X
MNJ> S-P4?8SLO[KZ_+R YRBNC_X5+\0?^A?_ /)N+_XNC_A4OQ!_Z%__ ,FX
MO_BZG^S<Q_Y\S_\  7_D!SE%='_PJ7X@_P#0O_\ DW%_\71_PJ7X@_\ 0O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBBB@#PO_ ()[_P#)$]6_['O6?_2DU[I7A?\ P3W_ .2)ZM_V/>L_^E)KW2@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#PO\ X)[_ /)$]6_['O6?_2DU[I7A?_!/
M?_DB>K?]CWK/_I2:]TH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \+_X)[_\D3U;
M_L>]9_\ 2DU[I7S%^S9\:OA9^S-X+U3X;?'GQK9^&-=?Q5J5^NF:B6$OV::<
MM%)\H(PR\CVKT/\ X;N_9#_Z+QHG_?4G_P 10!ZU17DO_#=W[(?_ $7C1/\
MOJ3_ .(H_P"&[OV0_P#HO&B?]]2?_$4 >M45Y+_PW=^R'_T7C1/^^I/_ (BC
M_AN[]D/_ *+QHG_?4G_Q% 'K5%>2_P##=W[(?_1>-$_[ZD_^(H_X;N_9#_Z+
MQHG_ 'U)_P#$4 >M45Y+_P -W?LA_P#1>-$_[ZD_^(H_X;N_9#_Z+QHG_?4G
M_P 10!ZU17DO_#=W[(?_ $7C1/\ OJ3_ .(H_P"&[OV0_P#HO&B?]]2?_$4
M>M45Y+_PW=^R'_T7C1/^^I/_ (BC_AN[]D/_ *+QHG_?4G_Q% 'K5%>2_P##
M=W[(?_1>-$_[ZD_^(H_X;N_9#_Z+QHG_ 'U)_P#$4 >M45Y+_P -W?LA_P#1
M>-$_[ZD_^(J-?V]?V0&G:V'QVTC<J@DE)@OX-LP?H#0!Z]17DO\ PW=^R'_T
M7C1/^^I/_B*/^&[OV0_^B\:)_P!]2?\ Q% 'K5%>2_\ #=W[(?\ T7C1/^^I
M/_B*/^&[OV0_^B\:)_WU)_\ $4 >M45Y+_PW=^R'_P!%XT3_ +ZD_P#B*/\
MAN[]D/\ Z+QHG_?4G_Q% 'K5%>2_\-W?LA_]%XT3_OJ3_P"(H_X;N_9#_P"B
M\:)_WU)_\10!ZU17DO\ PW=^R'_T7C1/^^I/_B*/^&[OV0_^B\:)_P!]2?\
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M_P#^":#_ .(H_P"%3?"O_HFGA_\ \$T'_P 17044 <__ ,*F^%?_ $33P_\
M^":#_P"(H_X5-\*_^B:>'_\ P30?_$5T%% '/_\ "IOA7_T33P__ .":#_XB
MC_A4WPK_ .B:>'__  30?_$5T%% '/\ _"IOA7_T33P__P"":#_XBC_A4WPK
M_P"B:>'_ /P30?\ Q%=!10!S_P#PJ;X5_P#1-/#_ /X)H/\ XBC_ (5-\*_^
MB:>'_P#P30?_ !%=!10!S_\ PJ;X5_\ 1-/#_P#X)H/_ (BO$_ OP\\ 3?MY
M>.]&F\#:.]G#X(TN2&T;3(C&CF1LL%VX!/<BOHRN;TSX4^$=(^*.J?&"SAG&
MM:OIL%C>NTY,9AB)* )V.3U[T 2?\*F^%?\ T33P_P#^":#_ .(H_P"%3?"O
M_HFGA_\ \$T'_P 17044 <__ ,*F^%?_ $33P_\ ^":#_P"(H_X5-\*_^B:>
M'_\ P30?_$5T%% '/_\ "IOA7_T33P__ .":#_XBC_A4WPK_ .B:>'__  30
M?_$5T%% '/\ _"IOA7_T33P__P"":#_XBC_A4WPK_P"B:>'_ /P30?\ Q%=!
M10!S_P#PJ;X5_P#1-/#_ /X)H/\ XBC_ (5-\*_^B:>'_P#P30?_ !%=!10!
MS_\ PJ;X5_\ 1-/#_P#X)H/_ (BC_A4WPK_Z)IX?_P#!-!_\17044 <__P *
MF^%?_1-/#_\ X)H/_B*/^%3?"O\ Z)IX?_\ !-!_\17044 <_P#\*F^%?_1-
M/#__ ()H/_B*/^%3?"O_ *)IX?\ _!-!_P#$5T%% '/_ /"IOA7_ -$T\/\
M_@F@_P#B*/\ A4WPK_Z)IX?_ /!-!_\ $5T%% '/_P#"IOA7_P!$T\/_ /@F
M@_\ B*/^%3?"O_HFGA__ ,$T'_Q%=!10!S__  J;X5_]$T\/_P#@F@_^(H_X
M5-\*_P#HFGA__P $T'_Q%=!10!S_ /PJ;X5_]$T\/_\ @F@_^(H_X5-\*_\
MHFGA_P#\$T'_ ,17044 <_\ \*F^%?\ T33P_P#^":#_ .(H_P"%3?"O_HFG
MA_\ \$T'_P 17044 <__ ,*F^%?_ $33P_\ ^":#_P"(H_X5-\*_^B:>'_\
MP30?_$5T%% '/_\ "IOA7_T33P__ .":#_XBC_A4WPK_ .B:>'__  30?_$5
MT%% '/\ _"IOA7_T33P__P"":#_XBC_A4WPK_P"B:>'_ /P30?\ Q%=!10!S
M_P#PJ;X5_P#1-/#_ /X)H/\ XBO$_P!J3X>> -.^,GP7M=/\#:/!%=^-Y8[J
M.'3(E69/LS':X"X89[&OHRN;\;_"GPC\0?$7ASQ1XCAG:[\+:DU]I)AG**LQ
M0H2P_B&#TH D_P"%3?"O_HFGA_\ \$T'_P 11_PJ;X5_]$T\/_\ @F@_^(KH
M** .?_X5-\*_^B:>'_\ P30?_$4?\*F^%?\ T33P_P#^":#_ .(KH** .?\
M^%3?"O\ Z)IX?_\ !-!_\11_PJ;X5_\ 1-/#_P#X)H/_ (BN@HH Y_\ X5-\
M*_\ HFGA_P#\$T'_ ,11_P *F^%?_1-/#_\ X)H/_B*Z"B@#G_\ A4WPK_Z)
MIX?_ /!-!_\ $4?\*F^%?_1-/#__ ()H/_B*Z"B@#G_^%3?"O_HFGA__ ,$T
M'_Q%'_"IOA7_ -$T\/\ _@F@_P#B*Z"B@#G_ /A4WPK_ .B:>'__  30?_$4
M?\*F^%?_ $33P_\ ^":#_P"(KH** .?_ .%3?"O_ *)IX?\ _!-!_P#$4?\
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MFLV#2O&+FTN(FBFC+(59=R.RY4@C.00>: /FW6/V^_VA_%?[!_P?_:R_9?\
MV$M6^)?BSXO:)HVHVWP_T_QE;6-OH<=_IK7S2W>IW,2HL$6!$9/*!=W0! 6Q
M7G'@+_@JU^U;\(OVI?AY^S#_ ,%+_P!A"U^%<?Q=U%]+^'?COPC\0(?$&E7&
MK!0RZ;=!88I+:5\JJ/\ ,'9P -H=U^Q? /@;X4_LT_!;2/ASX-M;/PUX)\!^
M&H;#38;J_;R-+TRS@"('FG<MLCBC&7D8G"DLQY-?GWX#O?$G_!<+]O'P#^U#
MX6TFXTS]EK]G+Q7<:IX"UZ\MVBG^)?BV+,2WULK %--M&4[)3@R.&'.YE@ /
MI']K[]J;_@H+\/OC):_!G]BO_@G2/B7;MH$.I:IX_P#$_P 1+;0-%L)))IHQ
M:*'BDFNI@(0[", (LL9)YK'_ &!/^"F7C#]IKX[^//V,/VHOV9+WX/?&OX=:
M=;:KJOA5O$$6KV&JZ3.0L>HV-[$B"6/<R!E*@H9%7<S!PGM7[77[7/P'_8<^
M NM_M'?M&>,X]&\-Z)$,D+ON+ZX;(BM+:+(,]Q*PVI&.O))"JS#Y>_X)9?LV
M_M"?$;]HKXB?\%=_VR_!C^#_ !O\7-#M-#\!_#61LS^#_"$#B6""\; S>SNL
M<\J?\LV&,*6:*, ^[**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *^5OV^/^"G5K^R9\4_!W[*7P)^ FL?&3XY_$*VE
MO/"WPUT+4X;!(;",L)-1U"]F#1V-J&1U$C*VYD8  *2/JFOS8_9=-L/^#GK]
MIX>.MO\ :Y^!?A;_ (03[1]_^QMMI]M\K/\ !]MV[L?Q4 =3K/\ P5S_ &K_
M -D+QOX7M/\ @JO^P/:?"WP#XPUJ'2+#XL^"OB'%X@TC2+^8D10ZG'Y$4MI&
MQ'_'Q\R>V Q7Z1_;:_:8^/O[-W@_1=1_9Q_8H\4_&_7]<U)[5-#\.:W::;%8
MJL9<3W5U='9#&3A0<'DUXS_P<2GP*/\ @BY\??\ A8?V?[%_PB</V3[3C'V_
M[=;?8]N?XOM/DX[YQ7OW["G_  F7_#$7P;_X6,)QXA_X55X>_M[[3GS/MO\
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MCD O^^:O;/\ @J?_ ,$V_P!LG_@HIH>L_"#X>?\ !2*#X8?"KQ-X7ATKQ-X
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ML=6WRF351'=7L4+W!5HE5GA9HC K(P.,>O\ [&W[,W_!1KX,?$R_\3_M??\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
F%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>biib-20220331_g18.jpg
<TEXT>
begin 644 biib-20220331_g18.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#5H=3N+F>(30"62XEC<$AU""0;1M0)7VS10 5X]^WW^QGX _X*#_ +(/C?\
M8]^)VMWVF:/XTT^&&34],"F>SG@N8KJWG4-PVR>")BIQN"E<C.1[#10!\:^*
MO^"='[:'QS_8M^+W['G[77_!1NQ^(*?$7PO!HWASQ-;_  9MM(F\/A3)Y\TT
M5O?D:@TH,/&Z *8F(SO('J7[0W[$O_"^O^"<^N_L _\ "S?[*_MKX9Q^$?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5;_Q->:1=&TU+7F9KZ]TH7LZZ=/.S$EV:T$!5R2738Q)+$G\Z?C=_P %H_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **\2_8(U34]7^#6J
MW.K:C/=2+XWUA%DN)F=@HN2 N6)X Z#M7MM !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% 'A?_  3W_P"2)ZM_V/>L_P#I2:]TKPO_ ()[_P#)$]6_['O6?_2DU[I0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!X7_ ,$]_P#DB>K?]CWK/_I2:]TKPO\
MX)[_ /)$]6_['O6?_2DU[I0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X7_P3W_Y
M(GJW_8]ZS_Z4FO=*\+_X)[_\D3U;_L>]9_\ 2DU[I0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!X7_P3W_Y(GJW_ &/>L_\ I2:]TKPO_@GO_P D3U;_ +'O6?\
MTI->Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 >%_\ !/?_ )(GJW_8]ZS_ .E)
MKW2O"_\ @GO_ ,D3U;_L>]9_]*37NE !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '
MA?\ P3W_ .2)ZM_V/>L_^E)KW2O"_P#@GO\ \D3U;_L>]9_]*37NE !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% 'A?_!/?_DB>K?]CWK/_I2:]TKPO_@GO_R1/5O^
MQ[UG_P!*37NE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'S]^P-X@T73/@UJUMJ&
MHQQ2?\)SK+;7/./M+<U[?_PF/AC_ *#4'_?5>,_\$_+2UG^"NK/-;1N?^$ZU
MD99 3_Q\FO<O[.T__GQA_P"_0H I_P#"8^&/^@U!_P!]4?\ "8^&/^@U!_WU
M5S^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0H I_\ "8^&/^@U!_WU1_PF/AC_ *#4
M'_?57/[.T_\ Y\8?^_0H_L[3_P#GQA_[]"@"G_PF/AC_ *#4'_?5'_"8^&/^
M@U!_WU5S^SM/_P"?&'_OT*/[.T__ )\8?^_0H I_\)CX8_Z#4'_?5'_"8^&/
M^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\ OT* *?\ PF/AC_H-0?\ ?5'_
M  F/AC_H-0?]]5<_L[3_ /GQA_[]"C^SM/\ ^?&'_OT* *?_  F/AC_H-0?]
M]4?\)CX8_P"@U!_WU5S^SM/_ .?&'_OT*/[.T_\ Y\8?^_0H I_\)CX8_P"@
MU!_WU1_PF/AC_H-0?]]5<_L[3_\ GQA_[]"C^SM/_P"?&'_OT* *?_"8^&/^
M@U!_WU1_PF/AC_H-0?\ ?57/[.T__GQA_P"_0H_L[3_^?&'_ +]"@"G_ ,)C
MX8_Z#4'_ 'U1_P )CX8_Z#4'_?57/[.T_P#Y\8?^_0H_L[3_ /GQA_[]"@"G
M_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]5<_L[3_P#GQA_[]"C^SM/_ .?&'_OT
M* *?_"8^&/\ H-0?]]4?\)CX8_Z#4'_?57/[.T__ )\8?^_0H_L[3_\ GQA_
M[]"@"G_PF/AC_H-0?]]4?\)CX8_Z#4'_ 'U5S^SM/_Y\8?\ OT*/[.T__GQA
M_P"_0H I_P#"8^&/^@U!_P!]4?\ "8^&/^@U!_WU5S^SM/\ ^?&'_OT*/[.T
M_P#Y\8?^_0H I_\ "8^&/^@U!_WU1_PF/AC_ *#4'_?57/[.T_\ Y\8?^_0H
M_L[3_P#GQA_[]"@"G_PF/AC_ *#4'_?5'_"8^&/^@U!_WU5S^SM/_P"?&'_O
MT*/[.T__ )\8?^_0H I_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]5<_L[3_^?&'_
M +]"C^SM/_Y\8?\ OT* *?\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]5<_L[3_
M /GQA_[]"C^SM/\ ^?&'_OT* *?_  F/AC_H-0?]]4?\)CX8_P"@U!_WU5S^
MSM/_ .?&'_OT*/[.T_\ Y\8?^_0H I_\)CX8_P"@U!_WU1_PF/AC_H-0?]]5
M<_L[3_\ GQA_[]"C^SM/_P"?&'_OT* *?_"8^&/^@U!_WU1_PF/AC_H-0?\
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M\)CX8_Z#4'_?5'_"8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\ OT*
M*?\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]5<_L[3_ /GQA_[]"C^SM/\ ^?&'
M_OT* *?_  F/AC_H-0?]]4?\)CX8_P"@U!_WU5S^SM/_ .?&'_OT*/[.T_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^2)ZM_V/>L_^E)KW2O"_^">__)$]6_['O6?_ $I->Z4 %%%% !1110 4444
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M>_\ R1/5O^Q[UG_TI->Z5X7_ ,$]_P#DB>K?]CWK/_I2:]TH **** "BBB@
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MO6?_ $I->Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM>?$G_@K>^E>,=0MX8(Y?"?[0$>GP6$,=O#!Y=JB9,".(5=U5L,Y9CR:[_\
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MXAWR,JXF*$9R<#FN+"T\9/+ZT5&3BK=':Z:O\[?@!^L]%%%>0 4444 %%%%
M!1110 5ZE\!O^0#>_P#7X/\ T 5Y;7J7P&_Y -[_ -?@_P#0!7O<-?\ (VCZ
M/\@.ZHHHK]* **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH \+_ .">_P#R1/5O^Q[UG_TI->Z5X7_P3W_Y(GJW_8]ZS_Z4FO=* "O(
MOC9_R.G_ &YQ_P VKUVO(OC9_P CI_VYQ_S:OG.*/^19_P!O+]0.0HHHK\Z
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *]2^ W_(!O?^OP?^@"O+:]2^ W_(!O?^OP?^@"O>X:_Y&T?1_D!W5%%%
M?I0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 >%_P#!/?\ Y(GJW_8]ZS_Z4FO=*\+_ .">_P#R1/5O^Q[UG_TI->Z4
M %>1?&S_ )'3_MSC_FU>NUY%\;/^1T_[<X_YM7SG%'_(L_[>7Z@<A1117YT
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MX31?^_<__P ;H_X>*?L4?]'":+_W[G_^-T?V;F/_ #YG_P" O_(#VFBO%O\
MAXI^Q1_T<)HO_?N?_P"-T?\ #Q3]BC_HX31?^_<__P ;H_LW,?\ GS/_ ,!?
M^0'M-%>+?\/%/V*/^CA-%_[]S_\ QNFC_@HQ^Q.9#&/V@]'R!DGR;C'Y^7BC
M^S<Q_P"?,_\ P%_Y >UT5XM_P\4_8H_Z.$T7_OW/_P#&Z/\ AXI^Q1_T<)HO
M_?N?_P"-T?V;F/\ SYG_ . O_(#VFBO%O^'BG[%'_1PFB_\ ?N?_ .-T?\/%
M/V*/^CA-%_[]S_\ QNC^S<Q_Y\S_ / 7_D![317BW_#Q3]BC_HX31?\ OW/_
M /&Z/^'BG[%'_1PFB_\ ?N?_ .-T?V;F/_/F?_@+_P @/::*\6_X>*?L4?\
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M_HWCP+_X25G_ /&J[FB@#AO^&7_V:?\ HWCP+_X25G_\:H_X9?\ V:?^C>/
MO_A)6?\ \:KN:* .&_X9?_9I_P"C>/ O_A)6?_QJC_AE_P#9I_Z-X\"_^$E9
M_P#QJNYHH X;_AE_]FG_ *-X\"_^$E9__&J/^&7_ -FG_HWCP+_X25G_ /&J
M[FB@#AO^&7_V:?\ HWCP+_X25G_\:H_X9?\ V:?^C>/ O_A)6?\ \:KN:* .
M&_X9?_9I_P"C>/ O_A)6?_QJC_AE_P#9I_Z-X\"_^$E9_P#QJNYHH X;_AE_
M]FG_ *-X\"_^$E9__&J/^&7_ -FG_HWCP+_X25G_ /&J[FB@#AO^&7_V:?\
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M"XZ,CK&"I]P:Z^BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "OAWXH?\%8?CC\2_VG/&/[)7_!,;]C+_ (7/K/PUN5L_
MB7XVU[QG%H'AS0-0.?\ B7K<-%*]Y=*597CC4>6P.2=K;?N*OS8_X-93;?\
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MJXU8*&73;H+#%);2OE51_F#LX &T.Z_8O@'P-\*?V:?@MI'PY\&VMGX:\$^
M_#4-AIL-U?MY&EZ99P!$#S3N6V1Q1C+R,3A268\FOS[\!WOB3_@N%^WCX!_:
MA\+:3<:9^RU^SEXKN-4\!:]>6[13_$OQ;%F);ZV5@"FFVC*=DIP9'##G<RP
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M** "OAWXH?\ !)WXW?#?]IWQA^UM_P $R/VSV^"VM?$FY6\^)?@K6_!<.O\
MAS7[\9_XF"V[RQ/9W3%F9Y(V/F,3D#<V[[BHH _,3_@F)^R]^T[<?\%-/B5\
M:O\ @JUH'C3QC\:/!5FVG_"3XD1:!Y7@0>&9P QTCR8EBM+]O,=)HIF,VQR
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M[#YD.^/?"HV;]P4D"OT>HH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
@@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>biib-20220331_g19.jpg
<TEXT>
begin 644 biib-20220331_g19.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#5H=3N+F>(30"62XEC<$AU""0;1M0)7VS10 5X]^WW^QGX _X*#_ +(/C?\
M8]^)VMWVF:/XTT^&&34],"F>SG@N8KJWG4-PVR>")BIQN"E<C.1[#10!\:^*
MO^"='[:'QS_8M^+W['G[77_!1NQ^(*?$7PO!HWASQ-;_  9MM(F\/A3)Y\TT
M5O?D:@TH,/&Z *8F(SO('J7[0W[$O_"^O^"<^N_L _\ "S?[*_MKX9Q^$?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5;_Q->:1=&TU+7F9KZ]TH7LZZ=/.S$EV:T$!5R2738Q)+$G\Z?C=_P %H_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH I7WB+1--G^RW^I1Q
M2  [&/.*B_X3'PQ_T&H/^^J\@_8-N;G7?@YJM[KEP]Y,OC;5XUENW,C!%N2%
M7+9. .@[5[7_ &=I_P#SXP_]^A0!3_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZJY
M_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\
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M^^J/^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\
M0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ% %/\
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M#_OJKG]G:?\ \^,/_?H4?V=I_P#SXP_]^A0!3_X3'PQ_T&H/^^J/^$Q\,?\
M0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 5K;Q1X?O)UM;758GD<X1%/
M)-7ZB2QLHV#QV<2L.A6, BI: "BBB@ HHHH **** "BBB@ HHHH \+_X)[_\
MD3U;_L>]9_\ 2DU[I7A?_!/?_DB>K?\ 8]ZS_P"E)KW2@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#PO_@GO_P D3U;_ +'O6?\ TI->Z5X7_P $]_\ DB>K?]CW
MK/\ Z4FO=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** /"_\ @GO_ ,D3U;_L>]9_
M]*37NE>%_P#!/?\ Y(GJW_8]ZS_Z4FO=* "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* /"_P#@GO\ \D3U;_L>]9_]*37NE>%_\$]_^2)ZM_V/>L_^E)KW2@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#PO_@GO_R1/5O^Q[UG_P!*37NE>%_\$]_^2)ZM
M_P!CWK/_ *4FO=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /AC]GS]JWXU?!OPG
MJW@_P%^Q-XW\?V'_  EFJS_V]X?N8$M][73@Q8?G<N!G_>%=W_P\$_:>_P"D
M77Q3_P# ZTKN/^">_P#R1/5O^Q[UG_TI->Z4 ?*?_#P3]I[_ *1=?%/_ ,#K
M2IH/V^OVDYH]\W_!.#QK:-G_ %6H^,-)M9/KLFE5L>^,&OJ:O(OC9_R.G_;G
M'_-J\G.<=6R[!^UII-W2U_X#0'G7_#>O[1W_ $CR\3_^'!T/_P"2*/\ AO7]
MH[_I'EXG_P##@Z'_ /)%:U%?*?ZV9C_)#[G_ /) 9/\ PWK^T=_TCR\3_P#A
MP=#_ /DBC_AO7]H[_I'EXG_\.#H?_P D5K44?ZV9C_)#[G_\D!D_\-Z_M'?]
M(\O$_P#X<'0__DBC_AO7]H[_ *1Y>)__  X.A_\ R16M11_K9F/\D/N?_P D
M!D_\-Z_M'?\ 2/+Q/_X<'0__ )(H_P"&]?VCO^D>7B?_ ,.#H?\ \D5K44?Z
MV9C_ "0^Y_\ R0&3_P -Z_M'?](\O$__ (<'0_\ Y(H_X;U_:._Z1Y>)_P#P
MX.A__)%:U%'^MF8_R0^Y_P#R0&3_ ,-Z_M'?](\O$_\ X<'0_P#Y(H_X;U_:
M._Z1Y>)__#@Z'_\ )%:U%'^MF8_R0^Y__) 9/_#>O[1W_2/+Q/\ ^'!T/_Y(
MH_X;U_:._P"D>7B?_P .#H?_ ,D5K44?ZV9C_)#[G_\ ) 9/_#>O[1W_ $CR
M\3_^'!T/_P"2*/\ AO7]H[_I'EXG_P##@Z'_ /)%:U%'^MF8_P D/N?_ ,D!
MD_\ #>O[1W_2/+Q/_P"'!T/_ .2*/^&]?VCO^D>7B?\ \.#H?_R16M11_K9F
M/\D/N?\ \D!D_P##>O[1W_2/+Q/_ .'!T/\ ^2*/^&]?VCO^D>7B?_PX.A__
M "16M11_K9F/\D/N?_R0&3_PWK^T=_TCR\3_ /AP=#_^2*/^&]?VCO\ I'EX
MG_\ #@Z'_P#)%:U%'^MF8_R0^Y__ "0&3_PWK^T=_P!(\O$__AP=#_\ DBC_
M (;U_:._Z1Y>)_\ PX.A_P#R16M11_K9F/\ )#[G_P#) 9/_  WK^T=_TCR\
M3_\ AP=#_P#DBC_AO7]H[_I'EXG_ /#@Z'_\D5K44?ZV9C_)#[G_ /) 9/\
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MQ/\ ^'!T/_Y(K6HKXS_6S,?Y(?<__D@,G_AO7]H[_I'EXG_\.#H?_P D4?\
M#>O[1W_2/+Q/_P"'!T/_ .2*UJ*/];,Q_DA]S_\ D@,G_AO7]H[_ *1Y>)__
M  X.A_\ R11_PWK^T=_TCR\3_P#AP=#_ /DBM:BC_6S,?Y(?<_\ Y(#)_P"&
M]?VCO^D>7B?_ ,.#H?\ \D4?\-Z_M'?](\O$_P#X<'0__DBM:BC_ %LS'^2'
MW/\ ^2 R?^&]?VCO^D>7B?\ \.#H?_R11_PWK^T=_P!(\O$__AP=#_\ DBM:
MBC_6S,?Y(?<__D@,G_AO7]H[_I'EXG_\.#H?_P D4?\ #>O[1W_2/+Q/_P"'
M!T/_ .2*UJ*/];,Q_DA]S_\ D@,G_AO7]H[_ *1Y>)__  X.A_\ R11_PWK^
MT=_TCR\3_P#AP=#_ /DBM:BC_6S,?Y(?<_\ Y(#)_P"&]?VCO^D>7B?_ ,.#
MH?\ \D4?\-Z_M'?](\O$_P#X<'0__DBM:BC_ %LS'^2'W/\ ^2 R?^&]?VCO
M^D>7B?\ \.#H?_R11_PWK^T=_P!(\O$__AP=#_\ DBM:BC_6S,?Y(?<__D@,
MG_AO7]H[_I'EXG_\.#H?_P D4?\ #>O[1W_2/+Q/_P"'!T/_ .2*UJ*/];,Q
M_DA]S_\ D@,G_AO7]H[_ *1Y>)__  X.A_\ R11_PWK^T=_TCR\3_P#AP=#_
M /DBM:BC_6S,?Y(?<_\ Y(#)_P"&]?VCO^D>7B?_ ,.#H?\ \D4?\-Z_M'?]
M(\O$_P#X<'0__DBM:BC_ %LS'^2'W/\ ^2 R?^&]?VCO^D>7B?\ \.#H?_R1
M1_PWK^T=_P!(\O$__AP=#_\ DBM:BC_6S,?Y(?<__D@,G_AO7]H[_I'EXG_\
M.#H?_P D5'/^WU^TG#'OA_X)P>-;ML_ZK3O&&DW4GUV0RLV/?&!6U77_  3_
M .1T_P"W.3^:UUX'B3'8K&4Z4HQM)I:)_P"8'F'_  \$_:>_Z1=?%/\ \#K2
MC_AX)^T]_P!(NOBG_P"!UI7U917VP'SG\+/VU/V@?'_Q#TCP9XF_X)[?$3PQ
M8:C=B&Z\0:I=VS6]BA!_>2!>2HQV]:^C*** "BBB@ HHHH **** "BBB@ HH
MHH \+_X)[_\ )$]6_P"Q[UG_ -*37NE>%_\ !/?_ )(GJW_8]ZS_ .E)KW2@
M KR+XV?\CI_VYQ_S:O7:\B^-G_(Z?]N<?\VKYSBC_D6?]O+]0.0HHHK\Z **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *]2^ W_(!O?^OP?^@"O+:]2^ W_(!O?^OP?^@"O>X:_P"1M'T?Y =U1117
MZ4 4444 %<+\>?\ D V7_7X?_0#7=5POQY_Y -E_U^'_ - ->3GO_(IJ^GZH
M#RVBBBORT HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ KK_@G_ ,CI_P!N<G\UKD*Z_P""?_(Z?]N<G\UKT<H_Y&='
M_$@/7:***_5P"BBB@ HHHH **** "O,OVLO#?[5_C'X4_P#"*_L<?$OPGX,\
M5:AJ4,-UXL\6Z))J2:38%7\ZXMK165+BZ!V>6DS"+EBV<!3Z;10!^?NJ?\&]
M7P/^,CGQ#^VK^VE^T-\9/$%Q\]W=Z]\2I=.L(G)R1:6%BL<=I'D B,%@#WJS
MH_\ P13^)/[+DG_"4_\ !-O_ (*2_&'X?ZA;G?%X-^(>M?\ "7>$[S'/E2V-
MT%EAW_=::*82*#E>0*\;^+/_  4H\)?L+_&/_@HAXJ^,7QWM])^)6F+HTGP?
M\&Z_K8#7T!\-0QZ9_9=G*V)E:^ED,_D(<-EI.E<U^S%^PKI__!,#]J3]B7Q?
MX&\7>+_^%M_'E=7T_P#:*MM:\47=X/%DO_"/2ZE=7-Q#/(RH]G>*FQT"G:1O
M+$DD _6GX='X@M\/M";XM)HZ^*CHUK_PDR^'6E.GC4/*7[0+4S?O#!YN_9O^
M?9MW<YK9HHH \+_X)[_\D3U;_L>]9_\ 2DU[I7A?_!/?_DB>K?\ 8]ZS_P"E
M)KW2@ KR+XV?\CI_VYQ_S:O7:\B^-G_(Z?\ ;G'_ #:OG.*/^19_V\OU Y"B
MBBOSH HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ KU+X#?\@&]_P"OP?\ H KRVO4O@-_R ;W_ *_!_P"@"O>X:_Y&
MT?1_D!W5%%%?I0!1110 5POQY_Y -E_U^'_T UW5<+\>?^0#9?\ 7X?_ $ U
MY.>_\BFKZ?J@/+:***_+0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "NO^"?_ ".G_;G)_-:Y"NO^"?\ R.G_ &YR
M?S6O1RC_ )&='_$@/7:***_5P"BBB@ HHHH **** "BBB@#\[?VV?VS/@[XN
M_;=O/@[\!_\ @CM-^U-\5_@Y!83>(/%YT?1[:#P=+<I]JM;:+5-0C=EN-K"8
M1Q[0I.02ZN$[#]GC]IC]K3]I#]KSP+JG[2O_  0RU7X=-I-OJD&G?%_Q!X[T
M759O"\4MG(\B0K"GGJ+EXH;=A&1GS%+9537E'Q!^*G_!0/\ 81_X*>?'#Q?^
MR_\ \$J?&WQ9^&?Q1FT34M9U>P\4V%B#K5OI<$$EW8M(2S0O'LAD@E52)K9I
M$DVR;![U^RY_P4+_ &W?CE\=M"^%OQ>_X)"?$CX7>'=4^U?VCXZU_P 7Z;=6
MFF>7:RS1^9% ?,;S)(TA&WHTJD\ T ?7]%%% 'A?_!/?_DB>K?\ 8]ZS_P"E
M)KW2O"_^">__ "1/5O\ L>]9_P#2DU[I0 5Y%\;/^1T_[<X_YM7KM>1?&S_D
M=/\ MSC_ )M7SG%'_(L_[>7Z@<A1117YT 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%17=]9:?$)[^\B@0L%#S2!02>@R>] 'YZ?%OQ)_P %$_\
M@H_^W!\5_P!FK]E;]L*/]G_X5? V]TW1O$7B/1/"MOJFO^*M:N[&.]DCC-P0
MMG;0QS1IN7#,V3\X;$9\(O$O_!1+_@G#^W#\*/V9OVJOVP8_V@/A7\<KO4]'
M\-^)-;\+6^E:_P"%M:M+&2]CCD-N2MY;31PR+O;+*^#\@7$G4?M6_P#!._\
M:-TK]K#Q%^V=_P $W_V\]-^#OC3QQ8V-M\3O"/BOP[!K&@^)7M(1#:W;1.P>
MTN4A"QF2,$NJCE<N77]E'_@G?^T9JG[6'AW]L[_@H_\ MY:=\8O&O@>QOK;X
M8^$?"GAV#1]!\,O=PF&ZNTB1B]U<O#NC$D@!16;[V$* 'W/1110!X7_P3W_Y
M(GJW_8]ZS_Z4FO=*\+_X)[_\D3U;_L>]9_\ 2DU[I0 5Y%\;/^1T_P"W./\
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M;*3MZ7 ****Y@"BBB@ KT/X.>'[+6-&NYKJ:=2ET% BF*C[H]*\\KU+X#?\
M(!O?^OP?^@"O>X:_Y&T?1_D!T7_"#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M6Q17
MZ4!C_P#"#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U<=
M\8_#]EH^C6DUK-.Q>Z*D2S%A]T^M>DUPOQY_Y -E_P!?A_\ 0#7DY[_R*:OI
M^J \MHHHK\M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M P.#77_\*E^(/_0O_P#DW%_\71_PJ7X@_P#0O_\ DW%_\73_ +.S*]_8S_\
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M &V/^#;?XK_$_P"(>DVMIX[T:X7PYXQ.CKBVN9['7;**YGB Z))!\[ ?*"7
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M3AKO56O-YNKF610,2NTC,&4#9A0N BX]UHISQE><5'1*]]$EJMGHD!\ 2?\
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M?_QNO1/V4?"?_!>[3/C[H%]^VG\5?V9-2^&:?:O^$ELOA[I6M1ZQ)FUF%O\
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M%% !1110 4444 %<+\>?^0#9?]?A_P#0#7=5POQY_P"0#9?]?A_] ->3GO\
MR*:OI^J \MHHHK\M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *X7X\_\ (!LO^OP_^@&NZKA?CS_R ;+_ *_#_P"@&O)S
MW_D4U?3]4!Y;1117Y: 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5U_P3_P"1T_[<Y/YK7(5U_P $_P#D=/\ MSD_
MFM>CE'_(SH_XD!Z[1117ZN 4444 %%%% !1110 4444 %%%% !1110!X7_P3
MW_Y(GJW_ &/>L_\ I2:]TKPO_@GO_P D3U;_ +'O6?\ TI->Z4 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M .+H_LW,?^?,_P#P%_Y <Y171_\ "I?B#_T+_P#Y-Q?_ !='_"I?B#_T+_\
MY-Q?_%T?V;F/_/F?_@+_ ,@.<HKH_P#A4OQ!_P"A?_\ )N+_ .+H_P"%2_$'
M_H7_ /R;B_\ BZ/[-S'_ )\S_P# 7_D!SE%='_PJ7X@_]"__ .3<7_Q='_"I
M?B#_ -"__P"3<7_Q=']FYC_SYG_X"_\ (#G**Z/_ (5+\0?^A?\ _)N+_P"+
MH_X5+\0?^A?_ /)N+_XNC^S<Q_Y\S_\  7_D!SE=?\$_^1T_[<Y/YK5/_A4O
MQ!_Z%_\ \FXO_BZZ/X7> _%?ASQ/_:.LZ5Y,/V9UW^?&W)(P,*Q/:N_*\!CJ
M>8TI2I224EJXO_(#T:BBBOTP HHHH **** "BBB@ HHHH **** "BBB@#PO_
M ()[_P#)$]6_['O6?_2DU[I7A?\ P3W_ .2)ZM_V/>L_^E)KW2@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#PO\ X)[_ /)$]6_['O6?_2DU[I7A?_!/?_DB>K?]
MCWK/_I2:]TH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M (;N_9#_ .B\:)_WU)_\11_PW=^R'_T7C1/^^I/_ (BNZ_X5-\*_^B:>'_\
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MG_?4G_Q%=U_PJ;X5_P#1-/#_ /X)H/\ XBC_ (5-\*_^B:>'_P#P30?_ !%
M'"_\-W?LA_\ 1>-$_P"^I/\ XBC_ (;N_9#_ .B\:)_WU)_\17=?\*F^%?\
MT33P_P#^":#_ .(H_P"%3?"O_HFGA_\ \$T'_P 10!PO_#=W[(?_ $7C1/\
MOJ3_ .(H_P"&[OV0_P#HO&B?]]2?_$5W7_"IOA7_ -$T\/\ _@F@_P#B*/\
MA4WPK_Z)IX?_ /!-!_\ $4 <+_PW=^R'_P!%XT3_ +ZD_P#B*/\ AN[]D/\
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M_P#B*/\ A4WPK_Z)IX?_ /!-!_\ $4 <+_PW=^R'_P!%XT3_ +ZD_P#B*/\
MAN[]D/\ Z+QHG_?4G_Q%=U_PJ;X5_P#1-/#_ /X)H/\ XBC_ (5-\*_^B:>'
M_P#P30?_ !% '"_\-W?LA_\ 1>-$_P"^I/\ XBC_ (;N_9#_ .B\:)_WU)_\
M17=?\*F^%?\ T33P_P#^":#_ .(H_P"%3?"O_HFGA_\ \$T'_P 10!PO_#=W
M[(?_ $7C1/\ OJ3_ .(H_P"&[OV0_P#HO&B?]]2?_$5W7_"IOA7_ -$T\/\
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M<R!E*@H9%7<S!P@!]:T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\)*8& DA64W\GV'S(=\>^%1LW[@I(% 'Z/4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
40 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>biib-20220331_g2.jpg
<TEXT>
begin 644 biib-20220331_g2.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "OS8_96_X+*_\ !33]MOX5'XY_LQ_\
M$7](U_PE)K5]IMIJEW^TUI]B\LMK.T,N89]+#K\RGJ,>A-?I/7XA_P#!!GX-
M?\%<_&?_  3_ +?7OV1/VU?AAX)\$R>/?$2V6@>*/A@^J7D4RZC*)G:X$Z!@
MSY(&. <4 ?LI\&/%/Q+\8_"C0O%OQI^%T/@?Q3?:<DVO>%(/$$>J1Z5<'.Z
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M<NW Y(.: /?]9U_0?#ELM[XAUNTL(7E$:2WMRL2LYZ*"Q ).#QUXJW7XY?\
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M]O D'Q#LOA1\2!\./AIX*\0SROIOA[3[6V1[BYBM@P4S74KB0RL"P*G:0.
M?6O[+W[:_C[XZ?\ !1']J/\ 8[\0^%-'L]#^!3^"AX=U2R$OVO4/[9TB2^G^
MT[G*?(Z!4V*ORD[LGFOI:OS _P""(_P+T7]FC_@JU^W[\#?"_BG4]6T?P]J7
MPVAT.;6-2DO)[6P;1[^6UL3-*S.Z6L+QVJ%V9MEN@))!-?I_0 4444 %%%%
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M_A*_^%O_ !TU[XC?\@'[#_9/]I>3_H'^OE\_R_*_UW[O?N_U:XYN^&?V&O\
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M:=(NG33:9NBTG2(YR/+FFENIGEE@SN6&$.1@KG[0ILTT5O$UQ<2JD:*6=W;
M4#DDD]!5?1]<T7Q%8KJGA_6+6^MG)"W%G<++&2.H#*2* /B7]K;_ ()4?M5_
M%;_@H4W_  40_9!_X*,0_!?Q+/\ "F#P'?64_P 'K/Q*)[%+]KUVW7=Y&B%Y
M/)X$6Y?)X?#D5Z5^Q]^S#_P4D^#GQ3N/%?[6_P#P5(M?C/X8DT::VM_"</P+
MTOPV8;QI(F2[^U6MQ([;$65/**[6\W).5&?HS7/%'AKPQ'%-XE\16.G)/)LA
M:^NTA$C?W5+D9/L*O A@&4Y!Z$4 > ?\$Y/V&?\ AW_\%O$/P@_X6C_PEO\
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M\,^-O#MEXO\ !GB*PU?2=3MDN=.U32[M+BVNH7&4DCDC)61&!!#*2"#Q5Z@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "OP1_X-4==UG]DS5_AQX9US4ICX._:Q\%Z_?:*9W)2#Q=X
M:UF^@GMXQT02Z4\4A/5FML8.W(_>ZOQ1_P""7O[$7Q=_;1_X-SO@'+^S#\0]
M(\'?%[X;?%#5/%OPT\5:X)!:VEY!XAU&*>*<Q1R.89;::=60(P9A&&&.0 >?
M?M4:]K/[6G_!</X/_MW2:G-)X1\/_M:Z3\'OAG&'_=36VCPRSZM=KVD634;A
ME20=5@(R<#'ZU?M8_'#_ (*&>"?B-9> _P!C;]ASPYX]TN30X[[4?&WC#XI1
M:'96URTTR&Q2V2VGN)I D:2&3"1@3* 2=V/@_P#:J_9&TK]A/0O^"9'[*NGZ
MA%?7/A/]H/3XM<U2$L5U'5)8))[^[!8!B);J6>0;OFPX!Z5/^WM\4?V<-=_X
M*]>,?@K_ ,%??VAO%_@3X*6'PTTB]^">@P^,=5\/>'O$=R^_^U;BYN=-DB:>
M[BEVQHCRC"9P.1D ^U_^"?\ _P % /%'[67BWXC_  !^//[/MU\*OB_\(]0L
M8/&_@N77HM5M6MKZ%IK*_L[R)$6X@F1'/W T97:W."?!?V/?^"Q7[:G_  4+
MT>+Q;^R?_P $T+<^'=$\;W.@^._$OBKXIPVUK:F"[,<BZ>IM%DOI1;&.=LK%
M&C2+$'D8,5\0_P"""</[.\'_  5G_:I?]D?X?^)?#_PRN/ GA"7P8/%=_JEQ
M=:K:8N!_:*MJDLET()Y!))#YC#,+1L%4,!7T#_P;1Q11_P#!,&W>.,*9/BGX
MQ9R!]X_VU<C)_  ?A0!O>)O^"HG[4/QR_:,\?? #_@F?^Q1IWQ.T_P"%&MMH
M?Q ^(WC/Q^F@:-!K2 &;2[,+;SRW<T6=LC@*L;#!!#(S>+?\%U/C-\6M3_X)
M+^ OC)^U#\ IOAQXET[X^^%KGQ%X+T_7X==:V2UU:0!X+FW55N1+%&LJ *KX
ME5&4,"*SO^">?[8W[/O_  2$^)_Q^_8A_P""AOCF/X9:KJ?QR\0>._ /BOQ+
M:31Z9XPT+4VBDBN+>["&-YX]FR6,MN5B$&YD<+T?_!:C]I'X*?M??\$Q/A?\
M>?V?_%X\1>#];_:.\(1Z7K']GSVZ7@@UI[>1D2X1'*>9$X5]NUU 9258$@'?
M^,_^"L7[9O[.WQ&^'_B7]M#_ ()P+\/O@_\ $KQK8^&--\6VOQ+MM3U?P[=W
MS%;)]5L8H D2R,,2"*:00\@N[!5?[YKX$_X.0?\ E'_X?/<?'/P3@^G_ !-X
MJ^^Z /B+_@IC^R?_ ,$2M&\90?MD?\%2/!OA(7VM"W\.:?X@\<:O?M;$QQ2R
MQVT-O'+Y*/L29RRQACM.6.!7DO\ P;Y>'=&TOXL_M):Q^Q]=>(#^R!>^*=)'
MP$AUZ>Z: WB6KC6GTY;L^>ME]I*JK.,-M7;EED-?0?[4'_!6C_@E)\%?C-KO
M[+O[8OQN\.Z!XE\+?9KJYT?QKX9N7MY$GM4GBGMI7MWAG_=S;#Y;%E8.I [_
M #C_ ,$4IO!GQ9_X*,_M.?M5_L2_#^_\-?LP^+K'0[;PU(-"ETK2O$GB.&,B
M\U/3K21$V1X#K(ZHF]I%)&<A0#S;_@J)_P $X/V:?V7/^"@/[(_[3_P_A\4Z
MAXZ\?_MAZ5_;VN^)_&%[J&V">>2Z:V@AED\F"%9-NU40%515SC.?V+K\8/\
M@N'_ ,%;/^">>K_M<?LU_#W3OVC;636/@7^U98ZA\5;(>']2!T&VL6DANI&8
MVVV?RW!7$)D)ZJ".:_2KPK_P4B_9%^)'[$_B?_@H-\(_B--XK^&/A30=7U:_
MU?2M*GAFFBTV*22ZCBANTA=I!Y3*H8*&; !P<T >ZUX3^VC_ ,$W_P!E'_@H
M1?>$5_:T\':GXHT?P;+>3:?X7'B&ZL]-NY[CR/WMU%;21FY:/R!Y8=MJ^9)E
M6W<>A_LZ?'3P=^T]\!?!_P"T5\/++4K?0?''ARTUO1H=8M1!=+:W,2RQ>9&&
M8*Q1@<!B.>":^2O^"Z?_  6!T7_@E1\%/#.D^'(K'_A8WQ3O;K3? M[KT$S:
M1HRP?9UNM4OC"CR/#;BZ@;R8U:24L %(#8 /!_ ?[.7P1_86_P"#A#X4_L__
M /!,[2I_#'A_Q-\,==U3]I'X>Z%J4\VCV-G';D:/?R0N[K;7+W1C08VG84(
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MX:\1>'+J.#4]#U:PN%GMKVTEDCD6.52&0ED8%)'4CYJ]2HH  "  3GW-%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **\
M2_8(U34]7^#6JW.K:C/=2+XWUA%DN)F=@HN2 N6)X Z#M7MM !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% 'A?_!/?_DB>K?\ 8]ZS_P"E)KW2O"_^">__ "1/5O\
ML>]9_P#2DU[I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X7_P $]_\ DB>K?]CW
MK/\ Z4FO=*\+_P"">_\ R1/5O^Q[UG_TI->Z4 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 >%_P#!/?\ Y(GJW_8]ZS_Z4FO=*\+_ .">_P#R1/5O^Q[UG_TI->Z4
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 >%_\$]_^2)ZM_V/>L_^E)KW2O"_^">_
M_)$]6_['O6?_ $I->Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >%_\$]_^2)ZM
M_P!CWK/_ *4FO=*\+_X)[_\ )$]6_P"Q[UG_ -*37NE !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% 'A?_  3W_P"2)ZM_V/>L_P#I2:]TKPO_ ()[_P#)$]6_['O6
M?_2DU[I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!X7_ ,$]_P#DB>K?]CWK/_I2
M:]TKYZ_8+MO$DOP<U9M)U*WBB_X3C6<K+"6.?M+<YKVW[%XW_P"@W9?^ Q_Q
MH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#
M'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_Q
MH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#
M'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_Q
MH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#
M'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_Q
MH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#
M'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_Q
MH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#
M'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_Q
MH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#
M'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_Q
MH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#
M'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_Q
MH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#
M'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_Q
MH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#
M'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_Q
MH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#
M'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_Q
MH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#
M'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_Q
MH V**R[.T\6I=(]]JUJ\0;]XB6Y!(]C6I0 4444 %%%% !1110 4444 %%%%
M 'A?_!/?_DB>K?\ 8]ZS_P"E)KW2O"_^">__ "1/5O\ L>]9_P#2DU[I0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >%_\
M!/?_ )(GJW_8]ZS_ .E)KW2O"_\ @GO_ ,D3U;_L>]9_]*37NE !1110 444
M4 %%%% !1110 4444 ([I&ADD<*JC+,QP /6O@?QE_P<.?L">'/VH-/^&FB?
M%J77?A_!X3UVY\3^.O#G@+7=4M;/5;.]TR"&**YM+62&>V\NZNS+/'YD<;I
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MJK-;( C$ Y!56K] :* $CC2)%BB0*J@!548 'H*6BB@ HHHH **** "BBB@
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MB@ HHHH **** /"_^">__)$]6_['O6?_ $I->Z5X7_P3W_Y(GJW_ &/>L_\
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M (,G_P#)!]6RG_H PO\ X28;_P"5$'_"Z?\ @I%_T?M_YBW1_P#XBC_A=/\
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MK?\ 8]ZS_P"E)KW2O"_^">__ "1/5O\ L>]9_P#2DU[I0 5\;_MS_P#)</\
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M5NG%Q:BYNHHIQZ3EJ[M/1VM\[LHHHK@/I0HHHH **** "BBB@ KZO_X)^_\
M)/\ 7?\ L,K_ .BEKY0KZO\ ^"?O_)/]=_[#*_\ HI:]G(/^1E'T?Y'P7B7_
M ,DG5_Q0_P#2D>^T445]^?S0%%%% !7@7_!0+_DG^A?]AEO_ $4U>^UX%_P4
M"_Y)_H7_ &&6_P#135YF<?\ (MJ>GZH^LX&_Y*S"?XG_ .DL^4****_.C^J
MHHHH **** "BBB@ HHHH **** -#4_$=UJFAZ9H4T$:QZ6DJPNN=SB20N<_B
M>U9]%%.4G)W9$*<*<;15E=OYMW?XL****184444 %%%% !1110 4444 %%%%
M !7LG[#'_)</^X-<?S2O&Z]D_88_Y+A_W!KC^:5W99_R,*7^)'SG%_\ R2^+
M_P"O<OR/LBBBBOTH_DX**** "BBB@ HHHH **** "BBB@ HHHH \+_X)[_\
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M_P#TEGRA1117YT?U0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_N#6_P#-Z\'B+_D7_P#;R_4_1_"W_DI_^X<OSB>-T445\*?T:%%%% !1110
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M)^PQ_P EP_[@UQ_-*\;KV3]AC_DN'_<&N/YI7=EG_(PI?XD?.<7_ /)+XO\
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M*** "BBB@#PO_@GO_P D3U;_ +'O6?\ TI->Z5X7_P $]_\ DB>K?]CWK/\
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MIJ\S./\ D6U/3]4?6<#?\E9A/\3_ /26?*%%%%?G1_5 4444 %%%% !1110
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MEO$L,,9DE9G?:B*-SLS'&22236S0!X7_ ,$]_P#DB>K?]CWK/_I2:]TKPO\
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MZ1@_=4>H  'X5VO[,,%_!XEUKQ%+?0PZ)I_A^X;Q)'-;F7[39L &@50RG<Q
MP<C&,\]#R4*=&IC%!*\;_AY_+<]G,<5CL)D,JTFHUE!7MJN9V345K=WTBM;N
MUR-_@WX#\4>&]8UGX4?$F?5+K0K)KR^T[4-)-LTENOWY8VWL#C^Z<'GZ9\WK
MW+P/>_#KQ/X6\7^'O@7HM[HFM7&B323OJ\OV@W-@I!E@C8$")F&.H;/3(ZCP
MVKQE.G",)02U3O:]M'YZW[F.18K%5JE>E6E)\CC9345-)Q3UY$HM-WY6K]4]
M@HHHKA/H0HHHH **** "OJ__ ()^_P#)/]=_[#*_^BEKY0KZO_X)^_\ )/\
M7?\ L,K_ .BEKV<@_P"1E'T?Y'P7B7_R2=7_ !0_]*1[[1117WY_- 4444 %
M>!?\% O^2?Z%_P!AEO\ T4U>^UX%_P % O\ DG^A?]AEO_135YF<?\BVIZ?J
MCZS@;_DK,)_B?_I+/E"BBBOSH_J@**** "BBB@ HHHH *6/8)%,@)7(W =<4
ME.B\OS%\[=LW#?MZX[XH!['U)J]Q\2];T+5;_P#9S\46=QHRPV'_  C^EZ+<
MPI+9HJGSDEB;!WD\G=DM^E?-7BJY\0W'B>_NO%$$D.IR74AOXW@$++*2=X*
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M"=(_9G\&Q^+O%UWIFE7TMQ=WMII5J);G4KIGPAPS*H6-!@ECW7C-87[1]_\
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M 'ZF4444 >%_\$]_^2)ZM_V/>L_^E)KW2O"_^">__)$]6_['O6?_ $I->Z4
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M?_P3]_Y)_KO_ &&5_P#12U\H5]7_ /!/W_DG^N_]AE?_ $4M>SD'_(RCZ/\
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M_-Z\'B+_ )%__;R_4_1_"W_DI_\ N'+\XGC=%%%?"G]&A1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7U?_P $_?\
MDG^N_P#897_T4M?*%?5__!/W_DG^N_\ 897_ -%+7LY!_P C*/H_R/@O$O\
MY).K_BA_Z4CWVBBBOOS^: HHHH *\"_X*!?\D_T+_L,M_P"BFKWVO O^"@7_
M "3_ $+_ +#+?^BFKS,X_P"1;4]/U1]9P-_R5F$_Q/\ ])9\H4445^=']4!1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7LG[#'_)</^X-<?S2O&Z]D_88_P"2X?\ <&N/YI7=EG_(PI?XD?.<7_\
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M5F$_Q/\ ])9\H4445^=']4!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7LG[#'_)</^X-<?S2O&Z]D_88_P"2X?\
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M?_DN'_<&M_YO7V17QO\ MS_\EP_[@UO_ #>O!XB_Y%__ &\OU/T?PM_Y*?\
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M^4****_.C^J HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KV3]AC_DN'_<&N/YI7C=>R?L,?\ )</^X-<?S2N[+/\
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M%_R+_P#MY?J?H_A;_P E/_W#E^<3QNBBBOA3^C0HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KZO\ ^"?O_)/]=_[#
M*_\ HI:^4*^K_P#@G[_R3_7?^PRO_HI:]G(/^1E'T?Y'P7B7_P DG5_Q0_\
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M** "BBB@ HHHH **** "OJ__ ()^_P#)/]=_[#*_^BEKY0KZO_X)^_\ )/\
M7?\ L,K_ .BEKV<@_P"1E'T?Y'P7B7_R2=7_ !0_]*1[[1117WY_- 4444 %
M>!?\% O^2?Z%_P!AEO\ T4U>^UX%_P % O\ DG^A?]AEO_135YF<?\BVIZ?J
MCZS@;_DK,)_B?_I+/E"BBBOSH_J@**** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KZO_X)^_\
M)/\ 7?\ L,K_ .BEKY0KZO\ ^"?O_)/]=_[#*_\ HI:]G(/^1E'T?Y'P7B7_
M ,DG5_Q0_P#2D>^T445]^?S0%%%% !7@7_!0+_DG^A?]AEO_ $4U>^UX%_P4
M"_Y)_H7_ &&6_P#135YF<?\ (MJ>GZH^LX&_Y*S"?XG_ .DL^4****_.C^J
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M^ 5?_EQV'_"4Z#_S_?\ D)O\*/\ A*=!_P"?[_R$W^%<?11_Q![AG_G]6_\
M H?_ "L/^)CN./\ H'PW_@%7_P"7'8?\)3H/_/\ ?^0F_P */^$IT'_G^_\
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M)O\ "C_A*=!_Y_O_ "$W^%<?11_Q![AG_G]6_P# H?\ RL/^)CN./^@?#?\
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M_P CN'I+\CZ8HHHK\9/UL**** "OF?\ X*<_\DP\._\ 8>;_ -$/7TQ7S/\
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M/_),/#O_ &'F_P#1#U[W#'_(^H>K_)GB<1_\B2MZ+\T?%=%%%?N1^-!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
MO/\ P3F_Y.(/_8!NO_0HZ\&KWG_@G-_R<0?^P#=?^A1UX_$'_(DQ'^%GJY'_
M ,CBA_B1]YT445^#G[6%%%% !1110 4444 %%%% !1110 4444 >%_\ !/?_
M )(GJW_8]ZS_ .E)KW2O"_\ @GO_ ,D3U;_L>]9_]*37NE !7P9_P49_Y.('
M_8!M?_0I*^\Z^#/^"C/_ "<0/^P#:_\ H4E?8<#_ /([_P"W9?H?*<8_\B?_
M +>7ZG@U%%%?L!^5!1110 4444 %%%% !6CX4\7>)O NO0>*/"&M3Z?J%L3Y
M%U;/M9<@@CW!!((/!!K.HJ91C.+C)73Z#C*4)*479H]4\:_M5_%'Q1X T[PK
M%XSN89I+>XBUYK6R@M_M(>4E5WQ*K$;#AAP#SG-<=\-OBSX_^$6J7&M?#W7%
ML+FZM_(GD:RAGW)N#8Q*C <@<@9KG**Y:>7X*E1E2C3CRR;;5E9W=]5;[CIJ
M8[&5*L:LJCYEHG=W6EM&>@^._P!J?X[?$OPU<^$/&WC=+W3[S9]H@_LBTC+;
M'5U^>.)6&&53P1TQTJ7PI^UG^T!X(\,V?@_PSX[2WTW3XS'9VS:/9R^6N2<;
MGA9CR3U)KSFBE_9N7>R]E[&'+>]N56OM>UK7MI<K^T<P]K[3VTN:UK\SO;>U
M[WM?H=7\1/C?\3_BO>V&H^/?$BWLVEEC8R)800>5N*D_ZI%W<JO7/2NH?]L[
M]H5XW=?%]HEU)&4?4HM$M$N2IX/[P1 Y]^OO7EE%.679?.$82HQ:CLN565][
M*VE^HHX_'0G*:JRO+=\SN[;7UZ&OX;\>^+_"7C*'X@Z%K<D>LP7#3QW\RK,Y
ME8'<["0,&)W'.X'K6MX%^.?Q3^&GB/4O%G@KQ0++4-7W?VC.;&"7SMS[S\LB
M,J_-SP!7)45K4PV&JIJ<$[JSND[I:I>B?0RAB,12:<)M6=U9M6;W?KYGI'B/
M]KG]H+Q;H%YX8\0>.HI[&_MW@NX1HEDA>-AAAN2$,..X(->;T444,+AL+%QH
MP44^R2_(*^)Q&)DG6FY-=VW^84445N8A1110 4444 %?:G_!,;_DF'B+_L/+
M_P"B$KXKK[4_X)C?\DP\1?\ 8>7_ -$)7RO&?_(AGZQ_,^EX2_Y'</27Y'TQ
M1117XR?K84444 %?,_\ P4Y_Y)AX=_[#S?\ HAZ^F*^%_P#@N_\ $7QC\./@
M/X+U+P9K'V.:X\7/%,_V>.3<OV60XQ(K <CM7T7"=.5;B+#PCNV_R9X'%%2-
M'(*\Y;)+\T?/=%?'_P#PU)\=O^AZ_P#*9:__ !JC_AJ3X[?]#U_Y3+7_ .-5
M_07]DXGNOQ_R/PK^UL-V?X?YGV!17Q__ ,-2?';_ *'K_P IEK_\:H_X:D^.
MW_0]?^4RU_\ C5']DXGNOQ_R#^UL-V?X?YGV!17Q_P#\-2?';_H>O_*9:_\
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M]@45\?\ _#4GQV_Z'K_RF6O_ ,:H_P"&I/CM_P!#U_Y3+7_XU1_9.)[K\?\
M(/[6PW9_A_F?8%%?'_\ PU)\=O\ H>O_ "F6O_QJC_AJ3X[?]#U_Y3+7_P"-
M4?V3B>Z_'_(/[6PW9_A_F?8%%?'_ /PU)\=O^AZ_\IEK_P#&J/\ AJ3X[?\
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M?DM1117]-G\XA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7V=_P $(?\ D^<_]B9J'_H<%?&-?9W_  0A_P"3YS_V
M)FH?^AP5\]Q9_P DUB_\$CWN%_\ DHL+_C1^SU%%%?RX?TL%%%% !1110 44
M44 %%%% !1110 4444 >%_\ !/?_ )(GJW_8]ZS_ .E)KW2O"_\ @GO_ ,D3
MU;_L>]9_]*37NE !7P9_P49_Y.('_8!M?_0I*^\Z^#/^"C/_ "<0/^P#:_\
MH4E?8<#_ /([_P"W9?H?*<8_\B?_ +>7ZG@U%%%?L!^5!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7VI_P $QO\
MDF'B+_L/+_Z(2OBNOM3_ ()C?\DP\1?]AY?_ $0E?*\9_P#(AGZQ_,^EX2_Y
M'</27Y'TQ1117XR?K84444 %?GY_P<+?\F]>!/\ L<W_ /226OT#K\_/^#A;
M_DWKP)_V.;_^DDM?4\%?\E3A?\3_ /26?,\8_P#),XG_  K\T?DM1117]-G\
MXA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9=?_ !JCZMB?Y']S#ZSAOYU]Z/0**\__ .&I/@3_ -#U_P"4RZ_^-4?\-2?
MG_H>O_*9=?\ QJCZMB?Y']S#ZSAOYU]Z/0**\_\ ^&I/@3_T/7_E,NO_ (U1
M_P -2? G_H>O_*9=?_&J/JV)_D?W,/K.&_G7WH] HKS_ /X:D^!/_0]?^4RZ
M_P#C5'_#4GP)_P"AZ_\ *9=?_&J/JV)_D?W,/K.&_G7WH] HKS__ (:D^!/_
M $/7_E,NO_C5'_#4GP)_Z'K_ ,IEU_\ &J/JV)_D?W,/K.&_G7WH] HKS_\
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M_P"ASU^SU?C#_P %WO\ D^<?]B9I_P#Z'/7Z%X9_\E)_VY+\T?!^(W_)._\
M;\?U/C&BBBOZ"/P<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *_6G_@WI_P"3>O'?_8YI_P"DD5?DM7ZT_P#!O3_R
M;UX[_P"QS3_TDBKX;Q%_Y):I_BA_Z4C[3P__ .2FI_X9?DS] Z***_G0_H *
M*** "OS\_P"#A;_DWKP)_P!CF_\ Z22U^@=?GY_P<+?\F]>!/^QS?_TDEKZG
M@K_DJ<+_ (G_ .DL^9XQ_P"29Q/^%?FC\EJ***_IL_G$**** "BBB@ HHHH
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M\=_]CFG_ *215\-XB_\ )+5/\4/_ $I'VGA__P E-3_PR_)GZ!T445_.A_0
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M?SH?T %%%% !7Y^?\'"W_)O7@3_L<W_])):_0.OS\_X.%O\ DWKP)_V.;_\
MI)+7U/!7_)4X7_$__26?,\8_\DSB?\*_-'Y+4445_39_.(4444 %%%% !111
M0 4Z",33)"TJH&8 N_1<GJ?:FT^VA^TW$=N)43S'"[Y&PJY.,D]A0]@6Y^@_
MQI\ ?L__ +%7@3XA_"9OV17\4:'I2>&3=>*?$7B'4(/^$M:=9)#<0/;ND<*1
MLS*HBSR#O)Z#XGT?XK:?X ^-W_"W/A1X(LM/M;+59+O0]!UO&IPVD9W;(I#(
M!Y^P,/F8#)4$BONC]FKP-_P5$^#?P:\3^$?#FN6^M:=:W>D1^&'U/Q)I^JZ
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M\GSG_L3-0_\ 0X*^>XL_Y)K%_P""1[W"_P#R46%_QH_9ZBBBOY</Z6"BBB@
MHHHH **** "BBB@ HHHH **** /"_P#@GO\ \D3U;_L>]9_]*37NE>%_\$]_
M^2)ZM_V/>L_^E)KW2@ K\8?^"[W_ "?./^Q,T_\ ]#GK]GJ_&'_@N]_R?./^
MQ,T__P!#GK]"\,_^2D_[<E^:/@_$;_DG?^WX_J?&-%%%?T$?@X4444 %%%%
M!1110 4Z%9FF1;=6,A8! @Y)SQC'>FTZ*66"59H9&1T8,CJ<%2.A!H ^Y?!_
M[7WACXX?"3QR?VS/V6+/Q+K%A>>'],U_5/#\UQI.MZH_F30Q23A"5EN(MF I
M50^0I  &/G#]N+]G_P ._LO?M1>*?@EX2U^XU+3-(FMWL9[S;YZ1SVT5PL4N
MT >8@EV$@#)7.!G ]$\(?\%2?VI=)^%OB31=;^,VHW/B6Y?3U\/:S-HUE-<0
M1QM+Y^^Y>(REBI3:Q+$$'!7DGP?0_B[\2/#WQ2M_C78^+;F7Q5:ZJ-3CUK4
MMW*UV&W^:XG#K*=W)WA@>X-?+93EN.P6,JS45"%FE!3DXM\L+-7BN1*S7NKK
M:UHJ_P!+FF8X+&82E!R<YZ-S<(J25YW3M)\S=T]7TO?WG;Z"^.7_ "BD^!O_
M &.OB/\ ]'&OEFOI.3_@KO\ \%"I8!:R?'J QKG;&?!>C8&>N!]CXKR?X!_M
M+_&O]F'Q%>^+/@AXPCT:_P!0LOLEW/)I-I>!X=ZOMVW,4BK\RJ<@ \8SBNS+
M*&:X/#58U*<.9RE**4Y6?/)R:;]FFK7LFE*_9'+F-?*\7B:4J<Y\JC&,KPC=
M<L5%-+VCO>VS<;=V>V?\%A_^3QC_ -B5HG_I(E<=_P $X?@II'QK_:NT&+QA
ML3PQX5CE\2^++B89BBL+("5O,_V&D$<9]I#4'QD_X*-_MD_M ^ +_P"%_P 7
M?B[%J^AZGY/VZS_X1G3+=I/*E26/][#;)(N'C0_*PSC!R"17GGP\^.'Q1^%'
MAKQ/X1^'WB?^S;'QEI7]F^)$2R@>2[M,DF$2.C/$IR=WELNX8#9 %8X3 9I2
MX>6!;C&HHJ":DVK62<M8II[M*S5TM==-<5CLMJY_]=7-*FY<[3BD[W;Y=)--
M;)NZ=F]--;O[3'QKU;]HOX^^+/C9K.]9/$.LRW,$4AR8+<'9!%_P")8T_P"
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M46%_QH_9ZBBBOY</Z6"BBB@ HHHH **** "BBB@ HHHH **** /"_P#@GO\
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MK/\ Z4FO=*\+_P"">_\ R1/5O^Q[UG_TI->Z4 %?C#_P7>_Y/G'_ &)FG_\
MH<]?L]7XP_\ !=[_ )/G'_8F:?\ ^ASU^A>&?_)2?]N2_-'P?B-_R3O_ &_'
M]3XQHHHK^@C\'"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "OUI_X-Z?\ DWKQW_V.:?\ I)%7Y+5^M/\ P;T_\F]>
M._\ L<T_])(J^&\1?^26J?XH?^E(^T\/_P#DIJ?^&7Y,_0.BBBOYT/Z "BBB
M@ K\_/\ @X6_Y-Z\"?\ 8YO_ .DDM?H'7Y^?\'"W_)O7@3_L<W_])):^IX*_
MY*G"_P")_P#I+/F>,?\ DF<3_A7YH_):BBBOZ;/YQ"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OL[_@A#_R?.?\
ML3-0_P#0X*^,:^SO^"$/_)\Y_P"Q,U#_ -#@KY[BS_DFL7_@D>]PO_R46%_Q
MH_9ZBBBOY</Z6"BBB@ HHHH **** "BBB@ HHHH **** /"_^">__)$]6_['
MO6?_ $I->Z5X7_P3W_Y(GJW_ &/>L_\ I2:]TH *_&'_ (+O?\GSC_L3-/\
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M_8F:A_Z'!7QC7V=_P0A_Y/G/_8F:A_Z'!7SW%G_)-8O_  2/>X7_ .2BPO\
MC1^SU%%%?RX?TL%%%% !1110 4444 %%%% !1110 4444 >2?$K]BWX0?%#Q
M5+XMU74/$6FS2QJCVVA:X]G;\?Q>6@QN.<D]2>:P/^'=7P/_ .AN\=_^%?/7
MO5% '@O_  [J^!__ $-WCO\ \*^>C_AW5\#_ /H;O'?_ (5\]>]44 >"_P##
MNKX'_P#0W>.__"OGH_X=U? __H;O'?\ X5\]>]44 >"_\.ZO@?\ ]#=X[_\
M"OGH_P"'=7P/_P"AN\=_^%?/7O5% '@O_#NKX'_]#=X[_P#"OGH_X=U? _\
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M ,*^>C_AW5\#_P#H;O'?_A7SU[U10!X+_P .ZO@?_P!#=X[_ /"OGH_X=U?
M_P#Z&[QW_P"%?/7O5% '@O\ P[J^!_\ T-WCO_PKYZ/^'=7P/_Z&[QW_ .%?
M/7O5% '@O_#NKX'_ /0W>.__  KYZ/\ AW5\#_\ H;O'?_A7SU[U10!X+_P[
MJ^!__0W>._\ PKYZ/^'=7P/_ .AN\=_^%?/7O5% '@O_  [J^!__ $-WCO\
M\*^>C_AW5\#_ /H;O'?_ (5\]>]44 >"_P##NKX'_P#0W>.__"OGH_X=U? _
M_H;O'?\ X5\]>]44 >"_\.ZO@?\ ]#=X[_\ "OGH_P"'=7P/_P"AN\=_^%?/
M7O5% 'C?@3]AWX1_#SQAI_C;1/$OC":[TVX$T$=]XGFFA9AV=#PPYZ&O9***
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MEI6O^!=4NMOVJV5+YECN[-F5-@1MR!<M@[C)^EE% 'Y/?L:>,/B7_P %IO\
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MA[2WBE,U[;-?SPQ-<;ECB0[B4,I<*2H(\!_X)GW?_!0#]C'PGX+_ &5/!_\
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M0DXR5FCUHRC.*E%W3"BBBI&%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %?CY_P<#_ /)Y?AG_ +)C9?\
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M_%K]L;XG_&OQ!\1+34M+_;/\<:7;1^$/B-J.CVY@6>*4%XK65$>3=,_SD;B
MHSA10!]Q_'!/VV?V%/\ @EG\?/B9\1_VX[SXJ?$;PSX'U_Q#X0\=7WP[TC1V
MTDP:9N@@%G:Q&VG"31/+NE1BWFE6!50*^4;SQ#_P6V^'/_!+'0_^"K&C_P#!
M6?3?&$\'P>TWXC:O\+_&'P-T&UTZ[MI=.BO[BR^VV*17"LJ.ZHR[2Y4#Y-VY
M?HW]M3]D+X4?L3?\$1_VE?@Y\'-2\376D2_"GQ5J+2^+/$]UJUUYTNENK 3W
M+LX3$:X3. <D=37POK7_  2+_:H^)W_!$'X:?&?X<?MV_%OXBV,'P:\+>+;S
M]G7Q9KCKX;\0:=%IMK>2:#&+ V]RD8C!2%?,8DQQKPQ$B@'[#_L??'Z+]JS]
ME#X:_M-1>'VTD?$#P+I7B%M+:3?]C:[M(YVAW8&X*7*AL#< #WK\UOV7?^"N
M_P"V-\0?^"FVC_$OX@^-;.7]D?XS_%/Q+\+OA#9+HUI&+35M+AM19ZG]K2$7
M$R:A<17D4:/*ZAFE&U1&F/5/VN_^"GWPRM/^"!NF?M-_L5:1'IUW\4?">G^!
M_@_X6THHLNFZU?C^SETZ$+A1+9;+G  "YLN."*^4OVA/V>O^"IUA_P $>O"W
M["7@_P#X(VW'A.X^#%AI/B'PK\1[#X^Z!>W.GZUI4OVR;58[&) \DL[&\)B1
MRV;I@I8XR ?N117DO["'[57AC]M_]CGX<?M7^$_*2V\<>%;;4+FVA;<MI>;=
MEW;9[F&X2:(^\9KD/VO/^'LW_"P[#_A@G_AG;_A$_P"Q4_M3_A;W]O?VC_:/
MG2[_ "O[._=>1Y7D8W?/O\S/&V@#Z)KXNT_]K/\ :!G_ .#@>^_8AE\?Y^%\
M/[*(\8Q^&/[*M.-;_P"$@CM/M7VGROM'^H8IY?F>7SG9NYKZY^'?_"P/^%?Z
M%_PMG^QO^$J_L:U_X2;_ (1WS?[/_M#RE^T?9?._>>1YN_R]_P ^S;NYS7Y\
M^*M3L/AC_P '47AO6/&ETEC:?$/]CFXT+PG<7#!$O]2M_$'VN:UC)^](L$+2
M%1SM8'O0!Z;_ ,%GOVL_V@?V3M(_9LNOV?\ Q_\ V _C_P#:N\)>#O%K?V5:
M77V_1+U;PW-K_I,4GE;_ "H_WD>R1=ORNN3GU3]I;_@J#^PO^R!\4I?@C^T-
M\=H?#_BZ/P7'XJ@\/G0[^YGO--DOOL$;6WD0.MS.]R#&MK$6G(!<1[%+#Y>_
MX. M3L/%WQ)_8F^ &@727/BK6/VQO"VO6>D1,&F.FZ<MQ]LNM@Y\N(7$;,W0
M U<\5^"_"OBO_@ZD\-:QXBT*VO+GP[^P]-J.B33Q!FL[H^*YK4S1D_=;R;F>
M/(YVRL.] 'TW^QI_P4F_9"_;TOO$GA[]G;XAWMSKW@Z6)/%/A;Q#X>O=(U73
M/-!,;R6M[%')L8 X=05SP2#Q7SW>_MI>!?V6?V+?VQ/VB?"G[:WB3XHZEX-^
M+'C*UT]M;\%ZI,G@CQ"MK$+;PS%%Y3M-96MPT/\ I" 6P6=V+JJLPBO[.UT3
M_@Z"T^XTFW2W?6OV))VU8PKM^UO%XJ18WDQ]YE4!0QY"@#.!BO&?V0X)KG]@
M#_@JG;6\3/))^T/\:%C11DLQT6$  >M 'U%_P2B_X*N_!W]O/X)_#OPW?^,-
M8O?BQ??#6PUKQM;'X;:UIFG+>>1 +LP7=Q9I9R*)I?E$4SAE.4W*":/B#_P7
MI_X)?_#;QUK/@K6/CSJ5_;^&M3.G>*/%7A[P+J^IZ%HUV&"F*XU*UM9+92"0
M&(<JI/S$8..6_9CN_B'=?\&VGA:?X&37$OBY?V/%3PJ=-8F;^U%\-LL"Q[>?
M,$X4 #G<,5\Y_P#!(KX9_P#!3WXC?\$IOA;X=_9;^-7[)DOPNU3P*+*30M9^
M&FLW=QOD5DO[;4&BU%8Y;DS-.LY"*'<L=H! H _37XO?M9_LV? ?]GFY_:P^
M*_QGT+2?AS;:5#J1\7&[\ZTGMI@I@>%HMQN/-WIY:Q!FD+J$#$BOSO\ ^"@G
M_!:3X,?&_P "_!OP]^Q=\?O%_A?Q7J'[1_@B#6-%U/P_J?AS4-5\.W5Y)%,\
M<=Y#";NRD)1':/>H+('V[ESYU^T7^R5XD_83_9#_ ."?'[)O[4/Q3TGQGX%\
M%?M36MIXTU^!'72I&>YU&;2H;@3$X@A,A@82'8/*PW KVK_@Y%/PD^Q_LC#Q
M)]@_X3/_ (:Y\)_\(KNV_:_LGG-]NV?Q>3G[)YF.-_D9YVT ?I?7YM>)?C/^
MW+_P45_X*=_'']BKX#?MJM\ / O[/]CH4-^/#OA2PU'Q!XKO-2M3<&XWWRN+
M:UAQL!C7+;HR2?,&S]):^/OVQO\ @D%_P3V_X*(?%J?XV^(Y=8\/_%'0 FEW
MWQ"^%/C-]+UNT*1J4@N&A+1M(J,FWSHVD5-@!"X% '6?L\^"/VG_ -A[P1\1
M?'G[<7[>6H?&7P5I6EVVI:!J,_PQAL]7T2"!;EKU)8])C=]2WJ;=DV1>;E'4
M*<C/S_\ \$8/^"W?@#]MGX,^$_!G[0/C?4I_B_XC\1ZS:1VFE?"S6X-->"&\
MN?LV;U;,V,9^RQ(6W3@A\JV'^6L7_@EM\0?VE/V;?^"J_P 8O^"3_CW]K7Q+
M\<O /A'X;6'B_P ->*_'%TMYKGAZXEN((CI5Y=KS,[QS^:-_18E*J@9A78?\
M&S#HO_!)SP[8LP$UIX_\70W46?FBD_MV\.UAV.&!P>Q% 'H/Q;_X+I_\$XO@
MMXZ\1^!O&'Q(\73?\(;K-SI/C+7-&^%FOWVE:)>6TK17$5Q>P630YC=&5RC.
M%((SP:S?^"MG_!3WP[^R=_P2TUG]M/\ 9L^).G:GJ'B#3K0_"[7;+1)]7TZ_
MN)V656<P(T<41MTG/F3-'&&"H6#LJGQK]F_]H7_@I/\ \%.?@/XH_;+^'G[:
M?PI_9[^$<7B#7;/2/#U]\)$\2WD6F6%Q-#/<ZO<7>H6\4,C>7)(R*@4(5)ZD
MGY6^".K7GB/_ (,ROB/!;:F=0M;%/$$6FRQVODJ+5?%)E&V+)\I,,S!,D*#C
MM0!^KG[%G_!1_P#9G_;.\*2O\,_&VLW&J:#X<M-0\5RZYX UK0K:W\R/YW2;
M4K."*50ROGRV? &3P03YK!_P7^_X)67'BJ/1(_VB+W^QI=8_LJ/Q^_@G5E\+
MM>;_ "_*_M<VOV/&_CS?,\KOOQS7/?\ !7R[^(=[_P &_7Q-OO@Q-<3:C-\%
M[%VETYB6?3&6U-^P*]4^PFY+'IMSVKR#X;?LN?\ !4S]J[_@FMH?P%^'GQ^_
M9$NO@SXW^%%OH^CV^F?#'6V$>DSV2Q1F-AJ119XP0P;;E)4R1N6@#[H_:]_;
M\_93_88\,Z%XE_:.^)ATQO%5\UGX4T?2M)NM4U+6YU4,R6MI9QRS3;0R%F5=
MB[TW,-RYH_L?_P#!13]F']N+4]?\-_ W6/$L>M>%K>UGU_0O%G@?5-$N[2&X
M,@@DV7UO$)%<PR &,MC8<XR,_-'CC_@EA^TU=?"[]ECX@?L]_MB>&-/^.O[-
M/P_DT/3-=\0Z"VJ:'XHL;JP@LI_/C\P3Q!TMT*W"$O\ ,^<DJR]S^P7^WW^U
MCXY_;&\<?\$ZOV^?@UX'T7XG^#/!5IXLL_%'PNUBYNM!UK2I[@6^5BNU%Q:2
MK(5^20L6&XX4*I< ^T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KX$_P""J'[&
M7P6_:*_:#T?QM\1OVK_^$%OK7P;;V,6D?\(+<ZIYT2W=W()_-BF0+EI679C(
M\O.?F&/ONOAS_@IC_P EWTG_ +%&#_TJNJ^LX,==9VO95'!\LM4HM_\ DT9+
M\#YCBY47DS56FIKF6C<DO_)7%_B?*/\ PZV_97_Z2+_^8BOO_DFC_AUM^RO_
M -)%_P#S$5]_\DUTM%?K_/FW_094_P# :/\ \J/RGV>5?] D/_ JO_RP_3K]
MG3PMI7@;]GSP)X)T+Q'_ &Q8Z/X-TNQL]7^QM;_;HHK2*-)_*8DQ;U4-L))7
M=@DXKLJY+X _\D(\$_\ 8HZ;_P"DL==;7\^XR_UNI=W?,]?F?NN$LL+3LK+E
M7Y!1117,= 5YU^U+^R;^S_\ MJ?":7X&?M,^ /\ A)?"T^I6M_+I?]JW=GNN
M+:42POYEI+%(-KJ#C=@XP01Q7HM?%'_!+W]K?]H;Q;^T_P#M*?L%_MB?$'_A
M(_'/PC^(":AX2UJ;2;2QDU/P=J40FTUO+M(HHY'B"E9) N=TR*Q)&2 ?97B/
MP_I'BWP]?^%?$%I]HL-3LI;2^@\QD\R&1"CKN4AAE21D$$9X(KX:MO\ @V4_
MX(D64"VMG^QO>Q1(/DCB^*_BI57Z :IQ6Y^T#^UM^T+XV_X+)_![_@GW^S3\
M0?[&\.^'?!6H^/OC[-!I-I=-<Z866VTW3O,GB<V[27 RYC*2F.965ACF7_@C
MM^UG^T#^U1K?[4UI\>?'_P#;T?PX_:N\6>#O!B_V5:6O]G:)9M"+:U_T>*/S
MMF]OWDN^1L_,YH ^B?@A^R-^SI^SM^SC9?LC?"KX8VUO\.+"RO+.'PMJ]Y<:
MK#);W4TLUQ%*]])-).CO/*2LC,,/MX4 #YFO/^#<_P#X)*7.H7(M/V?M<L-#
MOKIKF]\&:5\2M>M=$GD8Y;-E%>+$%)Y\M0$XQMQQ6AXH_:S_ &@=._X+_>&O
MV);/Q_L^&&H?LNS^+KOPS_95H?,UE=<GM1=?:3%]H'[E%3RQ((^,[,Y-?,'[
M)G_!5+]MI/\ @MK\0/@#^T5\5H=8^!6K?%WQ%\-/ ]@WAZPM?^$=UVVMX=0T
M]'NH8$FF%Q EU BRNY9QD\@&@#]#O&W[ '['GQ \$?#'X:^(/@;IL7A_X->+
M--\3?#/1M(NKC3K;0M4L-WV2=([22,2!-['RY=\;EB75C7L5?D=_P<C?\%5/
MVVOV1M8M_AK_ ,$^OBO#X3U'P'X'C\:?%?66\/:?J6VROM7L](TRR47L$T<<
MCS37$Q  <I""#MSGW?\ X+*?M ?ME> OVCOV5OV:OV0_VGYOA4_QE\>:OHOB
M3Q#;^#M,UIUAAM()8B(=0AD7*L7^Z4)W<DX% 'UK\'?V3OV?_@#\2_B%\8/A
M)X!_LGQ'\5-9@U;Q[J/]JW<_]J7D,;1QR^7-*\<&$9AMA5%.<D$\U\MZ9_P;
M5_\ !%?2;.+2[3]CFY-E"Y=-.N/BAXGFM<DDG,$FI&-LDDX*D'-=M\#?V,_^
M"G'P^^+6A^,_C'_P65UKX@^&-/O/-UGP9<? CPUIB:K%M8>4;JUC$T(R0VY#
MGY<=Z^??%7C[_@IA^UC_ ,%C?C_^QW\!/^"D=_\ !SP3\+?"?A?4]'TZQ^$^
M@:Z99+^QC>8&2^@\T?O-S\NWW\   "@#] /@%^SA\!/V5_AU;?"3]G#X0^'_
M  3X;M9#)%H_AS3([6%I& #2N$ ,DC8&Z1R6; R37R[\1O\ @W:_X(\_%CXE
M>)?B_P"//V2[J[\0^+_$%YK?B*_@^)?B6V%Y?W4S3SS>5!J*1H6D=FVHJJ,X
M   %8G_!,+]L#]L6Z_;<^.W_  3(_;>^(V@_$3Q+\(+'1M8T'XGZ!X=CTEM9
MT[4(%E"7=G"3%!.GF1<1X!R_W@%=L/\ 9M^-7[=O[;'QV_;2_9N\*_MF7/P^
MN?AI\6M(TKX;>)K3P#H^I/H&GM"TUQ;B">%4NO-";=\YD=-V5(Q0!]#_  6_
MX)3_ +!?[/7[-WCG]D;X1_ ^?3/A[\28;F+QIH$_C#5[PZBEQ;"UF'VBYNY)
MX=T("_NI$QU&&YKV?X2_"SP'\#/A7X:^"GPLT+^R_#'@_0+/1/#FF?:I9_LE
MA:P)!;P^9,SR2;8XT7<[,QQEB22:_*SXI0_\%FOAU_P5"^%O_!/*'_@M;J]U
M9_$3X?ZOXDF\4M^S_P"$TEL6LBX$*P?9B) ^WEBXQGH:]7_:GE_X*T?\$R_A
M3HO[8_B;]NS5_P!HOP=X&\4&\^,?@>?X4Z!HL\_A26)(IKJT:Q@$OVBS;=<_
MZQ5="=^$B.X ^BO"W_!(C_@GCX+;PVGAG]GPVMMX/^*%Q\1/"^F#Q;J[V.F^
M)9MF^^BM6NS"N#&I2'9Y,1W&.-"S$_21 (P1D'J#7P3^V;_P45^(OQ^\?_![
M]BC_ ()2_%O3W\=_&#3K3QAK/Q+LM-M]1M_!7@961Y-4:&YC>%I[G(@@BE0Y
M9F#!&,;5]X:?;365A!9W.H37<D4*I)=W"H))F  +L(U50QZG:JKD\ #B@#S[
M]EK]DK]GW]BOX6_\*4_9E\ GPQX5&K7>I1:*NK7=W%!<7,GF3&+[5+(T2,Y+
M>4A6-2Q*J,G/H]%% !7C_P"V-^P3^R9^WUX*T_P)^U9\'[3Q-;:->F\T&^6[
MGL[_ $FY.,RVMW;21SP,=J$A'"ML7<&VBO#_ /@AM^UE^T!^V'^S5\0_B!^T
M;X__ .$BU?0OCMXG\.Z5=_V5:6GD:;:2PK;P;;6*-6V!F^=@7;/S,:/AY^UE
M^T!KO_!>KX@_L7:KX_\ -^&FA_L[:?XGTOPU_95HODZK+J<4#W'V@1"X;,;,
MNQI"@SD*#S0!W'[*'_!(;]@G]C/XIR_'?X/?"*]NO'4EDUG%XS\8>*=0UW4K
M6V8$-%!+?SR_9U(+*3$%9E9E)(.*]9?]ESX%/^U(G[:3>!L_$Q/ 1\%KXE_M
M.ZXT,WOVXVGV?S?L_P#Q\_O/-\OS?X=^WY:^?O'7_!=__@F'X'CU**+X[ZIK
MU]HNM:CIFMZ-X6\!:SJ%[ITMA+Y-W+<016A>&W20%1<,!%(5?RV?8V.R^-W[
M4?[/'[1/_!,SQG^U!\(/VOIO"GP^UCP#J%[:?&+PI8W-S<:#"B.LE[%;QJ+C
MSX&1\P[1*KH5*A@10!Z?<_LN_ N[_:?MOVR[CP-N^)-GX(?PA;^)/[3NALT5
M[L7C6OV<2_9SF<!_,,?F=M^WBH?@Q^R9^SU^S[:>/=/^$WPWATZW^)_C;4O%
MWCNWN;ZXO(]6UC4%1;RX9;F20(LBQH##&%B 'RH,G/Q'^WU_P5IT[]@GP?\
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M0?L7^$_V38OVX?&_QG7P[\,[B62&VUSQ-X?U#3+B>9)Y(/)2PNK>.\>5I(I
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MBO:_^&=?V=/^CM__ "PKO_XY1_PSK^SI_P!';_\ EA7?_P <K]#_ -?>#_\
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MP7KLMM)JNC?VI=67GM;W$=Q"?.M)8I5VRQ1M\KC.W!R"0>0_;:_X)L_L6_\
M!1;3?#FD?MC?!Q_%T'A*ZN+GP\L?B;4],:SEG5%E8-87,#/N$:##E@,<8R<@
M'GG[-O\ P1;_ &/OV5_C7H?Q[^&7BCXJW&N>'WG:PA\1?%?5=1LF,MO) WF6
MT\S1R?)*Q&X'#;6'(%?&<_[(_C_]K/\ X.&/VL=&\ _MF_$_X.2Z-X"\$33W
MWPSU"WMY=2$FFQ*(Y_/BD#*A4E0,<L>:^O/@E_P0&_X)-_LZ?%KP_P#'/X._
MLP7ND^*/"VIQZAH6I2?$KQ'=+;7"'*N8;C4)(I,?W71E/<5] ^#/V3OV?_A[
M^T;XS_:U\'^ ?L?Q!^(6FV%AXP\0?VK=R?;[>RC$=JGD/*8(MB #,<:%NK%C
MS0!\!?\ !&GP=%^P/_P4'^/'_!/#]H^Y?Q)\7/%,5MX]\/\ QNUF[N9=3^)?
MATLT*BY-Q+)LGL9&>'RXBJ,/,8)^[,C]=_P1O_Y2.?\ !03_ ++=I7_I#-7V
M5\3OV0?V=OC%\>/ /[3GQ ^'OVKQY\,#>_\ "$>)+75KNTGL%NXQ'<1L+>5$
MN8G0;3'.LB#<V%&YLR_!O]D[]G_]G_XC_$'XM_"+P#_9'B'XIZY%K'CS4/[5
MN[C^U+V.,QI+Y<TKI!A6(VPJBG/()H ^+OVF_P#E9>_9E_[(/XL_]"EK]$-1
MT[3]7T^?2=6L8;JUNH6AN;:XB#QS1L"K(RMD,I!((/!!K@/$_P"R;^S_ .,O
MVE_#/[87B3P!]I^(W@[0;O1?#?B+^U;M/L=C<Y\^+[.LH@DW;C\SQLPSP17H
MM 'Y;?\ !LI^SY\'/A+#^UQJ_P /O MII]WI?[5_B;P;I]RI9Y+?0M,$!L;!
M6<DB*(W,Q [E^<X&/U)KSG]G;]DS]G[]D^'QE!\ / ']@)\0/'5_XQ\7#^U;
MNZ^WZW>^6+FZ_P!)ED\K?Y2?NX]D:[?E1<G/HU 'R]X._P"'TW_#1L7_  L#
M_AEW_A4?_"23>=_8_P#PD?\ PD?]C^8_E;?,_P!%^U>7Y>[/[O=NQQBOJ&BB
M@#\X?^#;?4['P]\&?VAO@+K-TEOXL\$_M3>+HO$.B2L!<6R320M#,4Z^7)LD
M"/T8Q/@G!H_9JU2P^)?_  <S_M!^,?!5TFHZ9X(_9XT'PQXCOK5@\5IJD][%
M=I;,PX$GEQR97J#&P."I ]\_:@_X(W?\$_/VN/B[-^T!\3OA#J&F^.KRU2VU
M/Q9X*\6ZEH-[J,*J%5+EK">(7&%5%#2!G"HJAL "O3/V0_V(?V6/V#_AO-\*
M?V4OA!8>$](N[UKW4C!/-<76HW3#!GN;FX=YKB3'&Z1VP.!@<4 ?(?\ P;F^
M"O"NB_!S]HKQEIFA6T6JZY^UIXV&JZ@L0\ZY2"YC2%&?J40,^U>@,CD#+'/S
MA\#[.UT7_@@;_P %"/"&D6Z6VF:%\7/BS8:/8PKMBL[9/+*0QJ.%0%FP!QR:
M_6+]GC]EWX%?LH^'==\)_ +P-_8&G^)?%M_XGUNW_M.ZNOM.JWKA[JXW7,LC
M)O90=BD(N/E5:Y?2/^">W[(&@_ OXC_LUZ5\(O*\$_%S6]7U?XA:+_;^H-_:
MM[JF/MTOG&X,T'F[1\L+QJF/D"T ?!O[:3I:_LQ?\$M]0N7$<"?'?X91O,YP
MJN^B2!%)/<D$#UKJ/^#FH^/O^%.?LZ#1]8\.Z=X8_P"&G?#A\5:AXSLI;G0;
M<[+C[(^JQ1.C26 FP95+*IPN3G;7VO\ &']A7]DW]H#]FS3/V0_C+\%]/\0_
M#S1;.QMM(T"_NK@FR6SC$5L\5PL@N(Y8T&T2K(),%LL=S9R?AO\ \$X/V+OA
M9^S7X@_8_P##WP634/AOXINY;G7O"_BS7M0UV.[ED2)&8R:E<3RK@01%0K@(
MR!T"MEJ /D3]L#_@G_\ \%B/VU_A]X>\%?'G]J/]FC3],\,^-M(\5:-KWACX
M?ZU:ZAIM]8W"RPS6T\U_*D3$;HR=IRLA QG-;G[/?]CC_@Y0_:&_X6KY7_"1
M'X$>%/\ A5/V['F?V#N;^TOLV[^#[=C?M[[L]Z])^'W_  09_P"":?PX\5:#
MXETKX7>+=0@\*ZG!J'A7P_K_ ,5/$&H:5I%Q!(LD+PV<]ZT/[ME4J'5@,#C(
MKU']L7_@FW^R#^W;J7A[Q/\ M"?#BZN/$/A)I#X9\6^'?$%[H^KZ:LG$D<=Y
M92Q2^6PSF-F*Y)( /- 'R+\%/^%2?\16'Q;_ .%9_8/[2_X9+LO^$Y^Q;=W]
MK_VS88\W;_RT^Q?8<YYQMK])M:U#1])T>[U7Q#?6UKI]K;22WUS>RJD,4*J2
M[R,V%5 H))/  .:\+_9E_P""7W[#'['?Q/'QK_9V^!<7A_Q:_A"3PS>>(/[>
MU"ZN+[3Y+W[=(+G[1.ZW$[W/[QKF0-.V IDV*%'N'B3PYH7C#P[?^$?%&EPW
MVF:K92V>HV5PNZ.X@E0I)&P[JRL01Z&@#\]OB5_P;V?L61RZS\>?V&/VDOB?
M^S;JVJQ2:M%K'PB^(4MMH/F,N_[1+:,QC:VQR8XI(H]G VKQ7R/^T'^V+\=_
MVW_^#33QE\:/VC]9M]:\2:1XXTO1;[Q=9VRPPZ];V/BS3HDU$*BJHW+A690%
M+QLV%S@?=%W_ ,&XW_!)>=)='L_@;XGL/#US*9+OP=IWQ5\0P:/.2=S!K5;[
M8%)Y*KA?85]07'[(G[,=S^S2W['$GP-\.#X7/HG]DGP/'IRI8?8\[O+$:XP=
MWS[P=^_Y]V_YJ /.?^"KG[;E[_P3W_8#\=?M<>'/!=CXEU'0(;"'1-,U&<I9
MRW=Y?6]G!).ZD$0))<+(V"I*H5#*6##\U/\ @X&\$?\ !1OX5?\ !,;4/BM^
MV!_P4B^&FL^?XH\/RZ'\._"?P6CL?,U==0AF3^S]5EU"2X4PQ)/-YGD[GBB=
M"%$A(_2;X1_\$C?^">WP/^$/CKX!> ?@ Q\&?$G3[:Q\8^&]>\7:OJ]K>6]O
MYODI&M_=S?9=AF<J8/+(8(V<QH5\]L?^#?#_ ()2#P1J'P[\6_L^ZQXITF^T
M^&P@@\6?$;7;]]+M(KB&X2"QDDO2]BOF6\.XP,C.J^6[,C,I .3_ ."BCI;?
M\%S/^"=E]<N(X1+\683*YPHDD\-6P1<^K$8 [FO-O^"\J?&Z7_@H9^PQ#\/O
M%/@K1--;QOXG&FZI\3-*N+WP[#XF^P6XTO[7#!+$[3D^<+4AP1,<\@$'[O\
MVN?V&?V4OV[?!FG> _VK/@]9^*[#1M1%_HTC7US976GW.W;YMO=6DL4\#$<'
M8ZYP,YP,8M__ ,$U_P!B76OV1H?V%/%/P,M]>^%MM)++;>'/$FM7^IRPRR3R
M7!F2]NIY+M)1)-(5D$P= VU&50  #Y>^*7[ ?_!5C]HW]H7X%?&+]J3]I+]G
MNWM/@Y\5;#Q+:77@;P-J]AJEU;Y\F\TU)[F]F41W,+%&3:-S)'DX4@Z?B[]A
MK_@I#^RS^T]\6/VI?^"8'QL^$WB+1?BYXBCUWQA\,/B]I-V@CU2&$6\QL]3L
M'WJ7\L@1S+LC;@YY->I_ _\ X(K_ + 'P#^*GA_XT>%_ OBW5_$/A&X\_P )
M7/C#XFZYK$.BR;"@:W@N[N2)2%8@$H2!T(JM\7_^"(/_  3S^-'Q.\2?%OQ%
MX#\8Z7JWC349;[QE'X6^*FOZ5::Y<2?ZQ[BVM;Q(B6'!V*N03F@#L/\ @ES^
MW<G_  49_8_T?]I*Z^&<G@_59-6U#1_$7AW^T%O(K34+*Y>"?R;A0HGB9EW*
MX ^]CDKD_0]<G\#/@3\'_P!F?X3Z+\#/@)\/=-\*^$O#MK]GT;0M)AV0VZ%B
M['DDLS.S.SL2SLS,Q+$D]90 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7R)^W
MW_R6+3?^Q9A_]*+BOKNOD3]OO_DL6F_]BS#_ .E%Q7A\0_\ (N?JC]#\,/\
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M[8OP?^+?C[^UO#GPK^)FEZ3X"T[^RK2#^R[.:SEDDB\R&)))\NJG=,SL,8!
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "OC_P#X* _%+]DKP1\9-,TKX\_M*?\ "&ZQ)X9A
MEMM,_P"$.O\ 4?-MC<7(6;S+=2JY=9%VGYALST(K[ K\=_\ @X._Y/-\,_\
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MR0-YEM/,T<GR2L1N!PVUAR!7QG/^R/X__:S_ .#AC]K'1O /[9OQ/^#DNC>
MO!$T]]\,]0M[>74A)IL2B.?SXI RH5)4#'+'FOKSX)?\$!O^"3?[.GQ:\/\
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MG]G?CY\!?A+^U!\&_$/[/_QW\'1^(/"'BO3FL=>T>6ZF@%S Q!V^9"Z21D$
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
$* /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>biib-20220331_g20.jpg
<TEXT>
begin 644 biib-20220331_g20.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#5H=3N+F>(30"62XEC<$AU""0;1M0)7VS10 5X]^WW^QGX _X*#_ +(/C?\
M8]^)VMWVF:/XTT^&&34],"F>SG@N8KJWG4-PVR>")BIQN"E<C.1[#10!\:^*
MO^"='[:'QS_8M^+W['G[77_!1NQ^(*?$7PO!HWASQ-;_  9MM(F\/A3)Y\TT
M5O?D:@TH,/&Z *8F(SO('J7[0W[$O_"^O^"<^N_L _\ "S?[*_MKX9Q^$?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5;_Q->:1=&TU+7F9KZ]TH7LZZ=/.S$EV:T$!5R2738Q)+$G\Z?C=_P %H_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MDJLT;;73GN#P:UJ\+_X)[_\ )$]6_P"Q[UG_ -*37NE !1110 4444 %%%%
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M@U.15MOL9C83>:S$*(_++;B2 !G-?D%\4_\ @G_\??\ @G9^TIX;G_X)M?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1E%?.=%'^M__ $X_\F_^U ^C**^<Z*/];_\ IQ_Y-_\ :@?1E%?.=%'^M_\
MTX_\F_\ M0/HRBOG.BC_ %O_ .G'_DW_ -J!]&45\YT4?ZW_ /3C_P F_P#M
M0/HRBOG.BC_6_P#Z<?\ DW_VH'T917SG7J7P&_Y -[_U^#_T 5WY;Q#_ &CB
MU0]ERWOKS7V^2 [JBBBOI0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS_D=/^W./^;5Z[7D7QL_Y'3_ +<X_P";5\YQ1_R+/^WE^H'(4445^= %%%%
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MP$QVTDH^620,25^4;<MN /L*BBB@#PO_ ()[_P#)$]6_['O6?_2DU[I7A?\
MP3W_ .2)ZM_V/>L_^E)KW2@ KR+XV?\ (Z?]N<?\VKUVO(OC9_R.G_;G'_-J
M^<XH_P"19_V\OU Y"BBBOSH HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ KU+X#?\ (!O?^OP?^@"O+:]2^ W_ " ;
MW_K\'_H KWN&O^1M'T?Y =U1117Z4 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M10 4444 %>A_!SP_9:QHUW-=33J4N@H$4Q4?='I7GE>I? ;_ ) -[_U^#_T
M5[W#7_(VCZ/\@.B_X0?2/^?F]_\  MJ/^$'TC_GYO?\ P+:MBBOTH#'_ .$'
MTC_GYO?_  +:C_A!](_Y^;W_ ,"VK8HH Q_^$'TC_GYO?_ MJ/\ A!](_P"?
MF]_\"VK8HH Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P# MJV** ,?_A!](_Y^
M;W_P+:C_ (0?2/\ GYO?_ MJV** ,?\ X0?2/^?F]_\  MJ/^$'TC_GYO?\
MP+:MBB@#'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:MBB@#'_ .$'TC_GYO?_
M  +:C_A!](_Y^;W_ ,"VK8HH Q_^$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VK8
MHH Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P# MJV** ,?_A!](_Y^;W_P+:C_
M (0?2/\ GYO?_ MJV** ,?\ X0?2/^?F]_\  MJ/^$'TC_GYO?\ P+:MBB@#
M'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:MBB@#'_ .$'TC_GYO?_  +:C_A!
M](_Y^;W_ ,"VK8HH Q_^$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VK8HH Q_P#A
M!](_Y^;W_P "VH_X0?2/^?F]_P# MJV** ,?_A!](_Y^;W_P+:C_ (0?2/\
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M\MKU+X#?\@&]_P"OP?\ H KWN&O^1M'T?Y =U1117Z4 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!^?7Q>_:)_P""A?[1_P"VU\4_
MV9?^"6/@KX3^ M.^'%WI=O\ %OXR_$729KJ?5M9GL8IH;*SMK8 SM!:M"KRS
MD@#"J4"KOO\ P._:T_X*9?LK_MB?#[]D+_@IMIOPV\9>'_B_)J%G\.OBQ\,+
M6YLC;ZK:6KW;6&I6<Y(4R0QR&.2+C*@$MEC'RGQP_9T_X+;_  ;_ ."CWQ/_
M &E/^"=7A;X!CX>?$2'2#K6@_$'7-2W:S>6FGPP'49(X$!M;H8>#,4GER10P
ML\9D!:N \8? 3_@Y.^)W[57@W]J7XI?#3]E75Y?AQ;WQ\ ^$8_$^M0:7I=[>
M0&WGU%P(S-<W/V=GA4O)Y<:R.4C5FW4 ?K!17EO['^K?MCZU\'4O?VZ?"7@'
M1?'9U*=9++X;W]U<Z:+0;?)8/= 2>8?FW#H.,5ZE0!X7_P $]_\ DB>K?]CW
MK/\ Z4FO=*\+_P"">_\ R1/5O^Q[UG_TI->Z4 %>1?&S_D=/^W./^;5Z[7D7
MQL_Y'3_MSC_FU?.<4?\ (L_[>7Z@<A1117YT 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5ZE\!O^0#>_]?@_] %>
M6UZE\!O^0#>_]?@_] %>]PU_R-H^C_(#NJ***_2@"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M110 4444 %%%% !1110 5ZE\!O\ D WO_7X/_0!7EM>I? ;_ ) -[_U^#_T
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MC!4?6K^C?$KP/KK^39>(8$ES@P7),3Y],/C)^E;M4-9\+>'/$*[=;T2VN3C
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M;_P4>O\ ]BKXP^'O!_BO]B_XQ^,?!&JZ1]LUSXE_#GP?-K-CX><S21^7=PP
MR@ ('9D#$*ZX5B<4 ?3-%4O#?B'2?%OAVP\5Z!<M-8:G917=E,\+QEX9$#HQ
M1P&4E6!VL 1T(!J[0!\]?L%VWB27X.:LVDZE;Q1?\)QK.5EA+'/VEN<U[;]B
M\;_]!NR_\!C_ (UY'_P3W_Y(GJW_ &/>L_\ I2:]TH Q_L7C?_H-V7_@,?\
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M@QK-IXR\.^$A\(_C1HWCZ6&U\%1W UM+!G)T]RLL7E+)OYD(D Q_JVKZ&O\
MX9Q:I!;VNIZ)X<N8K2+R[2.?1(W6%/[J CY1[#BNOHH ^3=&_P""8EMHG_!3
MR\_X*/6OCG0 MS\&T\"1>!D\&HL4$BZI'?C4EN!+C?\ N_+V"$$9W>9_#7>#
M]FK]I0?MRG]J4_M>Z@? Q^&__".#X._V7)_9HU+[9Y_]L^9]HV^=Y?[C;Y.=
MO/F?PU[M10!^9_B?_@B=_P %"(?V\OB!^W]\(O\ @KO8>'O%?C5Y+/36UKX
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M\8>=('<R1 #]T6R>=I /T4HHHH \+_X)[_\ )$]6_P"Q[UG_ -*37NE>%_\
M!/?_ )(GJW_8]ZS_ .E)KW2@ KR+XV?\CI_VYQ_S:O7:\B^-G_(Z?]N<?\VK
MYSBC_D6?]O+]0.0HHHK\Z **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *]2^ W_(!O?^OP?^@"O+:]2^ W_(!O?^OP
M?^@"O>X:_P"1M'T?Y =U1117Z4 4444 %<+\>?\ D V7_7X?_0#7=5POQY_Y
M -E_U^'_ - ->3GO_(IJ^GZH#RVL?6_ '@SQ%EM6\.VTCGK*B;'_ .^EP?UK
M8HK\UPV*Q6#J>TH3<)=XMI_>C*M0H8B')5@I+LTFOQ.3_P"%<:UI'S>#O'^H
MV@'W;:]Q<Q#V ;E1^=']M_%70N-7\*6>K1+UGTNYV/CU*/U/L*ZRBO4_MVO6
MTQ=*%;SE&TO_  .'+-_-LX/[*I4_]WG*GZ.Z_P# 9<T5\DCE[/XN>$7G%GK+
M76DW!_Y8:I:M$?SY7]:Z.SO['48!<Z?>Q3QGI)#(&4_B*+RRLM0@-M?VD4\;
M=8YHPRG\#7.WOPC\'RSF\TB&XTJX/2?2[EHB/P^[^E'_ !C^*_Y^47\JD?\
MVR27_@;#_A7H?R5%\X/_ -N3?_@)T]%<G_8/Q3T+G1?%UIJD0Z0:M;[7QZ;T
MY)]S1_PL37]'^7QA\/[^V4?>N; BYB^IV\J/SH_L*M6UPE6%;RC*TO\ P"?+
M)_),/[4IT_\ >*<J?FU=?^!1YHKYM'645C:)\0_!7B$A-+\1VS2'I#(_EOG_
M '6P:V:\O$X3%8.I[/$4Y0EVDFG]S.ZCB*&)ASTIJ2[IIK\ HHHKG-@HHHH
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M_7X?_0#7=5POQY_Y -E_U^'_ - ->3GO_(IJ^GZH#RVBBBORT HHHH ****
M"BBB@#,UOP;X5\1@_P!M:!:W#'K(T0#_ /?0P1^=8W_"KYM)^?P9XSU/3,?=
MMWD^T0#_ ( _^-=917J8;.LTPE/V<*K</Y96E'_P&5X_@<-;+<#7GSRIKF_F
M7NR_\"C9_B<G]O\ BYH)_P!-T73M;A'\=G,8)<>I5OE)]A3X?BYX<@E%KXEL
MK_1IB<!=1M&52?9AD$>_%=33)X(+F(P7,*2(PPR.H(/X&NC^TLMQ'^]857_F
MIMP?W/FA]T48_4L;1_@5WZ32DOO7++[Y,^>?BCHFEZ3XIENM O()["]S/;/;
MR!E7)^9..F#V]"*YRO</B;\(O#FI>';K4?#FAQ6VH0)YL?V9=HD Y9-HXR1G
M'&<XKP^OZ+X,SW"YWD\?92DY4[1ES64M%HW9N]UUZM/1'XYQ+E5?*\Q?/%)3
MO)<M[>:5TMGTZ)K4ZOX.^#O^$N\81&YBW6EEB>YR.&P?E3\3^@-?0-<I\'?!
MW_"(^#XA<Q;;N]Q/<Y'*Y'RI^ _4FNKK\-X\S[^W,^G[-WI4O<CV=OBE\W^"
M1^H\*93_ &7E4>=>_/WI?HODOQN%%%%?%'TP4444 %%%% !1110 4444 %=?
M\$_^1T_[<Y/YK7(5U_P3_P"1T_[<Y/YK7HY1_P C.C_B0'KM%%%?JX!1110
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M"U\;>#?A_HSZ;J7FVT4S>29-K'RVD:)LC[\3=JT?V,_VLKCXF?M)^&_!#_\
M!"WXD?!L7OVS/Q(U_P %Z5:6FD;+.>3]Y+;GS$\W9Y V]6G4'@F@#[NHHHH
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M\UPJ7DPD\]XYWC\V..;R5?RT KO/V7/V3?\ @KI\,_CMH7C?]I__ (*UZ/\
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M_D;1]'^0'=4445^E %%%% !7"_'G_D V7_7X?_0#7=5POQY_Y -E_P!?A_\
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M<K93310@/.(8U\QF95+$*, _65%4\;5E3E&23;OKUU:;\NG8 HHHKC ****
M"BBB@ HHHH *Z_X)_P#(Z?\ ;G)_-:Y"NO\ @G_R.G_;G)_-:]'*/^1G1_Q(
M#UVBBBOU< HHHH **** "BBB@ HHKSK]K#]I7PM^R%\!-<_:%\:>!O%OB33=
M -J+C1? VA-J6J7'GW45LODVRLIDVM,K-R-J*[=J /S?O=%_X)5:)_P6:_:2
MM?\ @JWK_P &-<\5ZZGANY^%TGQ?U'3+S3K#0ETJ))-/CBO6:"QNEN-TABD"
M2RI<131AED8U]9?LS>'O^"%=C\;M$NOV-]#_ &3(?B0GVG_A')/AE;>&%UP9
MMI1<?9C8CS_^/;S]^S_EEYF[Y=U?&_Q;_P""C_\ P18^/GQ"U#XM?&__ ((B
M?%OQ=XHU8Q'5/$/B/]E.WO+V[\J)(8_,FE9G?;%'&@R3A44#@"O1?^">W[1_
M_!('Q[^U_P"$/"?[+G_!'WQA\+?'=W_:']A>.]5_9PM= @TS;I]R\VZ_0[H/
M,@66$8^^90G1Z /TVHHHH ^,X?C7^T=^Q%JFJ_!/PG^Q#XU^)MD^KW&K1>*O
M#3^7:2?:G\WR5!B<[H\[6.1R#QCK-_P\I_:R_P"D3_Q3_P# L?\ R/7V-10!
M\<_\/*?VLO\ I$_\4_\ P+'_ ,CUR'C;]M7]K+QCK7]L?\.O/BG;?N53R\A^
MF><^4/6OO6BN;%83#XVE[.M&\=]VORL!^>?_  U7^UE_TC+^*?\ W['_ ,;H
M_P"&J_VLO^D9?Q3_ ._8_P#C=?H917G?ZO9/_P ^O_)I?Y@?GG_PU7^UE_TC
M+^*?_?L?_&Z/^&J_VLO^D9?Q3_[]C_XW7Z&44?ZO9/\ \^O_ ":7^8'YY_\
M#5?[67_2,OXI_P#?L?\ QNC_ (:K_:R_Z1E_%/\ []C_ .-U^AE%'^KV3_\
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M / L?_(]?8U%>D!\<_\ #RG]K+_I$_\ %/\ \"Q_\CT?\/*?VLO^D3_Q3_\
M L?_ "/7V-10!\<_\/*?VLO^D3_Q3_\  L?_ "/6%X\_;T_:R\;V$%C_ ,.L
M?BG:^3-OW>:'SP1C'DCUK[CHK&O0I8FDZ517B]_Z0'YY_P##5?[67_2,OXI_
M]^Q_\;H_X:K_ &LO^D9?Q3_[]C_XW7Z&45Y?^KV3_P#/K_R:7^8'YY_\-5_M
M9?\ 2,OXI_\ ?L?_ !NC_AJO]K+_ *1E_%/_ +]C_P"-U^AE%'^KV3_\^O\
MR:7^8'YY_P##5?[67_2,OXI_]^Q_\;H_X:K_ &LO^D9?Q3_[]C_XW7Z&44?Z
MO9/_ ,^O_)I?Y@?GG_PU7^UE_P!(R_BG_P!^Q_\ &Z/^&J_VLO\ I&7\4_\
MOV/_ (W7Z&44?ZO9/_SZ_P#)I?Y@?GG_ ,-5_M9?](R_BG_W['_QNC_AJO\
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MV#2[]K"XG2!K#4(+8"'SE:12C* S*C.Q.\*@!]]T444 %%%% !1110 4444
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M3X9_LL7VG>(_"6NVFLZ!J#_$[Q+<"VO;69)X)3%-J+QR!9$5MCJR-C#*02*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ;X:R^+M5M/M2RO8^1;O)=66_"B26*:*6WR -SIP.0*\"_X)9_\ *4W_ (*
M?]E)\(_^F*O@GXI>%_B+X+^./C'_ (-BO#&DZE:^&OBC^T9I_BSPWJ-JC)#9
M?#*\$FM:K:0.OW/L]Q9O$,XWEYER: /T=US_ (*_:IX,_8,^#/[3WC#]D_5F
M^*'Q]DM+;X8_ S0O$B75WJ-U=AIK97OI8(4@A%KY4\T[Q!8!)M(8@%H?!_\
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M'RI&>7S)!'RV!0!] '_@OI\%&_8=C_:&@^#FL/\ &"7QG_P@2_LX?VD!K_\
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MQ'<6>H>%;/XQ6\&D:/IZH6BU"6_DMB\VX[4\F.$ON.>%!:O(/CI%%)_P<C_
MAY(P2G[-OBAD)'W3]OC&1^!(_&N>_P""[GQ7D\$?'']FSP'^T1\8O&?P\_9C
M\4^(-=A^,_BOP9JEWIV^]CLHVT>QO;VSQ-;6LTYE#!2 X4EBOEAU /7?V</^
M"C7[14O[7ND_L,?M^_LB67PL\:>+_#=[K7PYUWPSXV37=%\3166PWMNDGD0R
MV]S"CK(8W0@IELKE-_RE^RQ^U#_P4\L/^"O_ .V]IWPZ_8CT/QK<V]_X CU#
MPIJ_Q_\ [/L_#4 T2<6DMK(^F3+,;V(?:)42.+R7&QC*?GKR'X+67_!.2T_X
M+^_LAR_\$S]"\0W_ (/:S^($.M_$"[\6Z]K&E:YJ*^'9F:TLI]6N9@[6J-&T
MKV^$)O8U9F:/"?07AS]LC]G'_@F?_P %M?VQ?%O[<WQ#/P[T3XQZ5\.=2^'&
MO:SI-VUEK46FZ)-9WBQS11.F^.9@I4D$X..AH ^D?VFO^"D/QDT;]JB;]A7]
MA']E:+XM?$W1?#MOKGCZYUGQ<FB:%X0L[@G[,MU=&&5Y;F8#<EO''NV$/G 8
M#<_8;_X*#^-?VA?C%XX_9&_:?_9XE^$_QF^'MC::GJGA>/Q#'J^GZOI%T66#
M4]/O$CC\Z$NI1T9%:)RJDEMP7\^/VL?@U\ _V:O^"S?QH^+G_!07X^?&/X3_
M  U^/.C^&]1^&_Q0^'GCS5="T>6^T_3Q976E:G/8?*)QM\V#SL*D9;!!EP?I
MG_@E1X'_ ."4&N_M?>+OC+^P[^UA\1OC)X_TSX?KH'B/Q/XM\;:MXAM+32I;
MV.XCM8[V]3RF?SH2XCCD8J&D) WY(!]R?'#XS?#W]G7X.>*/CS\6=<&F^&?!
M^@W6KZ[?%"QBMK>)I)"JCEVPI"J.68@#DBO@:Z_X+-?M\:%^SO#_ ,%!O%G_
M  2=N;3]GN6SCU>6^@^)UO+XMM?#KX9=9?2_LXC,9B*S& 3[E1MQ?8"]?2G_
M  5X_9T^(7[6?_!,[XT?L^?":V-QXF\1>"+E-"LE<*UY=0E;B.V!) !E,0B!
M) S(,D#)KXD^(O\ P6Z_8K\<_P#!(34/V=?"NIZA>?'3Q#\))/A[;_ *+PY=
MGQ#%XDFTTZ<]D]GY6X11RLS%SA3&G'SD)0!]2_MS_P#!7OP=^R1X)^ ?Q*^&
M/P5U/XLZ-^T!XBMM-\*?\(QJ@@NYDN[,7-G);PR1%;AYR\4:H[PJOF;F=0#6
M%X)_X*>_M=?#;]KSX<_LT?\ !0+]A#3?ACI?QEN;RR^'?B[PS\2HO$$$6IP0
MF?\ LV_5;:'RI7CX61"R,Y 4,-[)\Z?&GX!>,?V8/!7_  2J_9X^)6P^(/!_
MQ)TG3==B602)#>QZ(WG1*PR&5)-R!AP0@(KW'_@L_P ?M1?L+$=?^&IK'G_M
MPN: /ONO@&U_X*]?M6?&_P#:M^,W[&'[&7_!/BV\6>*/@WXH33]:\2^)/B4F
MFZ(MF\0>&>63[&TB7$SB5([6-9/EADD:50 K??U?D-^P[_P4+_9J_8E_X*@?
MMP^'?VL/%B>!M \3?&.TFT'QUJ]I*-*N+R"P'G:?+<JI2&<1O'+&CD>8IEVY
M*$$ ^Q/V1_\ @J-)^T/\&/C'J'Q+^ -]X!^+/P!:Z@^)WPMO];CN?LTZ6DEU
M;2P7L<>V:UNHXV,<P3^%B%90K/PO[ ?_  5-_;3_ ."C/A[X>?'7X0_\$YH/
M#OPB\2.L?B7QEXG^)D(N8G5FCN6TZS%LKWD$,JF/SI/)\UEDV)A0S>+_ +'&
MLR?M5_$C_@H'_P %.?A_HFH6OPK^)_@VQ\._#75M0L)+4^)8M%T&ZMKK4XXY
M55S TC*L3E1D;U.&1@/I#_@AAHL>K?\ !%3X#Z#!<-:B]^&$<7G0C#1F0R@N
M/?+$_6@#D/#_ /P53_;9_:KO/$WC_P#X)J_\$\=,^)/PL\+ZY>:5:>._&'Q3
MA\/GQ?=6DACN1I,!MILPB161+F9E1SD84JP'TE^P=^VG\//V^OV<-,_:$^'^
M@:GH;RWMUI?B+POKD82^T'5K25H;NPN .-\<BG!XW*R-@;L#\9?^"?7PU_8#
M_9$^"\W[&7_!33]NKX]?L_?%OX:ZQJ5GJGAN'XT:[H&@ZM9->S36VI:0D!%O
M);S1R GRSN:02.5^<$_H+^QI^Q!^Q'\>OV"[KP?^P#^UU\?/#/@7Q)\5+[Q9
M<?$;PMXVOM-UW7-3,?V:Z8WE];^=/:RLH<DIB62,2!CU(!E?\'1/Q*^.7PS_
M ."/GQ#U+X-Z!(MO<7>C1^(O%5EXK;3;SP];C6; QS01I&6NC++LMV19(MJ3
M,Y+!2C?17PG^/_\ P4 U?X8^.O%OQN_X)\:-X<US0-$6Y\#^&/#/QGMM9D\5
M7>R8M:--)8VD=@=R0J))"ZGSB3M$9W?*_P#P5^_8+^('PR_X('_'S]G?X8?%
MWXO_ !GUF^ET[7X;WXE>)6U_61#;:KI=Q<00R+$C>1'!9RRB,*2&:4Y.[ U?
MVVO^"L?@S]JG_@E/\>/B1_P2%^.$WBKXD>"/"FFSWT7A[2KI-4T"VN[M$N9A
M%-$C)/'9Q7[KM^9&@+#!49 -SXH?\%1_^"@/['=GI7QG_P""@'_!.+P_X0^$
M%YKMEIWB3QAX(^+T>N7?A!;N=+>&YO;9K. 30B66-'>%OEW9 8X5O:?V\?\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>biib-20220331_g21.jpg
<TEXT>
begin 644 biib-20220331_g21.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#5H=3N+F>(30"62XEC<$AU""0;1M0)7VS10 5X]^WW^QGX _X*#_ +(/C?\
M8]^)VMWVF:/XTT^&&34],"F>SG@N8KJWG4-PVR>")BIQN"E<C.1[#10!\:^*
MO^"='[:'QS_8M^+W['G[77_!1NQ^(*?$7PO!HWASQ-;_  9MM(F\/A3)Y\TT
M5O?D:@TH,/&Z *8F(SO('J7[0W[$O_"^O^"<^N_L _\ "S?[*_MKX9Q^$?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5;_Q->:1=&TU+7F9KZ]TH7LZZ=/.S$EV:T$!5R2738Q)+$G\Z?C=_P %H_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\
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M^^J/^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\
M0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ% %/\
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M#_OJKG]G:?\ \^,/_?H4?V=I_P#SXP_]^A0!3_X3'PQ_T&H/^^J/^$Q\,?\
M0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 5K;Q1X?O)UM;758GD<X1%/
M)-7ZB2QLHV#QV<2L.A6, BI: "BBB@ HHHH **** "BBB@ HHHH \+_X)[_\
MD3U;_L>]9_\ 2DU[I7A?_!/?_DB>K?\ 8]ZS_P"E)KW2@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#PO_@GO_P D3U;_ +'O6?\ TI->Z5X7_P $]_\ DB>K?]CW
MK/\ Z4FO=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***PO'GC7_ (0BP@OO
M[,^U>=-LV^=LQP3G.T^E8UZ]+#4G5J.T5O\ T@-VBO.?^%__ /4I?^3_ /\
M:Z/^%_\ _4I?^3__ -KKR_\ 6')_^?O_ )++_(#T:BO.?^%__P#4I?\ D_\
M_:Z/^%__ /4I?^3_ /\ :Z/]8<G_ .?O_DLO\@/1J*\Y_P"%_P#_ %*7_D__
M /:Z/^%__P#4I?\ D_\ _:Z/]8<G_P"?O_DLO\@/1J*\Y_X7_P#]2E_Y/_\
MVNC_ (7_ /\ 4I?^3_\ ]KH_UAR?_G[_ .2R_P @/1J*\Y_X7_\ ]2E_Y/\
M_P!KH_X7_P#]2E_Y/_\ VNC_ %AR?_G[_P"2R_R ]&HKSG_A?_\ U*7_ )/_
M /VNC_A?_P#U*7_D_P#_ &NC_6')_P#G[_Y++_(#T:BO.?\ A?\ _P!2E_Y/
M_P#VNC_A?_\ U*7_ )/_ /VNC_6')_\ G[_Y++_(#T:BO.?^%_\ _4I?^3__
M -KH_P"%_P#_ %*7_D__ /:Z/]8<G_Y^_P#DLO\ (#T:BO.?^%__ /4I?^3_
M /\ :Z/^%_\ _4I?^3__ -KH_P!8<G_Y^_\ DLO\@/1J*\Y_X7__ -2E_P"3
M_P#]KH_X7_\ ]2E_Y/\ _P!KH_UAR?\ Y^_^2R_R ]&HKSG_ (7_ /\ 4I?^
M3_\ ]KH_X7__ -2E_P"3_P#]KH_UAR?_ )^_^2R_R ]&HKSG_A?_ /U*7_D_
M_P#:Z/\ A?\ _P!2E_Y/_P#VNC_6')_^?O\ Y++_ " ]&HKSG_A?_P#U*7_D
M_P#_ &NC_A?_ /U*7_D__P#:Z/\ 6')_^?O_ )++_(#T:BO.?^%__P#4I?\
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MJBN:^,GCK7_AE\*]?^('A3X=:GXNU/2-+EN;#PQHI476J3*N4MXBW 9C@9/
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MZ3K?Q"\;6]^DVG>)M,EMF73'L8UAB^QPV\3>4;=U9E+Y\Q_NIW?Q/_X)R?M
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M/>L_^E)KW2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N%^//_(!LO^OP_P#H
M!KNJX7X\_P#(!LO^OP_^@&O)SW_D4U?3]4!Y;1117Y: 4444 %%%% !1110
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M1_PDNK_]"A>_]]+6Q10!C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM;%%
M&/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+6Q10!C_\ "2ZO_P!"A>_]]+1_
MPDNK_P#0H7O_ 'TM;%% &/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+6Q10!
MC_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM;%% &/\ \)+J_P#T*%[_ -]+
M1_PDNK_]"A>_]]+6Q10!C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM;%%
M&/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+6Q10!C_\ "2ZO_P!"A>_]]+1_
MPDNK_P#0H7O_ 'TM;%% &/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+6Q10!
MC_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM;%% &/\ \)+J_P#T*%[_ -]+
M1_PDNK_]"A>_]]+6Q10!C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM;%%
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M%% !1110 4444 %<+\>?^0#9?]?A_P#0#7=5POQY_P"0#9?]?A_] ->3GO\
MR*:OI^J \MHHHK\M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MMCW+"RKG[SLB]6H ^OZ*** /"_\ @GO_ ,D3U;_L>]9_]*37NE>%_P#!/?\
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MC3K'T<T ?H/1110!X7_P3W_Y(GJW_8]ZS_Z4FO=*\+_X)[_\D3U;_L>]9_\
M2DU[I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7"_'G_ ) -E_U^'_T UW5<
M+\>?^0#9?]?A_P#0#7DY[_R*:OI^J \MHHHK\M **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Z_X)_P#(Z?\ ;G)_
M-:Y"NO\ @G_R.G_;G)_-:]'*/^1G1_Q(#UVBBBOU< HHHH **** "BBB@ KR
M_P#:TN_VR+/X:6DO[#FD_#F\\7G7K87T7Q/GOH]/&F8?[0R&R_>>>#Y>P'Y/
MO9[5ZA10!\?_ +4.M?\ !>2T^.NNV_[&G@O]E>[^&RFV_P"$;N/B-J7B&/6G
M'V:(S_:%M!Y(Q<><$V?\LPF?FS2_LN:U_P %X;OX[:%;_MG>"_V6+3X:M]J_
MX22X^'&H^(9-:3_193;_ &=;P>2<W/D!]_\ RS,F/FQ7BOBKX/\ [5__  4I
M_P""BWQ^^#WB[_@H7\6/@CX*^"]YH.G^$/!7P<U6'2+[4H;[34NVU:[NVC=Y
MXY)3+&B@;%,++PR-N]J_9<_X).^+/V:/CMH7QMU/_@J5^U/\1X-$^U;_  9\
M1_B9'J&BZCYUK+;C[1;BV0R>691*GS#;)%&W.,$ ^OZ*** /GK]@OPW8:M\'
M-6NKF:X5AXXUE<13E1C[2W85[;_P@^D?\_-[_P"!;5Y'_P $]_\ DB>K?]CW
MK/\ Z4FO=* ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?
MF]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK
M8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"V
MH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,
M?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2
M/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](
M_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_
M\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_
M ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJV
M** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_
MX0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\
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M_:G\;SZ%]JV>%_B/\9)-5T6]\^UEMS]HM3;H)=@F,B?,-LD<;<[<5E?M5?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7"_'G_ ) -E_U^'_T UW5<+\>?^0#9?]?A_P#0#7DY[_R*:OI^J \M
MHHHK\M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "N%^//_(!LO^OP_P#H!KNJX7X\_P#(!LO^OP_^@&O)SW_D4U?3
M]4!Y;1117Y: 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*2__ !%'_"VOA]_T,'_DI+_\11_:67?\_H?^!+_,#HZ*YS_A;7P^_P"A@_\
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ME!^>52>>%!/.,4XQ<I)+=@=9138Y(YHUFAD5T=0593D$'H0:^/-0_P""\_\
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M-_R ;W_K\'_H KWN&O\ D;1]'^0'=4445^E %%%% !7"_'G_ ) -E_U^'_T
MUW5<+\>?^0#9?]?A_P#0#7DY[_R*:OI^J \MHHHK\M **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Z_X)_P#(Z?\
M;G)_-:Y"NO\ @G_R.G_;G)_-:]'*/^1G1_Q(#UVBBBOU< HHHH **** "BBB
M@ HHHH **** "BBB@#PO_@GO_P D3U;_ +'O6?\ TI->Z5X7_P $]_\ DB>K
M?]CWK/\ Z4FO=* "O(OC9_R.G_;G'_-J]=KR+XV?\CI_VYQ_S:OG.*/^19_V
M\OU Y"BBBOSH HHHH **** "BBB@ HHHH *_&_\ X*W>&] \,?M7_&'Q]_P4
M!^!_C/Q/X,U&Q\))\!O%T6DW>I>&_#EI'-;_ -LP3) 2MK=3.)3N=&=U!"D!
ME#?LA7PO_P %2_C'^W'X3^%_CGP=!^QMI?BGP!+K&A2^'_&F@?$*UM;F)1J%
M@_DWEC>*A#FX5HP\3NNUT8J,-7IY34E3Q2M;6RW47NMF^OEU5T![!_P39M?^
M">'_  IK4]<_X)LZMH4W@O5M=:[U*TT#4KF2&TOC%&K(;>Y8O9,42,^3MC'.
M[;\Q)\V_X*>?MD_M#_!'X?>.OA7\._\ @G+XI^('AN;P=+;S^,X[B&31;>*X
MMV29I[6));J2*!6+2(D1W*I ('(T/^"?W[+7[1'PR^,?Q]_;-^,/PR\.>!_$
M7QFO-+FTGX7Z!K*WD&EKIUI+$DMU=1(D4ES<22EY&C!4<G<Q8A<CQ!^W!_P5
MBU'PQ<^#?#7_  1SU&Q\93P-;VVI:A\6]%GT&VE9<"Y>56626)3\YB"J[ ;<
M@FK5.+QKDFII6^*:6MEUNKVU5U==0/2_^"1O@/X??#3_ ()N?"+P7\+?B_:^
M/=#M/"X>T\5V,;I#>O)/++*$20"2-8Y7DB".%=/*VLJL"H]]\5ZA=Z-X;OM>
MTWP[+JUWI]E-<V>FVY42W,J1L5BC+<*S_<!/'S<\5\H?LM?LO_M-_P#!-;_@
MDUI?P&^ 7AS1OB+\6?"^DW%U9:1<WHMM/U#4KN_>YFA6262 +%&)Y%5F:/=Y
M88@%MM>H_'+XT?MD_##X->#O'7PM_8]A^)'B:[BM_P#A._!^G>,[32YM,+6V
MZ5K:6Y+17&R?*>7ORRG(8XYYZ]/VV*E*$DTY.S;2OUN]K)]]$!\0?&KX_>//
MVP_^"BW[,O@_]J;]F76OV<[+PCXUDU[PKKGC=_M5UXMU-441Z+9W%I&UM '*
MJTBRS!I!Y:JA;:&_4VOST^+/@3]OC_@J!\:_A!HGQ4_8VD^"'PP^%OQ/T[QW
MK&L^*/&%CJ&K:S>6 D\BSM;>R9O)0F5@\CL 0VX',>Q_T+K3'N')2BK)I.Z3
MNEJWO=[]KNWX %%%%>: 4444 %%%% !1110 5ZE\!O\ D WO_7X/_0!7EM>I
M? ;_ ) -[_U^#_T 5[W#7_(VCZ/\@.ZHHHK]* **** "N%^//_(!LO\ K\/_
M * :[JN%^//_ " ;+_K\/_H!KR<]_P"135]/U0'EM%%%?EH!1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !77_!/_D=
M/^W.3^:UR%=?\$_^1T_[<Y/YK7HY1_R,Z/\ B0'KM%%%?JX!1110 4444 %%
M%% !1110 4444 %%%% 'A?\ P3W_ .2)ZM_V/>L_^E)KW2O"_P#@GO\ \D3U
M;_L>]9_]*37NE !7D7QL_P"1T_[<X_YM7KM>1?&S_D=/^W./^;5\YQ1_R+/^
MWE^H'(4445^= %%%% !1110 4444 %%%% !6;XN\'>%?'V@3>%?&OAZTU73;
MB2)Y[&^@$D3M'(LL9*G@E71&'H5![5I44TVG= %%%%( HHHH **** "BBB@
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M^%L?_C5'^J'_ $__ /)?_M@.ZHKA?^'(7[)O_11OBG_X6Q_^-4?\.0OV3?\
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M0_Z?_P#DO_VP'=5ZE\!O^0#>_P#7X/\ T 5\Y_\ #D+]DW_HHWQ3_P#"V/\
M\:H_X<A?LF_]%&^*?_A;'_XU7?EO#W]G8M5_:\UKZ<MM_FP/L:BOCG_AR%^R
M;_T4;XI_^%L?_C5'_#D+]DW_ **-\4__  MC_P#&J^E ^QJ*^.?^'(7[)O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ?#H5NNJ7%HI4BW>[">:\0*)A"Q4;5XX%=+110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 <UX]^#7P?^*FIZ'K7Q0^%/AKQ)>>&=1&H>&[O7M"M[R72;L%2+BV:5&,
M$H*J0Z%6^4<\"NEHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
IHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>biib-20220331_g22.jpg
<TEXT>
begin 644 biib-20220331_g22.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#5H=3N+F>(30"62XEC<$AU""0;1M0)7VS10 5X]^WW^QGX _X*#_ +(/C?\
M8]^)VMWVF:/XTT^&&34],"F>SG@N8KJWG4-PVR>")BIQN"E<C.1[#10!\:^*
MO^"='[:'QS_8M^+W['G[77_!1NQ^(*?$7PO!HWASQ-;_  9MM(F\/A3)Y\TT
M5O?D:@TH,/&Z *8F(SO('J7[0W[$O_"^O^"<^N_L _\ "S?[*_MKX9Q^$?\
MA+?[%\_R=MJD'VK[+YR;L[-WE^:.N-W>O>** /D[]IK_ ()6Z#^T%^S_ /!W
MP3X<^.NL>!_B?\!;:R?X8?%W0-,B>XTV[ALXK68R6<KE)[6X2)?-MF?#!54N
M0#N=\$OV9_\ @JU9?%;P]XH_:7_X*6^%M<\*:%<^;J/A/P3\%[?2Y/$(",JK
M<W<UW.\"[BKE8%7<5QD+D'ZKN[NTL+66_O[F."""-I)IIG"I&@&2S$\  #))
MK/\ !?C?P7\1_"]GXW^'GB_2]>T748S)I^KZ+J$=U:W*!BI:.6)F1QD$9!/(
M([4 :E?.G[=W[ ?_  VQ\1O@-X__ .%L_P#",_\ "DOB_8>.?LG]@_;?[:^S
M C['N\^+[-NS_K<28_N&OHNH[N\M+"UDO;^ZC@AB0M+-,X544=22> * /(?^
M"@7[)O\ PW5^QG\0?V1O^$__ .$6_P"$[T(Z;_PD']E?;OL.9$?S/(\V+S?N
M8V^8O7K63^U)^Q+_ ,-*?\$\/$7[!/\ PLW^Q?[?^'\/AC_A*_[%^T^1LBCC
M^T?9?.3=GR\[/-'7&[BO:]"\2>'?%%F=0\,Z]9:C;ARAGL;I)D##J-R$C/M5
MV@#Y?^*O_!-S_A9OC7]EKQA_PN;[#_PS3J)NOL__  COF_\ "1_\2M;#;N^T
M+]C^[YF<3==N/XJ[7]OS]ACX7_\ !0?]G^3X&_$G7-6T*YL=:M-=\(>+?#TX
MBU'PYK5HQ:UU"V8@@2(692#U21P"I(8>UT4 ?&7@C]D7_@L8FM:)HGQ2_P""
MMGAB]\-:3J%O)J=UX?\ @):6>LZ];1R*S03327DD-J95!5I(8MPW';@X(VOV
MP_\ @FOX\^*O[3.C_MU_L:?M.W'P<^,NF^&SX=U?5I?#46LZ1XGT?S?.2SU"
MQDDCWE).4G1U=!C[VU-GUG5#3O%/AG5]2N-'TGQ'875W9G%W:V]XCR0'_;52
M2OXT >$_LF_ 7_@H!X%^).H?$3]LC]NS1_B'8SZ*]CI?@CPG\,(-!TVQG::)
MS>M,;B>XN)=L90*SJBB5\*2<U[CXY\-?\)IX)UCP=]M^S?VMI5Q9_:?+W^5Y
ML;)OVY&[&[.,C..HK4Z=:IZ+XAT#Q);/>>'=<L[^&.4QR2V5RDJJXZJ2I(!&
M1Q0!\]?L3?\ !-KX6?LP?\$\_!/_  3U^,J^'_BYH'A*UFBNI_$_@Z#['J;-
M?S7B2-8SO<(I1I0!EWY0,""<";]JG]@"U_:4_:D_9U_:0L?B;'X<@^ 'B'5=
M3A\.Q>'Q.FLI>6<=L(5E$\8M!&(]P(27.<87&:]_USQ%X?\ #-F-0\2:[9Z?
M;EP@GOKI(D+'HNYR!D^E6H9H;F%+BWF62.10T<B,"K*1D$$=10!\=_M(_P#!
M-#XW7/[8FH_M\?L!?M8V_P )OB#XJ\/6NB_$?2]?\&IKNA^*[>U&VTGF@\Z&
M2&ZA3"+,CG*($PH9R_2?L"?\$XM1_9-\6?$?]H3XX_'N]^*OQG^+MS;2>.?'
MUYHL>G0+;6T1CM;"RLXW=;:VA5B,;R7(4L?E4+])WGBGPSIVKP>']0\16$%_
M=#-M937B+-,.GRH3N;\!5^@#P/\ X)@_L/\ _#M_]A?P+^Q;_P +/_X3/_A"
MH]17_A)?[%_L[[9]JU*ZO?\ CW\Z;R]OVG9_K&SLW<9VCQOX>?\ !$WP!HO_
M  1??_@CE\3/C;?Z]I,EM?!O'.F:&NGSK<2ZY+K-O,ELTTX7R9VB4J9#Y@B/
M*;\+]P44 ?&GB_\ X)S?MH?'C]BKXO?L=_M=_P#!1NP^( ^(WAJWTCPYXGMO
M@S;:1-X?"M(9YIHK>_*W[2YAXW0!#$Q&=Y ]3_:/_8E_X:"_X)TZ]^P'_P +
M-_LC^V_AO'X3_P"$L_L7[1Y.RW2'[3]E\Y-V=F[R_-'7&[O7O%% 'R]\5OV2
M?VZM'\"?#/PQ^QE^WEI7@/\ X0/P;;Z#K>E>)?A?!K.G>)3###%'<L#<QS6;
MJ(V($<C B3#9P#5']BS_ ()U_%/X,?M0>,?VZOVMOVF(?BA\6O%_A6U\+QWF
MC>$8]#TG1=$@G\];.WMEEE>1FFP[2R2%C@  <D_5]8_A#X@^ ?B"-3/@+QOH
M^MC1=7GTK63I&IQ7/V"_AQYUI-Y;'RITW+NB;#KN&0,T <[^U%\%?^&D_P!F
M;XB_LZ?\)+_8O_"?>!-7\.?VQ]C^T_8/MUE+:^?Y6]/-V>;OV;UW;<;ESD?$
M'P-_X)/_ /!7_P#9P^#OAGX"_!__ (+PV.E^%O"&C0:5H&G/^RMHMP;:TA0)
M&ADEOV=\* -S,2>Y-?HS5#1_%'AGQ#-<6_A_Q%87TEH^RZ2SNTE,+>CA2=I]
MC0!\R_'3_@G=\4/VE?!_[.%O\:OVJTUCQ7\"OBMI'CG7O%4?@2*V7Q=<64<Z
M-"+6&Y6/3_,\[.Y3*$V?<;/'5_MV_L-_\-KZK\$]3_X6A_PC/_"G?CIH?Q&V
M?V)]M_M?^SEN%^P9\Z+[/YGG_P"N_>;=O^K;/'ODTT5O$UQ<2JD:*6=W; 4#
MDDD]!5?1]<T7Q%8KJGA_6+6^MG)"W%G<++&2.H#*2* /DG]JC_@FU\:_$G[7
M\/[?/["'[5%K\)_B3J'A>/PYX[M-=\(+KFB^*M.B??;FXM_.A>*XA/"S(^2B
MJG W;J'[%/\ P2B^(?[,O[=OC/\ X*!_&+]LC4/B=XR^(7P^A\/^*8KSPC%I
MT(NH[N.59[417#K;VR0PPP):[&(\LR-,[.U?8.N>*/#7AB.*;Q+XBL=.2>39
M"U]=I")&_NJ7(R?85>!# ,IR#T(H ^$=%_X)8_M@?LG>/O%UY_P3*_;PTGX?
M> /&WB*YUZ^^%WCWX;)K^GZ+J5R=UQ-ILR75O+;Q.PW?9CNC4Y(/.*]0\7?\
M$[?$O[2_[!?C#]BW]O\ _:4O_BO>^-I))=1\:6/ABUT)].D#Q2VALK6 ND(M
MI88Y$W,Y<@^86#$'Z>HH _-/]H__ ((K_P#!07]N#]ER]_8__;#_ ."MB:WX
M3M;:W71;G0_A##:7>I7,$B&WN=8<7V;P1JI;R8VA#S%)7=S&%;]'?"VB?\(U
MX8T[PY]I\_\ L^PAMO.V;?,\M N[&3C.,XR:OT4 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5;_Q->:1=&TU+7F9KZ]TH7LZZ=/.S$EV:T$!5R2738Q)+$G\Z?C=_P %H_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **\2_8(U34]7^#6J
MW.K:C/=2+XWUA%DN)F=@HN2 N6)X Z#M7MM !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% 'A?_  3W_P"2)ZM_V/>L_P#I2:]TKPO_ ()[_P#)$]6_['O6?_2DU[I0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!X7_ ,$]_P#DB>K?]CWK/_I2:]TKPO\
MX)[_ /)$]6_['O6?_2DU[I0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X7_P3W_Y
M(GJW_8]ZS_Z4FO=*\+_X)[_\D3U;_L>]9_\ 2DU[I0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!X7_P3W_Y(GJW_ &/>L_\ I2:]TKPO_@GO_P D3U;_ +'O6?\
MTI->Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 >%_\ !/?_ )(GJW_8]ZS_ .E)
MKW2O"_\ @GO_ ,D3U;_L>]9_]*37NE !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '
MA?\ P3W_ .2)ZM_V/>L_^E)KW2O"_P#@GO\ \D3U;_L>]9_]*37NE !1110
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M7=0T:UN=:\.-J,=X=*NY(E::T,\7R3^4Y:/S$^5]FX<$5LT44 >%_P#!/?\
MY(GJW_8]ZS_Z4FO=*\+_ .">_P#R1/5O^Q[UG_TI->Z4 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M /"_^">__)$]6_['O6?_ $I->Z5X7_P3W_Y(GJW_ &/>L_\ I2:]TH ****
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M^:V\V-7MUQ_K&G6/HYH _0>BBB@#X8_9\_X)^?!7]I;PGJWQ(\>^*_&]G?\
M_"6:K:>3X?\ %L]E;[$NG(/EIQN^8Y/?BN[_ .'/7[,/_10?BG_X<2[KN/\
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MFT?\,-?LX_\ 0$\3_P#AQM<_^3:]<HH_M+,?^?T__ G_ )@>1_\ ##7[./\
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MK]G'_H">)_\ PXVN?_)M'_##7[./_0$\3_\ AQM<_P#DVO7**/[2S'_G]/\
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M^3:^HO\ A0'_ %-O_DA_]LH_X4!_U-O_ )(?_;*^,^H<4]Y_^#%_\D!\N_\
M##7[./\ T!/$_P#X<;7/_DVC_AAK]G'_ * GB?\ \.-KG_R;7U%_PH#_ *FW
M_P D/_ME'_"@/^IM_P#)#_[91]0XI[S_ /!B_P#D@/EW_AAK]G'_ * GB?\
M\.-KG_R;1_PPU^SC_P! 3Q/_ .'&US_Y-KZB_P"% ?\ 4V_^2'_VRC_A0'_4
MV_\ DA_]LH^H<4]Y_P#@Q?\ R0'R[_PPU^SC_P! 3Q/_ .'&US_Y-H_X8:_9
MQ_Z GB?_ ,.-KG_R;7U%_P * _ZFW_R0_P#ME'_"@/\ J;?_ "0_^V4?4.*>
M\_\ P8O_ )(#Y=_X8:_9Q_Z GB?_ ,.-KG_R;1_PPU^SC_T!/$__ (<;7/\
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MCZAQ3WG_ .#%_P#) ?+O_##7[./_ $!/$_\ X<;7/_DVC_AAK]G'_H">)_\
MPXVN?_)M?47_  H#_J;?_)#_ .V4?\* _P"IM_\ )#_[91]0XI[S_P#!B_\
MD@/EW_AAK]G'_H">)_\ PXVN?_)M'_##7[./_0$\3_\ AQM<_P#DVOJ+_A0'
M_4V_^2'_ -LH_P"% ?\ 4V_^2'_VRCZAQ3WG_P"#%_\ ) ?+O_##7[./_0$\
M3_\ AQM<_P#DVM3PA_P3E_9L\?:O_8,S^-=-7RFD^TZ=\1=6\SC'R_OKB1<'
M/]W/'6OH[_A0'_4V_P#DA_\ ;*U_!/PJ_P"$.UK^V/[>^T_N63R_LNSKCG.X
M^E=>!P7$4,93E6<N1-7O.^GIS >!?\.>OV8?^B@_%/\ \.)=T?\ #GK]F'_H
MH/Q3_P##B7=?5E%?; ?.?PL_X)A?L_?"'XAZ1\3/#/C7XB7%_HUV+FUAU3QQ
M<W%N[@$8DC;AUYZ&OHRBB@ HHHH **** "O+_P!K2[_;(L_AI:2_L.:3\.;S
MQ>=>MA?1?$^>^CT\:9A_M#(;+]YYX/E[ ?D^]GM7J%% 'Q_^U#K7_!>2T^.N
MNV_[&G@O]E>[^&RFV_X1NX^(VI>(8]:<?9HC/]H6T'DC%QYP39_RS"9^;-+^
MRYK7_!>&[^.VA6_[9W@O]EBT^&K?:O\ A)+CX<:CXADUI/\ 193;_9UO!Y)S
M<^0'W_\ +,R8^;%>*^*O@_\ M7_\%*?^"BWQ^^#WB[_@H7\6/@CX*^"]YH.G
M^$/!7P<U6'2+[4H;[34NVU:[NVC=YXY)3+&B@;%,++PR-N]J_9<_X).^+/V:
M/CMH7QMU/_@J5^U/\1X-$^U;_!GQ'^)D>H:+J/G6LMN/M%N+9#)Y9E$J?,-L
MD4;<XP0#Z_HHHH \+_X)[_\ )$]6_P"Q[UG_ -*37NE>%_\ !/?_ )(GJW_8
M]ZS_ .E)KW2@ KR+XV?\CI_VYQ_S:O7:\B^-G_(Z?]N<?\VKYSBC_D6?]O+]
M0.0HHHK\Z **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *]2^ W_(!O?^OP?^@"O+:]2^ W_(!O?^OP?^@"O>X:_P"1
MM'T?Y =U1117Z4 4444 %%%% !1110 4444 %%%% !1110 445YE^VEHWQX\
M1?L@_%#0?V7=2-G\2+WP!J\'@6Z6=8GBU5K25;5DD8A8W\TIM=OE5L$\ T ;
M%O\ 'SX?7/[0MW^S(ES./$]GX1M_$<J,J"$V<US/;H%;=N,@>W<E=N I4YYP
M-;XK?%'P)\$?AEX@^,7Q1\10:1X<\+:-<ZKKNIW)PEK:P1M)+(>YPJDX')Z#
M)-?@'^REH/\ P0WT[X\:%\&/^"D'[/VM_"KQ=<_!K1;#Q3<_&W3]9TK4[SQN
M+Z[.HZF-7W@H)<QNET9HD*!0NW857]%O^#@O7/\ A)?V6_@K^R7I&HL=%^/W
M[2/@GP%KTUO/GS=&N+IKF;#@Y*M]EB4X/S*[#)!((!])^*O^"A_[-7PO_8BT
MS_@H-\=M5UOP#\.=2T?3=3:?Q%X>N);ZS@OY8HK3SK2R6XE5Y&GA^50Q7S!N
MVX;'G_P*_P""XG_!,G]I3XMZ'\#/@S\>]:U3Q1XDNS;:-I]Q\+O$MDD\H1GV
MF>ZTZ.&/Y58Y=U'&,Y(JO_P6\_9$^-'[:'_!-#QA^R_^S+X7T^]\4:OJOAYM
M(T^\OXK*V2*TUBRN9"TCX5$2&%S@ D[<*I) KS*]_P""I'[?/['OQN\ >"_^
M"I/[&/@SPSX"^)_BNW\,Z#\3OA=XVEU.ST;5[DD6MKJ$%S#'(JR$']\N$4(Q
MPV"  ?H/7C_[8_[>W[)O[ O@>Q\>_M5_%^T\,VVKWAM-"L%M9[R_U:XX_=6M
MI;))/.PW+DHA"[UW%00:]@K\;/BO\<?VE?'/_!S!\4?!?P _9LT;XE^/OAI\
M)=%TKX;R^.->;3_#W@VPNK:WOM2U:9TBEE,\DM[#:H(4,KK,X+!(R" ?H[^Q
M;_P4B_9._;\G\2Z9^SEXNUJYU3P<+1O$^B^(O"&HZ/=V"W7G?9V:.]@BWK)]
MGFP4+ >6<XXKJ/V7OVM?A5^UIHGBG4?AQ'JEE?>"/&NH^%/%V@Z]:+!?:5J=
MG)MDCE17==KHT<L;JQ5XY48'D@>'?L'_ /!17XM_&7]J+QY^P3^VC^SWIGPX
M^-?@7P_;>(%C\.:Z=3T?Q-H,T@B74+*9XTD5$FD6-HY!E6<<[MZ)Y[\(M2E^
M!7_!R)\5_@UH!,6C?&O]FS1OB#JMNG$8UC3-3?1PX7HK/;9+,,;BJYR0#0!^
M@-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Y7^-O
MV&_$/_!4#_@KE\=+SX^?M8?$SX6M\$;+0]"^&FB_![6H- U2YT74+!+R6_N+
M\0/-=6\MT)T5 =B/#(N<JP/TC^RY_P $>?"?[+/QVT+X\:9_P4!_:G\;SZ%]
MJV>%_B/\9)-5T6]\^UEMS]HM3;H)=@F,B?,-LD<;<[<5E?M5?\$)/V1OVO/V
MHM5_:^^(?Q8^,FD>,M4M(+43>$?B3/IT%E!';Q0>3;(B$P1N(5=U5L-(S.1E
MJU?V7/\ @B]^SW^R;\=M"_:!\#_M#?'C7=4T#[5]ETKQG\6+O4]-G\^UEMF\
MZVD&V3:LS,N?NNJ-U6@#Z_HHHH \+_X)[_\ )$]6_P"Q[UG_ -*37NE>%_\
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MDDDDT ;%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% 'A?_!/?_DB>K?\ 8]ZS_P"E)KW2O"_^">__ "1/
M5O\ L>]9_P#2DU[I0 5Y%\;/^1T_[<X_YM7KM>1?&S_D=/\ MSC_ )M7SG%'
M_(L_[>7Z@<A1117YT 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5ZE\!O^0#>_P#7X/\ T 5Y;7J7P&_Y -[_ -?@
M_P#0!7O<-?\ (VCZ/\@.ZHHHK]* **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#PO_@GO_R1/5O^Q[UG_P!*37NE>%_\
M$]_^2)ZM_P!CWK/_ *4FO=* "O(OC9_R.G_;G'_-J]=KR+XV?\CI_P!N<?\
M-J^<XH_Y%G_;R_4#D****_.@"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "O4O@-_R ;W_ *_!_P"@"O+:]2^ W_(!
MO?\ K\'_ * *][AK_D;1]'^0'=4445^E %%%% !1110 4444 %%%% !1110
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M2_$'_H7_ /R;B_\ BZ/^%2_$'_H7_P#R;B_^+KVFBC_5/+OYY_>O_D0/%O\
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MX,U;7?!B^59>)+'2?"<VMD6EQ(L,DDUG#'(\MNH?,N$?";B5(!K\'/C+;?\
M!/GQ!\=/BCXJ_P"")']N:9^T/+\1O"?_  H6P^#6FZK8V1M&MK ZJNI6HC2T
M@T]6-X91<(F&&/\ 5;Q0!^G'_!:GQ!<_&?XH?LR_\$PX;ATTWX__ !5DN?'4
M$;D?;O#'A^%=4U"R..BS$6ZDYY577!#&L'_@X?\ "/B/6O@S\&U\;1>(1^SK
MIOQ:L)?VDK3PFUPL@\-!2JO<K:?OFT]'SYXCR5!C8#**RZ'_  52TZY^%/\
MP4X_8-_;$UT!- T3XC>(O FN7./W<-WXCTG[)8L2?N*9HI!D\9902,C/+_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \+_X)[_\ )$]6_P"Q
M[UG_ -*37NE>%_\ !/?_ )(GJW_8]ZS_ .E)KW2@ HHHH **** "BBB@ HHH
MH **** "N'^'7P*\._#?XL_$+XNZ5J][/>_$74]/O=4MK@IY5L]I80V2+%A0
M<%(58[B?F)Q@<5W%% 'FO[77[*7PG_;7^ &N_LY?&>"_&BZXL+K?Z/="WO\
M3;J"9)[>\M9BK>3/%+&DB/@@%<$,I(/H&EZ<^GZ-;:1>ZE/J#06J0RWEZ$,M
MR0H4R2;%5-S8R=JJN2< #BK5% %+1/#?AWPS;O:>&] LM/BD??)'8VJ1*S8Q
MDA0 3[TFN>&/#7B>*.W\2^'K'4(XFW1)?6B3!#Z@.#@U>HH 1$2-!'&@55&%
M4#  ]*6BB@#/M_"?A:SUJ3Q':>&M/BU&4$2W\=FBS/GKEP-Q_.N"_:]_92^'
M7[:_P.O_ -G7XO:SKEMX5UF_LIM?LM!ODMWU6VM[F.X-C,[1NWV>5HU254V.
MR%E#J&.?3:* (K&QLM,LH=-TVSBM[>WB6*WMX(PB1(HPJJHX4    < "I:**
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MWO\ !/\ Z&WQW_X65S_C1_P[W^"?_0V^._\ PLKG_&@#W2BO"_\ AWO\$_\
MH;?'?_A97/\ C1_P[W^"?_0V^.__  LKG_&@#W2BO"_^'>_P3_Z&WQW_ .%E
M<_XT?\.]_@G_ -#;X[_\+*Y_QH ]THKPO_AWO\$_^AM\=_\ A97/^->5^$_V
M0_AQJG[7?B[X577BKQA_9>E>%;"]M2GBFX$WFRNP;=)G++QP.U 'V117A?\
MP[W^"?\ T-OCO_PLKG_&C_AWO\$_^AM\=_\ A97/^- 'NE%>%_\ #O?X)_\
M0V^._P#PLKG_ !H_X=[_  3_ .AM\=_^%E<_XT >Z45X7_P[W^"?_0V^._\
MPLKG_&C_ (=[_!/_ *&WQW_X65S_ (T >Z45X7_P[W^"?_0V^.__  LKG_&C
M_AWO\$_^AM\=_P#A97/^- 'NE%>%_P##O?X)_P#0V^.__"RN?\:/^'>_P3_Z
M&WQW_P"%E<_XT >Z45X7_P .]_@G_P!#;X[_ /"RN?\ &C_AWO\ !/\ Z&WQ
MW_X65S_C0![I17A?_#O?X)_]#;X[_P#"RN?\:/\ AWO\$_\ H;?'?_A97/\
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M;CQ3<2.(A 7&PD_(V1U% 'V117A?_#O?X)_]#;X[_P#"RN?\:/\ AWO\$_\
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M=_XIGFA9L$8=&.&'/0UZ_0 4444 %%%% !1110 4444 %%%% !1110 4444
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M !5;^,M.^-WQ>UCQQJ>E:GH2)!9I?VUM ^G.C22+<H%M^78*&$A!08Y^>O\
M@X%^+?@C7?V0I_\ @FM\/O =MXX^,7Q]BBT+X;_#ZUB1WMD69&DUF?@BUM;1
M8VD$[8 >,8^5)&3[2_: \2?%[P?\#O%WBKX ?#JV\7^.=/\ #MY/X0\+WFHQ
MV<.J:DL3&WMWFD9$B1Y-H+,R@ GYAU'Y/_L%^'_^"S_[*OCOQA^TW\=O^"(V
MK?%GX[?$.Z?_ (2SXGZG^TCX3L_)L ^8-*TZUWR"PLHE"?NE<EV4,Q(6-4 /
MU*^#/[/VB^"OV9_ /[/WQ2@T_P 8-X-\)Z1IES>:O8I<)>75E:Q0_:]LH.'+
MQEPQY!/K7QC_ ,$8H8K?_@H!^W]!!$J(GQXL%1$7 4"Q<  #H*^M_B;\9?VI
M?"O[(]I\9?AU^QI-XJ^*<VBZ7=77P93X@:?9/;WDY@%Y9_VK,/LKFU$DQ\T?
M+-Y'R??6OSY_X)S6?_!8O]F_]LGXS?%#XD?\$=[JV\/?M!_%C3M;U;4A\?/#
M3_\ "(66T6\TC1Q2.]]Y:.TNU%C9MFT#)!H _6*BBB@ HHHH **** "BBB@
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MK?*.>!72T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
D !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>biib-20220331_g3.jpg
<TEXT>
begin 644 biib-20220331_g3.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#5H=3N+F>(30"62XEC<$AU""0;1M0)7VS10 5X]^WW^QGX _X*#_ +(/C?\
M8]^)VMWVF:/XTT^&&34],"F>SG@N8KJWG4-PVR>")BIQN"E<C.1[#10!\:^*
MO^"='[:'QS_8M^+W['G[77_!1NQ^(*?$7PO!HWASQ-;_  9MM(F\/A3)Y\TT
M5O?D:@TH,/&Z *8F(SO('J7[0W[$O_"^O^"<^N_L _\ "S?[*_MKX9Q^$?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 ?@M^W!J'B7]GS_@X&^-/_!2;PM<7
M7D_L_3_#>\\;VEOEA<>$]6T_^R]6_=C[[QI-#,N<A?)9NV1[1_P<Z>*[W]JS
MPI'^Q-X"UUI-!\#?!SQ'\;?B1=6$WRFVLK.:TT*'>O#+-?3/(4/5+<, <9'I
MOPD^$'@K]H+_ (+@_M[_  )^(^G_ &K0/&7P6\&:+K-O@9>VN=*DADQGHVUR
M0>Q /:O.)_\ @F3\?OV"?^"//[8GC7]L#XQZ'X_^(_B?X+/H%EK^A&<PVWAG
M1-!^Q:;:_OXXV67_ %TDN 0[,K%G;)H ^OOV;/B;^T3\*_\ @D1^SGKG[+W[
M-4?Q4\577PB\&VD7AZY\86^A6]O"VAP,]Y/=3I(!''L4%$1W8NH ZD9?PH_X
M*1_M5^!?VL_!'[)'_!1']C#2OAM<_%-;Z+X;>-O!GC]=>TC4;^U@-Q+IUP&M
MX);2;R061F!60_*HX)'RS^V#\6O&GPP_X),_L&V7B;XH^,O ?P/U_1O!5A\?
M/&W@.YN+:^T_1V\/P>1%)<VP,UM:S3X265,' 5<_/M;PSQII_P#P2TM?^"I?
M['<W_!,"S\0^);*'XQF/QM\1F\<>(=:T@W+V;M!I\4VJ74T,ER5$TTGD#,:B
M,,?W@6@#]"/V@/\ @K5\</"'_!07Q-_P37_9E_85NOB3X\TOP/I_B32M3?QU
M%IFG"WG8B>6^>6V86D,),2AD:62:29$6-<EUN_'3_@J#^T#\%)_A9^S#IG[&
M<?C+]J#XEZ+<ZI-\*M \;0QZ3X?L+>1XY=1O-6DB*I:Y7Y"(MTC*R#:P&>5_
M9_BB/_!Q_P#M!SF,%U_9Y\)JK8Y -W)D?H/R%<K^VS\0=)_X)U?\%N?"'_!2
M']HC3M0MO@OXZ^ 4OPRU;QW;Z;-=6WA+6(]8&H0M>>2K-!;SKMC5\8WEB2 C
M&@#Z*^'/QA_;M^('PM^)_AC]L_\ 8Y\/_#D:?X*N9]$\0^%/B3'KMCJ[/!.)
M(?+-O!/;21!4)+J5<2?*?E(KX%_X)'?MX?M__##_ ((V?#/Q-^RM_P $W$^(
M7@3X<^$;X^(/$.O_ !&AT6[UQK>[N9;M-)M/L\S3K"-R>;(4\R6.1(T?;EOT
M#\'_ /!1C]BO]MSX=_%'P=^R=\>]+\=W7A?P3<W&O3Z%;SO:VJSP3K$OVAHQ
M$[L8W.Q&9@!E@ 1GR/\ X(5HB_\ ! ?X2*J  _#;5"0!ZW5Z30!]6_LC_M-?
M#W]LS]F?P3^U+\*A<IH/CGP_!JEA!>J!/;;QAX)0I(\R.0/&V"1N0X)&#7(_
MM_?LH?L4?M1?!5KW]O;P9::UX"^'SS^*KU-3U:[M;.T%M:RF2YN!;2H9HXX3
M*Q1]R\9VD@8\4_X-P"3_ ,$3/@'D_P#,O7__ *=KVO;?VU/V_OV-_P!AG3O#
M\'[9OQ%B\+Z)XWDN["PU#4=#NKO3Y7C1#)!</#%(L6])>/- 1@K#.>" ?F?^
MS;X<_8(U'_@L/\%-8_X($72Q:#8Z;K$G[3;>";B^7PN=$-N%T]+D7!\E[IK@
MOY2P@L&"LP&W</IC_@OU_P $X/V:?VD/V2/B]^UW\88?%.J>(_A]\#-9;PII
M47C"]MM(M+JSM[R[@O&LH)$CFG$LO+2;E98XU92%P? _BG\</V.?V[O^"L'[
M+^L?\$@=(L=;\5_#_P 8W&H?&/XE> /#$MCIECX3,&V;3[Z[$,<=R9QN2)"7
MVL2!@R8/T9_P7Y_X*(_L;?LV?L3_ !9_92^-GQJ@T/X@?$GX+:_%X)\.R:/?
M3-J;SVMQ:Q 2PP/%'NF^3]XZXZG YH ]W_X)+?\ **[]FK_L@7@__P!,MI7T
M%7PG_P $&_\ @HC^QM^T]^Q3\)OV8?@5\:H-?\=?#+X'^%[3QSH$>CWT#:7-
M!I]M:RJ99X$BEVSHR9C=P<9&1S7T5^RS^V_\&_VO_&/Q4\$_":QUU+GX/_$&
MZ\&^*I]5T](8)=3M_P#6BV=9'\U!QR0IY&5&: .J_:2_9_\ !'[4WP1U_P#9
M_P#B3J.LVN@^)K>.WU:3P_JTEC=O"LJ2-&D\?SQA]FQBI!*.P!&<C\H_^"TO
M_!,_]@/_ ()N_LB>'OCC_P $^/A=-\+_ -H>R\>:'IGP1O/!6N7KZKKVJ3WT
M*2V+I+,YO4:V,[,)-W**I)#E'_47]L_]K+X9?L,?LN>,_P!K+XQ1W\OAWP5I
M/VR^M]+M_-N+EVD2&&&-20-TDTD<8+$*N_+$*"1^/?[#_P#P5]_X);_%S]H,
M?\%./^"HO[;>A-\5A%-;?"WX6VOA;7+S2OA7I4AP8XG2Q,=QJ4JX,]V,]=J$
M* % /L#_ (+9>)?B#\8?&_[*W_!-"Y\4WV@:;^T/\1)XOBC+X=OY+>:\T+2;
M2.ZU#38YE(9(YS,JE@<D( <JS*?._P!K']E3X$?\$:OVVOV5_P!I/]A'P,GP
M\\/?$SXNV/PG^*7A#1;V?^S=?M=4C<65S-"[LOGVTD4D@E&&8XW$\Y]"_P""
MUT.K^"O&/[*G_!5GP3X:U/Q)X2^!7Q"FO_&ZZ)I\D]S;>%]:M(H+O4UA WNL
M*1QLR@;@'R<*K$>>?M7?M6? C_@LQ^VU^RO^S?\ L(>-U^(7AWX9?%RQ^*_Q
M3\8:-8SC3-!M=+C<V5M--(BCS[F262,1#+*<;@!G !];?M ?\$:_^">O[6?[
M0&J?M*?M2_!.7X@^(M1L[>TM;?Q-K]Y)I^EP10K%LM;1)4ACW[=[,59RY)##
M.*^;?^"$.BZ9\,OVP/VO_P!G?]ESQ-JNJ?LS> _'&C6'PRCOM4EO;/2=::S=
M]:T^PGE9F:&*<HI7<0N(FR3(SOQ'_!;_ /X+.?#OP/\ M*V__!*'2?VF&^"5
MKJ&GPW/QH^,TNE7EQ=:+I4\*2KIND1VL,KM?7$,B_P"D%1' K\,7SY?U1_P2
M*_:O_P""3'Q$^%"_LF?\$K_B5IVJZ%\-M)@>]TNQT'4;1XDF=A]IFEO+>+[1
M-+(KL[Y9F8DG&10!YQ\>?^"#G_!%7X9? 3Q[\5/VB/A-+B'2[W6?%GQ8\3>,
M+^?6K5U5I&O4N6FQ'*AP42- C%57RVSM/??\&^_C7]HWXB?\$B/@[XP_:DU3
M5;_Q->:1=&TU+7F9KZ]TH7LZZ=/.S$EV:T$!5R2738Q)+$G\Z?C=_P %H_\
M@G1_P4Z_:^OO!W[;_P"U/%\/OV8OA;X@5M'^&5QH&JSWGQ2U:!\K?:I]DMI%
MBTR)U!CM&8/(P#2*/NI^RW[(_P"U3^S9^V3\$-.^-O[)?CNU\1>")YIK'3-1
MLM+N+.(-;MY3Q+%<11.H0KM'R <<<4 7_P!I;XA?&OX7_"*_\6_L\?  _$[Q
M;'<6\.E^$#XGM]&2Y\R54>22\N%9(8XT+2-\K,0FU59B!7R[X?\ ^"EW[9/P
M._:$^'7P;_X*-?L,Z)\/O#_Q:\2IX:\%_$'P/\25UZQAUV6-Y+;3;V)[6"6%
MYA&ZI*NY2PQC&YEJ_P#!P1\6/BY\(/V.?"&M>"O'GB_PCX'U#XR>'M.^.7C/
MP&94U70?!4KS?VA=02PJ9(/F%NAE0%@)-N"&(K\X_P!KJQ_X)%P_M)?LDW7_
M  3(NO$OC?5XOVM/ A\:_$9/B!XDUS2M/C>])ALII-1NY+47MPRM*JQKYJ)9
MRYV*X# 'Z:_M;_\ !5CXI? C_@H1I/\ P3A^!W[%NH?$SQEXG^$*^,O#=];>
M,8M.MA/_ &E/:/;WIEMV6TMHX;:6=KK>[%O+A2!GD4UK?L4_\%&?C7\6_P!K
M/Q?^P/\ MG_LMVOPK^*WAOP?!XNTB'1/%RZUI7B+0)+G[*UY;S^3$R&.X*Q-
M&ZYSDY&"!YU>(C?\'25F64$K^P7(5)'0_P#"9X_K3_$7'_!SWX<([_L0WN?_
M  JUH N:9_P54_;!_:-^*WC^#_@GG_P3[LOB;\-OAAXHN?#FN>-_$'Q,AT*3
MQ#JMKC[9;:1 ]M*LHB)"B:5TBD9@ RCFN1_X-KOB1IWQC^#7[4/Q=T?1=2TV
MT\5?MJ^.=8M=.UFU\B\M8[F+39EBGCR?+E4.%=<G:P(SQ7FW_!*K]O7]ES_@
MD_\ "+XA?\$\OV^OB./AWX_^'7Q.U^\TZVUK3+EG\8:3?7LEU9:CIWEQL;WS
MA(4$<>Z3* %<G%>B?\&S_C#4OB%\"_VF_'VL^";[PS>:Y^VAXWU"[\-ZI!Y5
MSI4DT.FR-:3)_!)$6,;+V9"* /M?]K;]DWX2_ML?!:\_9]^.9UJ3PMJ=[;3Z
MM8Z'KD^G27T<,HD^SR30,L@A<J ZJREEXR*_,#_@J-^P'^QY_P $V_'O[-_C
MK_@F!\.?^%:_'_7OC5I&B>%-&\'ZO=EO$NCLQ.I0WT$DKB:T2/RS+*X^4. S
M;6./T3_X*4?M]?#+_@F?^R!XG_:W^*>AW^K6NB+%;Z9HNFC$NI7\[^7;V^\@
MK$K.1ND8$(@8@,<(WY@_\$V?^"J/_!*$?&:?]O\ _P""@'[?V@^*_P!I3QW;
MI8:;IEGX-UU]*^'>ERMB+0M*#6153\^)[D$F1F<!V#223 'TW_P5KM+G]L7_
M (*-_LR_\$I?%FM:A;_##QC:Z[XU^+FDZ=J$MLWB&RTV#-EITKQ,K_9WN%?S
M4##<"C##1J:Y7Q7\ ?A5_P $A?\ @L/^SC9_L9^&O^$+^&G[2%OKWA3XC?#_
M $N[E_LMM2L;2.YT[4H8'9EBN"[B)F7 \M6XS(Y/5?\ !6RZNOV.O^"C/[,W
M_!5OQ7H>HW/PP\&VNN^"_B[JVFZ?+<MX>L=2@Q9:C*D2L_V=+AG\UPIV@(HR
MTBBN4\4?'_X5_P#!7W_@L-^SEJ'[&7B,^,_AG^S?;Z_XK^(WQ TVSF&EKJ=]
M:1VVG:;#/(JK+<!T$K*N1Y;-SF-P #Z0^+__  1"_P""9WQ_^,_BW]HO]I7X
M"'Q_XG\5R^9?:AXO\1WTT.GPK$L8@M(5F2*UC4)D%%#Y));ICQ3_ (-R=0U6
MW\ _'[X>_#'QMK/B/X!^$/CEJ6C_  "U?6M0DNQ_942@3P6D\A+364<FP1/D
MJ2TA!SNKPG_@K]_P61_9Y^+7[86J_P#!)[QY^U5/\$/A3X?"I\>OB#'I5_-J
MOB%65';P[I2VEO,T"2(X6>ZD"@J75=R@K/\ H#_P3%_:[_X)M?M&?!=_A9_P
M3+\<Z3J7@OX86UII3Z5HV@WUA#I:2+(T*8O((FD9_+E9G&YF;<SL6;) /@K]
MJK_@G!^S3^Q%_P %C_V(_B/\'H?%-]XF\>_$WQ0WBGQ#XM\87NJW-XL6G))%
M&!/(8XD1IY<"-%^]@Y &/V+K\4_^"IO_  6/_P"";/B;_@J#^R3XGT/]INUG
ML?@A\3/%2?%*<>'-47^PBUG%:J&#6H,^9HI$_<B3[N>A!/ZY_LV?M)_!/]KW
MX*:'^T5^SIXYC\2^#/$B3MHNMQ64]NMR(;B2WD(CN(XY%VRPR+\RC.W(R""0
M#N:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@".[M+6_M9+*^MHYH94*2PRH&5U(P00>"#Z5'I>E:7HEC'I>BZ;;VEM$#
MY5O:PK'&F3DX50 .23^-6** "F75K;7MM)9WMO'-#*A26*5 RNI&""#P01VI
M]% %71]#T7P]9#3= TBUL;96++;V=NL2 GJ=J@"K5%% !45_86.J6<FG:G90
MW-O,A6:">,.CJ>Q4\$?6I:* *NCZ%HGAVR&F^']'M;&V#%A;V=NL2 GJ=J@#
M-6J** "O.OV8_P!EKX/_ +(WP_O_ (=?!K1KBWM-6\3ZGXBUJ[OKDSW6HZG?
MW+W%S<SRGF1V9]H)Z(B*.%%>BT4 %%%% !531] T+P[;O:>']%M+&)Y#(\5G
M;+$K.>K$* ">!S[5;HH **** "BBB@!LL44\303QJZ.I5T<9# ]01W%5](T3
M1?#]D--T#2+6QME8LMO9VZQ(">IVJ .:M44 %%%% %2]T'0]2OK;5-1T:TN+
MFS8FSN)K=7D@)ZE&(RN<#IZ5;HHH **** &RQ13Q-!/&KHZE71UR&!Z@CN*@
MTC1=&\/V*Z9H.DVUE;*25M[2!8D!)R2%4 <U9HH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **\2_8(U34]7^#6J
MW.K:C/=2+XWUA%DN)F=@HN2 N6)X Z#M7MM !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% 'A?_  3W_P"2)ZM_V/>L_P#I2:]TKPO_ ()[_P#)$]6_['O6?_2DU[I0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!X7_ ,$]_P#DB>K?]CWK/_I2:]TKPO\
MX)[_ /)$]6_['O6?_2DU[I0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X7_P3W_Y
M(GJW_8]ZS_Z4FO=*\+_X)[_\D3U;_L>]9_\ 2DU[I0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!X7_P3W_Y(GJW_ &/>L_\ I2:]TKPO_@GO_P D3U;_ +'O6?\
MTI->Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 >%_\ !/?_ )(GJW_8]ZS_ .E)
MKW2O"_\ @GO_ ,D3U;_L>]9_]*37NE !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '
MA?\ P3W_ .2)ZM_V/>L_^E)KW2O"_P#@GO\ \D3U;_L>]9_]*37NE !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% 'A?_!/?_DB>K?]CWK/_I2:]TKPO_@GO_R1/5O^
MQ[UG_P!*37NE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4452UWQ)X=\+VD5_XFUZRTZ">]M[.":_NDA22XGE6&"%2Y ,D
MDKI&B#EG=5 )(% %VBBB@ HHJGIOB+P_K-U=6.CZ[9W<]E)Y=[#;722/;OS\
MKA22AX/!QTH N45'=W=K86LE[?7,<,,*%Y9I7"JB@9+$G@ #N:CTK5])U[3X
M]6T/5+>]M9@3%<VDZR1N <'#*2#R"/PH L4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?\P_XAUX@_\ 0GQ7_A/5_P#D#Z=HKYB_X?)?\$W?^CC?_+0UC_Y$H_X?)?\
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M"_\ @GO_ ,D3U;_L>]9_]*37NE>%_P#!/?\ Y(GJW_8]ZS_Z4FO=* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *_/G_@X=_Y-X\"?]CH__I)+7Z#5^?/_  <.
M_P#)O'@3_L='_P#226O!XF_Y$5?T7YH_5/!+_DZF5_XW_P"D3/R1HHHK\1/]
M/ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3?\ !+3X@_$/]J&ZDUO4? OBK28OAQXOU6!?MD\EQ.L=Y9B; :9%B.\@DG+
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MG@E_R=3*_P#&_P#TB9^2-%%%?B)_IX%%%% !1110 4444 %%%% &]\-/B?\
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M'EB2223R2:BHHKEW/=2459;!1110,**** "BBB@ K[1_X(.?\GU'_L2]1_\
M0X*^+J^T?^"#G_)]1_[$O4?_ $."O7R#_D=8?_$C\]\6?^3:YM_UXG^1^T=%
M%%?NI_EB%%%% !1110 4444 %%%% !1110 4444 >%_\$]_^2)ZM_P!CWK/_
M *4FO=*\+_X)[_\ )$]6_P"Q[UG_ -*37NE !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %?GS_ ,'#O_)O'@3_ +'1_P#TDEK]!J_/G_@X=_Y-X\"?]CH__I)+
M7@\3?\B*OZ+\T?JG@E_R=3*_\;_](F?DC1117XB?Z>!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7VC_P0<_Y/J/_
M &)>H_\ H<%?%U?:/_!!S_D^H_\ 8EZC_P"AP5Z^0?\ (ZP_^)'Y[XL_\FUS
M;_KQ/\C]HZ***_=3_+$**** "BBB@ HHHH **** "BBB@ HHHH \+_X)[_\
M)$]6_P"Q[UG_ -*37NE>%_\ !/?_ )(GJW_8]ZS_ .E)KW2@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "OE__ (*D_"?P!\6_A;X;TCX@Z!_:%O:Z^TT$?VJ6
M+:_D.N<Q.I/!/!XKZ@KP+_@H%_R3_0O^PRW_ **:O+SJ,9Y754E=6_5'V/A_
M7K8;C'!U:,G&2D[--IKW7LUJ?G]_PQ;^S/\ ]$U_\K-[_P#'J/\ ABW]F?\
MZ)K_ .5F]_\ CU>I45^:?5L-_(ON1_7?^L.?_P#075_\&3_S/+?^&+?V9_\
MHFO_ )6;W_X]1_PQ;^S/_P!$U_\ *S>__'J]2HH^K8;^1?<@_P!8<_\ ^@NK
M_P"#)_YGEO\ PQ;^S/\ ]$U_\K-[_P#'J/\ ABW]F?\ Z)K_ .5F]_\ CU>I
M44?5L-_(ON0?ZPY__P!!=7_P9/\ S/+?^&+?V9_^B:_^5F]_^/4?\,6_LS_]
M$U_\K-[_ /'J]2HH^K8;^1?<@_UAS_\ Z"ZO_@R?^9Y;_P ,6_LS_P#1-?\
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M2HH^K8;^1?<@_P!8<_\ ^@NK_P"#)_YGEO\ PQ;^S/\ ]$U_\K-[_P#'J/\
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M_P"O<OR/LBBBBOTH_DX**** "BBB@ HHHH **** "BBB@ HHHH \+_X)[_\
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M[;QS0RH4EBE0,KJ1@J0>"".U1Z7I6EZ)8QZ7HNFV]I;1 ^5;VL*QQIDY.%4
M#DD_C0!^6G_!1?Q1_P &^.A?MC>.O$7[3'[3/BCX3?&;2M/M+/XA+\/O$7B'
M0;[Q':O:0S6\4RZ>@CU$&&6-0T6Y_P"!F_=X7K?^#>K]DN#X _#[XW?MA0?
M6]^%OACXR>,8+WX>?#_4+9XK[3O">EV\D.FRW22,76YG66:5PY9F+"0NQDS7
MZ,ZAX<\/:M?6^IZKH-E<W-FVZTN+BU1Y(#G.48C*G('2KM 'P3^U3XH\'?\
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M\;_]!NR_\!C_ (UY'_P3W_Y(GJW_ &/>L_\ I2:]TH Q_L7C?_H-V7_@,?\
M&OQK_P""Z,>I1?MPA=5N8Y9?^$-T_P">)-HQOG[5^UE?BY_P7C_Y/J'_ &)>
MG?\ H<]?(<;?\B7_ +>7ZG]#?1D_Y.4_^O%3\X'Q=1117Y$?Z%!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7ZO\
M_!OO;^()OV?O')T?4((4'C)-XEB+$G[)%7Y05^MW_!O%_P F\>._^QT3_P!)
M(J^IX-_Y'L/27Y'X7](W_DU>)_QTO_2T?=WV+QO_ -!NR_\  8_XT?8O&_\
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MX[_['1/_ $DBKZG@W_D>P])?D?A?TC?^35XG_'2_]+1^@U%%%?L9_G&%%%%
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MR&%!+$59Q,FX+EX5/(!H _0NBBB@#PO_ ()[_P#)$]6_['O6?_2DU[I7A?\
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M%?>W_#%O[,__ $37_P K-[_\>H_X8M_9G_Z)K_Y6;W_X]1_9.)[K\?\ (/\
MB)^0?\^JO_@,/_DSX)K];O\ @WB_Y-X\=_\ 8Z)_Z215X/\ \,6_LS_]$U_\
MK-[_ /'J^WO^"6WPG\ ?"3X6^)-(^'V@?V?;W6OK-/']JEEW/Y"+G,KL1P!P
M.*^DX4P%;#YS"<FK6EW[>A^/^.G'&4YYX=5\)0A-2<Z;]Y12TFGTDW^!]044
M45^JG\*A1110 5X%_P % O\ DG^A?]AEO_135[[7@7_!0+_DG^A?]AEO_135
MYF<?\BVIZ?JCZS@;_DK,)_B?_I+/E"BBBOSH_J@**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]D_88_Y+A_W!KC^:
M5XW7LG[#'_)</^X-<?S2N[+/^1A2_P 2/G.+_P#DE\7_ ->Y?D?9%%%%?I1_
M)P4444 %%%% !1110 5Y=^UVG[:DGPH1?V"[GX71>.?[5A\QOB[#J4FD_8=K
M^;@:<RS>=N\O;SMQNSVKU&O"_P#@H3X#^%7Q'^ \'ACXP?MO^+O@!I<GB*U:
M'QSX)^(EKX8OI;C;*$L1>72.C+)EB8@-S&-2/NF@#P3[-_P<X_\ 09_80_\
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MO_135YF<?\BVIZ?JCZS@;_DK,)_B?_I+/E"BBBOSH_J@**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]D_88_Y+A_W
M!KC^:5XW7LG[#'_)</\ N#7'\TKNRS_D84O\2/G.+_\ DE\7_P!>Y?D?9%%%
M%?I1_)P4444 %%%% !1110 5R7QE^ OP1_:*\*P^!?CY\)/#GC/1;?48K^WT
MKQ/H\-];QW46[RYUCF5E$B[FPV,C<<=:ZVB@#\U_^"AOQ]_X(J^$?VNM>^'/
MQ<_X)I3_ +0WQH2QL[WQU;_#KX!6_BK5=-A:WC2T;4)W50I-ND012[,(PF0
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M&M_YO7@\1?\ (O\ ^WE^I^C^%O\ R4__ '#E^<3QNBBBOA3^C0HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KZO_X)
M^_\ )/\ 7?\ L,K_ .BEKY0KZO\ ^"?O_)/]=_[#*_\ HI:]G(/^1E'T?Y'P
M7B7_ ,DG5_Q0_P#2D>^T445]^?S0%%%% !7@7_!0+_DG^A?]AEO_ $4U>^U\
MW?\ !2S4;S3?AIX>ELIMC-KK G:#QY+^M']EXC._]AH-*<]$Y72[ZV3?3L>C
ME&?8/AC,J>:8J,I4Z3NU%)R=TUHFXKKU:/F2BN/_ .$IU[_G^_\ (2_X4?\
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M7'845Q__  E.O?\ /]_Y"7_"C_A*=>_Y_O\ R$O^%'_$'N)O^?U'_P "G_\
M*P_XF.X'_P"@?$_^ 4O_ )<=A17'_P#"4Z]_S_?^0E_PH_X2G7O^?[_R$O\
MA1_Q![B;_G]1_P# I_\ RL/^)CN!_P#H'Q/_ (!2_P#EQV%%<?\ \)3KW_/]
M_P"0E_PH_P"$IU[_ )_O_(2_X4?\0>XF_P"?U'_P*?\ \K#_ (F.X'_Z!\3_
M . 4O_EQV%%<?_PE.O?\_P!_Y"7_  H_X2G7O^?[_P A+_A1_P 0>XF_Y_4?
M_ I__*P_XF.X'_Z!\3_X!2_^7'845Q__  E.O?\ /]_Y"7_"C_A*=>_Y_O\
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M^>P3P5>%'VNC6E[23:OM=)MKY^AQ=%26EI<W]U%8V5N\LTTBQPQ1KEG8G 4
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MAZ][AC_D?4/5_DSQ.(_^1)6]%^:/BNBBBOW(_&@HHHH **** "BBB@ HHHH
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M&K[P7XZ\,:=K6CZG;-;ZEI.K64=S;7<+##1RQ2 I(A'!5@0: /A+PS_P;?\
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MT/7_ )3+7_XU1_9.)[K\?\@_M;#=G^'^9]@45\?_ /#4GQV_Z'K_ ,IEK_\
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M$\;HHHKX4_HT**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_DN'_<&M_P";UX/$7_(O_P"WE^I^C^%O_)3_ /<.7YQ/&Z***^%/Z-"BBB@
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M/^AIB?\ P?5_^2-#_A*=>_Y_O_(2_P"%'_"4Z]_S_?\ D)?\*SZ*/]5^&?\
MH!H_^"H?_(A_KWQQ_P!#3$_^#ZO_ ,D:'_"4Z]_S_?\ D)?\*/\ A*=>_P"?
M[_R$O^%9]%'^J_#/_0#1_P#!4/\ Y$/]>^./^AIB?_!]7_Y(T/\ A*=>_P"?
M[_R$O^%'_"4Z]_S_ '_D)?\ "L^BC_5?AG_H!H_^"H?_ "(?Z]\<?]#3$_\
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M0_\ )\Y_[$S4/_0X*^>XL_Y)K%_X)'O<+_\ )187_&C]GJ***_EP_I8****
M"BBB@ HHHH **** "BBB@ HHHH \+_X)[_\ )$]6_P"Q[UG_ -*37NE>%_\
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M (5^:/R6HHHK^FS^<0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*** "BBB@#PO_@GO_P D3U;_ +'O6?\ TI->Z5X7_P $]_\ DB>K?]CWK/\
MZ4FO=* "OQA_X+O?\GSC_L3-/_\ 0YZ_9ZOQA_X+O?\ )\X_[$S3_P#T.>OT
M+PS_ .2D_P"W)?FCX/Q&_P"2=_[?C^I\8T445_01^#A1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7ZT_\&]/_ ";U
MX[_['-/_ $DBK\EJ_6G_ (-Z?^3>O'?_ &.:?^DD5?#>(O\ R2U3_%#_ -*1
M]IX?_P#)34_\,OR9^@=%%%?SH?T %%%% !7Y^?\ !PM_R;UX$_['-_\ TDEK
M] Z_/S_@X6_Y-Z\"?]CF_P#Z22U]3P5_R5.%_P 3_P#26?,\8_\ ),XG_"OS
M1^2U%%%?TV?SB%%%% !1110 4444 %.@C$TR0M*J!F +OT7)ZGVIM/MH?M-Q
M';B5$\QPN^1L*N3C)/84/8%N?H/\:? '[/\ ^Q5X$^(?PF;]D5_%&AZ4GADW
M7BGQ%XAU"#_A+6G620W$#V[I'"D;,RJ(L\@[R>@^-O!'Q\O/@O\ '&Z^,WP$
M\+V>AF.:Z/A[3]71=4&E1RAE0!IEQ+)&K?+(Z]0"17VS^S5X&_X*B?!OX->)
M_"/AS7+?6M.M;O2(_##ZGXDT_5= >P\V;[2%DEE>..W,>PL,HP7[H#5XA\5/
MV;? '[7'_!337/@A^R)>Z)8^'=3U%7%_8$'3[01VL;WTMNJXWQB43;%3"L2
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M3_TDBK\EJ_6G_@WI_P"3>O'?_8YI_P"DD5?#>(O_ "2U3_%#_P!*1]IX?_\
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MB@ HHHH **** "BBB@ K[._X(0_\GSG_ +$S4/\ T."OC&OL[_@A#_R?.?\
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M)]4KM:\O8\_,K4<#A\/*2<X\[=FI))O173:Z-V3TN%%%%>X>,%%%% !1110
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M +'-_P#TDEK] Z_/S_@X6_Y-Z\"?]CF__I)+7U/!7_)4X7_$_P#TEGS/&/\
MR3.)_P *_-'Y+4445_39_.(4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5]G?\$(?^3YS_ -B9J'_H<%?&-?9W_!"'
M_D^<_P#8F:A_Z'!7SW%G_)-8O_!(][A?_DHL+_C1^SU%%%?RX?TL%%%% !11
M10 4444 %%%% !1110 4444 >%_\$]_^2)ZM_P!CWK/_ *4FO=*\+_X)[_\
M)$]6_P"Q[UG_ -*37NE !7XP_P#!=[_D^<?]B9I__H<]?L]7XP_\%WO^3YQ_
MV)FG_P#H<]?H7AG_ ,E)_P!N2_-'P?B-_P D[_V_']3XQHHHK^@C\'"BBB@
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M?DM1117]-G\XA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7V=_P $(?\ D^<_]B9J'_H<%?&-?9W_  0A_P"3YS_V
M)FH?^AP5\]Q9_P DUB_\$CWN%_\ DHL+_C1^SU%%%?RX?TL%%%% !1110 44
M44 %%%% !1110 4444 >%_\ !/?_ )(GJW_8]ZS_ .E)KW2O"_\ @GO_ ,D3
MU;_L>]9_]*37NE !7XP_\%WO^3YQ_P!B9I__ *'/7[/5^,/_  7>_P"3YQ_V
M)FG_ /H<]?H7AG_R4G_;DOS1\'XC?\D[_P!OQ_4^,:***_H(_!PHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K]:?^
M#>G_ )-Z\=_]CFG_ *215^2U?K3_ ,&]/_)O7CO_ +'-/_22*OAO$7_DEJG^
M*'_I2/M/#_\ Y*:G_AE^3/T#HHHK^=#^@ HHHH *_/S_ (.%O^3>O G_ &.;
M_P#I)+7Z!U^?G_!PM_R;UX$_['-__226OJ>"O^2IPO\ B?\ Z2SYGC'_ ))G
M$_X5^:/R6HHHK^FS^<0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ K[._X(0_\GSG_ +$S4/\ T."OC&OL[_@A#_R?
M.?\ L3-0_P#0X*^>XL_Y)K%_X)'O<+_\E%A?\:/V>HHHK^7#^E@HHHH ****
M "BBB@ HHHH **** "BBB@#PO_@GO_R1/5O^Q[UG_P!*37NE>%_\$]_^2)ZM
M_P!CWK/_ *4FO=* "OQA_P""[W_)\X_[$S3_ /T.>OV>K\8?^"[W_)\X_P"Q
M,T__ -#GK]"\,_\ DI/^W)?FCX/Q&_Y)W_M^/ZGQC1117]!'X.%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?K3_P
M;T_\F]>._P#L<T_])(J_):OUI_X-Z?\ DWKQW_V.:?\ I)%7PWB+_P DM4_Q
M0_\ 2D?:>'__ "4U/_#+\F?H'1117\Z'] !1110 5^?G_!PM_P F]>!/^QS?
M_P!)):_0.OS\_P"#A;_DWKP)_P!CF_\ Z22U]3P5_P E3A?\3_\ 26?,\8_\
MDSB?\*_-'Y+4445_39_.(4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5]G?\$(?^3YS_V)FH?^AP5\8U]G?\$(?^3Y
MS_V)FH?^AP5\]Q9_R36+_P $CWN%_P#DHL+_ (T?L]1117\N']+!1110 444
M4 %%%% !1110 4444 %%%% 'A?\ P3W_ .2)ZM_V/>L_^E)KW2O"_P#@GO\
M\D3U;_L>]9_]*37NE !7XP_\%WO^3YQ_V)FG_P#H<]?L]7XP_P#!=[_D^<?]
MB9I__H<]?H7AG_R4G_;DOS1\'XC?\D[_ -OQ_4^,:***_H(_!PHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K]:?\
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MPQ^PK\0M-^#OQ_\ BK?Q^--8TM=2TOP=X;\*:CK&I7%HTDD8G\JR@DV(6BD
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M>YL[R4&*"]B947,N%*1*!U=7^]** /QU_;7_ &I_VL?^"L'QQ\*?\$7?B_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=@)*.)I2IM[<T7&_I=(Z\+CL%CHN6&JQFEORR4K?<V%%%%<AU!1110 4444
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MRHC,?I0!^7__  6/_P""GG[>'P6_:VO_  A^P3KUN?"7[-_P_L/B#^T5I?\
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MZ19V"Z_X>:9[*ZMQ':0PQ&6UNH'R F]ED<G*QAC]'_\ !.S]JSX^?'7]O/\
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MRK0>5J[ZO#;M<_:!$+ALQ.R^69#'SD+GFC_@KW^UG^T#^R[X\_90T;X%>/\
M^P[;XE_M3^&?"'C:/^RK2Z_M+1;MW%Q:YN(I##O '[R(I(N/E<5YE9:G8?#/
M_@Z=OQXVNDT^/XB_LA1VOA":X8*FI7=MKB236T1/WI5B@EE*#D(N>A&3_@NI
MJ=AXO_:L_8.^!GAZZ2Z\477[5^B>)X](A8-/_9>EAI;RY*#D1QHX);IP?0T
M?3G[27_!4O\ 82_9(^*-Y\$/C[\=4T3QA9^%;?Q$GAM- U"ZNKRQGNVM(?LH
M@MW%U.\Z.HMXB\V$9R@12XT/V,O^"C?[(_[?"^([/]G#XB75[J_@ZZBM_%GA
MG7=!O-)U327E#&(S6EY%'*JN%;:X!4[2,Y! ^7[7P5X5\1_\'35[XEUW0[:[
MO?#_ .Q9;W.BW$\09K.>3Q++ \L>?NN8I)8]PYVRN.C&M+0+.UT/_@Z'U^#2
M+=+=-;_8<M;_ %985V_:[J+Q;]GCFDQ]YUA41@GD* .E %3Q%^W'X._9+_X)
MU_M8_M(^ OVU_$?Q7UKPK\3/'%IH&H:_X*U.9/"?B2.W!M?#:PM&Y>QM)Q&O
MVGY;7;(Q+JH+#U;_ ();?\%3?@K^WI\'O 7ARV\7:S??%";X5:7KWCJVE^&^
MM:58)>&WM%O3!=W5G':3*+FXPBPS2;E.Y-R*6'QO^S'!-<_\$?/^"G\%O$SN
MWQE^.85%&23_ &7T KZ0\)W?Q#NO^#:71+GX'S7$OB?_ (8ILAH#:8Q,_P!K
M'A2,*(=O/G!@0H'.\ =: .E\8_\ !?+_ ();^"?&>I^%=0^/^HWMAH6J_P!F
MZ_XST/P/J]_X>TR[W!/*FU2WM7M1ABH+B0HN[EA@X^@OCI^UQ^S7^S7^S_=?
MM3_&OXR:+HGP^M;""\_X2AKGS[>XAF"F V_DAVN3+N7RUB#L^X;0<U^:W_!,
M3X1?\%/_ (N?\$I/A?X)_9P^-G[)5Q\)M=^&4&G#1-1^&FM7,QCEMS'?6U\T
M6I+')=^<TZW!"J&F,AV@'%8'Q]_9;\0_L3_!W_@FQ^RK^U'\4=+\9^"? _Q_
M;3O%/B*-&72I]0 O&T&.02D@+%N,(#\#RF[4 =_^W;_P66^$/QUF_9P\)_L9
M?'KQ=X9\1ZI^UOX!T_Q7X<U30=3\.ZCJGAJ]FNXYLP7D,+7=C*RQJ[)O3.P/
M@LH/ZGU^:'_!PT?A)_PMO]A<:Q]@_P"$Z_X;,\(_\(]NV_:O[*^TC[?M[^5Y
MW]G;L<;O*K]+Z /S5E^,'[=?_!2O_@H]\>OV5_@?^V_)\ / /[/UQI.F2V7A
MCPG8:CK_ (GO+RW>9[R66^5Q;6R,K(@C7#@J3SR/I;X"^&?VDOV%OAK\0/'G
M[=O[=5_\8_"&DVMO?Z%K#?"^.TU;1[:-91<Q2PZ1&[:@6S"49(O,X<;3P3QG
M[7O_  1U_P"">G_!0?XO7G[0&H7NN^&/BAIA&E:I\1?A'XV?2M8B>)%58+EH
MB\32H@C ,L9D"JBYVA0/'?\ @D[\3?VEO@7_ ,%+_CO_ ,$J_B9^U;X@^.7@
MKX=^$=)\1>%O&OC*X6ZUO19+DQA]*O;I>9Y"LH<%SG$.0$#E% -C_@B3_P %
ML? _[=/[.GPW\(_M!^-M1N/CAXIN=934;/2OA?K5MI3"WO;UH=M\MH;!/]"@
MC)_TC[^4.)#LKT[XF_\ !=__ ()L_"7QAKOA3Q7\3?%LEOX5UBXTOQ5XDTSX
M6:_=Z/I%W;S-#/%->Q630_NY%969&900>>*X/_@U]=$_X(D_"2Q9AYUIJ7BF
M*ZBS\T4@\2:FVQAV.&!QZ$>M>>_LW_M#?\%'_P#@IU^R3J_[>OA_]MOX2_L^
M_!S4I]=_LWPG>_!U/$UQ::+8W-S;32ZO<7>H01I*RP2.Z)&$V,IP-Q% 'L__
M  64_P""H.G_ +&G_!+O5?VO_P!F?XB:;?ZYXCM=-;X7:U;:'-J^F:@9[B"1
MI'>%&BCB:T,S+),Z(6VJ&+LJGV3]D_\ X*+?LL?M?^']8U'X2^.]8E/A72+>
M]\477B3P'K.@6]I'(CDR"75+2W211Y4A8QLP0+EL @G\C?".JZIXD_X,B=;\
MV[EO!:V=Y#;.R$$6\?CK*C&3M54& ,G:J@=!7WW_ ,%[;OXB7?\ P09^,5[\
M&9KB:_F\ :8\LNG,6+Z4U[9'4&RO6,V)N2QZ;-W:@#HM(_X+]?\ !+#6_%UK
MX>M?VA;Z/2+_ %@:38^/+OP1J\'AFXO2Y3REU>2U%IC<"/,,@B.,AR.:]D_;
M!_X*!_LI?L)Z5H%[^T=\2)=.O?%EY):^$] T?1;O5=4UJ:-5:1;:SLXI9I @
M92SA=B[URP+*#\21?LD_\%3_ -L'_@G?;?L[>$_VA/V0[KX->.?AE#I.B#0_
MACK82'29;15MY;9CJ3(DL2['C?:=DD:MC*XKT'XF?\$POVI;[PY^S1\:?V:/
MVP/"MA\=OV?OA;'X8EU3Q3H+ZGH7BZTGL;>VN))D603VXD>W9UGC)8AV'H0
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M:A\9=$T'0Y-<.I7OPVTG0&T&QLK>>:[VIIRJ+@R(%/S\J8@%^\:^7/V5=/\
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M/(>'<\X=HSIYGAY492=TI*UTM+H****^5/>"BBB@#\0/^"%7_!/C]I;]J?\
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M\'6%PGP\^+_QGAM_A]J$]NT2ZO::5'<0/?Q*P!,<K3KAL?>1U/S(P'J>@_\
M!N=_P1GT#4[/5/\ AC&#4S8,IM+7Q)XZU_5K5-O0?9[V_EB(QQ@H1CBOLGPA
MX/\ "7P^\+V'@CP%X7T[1-%TJU2VTO2-(LH[:ULX$&%BBBC 2- . J@ "@#\
MP?#'[-?P-7_@[4USQ.OPWTX7D/[*_P#PF\3",[$\0OJ]OI3ZD$SM$[63-$6Q
MSN+'YSNK]3Z\YMOV3/V?K/\ :MN/VWK;P!M^*%UX%'@ZX\3_ -JW9W:(+M;L
M6OV8R_9Q^_17\P1^9QC?MR*]&H ^:_VK?^'P?_"TE_X8=_X9K_X0G^S(=W_"
MU_\ A(/[5^V[G\W']G_N?)QY>W^+.[/:OH?PU_PD?_".:?\ \)C]A_M?[#%_
M:O\ 9F_[-]IV#S?*W_-Y>_=MW<XQGFKM% 'YP_#/4['X<?\ !T-\3-#\9W2:
M?-\1/V8])NO!_P!J8(-3^R7R1SQPD_?D7RI7*#G;$[8P":/^"SVJ6'C+_@HC
M^P-\#O#5TEYXG/QWD\3R:3;L'FBTNPM@]Q<NHY6,+OPQP#Y;XSM;'UG^V7_P
M3O\ V/OV_-%T?2OVI?@_!KUSX<N6N/#6N6>HW.GZGI$K;=S6UY:21SQ E4)0
M/L8HI93M&.=_9"_X)/\ ["W[#_C[4/B[\"?A#<?\)IJMG]CO?&GBGQ'?:WJI
MML@^0EQ?32M#&<+E8]H;:-V<"@#Y[^&G@OPKK?\ P<\_$WQEJ^A6USJ6A_LL
M:,-(NYX@SVAGU1DE:,G[C,B["PYVLRYPQ!T?A+9VNA_\'+GQ<M](MTMDUO\
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M2[OXCZ?^SY<QP7VO'6[GP:/&&J?\(U)J.\/]I.C_ &G[&2& 8(8C&"!A!@8
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M*0_M_P#PZ8W'PX\?7=KX;\%:U"/]'UIM$T:[MKJ[@;I)$S21,D@X;S&YR"
M6O\ @W5_X*N_M;_M3I-^S[_P48\9P:SXX\5>$HO'_P */%*Z19V"Z_X>:9[*
MZMQ':0PQ&6UNH'R F]ED<G*QAC]'_P#!.S]JSX^?'7]O/]L7X+_%7QY_:OAK
MX5_$#0]-\!:;_9=K!_9=K<:?)--'YD,223[I%!W3,[#& 0.*^$?@;^SS\2K[
M_@WZ_95_X*&_LPZ09_C!^S+87WBWP_;0Y#ZYHGV^[76='<J"S)/:!FV@%B8M
MBX,A->Z?\&_O[0/PY_:M_;&_;7_:1^$FIF[\.>-?&OA'5M)E< .L<NCR,8Y
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MGQ6_X*&?&7_@MS8_\$]_V7_V];SX,>$$_9IC\=W4EE\-=$UY[C4%UR:Q<?\
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M)S?L8?\ !/T^+?\ AC_X)0>"T\<:G%?^)H+76;ZYBN9X_,\LI'=3R+;JOG2
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M7-Z_^U%\"_#'[1_A_P#9(UGQSY?Q#\4>';O7M%\.QZ9=2M+IULX2:Y>9(C#
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** /YV?VVO^3S?BY_V4_7_ /TXSUYC7ZP_&W_@@;_P
MN/XS^+OB[_PU?_9W_"5>)[_6/[/_ .$%\[[+]IN9)O*\S[<N_;OV[MJYQG S
MBN8_XAQO^KR/_,>?_?"OQS$\*Y]4Q$Y1HZ-M_%#O_B/]&<E\>/"C"9/AJ%7,
M;3A3A%KV-=V:BDUI2MOV/A/]B7_D\WX1_P#93] _].,%?T35^=GP2_X(&_\
M"G/C/X1^+O\ PU?_ &C_ ,(KXGL-8_L__A!?)^U?9KF.;RO,^W-LW;-N[:V,
MYP<8K]$Z^UX1RO'97AJL,3#E;::U3Z>39_-/T@^..%^.,YP5?),1[:%.G*,G
MR3A9N5TO?C%O3M<****^N/Y\"BBB@#\0/^"%7_!/C]I;]J?_ ()F6^H>&/\
M@J)\5?AGX*USQ?XDLKSP/X'TG2XA%&-1FCF:&]D@:XB>3EBP;Y2W''%>N_\
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MGB#XP^/O@GJ=EJ_C%PWCB+PIXWU;1;/Q*<Y)OK:QN8HKAFRVYRNYRS%BQ.:
M/RQNQ!_Q"C_M8'P;O_X5Z?COJO\ PJ7;GR/^$<_X2S2O(\C/'E>=]IQCC=N[
MYK]?OVL? GA/X7_\$IOB=\-_ >AV^F:)H/[/VMZ?I.G6D02*VMX=$G2.-5'
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
,% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>biib-20220331_g4.jpg
<TEXT>
begin 644 biib-20220331_g4.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@"
MF@)Z P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#5H=3N+F>(30"62XEC<$AU""0;1M0)7VS10 5X]^WW^QGX _X*#_ +(/C?\
M8]^)VMWVF:/XTT^&&34],"F>SG@N8KJWG4-PVR>")BIQN"E<C.1[#10!\:^*
MO^"='[:'QS_8M^+W['G[77_!1NQ^(*?$7PO!HWASQ-;_  9MM(F\/A3)Y\TT
M5O?D:@TH,/&Z *8F(SO('J7[0W[$O_"^O^"<^N_L _\ "S?[*_MKX9Q^$?\
MA+?[%\_R=MJD'VK[+YR;L[-WE^:.N-W>O>** /D[]IK_ ()6Z#^T%^S_ /!W
MP3X<^.NL>!_B?\!;:R?X8?%W0-,B>XTV[ALXK68R6<KE)[6X2)?-MF?#!54N
M0#N=\$OV9_\ @JU9?%;P]XH_:7_X*6^%M<\*:%<^;J/A/P3\%[?2Y/$(",JK
M<W<UW.\"[BKE8%7<5QD+D'ZKN[NTL+66_O[F."""-I)IIG"I&@&2S$\  #))
MK/\ !?C?P7\1_"]GXW^'GB_2]>T748S)I^KZ+J$=U:W*!BI:.6)F1QD$9!/(
M([4 :E?.G[=W[ ?_  VQ\1O@-X__ .%L_P#",_\ "DOB_8>.?LG]@_;?[:^S
M C['N\^+[-NS_K<28_N&OHNH[N\M+"UDO;^ZC@AB0M+-,X544=22> * /(?^
M"@7[)O\ PW5^QG\0?V1O^$__ .$6_P"$[T(Z;_PD']E?;OL.9$?S/(\V+S?N
M8V^8O7K63^U)^Q+_ ,-*?\$\/$7[!/\ PLW^Q?[?^'\/AC_A*_[%^T^1LBCC
M^T?9?.3=GR\[/-'7&[BO:]"\2>'?%%F=0\,Z]9:C;ARAGL;I)D##J-R$C/M5
MV@#Y?^*O_!-S_A9OC7]EKQA_PN;[#_PS3J)NOL__  COF_\ "1_\2M;#;N^T
M+]C^[YF<3==N/XJ[7]OS]ACX7_\ !0?]G^3X&_$G7-6T*YL=:M-=\(>+?#TX
MBU'PYK5HQ:UU"V8@@2(692#U21P"I(8>UT4 ?&7@C]D7_@L8FM:)HGQ2_P""
MMGAB]\-:3J%O)J=UX?\ @):6>LZ];1R*S03327DD-J95!5I(8MPW';@X(VOV
MP_\ @FOX\^*O[3.C_MU_L:?M.W'P<^,NF^&SX=U?5I?#46LZ1XGT?S?.2SU"
MQDDCWE).4G1U=!C[VU-GUG5#3O%/AG5]2N-'TGQ'875W9G%W:V]XCR0'_;52
M2OXT >$_LF_ 7_@H!X%^).H?$3]LC]NS1_B'8SZ*]CI?@CPG\,(-!TVQG::)
MS>M,;B>XN)=L90*SJBB5\*2<U[CXY\-?\)IX)UCP=]M^S?VMI5Q9_:?+W^5Y
ML;)OVY&[&[.,C..HK4Z=:IZ+XAT#Q);/>>'=<L[^&.4QR2V5RDJJXZJ2I(!&
M1Q0!\]?L3?\ !-KX6?LP?\$\_!/_  3U^,J^'_BYH'A*UFBNI_$_@Z#['J;-
M?S7B2-8SO<(I1I0!EWY0,""<";]JG]@"U_:4_:D_9U_:0L?B;'X<@^ 'B'5=
M3A\.Q>'Q.FLI>6<=L(5E$\8M!&(]P(27.<87&:]_USQ%X?\ #-F-0\2:[9Z?
M;EP@GOKI(D+'HNYR!D^E6H9H;F%+BWF62.10T<B,"K*1D$$=10!\=_M(_P#!
M-#XW7/[8FH_M\?L!?M8V_P )OB#XJ\/6NB_$?2]?\&IKNA^*[>U&VTGF@\Z&
M2&ZA3"+,CG*($PH9R_2?L"?\$XM1_9-\6?$?]H3XX_'N]^*OQG^+MS;2>.?'
MUYHL>G0+;6T1CM;"RLXW=;:VA5B,;R7(4L?E4+])WGBGPSIVKP>']0\16$%_
M=#-M937B+-,.GRH3N;\!5^@#P/\ X)@_L/\ _#M_]A?P+^Q;_P +/_X3/_A"
MH]17_A)?[%_L[[9]JU*ZO?\ CW\Z;R]OVG9_K&SLW<9VCQOX>?\ !$WP!HO_
M  1??_@CE\3/C;?Z]I,EM?!O'.F:&NGSK<2ZY+K-O,ELTTX7R9VB4J9#Y@B/
M*;\+]P44 ?&GB_\ X)S?MH?'C]BKXO?L=_M=_P#!1NP^( ^(WAJWTCPYXGMO
M@S;:1-X?"M(9YIHK>_*W[2YAXW0!#$Q&=Y ]3_:/_8E_X:"_X)TZ]^P'_P +
M-_LC^V_AO'X3_P"$L_L7[1Y.RW2'[3]E\Y-V=F[R_-'7&[O7O%% 'R]\5OV2
M?VZM'\"?#/PQ^QE^WEI7@/\ X0/P;;Z#K>E>)?A?!K.G>)3###%'<L#<QS6;
MJ(V($<C B3#9P#5']BS_ ()U_%/X,?M0>,?VZOVMOVF(?BA\6O%_A6U\+QWF
MC>$8]#TG1=$@G\];.WMEEE>1FFP[2R2%C@  <D_5]8_A#X@^ ?B"-3/@+QOH
M^MC1=7GTK63I&IQ7/V"_AQYUI-Y;'RITW+NB;#KN&0,T <[^U%\%?^&D_P!F
M;XB_LZ?\)+_8O_"?>!-7\.?VQ]C^T_8/MUE+:^?Y6]/-V>;OV;UW;<;ESD?$
M'P-_X)/_ /!7_P#9P^#OAGX"_!__ (+PV.E^%O"&C0:5H&G/^RMHMP;:TA0)
M&ADEOV=\* -S,2>Y-?HS5#1_%'AGQ#-<6_A_Q%87TEH^RZ2SNTE,+>CA2=I]
MC0!\R_'3_@G=\4/VE?!_[.%O\:OVJTUCQ7\"OBMI'CG7O%4?@2*V7Q=<64<Z
M-"+6&Y6/3_,\[.Y3*$V?<;/'5_MV_L-_\-KZK\$]3_X6A_PC/_"G?CIH?Q&V
M?V)]M_M?^SEN%^P9\Z+[/YGG_P"N_>;=O^K;/'ODTT5O$UQ<2JD:*6=W; 4#
MDDD]!5?1]<T7Q%8KJGA_6+6^MG)"W%G<++&2.H#*2* /DG]JC_@FU\:_$G[7
M\/[?/["'[5%K\)_B3J'A>/PYX[M-=\(+KFB^*M.B??;FXM_.A>*XA/"S(^2B
MJG W;J'[%/\ P2B^(?[,O[=OC/\ X*!_&+]LC4/B=XR^(7P^A\/^*8KSPC%I
MT(NH[N.59[417#K;VR0PPP):[&(\LR-,[.U?8.N>*/#7AB.*;Q+XBL=.2>39
M"U]=I")&_NJ7(R?85>!# ,IR#T(H ^$=%_X)8_M@?LG>/O%UY_P3*_;PTGX?
M> /&WB*YUZ^^%WCWX;)K^GZ+J5R=UQ-ILR75O+;Q.PW?9CNC4Y(/.*]0\7?\
M$[?$O[2_[!?C#]BW]O\ _:4O_BO>^-I))=1\:6/ABUT)].D#Q2VALK6 ND(M
MI88Y$W,Y<@^86#$'Z>HH _-/]H__ ((K_P#!07]N#]ER]_8__;#_ ."MB:WX
M3M;:W71;G0_A##:7>I7,$B&WN=8<7V;P1JI;R8VA#S%)7=S&%;]'?"VB?\(U
MX8T[PY]I\_\ L^PAMO.V;?,\M N[&3C.,XR:OT4 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5;_Q->:1=&TU+7F9KZ]TH7LZZ=/.S$EV:T$!5R2738Q)+$G\Z?C=_P %H_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\
MOJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ% %/\ X3'PQ_T&H/\ OJC_ (3'
MPQ_T&H/^^JN?V=I__/C#_P!^A1_9VG_\^,/_ 'Z% %/_ (3'PQ_T&H/^^J/^
M$Q\,?]!J#_OJKG]G:?\ \^,/_?H4?V=I_P#SXP_]^A0!3_X3'PQ_T&H/^^J/
M^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\ 0:@_
M[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ% %/\ X3'P
MQ_T&H/\ OJC_ (3'PQ_T&H/^^JN?V=I__/C#_P!^A1_9VG_\^,/_ 'Z% %/_
M (3'PQ_T&H/^^J/^$Q\,?]!J#_OJKG]G:?\ \^,/_?H4?V=I_P#SXP_]^A0!
M3_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H
M4 4_^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^
M,/\ WZ% %/\ X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^JN?V=I__/C#_P!^A1_9
MVG_\^,/_ 'Z% %/_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJKG]G:?\ \^,/_?H4
M?V=I_P#SXP_]^A0!3_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_W
MZ%']G:?_ ,^,/_?H4 4_^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^
M,/\ WZ%']G:?_P ^,/\ WZ% %/\ X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^JN?
MV=I__/C#_P!^A1_9VG_\^,/_ 'Z% %/_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJ
MKG]G:?\ \^,/_?H4?V=I_P#SXP_]^A0!3_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_
M[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\ 0:@_[ZH_X3'PQ_T&
MH/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ% %/\ X3'PQ_T&H/\ OJC_
M (3'PQ_T&H/^^JN?V=I__/C#_P!^A1_9VG_\^,/_ 'Z% %/_ (3'PQ_T&H/^
M^J/^$Q\,?]!J#_OJKG]G:?\ \^,/_?H4?V=I_P#SXP_]^A0!3_X3'PQ_T&H/
M^^J/^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\
M0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ% %/\
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M#_OJKG]G:?\ \^,/_?H4?V=I_P#SXP_]^A0!3_X3'PQ_T&H/^^J/^$Q\,?\
M0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 5K;Q1X?O)UM;758GD<X1%/
M)-7ZB2QLHV#QV<2L.A6, BI: "BBB@ HHHH **** "BBB@ HHHH \+_X)[_\
MD3U;_L>]9_\ 2DU[I7A?_!/?_DB>K?\ 8]ZS_P"E)KW2@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+:%888P3R0L:*N3SQ6U110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:&$;2=RKL5L,K ?7M?"O_!NA\,_CA\+/^"8^A:+\9_">O>'+2^\5ZSJ/P_\
M"OB@O]OT3PU/=%["UE60EDPI=U5N0DJ].@^ZJ "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH \+_ .">_P#R1/5O^Q[UG_TI
M->Z5X7_P3W_Y(GJW_8]ZS_Z4FO=* "ODG]M+]ISXX?"7XS?\(G\/O&_]GZ?_
M &1!-]G_ +-MI?G8OD[I(V;L.,XKZVKX,_X*,_\ )Q _[ -K_P"A25]5P=A\
M/BLWY*T%)<KT:373HSYKBNO7PV5<]*;B^9:IM/KV,'_ANG]JC_HJ7_E$L?\
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M&Z?VJ/\ HJ7_ )1+'_XQ1_PW3^U1_P!%2_\ *)8__&*\DHH_L;)_^@>G_P"
M1_R#^ULU_P"@B?\ X'+_ #/6_P#ANG]JC_HJ7_E$L?\ XQ1_PW3^U1_T5+_R
MB6/_ ,8KR2BC^QLG_P"@>G_X!'_(/[6S7_H(G_X'+_,];_X;I_:H_P"BI?\
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M[#2K./3M+L8;:WA7;#!;Q!$0>@4< ?2O*O\ ANG]E?\ Z*E_Y1+[_P",4?\
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M$OO_ (Q1_8V<?] ]3_P"7^0?VME7_01#_P #C_F>MT5Y)_PW3^RO_P!%2_\
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MI<UG;FYN7X97ORZWVMY7ZV/'O#[_  T\*_$*;_A*K6?Q3H-I),L*V4KV?V_
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M47=,SE&49.,E9H****8@HHHH **** "O>?\ @G-_R<0?^P#=?^A1UX-7O/\
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M=^5/?C->E?"N7X#_ +./BH?%I/C5'XJU/3K><:/HFD:1/")I9(FC#2R2@!%
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M_P"">_\ R1/5O^Q[UG_TI->Z4 %?!G_!1G_DX@?]@&U_]"DK[SKX,_X*,_\
M)Q _[ -K_P"A25]AP/\ \CO_ +=E^A\IQC_R)_\ MY?J>#4445^P'Y4%%%%
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M]%)I-68TVG=!1113$%%%% !1110 4444 %%%% !1110 4444 %%%% !7O/\
MP3F_Y.(/_8!NO_0HZ\&KWG_@G-_R<0?^P#=?^A1UX_$'_(DQ'^%GJY'_ ,CB
MA_B1]YT445^#G[6%%%% !1110 4444 %%%% !1110 4444 >%_\ !/?_ )(G
MJW_8]ZS_ .E)KW2O"_\ @GO_ ,D3U;_L>]9_]*37NE !7P9_P49_Y.('_8!M
M?_0I*^\Z^#/^"C/_ "<0/^P#:_\ H4E?8<#_ /([_P"W9?H?*<8_\B?_ +>7
MZG@U%%%?L!^5!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M /;R_4\&HHHK]@/RH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^28>(O\ L/+_ .B$KY7C/_D0S]8_F?2\)?\ ([AZ2_(^F****_&3];"BBB@
MKYG_ ."G/_),/#O_ &'F_P#1#U],5\S_ /!3G_DF'AW_ +#S?^B'KWN&/^1]
M0]7^3/$XC_Y$E;T7YH^*Z***_<C\:"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "O>?^"<W_)Q!_[ -U_Z%'7@U>\_
M\$YO^3B#_P!@&Z_]"CKQ^(/^1)B/\+/5R/\ Y'%#_$C[SHHHK\'/VL**** "
MBBB@ HHHH **** /@WXV_P#!0'_@HO\ &']KWXA?LK?\$Q_V4?AYKUK\'IK"
MT\=?$+XM>)[BSL&U.[M%NEL;."U7SG9(9%WRDD9)!"C8S]?^R]XH_P""XNL_
M'_0(_P!LGX&_LV:5\/=MTNOZKX#\0:O<:Q /LLI@%NMROEG=<"!7W'_5ER.0
M*\D^-/P4_P""T?P+_P""CWQ3_:(_X)[_  6^"5]\//B-;Z.==TWQSXJO(I=8
MO;.PBA_M'RXE!M+D?/;MM9HY8H(6:,2 N?7_ -ESXF?\%O/$'QVT+2/VOOV9
M/@/X>^'<WVK_ (2'6/!GC2_N]2M\6LK0>3%*H1]UP(5;)X1G(Y H ^OZ***
M/"_^">__ "1/5O\ L>]9_P#2DU[I7A?_  3W_P"2)ZM_V/>L_P#I2:]TH *^
M#/\ @HS_ ,G$#_L VO\ Z%)7WG7P9_P49_Y.('_8!M?_ $*2OL.!_P#D=_\
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "O>?^"<W_ "<0?^P#=?\
MH4=>#5[S_P $YO\ DX@_]@&Z_P#0HZ\?B#_D28C_  L]7(_^1Q0_Q(^\Z***
M_!S]K"BBB@ HHHH **** "BBN2^,OQZ^"/[.OA6'QU\?/BWX<\&:+<:C%86^
MJ^)]8AL;>2ZEW>7 LDS*ID;:V%SD[3CI0!^?WC;X%_$W_@KO_P %#/CO\'?B
MW^V#\2?A]\)O@'J>B^'](^''PK\2'1KG7;V\TR*^FU'4[A59Y(29?+ACQM(B
MW H0_F+X'^!GQ._X)$?\%#O@3\&/A+^U_P#$CXA?";X^ZCK>@ZM\.?BIXD.L
MW6@WMGIDE_#J.F7#*LD<(,7ES1D;0)-S%R4\M_\ P4C^%?\ P2^U?]K[4?B^
MO_!7>W_9;^/UEI=II?C*]\)_%73M,N=5LQ"DMK%JNGW+XG*PR1M&S!3L:/.]
M5CVK_P $V_A5_P $P-)_:]T_XNC_ (*ZP?M2?'Z^TN\TSP=>^+/BKI^J7.E6
M9A>:ZBTK3[9\0%H8Y&D90QV+)C8K2;@#]*:*** /"_\ @GO_ ,D3U;_L>]9_
M]*37NE>%_P#!/?\ Y(GJW_8]ZS_Z4FO=* "O@S_@HS_R<0/^P#:_^A25]YU\
M&?\ !1G_ ).('_8!M?\ T*2OL.!_^1W_ -NR_0^4XQ_Y$_\ V\OU/!J***_8
M#\J"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "OM3_ ()C?\DP\1?]AY?_ $0E?%=?:G_!,;_DF'B+_L/+_P"B$KY7
MC/\ Y$,_6/YGTO"7_([AZ2_(^F****_&3];"BBB@ KYG_P""G/\ R3#P[_V'
MF_\ 1#U],5\S_P#!3G_DF'AW_L/-_P"B'KWN&/\ D?4/5_DSQ.(_^1)6]%^:
M/BNBBBOW(_&@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1ED!/_'R:]R_L[3_ /GQA_[]"O$?^">__)$]6_['O6?_ $I->Z4 0_V=I_\
MSXP_]^A7PA_P44AB@_:&"0Q*B_V#;<*N!]Z2OO6ORW_X*]_M-_\ "IOVN!X4
M_P"$)_M#_BEK*;[1_:7E?>:7C;Y;>G7-?:<!4:E;/>6"N^27Z'R'&U:G0R7F
MF[+F7ZG-T5\__P##='_5+O\ RM__ &BC_ANC_JEW_E;_ /M%?M/]G8S^7\5_
MF?D/]HX/^;\'_D?0%%?/_P#PW1_U2[_RM_\ VBC_ (;H_P"J7?\ E;_^T4?V
M=C/Y?Q7^8?VC@_YOP?\ D?0%%?/_ /PW1_U2[_RM_P#VBC_ANC_JEW_E;_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P"7\7_F']HXS^;\%_D?0'_#='_5+O\ RM__ &BC_ANC_JEW_E;_ /M%?/\
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MBOZ"/P<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M  <+?\F]>!/^QS?_ -)):_0.OS\_X.%O^3>O G_8YO\ ^DDM?4\%?\E3A?\
M$_\ TEGS/&/_ "3.)_PK\T?DM1117]-G\XA1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7V=_P0A_Y/G/_ &)FH?\
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MBBB@ HHHH *_6G_@WI_Y-Z\=_P#8YI_Z215^2U?K3_P;T_\ )O7CO_L<T_\
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M /26?,\8_P#),XG_  K\T?DM1117]-G\XA1110 4444 %%%% !1110 4444
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M]^V+;?$W3[/]L>TU>W\4Z9IJ0Z?=ZG:0QRS6RR.RNL\ "W(#LP$NYSQC=\H
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M-/\ _0YZ_0O#/_DI/^W)?FCX/Q&_Y)W_ +?C^I\8T445_01^#A1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7ZT_\
M!O3_ ,F]>._^QS3_ -)(J_):OUI_X-Z?^3>O'?\ V.:?^DD5?#>(O_)+5/\
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MH **** "BBB@ HHHH **** /"_\ @GO_ ,D3U;_L>]9_]*37NE>%_P#!/?\
MY(GJW_8]ZS_Z4FO=* "OQA_X+O?\GSC_ +$S3_\ T.>OV>K\8?\ @N]_R?./
M^Q,T_P#]#GK]"\,_^2D_[<E^:/@_$;_DG?\ M^/ZGQC1117]!'X.%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?K3
M_P &]/\ R;UX[_['-/\ TDBK\EJ_6G_@WI_Y-Z\=_P#8YI_Z215\-XB_\DM4
M_P 4/_2D?:>'_P#R4U/_  R_)GZ!T445_.A_0 4444 %?GY_P<+?\F]>!/\
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M_DF<3_A7YH_):BBBOZ;/YQ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "OL[_@A#_R?.?^Q,U#_P!#@KXQK[._X(0_
M\GSG_L3-0_\ 0X*^>XL_Y)K%_P""1[W"_P#R46%_QH_9ZBBBOY</Z6"BBB@
MHHHH **** "BBB@ HHHH **** /"_P#@GO\ \D3U;_L>]9_]*37NE>%_\$]_
M^2)ZM_V/>L_^E)KW2@ K\8?^"[W_ "?./^Q,T_\ ]#GK]GJ_&'_@N]_R?./^
MQ,T__P!#GK]"\,_^2D_[<E^:/@_$;_DG?^WX_J?&-%%%?T$?@X4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^M/\
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M:?\ ^ASU^A>&?_)2?]N2_-'P?B-_R3O_ &_']3XQHHHK^@C\'"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OUI_X-
MZ?\ DWKQW_V.:?\ I)%7Y+5^M/\ P;T_\F]>._\ L<T_])(J^&\1?^26J?XH
M?^E(^T\/_P#DIJ?^&7Y,_0.BBBOYT/Z "BBB@ K\_/\ @X6_Y-Z\"?\ 8YO_
M .DDM?H'7Y^?\'"W_)O7@3_L<W_])):^IX*_Y*G"_P")_P#I+/F>,?\ DF<3
M_A7YH_):BBBOZ;/YQ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "OL[_@A#_R?.?\ L3-0_P#0X*^,:^SO^"$/_)\Y
M_P"Q,U#_ -#@KY[BS_DFL7_@D>]PO_R46%_QH_9ZBBBOY</Z6"BBB@ HHHH
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M]!/_ ))3_P#D _U%X5_Z!_\ R>?_ ,D?@'_P[W_:R_Z-D^*?_A$#_P"2*/\
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M.]_VLO\ HV3XI_\ A$#_ .2*_?RBC_7_ (M_Z"?_ "2G_P#(!_J+PK_T#_\
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M+PK_ - __D\__DC\ _\ AWO^UE_T;)\4_P#PB!_\D4?\.]_VLO\ HV3XI_\
MA$#_ .2*_?RBC_7_ (M_Z"?_ "2G_P#(!_J+PK_T#_\ D\__ )(_ /\ X=[_
M +67_1LGQ3_\(@?_ "11_P .]_VLO^C9/BG_ .$0/_DBOW\HH_U_XM_Z"?\
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M4 )/3<R?7O[5^@?MD?M%?"?PEJ7_  3O_:G\)?#E-:9+_4?&.N^#1KCRZ9-
M'A:TMY&2,N2RMF3C;Q0![Y4%WI>F7\\%S?:=!-):R;[:2:%6:)L8W*2/E..X
MKXL_X(%?M0_M+_M9_L.ZI\0/VL?BU_PF_BW2/BAX@T"3Q#_8-EIOVBWLYUBC
M_<6<4<2=ST)YY8XS7VU0 45\7_L4_'O]LG]I?PA^V#X8@^)FG+XL\$_'[Q5X
M0^#VI>(-!A2RT:U@T^R:P69+>)&NHHYYW=F??(X)!<X 'A?[:GPM_P""Q/\
MP3V_99\4?MYVO_!7]OB-K'P^L1K7B7P%XK^$ND:?X?UNS1U\ZTB%L!/:MM8[
M&23>Y4+N4ON !^HE%>">,O%W[4?[5W[#GA+XG_L8^.= ^&OC3QYX<T77+34?
M&6B-JD.DVMW!%<31& %1+,J2;%W87<.17S__ ,$5?V@_VUOB1\8OVG_V??VT
MOVF(_BEJ/P>^)5EH&B>(8?!FGZ&AB>U>23;!9QC +8QYCR,-OWN30!]]T444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2^'^D_"W]L7X3'Q?H6AZVNKZ78CQ!J&G&"\6*2$2^98W$+MA)9!M9BOS9QD
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M?6M3$EE)-#.\7E7]Y-&I,EO"V]5#C9@, S @'TK1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 <Q\;/B-_P *>^#7B[XN?V-_:/\ PBWAB_U?^S_M
M'D_:OLUO)-Y7F;6V;MFW=M;&<X.,5^>'_$1E_P!6=?\ F0O_ +WU]T_MK_\
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M[CPW\9H[RP\0ZD.$TV5I+%)K L<'[08Y4 )X)7!^/_\ @W7_ &BO^"@WB_\
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M5C^)_B%X!\$7^DZ7XS\<:/I%UKVH+8:';:IJ<5O)J-T06$$"R,#-*0"0B9;
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M\5O=1ZL)EDMKN(*MW;2PSPRQRA4)#E6165@ #]2Z*** "BBB@ HHHH ****
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MJ:YL%Z6TAUFZ+1#']TY7\*_0*;0=#N-7B\03Z-:/?P1F."]>W4S1H<Y57(W
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M^E4E<C7Z.>(/V,_V;/%.O7OB;7?AOY]]J-W)=7D_]L7B^9+(Q=VVK, ,L2<
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MP<^#?P@^&]YXA\4_!R3PIX]\0>#;" O<ZM<07/V_5K>- "9'$EU<R;<%F\K
M!8A35_X*R_\ !4;]D3_@J-_P3ZNOV$/^"?WC@_$WXK_'6\T?3-#\%Z;I5P+K
M0XTU&UNKF[U-6C L8[=(&#M(1M8AAE%9A^N54['P[X?TO4+C5M,T*SM[J\.;
MNY@M422<]<NP&6_&@#\^OC)X:3PO_P ' '[*'AB6Y-VVD_L]^++9;J5?F<QB
M&/?[$@'\S6M_P6B_Y.;_ &%_^SJM/_\ 2&YK[[HH _,6;]H3X5?\$LO^"W_[
M0?Q+_;4\1CP=X"_:7\)>$-1^'_Q$U:VD_LI+[0["2PNM*EN%4K#,0_GA7VC8
M%YRZ@Y/_  3T_:A\!?M?_P#!PS\:_C1\)--OF\'W'[.6CVGA?Q!>:;+:IXBM
M8=416U"!955VMVF\Z*.0@"18 ZY5E)_4;5]$T7Q!9'3=?TBUOK9F#-;WENLJ
M$CH=K C(JRJJBA$4!0,  < 4 +1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
K%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>biib-20220331_g5.jpg
<TEXT>
begin 644 biib-20220331_g5.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^0/^"CO_!2_XS_L:_M&
M?!#]E?\ 9Z_8YM_B_P",?C?_ ,)"-&L;KXCQ>'([0Z3;V]S(#+-9SH^^*:1N
M2F##@;BXQU_[)?[1W_!1GXL_$ZX\,_M8?\$T]*^$/AF/1Y;BW\467QRL?$CR
MWBR1*EK]EM[.%E#(TC>;NPOE8P=P(^0O^"W?AWX^^+/^"NG[!/A_]E_XD:+X
M1\=W#?$<:!XB\1:*=1L[-AI%DTIDMPRF3=")4'S##.&[8KZV_9A\'_\ !2?X
M*6?C'QK^W'^TWX#^)>F6GA][C0-+\%^ 7T::&XB#2.7=I9/,#* H&!@\T ?1
M5_XD\.Z5J-MI&J:]96UW>MML[6XND22<^B*3EC],U=K\CO\ @DW_ ,$MOV0O
M^"H/_!/:U_;I_;^\#'XF?%CXZW>KZIKWC;4M4N!=Z(BZA<VUM:Z8RR8L8[=(
M5*+&!M;*G**J#POX\_&[XS?&[_@U!^)?ASXM^/[KQ-XA^'?Q7M? ]KXOU&0R
M3ZM;Z?XLT^.UN97.3(PC=(RYR6\H%BS$D@'[M1Z[H<NL2>'HM9M&U"*$32V*
MW"F9(R0 Y3.X+DCG&.17C?\ P4:_;=\*_P#!.;]CGQ;^V+XU\#ZAXCTWPE)I
MR7&C:7<)%/<?;-1MK%=K2?*-K7*N<]0I'6LO]D'_ ()A_L@_L6>*)/BO\*/A
MRT_Q%U30WT[Q;\2M9U.YO-9\1F66&>YFO)II&\QY9X$E.  I&U J_+7S#_P=
M9_"'X:>//^"-_C[XB^,/!UGJ&M^"]5T&Y\*ZE<*3)ILUSKFG6D[QD' +P2R1
MG.?E<T ?6?\ P4B_:>\6_L7?L*?%#]JGP'X?T[5=8\#>%9M4T_3M7$GV:XD0
MJ LGELK[>?X6!]Z[KX*?%JR^)7PM\%>*]?O]-M-;\4^$K#6'TF&Y 8&>V25_
M+1F+E%+, >>!R:^&O^"GG[ 7[&O[#?\ P1U_:D;]DG]GKP_X#/B?X<8\0'0H
M73[=]F=O(W[F.=GGS8_ZZ&O"_P!L#_@DO^R1\,/^"(=[^V+H_AW4W^._A+X3
MZ5XUL?C2^NW9U]=9M[:WN Z3^9^[@ !ACMU CBBV!%!16 !^QI(4%F. .I-4
M]$\1^'O$ML]YX<UVRU"&.0QR2V5TDJJXZJ2I(!]J_)/_ (*U_M/?$CXW7?[$
M_P"RQXP^&OQ"\;>#/C9X9O/%WQ9\"_"F:.WU;Q@EEI-K=)IB,UQ;C[*99Y);
MB,2J3$@*_,JUB?"WX2:_\*/V]/@9\7/^";?_  1[^.?[/MHWC"+0OC4NL:?8
M6GA_6O"URIC>6Z@M]1N \]K*4GCDV \.69BJB@#]=OBAKOCGPO\ #7Q!XE^&
M'@*/Q5XDT_1+JY\/^&)M733TU>]2)F@M&NG5UMA+(%C,K*P3=N((&*_._P#:
M&_X+._\ !3W]EOQ/\._!_P 9O^"*FD:??_%/QK;^$_!<4'[3VGW N]4G_P!7
M$[1Z41$IQ]]\*.YK]+:_.G_@NY_R<7^P=_V=]H/\FH Z/XX_\%)?^"D_P"_8
MS^,W[3?Q_P#^":WAKX83?#OP<NK>&'NOC';>)[?6+O[1'&UO+%9V]M)"H1R^
M_?R1BOL;X2_%#3_'OP_\)Z[K.HZ=;:SXB\,6>JOI45R X\Z!9'\M&8N4!)&>
M>!R:^:/^#@3_ )0S_M!_]B(W_I1#7QQ^W1_P2=_9.^#/_!%G4?VR_"^@:F/C
MWX,^'6D>,K'XV/KMT?$#:S#';2F43F3"1$;HD@4"**/:$52BD '[%U4TW7=#
MUF2XAT?6;2[>SF,-VEM<+(8)!U1PI.UO8\U^5O\ P5P\*:E^V+\1?^"=?A[Q
M/XMU30W^('C2:;Q!J'AR]>SNA;W&APRWD4,T9#P&6(RQ!T(9!)E2" :A_P""
MQ'P>^$G_  3,_9*^'W[+_P#P3^^".M^"-)_:"^.^A>&/B!9_"FX:/6]7TPQ3
M-<6EE+<3J%O;E(D@5VD7<&=6)#&@#]5M,\2>'=:N[FPT;7K*[GLGV7D-M=)(
M\#<_*X4DJ>#P<=*GU#4=/TFRDU+5;Z&VMX5W37%Q*$1!ZECP!]:_#WXI_ :#
MX77/@#XJ?\$J?^"&/[1'P2^*_@7Q=IEQ:^)&LK""RUG1Q.BZAINJF/5IWNXI
MH-V6='?>J_,H+&N\_P""@OQ+M_VG_P#@M)XJ_9L_:*_8R^+/Q]^%OP7^'6CW
MFB?"KX=+;/I\NLZB!.^L:E#/>VHN=D;?9XE)=%*L=H))8 _873=3TW6;&+5-
M(U""[MIEW0W%M*)(Y!ZJRD@CZ52\<^)?^$+\$ZQXQ^Q?:?[)TJXO/LWF;/-\
MJ-GV;L';G;C.#C/0U^97_!*[X>?%7X,?\%+/$5K^SE_P3\^,'P(_9R\9_#9[
MCQ!X.^(,5M'IEAXNM[M/+O-/B@O+E;<36K-&\:E S(&(^50/T@^.7_)%/&'_
M &*VH?\ I-)0!\E_\$6O^"SFC?\ !7?P1XPU;4O@!-\,?$7A.XL9O^$=G\3C
M51?:7>1N;:_CF^S6^5:6"YB9 AV&$9;+;5ROBG_P7"T;P-_P5^\+_P#!*OPE
M^SE-K]MJ]];:9KWQ*_X2L6\.DZI+82Z@;-;3[(_VEDMA;LQ$Z;3<8*C:-_Y_
M?\$_OB?X=_X)G_L;?L5?\%7?$:3P>!=<^'_B;X8?&62TB+M]G?5-3U/1;G8.
M"RWEO-"9#T6X5<\X/1_"3X-^-?!/Q]_X)V?'_P",EAY/Q#^/OQM\>?$_QR&!
MW13ZMIEO+:VPS\RK#9"TB$9QL*L !TH _<;6-;T7P]8/JNOZO:V-K&0'N;RX
M6*-<\#+,0!4]M<V]Y;QW=I.DL4J!XI8V#*ZD9!!'!!'>OR_\*_LZ_"G_ (*M
M?\%G?VE]#_;?\/#QKX(_9RLO"V@?#7X;:O=2'2K6?4]/DN[S5)K965)IW9&1
M'<']VP!R8XRNU_P3?\)6O[$'_!6+]H;_ ()H?!?5+\?!U/ASI'Q!\&>%+O4)
M;F'PC=W,AM[NSM6E9FCAF=O.$9.%VKCJQ8 _1[5/$&@Z');Q:UK=I9M=S"*U
M6ZN5C,TAZ(FXC<WL.:\;_P""C'[;OA7_ ()T?L?^*?VO_&O@?4/$>F^%I]-B
MN-'TNX2*><WFH6]DI5I/E&UKA7.>H4CK7YF?\$'/^"-O[#W[:7_!&'X?_$3]
MK'X<3>.==\5:=K]EH^I:QJMP6\*62:S?PI!I:K($M/WJ27+.BAGEG?>64*H\
MK_:.E@_:V_X,Z/!7[0O[1%HOBKQOX*FM;+P_XEU:1Y;JU$/C-=&\P.3EG>QC
M6%F;)8$D\G- '[#?\%)_VH?%W[%?["7Q/_:K\!>']-U76/ WAB74]/T[5Q(;
M:XD5T4+)Y;*^WYC]U@:[[X,_%>Q^(WPS\&^)M=U#3;36_$_A2QU=])AN0&!F
MMTE?RT9BY0%F // Y-?"O_!43]@3]C;]AO\ X(X?M1_\,D_L]^'_  '_ ,)1
M\/5_X2#^PH73[=]FD/D;]S'.S[1-C'_/0UX=^V9_P29_9*^%/_!$F^_;'T+P
M]J9^/'A#X6Z3XTL?C4^NW9U\:S;P6TXD6?S/W<( ,20*!'%'L"*I16 !^P]_
M?V&E6<FHZG>PVUO"I::>>0(B+ZECP!]:BT37]"\2V"ZKX<UNTU"U<D+<V5RL
ML9/H&4D5^8__  4[^$'[0/[6G@O]DW]I[Q/^ROK'[0'PDT7P_-K7QB^"WAG6
M$M+C4[Z^TRU:RU%;5I(TU 6\IF(M]V1OP 5=ROI__!'OQE_P2AU3XE_$7PS^
MPS^R[KOP-^)=MI^G_P#"ROA?XQ\+7>@ZK;VR-)]EG>QDD> KNFD'FPDGYT#G
M#1Y /KK]J+XU?\,V?LS?$7]HO_A&O[:_X0'P)J_B/^Q_MGV;[?\ 8;*6Z\CS
M=C^5O\K9OV-MW9VMC!^+?@-_P5+_ ."N'[2GP7\+_'_X1_\ !$31+_PQXQT2
MWU;0;V?]J;3('GM9D#QN8Y-+#H2I'RL 1WKZ7_X*B_\ *,W]HK_LA7B[_P!,
MUW7P7_P2V^ O_!;S7O\ @G+\$]:^"/[?_P (?#_A"Z^&VE2^&]$U?X0R7EU8
MV9MT,4,LXN5$KJN 7P,D9Q0!^H_PC\1?$/Q;\+] \3_%KX<1>#_$]_I,$^O>
M%8-;34DTF[9 9+874:(MP$;*^8JJ&QD 5KV'B#0=5O;G3=+UNTN;FR<)>6]O
M<J[P,>@=0<J>.AQ7YG?\%W_AA\1/B!\/OV(/@[\1OBE<VWBC5OVH?"6E>)O&
M/A%6T^;[6^GW45W>66"3:LS&1XL$F,E>25K!_;C_ &$?V6?^"8?[57['G[1W
M["WPOB^'>O\ B3]H_1_AWXM;1=1N2GB#1=6@N1<1WPED?[2X,(<229?<=Q)*
MJ5 /U0UC7-%\/6)U/7]7M;&V5@K7%Y<+$@). -S$#)-?.7A/]MOQUXB_X*S^
M*?\ @G_)X7T8>&-#^!UAXWM-<B\TWLMW/J36C0L=_E^4$ 887=GOCBOEW4_V
M?OA;_P %2?\ @N-\>?A3^VEX>'C#P!^S5X+\)6?@+X>:K<2?V5+?ZY8O?76J
MRVZL%GF4+]G!?*A2O&54C'_8$_9<^'W['G_!Q-\8/@W\(+Z^3P?#^S-IE[X8
M\.7.HRW4?AVVFUB-GT^W,K,Z6XG$TR1DX07&U<*%  /U$U;Q)X=T"6W@UW7K
M*R>[D\NT2[NDC,S\?*@8C<>1P/6KM?@!^PSK7PB_X* _"KQ#^VG^W7_P1U^/
M7[2WC/XG>)=7=/%^GVEC=:/HFEQW<MO;Z3I*S:K ]I';K&5++&DGF%_G8!6/
MJ7BKXQ?\% ?V6_\ @@I\1?A;XUTSXC_#74Y_CI'\/_A+KOQ!N$/B'2? ^I7M
MH+6:>:*63]]%!/<V@D60[-B[&&Q" #]'O^"HO[;NL_L0?L"_%/\ :N^$5GX?
M\1^(?A[86LJ:/J5PTEOYLM[!;E)Q"ZNN%E8@94Y7ZU[]X.UF?Q'X1TKQ#=1)
M'+?Z;!<2)'G:K/&K$#/;)K\>O^"YO_!&7]A7]CK_ ((Y_$'XF?LH_#I_ ?B;
MP;H^F6]]XAT_5KC[1XHLY=2M(+BUU0LY6]$C2+,-ZDI/%$R; "#^O/PM_P"2
M9>'/^P#9_P#HE* -VBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH ^=?VE?V!/^&A_V[_V=OVV?^%L?V/_ ,*#?Q.W_",_V%]H_MW^V+".T_X^
M//3[+Y/E[_\ 5R[\X^3&:^B6564JR@@C!!'6EHH _/7PO_P2&_;;_9>T;Q3\
M"?\ @G=_P4M@^&?P<\4:Q>:AIOA'7/AA#K.H>"VO)#)<QZ1>FZBVQ%G9HTD0
M^43N!9RSMV/Q8_X(F_"3Q!_P2/3_ (),?!3XGWGA'18Y].N6\8ZGI(U2[NKJ
M#5H=3N+F>(30"62XEC<$AU""0;1M0)7VS10 5X]^WW^QGX _X*#_ +(/C?\
M8]^)VMWVF:/XTT^&&34],"F>SG@N8KJWG4-PVR>")BIQN"E<C.1[#10!\:^*
MO^"='[:'QS_8M^+W['G[77_!1NQ^(*?$7PO!HWASQ-;_  9MM(F\/A3)Y\TT
M5O?D:@TH,/&Z *8F(SO('J7[0W[$O_"^O^"<^N_L _\ "S?[*_MKX9Q^$?\
MA+?[%\_R=MJD'VK[+YR;L[-WE^:.N-W>O>** /D[]IK_ ()6Z#^T%^S_ /!W
MP3X<^.NL>!_B?\!;:R?X8?%W0-,B>XTV[ALXK68R6<KE)[6X2)?-MF?#!54N
M0#N=\$OV9_\ @JU9?%;P]XH_:7_X*6^%M<\*:%<^;J/A/P3\%[?2Y/$(",JK
M<W<UW.\"[BKE8%7<5QD+D'ZKN[NTL+66_O[F."""-I)IIG"I&@&2S$\  #))
MK/\ !?C?P7\1_"]GXW^'GB_2]>T748S)I^KZ+J$=U:W*!BI:.6)F1QD$9!/(
M([4 :E?.G[=W[ ?_  VQ\1O@-X__ .%L_P#",_\ "DOB_8>.?LG]@_;?[:^S
M C['N\^+[-NS_K<28_N&OHNH[N\M+"UDO;^ZC@AB0M+-,X544=22> * /(?^
M"@7[)O\ PW5^QG\0?V1O^$__ .$6_P"$[T(Z;_PD']E?;OL.9$?S/(\V+S?N
M8V^8O7K63^U)^Q+_ ,-*?\$\/$7[!/\ PLW^Q?[?^'\/AC_A*_[%^T^1LBCC
M^T?9?.3=GR\[/-'7&[BO:]"\2>'?%%F=0\,Z]9:C;ARAGL;I)D##J-R$C/M5
MV@#Y?^*O_!-S_A9OC7]EKQA_PN;[#_PS3J)NOL__  COF_\ "1_\2M;#;N^T
M+]C^[YF<3==N/XJ[7]OS]ACX7_\ !0?]G^3X&_$G7-6T*YL=:M-=\(>+?#TX
MBU'PYK5HQ:UU"V8@@2(692#U21P"I(8>UT4 ?&7@C]D7_@L8FM:)HGQ2_P""
MMGAB]\-:3J%O)J=UX?\ @):6>LZ];1R*S03327DD-J95!5I(8MPW';@X(VOV
MP_\ @FOX\^*O[3.C_MU_L:?M.W'P<^,NF^&SX=U?5I?#46LZ1XGT?S?.2SU"
MQDDCWE).4G1U=!C[VU-GUG5#3O%/AG5]2N-'TGQ'875W9G%W:V]XCR0'_;52
M2OXT >$_LF_ 7_@H!X%^).H?$3]LC]NS1_B'8SZ*]CI?@CPG\,(-!TVQG::)
MS>M,;B>XN)=L90*SJBB5\*2<U[CXY\-?\)IX)UCP=]M^S?VMI5Q9_:?+W^5Y
ML;)OVY&[&[.,C..HK4Z=:IZ+XAT#Q);/>>'=<L[^&.4QR2V5RDJJXZJ2I(!&
M1Q0!\]?L3?\ !-KX6?LP?\$\_!/_  3U^,J^'_BYH'A*UFBNI_$_@Z#['J;-
M?S7B2-8SO<(I1I0!EWY0,""<";]JG]@"U_:4_:D_9U_:0L?B;'X<@^ 'B'5=
M3A\.Q>'Q.FLI>6<=L(5E$\8M!&(]P(27.<87&:]_USQ%X?\ #-F-0\2:[9Z?
M;EP@GOKI(D+'HNYR!D^E6H9H;F%+BWF62.10T<B,"K*1D$$=10!\=_M(_P#!
M-#XW7/[8FH_M\?L!?M8V_P )OB#XJ\/6NB_$?2]?\&IKNA^*[>U&VTGF@\Z&
M2&ZA3"+,CG*($PH9R_2?L"?\$XM1_9-\6?$?]H3XX_'N]^*OQG^+MS;2>.?'
MUYHL>G0+;6T1CM;"RLXW=;:VA5B,;R7(4L?E4+])WGBGPSIVKP>']0\16$%_
M=#-M937B+-,.GRH3N;\!5^@#P/\ X)@_L/\ _#M_]A?P+^Q;_P +/_X3/_A"
MH]17_A)?[%_L[[9]JU*ZO?\ CW\Z;R]OVG9_K&SLW<9VCQOX>?\ !$WP!HO_
M  1??_@CE\3/C;?Z]I,EM?!O'.F:&NGSK<2ZY+K-O,ELTTX7R9VB4J9#Y@B/
M*;\+]P44 ?&GB_\ X)S?MH?'C]BKXO?L=_M=_P#!1NP^( ^(WAJWTCPYXGMO
M@S;:1-X?"M(9YIHK>_*W[2YAXW0!#$Q&=Y ]3_:/_8E_X:"_X)TZ]^P'_P +
M-_LC^V_AO'X3_P"$L_L7[1Y.RW2'[3]E\Y-V=F[R_-'7&[O7O%% 'R]\5OV2
M?VZM'\"?#/PQ^QE^WEI7@/\ X0/P;;Z#K>E>)?A?!K.G>)3###%'<L#<QS6;
MJ(V($<C B3#9P#5']BS_ ()U_%/X,?M0>,?VZOVMOVF(?BA\6O%_A6U\+QWF
MC>$8]#TG1=$@G\];.WMEEE>1FFP[2R2%C@  <D_5]8_A#X@^ ?B"-3/@+QOH
M^MC1=7GTK63I&IQ7/V"_AQYUI-Y;'RITW+NB;#KN&0,T <[^U%\%?^&D_P!F
M;XB_LZ?\)+_8O_"?>!-7\.?VQ]C^T_8/MUE+:^?Y6]/-V>;OV;UW;<;ESD?$
M'P-_X)/_ /!7_P#9P^#OAGX"_!__ (+PV.E^%O"&C0:5H&G/^RMHMP;:TA0)
M&ADEOV=\* -S,2>Y-?HS5#1_%'AGQ#-<6_A_Q%87TEH^RZ2SNTE,+>CA2=I]
MC0!\R_'3_@G=\4/VE?!_[.%O\:OVJTUCQ7\"OBMI'CG7O%4?@2*V7Q=<64<Z
M-"+6&Y6/3_,\[.Y3*$V?<;/'5_MV_L-_\-KZK\$]3_X6A_PC/_"G?CIH?Q&V
M?V)]M_M?^SEN%^P9\Z+[/YGG_P"N_>;=O^K;/'ODTT5O$UQ<2JD:*6=W; 4#
MDDD]!5?1]<T7Q%8KJGA_6+6^MG)"W%G<++&2.H#*2* /DG]JC_@FU\:_$G[7
M\/[?/["'[5%K\)_B3J'A>/PYX[M-=\(+KFB^*M.B??;FXM_.A>*XA/"S(^2B
MJG W;J'[%/\ P2B^(?[,O[=OC/\ X*!_&+]LC4/B=XR^(7P^A\/^*8KSPC%I
MT(NH[N.59[417#K;VR0PPP):[&(\LR-,[.U?8.N>*/#7AB.*;Q+XBL=.2>39
M"U]=I")&_NJ7(R?85>!# ,IR#T(H ^$=%_X)8_M@?LG>/O%UY_P3*_;PTGX?
M> /&WB*YUZ^^%WCWX;)K^GZ+J5R=UQ-ILR75O+;Q.PW?9CNC4Y(/.*]0\7?\
M$[?$O[2_[!?C#]BW]O\ _:4O_BO>^-I))=1\:6/ABUT)].D#Q2VALK6 ND(M
MI88Y$W,Y<@^86#$'Z>HH _-/]H__ ((K_P#!07]N#]ER]_8__;#_ ."MB:WX
M3M;:W71;G0_A##:7>I7,$B&WN=8<7V;P1JI;R8VA#S%)7=S&%;]'?"VB?\(U
MX8T[PY]I\_\ L^PAMO.V;?,\M N[&3C.,XR:OT4 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5;_Q->:1=&TU+7F9KZ]TH7LZZ=/.S$EV:T$!5R2738Q)+$G\Z?C=_P %H_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **\2_8(U34]7^#6J
MW.K:C/=2+XWUA%DN)F=@HN2 N6)X Z#M7MM !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% 'A?_  3W_P"2)ZM_V/>L_P#I2:]TKPO_ ()[_P#)$]6_['O6?_2DU[I0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!X7_ ,$]_P#DB>K?]CWK/_I2:]TKPO\
MX)[_ /)$]6_['O6?_2DU[I0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X7_P3W_Y
M(GJW_8]ZS_Z4FO=*^>OV"[;Q)+\'-6;2=2MXHO\ A.-9RLL)8Y^TMSFO;?L7
MC?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#
M8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\
M@,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_
M (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_
M .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-
M_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -B
MBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P"
MQ_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\
M@,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\
MZ#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_
M .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**
MQ_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'
M_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P"
MQ_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H
M-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\
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MT=_HM_/IMQ9O/;ORK&&YCCEB)_NNBL.XKIJ\9_8 _;=^%G_!1']E+PO^U?\
M"*QOK#3O$,4T=YHVJ*!=:5?02M#<VDP'&Y)48!APRE6  8"O9J "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \+_P"">_\
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M>(/!]U);^,K?PIX!UC5HM!DC)$@NI[6U>)"I!# ,Q4@Y KZ._9[_ &B_@?\
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M=^+?#_P;\,ZX'TK1IHK(QVEE+>!$C:>>49GGC01Y8,.X' _M&?M6_P#!:/\
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M5[\&K6R\4CXQ:U=?&*]:ZTZ5M.QI8@:>^%XH>Y^5OLH((_UN%H _7TD*"S'
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MHH8+&*_N[2:!%G1G";EA( ,@&[IN^MOA7\;/^"F$_P#P3UC^,GQ=_8M\.?\
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MK_S\_"/^1[M_PVM_U33_ ,K/_P!IH_X;6_ZII_Y6?_M->$T4?ZY\2_\ /_\
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MLJ_Y^?A+_(]VHKPG_AM;_JFG_E9_^TT?\-K?]4T_\K/_ -IH_P!<^&O^?_\
MY+/_ .1#^WLJ_P"?GX2_R/=J*\)_X;6_ZII_Y6?_ +31_P -K?\ 5-/_ "L_
M_::/]<^&O^?_ /Y+/_Y$/[>RK_GY^$O\CW:BO"?^&UO^J:?^5G_[31_PVM_U
M33_RL_\ VFC_ %SX:_Y__P#DL_\ Y$/[>RK_ )^?A+_(]VHKPG_AM;_JFG_E
M9_\ M-'_  VM_P!4T_\ *S_]IH_USX:_Y_\ _DL__D0_M[*O^?GX2_R/=J*\
M)_X;6_ZII_Y6?_M-'_#:W_5-/_*S_P#::/\ 7/AK_G__ .2S_P#D0_M[*O\
MGY^$O\CW:BO"?^&UO^J:?^5G_P"TT?\ #:W_ %33_P K/_VFC_7/AK_G_P#^
M2S_^1#^WLJ_Y^?A+_(]VHKPG_AM;_JFG_E9_^TT?\-K?]4T_\K/_ -IH_P!<
M^&O^?_\ Y+/_ .1#^WLJ_P"?GX2_R/=J*\)_X;6_ZII_Y6?_ +31_P -K?\
M5-/_ "L__::/]<^&O^?_ /Y+/_Y$/[>RK_GY^$O\CW:BO"?^&UO^J:?^5G_[
M37HOP9^+/_"W-%N]7_L#^S_LMT(?+^U^;N^4-G.Q<=>E=F!XDR7,L0J&&J\T
MW?3EDMO-I(WP^:X#%5?9TIW?H_U1V-%%%>X>@%%%% !7CO[9?_(F:3_V%#_Z
M+:O8J\=_;+_Y$S2?^PH?_1;5\[Q9_P D]B/1?FCR\Y_Y%E7T_5'SK1117X"?
MFX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^BOV-/\ D3-6_P"PH/\
MT6M?.M?17[&G_(F:M_V%!_Z+6OK^!O\ DH8>DOR/;X>_Y&<?1_D>Q4445^XG
MZ"%%%% !7CO[9?\ R)FD_P#84/\ Z+:O8J\=_;+_ .1,TG_L*'_T6U?.\6?\
MD]B/1?FCR\Y_Y%E7T_5'SK1117X"?FX4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5Z?\ LD_\E8/_ &"YOYI7F%>G
M_LD_\E8/_8+F_FE>UPY_R/L-_C1WY7_R,:7^)'T[1117]#'Z:%%%% !1110
M4444 %%%% 'Y3:S^WUX _P""7?\ P5I_:0T/Q-^RS\:?&N@?%2]\.ZW>>+/
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M1110!X7_ ,$]_P#DB>K?]CWK/_I2:]TKPO\ X)[_ /)$]6_['O6?_2DU[I0
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MHK\!/S<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKK_[5^G>);36-UA<)+YFFP_/<^5$TEP,?ZMH%D/"&@#]'Z*** /"_P#@GO\
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M:?\ (F:M_P!A0?\ HM:^OX&_Y*&'I+\CV^'O^1G'T?Y'L5%%%?N)^@A1110
M5X[^V7_R)FD_]A0_^BVKV*O'?VR_^1,TG_L*'_T6U?.\6?\ )/8CT7YH\O.?
M^195]/U1\ZT445^ GYN%%%% !1110 4444 %%%% !17R3\4O^"P_[)_@+X]:
M1\+M&\>R:YI$$FJ6_C76M \)ZKJ<6EW-LD12-)K2!XY<,S^;L\SRP%W;<\^Y
M^*_CAK&L?LZ+\>/V8? '_"S9]3TNUOO">B6VKQZ6-8BG>/:WVBY7; HC<R$N
MN<(1C/%=M3+L;14'4@XJ>S>BWMN[)=]7MKL;SPN(IJ+G%KFVOI^+_JVIZ'17
MQ?XS_P""C7[7W[,-_H?BS]N+]AO3_"OP_P!;URVTJZ\7^$OB%#J[:%-<-LB:
MZM_)C9HRWWI$.%Q@!F*JWNW[3/Q9_:P^&=YH\/[-/[(=E\4(;R.<ZO-=_$>V
MT'^SF4IY:A9H)?.WAG.1C;LYSNXJ>6XJG."?+:5[/GARNV_O<W*FNS=]5W14
ML)6C))VUV?,K:;ZWM^)ZU17R!\(?^"B_[4'BC]M[P_\ L3?&O]A&Q\%ZGJ_A
MBY\0ZCJEC\6(-9_LS38_,1)Y(H+)1^\N$2$*9%.9 W(&#=_;\_X*,_'/]BV'
MQ!XE\*_L&^(/&WA+PMIUM>:WXUG\76NDZ?&LS(@6+?'++,RO(BD(AP3Z FM%
MD^/>)C027-))KWX6:;LM>:VKV5[E?4L0ZJIV5VKKWHZ]-[V/K*BLOP/XE_X3
M/P5H_C#[%]F_M;2[>\^S^9O\KS8U?9NP-V-V,X&<=!57XI_$GPI\&_AGXA^+
MGCJ\>WT7POHEUJNK3QQ[V2VMXFED*K_$VU#@=S@5YZA-SY$M;VMYG*HR<N5;
MF]17PP?^"GW[::? ,?MJR?\ !.R$?" Z<-8,H^(\!U\:(1N_M'[)]G\O;Y7[
MWRO,SMYW8^:OLOX8_$3PM\7OAOX?^+'@>]:YT7Q/HEKJND3NFUI+:XA66)BI
M^Z2CKD=CQ75BLOQ6#CS5$K7:TDI6:W3LW9^3-ZV&K4%>:6]M&GKVT;LS<HHH
MKB.<**** "BBB@ KT_\ 9)_Y*P?^P7-_-*\PKT_]DG_DK!_[!<W\TKVN'/\
MD?8;_&CORO\ Y&-+_$CZ=HHHK^AC]-"BBB@ HHHH **** "BBB@#\UO%7P?_
M &K_ /@I3_P46^/WP>\7?\%"_BQ\$?!7P7O-!T_PAX*^#FJPZ1?:E#?::EVV
MK7=VT;O/')*98T4#8IA9>&1MWM7[+G_!)WQ9^S1\=M"^-NI_\%2OVI_B/!HG
MVK?X,^(_Q,CU#1=1\ZUEMQ]HMQ;(9/+,HE3YAMDBC;G&#\W>-OV&_$/_  5
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MI\SDFM[V?NJ_Q:6Y3UL9.A7A%RDN=]5S6M>5VU;O;9=_(^1_^"E'@?\ ;/\
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MI=_M>_L=_M%0?#CQGK^APZ3XUL]6\,)JVF:_!!Q;RR1&2-H[B)<*)%8Y50N
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MHR<DVDWS/KJG?Y]==R:>)K4YJ47JG>]D]?F?+/P5_9!_X*&?"_Q-X9B\1?\
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MW4GF7$\2QQ_NX7QN(W-M4<D5Y?\ \-R?\'#7_2#3P?\ ^)'Z/7HG[*/[5?\
MP63^)/Q]T#P5^U9_P2F\-_#7P#>_:O[>\:V'QKTW5YM.V6LTD&VTA^>7S)UA
MA./NB4L>%- 'V71110!X7_P3W_Y(GJW_ &/>L_\ I2:]TKPO_@GO_P D3U;_
M +'O6?\ TI->Z4 %?,7[6W_)6!_V"X?YO7T[7S%^UM_R5@?]@N'^;U\5Q]_R
M(?\ M^/ZG@<1_P#(N_[>7ZGF%%%%?BA\$%%%% !1110 4444 %%%% !1110
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M8I2RYFA/FH4!4,"5/IM% 'Y^ZG_P5%_X*E? =SX9_:9_X(A^.M?OK?Y%\2?
MWQA:>(--U+'!ECA94N+923PDV7 &35G1_P!LS_@M)^US)_PC7[.O_!-?2_@-
MI5P=D_Q'^/WBJ.ZFM4/#&#1+ ":291\R>;(L3' 8XS7WS10!C?#K0_%GAGX?
M:%X;\>^-V\3:[I^C6MMK7B1M.CLSJMW'$J379@B^2#S7#2>6GRIOVC@"MFBB
M@#PO_@GO_P D3U;_ +'O6?\ TI->Z5X7_P $]_\ DB>K?]CWK/\ Z4FO=* "
MOF+]K;_DK _[!</\WKZ=KYB_:V_Y*P/^P7#_ #>OBN/O^1#_ -OQ_4\#B/\
MY%W_ &\OU/,****_%#X(**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *^BOV-/^1,U;_L*#_P!%K7SK7T5^QI_R)FK?
M]A0?^BUKZ_@;_DH8>DOR/;X>_P"1G'T?Y'L5%%%?N)^@A1110 5X[^V7_P B
M9I/_ &%#_P"BVKV*O'?VR_\ D3-)_P"PH?\ T6U?.\6?\D]B/1?FCR\Y_P"1
M95]/U1\ZT445^ GYN%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %>G_LD_\E8/_8+F_FE>85Z?^R3_ ,E8/_8+F_FE
M>UPY_P C[#?XT=^5_P#(QI?XD?3M%%%?T,?IH4444 %%%% !1110 4444 %%
M%% !1110!X7_ ,$]_P#DB>K?]CWK/_I2:]TKPO\ X)[_ /)$]6_['O6?_2DU
M[I0 5\Q?M;?\E8'_ &"X?YO7T[7S%^UM_P E8'_8+A_F]?%<??\ (A_[?C^I
MX'$?_(N_[>7ZGF%%%%?BA\$%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %?17[&G_(F:M_V%!_Z+6OG6OHK]C3_D3-
M6_["@_\ 1:U]?P-_R4,/27Y'M\/?\C./H_R/8J***_<3]!"BBB@ KQW]LO\
MY$S2?^PH?_1;5[%7CO[9?_(F:3_V%#_Z+:OG>+/^2>Q'HOS1Y><_\BRKZ?JC
MYUHHHK\!/S<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *]/\ V2?^2L'_ +!<W\TKS"O3_P!DG_DK!_[!<W\TKVN'
M/^1]AO\ &CORO_D8TO\ $CZ=HHHK^AC]-"BBB@ HHHH **** "BBB@ HHHH
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M10 4444 %%%% !1110 5]8?\$:/^3Q3_ -BG??\ H<-?)]?6'_!&C_D\4_\
M8IWW_H<->AE/_(SI?XD=.#_WJ'JC]8****_5#Z\**** "BBB@ HHHH ****
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MD_\ \%E_^3Q1_P!BG8_^AS5^L%?D_P#\%E_^3Q1_V*=C_P"AS5\]Q-_R+/\
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MYXNBLK/3/#,-^ES):VULFT23R1_(TC?*< \<@XX%>A?!/7OC%XB\)3WWQO\
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M+PB0 .%/;<%&?7 JU111=L HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M *>?A_P3\M:*_4K_ (<A?LF_]%&^*?\ X6Q_^-4?\.0OV3?^BC?%/_PMC_\
M&J/]4O\ I]_Y+_\ ;!_8W_3S\/\ @GY:T5^I7_#D+]DW_HHWQ3_\+8__ !JC
M_AR%^R;_ -%&^*?_ (6Q_P#C5'^J7_3[_P E_P#M@_L;_IY^'_!/RUHK]2O^
M'(7[)O\ T4;XI_\ A;'_ .-5YCX6_P""37[.6K_M7>*O@[=>/?B,-*T?PQ8W
M]K*GB]A.TLKL&#/Y>"O' P,4?ZI?]/O_ "7_ .V#^QO^GGX?\$^ Z*_4K_AR
M%^R;_P!%&^*?_A;'_P"-4?\ #D+]DW_HHWQ3_P#"V/\ \:H_U2_Z??\ DO\
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M\$_+6OTT_P""''_)#?&7_8V)_P"DT=:W_#D+]DW_ **-\4__  MC_P#&J/\
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MRUKZP_X(T?\ )XI_[%.^_P#0X:^FO^'(7[)O_11OBG_X6Q_^-4?\.0OV3?\
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M^$_VT?BS\=;?2/AQXZMK";P=KLNC7SRZN+VV-U:I#:) ;DR20JSB,Q!P%.X
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MB@ HHHH **** "BBB@ HHHH *_,__@V;\/:1\7?V>/B=_P %$_'EG'J'Q/\
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M+-+99)+MY5RR)$KL5#-C"D@ ]:HKYQ_98_X*K?L@_M?_ !2/P3^%FI^,]/\
M%9TF;5+;1O&7PVUG1'NK*%T22:*2]M8XI K2QY4/N^<';P<?1U !1110 5D>
M,O'7A7X?Z;'J_B[5/LEO+.(8Y/(>3+D%@,(I/13STXK7KR7]L?\ Y)OI_P#V
M'(__ $3-7F9SC:N7975Q--)RBKJ^WSLU^9R8ZO/"X2=6&Z74W_\ AI?X)?\
M0Z_^4VY_^-T?\-+_  2_Z'7_ ,IMS_\ &Z^3J*_+O^(AYU_S[I_=+_Y,^0_U
MGQ_\L?N?_P D?:W@[QOX7\?:6^L^$M4^UVT<YA>3R'CPX )&'4'HPYQCFM:O
M*?V//^287G_8<E_]%0UZM7ZED^,JYAEE+$U$E*:N[;?*]_S/L,#7GB<)"K+=
MJ^@4445Z1U!117P!_P %?_CU^VIX8_;-_9+_ &2?V0_VJY_A+%\:-<\5V7BC
M7[;P5I6MOML;*SN;<B+4(9 ,%I5^1DSYF3G:H !]_P!%?FQ:?M!_\%(?^"=W
M_!27X$?LH_M:?M?:1^T!\/\ ]H9]9T[3-7N/AU8>'=9\-ZC86\<VX)I^(;B!
MS-$"67< S_=V#S/L/]L#]OW]E#]A'1-'U;]I;XHKH]SXDNVM?#&@Z?I=SJ6J
M:S.H!9+6RM(Y)YMNY=S*FU=Z[F7<,@'LE%>(?L>_\%%/V2?VZWU[3/V>?B/<
M76M^%9(T\4>%->T*\TC5]),@S&TUG>Q13*C ?+(%*'INR"!Y1XU_X+R_\$UO
M!7C/7/"*_%#Q5KUOX7U&:P\2^)?"'PQUS6-'TVYB;$L<E[9VDD+%/XC&S@>N
M>* /L:BOSV_X*+?\%GO!W[(W[9O[,_PLT'QY<)X+^( O]6^(LUO\.]5U*271
M9+ R:;+:/;VSM)(TZ-OBA$DJ)AI$16#'[2_9Y_:*^$_[5'POM/C)\%-7U.^\
M/WUQ-#;7&K^&K_29R\3E'!MM0@AG4!@<%D 8<@D<T =O17DG[8'[='[+7[!_
M@6P^('[4/Q3@\/6NL:BNGZ#8PV,][?ZO=MT@M;2V22>X?D9V(0NX%BH.:YS]
MDK_@IS^QG^VQJ/B/PQ\"OB9>/XD\(6PN?$_@[Q%X<OM(UG3X" 5F:RO(8YGC
M.5^=%9<NJDAF H ]^HK\</A3_P %&OA]_P %$?\ @J3\0?"/BK_@H%\?O /@
MGPYXQ\,:'\$O!/PQ\%ZOI5KK<L\*-=2:U(^D220K)=$)MNVME6)B<[!O'Z[_
M !$\?>%?A3\/]=^*/CK4)+31/#>CW6JZS=0V<MP\-I;Q--,ZQ0J\DI"(Q"(K
M.V,*I) H V**\,^)_P#P4I_8D^#7['FC_M\_$CXZ6^G?"7Q!9Z?=:/XL71;^
M?[5'>[?LVVUA@:Y#-NY0Q!DPV\+M;'2_$G]LG]FSX1Z3\-]<\>_$R.UM?B[X
MFT[0/AU);:9=79UF_OHFEM8T6WB=HT:-2QFE"1(,;W7(R >G45\Z?M9?\%6?
MV)/V+_B18?!;XQ?$G4KKQOJ.G'4(?!G@[PKJ&NZI'9 D&ZF@L(96@BXX:3;N
MYVYP<=E\ ?VYOV4OVHOV>KS]J?X#?&.P\1>!]-ANI-5U6TMIUET]K:/S)XKB
MV>-9X9D3#&)XQ)AE(4AER >LT5\I_"S_ (+6?\$Y?CM\2?!_PK^!GQKU'QCJ
M?C7[-_9LN@>"M6EM;,W";X%OIVMECL9'7D13E) &4LH#*3Q/_!%']H_QS\0?
MV0/BK\5_VD_C'>:E%X8^.GC>VE\0>*M6+)IFDV5V=B-+*<100Q*W4A44'H*
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MF>$GYECDL[8HY'7#8.#WP:J^$?VAO^"C/_!0W]J/XZ_#C]DC]HOX>_ WP/\
M!3Q^?!TU[JGPW/B?7==U**"-Y[J6*6\MH;>V.0L1 9F"MDG''O?Q1_X))_\
M!/GXQ?M&_P##6WC7X %/B&]]9WEUXCT+Q9JVDM>SVI0P27,5C=0PW17RT'[Y
M'R%"MD<5C_'[_@C'_P $]_VD_C?JW[0_Q%^$NKVOBCQ+;Q6_B^Y\*^.-6T6'
MQ%%&H1$OX;&YBCN?D&TEAN9>&) & #XA_P""06JZSJG[(7_!1+PN?BWIGCY;
M;XI^,V'B;P]H4>FV.L7DFBA+B[MK2*22.%)I(]P5'93P0QSFOI3_ ()DW?CR
MZ_X-W?A]/\%9I9?%:_L\72>&#8-F7^U%LIU@5,?QB<*,=0PQ7TS^S-^P]^RE
M^QQI_BC1_P!F;X,Z=X1L/&>K+J7B+3=/N)WM9[A8$MUV0RR/';H(HT011*D8
M ^[UKB_V:_\ @DU^P!^Q[\79OCA^S1\!Y/"&O317,7EZ9XNU<Z=&EP091'IT
MEVUE%D@8V0KM_AQ0!\ ?\$2O O\ P5!\9_\ !*WX;V'[(_QM_96C^']UH]U;
M7>B^(_AOK%Y?I=M/*+Z#4FBU!$EN#*S^9E%#*RG;M*UZYX)_X(H_%[3/^"9W
MP@_9!@_; T'2_B;\#OBY-XZ^&'C'2]#-[I5O?07M[-'8R6=S)OE@C^URQD;B
MT91>H4HWNGQ0_P""&O\ P3?^*/Q-USXM-\)M?\+ZMXJNFN?%D?P_^(.L^'[3
M6IF.6DN+:PNHH6=B6+.%5F+,6))S76^/O^"37[ WQ&_9K\'_ +).M? ^2T\#
M?#[4'O\ P3I^B^*-3L;G1KMS,7N(;N"Y2X,C-<3%F>1MQD8MG- 'CG[/G[>/
M[?\ \(/V]? __!.__@I/\+OA?J&J?$SPYJVJ?#[XC?!_4+U;6X.FQ>;<0WMC
M>@RV[F+GS%?R]Y"J&RQ3[PKYW_92_P""6'[%G[&WQ(OOC5\(OAWJMYXWU#3?
M[.G\9^,_%NHZ]JB6>0WV:*?4)Y6@C) )6/;NXW9P,?1% !1110 5Y+^V/_R3
M?3_^PY'_ .B9J]:KDOC'\+?^%M>&[?P]_;O]G^1?+<>=]E\W=A'7;C<N/OYS
MGM7D9]A:^-R>M0HJ\I*R6B_.R.+,:-2O@:E.FKMK0^0**]V_X8I_ZJ7_ .4;
M_P"W4?\ #%/_ %4O_P HW_VZOQ[_ %,XE_Y\?^30_P#DCX?^P<U_Y]_C'_,Z
M#]CS_DF%Y_V')?\ T5#7JU<I\'OAC_PJ?PO-X;_MS[?YM\]QYWV;RL;D1=N-
MS?W,YSWKJZ_8LBPU?!Y11H5E:48V:T>ORT/N<OI5*&"ITYJS2U"BBBO6.P*_
M+?\ X+O?"?7?CE_P4K_8(^%/AGXP^)O %]K/B?QU%;^,/!UQ'%J>FE=,L)"\
M#R(ZJQ"%#E3\KM7ZD5YU\5OV3OV?_C=\9/AU^T!\3_ /]I^+OA/>7]U\/]7_
M +5NX?[*EO84AN6\J*58I]\<:+B9) N,J%))H _,G6/V;M=_X)3?\%=_@G^T
M;^V+\=/%GQ\\$_$M)_ 7@GXG_%'4Y)M2^&?B&X1O)B0(ZVGD7RF2(R"%77$A
M+*JMYNA^TK9?MC:G_P ')]Y9? ;XA?"SP[XF;]FRT'PUG^+_ (=O=1M;BQ^W
MR'4$TU;6Y@*7?FB0R$%G,"OQMS7Z3_M3_LG?L^?MK?!N^^ '[3GPZB\4>$]0
MNK:ZN-->_N;1UGMY5EAECGM9(YH75U'S1NI(+*259@>:_:T_X)Z?LA_MQ>#M
M#\'?M,?"9?$/_"+S";PQK:ZO=VNK:1+A09+?4()4N8V.Q"W[S$A12X8@4 ?.
M_P !/V#OV_[?_@IKX;_;[_:X^/?P8N;O3?AMJ/A&^TGX9>%-1TR?6;&29+B+
MSS=W4WFB&<*X/&W=CN*\@TWX+?\ !4#_ ((9?LO>)=8_92\;?"#XU?LX?#Z#
M6/%D'A3QE%=:-XHT_2'EGU&YBMM0MS);7;+YDSB29=S\;%'RQU]D?LJ_\$L/
MV,OV.?B3>_&CX0^"?$%UXRU#1Y-)NO%?B_QUJVN7OV!Y(Y&MD>_N91'&7BC8
MA I)09)Q7E]O_P &]'_!*ZU2/1(?@QXI_P"$7CN5N/\ A I/BKXADT!G5@XW
M6#7QB9-P!\LC9QC;CB@#R']K?XZ>&_VD?VQ_^"8'[3GAK2[G2]$\>:MKFMZ?
M:ZB LEJFH>&89H8)"/EW_O O'!(XR,5^FU>1_M,_L(?LB_MA?"32O@7^T1\#
M-)U[PMH%S!<>'],A>:P.D2PQF.)[2:S>*6U*H2@\IUPO'3BN@_9M_9H^#?[)
M'PHL_@E\!?#M]I7ANPN)Y[6SU'Q#?:I*KS2&20FXOIIIF!8D@,Y Z  <4 ?$
MG[1W]AC_ (.7OV?S\8_)_L3_ (9V\0?\*M_M''D_\)1]O;[9Y&[CS_[/VYQ\
MVW;[4W]L3^PS_P ''/['_P#PJCR?^$K'PV\<_P#"U/L6/-_X1S[#_P 2S[5M
MY\K[?YWE[N/,QBOK[]L#]AC]EK]O#P)8_#W]J+X5P>(K32-174-"O8KV>RO]
M)NUZ3VMW;/'/;OP,[' ;: P8#%87['W_  33_8Z_87UW7O&O[/WPRN8?$_BE
M$C\1^,?$?B"]UG6-0B0@I"]Y?2RRB(;5_=JRH2BD@D T ?/?_!*W_E*)_P %
M /\ LI_A7_TQU]Z:MI6FZ[I=SHFL64=S:7EN\%U;S+N26-U*LC#N""01[UQ'
MPK_9=^!7P3^*/Q ^-'PQ\#?V9XE^*6J6FH^.]2_M.ZF_M.YMH/(@D\N65HX=
ML7RXB5%/4@GFN_H _!']D'P38?M1^*_A%_P0#^*@FU/2/V>OC7\2+SXA6L_S
M2RZ#I<4D>A7+9^]%+/KH5,\8M1QD+7:_\$NOB#XJ_;%_;4_9/_9#^(,S7.I?
ML2_#7Q@?B/;L"8UURTU!_#&FQ29_Y:I;6\=T@/($A/-?J]\//V%/V4?A3^U7
MXU_;;^'_ ,(;?3?BA\0]-AL/&'BF/4KMVO[>)8%1! \I@AXMH"QBC0N8PS%B
M22?!#]A3]E']G#XY_$7]I3X+?"&WT/QM\6+V*[\?ZY'J5W,VJ31M(ZL(II7B
MM\M+(S"%(P[$%@Q ( /D/_@D4-#'_!4/]O?_ (6)Y/\ PLW_ (6QIF?MN/MG
M_"+_ & ?V5Y>[YO(V?W?E_U>?X:\\_9L_L,_MZ_\%2#\&/)_X0#_ (1O1OMW
MV#'V+_A)_P#A'KS^T_*Q\OG>=YGVC'/F8W?PU]G_ +6?_!*?]B/]M'XC6/QG
M^,OPSU&W\;:=IQTZ#QGX/\5:AH6IR61))MI9[":)IXN3A9-VWG;C)SV?P"_8
M:_93_9>_9ZN_V6/@-\'+#PYX'U&"ZCU72;.XG:2_-S'Y<\MQ<O(9YIG3"F9Y
M#)A5 8!5P >!_P#!N[X#\)> ?^",WP(M?"6AV]DNI^%&U343!$%:YN[BYFDE
MF<CEV).,G)"JJ]% 'YX^)AX\/_!LM^V'_P *]^U_:?\ AH7Q/_:7V'/F_P!F
M_P#"46/VW&/X?LWG;\\;-^:_;/X!_ ;X4?LP?!OP]^S_ / SPK_8?A'PIIRV
M.@:3]NGN?LMNI)">;</)*_)/+NQ]ZPO@U^QS^S3\ ?A=XD^"GPN^%5I:>%/&
M&LZIJOB;0M0N[C4(-1NM1)-Z9!=R2Y27)#19\L D!0#B@#Y!_P""YA_9//\
MP;]?$$Z5_8'_  @)^'>D_P#"L_LOE_9_,\RV_LG[)CO_ *K;LYV;OX=U?7G[
M$W_)F?PC_P"R8Z!_Z;H*^>]&_P"#?'_@D_I6G:AX;N?V<M1U/0;RUN[>S\,Z
MQ\0-;NM-TA+I66<V%N]X4LI&5V EB"R(&(1E!.?K_P $^#?#?PZ\&:1\/O!N
MF_8]'T+2[?3M*M/.>3R+:"-8HH][EF;:BJ,L23C))/- &G1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
-10 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>biib-20220331_g6.jpg
<TEXT>
begin 644 biib-20220331_g6.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#5H=3N+F>(30"62XEC<$AU""0;1M0)7VS10 5X]^WW^QGX _X*#_ +(/C?\
M8]^)VMWVF:/XTT^&&34],"F>SG@N8KJWG4-PVR>")BIQN"E<C.1[#10!\:^*
MO^"='[:'QS_8M^+W['G[77_!1NQ^(*?$7PO!HWASQ-;_  9MM(F\/A3)Y\TT
M5O?D:@TH,/&Z *8F(SO('J7[0W[$O_"^O^"<^N_L _\ "S?[*_MKX9Q^$?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 ?@M^W!J'B7]GS_@X&^-/_!2;PM<7
M7D_L_3_#>\\;VEOEA<>$]6T_^R]6_=C[[QI-#,N<A?)9NV1[1_P<Z>*[W]JS
MPI'^Q-X"UUI-!\#?!SQ'\;?B1=6$WRFVLK.:TT*'>O#+-?3/(4/5+<, <9'I
MOPD^$'@K]H+_ (+@_M[_  )^(^G_ &K0/&7P6\&:+K-O@9>VN=*DADQGHVUR
M0>Q /:O.)_\ @F3\?OV"?^"//[8GC7]L#XQZ'X_^(_B?X+/H%EK^A&<PVWAG
M1-!^Q:;:_OXXV67_ %TDN 0[,K%G;)H ^OOV;/B;^T3\*_\ @D1^SGKG[+W[
M-4?Q4\577PB\&VD7AZY\86^A6]O"VAP,]Y/=3I(!''L4%$1W8NH ZD9?PH_X
M*1_M5^!?VL_!'[)'_!1']C#2OAM<_%-;Z+X;>-O!GC]=>TC4;^U@-Q+IUP&M
MX);2;R061F!60_*HX)'RS^V#\6O&GPP_X),_L&V7B;XH^,O ?P/U_1O!5A\?
M/&W@.YN+:^T_1V\/P>1%)<VP,UM:S3X265,' 5<_/M;PSQII_P#P2TM?^"I?
M['<W_!,"S\0^);*'XQF/QM\1F\<>(=:T@W+V;M!I\4VJ74T,ER5$TTGD#,:B
M,,?W@6@#]"/V@/\ @K5\</"'_!07Q-_P37_9E_85NOB3X\TOP/I_B32M3?QU
M%IFG"WG8B>6^>6V86D,),2AD:62:29$6-<EUN_'3_@J#^T#\%)_A9^S#IG[&
M<?C+]J#XEZ+<ZI-\*M \;0QZ3X?L+>1XY=1O-6DB*I:Y7Y"(MTC*R#:P&>5_
M9_BB/_!Q_P#M!SF,%U_9Y\)JK8Y -W)D?H/R%<K^VS\0=)_X)U?\%N?"'_!2
M']HC3M0MO@OXZ^ 4OPRU;QW;Z;-=6WA+6(]8&H0M>>2K-!;SKMC5\8WEB2 C
M&@#Z*^'/QA_;M^('PM^)_AC]L_\ 8Y\/_#D:?X*N9]$\0^%/B3'KMCJ[/!.)
M(?+-O!/;21!4)+J5<2?*?E(KX%_X)'?MX?M__##_ ((V?#/Q-^RM_P $W$^(
M7@3X<^$;X^(/$.O_ !&AT6[UQK>[N9;M-)M/L\S3K"-R>;(4\R6.1(T?;EOT
M#\'_ /!1C]BO]MSX=_%'P=^R=\>]+\=W7A?P3<W&O3Z%;SO:VJSP3K$OVAHQ
M$[L8W.Q&9@!E@ 1GR/\ X(5HB_\ ! ?X2*J  _#;5"0!ZW5Z30!]6_LC_M-?
M#W]LS]F?P3^U+\*A<IH/CGP_!JEA!>J!/;;QAX)0I(\R.0/&V"1N0X)&#7(_
MM_?LH?L4?M1?!5KW]O;P9::UX"^'SS^*KU-3U:[M;.T%M:RF2YN!;2H9HXX3
M*Q1]R\9VD@8\4_X-P"3_ ,$3/@'D_P#,O7__ *=KVO;?VU/V_OV-_P!AG3O#
M\'[9OQ%B\+Z)XWDN["PU#4=#NKO3Y7C1#)!</#%(L6])>/- 1@K#.>" ?F?^
MS;X<_8(U'_@L/\%-8_X($72Q:#8Z;K$G[3;>";B^7PN=$-N%T]+D7!\E[IK@
MOY2P@L&"LP&W</IC_@OU_P $X/V:?VD/V2/B]^UW\88?%.J>(_A]\#-9;PII
M47C"]MM(M+JSM[R[@O&LH)$CFG$LO+2;E98XU92%P? _BG\</V.?V[O^"L'[
M+^L?\$@=(L=;\5_#_P 8W&H?&/XE> /#$MCIECX3,&V;3[Z[$,<=R9QN2)"7
MVL2!@R8/T9_P7Y_X*(_L;?LV?L3_ !9_92^-GQJ@T/X@?$GX+:_%X)\.R:/?
M3-J;SVMQ:Q 2PP/%'NF^3]XZXZG YH ]W_X)+?\ **[]FK_L@7@__P!,MI7T
M%7PG_P $&_\ @HC^QM^T]^Q3\)OV8?@5\:H-?\=?#+X'^%[3QSH$>CWT#:7-
M!I]M:RJ99X$BEVSHR9C=P<9&1S7T5^RS^V_\&_VO_&/Q4\$_":QUU+GX/_$&
MZ\&^*I]5T](8)=3M_P#6BV=9'\U!QR0IY&5&: .J_:2_9_\ !'[4WP1U_P#9
M_P#B3J.LVN@^)K>.WU:3P_JTEC=O"LJ2-&D\?SQA]FQBI!*.P!&<C\H_^"TO
M_!,_]@/_ ()N_LB>'OCC_P $^/A=-\+_ -H>R\>:'IGP1O/!6N7KZKKVJ3WT
M*2V+I+,YO4:V,[,)-W**I)#E'_47]L_]K+X9?L,?LN>,_P!K+XQ1W\OAWP5I
M/VR^M]+M_-N+EVD2&&&-20-TDTD<8+$*N_+$*"1^/?[#_P#P5]_X);_%S]H,
M?\%./^"HO[;>A-\5A%-;?"WX6VOA;7+S2OA7I4AP8XG2Q,=QJ4JX,]V,]=J$
M* % /L#_ (+9>)?B#\8?&_[*W_!-"Y\4WV@:;^T/\1)XOBC+X=OY+>:\T+2;
M2.ZU#38YE(9(YS,JE@<D( <JS*?._P!K']E3X$?\$:OVVOV5_P!I/]A'P,GP
M\\/?$SXNV/PG^*7A#1;V?^S=?M=4C<65S-"[LOGVTD4D@E&&8XW$\Y]"_P""
MUT.K^"O&/[*G_!5GP3X:U/Q)X2^!7Q"FO_&ZZ)I\D]S;>%]:M(H+O4UA WNL
M*1QLR@;@'R<*K$>>?M7?M6? C_@LQ^VU^RO^S?\ L(>-U^(7AWX9?%RQ^*_Q
M3\8:-8SC3-!M=+C<V5M--(BCS[F262,1#+*<;@!G !];?M ?\$:_^">O[6?[
M0&J?M*?M2_!.7X@^(M1L[>TM;?Q-K]Y)I^EP10K%LM;1)4ACW[=[,59RY)##
M.*^;?^"$.BZ9\,OVP/VO_P!G?]ESQ-JNJ?LS> _'&C6'PRCOM4EO;/2=::S=
M]:T^PGE9F:&*<HI7<0N(FR3(SOQ'_!;_ /X+.?#OP/\ M*V__!*'2?VF&^"5
MKJ&GPW/QH^,TNE7EQ=:+I4\*2KIND1VL,KM?7$,B_P"D%1' K\,7SY?U1_P2
M*_:O_P""3'Q$^%"_LF?\$K_B5IVJZ%\-M)@>]TNQT'4;1XDF=A]IFEO+>+[1
M-+(KL[Y9F8DG&10!YQ\>?^"#G_!%7X9? 3Q[\5/VB/A-+B'2[W6?%GQ8\3>,
M+^?6K5U5I&O4N6FQ'*AP42- C%57RVSM/??\&^_C7]HWXB?\$B/@[XP_:DU3
M5;_Q->:1=&TU+7F9KZ]TH7LZZ=/.S$EV:T$!5R2738Q)+$G\Z?C=_P %H_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **\2_8(U34]7^#6J
MW.K:C/=2+XWUA%DN)F=@HN2 N6)X Z#M7MM !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% 'A?_  3W_P"2)ZM_V/>L_P#I2:]TKPO_ ()[_P#)$]6_['O6?_2DU[I0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!X7_ ,$]_P#DB>K?]CWK/_I2:]TKPO\
MX)[_ /)$]6_['O6?_2DU[I0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X7_P3W_Y
M(GJW_8]ZS_Z4FO=*\+_X)[_\D3U;_L>]9_\ 2DU[I0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!X7_P3W_Y(GJW_ &/>L_\ I2:]TKPO_@GO_P D3U;_ +'O6?\
MTI->Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 >%_\ !/?_ )(GJW_8]ZS_ .E)
MKW2O"_\ @GO_ ,D3U;_L>]9_]*37NE !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '
MA?\ P3W_ .2)ZM_V/>L_^E)KW2O"_P#@GO\ \D3U;_L>]9_]*37NE !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M Q_JV@60\(: /T?HHHH \+_X)[_\D3U;_L>]9_\ 2DU[I7A?_!/?_DB>K?\
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M/]8,W_Y^_P#DL?\ (/[2QO\ /^"_R/T(_P"'[_\ U:O_ .7Q_P#<-'_#]_\
MZM7_ /+X_P#N&OSWHH_U@S?_ )^_^2Q_R#^TL;_/^"_R/T(_X?O_ /5J_P#Y
M?'_W#1_P_?\ ^K5__+X_^X:_/>BC_6#-_P#G[_Y+'_(/[2QO\_X+_(_0C_A^
M_P#]6K_^7Q_]PT?\/W_^K5__ "^/_N&OSWHH_P!8,W_Y^_\ DL?\@_M+&_S_
M (+_ "/T(_X?O_\ 5J__ )?'_P!PT?\ #]__ *M7_P#+X_\ N&OSWHH_U@S?
M_G[_ .2Q_P @_M+&_P _X+_(_0C_ (?O_P#5J_\ Y?'_ -PT?\/W_P#JU?\
M\OC_ .X:_/>BC_6#-_\ G[_Y+'_(/[2QO\_X+_(_0C_A^_\ ]6K_ /E\?_<-
M'_#]_P#ZM7_\OC_[AK\]Z*/]8,W_ .?O_DL?\@_M+&_S_@O\C]"/^'[_ /U:
MO_Y?'_W#1_P_?_ZM7_\ +X_^X:_/>BC_ %@S?_G[_P"2Q_R#^TL;_/\ @O\
M(_0C_A^__P!6K_\ E\?_ '#1_P /W_\ JU?_ ,OC_P"X:_/>BC_6#-_^?O\
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MC'0D@5M_!SX8:)\%_A=H7PL\.S22VFAZ<EM'/*,-,PY>0CL68LQ X&ZO*/\
M@H%=Z->> ?"O@BWTBZNO%FM>-;)/ <UI>K;FPU1"6CNWD9' CC!.Y=K;@V!C
M[RY8>G1JXY02O"_X>?RW(IQISQ"CO&_X?UN3Q?M1_&+X?>._#'A;]HWX#VGA
M[3O&&JQZ7I&MZ+XD6_C@OI/]5;SIY:%2W0.I(X/4 D>ZU\C?%O2OCEX ^(GP
MR\;_ +7WBO2?%GA6R\6VL-K%X9M_L0T_6) PM[R>-E8W$:$-]UH]I.=I^Z?K
MFJQM*E",)02U3ORWMH^E];]QUX0BHN-M>U[?CJ%%%%<!SA1110 4444 %%%%
M !7Z:?\ !#C_ )(;XR_[&Q/_ $FCK\RZ_33_ ((<?\D-\9?]C8G_ *31U[O#
M?_(UCZ/\CT,K_P!\7HS[<HHHK]'/J HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>]9_]*37NE !7Y/_ /!9?_D\4?\ 8IV/_H<U?K!7Y/\ _!9?_D\4?]BG8_\
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MS[<HHHK]'/J HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR_4\S-O]T^:/D^BBBOSP^:"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#PO_@GO_R1/5O^Q[UG_P!*37NE>%_\$]_^
M2)ZM_P!CWK/_ *4FO=* "OR?_P""R_\ R>*/^Q3L?_0YJ_6"OR?_ ."R_P#R
M>*/^Q3L?_0YJ^>XF_P"19_V\OU/,S;_=/FCY/HHHK\\/F@HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K]-/\ @AQ_
MR0WQE_V-B?\ I-'7YEU^FG_!#C_DAOC+_L;$_P#2:.O=X;_Y&L?1_D>AE?\
MOB]&?;E%%%?HY]0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!X7_P $]_\ DB>K?]CWK/\ Z4FO=*\+_P"">_\ R1/5
MO^Q[UG_TI->Z4 %?D_\ \%E_^3Q1_P!BG8_^AS5^L%?D_P#\%E_^3Q1_V*=C
M_P"AS5\]Q-_R+/\ MY?J>9FW^Z?-'R?1117YX?-!1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Z:?\$./^2&^,O\
ML;$_])HZ_,NOTT_X(<?\D-\9?]C8G_I-'7N\-_\ (UCZ/\CT,K_WQ>C/MRBB
MBOT<^H"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-*T?PQ8W]K*GB]A.TLKL&#/Y>"O' P,4?ZI?]/O_ "7_ .V#^QO^GGX?\$^
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M /&J^C/4/L:BOCG_ (<A?LF_]%&^*?\ X6Q_^-4?\.0OV3?^BC?%/_PMC_\
M&J /L:BOCG_AR%^R;_T4;XI_^%L?_C5'_#D+]DW_ **-\4__  MC_P#&J /L
M:BOCG_AR%^R;_P!%&^*?_A;'_P"-4?\ #D+]DW_HHWQ3_P#"V/\ \:H ^QJ*
M^.?^'(7[)O\ T4;XI_\ A;'_ .-4?\.0OV3?^BC?%/\ \+8__&J /L:BOCG_
M (<A?LF_]%&^*?\ X6Q_^-4?\.0OV3?^BC?%/_PMC_\ &J /L:BOCG_AR%^R
M;_T4;XI_^%L?_C5'_#D+]DW_ **-\4__  MC_P#&J /L:BOCG_AR%^R;_P!%
M&^*?_A;'_P"-4?\ #D+]DW_HHWQ3_P#"V/\ \:H ^QJPOB=\3OAY\%_A]K'Q
M7^+/C33O#OAK0+"2]UK6]7NEAMK.!!EG=V. .WJ20!DD"OE;_AR%^R;_ -%&
M^*?_ (6Q_P#C5>5_ML_\&ZGP,_:+_9?\6?"'X5?&_P <Z-XEU2TB?0]0\2>(
M&OM/2ZAGCGC6Y@$8+Q,8]C$<KNW ,5"D ZKX#?\ !P!^P_\ &']H?Q#\*;KQ
M_J5CH%WK^B:5\,O$D_PW\06]MKLU_;QX22XEM!%"7N) D1D\I9$*LI8$,?O"
MOYV_#7PU\4?L._&'XFZC_P %-?V7O'"^"M USPWIOCWXI_!?XK"]TWPW+=6<
M$=O<36-S EW);2&2-]X),6X1X=]H;ZN_;O\ V7/V;?V2/C1\.OASX;^$/[4G
MCRS\32"YO]5\#1-JMO)"WFJ+:WE#1C[6#$)"F#B.1&S\W !^NU%?CU_PKG]D
MW_HP?_@HE_X19_\ CM;7PX^ W[)OQ%^(.A^ /^&,OV^-"_MO5K>Q_MOQ'X9-
MKI]AYLBIY]S-YC>5"F[<[X.U03@XH _6NBOCG_AR%^R;_P!%&^*?_A;'_P"-
M4?\ #D+]DW_HHWQ3_P#"V/\ \:H ^QJ*^.?^'(7[)O\ T4;XI_\ A;'_ .-4
M?\.0OV3?^BC?%/\ \+8__&J /L:BOCG_ (<A?LF_]%&^*?\ X6Q_^-4?\.0O
MV3?^BC?%/_PMC_\ &J /L:BOCG_AR%^R;_T4;XI_^%L?_C5'_#D+]DW_ **-
M\4__  MC_P#&J /L:BOCG_AR%^R;_P!%&^*?_A;'_P"-4?\ #D+]DW_HHWQ3
M_P#"V/\ \:H ^QJ*^.?^'(7[)O\ T4;XI_\ A;'_ .-4?\.0OV3?^BC?%/\
M\+8__&J /L:BOCG_ (<A?LF_]%&^*?\ X6Q_^-4?\.0OV3?^BC?%/_PMC_\
M&J /L:BOEOX2_P#!([]FOX-?$O1/BIX7\=?$6XU'0=02\LX-2\7&6W>1#D"1
M/+&]?49YKZDH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHKYQ_:\_P""L?["7[$/CNQ^$?QS^,<K>-=2M?M-GX(\*Z!>
MZWJ[08)$KVUC%*\*$ D-+L# ';G% 'T=17AW[&O_  4?_8S_ &^K75Q^R_\
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MCO?>6CM+M18V;9M R0: /UBHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH YJT^#7P?T_XHW7QPL/A3X:@\:WVG+I][XOAT*W75+BT4J1;O=A/->(%$
MPA8J-J\<"NEHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** .:\>_!KX/_%34]#UKXH?
M"GPUXDO/#.HC4/#=WKVA6]Y+I-V"I%Q;-*C&"4%5(="K?*.>!72T44 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >6_&_]M3]F?\
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M0+;]H:^32+S6!I-GX]N?!.KP^&)[TOL\I=7>U%IC<"/,,@B.,[\<U[S^UO\
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MI7A_4KM[F_\  ^A?$_7[#0)I'.Y_^)?!>I"B$]8T54[;<<5[E^T7^P)^R/\
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MA<'>2PS7SW^Q3\>OVFO$G[.'_!0']@[XZ?'^\^,=I\ ="U+1_!WQ/U&-6O\
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K HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>biib-20220331_g7.jpg
<TEXT>
begin 644 biib-20220331_g7.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@"
MF@)Z P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#5H=3N+F>(30"62XEC<$AU""0;1M0)7VS10 5X]^WW^QGX _X*#_ +(/C?\
M8]^)VMWVF:/XTT^&&34],"F>SG@N8KJWG4-PVR>")BIQN"E<C.1[#10!\:^*
MO^"='[:'QS_8M^+W['G[77_!1NQ^(*?$7PO!HWASQ-;_  9MM(F\/A3)Y\TT
M5O?D:@TH,/&Z *8F(SO('J7[0W[$O_"^O^"<^N_L _\ "S?[*_MKX9Q^$?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5;_Q->:1=&TU+7F9KZ]TH7LZZ=/.S$EV:T$!5R2738Q)+$G\Z?C=_P %H_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **\2_8(U34]7^#6J
MW.K:C/=2+XWUA%DN)F=@HN2 N6)X Z#M7MM !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% 'A?_  3W_P"2)ZM_V/>L_P#I2:]TKPO_ ()[_P#)$]6_['O6?_2DU[I0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!X7_ ,$]_P#DB>K?]CWK/_I2:]TKPO\
MX)[_ /)$]6_['O6?_2DU[I0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM(5@M_-E2&,$@$DM)(B  $EF '6O-_V(_P#@IQ^PY_P4:?Q4G[&'QSC\:_\
M"$RVD?B9XO#VHV*VC77G^1AKRWA$P?[--S&7 V<D97/I/@_P#\&/$/P2\.^!
M=!T[2?$_@>+0]/305O)4U6UN[.&.-K282RF07'RI%(LI+%B ^XGFOAK_ ()5
MVUM9_P#!9G_@HE:6=ND447B+X=)%%&@544:)>   < #TH ^L/VQ_V_\ ]D[]
M@CPWI'B+]I[XIIHDGB.^-EX9T6RTVYU#4]9N!MW1VMG:1R3S8W)N94VKO3<P
MW#-?]CC_ (*(?LE?MXVNNI^SC\2I;_5?"MQ'!XI\,:UHUWI6K:.[@F/[19WD
M<<R*X!VOM*-@@,2"!\8?MW?$?X?_ +'G_!P+\&_VR?VP[U-'^$6J_ 74?!WA
M'QOJT+'2_#GBLZC-<2-/+@K:O-9/Y0E;;N#L,[8W*^<:?^W5\"OCY_P=$?!O
MQ!^QMXIMO$?AOQ)\'->\'^-_&_A]"VEZY<6D%WJ@MX[E1Y=XUL4LBTB%@OGH
MF[Y<  _5;X\?'?X1_LQ?![Q#\??CQXXM?#?A#PKIS7VNZU>*[);0J0.$C5GD
M=F*JL:*SN[*JJS, <W]EW]J+X%?MH? K0OVEOV:?'/\ PDG@GQ*+DZ)K7]F7
M5G]I^SW,MK-^YNHHIDVS02I\R#.W(RI!/QO\:KK_ (>K_MD:Y\+[$_:_V?OV
M8[^2Z\72CYK;QI\08H2]OII[2VNEAEFF4G#73Q(RL(\U;_X-=_\ E!5\"_\
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M%?\ !/\ E^!?P[TOQKI?B'XV^)]:\>Z;JD>L1:?)YHTK2XK.1Y)$GF ;SI
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M:])HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXWD\91>"]7E^'5OITWB!=+N#H46L2.EH]X(V\A9VC!<1&3:&*@L%SCFORO\
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MI-[8Z'8^>CS/!;6+/->2%4(4J!M)SCH1^D_V+QO_ -!NR_\  8_XT?8O&_\
MT&[+_P !C_C0!4^#WPWTWX-_"/PM\(=&OYKJS\*^'+'1[2ZN?]9-';6Z0J[_
M .T0@)]S71UC_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^- &Q16/]B\;_
M /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\ ]!NR_P# 8_XT?8O&
M_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^- &Q
M16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\ ]!NR_P#
M8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\
MP&/^- &Q7(_%_P"*?_"J='M=5_L+[?\ :;DQ>7]J\K;\I.<[6STK6^Q>-_\
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M\-X+"X_,?95X\T>5NUVNW9H^8XMS'&99E/ML-+EES)7LGH[]TT=+_P -C_\
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M /)8?_(GMW_#8_\ U3G_ ,J__P!IH_X;'_ZIS_Y5_P#[37B-%'^J^1?\^?\
MR:7_ ,D'^N7$G_/_ /\ )8?_ ")[=_PV/_U3G_RK_P#VFC_AL?\ ZIS_ .5?
M_P"TUXC11_JOD7_/G_R:7_R0?ZY<2?\ /_\ \EA_\B>W?\-C_P#5.?\ RK__
M &FO0/A!\4_^%K:/=:K_ &%]@^S7(B\O[5YN[Y0<YVKCK7RC7T!^R#_R*&J_
M]A(?^BUKQ.(<CRO Y9*M0IVDFM;R>[\VT?1<+<1YUF6<0H8FKS0:>G+%;+R2
M9ZY1117YZ?J84444 %>1_M??\BAI7_82/_HMJ]<KR/\ :^_Y%#2O^PD?_1;5
M[7#O_(ZH^OZ,^>XK_P"2>Q'HOS1\_P!%%%?L1^"!1110 4444 %%%% !1110
M!YO^UQ^T[X$_8X_9Y\1_M%_$:RO;O3/#T$1%AIL8>XO+B:9((((P2!N>65%R
M> "2> :^;?@!^U1_P4<U_P#:1\;V/C']BFT?16US0(=4T2+XN6\MSX0M[BSB
M9I4C>V6*Y^1C-+'&ZG=N5=YP3],?M3_!7X*?M&_ O7/@9^T'Y/\ PB_B=8;.
MZ,E^+9Q.9D:W:*0GY9A.L;)URX48;.#^<_Q)U?\ ; _X)=^(OC%\=_A_^UO+
M\0O#'@7Q!X6M/$/A#XG:5!-J?B6"ZM;>*-8M1A"2_:HHY JC:0RH78,5*MXF
M95L1AZ\:CDU36_+RW6DFVTUJK6M;L]+V/HLHP^%Q6%G248NJ]%S<UFFX**3B
M]'>][]XZVN?>7[4_P<_:]^,6O:'I/[/G[64'PJ\.P6\[>);NR\(V^J:G?2ED
M\J.%KG]W;H%#DN 6R0 ,5X?\"OBU^UM^S+_P41TC]A+]H#X_+\7/#?CCP+=^
M(/"_B2^T"WL-6T:6V<J\%P+8!)H6"MB1AN+%0,!2#[I^V/\ MJ?#O]CGX76G
MC#Q+I%]K7B7Q#<+8>!O >E)NU/Q#J3X$=K#& 2 "R[Y,$(#W8JK<+^PM^R!\
M3?"'CC7OVU?VPM6M=5^-?CVQ2VO+:Q;=8^$=)#!XM&LN3E5(4RR G?(N<M\T
MDFM>"GCHJC)\Z:<O>?*H]FKVO+HK7^T8X>;IY=-XB,>1IJ'NQYG+NI6YK1ZN
M]OL]3R+XR?&3]JKXA?\ !1_XE_L\^%/^"B]G\%/"/A#PKH-]I4%YX-T*^6[N
M;R-O,027\8?.5W8WMUP !7US^S/X!^,OP[^'3Z3\</VEYOBMJESJ#W5IXGF\
M,6.D[;1XXPD"Q60$;J&5W$GWCYN.BBN7^*/_  3]_8:_:"^(6K?%3XN?LZ^%
M/%GB+48H[/4M5U>W^U2*L481(UW,1"57'W I[GDYKYZ_X(\?V?\ #SX\_M-?
MLN_"+Q1=ZK\(_AWXYTV/X?>??O=Q:;-<V\[ZAI\$KEB8X)HT7;N."2QRSL3G
M25;"XY*J[^TE*SYY.V\DG%^[9)6NMG;N:5I8?&9=)T5R^RC#F7)!7VBVIKWF
MW)WL]U?L?7_[0GBG7? WP"\<>-?"U]]EU/1_!^IWVG7/E*_DSQ6LDD;[7!5L
M,H.&!!QR"*^(?V+$_;Q_:M^"?@GXFR?\%GX;/7_$OAZVU74/!UG\*_"]Q<67
MF+N:,@1K)@#^(H/6ON:7Q!\(/C3\/-7L[;Q;HOB#PU?PW.E:Q/IVL1RV[!E,
M4T#2PO\ (V'VD!@PSV-?#_\ P4X_X)T_\$^?V?/V&O&/QJ^'/PJT+X8^*O V
ME'4O!'B_PS*UA?PZM&0;6(3*P:9I9-L>'+'Y]PPP#"LQA6;^L1=X1BVUSRC?
MK>\=-D]R<IJ4$OJLU:I.22;IPG;I9J6JU:;MJ?H117 _LJ>+_'/Q!_9?^&_C
MWXGV[0^)=;\!:/?^(8FBV%+Z:RBDG!7^$^8S<=NE=]7K0FJD%)==3Q*D'2J.
M#W3M]P44451 4444 %%%% !7I/[*W_)4O^X;-_-:\VKTG]E;_DJ7_<-F_FM>
M7G?_ "**_P#A9[/#O_(]PW^-?F?2=%%%?BY_084444 %%%% !1110 4444 %
M%%% !1110!X7_P $]_\ DB>K?]CWK/\ Z4FO=*\+_P"">_\ R1/5O^Q[UG_T
MI->Z4 %?-G[5/_)4O^X;#_-J^DZ^;/VJ?^2I?]PV'^;5]5P?_P C?_MU_H?%
M\>?\B+_M^/ZGFU%%%?J1^+A1110 4444 %%%% !1110!X9^UY^V3JO[/'C+P
M'\$_A;\';GQ]\1_B7=WL?A3PTNL1Z=;"&SA6:[NKF[D5Q#%&CJ<!&9R<*,BN
M#_X)G_'S]LSXG_#7PQI_[0?[/L,.B7>@7%U:_$JW^($>HO>3K<;5@N+5X8YH
MW*E\."Z8BP2I(%=W^V'^Q]\*OVL=>\(7.H?%;7? _P 1/!DMWJ/@3Q5X0UB.
MVU6P614BNMJ.&$UNX\I9%*X(PNX;CGY'_P"">/QT_:K_ &;OB-^S_P#LS_$G
MXN:+\1/ _P 8] UV70K8:!'8ZQX4?3TDG+2-"VVYMY""OF.H;<6Y&S#^)7K8
MBCF<74DU!Z*W+;7D5I77-\3W71K;4^BP^'PN(RB2I1BZBUES<U]%-WBT^6RB
MMGU3O?W3Z5^,'[+O[?'Q=^*>N^(=!_X*)7/P[\)>>H\*>&?"/@*PN984$:9D
MNKJZ!>5C)O/EJ H7'/6L7_@FW^TO^T;\8=/^,'[/_P ??$.C:_XY^#OC.7P\
MOC;3M/%K:ZXK1,\$\L$?RQ2@J?,1,  J ,@DW?VUOVS?B'IOQ M/V'_V)=/M
M=>^-GB6S\VYO)QOT_P #::V VJZ@P! 8!@8H2"78J2I!1)?2?V+?V0O ?[%7
MP4B^%?A/5KS6-1O+^;5O%WBK56W7FOZM.0UQ>SDD_,Q  &3M55!+$%CK"'-C
M[T92M&_.W)M7>T4FVKK?2UEIU,:E1PRRV(C'FER\B48J22WDVDG9K35OF>O2
MY\\?%?\ 9O\ ^"IOPW^#OB#X]S_\%31=>*_#FBW.L'PZ/AGIEOX>E6")IGLS
ME3,$(0IYY.\9W8!Z?1?[#/[1.I_M9_LC> /VB]<\.QZ3?^*_#T5W?V$.[RXK
M@%HY?+W9/EET9DR2=K+DGK7S9\:/B)XU_P""L_Q$UC]D7]F_Q#<Z5\"M OOL
M?QB^*>G/@^(I5(+Z#I4G1U/ GN!E=IP,J0)_L;3[3X5_L^_"VST>&?2/"GA#
MPMI<%G:FZNDMK/3K2)5BC0O(0J* %4%CZ<Y-&"BOK$ITI/V25KN3=Y7W5V]%
MLWLWZ!F$G]5A3K1C[9N]HQC%QBUHGRI:MV:3U2]3Y]_X*Y?'?XV_ ']G'PWK
M_P !/BH/!>M:[\4-"T&?Q"=)M+T6MI=RO'*WE7<;QG PV2 ?EZC)J]^RW\+O
MVHO^%AVGCOQ/_P %68OB]X6T\S1ZKX9L/AYX?M8KB1HG2,-=6(\R(HY63 (W
M>7M/!->M?&OX)?L]?M5^!=.\#?&SPGH_B[P]<WD.J:;I]Y<E[>ZDC1C'*H1P
M)E"R$X^92"#@\&OAW]L#]GKX ?L*?MN_LS^._P!BCPM8>!O&?C;XGVWAOQ1X
M3\+N8+;6_#<W%Y--:*=FV#Y6#A1AG#')C4KGC%6H8GZS)WA[JLIR5M;?"O=>
MZT>YI@'0Q.$^J17+4?.[N$)7TO;F?O1M9ZK9NY^D%%%%>T?/A1110 4444 %
M%%% !7T!^R#_ ,BAJO\ V$A_Z+6OG^OH#]D'_D4-5_["0_\ 1:U\WQ9_R)9^
ML?S/K>"/^2AAZ2_(]<HHHK\G/V\**** "O(_VOO^10TK_L)'_P!%M7KE?-'_
M  4X^-?_  I#X8^'=<_X1G^T_MFO-!Y7VWR-G[EVW9V-GIC&*]C()QIYQ1E+
M:_Z,\'B>G.KD->$5=M+\T>=45\X_\/ ?^J2_^5[_ .T4?\/ ?^J2_P#E>_\
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M?"OPLCM_ WBRXO9_$&@RZM>3+=R7>/M!,LLS2IOP.%<!?X<5Y9X2_P""+?\
MP3N\)^*-+\42?!K4=;_L.X$^BZ7XI\8ZGJEA9.#D%;:ZN'B8#T=6'M6W_P /
M ?\ JDO_ )7O_M%'_#P'_JDO_E>_^T5,UE,^7FA%\NWN[>FA4%GM/FY9R7-J
M_?W?=ZZGT<  , 8 Z 45\X_\/ ?^J2_^5[_[11_P\!_ZI+_Y7O\ [175]=PW
M\WX/_(X_[-QO\GXK_,^CJ*^<?^'@/_5)?_*]_P#:*/\ AX#_ -4E_P#*]_\
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MO^"<_P >/BGK?QK^*?[/LVH^)_$=R+C6=3B\:ZU:_:9 BH&,=O>)&ORJ!A5
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M?%7_  UM^T'_ -% _P#*5:?_ !JC_AK;]H/_ **!_P"4JT_^-4?VC0[/\/\
M,/[(Q/=?C_D?:M%?%7_#6W[0?_10/_*5:?\ QJC_ (:V_:#_ .B@?^4JT_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^J/^"/?_ "=X?^Q5O?\
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MD/V:9?&OQ'_9V^&)MM&3X&1:?!XQAM])%CI6D+=67VZ***0!8B$M\.X3B/<
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M>?  ZE+XG\9+<6\(L(+;PX^F65N(FD$LC74LOS;%95$9+'D9\V\5_#K]L_\
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MA .P7=@#T%><5VTYJI34UU5SSZM-TJLH/HVON"BBBK("BBB@ HHHH *^J/\
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M% 'A?_!/?_DB>K?]CWK/_I2:]TKPO_@GO_R1/5O^Q[UG_P!*37NE !7Y7_\
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MD8F;EA*<917-)MZ1BG;9+1+=W?W&]\(=7^$VA>,!J7QG\'ZGKNC);/C3=*U
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M$_Y.\'_8JV7_ *%-7N</_P#(P^3_ $/GN)O^19_V\OU/E>BBBON#\\"BBB@
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MU\KU]4?\$>_^3O#_ -BK>_\ H4-<.9_\B^KZ,]#*?^1G2_Q(_5"BBBOSD_5
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M=UE.K^;I]M LMQY,;/<+M(V- LAX0BN>_P""AOQ]_P""*OA']KK7OAS\7/\
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M_P!JH^M4._YA]2Q/\OXK_,]DHKQO_AK7_JG_ /Y5?_M5'_#6O_5/_P#RJ_\
MVJCZU0[_ )A]2Q/\OXK_ #/9**\;_P"&M?\ JG__ )5?_M5'_#6O_5/_ /RJ
M_P#VJCZU0[_F'U+$_P OXK_,]DHKQO\ X:U_ZI__ .57_P"U4?\ #6O_ %3_
M /\ *K_]JH^M4._YA]2Q/\OXK_,]DHKQO_AK7_JG_P#Y5?\ [51_PUK_ -4_
M_P#*K_\ :J/K5#O^8?4L3_+^*_S/9**\;_X:U_ZI_P#^57_[51_PUK_U3_\
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M&@/A'_T-O_DA<?\ QNOFFBOJ_KM7LOZ^9\;_ &=0[O\ #_(^EO\ AH#X1_\
M0V_^2%Q_\;H_X: ^$?\ T-O_ )(7'_QNOFFBCZ[5[+^OF']G4.[_  _R/I;_
M (: ^$?_ $-O_DA<?_&Z/^&@/A'_ -#;_P"2%Q_\;KYIHH^NU>R_KYA_9U#N
M_P /\CZ6_P"&@/A'_P!#;_Y(7'_QNC_AH#X1_P#0V_\ DA<?_&Z^::*/KM7L
MOZ^8?V=0[O\ #_(^EO\ AH#X1_\ 0V_^2%Q_\;H_X: ^$?\ T-O_ )(7'_QN
MOFFBCZ[5[+^OF']G4.[_  _R/I;_ (: ^$?_ $-O_DA<?_&Z/^&@/A'_ -#;
M_P"2%Q_\;KYIHH^NU>R_KYA_9U#N_P /\CZ6_P"&@/A'_P!#;_Y(7'_QNC_A
MH#X1_P#0V_\ DA<?_&Z^::*/KM7LOZ^8?V=0[O\ #_(^EO\ AH#X1_\ 0V_^
M2%Q_\;H_X: ^$?\ T-O_ )(7'_QNOFFBCZ[5[+^OF']G4.[_  _R/I;_ (:
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M\;K]0_\ @A%XV\,>-_@1XTOO"^I_:HH?%R1R-Y+IAOLL9QAU!Z&OPFK]FO\
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MT ?7]%%% 'A?_!/?_DB>K?\ 8]ZS_P"E)KW2OGK]@O6+^P^#FK06V@7%RO\
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MI:/^$EU?_H4+W_OI: -BOS9_X.7O^39_A[_V/3_^D4U?H=_PDNK_ /0H7O\
MWTM?G'_P<DZM>ZA^S;\/X[K0Y[4+XX<AY2,-_H<O'%=>!_WN!Q9A_N4_3]3\
M<Z***^I/D HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ K[J_X-X?\ E(.?^Q%U+_T.WKX5K[B_X-]+RXL?V_3/;:?)
M<M_P@^I#RXB,_?M^>:Y\7_NL_0ZL%_O</4_=ZBL?_A)=7_Z%"]_[Z6C_ (27
M5_\ H4+W_OI:^3/LC8HK+L]>U*YND@F\,W4*LV&E=EPON:U* "BBB@ HHHH
M*KZKJ^E:%8/JFMZG;V=K%CS;FZF6.-,D 99B ,D@?4U8KP;_ (*0M^P=J_[,
M-W\-_P#@I'JFD6OPK\8:[IVE:D=?U&ZLK%[L7"W5JL]U;,AM4\ZV1O,>2./*
MA6;YL$ ^:?VG_P#@FCXO^-?[;GB/]MCX*_\ !9;Q'\)=1U[2++2QH7A.RTMH
M([.V@1%AF9I1]L7SO.G7SU<Q-<R!"H)SW'[(_P"QO^T]\*?VA/#_ (^^(G_!
M;/QA\7='L/M?VSX>:IH>CPP:MOM)HTW/;GS1Y3NLXV]3" >":YGPS_P;?_\
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M]_RD''_8BZ;_ .AW%>EE?^]?)GEYO_NGS1\*T445]$?+A1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7[-?\&T/_)L
M_P 0O^QZ3_TBAK\9:_9K_@VA_P"39_B%_P!CTG_I%#7!F7^Z/Y'HY5_OJ]'^
M1^DU%%%?-'U84444 %?FS_P<O?\ )L_P]_['I_\ TBFK])J_-G_@Y>_Y-G^'
MO_8]/_Z135UX'_>X'%F'^Y3]/U/QEHHHKZD^0"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "ONK_@WA_Y2#G_L1=2_
M]#MZ^%:^ZO\ @WA_Y2#G_L1=2_\ 0[>N?%_[K/T.K!?[W#U/W6HHHKY,^R"B
MBB@ HHHH **** "L_P 6>$?"GCWPU?>"_'7AC3M:T?4[9K?4M)U:RCN;:[A8
M8:.6*0%)$(X*L"#6A10!\%^.?^#</_@FWJ_B*\\3?!>V^)'P<GU&4RZA;?"#
MXD7VD6DSG'(MBTD,0P,;8T10.U=;^SI_P08_X)I_L[>/K?XOR?!R_P#B%XTM
M'#VGB[XL^(;GQ%=V[*=R-&EVS01NIY61(@X/(:OL>B@ HHHH \+_ .">_P#R
M1/5O^Q[UG_TI->Z5X7_P3W_Y(GJW_8]ZS_Z4FO=* "OPI_X.'O\ E(./^Q%T
MW_T.XK]UJ_"G_@X>_P"4@X_[$73?_0[BO2RO_>ODSR\W_P!T^:/A6BBBOHCY
M<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#NGS1\*T445]$?+A1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG*IA4A4^%I^A4Z=2G\::]0HHHJR HHHH **** "OV:_X-H?^39_B%_V/2?\
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M(RNM/)-=7T\OZV.O%+GE&TM7WDG;1=?/^MSW;_@MU_R>_P#]R%H'_I$E9/\
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MOZ]7J%%%%:&84444 %%%% !7W5_P;P_\I!S_ -B+J7_H=O7PK7W5_P &\/\
MRD'/_8BZE_Z';USXO_=9^AU8+_>X>I^ZU%%%?)GV04444 %%%% !1110 444
M4 %%%% !1110!X7_ ,$]_P#DB>K?]CWK/_I2:]TKPO\ X)[_ /)$]6_['O6?
M_2DU[I0 5^%/_!P]_P I!Q_V(NF_^AW%?NM7X4_\'#W_ "D''_8BZ;_Z'<5Z
M65_[U\F>7F_^Z?-'PK1117T1\N%%%% !1110 4444 %%%% %_4?%'B+5]&T[
MP[JFM7-Q8:0DJ:7:2RDQVJR.9) @Z+N<ECCJ3FJ%%% ;A1110 4444 %%%%
M!1110 4444 %%%% !1110 5^S7_!M#_R;/\ $+_L>D_](H:_&6OV:_X-H?\
MDV?XA?\ 8])_Z10UP9E_NC^1Z.5?[ZO1_D?I-1117S1]6%%%% !7YL_\'+W_
M ";/\/?^QZ?_ -(IJ_2:OS9_X.7O^39_A[_V/3_^D4U=>!_WN!Q9A_N4_3]3
M\9:***^I/D HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ K[J_X-X?^4@Y_[$74O_0[>OA6ONK_ (-X?^4@Y_[$74O_
M $.WKGQ?^ZS]#JP7^]P]3]UJ***^3/L@HHHH **** "BBB@ HHHH **** "B
MBB@#PO\ X)[_ /)$]6_['O6?_2DU[I7A?_!/?_DB>K?]CWK/_I2:]TH *_"G
M_@X>_P"4@X_[$73?_0[BOW6K\*?^#A[_ )2#C_L1=-_]#N*]+*_]Z^3/+S?_
M '3YH^%:***^B/EPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ K]FO^#:'_DV?XA?]CTG_ *10U^,M?LU_P;0_\FS_
M !"_['I/_2*&N#,O]T?R/1RK_?5Z/\C])J***^:/JPHHHH *_-G_ (.7O^39
M_A[_ -CT_P#Z135^DU?FS_P<O?\ )L_P]_['I_\ TBFKKP/^]P.+,/\ <I^G
MZGXRT445]2?(!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH **** "BBB@ HHHH **** /"_\ @GO_ ,D3U;_L>]9_]*37NE>%_P#!/?\
MY(GJW_8]ZS_Z4FO=* "OPI_X.'O^4@X_[$73?_0[BOW6K\*?^#A[_E(./^Q%
MTW_T.XKTLK_WKY,\O-_]T^:/A6BBBOHCY<**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_9K_@VA_Y-G^(7_8])_Z1
M0U^,M?LU_P &T/\ R;/\0O\ L>D_](H:X,R_W1_(]'*O]]7H_P C])J***^:
M/JPHHHH *_-G_@Y>_P"39_A[_P!CT_\ Z135^DU?FS_P<O?\FS_#W_L>G_\
M2*:NO _[W XLP_W*?I^I^,M%%%?4GR 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5]U?\&\/_ "D'/_8BZE_Z';U\
M*U]U?\&\/_*0<_\ 8BZE_P"AV]<^+_W6?H=6"_WN'J?NM1117R9]D%%%% !1
M110 4444 %%%% !1110 4444 >%_\$]_^2)ZM_V/>L_^E)KW2O"_^">__)$]
M6_['O6?_ $I->Z4 %?A3_P '#W_*0<?]B+IO_H=Q7[K5^%/_  </?\I!Q_V(
MNF_^AW%>EE?^]?)GEYO_ +I\T?"M%%%?1'RX4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5^S7_!M#_P FS_$+_L>D
M_P#2*&OQEK]FO^#:'_DV?XA?]CTG_I%#7!F7^Z/Y'HY5_OJ]'^1^DU%%%?-'
MU84444 %?FS_ ,'+W_)L_P /?^QZ?_TBFK])J_-G_@Y>_P"39_A[_P!CT_\
MZ135UX'_ 'N!Q9A_N4_3]3\9:***^I/D HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ K[J_P"#>'_E(.?^Q%U+_P!#
MMZ^%:^ZO^#>'_E(.?^Q%U+_T.WKGQ?\ NL_0ZL%_O</4_=:BBBODS[(****
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M_P!%&^*?_A;'_P"-4?\ #D+]DW_HHWQ3_P#"V/\ \:K[&HH ^.?^'(7[)O\
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M_P#"V/\ \:K[&HH ^.?^'(7[)O\ T4;XI_\ A;'_ .-4?\.0OV3?^BC?%/\
M\+8__&J^QJ* /CG_ (<A?LF_]%&^*?\ X6Q_^-4?\.0OV3?^BC?%/_PMC_\
M&J^QJ* /CG_AR%^R;_T4;XI_^%L?_C5'_#D+]DW_ **-\4__  MC_P#&J^QJ
M* /CG_AR%^R;_P!%&^*?_A;'_P"-4?\ #D+]DW_HHWQ3_P#"V/\ \:K[&HH
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M:_6*B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?B/\
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M\2?%/Q7M];\0Z5?RW\/A_P"+.K:?9JR:G=Q+Y=O!,L<0VQKD*!DY/4FO5/\
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MVO/"*Z-'I9^(FG^(;>^\6:% '@NC/9!5@:2S<VXB=0TDC[@S?,%];_X)>?\
M*;__ (*-_P#86^&7_ICOZ /7O^"Z_P"TY\<?V-O^"4_Q8_:3_9N\;_\ ".>-
M?#-OI#:)K7]FVUY]F,^LV-M*?)NHY(7W0S2+\Z-C=D8(!'T_\.]5O]=^'^A:
MWJL_FW5YH]K/<R[0N^1XE9C@  9))P!BOB/_ (.=/^4&GQV_Z]- _P#4ATRO
MM3X2_P#)*O#/_8O67_HA* .@HHHH **** "BBB@ KP#_ (*B_P#)B_C?ZZ9_
MZ<[6O?Z\ _X*B_\ )B_C?ZZ9_P"G.UKKP'^_4O\ %'\T<69?\BZM_AE^3/R&
MHHHK])/R@^_?^"&_W/B?]=%_]OZ^^Z^!/^"&_P!SXG_71?\ V_K[[KX#._\
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M7QQ&I?%_PWIGBEM.\9#PUIL.R6ROY88'^R1VXM3M1 ,-$0?XLGFLCXF^*/\
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M?LB_L\Z/X/EULK_;.IQ3W%Y?WP4Y59KR[DEN)%!)(5I"H))QDDU\;^)/'O\
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M+K%C8:!X#@C\8?'7XDRZ6EXOAR[,$JZ1I-ONQBZF>0R2A65A!N 8@2H?=?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
&HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>biib-20220331_g8.jpg
<TEXT>
begin 644 biib-20220331_g8.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@"
MM )Z P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#5H=3N+F>(30"62XEC<$AU""0;1M0)7VS10 5X]^WW^QGX _X*#_ +(/C?\
M8]^)VMWVF:/XTT^&&34],"F>SG@N8KJWG4-PVR>")BIQN"E<C.1[#10!\:^*
MO^"='[:'QS_8M^+W['G[77_!1NQ^(*?$7PO!HWASQ-;_  9MM(F\/A3)Y\TT
M5O?D:@TH,/&Z *8F(SO('J7[0W[$O_"^O^"<^N_L _\ "S?[*_MKX9Q^$?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5;_Q->:1=&TU+7F9KZ]TH7LZZ=/.S$EV:T$!5R2738Q)+$G\Z?C=_P %H_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **\2_8(U34]7^#6J
MW.K:C/=2+XWUA%DN)F=@HN2 N6)X Z#M7MM !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MTAM8Y)9&=V50%0\FO#?V>?\ @M__ ,$Y/VE/C+I7[/G@_P"+VKZ'XQ\0 _\
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MV./^"B'[)7[>5KKJ?LX_$J6_U7PK<1P>*?#&M:-=Z5JVCNX)C^T6=Y'',BL
M=K[2C8(#$J0 #VVBBOE']I/_ (+8_P#!.3]E+XMZO\$?BM\:]0E\0>&(8YO&
M47ACP=JFLP>&HI "KZA-8V\L=MP<E6;>!R5&1D ^KJ*Q/AO\2/ /QA\ Z/\
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MWPL\=:S96WQUT.;XL2:I\8KV0V'A0,_VZYA^WWP995&W:UMFX&?D!YK]?:*
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M_!-#Q9KG@+5/"<FB7WQIU"9+GP[IEC>V"_:-5EL[.*>]:.R\V0MMBX:V+9
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M<N_BC\3D:6UM+RVW-#I5BUM"3:W=R79$EO?LJJB/N7J![E^T9_P1O^/&D?\
M!'#X'?L<_L[>+]%\0?$O]GGQ=H'C71(M9E:#3?$>JV$EQ+/9L[?ZN%VO)_+W
MX'R1AR@)9>:_;KT+_@J)_P %C?@OHO["?B3_ ()HZE\#/#FM^*=*OOB=\1/&
M7Q%TG4(M*M+.Y2X>+38K&1I;J9VC 27:BX&U@HDWJ :W[=OQ'^'_ .QY_P '
M WP<_;(_;#O4T;X1ZK\!-0\'>$?&^K0L=+\.>*SJ,MQ(9I<%;5YK)_*$K;=P
M=AG;&Y7SC3_VZO@5\?/^#HCX.>(/V-_%-MXC\-^)/@YKW@_QOXW\/H6TO7+B
MT@N]4%O'<*/+O&MC'9;I$+!?.1-WRX'WY^WO\:/VE?A58Z!I/P<_X)RS_M">
M&-:CNT\865EXNTNQFTIXV@-M_HNH )>)+NFSM8&,PJ2"&R/"?V&/V//VG_C#
M^W.O_!2;]LWX!:#\';7PCX%E\(?!+X)Z)J]M?OH5K<3&6\U.\GM%$ N9LF-8
MXN%C<JX#(&8 ^_';8A?:3@9P!R:_.3_@V)T32/B%_P $LI/VA/%VFVU_XC^-
M/Q&\5>)/'MW=Q+*^HW4NIW%LRS%@=Z^7 !M/'S-Q\QS]<_!;Q]^V9XA_:I^+
MO@OXV? W1-!^%&A'1_\ A3_C&QU6*:[\2"6V9M1^T0K<R/#Y,X5%WQ0[@<C?
MUKXA_9S\#_\ !3;_ ((^Z;\1OV1/V=O^"?\ +\=/AYJGC75/$'P1\3Z+X^TW
M2X]'BU"3S?[*U2*\D22-()B6\Z,$.'8C'1 #L?\ @VRGG\.?LJ?&?]G^QGD/
MA_X2?M3^-O!_A"!G++;Z9#-;W,<29_A$EU*?^!&OT0KY>_X) _L-^-?V!?V-
M+/X8?%_Q)9ZQ\0O%'B34O%_Q)U/323;3:WJ,WFSK$2 62-%BBW8&XQ%L -@?
M4- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 >%_P#!/?\ Y(GJW_8]ZS_Z4FO=*\+_ .">_P#R1/5O^Q[UG_TI->Z4 %?'
MG[</_!6'_AC/XV_\*<_X4'_PDG_$GM[_ /M'_A*OL?\ K2XV>7]EEZ;.N[G/
M05]AU^//_!<+_D]H?]B?8?\ H<U?;< 91EV=Y]]6QL.>'))VNUJK6UBT_P 3
M\Q\6N(<XX8X3^N995]G4]I&-^6,M&I75I*2Z+I<]B_XB$?\ JT7_ ,O[_P"X
M*/\ B(1_ZM%_\O[_ .X*_-NBOVS_ (AUP;_T"_\ D]3_ .3/YC_XC)XD?]!W
M_E*C_P#*S])/^(A'_JT7_P O[_[@H_XB$?\ JT7_ ,O[_P"X*_-NBC_B'7!O
M_0+_ .3U/_DP_P"(R>)'_0=_Y2H__*S])/\ B(1_ZM%_\O[_ .X*/^(A'_JT
M7_R_O_N"OS;HH_XAUP;_ - O_D]3_P"3#_B,GB1_T'?^4J/_ ,K/TD_XB$?^
MK1?_ "_O_N"C_B(1_P"K1?\ R_O_ +@K\VZ*/^(=<&_] O\ Y/4_^3#_ (C)
MXD?]!W_E*C_\K/TD_P"(A'_JT7_R_O\ [@H_XB$?^K1?_+^_^X*_-NBC_B'7
M!O\ T"_^3U/_ ),/^(R>)'_0=_Y2H_\ RL_23_B(1_ZM%_\ +^_^X*/^(A'_
M *M%_P#+^_\ N"OS;HH_XAUP;_T"_P#D]3_Y,/\ B,GB1_T'?^4J/_RL_23_
M (B$?^K1?_+^_P#N"C_B(1_ZM%_\O[_[@K\VZ*/^(=<&_P#0+_Y/4_\ DP_X
MC)XD?]!W_E*C_P#*S])/^(A'_JT7_P O[_[@H_XB$?\ JT7_ ,O[_P"X*_-N
MBC_B'7!O_0+_ .3U/_DP_P"(R>)'_0=_Y2H__*S])/\ B(1_ZM%_\O[_ .X*
M/^(A'_JT7_R_O_N"OS;HH_XAUP;_ - O_D]3_P"3#_B,GB1_T'?^4J/_ ,K/
MTD_XB$?^K1?_ "_O_N"C_B(1_P"K1?\ R_O_ +@K\VZ*/^(=<&_] O\ Y/4_
M^3#_ (C)XD?]!W_E*C_\K/TD_P"(A'_JT7_R_O\ [@H_XB$?^K1?_+^_^X*_
M-NBC_B'7!O\ T"_^3U/_ ),/^(R>)'_0=_Y2H_\ RL_23_B(1_ZM%_\ +^_^
MX*/^(A'_ *M%_P#+^_\ N"OS;HH_XAUP;_T"_P#D]3_Y,/\ B,GB1_T'?^4J
M/_RL_23_ (B$?^K1?_+^_P#N"C_B(1_ZM%_\O[_[@K\VZ*/^(=<&_P#0+_Y/
M4_\ DP_XC)XD?]!W_E*C_P#*S])/^(A'_JT7_P O[_[@KZJ_8$_;=_X;D\ :
MYXY_X5C_ ,(O_8VL"P^R_P!M?;?.S$LF_=Y,6W[V,8/3.:_#&OU4_P""!'_)
M ?&__8X)_P"DL5?(<<\'<.9/P[4Q6#H<LTXI/FF]W9Z.37X'Z)X6>(_&?$?&
M-+ YCBO:4I1FVN2G'51;6L8)[^9]Z4445^&']3!1110 445X+^WW^V[_ ,,-
M^ -#\<_\*Q_X2C^V=8-A]E_MK[%Y.(FDW[O)EW?=QC ZYS77@,#BLSQ<,+AH
M\TY:)72OUW;2^]GGYKFN R3+ZF.QL^2E35Y.S=E=+:*;>KZ(]ZHK\V_^(A'_
M *M%_P#+^_\ N"C_ (B$?^K1?_+^_P#N"OJ_^(=<9?\ 0+_Y/3_^3/@?^(R>
M&_\ T'?^4JW_ ,K/TDHK\V_^(A'_ *M%_P#+^_\ N"C_ (B$?^K1?_+^_P#N
M"C_B'7&7_0+_ .3T_P#Y,/\ B,GAO_T'?^4JW_RL_22BOS;_ .(A'_JT7_R_
MO_N"C_B(1_ZM%_\ +^_^X*/^(=<9?] O_D]/_P"3#_B,GAO_ -!W_E*M_P#*
MS])**_-O_B(1_P"K1?\ R_O_ +@H_P"(A'_JT7_R_O\ [@H_XAUQE_T"_P#D
M]/\ ^3#_ (C)X;_]!W_E*M_\K/TDK*\8>!?!WQ!TVVT?QQX9LM5M;/5;+4[6
MWO[<2)%>6ES'=6MPH/22*>**5&ZJZ*1R*_/#_B(1_P"K1?\ R_O_ +@H_P"(
MA'_JT7_R_O\ [@H_XAUQE_T"_P#D]/\ ^3#_ (C)X;_]!W_E*M_\K/TDHK\V
M_P#B(1_ZM%_\O[_[@H_XB$?^K1?_ "_O_N"C_B'7&7_0+_Y/3_\ DP_XC)X;
M_P#0=_Y2K?\ RL_22BOS;_XB$?\ JT7_ ,O[_P"X*/\ B(1_ZM%_\O[_ .X*
M/^(=<9?] O\ Y/3_ /DP_P"(R>&__0=_Y2K?_*S])**_-O\ XB$?^K1?_+^_
M^X*/^(A'_JT7_P O[_[@H_XAUQE_T"_^3T__ ),/^(R>&_\ T'?^4JW_ ,K/
MTDHK\V_^(A'_ *M%_P#+^_\ N"C_ (B$?^K1?_+^_P#N"C_B'7&7_0+_ .3T
M_P#Y,/\ B,GAO_T'?^4JW_RL_22BOS;_ .(A'_JT7_R_O_N"C_B(1_ZM%_\
M+^_^X*/^(=<9?] O_D]/_P"3#_B,GAO_ -!W_E*M_P#*S])**_-O_B(1_P"K
M1?\ R_O_ +@H_P"(A'_JT7_R_O\ [@H_XAUQE_T"_P#D]/\ ^3#_ (C)X;_]
M!W_E*M_\K/TDHK\V_P#B(1_ZM%_\O[_[@H_XB$?^K1?_ "_O_N"C_B'7&7_0
M+_Y/3_\ DP_XC)X;_P#0=_Y2K?\ RL_22BOS;_XB$?\ JT7_ ,O[_P"X*/\
MB(1_ZM%_\O[_ .X*/^(=<9?] O\ Y/3_ /DP_P"(R>&__0=_Y2K?_*S])**_
M-O\ XB$?^K1?_+^_^X*]A_8>_P""L/\ PV9\;?\ A3G_  H/_A&_^)/<7_\
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MFW&\9PFE*-N:+<)22DKJZ=GK?8JT445Z!Y 4444 %%%% !7V%_P0]_Y/:/\
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M_P#H<-?-\8?\DOC/^O<OR/L_#K_DNLN_Z^P_,_8:BBBOY+/]!0HHHH ****
M"BBB@ HHHH **** "BBB@#PO_@GO_P D3U;_ +'O6?\ TI->Z5X7_P $]_\
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MC_\  O\ TN)^5=%%%?U6?P2%%%% !1110 4444 %%%% !1110 4444 %%%%
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M+_TN)^5=%%%?U6?P2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M *!__)X?_)'HE%>=_P#"^_\ J5/_ ">_^UT?\+[_ .I4_P#)[_[71_K#D_\
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M?\+[_P"I4_\ )[_[71_K#D__ #]_\EE_D'^H_%/_ $#_ /D\/_DCT2BO._\
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M->Z4 %?C%_P7<\=>%?#O[<PT_6-4\F;_ (0S3VV>0[<%Y\'*J1VK]G:_!_\
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M/@^BBBOTH_) HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ K]I/^#9/_DV/XB?]CXG_ *10U^+=?M)_P;)_\FQ_$3_L
M?$_](H:^?XG_ .11/U7YGU'!_P#R/(>DOR/TLHHHK\O/V **** "OS3_ .#F
MS_DV/X=_]CX__I%-7Z65^:?_  <V?\FQ_#O_ +'Q_P#TBFKV,@_Y&]'U_1GA
M<2_\B.OZ+\T?BW1117ZP?B@4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5]X?\&ZG_ "D,;_L0]3_]&6]?!]?>'_!N
MI_RD,;_L0]3_ /1EO7FYS_R*JW^%GK9#_P CFA_B1^\%%%%?D)^Y!1110 44
M44 %%%% !1110 4444 %%%% 'A?_  3W_P"2)ZM_V/>L_P#I2:]TKPO_ ()[
M_P#)$]6_['O6?_2DU[I0 5^#_P#P<5_\I#%_[$/3/_1EQ7[P5^#_ /P<5_\
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MDGFE^('BEI9IG+,[&<Y))Y)KXZK]"_B-:?\ !,GQU^Q;\//V2XO^"G=O;2^
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M3_Y-C^(G_8^)_P"D4-?/\3_\BB?JOS/J.#_^1Y#TE^1^EE%%%?EY^P!1110
M5^:?_!S9_P FQ_#O_L?'_P#2*:OTLK\T_P#@YL_Y-C^'?_8^/_Z135[&0?\
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MU_1?FC\6Z***_6#\4"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&"2.>F:[\LQ5/!8^%>:;47TWV^1YN;X.KF&6U,/3:4I+2^VZ[7/Q HK]5O\
MB')^,/\ T,WPL_\  C7/_CE'_$.3\8?^AF^%G_@1KG_QROM_];\M_DG]T?\
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M^2#_ %&S;^>'WR_^1/S:HK]5O^(<GXP_]#-\+/\ P(US_P".4?\ $.3\8?\
MH9OA9_X$:Y_\<H_UORW^2?W1_P#D@_U&S;^>'WR_^1/RIHK]5O\ B')^,/\
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MJGQA_:F^'6K>%X-01]=TS3?#!BN+FV!^=(W\A=K$=#D8KZDH **** "BBB@
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MP)NGT^.\1IXU]60'<![D4 7Z*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "OR4_P""=7[+?PL_X+L:_P#$/_@I7_P4-TJY^('A>?XAZIX>^!_PRU/4
M[A=#\-Z%9.(1=?9HG1);N=BPD=P>8]P'S*(_UKK\D_\ @G9^U)\+?^"$OB#X
MA_\ !-7_ (*&ZG=> /"L/Q#U3Q#\#OB=J6EW#Z'XCT.]<3"U^TQ(ZPW<+!C(
MCD<R%0>%,@!L>./@YX?_ ."'O_!3?X!1?L@WFHZ)\"?VDO%-QX+\;_">75)[
MG3-)UYU0V&IZ>DSN;9Y)'VR*IV[(V 'S+Y>C_P ')G_!.#]FGXG_ +%/QE_;
MF^(4/BG5?&OA?P+;CPS:S>,+V/2=,DBN(T$T=C%(L+2$2-N,@<$X..!6;XS^
M,OAS_@N1_P %-O@+<?L?VNH:Y\"/V:?%EQXR\<_%B33)K?3-5\0QI']@TO3V
MF1#</&ZAY&4;=DI.<!/,Z'_@Y7_X*(_L;?"7]A3XM?L,?$/XU0:=\5?&?P\@
MO/#/A)M'OI'O89+T*CB>.!H$R;:<8>13\G(Y&0#[M_8Y_P"31/A7_P!DWT/_
M --\%+^V%X \5?%C]DGXI?"SP)IRWFN>)?ASK>E:-:-.D0GN[BPFAA0NY"IN
M=U&YB ,Y) KQ3_@DA_P41_8V_;9_9XT+X>?LO_&J#Q5K/PX\"^'[/QI90Z/?
M6ITV:2T,2(6N8(UDR]M.,QEA^[ZX(S]8T ?''P\_X)<_#C]H/_@F#^SW^QE^
MWAX/U65/ASX)\-IXH\(:5XIEMK>[U*RT@6<EK=2V,H^TP*[NVU)-C/&C98#!
M^4OVD_V//V9_^"=W_!63]DCPS_P2Y\(-X#\?^._%MQ;_ !.\#^%=3N&L=5\$
M11$W=Y?VSR.BB+$ABD8+OD5B-SQ*5^Q?^"QW_!4GP1_P29_9%F^/NO>%I->\
M0:UJJZ'X'T0[DM[G5)(I94:YE7F*WC2)Y'(^9@H1>6R/C#_@D1_P4"_X)%^#
M/BVGCOXJ?\%"],^+/[6/QYUJQTOQ)XK_ .$+UN*(7%S-'%::!I?G6*):6$<C
M11KDH)"JN^U51(P#[K_:E_X))_L*?MN?'2R^/W[6GPGN?'FI:5H$.DZ/HVMZ
M_=C2;&-)9I3,EE%(D33.9R&DD#DK&@&-O/R?_P $FOA]X-_9S_X+$_M,?LI?
ML0ZGJ(_9W\*^$M)GUCPXNJ37FE>&O&TLH\VSLGE9_++0"=IHU8[9$"-CRD59
M/^"\'_!:#0_V2OB1X:_X)W?#OXW6WPL\6_$#2TOO%_QCU?2;J[M_!&@RO+&9
M[2"VCDEN=0E\F5(@JA8SM9F4D/'ZC_P1@_:K_P""-]SX-C_88_X)A?'6'Q3J
M/A_19_$7B(W&A:G#J&K-YT$-UJU[<W=K$MQ<233PACG(#*J*L: * ?=U%%%
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MQUXV\,?#3P1K/Q&\;:G]BT;P_I5QJ6KWGDO)Y%K!$TLLFR-6=MJ*QVJ"QQ@
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MB@ HHHH **** /Y+Z*_K0HK[C_7/_IQ_Y-_]J?G?^H/_ %$_^2?_ &Q^2_\
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MSFBAL/&&C:E;I!>V/G3*T4-P!&C0R2C8C%F)R%!I_L^^/_CQ\0?C3X4TH?\
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MA7XC^,?@^^IV&M_"GQC<P6]IXPT._B5)8(KBX5H;>ZA=?,B:0!-SDL3L"/\
M<M% 'Q%^S3X\^./Q#^._A>PD_P""%-E\)=!@N'F\1?$'Q3KWAI)](9(9&C^Q
M6VG^;/<NTHC3?F-55BQ/ !^C+#]A_P#8LTKXE#XS:9^R#\+K;Q@-6;5!XK@\
M :<FI?;F<R-=?:A#YOG%R6,F[<6).<FO4:* /SQM?AA_P4(_86_X*4_M!_M
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MG]C[4/@9\)OV?K^^\0VFG>*/%.GZAJ_BOQ%/;^1 $CL)94@MK;F3S&;,A)4
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M'X7^)'@VPT/XG_#34[S3[75]/O+#Y+75=.DU >1*/( B> LK'&06R-GZ+44
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M;"&_U>W66YA+R(T:E(5\UL/@1OBOJ^BB@ HHHH **** "BBB@ HHHH ****
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M CJ"*]U_X+F?\H@?VBO^R6:G_P"BZ //?^">WP/_ ."HOQ%\!_"#]JWXU?\
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MAAI5QJ&KV&GZ?KB:=:QEY+FWL-1MKRY55'+$00RN% ))0 #)H XSX%?LS_\
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M_P!I=_AKKVL1VESH?Q"TSPW9:W]G@\V.5BEM>!H)EEB#)N8' DW+R!7Y"_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML/AS\"OC-\+_ (&>+]$U^YU?XM:Q?:;X;N=*TP36MM+:VWVB1KN0N/)0IPI
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MWQ!);^,_#&OZ7;V=TTFI3N\:I<2K("C$H<C!*G'%?8O_  5"^$GQA_X*-?\
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M/8_AE_P1V^//QF_X(W?&#]@_XVV$'@+QKXH^,/B'Q7X*O;N_MKZ&"3^UUO\
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M_BCPJ+30+83+Y]S:_8_,GOY$4.8U1(]S!2645>_X+/?LK?MB^--<^#W[;O\
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M$:U\/],TNULGU8RI#?Z:UJ@E@6!HS^Z>20N"NYFY([?]NG]E3]J3]IO]FO\
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M,UZ\NQ;QFW2UQ*;<&;<4ED9W2W ,@9RU</\ M;6?_!7S_@E[^R\/^"AOB_\
MX**2_&:?P7+8W_Q<^$^L^ M*L-'U#3YKB**ZCTN>VA2>U>#S<H[,=ZH69?\
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MS;>%OB%XNN?#"S6L%C;W-O\ :;C4H[2]M8UO(Y56*21945F!=58$-N&:X_\
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MU^T;HO@+Q-?Z3"L$WB+0]5CG%Q;W13'G[4@=$+Y*^><=L)X7\&_\%1_V(_\
M@J/^UE^T9\%?^"85]\8?!WQNU+PG-X:UFT^,/A[0EB72]+D@D+Q7<[38:6X9
M?FC4CR20&# UU>C_ +&G_!0W_@HU^V7\+?VH_P#@I#\/_!_PE^&_P3UP^(O
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M'[4W_!,YO@!H^BZ;;+X;G7XK:-XABU Y*&W2'3@#;+&BJ06^4@@#I0!\V?\
M!LEI6E_$#_@F_KO[1GBK3H;WQ-\9?BSXK\0^.+V[B$DM]</J$MOLE+ ED"1<
M(?E&]L#YCFU_P;@22>$O@#^T!^SEIDC?\(Y\(_VM/&_A/P;;[B8[32XIK>=(
M$]%$D\S8_P"FE<I^S[X%_P""EW_!'^X^)W[+G[.W[ 4_QV^&WB'QUJ?B?X,^
M(M#\>Z;I0T0:@PD?2=3BO)$>..&7YA/&&#JS'J=J?3'_  1^_8<\??L'?L@?
M\(+\:_$-CJWQ(\;>+]4\;?$V_P!+)-J^N:E*'F2(D LL<:0Q;OXC&6& 0  ?
M4M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445SOQ9^*G@GX(?#
M;6?BW\1[Z[MM"\/V+WFJ7%AI-S?S1PKU*6]K')-,?]F-&8]A0!T5%?G=_P $
M1_\ @MAX'_;J_9R^&OA+]H+QMJ-Q\<?%4^LIJ5GI7POUJVTIA;WM\T.V_6T.
MGI_H4$9/^D??RA_>'97F_P#P3M_X+7_ _P"!WP+^(-A^VY^T-XL\3>+K3XY>
M,UL]-L-"U/Q%J&EZ!;7YBADF2SAE-I9IM=$:78IV.$W;&P ?JS17"?!W]IW]
MG_X^_ /3OVI/A)\6-'U?X?:II,NIVOBM;GR;1;6+?YTDK2A3!Y9CD$BR!6C,
M;!PI4@?.7A?_ (+Z?\$M?%WC33O"VG?M :A!INL:P-*T;QOJ?@?5[3PW?7I<
MH(8]5FM5M>6# .9!&<<.>,@'V117CG[5'_!0+]CS]B37?"WAS]JGXWV'@RY\
M:V^JS>&FU.QNFANTTVV6YO,S11/'$4B="JR,IE9E2,.Y"UP>B_\ !8;]A#5O
MV=]6_:GO?'WB72O!FD>+(_#;7>L_#O6;>[O-1EA2:**VLFM?M4XD1P59(B#A
MNFTX /I^BOFO]ES_ (*U_L/?M=?%Q_V?_AE\0M:TOQW_ &>]_;>#_''@W4M
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ML8_LV?MU_"4_!/\ :B^&D'B70%U"+4+)#=S6MQ87L6[RKJVN('26"90S .C
ME693E6((!^87[<7A#]L+X)?\%.?V&X?VJ_\ @H%X2^)WB'4OC-*-"\/Z!\(+
M?PY=Z98RVWD7LOVB.^N));>3S(X2C*H<\Y)0BO7O!I^$G_$5CXR_X33[!_PD
M_P#PRS8?\(7]MV[_ #/MX^U>1N_Y;>1N^[\WE>=_#OKZ&^%__!%;_@G'\*/%
MWAWXE:1\#]0U3Q;X6\36VOZ/XQ\2^-]7U+58[ZW22. O<W%TSRPQK+(%MW)@
M!8MY9;YJ\-^*7_!-#P_^UO\ \%IOB?X[_:8^ >K:A\.+KX&>'H/"OC*WNKFP
M>TURVOY6)LKZUDCFM[E(Y&R8W4E'96RK$$ EU(VG_$3C,?@@+8ZD/V1)O^%I
M?9,>3]H_MA/[-^U[>/M&SRMN[Y_(VX^2OFW_ (($>'/^"L&O?L#>9^S7\<?V
M==*N5\?^(1\1]+\?^ M8O/$D'B(ZC-]I_M66WOXD>=D\HK\BD0F)3DJ2?T__
M &-_^">W[)W[!6E:]9_LU?#633+[Q7?+>>*O$.K:Q=:GJFL3+N"-<WEY))-(
M%#-M0MM7<Q !9B> ^.__  1?_P""?7[0/Q@U;X^^(/A;K?ASQAXA _X2;6_A
M]XYU7P\^M8_BNTT^YBCG?KF1EWMGEC0!\"_M^?L)?&7]AK_@VS_:B^#/Q.^(
M/A;Q1J&K?%*V\6VEGX#TR>UTS0;2[\1Z)=2Z?;P3.[PQ12)<RA2QVI(,DG)/
MTE_P<[?%'X>P_P#!"GXIZ@?%]@T/B^/P[!X7D2Y4C5)'UBPN5$'/[S,$4LO'
M\$;-T%?6GPH_8._9)^"G[,^H_L>?#[X+:?#\-]8@O8M9\,:E<W%_'J N\_:3
M<274DDLS29.YG<M[C KP72/^#>7_ ()+Z?X+U3X<ZQ^S?J6O:'J-@MA;Z;XB
M^(6N7J:3:+/'.(;!I+PO8 O%'EH&1V0%&8HS*0#CO^"B;I:_\%?_ /@G1?W+
MB.$:S\0X3*YPHDD\-PA%SZL> .YJY_P6Z_Y+;^P[_P!GA^'_ /TEO*^I/VL/
MV&_V4_VXOA_IWPQ_:E^#UGXJTG1]02^T827MS:7.GW*J5$MO=6LL4\#;3@E)
M%SQG.!6!H7_!-#]BWP[\/_AK\,+#X3WLNC?"'QJ/%OP]@U#QEJ]W+I>L!YG%
MR9Y[MY;G#3RXCG>2,!L;,*H !\N_LW_\(\/^#E;]I+_A<GD?\)0?@SX1_P"%
M-?VECS?^$?\ */\ :OV3=_#]O^_L[[\_Q5^BR_9_M#!=GF[%WXQNVY.W/?&=
MV/QKQ']L7_@G'^Q[^WBVA:E^TA\*CJ.M>%I7D\,>*=&UB[TK5]*+?>$%[92Q
M3*A[QEBA/.W.#6C^R#^PC^S7^PQH&MZ%^SSX6U6T?Q+?QWOB+5->\4ZAJ][J
M4\:>6CRSWTTK_*GRA5(4#MDDD ^5O^#IKR/^''WQ=^U;O*_M#PSYFS[VW_A(
M=.SCWQ2_\%SC^RP?^" ?CW^P/[#_ .$(/@+1_P#A5WV#9Y/G>;:_V3]BQSG_
M %6W9SY>[^'=7:_\'!_P)^+_ .TG_P $H?B'\'?@3\.M3\5^)]3U;PY)8Z%H
M]L9KBX2'7;">4J@ZA8HW<^RFN@T+_@A[_P $S_#WQFTKXV67[/TTMUH&N-K7
MAWPU>^*]3G\/Z1J+.7-U:Z3)<&S@8.2RJL01"<JJD @ ^;?VE/ =]\0/^"L_
M_!,W3/V@]#74==L/ /C/4M:M]3B#E=9MM L9O-8-_P M([I!(#U#QJ>HKKO^
M"UXT/_AN+]@P_&'R?^%9?\+WO?[=_M''V+^W?L _L3S=WR[O/\[;N_VO>OMC
MQU^RY\"OB5\?/ G[3_C;P-]M\<_#.VU2W\$:Y_:=U'_9L>HPK!>+Y,<JPS>9
M&BKF5'*XRFT\T_\ :4_9A^ 7[87P@U/X"_M+_"_3?%_A+5]AO=(U-6 WH<I+
M')&RR0RJ>5DC977LPH ^(O\ @N__ &$?V@/V&QX&\K_A:G_#66AGP]]FQ]L_
MX1_9)_;73YOLVS[+YW;&W-6/^"<UQH6G?\%P?VY]*^)TD"?$&]G\'7/AD7Q
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M6O\ QUX9LM7O4AOY]3B6&],;>?OM$>-%41V[1)&%'EJE 'QQ^T)\,O .@?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
7 **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>biib-20220331_g9.jpg
<TEXT>
begin 644 biib-20220331_g9.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#5H=3N+F>(30"62XEC<$AU""0;1M0)7VS10 5X]^WW^QGX _X*#_ +(/C?\
M8]^)VMWVF:/XTT^&&34],"F>SG@N8KJWG4-PVR>")BIQN"E<C.1[#10!\:^*
MO^"='[:'QS_8M^+W['G[77_!1NQ^(*?$7PO!HWASQ-;_  9MM(F\/A3)Y\TT
M5O?D:@TH,/&Z *8F(SO('J7[0W[$O_"^O^"<^N_L _\ "S?[*_MKX9Q^$?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5;_Q->:1=&TU+7F9KZ]TH7LZZ=/.S$EV:T$!5R2738Q)+$G\Z?C=_P %H_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[_X%M0!L45C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;4 ;%%8__  @^D?\
M/S>_^!;4?\(/I'_/S>_^!;4 ;%%8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@
M6U &Q16/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\
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M #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\
MX%M0!L45C_\ "#Z1_P _-[_X%M1_P@^D?\_-[_X%M0!L45C_ /"#Z1_S\WO_
M (%M1_P@^D?\_-[_ .!;4 ;%%8__  @^D?\ /S>_^!;4?\(/I'_/S>_^!;4
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M .!;4 ;%%9=GX2TVQNDNX;BZ+1ME0]RQ'XBM2@ HHHH **** "BBB@ HHHH
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MA9-06Z\7Q^'5TR34Q<ZE=7J[X1-,5\L7/EC,KYV9^7.T?0]% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'A?_!/?
M_DB>K?\ 8]ZS_P"E)KW2O"_^">__ "1/5O\ L>]9_P#2DU[I0 4444 %%%%
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MI9C_ ,_I_P#@3_S Z/\ X6U\0?\ H8/_ "4B_P#B*/\ A;7Q!_Z&#_R4B_\
MB*YRBC^TLQ_Y_3_\"?\ F!T?_"VOB#_T,'_DI%_\171_"[QYXK\1^)_[.UG5
M?.A^S.VSR(UY!&#E5![UYS77_!/_ )'3_MSD_FM=^5X_'5,QI1E5DTY+1R?^
M8'KM%%%?I@!1110 4444 %%%% !1110 4444 %%%% 'A?_!/?_DB>K?]CWK/
M_I2:]TKPO_@GO_R1/5O^Q[UG_P!*37NE !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %<+\>?\ D V7_7X?_0#7=5POQY_Y -E_U^'_ - ->3GO_(IJ^GZH#RVB
MBBORT HHHH **** "BBB@ HHHH \P_;*_:L^'W[$G[-GB?\ :9^)MA?WFE>&
M[>$_V=I<0>YO;B>>.WM[>,$@;GFEC7).%!+'@&OE_P#9S_:W_P""G'B+]J#Q
MY8>-_P!A2S?0VU[P[!JV@Q?&6WFNO!=O<64+/*D;VJ177R,9Y8XG4[PRKYAP
M3]3_ +6_P*^!7[3?[/\ K_P!_:0\G_A$_%:P6-V9-0%JXN#/&ULT,I/RS+.L
M31]<NJC# [3^9?Q1UG]M3_@DWXE^-G[0?PX_;*F^)7A3P!XC\)6?B3P7\5M(
MMY]5\46]W:VT42PZG"$E^UQ1RA5&TAUC+L&*E6]? 4J%:C*"2=1[<U[;QM9K
M9WOOY:VN!];?\%.?VC/VEO"WQX^ /[&'[-?Q)L_AY>_&WQ!J]OJWQ*O-&AOW
MTBVT^UCN#;VT,^83<3B0HA<'E0%&3E>1\%_$C]LC]C#_ (*6_"C]CGXH_M5W
MGQK\%_&3P]KMS&_B'PY96FK^%KG3;;[1]H:6R1%EMYN(P)%X;=M(*_-G?\%8
M5A_:B_;#_9R_X)R_$'4$\,^!/B-+JOB'6M?^PV_]J2W>FP"6VL;"YG1_L,Y8
M_/+%B7;(%5ADA^2G^!/@S_@EY_P5>^!NB?L^>+=6\3I\>[75M \9Z+XWOUUG
M5[&ULK=;B&]M+^=3=P0AR?,A,AA<1D[=R@IO1ITOJL8-+F<)NUEK;FL^;=-6
MT2TTZ78'T]^T-^R3^VW\9_BSJGBGX??\%,?$/PW\)/% NA>#_#'P]TJ9[218
M4$LDUY<AY;C?*'?9A552%&>37)_\$JOVF_VD/BIXI^-O[,_[3?CC2_'&M_!+
MQU%H5O\ $G1])CL8_$$,L+2 2P1?NH[F'9ME6/ 4NJD$J7?U[]K#]C7X(?MQ
M>'=.\+_%;Q!XFBMM OIGA;PAXON=,=9G0(Z2M;.I? Q\CY )Z<U\P?\ !&&5
M?@;\>_VCO^"=_P /-?M?$GPW^#?B;29/!_B>.PMH[KS=1M9)KNQNYK:-%NYX
M)8O+:9@92R.'/W57E@X5LOFG9RBE]E*RNE?F6K;O9I][ZV ^W/C)IOQ4UGX5
MZ_I/P/\ $FF:-XON=+EC\.ZMK5H9[6SNV7"2RQKS(JGG;WQBO@?]L7P?_P %
M2?\ @GU^SEK?[;D/_!3U_B/=>"5@O_$_@?Q7\-=+T_1]9M&GCCD@A-L/-M7_
M 'F5*N68@+D9K[[TCXO?"?Q!X.U#XB:!\3_#U_X?TGS_ .U-<LM:@EL[/R 6
MF\V97*1^6 2^XC:!SBOA9;?Q1_P7,^)UKJ-W8WVC_LA^"M?6XM4N86AN/BUJ
MEK+\KE6 9-(AD7H1F9E_O#_1YP#E"3<TN1/WKQ3_ .W5=7N^B5N_2X'W=\+O
M',/Q.^&7AWXE6VF364?B'0K/4X[*X/[RW6>%)1&W3YEWX/N*W:;%%%!$L$$:
MHB*%1$7 4#H .PIU><[-Z %%%%( HHHH **** "NO^"?_(Z?]N<G\UKD*Z_X
M)_\ (Z?]N<G\UKT<H_Y&='_$@/7:***_5P"BBB@ HHHH **** "BBB@ HHHH
M **** /"_P#@GO\ \D3U;_L>]9_]*37NE>%_\$]_^2)ZM_V/>L_^E)KW2@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "N%^//_ " ;+_K\/_H!KNJX7X\_\@&R
M_P"OP_\ H!KR<]_Y%-7T_5 >6T445^6@%%%% !1110 4444 %%%% '+?&CX(
M_"7]HKX;ZC\(/CC\/]-\3^&=65!J&C:M!YD,NQUD1L=597565@05*@@@BOE_
MX ?\$8OV//@_^TOXI^,U[\!-)O[*VU32[OX;1:QK^H:K_9#0V:)-((;R:2-)
M!.I:-L,4 &TI@ ?9-%;TL3B*,'"$FD_-_P!=/N \O_:I_8R_9J_;6\%6G@/]
MI3X7VWB*STV]%YI%P+J:UN].N0.)K>YMW2:%N!G:P#;1N! KD?V9_P#@F+^Q
MG^R=\1[GXR_"KX:WMQXRNK(V;>+?%/B2^UG4(K8]88I;V:0PJ1D'R]I()!)'
M%>_44HXC$1I>S4WR]KNWW ?,7QQ_X(^_L)?M ?%36OC5XU^'OB"R\2>)75_$
M=_X;\>ZMIJZF5C6,&:*WN4C)V(JY"@D#G->M_LS_ +*7[/'['7PVC^$?[-/P
MJTWPGH"W#7$EI8[W>XG8 &:::5FEGD(51OD9FPH&< "O0J*<\3B*E-4Y3;BN
MEW8#QOPQ_P $_OV1O!W[./B?]DGPW\)?LWP]\975[<>)/#_]O7[_ &R2[8-<
M-Y[3F>/>5'"2*%Q\N*\3A_X-[/\ @D/;1+!;_LJ7D:(,(B?$OQ( H] !J/%?
M:%%5#&XRFWR5)*^KLWJ_/4#+\#^#/#?PX\%Z/\//!NGFTTC0=+M].TJU:XDE
M,-M!&L42%Y&9WPBJ-S,6.,DDY-:E%%<[;;NP"BBBD 4444 %%%% !77_  3_
M .1T_P"W.3^:UR%=?\$_^1T_[<Y/YK7HY1_R,Z/^) >NT445^K@%%%% !111
M0 4444 %%%% !1110 4444 >%_\ !/?_ )(GJW_8]ZS_ .E)KW2O"_\ @GO_
M ,D3U;_L>]9_]*37NE !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<+\>?^0#9
M?]?A_P#0#7=5POQY_P"0#9?]?A_] ->3GO\ R*:OI^J \MHHHK\M **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Z_
MX)_\CI_VYR?S6N0KK_@G_P CI_VYR?S6O1RC_D9T?\2 ]=HHHK]7 **** "B
MBB@ HHHH **** "BBB@ HHHH \+_ .">_P#R1/5O^Q[UG_TI->Z5X7_P3W_Y
M(GJW_8]ZS_Z4FO=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X7X\_\ (!LO
M^OP_^@&NZKA?CS_R ;+_ *_#_P"@&O)SW_D4U?3]4!Y;1117Y: 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5U_P3
M_P"1T_[<Y/YK7(5U_P $_P#D=/\ MSD_FM>CE'_(SH_XD!Z[1117ZN 4444
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M -./_)O_ +4#Z,HKYSHH_P!;_P#IQ_Y-_P#:@?1E%?.=%'^M_P#TX_\ )O\
M[4#Z,HKYSHH_UO\ ^G'_ )-_]J!]&45\YUZE\!O^0#>_]?@_] %=^6\0_P!H
MXM4/9<M[Z\U]OD@.ZHHHKZ4 HHHH *X7X\_\@&R_Z_#_ .@&NZKA?CS_ ,@&
MR_Z_#_Z :\G/?^135]/U0'EM%%%?EH!1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !77_!/_D=/^W.3^:UR%=?\$_\
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M5Z[7D7QL_P"1T_[<X_YM7SG%'_(L_P"WE^H'(4445^= %%%% !1110 4444
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M6*_:=L?C5\.?'6M2_$J;PWJR^-_#?P\O-0?2Y8M&MXWTF65(\RP[3%/$T!=
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M %%%% !7J7P&_P"0#>_]?@_] %>6UZE\!O\ D WO_7X/_0!7O<-?\C:/H_R
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M=HHHK]7 **** "BBB@ HHHH **** "BBB@ HHHH \+_X)[_\D3U;_L>]9_\
M2DU[I7A?_!/?_DB>K?\ 8]ZS_P"E)KW2@ KR+XV?\CI_VYQ_S:O7:\B^-G_(
MZ?\ ;G'_ #:OG.*/^19_V\OU Y"BBBOSH HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KU+X#?\@&]_P"OP?\ H KR
MVO4O@-_R ;W_ *_!_P"@"O>X:_Y&T?1_D!W5%%%?I0!1110 5POQY_Y -E_U
M^'_T UW5<+\>?^0#9?\ 7X?_ $ UY.>_\BFKZ?J@/+:***_+0"BBB@ HHHH
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M_@G_ ,CI_P!N<G\UKT<H_P"1G1_Q(#UVBBBOU< HHHH **** "BBB@ HHHH
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MVYQ_S:O7:\B^-G_(Z?\ ;G'_ #:OG.*/^19_V\OU Y"BBBOSH HHHH ****
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MQC_T"_\ D]/_ .3#_7'AS_G_ /\ DL__ )$]6HKRG_AIS_J2/_*E_P#:Z/\
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M7_VNC_AIS_J2/_*E_P#:Z/\ B'?&/_0+_P"3T_\ Y,/]<>'/^?\ _P"2S_\
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M37NE !7Q?^WC_P ET'_8%M__ $*2OM"OB_\ ;Q_Y+H/^P+;_ /H4E?2<*_\
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MFI*3:LKW323L[I+JMFSHJ*^%?@CJW_!03]N[X.:E^V-\,?VJG^'EKJU[?/\
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M7_VNC_AIS_J2/_*E_P#:Z/\ B'?&/_0+_P"3T_\ Y,/]<>'/^?\ _P"2S_\
MD3U:BO*?^&G/^I(_\J7_ -KH_P"&G/\ J2/_ "I?_:Z/^(=\8_\ 0+_Y/3_^
M3#_7'AS_ )__ /DL_P#Y$]6HKRG_ (:<_P"I(_\ *E_]KH_X:<_ZDC_RI?\
MVNC_ (AWQC_T"_\ D]/_ .3#_7'AS_G_ /\ DL__ )$]6HKRG_AIS_J2/_*E
M_P#:Z/\ AIS_ *DC_P J7_VNC_B'?&/_ $"_^3T__DP_UQX<_P"?_P#Y+/\
M^1/5J*\I_P"&G/\ J2/_ "I?_:Z/^&G/^I(_\J7_ -KH_P"(=\8_] O_ )/3
M_P#DP_UQX<_Y_P#_ )+/_P"1/5J*\I_X:<_ZDC_RI?\ VNC_ (:<_P"I(_\
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M[XW?M1^)OV7_ ($?'?2_A1X5^&FE6-U\2_B1>Z?;7-P;R]4R6VG6PNB(8\Q
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M!J?_ (!'_(^-_P#AWM\?_P#H?/ G_@NO_P#X[1_P[V^/_P#T/G@3_P %U_\
M_':^R**/[3S+_G]/_P "?^8?V+DW_0-3_P# (_Y'QO\ \.]OC_\ ]#YX$_\
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M(%YH,\>BZAX/TZULM18#RY9HW8N@YZ@&C^T\R_Y_3_\  G_F']BY-_T#4_\
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M%<YC92>">O%?3=%73J5*4U.#::ZK1F=6C2KTW3JQ4HO=-73^3/C?_AWM\?\
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M:\[^//\ P1(A_:;73#\<-.^'.N3Z,TC:1?&VU6VNK(R;=_E3P7*2QAMJY"L
M=H]*_0RBHGC\=4CRSJR:[.3?ZFE+*LKHS4Z="$6NJC%/[TC\MOV&/^" >N_L
MF^"M/UFQTOX9VGCJ;3FMM<\0,NJ7]RZ>8S>6EQ--N6,C9E4"*2HR"1FJO[;/
M_!(/0OBW\1/AQ:_&BV\+76O:IJ\FEZ#XE\/7&J:;>V"E#(R-/!<)(T1^;Y,D
M L2 "2:_5.O(/VC_  +XN\6?%CX2:WX<T&>[M-#\8276K3P@%;6$P,H=N>F>
M*S^M8E4O9\[Y>UW;[MC5X'!.O[9TH\_\W*K_ 'VN?+/[/?\ P1<O_P!EGP=+
MX&^!A^'VBV5U=M=:A)]EU.>XOKAOO33SS7#23.?5F.!P,#BLO0/^"$^D^%_@
M;X@_9MT*S\"P>"O%-Q=SZ[HOVC6V^U27)!G/G-=F5-Q X1U [8K]&:*:Q>+4
M5%5)62:6KV>Z]'U)>7X!S<G2C=M-OE5VULWINNCZ'Y'Q?\&I7[)\$:PP_#'P
M<B*,*J^+/%@ 'L/[3KZ7\)?\$S?C%X&\*Z9X)\+^+_ UMIFCZ?#8Z=;-::E(
M8H(HQ'&F]YRS850-S$DXR23S7VS14T<3B,.VZ4W&_9M?D7B,%@\6DJ].,[;<
MR3M]Z/C?_AWM\?\ _H?/ G_@NO\ _P".T?\ #O;X_P#_ $/G@3_P77__ ,=K
M[(HKH_M/,O\ G]/_ ,"?^9R_V+DW_0-3_P# (_Y'QO\ \.]OC_\ ]#YX$_\
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M4<_=/O7LE%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQKX7\"VX\,VLWC"]CTG3)(KB-!-'8Q2+"TA$C;C('!.#C@4 ?J'17G'['/\
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M*_PY^.GPVT7XO_"+Q=::_P"&?$5@E[HFLV#$PWEN_P!V1"0"0?I70T %%%%
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M^Q8L/_2>.O$XO_W:EZO\CZ;P]_WRO_A7YG3T445\$?JP4444 ?CZ/V[OA_\
ML,_\'"?[7.O>/O@]\4/%\6O^"? L-O%\,_ EQKDEJ8M*B9FN%@YA4AQM)ZD-
MZ5W?_!"[5[;]KG]O7]JW_@J3\*/"">#OAG\2=4TCPYHOA.[NK9=4GU'3(/+O
M+W4;.WD?[#.SDN(Y,2-]I=SG.]_>/V7OV3OV@/AU_P %H_VH?VL_&7@'['\/
M_B+X0\'67@W7_P"U;23^T)[&Q6*Z3R$E:>+8X(S+&@;JI8<UGV_['_[0O[,'
M_!9EOVK_ -F3X<C5/A#\>?"K67QYT^TU:SMAH6OV(S8:XL$TL;3F9&,#K KO
MEIY7!++D \P^ _C;_@H;_P %=_B/\7_C#\'OV\-3^ GPH\!?$C4_!'PVT;PA
MX*TS4KS6[C3BJ3ZM?S7\;EHGD8;+=-@V@J<%=\E+X?\ [;?_  4H^/7_  36
M_:0\%^%_'.F:3^U'^S%XRO\ 1;_7M!\.6L]EXN33BEVLJ6=Q%(D9OK19H@B!
M2LFUT,8;8M[X$^"/^"A__!(KXC_%_P"#_P &OV$-1^/GPH\??$?4_''PWUCP
MCXVTS3+S0[C42KSZ1?PW\B$1)(H*7$>\;26();9'[?\ \$@OV,?CO^S-X!^)
MGQJ_:V_LF'XK_';XF7WC;QEHFA77VBST!9@J6VEQS#B;R(U(,@R"7*AG"AV
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M\4M5\-Q:GXQO9M(M;%H+FZ)N!9^3:111(;=)$MR0N6,)8DDDGVNBB@ HHHH
M**** "O,_CY_R$--_P"N,G\Q7IE>9_'S_D(:;_UQD_F*\/B/_D45/E^: \_H
MHHK\S ]O^&?_ "(NG?\ 7$_^A&MVL+X9_P#(BZ=_UQ/_ *$:W:_7<!_N-+_#
M'\D 4445U@%?F?\  7P]I'[4W_!RS^T!XP^,5E'JH_9O^&_A?1OA=IVH*'BT
MN75K-+ZZOXHSPLY9Y8_-'S;)0,\+M_3"O@;]LC]C_P#;(_9[_P""@\'_  59
M_P""=?@#2/B!JGB'PA%X6^,WP=U77X]*D\26<#*UK?V-Y-^YBNX@D:8EPI2,
M!<EW! &?\'*?P9\)>-?^"5_C3XZ!5TWQQ\'[K3_%OP[\76N([W1=1@O[<%H)
M1\R>9&60@'!;8V"R*1\[?MM:!^TS^TU_P4V_X)Q_%/PI^USK/@'5/B5\/_%^
MHZ"=-\':1>?\(A=_\(I:W5_+ MW;N+HW:RB%DN-ZQ",-$$8DGTS]JSP#_P %
M./\ @M'X<TO]COXE?L8WO[-_P.O]<LK[XL^)/%7C?3]1UO7[*UG2X72]/MK!
MW$.^2.-FGE(7Y1C[C1R^K_\ !2O]E7]IBW_:/_99_;1_8L^!.G?$"X_9VO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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B1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881466159656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>May 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-19311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOGEN INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000875045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0112644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">225 Binney Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">679-2000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0005 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BIIB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,452,013<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881468272824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Income (Unaudited) - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 2,531.8<span></span>
</td>
<td class="nump">$ 2,694.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Cost and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales, excluding amortization and impairment of acquired intangible assets</a></td>
<td class="nump">753.9<span></span>
</td>
<td class="nump">478.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">551.7<span></span>
</td>
<td class="nump">514.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">634.9<span></span>
</td>
<td class="nump">595.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="nump">66.9<span></span>
</td>
<td class="nump">98.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="num">(117.3)<span></span>
</td>
<td class="nump">68.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">(Gain) loss on fair value remeasurement of contingent consideration</a></td>
<td class="num">(7.1)<span></span>
</td>
<td class="num">(33.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">38.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total cost and expense</a></td>
<td class="nump">1,921.1<span></span>
</td>
<td class="nump">1,720.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">610.7<span></span>
</td>
<td class="nump">973.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(263.3)<span></span>
</td>
<td class="num">(506.9)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income tax expense and equity in loss of investee, net of tax</a></td>
<td class="nump">347.4<span></span>
</td>
<td class="nump">467.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="nump">125.6<span></span>
</td>
<td class="nump">44.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax', window );">Equity in (income) loss of investee, net of tax</a></td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">18.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">218.5<span></span>
</td>
<td class="nump">404.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net&#160;income (loss) attributable to noncontrolling interests, net&#160;of&#160;tax</a></td>
<td class="num">(85.3)<span></span>
</td>
<td class="num">(5.6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 303.8<span></span>
</td>
<td class="nump">$ 410.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">$ 2.06<span></span>
</td>
<td class="nump">$ 2.70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">$ 2.06<span></span>
</td>
<td class="nump">$ 2.69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used in calculating:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">147,100<span></span>
</td>
<td class="nump">151,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">147,600<span></span>
</td>
<td class="nump">152,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 2,066.3<span></span>
</td>
<td class="nump">$ 2,211.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenue from anti-CD20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">399.4<span></span>
</td>
<td class="nump">389.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 66.1<span></span>
</td>
<td class="nump">$ 93.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization and Impairment of Acquired Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationprofitlosssharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration profit (loss) sharing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationprofitlosssharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) from Equity Method Investments, Net of Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IncomeLossFromEquityMethodInvestmentsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881468655848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 303.8<span></span>
</td>
<td class="nump">$ 410.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gains (losses) on securities available for sale, net of tax</a></td>
<td class="num">(9.7)<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Unrealized gains (losses) on cash flow hedges, net of tax</a></td>
<td class="nump">15.9<span></span>
</td>
<td class="nump">149.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease', window );">Gains (losses) on net investment hedges, net of tax</a></td>
<td class="nump">6.2<span></span>
</td>
<td class="nump">22.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Unrealized gains (losses) on pension benefit obligation, net of tax</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Currency translation adjustment</a></td>
<td class="num">(21.8)<span></span>
</td>
<td class="num">(48.5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="num">(8.5)<span></span>
</td>
<td class="nump">124.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss) attributable to Biogen Inc.</a></td>
<td class="nump">295.3<span></span>
</td>
<td class="nump">534.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="num">(85.3)<span></span>
</td>
<td class="num">(4.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="nump">$ 210.0<span></span>
</td>
<td class="nump">$ 530.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the cumulative translation adjustment from gain (loss), after tax, on foreign currency derivatives, that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881466224152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,749.3<span></span>
</td>
<td class="nump">$ 2,261.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">2,002.4<span></span>
</td>
<td class="nump">1,541.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">1,632.0<span></span>
</td>
<td class="nump">1,549.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DuefromantiCD20therapeuticprograms', window );">Due from anti-CD20 therapeutic programs</a></td>
<td class="nump">389.4<span></span>
</td>
<td class="nump">412.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">1,215.4<span></span>
</td>
<td class="nump">1,351.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">927.4<span></span>
</td>
<td class="nump">740.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">7,915.9<span></span>
</td>
<td class="nump">7,856.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Marketable securities</a></td>
<td class="nump">1,001.6<span></span>
</td>
<td class="nump">892.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">3,372.8<span></span>
</td>
<td class="nump">3,416.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">359.0<span></span>
</td>
<td class="nump">375.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">2,150.8<span></span>
</td>
<td class="nump">2,221.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">5,758.0<span></span>
</td>
<td class="nump">5,761.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax asset</a></td>
<td class="nump">1,288.8<span></span>
</td>
<td class="nump">1,415.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Investments and other assets</a></td>
<td class="nump">1,767.5<span></span>
</td>
<td class="nump">1,939.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">23,614.4<span></span>
</td>
<td class="nump">23,877.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Current portion of notes payable</a></td>
<td class="nump">999.5<span></span>
</td>
<td class="nump">999.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Taxes payable</a></td>
<td class="nump">317.3<span></span>
</td>
<td class="nump">174.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">398.7<span></span>
</td>
<td class="nump">589.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accrued expense and other</a></td>
<td class="nump">2,231.1<span></span>
</td>
<td class="nump">2,535.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,946.6<span></span>
</td>
<td class="nump">4,298.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable</a></td>
<td class="nump">6,275.7<span></span>
</td>
<td class="nump">6,274.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">571.2<span></span>
</td>
<td class="nump">694.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">312.3<span></span>
</td>
<td class="nump">330.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,287.9<span></span>
</td>
<td class="nump">1,320.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">12,393.7<span></span>
</td>
<td class="nump">12,917.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments, contingencies and guarantees</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Biogen Idec Inc. shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.001 per share</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.0005 per share</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">119.0<span></span>
</td>
<td class="nump">68.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(115.2)<span></span>
</td>
<td class="num">(106.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">14,215.5<span></span>
</td>
<td class="nump">13,911.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost</a></td>
<td class="num">(2,977.1)<span></span>
</td>
<td class="num">(2,977.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Biogen Inc. shareholders&#8217; equity</a></td>
<td class="nump">11,242.3<span></span>
</td>
<td class="nump">10,896.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="num">(21.6)<span></span>
</td>
<td class="nump">63.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">11,220.7<span></span>
</td>
<td class="nump">10,959.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 23,614.4<span></span>
</td>
<td class="nump">$ 23,877.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DuefromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivable from anti-CD20 therapeutic programs for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DuefromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881468509656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0005<span></span>
</td>
<td class="nump">$ 0.0005<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881467472328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flow from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 218.5<span></span>
</td>
<td class="nump">$ 404.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash flow from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">143.1<span></span>
</td>
<td class="nump">102.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">44.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Excess and obsolescence charges related to inventory</a></td>
<td class="nump">281.5<span></span>
</td>
<td class="nump">11.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">67.6<span></span>
</td>
<td class="nump">70.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Contingent consideration</a></td>
<td class="num">(7.1)<span></span>
</td>
<td class="num">(33.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="num">(15.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi', window );">(Gain) loss on strategic investments</a></td>
<td class="nump">191.1<span></span>
</td>
<td class="nump">437.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Gain) loss on equity method investments</a></td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">18.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">43.3<span></span>
</td>
<td class="nump">59.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(87.5)<span></span>
</td>
<td class="nump">37.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties', window );">Due from anti-CD20 therapeutic programs</a></td>
<td class="nump">22.9<span></span>
</td>
<td class="nump">43.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(142.6)<span></span>
</td>
<td class="num">(112.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expense and other current liabilities</a></td>
<td class="num">(461.6)<span></span>
</td>
<td class="num">(283.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income tax assets and liabilities</a></td>
<td class="nump">101.9<span></span>
</td>
<td class="nump">64.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other changes in operating assets and liabilities, net</a></td>
<td class="num">(213.6)<span></span>
</td>
<td class="num">(80.9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flow provided by (used in) operating activities</a></td>
<td class="nump">161.8<span></span>
</td>
<td class="nump">769.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(57.9)<span></span>
</td>
<td class="num">(92.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="nump">543.6<span></span>
</td>
<td class="nump">819.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(1,133.5)<span></span>
</td>
<td class="num">(913.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from divestiture of Hiller&#248;d, Denmark manufacturing operations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">28.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from the sales of strategic investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(91.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="nump">2.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flow provided by (used in) investing activities</a></td>
<td class="num">(648.0)<span></span>
</td>
<td class="num">(64.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of treasury stock</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(600.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments related to issuance of stock for share-based compensation arrangements, net</a></td>
<td class="num">(20.8)<span></span>
</td>
<td class="num">(27.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of borrowings and premiums paid on debt exchange</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(169.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsToMinorityShareholders', window );">Net (distribution) contribution to noncontrolling interest</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="nump">4.1<span></span>
</td>
<td class="nump">11.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flow provided by (used in) financing activities</a></td>
<td class="num">(16.5)<span></span>
</td>
<td class="num">(785.0)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(502.7)<span></span>
</td>
<td class="num">(80.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(9.4)<span></span>
</td>
<td class="num">(33.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of the period</a></td>
<td class="nump">2,261.4<span></span>
</td>
<td class="nump">1,331.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of the period</a></td>
<td class="nump">$ 1,749.3<span></span>
</td>
<td class="nump">$ 1,217.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123583714&amp;loc=SL75117360-209713<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3444-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from (to) a noncontrolling interest. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881462822408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Equity Statement - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Preferred stock</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Retained earnings</div></th>
<th class="th"><div>Treasury stock</div></th>
<th class="th"><div>Parent</div></th>
<th class="th"><div>Noncontrolling interest</div></th>
<th class="th"><div>2020 Share Repurchase Program</div></th>
<th class="th">
<div>2020 Share Repurchase Program </div>
<div>Common stock</div>
</th>
<th class="th">
<div>2020 Share Repurchase Program </div>
<div>Additional paid-in capital</div>
</th>
<th class="th">
<div>2020 Share Repurchase Program </div>
<div>Retained earnings</div>
</th>
<th class="th">
<div>2020 Share Repurchase Program </div>
<div>Treasury stock</div>
</th>
<th class="th">
<div>2020 Share Repurchase Program </div>
<div>Parent</div>
</th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">176.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 10,686.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (299.0)<span></span>
</td>
<td class="nump">$ 13,976.3<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">$ 10,700.3<span></span>
</td>
<td class="num">$ (14.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">404.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">410.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">410.2<span></span>
</td>
<td class="num">(5.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">125.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124.7<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NoncontrollingInterestIncreaseDecreaseOther', window );">Capital contribution from noncontrolling interest</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (600.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (600.0)<span></span>
</td>
<td class="num">$ (600.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to Share Repurchase Progams, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (93.8)<span></span>
</td>
<td class="num">$ (506.2)<span></span>
</td>
<td class="nump">$ 600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">19.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under award plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(46.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(46.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(46.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">72.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Stockholders' Equity, Other</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">10,663.2<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(174.3)<span></span>
</td>
<td class="nump">13,833.5<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">10,682.2<span></span>
</td>
<td class="num">(19.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">174.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">170.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">10,959.7<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">68.2<span></span>
</td>
<td class="num">(106.7)<span></span>
</td>
<td class="nump">13,911.7<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">10,896.2<span></span>
</td>
<td class="nump">63.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">218.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">303.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">303.8<span></span>
</td>
<td class="num">(85.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(8.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NoncontrollingInterestIncreaseDecreaseOther', window );">Capital contribution from noncontrolling interest</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">18.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under award plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(39.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">70.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Stockholders' Equity, Other</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 11,220.7<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 119.0<span></span>
</td>
<td class="num">$ (115.2)<span></span>
</td>
<td class="nump">$ 14,215.5<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">$ 11,242.3<span></span>
</td>
<td class="num">$ (21.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">171.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NoncontrollingInterestIncreaseDecreaseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Increase (Decrease) Other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NoncontrollingInterestIncreaseDecreaseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockRetiredCostMethodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockRetiredCostMethodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881471411144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Overview</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. We have a leading portfolio of medicines to treat multiple sclerosis (MS), have introduced the first approved treatment for spinal muscular atrophy (SMA) and are providing the first and only approved treatment to address a defining pathology of Alzheimer's disease. We also commercialize biosimilars of advanced biologics and focus on advancing our pipeline in neuroscience and specialized immunology. Lastly, we are focused on accelerating our efforts in digital health to support our commercial and pipeline programs while also creating opportunities for potential digital therapeutics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS); and other potential anti-CD20 therapies, including mosunetuzumab, pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our audited consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended December 31, 2021 (2021 Form&#160;10-K).</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through our collaboration with Samsung Bioepis Co., Ltd. (Samsung Bioepis) we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe. We have also secured the exclusive rights to commercialize BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS, which was approved in the U.S., the European Union (E.U.) and the United Kingdom (U.K.) during the third quarter of 2021. For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these unaudited condensed consolidated financial statements (condensed consolidated financial statements). </span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2021 Form&#160;10-K. Our accounting policies are described in the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2021 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three months ended March 31, 2022, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate as one operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100.0% of the economics, we record net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including sales, expense, reserves and allowances, the supply chain, manufacturing, clinical trials, research and development costs and employee-related costs, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets. Additionally, the ongoing geopolitical tensions related to Russia's invasion of Ukraine, and the related sanctions and other penalties imposed, are creating substantial uncertainty in the global economy. The extent and duration of the conflict, sanctions and resulting market disruptions are highly unpredictable. We have made estimates of the impact of the COVID-19 pandemic and the ongoing geopolitical conflict within our condensed consolidated financial statements and there may be changes to those estimates in future periods.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that we adopt as of the specified effective date. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe that the adoption of recently issued standards have had or may have a material impact on our condensed consolidated financial statements or disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881468490920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Business Transformation and Other Cost Saving Initiatives<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring, Business Transformation and Other Cost Saving Initiatives</a></td>
<td class="text">RESTRUCTURING, BUSINESS TRANSFORMATION AND OTHER COST SAVING INITIATIVES <div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2022 Cost Saving Initiatives</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021 and May 2022 we announced our plans to implement a series of cost-reduction measures during 2022. These savings are expected to be achieved through a number of initiatives, including reductions to our workforce, primarily within our global Alzheimer's infrastructure, the consolidation of certain real estate locations and operating efficiency gains across our selling, general and administrative and research and development functions.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under these initiatives, we expect to incur restructuring charges ranging from approximately $100.0&#160;million to $150.0&#160;million. These amounts are primarily related to severance and are expected to be substantially incurred and paid by the end of 2022.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, we recognized $27.7&#160;million of employee related costs, primarily related to severance. These costs were recorded in restructuring charges in our condensed consolidated statements of income. Our restructuring reserve is included in accrued expense and other in our condensed consolidated balance sheets.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following an evaluation of our current capacity needs, in March 2022 we ceased using a patient services office space in Durham, North Carolina. We are marketing the space for sublease. Our decision to cease using the facility resulted in the immediate expense of certain leasehold improvements and other assets at this facility, which we do not believe can be adequately recovered in a sublease. As a result, for the three months ended March 31, 2022, we recognized approximately $10.4&#160;million of accelerated depreciation expense, which was recorded in restructuring charges in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the charges and spending related to our 2022 cost saving initiatives for the three months ended March 31, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Workforce Reduction</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI http://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881471411144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenues</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenue</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by product is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.550%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis (MS):</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fumarate</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">295.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">537.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">236.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">316.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">552.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interferon</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">182.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">309.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">241.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">284.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">236.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">520.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">273.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">503.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: MS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">709.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">685.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,394.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">751.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">732.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,483.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">309.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">472.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">371.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">520.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alzheimer's disease:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ADUHELM</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilars</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">194.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">194.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FUMADERM</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">875.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,191.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,066.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">899.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,311.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,211.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fumarate includes TECFIDERA and VUMERITY. VUMERITY became commercially available in the E.U. during the fourth quarter of 2021.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Interferon includes AVONEX and PLEGRIDY.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In June 2021 the U.S. Food and Drug Administration (FDA) granted accelerated approval of ADUHELM, which became commercially available in the U.S. during the second quarter of 2021. For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships - Eisai Co., Ltd. - ADUHELM Collaboration Agreement, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue from two wholesalers accounting for 26.3% and 10.5% of gross product revenue for the three months ended March 31, 2022, and 30.0% and 9.3% of gross product revenue for the three months ended March 31, 2021.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.155%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.114%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.7&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">759.6&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">935.3&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current provisions relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">659.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">832.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(40.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(46.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(101.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(271.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(373.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in prior years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(58.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(314.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(379.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">792.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">968.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.400%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reduction of accounts receivable</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">136.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Component of accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">831.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">802.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue-related reserves</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">968.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">935.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue from Anti-CD20 Therapeutic Programs</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from anti-CD20 therapeutic programs is summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OCREVUS and other revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">256.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">214.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">399.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">389.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:7pt;padding-right:2.25pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our consolidated financial statements included in our 2021 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Revenue</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from collaborative and other relationships:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue earned under our technical development agreement, manufacturing services agreements and royalty revenue on biosimilar products with Samsung Bioepis</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other royalty and corporate revenue:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other corporate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:7pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive royalties from net sales on products related to patents that we have out-licensed and we record other corporate revenue primarily from amounts earned under contract manufacturing agreements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881471395768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">354.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">349.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">655.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">814.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,215.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,351.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2022 the Centers for Medicare and Medicaid Services (CMS) released the final National Coverage Decision (NCD) for the class of anti-amyloid treatments in Alzheimer&#8217;s disease, including ADUHELM. The final NCD  confirmed coverage with evidence development, in which patients with Medicare can only access treatment if they are part of an approved clinical trial. We expect that this decision will reduce future demand for ADUHELM to a minimal level. During the first quarter of 2022 we wrote-off approximately $275.0&#160;million of inventory related to ADUHELM, as a result of this CMS decision, which was recognized in cost of sales within our condensed consolidated statements of income. We have recognized approximately $136.0&#160;million related to Eisai's 45.0% share of these charges in collaboration profit (loss) sharing within our condensed consolidated statements of income. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the fourth quarter of 2021 we wrote-off approximately $120.0&#160;million of inventory in excess of forecasted demand related to ADUHELM, which was recognized in cost of sales within our condensed consolidated statements of income. We have recognized approximately $59.0&#160;million related to Eisai's 45.0% share of these charges in collaboration profit (loss) sharing within our condensed consolidated statements of income during the fourth quarter of 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of March 31, 2022, our total ADUHELM inventory was de minimis. As of December 31, 2021, we had approximately $223.0&#160;million of ADUHELM inventory. For additional information please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 16, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881468478808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.257%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.396%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.972%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.972%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.669%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completed technology</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4-28 years</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,413.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,455.4)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,957.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,413.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,388.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,024.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite until commercialization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks&#160;and trade names</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,606.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,455.4)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,150.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,609.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,388.5)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,221.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization and Impairments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, amortization and impairment of acquired intangible assets totaled $66.9 million, compared to $98.1 million in the prior year comparative period. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended March 31, 2022, we had </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">no</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> impairment charges.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, amortization and impairment of acquired intangible assets reflects the impact of a $44.3&#160;million impairment charge related to vixotrigine (BIIB074) for the potential treatment of trigeminal neuralgia (TGN). </span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Completed Technology</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Completed technology primarily relates to our acquisition of all remaining rights to TYSABRI as well as other amounts related to our other marketed products and programs acquired through business combinations.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IPR&amp;D Related to Business Combinations</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In-process research and development (IPR&amp;D) represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. Included in IPR&amp;D balances are adjustments related to foreign currency exchange rate fluctuations. We review amounts capitalized as acquired IPR&amp;D for impairment annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable. The carrying value associated with our IPR&amp;D assets as of March 31, 2022, relates to the IPR&amp;D programs we acquired in connection with our acquisition of Convergence Pharmaceuticals Holdings Ltd. (Convergence). </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vixotrigine</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the periods since we acquired vixotrigine, there have been numerous delays in the initiation of Phase 3 studies for the potential treatment of TGN and for the potential treatment of diabetic painful neuropathy (DPN), another form of neuropathic pain. We have engaged with the FDA regarding the design of the Phase 3 studies of vixotrigine for the potential treatment of TGN and DPN and are now performing an additional clinical trial of vixotrigine, which is expected to be completed by the end of 2022.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance of this additional clinical trial delayed the initiation of the Phase 3 studies of vixotrigine for the potential treatment of TGN, and, as a result, we recognized an impairment charge of $44.3&#160;million related to vixotrigine for the potential treatment of TGN during the fi</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rst quarter of 2021. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, the carrying value associated with the remaining IPR&amp;D asset for DPN </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was $129.1&#160;million a</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd the fair value of this asset was not significantly in excess of its carrying value. Upon the completion of the additional clinical trial we will reevaluate the carrying value of the program.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estimated Future Amortization of Intangible Assets</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022 (remaining nine months)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">210.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">165.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,761.1&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,758.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, we had</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">no</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ac</span>cumulated impairment losses related to goodwill. Other includes adjustments related to foreign currency exchange rate fluctuations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881471513304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.796%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,283.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,283.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,579.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,579.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,252.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,252.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">171.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">171.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">860.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">607.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">253.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,281.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">607.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,674.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">214.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.796%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,632.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,632.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,108.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,108.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,192.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,192.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,048.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">866.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,228.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,046.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">219.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material impairments of our assets measured and carried at fair value as of March 31, 2022 and December 31, 2021. In addition, there have been no changes in valuation techniques as of March 31, 2022 and December 31, 2021. The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities was determined through third-party pricing services. The fair value of Level 2 instruments classified as marketable equity securities represents our investments in the common stock of Sangamo Therapeutics, Inc. (Sangamo) and Sage Therapeutics, Inc. (Sage) and are valued using an option pricing valuation model as the investments are each subject to certain holding period restrictions. The holding period restrictions for our investment in the common stock of Denali Therapeutics Inc. (Denali) and a portion of our Sangamo investment expired during the first quarter of 2022 and the second quarter of 2021, respectively. The fair value of our Denali investment and this portion of our Sangamo investment were Level 1 measurements as of March 31, 2022. For additional information on our investments in Sangamo, Denali and Sage common stock, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7, Financial Instruments,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies - Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2021 Form 10-K. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the significant unobservable inputs in the fair value measurement of our contingent consideration obligations as of March 31, 2022 and December 31, 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:24.266%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.773%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.020%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Input(s)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td rowspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td rowspan="2" style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202.0&#160;</span></td><td rowspan="2" style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.89%</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.89%</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected timing of achievement of development milestones</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023 to 2027</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Input(s)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"/><td rowspan="2" style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td rowspan="2" style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209.1&#160;</span></td><td rowspan="2" style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.30%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.30%</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected timing of achievement of development milestones</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023 to 2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average discount rate was calculated based on the relative fair value of our contingent consideration obligations. In addition, we apply various probabilities of technological and regulatory success, ranging from 10.9% to certain probability as of March 31, 2022, to the valuation models to estimate the fair values of our contingent consideration obligations.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:42.091%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.625% Senior Notes due September 15, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,008.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">999.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,020.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">999.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.050% Senior Notes due September 15, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,797.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,743.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,895.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,742.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.250% Senior Notes due May 1, 2030</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,341.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,492.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,475.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,492.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.200% Senior Notes due September 15, 2045</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,240.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,100.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,463.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,099.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.150% Senior Notes due May 1, 2050</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,225.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,473.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,457.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,473.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.250% Senior Notes due February 15, 2051</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">581.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">466.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">692.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">466.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,195.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,275.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,004.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,273.1&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. For additional information related to our Senior Notes, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 12,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2021 Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Obligations</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisitions of Convergence and Biogen International Neuroscience GmbH, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, beginning of period</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, end of period</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022 and December 31, 2021, approximately</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $202.0&#160;million</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $209.1 million, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our condensed consolidated balance sheets with any remaining balances reflected as a </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">component of accrued expense and other.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, changes in the fair value of our contingent consideration obligations were primarily due to an increase in discount rates used to revalue these obligations and delays in the expected timing of the achievement of certain remaining developmental milestones related to our vixotrigine programs.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, changes in the fair value of our contingent consideration obligations were primarily due to delays in the expected timing of the achievement of certain remaining developmental milestones related to our vixotrigine programs.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881471450456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Financial Instruments</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">278.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">247.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Overnight reverse repurchase agreements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">585.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">901.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">406.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">283.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,283.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,632.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and short-term debt securities approximate fair value due to their short-term maturities. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketable equity securities gains (losses) are recorded in other income (expense), net in our condensed consolidated statements of income. The following tables summarize our marketable debt and equity securities, classified as available-for-sale:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,126.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,124.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">460.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">454.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">878.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">877.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">379.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">375.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">171.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,019.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16.4)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,004.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, current</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,133.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(311.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">826.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,167.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(311.2)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">860.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">723.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">723.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">385.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">384.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">817.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">816.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">377.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">376.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,435.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,433.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, current</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,133.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(279.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,004.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,167.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160.9&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(279.4)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,048.5&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Contractual Maturities: Available-for-Sale Debt Securities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:41.924%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.413%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,002.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,006.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,541.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,541.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">982.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">993.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">868.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">870.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after five years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,004.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,019.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,433.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,435.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The average maturity of our marketable debt securities available-for-sale as of March 31, 2022 and December 31, 2021, was approximately 10 months.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Proceeds from Marketable Debt Securities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from maturities and sales</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">543.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">819.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized losses for the three months ended</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2022 and 2021, primarily relate to sales of corporate bonds, agency mortgage-backed securities and other asset-backed securities.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strategic Investments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022 and December 31, 2021, our strategic investment portfolio was comprised of investments totaling $919.5 million and $1,110.3 million, respectively, which are included in other current assets and investments and other assets in our condensed consolidated balance sheets. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6, Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in our strategic investment portfolio for the three months ended March 31, 2022, was primarily due to decreases in the fair value of our investments in Denali, Sage and Sangamo common stock.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our investments in Denali, Ionis Pharmaceuticals, Inc. (Ionis), Sage and Sangamo common stock, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2021 Form 10-K.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881471490168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Instruments</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Forward Contracts - Hedging Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the global nature of our operations, portions of our revenue and operating expense are recorded in currencies other than the U.S.&#160;dollar. The value of revenue and operating expense measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes, we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenue and operating expense.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency forward contracts in effect as of March 31, 2022 and December 31, 2021, had durations of 1 to </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18 months</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 1 to 15 months, respectively. These contracts have been designated as cash flow hedges and unrealized gains or losses on the portion of these foreign currency forward contracts that are included in the effectiveness test are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the table below). Realized gains and losses of such contracts are recognized in revenue when the sale of product in the currency being hedged is recognized and in operating expense when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from accumulated other comprehensive income (loss) and fair value changes of excluded portions in the same line item in our condensed consolidated statements of income that has been impacted by the hedged item.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional amount of foreign currency forward contracts that were entered into to hedge forecasted revenue and operating expense is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,631.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,828.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">British pound</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">166.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Swiss franc</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Japanese yen</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canadian dollar</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total foreign currency forward contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,986.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,126.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.785%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized (losses)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized gains (losses)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the net unrealized gains of $72.1&#160;million to be settled over the next 18 months, of which $72.0 million of these net unrealized gains are expected to be settled over the next 12 months, with any amounts in </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accumulated other comprehensive income (loss) to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of March 31, 2022 and December 31, 2021, credit risk did not materially change the fair value of our foreign currency forward contracts.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:22.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.154%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Operating Income (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23.1)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.5)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Investment Hedges - Hedging Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately 5.0% to approximately 49.9%. The share purchase transaction was completed in November 2018 and, upon closing, we paid 759.5 billion South Korean won ($676.6 million) to Samsung BioLogics. Our investment in the equity of Samsung Bioepis is exposed to the currency fluctuations in the South Korean won. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to mitigate the currency fluctuations between the U.S. dollar and South Korean won, we have entered into foreign currency forward contracts. Foreign currency forward contracts in effect as of March 31, 2022, had a remaining duration of seven months. These contracts have been designated as net investment hedges. We recognize changes in the spot exchange rate in accumulated other comprehensive income (loss). The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of $20.6 million and $10.6 million as of March 31, 2022 and December 31, 2021, respectively. We exclude fair value changes related to the forward rate from our hedging relationship and will amortize the forward points in other income (expense), net in our condensed consolidated statements of income over the term of the contract. The pre-tax portion of the fair value of the forward points that were included in accumulated other comprehensive income (loss) in total equity reflected net losses of $2.5 million and $3.6 million as of March 31, 2022 and December 31, 2021, respectively. In conjunction with the closing of our sale of equity in Samsung Bioepis to Samsung BioLogics, which occurred in April 2022, we concurrently closed our foreign currency forward contracts.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of our net investment hedge in our condensed consolidated financial statements:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:18.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.980%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.202%"/><td style="width:0.1%"/></tr><tr><td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) <br/>(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Net Income <br/>(Amounts Excluded from Effectiveness Testing) (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Forward Contracts - Other Derivative Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate notional amount of these outstanding foreign currency forward contracts was $1,333.4 million and $1,268.0 million as of March 31, 2022 and December 31, 2021, respectively. Net losses of $12.2 million and $17.4 million related to these contracts were recorded as a component of other income (expense), net for the three months ended March 31, 2022 and 2021, respectively.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Derivative Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:28.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.376%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Cash Flow Hedging Instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other Derivative Instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123477628&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881471505288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was $2,082.0 million and $2,006.6 million as of March 31, 2022 and December 31, 2021, respectively. For the three months ended March 31, 2022, depreciation expense totaled $76.3 million compared to $48.8 million in the prior year comparative period.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Solothurn, Switzerland Manufacturing Facility</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to support our future growth and drug development pipeline, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. Upon completion, this facility will include 393,000 square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and 51,000 square feet of administrative space. As of March 31, 2022 and December 31, 2021, we had approximately $682.6 million and $677.0 million, respectively, capitalized as construction in progress related to this facility. In the second quarter of 2021, a portion of the facility received a Good Manufacturing Practice multi-product license from the Swiss Agency for Therapeutic Products, resulting in approximately $1.2&#160;billion of fixed assets being placed in service during the second quarter of 2021. In April 2022 the FDA approved the Prior Approval Supplement for the Solothurn facility for ADUHELM. We estimate the remainder of the facility will be operational during the first half of 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881468777560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indebtedness<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Indebtedness</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exchange Offer</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021 we completed our Exchange Offer of our tendered 2045 Senior Notes for our 2051 Senior Notes and cash, and an offer to purchase our tendered 2045 Senior Notes for cash. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An aggregate principal amount of approximately $624.6&#160;million of our 2045 Senior Notes was exchanged for an aggregate principal amount of approximately $700.7&#160;million of our 2051 Senior Notes and aggregate cash payments of approximately $151.8&#160;million. Our Exchange Offer has been accounted for as a debt modification; as such, the cash component has been reflected as additional debt discount and is amortized as an adjustment to interest expense over the term of our 2051 Senior Notes.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we redeemed an aggregate principal amount of approximately $8.9&#160;million of our 2045 Senior Notes for aggregate cash payments of approximately $12.1&#160;million, excluding accrued and unpaid interest. The redemption has been accounted for as a debt extinguishment; as such, we recognized a pre-tax charge of </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.2&#160;million upon the extinguishment of such 2045 Senior Notes. This charge, which was recognized in interest expense in other income (expense), net in our condensed consolidated statements of income for the three months ended March 31, 2021, reflects the payment of an early call premium and the write-off of the remaining unamortized original debt issuance costs and discount balances associated with such 2045 Senior Notes.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon settlement, we also made aggregate cash payments of approximately $13.8&#160;million to settle all accrued and unpaid interest from the last interest payment date on our 2045 Senior Notes that were exchanged or redeemed. We incurred approximately $6.1&#160;million of costs associated with our Exchange Offer, which was recognized in interest expense in other income (expense), net in our condensed consolidated statements of income for the three months ended March 31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881471431128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchases</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (2020 Share Repurchase Program). Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired. Under our 2020 Share Repurchase Program, we repurchased and retired approximately 2.2 million shares of our common stock at a cost of approximately $600.0 million during the three months ended March 31, 2021. There were no share repurchases of our common stock during the three months ended March 31, 2022. Approximately $2.8 billion remained available under our 2020 Share Repurchase Program as of March 31, 2022.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income (Loss)</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.696%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.859%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses) on Net Investment Hedge, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.8&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(44.8)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(139.0)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(106.7)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.7)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21.8)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.9)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(43.9)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(160.8)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(115.2)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.696%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.859%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses) on Net Investment Hedge, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(179.0)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(66.3)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(46.6)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(299.0)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(48.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(48.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29.4)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(64.3)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(95.1)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(174.3)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts reclassified from accumulated other comprehensive income (loss):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:18pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts Reclassified from Accumulated Other Comprehensive Income (Loss)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on securities available for sale</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on cash flow hedges</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21.4)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881468483704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per Share</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">303.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">410.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dilutive potential common shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used in calculating diluted earnings per share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881471501304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Payments</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based Compensation Expense</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax effect</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in cash</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of our obligations associated with our performance stock units settled in cash at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recognized each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881468412216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tax Rate</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Statutory rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes on foreign earnings</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GILTI</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Neurimmune tax impacts</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:7pt"><span style="color:#00823b;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Tax Rate</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021 we recorded a net deferred tax asset in Switzerland of approximately $490.0&#160;million on Neurimmune SubOne AG's (Neurimmune) tax basis in ADUHELM, the realization of which is dependent on future sales of ADUHELM. During the fourth quarter of 2021, due to reduced future expected revenue associated with ADUHELM, we recorded a valuation allowance of approximately $390.0&#160;million. During the first quarter of 2022, upon issuance of the final NCD related to ADUHELM, we recorded an additional valuation allowance of approximately $85.0&#160;million to reduce the net value of this deferred tax asset to zero. These adjustments to our deferred tax assets and their valuation allowances are each recorded with an equal and offsetting amount assigned to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income, resulting in a zero net impact to net income attributable to Biogen Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, compared to the same period in 2021, the increase in our effective tax rate was primarily due to a deferred tax expense related to a valuation allowance, as discussed above, and the non-cash tax effects of changes in the value of our equity investments. The tax effects of this change in value of our equity investments were recorded discretely, since changes in value of equity investments cannot be forecasted.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For additional information on our collaboration arrangement with Neurimmune, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 17, Investments in Variable Interest Entities</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tax Basis in Samsung Bioepis</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022 and December 31, 2021, the carrying value of our investment in Samsung Bioepis totaled 709.4 billion South Korean won ($586.4 million) and 713.3 billion South Korean won ($599.9 million), respectively, which is classified as a component of investments and other assets in our condensed consolidated balance sheets. As of March 31, 2022, we have not recorded deferred taxes of approximately $70.0&#160;million on our tax over book basis related to this joint venture.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting for Uncertainty in Income Taxes</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2017 or state, local or non-U.S. income tax examinations for years before 2012.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration matters and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate that it is reasonably possible that our gross unrecognized tax benefits, exclusive of interest, could decrease by up to approximately $500.0 million, including approximately $455.0&#160;million related to the unrecognized tax benefits related to Neurimmune's tax basis in ADUHELM in the next 12 months as a result of various audit closures, settlements and expiration of the statute of limitations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881471497944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Other Consolidated Financial Statement Detail</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other income (expense), net, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(66.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(64.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on investments, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(191.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(436.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange gains (losses), net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(263.3)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(506.9)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains (losses) on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our gains (losses) on investments, net that relates to our equity securities held as of March 31, 2022 and 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net gains (losses) recognized during the period on equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(190.7)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(436.1)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net gains (losses) realized during the period on equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains (losses) recognized during the period on equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(190.9)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(442.3)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized losses recognized during the three months ended March 31, 2022, primarily reflect decreases in the aggregate fair value of our investments in Denali, Sage and Sangamo common stock of approximately $205.5&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expense and Other</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expense and other consists of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue-related reserves for discounts and allowances</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">831.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">802.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">266.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">324.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties and licensing fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">216.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">234.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">206.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">345.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">711.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">828.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,231.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,535.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Long-term Liabilities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities were $1,287.9 million and $1,320.5 million as of March 31, 2022 and December 31, 2021, respectively, and included accrued income taxes totaling $640.5 million and $664.5 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881471453336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative and Other Relationships</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Eisai Co., Ltd.</span></div><div style="margin-top:5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lecanemab Collaboration</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with Eisai Co., Ltd. (Eisai) to jointly develop and commercialize lecanemab (BAN2401), an anti-amyloid antibody, and elenbecestat, the oral BACE (base amyloid cleaving enzyme) inhibitor, two Eisai product candidates for the potential treatment of Alzheimer's disease (the Lecanemab Collaboration). In September 2019 we and Eisai discontinued the global Phase 3 studies of elenbecestat in early Alzheimer's disease.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eisai serves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product, and Eisai having final decision-making authority. All costs, including research, development, sales and marketing expense, are shared equally between us and Eisai. If lecanemab receives marketing approval, we and Eisai will co-promote lecanemab and share profits equally. In March 2022 we extended our supply agreement related to lecanemab from five years to ten years, and we will manufacture the lecanemab drug substance in our Solothurn manufacturing facility.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Lecanemab Collaboration also provided Eisai with an option to jointly develop and commercialize ADUHELM (aducanumab) (ADUHELM Option). In October 2017 Eisai exercised its ADUHELM Option and we entered into a new collaboration agreement for the joint development and commercialization of ADUHELM (aducanumab) (the ADUHELM Collaboration Agreement).</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development and sales and marketing expense related to the Lecanemab Collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total development expense incurred by the collaboration related to the advancement of lecanemab and elenbecestat</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of lecanemab and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total sales and marketing expense incurred by the Lecanemab Collaboration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of lecanemab and elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our Lecanemab Collaboration, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2021 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ADUHELM Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our initial ADUHELM Collaboration Agreement, we would lead the ongoing development of ADUHELM, and we and Eisai would co-promote ADUHELM with a region-based profit split. Beginning January 1, 2019, Eisai was reimbursing us for&#160;45.0%&#160;of development costs incurred by the collaboration for the advancement of ADUHELM (ADUHELM development expense). </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 ADUHELM was granted accelerated approval by the FDA for the treatment of Alzheimer's disease and had its first commercial sale. As a result of the launch of ADUHELM in the U.S., we made a $100.0&#160;million milestone payment to Neurimmune. During the second quarter of 2021 we recognized net profit-sharing income of $45.0&#160;million to reflect Eisai's 45.0% share of the $100.0&#160;million milestone payment, which was recorded in collaboration profit (loss) sharing in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022 we amended our ADUHELM Collaboration Agreement with Eisai. Effective March 2022 we have sole decision making and commercialization rights worldwide on ADUHELM and beginning January 1, 2023, Eisai will receive a tiered royalty based on net sales of ADUHELM, rather than sharing global profits and losses. Eisai's share of development, commercialization and manufacturing expense is limited to $335.0&#160;million for the period from January 1, 2022 to December 31, 2022. Once the tiered royalty model commences on January 1, 2023, Eisai will not participate in ADUHELM&#8217;s economics beyond these royalties.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development expense, sales and marketing expense and milestone payments related to the ADUHELM Collaboration Agreement is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total ADUHELM development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of ADUHELM development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total ADUHELM sales and marketing expense incurred by the ADUHELM Collaboration Agreement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of ADUHELM sales and marketing expense reflected in selling, general and administrative expense and collaboration profit (loss) sharing in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">o-promotion Profits and Losses</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S. we recognize revenue on sales to third parties as a component of product revenue, net in our condensed consolidated statements of income. We also record the related cost of revenue and sales and marketing expense in our condensed consolidated statements of income as these costs are incurred. Payments made to and received from Eisai for its 45.0% share of the co-promotion profits or losses in the U.S. are recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. For the three months ended March 31, 2022, we recognized a net reduction to our operating expense of </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$181.7&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to reflect Eisai's 45.0% share of net collaboration losses in the U.S.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2022 we recorded approximately $275.0&#160;million of gross charges associated with inventory and purchase commitments in excess of forecasted demand related to ADUHELM, as well as approximately $45.0&#160;million of gross idle capacity charges, which were recognized in cost of sales within our condensed consolidated statements of income. We have recognized approximately $160.0&#160;million related to Eisai's 45.0% share of these charges in collaboration profit (loss) sharing within our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts receivable from Eisai related to the agreements discussed above were </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$402.7&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $285.4&#160;million as of March 31, 2022 and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively. Amounts payable to Eisai related to the agreements discussed above were </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$36.5&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $46.5&#160;million as of March 31, 2022 and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021, respectively</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the ADUHELM Collaboration Agreement, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2021 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">UCB</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with UCB to jointly develop and commercialize dapirolizumab pegol, an anti-CD40L pegylated Fab, for the potential treatment of systemic lupus erythematosus and other future agreed indications. Either we or UCB may propose development of dapirolizumab pegol in additional indications. If the parties do not agree to add an indication as an agreed indication to the collaboration, we or UCB may, at the sole expense of the applicable party, pursue development in such excluded indication(s), subject to an opt-in right of the non-pursuing party after proof of clinical activity. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All costs incurred for agreed indications, including research, development, sales and marketing expense, are shared equally between us and UCB. Upon marketing approval, we and UCB will co-promote dapirolizumab pegol and share profits equally.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development expense related to the UCB collaboration agreement is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total UCB collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of UCB development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:7pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sage Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2020 we entered into a global collaboration and license agreement with Sage to jointly develop and commercialize BIIB125 (zuranolone) for the potential treatment of major depressive disorder and postpartum depression and BIIB124 (SAGE-324) for the potential treatment of essential tremor with potential in other neurological conditions such as epilepsy.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under this collaboration, both companies will share equal responsibility and costs for development as well as profits and losses for commercialization in the U.S. Outside of the U.S., we are responsible for development and commercialization, excluding Japan, Taiwan and South Korea, with respect to zuranolone and may pay Sage potential tiered royalties in the high teens to low twenties.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development and sales and marketing expense related to this collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sage collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Sage development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sage sales and marketing expense incurred by the collaboration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Sage sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Denali Therapeutics Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020 we entered into a collaboration and license agreement with Denali to co-develop and co-commercialize Denali's small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson's disease. Under this collaboration, both companies share responsibility and costs for global development based on specified percentages as well as profits and losses for commercialization in the U.S. and China. Outside the U.S. and China we are responsible for commercialization and may pay Denali potential tiered royalties.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the LRRK2 program, we also have an exclusive option to license two preclinical programs from Denali&#8217;s Transport Vehicle platform, including its Antibody Transport Vehicle (ATV): ATV enabled anti-amyloid beta program and a second program utilizing its Transport Vehicle technology. Further, we have the right of first negotiation on two additional ATV enabled therapeutics for indications within specific neurodegenerative diseases, should Denali decide to seek a collaboration for such programs.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development expense related to this collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Denali collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Denali development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sangamo Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020 we entered into a collaboration and license agreement with Sangamo to develop and commercialize ST-501 for tauopathies, including Alzheimer's disease; ST-502 for synucleinopathies, including Parkinson&#8217;s disease; a third neuromuscular disease target; and up to nine additional neurological disease targets to be identified and selected within a five-year period. The companies are leveraging Sangamo&#8217;s proprietary zinc finger protein technology delivered via adeno-associated virus to modulate the expression of key genes involved in neurological diseases. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this collaboration, we may pay Sangamo tiered royalties on potential net sales of any products developed under this collaboration in the high single digit to sub-teen percentages.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development expense related to this collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sangamo collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Sangamo development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">InnoCare Pharma Limited</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2021 we entered into a collaboration and license agreement with InnoCare Pharma Limited (InnoCare) for orelabrutinib, an oral small molecule Bruton&#8217;s tyrosine kinase inhibitor for the potential treatment of MS. Orelabrutinib is currently being studied in a multi-country, placebo-controlled Phase 2 trial in relapsing-remitting MS. Under the terms of the collaboration, we have exclusive rights to orelabrutinib in the field of MS worldwide and certain autoimmune diseases outside of China (including Hong Kong, Macau and Taiwan), while InnoCare retains ex</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">clusive worldwide rights to orelabrutinib in the field of oncology and certain autoimmune diseases in China (including Hong Kong, Macau and Taiwan). </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#0a0a0a;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the closing of this transaction in August 2021 we made an upfront payment of $125.0&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">that was recorded as research and development expense in our condensed consolidated statements of income. </span><span style="background-color:#ffffff;color:#0a0a0a;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We may also pay InnoCare up to approximately $812.5&#160;million in potential development milestones and potential commercial payments should this collaboration achieve certain development, commercial milestones and sales thresholds. In addition, we may pay InnoCare tiered royalties on potential net sales of any products developed under this collaboration in the low to high teen percentages.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Research and Discovery Arrangements</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, we recorded </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$19.5&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as research and development expense in our condensed consolidated statements of income related to other research and discovery related arrangements, compared to less than </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.0&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the prior year comparative period.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Samsung Bioepis Co., Ltd.</span></div><div style="margin-top:5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Joint Venture Agreement</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. As of March 31, 2022, our ownership percentage was approximately 49.9%.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in (income) loss of investee, net of tax in our condensed consolidated statements of income. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon investment, the equity method of accounting requires us to identify and allocate differences between the fair value of our investment and the carrying value of our interest in the underlying net assets of the investee. These basis differences are amortized over their economic life. The total basis difference was approximately $675.0 million and relates to inventory, developed technology, IPR&amp;D and deferred tax balances. The basis differences related to inventory were amortized, net of tax, over their estimated useful lives of 1.5 years, and the basis differences related to developed technology and IPR&amp;D for marketed products will be amortized, net of tax, over their estimated useful lives of 15 years.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, we recognized net losses on our investment of $3.3 million, reflecting our share of Samsung Bioepis' operating profits, net of tax totaling $4.0&#160;million offset by amortization of basis differences totaling $7.3&#160;million.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, we recognized net losses on our investment of $18.2 million, reflecting our share of Samsung Bioepis' operating losses, net of tax totaling $11.0&#160;million and amortization of basis differences totaling $7.2&#160;million.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022 and December 31, 2021, the carrying value of our investment in Samsung Bioepis totaled 709.4 billion South Korean won ($586.4 million) and 713.3 billion South Korean won ($599.9 million), respectively, which is classified as a component of investments and other assets in our condensed consolidated balance sheets.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022 we entered into an agreement to sell to Samsung BioLogics our equity in Samsung Bioepis, which was completed on April 20, 2022. Under the terms of the transaction, we received approximately $1.0&#160;billion in cash at closing and will receive approximately $1.3&#160;billion to be deferred over two payments of $812.5&#160;million due at the first anniversary and $437.5&#160;million due at the second anniversary of the closing of the transaction. We are also eligible to receive up to an additional $50.0&#160;million upon the achievement of certain commercial milestones.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 Development and Commercialization Agreement</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize two potential ophthalmology biosimilar products, BYOOVIZ (ranibizumab-nuna), a proposed ranibizumab biosimilar referencing LUCENTIS, and SB15, a proposed aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. Samsung Bioepis will be responsible for development and will supply both products to us at a pre-specified gross margin.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this transaction, we made an upfront payment of $100.0 million to Samsung Bioepis in January 2020, of which $63.0 million was recorded as research and development expense in our condensed consolidated statements of income in 2019 and $37.0 million was recorded as intangible assets, net in our condensed consolidated balance sheets in 2019. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2021 we accrued $15.0&#160;million in milestone payments related to the approval of BYOOVIZ in the U.S., the E.U. and the U.K., that were capitalized within intangible assets, net in our condensed consolidated balance sheets. We may also pay Samsung Bioepis up to approximately $180.0 million in additional development, regulatory and sales-based milestones.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also acquired an option to extend the term of our 2013 c</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ommercial agreement for BENEPALI, IMRALDI and FLIXABI by an additional five years, subject to payment of an option exercise fee of $60.0 million, and obtained an option to acquire exclusive rights to commercialize these products in China.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2013 Commercial Agreement</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We reflect revenue on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenue, net in our condensed consolidated statements of income and record the related cost of revenue and sales and marketing expense in our condensed consolidated statements of income to their respective line items when these costs are incurred. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We share 50.0% of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. For the three months ended March 31, 2022, we recognized net profit-sharing expense of $64.4&#160;million to reflect Samsung </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bioepis' 50.0% sharing of the net collaboration profits, compared to a net profit-sharing expense of $68.5 million in the prior year comparative period. </span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Services</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Simultaneous with the formation of Samsung Bioepis, we also entered into a technical development services agreement, a manufacturing agreement and a license agreement with Samsung Bioepis. Revenue related to these services is reflected in revenue from collaborative and other relationships as a component of other revenue in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts receivable from Samsung Bioepis related to the agreements discussed above were $5.8&#160;million and $4.1&#160;million as of March 31, 2022 and December 31, 2021, respectively. Amounts payable to Samsung Bioepis related to the agreements discussed above were $102.5&#160;million and $148.7&#160;million as of March 31, 2022 and December 31, 2021, respectively.</span></div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis and our other significant collaboration arrangements, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships,</span> to our consolidated financial statements included in our 2021 Form 10-K.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881468467112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Variable Interest Entities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentsInVariableInterestEntitiesAbstract', window );"><strong>Investments in Variable Interest Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">Investments in Variable Interest Entities</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidated Variable Interest Entities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neurimmune SubOne AG</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration and license agreement with Neurimmune for the development and commercialization of antibodies for the potential treatment of Alzheimer's disease, including ADUHELM (as amended, the Neurimmune Agreement). We are responsible for the development, manufacturing and commercialization of all collaboration products. The Neurimmune Agreement is effective for the longer of the duration of certain patents relating to a licensed product or 12 years from the first commercial sale of a licensed product.  </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#8217;s economic performance and we are required to fund 100.0% of the research and development costs incurred in support of the collaboration. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 ADUHELM was granted accelerated approval by the FDA. Under the terms of the Neurimmune Agreement, we were required to pay Neurimmune a milestone payment of $100.0&#160;million related to the launch of ADUHELM in the U.S. During the second quarter of 2021 we made this $100.0&#160;million payment, which was recognized as a charge to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income. In addition, during the second quarter of 2021 we recognized net profit-sharing income of $45.0&#160;million to reflect Eisai's </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45.0%</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> share of the $100.0&#160;million milestone payment, which was recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if aducanumab receives regulatory approval in the jurisdictions where we have submitted filings, we may pay additional milestones to Neurimmune, including $50.0&#160;million  if launched in Japan. Milestones payable to Neurimmune are shared expenses under the ADUHELM Collaboration Agreement.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs for which we reimburse Neurimmune are reflected in research and development expense in our condensed consolidated statements of income. During the three months ended March 31, 2022 and 2021, amounts reimbursed were immaterial.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021 we recorded a net deferred tax asset in Switzerland of approximately $490.0&#160;million on Neurimmune's tax basis in ADUHELM, the realization of which is dependent on future sales of ADUHELM. During the fourth quarter of 2021, due to reduced future expected revenue associated with ADUHELM, we recorded a valuation allowance of approximately $390.0&#160;million. During the first quarter of 2022, upon issuance of the final NCD related to ADUHELM, we recorded an additional valuation allowance of approximately $85.0&#160;million to reduce the net value of this deferred tax asset to zero. These adjustments to our deferred tax assets and their valuation allowances are each recorded with an equal and offsetting amount assigned to net income (loss) </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income, resulting in a zero net impact to net income attributable to Biogen Inc.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding the impact of the Neurimmune deferred tax asset, the assets and liabilities of Neurimmune are not significant to our condensed consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than contractually required amounts.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unconsolidated Variable Interest Entities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relationships with various variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022 and December 31, 2021, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled $24.1 million and $24.6 million, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previous contractually required amounts. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our investments in Neurimmune and other variable interest entities, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Investments in Variable Interest Entities,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2021 Form 10-K.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentsInVariableInterestEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments In Variable Interest Entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentsInVariableInterestEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881474093416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract', window );"><strong>Loss Contingency, Information about Litigation Matters [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Litigation</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2021 Form 10-K.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#8217; legal theories; and (v) the parties' settlement positions. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss Contingencies </span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ADUHELM Securities Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and certain current and former officers are named as defendants in actions filed by shareholders on November 13, 2020 and February 7, 2022, and pending in the U.S. District Court for the District of Massachusetts. The actions allege violations of federal securities laws under 15 U.S.C &#167;78j(b) and &#167;78t(a) and 17 C.F.R. &#167;240.10b-5 and seek declarations of the actions as class actions and monetary relief. We have filed a motion to dismiss the action filed on November 13, 2020, which is pending. An estimate of the possible loss or range of loss in these actions cannot be made at this time.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Action</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We and members of the Board of Directors are named as defendants in an action filed by a shareholder on February 9, 2022, in the U.S. District Court for the District of Massachusetts. The action alleges violations of federal securities laws under 15 U.S.C. &#167;78n(a) and 17 C.F.R. &#167;240 14.a-9, breaches of fiduciary duties and waste of corporate assets, and seeks declaratory and injunctive relief, monetary relief to Biogen, and attorneys&#8217; fees and costs to the plaintiff. An estimate of the possible loss or range of loss cannot be made at this time.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IMRALDI Patent Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018 Fresenius Kabi Deutschland GmbH (Fresenius Kabi) commenced proceedings for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris (the French proceeding) and in November 2018 against Biogen GmbH in the D&#252;sseldorf Regional Court (the German proceeding), alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis that Biogen has commercialized in Europe, infringes national counterparts of European Patent No. 3 148 510 (the EP '510 Patent, expiring in May 2035). In May 2020 the European Patent Office (EPO) held the EP '510 Patent invalid. Fresenius Kabi has appealed to the EPO's Technical Boards of Appeal, a hearing has been set for June 2022, and the German and French proceedings have been stayed pending the decision on appeal.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020 Fresenius Kabi commenced proceedings in Denmark's Maritime and Commercial High Court alleging that IMRALDI infringes the Danish counterpart of European Patent No. 3 145 488 (the EP '488 Patent, expiring in May 2035) and a Danish utility model. In September 2021 the Court ruled that the patent and utility model are invalid and not infringed. Fresenius Kabi has appealed to the High Court of Eastern Denmark and the appeal is pending. The EPO has scheduled a hearing on the validity of the EP '488 Patent for October 2022.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020 the Danish Patent Board of Appeal revoked the Danish utility models that Fresenius Kabi had asserted against Biogen and Fresenius Kabi has appealed to the Danish Maritime and Commercial High Court. No hearing has been scheduled.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019 Gedeon Richter Nyrt commenced proceedings for damages and injunctive relief against Biogen GmbH in the D&#252;sseldorf Regional Court alleging infringement of the German counterpart of European Patent No. 3 212 667, which expires in October 2035. The case has been stayed pending proceedings in the EPO seeking to invalidate the patent. In November 2020 Gedeon Richter Nyrt commenced additional proceedings against Biogen GmbH in the D&#252;sseldorf Regional Court alleging infringement of a German utility model. In October 2021 Biogen filed cancellation proceedings in respect of the German utility model and the infringement proceedings have been stayed pending the outcome of the cancellation proceedings.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An estimate of the possible loss or range of loss in the IMRALDI patent litigation described above cannot be made at this time.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Qui Tam Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2015 a qui tam action filed by Michael Bawduniak on behalf of the U.S. and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts and seeks damages of $981.1&#160;million plus statutory trebling of damages, civil penalties, attorneys&#8217; fees and costs. The U.S. has not made an intervention decision. A trial is scheduled for the third quarter of 2022. An estimate of the possible loss cannot be made at this time.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dispute with Former Convergence Shareholders</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November and December 2019 Shareholder Representative Services LLC, on behalf of the former shareholders of Convergence, sent us correspondence asserting claims of $200.0 million for alleged breach of the contract under which we acquired Convergence. We dispute the claims.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ERISA Class Action Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020 the U.S. District Court for the District of Massachusetts consolidated two cases filed against us in July and August 2020 by participants in the Biogen 401(k) Savings Plan alleging breach of fiduciary duty under ERISA. Plaintiffs seek a declaration of the action as a class action and monetary and other relief. An estimate of the possible loss or range of loss cannot be made at this time.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Humana Patient Assistance Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021 Humana Inc. (Humana) filed suit against us in the U.S. District Court for the District of Massachusetts alleging damages related to our providing MS patients with free medications and making charitable contributions to non-profit organizations that assist MS patients. Humana alleges violation of the federal RICO Act and state laws and seeks statutory treble damages, attorneys' fees and costs. We filed a motion to dismiss, which is pending. An estimate of the possible loss cannot be made at this time.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Investigations</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. House of Representatives Committees on Oversight and Reform and Energy and Commerce and the Office of Inspector General of the U.S. Department of Health and Human Services have announced investigations relating to ADUHELM. In addition, the Company has received a civil investigative demand from the Federal Trade Commission and a subpoena from the Securities and Exchange Commission seeking information relating to ADUHELM, including healthcare sites, ADUHELM&#8217;s approval and ADUHELM&#8217;s marketing.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TECFIDERA Patent Matters</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017 to 2020 we filed patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act (the Delaware Actions), against Accord Healthcare Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Cipla Limited, Graviti Pharmaceuticals Pvt. Ltd., Hetero USA, Inc., Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Prinston Pharmaceutical Inc., Sandoz Inc., Shilpa Medicare Limited, Slayback Pharma LLC, Sun Pharmaceutical Industries, Ltd., Sun Pharmaceutical Industries, Inc., Sun Pharma Global FZE, Torrent Pharmaceuticals Ltd., TWi Pharmaceuticals, Inc., Windlas Healthcare Pvt. Ltd. and Zydus Pharmaceuticals (USA) Inc. (collectively, the Delaware Defendants) in the U.S. District Court for the District of Delaware (the Delaware Court) and against Mylan (the West Virginia Action) in the U.S. District Court for the Northern District of West Virginia (the West Virginia Court).</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2021 the Federal Circuit affirmed the West Virginia Court judgment that the asserted claims of our U.S. Patent No. 8,399,514 (the '514 Patent) are invalid for lack of written description.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Delaware Court entered judgment for the Delaware Defendants on the grounds that the judgment of the West Virginia Court applies to the Delaware Actions under principles of collateral estoppel. The appeals in the Delaware Actions are stayed.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2018 Mylan Pharmaceuticals, Inc. (Mylan) also filed a petition with the U.S. Patent Trial and Appeal Board (PTAB) for </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">inter partes</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> review of the '514 Patent. In November 2021 the Federal Circuit ruled that the PTAB decision upholding the patentability of the &#8216;514 patent was moot, but in April 2022 the Federal Circuit vacated that ruling and stayed the appeal pending any final action by the United States Supreme Court in the West Virginia Action.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TYSABRI Patent Revocation Matters</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017 Swiss Pharma International AG, affiliated with the Polpharma Group, filed an action in the Commercial Court of Rome to invalidate the Italian counterpart of the European Patent No. 1 485 127 (the EP '127 Patent) which covers administration of natalizumab (TYSABRI) to treat MS and expires in February 2023. A hearing has been set for June 2022.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020 Polpharma Biologics S.A., also affiliated with the Polpharma Group, brought an action in the Polish Patent Office to revoke our Polish Patent No. 215263, which corresponds to the EP '127 Patent and expires in February 2023. The action was suspended by the Polish Patent Office in April 2021 pending examination of our amended patent claims.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 Polpharma Biologics S.A., Sandoz B.V. and Sandoz AG filed an action in the District Court of the Hague, Netherlands to invalidate the Dutch counterpart of our European Patent 2 676 967 (the EP '967 Patent), which expires in 2027 and covers methods of treatment using natalizumab (TYSABRI) and pre-treatment testing of patients. A hearing has been set for September 2022. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021 the EPO revoked the EP &#8216;967 Patent. We have appealed to the EPO&#8217;s Technical Boards of Appeal. A hearing date has not been set.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021 Polpharma Biologics S.A., Sandoz AG, Sandoz Limited and Sandoz GmbH filed an action in the English High Court to revoke the U.K. counterpart of the EP &#8216;967 Patent and seeking a declaration that the patent would not be infringed by the marketing of Polpharma&#8217;s proposed natalizumab biosimilar. A hearing has been set for November 2022.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Annulment Proceedings in General Court of the European Union relating to TECFIDERA</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical Works Polpharma SA (Polpharma) and Mylan Ireland Ltd. (Mylan Ireland) each filed actions in the General Court of the European Union (Polpharma in October 2018 and Mylan Ireland in November 2020) to annul the European Medicines Agency's (EMA) decision not to validate their applications to market generic versions of TECFIDERA on the grounds that TECFIDERA benefits from regulatory data protection. On May 5, 2021, the European General Court annulled the EMA's non-validation decision with respect to Polpharma. We have appealed the decision to the European Court of Justice and the appeal is pending. The case brought by Mylan Ireland has been stayed.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Liability and Other Legal Proceedings</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyInformationAboutLitigationMattersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881471499672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">SUBSEQUENT EVENTSOn May 3, 2022, Biogen Inc. (the "Company") announced that it had begun a search for a new Chief Executive Officer ("CEO"). The Company has agreed with its current CEO, Michel Vounatsos, that he will continue to serve as CEO during the interim period. Mr. Vounatsos will remain on the Board of Directors of Biogen until he steps down from his CEO position.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881469891608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_BusinessOverviewPolicyTextBlock', window );">Overview</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. We have a leading portfolio of medicines to treat multiple sclerosis (MS), have introduced the first approved treatment for spinal muscular atrophy (SMA) and are providing the first and only approved treatment to address a defining pathology of Alzheimer's disease. We also commercialize biosimilars of advanced biologics and focus on advancing our pipeline in neuroscience and specialized immunology. Lastly, we are focused on accelerating our efforts in digital health to support our commercial and pipeline programs while also creating opportunities for potential digital therapeutics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS); and other potential anti-CD20 therapies, including mosunetuzumab, pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our audited consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended December 31, 2021 (2021 Form&#160;10-K).</span></div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through our collaboration with Samsung Bioepis Co., Ltd. (Samsung Bioepis) we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe. We have also secured the exclusive rights to commercialize BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS, which was approved in the U.S., the European Union (E.U.) and the United Kingdom (U.K.) during the third quarter of 2021. For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span> to these unaudited condensed consolidated financial statements (condensed consolidated financial statements).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2021 Form&#160;10-K. Our accounting policies are described in the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2021 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three months ended March 31, 2022, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate as one operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100.0% of the economics, we record net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including sales, expense, reserves and allowances, the supply chain, manufacturing, clinical trials, research and development costs and employee-related costs, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets. Additionally, the ongoing geopolitical tensions related to Russia's invasion of Ukraine, and the related sanctions and other penalties imposed, are creating substantial uncertainty in the global economy. The extent and duration of the conflict, sanctions and resulting market disruptions are highly unpredictable. We have made estimates of the impact of the COVID-19 pandemic and the ongoing geopolitical conflict within our condensed consolidated financial statements and there may be changes to those estimates in future periods.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New accounting pronouncements</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that we adopt as of the specified effective date. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe that the adoption of recently issued standards have had or may have a material impact on our condensed consolidated financial statements or disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessOverviewPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes an overview of the company and its operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessOverviewPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881468356072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Business Transformation and Other Cost Saving Initiatives (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Restructuring Reserve by Type of Cost</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the charges and spending related to our 2022 cost saving initiatives for the three months ended March 31, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Workforce Reduction</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881466213576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Revenues by product</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by product is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.550%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis (MS):</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fumarate</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">295.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">537.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">236.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">316.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">552.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interferon</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">182.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">309.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">241.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">284.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">236.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">520.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">273.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">503.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: MS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">709.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">685.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,394.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">751.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">732.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,483.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">309.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">472.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">371.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">520.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alzheimer's disease:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ADUHELM</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilars</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">194.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">194.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FUMADERM</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">875.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,191.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,066.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">899.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,311.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,211.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fumarate includes TECFIDERA and VUMERITY. VUMERITY became commercially available in the E.U. during the fourth quarter of 2021.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Interferon includes AVONEX and PLEGRIDY.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In June 2021 the U.S. Food and Drug Administration (FDA) granted accelerated approval of ADUHELM, which became commercially available in the U.S. during the second quarter of 2021. For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships - Eisai Co., Ltd. - ADUHELM Collaboration Agreement, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock', window );">Analysis of change In reserves</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.155%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.114%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.7&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">759.6&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">935.3&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current provisions relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">659.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">832.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(40.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(46.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(101.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(271.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(373.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in prior years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(58.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(314.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(379.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">792.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">968.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock', window );">Total reserves included in consolidated balance sheets</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.400%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reduction of accounts receivable</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">136.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Component of accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">831.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">802.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue-related reserves</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">968.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">935.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from anti-CD20 therapeutic programs is summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OCREVUS and other revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">256.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">214.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">399.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">389.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OtherrevenuesTableTextBlock', window );">Other revenues</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from collaborative and other relationships:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue earned under our technical development agreement, manufacturing services agreements and royalty revenue on biosimilar products with Samsung Bioepis</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other royalty and corporate revenue:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other corporate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Analysis of amount of and change in product revenue reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherrevenuesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other revenues [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherrevenuesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from anti-CD20 therapeutic programs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of total product revenue reserves included in consolidated balance sheets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881468499384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Components of inventory</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">354.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">349.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">655.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">814.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,215.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,351.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881472743240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock', window );">Intangible assets</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.257%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.396%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.972%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.972%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.669%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completed technology</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4-28 years</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,413.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,455.4)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,957.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,413.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,388.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,024.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite until commercialization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks&#160;and trade names</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,606.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,455.4)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,150.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,609.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,388.5)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,221.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Estimated future amortization for acquired intangible assets</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022 (remaining nine months)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">210.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">165.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Summary of roll forward of the changes in goodwill</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,761.1&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,758.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible assets excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IntangibleAssetsExcludingGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881473020568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of assets and liabilities recorded at fair value</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.796%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,283.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,283.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,579.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,579.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,252.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,252.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">171.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">171.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">860.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">607.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">253.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,281.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">607.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,674.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">214.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.796%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,632.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,632.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,108.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,108.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,192.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,192.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,048.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">866.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,228.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,046.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">219.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Summary of fair and carrying value of debt instruments</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:42.091%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.625% Senior Notes due September 15, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,008.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">999.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,020.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">999.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.050% Senior Notes due September 15, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,797.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,743.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,895.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,742.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.250% Senior Notes due May 1, 2030</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,341.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,492.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,475.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,492.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.200% Senior Notes due September 15, 2045</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,240.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,100.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,463.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,099.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.150% Senior Notes due May 1, 2050</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,225.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,473.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,457.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,473.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.250% Senior Notes due February 15, 2051</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">581.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">466.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">692.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">466.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,195.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,275.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,004.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,273.1&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair value of contingent consideration obligations</a></td>
<td class="text">The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, beginning of period</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, end of period</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881469734536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">278.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">247.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Overnight reverse repurchase agreements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">585.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">901.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">406.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">283.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,283.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,632.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Marketable debt and equity securities</a></td>
<td class="text">The following tables summarize our marketable debt and equity securities, classified as available-for-sale:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,126.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,124.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">460.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">454.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">878.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">877.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">379.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">375.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">171.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,019.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16.4)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,004.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, current</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,133.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(311.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">826.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,167.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(311.2)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">860.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">723.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">723.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">385.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">384.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">817.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">816.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">377.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">376.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,435.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,433.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, current</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,133.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(279.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,004.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,167.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160.9&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(279.4)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,048.5&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Summary of contractual maturities: available-for-sale securities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:41.924%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.413%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,002.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,006.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,541.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,541.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">982.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">993.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">868.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">870.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after five years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,004.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,019.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,433.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,435.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock', window );">Proceeds from marketable debt securities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from maturities and sales</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">543.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">819.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized gains and losses on investments reported in the statement of income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881469579096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock', window );">Foreign currency forward contracts that were entered into to hedge forecasted revenue</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional amount of foreign currency forward contracts that were entered into to hedge forecasted revenue and operating expense is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,631.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,828.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">British pound</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">166.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Swiss franc</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Japanese yen</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canadian dollar</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total foreign currency forward contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,986.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,126.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of the effect of cash flow derivatives designated as hedging instruments on the condensed consolidated statements of income</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:22.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.154%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Operating Income (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23.1)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.5)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Summary of the effect of derivatives designated as net investment hedging instruments on our consolidated statement of income</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of our net investment hedge in our condensed consolidated financial statements:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:18.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.980%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.202%"/><td style="width:0.1%"/></tr><tr><td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) <br/>(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Net Income <br/>(Amounts Excluded from Effectiveness Testing) (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Summary of fair value and presentation of derivatives</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:28.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.376%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Cash Flow Hedging Instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other Derivative Instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock', window );">Derivative Instruments, Unrealized Gain (Loss)</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.785%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized (losses)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized gains (losses)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative Instruments, Unrealized Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the notional amounts of outstanding derivative positions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881468278168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.696%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.859%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses) on Net Investment Hedge, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.8&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(44.8)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(139.0)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(106.7)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.7)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21.8)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.9)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(43.9)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(160.8)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(115.2)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.696%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.859%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses) on Net Investment Hedge, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(179.0)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(66.3)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(46.6)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(299.0)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(48.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(48.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29.4)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(64.3)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(95.1)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(174.3)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts reclassified from accumulated other comprehensive income (loss):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:18pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts Reclassified from Accumulated Other Comprehensive Income (Loss)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on securities available for sale</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on cash flow hedges</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21.4)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881471508808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and diluted earnings per share</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">303.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">410.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dilutive potential common shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used in calculating diluted earnings per share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881469315992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-based compensation expense included in condensed consolidated statements of income</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax effect</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of share-based compensation expense associated with each of our share-based compensating programs</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in cash</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881471469496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Statutory rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes on foreign earnings</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GILTI</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Neurimmune tax impacts</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881466095560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Other income (expense), net</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other income (expense), net, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(66.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(64.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on investments, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(191.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(436.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange gains (losses), net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(263.3)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(506.9)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestmentsTextBlock', window );">Gain (loss) on investments in equity securities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our gains (losses) on investments, net that relates to our equity securities held as of March 31, 2022 and 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net gains (losses) recognized during the period on equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(190.7)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(436.1)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net gains (losses) realized during the period on equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains (losses) recognized during the period on equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(190.9)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(442.3)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>The net unrealized losses recognized during the three months ended March 31, 2022, primarily reflect decreases in the aggregate fair value of our investments in Denali, Sage and Sangamo common stock of approximately $205.5&#160;million.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued expenses and other</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expense and other consists of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue-related reserves for discounts and allowances</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">831.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">802.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">266.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">324.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties and licensing fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">216.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">234.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">206.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">345.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">711.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">828.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,231.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,535.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized and unrealized gain (loss) on investment in security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881469664520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock', window );">Summary of Activity Related to BAN2401 and Elenbecestat Collaboration</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total development expense incurred by the collaboration related to the advancement of lecanemab and elenbecestat</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of lecanemab and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total sales and marketing expense incurred by the Lecanemab Collaboration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of lecanemab and elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock', window );">Summary of Activity Related to Aducanumab Collaboration</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development expense, sales and marketing expense and milestone payments related to the ADUHELM Collaboration Agreement is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total ADUHELM development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of ADUHELM development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total ADUHELM sales and marketing expense incurred by the ADUHELM Collaboration Agreement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of ADUHELM sales and marketing expense reflected in selling, general and administrative expense and collaboration profit (loss) sharing in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock', window );">Summary of Activity Related to Denali Therapeutics Collaboration</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development expense related to this collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Denali collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Denali development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of Activity Related to Denali Therapeutics Collaboration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881469282440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InterestInSubsidiary', window );">Interest in subsidiary (less than given percentage)</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest in subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881468584648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Business Transformation and Other Cost Saving Initiatives - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 38.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Employee related costs</a></td>
<td class="nump">27.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveAcceleratedDepreciation', window );">Accelerated depreciation expense</a></td>
<td class="nump">$ 10.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveAcceleratedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveAcceleratedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881466191480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Business Transformation and Other Cost Saving Initiatives - Restructuring Reserve Roll Forward (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expense</a></td>
<td class="nump">$ 38.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=biib_WorkforceReductionMember', window );">Workforce Reduction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, beginning</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expense</a></td>
<td class="nump">27.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payment</a></td>
<td class="num">(6.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, ending</a></td>
<td class="nump">$ 21.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=biib_WorkforceReductionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=biib_WorkforceReductionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881461901608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues by product (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">$ 2,531.8<span></span>
</td>
<td class="nump">$ 2,694.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FumarateMember', window );">Fumarate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">537.9<span></span>
</td>
<td class="nump">552.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FumarateMember', window );">Fumarate | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">242.3<span></span>
</td>
<td class="nump">236.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FumarateMember', window );">Fumarate | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">295.6<span></span>
</td>
<td class="nump">316.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">309.6<span></span>
</td>
<td class="nump">400.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">182.3<span></span>
</td>
<td class="nump">241.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">127.3<span></span>
</td>
<td class="nump">158.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">520.8<span></span>
</td>
<td class="nump">503.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">284.5<span></span>
</td>
<td class="nump">273.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">236.3<span></span>
</td>
<td class="nump">230.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">26.2<span></span>
</td>
<td class="nump">26.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">26.2<span></span>
</td>
<td class="nump">26.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">MS Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">1,394.5<span></span>
</td>
<td class="nump">1,483.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">MS Product Revenues | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">709.1<span></span>
</td>
<td class="nump">751.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">MS Product Revenues | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">685.4<span></span>
</td>
<td class="nump">732.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">472.5<span></span>
</td>
<td class="nump">520.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">163.3<span></span>
</td>
<td class="nump">148.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">309.2<span></span>
</td>
<td class="nump">371.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ADUHELMMember', window );">ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ADUHELMMember', window );">ADUHELM | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ADUHELMMember', window );">ADUHELM | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">114.7<span></span>
</td>
<td class="nump">121.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">114.7<span></span>
</td>
<td class="nump">121.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">57.1<span></span>
</td>
<td class="nump">57.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">57.1<span></span>
</td>
<td class="nump">57.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">22.5<span></span>
</td>
<td class="nump">25.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">22.5<span></span>
</td>
<td class="nump">25.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">194.3<span></span>
</td>
<td class="nump">205.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">194.3<span></span>
</td>
<td class="nump">205.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">2.2<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">2.2<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">2,066.3<span></span>
</td>
<td class="nump">2,211.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">875.2<span></span>
</td>
<td class="nump">899.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">$ 1,191.1<span></span>
</td>
<td class="nump">$ 1,311.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FumarateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FumarateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_InterferonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_InterferonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TysabriProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TysabriProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FAMPYRAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_MSProductRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_SPINRAZAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ADUHELMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ADUHELMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_BENEPALIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_BENEPALIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_IMRALDIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_IMRALDIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FLIXABIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FLIXABIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_BiosimilarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FUMADERMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FUMADERMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881461845288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues Reserves for Discounts and Allowances (Details 1)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">$ 935.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">832.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="num">(46.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(373.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(379.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">968.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember', window );">Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">137.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">169.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="num">(3.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(101.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(58.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">142.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember', window );">Contractual adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">759.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">659.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="num">(40.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(271.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(314.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">792.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember', window );">Returns</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">38.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">4.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="num">(2.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(0.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(6.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">$ 32.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to product revenue reserves relating to sales in prior years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current provisions to product revenue reserves relating to sales in current year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to current year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to prior year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881466180600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenues- Reserves for Discounts and Allowances (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">$ 968.0<span></span>
</td>
<td class="nump">$ 935.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember', window );">Reduction of accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">136.9<span></span>
</td>
<td class="nump">133.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Component of accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">$ 831.1<span></span>
</td>
<td class="nump">$ 802.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881470495240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">$ 2,531.8<span></span>
</td>
<td class="nump">$ 2,694.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_RocheGroupGenentechMember', window );">Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareOfCoPromotionProfits', window );">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</a></td>
<td class="nump">143.2<span></span>
</td>
<td class="nump">174.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OtherrevenuesfromantiCD20therapeuticprograms', window );">Other revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">256.2<span></span>
</td>
<td class="nump">214.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenue from anti-CD20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">$ 399.4<span></span>
</td>
<td class="nump">$ 389.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherrevenuesfromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherrevenuesfromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareOfCoPromotionProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share of co promotion profits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareOfCoPromotionProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_RocheGroupGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_RocheGroupGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881462459928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Other Revenues (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 2,531.8<span></span>
</td>
<td class="nump">$ 2,694.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">10.6<span></span>
</td>
<td class="nump">6.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember', window );">Other corporate revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">47.5<span></span>
</td>
<td class="nump">83.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">66.1<span></span>
</td>
<td class="nump">93.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative arrangement | ZINBRYTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 8.0<span></span>
</td>
<td class="nump">$ 3.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_ZINBRYTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_ZINBRYTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881461896456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>wholesaler</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Other Revenues</a></td>
<td class="nump">$ 2,531.8<span></span>
</td>
<td class="nump">$ 2,694.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfWholesalers', window );">Number of wholesalers | wholesaler</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_DistributorOneMember', window );">Distributor One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors', window );">Percentage of revenues from major distributors</a></td>
<td class="nump">26.30%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_DistributorTwoMember', window );">Distributor Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors', window );">Percentage of revenues from major distributors</a></td>
<td class="nump">10.50%<span></span>
</td>
<td class="nump">9.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember', window );">Other corporate revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Other Revenues</a></td>
<td class="nump">$ 47.5<span></span>
</td>
<td class="nump">$ 83.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Other Revenues</a></td>
<td class="nump">$ 66.1<span></span>
</td>
<td class="nump">$ 93.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity wide percentage of revenue from major distributors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EntityWidePercentageOfRevenueFromMajorDistributors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfWholesalers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Wholesalers</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfWholesalers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_DistributorOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_DistributorOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_DistributorTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_DistributorTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881466107240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory - Components of Inventory (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Components of inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 354.5<span></span>
</td>
<td class="nump">$ 349.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">655.6<span></span>
</td>
<td class="nump">814.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">205.3<span></span>
</td>
<td class="nump">187.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Inventorynetcurrentandnoncurrent', window );">Total inventory</a></td>
<td class="nump">$ 1,215.4<span></span>
</td>
<td class="nump">$ 1,351.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Inventorynetcurrentandnoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory, net current and noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Inventorynetcurrentandnoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881462703224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Excess and obsolescence charges related to inventory</a></td>
<td class="nump">$ 281.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Gain) loss on equity method investments</a></td>
<td class="num">(3.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (18.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Gain) loss on equity method investments</a></td>
<td class="nump">$ 181.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai', window );">Percentage of future development costs related to Eisai</a></td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ADUHELMMember', window );">ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Excess and obsolescence charges related to inventory</a></td>
<td class="nump">$ 275.0<span></span>
</td>
<td class="nump">$ 120.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InventoryNetCurrentAndNoncurrent', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">223.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ADUHELMMember', window );">ADUHELM | Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Gain) loss on equity method investments</a></td>
<td class="nump">160.0<span></span>
</td>
<td class="nump">$ 59.0<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ADUHELMMember', window );">ADUHELM | Eisai | Centers for Medicare and Medicaid Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Gain) loss on equity method investments</a></td>
<td class="nump">$ 136.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InventoryNetCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory, Net Current and Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InventoryNetCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of future development costs related to Eisai</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageoffuturedevelopmentcostsrelatedtoEisai</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ADUHELMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ADUHELMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=biib_CentersForMedicareAndMedicaidServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=biib_CentersForMedicareAndMedicaidServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881462915784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Total intangible assets, gross</a></td>
<td class="nump">$ 7,606.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,609.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(5,455.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,388.5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">2,150.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,221.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="nump">66.9<span></span>
</td>
<td class="nump">$ 98.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Expected future amortization expense, 2019 (remaining three months)</a></td>
<td class="nump">200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Expected future amortization expense, 2020</a></td>
<td class="nump">210.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Expected future amortization expense, 2021</a></td>
<td class="nump">195.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Expected future amortization expense, 2022</a></td>
<td class="nump">195.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Expected future amortization expense, 2023</a></td>
<td class="nump">180.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Expected future amortization expense, 2024</a></td>
<td class="nump">165.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Completed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">7,413.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,413.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">1,957.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,024.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">$ (5,455.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,388.5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Completed technology | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Completed technology | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">28 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and Net</a></td>
<td class="nump">$ 129.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trademarks and Trade Names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and Net</a></td>
<td class="nump">64.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_VixotrigineMember', window );">Vixotrigine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="nump">44.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_TGNMember', window );">TGN | In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and Net</a></td>
<td class="nump">$ 129.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization and Impairment of Acquired Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_VixotrigineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_VixotrigineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_TGNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_TGNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881469231016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Summary of roll forward of the changes in goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning of period</a></td>
<td class="nump">$ 5,761,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Other</a></td>
<td class="num">(3,100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, end of period</a></td>
<td class="nump">5,758,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment losses related to goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="nump">$ 66,900,000<span></span>
</td>
<td class="nump">$ 98,100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization and Impairment of Acquired Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881466512632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 3,004.0<span></span>
</td>
<td class="nump">$ 2,433.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,283.7<span></span>
</td>
<td class="nump">1,632.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">860.3<span></span>
</td>
<td class="nump">1,048.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">97.2<span></span>
</td>
<td class="nump">80.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">35.8<span></span>
</td>
<td class="nump">33.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">5,281.0<span></span>
</td>
<td class="nump">5,228.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">12.5<span></span>
</td>
<td class="nump">10.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">202.0<span></span>
</td>
<td class="nump">209.1<span></span>
</td>
<td class="nump">$ 226.0<span></span>
</td>
<td class="nump">$ 259.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">214.5<span></span>
</td>
<td class="nump">219.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,579.4<span></span>
</td>
<td class="nump">1,108.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,252.7<span></span>
</td>
<td class="nump">1,192.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">171.9<span></span>
</td>
<td class="nump">132.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">607.0<span></span>
</td>
<td class="nump">181.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">607.0<span></span>
</td>
<td class="nump">181.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,283.7<span></span>
</td>
<td class="nump">1,632.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">253.3<span></span>
</td>
<td class="nump">866.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">97.2<span></span>
</td>
<td class="nump">80.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">35.8<span></span>
</td>
<td class="nump">33.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">4,674.0<span></span>
</td>
<td class="nump">5,046.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">12.5<span></span>
</td>
<td class="nump">10.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">12.5<span></span>
</td>
<td class="nump">10.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,579.4<span></span>
</td>
<td class="nump">1,108.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,252.7<span></span>
</td>
<td class="nump">1,192.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">171.9<span></span>
</td>
<td class="nump">132.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">202.0<span></span>
</td>
<td class="nump">209.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">202.0<span></span>
</td>
<td class="nump">209.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair values as of the balance sheet date of all assets of deferred compensation plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PlanAssetsForDeferredCompensationFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractAssetFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881468326280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration obligations</a></td>
<td class="nump">$ 202,000,000<span></span>
</td>
<td class="nump">$ 209,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_TechnologicalAndRegulatorySuccessProbability', window );">Technological and Regulatory Success, Probability</a></td>
<td class="nump">10.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.050% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_TechnologicalAndRegulatorySuccessProbability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Technological and Regulatory Success, Probability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_TechnologicalAndRegulatorySuccessProbability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881469891896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details) - Discount rate<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Discount rate</a></td>
<td class="nump">0.0289<span></span>
</td>
<td class="nump">0.0130<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Discount rate</a></td>
<td class="nump">0.0289<span></span>
</td>
<td class="nump">0.0130<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881468795064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Nonrecurring Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 44.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881466431784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,275.2<span></span>
</td>
<td class="nump">$ 7,273.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt instruments, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,195.0<span></span>
</td>
<td class="nump">8,004.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,008.7<span></span>
</td>
<td class="nump">1,020.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 999.5<span></span>
</td>
<td class="nump">999.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.050% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,797.6<span></span>
</td>
<td class="nump">1,895.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,743.4<span></span>
</td>
<td class="nump">1,742.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member', window );">2.250% Senior Notes due May 1, 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,240.0<span></span>
</td>
<td class="nump">1,475.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100.0<span></span>
</td>
<td class="nump">1,492.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,341.6<span></span>
</td>
<td class="nump">1,463.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,492.2<span></span>
</td>
<td class="nump">1,099.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_LongTermDebtExchangedAmount', window );">Long Term Debt, Exchanged, Amount</a></td>
<td class="nump">$ 624.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member', window );">3.150% Senior Notes due May 1, 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,225.3<span></span>
</td>
<td class="nump">1,457.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,473.3<span></span>
</td>
<td class="nump">1,473.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A3250SeniorNotesDueFebruary152051Member', window );">3.250% Senior Notes, Due February 15, 2051</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 581.8<span></span>
</td>
<td class="nump">692.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 466.8<span></span>
</td>
<td class="nump">$ 466.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_LongTermDebtExchangedAmount', window );">Long Term Debt, Exchanged, Amount</a></td>
<td class="nump">$ 700.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_LongTermDebtExchangedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Debt, Exchanged, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_LongTermDebtExchangedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A3250SeniorNotesDueFebruary152051Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A3250SeniorNotesDueFebruary152051Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881466111128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Contingent consideration impairment</a></td>
<td class="nump">$ 7.1<span></span>
</td>
<td class="nump">$ 33.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, beginning of period</a></td>
<td class="nump">209.1<span></span>
</td>
<td class="nump">259.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, end of period</a></td>
<td class="nump">$ 202.0<span></span>
</td>
<td class="nump">$ 226.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881469366792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 1,283.7<span></span>
</td>
<td class="nump">$ 1,632.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">278.5<span></span>
</td>
<td class="nump">247.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember', window );">Overnight reverse repurchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">13.9<span></span>
</td>
<td class="nump">200.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">585.0<span></span>
</td>
<td class="nump">901.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember', window );">Short-term debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 406.3<span></span>
</td>
<td class="nump">$ 283.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881462980360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 3,019.0<span></span>
</td>
<td class="nump">$ 2,435.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">1.4<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(16.4)<span></span>
</td>
<td class="num">(3.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">3,004.0<span></span>
</td>
<td class="nump">2,433.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract', window );"><strong>Marketable equity securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Amortized Cost</a></td>
<td class="nump">1,167.0<span></span>
</td>
<td class="nump">1,167.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">4.5<span></span>
</td>
<td class="nump">160.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(311.2)<span></span>
</td>
<td class="num">(279.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Fair Value</a></td>
<td class="nump">860.3<span></span>
</td>
<td class="nump">1,048.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember', window );">Corporate debt securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">1,126.7<span></span>
</td>
<td class="nump">723.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(2.2)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">1,124.6<span></span>
</td>
<td class="nump">723.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesNonCurrentMember', window );">Corporate debt securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">460.5<span></span>
</td>
<td class="nump">385.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(5.8)<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">454.8<span></span>
</td>
<td class="nump">384.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember', window );">Government securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">878.7<span></span>
</td>
<td class="nump">817.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(2.6)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">877.1<span></span>
</td>
<td class="nump">816.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesNonCurrentMember', window );">Government securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">379.0<span></span>
</td>
<td class="nump">377.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(3.6)<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">375.6<span></span>
</td>
<td class="nump">376.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember', window );">Mortgage and other asset backed securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember', window );">Mortgage and other asset backed securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">173.4<span></span>
</td>
<td class="nump">131.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(2.2)<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">171.2<span></span>
</td>
<td class="nump">131.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesCurrentMember', window );">Equity Securities, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract', window );"><strong>Marketable equity securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Amortized Cost</a></td>
<td class="nump">33.9<span></span>
</td>
<td class="nump">33.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">9.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Fair Value</a></td>
<td class="nump">33.9<span></span>
</td>
<td class="nump">43.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesNonCurrentMember', window );">Equity Securities, Non-Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract', window );"><strong>Marketable equity securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Amortized Cost</a></td>
<td class="nump">1,133.1<span></span>
</td>
<td class="nump">1,133.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">4.5<span></span>
</td>
<td class="nump">151.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(311.2)<span></span>
</td>
<td class="num">(279.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Fair Value</a></td>
<td class="nump">$ 826.4<span></span>
</td>
<td class="nump">$ 1,004.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881461791160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract', window );"><strong>Summary of Contractual Maturities: Available-for-Sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due in one year or less, amortized cost</a></td>
<td class="nump">$ 2,002.4<span></span>
</td>
<td class="nump">$ 1,541.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in one year or less, estimated fair value</a></td>
<td class="nump">2,006.0<span></span>
</td>
<td class="nump">1,541.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years, amortized cost</a></td>
<td class="nump">982.9<span></span>
</td>
<td class="nump">868.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years, estimated fair value</a></td>
<td class="nump">993.7<span></span>
</td>
<td class="nump">870.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost', window );">Due after five years, amortized cost</a></td>
<td class="nump">18.7<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue', window );">Due after five years, estimated fair value</a></td>
<td class="nump">19.3<span></span>
</td>
<td class="nump">24.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">3,004.0<span></span>
</td>
<td class="nump">2,433.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 3,019.0<span></span>
</td>
<td class="nump">$ 2,435.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881466159704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities and sales</a></td>
<td class="nump">$ 543.6<span></span>
</td>
<td class="nump">$ 819.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Realized gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Realized losses</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881468399864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AverageMaturityOfMarketableSecurities', window );">Average maturity of marketable securities, months</a></td>
<td class="text">10 months<span></span>
</td>
<td class="text">10 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AverageMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average remaining time to maturity of marketable debt securities, available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AverageMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881468270632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments Financial Instruments (Details Textual 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other noncurrent assets | Strategic Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_StrategicInvestmentPortfolio', window );">Strategic investment portfolio</a></td>
<td class="nump">$ 919.5<span></span>
</td>
<td class="nump">$ 1,110.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_StrategicInvestmentPortfolio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Strategic investment portfolio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_StrategicInvestmentPortfolio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_StrategicInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_StrategicInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881459817464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Details)<br> $ in Millions, &#8361; in Billions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>May 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">Gain (loss) on foreign currency derivative instruments not designated as hedging instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (12.2)<span></span>
</td>
<td class="nump">$ 17.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease', window );">Gains (losses) on net investment hedges, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.2<span></span>
</td>
<td class="nump">22.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,333.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,268.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other noncurrent assets | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,986.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,126.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember', window );">Foreign Exchange Forward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UnrealizedGainOnDerivatives', window );">Unrealized Gain on Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76.4<span></span>
</td>
<td class="nump">60.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UnrealizedLossOnDerivatives', window );">Unrealized Loss on Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.3)<span></span>
</td>
<td class="num">(7.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Unrealized Gain (Loss) on Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.1<span></span>
</td>
<td class="nump">53.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging [Member] | Foreign exchange contract | Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeTermOfContract', window );">Remaining duration of Net Investment Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax', window );">Unrealized gain (loss) on net investment hedges in AOCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax', window );">Derivative qualifying as net investment hedge, excluded component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease', window );">Gains (losses) on net investment hedges, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.1<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease', window );">Gains (losses) on net investment hedge, excluded component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.3)<span></span>
</td>
<td class="num">(1.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging | Foreign exchange contract | Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.9<span></span>
</td>
<td class="num">(23.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue | Cash flows, revenue | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain on interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.5)<span></span>
</td>
<td class="num">(3.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Operating expense | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Operating expense | Cash flows, operating expenses | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain on interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other income (expense) | Net Investment Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet', window );">Gain (loss) recognized in net income, excluded component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">Euro | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,631.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,828.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_GBP', window );">British pound | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CHF', window );">Swiss franc | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_JPY', window );">Japan, Yen | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CAD', window );">Canadian dollar | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 128.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction', window );">Percentage of stake in entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to acquire additional investment in equity method investment</a></td>
<td class="nump">$ 676.6<span></span>
</td>
<td class="nump">&#8361; 759.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeMaturityAxis=biib_ShorttermderivativeMember', window );">Short-term derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax', window );">Gain/Loss on fair value of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UnrealizedGainOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrealized Gain on Derivatives</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UnrealizedGainOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UnrealizedLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrealized Loss on Derivatives</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UnrealizedLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated gain (loss) from increase (decrease) in value of excluded component of derivative hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80784-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of gains and losses (net) on derivative instruments designated and qualifying as hedging instruments representing (a) the amount of the hedge ineffectiveness and (b) the amount, if any, excluded from the assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1),(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeRemainingMaturity1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeRemainingMaturity1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the cumulative translation adjustment from gain (loss), after tax, on foreign currency derivatives, that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_GBP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_GBP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_JPY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_JPY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CAD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CAD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DerivativeMaturityAxis=biib_ShorttermderivativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DerivativeMaturityAxis=biib_ShorttermderivativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881468571560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">$ 2,082.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,006.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 76.3<span></span>
</td>
<td class="nump">$ 48.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityTypeAxis=biib_BiologicsManufacturingMember', window );">Biologics Manufacturing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfSquareFeet', window );">Number of square feet | ft&#178;</a></td>
<td class="nump">393,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityTypeAxis=biib_WarehouseUtilitiesAndSupportSpaceMember', window );">Warehouse, Utilities and Support Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfSquareFeet', window );">Number of square feet | ft&#178;</a></td>
<td class="nump">290,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityTypeAxis=biib_AdministrativeSpaceMember', window );">Administrative Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfSquareFeet', window );">Number of square feet | ft&#178;</a></td>
<td class="nump">51,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember', window );">Solothurn, Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">$ 682.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 677.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets placed into service</a></td>
<td class="nump">$ 1,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfSquareFeet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Square Feet</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfSquareFeet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityTypeAxis=biib_BiologicsManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityTypeAxis=biib_BiologicsManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityTypeAxis=biib_WarehouseUtilitiesAndSupportSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityTypeAxis=biib_WarehouseUtilitiesAndSupportSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityTypeAxis=biib_AdministrativeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityTypeAxis=biib_AdministrativeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881461802504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indebtedness (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Repayments of Senior Debt</a></td>
<td class="nump">$ 151.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66.1<span></span>
</td>
<td class="nump">$ 64.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Repayments of Senior Debt</a></td>
<td class="nump">12.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DebtInstrumentRedemptionAmount', window );">Debt Instrument, Redemption, Amount</a></td>
<td class="nump">8.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_LongTermDebtExchangedAmount', window );">Long Term Debt, Exchanged, Amount</a></td>
<td class="nump">624.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on Extinguishment of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of borrowings and premiums paid on debt exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A3250SeniorNotesDueFebruary152051Member', window );">3.250% Senior Notes, Due February 15, 2051</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_LongTermDebtExchangedAmount', window );">Long Term Debt, Exchanged, Amount</a></td>
<td class="nump">$ 700.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DebtInstrumentRedemptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DebtInstrumentRedemptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_LongTermDebtExchangedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Debt, Exchanged, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_LongTermDebtExchangedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSeniorDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSeniorDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A3250SeniorNotesDueFebruary152051Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A3250SeniorNotesDueFebruary152051Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881469029464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Repurchases (Details) - USD ($)<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 600,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2020ShareRepurchaseProgramMember', window );">2020 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock Repurchase Program, Authorized Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Amount remaining under 2019 Share Repurchase Program</a></td>
<td class="nump">$ 2,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2020ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_A2020ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881461698776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="num">$ (106.7)<span></span>
</td>
<td class="num">$ (299.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">(115.2)<span></span>
</td>
<td class="num">(174.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="nump">8.4<span></span>
</td>
<td class="nump">103.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="num">(16.9)<span></span>
</td>
<td class="nump">21.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(8.5)<span></span>
</td>
<td class="nump">125.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(115.2)<span></span>
</td>
<td class="num">(174.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(8.5)<span></span>
</td>
<td class="nump">124.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized gains (losses) on securities available for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="num">(2.2)<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">(11.9)<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="num">(10.2)<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(9.7)<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(11.9)<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Unrealized gains (losses) on cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="nump">53.8<span></span>
</td>
<td class="num">(179.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="nump">69.7<span></span>
</td>
<td class="num">(29.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="nump">34.4<span></span>
</td>
<td class="nump">128.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="num">(18.5)<span></span>
</td>
<td class="nump">21.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">15.9<span></span>
</td>
<td class="nump">149.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="nump">69.7<span></span>
</td>
<td class="num">(29.4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Gains (losses) on net investment hedge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="nump">25.5<span></span>
</td>
<td class="num">(8.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="nump">31.7<span></span>
</td>
<td class="nump">13.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="nump">5.1<span></span>
</td>
<td class="nump">22.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">6.2<span></span>
</td>
<td class="nump">22.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="nump">31.7<span></span>
</td>
<td class="nump">13.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Unfunded status of postretirement benefit plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="num">(44.8)<span></span>
</td>
<td class="num">(66.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">(43.9)<span></span>
</td>
<td class="num">(64.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(43.9)<span></span>
</td>
<td class="num">(64.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Currency translation adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="num">(139.0)<span></span>
</td>
<td class="num">(46.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">(160.8)<span></span>
</td>
<td class="num">(95.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="num">(21.8)<span></span>
</td>
<td class="num">(48.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(21.8)<span></span>
</td>
<td class="num">(48.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">$ (160.8)<span></span>
</td>
<td class="num">$ (95.1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881462915848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense)</a></td>
<td class="num">$ (263.3)<span></span>
</td>
<td class="num">$ (506.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">125.6<span></span>
</td>
<td class="nump">44.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">2,531.8<span></span>
</td>
<td class="nump">2,694.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">303.8<span></span>
</td>
<td class="nump">410.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">16.9<span></span>
</td>
<td class="num">(21.4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized gains (losses) on securities available for sale | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense)</a></td>
<td class="num">(0.6)<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Unrealized gains (losses) on cash flow hedges | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense)</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="num">(2.0)<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">20.9<span></span>
</td>
<td class="num">(23.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating Expenses</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Gains (losses) on net investment hedge | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense)</a></td>
<td class="num">$ (1.1)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881462529448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Details) - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 303.8<span></span>
</td>
<td class="nump">$ 410.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used in calculating:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding</a></td>
<td class="nump">147,100<span></span>
</td>
<td class="nump">151,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive potential common shares</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in calculating diluted earnings per share</a></td>
<td class="nump">147,600<span></span>
</td>
<td class="nump">152,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember', window );">Performance stock units settled in stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881558133592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">$ (70.4)<span></span>
</td>
<td class="num">$ (72.6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="nump">71.8<span></span>
</td>
<td class="nump">78.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="num">(2.8)<span></span>
</td>
<td class="num">(2.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total costs and expenses</a></td>
<td class="nump">69.0<span></span>
</td>
<td class="nump">75.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Income tax effect</a></td>
<td class="num">(12.8)<span></span>
</td>
<td class="num">(14.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">25.7<span></span>
</td>
<td class="nump">33.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">46.1<span></span>
</td>
<td class="nump">44.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember', window );">Total share-based compensation expense, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 56.2<span></span>
</td>
<td class="nump">$ 61.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881461746792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">$ (70.4)<span></span>
</td>
<td class="num">$ (72.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="nump">71.8<span></span>
</td>
<td class="nump">78.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="num">(2.8)<span></span>
</td>
<td class="num">(2.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total costs and expenses</a></td>
<td class="nump">69.0<span></span>
</td>
<td class="nump">75.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">5.9<span></span>
</td>
<td class="nump">16.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">51.3<span></span>
</td>
<td class="nump">42.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember', window );">Performance stock units settled in stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">8.3<span></span>
</td>
<td class="nump">6.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember', window );">Performance stock units settled in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">1.4<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 4.9<span></span>
</td>
<td class="nump">$ 6.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of share-based compensation expense associated with different programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881461646408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details Textual)<br> $ in Millions, &#8361; in Billions</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax assets, unrecognized tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 390.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 490.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">586.4<span></span>
</td>
<td class="nump">&#8361; 709.4<span></span>
</td>
<td class="nump">$ 599.9<span></span>
</td>
<td class="nump">&#8361; 713.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Decrease in unrecognized tax benefits is reasonably possible</a></td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax assets, unrecognized tax benefit</a></td>
<td class="nump">$ 455.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881462453944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation between the U.S. federal statutory tax rate and effective tax rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="num">(0.40%)<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Taxes on foreign earnings</a></td>
<td class="num">(10.80%)<span></span>
</td>
<td class="num">(10.90%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Credits and net operating loss utilization</a></td>
<td class="num">(2.50%)<span></span>
</td>
<td class="num">(3.70%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization', window );">Purchased intangible assets</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EffectiveTaxRateReconciliationGILTItax', window );">GILTI</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts', window );">Neurimmune tax impacts</a></td>
<td class="nump">0.242<span></span>
</td>
<td class="num">(0.006)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">3.80%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">36.20%<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveTaxRateReconciliationGILTItax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Tax Rate Reconciliation, GILTI tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveTaxRateReconciliationGILTItax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Tax Rate Reconciliation, NuerImmune Tax Impacts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881459789512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNetAbstract', window );"><strong>Other Income (Expense), Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">$ 2.9<span></span>
</td>
<td class="nump">$ 2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(66.1)<span></span>
</td>
<td class="num">(64.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Gains (losses) on investments, net</a></td>
<td class="num">(191.1)<span></span>
</td>
<td class="num">(436.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gains (losses), net</a></td>
<td class="num">(8.3)<span></span>
</td>
<td class="num">(8.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="num">(0.7)<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="num">(263.3)<span></span>
</td>
<td class="num">(506.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract', window );"><strong>Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Net gains (losses) recognized during the period on equity securities</a></td>
<td class="num">(190.7)<span></span>
</td>
<td class="num">(436.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Less: Net gains (losses) realized during the period on equity securities</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">6.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gains (losses) recognized during the period on equity securities</a></td>
<td class="num">(190.9)<span></span>
</td>
<td class="num">$ (442.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">968.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 935.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Collaboration expense</a></td>
<td class="nump">206.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">345.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties and licensing fees</a></td>
<td class="nump">216.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">234.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationexpensesaccrual', window );">Collaboration expense</a></td>
<td class="nump">266.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">324.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">711.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">828.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total accrued expense and other</a></td>
<td class="nump">2,231.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,535.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember', window );">Ionis, Sangamo, Denali and Sage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract', window );"><strong>Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gains (losses) recognized during the period on equity securities</a></td>
<td class="nump">205.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Component of accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">$ 831.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 802.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationexpensesaccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration expenses accrual</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationexpensesaccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.3(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881469189320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net gains recognized on the increase in fair value of equity securities</a></td>
<td class="num">$ (190.9)<span></span>
</td>
<td class="num">$ (442.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Net gains (losses) realized during the period on equity securities</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">$ 6.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,287.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,320.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Accrued income taxes</a></td>
<td class="nump">640.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 664.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember', window );">Ionis, Sangamo, Denali and Sage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net gains recognized on the increase in fair value of equity securities</a></td>
<td class="nump">$ 205.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881459952872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Collaborations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and Development Expense (Excluding Acquired in Process Cost)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 551.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 514.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales, excluding amortization and impairment of acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">753.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">478.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Gain) loss on equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 335.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Gain) loss on equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions', window );">Loss recorded on Samsung Bioepis joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ADUHELMMember', window );">ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales, excluding amortization and impairment of acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 275.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai', window );">Percentage of future development costs related to Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationAgreementTerm', window );">Collaboration agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CostOfGoodsSoldCapacityCharges', window );">Cost of Goods Sold, Capacity Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Gain) loss on equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">181.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Due from Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">402.7<span></span>
</td>
<td class="nump">$ 285.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 285.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.5<span></span>
</td>
<td class="nump">46.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai | BAN2401 and Elenbecestat</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpenseIncurredByCollaboration', window );">Expense Incurred By Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai | ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Gain) loss on equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160.0<span></span>
</td>
<td class="nump">59.0<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="nump">45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationAgreementTerm', window );">Collaboration agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Due from Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.8<span></span>
</td>
<td class="nump">4.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 102.5<span></span>
</td>
<td class="nump">$ 148.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SangamoTherapeuticsInc.AgreementMember', window );">Sangamo Therapeutics, Inc. Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Termofcollaborationagreement', window );">Term of collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_OtherresearchanddiscoveryMember', window );">Other research and discovery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and Development Expense (Excluding Acquired in Process Cost)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_InnoCarePharmaLimitedInnoCareAgreementMember', window );">InnoCare Pharma Limited (InnoCare) Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments made to collaborative partner</a></td>
<td class="nump">$ 125.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ContingentMilestonePaymentsMadeToCollaborativePartner', window );">Contingent additional milestone payment</a></td>
<td class="nump">$ 812.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Eisai | ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Denali Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Sage Therapeutics Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | UCB Pharma S.A. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Eisai | BAN2401 and Elenbecestat</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Eisai | ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Sage Therapeutics Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdditionalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdditionalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CollaborationAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CollaborationAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ContingentMilestonePaymentsMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Milestone Payments Made To Collaborative Partner</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ContingentMilestonePaymentsMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CostOfGoodsSoldCapacityCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of Goods Sold, Capacity Charges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CostOfGoodsSoldCapacityCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpenseIncurredByCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total expense incurred by collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpenseIncurredByCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expenseincurredbythecollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense incurred by the collaboration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expenseincurredbythecollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expensereflectedwithinstatementsofincome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense reflected within statements of income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expensereflectedwithinstatementsofincome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of future development costs related to Eisai</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageoffuturedevelopmentcostsrelatedtoEisai</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Termofcollaborationagreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of collaboration agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Termofcollaborationagreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total upfront and milestone payments made to collaborative partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ADUHELMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ADUHELMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_E2609andBAN2401Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_E2609andBAN2401Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SangamoTherapeuticsInc.AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SangamoTherapeuticsInc.AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_OtherresearchanddiscoveryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_OtherresearchanddiscoveryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_InnoCarePharmaLimitedInnoCareAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_InnoCarePharmaLimitedInnoCareAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_DenaliTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_DenaliTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SageTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SageTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_UCBPharmaS.A.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_UCBPharmaS.A.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881466799320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Equity Method Investments (Details)<br> $ in Millions, &#8361; in Billions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 07, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (18.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (117.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of stake in entity maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity', window );">Amortization of basis differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 675.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions', window );">Loss recorded on Samsung Bioepis joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">586.4<span></span>
</td>
<td class="nump">$ 599.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 709.4<span></span>
</td>
<td class="nump">&#8361; 713.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">181.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.5<span></span>
</td>
<td class="nump">46.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai | ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160.0<span></span>
</td>
<td class="nump">59.0<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture', window );">Proceeds from Divestiture of Interest in Joint Venture</a></td>
<td class="nump">$ 1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PayablesToDivestitureOfInterestInJointVenture', window );">Payables To Divestiture Of Interest In Joint Venture</a></td>
<td class="nump">1,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityMethodInvestmentsExpectedProfitShare', window );">Equity Method Investments, Expected Profit Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AccruedMilestonePayments', window );">Accrued milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="nump">50.0<span></span>
</td>
<td class="nump">180.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ContractOptionExerciseFee', window );">Contract Option Exercise Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 102.5<span></span>
</td>
<td class="nump">$ 148.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis | Payment Due At First Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PayablesToDivestitureOfInterestInJointVenture', window );">Payables To Divestiture Of Interest In Joint Venture</a></td>
<td class="nump">812.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis | Payment Due At Second Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PayablesToDivestitureOfInterestInJointVenture', window );">Payables To Divestiture Of Interest In Joint Venture</a></td>
<td class="nump">$ 437.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_InventoriesMember', window );">Inventory | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod', window );">Equity method investment basis difference amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod', window );">Equity method investment basis difference amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AccruedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AccruedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationprofitlosssharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration profit (loss) sharing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationprofitlosssharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ContractOptionExerciseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract Option Exercise Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ContractOptionExerciseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentsExpectedProfitShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Expected Profit Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentsExpectedProfitShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity method investment basis difference amortization period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Equitymethodinvestmentbasisdifferenceamortizationperiod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated additional payments upon achievement of development and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PayablesToDivestitureOfInterestInJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payables To Divestiture Of Interest In Joint Venture</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PayablesToDivestitureOfInterestInJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total upfront and milestone payments made to collaborative partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of an investment interest in a joint venture that the reporting entity has not previously accounted for using consolidation or the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfInterestInJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ADUHELMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ADUHELMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_PaymentDueAtFirstAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_PaymentDueAtFirstAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_PaymentDueAtSecondAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_PaymentDueAtSecondAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_InventoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_InventoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881462587320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Variable Interest Entities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Gain) loss on equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (18.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets, net</a></td>
<td class="nump">$ 490.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 490.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax assets, unrecognized tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.0<span></span>
</td>
<td class="nump">$ 390.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 390.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities', window );">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.1<span></span>
</td>
<td class="nump">24.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=biib_NeurimmuneMember', window );">Neurimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationAgreementTerm', window );">Collaboration agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchAndDevelopmentCostsPercentage', window );">Research and development costs, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationAgreementTerm', window );">Collaboration agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Gain) loss on equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 181.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai', window );">Percentage of future development costs related to Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai | ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Gain) loss on equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160.0<span></span>
</td>
<td class="nump">$ 59.0<span></span>
</td>
<td class="nump">45.0<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai | ADUHELM | JAPAN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="nump">50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai | Regulatory Milestones | Neurimmune | ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment to third party</a></td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdditionalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdditionalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CollaborationAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CollaborationAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of future development costs related to Eisai</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageoffuturedevelopmentcostsrelatedtoEisai</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential future milestone payments commitment to third party approximately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchAndDevelopmentCostsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Costs, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchAndDevelopmentCostsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=biib_NeurimmuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=biib_NeurimmuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ADUHELMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ADUHELMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139881468399864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Litigation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jul. 15, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract', window );"><strong>Loss Contingency, Information about Litigation Matters [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss Contingency, Estimate of Possible Loss</a></td>
<td class="nump">$ 981.1<span></span>
</td>
<td class="nump">$ 200.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12021-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyInformationAboutLitigationMattersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>biib-20220331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:biib="http://www.biogenidec.com/20220331"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:currency="http://xbrl.sec.gov/currency/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="biib-20220331.xsd" xlink:type="simple"/>
    <context id="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ica34c492e95e460da92f264a157fc2cc_I20220502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2022-05-02</instant>
        </period>
    </context>
    <context id="i70fc67330ce0470db37abf6a0dc4fb6a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i22a0a13c266f4d788d5ba6423911ebd9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia5e84907dfd54cd09fdf7dc476b17545_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if6b11452af4d4ae0bf50278351f22899_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i36b52f54c6e84045a18f6f934ed61b63_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iee301b6f981549919f1dd915c03e2623_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id525e35f363e449aa36c9833e703f6f9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i609afa0be8424634b9ec333da2c2f549_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if8f47af926b14294931310a85ceac0ce_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8239e2124c804a2ea880e06ae55914e8_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie941cd89b1e6451a9094413808a742ce_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i78d18bc7ad434dbbb7aebc8184bdf0b7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8ec0412c74a64f2a8f0fe89d886801fd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i59bfec7053f64e28a514a578cced1277_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if7bb17477f1d45768747b659ec408858_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia38ac114688d4dc79f2cdfac46866743_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie2ab94bf8dc040fba955fc08e64b5851_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3cab2b42650840b8ad130b5ce90c072e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0a99695583d54417b14f147c2e47f0ce_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i548f861f837e49619231dee37689ae5e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6d4017cf2e7f4c638778c899d7ee5f81_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i377219a6f8954472a10644270fc0f641_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie8cfe2b3484547cb8b869f3703fbe7c6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7ba81a995fb24572ac4a052b330190f7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie711522c60db4065b671794dadaf1a8a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i17ade9377df944b2b6a0b1d325fc48e3_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if5517a2fe985436cb5f65e1183b54903_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iac6522198e5e47e2a87d575d4f0cf5fb_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3d4a878ad70149fc8ebc17f38fb2c3bb_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i623c94faf2524ab6b84a4328c9fbfc71_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib24a1c0ce66c4661bdc85bb559c07e50_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iaf88a450e4df44f4ad8703ca0a5d3d6f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic54a4fcce0664582818adb93f242f27f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie4f31a85cb5f4aeb9edd4a49ddc2205a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic33c429907664938b302242bae096aa3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i95735dc725534e82a2c616cddefbdcd3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i83d657be8c0141d3bbd283fd85ddc533_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7af6de98bde64694848ffc34847a8d52_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iedf3697c5b544792bd0663883b4528a0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i45721a1b1a8a4773b726c7ab76d5f1ec_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib2ccdc021de64ec580af92fa350db35b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i00c0c236fb7541c28d07fbbdf09baf1a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id8b2525325d746868ee2c18985898556_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie16d6112315b4c80ab9519df7448188a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2c1a3584d9f04422972632d1a69a2814_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9ef7dff5a368420bbd853026208ceb4c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8035064229a94dc1909b26988c0c3fc7_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ide815a728f624d74849b4eae66187c0b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7810c7b681664742a2f6a5378d83f3f8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9609a3cc1f21413e9387d3f994a752ea_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i35b4f4d780094f18808d017b4f134084_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if08130086aa74dc58e95ffbe7e3e1cc2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic151146309d249e6b3efce405c9339a7_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i07a17833f117433192dfb2a5c084ff23_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i62a58c1e7d3f4fa9bef57b7a1f8c7c8e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9948ac905c84412a859b84aa29f53e12_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie1ecc04b333e4da4ac25243469cdb953_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i763b233fe41d42f8aa4eb102c4f5c9e1_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2e4fb5422af74378bdf258c1594fe372_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iaad911ccb4124b46ace623b2c56be18b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8c3728b044d743d0b57e33fc6e523b46_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4afdc1a2dcdf424eabd0653274b690c7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic4b04ecc1818447ebb524096be801f20_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:WorkforceReductionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i929ddd179174497bb90c576f4da728fd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:WorkforceReductionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i60bd213e6b2f4cef984449f784cce8aa_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:WorkforceReductionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4019bfee1947475697fa8390601cf107_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2d56b6894b294cb3b2fbfc394c2be8f3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i45e6439716cb4f31b5a5f0feef64721a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia9ae9e65490748f2acefb5047af75a92_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8085faadc8004a108e4be4098084c970_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i40537541890549888c403ef75418b3d7_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0f199ee2171447a5b18611c5c256d297_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i958877fcc74e4539915b329079fa6389_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i757cf428860849798a536a290e69a744_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i80aabd0ba40a4666859ae614cdd27a07_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5f4e5fdc87be405f92ffd881cb8662ce_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie4c2e7acd9be4bfea25698309d8d8828_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i487df1d2304e478d8603ddfb4616b0f6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icea6a5dee2a24c37ac79226e11fc7e81_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i49af7fbee4534ecc9b44e33e68ad9bac_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8b15c52761ae42e58d6abc7911f80917_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5540cfaf99944f5fa1f892083859fd1b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia2efe312a1ed4c21bc651416d90150b4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if4cb5e1b131d44a689b572c1d03b1392_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9f8158b854de46d7949a3f0ff441a7c9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie44c413a93ec48a59784c0ea0623dded_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if54e432976f24dfa9de95d847fc16af1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7331caa9ccd84bd5be10521a9f0d0481_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3ec978dde6374ab7a39346cd84c5c36c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie66c008431754250a1c7ad1581031751_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9d4fca69d176447480f070d481fc6e1d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i55f4f5b3d91e4c279119147eedb46915_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iaf5d43d131c84980b40ac7f048729534_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3a4ea8f03c0f42738c05eac690b20806_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i60267e464f984999be2095717c97a319_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2c070dfe729642198b279735cad93c30_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i78c6eccdad234026bb1aeeb838de571d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6828112d9c4f41f0bf08dd88efb7662e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id1098dcaf54d41aca1af33ac1c235c78_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iceae2cc273d1444eae0aa9c381b2d61b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib8ac52ff6b5e42babf12a9c71a39395c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3f41e9d658b94408b5d6df1021553899_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id06f574f06e14c8ba3b25d199ce88210_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i722a1d8416ce4b6b9e7ebbb4433afb51_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i816d25b468bc4d96aab34518cf3f4c6c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1004f5d220be40cd9e39fe595414dfaa_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i30b4707892bc4fec9b74d5cc51e6529e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if7921192dedf4f4a988ac6e9ce17c61b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if8e1bccba2b844138516eb1ac75d4fdf_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3e8b6707e4854fa388edc206ac7d95bd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i670a74b23f5f4caea6103368f4c95973_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if08c5715a87047d6916a728b0059e603_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id811739973f8445d958ab0cb2731f205_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8ed53a25b23d434ebf3a733a39cbbcb7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i403756a186e6453a9c24141d0b5678f5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i534b8a9915d9400f837298b0f6d411f1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i66f6ed4993f14e3290ab6c4742235f3d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia6f7347790a54edbabf24343e2257691_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i68ba8dee324c40978fe4ee8211658faa_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic81d1b50ecdb40b391c62c6287303f8b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i32b306330d79453787a5388f0c9b87dd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i61d231d430914084bd5b37c094531f73_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic570d7e37f3246c9a7c17df8eb70bf29_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7cb87c336f514d67ab337ffa3b0d63a2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1049089607294f30837a3ada694dc739_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0d04af7411eb4ffd942a725be50edb92_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i15bc81eea1fc4013a923d18d25b1aee3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ifaf74ee71f7f4592b819c8e204ed6c90_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i36dbeb0ba18e4a5b94216f5fdfb3a00a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i057f89827dbc42819caa6b53dc6ff8c7_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic026373e31634ffb9f84acb0c02d47ac_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2ae65a6ea2994e1da2df20adab69bd79_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2f713481ad2048ecae97763950260fd1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iee11fd74051f4269a45be312fa23f68f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i98bd7ced87284d89af6b6ae7d70f8d7d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i782884b4f8aa48df9e97e2cb2755409f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9e33621ceef64fc2ad12d006a54bc1b8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i56fe223e37e040f490923df9b519d2a6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibbd8a4f5465946c0aa38c26ef4752572_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ifeeb3b4588f74e0586c4e89af4306f7b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if7ae353a26bd4fff8785a4632e4afbfa_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i03f9978c12b14dfc8ee889cdf2bdb6f0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7d6f800c7c994872a26f2506f98306ad_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i94c39b003aff4990a1610f96586f03dd_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic5db3734293a4e20858f95205c4aac6c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i724aaa93e18442fc9a55e613a9dda9bd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i67b699450f32425283dbf73b59e9a343_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0c857804af6a41aeb371a364d6599e30_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i29cfc0f0c2944f219a39cbd064853d72_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9f9240206d2e4fdfa0bf34f005ce7fdc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0962864d41e04b9897a3e8d3c6267a4e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i06abbb84d032422fb1a3f75785252f65_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ifc6e75dd023146aeb4a6678f69c4242c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia76f9cf51eab4d948a5698ec20d971c9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id33287c4ca8e4b7c9960bc9a3c2091e4_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iaac99eb6afb34c03b2e78fd08137df46_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0bdcfb675756479fa2aa02a4f8a3a6ce_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3d7e46af1def46ae846f93734361fcc5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iddf807d85db941d0a2233de6ebb901c4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7a4a7cbdeb574c34acd8f0fd4451328e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i35f562ab50824cc2bc7a3c789fec1b1c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9173e074bac74af1b3732b3d6a272a0e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6985304f226c46fca0470a43faf8887c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6a84089481564844bfa9bc6d09008d08_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8fc4bd215e8a4eda8144b5304af45e97_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iaf64235b712a458e82807e9c3b0ae91f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9a8520df9645495bbf150a3c973688bb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">biib:CentersForMedicareAndMedicaidServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8a12e5f049a6452f9e97a9998e1ce4b6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i20495f1f0a824d538aee78626f0d54b7_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2a241cb8f282478689ee6d7bba151c98_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idee35b744e58496a91eb6fe7628d49eb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6011e1fbb7ec4eafa87167881be73a90_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i96046c4bfde14c4a9405390c5dd1681e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2c9e43d132c24282b7716b0c5a1f9cfc_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4fb812dd0c044aa5a8506c4bc6e9c90a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ica5c719f9e5e4e2d9b3c6b1da3536e36_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1c35d264b82c493ba58144b8a17842a9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i46b4be49d678422682879c3bf61b0688_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:VixotrigineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6c345c953cb94d34804e7d2a988c33be_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:TGNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia54a50706b514096bba4ab26af0acaa8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic399f673115248b988b9405c7bf5aa12_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia69f061a62954ac7af98aa5c677f4971_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i64a5ad19dcce4cf8b7c43a569fe0c245_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i42f910d9635f4c0480b7fb380b5fe276_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3396020533494d35b8c27ddcd8a5252e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5bb9349b48fb4c629485bfe7b5880e8c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id2a85ce0b81243eba23da6278ed1f57e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib3e9c1bab79f40279289b0b3dcc2c161_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iec22cc68ef57484183e4ae80b280d372_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib1f4d496ec7641838d1ecec434c28f66_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2c661d66c6224d4a81bd51c24ea79d40_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iac84ce7144dd4bcc82d4253f927d2752_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if398ac5e39c747a6af59aeb27650b335_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i09eff9f500604711ab6a499956c8d5f3_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5ccde35ecf6c42b486ba8b193205887c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i289d8737ebbf49019c8cd089b87cc769_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6f9738b4665048cfa86018d909055f8e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i264ccf816a664702a7ba8ff1332adb5a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie241349e66f143e1b0f96548fcc184b5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1b5576a00f6d4d15946a9368e3767e64_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i421472e2622c437d8bf685a39d6aecc3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8cec5ba41ae343fba33cd31f8de35a45_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ied9fbb6e460240998c2c685327f742f9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if386e194b1a943d8871f1a74fa3cf259_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i91224f4cdc6744fbae4bcd98dc85a3a0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id787117c37b84ec99ac24ed6b36b3e3f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie3422e6ed664422993d44483803e8115_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4a7eda1ce0584e48809dc53d22b2b031_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iec70156770664cf39f79a786ae051946_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia81961b9f3eb48868302e49901fb6144_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i239a26613bda429395a6a963a2cde2c7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib469728d72fa415a9631ce58a0a2133d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i99b3022f714c46afa3ad4d95b9e0cc1c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4a551835cbc34cf1af2a3029ace704ab_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2985054f44d640bd846c15c69370c8e1_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i939e4f82661e4da6ab148f59a8ec8270_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i708bc707f83a45a6b58bb6226275def9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic6518b6b1ff547bda3f65b2aff26f52a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ief5ba800372a46ebb499feb08bd01f68_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i59761a7057b84b83b94391f9934d130e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie0eb428de5f74817b5197dce23437c27_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9f6dd011d88b4ac782dc7a1775ddccb8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id66b49914ec440e8ade962aeaba44c27_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i53483a1cc9e941e09201232721818ef2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4bed4b676403412ba1adb6018bde8953_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib6864de98b5c49cab9140ebeace06324_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8e6a4a2c46af47cd94c9fdc6dd993664_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3f6d74e47a314e6c9c9ceec4cbe4c782_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3250SeniorNotesDueFebruary152051Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6ec2168b953d46088128b4f2e3774ed2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3250SeniorNotesDueFebruary152051Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ief3a3f71bf3549c59cbe89249ff122bd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0f6c7df5e15646bebd2254ac4e7a08fa_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie1a0391f5d734ca4b2c1b7de94fd8721_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8c2efbd4b9c74a8da864a279a9e91498_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieed6ef51023543d0bb40d96a559c5941_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0c8bc783a7334b3d8875f060ac7bb1a2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i185e162f6d4545b68e3749067e1070d6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if1e2bbc4c00345d494de8e8b436b2968_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8bf885a6fb7c456e9521985a665b058e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i11d469fdaeea46ac984f86f25cf7aefd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i154d489ea3c6499a8e77ce72f6e567a2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iabd8430987f44ff08faf10d31756ef75_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iaf11806fefce4b389ac4b64510af48f2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie09432231a464e39a944c6a44cd6b69c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i96ee067d94d34ad18d8184a7addb8ae6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4cd3f693083d457bbe88209270fd1b39_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0d92b30f82ea4eed911cc841fff8bf84_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia3b43bd6e13a4a9c9403015c85ba502f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic4c19e0ddd2b4245bded3c176e7644d5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id7202374646d4a99bbde3c93490e6ecd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icd0e0d8d79a54c8e9e1b178519ddc273_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib018ee899f4e4ac48084e28043d8cddf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5d2052cb740a446b8e69b4604e07264e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8e32269d553441f28cfce5965c1b73f6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4753836c14c24f67acbeca373ca2d5d4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i441022c1a0eb4576a80a097476642f3d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaf0a6c3fc8694a58a8f2838a236b6959_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3803e965a1724d08a4f85f6e2e7521f4_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7fc3a5a6750b4a08b8ea8136ff17e32f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i272a8c61f3584e998890821513df00d8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i406fa505aaae46879e51842eed75d4ce_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i249928d43b8e4fa299b055c1da71dd67_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3bd066a82d6840d8b01775d5dad75db4_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id58fea331b54435bbde5915e58d7c5a1_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2bbc3b1e9fdb469cb4328efd19cda789_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i39a50582990a42dcb07d38607ad68af5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i240c4ec54c41471f939a44ea69015b0a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i28837dfd41bf48e4a23a28d077a47405_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0736edb3bf194531887102c104754d6b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i598f0b3c24fe484495f6ccb41c9c3f69_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2e3ec7e46b3849eab9fbf5b26dbd2c8c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i694ddc9c46354d1e860c687aa876734c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iac85fcf21047427c834103ba4c06b629_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id06b33f7f9d2442c99ed5a3715b1fb03_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic777b57bc84141bcbc813beba9a72c17_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i59dedd55a80f4d2a830844b533c8f387_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8c177fb43a1c4b4e8e78a519ab0c6de9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i317559ce8f9e4b26a225b70d06a61b25_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ibfad3eb157664139a953f3e9ba192977_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i930b3a82003f4bec8f1d94de444724dc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5b9c2fab12ac4d2bb51603b6415c4055_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i355096b3d6354bf5a1914fc120d6d527_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2469406df0d54a489bd5f64e3dea3d36_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iabceb3a0623e41c4a664ac8948832356_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9ea5c7e3d1434a96a8496e2352fabe5b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8992ee77c09249988dad3a68bcc5843f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i62cbd491b5784eedb300e49ae6efc87a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2b7ac531239c4d9aac8a7b0c71f6fdf5_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="ia5fabf9c71294456a0158d60a5f483a4_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i76b1491614cc49378a38f3c27aafce95_D20181101-20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="ifb6cf45b64754d4b88c6cd9ba8980d50_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0df6dbddbff746298274ecd0b63baf47_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib51e9913c2884e49a66dce4cf9163f6d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5062e91336b74ad5ab0ffa4f2982b8e3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib1d439a992034e5a880d6b7d7d1fd8ff_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i04123d710b8e48c89a62fd25aa7cc3dc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i49647cb8da844b74bee321a532e55b36_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9f94fcf078da46ef9117103ab626567e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1d28240f464f4a5c8cc87e17a9a57d40_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ife02cc8b68b74e45a4550426f8f6e028_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i55597e78171f481ea55329770d91ef68_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8f169aefbf5349eb87fe05cb8688fca5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ifb5afc172aec4efebd6f1b568ac8ba97_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iadd2bb0a22624c17a5f24102ad78024e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9ca7b68a94cf428e9116acf90742cf4c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0a575848d988444ca4869d5a47cae38a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib79aa8e4e7624556b3ddeed5fa194e23_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i493a11d6c18c49269d42f6e6982e8f44_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i639c896977df489fbc54f9088f6147de_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id0a4f26886de44beaaa9fd8add3e3cd9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i46e754dc01c0498393cd6a5acbb81bc2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i52be7c4aa2b64ac78381cc2d75fa44bd_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic91d51f7faa640ed87d6899c2a544613_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6f64e07d384c415c831dd4b33c3b6b7f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:BiologicsManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i099a9481f0f445269310c0321517d33c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:WarehouseUtilitiesAndSupportSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ieed6363c4f674d66a54d0dc0c55f0f52_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:AdministrativeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3e94ec2413a34ad39baef4a302252a4a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie078509e1f7d4077a083b848308445a3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id425e7508d5f4fcf9ccfcc07674b63de_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="ie3968065f0a74bfead74be1f343078f9_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3250SeniorNotesDueFebruary152051Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="id164d47b16824f0c874ceeea51fbbcbc_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="if242145ab9704eacb41a099fd01ce221_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i927398c21f2c4253b9e5fc9aa1970ccb_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="i8aed478a3bb84a26a97e98654c7ce707_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia823c01230e94f078e3bd77c94d36863_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i89079b4dcd7340cc8676a18916e07cce_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia1ba18679af24668b4316adb5b46bbeb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic535854c80b1412f924435f8c91f63b8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib29fa61175a74b01bcdc01a071bd7d48_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3e87abb1f9db4300857139f5ddaa4d14_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icc0ec6584c7c4d459947e00620f435cd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8d0f10b22c834ba396c8b4c6a3188b23_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5838303fd7294f56a6ba30fc62e8ecac_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8b54fa2358e34e17ae6d8739b9b3339b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9b84e664424c4f9c9c3be2725156b218_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i405ecf1b53c842e8ab96a5daf031a812_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1ac817d516214d4294329c0c3985e64a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie992e5401cf74a7eb8a5100825da7530_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id9dc7e3bd5af43b9ae44d024af7d45ee_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1b8f47e6df9047dc9800a3ef46b3a47a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3c403b59149b4448b3ab41d54ea6da30_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i07e5a2d28d8644f0a7750374306253d1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic788e2af1c2a42bdad2a187fa0f3f0f9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9905d8e67a1c49bba25ddc2283754bd9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i56c6c6dbd77141ebb3ba11ea6d1906c2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i21cbbb23fa0942b0b38de55781a30060_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i76808577ee454761a0b2fc6e21960006_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6abbeadb96ac4f689ba74b0475350c98_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="idf39efdb65104bcb856efd226f4e02aa_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="idd3f194d4161459fa9fc9aaed46498ea_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i70ab7808a4b842c9925eda0753188c9f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id8c8dc8cb4ac4de98e44bab2c31b1282_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id4e7315860ff46c0acb88d0816fd6daf_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i52bad0c11e3144e899c81a5bb55aabb2_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i54a289067eb44a92a43277cf25c506fe_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iaaff40b00b8a475aa7213303ae060f69_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i82e69258ff2a411eb0af8d55689ed83c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia89aa06c882742e4a448659b8c11481c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i53aa42306e12421f90d4b595dc6b62f5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9477047c7de34040997c009eedbe4518_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia4e4d15b86ad443eb9d3edf6dee5f7b5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie709fcb90ef24b93b760d2540d00088a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i810555191bc946a183d59137a3d60baf_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i091a772781f844e0996d9dd61c0fbb5f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i39e928655ba643399618f0c17b2b0812_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic6d836e623c94a73a4c74c493f93fee4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iddfb71709ed840e98b85ca08ce7bdeaf_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9afd12c183494d549b839596293da75e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ida7d6be5a5da461dbf5390a92f2c5e9d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0163dd5e3d654e748b422f150d2d5a9c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4eff7cd113a74d2e910753e991374627_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i286ad499ff5d462799e0f941ef3e205f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib96d4930fa9c4ea4920b41bc8432568c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ifa0242e914b24b17a8a259457c37203f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic7e00bf0cede4201ac36bccc9be5e5fd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i650e185cf72a422c97cc333e4de95e3e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie511e6e4286f476b8bf2a94aa1d42b95_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6dc6984b1c814916847de41632ad1d34_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6e2fa4eb32484e43801f3346334b0be3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id7c53ba95781468ab194b339910b54ea_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iadfc29fbc15b47a0bb4c9a7e11d2d1f6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9b5373d736be447fa8c13cecb1075da6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7fecd952a0f246f4bc6ae41add94430d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i11b85385e04c4d72bb460d8796578ce0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i350f52cf56ca419f9abcc85ddabdf66a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i9fcfddd14c424cd095a98f9df64e862f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8cc3940c5a604d08b1a0524870f97a03_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i20649c5c9db8492a84683240d40b1cc8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:IonisSangamoDenaliAndSageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7720f6aec35b4d8da3f83be28c73da37_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic53a168048b7491ea87c3962591ce459_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic988722c1187407388795922a811a006_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5eb97d60723b4bd0984e9c72d9e41857_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibfdf8192d59c42ea96f70ac07a430dab_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ica3cdddcf72b46f8b05a616e0b059254_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i20e19171955440b582851c5ac5d45b30_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i90093effd3884afba4d3e630d74c241a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i95c7cf13e2f1475ea47f58a3f48df9e2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i534d34ae3d78433f9a80a80261d8c791_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i535bbd28d8064cd99845c7aad7ef40b6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i140fc83df9b443f8947b6e9c5a831662_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i11a20f8ab31748a3a765230d484a950c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i30f95d1127004fdb916215bc0644001f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4e6c000a5c1747719d713bf44ab5594d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i385de3e6fdd648569c6459df74a3f24c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i81ff85ba433e49f3bf5366754bf14dfd_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id6f28921d58149e88f70f267093af3ed_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i84748af08d094521ad62103f37c3ba5e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if9f8dc7db02f46a382226b3a06689770_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iccef06de5f364c6e864a306f6c4d2222_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i22e581ce75fe402f95badbea9059a2fd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id0323b821ee4490ab9cd6f46708b92d2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7cab4c6e22304f01a6e538f0a28da4a6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SangamoTherapeuticsInc.AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia2f3b87f1c704bfeaa184c005c15f509_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1980e9c4bcf04c69813dff866529db3b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i416b5c2161cb4be49401dc463e803f6e_D20210801-20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:InnoCarePharmaLimitedInnoCareAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="i871bd576e8054a32a94dd16a50cc8f38_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i69f6f1c65f31482a9985575399db62f4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i17a7835e9c634cd3898253b27970e1ae_I20181107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-07</instant>
        </period>
    </context>
    <context id="i3777c8eb44d147d2bc71177545a1a119_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i81aebf0e69b74044934ae698e82a35a4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id6783744f49842d8974c9aa1108f7b92_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idb43218ef58b4c47acc0ed3d32fc1c8a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i54ef960b3f344a6284182d87fe3863d1_D20220101-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="i9a34f5e20a214f4fb6abb8675f411f59_I20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="ice9f6a67517e4256bcc4feff2a07a95c_I20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtFirstAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="ifbc3564cb9f74c5e96af956bdb92ace9_I20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtSecondAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="i8140a335ecc449f6bb7f8e4660aac8ea_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i8c93649201d542fd82a365350912101f_I20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="ib0074296436b4840ada078b60b901e66_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia9e98bb878a84e13ac251a6b98a15e94_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i33310cbd0d8e4927a25d422f87b6a6e3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5e6825d4d7fc4c049bc35822d827b16a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie40c7dd8da0c4c3d8730bcde07b49856_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i08f827f32a3b446c825d77324ed50eb7_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i22cd2c200d674e7185cf096a998f436a_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i179745ea816f45eeb6066bd1ea79e129_I20210715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2021-07-15</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>biib:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="wholesaler">
        <measure>biib:wholesaler</measure>
    </unit>
    <unit id="krw">
        <measure>iso4217:KRW</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80L2ZyYWc6NDkyNWZkZmFjYjZkNDY0ZmE1NmExNmRkMTU5ZjcxZmMvdGFibGU6NzFjOTI1Y2UzMGQwNGI2MGIyMTEyZmIyODBkN2Y3NjIvdGFibGVyYW5nZTo3MWM5MjVjZTMwZDA0YjYwYjIxMTJmYjI4MGQ3Zjc2Ml8xLTEtMS0xLTc1MTQw_fc4c4863-128e-4f45-8760-c0c02cca8d64">0000875045</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80L2ZyYWc6NDkyNWZkZmFjYjZkNDY0ZmE1NmExNmRkMTU5ZjcxZmMvdGFibGU6NzFjOTI1Y2UzMGQwNGI2MGIyMTEyZmIyODBkN2Y3NjIvdGFibGVyYW5nZTo3MWM5MjVjZTMwZDA0YjYwYjIxMTJmYjI4MGQ3Zjc2Ml8yLTEtMS0xLTc1MTQw_69d39f3e-c17a-42de-a0ed-6b55ea848958">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80L2ZyYWc6NDkyNWZkZmFjYjZkNDY0ZmE1NmExNmRkMTU5ZjcxZmMvdGFibGU6NzFjOTI1Y2UzMGQwNGI2MGIyMTEyZmIyODBkN2Y3NjIvdGFibGVyYW5nZTo3MWM5MjVjZTMwZDA0YjYwYjIxMTJmYjI4MGQ3Zjc2Ml8zLTEtMS0xLTc1MTQw_a8cf6183-4a38-4621-b77a-c4b92c8dd29c">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80L2ZyYWc6NDkyNWZkZmFjYjZkNDY0ZmE1NmExNmRkMTU5ZjcxZmMvdGFibGU6NzFjOTI1Y2UzMGQwNGI2MGIyMTEyZmIyODBkN2Y3NjIvdGFibGVyYW5nZTo3MWM5MjVjZTMwZDA0YjYwYjIxMTJmYjI4MGQ3Zjc2Ml80LTEtMS0xLTc1MTQw_e98e6de0-879b-4444-a0ca-eef7eff61c46">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80L2ZyYWc6NDkyNWZkZmFjYjZkNDY0ZmE1NmExNmRkMTU5ZjcxZmMvdGFibGU6NzFjOTI1Y2UzMGQwNGI2MGIyMTEyZmIyODBkN2Y3NjIvdGFibGVyYW5nZTo3MWM5MjVjZTMwZDA0YjYwYjIxMTJmYjI4MGQ3Zjc2Ml81LTEtMS0xLTc1MTQw_2b6ea03e-d673-4001-9a13-c3044d2542ec">false</dei:AmendmentFlag>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ica34c492e95e460da92f264a157fc2cc_I20220502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80L2ZyYWc6NDkyNWZkZmFjYjZkNDY0ZmE1NmExNmRkMTU5ZjcxZmMvdGFibGU6NzFjOTI1Y2UzMGQwNGI2MGIyMTEyZmIyODBkN2Y3NjIvdGFibGVyYW5nZTo3MWM5MjVjZTMwZDA0YjYwYjIxMTJmYjI4MGQ3Zjc2Ml82LTItMS0xLTc1MTQw_9960cfcc-ab45-40ca-b29c-a02b0d470ed1"
      unitRef="shares">146452013</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yOC9mcmFnOjEyNDU0MDQ4MDVjNjQxNGJiMjVjNGI5NGZiM2UxOWFiL3RhYmxlOjkzMmZiMTZkNTA4YTRhZTY4MjEyNWY0MjE5NGQ4OGZhL3RhYmxlcmFuZ2U6OTMyZmIxNmQ1MDhhNGFlNjgyMTI1ZjQyMTk0ZDg4ZmFfMS0xLTEtMS03NTE0MA_eb8f1bdd-a933-431c-a940-e7e9ba793c9b"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yOC9mcmFnOjEyNDU0MDQ4MDVjNjQxNGJiMjVjNGI5NGZiM2UxOWFiL3RhYmxlOjkzMmZiMTZkNTA4YTRhZTY4MjEyNWY0MjE5NGQ4OGZhL3RhYmxlcmFuZ2U6OTMyZmIxNmQ1MDhhNGFlNjgyMTI1ZjQyMTk0ZDg4ZmFfMS0zLTEtMS03NTE0MA_8196c2cb-a6a0-4817-8f74-c4dc8af37ae0"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yOC9mcmFnOjEyNDU0MDQ4MDVjNjQxNGJiMjVjNGI5NGZiM2UxOWFiL3RhYmxlOjkzMmZiMTZkNTA4YTRhZTY4MjEyNWY0MjE5NGQ4OGZhL3RhYmxlcmFuZ2U6OTMyZmIxNmQ1MDhhNGFlNjgyMTI1ZjQyMTk0ZDg4ZmFfMi0xLTEtMS03NTE0MA_d6043e13-c92d-41b0-a2f0-e6838f143091"
      unitRef="usdPerShare">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yOC9mcmFnOjEyNDU0MDQ4MDVjNjQxNGJiMjVjNGI5NGZiM2UxOWFiL3RhYmxlOjkzMmZiMTZkNTA4YTRhZTY4MjEyNWY0MjE5NGQ4OGZhL3RhYmxlcmFuZ2U6OTMyZmIxNmQ1MDhhNGFlNjgyMTI1ZjQyMTk0ZDg4ZmFfMi0zLTEtMS03NTE0MA_1e652cbf-bd85-4033-ae7e-1bba4ac3c86b"
      unitRef="usdPerShare">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ia54a50706b514096bba4ab26af0acaa8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82NC9mcmFnOjk5ZmIzMTVmZDM2NDQyOWJhZTc4NDNkNTc2YzkyZmFkL3RhYmxlOjYwYTUxMGU2YzUyNTRmZmQ5OWExYjAzZDkwZjYwOTdhL3RhYmxlcmFuZ2U6NjBhNTEwZTZjNTI1NGZmZDk5YTFiMDNkOTBmNjA5N2FfMS0xLTEtMS03NTE0MA_3f301b5e-16d0-4e3d-8772-1ba3b53397f3">P4Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ic399f673115248b988b9405c7bf5aa12_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82NC9mcmFnOjk5ZmIzMTVmZDM2NDQyOWJhZTc4NDNkNTc2YzkyZmFkL3RhYmxlOjYwYTUxMGU2YzUyNTRmZmQ5OWExYjAzZDkwZjYwOTdhL3RhYmxlcmFuZ2U6NjBhNTEwZTZjNTI1NGZmZDk5YTFiMDNkOTBmNjA5N2FfMi0xLTEtMS03NTE0MA_af06af3f-bdef-4b8e-9e62-f41e7161d0a1">P28Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic6518b6b1ff547bda3f65b2aff26f52a_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83MC9mcmFnOmVkNTg1ZWY1YTMxNDRhYTQ5MTljZDhmNDY2YzNkNzdiL3RhYmxlOjg5OTEwMWI0YjlmODQwY2E4YzUzMzI4NWU5ZDZiYjk3L3RhYmxlcmFuZ2U6ODk5MTAxYjRiOWY4NDBjYThjNTMzMjg1ZTlkNmJiOTdfNi0xLTEtMS03NTE0MA_657af6c6-122c-488c-a3e3-2671f9883256"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i59761a7057b84b83b94391f9934d130e_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83MC9mcmFnOmVkNTg1ZWY1YTMxNDRhYTQ5MTljZDhmNDY2YzNkNzdiL3RhYmxlOjg5OTEwMWI0YjlmODQwY2E4YzUzMzI4NWU5ZDZiYjk3L3RhYmxlcmFuZ2U6ODk5MTAxYjRiOWY4NDBjYThjNTMzMjg1ZTlkNmJiOTdfNy0xLTEtMS03NTE0MA_80b654a9-4358-4da6-b763-9d31bcf9230e"
      unitRef="number">0.04050</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9f6dd011d88b4ac782dc7a1775ddccb8_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83MC9mcmFnOmVkNTg1ZWY1YTMxNDRhYTQ5MTljZDhmNDY2YzNkNzdiL3RhYmxlOjg5OTEwMWI0YjlmODQwY2E4YzUzMzI4NWU5ZDZiYjk3L3RhYmxlcmFuZ2U6ODk5MTAxYjRiOWY4NDBjYThjNTMzMjg1ZTlkNmJiOTdfOC0xLTEtMS03NTE0MA_eba8fb05-cb02-4c76-8dd1-6f8145f190b9"
      unitRef="number">0.05200</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i53483a1cc9e941e09201232721818ef2_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83MC9mcmFnOmVkNTg1ZWY1YTMxNDRhYTQ5MTljZDhmNDY2YzNkNzdiL3RhYmxlOjg5OTEwMWI0YjlmODQwY2E4YzUzMzI4NWU5ZDZiYjk3L3RhYmxlcmFuZ2U6ODk5MTAxYjRiOWY4NDBjYThjNTMzMjg1ZTlkNmJiOTdfOS0xLTEtMS03NTE0MA_8b30fbfb-019d-4aea-95ee-b9b59648859c"
      unitRef="number">0.02250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib6864de98b5c49cab9140ebeace06324_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83MC9mcmFnOmVkNTg1ZWY1YTMxNDRhYTQ5MTljZDhmNDY2YzNkNzdiL3RhYmxlOjg5OTEwMWI0YjlmODQwY2E4YzUzMzI4NWU5ZDZiYjk3L3RhYmxlcmFuZ2U6ODk5MTAxYjRiOWY4NDBjYThjNTMzMjg1ZTlkNmJiOTdfMTAtMS0xLTEtNzUxNDA_fe74fc16-c47d-47bc-9f2d-084fcaa3a8b3"
      unitRef="number">0.03150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3f6d74e47a314e6c9c9ceec4cbe4c782_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83MC9mcmFnOmVkNTg1ZWY1YTMxNDRhYTQ5MTljZDhmNDY2YzNkNzdiL3RhYmxlOjg5OTEwMWI0YjlmODQwY2E4YzUzMzI4NWU5ZDZiYjk3L3RhYmxlcmFuZ2U6ODk5MTAxYjRiOWY4NDBjYThjNTMzMjg1ZTlkNmJiOTdfMTEtMS0xLTEtNzUxNDA_eb3a8507-e014-46bd-a651-06df60e31d74"
      unitRef="number">0.03250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:AssetImpairmentCharges
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83MC9mcmFnOmVkNTg1ZWY1YTMxNDRhYTQ5MTljZDhmNDY2YzNkNzdiL3RleHRyZWdpb246ZWQ1ODVlZjVhMzE0NGFhNDkxOWNkOGY0NjZjM2Q3N2JfOQ_161050dc-2a2e-4209-ad49-d26ae82d2e45"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <dei:DocumentType
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xL2ZyYWc6YTlkNWJiMWM2YTA4NGVlOGE4NTdjOTJlZGQyZGRiN2YvdGV4dHJlZ2lvbjphOWQ1YmIxYzZhMDg0ZWU4YTg1N2M5MmVkZDJkZGI3Zl8yMDA4_77e55ad9-aa66-4098-9f57-39ff689a0d70">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xL2ZyYWc6YTlkNWJiMWM2YTA4NGVlOGE4NTdjOTJlZGQyZGRiN2YvdGFibGU6NjI2MDAxYjk0NzExNDQ2Y2JhZjMxMDViNmY5ZjYwNGQvdGFibGVyYW5nZTo2MjYwMDFiOTQ3MTE0NDZjYmFmMzEwNWI2ZjlmNjA0ZF8wLTAtMS0xLTc1MTQw_f484645b-d3a8-45c5-856a-e811b38d7b93">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xL2ZyYWc6YTlkNWJiMWM2YTA4NGVlOGE4NTdjOTJlZGQyZGRiN2YvdGV4dHJlZ2lvbjphOWQ1YmIxYzZhMDg0ZWU4YTg1N2M5MmVkZDJkZGI3Zl8xMjM_9c966c9c-f070-4e25-808f-aae65be16dbe">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xL2ZyYWc6YTlkNWJiMWM2YTA4NGVlOGE4NTdjOTJlZGQyZGRiN2YvdGFibGU6ZWQ0YTA3ZDAzNjFkNDkwZjllMWY1YjliYjEzMzhiZmEvdGFibGVyYW5nZTplZDRhMDdkMDM2MWQ0OTBmOWUxZjViOWJiMTMzOGJmYV8wLTAtMS0xLTc1MTQw_a2f8f233-5ec7-4059-911d-1c9cf09dd635">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xL2ZyYWc6YTlkNWJiMWM2YTA4NGVlOGE4NTdjOTJlZGQyZGRiN2YvdGV4dHJlZ2lvbjphOWQ1YmIxYzZhMDg0ZWU4YTg1N2M5MmVkZDJkZGI3Zl8yMDA5_0ed15201-5f1c-4a67-8b3d-4edd0c561b85">0-19311</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xL2ZyYWc6YTlkNWJiMWM2YTA4NGVlOGE4NTdjOTJlZGQyZGRiN2YvdGV4dHJlZ2lvbjphOWQ1YmIxYzZhMDg0ZWU4YTg1N2M5MmVkZDJkZGI3Zl8yMDEw_5ebbfc6f-85c7-47c7-bc6b-b1c61dbfdc54">BIOGEN INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xL2ZyYWc6YTlkNWJiMWM2YTA4NGVlOGE4NTdjOTJlZGQyZGRiN2YvdGFibGU6YjNiMWQxZTYzZGZkNDFmZWJlZjNlNGNkZWYyODJhZjgvdGFibGVyYW5nZTpiM2IxZDFlNjNkZmQ0MWZlYmVmM2U0Y2RlZjI4MmFmOF8wLTAtMS0xLTc1MTQw_ecb93006-5771-4a3c-8ad8-4cfbb19e8232">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xL2ZyYWc6YTlkNWJiMWM2YTA4NGVlOGE4NTdjOTJlZGQyZGRiN2YvdGFibGU6YjNiMWQxZTYzZGZkNDFmZWJlZjNlNGNkZWYyODJhZjgvdGFibGVyYW5nZTpiM2IxZDFlNjNkZmQ0MWZlYmVmM2U0Y2RlZjI4MmFmOF8wLTItMS0xLTc1MTQw_b7534640-fbf6-4f37-895e-cee1e647980b">33-0112644</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xL2ZyYWc6YTlkNWJiMWM2YTA4NGVlOGE4NTdjOTJlZGQyZGRiN2YvdGV4dHJlZ2lvbjphOWQ1YmIxYzZhMDg0ZWU4YTg1N2M5MmVkZDJkZGI3Zl8yMDEx_007a929f-130e-4f0c-82f8-9ec82729ca02">225 Binney Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xL2ZyYWc6YTlkNWJiMWM2YTA4NGVlOGE4NTdjOTJlZGQyZGRiN2YvdGV4dHJlZ2lvbjphOWQ1YmIxYzZhMDg0ZWU4YTg1N2M5MmVkZDJkZGI3Zl8yMDA2_986dbfae-400c-48a0-958a-b9d406f55a5b">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xL2ZyYWc6YTlkNWJiMWM2YTA4NGVlOGE4NTdjOTJlZGQyZGRiN2YvdGV4dHJlZ2lvbjphOWQ1YmIxYzZhMDg0ZWU4YTg1N2M5MmVkZDJkZGI3Zl8yMDE0_031ed8d5-1fbd-4f4c-83ec-5d48150fc327">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xL2ZyYWc6YTlkNWJiMWM2YTA4NGVlOGE4NTdjOTJlZGQyZGRiN2YvdGV4dHJlZ2lvbjphOWQ1YmIxYzZhMDg0ZWU4YTg1N2M5MmVkZDJkZGI3Zl8yMDA3_9321bffa-47b8-43e7-844f-f32ce6c9a2d9">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xL2ZyYWc6YTlkNWJiMWM2YTA4NGVlOGE4NTdjOTJlZGQyZGRiN2YvdGV4dHJlZ2lvbjphOWQ1YmIxYzZhMDg0ZWU4YTg1N2M5MmVkZDJkZGI3Zl8yMDE1_57c18591-6202-4aa0-a877-e9ae70d6d8cb">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xL2ZyYWc6YTlkNWJiMWM2YTA4NGVlOGE4NTdjOTJlZGQyZGRiN2YvdGV4dHJlZ2lvbjphOWQ1YmIxYzZhMDg0ZWU4YTg1N2M5MmVkZDJkZGI3Zl8yMDE2_a84ddf84-38a0-4fd8-8507-f7d8278913c7">679-2000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xL2ZyYWc6YTlkNWJiMWM2YTA4NGVlOGE4NTdjOTJlZGQyZGRiN2YvdGFibGU6NmEyODk3NzAwMjJkNDhmNmI5NWIyZWU3Yzg4NGRkNDgvdGFibGVyYW5nZTo2YTI4OTc3MDAyMmQ0OGY2Yjk1YjJlZTdjODg0ZGQ0OF8xLTAtMS0xLTc1MTQw_668b6d8d-8da8-49fd-8c6b-c55d5cae492b">Common Stock, $0.0005 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xL2ZyYWc6YTlkNWJiMWM2YTA4NGVlOGE4NTdjOTJlZGQyZGRiN2YvdGFibGU6NmEyODk3NzAwMjJkNDhmNmI5NWIyZWU3Yzg4NGRkNDgvdGFibGVyYW5nZTo2YTI4OTc3MDAyMmQ0OGY2Yjk1YjJlZTdjODg0ZGQ0OF8xLTItMS0xLTc1MTQw_a0e0ebf6-6e38-4c70-b3aa-4a98629a9585">BIIB</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xL2ZyYWc6YTlkNWJiMWM2YTA4NGVlOGE4NTdjOTJlZGQyZGRiN2YvdGFibGU6NmEyODk3NzAwMjJkNDhmNmI5NWIyZWU3Yzg4NGRkNDgvdGFibGVyYW5nZTo2YTI4OTc3MDAyMmQ0OGY2Yjk1YjJlZTdjODg0ZGQ0OF8xLTQtMS0xLTc1MTQw_72251eb3-1b25-4a16-b223-9d3f38fa88b6">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xL2ZyYWc6YTlkNWJiMWM2YTA4NGVlOGE4NTdjOTJlZGQyZGRiN2YvdGV4dHJlZ2lvbjphOWQ1YmIxYzZhMDg0ZWU4YTg1N2M5MmVkZDJkZGI3Zl8yMDE3_84ac3625-6e2f-4c6b-90cd-870ae699bb00">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xL2ZyYWc6YTlkNWJiMWM2YTA4NGVlOGE4NTdjOTJlZGQyZGRiN2YvdGV4dHJlZ2lvbjphOWQ1YmIxYzZhMDg0ZWU4YTg1N2M5MmVkZDJkZGI3Zl8yMDEy_d1c99633-a010-4a4b-a163-10ef6d39681e">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xL2ZyYWc6YTlkNWJiMWM2YTA4NGVlOGE4NTdjOTJlZGQyZGRiN2YvdGFibGU6NTRhZjMwYzgxOTUyNDRkN2JkMDhhODJiNzk3MDdmZmQvdGFibGVyYW5nZTo1NGFmMzBjODE5NTI0NGQ3YmQwOGE4MmI3OTcwN2ZmZF8wLTAtMS0xLTc1MTQw_cfc53e27-42a7-4e3b-8cb5-e952c7678cac">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xL2ZyYWc6YTlkNWJiMWM2YTA4NGVlOGE4NTdjOTJlZGQyZGRiN2YvdGFibGU6NTRhZjMwYzgxOTUyNDRkN2JkMDhhODJiNzk3MDdmZmQvdGFibGVyYW5nZTo1NGFmMzBjODE5NTI0NGQ3YmQwOGE4MmI3OTcwN2ZmZF8xLTQtMS0xLTc1MTQw_ff1f080e-06bf-4b74-b9c0-8b4ff83ffece">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xL2ZyYWc6YTlkNWJiMWM2YTA4NGVlOGE4NTdjOTJlZGQyZGRiN2YvdGFibGU6NTRhZjMwYzgxOTUyNDRkN2JkMDhhODJiNzk3MDdmZmQvdGFibGVyYW5nZTo1NGFmMzBjODE5NTI0NGQ3YmQwOGE4MmI3OTcwN2ZmZF8yLTQtMS0xLTc1MTQw_d1091690-510b-42a4-adb6-f4c90b547890">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xL2ZyYWc6YTlkNWJiMWM2YTA4NGVlOGE4NTdjOTJlZGQyZGRiN2YvdGV4dHJlZ2lvbjphOWQ1YmIxYzZhMDg0ZWU4YTg1N2M5MmVkZDJkZGI3Zl8yMDEz_cd0a7340-5fab-4d95-bd54-a588218916aa">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ica34c492e95e460da92f264a157fc2cc_I20220502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xL2ZyYWc6YTlkNWJiMWM2YTA4NGVlOGE4NTdjOTJlZGQyZGRiN2YvdGV4dHJlZ2lvbjphOWQ1YmIxYzZhMDg0ZWU4YTg1N2M5MmVkZDJkZGI3Zl8xOTk1_9960cfcc-ab45-40ca-b29c-a02b0d470ed1"
      unitRef="shares">146452013</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Revenues
      contextRef="i70fc67330ce0470db37abf6a0dc4fb6a_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMy0xLTEtMS03NTE0MA_af3207d6-e1d6-4a5c-b9cc-77b6d3547b81"
      unitRef="usd">2066300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i22a0a13c266f4d788d5ba6423911ebd9_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMy0zLTEtMS03NTE0MA_775ea51e-2921-43c4-9b93-d60c743c2720"
      unitRef="usd">2211700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia5e84907dfd54cd09fdf7dc476b17545_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfNC0xLTEtMS03NTE0MA_423ab823-662f-438e-95df-7e317571cbe3"
      unitRef="usd">399400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if6b11452af4d4ae0bf50278351f22899_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfNC0zLTEtMS03NTE0MA_bb2bb5ba-30d6-4e93-af45-67781a4e1003"
      unitRef="usd">389000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i36b52f54c6e84045a18f6f934ed61b63_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfNS0xLTEtMS03NTE0MA_1538e6ce-5262-4178-aec3-fc0945b503c8"
      unitRef="usd">66100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iee301b6f981549919f1dd915c03e2623_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfNS0zLTEtMS03NTE0MA_5dd6b1fb-54bb-4f46-b364-82da6ace0990"
      unitRef="usd">93300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfNi0xLTEtMS03NTE0MA_ccf75f54-c903-46cb-8de8-c384ee8ebe14"
      unitRef="usd">2531800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfNi0zLTEtMS03NTE0MA_8dd9856b-4c8b-4850-b271-58296a0bf6ae"
      unitRef="usd">2694000000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfOC0xLTEtMS03NTE0MA_ed392968-6637-436e-bd1c-c6c8b4c37299"
      unitRef="usd">753900000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfOC0zLTEtMS03NTE0MA_83a3f53b-8420-493e-81da-427d444ad79b"
      unitRef="usd">478100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfOS0xLTEtMS03NTE0MA_23409b29-6b8c-498d-91f4-6e2b1dee275c"
      unitRef="usd">551700000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfOS0zLTEtMS03NTE0MA_f388dcf9-02b4-4f1e-beb3-26e30d313431"
      unitRef="usd">514200000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMTAtMS0xLTEtNzUxNDA_6ae67d1e-3c70-475a-a78b-c31fd8d68664"
      unitRef="usd">634900000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMTAtMy0xLTEtNzUxNDA_d57a977e-6bad-4ae5-85ce-cb66dbdf70d2"
      unitRef="usd">595000000.0</us-gaap:SellingGeneralAndAdministrativeExpense>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMTEtMS0xLTEtNzUxNDA_35824f57-87e7-4005-a133-6ebc714e8bff"
      unitRef="usd">66900000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMTEtMy0xLTEtNzUxNDA_8514b729-4696-4885-a867-5953ecef18ed"
      unitRef="usd">98100000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:Collaborationprofitlosssharing
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMTItMS0xLTEtNzUxNDA_dc518c33-9deb-4738-ba0c-4a07622da5d5"
      unitRef="usd">-117300000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMTItMy0xLTEtNzUxNDA_09f8b830-f87d-412b-8c0b-a9d5b5da04bc"
      unitRef="usd">68500000</biib:Collaborationprofitlosssharing>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMTQtMS0xLTEtNzUxNDA_f0806090-8db0-4b8e-8e2e-a4616edb32b1"
      unitRef="usd">7100000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMTQtMy0xLTEtNzUxNDA_5ff1c09a-2d2b-4f86-8c47-84ecbdc3d19b"
      unitRef="usd">33800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:RestructuringCharges
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMTYtMS0xLTEtNzUxNDA_4264e842-5ab8-4179-960a-c2bef867af5c"
      unitRef="usd">38100000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMTYtMy0xLTEtNzUxNDA_ba14be48-97fb-4009-b4f3-46fd53f4bd21"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:CostsAndExpenses
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMTctMS0xLTEtNzUxNDA_ec34d0bf-63bc-4faa-8452-b7de24b30937"
      unitRef="usd">1921100000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMTctMy0xLTEtNzUxNDA_2de997fc-ee98-443d-b290-711abd3e9e36"
      unitRef="usd">1720100000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMTgtMS0xLTEtNzUxNDA_f07e2e7b-be24-40c1-9f99-e76e1cd21da5"
      unitRef="usd">610700000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMTgtMy0xLTEtNzUxNDA_c40b69ff-d450-412c-bc29-fd4686ee9bf0"
      unitRef="usd">973900000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMTktMS0xLTEtNzUxNDA_1731991f-2f1c-4480-9560-120ae3e163fa"
      unitRef="usd">-263300000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMTktMy0xLTEtNzUxNDA_86991e09-55bf-4425-b692-72ae572c7dcb"
      unitRef="usd">-506900000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMjAtMS0xLTEtNzUxNDA_54ae3d68-bef2-4697-a14d-eda4f321f03c"
      unitRef="usd">347400000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMjAtMy0xLTEtNzUxNDA_46479eb0-91ff-4100-9315-63d117a89bda"
      unitRef="usd">467000000.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMjEtMS0xLTEtNzUxNDA_08131bf3-cc36-4d9b-ae8a-d2a02709c9e1"
      unitRef="usd">125600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMjEtMy0xLTEtNzUxNDA_4a929279-8140-4d33-a547-5382cf333997"
      unitRef="usd">44200000</us-gaap:IncomeTaxExpenseBenefit>
    <biib:IncomeLossFromEquityMethodInvestmentsNetOfTax
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMjItMS0xLTEtNzUxNDA_1461d274-5a86-4233-94dc-4c9ac27c58cf"
      unitRef="usd">-3300000</biib:IncomeLossFromEquityMethodInvestmentsNetOfTax>
    <biib:IncomeLossFromEquityMethodInvestmentsNetOfTax
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMjItMy0xLTEtNzUxNDA_373c9097-f81f-4957-a7e9-e669ac4dbf14"
      unitRef="usd">-18200000</biib:IncomeLossFromEquityMethodInvestmentsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMjMtMS0xLTEtNzUxNDA_f24d4a71-28b7-4a86-9966-84c007d19791"
      unitRef="usd">218500000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMjMtMy0xLTEtNzUxNDA_3c707c8f-62b9-4d5f-a8e7-d4fa358db100"
      unitRef="usd">404600000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMjQtMS0xLTEtNzUxNDA_ea091d31-908b-4695-80af-ddbc72ae44a1"
      unitRef="usd">-85300000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMjQtMy0xLTEtNzUxNDA_6bf14db9-6d0f-4719-b6fc-bef54e4ab17b"
      unitRef="usd">-5600000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMjUtMS0xLTEtNzUxNDA_6c52809a-f550-4c58-a5cd-ee28cf287ec2"
      unitRef="usd">303800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMjUtMy0xLTEtNzUxNDA_7807fd1e-f962-4718-aadb-c9d7552c82cb"
      unitRef="usd">410200000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMjgtMS0xLTEtNzUxNDA_c8dcb420-c95e-4600-9731-083b0cf29f37"
      unitRef="usdPerShare">2.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMjgtMy0xLTEtNzUxNDA_6b2fab92-92d5-4de1-b865-98e72066586c"
      unitRef="usdPerShare">2.70</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMjktMS0xLTEtNzUxNDA_62f008f8-e626-4ed1-8297-f0c2197d436f"
      unitRef="usdPerShare">2.06</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMjktMy0xLTEtNzUxNDA_3f90afbf-a321-4de2-909b-0531ec276ec2"
      unitRef="usdPerShare">2.69</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMzItMS0xLTEtNzUxNDA_a0bf2124-9e10-46c6-93d2-6d813151a599"
      unitRef="shares">147100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMzItMy0xLTEtNzUxNDA_e1734bd6-7a2b-4bc4-b308-fe9cd8304a6a"
      unitRef="shares">151900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMzMtMS0xLTEtNzUxNDA_20b38ca0-ad7a-4eef-8785-d39fc85ec996"
      unitRef="shares">147600000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xOS9mcmFnOjQxM2MwMzk3ZjRmMjRmYjU4ZGQ5ZTRkNDJmOGJmZWEyL3RhYmxlOjA1ZDhkMzljOThiMTQyYzg5YjVhZDFkODQ4M2JkY2Y2L3RhYmxlcmFuZ2U6MDVkOGQzOWM5OGIxNDJjODliNWFkMWQ4NDgzYmRjZjZfMzMtMy0xLTEtNzUxNDA_9bfa4cfe-090a-4024-83be-cfa34fdd1987"
      unitRef="shares">152300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMi9mcmFnOjg2Yjc1MDkyMjBmMTQ1ZTlhNjUzNTkzNWRmYzRmZWNiL3RhYmxlOmY5NzE1NDQyNzcxMTRmNTA5MTE1Y2RmZDI3MDRkOTIyL3RhYmxlcmFuZ2U6Zjk3MTU0NDI3NzExNGY1MDkxMTVjZGZkMjcwNGQ5MjJfMi0xLTEtMS03NTE0MA_e6624722-adeb-47d4-aa70-333845803d83"
      unitRef="usd">303800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMi9mcmFnOjg2Yjc1MDkyMjBmMTQ1ZTlhNjUzNTkzNWRmYzRmZWNiL3RhYmxlOmY5NzE1NDQyNzcxMTRmNTA5MTE1Y2RmZDI3MDRkOTIyL3RhYmxlcmFuZ2U6Zjk3MTU0NDI3NzExNGY1MDkxMTVjZGZkMjcwNGQ5MjJfMi0zLTEtMS03NTE0MA_55640f2c-0621-469e-889b-daff28e1b6b7"
      unitRef="usd">410200000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMi9mcmFnOjg2Yjc1MDkyMjBmMTQ1ZTlhNjUzNTkzNWRmYzRmZWNiL3RhYmxlOmY5NzE1NDQyNzcxMTRmNTA5MTE1Y2RmZDI3MDRkOTIyL3RhYmxlcmFuZ2U6Zjk3MTU0NDI3NzExNGY1MDkxMTVjZGZkMjcwNGQ5MjJfNC0xLTEtMS03NTE0MA_e1b66e28-8534-43a1-be79-89bc5c123400"
      unitRef="usd">-9700000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMi9mcmFnOjg2Yjc1MDkyMjBmMTQ1ZTlhNjUzNTkzNWRmYzRmZWNiL3RhYmxlOmY5NzE1NDQyNzcxMTRmNTA5MTE1Y2RmZDI3MDRkOTIyL3RhYmxlcmFuZ2U6Zjk3MTU0NDI3NzExNGY1MDkxMTVjZGZkMjcwNGQ5MjJfNC0zLTEtMS03NTE0MA_28529811-d87d-430c-a512-439be9e2e799"
      unitRef="usd">-800000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMi9mcmFnOjg2Yjc1MDkyMjBmMTQ1ZTlhNjUzNTkzNWRmYzRmZWNiL3RhYmxlOmY5NzE1NDQyNzcxMTRmNTA5MTE1Y2RmZDI3MDRkOTIyL3RhYmxlcmFuZ2U6Zjk3MTU0NDI3NzExNGY1MDkxMTVjZGZkMjcwNGQ5MjJfNS0xLTEtMS03NTE0MA_bd8cb233-7261-491c-9bdd-bb949c61fb08"
      unitRef="usd">15900000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMi9mcmFnOjg2Yjc1MDkyMjBmMTQ1ZTlhNjUzNTkzNWRmYzRmZWNiL3RhYmxlOmY5NzE1NDQyNzcxMTRmNTA5MTE1Y2RmZDI3MDRkOTIyL3RhYmxlcmFuZ2U6Zjk3MTU0NDI3NzExNGY1MDkxMTVjZGZkMjcwNGQ5MjJfNS0zLTEtMS03NTE0MA_9eae2cd2-55b8-453f-b5af-a5ff0d990ac1"
      unitRef="usd">149600000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMi9mcmFnOjg2Yjc1MDkyMjBmMTQ1ZTlhNjUzNTkzNWRmYzRmZWNiL3RhYmxlOmY5NzE1NDQyNzcxMTRmNTA5MTE1Y2RmZDI3MDRkOTIyL3RhYmxlcmFuZ2U6Zjk3MTU0NDI3NzExNGY1MDkxMTVjZGZkMjcwNGQ5MjJfNi0xLTEtMS03NTE0MA_73ed8e04-a5ba-4a15-8531-f8e59d63a4ac"
      unitRef="usd">6200000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMi9mcmFnOjg2Yjc1MDkyMjBmMTQ1ZTlhNjUzNTkzNWRmYzRmZWNiL3RhYmxlOmY5NzE1NDQyNzcxMTRmNTA5MTE1Y2RmZDI3MDRkOTIyL3RhYmxlcmFuZ2U6Zjk3MTU0NDI3NzExNGY1MDkxMTVjZGZkMjcwNGQ5MjJfNi0zLTEtMS03NTE0MA_81590992-2867-44b3-9c30-82999cadbe2c"
      unitRef="usd">22400000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMi9mcmFnOjg2Yjc1MDkyMjBmMTQ1ZTlhNjUzNTkzNWRmYzRmZWNiL3RhYmxlOmY5NzE1NDQyNzcxMTRmNTA5MTE1Y2RmZDI3MDRkOTIyL3RhYmxlcmFuZ2U6Zjk3MTU0NDI3NzExNGY1MDkxMTVjZGZkMjcwNGQ5MjJfNy0xLTEtMS03NTE0MA_b55493b8-7603-4437-a4c3-88c68b825f7c"
      unitRef="usd">-900000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMi9mcmFnOjg2Yjc1MDkyMjBmMTQ1ZTlhNjUzNTkzNWRmYzRmZWNiL3RhYmxlOmY5NzE1NDQyNzcxMTRmNTA5MTE1Y2RmZDI3MDRkOTIyL3RhYmxlcmFuZ2U6Zjk3MTU0NDI3NzExNGY1MDkxMTVjZGZkMjcwNGQ5MjJfNy0zLTEtMS03NTE0MA_b4bf5ba1-2c11-4866-8eda-55179bfeac27"
      unitRef="usd">-2000000.0</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMi9mcmFnOjg2Yjc1MDkyMjBmMTQ1ZTlhNjUzNTkzNWRmYzRmZWNiL3RhYmxlOmY5NzE1NDQyNzcxMTRmNTA5MTE1Y2RmZDI3MDRkOTIyL3RhYmxlcmFuZ2U6Zjk3MTU0NDI3NzExNGY1MDkxMTVjZGZkMjcwNGQ5MjJfOC0xLTEtMS03NTE0MA_a82eb78d-5aa9-4007-86db-e249275ddf71"
      unitRef="usd">-21800000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMi9mcmFnOjg2Yjc1MDkyMjBmMTQ1ZTlhNjUzNTkzNWRmYzRmZWNiL3RhYmxlOmY5NzE1NDQyNzcxMTRmNTA5MTE1Y2RmZDI3MDRkOTIyL3RhYmxlcmFuZ2U6Zjk3MTU0NDI3NzExNGY1MDkxMTVjZGZkMjcwNGQ5MjJfOC0zLTEtMS03NTE0MA_aaec0529-1c84-44be-82c7-1530265bd32e"
      unitRef="usd">-48500000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMi9mcmFnOjg2Yjc1MDkyMjBmMTQ1ZTlhNjUzNTkzNWRmYzRmZWNiL3RhYmxlOmY5NzE1NDQyNzcxMTRmNTA5MTE1Y2RmZDI3MDRkOTIyL3RhYmxlcmFuZ2U6Zjk3MTU0NDI3NzExNGY1MDkxMTVjZGZkMjcwNGQ5MjJfOS0xLTEtMS03NTE0MA_18a7e384-cbd5-4664-8995-56d8391e883e"
      unitRef="usd">-8500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMi9mcmFnOjg2Yjc1MDkyMjBmMTQ1ZTlhNjUzNTkzNWRmYzRmZWNiL3RhYmxlOmY5NzE1NDQyNzcxMTRmNTA5MTE1Y2RmZDI3MDRkOTIyL3RhYmxlcmFuZ2U6Zjk3MTU0NDI3NzExNGY1MDkxMTVjZGZkMjcwNGQ5MjJfOS0zLTEtMS03NTE0MA_626eab0e-e848-4608-9b94-0520a618b930"
      unitRef="usd">124700000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMi9mcmFnOjg2Yjc1MDkyMjBmMTQ1ZTlhNjUzNTkzNWRmYzRmZWNiL3RhYmxlOmY5NzE1NDQyNzcxMTRmNTA5MTE1Y2RmZDI3MDRkOTIyL3RhYmxlcmFuZ2U6Zjk3MTU0NDI3NzExNGY1MDkxMTVjZGZkMjcwNGQ5MjJfMTAtMS0xLTEtNzUxNDA_516f6cc4-b34f-4365-9415-628a89bc1db3"
      unitRef="usd">295300000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMi9mcmFnOjg2Yjc1MDkyMjBmMTQ1ZTlhNjUzNTkzNWRmYzRmZWNiL3RhYmxlOmY5NzE1NDQyNzcxMTRmNTA5MTE1Y2RmZDI3MDRkOTIyL3RhYmxlcmFuZ2U6Zjk3MTU0NDI3NzExNGY1MDkxMTVjZGZkMjcwNGQ5MjJfMTAtMy0xLTEtNzUxNDA_3e5c6a9b-defa-4b31-adac-dbfaaa942da4"
      unitRef="usd">534900000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMi9mcmFnOjg2Yjc1MDkyMjBmMTQ1ZTlhNjUzNTkzNWRmYzRmZWNiL3RhYmxlOmY5NzE1NDQyNzcxMTRmNTA5MTE1Y2RmZDI3MDRkOTIyL3RhYmxlcmFuZ2U6Zjk3MTU0NDI3NzExNGY1MDkxMTVjZGZkMjcwNGQ5MjJfMTEtMS0xLTEtNzUxNDA_6a7f29e4-9e95-4934-a58e-3e9f538094e5"
      unitRef="usd">-85300000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMi9mcmFnOjg2Yjc1MDkyMjBmMTQ1ZTlhNjUzNTkzNWRmYzRmZWNiL3RhYmxlOmY5NzE1NDQyNzcxMTRmNTA5MTE1Y2RmZDI3MDRkOTIyL3RhYmxlcmFuZ2U6Zjk3MTU0NDI3NzExNGY1MDkxMTVjZGZkMjcwNGQ5MjJfMTEtMy0xLTEtNzUxNDA_54100a99-0701-4e12-bb65-a850707b1def"
      unitRef="usd">-4900000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMi9mcmFnOjg2Yjc1MDkyMjBmMTQ1ZTlhNjUzNTkzNWRmYzRmZWNiL3RhYmxlOmY5NzE1NDQyNzcxMTRmNTA5MTE1Y2RmZDI3MDRkOTIyL3RhYmxlcmFuZ2U6Zjk3MTU0NDI3NzExNGY1MDkxMTVjZGZkMjcwNGQ5MjJfMTItMS0xLTEtNzUxNDA_5caab16b-31d3-49b2-ba01-7a4933eab4fb"
      unitRef="usd">210000000.0</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMi9mcmFnOjg2Yjc1MDkyMjBmMTQ1ZTlhNjUzNTkzNWRmYzRmZWNiL3RhYmxlOmY5NzE1NDQyNzcxMTRmNTA5MTE1Y2RmZDI3MDRkOTIyL3RhYmxlcmFuZ2U6Zjk3MTU0NDI3NzExNGY1MDkxMTVjZGZkMjcwNGQ5MjJfMTItMy0xLTEtNzUxNDA_6b9b06da-b7c4-48e2-bc5e-d643c94349f2"
      unitRef="usd">530000000.0</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMy0xLTEtMS03NTE0MA_d06e4ca1-fec4-41af-8f60-0671f4601f36"
      unitRef="usd">1749300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMy0zLTEtMS03NTE0MA_72a13fb3-e84f-4ffb-8311-0f8a8847cdd5"
      unitRef="usd">2261400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfNC0xLTEtMS03NTE0MA_51beb278-8694-4cb3-85c8-8cc5f8e432ab"
      unitRef="usd">2002400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfNC0zLTEtMS03NTE0MA_c48b8fd3-f782-4ac5-9ad1-95ec2baf4105"
      unitRef="usd">1541100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfNS0xLTEtMS03NTE0MA_15babc22-f4d5-4d53-9995-bfa0d9c06efc"
      unitRef="usd">1632000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfNS0zLTEtMS03NTE0MA_d3fb7dcf-d812-41f3-8c96-93019eaecdb1"
      unitRef="usd">1549400000</us-gaap:AccountsReceivableNetCurrent>
    <biib:DuefromantiCD20therapeuticprograms
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfNi0xLTEtMS03NTE0MA_2f037684-5135-4c74-9204-b6b877d341c0"
      unitRef="usd">389400000</biib:DuefromantiCD20therapeuticprograms>
    <biib:DuefromantiCD20therapeuticprograms
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfNi0zLTEtMS03NTE0MA_157d57f3-e1e1-472f-b58a-19536b7b9a7c"
      unitRef="usd">412300000</biib:DuefromantiCD20therapeuticprograms>
    <us-gaap:InventoryNet
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfNy0xLTEtMS03NTE0MA_6f9ffac2-925c-4647-a459-84757d34f28b"
      unitRef="usd">1215400000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfNy0zLTEtMS03NTE0MA_38818a66-7f4f-42db-8ae1-f7c38c4f22ef"
      unitRef="usd">1351500000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfOC0xLTEtMS03NTE0MA_7df30da5-5fe7-4ee5-9880-1e3a97353cb2"
      unitRef="usd">927400000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfOC0zLTEtMS03NTE0MA_4184c856-342f-4fbe-a5ca-4f2d2e4e5055"
      unitRef="usd">740800000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfOS0xLTEtMS03NTE0MA_2b7ff05a-7436-482f-8ad1-55684949a0a6"
      unitRef="usd">7915900000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfOS0zLTEtMS03NTE0MA_685c9fbd-f661-477a-944f-4fbc80cfbbfc"
      unitRef="usd">7856500000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMTAtMS0xLTEtNzUxNDA_3806dc3d-293b-413b-854c-86a83f441ae9"
      unitRef="usd">1001600000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMTAtMy0xLTEtNzUxNDA_03746a57-7eab-4a70-b730-ed2151c1c197"
      unitRef="usd">892000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMTEtMS0xLTEtNzUxNDA_33a3d467-4024-4433-a5a7-536dc72cb21d"
      unitRef="usd">3372800000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMTEtMy0xLTEtNzUxNDA_28a0a869-9552-42a9-acba-718c110026d1"
      unitRef="usd">3416400000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMTItMS0xLTEtNzUxNDA_a2a290d5-3832-4926-b35a-2e3d0e9e15d0"
      unitRef="usd">359000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMTItMy0xLTEtNzUxNDA_51b80276-7843-47ef-b3ef-699aab98b38c"
      unitRef="usd">375400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMTMtMS0xLTEtNzUxNDA_abf936e7-f140-46f0-87e1-108af94a3a2d"
      unitRef="usd">2150800000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMTMtMy0xLTEtNzUxNDA_ad31bd98-dc2a-4080-ad2e-57de755fe2d5"
      unitRef="usd">2221300000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMTQtMS0xLTEtNzUxNDA_9bae4871-7030-49ad-acc4-e48d7ebfe89f"
      unitRef="usd">5758000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMTQtMy0xLTEtNzUxNDA_54f46cd6-dfd4-409b-a3a4-43343e84b85f"
      unitRef="usd">5761100000</us-gaap:Goodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMTUtMS0xLTEtNzUxNDA_9ecc3e8c-b6a2-4181-a2c6-bc120bcc72a8"
      unitRef="usd">1288800000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMTUtMy0xLTEtNzUxNDA_bd29300a-5cf5-474d-9eb8-370c5ff91bd9"
      unitRef="usd">1415100000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMTYtMS0xLTEtNzUxNDA_8b8aead6-35a3-486e-9547-d0e83486896f"
      unitRef="usd">1767500000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMTYtMy0xLTEtNzUxNDA_e078e268-48ed-49bf-9fad-e952300afcdb"
      unitRef="usd">1939500000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMTctMS0xLTEtNzUxNDA_a6f4818b-11ad-428c-8f73-54a030caeae7"
      unitRef="usd">23614400000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMTctMy0xLTEtNzUxNDA_e4ab488b-1bb4-4fc4-8cc5-0b0855d4aaa3"
      unitRef="usd">23877300000</us-gaap:Assets>
    <us-gaap:NotesPayableCurrent
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMjAtMS0xLTEtNzUxNDA_3328ab25-b772-4145-8169-8408c1c9fa84"
      unitRef="usd">999500000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMjAtMy0xLTEtNzUxNDA_54631e37-920a-4e27-afcb-de581b04d0ef"
      unitRef="usd">999100000</us-gaap:NotesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMjEtMS0xLTEtNzUxNDA_f95bfdff-4c72-42d2-b440-e86a3b258b33"
      unitRef="usd">317300000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMjEtMy0xLTEtNzUxNDA_157b0cfa-a881-4141-9998-78e3c92742f9"
      unitRef="usd">174700000</us-gaap:TaxesPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMjItMS0xLTEtNzUxNDA_08419938-24b4-4fbc-9d8b-2306302c30f3"
      unitRef="usd">398700000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMjItMy0xLTEtNzUxNDA_b38639b0-d862-445b-bd18-8d80cc97c9ed"
      unitRef="usd">589200000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMjMtMS0xLTEtNzUxNDA_d8515f2d-5c34-4a06-ac3d-2e7660a67213"
      unitRef="usd">2231100000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMjMtMy0xLTEtNzUxNDA_5fb31e60-8834-4e3c-b136-2d311762a7e2"
      unitRef="usd">2535200000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMjQtMS0xLTEtNzUxNDA_44706d82-c739-4543-93ae-159fb5fb6412"
      unitRef="usd">3946600000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMjQtMy0xLTEtNzUxNDA_e529c4e2-3b60-4eac-969e-dd46f397a2f1"
      unitRef="usd">4298200000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebt
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMjUtMS0xLTEtNzUxNDA_554eb3ee-bb44-4850-87db-49227497b6b4"
      unitRef="usd">6275700000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMjUtMy0xLTEtNzUxNDA_523a2d76-07f7-482b-b744-90a15cd8f0ab"
      unitRef="usd">6274000000</us-gaap:LongTermDebt>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMjYtMS0xLTEtNzUxNDA_6e1b71dc-2d6e-4835-87b8-403c8f2bdaf8"
      unitRef="usd">571200000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMjYtMy0xLTEtNzUxNDA_2ddd193d-8199-42df-9f54-ae3463fe815b"
      unitRef="usd">694500000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMjctMS0xLTEtNzUxNDA_a3758c18-86de-425c-aaab-740ed256fea2"
      unitRef="usd">312300000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMjctMy0xLTEtNzUxNDA_79b4511a-b486-4ebf-8660-260292b24d28"
      unitRef="usd">330400000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMjgtMS0xLTEtNzUxNDA_ae9b79e7-c50a-4224-bacb-005459810b00"
      unitRef="usd">1287900000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMjgtMy0xLTEtNzUxNDA_2b393ea2-2d62-4e7f-b365-49ddd66c9824"
      unitRef="usd">1320500000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMjktMS0xLTEtNzUxNDA_cd9d06ec-7284-4937-aaf8-06a089c00faa"
      unitRef="usd">12393700000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMjktMy0xLTEtNzUxNDA_c4966121-7634-45be-91de-00e229bd625c"
      unitRef="usd">12917600000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMzAtMS0xLTEtNzUxNDA_7060e6ab-126a-485d-b387-0c72b9121115"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMzAtMy0xLTEtNzUxNDA_d835182d-c73b-4063-b6dc-db91f81c1c28"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMzMtMS0xLTEtNzUxNDA_298a4fa9-bc8a-4793-ac0e-120938008c47"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMzMtMy0xLTEtNzUxNDA_d1840a06-bd26-4695-b159-08a7b5f75b5d"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMzQtMS0xLTEtNzUxNDA_2dc960d8-a5b8-41d7-b070-b91f768e4ca1"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMzQtMy0xLTEtNzUxNDA_f9dbbff8-7102-464c-9e9e-9d1cbaa777fa"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMzUtMS0xLTEtNzUxNDA_a39f8864-3a36-4d7e-918d-2cea1cbcfb49"
      unitRef="usd">119000000.0</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMzUtMy0xLTEtNzUxNDA_38ee2fae-0e3c-4fc6-ac06-37c848efb74a"
      unitRef="usd">68200000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMzYtMS0xLTEtNzUxNDA_c6a1ab44-8a89-413a-8939-7dfcc6a08460"
      unitRef="usd">-115200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMzYtMy0xLTEtNzUxNDA_a384e6e0-571e-47fb-a1c2-b454ef7219f2"
      unitRef="usd">-106700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMzctMS0xLTEtNzUxNDA_95457275-cf2e-4d9d-b6cb-b6e9391ce5c6"
      unitRef="usd">14215500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMzctMy0xLTEtNzUxNDA_fdf62bc1-3e11-4e52-8fd6-68b9e39098d9"
      unitRef="usd">13911700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockValue
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMzgtMS0xLTEtNzUxNDA_0d3e8dbf-7670-45cd-95d7-160b7eeda179"
      unitRef="usd">2977100000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMzgtMy0xLTEtNzUxNDA_d5792b37-3e51-4734-a4db-a4354c373032"
      unitRef="usd">2977100000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMzktMS0xLTEtNzUxNDA_26adb43f-6cda-47e4-b3d7-109945d2ae1c"
      unitRef="usd">11242300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfMzktMy0xLTEtNzUxNDA_b508ed4c-d589-4818-aeea-559b1e36540d"
      unitRef="usd">10896200000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfNDAtMS0xLTEtNzUxNDA_6cd4f492-8df6-4589-85a4-ed6681824388"
      unitRef="usd">-21600000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfNDAtMy0xLTEtNzUxNDA_7d3ebae2-00ca-4db9-8167-7da98d6512e4"
      unitRef="usd">63500000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfNDEtMS0xLTEtNzUxNDA_7f933b33-769f-4558-ab08-c1af5130f6dd"
      unitRef="usd">11220700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfNDEtMy0xLTEtNzUxNDA_6e9ebb14-3e9f-40b1-96ec-8f11d311e5f2"
      unitRef="usd">10959700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfNDItMS0xLTEtNzUxNDA_dcce3b69-0040-41fb-8561-7623e228e4dd"
      unitRef="usd">23614400000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yNS9mcmFnOjE5OTBhNjk0ZjBjYzQxNzNiYWYxNmZjNTQwYjFiMTkzL3RhYmxlOjQ0NjZlM2Y0NjdmODQ5NjRhMTQyNTgwZDE2MTQwYmUzL3RhYmxlcmFuZ2U6NDQ2NmUzZjQ2N2Y4NDk2NGExNDI1ODBkMTYxNDBiZTNfNDItMy0xLTEtNzUxNDA_be15d785-3fdf-4f16-b826-8322195300be"
      unitRef="usd">23877300000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMy0xLTEtMS03NTE0MA_7942bf81-e159-4da8-b094-5a28507affe3"
      unitRef="usd">218500000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMy0zLTEtMS03NTE0MA_52051140-afd8-41d2-8934-ec66d60c2bb9"
      unitRef="usd">404600000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfNS0xLTEtMS03NTE0MA_13d9cb21-3967-4556-8f4d-835e7b0c3e49"
      unitRef="usd">143100000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfNS0zLTEtMS03NTE0MA_23c9b3a1-fa84-44dc-a5b0-45133cf32915"
      unitRef="usd">102600000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfNi0xLTEtMS03NTE0MA_0369c383-44d8-4420-b52e-4bf78af810d5"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfNi0zLTEtMS03NTE0MA_a29b029d-523e-48de-85b7-d4f3079cfeff"
      unitRef="usd">44300000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:InventoryWriteDown
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfNy0xLTEtMS03NTE0MA_cec9e047-e276-4a48-9791-856c1b9ad753"
      unitRef="usd">281500000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfNy0zLTEtMS03NTE0MA_b8938434-9c0d-40db-a3de-1bdf0d9609a1"
      unitRef="usd">11900000</us-gaap:InventoryWriteDown>
    <us-gaap:ShareBasedCompensation
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfOS0xLTEtMS03NTE0MA_7de3d05c-d1cf-4a76-a42f-5a3f7f6eb036"
      unitRef="usd">67600000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfOS0zLTEtMS03NTE0MA_8eaa64e0-e531-4a80-aeca-0f8c669757df"
      unitRef="usd">70000000.0</us-gaap:ShareBasedCompensation>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMTAtMS0xLTEtNzUxNDA_16d55c8d-ca4e-44a9-b0ff-19581628ccfc"
      unitRef="usd">7100000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMTAtMy0xLTEtNzUxNDA_a865cad2-2453-4b71-ba4b-b9e093538440"
      unitRef="usd">33800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMTEtMS0xLTEtNzUxNDA_28c0f8f0-77d7-431b-a620-a9081538c6f7"
      unitRef="usd">1000000.0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMTEtMy0xLTEtNzUxNDA_2e6b9102-abaf-4157-950b-1d20996d5d7d"
      unitRef="usd">-15000000.0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMTItMS0xLTEtNzUxNDA_394c2b6d-6d77-4e97-b925-c36d57c82ddc"
      unitRef="usd">-191100000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMTItMy0xLTEtNzUxNDA_7fcbaa6a-e9f9-4718-9864-2c0ff4f57c81"
      unitRef="usd">-437600000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMTMtMS0xLTEtNzUxNDA_89ac0c0b-4349-48c7-8800-e89e135202b2"
      unitRef="usd">-3300000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMTMtMy0xLTEtNzUxNDA_efdc588a-fd49-493b-8931-337b977afdc5"
      unitRef="usd">-18200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMTQtMS0xLTEtNzUxNDA_4b141fa5-89d5-4c45-a6e4-c7c9e92e3d69"
      unitRef="usd">-43300000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMTQtMy0xLTEtNzUxNDA_815fb112-f702-436d-a26b-9eae2982cae7"
      unitRef="usd">-59800000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMTYtMS0xLTEtNzUxNDA_9c0864f6-cf6e-4654-a35c-89290a7d5f36"
      unitRef="usd">87500000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMTYtMy0xLTEtNzUxNDA_13e095c1-8b75-4471-9d6d-0947be4d6dfc"
      unitRef="usd">-37200000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMTctMS0xLTEtNzUxNDA_46d8cc02-d79f-4e85-9668-5baa6c1eb971"
      unitRef="usd">-22900000</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMTctMy0xLTEtNzUxNDA_a30729c0-808b-4ed6-8297-4bb084bf3a78"
      unitRef="usd">-43800000</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMTgtMS0xLTEtNzUxNDA_e7e0eb5d-6c67-4038-b5e7-6cb7798175c5"
      unitRef="usd">142600000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMTgtMy0xLTEtNzUxNDA_13333115-a399-4b6a-aca8-0e6bb3dfeaf1"
      unitRef="usd">112500000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMTktMS0xLTEtNzUxNDA_441eec7d-22f9-4010-9fd9-4a9d4ddfc75a"
      unitRef="usd">-461600000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMTktMy0xLTEtNzUxNDA_993f1d57-98fe-4fd1-9acd-d5cbea05198a"
      unitRef="usd">-283600000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMjAtMS0xLTEtNzUxNDA_1ae1cc71-b7e0-4476-be45-480b8c247ad7"
      unitRef="usd">101900000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMjAtMy0xLTEtNzUxNDA_87e9854b-88bb-42ff-baa8-a32f4816feb4"
      unitRef="usd">64800000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMjEtMS0xLTEtNzUxNDA_3496527f-ba12-49ac-be0d-41385525260d"
      unitRef="usd">213600000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMjEtMy0xLTEtNzUxNDA_db393018-5402-4f57-a230-4c31146b089b"
      unitRef="usd">80900000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMjItMS0xLTEtNzUxNDA_c7d49393-2afc-44cd-9d01-b76495865e8f"
      unitRef="usd">161800000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMjItMy0xLTEtNzUxNDA_e31c7de8-9e6f-48f7-b17c-3e11255725ef"
      unitRef="usd">769000000.0</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMjQtMS0xLTEtNzUxNDA_795442cd-0818-4f9e-96a1-40ca68e9bb13"
      unitRef="usd">57900000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMjQtMy0xLTEtNzUxNDA_63bfa1c2-8584-4cc8-afaf-6d807fb81c38"
      unitRef="usd">92600000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMjUtMS0xLTEtNzUxNDA_736a63c6-c21e-478f-8b00-0ff98022b2a3"
      unitRef="usd">543600000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMjUtMy0xLTEtNzUxNDA_61a1e701-eab7-4eed-96f3-846f38687c90"
      unitRef="usd">819200000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMjYtMS0xLTEtNzUxNDA_4ae4f9f8-3315-40ff-abc3-597d2552b7ed"
      unitRef="usd">1133500000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMjYtMy0xLTEtNzUxNDA_08ae293a-15d2-4b7c-9e37-6ffc151fbb82"
      unitRef="usd">913300000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMjctMS0xLTEtNzUxNDA_d63bd475-3238-4a6f-88dd-5aaad21c066a"
      unitRef="usd">0</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMjctMy0xLTEtNzUxNDA_9e2e8262-18ae-41c6-9ec6-86eef01a281e"
      unitRef="usd">28100000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMzAtMS0xLTEtNzUxNDA_2e4c70b6-ce8d-48c2-b957-9c132503fd16"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMzAtMy0xLTEtNzUxNDA_07e00d9f-22de-494b-b3f1-dd4987e6f128"
      unitRef="usd">91200000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMzEtMS0xLTEtNzUxNDA_5027c699-3185-4ad9-97db-efb231855c5d"
      unitRef="usd">200000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMzEtMy0xLTEtNzUxNDA_71e44140-b4e3-4162-8796-8355698e6799"
      unitRef="usd">-2700000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMzYtMS0xLTEtNzUxNDA_9cc60a7c-19b3-46e8-a900-98f02bb386f0"
      unitRef="usd">-648000000.0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMzYtMy0xLTEtNzUxNDA_244aadd6-60a8-4685-8a8a-70a6c6aa2e7d"
      unitRef="usd">-64700000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMzgtMS0xLTEtNzUxNDA_865bd96b-3b72-4a6c-975e-8d04250a9fde"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMzgtMy0xLTEtNzUxNDA_0b05912c-4029-4186-98c5-4025fa2dfc34"
      unitRef="usd">600000000.0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMzktMS0xLTEtNzUxNDA_d2f460b4-7b2c-4ec1-a6b7-09134942a4b9"
      unitRef="usd">20800000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfMzktMy0xLTEtNzUxNDA_a0d6df23-bbbc-4c1f-90b4-9556baeed4bc"
      unitRef="usd">27100000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfNDAtMS0xLTEtNzUxNDA_681fedba-8e9f-4541-9b05-244a42811620"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfNDAtMy0xLTEtNzUxNDA_422b2099-ae1f-4a06-9bc0-9af3bae54242"
      unitRef="usd">169300000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromPaymentsToMinorityShareholders
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfNDQtMS0xLTEtNzUxNDA_f88bce75-3f74-4811-ac66-a28324b7324d"
      unitRef="usd">200000</us-gaap:ProceedsFromPaymentsToMinorityShareholders>
    <us-gaap:ProceedsFromPaymentsToMinorityShareholders
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfNDQtMy0xLTEtNzUxNDA_c80140a7-7424-43a8-93aa-848edfce824c"
      unitRef="usd">0</us-gaap:ProceedsFromPaymentsToMinorityShareholders>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfNDUtMS0xLTEtNzUxNDA_64b51915-ec1e-4582-b582-f6fcdfee2df7"
      unitRef="usd">4100000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfNDUtMy0xLTEtNzUxNDA_5da38ae0-9d6e-4449-834e-f56abbb4a096"
      unitRef="usd">11400000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfNDYtMS0xLTEtNzUxNDA_3a7c61d2-0976-4bc9-91ae-1f96ee87c2b7"
      unitRef="usd">-16500000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfNDYtMy0xLTEtNzUxNDA_80983bb4-71e8-44e0-a90e-f1cc48efd459"
      unitRef="usd">-785000000.0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfNDctMS0xLTEtNzUxNDA_8c63eea2-3902-4941-9f04-f0e1b826d88e"
      unitRef="usd">-502700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfNDctMy0xLTEtNzUxNDA_63d8356b-99e5-4c0a-8f2a-99b91cbc04b3"
      unitRef="usd">-80700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfNDgtMS0xLTEtNzUxNDA_8c7fd04b-5ebe-4858-ab33-6d761fc3ea0a"
      unitRef="usd">-9400000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfNDgtMy0xLTEtNzUxNDA_05792b07-9b88-40d9-94b6-9b88b52cea7e"
      unitRef="usd">-33000000.0</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfNDktMS0xLTEtNzUxNDA_fd826ab7-6e36-4b52-a998-a3806e7f70eb"
      unitRef="usd">2261400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if8f47af926b14294931310a85ceac0ce_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfNDktMy0xLTEtNzUxNDA_e5019d67-529c-4213-84b3-9dcc1dcbaee1"
      unitRef="usd">1331200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfNTAtMS0xLTEtNzUxNDA_5c29cea5-64a0-4b45-b890-d2b4bb54c89e"
      unitRef="usd">1749300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8239e2124c804a2ea880e06ae55914e8_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zMS9mcmFnOmI4NzgyNDRjYTgyYTQ3OTRhMTM1MzUwNzYxY2JjZDA4L3RhYmxlOjc0MDU5MDNlYTJhMTQ5NTQ5NTQyODI0ZWIyYzA0NWU5L3RhYmxlcmFuZ2U6NzQwNTkwM2VhMmExNDk1NDk1NDI4MjRlYjJjMDQ1ZTlfNTAtMy0xLTEtNzUxNDA_ef669221-b6e3-4a95-8183-3e5c4e5f8916"
      unitRef="usd">1217500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie941cd89b1e6451a9094413808a742ce_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMi0xLTEtMS03NTE0MA_fe410720-a5af-45cf-866e-c601fc542b5a"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie941cd89b1e6451a9094413808a742ce_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMi0zLTEtMS03NTE0MA_980405d6-9837-4ed5-b92d-ce30fb17bed5"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i78d18bc7ad434dbbb7aebc8184bdf0b7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMi01LTEtMS03NTE0MA_f1b415db-0f82-4bea-9cea-9aa38ea12ead"
      unitRef="shares">170800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i78d18bc7ad434dbbb7aebc8184bdf0b7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMi03LTEtMS03NTE0MA_317f25ff-653b-4d50-8534-30ff3a18f628"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8ec0412c74a64f2a8f0fe89d886801fd_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMi05LTEtMS03NTE0MA_f2bca02e-3576-4c66-943a-66baa30ac8dd"
      unitRef="usd">68200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i59bfec7053f64e28a514a578cced1277_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMi0xMS0xLTEtNzUxNDA_c5c79645-2c50-40f5-93de-be3e1dbdc4ee"
      unitRef="usd">-106700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if7bb17477f1d45768747b659ec408858_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMi0xMy0xLTEtNzUxNDA_9a0b9a9d-bc41-4fe7-9e36-8f6ccdcf7641"
      unitRef="usd">13911700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia38ac114688d4dc79f2cdfac46866743_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMi0xNS0xLTEtNzUxNDA_af747a62-137f-45c8-b085-382a67e7d8e9"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia38ac114688d4dc79f2cdfac46866743_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMi0xNy0xLTEtNzUxNDA_90c7d685-687e-4b17-913a-a8e8d45e229b"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie2ab94bf8dc040fba955fc08e64b5851_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMi0xOS0xLTEtNzUxNDA_c5828e0b-484c-4434-a5df-cf1264a007db"
      unitRef="usd">10896200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3cab2b42650840b8ad130b5ce90c072e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMi0yMS0xLTEtNzUxNDA_26babcfc-e82a-475f-9a15-4f1649fd9d58"
      unitRef="usd">63500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMi0yMy0xLTEtNzUxNDA_8d421417-c323-47c9-b99c-fc8f0da5a657"
      unitRef="usd">10959700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i0a99695583d54417b14f147c2e47f0ce_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMy0xMy0xLTEtNzUxNDA_58bc0f0a-1207-4676-a619-d0a670a4fc3c"
      unitRef="usd">303800000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i548f861f837e49619231dee37689ae5e_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMy0xOS0xLTEtNzUxNDA_b4d2e789-f976-4dda-ba60-3f90cdb6e8eb"
      unitRef="usd">303800000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6d4017cf2e7f4c638778c899d7ee5f81_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMy0yMS0xLTEtNzUxNDA_3d92208f-b9f1-44b9-8b99-c76ed4176acf"
      unitRef="usd">-85300000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMy0yMy0xLTEtNzUxNDA_35f16ec6-f6b8-4b31-ba96-1e77df005317"
      unitRef="usd">218500000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i377219a6f8954472a10644270fc0f641_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfNC0xMS0xLTEtNzUxNDA_d621429d-7f8e-4f1c-a491-7b76de513ac1"
      unitRef="usd">-8500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i548f861f837e49619231dee37689ae5e_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfNC0xOS0xLTEtNzUxNDA_b1d9e91b-0746-463b-a782-e7339f150db7"
      unitRef="usd">-8500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfNC0yMy0xLTEtNzUxNDA_805f203a-a4f3-46e9-9350-fd2daae4368e"
      unitRef="usd">-8500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <biib:NoncontrollingInterestIncreaseDecreaseOther
      contextRef="i6d4017cf2e7f4c638778c899d7ee5f81_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfNi0yMS0xLTEtNzUxNDA_67951dd9-c434-4140-8c14-59a9b264d4eb"
      unitRef="usd">200000</biib:NoncontrollingInterestIncreaseDecreaseOther>
    <biib:NoncontrollingInterestIncreaseDecreaseOther
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfNi0yMy0xLTEtNzUxNDA_e7cba5c8-e25a-462f-a58d-ae2f753b1cbf"
      unitRef="usd">200000</biib:NoncontrollingInterestIncreaseDecreaseOther>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="ie8cfe2b3484547cb8b869f3703fbe7c6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfOS01LTEtMS03NTE0MA_164b6f55-e91f-47b2-99b0-6fa6a791a85f"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i7ba81a995fb24572ac4a052b330190f7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfOS05LTEtMS03NTE0MA_33299b18-708f-4843-bd63-2684e212bfed"
      unitRef="usd">18900000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i548f861f837e49619231dee37689ae5e_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfOS0xOS0xLTEtNzUxNDA_2ef83a2a-1936-4d7d-bdb8-e5f1344bc865"
      unitRef="usd">18900000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfOS0yMy0xLTEtNzUxNDA_f0becc34-476d-467d-be46-089c9b3cc936"
      unitRef="usd">18900000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ie8cfe2b3484547cb8b869f3703fbe7c6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMTAtNS0xLTEtNzUxNDA_1400f2fa-47c8-436b-9ff5-23269361acf5"
      unitRef="shares">400000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i7ba81a995fb24572ac4a052b330190f7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMTAtOS0xLTEtNzUxNDA_249f41af-e536-45f7-8b2d-41d5777bced3"
      unitRef="usd">-39700000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i0a99695583d54417b14f147c2e47f0ce_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMTAtMTMtMS0xLTc1MTQw_269bbfc8-2712-4b60-82d8-ecbd48aaed08"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i548f861f837e49619231dee37689ae5e_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMTAtMTktMS0xLTc1MTQw_e92f37c9-dbb0-4559-8ef0-94a32871248a"
      unitRef="usd">-39700000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMTAtMjMtMS0xLTc1MTQw_52309363-6b50-40e1-bbac-f4621b950486"
      unitRef="usd">-39700000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7ba81a995fb24572ac4a052b330190f7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMTEtOS0xLTEtNzUxNDA_aaf6fb93-e99d-4a56-8f24-031c67350c55"
      unitRef="usd">-70400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i548f861f837e49619231dee37689ae5e_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMTEtMTktMS0xLTc1MTQw_4d248946-8742-487a-a768-f3c69665db00"
      unitRef="usd">-70400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMTEtMjMtMS0xLTc1MTQw_18a6ba13-4e18-4749-9c25-6789ea4da80f"
      unitRef="usd">-70400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityOther
      contextRef="i7ba81a995fb24572ac4a052b330190f7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMTItOS0xLTEtNzUxNDA_5f32987c-167c-43bf-8a3d-51cde2e0483c"
      unitRef="usd">-1200000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i548f861f837e49619231dee37689ae5e_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMTItMTktMS0xLTc1MTQw_d9317180-9130-46ea-9019-91db620c46b9"
      unitRef="usd">-1200000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMTItMjMtMS0xLTc1MTQw_2e0b257a-9028-45ec-8f53-be1b2dfeaf38"
      unitRef="usd">-1200000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie711522c60db4065b671794dadaf1a8a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMTMtMS0xLTEtNzUxNDA_63aed028-78df-443c-a906-12a474af65d7"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie711522c60db4065b671794dadaf1a8a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMTMtMy0xLTEtNzUxNDA_8fbebe13-1f79-4755-ae2f-c9cfc48d4d2e"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i17ade9377df944b2b6a0b1d325fc48e3_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMTMtNS0xLTEtNzUxNDA_db024e01-f1ad-40c4-82c1-6a646488bbe4"
      unitRef="shares">171300000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i17ade9377df944b2b6a0b1d325fc48e3_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMTMtNy0xLTEtNzUxNDA_b2c0413f-7083-4a7b-a48f-e05d2e918e1f"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if5517a2fe985436cb5f65e1183b54903_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMTMtOS0xLTEtNzUxNDA_203abdaf-d637-4f0d-b839-0366028f5401"
      unitRef="usd">119000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iac6522198e5e47e2a87d575d4f0cf5fb_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMTMtMTEtMS0xLTc1MTQw_3baad367-dd57-4d5b-9387-817234e367a9"
      unitRef="usd">-115200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3d4a878ad70149fc8ebc17f38fb2c3bb_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMTMtMTMtMS0xLTc1MTQw_8467b910-b94f-4ec5-bec8-b3ec9973af99"
      unitRef="usd">14215500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i623c94faf2524ab6b84a4328c9fbfc71_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMTMtMTUtMS0xLTc1MTQw_f3f694c2-1a3a-48fa-8ea8-5270f018897b"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i623c94faf2524ab6b84a4328c9fbfc71_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMTMtMTctMS0xLTc1MTQw_b8b37a03-85a0-4efb-b676-3da3b1b6dc43"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib24a1c0ce66c4661bdc85bb559c07e50_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMTMtMTktMS0xLTc1MTQw_84fb9c04-7f13-4c8a-9c60-209abe8f0d9b"
      unitRef="usd">11242300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaf88a450e4df44f4ad8703ca0a5d3d6f_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMTMtMjEtMS0xLTc1MTQw_598d411a-54a5-4125-9ffb-ec8aa680b902"
      unitRef="usd">-21600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmM3ZGEwYzU1ZTZmNTQyYTBhNDA5ZGY3NjFlNGYwMmQ0L3RhYmxlcmFuZ2U6YzdkYTBjNTVlNmY1NDJhMGE0MDlkZjc2MWU0ZjAyZDRfMTMtMjMtMS0xLTc1MTQw_0e2c10e0-2673-4b46-ac6f-e702fe630922"
      unitRef="usd">11220700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic54a4fcce0664582818adb93f242f27f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMi0xLTEtMS03NTE0MA_a9a5dae6-b2dd-47e8-853c-4547e7cc19a5"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic54a4fcce0664582818adb93f242f27f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMi0zLTEtMS03NTE0MA_eba9f936-bf01-486f-84b1-989a179b2089"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie4f31a85cb5f4aeb9edd4a49ddc2205a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMi01LTEtMS03NTE0MA_aa967147-f092-4613-93ba-cea65805770e"
      unitRef="shares">176200000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie4f31a85cb5f4aeb9edd4a49ddc2205a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMi03LTEtMS03NTE0MA_e98fd788-1c1f-42a9-9caa-e1f7d100e766"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic33c429907664938b302242bae096aa3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMi05LTEtMS03NTE0MA_62a0a2c5-6edf-48b4-86f8-5368399b9854"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i95735dc725534e82a2c616cddefbdcd3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMi0xMS0xLTEtNzUxNDA_9ed113b0-40f0-417f-a556-b84e9ef12bac"
      unitRef="usd">-299000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i83d657be8c0141d3bbd283fd85ddc533_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMi0xMy0xLTEtNzUxNDA_230696c4-4b05-4c47-8fd4-8fe84995948b"
      unitRef="usd">13976300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7af6de98bde64694848ffc34847a8d52_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMi0xNS0xLTEtNzUxNDA_72d4a52f-46a2-4390-91ba-c1b8766399ed"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7af6de98bde64694848ffc34847a8d52_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMi0xNy0xLTEtNzUxNDA_7c875249-ae1c-4c2e-8510-7f7c80c05c8e"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iedf3697c5b544792bd0663883b4528a0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMi0xOS0xLTEtNzUxNDA_322921cc-4f9c-4e86-9663-c2bec3f7db34"
      unitRef="usd">10700300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i45721a1b1a8a4773b726c7ab76d5f1ec_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMi0yMS0xLTEtNzUxNDA_95ca5eec-6f8e-49d3-b307-9db99fe6f5bc"
      unitRef="usd">-14200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if8f47af926b14294931310a85ceac0ce_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMi0yMy0xLTEtNzUxNDA_e8527bdd-af18-4418-90b4-2b111fa0da74"
      unitRef="usd">10686100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="ib2ccdc021de64ec580af92fa350db35b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMy0xMy0xLTEtNzUxNDA_c202ce80-00ce-48fa-b189-793c7cc0e58e"
      unitRef="usd">410200000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i00c0c236fb7541c28d07fbbdf09baf1a_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMy0xOS0xLTEtNzUxNDA_46b540ed-7109-4ff4-83d0-b32a8c7fa489"
      unitRef="usd">410200000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id8b2525325d746868ee2c18985898556_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMy0yMS0xLTEtNzUxNDA_5cd42720-10df-42f2-acfe-fcfe123ff216"
      unitRef="usd">-5600000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMy0yMy0xLTEtNzUxNDA_c0c35089-c1a3-4794-ab0e-c89d12a84a37"
      unitRef="usd">404600000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie16d6112315b4c80ab9519df7448188a_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfNC0xMS0xLTEtNzUxNDA_158dff6f-ca20-4ec8-86eb-719b610bae5e"
      unitRef="usd">124700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i00c0c236fb7541c28d07fbbdf09baf1a_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfNC0xOS0xLTEtNzUxNDA_45b65d51-f9fe-408b-84a3-3c447f322742"
      unitRef="usd">124700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="id8b2525325d746868ee2c18985898556_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfNC0yMS0xLTEtNzUxNDA_b4068c7a-f237-4503-8b91-244d6e1d561d"
      unitRef="usd">700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfNC0yMy0xLTEtNzUxNDA_7b289b75-7b48-474a-b328-75c27c5b517f"
      unitRef="usd">125400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <biib:NoncontrollingInterestIncreaseDecreaseOther
      contextRef="id8b2525325d746868ee2c18985898556_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfNi0yMS0xLTEtNzUxNDA_6aa78885-c48a-4fa7-ad56-2b681923608a"
      unitRef="usd">100000</biib:NoncontrollingInterestIncreaseDecreaseOther>
    <biib:NoncontrollingInterestIncreaseDecreaseOther
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfNi0yMy0xLTEtNzUxNDA_5a064d43-4072-4ca6-aada-8cde084dafd3"
      unitRef="usd">100000</biib:NoncontrollingInterestIncreaseDecreaseOther>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i2c1a3584d9f04422972632d1a69a2814_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfNy0xNS0xLTEtNzUxNDA_ff3926e4-8f30-4012-a6cf-f59d2d78fa0e"
      unitRef="shares">2200000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i2c1a3584d9f04422972632d1a69a2814_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfNy0xNy0xLTEtNzUxNDA_7720fb69-5f2f-4898-8e99-5daf913c6a3b"
      unitRef="usd">600000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i9ef7dff5a368420bbd853026208ceb4c_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfNy0xOS0xLTEtNzUxNDA_3e7b9673-a5ed-4b01-b37a-b9952a85a159"
      unitRef="usd">600000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i8035064229a94dc1909b26988c0c3fc7_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfNy0yMy0xLTEtNzUxNDA_afcd8a7b-bb71-4c4c-8d0b-2bdbcc79cbe2"
      unitRef="usd">600000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="ide815a728f624d74849b4eae66187c0b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfOC01LTEtMS03NTE0MA_126cd726-a4f7-432e-8cec-893d438edfdc"
      unitRef="shares">2200000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i7810c7b681664742a2f6a5378d83f3f8_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfOC05LTEtMS03NTE0MA_67f043e3-8ac4-41b2-b7c4-902168e9537c"
      unitRef="usd">93800000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i9609a3cc1f21413e9387d3f994a752ea_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfOC0xMy0xLTEtNzUxNDA_057a7560-d510-4b46-b808-4b8bb8614b66"
      unitRef="usd">506200000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i2c1a3584d9f04422972632d1a69a2814_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfOC0xNS0xLTEtNzUxNDA_32037939-4556-41f3-b482-9ef1fd3b30e6"
      unitRef="shares">2200000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i2c1a3584d9f04422972632d1a69a2814_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfOC0xNy0xLTEtNzUxNDA_643073de-000b-43fa-a32e-42d02cd653b9"
      unitRef="usd">-600000000.0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="i35b4f4d780094f18808d017b4f134084_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfOS01LTEtMS03NTE0MA_aac9a66e-7358-462b-b4fc-30e8919259e2"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="if08130086aa74dc58e95ffbe7e3e1cc2_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfOS05LTEtMS03NTE0MA_28640237-2778-4cc9-a2b8-d69aaeb026dd"
      unitRef="usd">19700000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i00c0c236fb7541c28d07fbbdf09baf1a_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfOS0xOS0xLTEtNzUxNDA_2d7e90f1-98c6-420d-b7ed-2f2c98c37506"
      unitRef="usd">19700000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfOS0yMy0xLTEtNzUxNDA_7bdf9f28-c4fb-42b6-b321-d8a2681a0d31"
      unitRef="usd">19700000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i35b4f4d780094f18808d017b4f134084_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMTAtNS0xLTEtNzUxNDA_073e2b4d-99ac-45ce-a35e-bac679572946"
      unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ib2ccdc021de64ec580af92fa350db35b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMTAtMTMtMS0xLTc1MTQw_1260b6ef-97a9-4f28-bcbe-2d3eae77787b"
      unitRef="usd">-46800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i00c0c236fb7541c28d07fbbdf09baf1a_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMTAtMTktMS0xLTc1MTQw_a8794c03-7418-449d-803a-6b2bbce07d32"
      unitRef="usd">-46800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMTAtMjMtMS0xLTc1MTQw_d9d4ab14-e045-4f58-b870-a3da03c3c570"
      unitRef="usd">-46800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if08130086aa74dc58e95ffbe7e3e1cc2_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMTEtOS0xLTEtNzUxNDA_8e144597-ff50-4f37-bbb6-1c0758e830b9"
      unitRef="usd">-72600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i00c0c236fb7541c28d07fbbdf09baf1a_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMTEtMTktMS0xLTc1MTQw_755da92f-bb26-485a-862f-b6c41ca626c1"
      unitRef="usd">-72600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMTEtMjMtMS0xLTc1MTQw_e6b056e7-fd56-44e3-b046-aefd9ccc0661"
      unitRef="usd">-72600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityOther
      contextRef="if08130086aa74dc58e95ffbe7e3e1cc2_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMTItOS0xLTEtNzUxNDA_b22d6c6a-c293-4863-b293-ce8d579bdaf2"
      unitRef="usd">-1500000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i00c0c236fb7541c28d07fbbdf09baf1a_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMTItMTktMS0xLTc1MTQw_e4ef3db6-eb6d-4f8f-bab3-9fa927aa5bd3"
      unitRef="usd">-1500000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMTItMjMtMS0xLTc1MTQw_ce401cb2-6427-4d49-a0a9-44b00dfac0c8"
      unitRef="usd">-1500000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic151146309d249e6b3efce405c9339a7_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMTUtMS0xLTEtNzUxNDA_20af5440-08d6-40c1-9460-fbdff165d71b"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic151146309d249e6b3efce405c9339a7_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMTUtMy0xLTEtNzUxNDA_4948dd58-ef9c-42a0-b304-06e9be61f5eb"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i07a17833f117433192dfb2a5c084ff23_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMTUtNS0xLTEtNzUxNDA_93d3dfe6-e358-406f-8787-aa35fcf1351b"
      unitRef="shares">174400000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i07a17833f117433192dfb2a5c084ff23_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMTUtNy0xLTEtNzUxNDA_a435947d-e48e-4b4d-a4d1-4b201b0debd9"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i62a58c1e7d3f4fa9bef57b7a1f8c7c8e_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMTUtOS0xLTEtNzUxNDA_6afe4259-cd8d-42a3-8f0f-d1243f6207f8"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9948ac905c84412a859b84aa29f53e12_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMTUtMTEtMS0xLTc1MTQw_8e3a80f2-8cf3-4dce-bf86-8d7b2a0b7e35"
      unitRef="usd">-174300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie1ecc04b333e4da4ac25243469cdb953_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMTUtMTMtMS0xLTc1MTQw_3a7293b2-d94c-4c8f-91f1-04e03d208aed"
      unitRef="usd">13833500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i763b233fe41d42f8aa4eb102c4f5c9e1_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMTUtMTUtMS0xLTc1MTQw_59ae222c-bf03-4b3a-9ecf-9aa7c947a672"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i763b233fe41d42f8aa4eb102c4f5c9e1_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMTUtMTctMS0xLTc1MTQw_67813a2e-02cd-455a-8887-b290bea08cde"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2e4fb5422af74378bdf258c1594fe372_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMTUtMTktMS0xLTc1MTQw_508d4e76-5535-471f-a314-3c9bf2ba664e"
      unitRef="usd">10682200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaad911ccb4124b46ace623b2c56be18b_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMTUtMjEtMS0xLTc1MTQw_70335091-4a30-4c28-9a02-e4cdd00e02b3"
      unitRef="usd">-19000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8239e2124c804a2ea880e06ae55914e8_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8zNC9mcmFnOmNhY2MxZmYyY2NmNjQyMzdhMzhkZjA3NDY5MmFkMDk0L3RhYmxlOmE2YjFmYjQxY2YzZDQ1NTVhNmI1ZTYyNGQ0NDZmNTBiL3RhYmxlcmFuZ2U6YTZiMWZiNDFjZjNkNDU1NWE2YjVlNjI0ZDQ0NmY1MGJfMTUtMjMtMS0xLTc1MTQw_19aad92f-b5bf-4c29-8935-cbbfb73c8749"
      unitRef="usd">10663200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80MC9mcmFnOjExMzk3NzJmZWM1MjQ0MTNhZGU3YjY3NzQ2MTk5OGQyL3RleHRyZWdpb246MTEzOTc3MmZlYzUyNDQxM2FkZTdiNjc3NDYxOTk4ZDJfODA4Mw_e7d6cc37-e126-4a9c-b1f4-ccfbc2e9ab70">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. We have a leading portfolio of medicines to treat multiple sclerosis (MS), have introduced the first approved treatment for spinal muscular atrophy (SMA) and are providing the first and only approved treatment to address a defining pathology of Alzheimer's disease. We also commercialize biosimilars of advanced biologics and focus on advancing our pipeline in neuroscience and specialized immunology. Lastly, we are focused on accelerating our efforts in digital health to support our commercial and pipeline programs while also creating opportunities for potential digital therapeutics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS); and other potential anti-CD20 therapies, including mosunetuzumab, pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our audited consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended December 31, 2021 (2021 Form&#160;10-K).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through our collaboration with Samsung Bioepis Co., Ltd. (Samsung Bioepis) we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe. We have also secured the exclusive rights to commercialize BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS, which was approved in the U.S., the European Union (E.U.) and the United Kingdom (U.K.) during the third quarter of 2021. For additional information on our collaboration arrangements with Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 16, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these unaudited condensed consolidated financial statements (condensed consolidated financial statements). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2021 Form&#160;10-K. Our accounting policies are described in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Notes to Consolidated Financial Statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our 2021 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three months ended March 31, 2022, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate as one operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100.0% of the economics, we record net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including sales, expense, reserves and allowances, the supply chain, manufacturing, clinical trials, research and development costs and employee-related costs, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets. Additionally, the ongoing geopolitical tensions related to Russia's invasion of Ukraine, and the related sanctions and other penalties imposed, are creating substantial uncertainty in the global economy. The extent and duration of the conflict, sanctions and resulting market disruptions are highly unpredictable. We have made estimates of the impact of the COVID-19 pandemic and the ongoing geopolitical conflict within our condensed consolidated financial statements and there may be changes to those estimates in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;New Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that we adopt as of the specified effective date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not believe that the adoption of recently issued standards have had or may have a material impact on our condensed consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <biib:BusinessOverviewPolicyTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80MC9mcmFnOjExMzk3NzJmZWM1MjQ0MTNhZGU3YjY3NzQ2MTk5OGQyL3RleHRyZWdpb246MTEzOTc3MmZlYzUyNDQxM2FkZTdiNjc3NDYxOTk4ZDJfODEwMw_796a99f0-2867-4e17-9f1f-c8f722bf61d5">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. We have a leading portfolio of medicines to treat multiple sclerosis (MS), have introduced the first approved treatment for spinal muscular atrophy (SMA) and are providing the first and only approved treatment to address a defining pathology of Alzheimer's disease. We also commercialize biosimilars of advanced biologics and focus on advancing our pipeline in neuroscience and specialized immunology. Lastly, we are focused on accelerating our efforts in digital health to support our commercial and pipeline programs while also creating opportunities for potential digital therapeutics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS); and other potential anti-CD20 therapies, including mosunetuzumab, pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our audited consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended December 31, 2021 (2021 Form&#160;10-K).&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through our collaboration with Samsung Bioepis Co., Ltd. (Samsung Bioepis) we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe. We have also secured the exclusive rights to commercialize BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS, which was approved in the U.S., the European Union (E.U.) and the United Kingdom (U.K.) during the third quarter of 2021. For additional information on our collaboration arrangements with Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 16, Collaborative and Other Relationships,&lt;/span&gt; to these unaudited condensed consolidated financial statements (condensed consolidated financial statements).</biib:BusinessOverviewPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80MC9mcmFnOjExMzk3NzJmZWM1MjQ0MTNhZGU3YjY3NzQ2MTk5OGQyL3RleHRyZWdpb246MTEzOTc3MmZlYzUyNDQxM2FkZTdiNjc3NDYxOTk4ZDJfODA4OQ_add1087f-d5d5-4b24-8971-3a5b198feeee">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2021 Form&#160;10-K. Our accounting policies are described in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Notes to Consolidated Financial Statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our 2021 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three months ended March 31, 2022, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate as one operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80MC9mcmFnOjExMzk3NzJmZWM1MjQ0MTNhZGU3YjY3NzQ2MTk5OGQyL3RleHRyZWdpb246MTEzOTc3MmZlYzUyNDQxM2FkZTdiNjc3NDYxOTk4ZDJfNDA0Ng_7cad88b5-e533-40ce-8216-5359a7ac2edf"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80MC9mcmFnOjExMzk3NzJmZWM1MjQ0MTNhZGU3YjY3NzQ2MTk5OGQyL3RleHRyZWdpb246MTEzOTc3MmZlYzUyNDQxM2FkZTdiNjc3NDYxOTk4ZDJfODA3MA_dd23339a-b18d-4c5f-80b8-be927dae88e6">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100.0% of the economics, we record net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <biib:InterestInSubsidiary
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80MC9mcmFnOjExMzk3NzJmZWM1MjQ0MTNhZGU3YjY3NzQ2MTk5OGQyL3RleHRyZWdpb246MTEzOTc3MmZlYzUyNDQxM2FkZTdiNjc3NDYxOTk4ZDJfNDU1Ng_036c4327-c66a-43cb-94f1-8597a3c0fc09"
      unitRef="number">1.000</biib:InterestInSubsidiary>
    <us-gaap:UseOfEstimates
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80MC9mcmFnOjExMzk3NzJmZWM1MjQ0MTNhZGU3YjY3NzQ2MTk5OGQyL3RleHRyZWdpb246MTEzOTc3MmZlYzUyNDQxM2FkZTdiNjc3NDYxOTk4ZDJfODEwMg_6c4613f7-817b-4fac-9934-7df3b68f7a7d">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including sales, expense, reserves and allowances, the supply chain, manufacturing, clinical trials, research and development costs and employee-related costs, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets. Additionally, the ongoing geopolitical tensions related to Russia's invasion of Ukraine, and the related sanctions and other penalties imposed, are creating substantial uncertainty in the global economy. The extent and duration of the conflict, sanctions and resulting market disruptions are highly unpredictable. We have made estimates of the impact of the COVID-19 pandemic and the ongoing geopolitical conflict within our condensed consolidated financial statements and there may be changes to those estimates in future periods.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80MC9mcmFnOjExMzk3NzJmZWM1MjQ0MTNhZGU3YjY3NzQ2MTk5OGQyL3RleHRyZWdpb246MTEzOTc3MmZlYzUyNDQxM2FkZTdiNjc3NDYxOTk4ZDJfODA4Ng_4c53dc7e-1380-4989-ae26-7e5a1105f16a">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that we adopt as of the specified effective date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not believe that the adoption of recently issued standards have had or may have a material impact on our condensed consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80OS9mcmFnOjE1NzM2OWY1MWM3OTRkMGI4N2Y2MjZhYWZkNTVjYjc1L3RleHRyZWdpb246MTU3MzY5ZjUxYzc5NGQwYjg3ZjYyNmFhZmQ1NWNiNzVfMTMxOTQxMzk1NDY5NjM_cd90bf51-6bc6-4a16-a64c-88c2e7b11c91">RESTRUCTURING, BUSINESS TRANSFORMATION AND OTHER COST SAVING INITIATIVES &lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2022 Cost Saving Initiatives&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2021 and May 2022 we announced our plans to implement a series of cost-reduction measures during 2022. These savings are expected to be achieved through a number of initiatives, including reductions to our workforce, primarily within our global Alzheimer's infrastructure, the consolidation of certain real estate locations and operating efficiency gains across our selling, general and administrative and research and development functions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under these initiatives, we expect to incur restructuring charges ranging from approximately $100.0&#160;million to $150.0&#160;million. These amounts are primarily related to severance and are expected to be substantially incurred and paid by the end of 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March 31, 2022, we recognized $27.7&#160;million of employee related costs, primarily related to severance. These costs were recorded in restructuring charges in our condensed consolidated statements of income. Our restructuring reserve is included in accrued expense and other in our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following an evaluation of our current capacity needs, in March 2022 we ceased using a patient services office space in Durham, North Carolina. We are marketing the space for sublease. Our decision to cease using the facility resulted in the immediate expense of certain leasehold improvements and other assets at this facility, which we do not believe can be adequately recovered in a sublease. As a result, for the three months ended March 31, 2022, we recognized approximately $10.4&#160;million of accelerated depreciation expense, which was recorded in restructuring charges in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the charges and spending related to our 2022 cost saving initiatives for the three months ended March 31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Workforce Reduction&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserve as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserve as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringCharges
      contextRef="i8c3728b044d743d0b57e33fc6e523b46_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80OS9mcmFnOjE1NzM2OWY1MWM3OTRkMGI4N2Y2MjZhYWZkNTVjYjc1L3RleHRyZWdpb246MTU3MzY5ZjUxYzc5NGQwYjg3ZjYyNmFhZmQ1NWNiNzVfMTA5OTUxMTY0MDMxMA_7757f36e-1765-477c-9ac4-fd5bc273bada"
      unitRef="usd">100000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i4afdc1a2dcdf424eabd0653274b690c7_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80OS9mcmFnOjE1NzM2OWY1MWM3OTRkMGI4N2Y2MjZhYWZkNTVjYjc1L3RleHRyZWdpb246MTU3MzY5ZjUxYzc5NGQwYjg3ZjYyNmFhZmQ1NWNiNzVfMTA5OTUxMTYzMTU4OA_5d273450-c405-446c-829b-c2ef58f66cc6"
      unitRef="usd">150000000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80OS9mcmFnOjE1NzM2OWY1MWM3OTRkMGI4N2Y2MjZhYWZkNTVjYjc1L3RleHRyZWdpb246MTU3MzY5ZjUxYzc5NGQwYjg3ZjYyNmFhZmQ1NWNiNzVfMTA5OTUxMTYzNjU5OQ_2c710b30-fdbd-439d-92d1-0718cace4812"
      unitRef="usd">27700000</us-gaap:SeveranceCosts1>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80OS9mcmFnOjE1NzM2OWY1MWM3OTRkMGI4N2Y2MjZhYWZkNTVjYjc1L3RleHRyZWdpb246MTU3MzY5ZjUxYzc5NGQwYjg3ZjYyNmFhZmQ1NWNiNzVfMTA5OTUxMTYzNzUwNQ_12834c9a-8f35-46a1-964e-850e14779284"
      unitRef="usd">10400000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80OS9mcmFnOjE1NzM2OWY1MWM3OTRkMGI4N2Y2MjZhYWZkNTVjYjc1L3RleHRyZWdpb246MTU3MzY5ZjUxYzc5NGQwYjg3ZjYyNmFhZmQ1NWNiNzVfMTMxOTQxMzk1NDY5NjI_2876449a-d4a4-4e85-93f9-8afc108559d7">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the charges and spending related to our 2022 cost saving initiatives for the three months ended March 31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Workforce Reduction&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserve as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserve as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="ic4b04ecc1818447ebb524096be801f20_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80OS9mcmFnOjE1NzM2OWY1MWM3OTRkMGI4N2Y2MjZhYWZkNTVjYjc1L3RhYmxlOmExNWU5MDgxYjRhNjQyYzJhZGUwNWEzNjZjOWQ1MThkL3RhYmxlcmFuZ2U6YTE1ZTkwODFiNGE2NDJjMmFkZTA1YTM2NmM5ZDUxOGRfMS0yLTEtMS05MTM3MA_163b9aaf-593d-4b96-802b-420f17dabc39"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ic4b04ecc1818447ebb524096be801f20_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80OS9mcmFnOjE1NzM2OWY1MWM3OTRkMGI4N2Y2MjZhYWZkNTVjYjc1L3RhYmxlOmExNWU5MDgxYjRhNjQyYzJhZGUwNWEzNjZjOWQ1MThkL3RhYmxlcmFuZ2U6YTE1ZTkwODFiNGE2NDJjMmFkZTA1YTM2NmM5ZDUxOGRfMS00LTEtMS0xMDUwMjc_4aa18866-3248-4b4c-8f50-80024000a3af"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges
      contextRef="i929ddd179174497bb90c576f4da728fd_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80OS9mcmFnOjE1NzM2OWY1MWM3OTRkMGI4N2Y2MjZhYWZkNTVjYjc1L3RhYmxlOmExNWU5MDgxYjRhNjQyYzJhZGUwNWEzNjZjOWQ1MThkL3RhYmxlcmFuZ2U6YTE1ZTkwODFiNGE2NDJjMmFkZTA1YTM2NmM5ZDUxOGRfMi0yLTEtMS05MTM3MA_5514dae4-7ecc-4239-a5ae-5686ec7fe363"
      unitRef="usd">27700000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i929ddd179174497bb90c576f4da728fd_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80OS9mcmFnOjE1NzM2OWY1MWM3OTRkMGI4N2Y2MjZhYWZkNTVjYjc1L3RhYmxlOmExNWU5MDgxYjRhNjQyYzJhZGUwNWEzNjZjOWQ1MThkL3RhYmxlcmFuZ2U6YTE1ZTkwODFiNGE2NDJjMmFkZTA1YTM2NmM5ZDUxOGRfMi00LTEtMS0xMDUwMjc_ea074121-b3b1-468e-a286-13e279f98fc2"
      unitRef="usd">27700000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring
      contextRef="i929ddd179174497bb90c576f4da728fd_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80OS9mcmFnOjE1NzM2OWY1MWM3OTRkMGI4N2Y2MjZhYWZkNTVjYjc1L3RhYmxlOmExNWU5MDgxYjRhNjQyYzJhZGUwNWEzNjZjOWQ1MThkL3RhYmxlcmFuZ2U6YTE1ZTkwODFiNGE2NDJjMmFkZTA1YTM2NmM5ZDUxOGRfMy0yLTEtMS05MTM3MA_4e784a52-630c-4700-8b5f-dcf2dbbe50a3"
      unitRef="usd">6200000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i929ddd179174497bb90c576f4da728fd_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80OS9mcmFnOjE1NzM2OWY1MWM3OTRkMGI4N2Y2MjZhYWZkNTVjYjc1L3RhYmxlOmExNWU5MDgxYjRhNjQyYzJhZGUwNWEzNjZjOWQ1MThkL3RhYmxlcmFuZ2U6YTE1ZTkwODFiNGE2NDJjMmFkZTA1YTM2NmM5ZDUxOGRfMy00LTEtMS0xMDUwMjc_73a3f8e5-c54a-4998-8002-6756e2eb5458"
      unitRef="usd">6200000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve
      contextRef="i60bd213e6b2f4cef984449f784cce8aa_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80OS9mcmFnOjE1NzM2OWY1MWM3OTRkMGI4N2Y2MjZhYWZkNTVjYjc1L3RhYmxlOmExNWU5MDgxYjRhNjQyYzJhZGUwNWEzNjZjOWQ1MThkL3RhYmxlcmFuZ2U6YTE1ZTkwODFiNGE2NDJjMmFkZTA1YTM2NmM5ZDUxOGRfNS0yLTEtMS0xMDUwMjQ_96844c9b-fd58-4384-90b9-455cbbbe9cb0"
      unitRef="usd">21500000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i60bd213e6b2f4cef984449f784cce8aa_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl80OS9mcmFnOjE1NzM2OWY1MWM3OTRkMGI4N2Y2MjZhYWZkNTVjYjc1L3RhYmxlOmExNWU5MDgxYjRhNjQyYzJhZGUwNWEzNjZjOWQ1MThkL3RhYmxlcmFuZ2U6YTE1ZTkwODFiNGE2NDJjMmFkZTA1YTM2NmM5ZDUxOGRfNS00LTEtMS0xMDUwMjc_5275d055-192c-4836-9b83-39f678d7dd3e"
      unitRef="usd">21500000</us-gaap:RestructuringReserve>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RleHRyZWdpb246YTIyMjQwMjQ3OTQ4NGY5ZTg3OTE5ZmYwNTMwYWFmYjhfMjA0OQ_50370079-f5dd-4f1f-b9e2-346fc92c774b">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue by product is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Multiple Sclerosis (MS):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fumarate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;242.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;295.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;537.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;236.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;316.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;552.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interferon&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;182.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;309.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;241.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;158.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;400.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TYSABRI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;284.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;236.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;520.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;273.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;230.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;503.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FAMPYRA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: MS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;709.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;685.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,394.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;751.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;732.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,483.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Spinal Muscular Atrophy:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SPINRAZA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;163.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;309.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;472.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;371.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;520.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Alzheimer's disease:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;ADUHELM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biosimilars:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BENEPALI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IMRALDI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FLIXABI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Biosimilars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;194.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;194.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;205.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;205.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FUMADERM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;875.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,191.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,066.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;899.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,311.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,211.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Fumarate includes TECFIDERA and VUMERITY. VUMERITY became commercially available in the E.U. during the fourth quarter of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Interferon includes AVONEX and PLEGRIDY.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In June 2021 the U.S. Food and Drug Administration (FDA) granted accelerated approval of ADUHELM, which became commercially available in the U.S. during the second quarter of 2021. For additional information, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 16, Collaborative and Other Relationships - Eisai Co., Ltd. - ADUHELM Collaboration Agreement, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized revenue from two wholesalers accounting for 26.3% and 10.5% of gross product revenue for the three months ended March 31, 2022, and 30.0% and 9.3% of gross product revenue for the three months ended March 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;759.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;935.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current provisions relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;169.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;659.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;832.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(40.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(46.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/credits relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(101.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(271.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(373.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/credits relating to sales in prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(58.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(314.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(379.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;142.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;792.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;968.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reduction of accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;136.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;133.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Component of accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;831.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;802.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue-related reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;968.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;935.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue from Anti-CD20 Therapeutic Programs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from anti-CD20 therapeutic programs is summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen&#x2019;s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;143.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;174.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;OCREVUS and other revenue from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;256.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;214.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;399.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;389.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-right:2.25pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements with Genentech, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative and Other Relationships, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to our consolidated financial statements included in our 2021 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenue is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue from collaborative and other relationships:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue earned under our technical development agreement, manufacturing services agreements and royalty revenue on biosimilar products with Samsung Bioepis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other royalty and corporate revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;93.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We receive royalties from net sales on products related to patents that we have out-licensed and we record other corporate revenue primarily from amounts earned under contract manufacturing agreements.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RleHRyZWdpb246YTIyMjQwMjQ3OTQ4NGY5ZTg3OTE5ZmYwNTMwYWFmYjhfMjA1Ng_6536dd4d-2fdd-4629-a2a4-c0b500434138">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue by product is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Multiple Sclerosis (MS):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fumarate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;242.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;295.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;537.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;236.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;316.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;552.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interferon&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;182.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;309.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;241.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;158.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;400.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TYSABRI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;284.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;236.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;520.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;273.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;230.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;503.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FAMPYRA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: MS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;709.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;685.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,394.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;751.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;732.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,483.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Spinal Muscular Atrophy:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SPINRAZA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;163.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;309.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;472.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;371.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;520.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Alzheimer's disease:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;ADUHELM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biosimilars:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BENEPALI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IMRALDI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FLIXABI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Biosimilars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;194.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;194.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;205.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;205.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FUMADERM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;875.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,191.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,066.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;899.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,311.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,211.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Fumarate includes TECFIDERA and VUMERITY. VUMERITY became commercially available in the E.U. during the fourth quarter of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Interferon includes AVONEX and PLEGRIDY.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In June 2021 the U.S. Food and Drug Administration (FDA) granted accelerated approval of ADUHELM, which became commercially available in the U.S. during the second quarter of 2021. For additional information, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 16, Collaborative and Other Relationships - Eisai Co., Ltd. - ADUHELM Collaboration Agreement, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="i4019bfee1947475697fa8390601cf107_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfNC0yLTEtMS03NTE0MA_e23932ce-e38b-467c-be93-62bdb8e9ffd5"
      unitRef="usd">242300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2d56b6894b294cb3b2fbfc394c2be8f3_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfNC00LTEtMS03NTE0MA_69a524b8-efc0-4038-896c-7c5b6f1e9f65"
      unitRef="usd">295600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i45e6439716cb4f31b5a5f0feef64721a_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfNC02LTEtMS03NTE0MA_ee7fbfba-fffd-4b10-b9b9-e7e13a039a42"
      unitRef="usd">537900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia9ae9e65490748f2acefb5047af75a92_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfNC04LTEtMS03NTE0MA_ebaf91bb-8a9b-40a0-be23-4acffbeb8c63"
      unitRef="usd">236000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8085faadc8004a108e4be4098084c970_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfNC0xMC0xLTEtNzUxNDA_1428b2c2-f506-4d90-aa37-3caa4360eaf1"
      unitRef="usd">316900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i40537541890549888c403ef75418b3d7_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfNC0xMi0xLTEtNzUxNDA_6659c253-53d4-4abc-8146-a52a77b73aa2"
      unitRef="usd">552900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0f199ee2171447a5b18611c5c256d297_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfNS0yLTEtMS03NTE0MA_6b60328f-f9d9-4759-9c39-e47f6047cc2c"
      unitRef="usd">182300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i958877fcc74e4539915b329079fa6389_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfNS00LTEtMS03NTE0MA_fada9a83-8c4e-4655-952f-3467252bb274"
      unitRef="usd">127300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i757cf428860849798a536a290e69a744_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfNS02LTEtMS03NTE0MA_9fd3f65a-850d-49cc-ac3c-8c5be3e6a5d2"
      unitRef="usd">309600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i80aabd0ba40a4666859ae614cdd27a07_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfNS04LTEtMS03NTE0MA_fc152246-8862-4d5a-8a26-a2df644175e3"
      unitRef="usd">241800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5f4e5fdc87be405f92ffd881cb8662ce_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfNS0xMC0xLTEtNzUxNDA_94c5ff86-5b3b-423d-a1bd-a6fb10c85fe9"
      unitRef="usd">158700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie4c2e7acd9be4bfea25698309d8d8828_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfNS0xMi0xLTEtNzUxNDA_4d8a5e6b-ed64-462c-8545-af5f562d5552"
      unitRef="usd">400500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i487df1d2304e478d8603ddfb4616b0f6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfNi0yLTEtMS03NTE0MA_8d6d34b8-53e5-4a2a-afc3-5dbcb5e1e8ce"
      unitRef="usd">284500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icea6a5dee2a24c37ac79226e11fc7e81_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfNi00LTEtMS03NTE0MA_bb6057bc-0636-4721-96ea-96b24443ea89"
      unitRef="usd">236300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i49af7fbee4534ecc9b44e33e68ad9bac_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfNi02LTEtMS03NTE0MA_0efce265-e368-41ce-bda2-077bfa1fb204"
      unitRef="usd">520800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8b15c52761ae42e58d6abc7911f80917_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfNi04LTEtMS03NTE0MA_3c710fa6-df79-4c2f-a04e-a7caf6214b2a"
      unitRef="usd">273300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5540cfaf99944f5fa1f892083859fd1b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfNi0xMC0xLTEtNzUxNDA_6f86c958-2c53-41aa-9d7d-81b0a919233c"
      unitRef="usd">230000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia2efe312a1ed4c21bc651416d90150b4_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfNi0xMi0xLTEtNzUxNDA_4844d062-b3d5-4d06-89e3-c5261253412d"
      unitRef="usd">503300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if4cb5e1b131d44a689b572c1d03b1392_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfNy0yLTEtMS03NTE0MA_a9311108-16cc-4b8d-8bd9-bddd7276fde2"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9f8158b854de46d7949a3f0ff441a7c9_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfNy00LTEtMS03NTE0MA_d63460e3-11a5-442d-a499-45283e9b5dc5"
      unitRef="usd">26200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie44c413a93ec48a59784c0ea0623dded_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfNy02LTEtMS03NTE0MA_5a584146-bc31-425e-b7e3-fdd6f09f272b"
      unitRef="usd">26200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if54e432976f24dfa9de95d847fc16af1_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfNy04LTEtMS03NTE0MA_f961e95e-cf9e-4073-989b-25ca5913ecf9"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7331caa9ccd84bd5be10521a9f0d0481_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfNy0xMC0xLTEtNzUxNDA_f31eb4c2-740a-4564-8031-d017ce11c0f8"
      unitRef="usd">26600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3ec978dde6374ab7a39346cd84c5c36c_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfNy0xMi0xLTEtNzUxNDA_df9edc0d-6e17-409f-8336-0b54b695cc39"
      unitRef="usd">26600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie66c008431754250a1c7ad1581031751_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfOC0yLTEtMS03NTE0MA_885ad4ba-0e7d-43bb-b7c9-500fc3e65f11"
      unitRef="usd">709100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9d4fca69d176447480f070d481fc6e1d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfOC00LTEtMS03NTE0MA_44853856-0e96-4a4c-b8de-c8016cf6fc97"
      unitRef="usd">685400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i55f4f5b3d91e4c279119147eedb46915_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfOC02LTEtMS03NTE0MA_e87d69b6-49c5-455d-901a-17ceec3008f1"
      unitRef="usd">1394500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaf5d43d131c84980b40ac7f048729534_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfOC04LTEtMS03NTE0MA_fbc39eb2-f177-4452-87d0-3a685eaec869"
      unitRef="usd">751100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3a4ea8f03c0f42738c05eac690b20806_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfOC0xMC0xLTEtNzUxNDA_4fa4fe47-2616-41bc-b0fa-75b8fc2ba19a"
      unitRef="usd">732200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i60267e464f984999be2095717c97a319_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfOC0xMi0xLTEtNzUxNDA_46c2ff58-7695-4027-9a87-eaf6bbb03565"
      unitRef="usd">1483300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2c070dfe729642198b279735cad93c30_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTEtMi0xLTEtNzUxNDA_8d3f5992-3cab-46d4-ad37-e8ad866c7828"
      unitRef="usd">163300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i78c6eccdad234026bb1aeeb838de571d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTEtNC0xLTEtNzUxNDA_41f3c44d-7b01-4379-b57d-595be44d260d"
      unitRef="usd">309200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6828112d9c4f41f0bf08dd88efb7662e_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTEtNi0xLTEtNzUxNDA_ad6dde6e-faeb-42bc-9615-03ea26c56d90"
      unitRef="usd">472500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id1098dcaf54d41aca1af33ac1c235c78_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTEtOC0xLTEtNzUxNDA_f984507c-75ff-4f6b-8a8c-c4a5283900b7"
      unitRef="usd">148700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iceae2cc273d1444eae0aa9c381b2d61b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTEtMTAtMS0xLTc1MTQw_23204f4f-22a8-4f45-8239-25b3e76bd25d"
      unitRef="usd">371800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib8ac52ff6b5e42babf12a9c71a39395c_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTEtMTItMS0xLTc1MTQw_5d2a817f-170f-4f8a-aa1c-fe06c5caae30"
      unitRef="usd">520500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3f41e9d658b94408b5d6df1021553899_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTQtMi0xLTEtNzUxNDA_d0b66127-1707-4221-a1e9-b8d9236edbfd"
      unitRef="usd">2800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id06f574f06e14c8ba3b25d199ce88210_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTQtNC0xLTEtNzUxNDA_56c91f1b-c19b-4efd-9ab2-48c6e2ff8f0e"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i722a1d8416ce4b6b9e7ebbb4433afb51_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTQtNi0xLTEtNzUxNDA_ccb9eea1-6ffb-4d72-8d7b-69a505342331"
      unitRef="usd">2800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i816d25b468bc4d96aab34518cf3f4c6c_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTQtOC0xLTEtNzUxNDA_533df871-7777-4ddc-809b-a4acfd239703"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1004f5d220be40cd9e39fe595414dfaa_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTQtMTAtMS0xLTc1MTQw_6d0c3225-8e88-495f-9e3f-08368233c2b3"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i30b4707892bc4fec9b74d5cc51e6529e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTQtMTItMS0xLTc1MTQw_719596c1-4179-45c2-976a-982039b4c8b2"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if7921192dedf4f4a988ac6e9ce17c61b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTctMi0xLTEtNzUxNDA_fc68729d-47bf-43e8-b7a7-d4ee80b2f9b8"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if8e1bccba2b844138516eb1ac75d4fdf_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTctNC0xLTEtNzUxNDA_31a50909-1de5-4c2a-bb2e-a0ea12a61a37"
      unitRef="usd">114700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3e8b6707e4854fa388edc206ac7d95bd_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTctNi0xLTEtNzUxNDA_3a5c5977-1f9c-4fbf-975b-00e4031d03b5"
      unitRef="usd">114700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i670a74b23f5f4caea6103368f4c95973_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTctOC0xLTEtNzUxNDA_523d7ecd-b819-4d0d-8864-f49804ef2843"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if08c5715a87047d6916a728b0059e603_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTctMTAtMS0xLTc1MTQw_2eb96090-c471-462e-b62f-88c05ef46578"
      unitRef="usd">121700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id811739973f8445d958ab0cb2731f205_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTctMTItMS0xLTc1MTQw_cabf90d5-a05a-4c82-b1a8-8c45dae5ad8c"
      unitRef="usd">121700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8ed53a25b23d434ebf3a733a39cbbcb7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTgtMi0xLTEtNzUxNDA_b371f05b-ffb3-45b9-84fb-f832a9c53490"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i403756a186e6453a9c24141d0b5678f5_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTgtNC0xLTEtNzUxNDA_7afe5ae4-a991-4d79-91bd-8ef870a09365"
      unitRef="usd">57100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i534b8a9915d9400f837298b0f6d411f1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTgtNi0xLTEtNzUxNDA_89e9a356-cd0c-4e14-a8a7-b39dcfbe8381"
      unitRef="usd">57100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i66f6ed4993f14e3290ab6c4742235f3d_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTgtOC0xLTEtNzUxNDA_75e52fb3-9725-4797-897a-ff6044eb9904"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia6f7347790a54edbabf24343e2257691_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTgtMTAtMS0xLTc1MTQw_27f8bd7e-96d5-47de-a289-8200d7054111"
      unitRef="usd">57900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i68ba8dee324c40978fe4ee8211658faa_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTgtMTItMS0xLTc1MTQw_eaee56de-149b-45d7-8932-cdb2b14d588d"
      unitRef="usd">57900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic81d1b50ecdb40b391c62c6287303f8b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTktMi0xLTEtNzUxNDA_21e929d2-af26-4178-ad75-8a80b244baf1"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i32b306330d79453787a5388f0c9b87dd_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTktNC0xLTEtNzUxNDA_abd94eca-cf66-4f63-85ee-5981f49e8760"
      unitRef="usd">22500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i61d231d430914084bd5b37c094531f73_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTktNi0xLTEtNzUxNDA_797263fa-4031-4bf2-87ed-22863db4f5aa"
      unitRef="usd">22500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic570d7e37f3246c9a7c17df8eb70bf29_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTktOC0xLTEtNzUxNDA_df26a5c0-b501-402a-8fde-f142bdbed3f4"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7cb87c336f514d67ab337ffa3b0d63a2_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTktMTAtMS0xLTc1MTQw_f2ca52af-404f-4eb2-8dc3-55cc8cb16748"
      unitRef="usd">25500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1049089607294f30837a3ada694dc739_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMTktMTItMS0xLTc1MTQw_4da4ff3b-d841-4075-b822-ebedfb754d00"
      unitRef="usd">25500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0d04af7411eb4ffd942a725be50edb92_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMjAtMi0xLTEtNzUxNDA_cc9a9f2f-fefe-409e-b77a-2205b23096fd"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i15bc81eea1fc4013a923d18d25b1aee3_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMjAtNC0xLTEtNzUxNDA_4683fbdd-0130-4038-a901-ec5dbeefac07"
      unitRef="usd">194300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifaf74ee71f7f4592b819c8e204ed6c90_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMjAtNi0xLTEtNzUxNDA_be3aa97c-c4fd-4810-8e29-a1aca89bb46f"
      unitRef="usd">194300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i36dbeb0ba18e4a5b94216f5fdfb3a00a_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMjAtOC0xLTEtNzUxNDA_de261273-e4fe-48ee-8c38-29b3cca8b10c"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i057f89827dbc42819caa6b53dc6ff8c7_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMjAtMTAtMS0xLTc1MTQw_d33f5dbf-b517-46b0-a884-75586d5abe3f"
      unitRef="usd">205100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic026373e31634ffb9f84acb0c02d47ac_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMjAtMTItMS0xLTc1MTQw_6f4724e9-1b78-4f4f-be8d-0482d35bdbd1"
      unitRef="usd">205100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2ae65a6ea2994e1da2df20adab69bd79_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMjMtMi0xLTEtNzUxNDA_37eec983-a069-4832-b468-cce2b02c9227"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2f713481ad2048ecae97763950260fd1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMjMtNC0xLTEtNzUxNDA_1521ddb9-2955-4bec-a54b-1578133d99b1"
      unitRef="usd">2200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iee11fd74051f4269a45be312fa23f68f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMjMtNi0xLTEtNzUxNDA_43cb533b-4d83-40eb-bdb9-57682c0aa15a"
      unitRef="usd">2200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i98bd7ced87284d89af6b6ae7d70f8d7d_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMjMtOC0xLTEtNzUxNDA_74bc531d-7a62-4c08-966c-57fc29fe3240"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i782884b4f8aa48df9e97e2cb2755409f_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMjMtMTAtMS0xLTc1MTQw_3123852a-7887-48e2-9876-3eb6e1d8775d"
      unitRef="usd">2800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9e33621ceef64fc2ad12d006a54bc1b8_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMjMtMTItMS0xLTc1MTQw_5ebb2dd9-d256-4187-9803-15bfbc31ac6a"
      unitRef="usd">2800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i56fe223e37e040f490923df9b519d2a6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMjQtMi0xLTEtNzUxNDA_7bd75a5e-f9b8-4365-ae0a-54638609e9ab"
      unitRef="usd">875200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibbd8a4f5465946c0aa38c26ef4752572_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMjQtNC0xLTEtNzUxNDA_14819aad-1213-494a-8947-aa6947940284"
      unitRef="usd">1191100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i70fc67330ce0470db37abf6a0dc4fb6a_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMjQtNi0xLTEtNzUxNDA_6a739c72-f5bc-4219-a8a9-664684ce2e49"
      unitRef="usd">2066300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifeeb3b4588f74e0586c4e89af4306f7b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMjQtOC0xLTEtNzUxNDA_f5617f0c-d458-4dd4-8d09-101027d71036"
      unitRef="usd">899800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if7ae353a26bd4fff8785a4632e4afbfa_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMjQtMTAtMS0xLTc1MTQw_fb129bb6-43be-40f7-b6b2-d7249570ed13"
      unitRef="usd">1311900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i22a0a13c266f4d788d5ba6423911ebd9_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmQzMmU3OTRmMzA4YzRhYTU5NDliNTcwNTIwMDUxOTg5L3RhYmxlcmFuZ2U6ZDMyZTc5NGYzMDhjNGFhNTk0OWI1NzA1MjAwNTE5ODlfMjQtMTItMS0xLTc1MTQw_5022e5a6-c3d8-4d22-8794-19c192c2b971"
      unitRef="usd">2211700000</us-gaap:Revenues>
    <biib:NumberOfWholesalers
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RleHRyZWdpb246YTIyMjQwMjQ3OTQ4NGY5ZTg3OTE5ZmYwNTMwYWFmYjhfNzc0_6896be53-2a2c-4e25-a48c-8e55869bd7c5"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:NumberOfWholesalers
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RleHRyZWdpb246YTIyMjQwMjQ3OTQ4NGY5ZTg3OTE5ZmYwNTMwYWFmYjhfNzc0_d1d00e1d-2220-4b94-a544-0af680e7c8ab"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="i03f9978c12b14dfc8ee889cdf2bdb6f0_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RleHRyZWdpb246YTIyMjQwMjQ3OTQ4NGY5ZTg3OTE5ZmYwNTMwYWFmYjhfODA0_19ebe6a7-8048-40a8-983b-4cc08a4a5d25"
      unitRef="number">0.263</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="i7d6f800c7c994872a26f2506f98306ad_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RleHRyZWdpb246YTIyMjQwMjQ3OTQ4NGY5ZTg3OTE5ZmYwNTMwYWFmYjhfODEx_b367c0ab-c0c6-42db-8004-378f572c9009"
      unitRef="number">0.105</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="i94c39b003aff4990a1610f96586f03dd_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RleHRyZWdpb246YTIyMjQwMjQ3OTQ4NGY5ZTg3OTE5ZmYwNTMwYWFmYjhfMTA5OTUxMTYzMDExNw_f5e6af32-46b1-42af-8c79-b7fe66faaf08"
      unitRef="number">0.300</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="ic5db3734293a4e20858f95205c4aac6c_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RleHRyZWdpb246YTIyMjQwMjQ3OTQ4NGY5ZTg3OTE5ZmYwNTMwYWFmYjhfMTA5OTUxMTYzMDEyMQ_0a7a3bf1-cc60-4000-b4d3-38e6e6787102"
      unitRef="number">0.093</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RleHRyZWdpb246YTIyMjQwMjQ3OTQ4NGY5ZTg3OTE5ZmYwNTMwYWFmYjhfMjA0NA_7d2cd41d-91ef-4b99-b98b-75dd6e6d4f9a">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;759.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;935.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current provisions relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;169.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;659.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;832.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(40.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(46.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/credits relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(101.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(271.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(373.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/credits relating to sales in prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(58.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(314.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(379.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;142.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;792.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;968.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i724aaa93e18442fc9a55e613a9dda9bd_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjk0Yzk5NGIyN2ZjZTQwNWVhODU0NjA5MmYyYWE0ZDJlL3RhYmxlcmFuZ2U6OTRjOTk0YjI3ZmNlNDA1ZWE4NTQ2MDkyZjJhYTRkMmVfMS0yLTEtMS03NTE0MA_1574063e-35ab-4760-8915-19c714668a83"
      unitRef="usd">137700000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i67b699450f32425283dbf73b59e9a343_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjk0Yzk5NGIyN2ZjZTQwNWVhODU0NjA5MmYyYWE0ZDJlL3RhYmxlcmFuZ2U6OTRjOTk0YjI3ZmNlNDA1ZWE4NTQ2MDkyZjJhYTRkMmVfMS00LTEtMS03NTE0MA_4c06ca6d-fca0-458e-9b9f-b59654270504"
      unitRef="usd">759600000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i0c857804af6a41aeb371a364d6599e30_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjk0Yzk5NGIyN2ZjZTQwNWVhODU0NjA5MmYyYWE0ZDJlL3RhYmxlcmFuZ2U6OTRjOTk0YjI3ZmNlNDA1ZWE4NTQ2MDkyZjJhYTRkMmVfMS02LTEtMS03NTE0MA_2c6632f1-3e1a-41ec-8ede-d09c0b9713ab"
      unitRef="usd">38000000.0</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjk0Yzk5NGIyN2ZjZTQwNWVhODU0NjA5MmYyYWE0ZDJlL3RhYmxlcmFuZ2U6OTRjOTk0YjI3ZmNlNDA1ZWE4NTQ2MDkyZjJhYTRkMmVfMS04LTEtMS03NTE0MA_5be7fd09-a242-460a-91b7-7a35cd341c36"
      unitRef="usd">935300000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="i29cfc0f0c2944f219a39cbd064853d72_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjk0Yzk5NGIyN2ZjZTQwNWVhODU0NjA5MmYyYWE0ZDJlL3RhYmxlcmFuZ2U6OTRjOTk0YjI3ZmNlNDA1ZWE4NTQ2MDkyZjJhYTRkMmVfMi0yLTEtMS03NTE0MA_0869fb6d-b606-46cb-8320-67fde057bcb6"
      unitRef="usd">169000000.0</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="i9f9240206d2e4fdfa0bf34f005ce7fdc_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjk0Yzk5NGIyN2ZjZTQwNWVhODU0NjA5MmYyYWE0ZDJlL3RhYmxlcmFuZ2U6OTRjOTk0YjI3ZmNlNDA1ZWE4NTQ2MDkyZjJhYTRkMmVfMi00LTEtMS03NTE0MA_b2ad1e2e-2627-4f10-badd-f2c02a5c1579"
      unitRef="usd">659500000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="i0962864d41e04b9897a3e8d3c6267a4e_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjk0Yzk5NGIyN2ZjZTQwNWVhODU0NjA5MmYyYWE0ZDJlL3RhYmxlcmFuZ2U6OTRjOTk0YjI3ZmNlNDA1ZWE4NTQ2MDkyZjJhYTRkMmVfMi02LTEtMS03NTE0MA_c21aa08a-1c2d-4930-bb5e-e5ec4867fa9c"
      unitRef="usd">4000000.0</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjk0Yzk5NGIyN2ZjZTQwNWVhODU0NjA5MmYyYWE0ZDJlL3RhYmxlcmFuZ2U6OTRjOTk0YjI3ZmNlNDA1ZWE4NTQ2MDkyZjJhYTRkMmVfMi04LTEtMS03NTE0MA_8b41c8a1-be05-4354-a421-378269d626c2"
      unitRef="usd">832500000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="i29cfc0f0c2944f219a39cbd064853d72_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjk0Yzk5NGIyN2ZjZTQwNWVhODU0NjA5MmYyYWE0ZDJlL3RhYmxlcmFuZ2U6OTRjOTk0YjI3ZmNlNDA1ZWE4NTQ2MDkyZjJhYTRkMmVfMy0yLTEtMS03NTE0MA_8c46bc57-68d6-4c32-9d53-b5389f2d8759"
      unitRef="usd">3900000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="i9f9240206d2e4fdfa0bf34f005ce7fdc_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjk0Yzk5NGIyN2ZjZTQwNWVhODU0NjA5MmYyYWE0ZDJlL3RhYmxlcmFuZ2U6OTRjOTk0YjI3ZmNlNDA1ZWE4NTQ2MDkyZjJhYTRkMmVfMy00LTEtMS03NTE0MA_37b17000-9296-47a7-b62e-c83da8a4da21"
      unitRef="usd">40200000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="i0962864d41e04b9897a3e8d3c6267a4e_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjk0Yzk5NGIyN2ZjZTQwNWVhODU0NjA5MmYyYWE0ZDJlL3RhYmxlcmFuZ2U6OTRjOTk0YjI3ZmNlNDA1ZWE4NTQ2MDkyZjJhYTRkMmVfMy02LTEtMS03NTE0MA_49fadcd1-fb9c-4383-aad3-1e15c4b409a1"
      unitRef="usd">2500000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjk0Yzk5NGIyN2ZjZTQwNWVhODU0NjA5MmYyYWE0ZDJlL3RhYmxlcmFuZ2U6OTRjOTk0YjI3ZmNlNDA1ZWE4NTQ2MDkyZjJhYTRkMmVfMy04LTEtMS03NTE0MA_33bc0b6f-212b-4cf2-b26f-5e2286c3e15d"
      unitRef="usd">46600000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="i29cfc0f0c2944f219a39cbd064853d72_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjk0Yzk5NGIyN2ZjZTQwNWVhODU0NjA5MmYyYWE0ZDJlL3RhYmxlcmFuZ2U6OTRjOTk0YjI3ZmNlNDA1ZWE4NTQ2MDkyZjJhYTRkMmVfNC0yLTEtMS03NTE0MA_b0dca2ba-716b-4b76-81fc-4311fffe0b70"
      unitRef="usd">101200000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="i9f9240206d2e4fdfa0bf34f005ce7fdc_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjk0Yzk5NGIyN2ZjZTQwNWVhODU0NjA5MmYyYWE0ZDJlL3RhYmxlcmFuZ2U6OTRjOTk0YjI3ZmNlNDA1ZWE4NTQ2MDkyZjJhYTRkMmVfNC00LTEtMS03NTE0MA_8bda8452-f0fd-4f82-b101-c82c22a5e8f5"
      unitRef="usd">271600000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="i0962864d41e04b9897a3e8d3c6267a4e_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjk0Yzk5NGIyN2ZjZTQwNWVhODU0NjA5MmYyYWE0ZDJlL3RhYmxlcmFuZ2U6OTRjOTk0YjI3ZmNlNDA1ZWE4NTQ2MDkyZjJhYTRkMmVfNC02LTEtMS03NTE0MA_d52b3e7c-5762-4896-9299-b8c0f01f39a6"
      unitRef="usd">500000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjk0Yzk5NGIyN2ZjZTQwNWVhODU0NjA5MmYyYWE0ZDJlL3RhYmxlcmFuZ2U6OTRjOTk0YjI3ZmNlNDA1ZWE4NTQ2MDkyZjJhYTRkMmVfNC04LTEtMS03NTE0MA_a206c8e7-7ecb-4da1-a811-8518f6f71494"
      unitRef="usd">373300000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="i29cfc0f0c2944f219a39cbd064853d72_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjk0Yzk5NGIyN2ZjZTQwNWVhODU0NjA5MmYyYWE0ZDJlL3RhYmxlcmFuZ2U6OTRjOTk0YjI3ZmNlNDA1ZWE4NTQ2MDkyZjJhYTRkMmVfNS0yLTEtMS03NTE0MA_7fdfa4c9-037c-44cb-b974-80251aa78ec4"
      unitRef="usd">58900000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="i9f9240206d2e4fdfa0bf34f005ce7fdc_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjk0Yzk5NGIyN2ZjZTQwNWVhODU0NjA5MmYyYWE0ZDJlL3RhYmxlcmFuZ2U6OTRjOTk0YjI3ZmNlNDA1ZWE4NTQ2MDkyZjJhYTRkMmVfNS00LTEtMS03NTE0MA_49feda2e-595f-47d0-9751-0182d5ad3ef2"
      unitRef="usd">314500000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="i0962864d41e04b9897a3e8d3c6267a4e_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjk0Yzk5NGIyN2ZjZTQwNWVhODU0NjA5MmYyYWE0ZDJlL3RhYmxlcmFuZ2U6OTRjOTk0YjI3ZmNlNDA1ZWE4NTQ2MDkyZjJhYTRkMmVfNS02LTEtMS03NTE0MA_2404d193-6ae4-4f46-acdc-6e55d59d6420"
      unitRef="usd">6500000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjk0Yzk5NGIyN2ZjZTQwNWVhODU0NjA5MmYyYWE0ZDJlL3RhYmxlcmFuZ2U6OTRjOTk0YjI3ZmNlNDA1ZWE4NTQ2MDkyZjJhYTRkMmVfNS04LTEtMS03NTE0MA_509a0a7d-215d-458d-b4fe-f0bb639f70e7"
      unitRef="usd">379900000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i06abbb84d032422fb1a3f75785252f65_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjk0Yzk5NGIyN2ZjZTQwNWVhODU0NjA5MmYyYWE0ZDJlL3RhYmxlcmFuZ2U6OTRjOTk0YjI3ZmNlNDA1ZWE4NTQ2MDkyZjJhYTRkMmVfNi0yLTEtMS03NTE0MA_6cc5b693-209a-4629-b499-b134a014a51e"
      unitRef="usd">142700000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ifc6e75dd023146aeb4a6678f69c4242c_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjk0Yzk5NGIyN2ZjZTQwNWVhODU0NjA5MmYyYWE0ZDJlL3RhYmxlcmFuZ2U6OTRjOTk0YjI3ZmNlNDA1ZWE4NTQ2MDkyZjJhYTRkMmVfNi00LTEtMS03NTE0MA_ba73fdef-3e45-4bf8-b67f-606e7f84e4ee"
      unitRef="usd">792800000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ia76f9cf51eab4d948a5698ec20d971c9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjk0Yzk5NGIyN2ZjZTQwNWVhODU0NjA5MmYyYWE0ZDJlL3RhYmxlcmFuZ2U6OTRjOTk0YjI3ZmNlNDA1ZWE4NTQ2MDkyZjJhYTRkMmVfNi02LTEtMS03NTE0MA_b513b16a-063f-4e2f-8e7b-535645c58a7b"
      unitRef="usd">32500000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjk0Yzk5NGIyN2ZjZTQwNWVhODU0NjA5MmYyYWE0ZDJlL3RhYmxlcmFuZ2U6OTRjOTk0YjI3ZmNlNDA1ZWE4NTQ2MDkyZjJhYTRkMmVfNi04LTEtMS03NTE0MA_3ac355fb-972c-45f7-9d42-d904ecd70ee5"
      unitRef="usd">968000000.0</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RleHRyZWdpb246YTIyMjQwMjQ3OTQ4NGY5ZTg3OTE5ZmYwNTMwYWFmYjhfMjAzNw_1da6d036-2a49-4a87-9e4a-af2d08aa5d84">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reduction of accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;136.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;133.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Component of accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;831.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;802.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue-related reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;968.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;935.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="id33287c4ca8e4b7c9960bc9a3c2091e4_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjA1OTkyMTkzNTliODQ3ODQ4MGI2NWNiYTFhZGUxMWRkL3RhYmxlcmFuZ2U6MDU5OTIxOTM1OWI4NDc4NDgwYjY1Y2JhMWFkZTExZGRfMS0yLTEtMS03NTE0MA_1cd35601-e37c-4903-a958-2014d1810892"
      unitRef="usd">136900000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="iaac99eb6afb34c03b2e78fd08137df46_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjA1OTkyMTkzNTliODQ3ODQ4MGI2NWNiYTFhZGUxMWRkL3RhYmxlcmFuZ2U6MDU5OTIxOTM1OWI4NDc4NDgwYjY1Y2JhMWFkZTExZGRfMS00LTEtMS03NTE0MA_54ed180b-cd05-4316-b71d-ffb0058f6de0"
      unitRef="usd">133200000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i0bdcfb675756479fa2aa02a4f8a3a6ce_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjA1OTkyMTkzNTliODQ3ODQ4MGI2NWNiYTFhZGUxMWRkL3RhYmxlcmFuZ2U6MDU5OTIxOTM1OWI4NDc4NDgwYjY1Y2JhMWFkZTExZGRfMi0yLTEtMS03NTE0MA_2f2b96cb-0138-4e84-8b4f-4487a0ff00a5"
      unitRef="usd">831100000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i3d7e46af1def46ae846f93734361fcc5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjA1OTkyMTkzNTliODQ3ODQ4MGI2NWNiYTFhZGUxMWRkL3RhYmxlcmFuZ2U6MDU5OTIxOTM1OWI4NDc4NDgwYjY1Y2JhMWFkZTExZGRfMi00LTEtMS03NTE0MA_6203e8ed-01e8-473b-ac8b-2461654103e5"
      unitRef="usd">802100000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjA1OTkyMTkzNTliODQ3ODQ4MGI2NWNiYTFhZGUxMWRkL3RhYmxlcmFuZ2U6MDU5OTIxOTM1OWI4NDc4NDgwYjY1Y2JhMWFkZTExZGRfMy0yLTEtMS03NTE0MA_d28e6c10-3e37-4986-8254-2fcff1a338b4"
      unitRef="usd">968000000.0</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjA1OTkyMTkzNTliODQ3ODQ4MGI2NWNiYTFhZGUxMWRkL3RhYmxlcmFuZ2U6MDU5OTIxOTM1OWI4NDc4NDgwYjY1Y2JhMWFkZTExZGRfMy00LTEtMS03NTE0MA_64bb30b5-70bf-48f6-8058-e610fc0db8a5"
      unitRef="usd">935300000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RleHRyZWdpb246YTIyMjQwMjQ3OTQ4NGY5ZTg3OTE5ZmYwNTMwYWFmYjhfMjA2NA_03aa0596-4092-4d7f-933e-a37640c1ef63">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from anti-CD20 therapeutic programs is summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen&#x2019;s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;143.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;174.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;OCREVUS and other revenue from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;256.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;214.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;399.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;389.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock>
    <biib:ShareOfCoPromotionProfits
      contextRef="iddf807d85db941d0a2233de6ebb901c4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjRjOGM3NDdhNmE4MjQ2ODRiZGJkYTAwYmEzMzUyNWFiL3RhYmxlcmFuZ2U6NGM4Yzc0N2E2YTgyNDY4NGJkYmRhMDBiYTMzNTI1YWJfMi0yLTEtMS03NTE0MA_7e92ddc4-467f-436d-a266-b729eba89b90"
      unitRef="usd">143200000</biib:ShareOfCoPromotionProfits>
    <biib:ShareOfCoPromotionProfits
      contextRef="i7a4a7cbdeb574c34acd8f0fd4451328e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjRjOGM3NDdhNmE4MjQ2ODRiZGJkYTAwYmEzMzUyNWFiL3RhYmxlcmFuZ2U6NGM4Yzc0N2E2YTgyNDY4NGJkYmRhMDBiYTMzNTI1YWJfMi00LTEtMS03NTE0MA_d04ebf87-7bdd-48d0-9e5c-ec4542038df5"
      unitRef="usd">174100000</biib:ShareOfCoPromotionProfits>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms
      contextRef="iddf807d85db941d0a2233de6ebb901c4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjRjOGM3NDdhNmE4MjQ2ODRiZGJkYTAwYmEzMzUyNWFiL3RhYmxlcmFuZ2U6NGM4Yzc0N2E2YTgyNDY4NGJkYmRhMDBiYTMzNTI1YWJfMy0yLTEtMS03NTE0MA_f94cada1-a071-4dcf-bf2e-ea8d0cd4936b"
      unitRef="usd">256200000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms
      contextRef="i7a4a7cbdeb574c34acd8f0fd4451328e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjRjOGM3NDdhNmE4MjQ2ODRiZGJkYTAwYmEzMzUyNWFiL3RhYmxlcmFuZ2U6NGM4Yzc0N2E2YTgyNDY4NGJkYmRhMDBiYTMzNTI1YWJfMy00LTEtMS03NTE0MA_3300019c-aefd-4b5c-9221-44687b5e043d"
      unitRef="usd">214900000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <us-gaap:Revenues
      contextRef="ia5e84907dfd54cd09fdf7dc476b17545_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjRjOGM3NDdhNmE4MjQ2ODRiZGJkYTAwYmEzMzUyNWFiL3RhYmxlcmFuZ2U6NGM4Yzc0N2E2YTgyNDY4NGJkYmRhMDBiYTMzNTI1YWJfNC0yLTEtMS03NTE0MA_a3e3c348-9721-4f10-80b2-bdc63c1368d0"
      unitRef="usd">399400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if6b11452af4d4ae0bf50278351f22899_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOjRjOGM3NDdhNmE4MjQ2ODRiZGJkYTAwYmEzMzUyNWFiL3RhYmxlcmFuZ2U6NGM4Yzc0N2E2YTgyNDY4NGJkYmRhMDBiYTMzNTI1YWJfNC00LTEtMS03NTE0MA_67c2e6e2-3bdc-49e1-8907-3a3fb6c610dc"
      unitRef="usd">389000000.0</us-gaap:Revenues>
    <biib:OtherrevenuesTableTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RleHRyZWdpb246YTIyMjQwMjQ3OTQ4NGY5ZTg3OTE5ZmYwNTMwYWFmYjhfMjA2MQ_9dad7099-0ba0-4a60-be5f-2294df024e7a">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenue is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue from collaborative and other relationships:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue earned under our technical development agreement, manufacturing services agreements and royalty revenue on biosimilar products with Samsung Bioepis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other royalty and corporate revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;93.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:OtherrevenuesTableTextBlock>
    <us-gaap:Revenues
      contextRef="i35f562ab50824cc2bc7a3c789fec1b1c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmJjYzA4ZmEwMzA2YzQ5Yjc5NzEzYjNlYjljMDY4MmY0L3RhYmxlcmFuZ2U6YmNjMDhmYTAzMDZjNDliNzk3MTNiM2ViOWMwNjgyZjRfMy0yLTEtMS03NTE0MA_7fa16384-6e14-4414-8e15-37a6bfa463be"
      unitRef="usd">8000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9173e074bac74af1b3732b3d6a272a0e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmJjYzA4ZmEwMzA2YzQ5Yjc5NzEzYjNlYjljMDY4MmY0L3RhYmxlcmFuZ2U6YmNjMDhmYTAzMDZjNDliNzk3MTNiM2ViOWMwNjgyZjRfMy00LTEtMS03NTE0MA_7e0f02fa-8652-4395-8de9-e0123a2c7745"
      unitRef="usd">3900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6985304f226c46fca0470a43faf8887c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmJjYzA4ZmEwMzA2YzQ5Yjc5NzEzYjNlYjljMDY4MmY0L3RhYmxlcmFuZ2U6YmNjMDhmYTAzMDZjNDliNzk3MTNiM2ViOWMwNjgyZjRfNi0yLTEtMS03NTE0MA_6c2eb642-0d21-4731-a6a2-bb1eafbf87dc"
      unitRef="usd">10600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6a84089481564844bfa9bc6d09008d08_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmJjYzA4ZmEwMzA2YzQ5Yjc5NzEzYjNlYjljMDY4MmY0L3RhYmxlcmFuZ2U6YmNjMDhmYTAzMDZjNDliNzk3MTNiM2ViOWMwNjgyZjRfNi00LTEtMS03NTE0MA_a673b9f9-f433-4829-aa26-e3d4cc990b87"
      unitRef="usd">6200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8fc4bd215e8a4eda8144b5304af45e97_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmJjYzA4ZmEwMzA2YzQ5Yjc5NzEzYjNlYjljMDY4MmY0L3RhYmxlcmFuZ2U6YmNjMDhmYTAzMDZjNDliNzk3MTNiM2ViOWMwNjgyZjRfNy0yLTEtMS03NTE0MA_be0d46cb-a692-4cc0-bb29-1efeaf8054b1"
      unitRef="usd">47500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaf64235b712a458e82807e9c3b0ae91f_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmJjYzA4ZmEwMzA2YzQ5Yjc5NzEzYjNlYjljMDY4MmY0L3RhYmxlcmFuZ2U6YmNjMDhmYTAzMDZjNDliNzk3MTNiM2ViOWMwNjgyZjRfNy00LTEtMS03NTE0MA_40165e94-3bcc-40ba-9a48-1e46d44466fe"
      unitRef="usd">83200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i36b52f54c6e84045a18f6f934ed61b63_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmJjYzA4ZmEwMzA2YzQ5Yjc5NzEzYjNlYjljMDY4MmY0L3RhYmxlcmFuZ2U6YmNjMDhmYTAzMDZjNDliNzk3MTNiM2ViOWMwNjgyZjRfOC0yLTEtMS03NTE0MA_d828b7c0-3823-4681-b4b8-93cd14911cec"
      unitRef="usd">66100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iee301b6f981549919f1dd915c03e2623_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81Mi9mcmFnOmEyMjI0MDI0Nzk0ODRmOWU4NzkxOWZmMDUzMGFhZmI4L3RhYmxlOmJjYzA4ZmEwMzA2YzQ5Yjc5NzEzYjNlYjljMDY4MmY0L3RhYmxlcmFuZ2U6YmNjMDhmYTAzMDZjNDliNzk3MTNiM2ViOWMwNjgyZjRfOC00LTEtMS03NTE0MA_a6bccb6d-a9c1-4977-8882-6409c74a70fc"
      unitRef="usd">93300000</us-gaap:Revenues>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81OC9mcmFnOjlhNDVlZTBiNzM1NjRhN2NhM2NiN2U3OTQ3YWQ0YmE5L3RleHRyZWdpb246OWE0NWVlMGI3MzU2NGE3Y2EzY2I3ZTc5NDdhZDRiYTlfNzA_18868e42-e646-49fd-bd0d-9968f57780e5">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of inventory are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;354.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;349.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;655.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;814.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;205.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;187.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,215.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,351.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In April 2022 the Centers for Medicare and Medicaid Services (CMS) released the final National Coverage Decision (NCD) for the class of anti-amyloid treatments in Alzheimer&#x2019;s disease, including ADUHELM. The final NCD  confirmed coverage with evidence development, in which patients with Medicare can only access treatment if they are part of an approved clinical trial. We expect that this decision will reduce future demand for ADUHELM to a minimal level. During the first quarter of 2022 we wrote-off approximately $275.0&#160;million of inventory related to ADUHELM, as a result of this CMS decision, which was recognized in cost of sales within our condensed consolidated statements of income. We have recognized approximately $136.0&#160;million related to Eisai's 45.0% share of these charges in collaboration profit (loss) sharing within our condensed consolidated statements of income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During the fourth quarter of 2021 we wrote-off approximately $120.0&#160;million of inventory in excess of forecasted demand related to ADUHELM, which was recognized in cost of sales within our condensed consolidated statements of income. We have recognized approximately $59.0&#160;million related to Eisai's 45.0% share of these charges in collaboration profit (loss) sharing within our condensed consolidated statements of income during the fourth quarter of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As of March 31, 2022, our total ADUHELM inventory was de minimis. As of December 31, 2021, we had approximately $223.0&#160;million of ADUHELM inventory. For additional information please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Note 16, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81OC9mcmFnOjlhNDVlZTBiNzM1NjRhN2NhM2NiN2U3OTQ3YWQ0YmE5L3RleHRyZWdpb246OWE0NWVlMGI3MzU2NGE3Y2EzY2I3ZTc5NDdhZDRiYTlfNzk_95b265ed-99c1-4ba3-ae96-02396d0d5a0a">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of inventory are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;354.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;349.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;655.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;814.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;205.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;187.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,215.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,351.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81OC9mcmFnOjlhNDVlZTBiNzM1NjRhN2NhM2NiN2U3OTQ3YWQ0YmE5L3RhYmxlOjIyYjc2Njg1MGY2ZTQ3Y2FiODY4MDIyZDdiOTMxNGZjL3RhYmxlcmFuZ2U6MjJiNzY2ODUwZjZlNDdjYWI4NjgwMjJkN2I5MzE0ZmNfMS0yLTEtMS03NTE0MA_5596ef5b-1073-43b9-8db8-b998b492063c"
      unitRef="usd">354500000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81OC9mcmFnOjlhNDVlZTBiNzM1NjRhN2NhM2NiN2U3OTQ3YWQ0YmE5L3RhYmxlOjIyYjc2Njg1MGY2ZTQ3Y2FiODY4MDIyZDdiOTMxNGZjL3RhYmxlcmFuZ2U6MjJiNzY2ODUwZjZlNDdjYWI4NjgwMjJkN2I5MzE0ZmNfMS00LTEtMS03NTE0MA_c199d70e-78fe-4695-9775-72048555e6c4"
      unitRef="usd">349600000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81OC9mcmFnOjlhNDVlZTBiNzM1NjRhN2NhM2NiN2U3OTQ3YWQ0YmE5L3RhYmxlOjIyYjc2Njg1MGY2ZTQ3Y2FiODY4MDIyZDdiOTMxNGZjL3RhYmxlcmFuZ2U6MjJiNzY2ODUwZjZlNDdjYWI4NjgwMjJkN2I5MzE0ZmNfMi0yLTEtMS03NTE0MA_a8b08220-4ebe-4f7b-ab9a-4d62e5c19ef1"
      unitRef="usd">655600000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81OC9mcmFnOjlhNDVlZTBiNzM1NjRhN2NhM2NiN2U3OTQ3YWQ0YmE5L3RhYmxlOjIyYjc2Njg1MGY2ZTQ3Y2FiODY4MDIyZDdiOTMxNGZjL3RhYmxlcmFuZ2U6MjJiNzY2ODUwZjZlNDdjYWI4NjgwMjJkN2I5MzE0ZmNfMi00LTEtMS03NTE0MA_951f4969-4778-46c8-a245-30cfcc43a9a2"
      unitRef="usd">814000000.0</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81OC9mcmFnOjlhNDVlZTBiNzM1NjRhN2NhM2NiN2U3OTQ3YWQ0YmE5L3RhYmxlOjIyYjc2Njg1MGY2ZTQ3Y2FiODY4MDIyZDdiOTMxNGZjL3RhYmxlcmFuZ2U6MjJiNzY2ODUwZjZlNDdjYWI4NjgwMjJkN2I5MzE0ZmNfMy0yLTEtMS03NTE0MA_a6e92b14-3ca5-4d06-8d19-c61ce81b6b01"
      unitRef="usd">205300000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81OC9mcmFnOjlhNDVlZTBiNzM1NjRhN2NhM2NiN2U3OTQ3YWQ0YmE5L3RhYmxlOjIyYjc2Njg1MGY2ZTQ3Y2FiODY4MDIyZDdiOTMxNGZjL3RhYmxlcmFuZ2U6MjJiNzY2ODUwZjZlNDdjYWI4NjgwMjJkN2I5MzE0ZmNfMy00LTEtMS03NTE0MA_c94c797b-a669-421c-a8d1-39503af3db83"
      unitRef="usd">187900000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <biib:Inventorynetcurrentandnoncurrent
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81OC9mcmFnOjlhNDVlZTBiNzM1NjRhN2NhM2NiN2U3OTQ3YWQ0YmE5L3RhYmxlOjIyYjc2Njg1MGY2ZTQ3Y2FiODY4MDIyZDdiOTMxNGZjL3RhYmxlcmFuZ2U6MjJiNzY2ODUwZjZlNDdjYWI4NjgwMjJkN2I5MzE0ZmNfNC0yLTEtMS03NTE0MA_8cdf75d1-04a2-445d-ad2d-9825e117cc66"
      unitRef="usd">1215400000</biib:Inventorynetcurrentandnoncurrent>
    <biib:Inventorynetcurrentandnoncurrent
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81OC9mcmFnOjlhNDVlZTBiNzM1NjRhN2NhM2NiN2U3OTQ3YWQ0YmE5L3RhYmxlOjIyYjc2Njg1MGY2ZTQ3Y2FiODY4MDIyZDdiOTMxNGZjL3RhYmxlcmFuZ2U6MjJiNzY2ODUwZjZlNDdjYWI4NjgwMjJkN2I5MzE0ZmNfNC00LTEtMS03NTE0MA_a75d198e-3df7-4935-9b55-80a8667ea4aa"
      unitRef="usd">1351500000</biib:Inventorynetcurrentandnoncurrent>
    <us-gaap:InventoryWriteDown
      contextRef="i722a1d8416ce4b6b9e7ebbb4433afb51_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81OC9mcmFnOjlhNDVlZTBiNzM1NjRhN2NhM2NiN2U3OTQ3YWQ0YmE5L3RleHRyZWdpb246OWE0NWVlMGI3MzU2NGE3Y2EzY2I3ZTc5NDdhZDRiYTlfMTA5OTUxMTYzMDE4OQ_df37636d-e606-404a-a319-039e00e327fe"
      unitRef="usd">275000000</us-gaap:InventoryWriteDown>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i9a8520df9645495bbf150a3c973688bb_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81OC9mcmFnOjlhNDVlZTBiNzM1NjRhN2NhM2NiN2U3OTQ3YWQ0YmE5L3RleHRyZWdpb246OWE0NWVlMGI3MzU2NGE3Y2EzY2I3ZTc5NDdhZDRiYTlfMTA5OTUxMTYzNDM3MA_4a33a482-a18a-4a2b-b09d-dd46551efe17"
      unitRef="usd">136000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="i8a12e5f049a6452f9e97a9998e1ce4b6_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81OC9mcmFnOjlhNDVlZTBiNzM1NjRhN2NhM2NiN2U3OTQ3YWQ0YmE5L3RleHRyZWdpb246OWE0NWVlMGI3MzU2NGE3Y2EzY2I3ZTc5NDdhZDRiYTlfMTA5OTUxMTYzNDM0NA_05cf3daf-ff6a-4232-a16a-6ff1e749730b"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <us-gaap:InventoryWriteDown
      contextRef="i20495f1f0a824d538aee78626f0d54b7_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81OC9mcmFnOjlhNDVlZTBiNzM1NjRhN2NhM2NiN2U3OTQ3YWQ0YmE5L3RleHRyZWdpb246OWE0NWVlMGI3MzU2NGE3Y2EzY2I3ZTc5NDdhZDRiYTlfMTA5OTUxMTYzNTA5OQ_f50ad61d-ea33-443a-943a-4a23dd0581c6"
      unitRef="usd">120000000</us-gaap:InventoryWriteDown>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i2a241cb8f282478689ee6d7bba151c98_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81OC9mcmFnOjlhNDVlZTBiNzM1NjRhN2NhM2NiN2U3OTQ3YWQ0YmE5L3RleHRyZWdpb246OWE0NWVlMGI3MzU2NGE3Y2EzY2I3ZTc5NDdhZDRiYTlfNTQ5NzU1ODE0NjAzMw_8df9b84f-320e-40c4-b576-0b3eaf6cf257"
      unitRef="usd">59000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="i8a12e5f049a6452f9e97a9998e1ce4b6_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81OC9mcmFnOjlhNDVlZTBiNzM1NjRhN2NhM2NiN2U3OTQ3YWQ0YmE5L3RleHRyZWdpb246OWE0NWVlMGI3MzU2NGE3Y2EzY2I3ZTc5NDdhZDRiYTlfNTQ5NzU1ODE0NjAyNg_05cf3daf-ff6a-4232-a16a-6ff1e749730b"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <biib:InventoryNetCurrentAndNoncurrent
      contextRef="idee35b744e58496a91eb6fe7628d49eb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl81OC9mcmFnOjlhNDVlZTBiNzM1NjRhN2NhM2NiN2U3OTQ3YWQ0YmE5L3RleHRyZWdpb246OWE0NWVlMGI3MzU2NGE3Y2EzY2I3ZTc5NDdhZDRiYTlfMTA5OTUxMTYzMTY4Nw_d94f5cef-b1ca-40da-a516-0e01a02f8de0"
      unitRef="usd">223000000</biib:InventoryNetCurrentAndNoncurrent>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RleHRyZWdpb246ODY4NzYyZjk4NDAwNDdhMGI0MzEyMTg3MzUwNTg1NTZfNDY3Mw_a1572208-07cb-44ac-ac01-65c306255965">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.972%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.972%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.669%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Completed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4-28 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,413.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,455.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,957.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,413.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,388.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,024.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;In-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite until commercialization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;129.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;129.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks&#160;and trade names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,606.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,455.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,150.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,609.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,388.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,221.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amortization and Impairments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March 31, 2022, amortization and impairment of acquired intangible assets totaled $66.9 million, compared to $98.1 million in the prior year comparative period. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; months ended March 31, 2022, we had &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;no&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; impairment charges.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; months ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March 31, 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, amortization and impairment of acquired intangible assets reflects the impact of a $44.3&#160;million impairment charge related to vixotrigine (BIIB074) for the potential treatment of trigeminal neuralgia (TGN). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Completed Technology&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Completed technology primarily relates to our acquisition of all remaining rights to TYSABRI as well as other amounts related to our other marketed products and programs acquired through business combinations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;IPR&amp;amp;D Related to Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In-process research and development (IPR&amp;amp;D) represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. Included in IPR&amp;amp;D balances are adjustments related to foreign currency exchange rate fluctuations. We review amounts capitalized as acquired IPR&amp;amp;D for impairment annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable. The carrying value associated with our IPR&amp;amp;D assets as of March 31, 2022, relates to the IPR&amp;amp;D programs we acquired in connection with our acquisition of Convergence Pharmaceuticals Holdings Ltd. (Convergence). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Vixotrigine&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the periods since we acquired vixotrigine, there have been numerous delays in the initiation of Phase 3 studies for the potential treatment of TGN and for the potential treatment of diabetic painful neuropathy (DPN), another form of neuropathic pain. We have engaged with the FDA regarding the design of the Phase 3 studies of vixotrigine for the potential treatment of TGN and DPN and are now performing an additional clinical trial of vixotrigine, which is expected to be completed by the end of 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The performance of this additional clinical trial delayed the initiation of the Phase 3 studies of vixotrigine for the potential treatment of TGN, and, as a result, we recognized an impairment charge of $44.3&#160;million related to vixotrigine for the potential treatment of TGN during the fi&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;rst quarter of 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2022, the carrying value associated with the remaining IPR&amp;amp;D asset for DPN &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;was $129.1&#160;million a&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nd the fair value of this asset was not significantly in excess of its carrying value. Upon the completion of the additional clinical trial we will reevaluate the carrying value of the program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Estimated Future Amortization of Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022 (remaining nine months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;210.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;180.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;165.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,761.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill, March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,758.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2022, we had&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;no&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ac&lt;/span&gt;cumulated impairment losses related to goodwill. Other includes adjustments related to foreign currency exchange rate fluctuations.</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <biib:IntangibleAssetsExcludingGoodwillTableTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RleHRyZWdpb246ODY4NzYyZjk4NDAwNDdhMGI0MzEyMTg3MzUwNTg1NTZfNDY0MA_75a96891-957b-4a63-82e1-9d01b667334b">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.972%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.972%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.669%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Completed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4-28 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,413.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,455.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,957.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,413.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,388.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,024.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;In-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite until commercialization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;129.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;129.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks&#160;and trade names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,606.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,455.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,150.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,609.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,388.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,221.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:IntangibleAssetsExcludingGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6011e1fbb7ec4eafa87167881be73a90_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOmMyNWFjMDg3ZTEzNTRkOWE4ZjkxNjIzZTYyMjM3MTA5L3RhYmxlcmFuZ2U6YzI1YWMwODdlMTM1NGQ5YThmOTE2MjNlNjIyMzcxMDlfMi00LTEtMS03NTE0MA_8880b5a7-781d-45cf-96da-c8c02843d5f0"
      unitRef="usd">7413100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6011e1fbb7ec4eafa87167881be73a90_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOmMyNWFjMDg3ZTEzNTRkOWE4ZjkxNjIzZTYyMjM3MTA5L3RhYmxlcmFuZ2U6YzI1YWMwODdlMTM1NGQ5YThmOTE2MjNlNjIyMzcxMDlfMi02LTEtMS03NTE0MA_68ba5d2d-074d-4c6e-b7b1-a16c28ad063c"
      unitRef="usd">5455400000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6011e1fbb7ec4eafa87167881be73a90_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOmMyNWFjMDg3ZTEzNTRkOWE4ZjkxNjIzZTYyMjM3MTA5L3RhYmxlcmFuZ2U6YzI1YWMwODdlMTM1NGQ5YThmOTE2MjNlNjIyMzcxMDlfMi04LTEtMS03NTE0MA_e75c9cd1-2ffb-4b27-baa1-2eb79fb438c3"
      unitRef="usd">1957700000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i96046c4bfde14c4a9405390c5dd1681e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOmMyNWFjMDg3ZTEzNTRkOWE4ZjkxNjIzZTYyMjM3MTA5L3RhYmxlcmFuZ2U6YzI1YWMwODdlMTM1NGQ5YThmOTE2MjNlNjIyMzcxMDlfMi0xMC0xLTEtNzUxNDA_dc7888e1-e75f-4915-88cc-9df9f00d7533"
      unitRef="usd">7413100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i96046c4bfde14c4a9405390c5dd1681e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOmMyNWFjMDg3ZTEzNTRkOWE4ZjkxNjIzZTYyMjM3MTA5L3RhYmxlcmFuZ2U6YzI1YWMwODdlMTM1NGQ5YThmOTE2MjNlNjIyMzcxMDlfMi0xMi0xLTEtNzUxNDA_74ea66ad-fc22-4f4a-bd44-a968f96af08a"
      unitRef="usd">5388500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i96046c4bfde14c4a9405390c5dd1681e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOmMyNWFjMDg3ZTEzNTRkOWE4ZjkxNjIzZTYyMjM3MTA5L3RhYmxlcmFuZ2U6YzI1YWMwODdlMTM1NGQ5YThmOTE2MjNlNjIyMzcxMDlfMi0xNC0xLTEtNzUxNDA_65661db9-9c76-4b38-869b-f7f673e564af"
      unitRef="usd">2024600000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i2c9e43d132c24282b7716b0c5a1f9cfc_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOmMyNWFjMDg3ZTEzNTRkOWE4ZjkxNjIzZTYyMjM3MTA5L3RhYmxlcmFuZ2U6YzI1YWMwODdlMTM1NGQ5YThmOTE2MjNlNjIyMzcxMDlfMy00LTEtMS03NTE0MA_2e10aa90-a529-4e2e-a1f3-636b46cf8403"
      unitRef="usd">129100000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i2c9e43d132c24282b7716b0c5a1f9cfc_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOmMyNWFjMDg3ZTEzNTRkOWE4ZjkxNjIzZTYyMjM3MTA5L3RhYmxlcmFuZ2U6YzI1YWMwODdlMTM1NGQ5YThmOTE2MjNlNjIyMzcxMDlfMy02LTEtMS03NTE0MA_05fda5bf-032d-4415-a569-1499172fcee8"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i2c9e43d132c24282b7716b0c5a1f9cfc_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOmMyNWFjMDg3ZTEzNTRkOWE4ZjkxNjIzZTYyMjM3MTA5L3RhYmxlcmFuZ2U6YzI1YWMwODdlMTM1NGQ5YThmOTE2MjNlNjIyMzcxMDlfMy04LTEtMS03NTE0MA_fe6389d8-5d99-4cf4-ae0f-5af94a3ba3f0"
      unitRef="usd">129100000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i4fb812dd0c044aa5a8506c4bc6e9c90a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOmMyNWFjMDg3ZTEzNTRkOWE4ZjkxNjIzZTYyMjM3MTA5L3RhYmxlcmFuZ2U6YzI1YWMwODdlMTM1NGQ5YThmOTE2MjNlNjIyMzcxMDlfMy0xMC0xLTEtNzUxNDA_219f8242-199c-4e61-8d2a-2336b13ae7bd"
      unitRef="usd">132700000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i4fb812dd0c044aa5a8506c4bc6e9c90a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOmMyNWFjMDg3ZTEzNTRkOWE4ZjkxNjIzZTYyMjM3MTA5L3RhYmxlcmFuZ2U6YzI1YWMwODdlMTM1NGQ5YThmOTE2MjNlNjIyMzcxMDlfMy0xMi0xLTEtNzUxNDA_67b060bb-36aa-44b7-abd9-e5306bf97729"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i4fb812dd0c044aa5a8506c4bc6e9c90a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOmMyNWFjMDg3ZTEzNTRkOWE4ZjkxNjIzZTYyMjM3MTA5L3RhYmxlcmFuZ2U6YzI1YWMwODdlMTM1NGQ5YThmOTE2MjNlNjIyMzcxMDlfMy0xNC0xLTEtNzUxNDA_9c2fd82e-9735-4a75-b8c8-8f070c2cf861"
      unitRef="usd">132700000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ica5c719f9e5e4e2d9b3c6b1da3536e36_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOmMyNWFjMDg3ZTEzNTRkOWE4ZjkxNjIzZTYyMjM3MTA5L3RhYmxlcmFuZ2U6YzI1YWMwODdlMTM1NGQ5YThmOTE2MjNlNjIyMzcxMDlfNC00LTEtMS03NTE0MA_8c9cf1aa-0b12-48cf-90e4-484ae2dba747"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ica5c719f9e5e4e2d9b3c6b1da3536e36_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOmMyNWFjMDg3ZTEzNTRkOWE4ZjkxNjIzZTYyMjM3MTA5L3RhYmxlcmFuZ2U6YzI1YWMwODdlMTM1NGQ5YThmOTE2MjNlNjIyMzcxMDlfNC02LTEtMS03NTE0MA_073ac49e-4b5c-48e0-8672-a19c59ae1bde"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ica5c719f9e5e4e2d9b3c6b1da3536e36_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOmMyNWFjMDg3ZTEzNTRkOWE4ZjkxNjIzZTYyMjM3MTA5L3RhYmxlcmFuZ2U6YzI1YWMwODdlMTM1NGQ5YThmOTE2MjNlNjIyMzcxMDlfNC04LTEtMS03NTE0MA_6fee93e0-4c8c-41d0-874d-628c77c14223"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i1c35d264b82c493ba58144b8a17842a9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOmMyNWFjMDg3ZTEzNTRkOWE4ZjkxNjIzZTYyMjM3MTA5L3RhYmxlcmFuZ2U6YzI1YWMwODdlMTM1NGQ5YThmOTE2MjNlNjIyMzcxMDlfNC0xMC0xLTEtNzUxNDA_f81a6e3a-3d64-4aec-9c84-60c1698e90a6"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i1c35d264b82c493ba58144b8a17842a9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOmMyNWFjMDg3ZTEzNTRkOWE4ZjkxNjIzZTYyMjM3MTA5L3RhYmxlcmFuZ2U6YzI1YWMwODdlMTM1NGQ5YThmOTE2MjNlNjIyMzcxMDlfNC0xMi0xLTEtNzUxNDA_1904ef61-fe3d-478d-9c6b-5849a1e50be2"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i1c35d264b82c493ba58144b8a17842a9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOmMyNWFjMDg3ZTEzNTRkOWE4ZjkxNjIzZTYyMjM3MTA5L3RhYmxlcmFuZ2U6YzI1YWMwODdlMTM1NGQ5YThmOTE2MjNlNjIyMzcxMDlfNC0xNC0xLTEtNzUxNDA_2c8e56dc-f084-4165-8a19-7cb2e5873e86"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOmMyNWFjMDg3ZTEzNTRkOWE4ZjkxNjIzZTYyMjM3MTA5L3RhYmxlcmFuZ2U6YzI1YWMwODdlMTM1NGQ5YThmOTE2MjNlNjIyMzcxMDlfNS00LTEtMS03NTE0MA_bf3668be-8580-44ef-b2cf-19496e7f7682"
      unitRef="usd">7606200000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOmMyNWFjMDg3ZTEzNTRkOWE4ZjkxNjIzZTYyMjM3MTA5L3RhYmxlcmFuZ2U6YzI1YWMwODdlMTM1NGQ5YThmOTE2MjNlNjIyMzcxMDlfNS02LTEtMS03NTE0MA_1e2a8abf-bbd4-49a6-bd8c-20ea7a7e39ed"
      unitRef="usd">5455400000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOmMyNWFjMDg3ZTEzNTRkOWE4ZjkxNjIzZTYyMjM3MTA5L3RhYmxlcmFuZ2U6YzI1YWMwODdlMTM1NGQ5YThmOTE2MjNlNjIyMzcxMDlfNS04LTEtMS03NTE0MA_d8218f1a-36b0-4272-8853-870411b260fb"
      unitRef="usd">2150800000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOmMyNWFjMDg3ZTEzNTRkOWE4ZjkxNjIzZTYyMjM3MTA5L3RhYmxlcmFuZ2U6YzI1YWMwODdlMTM1NGQ5YThmOTE2MjNlNjIyMzcxMDlfNS0xMC0xLTEtNzUxNDA_deff1f95-637c-443d-9db2-97edea8723eb"
      unitRef="usd">7609800000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOmMyNWFjMDg3ZTEzNTRkOWE4ZjkxNjIzZTYyMjM3MTA5L3RhYmxlcmFuZ2U6YzI1YWMwODdlMTM1NGQ5YThmOTE2MjNlNjIyMzcxMDlfNS0xMi0xLTEtNzUxNDA_edb69a54-d0f4-4872-9b66-7c2ecf6f11e2"
      unitRef="usd">5388500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOmMyNWFjMDg3ZTEzNTRkOWE4ZjkxNjIzZTYyMjM3MTA5L3RhYmxlcmFuZ2U6YzI1YWMwODdlMTM1NGQ5YThmOTE2MjNlNjIyMzcxMDlfNS0xNC0xLTEtNzUxNDA_ad31bd98-dc2a-4080-ad2e-57de755fe2d5"
      unitRef="usd">2221300000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RleHRyZWdpb246ODY4NzYyZjk4NDAwNDdhMGI0MzEyMTg3MzUwNTg1NTZfMjE5OTAyMzI2MTQzNA_35824f57-87e7-4005-a133-6ebc714e8bff"
      unitRef="usd">66900000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RleHRyZWdpb246ODY4NzYyZjk4NDAwNDdhMGI0MzEyMTg3MzUwNTg1NTZfMjE5OTAyMzI2MTQ2Ng_8514b729-4696-4885-a867-5953ecef18ed"
      unitRef="usd">98100000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i46b4be49d678422682879c3bf61b0688_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RleHRyZWdpb246ODY4NzYyZjk4NDAwNDdhMGI0MzEyMTg3MzUwNTg1NTZfODcw_53e19f77-e9e9-4758-a505-0cb61c6736bc"
      unitRef="usd">44300000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i46b4be49d678422682879c3bf61b0688_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RleHRyZWdpb246ODY4NzYyZjk4NDAwNDdhMGI0MzEyMTg3MzUwNTg1NTZfMjgyMQ_53e19f77-e9e9-4758-a505-0cb61c6736bc"
      unitRef="usd">44300000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i6c345c953cb94d34804e7d2a988c33be_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RleHRyZWdpb246ODY4NzYyZjk4NDAwNDdhMGI0MzEyMTg3MzUwNTg1NTZfMzAxMQ_c5910725-89d2-41a5-8800-9ba9768bd866"
      unitRef="usd">129100000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RleHRyZWdpb246ODY4NzYyZjk4NDAwNDdhMGI0MzEyMTg3MzUwNTg1NTZfNDYyOQ_48e3bb80-f5e6-47ac-87d6-a6a3e9e46d81">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022 (remaining nine months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;210.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;180.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;165.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOjkyMTA1OWExNWU5MjRkMjU4ZTRkMWZiMWJhZmZlMDhiL3RhYmxlcmFuZ2U6OTIxMDU5YTE1ZTkyNGQyNThlNGQxZmIxYmFmZmUwOGJfMS0yLTEtMS03NTE0MA_018dff18-1e2e-4254-93c4-c054001b5654"
      unitRef="usd">200000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOjkyMTA1OWExNWU5MjRkMjU4ZTRkMWZiMWJhZmZlMDhiL3RhYmxlcmFuZ2U6OTIxMDU5YTE1ZTkyNGQyNThlNGQxZmIxYmFmZmUwOGJfMi0yLTEtMS03NTE0MA_b0c728bf-4766-4ea7-a734-122aa515923b"
      unitRef="usd">210000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOjkyMTA1OWExNWU5MjRkMjU4ZTRkMWZiMWJhZmZlMDhiL3RhYmxlcmFuZ2U6OTIxMDU5YTE1ZTkyNGQyNThlNGQxZmIxYmFmZmUwOGJfMy0yLTEtMS03NTE0MA_d3c31d2a-3b19-4598-9e56-a30080bac7c9"
      unitRef="usd">195000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOjkyMTA1OWExNWU5MjRkMjU4ZTRkMWZiMWJhZmZlMDhiL3RhYmxlcmFuZ2U6OTIxMDU5YTE1ZTkyNGQyNThlNGQxZmIxYmFmZmUwOGJfNC0yLTEtMS03NTE0MA_5ad7c384-3f82-4bff-b16c-afd48ea6013e"
      unitRef="usd">195000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOjkyMTA1OWExNWU5MjRkMjU4ZTRkMWZiMWJhZmZlMDhiL3RhYmxlcmFuZ2U6OTIxMDU5YTE1ZTkyNGQyNThlNGQxZmIxYmFmZmUwOGJfNS0yLTEtMS03NTE0MA_c84702fd-1ea9-4605-87f8-b735bf0106ff"
      unitRef="usd">180000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOjkyMTA1OWExNWU5MjRkMjU4ZTRkMWZiMWJhZmZlMDhiL3RhYmxlcmFuZ2U6OTIxMDU5YTE1ZTkyNGQyNThlNGQxZmIxYmFmZmUwOGJfNi0yLTEtMS03NTE0MA_1276d175-bf66-4e08-a7a5-a47edc45d813"
      unitRef="usd">165000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RleHRyZWdpb246ODY4NzYyZjk4NDAwNDdhMGI0MzEyMTg3MzUwNTg1NTZfNDY1Ng_e212d4e0-1e55-464f-9678-27e0b003e635">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,761.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill, March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,758.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOjUzZDA1YjZlNGFiNjRmZmNiMjg1ZjRkYjQyMjJiOWNhL3RhYmxlcmFuZ2U6NTNkMDViNmU0YWI2NGZmY2IyODVmNGRiNDIyMmI5Y2FfMS0yLTEtMS03NTE0MA_54f46cd6-dfd4-409b-a3a4-43343e84b85f"
      unitRef="usd">5761100000</us-gaap:Goodwill>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOjUzZDA1YjZlNGFiNjRmZmNiMjg1ZjRkYjQyMjJiOWNhL3RhYmxlcmFuZ2U6NTNkMDViNmU0YWI2NGZmY2IyODVmNGRiNDIyMmI5Y2FfMy0yLTEtMS03NTE0MA_db80dd2e-de28-4796-b3fd-e28286ea6646"
      unitRef="usd">-3100000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RhYmxlOjUzZDA1YjZlNGFiNjRmZmNiMjg1ZjRkYjQyMjJiOWNhL3RhYmxlcmFuZ2U6NTNkMDViNmU0YWI2NGZmY2IyODVmNGRiNDIyMmI5Y2FfNC0yLTEtMS03NTE0MA_0aa6514d-b5ad-4dba-a7a5-27e8e35f0673"
      unitRef="usd">5758000000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82MS9mcmFnOjg2ODc2MmY5ODQwMDQ3YTBiNDMxMjE4NzM1MDU4NTU2L3RleHRyZWdpb246ODY4NzYyZjk4NDAwNDdhMGI0MzEyMTg3MzUwNTg1NTZfNDQ5MQ_6f05ec49-3a43-4820-8b2f-bc682623c43a"
      unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RleHRyZWdpb246ZmY0MDI4MzgxMGFkNDY5OWFjMzU4M2JmY2Y4NzkwMTNfNDg5NQ_a4efc4dc-87e2-46de-9dbe-0619036a8815">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,283.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,283.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,579.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,579.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,252.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,252.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;171.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;171.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;860.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;607.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;253.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,281.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;607.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,674.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;202.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;202.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;214.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;202.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,632.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,632.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,108.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,108.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,192.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,192.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,048.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;866.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,228.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,046.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;219.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no material impairments of our assets measured and carried at fair value as of March 31, 2022 and December 31, 2021. In addition, there have been no changes in valuation techniques as of March 31, 2022 and December 31, 2021. The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities was determined through third-party pricing services. The fair value of Level 2 instruments classified as marketable equity securities represents our investments in the common stock of Sangamo Therapeutics, Inc. (Sangamo) and Sage Therapeutics, Inc. (Sage) and are valued using an option pricing valuation model as the investments are each subject to certain holding period restrictions. The holding period restrictions for our investment in the common stock of Denali Therapeutics Inc. (Denali) and a portion of our Sangamo investment expired during the first quarter of 2022 and the second quarter of 2021, respectively. The fair value of our Denali investment and this portion of our Sangamo investment were Level 1 measurements as of March 31, 2022. For additional information on our investments in Sangamo, Denali and Sage common stock, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 7, Financial Instruments,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1, Summary of Significant Accounting Policies - Fair Value Measurements,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2021 Form 10-K. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the significant unobservable inputs in the fair value measurement of our contingent consideration obligations as of March 31, 2022 and December 31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.266%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.773%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.020%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable Input(s)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td rowspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td rowspan="2" style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;202.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td rowspan="2" style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.89%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.89%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected timing of achievement of development milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023 to 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable Input(s)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td rowspan="2" style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td rowspan="2" style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td rowspan="2" style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.30%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.30%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected timing of achievement of development milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023 to 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average discount rate was calculated based on the relative fair value of our contingent consideration obligations. In addition, we apply various probabilities of technological and regulatory success, ranging from 10.9% to certain probability as of March 31, 2022, to the valuation models to estimate the fair values of our contingent consideration obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Debt Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.091%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.625% Senior Notes due September 15, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,008.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;999.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,020.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;999.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.050% Senior Notes due September 15, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,797.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,743.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,895.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,742.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.250% Senior Notes due May 1, 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,341.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,492.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,475.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,492.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.200% Senior Notes due September 15, 2045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,240.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,463.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,099.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.150% Senior Notes due May 1, 2050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,225.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,473.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,457.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,473.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.250% Senior Notes due February 15, 2051&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;581.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;466.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;692.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;466.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,195.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,275.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,004.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,273.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. For additional information related to our Senior Notes, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 12,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Indebtedness,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2021 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisitions of Convergence and Biogen International Neuroscience GmbH, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(33.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value, end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;202.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;226.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2022 and December 31, 2021, approximately&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $202.0&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and $209.1 million, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our condensed consolidated balance sheets with any remaining balances reflected as a &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;component of accrued expense and other.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March 31, 2022, changes in the fair value of our contingent consideration obligations were primarily due to an increase in discount rates used to revalue these obligations and delays in the expected timing of the achievement of certain remaining developmental milestones related to our vixotrigine programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March 31, 2021, changes in the fair value of our contingent consideration obligations were primarily due to delays in the expected timing of the achievement of certain remaining developmental milestones related to our vixotrigine programs.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RleHRyZWdpb246ZmY0MDI4MzgxMGFkNDY5OWFjMzU4M2JmY2Y4NzkwMTNfNDg5Ng_0a42ce77-77af-4cf2-a3a8-f4b72bb01f37">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,283.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,283.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,579.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,579.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,252.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,252.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;171.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;171.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;860.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;607.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;253.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,281.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;607.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,674.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;202.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;202.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;214.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;202.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,632.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,632.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,108.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,108.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,192.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,192.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,048.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;866.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,228.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,046.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;219.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia69f061a62954ac7af98aa5c677f4971_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfMy0yLTEtMS03NTE0MA_43d4b96d-6622-4de8-9771-0eee8b7ae82c"
      unitRef="usd">1283700000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i64a5ad19dcce4cf8b7c43a569fe0c245_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfMy00LTEtMS03NTE0MA_b32bff68-18d3-460b-ac88-62e75d673060"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i42f910d9635f4c0480b7fb380b5fe276_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfMy02LTEtMS03NTE0MA_7b058479-1b7f-4966-b998-69646150be44"
      unitRef="usd">1283700000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3396020533494d35b8c27ddcd8a5252e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfMy04LTEtMS03NTE0MA_f3454b38-b7c1-4572-8837-eb5db0a67599"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5bb9349b48fb4c629485bfe7b5880e8c_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfNS0yLTEtMS03NTE0MA_6b3d8e5c-f51e-4b47-b1fb-5d99af83a5eb"
      unitRef="usd">1579400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id2a85ce0b81243eba23da6278ed1f57e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfNS00LTEtMS03NTE0MA_e4458948-47a7-4b34-9a09-139045e84889"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib3e9c1bab79f40279289b0b3dcc2c161_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfNS02LTEtMS03NTE0MA_c451a9c8-dbfb-4fc7-a095-98e7505ba7be"
      unitRef="usd">1579400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iec22cc68ef57484183e4ae80b280d372_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfNS04LTEtMS03NTE0MA_2deead9b-de75-4370-8e56-20a5d5492778"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib1f4d496ec7641838d1ecec434c28f66_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfNi0yLTEtMS03NTE0MA_6acb22c2-fbcf-42c7-96fb-f97b5bb92f01"
      unitRef="usd">1252700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2c661d66c6224d4a81bd51c24ea79d40_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfNi00LTEtMS03NTE0MA_51b068d7-cee6-47ee-a8eb-0e001a0e7821"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iac84ce7144dd4bcc82d4253f927d2752_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfNi02LTEtMS03NTE0MA_6615b28b-2f60-44f7-8a68-5145776e912f"
      unitRef="usd">1252700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if398ac5e39c747a6af59aeb27650b335_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfNi04LTEtMS03NTE0MA_592d774f-921f-4cee-90bd-dad27b11b44d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i09eff9f500604711ab6a499956c8d5f3_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfNy0yLTEtMS03NTE0MA_98dbbc43-51d3-417e-a957-e692257ed04b"
      unitRef="usd">171900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5ccde35ecf6c42b486ba8b193205887c_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfNy00LTEtMS03NTE0MA_859e55b0-d113-4511-b515-725be89af23b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i289d8737ebbf49019c8cd089b87cc769_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfNy02LTEtMS03NTE0MA_2de3ad26-6e5a-47b9-9047-31d1f1371f75"
      unitRef="usd">171900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6f9738b4665048cfa86018d909055f8e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfNy04LTEtMS03NTE0MA_1726ff4d-4e4a-4a32-89c1-91afd957b5a8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ia69f061a62954ac7af98aa5c677f4971_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfOC0yLTEtMS03NTE0MA_15790787-5faa-414e-b934-b96c8fb40999"
      unitRef="usd">860300000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i64a5ad19dcce4cf8b7c43a569fe0c245_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfOC00LTEtMS03NTE0MA_868c9c12-838f-40dd-8bf3-30c9e5596fb0"
      unitRef="usd">607000000.0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i42f910d9635f4c0480b7fb380b5fe276_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfOC02LTEtMS03NTE0MA_ea284378-26ec-4fbf-b6d6-65b82393e638"
      unitRef="usd">253300000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i3396020533494d35b8c27ddcd8a5252e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfOC04LTEtMS03NTE0MA_d8da7e9e-f415-43ef-af1f-30b5b895a5f8"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="ia69f061a62954ac7af98aa5c677f4971_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfOS0yLTEtMS03NTE0MA_b29fce95-40f1-44d8-8e3a-982339e32ee6"
      unitRef="usd">97200000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i64a5ad19dcce4cf8b7c43a569fe0c245_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfOS00LTEtMS03NTE0MA_fe30e444-bae9-4bb9-ba01-a68a9511995e"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i42f910d9635f4c0480b7fb380b5fe276_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfOS02LTEtMS03NTE0MA_38eaac85-ff20-4947-b10a-0fa077f3c96e"
      unitRef="usd">97200000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i3396020533494d35b8c27ddcd8a5252e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfOS04LTEtMS03NTE0MA_01034bb3-0b92-450c-8283-58afdb30ee48"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="ia69f061a62954ac7af98aa5c677f4971_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfMTAtMi0xLTEtNzUxNDA_bffe4ffa-6809-46ec-ac3c-a9bbc769e900"
      unitRef="usd">35800000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="i64a5ad19dcce4cf8b7c43a569fe0c245_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfMTAtNC0xLTEtNzUxNDA_30dfd5da-df64-4b07-92c1-b6359c8085cb"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="i42f910d9635f4c0480b7fb380b5fe276_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfMTAtNi0xLTEtNzUxNDA_f1d9a41b-e569-4053-9a22-b7b7c2592899"
      unitRef="usd">35800000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="i3396020533494d35b8c27ddcd8a5252e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfMTAtOC0xLTEtNzUxNDA_e9ec2bac-ee87-4e29-a5d0-78cf90eaebd8"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia69f061a62954ac7af98aa5c677f4971_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfMTEtMi0xLTEtNzUxNDA_e354d4bd-f291-4efb-856e-e480fffff770"
      unitRef="usd">5281000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i64a5ad19dcce4cf8b7c43a569fe0c245_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfMTEtNC0xLTEtNzUxNDA_c28bae9b-9881-4b36-9564-079b0b5fad37"
      unitRef="usd">607000000.0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i42f910d9635f4c0480b7fb380b5fe276_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfMTEtNi0xLTEtNzUxNDA_7be127fc-578a-47d2-adca-802334779954"
      unitRef="usd">4674000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3396020533494d35b8c27ddcd8a5252e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfMTEtOC0xLTEtNzUxNDA_d0708041-f85d-412e-8866-ca731a811d22"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="ia69f061a62954ac7af98aa5c677f4971_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfMTMtMi0xLTEtNzUxNDA_120b410f-7e11-40cb-bee3-1b80cf33fa99"
      unitRef="usd">12500000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i64a5ad19dcce4cf8b7c43a569fe0c245_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfMTMtNC0xLTEtNzUxNDA_55bbf9db-d355-4c04-afe5-8311e82c835c"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i42f910d9635f4c0480b7fb380b5fe276_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfMTMtNi0xLTEtNzUxNDA_cc88cab2-9210-4a82-a6fa-e58c584456dc"
      unitRef="usd">12500000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i3396020533494d35b8c27ddcd8a5252e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfMTMtOC0xLTEtNzUxNDA_603f1807-8019-4453-b2ba-c755fba5f23c"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ia69f061a62954ac7af98aa5c677f4971_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfMTQtMi0xLTEtNzUxNDA_2f76279d-86ac-42ac-b10d-f26669c0785f"
      unitRef="usd">202000000.0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i64a5ad19dcce4cf8b7c43a569fe0c245_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfMTQtNC0xLTEtNzUxNDA_199e3496-9e1f-4d0e-bb6c-b6ae33492815"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i42f910d9635f4c0480b7fb380b5fe276_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfMTQtNi0xLTEtNzUxNDA_ef56686e-1f87-43be-ab50-0d5894f91de6"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i3396020533494d35b8c27ddcd8a5252e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfMTQtOC0xLTEtNzUxNDA_2e4cf290-1970-4fc4-8077-92d6909aa016"
      unitRef="usd">202000000.0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ia69f061a62954ac7af98aa5c677f4971_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfMTUtMi0xLTEtNzUxNDA_940699e9-2db1-4972-a2c5-d0d13989a6a3"
      unitRef="usd">214500000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i64a5ad19dcce4cf8b7c43a569fe0c245_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfMTUtNC0xLTEtNzUxNDA_877584b3-d954-428e-be83-9a12757ca83b"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i42f910d9635f4c0480b7fb380b5fe276_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfMTUtNi0xLTEtNzUxNDA_1d88cd2c-b24b-4db3-ae7d-dbd2f86e534e"
      unitRef="usd">12500000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i3396020533494d35b8c27ddcd8a5252e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjBlMDRjNmUyYjA1MDRkNGZhYjE2YzI0M2NkODExNWE2L3RhYmxlcmFuZ2U6MGUwNGM2ZTJiMDUwNGQ0ZmFiMTZjMjQzY2Q4MTE1YTZfMTUtOC0xLTEtNzUxNDA_37247464-b035-4331-b00f-d69b61b44f7b"
      unitRef="usd">202000000.0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i264ccf816a664702a7ba8ff1332adb5a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfMy0yLTEtMS03NTE0MA_14bd4658-8b41-474c-8548-0d4e2b4758df"
      unitRef="usd">1632200000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie241349e66f143e1b0f96548fcc184b5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfMy00LTEtMS03NTE0MA_ea5deb0d-7065-4a8d-846c-f3b685fa70e2"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1b5576a00f6d4d15946a9368e3767e64_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfMy02LTEtMS03NTE0MA_af0bb7c9-16af-4209-9de5-2734e19b9463"
      unitRef="usd">1632200000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i421472e2622c437d8bf685a39d6aecc3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfMy04LTEtMS03NTE0MA_0e0d2b4f-28b2-49bf-87dc-a91f558bac47"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8cec5ba41ae343fba33cd31f8de35a45_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfNS0yLTEtMS03NTE0MA_c53078f7-0516-485e-b72c-f60587273ba4"
      unitRef="usd">1108200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ied9fbb6e460240998c2c685327f742f9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfNS00LTEtMS03NTE0MA_3394d51c-e3a2-4b75-82f4-4907ce98b167"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if386e194b1a943d8871f1a74fa3cf259_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfNS02LTEtMS03NTE0MA_dc42fb10-a8d5-4743-86a2-043b2d5c7d9c"
      unitRef="usd">1108200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i91224f4cdc6744fbae4bcd98dc85a3a0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfNS04LTEtMS03NTE0MA_52de75bd-017f-4390-8fdd-5db16be8fc4e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id787117c37b84ec99ac24ed6b36b3e3f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfNi0yLTEtMS03NTE0MA_819d5b11-cff3-4edf-9e63-2aa7152f984b"
      unitRef="usd">1192700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie3422e6ed664422993d44483803e8115_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfNi00LTEtMS03NTE0MA_3dfc33e2-8b5c-49c1-a519-1f937a06a20d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4a7eda1ce0584e48809dc53d22b2b031_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfNi02LTEtMS03NTE0MA_bbb42c9e-cc50-4196-acb4-cf8a31bfdf49"
      unitRef="usd">1192700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iec70156770664cf39f79a786ae051946_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfNi04LTEtMS03NTE0MA_4abd1c40-efeb-4f76-9025-120d25c129fb"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia81961b9f3eb48868302e49901fb6144_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfNy0yLTEtMS03NTE0MA_ba509dcc-4ae4-443a-b7a9-ed240258bc19"
      unitRef="usd">132200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i239a26613bda429395a6a963a2cde2c7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfNy00LTEtMS03NTE0MA_4b8a5a61-687f-4ab3-bc07-37936ef3d51a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib469728d72fa415a9631ce58a0a2133d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfNy02LTEtMS03NTE0MA_03137d00-fe02-4269-8c80-172301278c74"
      unitRef="usd">132200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i99b3022f714c46afa3ad4d95b9e0cc1c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfNy04LTEtMS03NTE0MA_d4dd2142-548d-4157-badc-dc2c2eb7695f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i264ccf816a664702a7ba8ff1332adb5a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfOC0yLTEtMS03NTE0MA_1b32636f-fb8e-4ad9-8a4b-4f8384403e6a"
      unitRef="usd">1048500000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ie241349e66f143e1b0f96548fcc184b5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfOC00LTEtMS03NTE0MA_9d25824c-fd9a-4566-afa8-549fbf500eac"
      unitRef="usd">181700000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i1b5576a00f6d4d15946a9368e3767e64_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfOC02LTEtMS03NTE0MA_419e7da8-1449-4dc8-9181-90ad1d681f69"
      unitRef="usd">866800000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i421472e2622c437d8bf685a39d6aecc3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfOC04LTEtMS03NTE0MA_1c7e8d28-ca88-42a2-bed7-7c0eee3e5161"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i264ccf816a664702a7ba8ff1332adb5a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfOS0yLTEtMS03NTE0MA_4370b6f4-babd-4105-b7b7-e6b520b54ed9"
      unitRef="usd">80900000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="ie241349e66f143e1b0f96548fcc184b5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfOS00LTEtMS03NTE0MA_2c76c490-5d05-4f25-9e8d-296ad825ac4e"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i1b5576a00f6d4d15946a9368e3767e64_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfOS02LTEtMS03NTE0MA_923d5297-f22c-4233-abae-53b21dc54933"
      unitRef="usd">80900000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i421472e2622c437d8bf685a39d6aecc3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfOS04LTEtMS03NTE0MA_93c00767-5dee-4172-9f17-6f3e758bf213"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="i264ccf816a664702a7ba8ff1332adb5a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfMTAtMi0xLTEtNzUxNDA_5e9717ac-f8fe-4848-8dcb-686466b41dba"
      unitRef="usd">33400000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="ie241349e66f143e1b0f96548fcc184b5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfMTAtNC0xLTEtNzUxNDA_c5fc832f-3219-4e2b-ab2d-39a4cb23ec72"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="i1b5576a00f6d4d15946a9368e3767e64_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfMTAtNi0xLTEtNzUxNDA_fab91967-57fe-486b-88e8-5eae6406517b"
      unitRef="usd">33400000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="i421472e2622c437d8bf685a39d6aecc3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfMTAtOC0xLTEtNzUxNDA_2b02f1de-be8e-4707-b837-6ff7066bb134"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i264ccf816a664702a7ba8ff1332adb5a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfMTEtMi0xLTEtNzUxNDA_7363918e-b52e-48d5-937c-69967b517398"
      unitRef="usd">5228100000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie241349e66f143e1b0f96548fcc184b5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfMTEtNC0xLTEtNzUxNDA_6c9282c0-0fea-4e1e-a221-13d9f5994466"
      unitRef="usd">181700000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1b5576a00f6d4d15946a9368e3767e64_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfMTEtNi0xLTEtNzUxNDA_d9832cca-b657-4107-bb63-eb0f510f8403"
      unitRef="usd">5046400000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i421472e2622c437d8bf685a39d6aecc3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfMTEtOC0xLTEtNzUxNDA_1d4ad76d-47d0-48e9-90ee-aba5a459cd26"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i264ccf816a664702a7ba8ff1332adb5a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfMTMtMi0xLTEtNzUxNDA_94b9abc8-6a75-4507-a66e-54801c7eeac0"
      unitRef="usd">10800000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="ie241349e66f143e1b0f96548fcc184b5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfMTMtNC0xLTEtNzUxNDA_9eeecdff-ccda-4b08-a2ed-04c464c411d4"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i1b5576a00f6d4d15946a9368e3767e64_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfMTMtNi0xLTEtNzUxNDA_4f7a7b15-f0fe-4453-8030-41a0ca4a06fa"
      unitRef="usd">10800000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i421472e2622c437d8bf685a39d6aecc3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfMTMtOC0xLTEtNzUxNDA_42792936-0a28-43c2-a6e6-39fadd3a53c5"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i264ccf816a664702a7ba8ff1332adb5a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfMTQtMi0xLTEtNzUxNDA_d5952c64-02b7-410f-a4f4-5f7257ee911a"
      unitRef="usd">209100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ie241349e66f143e1b0f96548fcc184b5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfMTQtNC0xLTEtNzUxNDA_f8497f34-74e2-4e08-ba24-72de26ee9349"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i1b5576a00f6d4d15946a9368e3767e64_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfMTQtNi0xLTEtNzUxNDA_5914ab19-e8a8-4ebc-9a1b-1c3da9464dda"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i421472e2622c437d8bf685a39d6aecc3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfMTQtOC0xLTEtNzUxNDA_fcf5477c-8384-45f6-897e-a41a74d6d908"
      unitRef="usd">209100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i264ccf816a664702a7ba8ff1332adb5a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfMTUtMi0xLTEtNzUxNDA_fd45a669-a587-4fdc-a0eb-10f3391d468d"
      unitRef="usd">219900000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ie241349e66f143e1b0f96548fcc184b5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfMTUtNC0xLTEtNzUxNDA_58d6a93c-d71e-4b19-b573-73bc9d52f921"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i1b5576a00f6d4d15946a9368e3767e64_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfMTUtNi0xLTEtNzUxNDA_f6bfff59-4461-4742-be94-45303d93e2b8"
      unitRef="usd">10800000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i421472e2622c437d8bf685a39d6aecc3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjIwNTdjNGIyZDhmOTQwYzM5YmFhNWFlMjBkODllMTU2L3RhYmxlcmFuZ2U6MjA1N2M0YjJkOGY5NDBjMzliYWE1YWUyMGQ4OWUxNTZfMTUtOC0xLTEtNzUxNDA_c4320e93-e8a2-4b54-99df-48121e10dd5e"
      unitRef="usd">209100000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetImpairmentCharges
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RleHRyZWdpb246ZmY0MDI4MzgxMGFkNDY5OWFjMzU4M2JmY2Y4NzkwMTNfMjgy_05c1abea-a748-4fe0-9b1c-805a48dbd6ca"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RleHRyZWdpb246ZmY0MDI4MzgxMGFkNDY5OWFjMzU4M2JmY2Y4NzkwMTNfMjgy_ded37167-7d51-4253-a28b-f12abc614620"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ia69f061a62954ac7af98aa5c677f4971_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOmM0MjZmMzZkZmQ5MjRkNDlhM2NlMzBmNGIxY2FhYTJlL3RhYmxlcmFuZ2U6YzQyNmYzNmRmZDkyNGQ0OWEzY2UzMGY0YjFjYWFhMmVfMy0yLTEtMS03NTE0MA_2f76279d-86ac-42ac-b10d-f26669c0785f"
      unitRef="usd">202000000.0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i4a551835cbc34cf1af2a3029ace704ab_I20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOmM0MjZmMzZkZmQ5MjRkNDlhM2NlMzBmNGIxY2FhYTJlL3RhYmxlcmFuZ2U6YzQyNmYzNmRmZDkyNGQ0OWEzY2UzMGY0YjFjYWFhMmVfMy04LTEtMS03NTE0MA_92f52db6-585a-4279-b6ea-3ce23e9bee5b"
      unitRef="number">0.0289</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i2985054f44d640bd846c15c69370c8e1_I20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOmM0MjZmMzZkZmQ5MjRkNDlhM2NlMzBmNGIxY2FhYTJlL3RhYmxlcmFuZ2U6YzQyNmYzNmRmZDkyNGQ0OWEzY2UzMGY0YjFjYWFhMmVfMy0xMC0xLTEtNzUxNDA_e47cad10-4c08-4bbc-8c9b-aecce7651b59"
      unitRef="number">0.0289</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i264ccf816a664702a7ba8ff1332adb5a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOmM0MjZmMzZkZmQ5MjRkNDlhM2NlMzBmNGIxY2FhYTJlL3RhYmxlcmFuZ2U6YzQyNmYzNmRmZDkyNGQ0OWEzY2UzMGY0YjFjYWFhMmVfOS0yLTEtMS03NTE0MA_d5952c64-02b7-410f-a4f4-5f7257ee911a"
      unitRef="usd">209100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i939e4f82661e4da6ab148f59a8ec8270_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOmM0MjZmMzZkZmQ5MjRkNDlhM2NlMzBmNGIxY2FhYTJlL3RhYmxlcmFuZ2U6YzQyNmYzNmRmZDkyNGQ0OWEzY2UzMGY0YjFjYWFhMmVfOS04LTEtMS03NTE0MA_e7d7f9c3-0e23-4a3f-b6f6-422e56627f6b"
      unitRef="number">0.0130</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i708bc707f83a45a6b58bb6226275def9_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOmM0MjZmMzZkZmQ5MjRkNDlhM2NlMzBmNGIxY2FhYTJlL3RhYmxlcmFuZ2U6YzQyNmYzNmRmZDkyNGQ0OWEzY2UzMGY0YjFjYWFhMmVfOS0xMC0xLTEtNzUxNDA_16d0bdf2-c257-4abb-bf35-8d93aca71ce0"
      unitRef="number">0.0130</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <biib:TechnologicalAndRegulatorySuccessProbability
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RleHRyZWdpb246ZmY0MDI4MzgxMGFkNDY5OWFjMzU4M2JmY2Y4NzkwMTNfMjA5Mg_c2f9371e-4cf5-4e1f-838b-372459ef001c"
      unitRef="number">0.109</biib:TechnologicalAndRegulatorySuccessProbability>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RleHRyZWdpb246ZmY0MDI4MzgxMGFkNDY5OWFjMzU4M2JmY2Y4NzkwMTNfNDkxNQ_84b73552-db30-4823-b152-de921229e378">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.091%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.625% Senior Notes due September 15, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,008.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;999.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,020.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;999.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.050% Senior Notes due September 15, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,797.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,743.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,895.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,742.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.250% Senior Notes due May 1, 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,341.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,492.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,475.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,492.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.200% Senior Notes due September 15, 2045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,240.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,463.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,099.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.150% Senior Notes due May 1, 2050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,225.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,473.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,457.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,473.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.250% Senior Notes due February 15, 2051&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;581.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;466.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;692.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;466.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,195.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,275.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,004.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,273.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="ic6518b6b1ff547bda3f65b2aff26f52a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfMy0yLTEtMS03NTE0MA_6623b696-de61-431a-9af5-df7a00b77e41"
      unitRef="usd">1008700000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="ic6518b6b1ff547bda3f65b2aff26f52a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfMy00LTEtMS03NTE0MA_2103e848-dbff-43d1-bd6c-aebe4bcfda84"
      unitRef="usd">999500000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="ief5ba800372a46ebb499feb08bd01f68_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfMy02LTEtMS03NTE0MA_c762e12d-782d-484a-8f90-e30a3bad482b"
      unitRef="usd">1020000000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="ief5ba800372a46ebb499feb08bd01f68_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfMy04LTEtMS03NTE0MA_6cd6831c-8ccb-4630-b7cb-0ec8e13b3c4a"
      unitRef="usd">999100000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i59761a7057b84b83b94391f9934d130e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfNC0yLTEtMS03NTE0MA_09fa1a83-9d4a-49c7-a662-6e9031e169f0"
      unitRef="usd">1797600000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i59761a7057b84b83b94391f9934d130e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfNC00LTEtMS03NTE0MA_b1800657-fd33-433b-88fe-f744b38a8b58"
      unitRef="usd">1743400000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="ie0eb428de5f74817b5197dce23437c27_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfNC02LTEtMS03NTE0MA_da26df59-c2e9-4c14-9078-fbee3dfb864c"
      unitRef="usd">1895200000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="ie0eb428de5f74817b5197dce23437c27_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfNC04LTEtMS03NTE0MA_aac8b47a-9a08-4505-840d-b913158e4358"
      unitRef="usd">1742900000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i9f6dd011d88b4ac782dc7a1775ddccb8_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfNS0yLTEtMS03NTE0MA_64d81b1d-98a0-42bb-8d1c-049552f0a055"
      unitRef="usd">1341600000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i9f6dd011d88b4ac782dc7a1775ddccb8_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfNS00LTEtMS03NTE0MA_0e6bebc5-e4b3-41e7-8d13-e6092ae6c7bc"
      unitRef="usd">1492200000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="id66b49914ec440e8ade962aeaba44c27_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfNS02LTEtMS03NTE0MA_b6161273-e87f-422e-9552-975574e88c42"
      unitRef="usd">1475900000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="id66b49914ec440e8ade962aeaba44c27_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfNS04LTEtMS03NTE0MA_78472c5c-744a-4992-81ed-9c1ca725d019"
      unitRef="usd">1492000000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i53483a1cc9e941e09201232721818ef2_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfNi0yLTEtMS03NTE0MA_8c7b34b2-e78f-4d60-8318-d8f1d790f92b"
      unitRef="usd">1240000000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i53483a1cc9e941e09201232721818ef2_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfNi00LTEtMS03NTE0MA_191655b7-446e-47f7-81f8-0ceb27b8a15e"
      unitRef="usd">1100000000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i4bed4b676403412ba1adb6018bde8953_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfNi02LTEtMS03NTE0MA_3e40bab0-2e62-48ca-9a7e-4c56a40b5aae"
      unitRef="usd">1463000000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i4bed4b676403412ba1adb6018bde8953_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfNi04LTEtMS03NTE0MA_878135d0-a68c-4e86-9777-951f840bb5b5"
      unitRef="usd">1099900000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="ib6864de98b5c49cab9140ebeace06324_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfNy0yLTEtMS03NTE0MA_721d6ab6-b8e1-4b7a-9be3-704012f2c6cc"
      unitRef="usd">1225300000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="ib6864de98b5c49cab9140ebeace06324_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfNy00LTEtMS03NTE0MA_6f06e62d-4a24-4ea0-a774-a95dd4fc7683"
      unitRef="usd">1473300000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i8e6a4a2c46af47cd94c9fdc6dd993664_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfNy02LTEtMS03NTE0MA_a2010bcc-4446-4319-8897-06e1bbd28bd7"
      unitRef="usd">1457700000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i8e6a4a2c46af47cd94c9fdc6dd993664_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfNy04LTEtMS03NTE0MA_5ac5e8d5-1fa1-4819-9ca3-45846399936e"
      unitRef="usd">1473200000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i3f6d74e47a314e6c9c9ceec4cbe4c782_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfOC0yLTEtMS03NTE0MA_039ef08d-b566-4f8a-bc25-a835774de367"
      unitRef="usd">581800000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i3f6d74e47a314e6c9c9ceec4cbe4c782_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfOC00LTEtMS03NTE0MA_2ecd6a67-cafe-4c50-be28-55000c8d233d"
      unitRef="usd">466800000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i6ec2168b953d46088128b4f2e3774ed2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfOC02LTEtMS03NTE0MA_a8d2d491-164d-46fe-ab0e-382835d3306c"
      unitRef="usd">692900000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i6ec2168b953d46088128b4f2e3774ed2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfOC04LTEtMS03NTE0MA_14bf7e91-5888-42b9-b04e-162a3ebc4ba8"
      unitRef="usd">466000000.0</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentFairValue
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfOS0yLTEtMS03NTE0MA_55fd020e-d05a-4e4a-9305-56f8df17d31a"
      unitRef="usd">7195000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:NotesPayable
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfOS00LTEtMS03NTE0MA_e949de00-6d7a-40f2-81ad-0f19b6067a9d"
      unitRef="usd">7275200000</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfOS02LTEtMS03NTE0MA_eae27cae-4a4a-486b-9b9b-3aa5c457cc39"
      unitRef="usd">8004700000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:NotesPayable
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjdhMGU1YzI4OTg2NTQ3ZjJhYzU5N2E4MDk2YzQ4MGNkL3RhYmxlcmFuZ2U6N2EwZTVjMjg5ODY1NDdmMmFjNTk3YTgwOTZjNDgwY2RfOS04LTEtMS03NTE0MA_ec78d7b3-e749-485e-b3c6-c8525b603fff"
      unitRef="usd">7273100000</us-gaap:NotesPayable>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RleHRyZWdpb246ZmY0MDI4MzgxMGFkNDY5OWFjMzU4M2JmY2Y4NzkwMTNfNDkwNA_ad10538f-26e1-44f9-b013-c717e5f6981d">The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(33.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value, end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;202.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;226.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i264ccf816a664702a7ba8ff1332adb5a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjRiNjFhMjBkYzdkNzRmN2JhODAwMmI1MzgxY2MzNGEzL3RhYmxlcmFuZ2U6NGI2MWEyMGRjN2Q3NGY3YmE4MDAyYjUzODFjYzM0YTNfMi0yLTEtMS03NTE0MA_04ac20e3-953f-4668-ae14-9656eaa3d7aa"
      unitRef="usd">209100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ief3a3f71bf3549c59cbe89249ff122bd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjRiNjFhMjBkYzdkNzRmN2JhODAwMmI1MzgxY2MzNGEzL3RhYmxlcmFuZ2U6NGI2MWEyMGRjN2Q3NGY3YmE4MDAyYjUzODFjYzM0YTNfMi00LTEtMS03NTE0MA_b5a77246-f39a-431a-8e4a-82474e365cdf"
      unitRef="usd">259800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjRiNjFhMjBkYzdkNzRmN2JhODAwMmI1MzgxY2MzNGEzL3RhYmxlcmFuZ2U6NGI2MWEyMGRjN2Q3NGY3YmE4MDAyYjUzODFjYzM0YTNfMy0yLTEtMS03NTE0MA_f0806090-8db0-4b8e-8e2e-a4616edb32b1"
      unitRef="usd">7100000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjRiNjFhMjBkYzdkNzRmN2JhODAwMmI1MzgxY2MzNGEzL3RhYmxlcmFuZ2U6NGI2MWEyMGRjN2Q3NGY3YmE4MDAyYjUzODFjYzM0YTNfMy00LTEtMS03NTE0MA_5ff1c09a-2d2b-4f86-8c47-84ecbdc3d19b"
      unitRef="usd">33800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ia69f061a62954ac7af98aa5c677f4971_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjRiNjFhMjBkYzdkNzRmN2JhODAwMmI1MzgxY2MzNGEzL3RhYmxlcmFuZ2U6NGI2MWEyMGRjN2Q3NGY3YmE4MDAyYjUzODFjYzM0YTNfNS0yLTEtMS03NTE0MA_84fd7349-fce2-484c-881f-09b4733aebc0"
      unitRef="usd">202000000.0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i0f6c7df5e15646bebd2254ac4e7a08fa_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RhYmxlOjRiNjFhMjBkYzdkNzRmN2JhODAwMmI1MzgxY2MzNGEzL3RhYmxlcmFuZ2U6NGI2MWEyMGRjN2Q3NGY3YmE4MDAyYjUzODFjYzM0YTNfNS00LTEtMS03NTE0MA_2fa45222-e1e4-4c5d-bfd4-c59f51bc3672"
      unitRef="usd">226000000.0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RleHRyZWdpb246ZmY0MDI4MzgxMGFkNDY5OWFjMzU4M2JmY2Y4NzkwMTNfMzg2Mg_e8717eb9-3fab-4877-8f55-b371fb9868e6"
      unitRef="usd">202000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl82Ny9mcmFnOmZmNDAyODM4MTBhZDQ2OTlhYzM1ODNiZmNmODc5MDEzL3RleHRyZWdpb246ZmY0MDI4MzgxMGFkNDY5OWFjMzU4M2JmY2Y4NzkwMTNfMzg2OQ_ac9c678a-e4b9-4c34-a6ae-d77186f3dab2"
      unitRef="usd">209100000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RleHRyZWdpb246NTYzMmJhNmE4ZDFkNDU1YmFmMTU2NGVjOTY4YjJmMzdfNDkxOQ_7fbe1d4c-d5bd-45dc-87d3-cf7784db7b8a">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;278.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;247.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Overnight reverse repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;585.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;901.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;406.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;283.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,283.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,632.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and short-term debt securities approximate fair value due to their short-term maturities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our marketable equity securities gains (losses) are recorded in other income (expense), net in our condensed consolidated statements of income. The following tables summarize our marketable debt and equity securities, classified as available-for-sale:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,126.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,124.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;460.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;454.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;878.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;877.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;379.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;375.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;173.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;171.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,019.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(16.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,004.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,133.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(311.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;826.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,167.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(311.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;860.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;723.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;723.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;385.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;384.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;817.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;816.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;377.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;376.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,435.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,433.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,133.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;151.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(279.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,004.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,167.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(279.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,048.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of Contractual Maturities: Available-for-Sale Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.924%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,002.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,006.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,541.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,541.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;982.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;993.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;868.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;870.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due after five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,004.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,019.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,433.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,435.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The average maturity of our marketable debt securities available-for-sale as of March 31, 2022 and December 31, 2021, was approximately 10 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Proceeds from Marketable Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Proceeds from maturities and sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;543.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;819.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realized losses for the three months ended&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March 31, 2022 and 2021, primarily relate to sales of corporate bonds, agency mortgage-backed securities and other asset-backed securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Strategic Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2022 and December 31, 2021, our strategic investment portfolio was comprised of investments totaling $919.5 million and $1,110.3 million, respectively, which are included in other current assets and investments and other assets in our condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 6, Fair Value Measurements,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these condensed consolidated financial statements, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The decrease in our strategic investment portfolio for the three months ended March 31, 2022, was primarily due to decreases in the fair value of our investments in Denali, Sage and Sangamo common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our investments in Denali, Ionis Pharmaceuticals, Inc. (Ionis), Sage and Sangamo common stock, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to our consolidated financial statements included in our 2021 Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RleHRyZWdpb246NTYzMmJhNmE4ZDFkNDU1YmFmMTU2NGVjOTY4YjJmMzdfNDkzNA_57bf3d85-03f3-4e2b-a44b-edcfbaf0fb47">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;278.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;247.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Overnight reverse repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;585.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;901.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;406.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;283.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,283.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,632.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="ie1a0391f5d734ca4b2c1b7de94fd8721_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjA2NmMxOTY2MzQzNzQ4NzRiNDYzNTg0ODM3ODM5NGU2L3RhYmxlcmFuZ2U6MDY2YzE5NjYzNDM3NDg3NGI0NjM1ODQ4Mzc4Mzk0ZTZfMS0yLTEtMS03NTE0MA_7132be67-090b-4c5d-a0ad-c774bf2a9259"
      unitRef="usd">278500000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i8c2efbd4b9c74a8da864a279a9e91498_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjA2NmMxOTY2MzQzNzQ4NzRiNDYzNTg0ODM3ODM5NGU2L3RhYmxlcmFuZ2U6MDY2YzE5NjYzNDM3NDg3NGI0NjM1ODQ4Mzc4Mzk0ZTZfMS00LTEtMS03NTE0MA_c3d70c5f-ef67-4e92-bf45-46e969e83c3a"
      unitRef="usd">247600000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="ieed6ef51023543d0bb40d96a559c5941_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjA2NmMxOTY2MzQzNzQ4NzRiNDYzNTg0ODM3ODM5NGU2L3RhYmxlcmFuZ2U6MDY2YzE5NjYzNDM3NDg3NGI0NjM1ODQ4Mzc4Mzk0ZTZfMi0yLTEtMS03NTE0MA_1df19e27-6bcc-4de5-9054-6d521158c671"
      unitRef="usd">13900000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i0c8bc783a7334b3d8875f060ac7bb1a2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjA2NmMxOTY2MzQzNzQ4NzRiNDYzNTg0ODM3ODM5NGU2L3RhYmxlcmFuZ2U6MDY2YzE5NjYzNDM3NDg3NGI0NjM1ODQ4Mzc4Mzk0ZTZfMi00LTEtMS03NTE0MA_e9d3c001-27c4-496a-b11c-4172ddf4bcbf"
      unitRef="usd">200000000.0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i185e162f6d4545b68e3749067e1070d6_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjA2NmMxOTY2MzQzNzQ4NzRiNDYzNTg0ODM3ODM5NGU2L3RhYmxlcmFuZ2U6MDY2YzE5NjYzNDM3NDg3NGI0NjM1ODQ4Mzc4Mzk0ZTZfMy0yLTEtMS03NTE0MA_12b1dc06-642e-4b3f-b706-67f425472384"
      unitRef="usd">585000000.0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="if1e2bbc4c00345d494de8e8b436b2968_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjA2NmMxOTY2MzQzNzQ4NzRiNDYzNTg0ODM3ODM5NGU2L3RhYmxlcmFuZ2U6MDY2YzE5NjYzNDM3NDg3NGI0NjM1ODQ4Mzc4Mzk0ZTZfMy00LTEtMS03NTE0MA_f0e13d50-7f32-4491-9a85-f281b8795f97"
      unitRef="usd">901600000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i8bf885a6fb7c456e9521985a665b058e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjA2NmMxOTY2MzQzNzQ4NzRiNDYzNTg0ODM3ODM5NGU2L3RhYmxlcmFuZ2U6MDY2YzE5NjYzNDM3NDg3NGI0NjM1ODQ4Mzc4Mzk0ZTZfNC0yLTEtMS03NTE0MA_f0ba5617-0985-41fb-8003-9c1db675b0b9"
      unitRef="usd">406300000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i11d469fdaeea46ac984f86f25cf7aefd_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjA2NmMxOTY2MzQzNzQ4NzRiNDYzNTg0ODM3ODM5NGU2L3RhYmxlcmFuZ2U6MDY2YzE5NjYzNDM3NDg3NGI0NjM1ODQ4Mzc4Mzk0ZTZfNC00LTEtMS03NTE0MA_e7e41ef7-1cc6-48d9-9988-03fe9a30981e"
      unitRef="usd">283000000.0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjA2NmMxOTY2MzQzNzQ4NzRiNDYzNTg0ODM3ODM5NGU2L3RhYmxlcmFuZ2U6MDY2YzE5NjYzNDM3NDg3NGI0NjM1ODQ4Mzc4Mzk0ZTZfNS0yLTEtMS03NTE0MA_e618e560-0571-473e-94ce-a9536baab4bc"
      unitRef="usd">1283700000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjA2NmMxOTY2MzQzNzQ4NzRiNDYzNTg0ODM3ODM5NGU2L3RhYmxlcmFuZ2U6MDY2YzE5NjYzNDM3NDg3NGI0NjM1ODQ4Mzc4Mzk0ZTZfNS00LTEtMS03NTE0MA_d9e5b0ae-2591-4adc-b52e-07435343c9b4"
      unitRef="usd">1632200000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RleHRyZWdpb246NTYzMmJhNmE4ZDFkNDU1YmFmMTU2NGVjOTY4YjJmMzdfNDkyNA_c79cbf31-3e57-43ed-824b-6f660b3d849d">The following tables summarize our marketable debt and equity securities, classified as available-for-sale:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,126.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,124.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;460.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;454.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;878.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;877.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;379.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;375.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;173.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;171.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,019.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(16.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,004.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,133.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(311.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;826.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,167.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(311.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;860.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;723.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;723.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;385.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;384.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;817.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;816.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;377.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;376.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,435.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,433.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,133.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;151.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(279.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,004.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,167.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(279.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,048.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i154d489ea3c6499a8e77ce72f6e567a2_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfNC0yLTEtMS03NTE0MA_f5443610-1346-4318-9932-d4c4ca259809"
      unitRef="usd">1126700000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i154d489ea3c6499a8e77ce72f6e567a2_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfNC00LTEtMS03NTE0MA_700e87b1-8a5c-4595-bfe6-061f9ddf920d"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i154d489ea3c6499a8e77ce72f6e567a2_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfNC02LTEtMS03NTE0MA_674af1c5-8bbe-400d-b277-96b0c08cd7e4"
      unitRef="usd">2200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i154d489ea3c6499a8e77ce72f6e567a2_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfNC04LTEtMS03NTE0MA_8e82077b-ed4a-454e-94af-cba515eb64f7"
      unitRef="usd">1124600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iabd8430987f44ff08faf10d31756ef75_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfNS0yLTEtMS03NTE0MA_e9a4aa30-2ebb-4e37-8aef-e32ebd7b93ea"
      unitRef="usd">460500000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iabd8430987f44ff08faf10d31756ef75_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfNS00LTEtMS03NTE0MA_4d9cf59e-0234-45c7-b2a2-2106d3bff7db"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iabd8430987f44ff08faf10d31756ef75_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfNS02LTEtMS03NTE0MA_d69b734d-fa55-45f5-acbb-58008ac637ea"
      unitRef="usd">5800000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iabd8430987f44ff08faf10d31756ef75_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfNS04LTEtMS03NTE0MA_19cd3d39-d995-4b27-9ec8-3821749416d6"
      unitRef="usd">454800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iaf11806fefce4b389ac4b64510af48f2_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfNy0yLTEtMS03NTE0MA_9da8f849-fecb-40bd-88b8-cccde3ea6bbf"
      unitRef="usd">878700000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iaf11806fefce4b389ac4b64510af48f2_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfNy00LTEtMS03NTE0MA_fac81ed8-f696-4b86-a846-7834b0f1ca42"
      unitRef="usd">1000000.0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iaf11806fefce4b389ac4b64510af48f2_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfNy02LTEtMS03NTE0MA_cee0142e-6150-4f2a-9598-2abd78a9bc34"
      unitRef="usd">2600000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaf11806fefce4b389ac4b64510af48f2_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfNy04LTEtMS03NTE0MA_2ce09a25-dad5-4db9-a1d4-2daacfe90a1d"
      unitRef="usd">877100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie09432231a464e39a944c6a44cd6b69c_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfOC0yLTEtMS03NTE0MA_a9c6b7b7-bb3e-43fd-a5e6-56a8c7fe7f82"
      unitRef="usd">379000000.0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie09432231a464e39a944c6a44cd6b69c_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfOC00LTEtMS03NTE0MA_a982bb42-be10-4f46-88f7-0cd115a084e1"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie09432231a464e39a944c6a44cd6b69c_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfOC02LTEtMS03NTE0MA_26ea3104-7ca3-4fba-b27e-0d4e4b57e579"
      unitRef="usd">3600000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie09432231a464e39a944c6a44cd6b69c_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfOC04LTEtMS03NTE0MA_0bf87e6c-6489-4d6c-9231-6e3f41e6009e"
      unitRef="usd">375600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i96ee067d94d34ad18d8184a7addb8ae6_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfMTAtMi0xLTEtNzUxNDA_7e09e259-a963-499d-852d-ca90907f6283"
      unitRef="usd">700000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i96ee067d94d34ad18d8184a7addb8ae6_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfMTAtNC0xLTEtNzUxNDA_c446c2ed-c44c-477b-9a49-5558f00cbb72"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i96ee067d94d34ad18d8184a7addb8ae6_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfMTAtNi0xLTEtNzUxNDA_8a69d706-5bf8-4aa5-b713-b4af553768de"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i96ee067d94d34ad18d8184a7addb8ae6_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfMTAtOC0xLTEtNzUxNDA_c7fdcc46-218c-4fc6-b997-013b890f64a1"
      unitRef="usd">700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4cd3f693083d457bbe88209270fd1b39_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfMTEtMi0xLTEtNzUxNDA_6d66c31e-1963-49ca-abca-c780c4b857bb"
      unitRef="usd">173400000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4cd3f693083d457bbe88209270fd1b39_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfMTEtNC0xLTEtNzUxNDA_4b6b7e30-4216-4aec-972d-9fa1d2ddcbab"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4cd3f693083d457bbe88209270fd1b39_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfMTEtNi0xLTEtNzUxNDA_296bc1aa-e493-4070-9ef4-feb15b4207f3"
      unitRef="usd">2200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4cd3f693083d457bbe88209270fd1b39_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfMTEtOC0xLTEtNzUxNDA_265b04e8-4de9-4c21-bbfd-5c993aae8425"
      unitRef="usd">171200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfMTItMi0xLTEtNzUxNDA_cbff79b6-887b-44bf-8b2f-e01357dcbcac"
      unitRef="usd">3019000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfMTItNC0xLTEtNzUxNDA_0bdc1be1-006b-4752-b331-814482f2d22e"
      unitRef="usd">1400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfMTItNi0xLTEtNzUxNDA_2cb50029-fa4e-42c6-892b-ae4a14abfda6"
      unitRef="usd">16400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfMTItOC0xLTEtNzUxNDA_889e54ba-0535-4d90-bed8-4037b2cc5277"
      unitRef="usd">3004000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="i0d92b30f82ea4eed911cc841fff8bf84_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfMTUtMi0xLTEtNzUxNDA_c80c9b1b-8850-4bd2-bbd1-af1633e1e5e3"
      unitRef="usd">33900000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0d92b30f82ea4eed911cc841fff8bf84_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfMTUtNC0xLTEtNzUxNDA_c171ecc0-bbcb-41f5-b0d7-868fe52b8631"
      unitRef="usd">0</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0d92b30f82ea4eed911cc841fff8bf84_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfMTUtNi0xLTEtNzUxNDA_d1b8416a-45ce-4fe7-8f49-523e3e4c524f"
      unitRef="usd">0</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i0d92b30f82ea4eed911cc841fff8bf84_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfMTUtOC0xLTEtNzUxNDA_5b1cf6f8-8ec2-4daa-9409-9052b287cde4"
      unitRef="usd">33900000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="ia3b43bd6e13a4a9c9403015c85ba502f_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfMTYtMi0xLTEtNzUxNDA_46d62430-75dc-4cb9-a928-338579f45d01"
      unitRef="usd">1133100000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia3b43bd6e13a4a9c9403015c85ba502f_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfMTYtNC0xLTEtNzUxNDA_b6211fe0-597d-44af-ae3b-5c4310dec64c"
      unitRef="usd">4500000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia3b43bd6e13a4a9c9403015c85ba502f_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfMTYtNi0xLTEtNzUxNDA_c9153dfe-c59f-4e82-b2ae-aa41ed12cbb7"
      unitRef="usd">311200000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ia3b43bd6e13a4a9c9403015c85ba502f_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfMTYtOC0xLTEtNzUxNDA_bbe9a9bc-b57e-47f7-8c65-aaad103a7a34"
      unitRef="usd">826400000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfMTctMi0xLTEtNzUxNDA_6b17208d-385f-49fe-b27f-e3ad5c22e44f"
      unitRef="usd">1167000000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfMTctNC0xLTEtNzUxNDA_7f2e13f1-5131-4dd8-a976-32eaf2358270"
      unitRef="usd">4500000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfMTctNi0xLTEtNzUxNDA_9d650054-413f-4aa2-b586-9562b4f94ae2"
      unitRef="usd">311200000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjJhOGJkZGEyNjhiNDQyOTI5NzhkOTAyOWFmZjkyMTdkL3RhYmxlcmFuZ2U6MmE4YmRkYTI2OGI0NDI5Mjk3OGQ5MDI5YWZmOTIxN2RfMTctOC0xLTEtNzUxNDA_cac40bab-7675-4d98-b08a-10f80bd6b5c6"
      unitRef="usd">860300000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic4c19e0ddd2b4245bded3c176e7644d5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfNC0yLTEtMS03NTE0MA_70cc922a-ed53-4821-bd8e-15ee4c4259d7"
      unitRef="usd">723600000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic4c19e0ddd2b4245bded3c176e7644d5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfNC00LTEtMS03NTE0MA_30b6b30a-2c47-41c1-9e1d-a2b1d364bf10"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic4c19e0ddd2b4245bded3c176e7644d5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfNC02LTEtMS03NTE0MA_160a8844-986e-4c5c-afaf-95006b05d18b"
      unitRef="usd">300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic4c19e0ddd2b4245bded3c176e7644d5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfNC04LTEtMS03NTE0MA_7880e81d-5d38-449f-b590-40c9a2362098"
      unitRef="usd">723400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id7202374646d4a99bbde3c93490e6ecd_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfNS0yLTEtMS03NTE0MA_ed8c05b5-b866-46be-affe-a3184a5a392a"
      unitRef="usd">385400000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id7202374646d4a99bbde3c93490e6ecd_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfNS00LTEtMS03NTE0MA_c11028f2-7306-427c-82f4-7f26847bf822"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id7202374646d4a99bbde3c93490e6ecd_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfNS02LTEtMS03NTE0MA_f88a1a8a-54f1-4649-ae5a-93cb70bd691b"
      unitRef="usd">800000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id7202374646d4a99bbde3c93490e6ecd_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfNS04LTEtMS03NTE0MA_bc1b1dd7-759d-41cb-9f3e-12994e02ba77"
      unitRef="usd">384800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="icd0e0d8d79a54c8e9e1b178519ddc273_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfNy0yLTEtMS03NTE0MA_46dade40-b455-471a-adc8-33b2ede82248"
      unitRef="usd">817000000.0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="icd0e0d8d79a54c8e9e1b178519ddc273_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfNy00LTEtMS03NTE0MA_2e65aaa8-ee5c-4337-aeeb-c29ca80c8381"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="icd0e0d8d79a54c8e9e1b178519ddc273_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfNy02LTEtMS03NTE0MA_d7da48fc-bac7-4beb-8871-73dfdeae1830"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icd0e0d8d79a54c8e9e1b178519ddc273_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfNy04LTEtMS03NTE0MA_bc388dc5-e737-4f52-bc07-60bc3e6e7e69"
      unitRef="usd">816600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib018ee899f4e4ac48084e28043d8cddf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfOC0yLTEtMS03NTE0MA_af784bde-4a8a-4423-a8ff-8beede11fee7"
      unitRef="usd">377000000.0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib018ee899f4e4ac48084e28043d8cddf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfOC00LTEtMS03NTE0MA_2388bcbe-cb9c-48e6-acbd-db1f7357d7e5"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib018ee899f4e4ac48084e28043d8cddf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfOC02LTEtMS03NTE0MA_7db62285-78bc-4569-8f9c-17fefd10bd99"
      unitRef="usd">1000000.0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib018ee899f4e4ac48084e28043d8cddf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfOC04LTEtMS03NTE0MA_df5cf0e5-1631-42d6-b013-5c651ffa586f"
      unitRef="usd">376100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5d2052cb740a446b8e69b4604e07264e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfMTAtMi0xLTEtNzUxNDA_d6476403-0168-4572-b73d-5e5995fdfa56"
      unitRef="usd">1100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5d2052cb740a446b8e69b4604e07264e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfMTAtNC0xLTEtNzUxNDA_55115496-77eb-4511-b901-2b3c1d66a1bb"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5d2052cb740a446b8e69b4604e07264e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfMTAtNi0xLTEtNzUxNDA_ddb9405a-26dd-4c77-ae16-f32b4f38ef35"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5d2052cb740a446b8e69b4604e07264e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfMTAtOC0xLTEtNzUxNDA_0418f578-5275-40d8-9411-a8695df8cf30"
      unitRef="usd">1100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8e32269d553441f28cfce5965c1b73f6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfMTEtMi0xLTEtNzUxNDA_3a3bc388-f650-4bde-8d9b-3b7b69ef44ed"
      unitRef="usd">131800000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8e32269d553441f28cfce5965c1b73f6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfMTEtNC0xLTEtNzUxNDA_169e7b2e-fe12-4e9e-8346-13d0e666e2de"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8e32269d553441f28cfce5965c1b73f6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfMTEtNi0xLTEtNzUxNDA_86d5b1aa-3385-4073-a8dd-65b2fc7c9b5d"
      unitRef="usd">700000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8e32269d553441f28cfce5965c1b73f6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfMTEtOC0xLTEtNzUxNDA_349c0552-6da1-4ad1-b6b6-8a1bd8789057"
      unitRef="usd">131100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfMTItMi0xLTEtNzUxNDA_a103a534-606c-463f-87f6-5af4e13e9827"
      unitRef="usd">2435900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfMTItNC0xLTEtNzUxNDA_7b0cde6b-7c3f-497a-94a1-a91ab7e2009b"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfMTItNi0xLTEtNzUxNDA_a6bc9266-e8fd-4b43-a12a-15bb80496371"
      unitRef="usd">3200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfMTItOC0xLTEtNzUxNDA_47f6d57c-141b-40fa-8eb7-fe06e3c97a23"
      unitRef="usd">2433100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="i4753836c14c24f67acbeca373ca2d5d4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfMTUtMi0xLTEtNzUxNDA_78186751-3e5e-408e-84cf-d27b6f6894a6"
      unitRef="usd">33900000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4753836c14c24f67acbeca373ca2d5d4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfMTUtNC0xLTEtNzUxNDA_f5ba22dc-8205-41dc-9171-6bf3508fb90f"
      unitRef="usd">9900000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4753836c14c24f67acbeca373ca2d5d4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfMTUtNi0xLTEtNzUxNDA_b1f84b21-a12a-4b95-9475-548d9891673b"
      unitRef="usd">0</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i4753836c14c24f67acbeca373ca2d5d4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfMTUtOC0xLTEtNzUxNDA_a5f274b3-3b8a-4487-a831-87eb61dc1424"
      unitRef="usd">43800000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="i441022c1a0eb4576a80a097476642f3d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfMTYtMi0xLTEtNzUxNDA_4a3f112d-b9ad-4c0f-a439-2bc132ae22f4"
      unitRef="usd">1133100000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i441022c1a0eb4576a80a097476642f3d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfMTYtNC0xLTEtNzUxNDA_49f93c17-28ee-4da7-8804-092b4da33d1b"
      unitRef="usd">151000000.0</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i441022c1a0eb4576a80a097476642f3d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfMTYtNi0xLTEtNzUxNDA_4d198ae9-87cd-4a4f-b4d3-be3072c2bc67"
      unitRef="usd">279400000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i441022c1a0eb4576a80a097476642f3d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfMTYtOC0xLTEtNzUxNDA_e55f6364-4be3-47bd-9af8-1f18109ed377"
      unitRef="usd">1004700000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfMTctMi0xLTEtNzUxNDA_6e4f1624-bb0c-4849-b366-f31e2d93e4b3"
      unitRef="usd">1167000000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfMTctNC0xLTEtNzUxNDA_9eb5f849-4e2e-48bb-8011-02a9dd55c0d9"
      unitRef="usd">160900000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfMTctNi0xLTEtNzUxNDA_4e7a07a3-77c9-41a8-8a63-da3369017a65"
      unitRef="usd">279400000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmQ2YzNkM2E0N2QwMzQ0ODhiYzcwMDE5NmRlOTdhNzczL3RhYmxlcmFuZ2U6ZDZjM2QzYTQ3ZDAzNDQ4OGJjNzAwMTk2ZGU5N2E3NzNfMTctOC0xLTEtNzUxNDA_6f91b020-d50a-4cb6-8c0e-2206553b2ba1"
      unitRef="usd">1048500000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RleHRyZWdpb246NTYzMmJhNmE4ZDFkNDU1YmFmMTU2NGVjOTY4YjJmMzdfNDkzNw_39f401c8-48fe-44e5-80b3-6b2a2055c3dd">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.924%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,002.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,006.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,541.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,541.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;982.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;993.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;868.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;870.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due after five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,004.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,019.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,433.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,435.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmUxZGZiZTdiNTVlNDQyOWRhNzFjNDZmNjVlMzdlN2I5L3RhYmxlcmFuZ2U6ZTFkZmJlN2I1NWU0NDI5ZGE3MWM0NmY2NWUzN2U3YjlfMi0yLTEtMS03NTE0MA_fbb38f1d-6824-49e9-ad1c-3664fcbaa4a3"
      unitRef="usd">2002400000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmUxZGZiZTdiNTVlNDQyOWRhNzFjNDZmNjVlMzdlN2I5L3RhYmxlcmFuZ2U6ZTFkZmJlN2I1NWU0NDI5ZGE3MWM0NmY2NWUzN2U3YjlfMi00LTEtMS03NTE0MA_926b0068-20a7-4484-805a-3d9b150bad59"
      unitRef="usd">2006000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmUxZGZiZTdiNTVlNDQyOWRhNzFjNDZmNjVlMzdlN2I5L3RhYmxlcmFuZ2U6ZTFkZmJlN2I1NWU0NDI5ZGE3MWM0NmY2NWUzN2U3YjlfMi02LTEtMS03NTE0MA_1779927e-7791-422a-8583-592e8c8b04a6"
      unitRef="usd">1541100000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmUxZGZiZTdiNTVlNDQyOWRhNzFjNDZmNjVlMzdlN2I5L3RhYmxlcmFuZ2U6ZTFkZmJlN2I1NWU0NDI5ZGE3MWM0NmY2NWUzN2U3YjlfMi04LTEtMS03NTE0MA_965f7f0d-74a6-4a77-9887-8b58b13e280e"
      unitRef="usd">1541700000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmUxZGZiZTdiNTVlNDQyOWRhNzFjNDZmNjVlMzdlN2I5L3RhYmxlcmFuZ2U6ZTFkZmJlN2I1NWU0NDI5ZGE3MWM0NmY2NWUzN2U3YjlfMy0yLTEtMS03NTE0MA_3fc54cfc-1f80-49a7-a333-1204ea9dcf7f"
      unitRef="usd">982900000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmUxZGZiZTdiNTVlNDQyOWRhNzFjNDZmNjVlMzdlN2I5L3RhYmxlcmFuZ2U6ZTFkZmJlN2I1NWU0NDI5ZGE3MWM0NmY2NWUzN2U3YjlfMy00LTEtMS03NTE0MA_ae4908f2-d52b-46cc-b37e-1d11ad90faa0"
      unitRef="usd">993700000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmUxZGZiZTdiNTVlNDQyOWRhNzFjNDZmNjVlMzdlN2I5L3RhYmxlcmFuZ2U6ZTFkZmJlN2I1NWU0NDI5ZGE3MWM0NmY2NWUzN2U3YjlfMy02LTEtMS03NTE0MA_5670c6fb-e9d5-4fb7-93ee-2085a3230ffa"
      unitRef="usd">868200000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmUxZGZiZTdiNTVlNDQyOWRhNzFjNDZmNjVlMzdlN2I5L3RhYmxlcmFuZ2U6ZTFkZmJlN2I1NWU0NDI5ZGE3MWM0NmY2NWUzN2U3YjlfMy04LTEtMS03NTE0MA_1c206c2b-09b3-4a8f-b0a5-c4e793338506"
      unitRef="usd">870200000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmUxZGZiZTdiNTVlNDQyOWRhNzFjNDZmNjVlMzdlN2I5L3RhYmxlcmFuZ2U6ZTFkZmJlN2I1NWU0NDI5ZGE3MWM0NmY2NWUzN2U3YjlfNC0yLTEtMS03NTE0MA_ae8a814e-67e4-4ffe-8bf3-e0037553c5b1"
      unitRef="usd">18700000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmUxZGZiZTdiNTVlNDQyOWRhNzFjNDZmNjVlMzdlN2I5L3RhYmxlcmFuZ2U6ZTFkZmJlN2I1NWU0NDI5ZGE3MWM0NmY2NWUzN2U3YjlfNC00LTEtMS03NTE0MA_d6f1658f-ff9c-4d8a-8ecc-11d191d48cff"
      unitRef="usd">19300000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmUxZGZiZTdiNTVlNDQyOWRhNzFjNDZmNjVlMzdlN2I5L3RhYmxlcmFuZ2U6ZTFkZmJlN2I1NWU0NDI5ZGE3MWM0NmY2NWUzN2U3YjlfNC02LTEtMS03NTE0MA_30a4102f-6962-48f3-b690-68a0c8b79800"
      unitRef="usd">23800000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmUxZGZiZTdiNTVlNDQyOWRhNzFjNDZmNjVlMzdlN2I5L3RhYmxlcmFuZ2U6ZTFkZmJlN2I1NWU0NDI5ZGE3MWM0NmY2NWUzN2U3YjlfNC04LTEtMS03NTE0MA_845c034c-126b-48c7-a9eb-51efc4db7ab2"
      unitRef="usd">24000000.0</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmUxZGZiZTdiNTVlNDQyOWRhNzFjNDZmNjVlMzdlN2I5L3RhYmxlcmFuZ2U6ZTFkZmJlN2I1NWU0NDI5ZGE3MWM0NmY2NWUzN2U3YjlfNS0yLTEtMS03NTE0MA_da88f0ae-5d4a-4124-9ae7-c42ebc4678fa"
      unitRef="usd">3004000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmUxZGZiZTdiNTVlNDQyOWRhNzFjNDZmNjVlMzdlN2I5L3RhYmxlcmFuZ2U6ZTFkZmJlN2I1NWU0NDI5ZGE3MWM0NmY2NWUzN2U3YjlfNS00LTEtMS03NTE0MA_1909d69b-3944-4a83-b7fb-f72f6a1f9515"
      unitRef="usd">3019000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmUxZGZiZTdiNTVlNDQyOWRhNzFjNDZmNjVlMzdlN2I5L3RhYmxlcmFuZ2U6ZTFkZmJlN2I1NWU0NDI5ZGE3MWM0NmY2NWUzN2U3YjlfNS02LTEtMS03NTE0MA_82e3c898-32ec-451e-81aa-0a3365e98936"
      unitRef="usd">2433100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOmUxZGZiZTdiNTVlNDQyOWRhNzFjNDZmNjVlMzdlN2I5L3RhYmxlcmFuZ2U6ZTFkZmJlN2I1NWU0NDI5ZGE3MWM0NmY2NWUzN2U3YjlfNS04LTEtMS03NTE0MA_73f0a9d8-6483-4bbc-813e-95153e95e472"
      unitRef="usd">2435900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <biib:AverageMaturityOfMarketableSecurities
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RleHRyZWdpb246NTYzMmJhNmE4ZDFkNDU1YmFmMTU2NGVjOTY4YjJmMzdfMTAyMw_46707cf7-a575-4a41-a85c-758aff2c58c8">P10M</biib:AverageMaturityOfMarketableSecurities>
    <biib:AverageMaturityOfMarketableSecurities
      contextRef="iaf0a6c3fc8694a58a8f2838a236b6959_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RleHRyZWdpb246NTYzMmJhNmE4ZDFkNDU1YmFmMTU2NGVjOTY4YjJmMzdfMTAyMw_dfa8c8e1-210b-4258-83cb-684bcd85d710">P10M</biib:AverageMaturityOfMarketableSecurities>
    <us-gaap:RealizedGainLossOnInvestmentsTableTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RleHRyZWdpb246NTYzMmJhNmE4ZDFkNDU1YmFmMTU2NGVjOTY4YjJmMzdfNDk0OA_3a5a49be-eeef-4059-b24b-be4cd01a1019">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Proceeds from maturities and sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;543.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;819.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RealizedGainLossOnInvestmentsTableTextBlock>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjNjMTI4NzJlY2U2YjQwNTVhNDFiMzUwN2RkNDRjNDQ1L3RhYmxlcmFuZ2U6M2MxMjg3MmVjZTZiNDA1NWE0MWIzNTA3ZGQ0NGM0NDVfMi0yLTEtMS03NTE0MA_5e134050-ce75-4181-a218-2a624ebacc15"
      unitRef="usd">543600000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjNjMTI4NzJlY2U2YjQwNTVhNDFiMzUwN2RkNDRjNDQ1L3RhYmxlcmFuZ2U6M2MxMjg3MmVjZTZiNDA1NWE0MWIzNTA3ZGQ0NGM0NDVfMi00LTEtMS03NTE0MA_fa02abca-8b5a-4ef7-b426-22c6dee1ae94"
      unitRef="usd">819200000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjNjMTI4NzJlY2U2YjQwNTVhNDFiMzUwN2RkNDRjNDQ1L3RhYmxlcmFuZ2U6M2MxMjg3MmVjZTZiNDA1NWE0MWIzNTA3ZGQ0NGM0NDVfMy0yLTEtMS03NTE0MA_468e1b42-6706-475f-b035-64e590d63e03"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjNjMTI4NzJlY2U2YjQwNTVhNDFiMzUwN2RkNDRjNDQ1L3RhYmxlcmFuZ2U6M2MxMjg3MmVjZTZiNDA1NWE0MWIzNTA3ZGQ0NGM0NDVfMy00LTEtMS03NTE0MA_14f60ba8-9079-4491-8437-9e3066610567"
      unitRef="usd">200000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjNjMTI4NzJlY2U2YjQwNTVhNDFiMzUwN2RkNDRjNDQ1L3RhYmxlcmFuZ2U6M2MxMjg3MmVjZTZiNDA1NWE0MWIzNTA3ZGQ0NGM0NDVfNC0yLTEtMS03NTE0MA_66ddcb20-1510-4350-a061-e466fd680831"
      unitRef="usd">-600000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RhYmxlOjNjMTI4NzJlY2U2YjQwNTVhNDFiMzUwN2RkNDRjNDQ1L3RhYmxlcmFuZ2U6M2MxMjg3MmVjZTZiNDA1NWE0MWIzNTA3ZGQ0NGM0NDVfNC00LTEtMS03NTE0MA_6a79f16f-01bb-4421-a83f-14c1eae2213e"
      unitRef="usd">-700000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <biib:StrategicInvestmentPortfolio
      contextRef="i3803e965a1724d08a4f85f6e2e7521f4_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RleHRyZWdpb246NTYzMmJhNmE4ZDFkNDU1YmFmMTU2NGVjOTY4YjJmMzdfMTMzOQ_f6a662b2-dfe5-496e-b2bf-418aadf5806b"
      unitRef="usd">919500000</biib:StrategicInvestmentPortfolio>
    <biib:StrategicInvestmentPortfolio
      contextRef="i7fc3a5a6750b4a08b8ea8136ff17e32f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83My9mcmFnOjU2MzJiYTZhOGQxZDQ1NWJhZjE1NjRlYzk2OGIyZjM3L3RleHRyZWdpb246NTYzMmJhNmE4ZDFkNDU1YmFmMTU2NGVjOTY4YjJmMzdfMTM0Ng_d995ff3e-4987-44b5-99dd-081e8646f573"
      unitRef="usd">1110300000</biib:StrategicInvestmentPortfolio>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfNjk2MA_ac5f7b98-8129-4aea-bda7-d2a0623c07b7">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Forward Contracts - Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the global nature of our operations, portions of our revenue and operating expense are recorded in currencies other than the U.S.&#160;dollar. The value of revenue and operating expense measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes, we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenue and operating expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign currency forward contracts in effect as of March 31, 2022 and December 31, 2021, had durations of 1 to &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18 months&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and 1 to 15 months, respectively. These contracts have been designated as cash flow hedges and unrealized gains or losses on the portion of these foreign currency forward contracts that are included in the effectiveness test are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the table below). Realized gains and losses of such contracts are recognized in revenue when the sale of product in the currency being hedged is recognized and in operating expense when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from accumulated other comprehensive income (loss) and fair value changes of excluded portions in the same line item in our condensed consolidated statements of income that has been impacted by the hedged item.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The notional amount of foreign currency forward contracts that were entered into to hedge forecasted revenue and operating expense is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Euro&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,631.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,828.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;British pound&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;126.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;166.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Swiss franc&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Japanese yen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canadian dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,986.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,126.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.785%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net unrealized gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We expect the net unrealized gains of $72.1&#160;million to be settled over the next 18 months, of which $72.0 million of these net unrealized gains are expected to be settled over the next 12 months, with any amounts in &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;accumulated other comprehensive income (loss) to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties&#x2019; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of March 31, 2022 and December 31, 2021, credit risk did not materially change the fair value of our foreign currency forward contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.154%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(23.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Investment Hedges - Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately 5.0% to approximately 49.9%. The share purchase transaction was completed in November 2018 and, upon closing, we paid 759.5 billion South Korean won ($676.6 million) to Samsung BioLogics. Our investment in the equity of Samsung Bioepis is exposed to the currency fluctuations in the South Korean won. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to mitigate the currency fluctuations between the U.S. dollar and South Korean won, we have entered into foreign currency forward contracts. Foreign currency forward contracts in effect as of March 31, 2022, had a remaining duration of seven months. These contracts have been designated as net investment hedges. We recognize changes in the spot exchange rate in accumulated other comprehensive income (loss). The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of $20.6 million and $10.6 million as of March 31, 2022 and December 31, 2021, respectively. We exclude fair value changes related to the forward rate from our hedging relationship and will amortize the forward points in other income (expense), net in our condensed consolidated statements of income over the term of the contract. The pre-tax portion of the fair value of the forward points that were included in accumulated other comprehensive income (loss) in total equity reflected net losses of $2.5 million and $3.6 million as of March 31, 2022 and December 31, 2021, respectively. In conjunction with the closing of our sale of equity in Samsung Bioepis to Samsung BioLogics, which occurred in April 2022, we concurrently closed our foreign currency forward contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the effect of our net investment hedge in our condensed consolidated financial statements:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Effective Portion) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) &lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Net Income &lt;br/&gt;(Amounts Excluded from Effectiveness Testing) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements with Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 16, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Forward Contracts - Other Derivative Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate notional amount of these outstanding foreign currency forward contracts was $1,333.4 million and $1,268.0 million as of March 31, 2022 and December 31, 2021, respectively. Net losses of $12.2 million and $17.4 million related to these contracts were recorded as a component of other income (expense), net for the three months ended March 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of Derivative Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cash Flow Hedging Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investments and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Net Investment Hedging Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Derivative Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="i272a8c61f3584e998890821513df00d8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfNjIz_1d0c20f6-ca74-4a90-b35f-2fbc1ad4f016">P1M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="i406fa505aaae46879e51842eed75d4ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfNjI5_92631d7e-f2d7-4f5c-8eaa-c1d22ede45c0">P18M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="i249928d43b8e4fa299b055c1da71dd67_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfNjM2_7dc59cf4-eba5-435f-b6e9-ed0f3504f826">P1M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="i3bd066a82d6840d8b01775d5dad75db4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfNjQy_cd0f6328-3e0d-4ef7-b0ea-86d73214ac5c">P15M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfNjk2OQ_92d6111e-fc75-4a40-8c0e-73d004cf9171">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The notional amount of foreign currency forward contracts that were entered into to hedge forecasted revenue and operating expense is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Euro&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,631.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,828.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;British pound&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;126.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;166.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Swiss franc&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Japanese yen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canadian dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,986.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,126.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock>
    <us-gaap:DerivativeNotionalAmount
      contextRef="id58fea331b54435bbde5915e58d7c5a1_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjQwM2Q1NzdiMThhZTRmODZhZDQwNDVmMGIxNzIxNWE0L3RhYmxlcmFuZ2U6NDAzZDU3N2IxOGFlNGY4NmFkNDA0NWYwYjE3MjE1YTRfMi0yLTEtMS03NTE0MA_1329c9e0-b0ad-4820-a299-129ce27b9e47"
      unitRef="usd">1631200000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i2bbc3b1e9fdb469cb4328efd19cda789_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjQwM2Q1NzdiMThhZTRmODZhZDQwNDVmMGIxNzIxNWE0L3RhYmxlcmFuZ2U6NDAzZDU3N2IxOGFlNGY4NmFkNDA0NWYwYjE3MjE1YTRfMi00LTEtMS03NTE0MA_43ff5cac-d4df-419e-a7ac-b29d1f2eb3e7"
      unitRef="usd">1828000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i39a50582990a42dcb07d38607ad68af5_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjQwM2Q1NzdiMThhZTRmODZhZDQwNDVmMGIxNzIxNWE0L3RhYmxlcmFuZ2U6NDAzZDU3N2IxOGFlNGY4NmFkNDA0NWYwYjE3MjE1YTRfMy0yLTEtMS03NTE0MA_7d9a5fd1-a5f1-4308-8e70-421ff9f1550f"
      unitRef="usd">126600000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i240c4ec54c41471f939a44ea69015b0a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjQwM2Q1NzdiMThhZTRmODZhZDQwNDVmMGIxNzIxNWE0L3RhYmxlcmFuZ2U6NDAzZDU3N2IxOGFlNGY4NmFkNDA0NWYwYjE3MjE1YTRfMy00LTEtMS03NTE0MA_357a8f3f-7f07-4b27-9c47-17de38a35229"
      unitRef="usd">166200000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i28837dfd41bf48e4a23a28d077a47405_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjQwM2Q1NzdiMThhZTRmODZhZDQwNDVmMGIxNzIxNWE0L3RhYmxlcmFuZ2U6NDAzZDU3N2IxOGFlNGY4NmFkNDA0NWYwYjE3MjE1YTRfNC0yLTEtMS03NTE0MA_aa943e42-2983-4db4-8e4b-54d2976e5d1c"
      unitRef="usd">128600000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i0736edb3bf194531887102c104754d6b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjQwM2Q1NzdiMThhZTRmODZhZDQwNDVmMGIxNzIxNWE0L3RhYmxlcmFuZ2U6NDAzZDU3N2IxOGFlNGY4NmFkNDA0NWYwYjE3MjE1YTRfNC00LTEtMS03NTE0MA_b9847e6d-bdd4-48c5-86c9-dd351ba9c537"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i598f0b3c24fe484495f6ccb41c9c3f69_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjQwM2Q1NzdiMThhZTRmODZhZDQwNDVmMGIxNzIxNWE0L3RhYmxlcmFuZ2U6NDAzZDU3N2IxOGFlNGY4NmFkNDA0NWYwYjE3MjE1YTRfNS0yLTEtMS03NTE0MA_c31c653b-3bfa-4344-9a9b-8195aa31cde8"
      unitRef="usd">55000000.0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i2e3ec7e46b3849eab9fbf5b26dbd2c8c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjQwM2Q1NzdiMThhZTRmODZhZDQwNDVmMGIxNzIxNWE0L3RhYmxlcmFuZ2U6NDAzZDU3N2IxOGFlNGY4NmFkNDA0NWYwYjE3MjE1YTRfNS00LTEtMS03NTE0MA_0ab8a0f7-b9ae-4226-bba8-74c6fbaddb15"
      unitRef="usd">72700000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i694ddc9c46354d1e860c687aa876734c_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjQwM2Q1NzdiMThhZTRmODZhZDQwNDVmMGIxNzIxNWE0L3RhYmxlcmFuZ2U6NDAzZDU3N2IxOGFlNGY4NmFkNDA0NWYwYjE3MjE1YTRfNi0yLTEtMS03NTE0MA_4ec0f4b6-228d-4588-96e9-4f5bfb696bff"
      unitRef="usd">44600000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="iac85fcf21047427c834103ba4c06b629_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjQwM2Q1NzdiMThhZTRmODZhZDQwNDVmMGIxNzIxNWE0L3RhYmxlcmFuZ2U6NDAzZDU3N2IxOGFlNGY4NmFkNDA0NWYwYjE3MjE1YTRfNi00LTEtMS03NTE0MA_42196576-faff-41d4-b8a8-1c32748146a7"
      unitRef="usd">59900000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="id06b33f7f9d2442c99ed5a3715b1fb03_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjQwM2Q1NzdiMThhZTRmODZhZDQwNDVmMGIxNzIxNWE0L3RhYmxlcmFuZ2U6NDAzZDU3N2IxOGFlNGY4NmFkNDA0NWYwYjE3MjE1YTRfNy0yLTEtMS03NTE0MA_a8e14a7e-9094-463f-9ff9-e0948ca49be5"
      unitRef="usd">1986000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ic777b57bc84141bcbc813beba9a72c17_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjQwM2Q1NzdiMThhZTRmODZhZDQwNDVmMGIxNzIxNWE0L3RhYmxlcmFuZ2U6NDAzZDU3N2IxOGFlNGY4NmFkNDA0NWYwYjE3MjE1YTRfNy00LTEtMS03NTE0MA_62a0deaf-c801-4c62-92be-f6adee58fe95"
      unitRef="usd">2126800000</us-gaap:DerivativeNotionalAmount>
    <biib:DerivativeInstrumentsUnrealizedGainLossTableTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfNjU5NzA2OTc3NzgyNQ_68f56211-2714-4a5d-9ded-f8876c1eaa8f">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.785%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net unrealized gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:DerivativeInstrumentsUnrealizedGainLossTableTextBlock>
    <biib:UnrealizedGainOnDerivatives
      contextRef="i59dedd55a80f4d2a830844b533c8f387_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjAzNGQxZTg3MGU2MDQyMTFhNmJmYjNkOTY1Njk5ZmY1L3RhYmxlcmFuZ2U6MDM0ZDFlODcwZTYwNDIxMWE2YmZiM2Q5NjU2OTlmZjVfMi0yLTEtMS0xMDUwNjE_47618693-40c5-4078-938f-6f84ec419f26"
      unitRef="usd">76400000</biib:UnrealizedGainOnDerivatives>
    <biib:UnrealizedGainOnDerivatives
      contextRef="i8c177fb43a1c4b4e8e78a519ab0c6de9_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjAzNGQxZTg3MGU2MDQyMTFhNmJmYjNkOTY1Njk5ZmY1L3RhYmxlcmFuZ2U6MDM0ZDFlODcwZTYwNDIxMWE2YmZiM2Q5NjU2OTlmZjVfMi00LTEtMS0xMDUwNjM_7f4a8436-8444-4d2f-9a68-f466f70732f3"
      unitRef="usd">60800000</biib:UnrealizedGainOnDerivatives>
    <biib:UnrealizedLossOnDerivatives
      contextRef="i59dedd55a80f4d2a830844b533c8f387_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjAzNGQxZTg3MGU2MDQyMTFhNmJmYjNkOTY1Njk5ZmY1L3RhYmxlcmFuZ2U6MDM0ZDFlODcwZTYwNDIxMWE2YmZiM2Q5NjU2OTlmZjVfMy0yLTEtMS0xMDUwNjE_6bb1535d-0be6-42ce-8a03-7c5d6ecb7c8d"
      unitRef="usd">4300000</biib:UnrealizedLossOnDerivatives>
    <biib:UnrealizedLossOnDerivatives
      contextRef="i8c177fb43a1c4b4e8e78a519ab0c6de9_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjAzNGQxZTg3MGU2MDQyMTFhNmJmYjNkOTY1Njk5ZmY1L3RhYmxlcmFuZ2U6MDM0ZDFlODcwZTYwNDIxMWE2YmZiM2Q5NjU2OTlmZjVfMy00LTEtMS0xMDUwNjM_ea7b8aec-345e-4529-8de5-26e54db27045"
      unitRef="usd">7000000.0</biib:UnrealizedLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="i59dedd55a80f4d2a830844b533c8f387_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjAzNGQxZTg3MGU2MDQyMTFhNmJmYjNkOTY1Njk5ZmY1L3RhYmxlcmFuZ2U6MDM0ZDFlODcwZTYwNDIxMWE2YmZiM2Q5NjU2OTlmZjVfNC0yLTEtMS04NDQxOA_73c23b64-d473-49d1-918f-cd5ca701c6c4"
      unitRef="usd">72100000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="i8c177fb43a1c4b4e8e78a519ab0c6de9_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjAzNGQxZTg3MGU2MDQyMTFhNmJmYjNkOTY1Njk5ZmY1L3RhYmxlcmFuZ2U6MDM0ZDFlODcwZTYwNDIxMWE2YmZiM2Q5NjU2OTlmZjVfNC00LTEtMS0xMDUwNjM_7888ec6d-d92b-4b76-ac6a-1168651a325d"
      unitRef="usd">53800000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="i59dedd55a80f4d2a830844b533c8f387_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfMTMxOTQxMzk1NDQ0Njc_8d91d1b0-b850-4483-a16b-446afadb3736"
      unitRef="usd">72100000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="i406fa505aaae46879e51842eed75d4ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfMjA1NQ_74856495-19ca-4005-aa59-5c404b459232">P18M</us-gaap:DerivativeRemainingMaturity1>
    <biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="i317559ce8f9e4b26a225b70d06a61b25_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfMjA2OA_74516da5-6e52-4185-bd9f-89ce8883a77d"
      unitRef="usd">72000000</biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="ibfad3eb157664139a953f3e9ba192977_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfMjEzMg_540aaf11-64c2-48c0-8136-0835fd7d1338">P12M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfNjk2OA_2257e678-cfab-4b5d-8b54-f98d428c3c35">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.154%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(23.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i930b3a82003f4bec8f1d94de444724dc_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOmQ3ODc0ZjM5ZjY1ZTRmYTJiMGFhY2Q1ODhmZjIxYWVlL3RhYmxlcmFuZ2U6ZDc4NzRmMzlmNjVlNGZhMmIwYWFjZDU4OGZmMjFhZWVfMy0yLTEtMS03NTE0MA_3a65614b-cd9b-4881-ad64-7fbe88d4e157"
      unitRef="usd">20900000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i5b9c2fab12ac4d2bb51603b6415c4055_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOmQ3ODc0ZjM5ZjY1ZTRmYTJiMGFhY2Q1ODhmZjIxYWVlL3RhYmxlcmFuZ2U6ZDc4NzRmMzlmNjVlNGZhMmIwYWFjZDU4OGZmMjFhZWVfMy00LTEtMS03NTE0MA_5e1782ae-55d6-4456-ba97-6d11fdfc11b8"
      unitRef="usd">-23100000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i355096b3d6354bf5a1914fc120d6d527_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOmQ3ODc0ZjM5ZjY1ZTRmYTJiMGFhY2Q1ODhmZjIxYWVlL3RhYmxlcmFuZ2U6ZDc4NzRmMzlmNjVlNGZhMmIwYWFjZDU4OGZmMjFhZWVfMy04LTEtMS03NTE0MA_cc25a29b-bcc9-4cb7-9e4c-282417fcb507"
      unitRef="usd">-6500000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i2469406df0d54a489bd5f64e3dea3d36_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOmQ3ODc0ZjM5ZjY1ZTRmYTJiMGFhY2Q1ODhmZjIxYWVlL3RhYmxlcmFuZ2U6ZDc4NzRmMzlmNjVlNGZhMmIwYWFjZDU4OGZmMjFhZWVfMy0xMC0xLTEtNzUxNDA_bcca13ed-f10b-465e-9d3d-ec4401d5b506"
      unitRef="usd">-3000000.0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="iabceb3a0623e41c4a664ac8948832356_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOmQ3ODc0ZjM5ZjY1ZTRmYTJiMGFhY2Q1ODhmZjIxYWVlL3RhYmxlcmFuZ2U6ZDc4NzRmMzlmNjVlNGZhMmIwYWFjZDU4OGZmMjFhZWVfNC0yLTEtMS03NTE0MA_cfae4bcb-06f8-4776-814e-9a4da3f6be8e"
      unitRef="usd">-300000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i9ea5c7e3d1434a96a8496e2352fabe5b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOmQ3ODc0ZjM5ZjY1ZTRmYTJiMGFhY2Q1ODhmZjIxYWVlL3RhYmxlcmFuZ2U6ZDc4NzRmMzlmNjVlNGZhMmIwYWFjZDU4OGZmMjFhZWVfNC00LTEtMS03NTE0MA_9dc8f1a4-268e-4955-8d32-a8979761796b"
      unitRef="usd">-400000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i8992ee77c09249988dad3a68bcc5843f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOmQ3ODc0ZjM5ZjY1ZTRmYTJiMGFhY2Q1ODhmZjIxYWVlL3RhYmxlcmFuZ2U6ZDc4NzRmMzlmNjVlNGZhMmIwYWFjZDU4OGZmMjFhZWVfNC04LTEtMS03NTE0MA_cb1129ad-8a44-4766-8767-a5a8919d08c7"
      unitRef="usd">-100000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i62cbd491b5784eedb300e49ae6efc87a_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOmQ3ODc0ZjM5ZjY1ZTRmYTJiMGFhY2Q1ODhmZjIxYWVlL3RhYmxlcmFuZ2U6ZDc4NzRmMzlmNjVlNGZhMmIwYWFjZDU4OGZmMjFhZWVfNC0xMC0xLTEtNzUxNDA_1e13420d-1117-4070-a080-9fb4cbcbc6f7"
      unitRef="usd">-100000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction
      contextRef="i2b7ac531239c4d9aac8a7b0c71f6fdf5_I20180531"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfMjE5OTAyMzI2NjQyMA_3af745c8-8944-4ffb-b23a-3d18d76c0d55"
      unitRef="number">0.050</biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ia5fabf9c71294456a0158d60a5f483a4_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfNDA2NQ_0952b3aa-e388-47ac-91cb-321e4a6f024f"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i76b1491614cc49378a38f3c27aafce95_D20181101-20181130"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfMjE5OTAyMzI2NDQ3OQ_a4b7ab0b-46d6-41ce-af0e-b9b52fedc146"
      unitRef="krw">759500000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i76b1491614cc49378a38f3c27aafce95_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfMjE5OTAyMzI2NDQ5NQ_c3a7f988-7e5a-4879-a634-e5f881d90aea"
      unitRef="usd">676600000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:DerivativeTermOfContract
      contextRef="ifb6cf45b64754d4b88c6cd9ba8980d50_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfNDU1Mg_ab35018e-421d-40db-856a-6ab49683c2aa">P7M</us-gaap:DerivativeTermOfContract>
    <us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="ifb6cf45b64754d4b88c6cd9ba8980d50_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfNDkwNQ_7cd2f09e-c0bf-4116-8ddd-486281cfdaf1"
      unitRef="usd">20600000</us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax>
    <us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="i0df6dbddbff746298274ecd0b63baf47_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfNDkyNg_ed69c8a4-c7a1-4117-9560-4f8f5b15aca6"
      unitRef="usd">10600000</us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax>
    <us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax
      contextRef="ib51e9913c2884e49a66dce4cf9163f6d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfNTM2MQ_d7499e49-1ae8-4ad0-a2de-0d4521c868a6"
      unitRef="usd">2500000</us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax>
    <us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax
      contextRef="i5062e91336b74ad5ab0ffa4f2982b8e3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfNTM2OA_8ad3b881-f278-40ba-b7dc-a54d0fb02d06"
      unitRef="usd">3600000</us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax>
    <us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfNjk1MQ_cd119b7c-3d83-4c18-845b-4c5bfb85e5e8">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the effect of our net investment hedge in our condensed consolidated financial statements:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Effective Portion) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) &lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Net Income &lt;br/&gt;(Amounts Excluded from Effectiveness Testing) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="ifb6cf45b64754d4b88c6cd9ba8980d50_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjlkZDJhNjk4OTIyZTQ2YjJiYmI3ZDRkZWU4ZmM1Y2I1L3RhYmxlcmFuZ2U6OWRkMmE2OTg5MjJlNDZiMmJiYjdkNGRlZThmYzVjYjVfMy0yLTEtMS03NTE0MA_0c301916-e909-4c89-b5c7-f967fe88a8b8"
      unitRef="usd">10100000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="ib1d439a992034e5a880d6b7d7d1fd8ff_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjlkZDJhNjk4OTIyZTQ2YjJiYmI3ZDRkZWU4ZmM1Y2I1L3RhYmxlcmFuZ2U6OWRkMmE2OTg5MjJlNDZiMmJiYjdkNGRlZThmYzVjYjVfMy00LTEtMS03NTE0MA_ca04fe11-20ff-4c30-a57a-f29757557248"
      unitRef="usd">23800000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease
      contextRef="ifb6cf45b64754d4b88c6cd9ba8980d50_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjlkZDJhNjk4OTIyZTQ2YjJiYmI3ZDRkZWU4ZmM1Y2I1L3RhYmxlcmFuZ2U6OWRkMmE2OTg5MjJlNDZiMmJiYjdkNGRlZThmYzVjYjVfMy04LTEtMS03NTE0MA_fc184ed2-e37c-4402-a7be-df896ce19e97"
      unitRef="usd">-3300000</biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease>
    <biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease
      contextRef="ib1d439a992034e5a880d6b7d7d1fd8ff_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjlkZDJhNjk4OTIyZTQ2YjJiYmI3ZDRkZWU4ZmM1Y2I1L3RhYmxlcmFuZ2U6OWRkMmE2OTg5MjJlNDZiMmJiYjdkNGRlZThmYzVjYjVfMy0xMC0xLTEtNzUxNDA_73f92e86-1777-409b-a6fb-783a32e272e6"
      unitRef="usd">-1400000</biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="i04123d710b8e48c89a62fd25aa7cc3dc_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjlkZDJhNjk4OTIyZTQ2YjJiYmI3ZDRkZWU4ZmM1Y2I1L3RhYmxlcmFuZ2U6OWRkMmE2OTg5MjJlNDZiMmJiYjdkNGRlZThmYzVjYjVfMy0xNC0xLTEtNzUxNDA_bcefbb36-9433-4013-ae33-d36a90b67a64"
      unitRef="usd">-1100000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="i49647cb8da844b74bee321a532e55b36_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjlkZDJhNjk4OTIyZTQ2YjJiYmI3ZDRkZWU4ZmM1Y2I1L3RhYmxlcmFuZ2U6OWRkMmE2OTg5MjJlNDZiMmJiYjdkNGRlZThmYzVjYjVfMy0xNi0xLTEtNzUxNDA_8999cafd-10e9-4d50-a442-5460fe0d2e1e"
      unitRef="usd">100000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i9f94fcf078da46ef9117103ab626567e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfNjA4Nw_fc88f027-f2b0-4bce-bacf-494236f37d40"
      unitRef="usd">1333400000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i1d28240f464f4a5c8cc87e17a9a57d40_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfNjA5NA_eec8b929-89e1-4313-ae46-1b02cf0ac407"
      unitRef="usd">1268000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfNjE0Mg_efbde012-2cdb-4eba-abbc-0b57b2b399c5"
      unitRef="usd">-12200000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfMjE5OTAyMzI2NDU1MA_f200f3b1-601e-44d8-8ca2-3a2bd2983396"
      unitRef="usd">17400000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RleHRyZWdpb246ZjdkZjQzY2M2NjUzNDAwZGI3N2U0ZGE2NjZlMjZmNmVfNjk1Mw_e794306c-2a8b-4071-b58b-6a0900531c27">&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cash Flow Hedging Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investments and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Net Investment Hedging Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Derivative Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ife02cc8b68b74e45a4550426f8f6e028_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjMwNGUzYWI5ZDhmZDQ3YWI5MDQ5YTMwMDJkN2UzNWEwL3RhYmxlcmFuZ2U6MzA0ZTNhYjlkOGZkNDdhYjkwNDlhMzAwMmQ3ZTM1YTBfMi00LTEtMS03NTE0MA_091fe025-d90d-4098-87e2-7fa96c4aabae"
      unitRef="usd">79800000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i55597e78171f481ea55329770d91ef68_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjMwNGUzYWI5ZDhmZDQ3YWI5MDQ5YTMwMDJkN2UzNWEwL3RhYmxlcmFuZ2U6MzA0ZTNhYjlkOGZkNDdhYjkwNDlhMzAwMmQ3ZTM1YTBfMi02LTEtMS03NTE0MA_6e6f3bb8-a6df-4859-845e-a5fc9e1cdfff"
      unitRef="usd">66200000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i8f169aefbf5349eb87fe05cb8688fca5_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjMwNGUzYWI5ZDhmZDQ3YWI5MDQ5YTMwMDJkN2UzNWEwL3RhYmxlcmFuZ2U6MzA0ZTNhYjlkOGZkNDdhYjkwNDlhMzAwMmQ3ZTM1YTBfMy00LTEtMS03NTE0MA_7793cdb6-fa1d-45c1-b9ef-c1c2e24b62d3"
      unitRef="usd">1600000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ifb5afc172aec4efebd6f1b568ac8ba97_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjMwNGUzYWI5ZDhmZDQ3YWI5MDQ5YTMwMDJkN2UzNWEwL3RhYmxlcmFuZ2U6MzA0ZTNhYjlkOGZkNDdhYjkwNDlhMzAwMmQ3ZTM1YTBfMy02LTEtMS03NTE0MA_f66dd465-7adc-42b8-804d-e801c24263ff"
      unitRef="usd">5500000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="iadd2bb0a22624c17a5f24102ad78024e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjMwNGUzYWI5ZDhmZDQ3YWI5MDQ5YTMwMDJkN2UzNWEwL3RhYmxlcmFuZ2U6MzA0ZTNhYjlkOGZkNDdhYjkwNDlhMzAwMmQ3ZTM1YTBfNC00LTEtMS03NTE0MA_750df7c7-17ec-406c-8755-42f5123ee4c9"
      unitRef="usd">2400000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i9ca7b68a94cf428e9116acf90742cf4c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjMwNGUzYWI5ZDhmZDQ3YWI5MDQ5YTMwMDJkN2UzNWEwL3RhYmxlcmFuZ2U6MzA0ZTNhYjlkOGZkNDdhYjkwNDlhMzAwMmQ3ZTM1YTBfNC02LTEtMS03NTE0MA_82df4ca1-a704-4741-8c1a-e48d752fadcb"
      unitRef="usd">6600000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i0a575848d988444ca4869d5a47cae38a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjMwNGUzYWI5ZDhmZDQ3YWI5MDQ5YTMwMDJkN2UzNWEwL3RhYmxlcmFuZ2U6MzA0ZTNhYjlkOGZkNDdhYjkwNDlhMzAwMmQ3ZTM1YTBfNS00LTEtMS03NTE0MA_3b5de5a5-15bd-47d6-bc34-3a20d630316b"
      unitRef="usd">2200000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ib79aa8e4e7624556b3ddeed5fa194e23_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjMwNGUzYWI5ZDhmZDQ3YWI5MDQ5YTMwMDJkN2UzNWEwL3RhYmxlcmFuZ2U6MzA0ZTNhYjlkOGZkNDdhYjkwNDlhMzAwMmQ3ZTM1YTBfNS02LTEtMS03NTE0MA_53c9ab48-b674-41a8-9653-a378517f7630"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i493a11d6c18c49269d42f6e6982e8f44_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjMwNGUzYWI5ZDhmZDQ3YWI5MDQ5YTMwMDJkN2UzNWEwL3RhYmxlcmFuZ2U6MzA0ZTNhYjlkOGZkNDdhYjkwNDlhMzAwMmQ3ZTM1YTBfOC00LTEtMS03NTE0MA_070cb9d9-4f5c-4f66-b169-54b562e77c17"
      unitRef="usd">10900000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i639c896977df489fbc54f9088f6147de_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjMwNGUzYWI5ZDhmZDQ3YWI5MDQ5YTMwMDJkN2UzNWEwL3RhYmxlcmFuZ2U6MzA0ZTNhYjlkOGZkNDdhYjkwNDlhMzAwMmQ3ZTM1YTBfOC02LTEtMS03NTE0MA_a5b4408f-c275-4fdd-8273-4e57a43a0e6a"
      unitRef="usd">4100000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="id0a4f26886de44beaaa9fd8add3e3cd9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjMwNGUzYWI5ZDhmZDQ3YWI5MDQ5YTMwMDJkN2UzNWEwL3RhYmxlcmFuZ2U6MzA0ZTNhYjlkOGZkNDdhYjkwNDlhMzAwMmQ3ZTM1YTBfMTYtNC0xLTEtNzUxNDA_c92c7d9b-bd8f-48ee-898b-474a3c5ed358"
      unitRef="usd">4900000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i46e754dc01c0498393cd6a5acbb81bc2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjMwNGUzYWI5ZDhmZDQ3YWI5MDQ5YTMwMDJkN2UzNWEwL3RhYmxlcmFuZ2U6MzA0ZTNhYjlkOGZkNDdhYjkwNDlhMzAwMmQ3ZTM1YTBfMTYtNi0xLTEtNzUxNDA_ed258236-ffb7-42b8-bf34-9000cacaffa4"
      unitRef="usd">5100000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i52be7c4aa2b64ac78381cc2d75fa44bd_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjMwNGUzYWI5ZDhmZDQ3YWI5MDQ5YTMwMDJkN2UzNWEwL3RhYmxlcmFuZ2U6MzA0ZTNhYjlkOGZkNDdhYjkwNDlhMzAwMmQ3ZTM1YTBfMTctNC0xLTEtNzUxNDA_0e947e1f-8780-4f33-b621-b16274f4d104"
      unitRef="usd">7900000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ic91d51f7faa640ed87d6899c2a544613_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl83OS9mcmFnOmY3ZGY0M2NjNjY1MzQwMGRiNzdlNGRhNjY2ZTI2ZjZlL3RhYmxlOjMwNGUzYWI5ZDhmZDQ3YWI5MDQ5YTMwMDJkN2UzNWEwL3RhYmxlcmFuZ2U6MzA0ZTNhYjlkOGZkNDdhYjkwNDlhMzAwMmQ3ZTM1YTBfMTctNi0xLTEtNzUxNDA_758f060e-03ab-4a97-b459-19a9325c6b33"
      unitRef="usd">4200000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl84NS9mcmFnOmI1NDczMDk0NjVlNjQxZDg4NWM1YmEwMzZjNDhkODlhL3RleHRyZWdpb246YjU0NzMwOTQ2NWU2NDFkODg1YzViYTAzNmM0OGQ4OWFfMTIwMw_f250b035-f7d7-4507-b8ce-14bb5cf8761b">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was $2,082.0 million and $2,006.6 million as of March 31, 2022 and December 31, 2021, respectively. For the three months ended March 31, 2022, depreciation expense totaled $76.3 million compared to $48.8 million in the prior year comparative period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Solothurn, Switzerland Manufacturing Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to support our future growth and drug development pipeline, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. Upon completion, this facility will include 393,000 square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and 51,000 square feet of administrative space. As of March 31, 2022 and December 31, 2021, we had approximately $682.6 million and $677.0 million, respectively, capitalized as construction in progress related to this facility. In the second quarter of 2021, a portion of the facility received a Good Manufacturing Practice multi-product license from the Swiss Agency for Therapeutic Products, resulting in approximately $1.2&#160;billion of fixed assets being placed in service during the second quarter of 2021. In April 2022 the FDA approved the Prior Approval Supplement for the Solothurn facility for ADUHELM. We estimate the remainder of the facility will be operational during the first half of 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl84NS9mcmFnOmI1NDczMDk0NjVlNjQxZDg4NWM1YmEwMzZjNDhkODlhL3RleHRyZWdpb246YjU0NzMwOTQ2NWU2NDFkODg1YzViYTAzNmM0OGQ4OWFfMTcx_100944c1-d97b-443e-847a-aa02406a9c92"
      unitRef="usd">2082000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl84NS9mcmFnOmI1NDczMDk0NjVlNjQxZDg4NWM1YmEwMzZjNDhkODlhL3RleHRyZWdpb246YjU0NzMwOTQ2NWU2NDFkODg1YzViYTAzNmM0OGQ4OWFfMTc4_c8c73942-39ba-4d56-b238-9235fcca6918"
      unitRef="usd">2006600000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:Depreciation
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl84NS9mcmFnOmI1NDczMDk0NjVlNjQxZDg4NWM1YmEwMzZjNDhkODlhL3RleHRyZWdpb246YjU0NzMwOTQ2NWU2NDFkODg1YzViYTAzNmM0OGQ4OWFfMjc2_d93b0bf2-eb7c-4d8a-96cb-bf19b10be2e2"
      unitRef="usd">76300000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl84NS9mcmFnOmI1NDczMDk0NjVlNjQxZDg4NWM1YmEwMzZjNDhkODlhL3RleHRyZWdpb246YjU0NzMwOTQ2NWU2NDFkODg1YzViYTAzNmM0OGQ4OWFfMzEz_ec7bd608-37a6-43fa-9ae0-8c72e12f4e63"
      unitRef="usd">48800000</us-gaap:Depreciation>
    <biib:NumberOfSquareFeet
      contextRef="i6f64e07d384c415c831dd4b33c3b6b7f_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl84NS9mcmFnOmI1NDczMDk0NjVlNjQxZDg4NWM1YmEwMzZjNDhkODlhL3RleHRyZWdpb246YjU0NzMwOTQ2NWU2NDFkODg1YzViYTAzNmM0OGQ4OWFfNjI2_17bf9b78-b96c-494f-aa14-448af7b00e33"
      unitRef="sqft">393000</biib:NumberOfSquareFeet>
    <biib:NumberOfSquareFeet
      contextRef="i099a9481f0f445269310c0321517d33c_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl84NS9mcmFnOmI1NDczMDk0NjVlNjQxZDg4NWM1YmEwMzZjNDhkODlhL3RleHRyZWdpb246YjU0NzMwOTQ2NWU2NDFkODg1YzViYTAzNmM0OGQ4OWFfNzAw_798a7fcc-0110-4fb8-b797-275db855d0d7"
      unitRef="sqft">290000</biib:NumberOfSquareFeet>
    <biib:NumberOfSquareFeet
      contextRef="ieed6363c4f674d66a54d0dc0c55f0f52_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl84NS9mcmFnOmI1NDczMDk0NjVlNjQxZDg4NWM1YmEwMzZjNDhkODlhL3RleHRyZWdpb246YjU0NzMwOTQ2NWU2NDFkODg1YzViYTAzNmM0OGQ4OWFfNzYx_4ed22dab-091a-436a-8f35-85cdcbf1c20f"
      unitRef="sqft">51000</biib:NumberOfSquareFeet>
    <us-gaap:ConstructionInProgressGross
      contextRef="i3e94ec2413a34ad39baef4a302252a4a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl84NS9mcmFnOmI1NDczMDk0NjVlNjQxZDg4NWM1YmEwMzZjNDhkODlhL3RleHRyZWdpb246YjU0NzMwOTQ2NWU2NDFkODg1YzViYTAzNmM0OGQ4OWFfODM5_b3bfdecb-3cc1-4e55-aa7c-1b35a97e8889"
      unitRef="usd">682600000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="ie078509e1f7d4077a083b848308445a3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl84NS9mcmFnOmI1NDczMDk0NjVlNjQxZDg4NWM1YmEwMzZjNDhkODlhL3RleHRyZWdpb246YjU0NzMwOTQ2NWU2NDFkODg1YzViYTAzNmM0OGQ4OWFfODQ2_3a99950e-d261-49cf-a47a-e89a2e679c9a"
      unitRef="usd">677000000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3e94ec2413a34ad39baef4a302252a4a_I20220331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl84NS9mcmFnOmI1NDczMDk0NjVlNjQxZDg4NWM1YmEwMzZjNDhkODlhL3RleHRyZWdpb246YjU0NzMwOTQ2NWU2NDFkODg1YzViYTAzNmM0OGQ4OWFfMTEyMw_0f4119c7-8bc3-4b9d-a20e-fce55f4f1370"
      unitRef="usd">1200000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl84OC9mcmFnOjA1ZmRmODU1OWJiZTQwODM4N2RiZmUxZjJkNzcyMjA5L3RleHRyZWdpb246MDVmZGY4NTU5YmJlNDA4Mzg3ZGJmZTFmMmQ3NzIyMDlfMzU2Ng_a755fd17-777c-43bb-9f06-24cadf4d0c51">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Exchange Offer&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021 we completed our Exchange Offer of our tendered 2045 Senior Notes for our 2051 Senior Notes and cash, and an offer to purchase our tendered 2045 Senior Notes for cash. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An aggregate principal amount of approximately $624.6&#160;million of our 2045 Senior Notes was exchanged for an aggregate principal amount of approximately $700.7&#160;million of our 2051 Senior Notes and aggregate cash payments of approximately $151.8&#160;million. Our Exchange Offer has been accounted for as a debt modification; as such, the cash component has been reflected as additional debt discount and is amortized as an adjustment to interest expense over the term of our 2051 Senior Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, we redeemed an aggregate principal amount of approximately $8.9&#160;million of our 2045 Senior Notes for aggregate cash payments of approximately $12.1&#160;million, excluding accrued and unpaid interest. The redemption has been accounted for as a debt extinguishment; as such, we recognized a pre-tax charge of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$3.2&#160;million upon the extinguishment of such 2045 Senior Notes. This charge, which was recognized in interest expense in other income (expense), net in our condensed consolidated statements of income for the three months ended March 31, 2021, reflects the payment of an early call premium and the write-off of the remaining unamortized original debt issuance costs and discount balances associated with such 2045 Senior Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon settlement, we also made aggregate cash payments of approximately $13.8&#160;million to settle all accrued and unpaid interest from the last interest payment date on our 2045 Senior Notes that were exchanged or redeemed. We incurred approximately $6.1&#160;million of costs associated with our Exchange Offer, which was recognized in interest expense in other income (expense), net in our condensed consolidated statements of income for the three months ended March 31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <biib:LongTermDebtExchangedAmount
      contextRef="id425e7508d5f4fcf9ccfcc07674b63de_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl84OC9mcmFnOjA1ZmRmODU1OWJiZTQwODM4N2RiZmUxZjJkNzcyMjA5L3RleHRyZWdpb246MDVmZGY4NTU5YmJlNDA4Mzg3ZGJmZTFmMmQ3NzIyMDlfMjYx_8c9e4c52-23ae-474a-a1f8-8996b71597ed"
      unitRef="usd">624600000</biib:LongTermDebtExchangedAmount>
    <biib:LongTermDebtExchangedAmount
      contextRef="ie3968065f0a74bfead74be1f343078f9_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl84OC9mcmFnOjA1ZmRmODU1OWJiZTQwODM4N2RiZmUxZjJkNzcyMjA5L3RleHRyZWdpb246MDVmZGY4NTU5YmJlNDA4Mzg3ZGJmZTFmMmQ3NzIyMDlfMzU0_89100470-eb17-4863-a884-6388ed14ff16"
      unitRef="usd">700700000</biib:LongTermDebtExchangedAmount>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="id164d47b16824f0c874ceeea51fbbcbc_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl84OC9mcmFnOjA1ZmRmODU1OWJiZTQwODM4N2RiZmUxZjJkNzcyMjA5L3RleHRyZWdpb246MDVmZGY4NTU5YmJlNDA4Mzg3ZGJmZTFmMmQ3NzIyMDlfNDI3_1ee51db3-4b36-4f61-8a0f-59cddc0c1cef"
      unitRef="usd">151800000</us-gaap:RepaymentsOfSeniorDebt>
    <biib:DebtInstrumentRedemptionAmount
      contextRef="id425e7508d5f4fcf9ccfcc07674b63de_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl84OC9mcmFnOjA1ZmRmODU1OWJiZTQwODM4N2RiZmUxZjJkNzcyMjA5L3RleHRyZWdpb246MDVmZGY4NTU5YmJlNDA4Mzg3ZGJmZTFmMmQ3NzIyMDlfNzM4_e3d1a2f7-be95-47e6-9610-2d7c5103454e"
      unitRef="usd">8900000</biib:DebtInstrumentRedemptionAmount>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="id425e7508d5f4fcf9ccfcc07674b63de_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl84OC9mcmFnOjA1ZmRmODU1OWJiZTQwODM4N2RiZmUxZjJkNzcyMjA5L3RleHRyZWdpb246MDVmZGY4NTU5YmJlNDA4Mzg3ZGJmZTFmMmQ3NzIyMDlfODEx_480be16f-1fa0-435a-8051-644eb252cac5"
      unitRef="usd">12100000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="if242145ab9704eacb41a099fd01ce221_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl84OC9mcmFnOjA1ZmRmODU1OWJiZTQwODM4N2RiZmUxZjJkNzcyMjA5L3RleHRyZWdpb246MDVmZGY4NTU5YmJlNDA4Mzg3ZGJmZTFmMmQ3NzIyMDlfOTYx_1fcc8c44-a120-42b0-9a57-65a83c90012e"
      unitRef="usd">3200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="if242145ab9704eacb41a099fd01ce221_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl84OC9mcmFnOjA1ZmRmODU1OWJiZTQwODM4N2RiZmUxZjJkNzcyMjA5L3RleHRyZWdpb246MDVmZGY4NTU5YmJlNDA4Mzg3ZGJmZTFmMmQ3NzIyMDlfMTQyNw_763c10aa-64a9-4bf6-adc8-5807cc92bffc"
      unitRef="usd">13800000</us-gaap:RepaymentsOfDebt>
    <us-gaap:InterestExpense
      contextRef="if242145ab9704eacb41a099fd01ce221_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl84OC9mcmFnOjA1ZmRmODU1OWJiZTQwODM4N2RiZmUxZjJkNzcyMjA5L3RleHRyZWdpb246MDVmZGY4NTU5YmJlNDA4Mzg3ZGJmZTFmMmQ3NzIyMDlfMTU5Mg_3e483d7b-1e22-498e-b3b5-8effed6bd05d"
      unitRef="usd">6100000</us-gaap:InterestExpense>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RleHRyZWdpb246ZWE2MjIzNjgyOGJkNDBlMzkyZWFmMGM3ODBjOTk4MzlfMTgwNA_721ecbfa-665a-4670-b640-29b63b1383f5">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share Repurchases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (2020 Share Repurchase Program). Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired. Under our 2020 Share Repurchase Program, we repurchased and retired approximately 2.2 million shares of our common stock at a cost of approximately $600.0 million during the three months ended March 31, 2021. There were no share repurchases of our common stock during the three months ended March 31, 2022. Approximately $2.8 billion remained available under our 2020 Share Repurchase Program as of March 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accumulated Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains (Losses) on Net Investment Hedge, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(44.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(139.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(106.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(16.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(43.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(160.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(115.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains (Losses) on Net Investment Hedge, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(179.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(66.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(46.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(299.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(48.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;149.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(48.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;124.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(64.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(95.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(174.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amounts reclassified from accumulated other comprehensive income (loss):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Income Statement Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts Reclassified from Accumulated Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on securities available for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(23.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i927398c21f2c4253b9e5fc9aa1970ccb_I20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RleHRyZWdpb246ZWE2MjIzNjgyOGJkNDBlMzkyZWFmMGM3ODBjOTk4MzlfMTEx_02d312d2-f814-4c4c-81d4-4435c19e433f"
      unitRef="usd">5000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i8035064229a94dc1909b26988c0c3fc7_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RleHRyZWdpb246ZWE2MjIzNjgyOGJkNDBlMzkyZWFmMGM3ODBjOTk4MzlfMjE5OTAyMzI1NzM5Mg_cb4694b6-7fc3-4cf7-8f21-fe0639dfe2e8"
      unitRef="shares">2200000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i8035064229a94dc1909b26988c0c3fc7_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RleHRyZWdpb246ZWE2MjIzNjgyOGJkNDBlMzkyZWFmMGM3ODBjOTk4MzlfMjE5OTAyMzI1NzQwMg_0e4a0b63-a411-4f1e-bdd0-ffa9255e56e0"
      unitRef="usd">600000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="i8aed478a3bb84a26a97e98654c7ce707_I20220331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RleHRyZWdpb246ZWE2MjIzNjgyOGJkNDBlMzkyZWFmMGM3ODBjOTk4MzlfNTM2_aa35c789-8110-400c-97a7-8ce3f5ece43f"
      unitRef="usd">2800000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RleHRyZWdpb246ZWE2MjIzNjgyOGJkNDBlMzkyZWFmMGM3ODBjOTk4MzlfMTc5Ng_947fbb7d-cf5b-4e03-8c3b-7d86be263e17">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains (Losses) on Net Investment Hedge, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(44.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(139.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(106.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(16.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(43.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(160.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(115.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains (Losses) on Net Investment Hedge, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(179.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(66.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(46.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(299.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(48.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;149.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(48.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;124.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(64.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(95.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(174.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ia823c01230e94f078e3bd77c94d36863_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfMS0yLTEtMS03NTE0MA_ab6749e4-28c3-4014-8f1b-c459945357b7"
      unitRef="usd">-2200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i89079b4dcd7340cc8676a18916e07cce_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfMS00LTEtMS03NTE0MA_796a9792-1606-4d75-94e2-1fcd3d7f5eb5"
      unitRef="usd">53800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ia1ba18679af24668b4316adb5b46bbeb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfMS02LTEtMS03NTE0MA_f9efcd74-bbf9-4fb3-a784-c2f48086330f"
      unitRef="usd">25500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ic535854c80b1412f924435f8c91f63b8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfMS04LTEtMS03NTE0MA_0a5886ce-e958-4187-af35-b20ffa2a8a17"
      unitRef="usd">-44800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ib29fa61175a74b01bcdc01a071bd7d48_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfMS0xMC0xLTEtNzUxNDA_34a64969-a98d-412a-8c14-362024cf654d"
      unitRef="usd">-139000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfMS0xMi0xLTEtNzUxNDA_a384e6e0-571e-47fb-a1c2-b454ef7219f2"
      unitRef="usd">-106700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i3e87abb1f9db4300857139f5ddaa4d14_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfMi0yLTEtMS03NTE0MA_f3fac3d8-18ec-45d3-96ea-8a7669232291"
      unitRef="usd">-10200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="icc0ec6584c7c4d459947e00620f435cd_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfMi00LTEtMS03NTE0MA_a352c8d7-b75b-4c24-b5d4-88efbe20b448"
      unitRef="usd">34400000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i8d0f10b22c834ba396c8b4c6a3188b23_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfMi02LTEtMS03NTE0MA_5003f3f0-6003-4667-ae8d-4ca6b9022a00"
      unitRef="usd">5100000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i5838303fd7294f56a6ba30fc62e8ecac_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfMi04LTEtMS03NTE0MA_600bf9bb-be0c-4a79-bcc1-6a4b2a412435"
      unitRef="usd">900000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i8b54fa2358e34e17ae6d8739b9b3339b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfMi0xMC0xLTEtNzUxNDA_2bcf48a2-075c-4af7-80ec-7ef4ba847474"
      unitRef="usd">-21800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfMi0xMi0xLTEtNzUxNDA_00863554-908b-407e-9312-3af3ded2aa49"
      unitRef="usd">8400000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i3e87abb1f9db4300857139f5ddaa4d14_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfMy0yLTEtMS03NTE0MA_47253f8a-5be7-4bf9-b4be-6d125d739e4c"
      unitRef="usd">500000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="icc0ec6584c7c4d459947e00620f435cd_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfMy00LTEtMS03NTE0MA_6ed84316-8fb6-47b5-a57c-030c51b37b3c"
      unitRef="usd">-18500000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i8d0f10b22c834ba396c8b4c6a3188b23_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfMy02LTEtMS03NTE0MA_d29dd85f-e0f4-4d47-813a-396bd3b84176"
      unitRef="usd">1100000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i5838303fd7294f56a6ba30fc62e8ecac_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfMy04LTEtMS03NTE0MA_e0f3a938-d96a-4346-baad-ece32dc79e51"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i8b54fa2358e34e17ae6d8739b9b3339b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfMy0xMC0xLTEtNzUxNDA_738cd259-6cf5-4a9c-a461-51a923c74bb0"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfMy0xMi0xLTEtNzUxNDA_7c90ee49-555f-4359-a446-8b6a1de0b14c"
      unitRef="usd">-16900000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i3e87abb1f9db4300857139f5ddaa4d14_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfNC0yLTEtMS03NTE0MA_fe42be91-0f56-4d3f-93c0-399948e3d737"
      unitRef="usd">-9700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="icc0ec6584c7c4d459947e00620f435cd_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfNC00LTEtMS03NTE0MA_a18a1867-33e8-422a-add8-f4d7c46ee5a3"
      unitRef="usd">15900000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8d0f10b22c834ba396c8b4c6a3188b23_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfNC02LTEtMS03NTE0MA_1b6cc1be-7c27-45a0-9dac-6113adcd5d39"
      unitRef="usd">6200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i5838303fd7294f56a6ba30fc62e8ecac_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfNC04LTEtMS03NTE0MA_cc4a133a-0753-4440-997f-0ac2e2ab935f"
      unitRef="usd">900000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8b54fa2358e34e17ae6d8739b9b3339b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfNC0xMC0xLTEtNzUxNDA_151e655a-46f3-4b2e-917f-09e50cbdbb0d"
      unitRef="usd">-21800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfNC0xMi0xLTEtNzUxNDA_dd40b563-ee21-4b5f-a2b1-a9c8844df5a5"
      unitRef="usd">-8500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i9b84e664424c4f9c9c3be2725156b218_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfNS0yLTEtMS03NTE0MA_e38a5852-f066-43a8-8569-28ed6c1061c8"
      unitRef="usd">-11900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i405ecf1b53c842e8ab96a5daf031a812_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfNS00LTEtMS03NTE0MA_2eb5b6fb-14c6-4d2f-aa13-be9b252029e9"
      unitRef="usd">69700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i1ac817d516214d4294329c0c3985e64a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfNS02LTEtMS03NTE0MA_8c0e4d5f-3c3a-4b44-ae8e-a7c32fc68948"
      unitRef="usd">31700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ie992e5401cf74a7eb8a5100825da7530_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfNS04LTEtMS03NTE0MA_150fd91e-b1af-4ab0-b766-67f005d21a10"
      unitRef="usd">-43900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="id9dc7e3bd5af43b9ae44d024af7d45ee_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfNS0xMC0xLTEtNzUxNDA_74a5c93d-ff50-4912-95d4-5cbabd8dffc5"
      unitRef="usd">-160800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOjI0MTNhYTBiMWFjOTQ0ODY5ZWQwYzgzNTdlMzRkM2RhL3RhYmxlcmFuZ2U6MjQxM2FhMGIxYWM5NDQ4NjllZDBjODM1N2UzNGQzZGFfNS0xMi0xLTEtNzUxNDA_519023d8-cb42-48af-820c-44b6bf0e6f36"
      unitRef="usd">-115200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i1b8f47e6df9047dc9800a3ef46b3a47a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfMS0yLTEtMS03NTE0MA_0f9ef1ed-f181-4fff-afdd-7dfb13a38a14"
      unitRef="usd">1400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i3c403b59149b4448b3ab41d54ea6da30_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfMS00LTEtMS03NTE0MA_c6b0a468-f5d7-4d63-954b-fa0d2b8495e7"
      unitRef="usd">-179000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i07e5a2d28d8644f0a7750374306253d1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfMS02LTEtMS03NTE0MA_2a3d63ae-9b39-487f-b032-46fcdcb5a5e9"
      unitRef="usd">-8500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ic788e2af1c2a42bdad2a187fa0f3f0f9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfMS04LTEtMS03NTE0MA_92331b64-c9ec-4e02-a542-fb833fc14ab0"
      unitRef="usd">-66300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i9905d8e67a1c49bba25ddc2283754bd9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfMS0xMC0xLTEtNzUxNDA_11f7d9ae-a1c6-497f-98a7-c277e5fd7ceb"
      unitRef="usd">-46600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="if8f47af926b14294931310a85ceac0ce_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfMS0xMi0xLTEtNzUxNDA_d9bbd22a-3946-4ee9-9c32-5b23d27de2e5"
      unitRef="usd">-299000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i56c6c6dbd77141ebb3ba11ea6d1906c2_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfMi0yLTEtMS03NTE0MA_f2a5ed10-de46-4d35-a48d-d089a39d2c45"
      unitRef="usd">-1200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i21cbbb23fa0942b0b38de55781a30060_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfMi00LTEtMS03NTE0MA_22d26899-2045-43b6-9f3d-155712e27fe0"
      unitRef="usd">128600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i76808577ee454761a0b2fc6e21960006_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfMi02LTEtMS03NTE0MA_aca03bea-bc37-456f-a2d2-f5121fd31760"
      unitRef="usd">22400000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i6abbeadb96ac4f689ba74b0475350c98_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfMi04LTEtMS03NTE0MA_a96a376d-2743-4aaf-8c1d-95cb7f6e06a6"
      unitRef="usd">2000000.0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="idf39efdb65104bcb856efd226f4e02aa_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfMi0xMC0xLTEtNzUxNDA_3725a310-2b6d-4e26-b696-f00cae92e65b"
      unitRef="usd">-48500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfMi0xMi0xLTEtNzUxNDA_d51716b3-6d6e-47dc-a9f7-9928eb4c4795"
      unitRef="usd">103300000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i56c6c6dbd77141ebb3ba11ea6d1906c2_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfMy0yLTEtMS03NTE0MA_b52c1fbd-d614-46ff-8bde-bf1034a99fa2"
      unitRef="usd">400000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i21cbbb23fa0942b0b38de55781a30060_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfMy00LTEtMS03NTE0MA_dd28e6ab-b924-4bf3-b7eb-9ef6044eb4f1"
      unitRef="usd">21000000.0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i76808577ee454761a0b2fc6e21960006_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfMy02LTEtMS03NTE0MA_02f348e2-b569-4856-bf2d-eae508cce7b5"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i6abbeadb96ac4f689ba74b0475350c98_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfMy04LTEtMS03NTE0MA_715d7057-b043-4a28-9da4-38ab7d938ba2"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="idf39efdb65104bcb856efd226f4e02aa_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfMy0xMC0xLTEtNzUxNDA_20442a7d-fef0-48df-9bbf-8f48688c09aa"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfMy0xMi0xLTEtNzUxNDA_f1ae373a-59af-4b29-9518-8c57a6c11ec4"
      unitRef="usd">21400000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i56c6c6dbd77141ebb3ba11ea6d1906c2_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfNC0yLTEtMS03NTE0MA_18aa45dd-cd82-40ae-8cb4-b9a10a7aafde"
      unitRef="usd">-800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i21cbbb23fa0942b0b38de55781a30060_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfNC00LTEtMS03NTE0MA_ff0d86b4-e744-488f-b5a6-2d6349a3922e"
      unitRef="usd">149600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i76808577ee454761a0b2fc6e21960006_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfNC02LTEtMS03NTE0MA_59abcbd3-b272-44b6-81f8-850dcd8ce26d"
      unitRef="usd">22400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6abbeadb96ac4f689ba74b0475350c98_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfNC04LTEtMS03NTE0MA_17b6ca38-491d-4849-b1bd-811ae3a9cf4d"
      unitRef="usd">2000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="idf39efdb65104bcb856efd226f4e02aa_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfNC0xMC0xLTEtNzUxNDA_8f24ced6-2559-43ac-b6f3-f18545f5a431"
      unitRef="usd">-48500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfNC0xMi0xLTEtNzUxNDA_5766aa41-d324-4abf-891f-f85b853e6f99"
      unitRef="usd">124700000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="idd3f194d4161459fa9fc9aaed46498ea_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfNS0yLTEtMS03NTE0MA_8bfd775b-e23c-4465-bffd-5b6f89d5dfff"
      unitRef="usd">600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i70ab7808a4b842c9925eda0753188c9f_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfNS00LTEtMS03NTE0MA_31c44d89-1a9c-41f9-a3fb-67b18cb04706"
      unitRef="usd">-29400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="id8c8dc8cb4ac4de98e44bab2c31b1282_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfNS02LTEtMS03NTE0MA_0d38c4c5-6ee3-483c-bfce-dfd9610ea034"
      unitRef="usd">13900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="id4e7315860ff46c0acb88d0816fd6daf_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfNS04LTEtMS03NTE0MA_ae547820-903d-4b60-8d4d-e59b87a0d93d"
      unitRef="usd">-64300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i52bad0c11e3144e899c81a5bb55aabb2_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfNS0xMC0xLTEtNzUxNDA_7b689544-0969-4cd0-8d87-47ec2ffe9eec"
      unitRef="usd">-95100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i8239e2124c804a2ea880e06ae55914e8_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmMxOTFkYWQ4MzBmZDRhNjViMWIxYzA3ZTUzOWJjMTJiL3RhYmxlcmFuZ2U6YzE5MWRhZDgzMGZkNGE2NWIxYjFjMDdlNTM5YmMxMmJfNS0xMi0xLTEtNzUxNDA_8193a3ca-614f-4442-a4ca-25d2cff30b47"
      unitRef="usd">-174300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RleHRyZWdpb246ZWE2MjIzNjgyOGJkNDBlMzkyZWFmMGM3ODBjOTk4MzlfMTc5Mg_5a64af82-8ef9-430b-8029-d8ebadd3d13c">&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amounts reclassified from accumulated other comprehensive income (loss):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Income Statement Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts Reclassified from Accumulated Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on securities available for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(23.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i54a289067eb44a92a43277cf25c506fe_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmUwYjczNGJlYjBmNTRhYTc5NDMyOGI2ZjRjOGIwZjk2L3RhYmxlcmFuZ2U6ZTBiNzM0YmViMGY1NGFhNzk0MzI4YjZmNGM4YjBmOTZfMy0zLTEtMS03NTE0MA_4dba1bcf-6f82-4b11-a4d1-f31e13cdf7cb"
      unitRef="usd">-600000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="iaaff40b00b8a475aa7213303ae060f69_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmUwYjczNGJlYjBmNTRhYTc5NDMyOGI2ZjRjOGIwZjk2L3RhYmxlcmFuZ2U6ZTBiNzM0YmViMGY1NGFhNzk0MzI4YjZmNGM4YjBmOTZfMy01LTEtMS03NTE0MA_7f8f363e-0942-4280-9569-8a9ee0fd5186"
      unitRef="usd">-500000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i54a289067eb44a92a43277cf25c506fe_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmUwYjczNGJlYjBmNTRhYTc5NDMyOGI2ZjRjOGIwZjk2L3RhYmxlcmFuZ2U6ZTBiNzM0YmViMGY1NGFhNzk0MzI4YjZmNGM4YjBmOTZfNC0zLTEtMS03NTE0MA_7504d899-916c-4a2a-8c02-c16b0bacc7f4"
      unitRef="usd">100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iaaff40b00b8a475aa7213303ae060f69_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmUwYjczNGJlYjBmNTRhYTc5NDMyOGI2ZjRjOGIwZjk2L3RhYmxlcmFuZ2U6ZTBiNzM0YmViMGY1NGFhNzk0MzI4YjZmNGM4YjBmOTZfNC01LTEtMS03NTE0MA_54c6bf91-f5df-440a-8550-06974e59cd25"
      unitRef="usd">100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:Revenues
      contextRef="i82e69258ff2a411eb0af8d55689ed83c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmUwYjczNGJlYjBmNTRhYTc5NDMyOGI2ZjRjOGIwZjk2L3RhYmxlcmFuZ2U6ZTBiNzM0YmViMGY1NGFhNzk0MzI4YjZmNGM4YjBmOTZfNi0zLTEtMS03NTE0MA_f314ea47-ddca-4cb9-b05e-a0355653ec71"
      unitRef="usd">20900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia89aa06c882742e4a448659b8c11481c_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmUwYjczNGJlYjBmNTRhYTc5NDMyOGI2ZjRjOGIwZjk2L3RhYmxlcmFuZ2U6ZTBiNzM0YmViMGY1NGFhNzk0MzI4YjZmNGM4YjBmOTZfNi01LTEtMS03NTE0MA_027a6f46-5219-45d7-8c41-da07dcbf7ceb"
      unitRef="usd">-23100000</us-gaap:Revenues>
    <us-gaap:OperatingExpenses
      contextRef="i82e69258ff2a411eb0af8d55689ed83c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmUwYjczNGJlYjBmNTRhYTc5NDMyOGI2ZjRjOGIwZjk2L3RhYmxlcmFuZ2U6ZTBiNzM0YmViMGY1NGFhNzk0MzI4YjZmNGM4YjBmOTZfNy0zLTEtMS03NTE0MA_0bcccae9-b6af-46b4-bc8e-04eb8aed4ae6"
      unitRef="usd">300000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ia89aa06c882742e4a448659b8c11481c_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmUwYjczNGJlYjBmNTRhYTc5NDMyOGI2ZjRjOGIwZjk2L3RhYmxlcmFuZ2U6ZTBiNzM0YmViMGY1NGFhNzk0MzI4YjZmNGM4YjBmOTZfNy01LTEtMS03NTE0MA_1cbea698-6d2f-4a1e-91ff-4e20c92d2823"
      unitRef="usd">400000</us-gaap:OperatingExpenses>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i82e69258ff2a411eb0af8d55689ed83c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmUwYjczNGJlYjBmNTRhYTc5NDMyOGI2ZjRjOGIwZjk2L3RhYmxlcmFuZ2U6ZTBiNzM0YmViMGY1NGFhNzk0MzI4YjZmNGM4YjBmOTZfOC0zLTEtMS03NTE0MA_afea7d44-c9cd-4a52-bb18-45ec6051bb25"
      unitRef="usd">-100000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ia89aa06c882742e4a448659b8c11481c_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmUwYjczNGJlYjBmNTRhYTc5NDMyOGI2ZjRjOGIwZjk2L3RhYmxlcmFuZ2U6ZTBiNzM0YmViMGY1NGFhNzk0MzI4YjZmNGM4YjBmOTZfOC01LTEtMS03NTE0MA_c7517061-aa29-403e-86f5-888b82f5877c"
      unitRef="usd">200000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i82e69258ff2a411eb0af8d55689ed83c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmUwYjczNGJlYjBmNTRhYTc5NDMyOGI2ZjRjOGIwZjk2L3RhYmxlcmFuZ2U6ZTBiNzM0YmViMGY1NGFhNzk0MzI4YjZmNGM4YjBmOTZfOS0zLTEtMS03NTE0MA_300d9495-61ba-4fd3-83b6-e4cbb634d8a6"
      unitRef="usd">-2000000.0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia89aa06c882742e4a448659b8c11481c_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmUwYjczNGJlYjBmNTRhYTc5NDMyOGI2ZjRjOGIwZjk2L3RhYmxlcmFuZ2U6ZTBiNzM0YmViMGY1NGFhNzk0MzI4YjZmNGM4YjBmOTZfOS01LTEtMS03NTE0MA_0c94ee58-d438-4b7d-a79c-e8b2de16f2b1"
      unitRef="usd">2300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i53aa42306e12421f90d4b595dc6b62f5_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmUwYjczNGJlYjBmNTRhYTc5NDMyOGI2ZjRjOGIwZjk2L3RhYmxlcmFuZ2U6ZTBiNzM0YmViMGY1NGFhNzk0MzI4YjZmNGM4YjBmOTZfMTEtMy0xLTEtNzUxNDA_ce669462-67fc-4d69-8c36-21669ddcb1ef"
      unitRef="usd">-1100000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i9477047c7de34040997c009eedbe4518_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmUwYjczNGJlYjBmNTRhYTc5NDMyOGI2ZjRjOGIwZjk2L3RhYmxlcmFuZ2U6ZTBiNzM0YmViMGY1NGFhNzk0MzI4YjZmNGM4YjBmOTZfMTEtNS0xLTEtNzUxNDA_9e93cc37-00aa-4356-a927-78a466d43965"
      unitRef="usd">0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="ia4e4d15b86ad443eb9d3edf6dee5f7b5_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmUwYjczNGJlYjBmNTRhYTc5NDMyOGI2ZjRjOGIwZjk2L3RhYmxlcmFuZ2U6ZTBiNzM0YmViMGY1NGFhNzk0MzI4YjZmNGM4YjBmOTZfMTQtMy0xLTEtNzUxNDA_2deb5dac-0844-40bd-bb61-f6734a418c27"
      unitRef="usd">16900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie709fcb90ef24b93b760d2540d00088a_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl85Ny9mcmFnOmVhNjIyMzY4MjhiZDQwZTM5MmVhZjBjNzgwYzk5ODM5L3RhYmxlOmUwYjczNGJlYjBmNTRhYTc5NDMyOGI2ZjRjOGIwZjk2L3RhYmxlcmFuZ2U6ZTBiNzM0YmViMGY1NGFhNzk0MzI4YjZmNGM4YjBmOTZfMTQtNS0xLTEtNzUxNDA_928d4580-d9bf-47a6-a89c-63d518f4e5a1"
      unitRef="usd">-21400000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDAvZnJhZzo4ZmU4Njg2OTllZTk0YjhhODViNWFiM2YwMDY2MzU2NC90ZXh0cmVnaW9uOjhmZTg2ODY5OWVlOTRiOGE4NWI1YWIzZjAwNjYzNTY0XzI2MA_1d327ce6-6a54-46e9-b807-d91c5e374156">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;303.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;410.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;147.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;151.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Market stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dilutive potential common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares used in calculating diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;147.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;152.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDAvZnJhZzo4ZmU4Njg2OTllZTk0YjhhODViNWFiM2YwMDY2MzU2NC90ZXh0cmVnaW9uOjhmZTg2ODY5OWVlOTRiOGE4NWI1YWIzZjAwNjYzNTY0XzI2Nw_12aa6e13-201c-4bea-ba1d-f089b2536e31">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;303.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;410.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;147.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;151.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Market stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dilutive potential common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares used in calculating diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;147.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;152.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDAvZnJhZzo4ZmU4Njg2OTllZTk0YjhhODViNWFiM2YwMDY2MzU2NC90YWJsZTo5OGQ5ODNmNDZjNjQ0NTU5YTU1ZjkyMTU4NGIzZGNhZS90YWJsZXJhbmdlOjk4ZDk4M2Y0NmM2NDQ1NTlhNTVmOTIxNTg0YjNkY2FlXzMtMi0xLTEtNzUxNDA_6c52809a-f550-4c58-a5cd-ee28cf287ec2"
      unitRef="usd">303800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDAvZnJhZzo4ZmU4Njg2OTllZTk0YjhhODViNWFiM2YwMDY2MzU2NC90YWJsZTo5OGQ5ODNmNDZjNjQ0NTU5YTU1ZjkyMTU4NGIzZGNhZS90YWJsZXJhbmdlOjk4ZDk4M2Y0NmM2NDQ1NTlhNTVmOTIxNTg0YjNkY2FlXzMtNC0xLTEtNzUxNDA_7807fd1e-f962-4718-aadb-c9d7552c82cb"
      unitRef="usd">410200000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDAvZnJhZzo4ZmU4Njg2OTllZTk0YjhhODViNWFiM2YwMDY2MzU2NC90YWJsZTo5OGQ5ODNmNDZjNjQ0NTU5YTU1ZjkyMTU4NGIzZGNhZS90YWJsZXJhbmdlOjk4ZDk4M2Y0NmM2NDQ1NTlhNTVmOTIxNTg0YjNkY2FlXzUtMi0xLTEtNzUxNDA_fd6f7d5c-d2a1-4999-8d2e-d7762cb1fd14"
      unitRef="shares">147100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDAvZnJhZzo4ZmU4Njg2OTllZTk0YjhhODViNWFiM2YwMDY2MzU2NC90YWJsZTo5OGQ5ODNmNDZjNjQ0NTU5YTU1ZjkyMTU4NGIzZGNhZS90YWJsZXJhbmdlOjk4ZDk4M2Y0NmM2NDQ1NTlhNTVmOTIxNTg0YjNkY2FlXzUtNC0xLTEtNzUxNDA_4d9c2bf2-0fd4-48d9-aae5-555bcccc37a0"
      unitRef="shares">151900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i810555191bc946a183d59137a3d60baf_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDAvZnJhZzo4ZmU4Njg2OTllZTk0YjhhODViNWFiM2YwMDY2MzU2NC90YWJsZTo5OGQ5ODNmNDZjNjQ0NTU5YTU1ZjkyMTU4NGIzZGNhZS90YWJsZXJhbmdlOjk4ZDk4M2Y0NmM2NDQ1NTlhNTVmOTIxNTg0YjNkY2FlXzgtMi0xLTEtNzUxNDA_7bdd1223-776e-47f5-9c91-5950cf436c6c"
      unitRef="shares">300000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i091a772781f844e0996d9dd61c0fbb5f_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDAvZnJhZzo4ZmU4Njg2OTllZTk0YjhhODViNWFiM2YwMDY2MzU2NC90YWJsZTo5OGQ5ODNmNDZjNjQ0NTU5YTU1ZjkyMTU4NGIzZGNhZS90YWJsZXJhbmdlOjk4ZDk4M2Y0NmM2NDQ1NTlhNTVmOTIxNTg0YjNkY2FlXzgtNC0xLTEtNzUxNDA_1f8d1392-be57-4940-ae74-bfb8de55ad58"
      unitRef="shares">200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i39e928655ba643399618f0c17b2b0812_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDAvZnJhZzo4ZmU4Njg2OTllZTk0YjhhODViNWFiM2YwMDY2MzU2NC90YWJsZTo5OGQ5ODNmNDZjNjQ0NTU5YTU1ZjkyMTU4NGIzZGNhZS90YWJsZXJhbmdlOjk4ZDk4M2Y0NmM2NDQ1NTlhNTVmOTIxNTg0YjNkY2FlXzktMi0xLTEtNzUxNDA_1b0ca4b6-9687-4d0a-8312-a162f991867b"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ic6d836e623c94a73a4c74c493f93fee4_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDAvZnJhZzo4ZmU4Njg2OTllZTk0YjhhODViNWFiM2YwMDY2MzU2NC90YWJsZTo5OGQ5ODNmNDZjNjQ0NTU5YTU1ZjkyMTU4NGIzZGNhZS90YWJsZXJhbmdlOjk4ZDk4M2Y0NmM2NDQ1NTlhNTVmOTIxNTg0YjNkY2FlXzktNC0xLTEtNzUxNDA_45dc2017-f7f7-4528-9fcc-1faa72416d6f"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="iddfb71709ed840e98b85ca08ce7bdeaf_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDAvZnJhZzo4ZmU4Njg2OTllZTk0YjhhODViNWFiM2YwMDY2MzU2NC90YWJsZTo5OGQ5ODNmNDZjNjQ0NTU5YTU1ZjkyMTU4NGIzZGNhZS90YWJsZXJhbmdlOjk4ZDk4M2Y0NmM2NDQ1NTlhNTVmOTIxNTg0YjNkY2FlXzEwLTItMS0xLTc1MTQw_b6034148-7120-4d27-811d-2c990f47a56f"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i9afd12c183494d549b839596293da75e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDAvZnJhZzo4ZmU4Njg2OTllZTk0YjhhODViNWFiM2YwMDY2MzU2NC90YWJsZTo5OGQ5ODNmNDZjNjQ0NTU5YTU1ZjkyMTU4NGIzZGNhZS90YWJsZXJhbmdlOjk4ZDk4M2Y0NmM2NDQ1NTlhNTVmOTIxNTg0YjNkY2FlXzEwLTQtMS0xLTc1MTQw_42c13a62-49ca-454c-a342-d1122e7f6332"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDAvZnJhZzo4ZmU4Njg2OTllZTk0YjhhODViNWFiM2YwMDY2MzU2NC90YWJsZTo5OGQ5ODNmNDZjNjQ0NTU5YTU1ZjkyMTU4NGIzZGNhZS90YWJsZXJhbmdlOjk4ZDk4M2Y0NmM2NDQ1NTlhNTVmOTIxNTg0YjNkY2FlXzExLTItMS0xLTc1MTQw_28d788b6-413b-474f-8867-bbd393f2cf7d"
      unitRef="shares">500000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDAvZnJhZzo4ZmU4Njg2OTllZTk0YjhhODViNWFiM2YwMDY2MzU2NC90YWJsZTo5OGQ5ODNmNDZjNjQ0NTU5YTU1ZjkyMTU4NGIzZGNhZS90YWJsZXJhbmdlOjk4ZDk4M2Y0NmM2NDQ1NTlhNTVmOTIxNTg0YjNkY2FlXzExLTQtMS0xLTc1MTQw_df26a7fb-e229-4668-b9d7-b3cc6f4ef6d3"
      unitRef="shares">400000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDAvZnJhZzo4ZmU4Njg2OTllZTk0YjhhODViNWFiM2YwMDY2MzU2NC90YWJsZTo5OGQ5ODNmNDZjNjQ0NTU5YTU1ZjkyMTU4NGIzZGNhZS90YWJsZXJhbmdlOjk4ZDk4M2Y0NmM2NDQ1NTlhNTVmOTIxNTg0YjNkY2FlXzEyLTItMS0xLTc1MTQw_f4b581b2-fb79-4501-bc1d-b9dab6daea06"
      unitRef="shares">147600000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDAvZnJhZzo4ZmU4Njg2OTllZTk0YjhhODViNWFiM2YwMDY2MzU2NC90YWJsZTo5OGQ5ODNmNDZjNjQ0NTU5YTU1ZjkyMTU4NGIzZGNhZS90YWJsZXJhbmdlOjk4ZDk4M2Y0NmM2NDQ1NTlhNTVmOTIxNTg0YjNkY2FlXzEyLTQtMS0xLTc1MTQw_3d8ae53f-3039-4572-88d0-b89bb6709322"
      unitRef="shares">152300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90ZXh0cmVnaW9uOmVjODkxNDU2ZmZkMjQyNjViNTk3Y2IyNzIxYjY5NDAwXzY0Mg_c052d51a-393d-4cec-890f-b34edd1b1a38">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalized share-based compensation costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in total cost and expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in net income attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Market stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalized share-based compensation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in total cost and expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the fair value of our obligations associated with our performance stock units settled in cash at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recognized each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90ZXh0cmVnaW9uOmVjODkxNDU2ZmZkMjQyNjViNTk3Y2IyNzIxYjY5NDAwXzY0NQ_44099aa2-52b6-4dbf-8a6a-e0bbe791059d">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalized share-based compensation costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in total cost and expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in net income attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ida7d6be5a5da461dbf5390a92f2c5e9d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTo3MmJhNDExYWRmOTQ0ZGI1YjMxYzg1M2U4YjVmYjVkZS90YWJsZXJhbmdlOjcyYmE0MTFhZGY5NDRkYjViMzFjODUzZThiNWZiNWRlXzItMi0xLTEtNzUxNDA_800f2e24-c402-4051-b685-692d9f33db8b"
      unitRef="usd">25700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0163dd5e3d654e748b422f150d2d5a9c_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTo3MmJhNDExYWRmOTQ0ZGI1YjMxYzg1M2U4YjVmYjVkZS90YWJsZXJhbmdlOjcyYmE0MTFhZGY5NDRkYjViMzFjODUzZThiNWZiNWRlXzItNC0xLTEtNzUxNDA_930ccf61-ed0d-442d-9e33-cad89240dc6d"
      unitRef="usd">33600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4eff7cd113a74d2e910753e991374627_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTo3MmJhNDExYWRmOTQ0ZGI1YjMxYzg1M2U4YjVmYjVkZS90YWJsZXJhbmdlOjcyYmE0MTFhZGY5NDRkYjViMzFjODUzZThiNWZiNWRlXzMtMi0xLTEtNzUxNDA_12cdea00-80ac-459c-91fd-2c6457e196f4"
      unitRef="usd">46100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i286ad499ff5d462799e0f941ef3e205f_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTo3MmJhNDExYWRmOTQ0ZGI1YjMxYzg1M2U4YjVmYjVkZS90YWJsZXJhbmdlOjcyYmE0MTFhZGY5NDRkYjViMzFjODUzZThiNWZiNWRlXzMtNC0xLTEtNzUxNDA_02d4971e-f5e3-4663-9c3c-9871bc9963d2"
      unitRef="usd">44900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTo3MmJhNDExYWRmOTQ0ZGI1YjMxYzg1M2U4YjVmYjVkZS90YWJsZXJhbmdlOjcyYmE0MTFhZGY5NDRkYjViMzFjODUzZThiNWZiNWRlXzQtMi0xLTEtNzUxNDA_b4684005-92d5-4be9-b36d-99309574833b"
      unitRef="usd">71800000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTo3MmJhNDExYWRmOTQ0ZGI1YjMxYzg1M2U4YjVmYjVkZS90YWJsZXJhbmdlOjcyYmE0MTFhZGY5NDRkYjViMzFjODUzZThiNWZiNWRlXzQtNC0xLTEtNzUxNDA_624596a2-6cfc-41e9-9b37-a9c2f45c2275"
      unitRef="usd">78500000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTo3MmJhNDExYWRmOTQ0ZGI1YjMxYzg1M2U4YjVmYjVkZS90YWJsZXJhbmdlOjcyYmE0MTFhZGY5NDRkYjViMzFjODUzZThiNWZiNWRlXzUtMi0xLTEtNzUxNDA_82c8baea-3255-40aa-b047-8a61b913cd6f"
      unitRef="usd">2800000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTo3MmJhNDExYWRmOTQ0ZGI1YjMxYzg1M2U4YjVmYjVkZS90YWJsZXJhbmdlOjcyYmE0MTFhZGY5NDRkYjViMzFjODUzZThiNWZiNWRlXzUtNC0xLTEtNzUxNDA_a339e818-118a-4790-a906-4c1d45ba0320"
      unitRef="usd">2600000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTo3MmJhNDExYWRmOTQ0ZGI1YjMxYzg1M2U4YjVmYjVkZS90YWJsZXJhbmdlOjcyYmE0MTFhZGY5NDRkYjViMzFjODUzZThiNWZiNWRlXzYtMi0xLTEtNzUxNDA_f3abc44a-11a8-4bb0-998f-e858967fe46a"
      unitRef="usd">69000000.0</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTo3MmJhNDExYWRmOTQ0ZGI1YjMxYzg1M2U4YjVmYjVkZS90YWJsZXJhbmdlOjcyYmE0MTFhZGY5NDRkYjViMzFjODUzZThiNWZiNWRlXzYtNC0xLTEtNzUxNDA_76bfa8c9-297a-41e8-876c-ecab2358a1ec"
      unitRef="usd">75900000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTo3MmJhNDExYWRmOTQ0ZGI1YjMxYzg1M2U4YjVmYjVkZS90YWJsZXJhbmdlOjcyYmE0MTFhZGY5NDRkYjViMzFjODUzZThiNWZiNWRlXzctMi0xLTEtNzUxNDA_3b9fc1f1-ee98-43ea-8d64-dabcb2beee10"
      unitRef="usd">12800000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTo3MmJhNDExYWRmOTQ0ZGI1YjMxYzg1M2U4YjVmYjVkZS90YWJsZXJhbmdlOjcyYmE0MTFhZGY5NDRkYjViMzFjODUzZThiNWZiNWRlXzctNC0xLTEtNzUxNDA_00978f65-f230-4656-99e9-4c7a396d4eb9"
      unitRef="usd">14000000.0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib96d4930fa9c4ea4920b41bc8432568c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTo3MmJhNDExYWRmOTQ0ZGI1YjMxYzg1M2U4YjVmYjVkZS90YWJsZXJhbmdlOjcyYmE0MTFhZGY5NDRkYjViMzFjODUzZThiNWZiNWRlXzgtMi0xLTEtNzUxNDA_08c5002d-f842-42c7-a62e-5ff974ffcda7"
      unitRef="usd">56200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifa0242e914b24b17a8a259457c37203f_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTo3MmJhNDExYWRmOTQ0ZGI1YjMxYzg1M2U4YjVmYjVkZS90YWJsZXJhbmdlOjcyYmE0MTFhZGY5NDRkYjViMzFjODUzZThiNWZiNWRlXzgtNC0xLTEtNzUxNDA_1b98c42e-23e5-4ef8-84b0-a4fd10814935"
      unitRef="usd">61900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90ZXh0cmVnaW9uOmVjODkxNDU2ZmZkMjQyNjViNTk3Y2IyNzIxYjY5NDAwXzY2NQ_2f70ebfb-4367-4f37-8c50-40eba4f9a2f5">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Market stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalized share-based compensation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in total cost and expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic7e00bf0cede4201ac36bccc9be5e5fd_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTpmOGRkY2UzOGRjZTA0YWRjYjk5YjQ5MWI3OGM1Y2EwMy90YWJsZXJhbmdlOmY4ZGRjZTM4ZGNlMDRhZGNiOTliNDkxYjc4YzVjYTAzXzItMi0xLTEtNzUxNDA_254016de-e4dc-4616-bbd4-c08f760866ea"
      unitRef="usd">5900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i650e185cf72a422c97cc333e4de95e3e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTpmOGRkY2UzOGRjZTA0YWRjYjk5YjQ5MWI3OGM1Y2EwMy90YWJsZXJhbmdlOmY4ZGRjZTM4ZGNlMDRhZGNiOTliNDkxYjc4YzVjYTAzXzItNC0xLTEtNzUxNDA_e9a7bde9-088e-44c6-a37c-b928c79de50d"
      unitRef="usd">16500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie511e6e4286f476b8bf2a94aa1d42b95_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTpmOGRkY2UzOGRjZTA0YWRjYjk5YjQ5MWI3OGM1Y2EwMy90YWJsZXJhbmdlOmY4ZGRjZTM4ZGNlMDRhZGNiOTliNDkxYjc4YzVjYTAzXzMtMi0xLTEtNzUxNDA_a33fdd58-1d88-4fe8-b9ab-e7adccaa3444"
      unitRef="usd">51300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6dc6984b1c814916847de41632ad1d34_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTpmOGRkY2UzOGRjZTA0YWRjYjk5YjQ5MWI3OGM1Y2EwMy90YWJsZXJhbmdlOmY4ZGRjZTM4ZGNlMDRhZGNiOTliNDkxYjc4YzVjYTAzXzMtNC0xLTEtNzUxNDA_a20c8dd3-b5b5-424e-987b-fd2ee09140bb"
      unitRef="usd">42800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6e2fa4eb32484e43801f3346334b0be3_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTpmOGRkY2UzOGRjZTA0YWRjYjk5YjQ5MWI3OGM1Y2EwMy90YWJsZXJhbmdlOmY4ZGRjZTM4ZGNlMDRhZGNiOTliNDkxYjc4YzVjYTAzXzYtMi0xLTEtNzUxNDA_01da5769-4768-400a-9056-0561553e9de1"
      unitRef="usd">8300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id7c53ba95781468ab194b339910b54ea_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTpmOGRkY2UzOGRjZTA0YWRjYjk5YjQ5MWI3OGM1Y2EwMy90YWJsZXJhbmdlOmY4ZGRjZTM4ZGNlMDRhZGNiOTliNDkxYjc4YzVjYTAzXzYtNC0xLTEtNzUxNDA_a2f04942-3483-4812-9c3b-479466e6fa0e"
      unitRef="usd">6300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iadfc29fbc15b47a0bb4c9a7e11d2d1f6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTpmOGRkY2UzOGRjZTA0YWRjYjk5YjQ5MWI3OGM1Y2EwMy90YWJsZXJhbmdlOmY4ZGRjZTM4ZGNlMDRhZGNiOTliNDkxYjc4YzVjYTAzXzctMi0xLTEtNzUxNDA_963e97d1-ac40-4e2d-9732-f0038e2b496b"
      unitRef="usd">1400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9b5373d736be447fa8c13cecb1075da6_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTpmOGRkY2UzOGRjZTA0YWRjYjk5YjQ5MWI3OGM1Y2EwMy90YWJsZXJhbmdlOmY4ZGRjZTM4ZGNlMDRhZGNiOTliNDkxYjc4YzVjYTAzXzctNC0xLTEtNzUxNDA_77b1a78a-01cb-41c4-9374-14fe35ab262c"
      unitRef="usd">6000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7fecd952a0f246f4bc6ae41add94430d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTpmOGRkY2UzOGRjZTA0YWRjYjk5YjQ5MWI3OGM1Y2EwMy90YWJsZXJhbmdlOmY4ZGRjZTM4ZGNlMDRhZGNiOTliNDkxYjc4YzVjYTAzXzgtMi0xLTEtNzUxNDA_72f2b29e-8339-49d1-b35a-24efa8182b74"
      unitRef="usd">4900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i11b85385e04c4d72bb460d8796578ce0_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTpmOGRkY2UzOGRjZTA0YWRjYjk5YjQ5MWI3OGM1Y2EwMy90YWJsZXJhbmdlOmY4ZGRjZTM4ZGNlMDRhZGNiOTliNDkxYjc4YzVjYTAzXzgtNC0xLTEtNzUxNDA_79cd1407-d92c-48dc-898d-1d5b22dbf364"
      unitRef="usd">6900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTpmOGRkY2UzOGRjZTA0YWRjYjk5YjQ5MWI3OGM1Y2EwMy90YWJsZXJhbmdlOmY4ZGRjZTM4ZGNlMDRhZGNiOTliNDkxYjc4YzVjYTAzXzEwLTItMS0xLTc1MTQw_d2cc5cd7-6847-48a1-afd2-5a7a35ab47f6"
      unitRef="usd">71800000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTpmOGRkY2UzOGRjZTA0YWRjYjk5YjQ5MWI3OGM1Y2EwMy90YWJsZXJhbmdlOmY4ZGRjZTM4ZGNlMDRhZGNiOTliNDkxYjc4YzVjYTAzXzEwLTQtMS0xLTc1MTQw_bcb4f965-74d8-40a7-8426-70fa89e7731d"
      unitRef="usd">78500000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTpmOGRkY2UzOGRjZTA0YWRjYjk5YjQ5MWI3OGM1Y2EwMy90YWJsZXJhbmdlOmY4ZGRjZTM4ZGNlMDRhZGNiOTliNDkxYjc4YzVjYTAzXzExLTItMS0xLTc1MTQw_c13011b0-e1b7-4456-9e6c-0276040edbf7"
      unitRef="usd">2800000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTpmOGRkY2UzOGRjZTA0YWRjYjk5YjQ5MWI3OGM1Y2EwMy90YWJsZXJhbmdlOmY4ZGRjZTM4ZGNlMDRhZGNiOTliNDkxYjc4YzVjYTAzXzExLTQtMS0xLTc1MTQw_135937b1-8fd6-46db-9029-1309618daa79"
      unitRef="usd">2600000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTpmOGRkY2UzOGRjZTA0YWRjYjk5YjQ5MWI3OGM1Y2EwMy90YWJsZXJhbmdlOmY4ZGRjZTM4ZGNlMDRhZGNiOTliNDkxYjc4YzVjYTAzXzEyLTItMS0xLTc1MTQw_4b2a25ed-28bd-4232-aeb1-70292e6811ce"
      unitRef="usd">69000000.0</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDMvZnJhZzplYzg5MTQ1NmZmZDI0MjY1YjU5N2NiMjcyMWI2OTQwMC90YWJsZTpmOGRkY2UzOGRjZTA0YWRjYjk5YjQ5MWI3OGM1Y2EwMy90YWJsZXJhbmdlOmY4ZGRjZTM4ZGNlMDRhZGNiOTliNDkxYjc4YzVjYTAzXzEyLTQtMS0xLTc1MTQw_39b64aa9-821b-48b6-8ebc-5e75d3ba97c1"
      unitRef="usd">75900000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90ZXh0cmVnaW9uOjVlODA0YWZjNTczZjRmMTA5NDdlMjczYzY4ZTAwMmY4XzU0NTg_5a0f3146-8d23-4fae-956e-12f308661970">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Tax Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Taxes on foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchased intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;GILTI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Neurimmune tax impacts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#00823b;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Changes in Tax Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2021 we recorded a net deferred tax asset in Switzerland of approximately $490.0&#160;million on Neurimmune SubOne AG's (Neurimmune) tax basis in ADUHELM, the realization of which is dependent on future sales of ADUHELM. During the fourth quarter of 2021, due to reduced future expected revenue associated with ADUHELM, we recorded a valuation allowance of approximately $390.0&#160;million. During the first quarter of 2022, upon issuance of the final NCD related to ADUHELM, we recorded an additional valuation allowance of approximately $85.0&#160;million to reduce the net value of this deferred tax asset to zero. These adjustments to our deferred tax assets and their valuation allowances are each recorded with an equal and offsetting amount assigned to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income, resulting in a zero net impact to net income attributable to Biogen Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March 31, 2022, compared to the same period in 2021, the increase in our effective tax rate was primarily due to a deferred tax expense related to a valuation allowance, as discussed above, and the non-cash tax effects of changes in the value of our equity investments. The tax effects of this change in value of our equity investments were recorded discretely, since changes in value of equity investments cannot be forecasted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;For additional information on our collaboration arrangement with Neurimmune, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Note 17, Investments in Variable Interest Entities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Tax Basis in Samsung Bioepis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2022 and December 31, 2021, the carrying value of our investment in Samsung Bioepis totaled 709.4 billion South Korean won ($586.4 million) and 713.3 billion South Korean won ($599.9 million), respectively, which is classified as a component of investments and other assets in our condensed consolidated balance sheets. As of March 31, 2022, we have not recorded deferred taxes of approximately $70.0&#160;million on our tax over book basis related to this joint venture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting for Uncertainty in Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2017 or state, local or non-U.S. income tax examinations for years before 2012.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The U.S. Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration matters and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate that it is reasonably possible that our gross unrecognized tax benefits, exclusive of interest, could decrease by up to approximately $500.0 million, including approximately $455.0&#160;million related to the unrecognized tax benefits related to Neurimmune's tax basis in ADUHELM in the next 12 months as a result of various audit closures, settlements and expiration of the statute of limitations.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90ZXh0cmVnaW9uOjVlODA0YWZjNTczZjRmMTA5NDdlMjczYzY4ZTAwMmY4XzU0NzU_e9ff538f-656e-4845-9cb6-2b509040d193">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Taxes on foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchased intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;GILTI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Neurimmune tax impacts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90YWJsZTphOTJiYmJjZjFmNzE0Y2E0YWY5Yjc0ZDRmODQ1ZThjOC90YWJsZXJhbmdlOmE5MmJiYmNmMWY3MTRjYTRhZjliNzRkNGY4NDVlOGM4XzItMS0xLTEtNzUxNDA_ea67009b-3f41-4f31-96da-a7d1370b69bd"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90YWJsZTphOTJiYmJjZjFmNzE0Y2E0YWY5Yjc0ZDRmODQ1ZThjOC90YWJsZXJhbmdlOmE5MmJiYmNmMWY3MTRjYTRhZjliNzRkNGY4NDVlOGM4XzItMy0xLTEtNzUxNDA_ad18f569-efe3-4e75-a648-81e8080836bb"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90YWJsZTphOTJiYmJjZjFmNzE0Y2E0YWY5Yjc0ZDRmODQ1ZThjOC90YWJsZXJhbmdlOmE5MmJiYmNmMWY3MTRjYTRhZjliNzRkNGY4NDVlOGM4XzMtMS0xLTEtNzUxNDA_a1efd00c-f079-46f9-bbfb-8597b64f88bb"
      unitRef="number">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90YWJsZTphOTJiYmJjZjFmNzE0Y2E0YWY5Yjc0ZDRmODQ1ZThjOC90YWJsZXJhbmdlOmE5MmJiYmNmMWY3MTRjYTRhZjliNzRkNGY4NDVlOGM4XzMtMy0xLTEtNzUxNDA_5b292d10-0b6f-491c-9d90-1d33e12157cc"
      unitRef="number">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90YWJsZTphOTJiYmJjZjFmNzE0Y2E0YWY5Yjc0ZDRmODQ1ZThjOC90YWJsZXJhbmdlOmE5MmJiYmNmMWY3MTRjYTRhZjliNzRkNGY4NDVlOGM4XzQtMS0xLTEtNzUxNDA_26f79ce4-91ed-4003-937e-f4b80d472339"
      unitRef="number">-0.108</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90YWJsZTphOTJiYmJjZjFmNzE0Y2E0YWY5Yjc0ZDRmODQ1ZThjOC90YWJsZXJhbmdlOmE5MmJiYmNmMWY3MTRjYTRhZjliNzRkNGY4NDVlOGM4XzQtMy0xLTEtNzUxNDA_697b5e85-a982-4e33-9877-71381a3268a6"
      unitRef="number">-0.109</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90YWJsZTphOTJiYmJjZjFmNzE0Y2E0YWY5Yjc0ZDRmODQ1ZThjOC90YWJsZXJhbmdlOmE5MmJiYmNmMWY3MTRjYTRhZjliNzRkNGY4NDVlOGM4XzUtMS0xLTEtNzUxNDA_02b91cf7-37a1-4bbd-b671-3eb9de5148db"
      unitRef="number">0.025</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90YWJsZTphOTJiYmJjZjFmNzE0Y2E0YWY5Yjc0ZDRmODQ1ZThjOC90YWJsZXJhbmdlOmE5MmJiYmNmMWY3MTRjYTRhZjliNzRkNGY4NDVlOGM4XzUtMy0xLTEtNzUxNDA_5227ca58-6ee4-4e76-b192-8af275ae7e39"
      unitRef="number">0.037</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90YWJsZTphOTJiYmJjZjFmNzE0Y2E0YWY5Yjc0ZDRmODQ1ZThjOC90YWJsZXJhbmdlOmE5MmJiYmNmMWY3MTRjYTRhZjliNzRkNGY4NDVlOGM4XzYtMS0xLTEtNzUxNDA_f577b567-2ccb-48a3-9a54-0022f0757fc1"
      unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90YWJsZTphOTJiYmJjZjFmNzE0Y2E0YWY5Yjc0ZDRmODQ1ZThjOC90YWJsZXJhbmdlOmE5MmJiYmNmMWY3MTRjYTRhZjliNzRkNGY4NDVlOGM4XzYtMy0xLTEtNzUxNDA_88d0ea06-c6a2-4b9c-b8fe-46f1e3237c4a"
      unitRef="number">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <biib:EffectiveTaxRateReconciliationGILTItax
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90YWJsZTphOTJiYmJjZjFmNzE0Y2E0YWY5Yjc0ZDRmODQ1ZThjOC90YWJsZXJhbmdlOmE5MmJiYmNmMWY3MTRjYTRhZjliNzRkNGY4NDVlOGM4XzEwLTEtMS0xLTc1MTQw_319a502e-c937-457c-a736-53758477d709"
      unitRef="number">0.003</biib:EffectiveTaxRateReconciliationGILTItax>
    <biib:EffectiveTaxRateReconciliationGILTItax
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90YWJsZTphOTJiYmJjZjFmNzE0Y2E0YWY5Yjc0ZDRmODQ1ZThjOC90YWJsZXJhbmdlOmE5MmJiYmNmMWY3MTRjYTRhZjliNzRkNGY4NDVlOGM4XzEwLTMtMS0xLTc1MTQw_429543ab-4326-41cb-a9b2-39369e7db33e"
      unitRef="number">0.009</biib:EffectiveTaxRateReconciliationGILTItax>
    <biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90YWJsZTphOTJiYmJjZjFmNzE0Y2E0YWY5Yjc0ZDRmODQ1ZThjOC90YWJsZXJhbmdlOmE5MmJiYmNmMWY3MTRjYTRhZjliNzRkNGY4NDVlOGM4XzEzLTEtMS0xLTc1MTQw_3c97118b-5a87-4132-860e-4b646db528a2"
      unitRef="number">0.242</biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts>
    <biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90YWJsZTphOTJiYmJjZjFmNzE0Y2E0YWY5Yjc0ZDRmODQ1ZThjOC90YWJsZXJhbmdlOmE5MmJiYmNmMWY3MTRjYTRhZjliNzRkNGY4NDVlOGM4XzEzLTMtMS0xLTc1MTQw_c3233040-c1f6-4cd6-b4fe-11b1ff5d64f9"
      unitRef="number">-0.006</biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90YWJsZTphOTJiYmJjZjFmNzE0Y2E0YWY5Yjc0ZDRmODQ1ZThjOC90YWJsZXJhbmdlOmE5MmJiYmNmMWY3MTRjYTRhZjliNzRkNGY4NDVlOGM4XzE1LTEtMS0xLTc1MTQw_21732c6e-4d99-4a6e-b73a-4b796015f9a0"
      unitRef="number">0.038</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90YWJsZTphOTJiYmJjZjFmNzE0Y2E0YWY5Yjc0ZDRmODQ1ZThjOC90YWJsZXJhbmdlOmE5MmJiYmNmMWY3MTRjYTRhZjliNzRkNGY4NDVlOGM4XzE1LTMtMS0xLTc1MTQw_a97d0fd7-8787-49f0-8724-1fc8702d7a3c"
      unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90YWJsZTphOTJiYmJjZjFmNzE0Y2E0YWY5Yjc0ZDRmODQ1ZThjOC90YWJsZXJhbmdlOmE5MmJiYmNmMWY3MTRjYTRhZjliNzRkNGY4NDVlOGM4XzE2LTEtMS0xLTc1MTQw_0f802476-0803-4a25-b73e-fd9a3275acd6"
      unitRef="number">0.362</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90YWJsZTphOTJiYmJjZjFmNzE0Y2E0YWY5Yjc0ZDRmODQ1ZThjOC90YWJsZXJhbmdlOmE5MmJiYmNmMWY3MTRjYTRhZjliNzRkNGY4NDVlOGM4XzE2LTMtMS0xLTc1MTQw_d8c32e1d-9e46-4b05-b45a-9bcfadb07654"
      unitRef="number">0.095</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i350f52cf56ca419f9abcc85ddabdf66a_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90ZXh0cmVnaW9uOjVlODA0YWZjNTczZjRmMTA5NDdlMjczYzY4ZTAwMmY4XzEwOTk1MTE2NDE5MDY_5a1e626e-1911-40d4-bd13-9d2536359647"
      unitRef="usd">490000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i350f52cf56ca419f9abcc85ddabdf66a_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90ZXh0cmVnaW9uOjVlODA0YWZjNTczZjRmMTA5NDdlMjczYzY4ZTAwMmY4XzEwOTk1MTE2NDE5MDY_a6fd5756-faf6-433e-abf0-882ac35e6c15"
      unitRef="usd">490000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90ZXh0cmVnaW9uOjVlODA0YWZjNTczZjRmMTA5NDdlMjczYzY4ZTAwMmY4XzEwOTk1MTE2NDE5MzE_f162b270-dd9d-4e6d-a19a-875190f5c2ca"
      unitRef="usd">390000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90ZXh0cmVnaW9uOjVlODA0YWZjNTczZjRmMTA5NDdlMjczYzY4ZTAwMmY4XzEwOTk1MTE2NDE5NTE_66d041a0-5993-465d-9d7e-ea7cbebc52ff"
      unitRef="usd">85000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:EquityMethodInvestments
      contextRef="ia5fabf9c71294456a0158d60a5f483a4_I20220331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90ZXh0cmVnaW9uOjVlODA0YWZjNTczZjRmMTA5NDdlMjczYzY4ZTAwMmY4XzEwOTk1MTE2NDM2MDA_42b8f7c7-8367-40a5-a788-0ce0ca5abd0f"
      unitRef="krw">709400000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ia5fabf9c71294456a0158d60a5f483a4_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90ZXh0cmVnaW9uOjVlODA0YWZjNTczZjRmMTA5NDdlMjczYzY4ZTAwMmY4XzEwOTk1MTE2NDM2MjI_242c97d3-6430-48e6-9d3f-2fbb9fe5f8cc"
      unitRef="usd">586400000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i9fcfddd14c424cd095a98f9df64e862f_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90ZXh0cmVnaW9uOjVlODA0YWZjNTczZjRmMTA5NDdlMjczYzY4ZTAwMmY4XzEwOTk1MTE2NDM2MzE_87266759-74dd-482d-9478-742073642902"
      unitRef="krw">713300000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i9fcfddd14c424cd095a98f9df64e862f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90ZXh0cmVnaW9uOjVlODA0YWZjNTczZjRmMTA5NDdlMjczYzY4ZTAwMmY4XzEwOTk1MTE2NDM2NTM_36c5f1d6-739a-424b-9e0f-fa7c3dd89332"
      unitRef="usd">599900000</us-gaap:EquityMethodInvestments>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="ia5fabf9c71294456a0158d60a5f483a4_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90ZXh0cmVnaW9uOjVlODA0YWZjNTczZjRmMTA5NDdlMjczYzY4ZTAwMmY4XzEwOTk1MTE2NDM4MDI_b2b4f694-0031-4164-948a-2417b0fb8fc4"
      unitRef="usd">70000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="i8cc3940c5a604d08b1a0524870f97a03_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90ZXh0cmVnaW9uOjVlODA0YWZjNTczZjRmMTA5NDdlMjczYzY4ZTAwMmY4XzUzMzY_39cafb40-e73a-46de-bf5f-32ab01436dc4"
      unitRef="usd">500000000</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i8cc3940c5a604d08b1a0524870f97a03_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMDYvZnJhZzo1ZTgwNGFmYzU3M2Y0ZjEwOTQ3ZTI3M2M2OGUwMDJmOC90ZXh0cmVnaW9uOjVlODA0YWZjNTczZjRmMTA5NDdlMjczYzY4ZTAwMmY4XzIxOTkwMjMyNjYzNjY_1ca40358-2691-4ec9-ad6b-22f4cea909c8"
      unitRef="usd">455000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90ZXh0cmVnaW9uOmUyMTU0MTI5NTg1ZDRlYzg5Y2ExMzlkNTVmNDk5NTA1XzE4MTc_cc9c5eaa-fee8-4f24-8c3f-61ed76d81cf9">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Income (Expense), Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of other income (expense), net, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(66.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(64.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on investments, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(191.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(436.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange gains (losses), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(263.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(506.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gains (losses) on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our gains (losses) on investments, net that relates to our equity securities held as of March 31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net gains (losses) recognized during the period on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(190.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(436.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Net gains (losses) realized during the period on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized gains (losses) recognized during the period on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(190.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(442.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net unrealized losses recognized during the three months ended March 31, 2022, primarily reflect decreases in the aggregate fair value of our investments in Denali, Sage and Sangamo common stock of approximately $205.5&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expense and Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expense and other consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue-related reserves for discounts and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;831.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;802.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Collaboration expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;266.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;324.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalties and licensing fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;216.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;234.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;206.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;345.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;711.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;828.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,231.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,535.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Long-term Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other long-term liabilities were $1,287.9 million and $1,320.5 million as of March 31, 2022 and December 31, 2021, respectively, and included accrued income taxes totaling $640.5 million and $664.5 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90ZXh0cmVnaW9uOmUyMTU0MTI5NTg1ZDRlYzg5Y2ExMzlkNTVmNDk5NTA1XzE3ODg_6349b01d-b205-4a0c-bb13-277a1277d403">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of other income (expense), net, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(66.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(64.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on investments, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(191.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(436.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange gains (losses), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(263.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(506.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTpmZDE4NGFhMWNmZDc0NWU2ODRhYjYyMTJmZTdlMWI3MC90YWJsZXJhbmdlOmZkMTg0YWExY2ZkNzQ1ZTY4NGFiNjIxMmZlN2UxYjcwXzItMi0xLTEtNzUxNDA_6e84a208-5600-457d-8c88-4ff5cf67929f"
      unitRef="usd">2900000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTpmZDE4NGFhMWNmZDc0NWU2ODRhYjYyMTJmZTdlMWI3MC90YWJsZXJhbmdlOmZkMTg0YWExY2ZkNzQ1ZTY4NGFiNjIxMmZlN2UxYjcwXzItNC0xLTEtNzUxNDA_af3ff6e1-f64c-449b-8d5a-f34b1b8e9ba7"
      unitRef="usd">2900000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTpmZDE4NGFhMWNmZDc0NWU2ODRhYjYyMTJmZTdlMWI3MC90YWJsZXJhbmdlOmZkMTg0YWExY2ZkNzQ1ZTY4NGFiNjIxMmZlN2UxYjcwXzMtMi0xLTEtNzUxNDA_6b02d887-a339-488e-9177-2416d9f35c22"
      unitRef="usd">66100000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTpmZDE4NGFhMWNmZDc0NWU2ODRhYjYyMTJmZTdlMWI3MC90YWJsZXJhbmdlOmZkMTg0YWExY2ZkNzQ1ZTY4NGFiNjIxMmZlN2UxYjcwXzMtNC0xLTEtNzUxNDA_19e49ae5-6d3f-41c9-a3c7-9616831e96d1"
      unitRef="usd">64700000</us-gaap:InterestExpense>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTpmZDE4NGFhMWNmZDc0NWU2ODRhYjYyMTJmZTdlMWI3MC90YWJsZXJhbmdlOmZkMTg0YWExY2ZkNzQ1ZTY4NGFiNjIxMmZlN2UxYjcwXzQtMi0xLTEtNzUxNDA_0b8a95e1-14cf-4c51-9dab-f330b145d5ea"
      unitRef="usd">-191100000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTpmZDE4NGFhMWNmZDc0NWU2ODRhYjYyMTJmZTdlMWI3MC90YWJsZXJhbmdlOmZkMTg0YWExY2ZkNzQ1ZTY4NGFiNjIxMmZlN2UxYjcwXzQtNC0xLTEtNzUxNDA_12017785-9560-43d5-b12c-24ece7eb7739"
      unitRef="usd">-436600000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTpmZDE4NGFhMWNmZDc0NWU2ODRhYjYyMTJmZTdlMWI3MC90YWJsZXJhbmdlOmZkMTg0YWExY2ZkNzQ1ZTY4NGFiNjIxMmZlN2UxYjcwXzUtMi0xLTEtNzUxNDA_6c6e7036-3e51-42e2-8bed-1ba68f4cafcd"
      unitRef="usd">-8300000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTpmZDE4NGFhMWNmZDc0NWU2ODRhYjYyMTJmZTdlMWI3MC90YWJsZXJhbmdlOmZkMTg0YWExY2ZkNzQ1ZTY4NGFiNjIxMmZlN2UxYjcwXzUtNC0xLTEtNzUxNDA_5503d5f8-3a7a-43ca-b356-53c08412381f"
      unitRef="usd">-8600000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTpmZDE4NGFhMWNmZDc0NWU2ODRhYjYyMTJmZTdlMWI3MC90YWJsZXJhbmdlOmZkMTg0YWExY2ZkNzQ1ZTY4NGFiNjIxMmZlN2UxYjcwXzYtMi0xLTEtNzUxNDA_c8a1c556-84ce-4bac-8c42-2879597c498d"
      unitRef="usd">-700000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTpmZDE4NGFhMWNmZDc0NWU2ODRhYjYyMTJmZTdlMWI3MC90YWJsZXJhbmdlOmZkMTg0YWExY2ZkNzQ1ZTY4NGFiNjIxMmZlN2UxYjcwXzYtNC0xLTEtNzUxNDA_ab03901e-f71e-4117-a0d0-beafe90c340c"
      unitRef="usd">100000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTpmZDE4NGFhMWNmZDc0NWU2ODRhYjYyMTJmZTdlMWI3MC90YWJsZXJhbmdlOmZkMTg0YWExY2ZkNzQ1ZTY4NGFiNjIxMmZlN2UxYjcwXzctMi0xLTEtNzUxNDA_6c34fb6b-3aa8-451f-9ad9-e5f9ab94e55a"
      unitRef="usd">-263300000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTpmZDE4NGFhMWNmZDc0NWU2ODRhYjYyMTJmZTdlMWI3MC90YWJsZXJhbmdlOmZkMTg0YWExY2ZkNzQ1ZTY4NGFiNjIxMmZlN2UxYjcwXzctNC0xLTEtNzUxNDA_966b9cc7-663e-4cfa-acd1-26d806133b83"
      unitRef="usd">-506900000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:GainLossOnInvestmentsTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90ZXh0cmVnaW9uOmUyMTU0MTI5NTg1ZDRlYzg5Y2ExMzlkNTVmNDk5NTA1XzE3Nzg_ab7af4a1-a2e9-4474-b5e9-78d93053a40a">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our gains (losses) on investments, net that relates to our equity securities held as of March 31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net gains (losses) recognized during the period on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(190.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(436.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Net gains (losses) realized during the period on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized gains (losses) recognized during the period on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(190.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(442.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The net unrealized losses recognized during the three months ended March 31, 2022, primarily reflect decreases in the aggregate fair value of our investments in Denali, Sage and Sangamo common stock of approximately $205.5&#160;million.</us-gaap:GainLossOnInvestmentsTextBlock>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTpiZDI0YjdhYjkyMjc0YzlmYWY0YjBiMjE2ZGZhN2VhYy90YWJsZXJhbmdlOmJkMjRiN2FiOTIyNzRjOWZhZjRiMGIyMTZkZmE3ZWFjXzItMi0xLTEtNzUxNDA_dbf18ecd-d417-4035-855f-6bcfe45ca8af"
      unitRef="usd">-190700000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTpiZDI0YjdhYjkyMjc0YzlmYWY0YjBiMjE2ZGZhN2VhYy90YWJsZXJhbmdlOmJkMjRiN2FiOTIyNzRjOWZhZjRiMGIyMTZkZmE3ZWFjXzItNC0xLTEtNzUxNDA_18379e3a-3ea0-46f8-a2ee-7854eeb8d26a"
      unitRef="usd">-436100000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTpiZDI0YjdhYjkyMjc0YzlmYWY0YjBiMjE2ZGZhN2VhYy90YWJsZXJhbmdlOmJkMjRiN2FiOTIyNzRjOWZhZjRiMGIyMTZkZmE3ZWFjXzMtMi0xLTEtNzUxNDA_edc69e89-6f31-49dd-9a3b-2d7104695689"
      unitRef="usd">200000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTpiZDI0YjdhYjkyMjc0YzlmYWY0YjBiMjE2ZGZhN2VhYy90YWJsZXJhbmdlOmJkMjRiN2FiOTIyNzRjOWZhZjRiMGIyMTZkZmE3ZWFjXzMtNC0xLTEtNzUxNDA_6c207532-0bce-4a8c-9a70-8b1e5c6fea0f"
      unitRef="usd">6200000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTpiZDI0YjdhYjkyMjc0YzlmYWY0YjBiMjE2ZGZhN2VhYy90YWJsZXJhbmdlOmJkMjRiN2FiOTIyNzRjOWZhZjRiMGIyMTZkZmE3ZWFjXzQtMi0xLTEtNzUxNDA_8d94cf97-4173-46e7-85fd-9a2b6d7b1d64"
      unitRef="usd">-190900000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ifa9e7dbaa23449a7851a71f4d34278bf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTpiZDI0YjdhYjkyMjc0YzlmYWY0YjBiMjE2ZGZhN2VhYy90YWJsZXJhbmdlOmJkMjRiN2FiOTIyNzRjOWZhZjRiMGIyMTZkZmE3ZWFjXzQtNC0xLTEtNzUxNDA_a8ba648a-09e4-4f7a-8239-087ff5e65964"
      unitRef="usd">-442300000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i20649c5c9db8492a84683240d40b1cc8_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90ZXh0cmVnaW9uOmUyMTU0MTI5NTg1ZDRlYzg5Y2ExMzlkNTVmNDk5NTA1XzIxOTkwMjMyNTc2NDg_7b3dd0f1-9a52-4727-9a29-9bde5bc25387"
      unitRef="usd">205500000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90ZXh0cmVnaW9uOmUyMTU0MTI5NTg1ZDRlYzg5Y2ExMzlkNTVmNDk5NTA1XzE3ODA_3b6a39c5-f547-48c1-916a-6cad83ab09b7">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expense and other consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue-related reserves for discounts and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;831.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;802.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Collaboration expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;266.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;324.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalties and licensing fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;216.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;234.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;206.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;345.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;711.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;828.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,231.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,535.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i0bdcfb675756479fa2aa02a4f8a3a6ce_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTplY2Q2ZTFmYmY3M2U0ODdiYmE0YmU5NDFhYjQyNjg1MC90YWJsZXJhbmdlOmVjZDZlMWZiZjczZTQ4N2JiYTRiZTk0MWFiNDI2ODUwXzEtMi0xLTEtNzUxNDA_06bf2ee8-bdd7-4e4a-b3e2-9ca1430b2276"
      unitRef="usd">831100000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i3d7e46af1def46ae846f93734361fcc5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTplY2Q2ZTFmYmY3M2U0ODdiYmE0YmU5NDFhYjQyNjg1MC90YWJsZXJhbmdlOmVjZDZlMWZiZjczZTQ4N2JiYTRiZTk0MWFiNDI2ODUwXzEtNC0xLTEtNzUxNDA_255c09a8-884f-4cd0-ade3-a392b701ca44"
      unitRef="usd">802100000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:Collaborationexpensesaccrual
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTplY2Q2ZTFmYmY3M2U0ODdiYmE0YmU5NDFhYjQyNjg1MC90YWJsZXJhbmdlOmVjZDZlMWZiZjczZTQ4N2JiYTRiZTk0MWFiNDI2ODUwXzItMi0xLTEtNzUxNDA_c911af61-6742-4740-b303-9e775bc829a0"
      unitRef="usd">266200000</biib:Collaborationexpensesaccrual>
    <biib:Collaborationexpensesaccrual
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTplY2Q2ZTFmYmY3M2U0ODdiYmE0YmU5NDFhYjQyNjg1MC90YWJsZXJhbmdlOmVjZDZlMWZiZjczZTQ4N2JiYTRiZTk0MWFiNDI2ODUwXzItNC0xLTEtNzUxNDA_dcba1e65-e5c9-4108-bb7e-420a6799afd6"
      unitRef="usd">324700000</biib:Collaborationexpensesaccrual>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTplY2Q2ZTFmYmY3M2U0ODdiYmE0YmU5NDFhYjQyNjg1MC90YWJsZXJhbmdlOmVjZDZlMWZiZjczZTQ4N2JiYTRiZTk0MWFiNDI2ODUwXzMtMi0xLTEtMTAyMTUz_250db3fb-5396-458a-a35a-41c613b1ee31"
      unitRef="usd">216000000.0</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTplY2Q2ZTFmYmY3M2U0ODdiYmE0YmU5NDFhYjQyNjg1MC90YWJsZXJhbmdlOmVjZDZlMWZiZjczZTQ4N2JiYTRiZTk0MWFiNDI2ODUwXzMtNC0xLTEtMTAyMTUz_42337be6-0972-45e2-b6b7-10e5f39ee7aa"
      unitRef="usd">234700000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTplY2Q2ZTFmYmY3M2U0ODdiYmE0YmU5NDFhYjQyNjg1MC90YWJsZXJhbmdlOmVjZDZlMWZiZjczZTQ4N2JiYTRiZTk0MWFiNDI2ODUwXzMtMi0xLTEtNzUxNDA_4f8509bf-2266-4f2e-bbad-028d2cb82dd7"
      unitRef="usd">206600000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTplY2Q2ZTFmYmY3M2U0ODdiYmE0YmU5NDFhYjQyNjg1MC90YWJsZXJhbmdlOmVjZDZlMWZiZjczZTQ4N2JiYTRiZTk0MWFiNDI2ODUwXzMtNC0xLTEtNzUxNDA_93aa8493-8ea8-47d0-af98-d65251f55219"
      unitRef="usd">345100000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTplY2Q2ZTFmYmY3M2U0ODdiYmE0YmU5NDFhYjQyNjg1MC90YWJsZXJhbmdlOmVjZDZlMWZiZjczZTQ4N2JiYTRiZTk0MWFiNDI2ODUwXzctMi0xLTEtNzUxNDA_750e20ef-e1da-45c2-8c8e-ae71f3703baf"
      unitRef="usd">711200000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTplY2Q2ZTFmYmY3M2U0ODdiYmE0YmU5NDFhYjQyNjg1MC90YWJsZXJhbmdlOmVjZDZlMWZiZjczZTQ4N2JiYTRiZTk0MWFiNDI2ODUwXzctNC0xLTEtNzUxNDA_c1950049-faf2-4ae1-a954-9f7dc0e2ac8b"
      unitRef="usd">828600000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTplY2Q2ZTFmYmY3M2U0ODdiYmE0YmU5NDFhYjQyNjg1MC90YWJsZXJhbmdlOmVjZDZlMWZiZjczZTQ4N2JiYTRiZTk0MWFiNDI2ODUwXzgtMi0xLTEtNzUxNDA_6ecf8ad0-fe22-4999-b7f4-69b2c0c1f216"
      unitRef="usd">2231100000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90YWJsZTplY2Q2ZTFmYmY3M2U0ODdiYmE0YmU5NDFhYjQyNjg1MC90YWJsZXJhbmdlOmVjZDZlMWZiZjczZTQ4N2JiYTRiZTk0MWFiNDI2ODUwXzgtNC0xLTEtNzUxNDA_1bbaad9e-54f5-4ce1-a000-f6d7e8d19a0b"
      unitRef="usd">2535200000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90ZXh0cmVnaW9uOmUyMTU0MTI5NTg1ZDRlYzg5Y2ExMzlkNTVmNDk5NTA1XzE2NjU_ae9b79e7-c50a-4224-bacb-005459810b00"
      unitRef="usd">1287900000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90ZXh0cmVnaW9uOmUyMTU0MTI5NTg1ZDRlYzg5Y2ExMzlkNTVmNDk5NTA1XzE2NzI_2b393ea2-2d62-4e7f-b365-49ddd66c9824"
      unitRef="usd">1320500000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90ZXh0cmVnaW9uOmUyMTU0MTI5NTg1ZDRlYzg5Y2ExMzlkNTVmNDk5NTA1XzE3NDk_d680cbe1-88f9-4d61-996a-8e74f4184ea6"
      unitRef="usd">640500000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTIvZnJhZzplMjE1NDEyOTU4NWQ0ZWM4OWNhMTM5ZDU1ZjQ5OTUwNS90ZXh0cmVnaW9uOmUyMTU0MTI5NTg1ZDRlYzg5Y2ExMzlkNTVmNDk5NTA1XzE3NTY_0f9310db-f2f1-45bf-b3f4-2f302f691e30"
      unitRef="usd">664500000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzIwMTEw_61ac2d7d-c64b-49c1-8038-aa17ed122a50">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Eisai Co., Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lecanemab Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a collaboration agreement with Eisai Co., Ltd. (Eisai) to jointly develop and commercialize lecanemab (BAN2401), an anti-amyloid antibody, and elenbecestat, the oral BACE (base amyloid cleaving enzyme) inhibitor, two Eisai product candidates for the potential treatment of Alzheimer's disease (the Lecanemab Collaboration). In September 2019 we and Eisai discontinued the global Phase 3 studies of elenbecestat in early Alzheimer's disease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Eisai serves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product, and Eisai having final decision-making authority. All costs, including research, development, sales and marketing expense, are shared equally between us and Eisai. If lecanemab receives marketing approval, we and Eisai will co-promote lecanemab and share profits equally. In March 2022 we extended our supply agreement related to lecanemab from five years to ten years, and we will manufacture the lecanemab drug substance in our Solothurn manufacturing facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Lecanemab Collaboration also provided Eisai with an option to jointly develop and commercialize ADUHELM (aducanumab) (ADUHELM Option). In October 2017 Eisai exercised its ADUHELM Option and we entered into a new collaboration agreement for the joint development and commercialization of ADUHELM (aducanumab) (the ADUHELM Collaboration Agreement).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of development and sales and marketing expense related to the Lecanemab Collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total development expense incurred by the collaboration related to the advancement of lecanemab and elenbecestat&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of lecanemab and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total sales and marketing expense incurred by the Lecanemab Collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of lecanemab and elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our Lecanemab Collaboration, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to our consolidated financial statements included in our 2021 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ADUHELM Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under our initial ADUHELM Collaboration Agreement, we would lead the ongoing development of ADUHELM, and we and Eisai would co-promote ADUHELM with a region-based profit split. Beginning January 1, 2019, Eisai was reimbursing us for&#160;45.0%&#160;of development costs incurred by the collaboration for the advancement of ADUHELM (ADUHELM development expense). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021 ADUHELM was granted accelerated approval by the FDA for the treatment of Alzheimer's disease and had its first commercial sale. As a result of the launch of ADUHELM in the U.S., we made a $100.0&#160;million milestone payment to Neurimmune. During the second quarter of 2021 we recognized net profit-sharing income of $45.0&#160;million to reflect Eisai's 45.0% share of the $100.0&#160;million milestone payment, which was recorded in collaboration profit (loss) sharing in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2022 we amended our ADUHELM Collaboration Agreement with Eisai. Effective March 2022 we have sole decision making and commercialization rights worldwide on ADUHELM and beginning January 1, 2023, Eisai will receive a tiered royalty based on net sales of ADUHELM, rather than sharing global profits and losses. Eisai's share of development, commercialization and manufacturing expense is limited to $335.0&#160;million for the period from January 1, 2022 to December 31, 2022. Once the tiered royalty model commences on January 1, 2023, Eisai will not participate in ADUHELM&#x2019;s economics beyond these royalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of development expense, sales and marketing expense and milestone payments related to the ADUHELM Collaboration Agreement is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total ADUHELM development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of ADUHELM development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total ADUHELM sales and marketing expense incurred by the ADUHELM Collaboration Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;95.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;111.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of ADUHELM sales and marketing expense reflected in selling, general and administrative expense and collaboration profit (loss) sharing in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;o-promotion Profits and Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the U.S. we recognize revenue on sales to third parties as a component of product revenue, net in our condensed consolidated statements of income. We also record the related cost of revenue and sales and marketing expense in our condensed consolidated statements of income as these costs are incurred. Payments made to and received from Eisai for its 45.0% share of the co-promotion profits or losses in the U.S. are recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. For the three months ended March 31, 2022, we recognized a net reduction to our operating expense of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$181.7&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to reflect Eisai's 45.0% share of net collaboration losses in the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, we and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the first quarter of 2022 we recorded approximately $275.0&#160;million of gross charges associated with inventory and purchase commitments in excess of forecasted demand related to ADUHELM, as well as approximately $45.0&#160;million of gross idle capacity charges, which were recognized in cost of sales within our condensed consolidated statements of income. We have recognized approximately $160.0&#160;million related to Eisai's 45.0% share of these charges in collaboration profit (loss) sharing within our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts receivable from Eisai related to the agreements discussed above were &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$402.7&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and $285.4&#160;million as of March 31, 2022 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, respectively. Amounts payable to Eisai related to the agreements discussed above were &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$36.5&#160;million &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and $46.5&#160;million as of March 31, 2022 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2021, respectively&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on the ADUHELM Collaboration Agreement, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2021 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;UCB&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a collaboration agreement with UCB to jointly develop and commercialize dapirolizumab pegol, an anti-CD40L pegylated Fab, for the potential treatment of systemic lupus erythematosus and other future agreed indications. Either we or UCB may propose development of dapirolizumab pegol in additional indications. If the parties do not agree to add an indication as an agreed indication to the collaboration, we or UCB may, at the sole expense of the applicable party, pursue development in such excluded indication(s), subject to an opt-in right of the non-pursuing party after proof of clinical activity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All costs incurred for agreed indications, including research, development, sales and marketing expense, are shared equally between us and UCB. Upon marketing approval, we and UCB will co-promote dapirolizumab pegol and share profits equally.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of development expense related to the UCB collaboration agreement is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total UCB collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of UCB development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sage Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In November 2020 we entered into a global collaboration and license agreement with Sage to jointly develop and commercialize BIIB125 (zuranolone) for the potential treatment of major depressive disorder and postpartum depression and BIIB124 (SAGE-324) for the potential treatment of essential tremor with potential in other neurological conditions such as epilepsy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Under this collaboration, both companies will share equal responsibility and costs for development as well as profits and losses for commercialization in the U.S. Outside of the U.S., we are responsible for development and commercialization, excluding Japan, Taiwan and South Korea, with respect to zuranolone and may pay Sage potential tiered royalties in the high teens to low twenties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A summary of development and sales and marketing expense related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Sage collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of Sage development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Sage sales and marketing expense incurred by the collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of Sage sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Denali Therapeutics Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020 we entered into a collaboration and license agreement with Denali to co-develop and co-commercialize Denali's small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson's disease. Under this collaboration, both companies share responsibility and costs for global development based on specified percentages as well as profits and losses for commercialization in the U.S. and China. Outside the U.S. and China we are responsible for commercialization and may pay Denali potential tiered royalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the LRRK2 program, we also have an exclusive option to license two preclinical programs from Denali&#x2019;s Transport Vehicle platform, including its Antibody Transport Vehicle (ATV): ATV enabled anti-amyloid beta program and a second program utilizing its Transport Vehicle technology. Further, we have the right of first negotiation on two additional ATV enabled therapeutics for indications within specific neurodegenerative diseases, should Denali decide to seek a collaboration for such programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A summary of development expense related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Denali collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of Denali development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sangamo Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2020 we entered into a collaboration and license agreement with Sangamo to develop and commercialize ST-501 for tauopathies, including Alzheimer's disease; ST-502 for synucleinopathies, including Parkinson&#x2019;s disease; a third neuromuscular disease target; and up to nine additional neurological disease targets to be identified and selected within a five-year period. The companies are leveraging Sangamo&#x2019;s proprietary zinc finger protein technology delivered via adeno-associated virus to modulate the expression of key genes involved in neurological diseases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under this collaboration, we may pay Sangamo tiered royalties on potential net sales of any products developed under this collaboration in the high single digit to sub-teen percentages.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of development expense related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Sangamo collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of Sangamo development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;InnoCare Pharma Limited&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In July 2021 we entered into a collaboration and license agreement with InnoCare Pharma Limited (InnoCare) for orelabrutinib, an oral small molecule Bruton&#x2019;s tyrosine kinase inhibitor for the potential treatment of MS. Orelabrutinib is currently being studied in a multi-country, placebo-controlled Phase 2 trial in relapsing-remitting MS. Under the terms of the collaboration, we have exclusive rights to orelabrutinib in the field of MS worldwide and certain autoimmune diseases outside of China (including Hong Kong, Macau and Taiwan), while InnoCare retains ex&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;clusive worldwide rights to orelabrutinib in the field of oncology and certain autoimmune diseases in China (including Hong Kong, Macau and Taiwan). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#0a0a0a;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In connection with the closing of this transaction in August 2021 we made an upfront payment of $125.0&#160;million &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;that was recorded as research and development expense in our condensed consolidated statements of income. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#0a0a0a;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We may also pay InnoCare up to approximately $812.5&#160;million in potential development milestones and potential commercial payments should this collaboration achieve certain development, commercial milestones and sales thresholds. In addition, we may pay InnoCare tiered royalties on potential net sales of any products developed under this collaboration in the low to high teen percentages.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Research and Discovery Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March 31, 2022, we recorded &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$19.5&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as research and development expense in our condensed consolidated statements of income related to other research and discovery related arrangements, compared to less than &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$1.0&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the prior year comparative period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Samsung Bioepis Co., Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Joint Venture Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. As of March 31, 2022, our ownership percentage was approximately 49.9%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in (income) loss of investee, net of tax in our condensed consolidated statements of income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon investment, the equity method of accounting requires us to identify and allocate differences between the fair value of our investment and the carrying value of our interest in the underlying net assets of the investee. These basis differences are amortized over their economic life. The total basis difference was approximately $675.0 million and relates to inventory, developed technology, IPR&amp;amp;D and deferred tax balances. The basis differences related to inventory were amortized, net of tax, over their estimated useful lives of 1.5 years, and the basis differences related to developed technology and IPR&amp;amp;D for marketed products will be amortized, net of tax, over their estimated useful lives of 15 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March 31, 2022, we recognized net losses on our investment of $3.3 million, reflecting our share of Samsung Bioepis' operating profits, net of tax totaling $4.0&#160;million offset by amortization of basis differences totaling $7.3&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March 31, 2021, we recognized net losses on our investment of $18.2 million, reflecting our share of Samsung Bioepis' operating losses, net of tax totaling $11.0&#160;million and amortization of basis differences totaling $7.2&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2022 and December 31, 2021, the carrying value of our investment in Samsung Bioepis totaled 709.4 billion South Korean won ($586.4 million) and 713.3 billion South Korean won ($599.9 million), respectively, which is classified as a component of investments and other assets in our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2022 we entered into an agreement to sell to Samsung BioLogics our equity in Samsung Bioepis, which was completed on April 20, 2022. Under the terms of the transaction, we received approximately $1.0&#160;billion in cash at closing and will receive approximately $1.3&#160;billion to be deferred over two payments of $812.5&#160;million due at the first anniversary and $437.5&#160;million due at the second anniversary of the closing of the transaction. We are also eligible to receive up to an additional $50.0&#160;million upon the achievement of certain commercial milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2019 Development and Commercialization Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize two potential ophthalmology biosimilar products, BYOOVIZ (ranibizumab-nuna), a proposed ranibizumab biosimilar referencing LUCENTIS, and SB15, a proposed aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. Samsung Bioepis will be responsible for development and will supply both products to us at a pre-specified gross margin.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with this transaction, we made an upfront payment of $100.0 million to Samsung Bioepis in January 2020, of which $63.0 million was recorded as research and development expense in our condensed consolidated statements of income in 2019 and $37.0 million was recorded as intangible assets, net in our condensed consolidated balance sheets in 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the third quarter of 2021 we accrued $15.0&#160;million in milestone payments related to the approval of BYOOVIZ in the U.S., the E.U. and the U.K., that were capitalized within intangible assets, net in our condensed consolidated balance sheets. We may also pay Samsung Bioepis up to approximately $180.0 million in additional development, regulatory and sales-based milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also acquired an option to extend the term of our 2013 c&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ommercial agreement for BENEPALI, IMRALDI and FLIXABI by an additional five years, subject to payment of an option exercise fee of $60.0 million, and obtained an option to acquire exclusive rights to commercialize these products in China.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2013 Commercial Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We reflect revenue on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenue, net in our condensed consolidated statements of income and record the related cost of revenue and sales and marketing expense in our condensed consolidated statements of income to their respective line items when these costs are incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We share 50.0% of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. For the three months ended March 31, 2022, we recognized net profit-sharing expense of $64.4&#160;million to reflect Samsung &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bioepis' 50.0% sharing of the net collaboration profits, compared to a net profit-sharing expense of $68.5 million in the prior year comparative period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Services&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Simultaneous with the formation of Samsung Bioepis, we also entered into a technical development services agreement, a manufacturing agreement and a license agreement with Samsung Bioepis. Revenue related to these services is reflected in revenue from collaborative and other relationships as a component of other revenue in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts receivable from Samsung Bioepis related to the agreements discussed above were $5.8&#160;million and $4.1&#160;million as of March 31, 2022 and December 31, 2021, respectively. Amounts payable to Samsung Bioepis related to the agreements discussed above were $102.5&#160;million and $148.7&#160;million as of March 31, 2022 and December 31, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements with Samsung Bioepis and our other significant collaboration arrangements, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative and Other Relationships,&lt;/span&gt; to our consolidated financial statements included in our 2021 Form 10-K.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <biib:CollaborationAgreementTerm
      contextRef="i7720f6aec35b4d8da3f83be28c73da37_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzEwOTk1MTE2NjUwMDY_61223c0e-c4c4-44c8-9d3d-3862a8f2040c">P5Y</biib:CollaborationAgreementTerm>
    <biib:CollaborationAgreementTerm
      contextRef="i8a12e5f049a6452f9e97a9998e1ce4b6_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzEwOTk1MTE2NjUwMTQ_2e8c3d93-6ea1-45c8-91a0-3e0de1576f4d">P10Y</biib:CollaborationAgreementTerm>
    <biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzIwMDk0_901075db-d9d0-4855-8754-b238dd3fb482">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total development expense incurred by the collaboration related to the advancement of lecanemab and elenbecestat&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of lecanemab and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total sales and marketing expense incurred by the Lecanemab Collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of lecanemab and elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock>
    <biib:ExpenseIncurredByCollaboration
      contextRef="ic53a168048b7491ea87c3962591ce459_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTo0MDkzYzgzZjkwNGU0YmZmOGViYmMwM2QzMTMyMDU1MS90YWJsZXJhbmdlOjQwOTNjODNmOTA0ZTRiZmY4ZWJiYzAzZDMxMzIwNTUxXzItMi0xLTEtNzUxNDA_3023fb82-99e0-4032-9b4f-14b8efe26bdd"
      unitRef="usd">77000000.0</biib:ExpenseIncurredByCollaboration>
    <biib:ExpenseIncurredByCollaboration
      contextRef="ic988722c1187407388795922a811a006_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTo0MDkzYzgzZjkwNGU0YmZmOGViYmMwM2QzMTMyMDU1MS90YWJsZXJhbmdlOjQwOTNjODNmOTA0ZTRiZmY4ZWJiYzAzZDMxMzIwNTUxXzItNC0xLTEtNzUxNDA_f7ceb55a-3763-473c-aae9-1c0889b7a7e0"
      unitRef="usd">55500000</biib:ExpenseIncurredByCollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="ic53a168048b7491ea87c3962591ce459_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTo0MDkzYzgzZjkwNGU0YmZmOGViYmMwM2QzMTMyMDU1MS90YWJsZXJhbmdlOjQwOTNjODNmOTA0ZTRiZmY4ZWJiYzAzZDMxMzIwNTUxXzMtMi0xLTEtNzUxNDA_e114e398-61ba-4f90-ab02-84ad1fc577ab"
      unitRef="usd">38500000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="ic988722c1187407388795922a811a006_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTo0MDkzYzgzZjkwNGU0YmZmOGViYmMwM2QzMTMyMDU1MS90YWJsZXJhbmdlOjQwOTNjODNmOTA0ZTRiZmY4ZWJiYzAzZDMxMzIwNTUxXzMtNC0xLTEtNzUxNDA_c36c33d5-2868-4c10-83aa-50115b555821"
      unitRef="usd">27700000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expenseincurredbythecollaboration
      contextRef="i5eb97d60723b4bd0984e9c72d9e41857_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTo0MDkzYzgzZjkwNGU0YmZmOGViYmMwM2QzMTMyMDU1MS90YWJsZXJhbmdlOjQwOTNjODNmOTA0ZTRiZmY4ZWJiYzAzZDMxMzIwNTUxXzQtMi0xLTEtNzUxNDA_20731138-5d68-4187-89d8-4c6e6c8a1585"
      unitRef="usd">15900000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="ibfdf8192d59c42ea96f70ac07a430dab_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTo0MDkzYzgzZjkwNGU0YmZmOGViYmMwM2QzMTMyMDU1MS90YWJsZXJhbmdlOjQwOTNjODNmOTA0ZTRiZmY4ZWJiYzAzZDMxMzIwNTUxXzQtNC0xLTEtODE5MzA_be641104-176e-4080-b236-f95dc8999e3c"
      unitRef="usd">5700000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i5eb97d60723b4bd0984e9c72d9e41857_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTo0MDkzYzgzZjkwNGU0YmZmOGViYmMwM2QzMTMyMDU1MS90YWJsZXJhbmdlOjQwOTNjODNmOTA0ZTRiZmY4ZWJiYzAzZDMxMzIwNTUxXzUtMi0xLTEtNzUxNDA_3734ce90-73b0-4f96-91a5-f9a3b22a0dfd"
      unitRef="usd">8000000.0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="ibfdf8192d59c42ea96f70ac07a430dab_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTo0MDkzYzgzZjkwNGU0YmZmOGViYmMwM2QzMTMyMDU1MS90YWJsZXJhbmdlOjQwOTNjODNmOTA0ZTRiZmY4ZWJiYzAzZDMxMzIwNTUxXzUtNC0xLTEtODE5MzA_acbac4a3-26cd-4bb5-940a-2d62708fcab9"
      unitRef="usd">2900000</biib:Expensereflectedwithinstatementsofincome>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="i8a12e5f049a6452f9e97a9998e1ce4b6_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzI0NDQ_05cf3daf-ff6a-4232-a16a-6ff1e749730b"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <biib:AdditionalMilestonePayment
      contextRef="ica3cdddcf72b46f8b05a616e0b059254_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzM5NjM_dccfd1b1-f695-4163-9720-2d4130fcf448"
      unitRef="usd">100000000</biib:AdditionalMilestonePayment>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i20e19171955440b582851c5ac5d45b30_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzQwNzA_6cfa1de8-eeb2-4b32-b090-bb112aa7a6a4"
      unitRef="usd">45000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="i8a12e5f049a6452f9e97a9998e1ce4b6_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzQwOTI_05cf3daf-ff6a-4232-a16a-6ff1e749730b"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <biib:AdditionalMilestonePayment
      contextRef="ica3cdddcf72b46f8b05a616e0b059254_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzQxMDg_dccfd1b1-f695-4163-9720-2d4130fcf448"
      unitRef="usd">100000000</biib:AdditionalMilestonePayment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i4afdc1a2dcdf424eabd0653274b690c7_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzEwOTk1MTE2NjYzMDQ_389955b6-bcc7-4d0e-a090-f9459a2d8f65"
      unitRef="usd">335000000</us-gaap:ResearchAndDevelopmentExpense>
    <biib:SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzIwMTEy_b55bfee7-441f-4e36-b93c-18c24c733f48">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of development expense, sales and marketing expense and milestone payments related to the ADUHELM Collaboration Agreement is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total ADUHELM development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of ADUHELM development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total ADUHELM sales and marketing expense incurred by the ADUHELM Collaboration Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;95.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;111.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of ADUHELM sales and marketing expense reflected in selling, general and administrative expense and collaboration profit (loss) sharing in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock>
    <biib:Expenseincurredbythecollaboration
      contextRef="i90093effd3884afba4d3e630d74c241a_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTpkNzFmMDhhYzM3OTg0NzFhYjBjYTExZjIwZDc1ZmViMC90YWJsZXJhbmdlOmQ3MWYwOGFjMzc5ODQ3MWFiMGNhMTFmMjBkNzVmZWIwXzItMi0xLTEtNzUxNDA_4632e2f3-bdb4-49a5-91fe-82fb8c5525c4"
      unitRef="usd">44200000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i95c7cf13e2f1475ea47f58a3f48df9e2_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTpkNzFmMDhhYzM3OTg0NzFhYjBjYTExZjIwZDc1ZmViMC90YWJsZXJhbmdlOmQ3MWYwOGFjMzc5ODQ3MWFiMGNhMTFmMjBkNzVmZWIwXzItNC0xLTEtNzUxNDA_ead91645-9579-4cad-b160-6554556e83f3"
      unitRef="usd">47000000.0</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i90093effd3884afba4d3e630d74c241a_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTpkNzFmMDhhYzM3OTg0NzFhYjBjYTExZjIwZDc1ZmViMC90YWJsZXJhbmdlOmQ3MWYwOGFjMzc5ODQ3MWFiMGNhMTFmMjBkNzVmZWIwXzMtMi0xLTEtNzUxNDA_3c8fbbd8-2bcb-49cc-ac61-562580e535d4"
      unitRef="usd">24300000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i95c7cf13e2f1475ea47f58a3f48df9e2_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTpkNzFmMDhhYzM3OTg0NzFhYjBjYTExZjIwZDc1ZmViMC90YWJsZXJhbmdlOmQ3MWYwOGFjMzc5ODQ3MWFiMGNhMTFmMjBkNzVmZWIwXzMtNC0xLTEtNzUxNDA_31624ac6-2ee2-48f8-9565-32eae78baae6"
      unitRef="usd">25800000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expenseincurredbythecollaboration
      contextRef="i534d34ae3d78433f9a80a80261d8c791_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTpkNzFmMDhhYzM3OTg0NzFhYjBjYTExZjIwZDc1ZmViMC90YWJsZXJhbmdlOmQ3MWYwOGFjMzc5ODQ3MWFiMGNhMTFmMjBkNzVmZWIwXzQtMi0xLTEtNzUxNDA_7dbecd71-f1ff-43fa-a7c7-8fdc1e5a9d98"
      unitRef="usd">95000000.0</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i535bbd28d8064cd99845c7aad7ef40b6_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTpkNzFmMDhhYzM3OTg0NzFhYjBjYTExZjIwZDc1ZmViMC90YWJsZXJhbmdlOmQ3MWYwOGFjMzc5ODQ3MWFiMGNhMTFmMjBkNzVmZWIwXzQtNC0xLTEtNzUxNDA_e0a0fb8d-98e8-4c81-b214-5a30aed4fe59"
      unitRef="usd">111800000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i534d34ae3d78433f9a80a80261d8c791_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTpkNzFmMDhhYzM3OTg0NzFhYjBjYTExZjIwZDc1ZmViMC90YWJsZXJhbmdlOmQ3MWYwOGFjMzc5ODQ3MWFiMGNhMTFmMjBkNzVmZWIwXzUtMi0xLTEtNzUxNDA_51385a97-a259-44c5-a8a0-17fc36938b49"
      unitRef="usd">50900000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i535bbd28d8064cd99845c7aad7ef40b6_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTpkNzFmMDhhYzM3OTg0NzFhYjBjYTExZjIwZDc1ZmViMC90YWJsZXJhbmdlOmQ3MWYwOGFjMzc5ODQ3MWFiMGNhMTFmMjBkNzVmZWIwXzUtNC0xLTEtNzUxNDA_7eb62fa0-03d6-42d1-884c-e2ae772ca7a0"
      unitRef="usd">60300000</biib:Expensereflectedwithinstatementsofincome>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="i8a12e5f049a6452f9e97a9998e1ce4b6_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzQ3OTY_05cf3daf-ff6a-4232-a16a-6ff1e749730b"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i8a12e5f049a6452f9e97a9998e1ce4b6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzUwMzI_9ad781aa-deba-43a7-9a80-f0cf4a57a16e"
      unitRef="usd">181700000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="i140fc83df9b443f8947b6e9c5a831662_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzUwNzY_adec97ed-40df-4fea-8402-228ea0e15490"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i722a1d8416ce4b6b9e7ebbb4433afb51_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzIxOTkwMjMyOTQ4Nzk_93da7398-8194-4a20-87bb-0a10fd68a3dd"
      unitRef="usd">275000000</us-gaap:CostOfGoodsAndServicesSold>
    <biib:CostOfGoodsSoldCapacityCharges
      contextRef="i8a12e5f049a6452f9e97a9998e1ce4b6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzEwOTk1MTE2NzI2MDQ_97b8d295-1432-4a71-94c6-4067faa38a4a"
      unitRef="usd">45000000</biib:CostOfGoodsSoldCapacityCharges>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i11a20f8ab31748a3a765230d484a950c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzEwOTk1MTE2NzcyODQ_ebfcb53e-3e77-4cfc-b25b-959829a17d04"
      unitRef="usd">160000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="i8a12e5f049a6452f9e97a9998e1ce4b6_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzEwOTk1MTE2NjY5OTg_05cf3daf-ff6a-4232-a16a-6ff1e749730b"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <us-gaap:DueFromRelatedParties
      contextRef="i30f95d1127004fdb916215bc0644001f_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzIxOTkwMjMyODI4MDc_dd0a5a40-69b9-4bc1-88dc-bd8adc50c55b"
      unitRef="usd">402700000</us-gaap:DueFromRelatedParties>
    <us-gaap:DueFromRelatedParties
      contextRef="i4e6c000a5c1747719d713bf44ab5594d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzIxOTkwMjMyODI4MjY_34ac071a-d581-48b2-8590-751c9ebbdf4c"
      unitRef="usd">285400000</us-gaap:DueFromRelatedParties>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="i30f95d1127004fdb916215bc0644001f_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzIxOTkwMjMyODI5Mzc_35cd03e0-5f85-4a7f-bc7a-7261264c444c"
      unitRef="usd">36500000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="i4e6c000a5c1747719d713bf44ab5594d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzIxOTkwMjMyODI5MjA_299ca192-1067-469d-a4c8-dfc801b6704e"
      unitRef="usd">46500000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <biib:Expenseincurredbythecollaboration
      contextRef="i385de3e6fdd648569c6459df74a3f24c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZToyMmYyNTNkYTNlNWI0ZWY1ODEzMWJjYWIwZDczMDEzZS90YWJsZXJhbmdlOjIyZjI1M2RhM2U1YjRlZjU4MTMxYmNhYjBkNzMwMTNlXzItMi0xLTEtNzUxNDA_93659a77-c37a-432d-a486-ac39454e5c66"
      unitRef="usd">17600000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i81ff85ba433e49f3bf5366754bf14dfd_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZToyMmYyNTNkYTNlNWI0ZWY1ODEzMWJjYWIwZDczMDEzZS90YWJsZXJhbmdlOjIyZjI1M2RhM2U1YjRlZjU4MTMxYmNhYjBkNzMwMTNlXzItNC0xLTEtNzUxNDA_17569137-bbfc-4642-a628-1887d82f3318"
      unitRef="usd">16900000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i385de3e6fdd648569c6459df74a3f24c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZToyMmYyNTNkYTNlNWI0ZWY1ODEzMWJjYWIwZDczMDEzZS90YWJsZXJhbmdlOjIyZjI1M2RhM2U1YjRlZjU4MTMxYmNhYjBkNzMwMTNlXzMtMi0xLTEtNzUxNDA_54f54254-5fdb-4807-ad7d-ca281f1c0562"
      unitRef="usd">8800000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i81ff85ba433e49f3bf5366754bf14dfd_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZToyMmYyNTNkYTNlNWI0ZWY1ODEzMWJjYWIwZDczMDEzZS90YWJsZXJhbmdlOjIyZjI1M2RhM2U1YjRlZjU4MTMxYmNhYjBkNzMwMTNlXzMtNC0xLTEtNzUxNDA_a5e25a1e-a8a5-4a7a-abb5-d0033762d9b9"
      unitRef="usd">8400000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expenseincurredbythecollaboration
      contextRef="id6f28921d58149e88f70f267093af3ed_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTo0NGE3YWYyZGZlOWM0MGRhYTFmNWU2YTJiZWU0MGIyMS90YWJsZXJhbmdlOjQ0YTdhZjJkZmU5YzQwZGFhMWY1ZTZhMmJlZTQwYjIxXzItMi0xLTEtNzUxNDA_abf1c9c1-ae19-451b-a13a-829403d93023"
      unitRef="usd">38700000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i84748af08d094521ad62103f37c3ba5e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTo0NGE3YWYyZGZlOWM0MGRhYTFmNWU2YTJiZWU0MGIyMS90YWJsZXJhbmdlOjQ0YTdhZjJkZmU5YzQwZGFhMWY1ZTZhMmJlZTQwYjIxXzItNC0xLTEtNzUxNDA_c3b13feb-edf9-41e6-ae7d-2005fd8181c3"
      unitRef="usd">39800000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="id6f28921d58149e88f70f267093af3ed_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTo0NGE3YWYyZGZlOWM0MGRhYTFmNWU2YTJiZWU0MGIyMS90YWJsZXJhbmdlOjQ0YTdhZjJkZmU5YzQwZGFhMWY1ZTZhMmJlZTQwYjIxXzMtMi0xLTEtNzUxNDA_ebf29024-0809-4577-945d-d750ed9fa3f4"
      unitRef="usd">19400000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i84748af08d094521ad62103f37c3ba5e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTo0NGE3YWYyZGZlOWM0MGRhYTFmNWU2YTJiZWU0MGIyMS90YWJsZXJhbmdlOjQ0YTdhZjJkZmU5YzQwZGFhMWY1ZTZhMmJlZTQwYjIxXzMtNC0xLTEtNzUxNDA_6a067ebb-9a72-4bfc-8599-b7ffffb2dccc"
      unitRef="usd">19900000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expenseincurredbythecollaboration
      contextRef="if9f8dc7db02f46a382226b3a06689770_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTo0NGE3YWYyZGZlOWM0MGRhYTFmNWU2YTJiZWU0MGIyMS90YWJsZXJhbmdlOjQ0YTdhZjJkZmU5YzQwZGFhMWY1ZTZhMmJlZTQwYjIxXzQtMi0xLTEtNzUxNDA_4a611faa-568a-4dcf-9d16-3250e23969e3"
      unitRef="usd">18400000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="iccef06de5f364c6e864a306f6c4d2222_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTo0NGE3YWYyZGZlOWM0MGRhYTFmNWU2YTJiZWU0MGIyMS90YWJsZXJhbmdlOjQ0YTdhZjJkZmU5YzQwZGFhMWY1ZTZhMmJlZTQwYjIxXzQtNC0xLTEtNzUxNDA_d09af062-fc4a-4751-ab73-cef26cf6d8da"
      unitRef="usd">5300000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="if9f8dc7db02f46a382226b3a06689770_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTo0NGE3YWYyZGZlOWM0MGRhYTFmNWU2YTJiZWU0MGIyMS90YWJsZXJhbmdlOjQ0YTdhZjJkZmU5YzQwZGFhMWY1ZTZhMmJlZTQwYjIxXzUtMi0xLTEtNzUxNDA_7f712296-aaee-464c-bf44-329d938c48a7"
      unitRef="usd">9200000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="iccef06de5f364c6e864a306f6c4d2222_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTo0NGE3YWYyZGZlOWM0MGRhYTFmNWU2YTJiZWU0MGIyMS90YWJsZXJhbmdlOjQ0YTdhZjJkZmU5YzQwZGFhMWY1ZTZhMmJlZTQwYjIxXzUtNC0xLTEtNzUxNDA_723555b3-e34e-4c8c-9009-6cf4253e7a1c"
      unitRef="usd">2700000</biib:Expensereflectedwithinstatementsofincome>
    <biib:SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzIwMTE3_ad0f28d4-f089-4965-84b4-6b1a89f35cab">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A summary of development expense related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Denali collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of Denali development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock>
    <biib:Expenseincurredbythecollaboration
      contextRef="i22e581ce75fe402f95badbea9059a2fd_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTowZGM3M2UzMDczNjc0NWM4YjBhOTAwMzhjYjNhOGY4OS90YWJsZXJhbmdlOjBkYzczZTMwNzM2NzQ1YzhiMGE5MDAzOGNiM2E4Zjg5XzItMi0xLTEtNzUxNDA_c706b096-4bf0-47eb-a1ac-09d16e976f96"
      unitRef="usd">14900000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="id0323b821ee4490ab9cd6f46708b92d2_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTowZGM3M2UzMDczNjc0NWM4YjBhOTAwMzhjYjNhOGY4OS90YWJsZXJhbmdlOjBkYzczZTMwNzM2NzQ1YzhiMGE5MDAzOGNiM2E4Zjg5XzItNC0xLTEtNzUxNDA_a17b2649-3ec9-4d82-8284-175dd214e175"
      unitRef="usd">15400000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i22e581ce75fe402f95badbea9059a2fd_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTowZGM3M2UzMDczNjc0NWM4YjBhOTAwMzhjYjNhOGY4OS90YWJsZXJhbmdlOjBkYzczZTMwNzM2NzQ1YzhiMGE5MDAzOGNiM2E4Zjg5XzMtMi0xLTEtNzUxNDA_2c5ebbdf-396b-4463-b3b6-1cdf7d081c70"
      unitRef="usd">8900000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="id0323b821ee4490ab9cd6f46708b92d2_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTowZGM3M2UzMDczNjc0NWM4YjBhOTAwMzhjYjNhOGY4OS90YWJsZXJhbmdlOjBkYzczZTMwNzM2NzQ1YzhiMGE5MDAzOGNiM2E4Zjg5XzMtNC0xLTEtNzUxNDA_95a5065f-e5c4-4f2d-a474-5fce93c65ced"
      unitRef="usd">9200000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Termofcollaborationagreement
      contextRef="i7cab4c6e22304f01a6e538f0a28da4a6_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzIwMTE4_e86061f5-2ad9-4318-9e56-c9b91d3d8bfe">P5Y</biib:Termofcollaborationagreement>
    <biib:Expenseincurredbythecollaboration
      contextRef="ia2f3b87f1c704bfeaa184c005c15f509_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTo4NDBmYjNmNzdkYWY0ZjNjYjk1ZjczMWExYzQ2NjJhZi90YWJsZXJhbmdlOjg0MGZiM2Y3N2RhZjRmM2NiOTVmNzMxYTFjNDY2MmFmXzItMi0xLTEtODU2MTk_322ad19d-004a-4ecf-9f03-a51a579fd22e"
      unitRef="usd">8300000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i1980e9c4bcf04c69813dff866529db3b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTo4NDBmYjNmNzdkYWY0ZjNjYjk1ZjczMWExYzQ2NjJhZi90YWJsZXJhbmdlOjg0MGZiM2Y3N2RhZjRmM2NiOTVmNzMxYTFjNDY2MmFmXzItNC0xLTEtODU2MTk_5206a14c-15f0-4ff4-b27b-1784c3838b4a"
      unitRef="usd">4800000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="ia2f3b87f1c704bfeaa184c005c15f509_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTo4NDBmYjNmNzdkYWY0ZjNjYjk1ZjczMWExYzQ2NjJhZi90YWJsZXJhbmdlOjg0MGZiM2Y3N2RhZjRmM2NiOTVmNzMxYTFjNDY2MmFmXzMtMi0xLTEtODU2MTk_24f8f214-96b6-4a12-8583-705921db05bd"
      unitRef="usd">5500000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i1980e9c4bcf04c69813dff866529db3b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90YWJsZTo4NDBmYjNmNzdkYWY0ZjNjYjk1ZjczMWExYzQ2NjJhZi90YWJsZXJhbmdlOjg0MGZiM2Y3N2RhZjRmM2NiOTVmNzMxYTFjNDY2MmFmXzMtNC0xLTEtODU2MTk_d41fa814-d182-4175-a27b-995775ffd869"
      unitRef="usd">4200000</biib:Expensereflectedwithinstatementsofincome>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="i416b5c2161cb4be49401dc463e803f6e_D20210801-20210831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzEyOTAy_466b79c8-d665-4c11-bf4a-97c8e3f394c3"
      unitRef="usd">125000000</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <biib:ContingentMilestonePaymentsMadeToCollaborativePartner
      contextRef="i416b5c2161cb4be49401dc463e803f6e_D20210801-20210831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzEzMDA1_4c3b2732-2d67-40db-b917-2dad4b9872f0"
      unitRef="usd">812500000</biib:ContingentMilestonePaymentsMadeToCollaborativePartner>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i871bd576e8054a32a94dd16a50cc8f38_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzEzNjE0_c09e7284-7322-418e-a3e6-bc50db883288"
      unitRef="usd">19500000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i69f6f1c65f31482a9985575399db62f4_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzEzODAw_350fafba-47de-4d28-bc7c-4be35f6abdff"
      unitRef="usd">1000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ia5fabf9c71294456a0158d60a5f483a4_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzE0NDYw_0952b3aa-e388-47ac-91cb-321e4a6f024f"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity
      contextRef="i17a7835e9c634cd3898253b27970e1ae_I20181107"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzE1NDc1_8f3f1be1-d7b3-447d-ab51-2f9211baf253"
      unitRef="usd">675000000</us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity>
    <biib:Equitymethodinvestmentbasisdifferenceamortizationperiod
      contextRef="i3777c8eb44d147d2bc71177545a1a119_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzE1NjY3_4261d8ea-715a-40ce-94a9-5b41b2c47133">P1Y6M</biib:Equitymethodinvestmentbasisdifferenceamortizationperiod>
    <biib:Equitymethodinvestmentbasisdifferenceamortizationperiod
      contextRef="i81aebf0e69b74044934ae698e82a35a4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzE1ODM1_d3c5cd01-c15c-496e-9973-ab6c025263e5">P15Y</biib:Equitymethodinvestmentbasisdifferenceamortizationperiod>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
      contextRef="id6783744f49842d8974c9aa1108f7b92_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzE2MzQy_5fbb7013-3aa7-43db-a58f-65b10610df91"
      unitRef="usd">3300000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="id6783744f49842d8974c9aa1108f7b92_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzEwOTk1MTE2NjI0NjM_dbc08def-9ad8-48b6-8a27-24461609946b"
      unitRef="usd">4000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:AdjustmentForAmortization
      contextRef="id6783744f49842d8974c9aa1108f7b92_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzEwOTk1MTE2NjI0Nzc_3039608b-e6a2-4327-8ae8-cfca1e0be7bb"
      unitRef="usd">7300000</us-gaap:AdjustmentForAmortization>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
      contextRef="idb43218ef58b4c47acc0ed3d32fc1c8a_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzE2NTIx_1afc735c-f367-4705-9a52-3b7795286c88"
      unitRef="usd">18200000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="idb43218ef58b4c47acc0ed3d32fc1c8a_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzEwOTk1MTE2NjI3OTg_8fe17270-8c7a-4c0d-bb88-aa0e80a4f45e"
      unitRef="usd">11000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:AdjustmentForAmortization
      contextRef="idb43218ef58b4c47acc0ed3d32fc1c8a_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzEwOTk1MTE2NjI4MTU_686221a2-af77-47f1-851a-5ec154b5684a"
      unitRef="usd">7200000</us-gaap:AdjustmentForAmortization>
    <us-gaap:EquityMethodInvestments
      contextRef="ia5fabf9c71294456a0158d60a5f483a4_I20220331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzE2NzQw_42b8f7c7-8367-40a5-a788-0ce0ca5abd0f"
      unitRef="krw">709400000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ia5fabf9c71294456a0158d60a5f483a4_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzE2NzYx_242c97d3-6430-48e6-9d3f-2fbb9fe5f8cc"
      unitRef="usd">586400000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i9fcfddd14c424cd095a98f9df64e862f_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzE2NzY5_87266759-74dd-482d-9478-742073642902"
      unitRef="krw">713300000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i9fcfddd14c424cd095a98f9df64e862f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzE2Nzkw_36c5f1d6-739a-424b-9e0f-fa7c3dd89332"
      unitRef="usd">599900000</us-gaap:EquityMethodInvestments>
    <us-gaap:ProceedsFromDivestitureOfInterestInJointVenture
      contextRef="i54ef960b3f344a6284182d87fe3863d1_D20220101-20220131"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzEwOTk1MTE2NjExNzU_fce74663-058b-43f8-bf9e-f72ace1396b5"
      unitRef="usd">1000000000</us-gaap:ProceedsFromDivestitureOfInterestInJointVenture>
    <biib:PayablesToDivestitureOfInterestInJointVenture
      contextRef="i9a34f5e20a214f4fb6abb8675f411f59_I20220131"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzEwOTk1MTE2NjExODk_0a15c1c7-1dde-49d3-8593-4c152ba1480f"
      unitRef="usd">1300000000</biib:PayablesToDivestitureOfInterestInJointVenture>
    <biib:PayablesToDivestitureOfInterestInJointVenture
      contextRef="ice9f6a67517e4256bcc4feff2a07a95c_I20220131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzEwOTk1MTE2NjEyMDM_d3527318-ce7f-4266-9f36-82648329f8a3"
      unitRef="usd">812500000</biib:PayablesToDivestitureOfInterestInJointVenture>
    <biib:PayablesToDivestitureOfInterestInJointVenture
      contextRef="ifbc3564cb9f74c5e96af956bdb92ace9_I20220131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzEwOTk1MTE2NjEyMTk_eafa605f-1217-427f-b0c8-b50618a96d07"
      unitRef="usd">437500000</biib:PayablesToDivestitureOfInterestInJointVenture>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones
      contextRef="i54ef960b3f344a6284182d87fe3863d1_D20220101-20220131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzEwOTk1MTE2NjEyMzU_99895d95-1041-4fda-82d0-8c3a5f51e837"
      unitRef="usd">50000000</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="i8140a335ecc449f6bb7f8e4660aac8ea_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzE3NTU0_361043e1-e17c-4a9c-a0ff-a9ec14e679b8"
      unitRef="usd">100000000</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i8140a335ecc449f6bb7f8e4660aac8ea_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzE3NjAy_0973ed1b-1a60-4075-8ca3-f9db8d7e873b"
      unitRef="usd">63000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="i8c93649201d542fd82a365350912101f_I20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzE3NjY2_66be4540-57fe-4c67-a05d-dd53062232f6"
      unitRef="usd">37000000</us-gaap:PrepaidExpenseAndOtherAssets>
    <biib:AccruedMilestonePayments
      contextRef="ib0074296436b4840ada078b60b901e66_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzE3OTUz_87dcbfd0-339f-4cdd-a808-ff9a6c3e0e27"
      unitRef="usd">15000000</biib:AccruedMilestonePayments>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones
      contextRef="ib0074296436b4840ada078b60b901e66_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzE4MTA3_6b667a39-203f-4a51-855e-53fe9b6b1236"
      unitRef="usd">180000000</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <biib:CollaborationAgreementTerm
      contextRef="ib0074296436b4840ada078b60b901e66_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzE4MzA2_c4222ced-8565-48ea-9d5b-820d3ece4302">P5Y</biib:CollaborationAgreementTerm>
    <biib:ContractOptionExerciseFee
      contextRef="ib0074296436b4840ada078b60b901e66_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzE4MzU4_4a36a6f3-eb35-49b5-9e10-f8b0b75ddea7"
      unitRef="usd">60000000</biib:ContractOptionExerciseFee>
    <biib:EquityMethodInvestmentsExpectedProfitShare
      contextRef="ib0074296436b4840ada078b60b901e66_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzEwOTk1MTE2NDg0Nzk_7323f3fd-6ae4-4ecc-972e-8ed6e5c77f82"
      unitRef="number">0.500</biib:EquityMethodInvestmentsExpectedProfitShare>
    <biib:Collaborationprofitlosssharing
      contextRef="id6783744f49842d8974c9aa1108f7b92_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzE5MDk0_40eaca52-c94d-46a7-9d77-15ee9f716d38"
      unitRef="usd">64400000</biib:Collaborationprofitlosssharing>
    <biib:EquityMethodInvestmentsExpectedProfitShare
      contextRef="ib0074296436b4840ada078b60b901e66_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzEwOTk1MTE2NDg0ODM_7323f3fd-6ae4-4ecc-972e-8ed6e5c77f82"
      unitRef="number">0.500</biib:EquityMethodInvestmentsExpectedProfitShare>
    <biib:Collaborationprofitlosssharing
      contextRef="idb43218ef58b4c47acc0ed3d32fc1c8a_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzE5MjM2_f28b7aea-0a13-4e30-982c-5944704dffe7"
      unitRef="usd">68500000</biib:Collaborationprofitlosssharing>
    <us-gaap:DueFromRelatedParties
      contextRef="ia9e98bb878a84e13ac251a6b98a15e94_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzEwOTk1MTE2NjIxNjA_4982cf4f-ec93-4f6e-ac42-783dc5dce201"
      unitRef="usd">5800000</us-gaap:DueFromRelatedParties>
    <us-gaap:DueFromRelatedParties
      contextRef="i33310cbd0d8e4927a25d422f87b6a6e3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzEwOTk1MTE2NjIxNzc_e8abf0d0-5f05-49a8-9e84-95f332f40a88"
      unitRef="usd">4100000</us-gaap:DueFromRelatedParties>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="ia9e98bb878a84e13ac251a6b98a15e94_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzE5Nzcz_2bb4d91e-d8dd-40e1-ba81-c8774bee23d5"
      unitRef="usd">102500000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="i33310cbd0d8e4927a25d422f87b6a6e3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMTUvZnJhZzo1NTYxZTNhMTk2MmE0ZGE5YTgzZDU5NDI3ZDM2ZjBmZi90ZXh0cmVnaW9uOjU1NjFlM2ExOTYyYTRkYTlhODNkNTk0MjdkMzZmMGZmXzE5Nzgw_be707371-8450-46c0-ac00-c237c0bc43c5"
      unitRef="usd">148700000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:VariableInterestEntityDisclosureTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMjEvZnJhZzowNWVkOTJlYWFjOTk0NmVjYTBlMDM3NWQxMDRhZDFjMy90ZXh0cmVnaW9uOjA1ZWQ5MmVhYWM5OTQ2ZWNhMGUwMzc1ZDEwNGFkMWMzXzY1Njc_3cd8d8b2-e595-448c-bc13-e6633037a114">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Consolidated Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Neurimmune SubOne AG&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a collaboration and license agreement with Neurimmune for the development and commercialization of antibodies for the potential treatment of Alzheimer's disease, including ADUHELM (as amended, the Neurimmune Agreement). We are responsible for the development, manufacturing and commercialization of all collaboration products. The Neurimmune Agreement is effective for the longer of the duration of certain patents relating to a licensed product or 12 years from the first commercial sale of a licensed product.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#x2019;s economic performance and we are required to fund 100.0% of the research and development costs incurred in support of the collaboration. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021 ADUHELM was granted accelerated approval by the FDA. Under the terms of the Neurimmune Agreement, we were required to pay Neurimmune a milestone payment of $100.0&#160;million related to the launch of ADUHELM in the U.S. During the second quarter of 2021 we made this $100.0&#160;million payment, which was recognized as a charge to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income. In addition, during the second quarter of 2021 we recognized net profit-sharing income of $45.0&#160;million to reflect Eisai's &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45.0%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; share of the $100.0&#160;million milestone payment, which was recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, if aducanumab receives regulatory approval in the jurisdictions where we have submitted filings, we may pay additional milestones to Neurimmune, including $50.0&#160;million  if launched in Japan. Milestones payable to Neurimmune are shared expenses under the ADUHELM Collaboration Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs for which we reimburse Neurimmune are reflected in research and development expense in our condensed consolidated statements of income. During the three months ended March 31, 2022 and 2021, amounts reimbursed were immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2021 we recorded a net deferred tax asset in Switzerland of approximately $490.0&#160;million on Neurimmune's tax basis in ADUHELM, the realization of which is dependent on future sales of ADUHELM. During the fourth quarter of 2021, due to reduced future expected revenue associated with ADUHELM, we recorded a valuation allowance of approximately $390.0&#160;million. During the first quarter of 2022, upon issuance of the final NCD related to ADUHELM, we recorded an additional valuation allowance of approximately $85.0&#160;million to reduce the net value of this deferred tax asset to zero. These adjustments to our deferred tax assets and their valuation allowances are each recorded with an equal and offsetting amount assigned to net income (loss) &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income, resulting in a zero net impact to net income attributable to Biogen Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Excluding the impact of the Neurimmune deferred tax asset, the assets and liabilities of Neurimmune are not significant to our condensed consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than contractually required amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements with Eisai, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 16, Collaborative and Other Relationships, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unconsolidated Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have relationships with various variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2022 and December 31, 2021, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled $24.1 million and $24.6 million, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previous contractually required amounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our investments in Neurimmune and other variable interest entities, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19, Investments in Variable Interest Entities,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2021 Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:VariableInterestEntityDisclosureTextBlock>
    <biib:CollaborationAgreementTerm
      contextRef="i5e6825d4d7fc4c049bc35822d827b16a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMjEvZnJhZzowNWVkOTJlYWFjOTk0NmVjYTBlMDM3NWQxMDRhZDFjMy90ZXh0cmVnaW9uOjA1ZWQ5MmVhYWM5OTQ2ZWNhMGUwMzc1ZDEwNGFkMWMzXzc0Mg_713c9e9b-be48-4893-a734-6a6536d0fd6c">P12Y</biib:CollaborationAgreementTerm>
    <biib:ResearchAndDevelopmentCostsPercentage
      contextRef="i5e6825d4d7fc4c049bc35822d827b16a_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMjEvZnJhZzowNWVkOTJlYWFjOTk0NmVjYTBlMDM3NWQxMDRhZDFjMy90ZXh0cmVnaW9uOjA1ZWQ5MmVhYWM5OTQ2ZWNhMGUwMzc1ZDEwNGFkMWMzXzEwODU_9b76dfae-b24e-4e3b-8178-f56308da58db"
      unitRef="number">1.000</biib:ResearchAndDevelopmentCostsPercentage>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="ie40c7dd8da0c4c3d8730bcde07b49856_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMjEvZnJhZzowNWVkOTJlYWFjOTk0NmVjYTBlMDM3NWQxMDRhZDFjMy90ZXh0cmVnaW9uOjA1ZWQ5MmVhYWM5OTQ2ZWNhMGUwMzc1ZDEwNGFkMWMzXzMwNDE_710abec4-304c-4b61-a323-9da980121c51"
      unitRef="usd">100000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="ie40c7dd8da0c4c3d8730bcde07b49856_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMjEvZnJhZzowNWVkOTJlYWFjOTk0NmVjYTBlMDM3NWQxMDRhZDFjMy90ZXh0cmVnaW9uOjA1ZWQ5MmVhYWM5OTQ2ZWNhMGUwMzc1ZDEwNGFkMWMzXzMxMzY_710abec4-304c-4b61-a323-9da980121c51"
      unitRef="usd">100000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i08f827f32a3b446c825d77324ed50eb7_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMjEvZnJhZzowNWVkOTJlYWFjOTk0NmVjYTBlMDM3NWQxMDRhZDFjMy90ZXh0cmVnaW9uOjA1ZWQ5MmVhYWM5OTQ2ZWNhMGUwMzc1ZDEwNGFkMWMzXzMzOTc_7bd43a88-806c-4e5d-8106-57876d218e1f"
      unitRef="usd">45000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="i8a12e5f049a6452f9e97a9998e1ce4b6_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMjEvZnJhZzowNWVkOTJlYWFjOTk0NmVjYTBlMDM3NWQxMDRhZDFjMy90ZXh0cmVnaW9uOjA1ZWQ5MmVhYWM5OTQ2ZWNhMGUwMzc1ZDEwNGFkMWMzXzEwOTk1MTE2Mzk1NzE_05cf3daf-ff6a-4232-a16a-6ff1e749730b"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="ie40c7dd8da0c4c3d8730bcde07b49856_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMjEvZnJhZzowNWVkOTJlYWFjOTk0NmVjYTBlMDM3NWQxMDRhZDFjMy90ZXh0cmVnaW9uOjA1ZWQ5MmVhYWM5OTQ2ZWNhMGUwMzc1ZDEwNGFkMWMzXzM0MzU_710abec4-304c-4b61-a323-9da980121c51"
      unitRef="usd">100000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:AdditionalMilestonePayment
      contextRef="i22cd2c200d674e7185cf096a998f436a_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMjEvZnJhZzowNWVkOTJlYWFjOTk0NmVjYTBlMDM3NWQxMDRhZDFjMy90ZXh0cmVnaW9uOjA1ZWQ5MmVhYWM5OTQ2ZWNhMGUwMzc1ZDEwNGFkMWMzXzIxOTkwMjMyNjgyMDk_0296fd27-8656-4ab7-abcf-eecd851ad69e"
      unitRef="usd">50000000</biib:AdditionalMilestonePayment>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i350f52cf56ca419f9abcc85ddabdf66a_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMjEvZnJhZzowNWVkOTJlYWFjOTk0NmVjYTBlMDM3NWQxMDRhZDFjMy90ZXh0cmVnaW9uOjA1ZWQ5MmVhYWM5OTQ2ZWNhMGUwMzc1ZDEwNGFkMWMzXzEwOTk1MTE2NDE3MTI_5a1e626e-1911-40d4-bd13-9d2536359647"
      unitRef="usd">490000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i350f52cf56ca419f9abcc85ddabdf66a_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMjEvZnJhZzowNWVkOTJlYWFjOTk0NmVjYTBlMDM3NWQxMDRhZDFjMy90ZXh0cmVnaW9uOjA1ZWQ5MmVhYWM5OTQ2ZWNhMGUwMzc1ZDEwNGFkMWMzXzEwOTk1MTE2NDE3MTI_a6fd5756-faf6-433e-abf0-882ac35e6c15"
      unitRef="usd">490000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMjEvZnJhZzowNWVkOTJlYWFjOTk0NmVjYTBlMDM3NWQxMDRhZDFjMy90ZXh0cmVnaW9uOjA1ZWQ5MmVhYWM5OTQ2ZWNhMGUwMzc1ZDEwNGFkMWMzXzEwOTk1MTE2NDE3NjM_f162b270-dd9d-4e6d-a19a-875190f5c2ca"
      unitRef="usd">390000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMjEvZnJhZzowNWVkOTJlYWFjOTk0NmVjYTBlMDM3NWQxMDRhZDFjMy90ZXh0cmVnaW9uOjA1ZWQ5MmVhYWM5OTQ2ZWNhMGUwMzc1ZDEwNGFkMWMzXzEwOTk1MTE2NDE3NzI_66d041a0-5993-465d-9d7e-ea7cbebc52ff"
      unitRef="usd">85000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities
      contextRef="id525e35f363e449aa36c9833e703f6f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMjEvZnJhZzowNWVkOTJlYWFjOTk0NmVjYTBlMDM3NWQxMDRhZDFjMy90ZXh0cmVnaW9uOjA1ZWQ5MmVhYWM5OTQ2ZWNhMGUwMzc1ZDEwNGFkMWMzXzU3Mzg_97299af9-07c2-4930-b813-4fbc60ddee66"
      unitRef="usd">24100000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
    <biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities
      contextRef="i609afa0be8424634b9ec333da2c2f549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMjEvZnJhZzowNWVkOTJlYWFjOTk0NmVjYTBlMDM3NWQxMDRhZDFjMy90ZXh0cmVnaW9uOjA1ZWQ5MmVhYWM5OTQ2ZWNhMGUwMzc1ZDEwNGFkMWMzXzU3NDU_8bf55fc6-d429-44c5-a65c-294d01c05a73"
      unitRef="usd">24600000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMjcvZnJhZzoxMjZjMDFjOTg5YjU0Y2UyOWEwNTc0NDBmMzc3MDczNi90ZXh0cmVnaW9uOjEyNmMwMWM5ODliNTRjZTI5YTA1NzQ0MGYzNzcwNzM2XzExOTU0_e08af882-dcdd-442c-8916-db4609bfef0d">&lt;div style="margin-top:6pt;padding-left:4.5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1, Summary of Significant Accounting Policies,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2021 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#x2019; legal theories; and (v) the parties' settlement positions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Loss Contingencies &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ADUHELM Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We and certain current and former officers are named as defendants in actions filed by shareholders on November 13, 2020 and February 7, 2022, and pending in the U.S. District Court for the District of Massachusetts. The actions allege violations of federal securities laws under 15 U.S.C &#xa7;78j(b) and &#xa7;78t(a) and 17 C.F.R. &#xa7;240.10b-5 and seek declarations of the actions as class actions and monetary relief. We have filed a motion to dismiss the action filed on November 13, 2020, which is pending. An estimate of the possible loss or range of loss in these actions cannot be made at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivative Action&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We and members of the Board of Directors are named as defendants in an action filed by a shareholder on February 9, 2022, in the U.S. District Court for the District of Massachusetts. The action alleges violations of federal securities laws under 15 U.S.C. &#xa7;78n(a) and 17 C.F.R. &#xa7;240 14.a-9, breaches of fiduciary duties and waste of corporate assets, and seeks declaratory and injunctive relief, monetary relief to Biogen, and attorneys&#x2019; fees and costs to the plaintiff. An estimate of the possible loss or range of loss cannot be made at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;IMRALDI Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2018 Fresenius Kabi Deutschland GmbH (Fresenius Kabi) commenced proceedings for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris (the French proceeding) and in November 2018 against Biogen GmbH in the D&#xfc;sseldorf Regional Court (the German proceeding), alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis that Biogen has commercialized in Europe, infringes national counterparts of European Patent No. 3 148 510 (the EP '510 Patent, expiring in May 2035). In May 2020 the European Patent Office (EPO) held the EP '510 Patent invalid. Fresenius Kabi has appealed to the EPO's Technical Boards of Appeal, a hearing has been set for June 2022, and the German and French proceedings have been stayed pending the decision on appeal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020 Fresenius Kabi commenced proceedings in Denmark's Maritime and Commercial High Court alleging that IMRALDI infringes the Danish counterpart of European Patent No. 3 145 488 (the EP '488 Patent, expiring in May 2035) and a Danish utility model. In September 2021 the Court ruled that the patent and utility model are invalid and not infringed. Fresenius Kabi has appealed to the High Court of Eastern Denmark and the appeal is pending. The EPO has scheduled a hearing on the validity of the EP '488 Patent for October 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2020 the Danish Patent Board of Appeal revoked the Danish utility models that Fresenius Kabi had asserted against Biogen and Fresenius Kabi has appealed to the Danish Maritime and Commercial High Court. No hearing has been scheduled.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2019 Gedeon Richter Nyrt commenced proceedings for damages and injunctive relief against Biogen GmbH in the D&#xfc;sseldorf Regional Court alleging infringement of the German counterpart of European Patent No. 3 212 667, which expires in October 2035. The case has been stayed pending proceedings in the EPO seeking to invalidate the patent. In November 2020 Gedeon Richter Nyrt commenced additional proceedings against Biogen GmbH in the D&#xfc;sseldorf Regional Court alleging infringement of a German utility model. In October 2021 Biogen filed cancellation proceedings in respect of the German utility model and the infringement proceedings have been stayed pending the outcome of the cancellation proceedings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An estimate of the possible loss or range of loss in the IMRALDI patent litigation described above cannot be made at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Qui Tam Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2015 a qui tam action filed by Michael Bawduniak on behalf of the U.S. and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts and seeks damages of $981.1&#160;million plus statutory trebling of damages, civil penalties, attorneys&#x2019; fees and costs. The U.S. has not made an intervention decision. A trial is scheduled for the third quarter of 2022. An estimate of the possible loss cannot be made at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Dispute with Former Convergence Shareholders&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November and December 2019 Shareholder Representative Services LLC, on behalf of the former shareholders of Convergence, sent us correspondence asserting claims of $200.0 million for alleged breach of the contract under which we acquired Convergence. We dispute the claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ERISA Class Action Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020 the U.S. District Court for the District of Massachusetts consolidated two cases filed against us in July and August 2020 by participants in the Biogen 401(k) Savings Plan alleging breach of fiduciary duty under ERISA. Plaintiffs seek a declaration of the action as a class action and monetary and other relief. An estimate of the possible loss or range of loss cannot be made at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Humana Patient Assistance Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021 Humana Inc. (Humana) filed suit against us in the U.S. District Court for the District of Massachusetts alleging damages related to our providing MS patients with free medications and making charitable contributions to non-profit organizations that assist MS patients. Humana alleges violation of the federal RICO Act and state laws and seeks statutory treble damages, attorneys' fees and costs. We filed a motion to dismiss, which is pending. An estimate of the possible loss cannot be made at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Investigations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The U.S. House of Representatives Committees on Oversight and Reform and Energy and Commerce and the Office of Inspector General of the U.S. Department of Health and Human Services have announced investigations relating to ADUHELM. In addition, the Company has received a civil investigative demand from the Federal Trade Commission and a subpoena from the Securities and Exchange Commission seeking information relating to ADUHELM, including healthcare sites, ADUHELM&#x2019;s approval and ADUHELM&#x2019;s marketing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;TECFIDERA Patent Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017 to 2020 we filed patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act (the Delaware Actions), against Accord Healthcare Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Cipla Limited, Graviti Pharmaceuticals Pvt. Ltd., Hetero USA, Inc., Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Prinston Pharmaceutical Inc., Sandoz Inc., Shilpa Medicare Limited, Slayback Pharma LLC, Sun Pharmaceutical Industries, Ltd., Sun Pharmaceutical Industries, Inc., Sun Pharma Global FZE, Torrent Pharmaceuticals Ltd., TWi Pharmaceuticals, Inc., Windlas Healthcare Pvt. Ltd. and Zydus Pharmaceuticals (USA) Inc. (collectively, the Delaware Defendants) in the U.S. District Court for the District of Delaware (the Delaware Court) and against Mylan (the West Virginia Action) in the U.S. District Court for the Northern District of West Virginia (the West Virginia Court).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In November 2021 the Federal Circuit affirmed the West Virginia Court judgment that the asserted claims of our U.S. Patent No. 8,399,514 (the '514 Patent) are invalid for lack of written description.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Delaware Court entered judgment for the Delaware Defendants on the grounds that the judgment of the West Virginia Court applies to the Delaware Actions under principles of collateral estoppel. The appeals in the Delaware Actions are stayed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In July 2018 Mylan Pharmaceuticals, Inc. (Mylan) also filed a petition with the U.S. Patent Trial and Appeal Board (PTAB) for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;inter partes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; review of the '514 Patent. In November 2021 the Federal Circuit ruled that the PTAB decision upholding the patentability of the &#x2018;514 patent was moot, but in April 2022 the Federal Circuit vacated that ruling and stayed the appeal pending any final action by the United States Supreme Court in the West Virginia Action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;TYSABRI Patent Revocation Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2017 Swiss Pharma International AG, affiliated with the Polpharma Group, filed an action in the Commercial Court of Rome to invalidate the Italian counterpart of the European Patent No. 1 485 127 (the EP '127 Patent) which covers administration of natalizumab (TYSABRI) to treat MS and expires in February 2023. A hearing has been set for June 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020 Polpharma Biologics S.A., also affiliated with the Polpharma Group, brought an action in the Polish Patent Office to revoke our Polish Patent No. 215263, which corresponds to the EP '127 Patent and expires in February 2023. The action was suspended by the Polish Patent Office in April 2021 pending examination of our amended patent claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021 Polpharma Biologics S.A., Sandoz B.V. and Sandoz AG filed an action in the District Court of the Hague, Netherlands to invalidate the Dutch counterpart of our European Patent 2 676 967 (the EP '967 Patent), which expires in 2027 and covers methods of treatment using natalizumab (TYSABRI) and pre-treatment testing of patients. A hearing has been set for September 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2021 the EPO revoked the EP &#x2018;967 Patent. We have appealed to the EPO&#x2019;s Technical Boards of Appeal. A hearing date has not been set.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021 Polpharma Biologics S.A., Sandoz AG, Sandoz Limited and Sandoz GmbH filed an action in the English High Court to revoke the U.K. counterpart of the EP &#x2018;967 Patent and seeking a declaration that the patent would not be infringed by the marketing of Polpharma&#x2019;s proposed natalizumab biosimilar. A hearing has been set for November 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Annulment Proceedings in General Court of the European Union relating to TECFIDERA&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmaceutical Works Polpharma SA (Polpharma) and Mylan Ireland Ltd. (Mylan Ireland) each filed actions in the General Court of the European Union (Polpharma in October 2018 and Mylan Ireland in November 2020) to annul the European Medicines Agency's (EMA) decision not to validate their applications to market generic versions of TECFIDERA on the grounds that TECFIDERA benefits from regulatory data protection. On May 5, 2021, the European General Court annulled the EMA's non-validation decision with respect to Polpharma. We have appealed the decision to the European Court of Justice and the appeal is pending. The case brought by Mylan Ireland has been stayed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Liability and Other Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i179745ea816f45eeb6066bd1ea79e129_I20210715"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMjcvZnJhZzoxMjZjMDFjOTg5YjU0Y2UyOWEwNTc0NDBmMzc3MDczNi90ZXh0cmVnaW9uOjEyNmMwMWM5ODliNTRjZTI5YTA1NzQ0MGYzNzcwNzM2XzQ2NTE_1b7b0dfc-4a0f-4d9e-89d2-62d8c2f1ab54"
      unitRef="usd">981100000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="if8f47af926b14294931310a85ceac0ce_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMjcvZnJhZzoxMjZjMDFjOTg5YjU0Y2UyOWEwNTc0NDBmMzc3MDczNi90ZXh0cmVnaW9uOjEyNmMwMWM5ODliNTRjZTI5YTA1NzQ0MGYzNzcwNzM2XzUwODQ_69b2e76f-0ea6-487d-bbf0-cad0245a0c40"
      unitRef="usd">200000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8xMzAvZnJhZzoyYjY1ODZkMDU2YzQ0NzU3YjE5OTAxNjAwNDVhYzhmMy90ZXh0cmVnaW9uOjJiNjU4NmQwNTZjNDQ3NTdiMTk5MDE2MDA0NWFjOGYzXzQ2_acda27b8-5aa4-47bf-a5cf-11967ec34d6a">SUBSEQUENT EVENTSOn May 3, 2022, Biogen Inc. (the "Company") announced that it had begun a search for a new Chief Executive Officer ("CEO"). The Company has agreed with its current CEO, Michel Vounatsos, that he will continue to serve as CEO during the interim period. Mr. Vounatsos will remain on the Board of Directors of Biogen until he steps down from his CEO position.</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:RestructuringCharges
      contextRef="i8c3728b044d743d0b57e33fc6e523b46_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMDc2L2ZyYWc6NWYwMzJkZjM4N2ZkNDI3MDlhNzVkMmVjN2Q2NTc1N2MvdGV4dHJlZ2lvbjo1ZjAzMmRmMzg3ZmQ0MjcwOWE3NWQyZWM3ZDY1NzU3Y18xMDk5NTExNjMzNjI1_7757f36e-1765-477c-9ac4-fd5bc273bada"
      unitRef="usd">100000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i4afdc1a2dcdf424eabd0653274b690c7_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMDc2L2ZyYWc6NWYwMzJkZjM4N2ZkNDI3MDlhNzVkMmVjN2Q2NTc1N2MvdGV4dHJlZ2lvbjo1ZjAzMmRmMzg3ZmQ0MjcwOWE3NWQyZWM3ZDY1NzU3Y18xMDk5NTExNjMzNjMy_5d273450-c405-446c-829b-c2ef58f66cc6"
      unitRef="usd">150000000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMDc2L2ZyYWc6NWYwMzJkZjM4N2ZkNDI3MDlhNzVkMmVjN2Q2NTc1N2MvdGV4dHJlZ2lvbjo1ZjAzMmRmMzg3ZmQ0MjcwOWE3NWQyZWM3ZDY1NzU3Y18xMDk5NTExNjMzNTEy_2c710b30-fdbd-439d-92d1-0718cace4812"
      unitRef="usd">27700000</us-gaap:SeveranceCosts1>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMDc2L2ZyYWc6NWYwMzJkZjM4N2ZkNDI3MDlhNzVkMmVjN2Q2NTc1N2MvdGV4dHJlZ2lvbjo1ZjAzMmRmMzg3ZmQ0MjcwOWE3NWQyZWM3ZDY1NzU3Y18xMDk5NTExNjMzNTk4_12834c9a-8f35-46a1-964e-850e14779284"
      unitRef="usd">10400000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserve
      contextRef="ic4b04ecc1818447ebb524096be801f20_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMDc2L2ZyYWc6NWYwMzJkZjM4N2ZkNDI3MDlhNzVkMmVjN2Q2NTc1N2MvdGFibGU6NWUzMDEyNDYwNWM2NGFjZjg4M2YzYTUxOGQ1ZDg0M2UvdGFibGVyYW5nZTo1ZTMwMTI0NjA1YzY0YWNmODgzZjNhNTE4ZDVkODQzZV8xLTItMS0xLTkxMzcy_163b9aaf-593d-4b96-802b-420f17dabc39"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges
      contextRef="i929ddd179174497bb90c576f4da728fd_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMDc2L2ZyYWc6NWYwMzJkZjM4N2ZkNDI3MDlhNzVkMmVjN2Q2NTc1N2MvdGFibGU6NWUzMDEyNDYwNWM2NGFjZjg4M2YzYTUxOGQ1ZDg0M2UvdGFibGVyYW5nZTo1ZTMwMTI0NjA1YzY0YWNmODgzZjNhNTE4ZDVkODQzZV8yLTItMS0xLTkxMzcy_5514dae4-7ecc-4239-a5ae-5686ec7fe363"
      unitRef="usd">27700000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring
      contextRef="i929ddd179174497bb90c576f4da728fd_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NjU4ZmJhMmJhZjRlMzc5OWIxMTc1ZjY5ZWFlZDQ2L3NlYzplOTY1OGZiYTJiYWY0ZTM3OTliMTE3NWY2OWVhZWQ0Nl8yMDc2L2ZyYWc6NWYwMzJkZjM4N2ZkNDI3MDlhNzVkMmVjN2Q2NTc1N2MvdGFibGU6NWUzMDEyNDYwNWM2NGFjZjg4M2YzYTUxOGQ1ZDg0M2UvdGFibGVyYW5nZTo1ZTMwMTI0NjA1YzY0YWNmODgzZjNhNTE4ZDVkODQzZV8zLTItMS0xLTkxMzcy_4e784a52-630c-4700-8b5f-dcf2dbbe50a3"
      unitRef="usd">6200000</us-gaap:PaymentsForRestructuring>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>116
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MSJ BR:JIKB9:[&U?NA4:NEP[S.%#A$@C /L[(?3+Q#AH/FU6_P!02P,$%
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M:&5E=#<N>&ULM5I;<YLX%/XK&D]GMIV);23NG20SC9,X>-O&DVQWGPE68J:
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M..S8^I\I<GM977Y4AX -M8)J;O4>5DNG3 FI<OF&?34*Y0VANJXWW NJR=>
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M?7;SY0#V^R,A]'"2O^M2OV9W_C]02P,$%     @ #H*C5&T3@10D#@  'B0
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MDW7&? M;WL&DD*>*R3;=KU,@RZNT='?O:&EDK"#$$RT9QT22I"P.;DOSLN7
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MFD/WE=+3 885VCM8A5S_*/Q]J6",,KNK5?JH5FDV?D@K@.&;6)[81L%P+ER
MT970?5+^UT+-GO]?=:+B>S(E]P[Z80SDXP#>->RM1"'3!;?-*UWRT+_",)1
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M@%&'TV8WR_/TT+U^U/N64E(#HR]&-#IAW B?5;K=[J/45?@6LSL>OFA!-*J
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MTP*\7RADO&I !S3?X2__ U!+ P04    "  .@J-4W"0C$R((  #3%@  &0
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MZK?B*ZP<L7":>&/ZC:?>A'UY%*JF $2BP! :*-$IPY=*"&M[%D3>#"1]SR?
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MQ<<#IMP3JOLP<F6?+>?2&%G980Z#"$4;L+Z0L$S[00RZ=^S+_P!02P,$%
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M:W-H965T<R]S:&5E=#$V+GAM;*U6VV[;.!#]E8&11U=V;-=)"\> TR3; AO
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M,CCRVMHJUK5EUA4MMBK:H*+; )8YXG<:@I".6[_5L\\[UL;DVF9;:.O%OCN
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M"M@>M! 8!0++!(&T!P+[4 O,?3)=2E^#]Y*\<8Q.30GP!L2BU *M+=N#R2O
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MR/,![!<.8T?SP@+:3W27_P!02P,$%     @ #H*C5(,S^#TH!0  J0P  !D
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M)]8E^S_*?,Y?'HC@O<Q3_G4&-E1!+^#S20Y^W!^T0/UMDB_^#5!+ P04
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MI(,'?,!(1O.:>*F]U.!'NO^5H(,JQ7\'Q'LQ?0!..'Z/UF!4 G-CVY?C,VW
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M&X(M^>,2F"A'#^#^W *<Y@LI:']#.?\O4$L#!!0    (  Z"HU0A,^=?K!(
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MDA.(5>V^G&CP?37391JDB2=9D42@V))P3B1U&8CVQ0AZ3H$ LN:Z2L@N($C
MS2^/][&08:3@ I:$(,G&YC:;F[*QEZG)X()(/K3QF00^)3DJ59+1ZGP.D&(>
MBVY26XC+F57'RMT*EFA"3"4#TDFRM?\ CE_89)QU3OW.B.G*)0J--02YDI-C
MJZ\5?896@&G:3*)*L@^76>BJ12B;QEP^,B:QAHT<ES>)GBC-H\PJY_=4X3[2
M]%WL#0X->0]DHP( (AWUQ4I<HXFC\]\N+SY>B[%"M&!>XLA&@810Y1GV <7)
M!_8+5V.FX(]" YE"(7.R XH34U6DTKE,WB>)=:HSQ="R,XR>F2REB5CF$WQ#
M/@&UP3['\#U>X;V:E#6Y\&,7V'O\%GOFN "ZA(+?^N.^.->(NQKJ/H.R*W9S
M]%WS&J*\EM;*9%:3T7LK#VR1Q4 Q"VTRKW^,GRHP1\Z_E4LFEQ9^-R4^#WGA
M,_'S3X.CX]?')W]L3W:8O?"BVI;NQ>!8G/7?]V_[_JOAP5Y_L#=Y>>B\FE(/
MD!:LJFS7KF+FV E";<T+S,IA#A5)!BY"JVF?],0&X"0L@Z,& N!Y<VUM1-,/
MVB3VGO=LV@8QL^'^S4CE-&/;/:R$+C@*X!(L(4F'[F"O"\GA993$H,N9MT8@
MIT8"RG@XUR4,SGP#<D5WMP"=C&%'VV_P]2K@ZY_"E(>4_2%,]1L,%<]@2 P.
M^O(E.)\@ZT'%Y1;0"!":MI36P2V(I;1.=8DI$4%)C^!;5;;7(- V$#282V]U
M\4==<.'C,=9;!1V!ZU0;^!%'!QFB*0OUV,1@]D$N6;-5&^(1/^!_IM,?0=:S
M0+JZOAU]/+\2-\XQ1U[LJH![FU<.Z\.]P8EX#[^O"HTL^%=X:V"PKE"V9L3M
MAWQR*;:[ W:PASRGE"/M1"D"14A5-DI-R'MLUU9>4E@7,46)\6@<L':'=+J&
M%X<&Q =\BW]7F,##\/D&R;H5VS02+!6PS7;]';]F:\>\MY4E>3]^L?.??QH>
M#E]#^UEJRJFX5?>0#Q9W&.=E/BCD946\3,_!V=4"D+D7=,_YE!2)15[G<B(F
M&H$RU\!12%4X^9:YK3$5[*BY]HF"YXUR5I9L28%6_^42ZXNZY)0EI!(61EXY
M/CEW5R4%- :\&PIVO=(_&=2!,(T3<3C8<_NYN!$OZ,&-Z"'_G>O2!Y!K^0B9
M[1_N] DC[@G!AZ>M4/[,<4YL7]Q\WG$ITCIQ2@4IS>JOXHOV*><@1Z[(&P((
MO;#B3B6S @$^<_Z--S7BD9 ZUI',*LV?* @,9LN@^U>-?*B-B9'>.'"N(L6Z
MZ.!(5/)1M6&4IL+X-3=+R'/QXBR/L,C>ZG8V&P/D>:X*U%P/V!<J<DUFR?R<
M-2H6EQK5@$/;1E!%2F? RD+;6:SVY[1^* Y.3EJMT\.S6G=^*RP"C\EI6VY2
MY000.PW4>437L5[6K,@9.Z"0.3.U#I%0'A F^%MR7F&#WX>22%ZT<7+E92/G
M1O=N5B=LWSF(,5'JR*6URPP"I(SS"&U9,!7K<F.L?4:P]3(8>EQDD:%XZ?D)
M391V((8;7)@'E<8C.R+R_F!-$BG'J))2]!5_Y@'^+<'YQ;Z-PS[@L\'0@LCB
M'0]>P<I2!='=(DN")L2G1RCF'XH-?\-1-Z83P!0*AL@1?)?-# =#<71T'/(^
MMA+%IMQJ??_0%\748FD%U'4C*X[ .SA.+GP%Z^V @GUK,RS=*'P!4\]+6*:I
M]K$@7O+_090R"'+=+T06,0A+NC0SH;B=N91O52:A+=15TXK#\ ;=8>:[_7@H
MK/T*3S'SXSE]XZ6]Q\O:'*OM#,H)]/E\JO:?M19W,E_)T8*5H3(2?V)$A1&K
M2?PU8"$AJ%.Y3.M"RP=R9!,UD]DT[(2S][AJY?Z=I3P8F;9U7H+[%_]DIF]!
MUADZ).W*+V"LK?"Y\QJJ@::%X0N"]S*#;9VYU@JJ()>8$]M4('2SGBAG]]X%
MQ/[CU<F@/Q!(OC)6=@;72/-K3NBK4DTR=OK3MHV0@+&L[2#TOI7 NUVSP,@)
MD'*=9@ML#=PM  @'!)=, &586+NPU$:@(%W7F?@3]5?%700?7KZ)S.=K26WG
M-68NJ0W[WC4HSDRQ4"6U.Y!WQWV'V//0+L]5TF31K^*A<!ES#CB5*U/'V"QR
M02L^?CSKK>//-T:Z/8YIS$=/$#%!/7A3DELP!?<S?<PC3?DV&ZEVN+?7WVM4
M2_)SF$M]Z=>8NRGX\,&7DVV/,H$QE2J-.>".0>JE534=S[ZXN+T:CPB)UH9R
M_.E"RF< /V1$W39<M30<7T*/*/CSFNV&'0.I:%3?UWC+*\."N:^5Z'DH^KE-
MX-SQP=Y@^V$'Q<>"W>9-)HO6U;=RZQ3,CUYR+(,^S7&5JG5=&AGW:;IM&NH_
MR$Z?IMNFH0=NIS8-FW^X]KVLZ22 8KLF9(U R=>0SVAO$*9=%4E?;+N'':\!
M6^MJ10T_KNM&\L%E<6O;)6N^L[W0',:NQQ1;-#>BV8JGI<*.$;B2J#>;2\XJ
M$ J0W4F2&8,?E;0; [*%*5Z"[!2[,.4]DL&__'S.-R4+*%ZMD>%:ZV;56=]>
MG7U>=]*Q8U[QO*IUNHV/?;'F7;\\T[W[H;[<LX#YS&@,!Y<?Z&RFX&3C"C["
M!LC8UN=?&G\0UW6&EI-J#3**.[F?J<5/!]J\M5M%SI _7A1P/8]Q&JZ:;,?7
MUB!^57".!$!]4 5+.P[JYXHL/B1HEXCD  @18=6U?MF=!6#W->>,NKNE^%C%
M=[\YJPNI9<\7>OF<3B<HUI6(#)I/>'S4C"C2"9G*N2&.N,]3WWN@W)4D=Y:/
MM<$G2%C69&X0=ML)4>^=1?45P";3CZ:&1#H^-]NPD?C@=,;R2:@&M;HB]/E!
M/KYSS03#DR[M7/V2"DQ5N5KRXNS]U?G%[2@4#P$WD!J"Y3$QP#YY&3 \#_V0
M)]+8F/66^F?V>"]/C7E :FFKAA!@7Y>VIF.04-Z5];VX*0DVI"DPVGA=S^,=
M\FL T%;&>^R1\TR#5R<'/:XH3(&P\E"8I3N"I&I;5LGLY1?YE>!$X[F7< YF
MER1&%Q M-<2\8Z339*0QEZVHR9="TMF#0GJ+5)A[JGRJ4J7T15Y067P#SY7+
M1,%?)<C]7"9QIN>9A,.&.:FT1]U 2AW7QMXL4#8Y:I<*:C#BM_&HYQ?^6,_A
MJ4<5XET%8[]$_L$"IQ'7,LF42>TJQ9ZG=CW^U&4Y6LE-@31@9OT1O2A) !!K
MEYAG8PQ%F+_"PTQG<RFNV8F7JMWA.)./$YD\>!I."N-Z \VTIM"B&E:_,<BO
MVPP2'S(SH3S[WQ<]<6?<(=::#ICRW9<UB0=Z7W21(L3'VFXDQ,C[]R-86*.[
M#?7L^!B;F(RO%2U4]NC\3 .N\^;\8N?O!MN&1A>N/,$WN3Q>KQ\I$>)A7V :
MXG==(BYKZ:']72M_,GS)H.BPT*6V80''S%J]/^AXS#-=)IQW(""4N6\;;: C
M_JC3>W8J30^N:1>UF3-E%KR1J.5QTMM_]:IW.#AP/+Z@3^[KG4ZWCC:;$31!
M9UE2? LE[KSBXN9N3=)"41D$#AKF&EVMZSCTW^Y+!*G4MOMH)OO MVGW\-N9
M;D_X5_V33V/GL% DQYFK$ EY=#8.*9-/G,^IEW'7] Z;!&^-&,</[C5T6F$G
M'DL;;45L\Y<[[DI$2&L:+\V)70.SX*^Y5N1(Y%J'KI6X?7,W.MUA47*9R4D_
M9Y +NKKGI13I\3LAMM+"I57:/G@]GSG'&;6J5FY+<)P\>DWK^F!'_87<F*HG
MD(:2.$?00,9U[48.%C)Q.3#Q ';"30;?V(GZNJ''0_D(74O(0I$1NA@%^5,Q
M=GV.<8T$+0^@]&K=9.W0_W^-1Z>WS9'9K5J8I'NEK2M+A/KQDDZ3O5N](HTT
MAS.C#SVVW$SSOAHMWYAL[MTPT#[O!4 T1[2>QZ@]VW2\;ZF?M=X]O*KPM-[D
MW'1P0U8_$ <GAV(P/&X/!^@A&+Z_!45),/">YI 1W>,+R3\V2(=3?,:U[46V
MP\:'.I*+"%);U#MM#I:A^WWJ@WS['(=1&Y>WK=!0T6;F7B?61UZVJ>^2\X0O
M7U7KDJ:;;VW/WJ??V)#KUK/C[ XA(0X'A\.C_5XCK="YL.V)5BS6;P@E:J&1
MX=C:$LK;SMQ&%F.C&C1F03?:=-&HBR\?YHZ8-\W0W8@.M0;/2-AG+Z?]WUU<
M]\^C#T\A=R52>B1>ROM:]<0G1>&2SI;M!B2?UU6R=L!%6UC%\5 <'1^)5T<1
MANG!8WA#!Q^;//8%)@,[!Q_&G3 R<'/7@R();D:X:V:JE^WHBJH>UT=LZ^9G
MX-UI-W0/CP;-&4%\1(1=><?:[JV]W;+A"+4I5YX^2(TY9+&']F5@==-9WS?!
M0<[.?_3Y; P5/H!X BP7Q3U#.SK::TW/1<5?^QL]VP;A-%T'C@^=#M7J\>22
MK]3YED!S"AGLK2GW:+5F]XUX4;S-C<7P&"KM@?^S*(B#,;=XBSIC.-UT#TA"
MR=\QHL8,$.16:MZH+.V6 E_HEPF1"L<CI!'AR>':)2]71 Y/G,%O=][M".X1
M>AWZ7,AK\'L8;1?LGJ;1!8VU]?7*(1A'%TERZI+F$HHN,HH1WTM_@>KBXAK5
M19.YD'HQ-W8QNG0)8VB@X6NG;'%/^]")X)Z-OZ/4"G53AMI^.\'<J48BRUV,
M4MW7F;L]A&5E="NR+SZ[$_=#OF0UZ'5WU!4E;SD+ON!Z],)R'\_O)CY=<%$O
MNFG=B'N3NXCO. 3?$3AHE/@OQ%X==:6>.%3G8] 06>E$JJ/)E?/1/F&<;\)\
MU"&!I&&N_?:1[Q;'5N O[ON;Q.V=_7"?)FNH1%>476=Y_:+RO9,M7_]/Z,9T
M17>B7<>UH"Y2UMZ+;0^J(#_4ZVKU0/'IF[I-FU$F24W7R[ @P@:0RD7^$K(W
MWNV@:EDXRG7F6Y=0H<GJ$+L[JZBOVH6;\.L#Y\%6;_J&:\5J.E6;;_RV5WD3
MY"M<@_0W_4)C-_HY3$XG)?2C'^M<L?ME3/.V^5W1R/V<IAWN?I1T+2G5MM#*
M%%/W^L>'6Z)T/_1Q#RC!^,<U$U-5)N>/<*"H$&@ OI^BD@@/M$#S:ZMW_PM0
M2P,$%     @ #H*C5#W[$<V[ @  M 4  !D   !X;"]W;W)K<VAE971S+W-H
M965T,C8N>&ULI9113]LP$,>_RLE/0ZJ:DI:-H;82*9W&0P>CP!ZF/;C));%(
M['!V"'S[G9,TZZ3!)NW%\=F^W_W/\=V\,?1@<T0'SV6A[4+DSE5G06#C'$MI
MQZ9"S3NIH5(Z-BD+;$4HD]:I+()P,GD?E%)IL9RW:]>TG)O:%4KC-8&MRU+2
M2X2%:1;B6.P7;E26.[\0+.>5S'"+[JZZ)K:"@9*H$K551@-ANA#GQV?1S)]O
M#]PK;.S!''PF.V,>O'&9+,3$"\("8^<)DC]/N,*B\""6\=@SQ1#2.Q[.]_1/
M;>Z<RTY:7)GBFTI<OA"G A),95VX&]-\QCZ?$\^+36';$9KN;/A10%Q;9\K>
MF1642G=?^=S?PX'#Z>05A[!W"%O=7:!6Y85T<CDGTP#YTTSSDS;5UIO%*>U_
MRM81[RKV<\MMO;/X6*-VL'[BT<X#QUB_&<0](NH0X2N(*6R,=KF%M4XP^=T_
M8#F#IG"O*0K?!&XDC6%Z/()P$H9O\*9#CM.6-_W7'.'[^<XZXA?QXPW\;,#/
M6OSL?Z[P+XB[:+O^>K?^<@OK>QZW5QHV\@6FW1V,(%(F0PV7.A[#.Y<CB)4I
M*ZE?Q!%(K4VM8TS Y=*!<I#+!':8U?SHP:*D. <N7S8T5\DJ5YC"^AGCVA<$
M7*6IBI'@G5BMK\31&&X9W].99$%FA QOE,L9;OE5$OED^?@(-HK;1 'WK("[
M@[&C3@0C&E44$//+4+I&<(:5$(=C(#M"4I/2&?A4E'9(JH2*1Y.,8<-_?^!U
M&$+?7X"KV#M$1E(")H4+15S<AJPW^BNJ.6#AXUN'E87$-!I2,B7DJHM<&:M\
M0QC_Z=<'!Y54(F5MO^"468[KBFI8'5K2>5>)OXYW_8Q?<::TA0)3=IV,/YP(
MH*Y'=(8S55N7.^.XRMMISFT5R1_@_=08MS=\@*%1+W\"4$L#!!0    (  Z"
MHU2VRP(8#PX  /LD   9    >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;-U:
M:V_;.!;]*T2 Q:2 ZSPZ[72G#\!)W-:8.,G:36<ZB_U 2[3%5B)5DDKB_OHY
M]U(OM[8Q!>;3 D5C2^+E?9Y[+N67]]9]]IE203P4N?&O#K(0RE^/CGR2J4+Z
MH2V5P9VE=84,^.I61[YT2J:\J,B/3H^/GQT54IN#UR_YVHU[_=)6(==&W3CA
MJZ*0;GVF<GO_ZN#DH+DPTZLLT(6CUR]+N5)S%6[+&X=O1ZV45!?*>&V-<&KY
MZF!T\NO9<WJ>'_B@U;WO?19DR<+:S_1EDKXZ.":%5*Z20!(D_MRI<Y7G) AJ
M?*EE'K1;TL+^YT;Z&[8=MBRD5^<V_UVG(7MU\/Q I&HIJSS,[/T[5=OSE.0E
M-O?\O[BOGST^$$GE@RWJQ="@T";^E0^U'_[.@M-ZP2GK'3=B+2]DD*]?.GLO
M'#T-:?2!3>754$X;"LH\.-S56!=>SV,PA%V*N5X9O=2)-$&,DL16)FBS$C<V
MUXE67OS HX?-IT<OCP*TI+V.DEJCLZC1Z0Z-GHBI-2'S8FQ2E6ZN/X)UK8FG
MC8EGIWL%3J4;BB<G W%Z?'JZ1]Z3UF5/6-Z3'?*V&?S?T<('AQ3[WYX-?FXW
M^)DW^'G'!M=WRMTA_;;Y;O_*,VU7R@CMA12KW"YD+A;:EIE$_B:J"HA8+A);
ME-*LQ=(BOU0J4!NI]HG%KK!I@)R^0ZV69)\T*;[F.MZB LM3Y*<2VAA[)ZF@
M1,B4DR4Y 1 A2F7+7 DLX04Z9,)CL:V\,*IR-K<K5H(D\X5406-(8%G00Z'$
MH+X7]ZA4^NM4+@/4C/NP$4*FGV"/(=</Q>]*9!*+I<B!2K1M:5U8(C26<K50
M*6)D(#18$0!<010H64UJ^B17SGKXZW Z?S2(<K0)4*M*XIYBJ9T/0I:E@X?2
M* &H%-A<#S?!FJ+R295+)R26EME:',ZGHT=LI'1*T%+-FO4$&O)\OMXF&8K*
M-'7*4QP!,=JP53)DY#^NP%'^-5- 1_>3;[S&GI"YMQ1AW$FTS/5711G@=:&A
MGJ>5,KV3AHS#=8Z&9UTX&R@7XGW:T%:(IRX591F\$N/EX70LYS6^5/4FJ=!%
M41E6;R@NI0_Y>H 0LOF]1)-) D"F:-?RU1)N#)[$IWJE YR9*9DC;> $7Y44
M2GZPLXFW;O6"\U9.%LB73.>-_>1)WH'75T:'-C]M@(=)2K-=+Z]B,O5W35VU
M:JMC7=<#EP<'JM$^9,Y6JXS#2XKJ&$=XV_>0$@&%S"1F8BMT0->5=$GVG?C6
M-KJQJ#QEL=]X8L/ H;B&RL#HSXH*IN0L9M\F>86B?3\^?S.Y&,]& _'A=CJ>
M3=Y_'(C1A^NK\1\#<7,Y?CN;7.#*^X_ST=ELPIN^&4UO/LY&[#HRKLM1V#:=
MOQ#SF\G5;/3GCB=0!2_$Z.+VW?ARNOV)+7G\(NY\.QU!UQW+/'Q A97++Q7^
M>.NT1!EW8) H%T!).J]QCJ-8#:>0HV;M(S[!_<ACKCJXY/:/T=7V/8TUC]_9
M=/59&RB;KXLRLX4<B 3!-P"E>"59$T#EJOJL"BW%X?GE900"2XF&[#"I)C[B
M7[2[O?MX/K[<X<'MF[) 2'XAWH[^_/AAQUH\4)=VCC;%^-0(>"&NSV?C#[?S
M[2M+I[G5<P+">X3-TSG:^@U@DF42*I>>:HRNSW#Y1<_*KLJ0]_KQ^<7I<=<G
M!G5"TN+"^LJH4'VM"KD8B+)ROI(1 6/1Y[E<6,(+ @_GI%DI4K(.W5NT#A-4
MD@W$Q"1#<=A> )A+0 +6KQ_;>X-R*%2Q@&JPCLR=6=!;\19E6PX%^!T!+L<%
M.FL3R2[M2?]^3!'T%22Q((8LKN '<?)\(,Z[]7<1.Z_943-J;I0-F2[AF-IL
M">=0!2-9/-I8ROVO2UX?<"%N7I=V2OA)*T?&5'ABIB*"&3*M$"?'CW]K [T&
MU@A%W$I<J"0ZI69')^*0_V\7/8J0TNOV$1!["$2V]/N-[,AV1%WJ $0Y<E:9
M^LZ:5>W:4E>D(4-W5@^@)ZGG7N$9*[L6'E./FK.OP1:M=%&Y%*R'#(R](Z$]
M_=K#2X"$]S4X?Q]'#MT< %LA%<&=5 DF<&Z' W$94F33-[<>44.+\!K;'S&4
ML_'5^&9T.4&^&:&"!)=)5!GZYF'. %C%GCJ^.IN-+Y&NT]GH\B*NDBD<5U %
M[%KU[G8Z(=AF8+R<_#$ZBRN1J;E^T'M6SL;3R3F E(JN!47FKXZ"@R]C-/52
M]6@4=5"ODLK5!$@](,<8 FK4#-\RC+./U]<?)G]2R:$P]$)_W6?,Y>WY^.K]
M9#Z@EHVN=P^2UY(@*$1[W@[GB )]BNK!UEM#(3L<#V^'$8+X.<.%\AODIK80
MA[?#WW WK5Q#MD*F72J^5-*%6/R4X/]$Q7^3&]OJ_MG?K?L],\/3=F9XNI_Y
M4_N+T TV80)+WS9 [!<SB>XG]L^^ 'V61D;#![5? !W&_P@Z(:5RHNR89OGZ
M@)=J'RD:]3CX'CV9<HX#A\IW@#$\:!1A +4BJFXIEE*[;@=:3#IMW9P6@,IC
M^"@PE6 $23G=(=NZE!APC*/LICET/4A!'+V(,TE.]#RA<NYE9LRX.6WD*>'F
M0S3AT<TC AJUD4E]<$8>^B8-(=5]!]#_$3ZS50YXK'.(Z]1\JDS28=6/-8>F
M2,A$'OG(2&.#^KYO;,)^1/V^9YHYEX U53YQ>M&YY(I% A7.^RJ]:56:]S-B
MRW:L:%7RL@&-?&W4!ZWKHL.BCZF#/5;<=[;F(L9>CF\\U<(UV50%><JZ. '7
M-0G*45H:.0F&4N0)H=#2 4SZSM[FWP$:#\1;K(53-Y*=R'T.:H-=H?F72KO8
M]]ILB8;@-B91+EM@7(0:WS&RS"GTFW@8$AOVE,>$YBQCP.&@O1N'::26!L%,
MHFTUUZEE(X[-ALT6RPK*,B' !:XPLZXIG*\6'II3E6U6$7>**%)1L*SI[^#5
M*F+%_\GIPAYH?M9"\[.]F-I5Q0Y(WK_\^@=!%ZV6CCQW B.U521\@YT;')F"
MKE,MF1M$^*@?;:C#'>[)1:YB4BBP+R+Z3/3N,QK)ZIF?LJN9(A8( 49@B%W'
MSKMAQ/?KH0OE(XD!%[1D-L EKPFB 68<#X__U62W@C1;8'CG\P8T$< [@L\%
M:0LE#E&(H&XR@/&@8%EYB,-@A87!T6R$7&K,X9[#C27(AP:N=KB_YW0\7V^'
MFJ%#!1L]0&00S7BEOM66#"2?.V( G3.=(B]':/45:KWU#M C1,B@8972^1L+
M@&CQ$&!"PII#OAH+ZVB"Q'B91)AA]X)W(D7J]I;T$Y7DH#HAJHC'3P@/ \/^
M /,)TZXLJ8^$RI+Z*G7#7(>:&1'_DTD6)X!FVY@4S:[,3A= )W%X\BCN;^]Q
MBP]3'$_P/0=S\^Z?OO1&DB86K!-[YO T2K2+7*]B]Z9#N(6W;B$H@7C50-2X
MR428GL"VBO2/'B!D1><8]*6S00EW]G8JSLEE&\IQOLC&30RQ%%MM*F ;>8LT
M\/](# CUDHS8+/=L]5 3,=>GI-P/JE#1)OVD*>2Z;B*4,(#=7LX0F7.(W3>7
MJ#TXM#'70DY'K:WCG2AUJ13VH>TO+=K^LA<N;R->P5[X!;QD&^#NE_">O:HB
M0X@D^$>);]WS/7F(YE?Y674:#<2G*EUU% VQK8HR^I>3@)PLE\LFHR/UP5:R
M(#X6#W&1#X15.4*L<\[J 4$/UYA#BS55'#< H*1T>V9#<CIVPLC.>;;B69ZE
M\K,]P6"#AH9-:U:6(KK@40,IJ.YD7A$+X(/<OV$>YS6]0]M<01P!' _9P,V;
M5';=(;.-38=Z?&0FW_GKGNHOU^HN5@78L\=4A]0?-)#9L*PX<!)#YSO1$B(6
MB!"9UM-\8:OH_@2S'S-GLE;M\GYT-@>@X]T<+UJP)2)#,4I"Q6-/5(^BGFJ$
MW47Z"0F^ES61,>;*K&@. (#I(LIC#J<>0OWB()I(VY]C)K]X?/)O0<<IBGI.
MA$G "8]&[3>-5D'GQ'PJ4Q_%#':0T\UCU/8TLW^FYV7.V1CMC,?;[JYV$<#/
MWG-'BL&APW:H $#2$()ALUI"ERIRQ02ER2F!ULWCX,Z3<CH'JF-0E+E=*_6X
MR7:^1;P3ZJ2<:S6P]=;7B439DP':H1#&KLAX!D2*/M7GPQ$WV_<Z%"XZ6.5[
M@ P0[]#W!!UL-'!)<ZZZWY@/VV(':K@5(SXVY6;;QJZ;X>J$!Y28> )CF)!1
M1^*76MV2CMUN,(X89G) ;N%4\N:*CS] >61]$$+;<;]HK\1WT !GOA=/OY",
MH_;PA%[T<.NLX6$%CFZI*#AP\?5]CV=;,:N\U_(G&@;OI*\1]O:S(^(S: UN
M%GAIDB[UZN-EA7VYZF 3\<,X";6O?8C&!AD/H-M AG4SK]9O1J-CUK&PZ@+B
MO*HZX(]GC'3*1I'=U"4&ED^QXYD@<-559<>NVE2J4X,@J3MG*V2J^A@8-VN"
MM-Q1PHU[MGJ[T90GH_W<==^!@5.<E: H/9X0)X%.7]W647VXLJ]Y/V^;]_.]
MK?<*%;)Q((,(40!9O6V=?+^X-XRC!)1D /X.N 9W[L!1TV@O<5HG/W>G&+W7
M_G,D5RH=T.3,X@]S^3@TUS<PE09^<F%3K;HV)5-;!AZ:8WSY!>I2TQ3$_9ZG
M5+B7LR2U/-LWK8UE,!20D#H_B7\:QO"HM6\UXQS+)"M'T:Q?D5/P"$Q[:/"C
M64(DKSO?V!KVH]X/4AC;Z&<W/IX[Q]^FM%?;7_:,X@]:NL?CSX*FTJTT"BI7
M2RP]'O[R]"#2[^9+L"7_O 63 8"*/V8*M>7H =Q?6M#N^@MMT/[>Z?5?4$L#
M!!0    (  Z"HU2M"=7?T0(  !\&   9    >&PO=V]R:W-H965T<R]S:&5E
M=#(X+GAM;(U5VV[:0!#]E9%;58D483#D(@I(D*1J'J(BH,U#U8?%'O JZUVZ
M.PZA7]_9M7%)E:"\[,TS9V;.7#S8&OOH<D2"YT)I-XQRHDT_CEV:8R%<RVQ0
M\Y>5L84@OMIU[#8611:4"A4G[?9%7 BIH]$@O$WM:&!*4E+CU((KBT+8W025
MV0ZC3K1_F,EU3OXA'@TV8HUSI.^;J>5;W*!DLD#MI-%@<36,QIW^I.?E@\ /
MB5MW< 8?R=*81W^YRX91VSN$"E/R"(*W)[Q&I3P0N_&[QHP:DU[Q\+Q'_Q)B
MYUB6PN&U40\RHWP87460X4J4BF9F^Q7K>,X]7FJ4"RML:]EV!&GIR!2U,GM0
M2%WMXKGFX3T*2:V0!+\K0\'+&T%B-+!F"]9+,YH_A%"#-CLGM4_*G"Q_E:Q'
MHQDZLF5*I95Z?0:3TK& <["P0KLJYX$\G<$WRM'"M7$$<_'$XG"G)4GA:75P
MLA!+A>YT$!.[Y<'CM'9A4KF0O.%"%^Z-IMS!K<XP>ZD?<SA-3,D^IDER%/!>
MV!9T.V>0M)/D"%ZWX:@;\+KOX2A0,4,E"#,8^YIB#CC^G^,E2W&1_3IBL==8
M[ 6+O3<LSKGWLE(AF!6\M,XWM$\(RQTL=IL@X#/R&NM'3?AF[[N-2'$8<3<'
MT&BTR!%61G&G>EOD,UJWJ_S#,7(!0)H+N^:SI\'Q:,B\I*WY( .FM(%W2'VA
MN*I0Y$&A<%$%(,HM(A15ZM&G'CAQ:=YDK@\G=YIK7BFN0'<*#]S>K)PBDY"5
M55,O# GU'T5U-""<9^<&4RR67+@U; <^PJ</5TDG^7QPNGWF4!Q"<MFZK):I
MV/'L(3BY:"6G]7K,SDO?&3KIM,[WVVLE$1\T;8',J1]-CFDK-57]V[PVTV]<
M-?T_\6ITLNVUU X4KEBUW;H\C\!6XZBZD-F$$; TQ ,E''.>X&B] ']?&4/[
MBS?0_!-&?P%02P,$%     @ #H*C5,5'H[,%"   M!,  !D   !X;"]W;W)K
M<VAE971S+W-H965T,CDN>&ULI5AK4^/(%?TK7<Y48JH\LAZ6'RQ0)<#L.(49
MR@8R;"H?VE+;5E96:[M;,.ROS[DM6=@SX)#*![>D5M_WN0_KY%FJW_5:",.^
M;[)<G[;6QA3'W:Z.UV+#M2,+D>/-4JH--WA4JZXNE."))=ID7=]U^]T-3_/6
MV8G=NU5G)[(T69J+6\5TN=EP]7(N,OE\VO):VXU9NEH;VNB>G11\)>;"W!>W
M"D_=ADN2;D2N4YDS)9:GK<@[/A_2>7O@(17/>N>>D24+*7^GATERVG))(9&)
MV! 'CLN3N!!91HR@QA\USU8CD@AW[[?<KZSML&7!M;B0V3_2Q*Q/6\,62\22
MEYF9R><OHK8G)'ZQS+1=V7-U-@Q;+"ZUD9N:&!ILTKRZ\N^U'W8(ANX[!'Y-
MX%N]*T%6RTMN^-F)DL],T6EPHQMKJJ6&<FE.09D;A;<IZ,S93#R)O!2:M>_X
M(A/ZZ*1KP)9>=N.:Q7G%PG^'1<"F,C=KS<9Y(I)]^B[4:73RMSJ=^P<93KER
M6.!UF._Z_@%^06-C8/D%AVUD2R4W[ *Z*F !?C9K=F$]+!3[9[30=O]?!P3V
M&H$]*[#WWYRZ>&&%DDD9F[?<^B$F.SQ8JNOD2?\4">.:+66&K-+'# AE9BW8
MW5H)L1</!F_&Z\:=M'BL/<D!IBQ#7N@C=I^G!@=G0ALFE^Q.&IZ]O3D%UM,B
M$VP>9T))#87:T_D1Y)?0BAO!VMX1^\3\GN\$=!V%3A_7,!@X(WH.^HZ+:^#U
M[7,8^KA.<B/4$OQRUO:/F#<D8L\?8 W<$1CX/<\9,B\<.@/6<UTG9'>/\^A\
M-F'^L(<G8ANPT'=QRA\$N/<#%X)"E^ZOHNGMXRQB?_W+T/?\7YC?=_QJV=GI
M5\N\7!BR])A-YVP X1[K#T.GQ[Q.,")1@]##WB#P0>YU>D,2,"_2W#I'QV7&
M%8N,DL7ZY9C-;R<WL^BWB'G]H#;&9[V!#SY>CXP)!F08*1ZR*/MS+5#OU-\T
M2U(M4&J.671Y_V5\/67MX(CY.-IHO'/_X_4\16 07:X C//QS?@VNIXT;SVO
M!\'5VNSY'NW9=3*=1=>7K^?# >RUR\[.J%JNKB??HO/7LSY99I=F)Z0=6EX]
MNZ/?JP9P;E"O#:T;0FJU?@6X%6!V/XTNQ[/ICA]\^]OU"_TJN&[S1M6I](D-
M!R%.?T+HO!$%$I#LN/V^!>MP- (EO0L\KX)KQ_?()P3J!N%I'F=E@N2^&U]<
M3:!-Q'B>L(?[Z7@VN7MTFCNV$#'?"!;+#:(:ISS+7AA_XK <E19\;,:.G7N'
M):5*\Y5]7LI2H3#]47*%K*#4HXQU;&;L)$JC1?3P]6;\S:IP>SW^=3:YA H$
M%Z3XW\M<5 E/G.^=N8-"(1-[^%*5*Q8E:"DI%3[;(MM7E]$16RF>4^KS.$;S
M))MQ7\"73W I]*DQV6'/ZQ25Y4-66MD[5FH12RCQDY54QWB2I*0.I*5Y-7;@
MJ<-0=Y 3C$8/=B,1":_?03G/($B2 4_"&F:A@KJ563*]3@O-/K-QJGF*TTZ'
M79O$P<XVM78XP 71"@440X?I,"-)54VFH9#F&F[ G999FEB?+)'U.1G,M,$&
M$6GG0/<(F^X1'BS\$2Q_H=(*K\1KGJ\$Q5)!$_4D]%N-Y" _&NN.=<%C<=HJ
M:BXM"(&S7N503&I9Z:LL@%%1+8IE"=NL=SDU')B-E^]WH_WV<MDPV/;>$CZ;
M"5.J7->9>LXS8MIAER(6FP4"6#<L2E$/W6. ZR <V6X2#&T3&04A\O:B5 J>
MIUQ_2FE4U%"?8D](DTSSC%3-,4M5YUX$*K37'X%%'_Q"UL/=,*"B%27_QCA@
MX[C'HU I_$"$:'>!,SIB[9[K(!_;H*('=(XC=LM?+&DW5@( _H@:;<_U*C[H
M V#1=BV_@%K81QGN*8<.2=H%J.[$J%^S&]%NX^(?!@+X%]W:^G?DVP)HG0'_
M]LG/!P#=;P#=/PCH*L0-J.K2E5AW[";4HM*0V6GV3: ?E/,VT.^ ;+.O ++]
M26S+%U=B3R.4W_<2?E^_CB7]4 9$-L=^\'NU^3/>9X)Z%M4BO$8-KE)'X5SZ
M9$LJ)40U/GE!@&YV(3>%S E4%8$JH8SX7I %-F>EK8C#@!K>T/6Q;B-BV^)G
MBRO0- [:QGZ;8P<P,&@P,/C82&R'<#28]//%I>]2X5&\$*5)8TIA])[-FY$_
MR/WMR.^-_8<E_E#+ZJ9EK+L7],?5:2;LHE2%U**NFBG%7)H<[0B HN:$]DSY
MB0'@_EMT8_V_O?_R>#&^CH"IS/XG?1+4*?7VM?.Q(7X?6:\C/::JE<CM'#3X
M!=:L"9W0$?[X;/AW,G5)162W(5-YWU7TU^BWQX?(5H2@&I,&/1J^+F;CA_OY
M#I;4_^!:/[3S-DK2:!]W'Z)&-<)8UK-5?W2X' T;* X/0O'KK@EO@NT@_=M@
MVV/Z__Y1>R_&>XB.?YI\MK'9F7R.&QHTB!Q"2HA2ML@9$:_S-$8\$AS)9$'-
MAO'7^6?#\W))W=I.;61G2FV_.5$-!$J^\,R\-*:C;BV: 7\[@>OJW_8<$2W!
M"U@514K!K:H,>FH]MFVY$>=8(M/LR%WSAC'U:\_%($"PJJA>3_8&:%U# F\%
MM7VX?F(8]3U;UMZI:MV=+RD89U?V>Y%FM@A7'U6:W>:35%1]B7D]7GW/0CA7
M*::13"Q!ZCH#3&FJ^D94/1A9V.\R"VF,W-C;-69;H>@ WE-AV3Z0@.9#W=E_
M %!+ P04    "  .@J-4"HZ6J7\"  !)!0  &0   'AL+W=O<FMS:&5E=',O
M<VAE970S,"YX;6R%5-]/VS 0_E=.$0\@H?P.E*JMU,+0>$"J@(V':0]N<FTL
M'#NS70+[ZW=VVJR3H'N)?>>[[_O.N?.D4_K%U(@6WAHAS32HK6W'463*&AMF
M0M6BI).UT@VS9.I-9%J-K/))C8C2.+Z(&L9E,)MXWU+/)FIK!9>XU&"V3</T
M^P*%ZJ9!$NP=#WQ36^>(9I.6;? 1[;=VJ<F*!I2*-R@-5Q(TKJ?!/!DO<A?O
M [YS[,S!'EPE*Z5>G'%738/8"4*!I74(C)97O$8A'!#)^+7## 9*EWBXWZ/?
M^MJIEA4S>*W$,Z]L/0U& 52X9EMA'U3W%7?U% ZO5,+X+W1];)8&4&Z-5<TN
MF10T7/8K>]O=PT'"*/XD(=TEI%YW3^15WC#+9A.M.M NFM#<QI?JLTD<E^ZG
M/%I-IYSR[.Q.OJ*T2K_#Z1-;"31GD\@2KCN-RAW&HL=(/\'(X%Y)6QOX(BNL
M_LV/2,\@*MV+6J1' >^9#B%+SB&-T_0(7C84F7F\[+]%WG!3"F6V&N''?&6L
MIJ[X>80A'QARSY!_PG"MFE9)(C&@UL#W?!_=Y5$@-X-CT[(2IP$-F4']BL'L
MJ48H/V8 1J7T$\5_8P7,P%H)&C4SAM,[22TC!'6_.8.Y3Z2K+>OA;G?.&RRQ
M6:'>^Q-X8!UUF47-F3!P EF1AX5;\ZOP IYIT$@"M%J5: Q<% 5Y1TD>QG#+
M):=VK&"C5&4(K0@S2$:7X14\*<O$@?032,[3I ASO\N*A"@^^A?107LWJ#=^
MB W=R%;:OM,'[_!.S/OQ^!O>/S)4_H9+ P+7E!J'ET4 NA_<WK"J]<.R4I9&
MSV]K>NM0NP Z7RME]X8C&%[/V1]02P,$%     @ #H*C5-['5>$5!   ( H
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MV(E=NCQH^O&'V.?^3\T_];6U\2@8A,UH[2Z/.+37]&['M;6A!RSH>YR,Q?Y
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MZ_K30/U@U=*]CD^5Q<N]:Z92S*2F"1B?*V77#Z2@^3YS_B]02P,$%     @
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MY1UJ0XW$U#9/P):5523,##>5MM,WDA2 )E?H;*98XC(W<"-XN0]W52F%9?(
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M[G[Z1\KL5*R=_V!JMU+K'JUA5TT5(N=D#DLF!&[M<[M@;/_;R%Z51.^SG2V
MO9I6V&UT]\M=5G*71^4F]!6'O=DG=_F7W$6G$>Z7:P9O<RSXC,D@D@,.EWSU
M QTV&^UW>?BUT9J!6KH;1Y-8YL(4,Z7:K6ZU:S?+W^V/[&WG1O8;37%5XL3
M@Z )AP52!HTN=ET5MT^Q,'+E!OA<&KP.W&.*-S8H&X#O%U*:[<(*5/\!AG\
M4$L#!!0    (  Z"HU3FZOQI*P@  "H[   9    >&PO=V]R:W-H965T<R]S
M:&5E=#0T+GAM;+6;VV[CMA:&7T4P>M$"K<TSI2()X$P2-$!<!,[.[F%C7VAB
M)A%J6ZFD3%J@#U])EK4HDZ($:'@S\6%QB?S%^<R?6CS[2+,_\E>EBN"OW7:?
MG\]>B^+MQ\4B?WI5NSB?IV]J7W[SG&:[N"C?9B^+_"U3\:9NM-LN"$)BL8N3
M_>SBK/[L/KLX2]^+;;)7]UF0O^]V<?;WI=JF'^<S/#M^L$Y>7HOJ@\7%V5O\
MHAY4\?AVGY7O%FV63;)3^SQ)]T&FGL]G2_SC)TSJ%G7(?Q/UD6NO@VHLG]/T
MC^K-[>9\AJHNJ:UZ*JH<<?GGB_JDMMLJ5=F1/YNLL_:B54/]]3'[33WZ<C2?
MXUQ]2K>_))OB]7P6SH*->H[?M\4Z_?A)-2/B5;ZG=)O7_P8?AUC!9\'3>UZD
MNZ9QV8-=LC_\C?]JE- :X+X&I&E 3ANPG@:T:4#K@1YZ5@_K*B[BB[,L_0BR
M*KK,5KVHM:E;EZ-)]M5]?"BR\MND;%=<K-47M7]7>?!#T+[\_'?PEJ6;]Z<B
M^/9*%7&RS;\KOW]\N J^_>:[X)L@V0>K9+LM;T-^MBC*7E2Y%D_-%2\/5R0]
M5Z3!*MT7KWEPO=^H3;?]HNQ].P1R',(E<29<Q=D\H/C[@"!"+/WY-+XY=G2'
MMHK2.A_MR7>5Y/'+2Z9>XGJ>IL]'88/_W96AP6VA=OG_'1=B[858?2'6<Z'[
MYAYES7VSW8I#!E%GJ/Y+?[D@G.)Y>+;XHBMT")-ZF(A8&]3I'F^[QYW=NWDO
MP1 7RC%2T:82?B65[87D9$D/&4)-*T[E/#I1U!+%B1;5Z5[8=B\<)6GP3_ X
M?Y@[!ARU&2._RF($H$&3M6U2Z+(11N;T1-PFC.MA5-BUQ1H)\5AUURHO*C%^
M2;.M"U&80'+B66C@#Z;3A::FT!&?BU.AS3"*1=\TQD N[$;7[;Y0V;/*TKUK
MQ$ :S#V+"R3"8KJXPE0-1::X9AA#:,Y[Q 6&83?$0-QA3F! #PX]:PQ,PM%T
MC2-#/!Q:2&&&$:;__G57'  SXH991^.QM"" (H+]BDT 3(1,%KM)T1&;2$-L
M6Q@/Y[)';  :<0/M/[\]+"_7MZ[A GD(\ZPL4(FX%T"CE.7F.H$@8WUF"T-4
MNP'=+@+-B)MFC;+#G"! 'R(]"PQ((N[ET"B!0Q, (=,@VPAL"9/] @/*B!ME
M(/!82%!@$$5^E:; (^I>&HU1NDG1D9 * Q)-6'?MANPZ4Z 8=5/L9KFZ_VV]
M= U6\V^>#1P%&M'I%JY)T=%5S,FIK-:HGC4Q!8;1 1-WT'48$!280SV;.0HL
MHM/M7)-"GX_H5%M72+=KP"XZ8.5:84># :!#/9LZ!@QBTTT=LY@Z<P+;HWHF
M, -R,3>Y5@_!L8]K:Q^[>0$XS+.?8\ C-MW/,=.H81J9OW.V.!;V_M Q;2_*
M33*+SL/08, AYMGA,> 3F^[PF&G=9.GP\*G:EC".M;!N%X%KS,TUN]AC0<(
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M* O _:V4YFUB^\3PMY#_!5!+ P04    "  .@J-4%"'VOQ(#   Z"0  &0
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M4QT]M71SZ YYE,1NDGF'<4,F4/&-FPZH#][BP5M\UMN+/F)FD(W@!<A)=YW
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M8:B3' JJKV0) G>V4A74X%1EH2X5T-2!"AY&O=XH+"@3P7SJUA[4?"HKPYF
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MY<N5#'4#*0#Z\X<T5;_?%,_R[[\=<O4_4$L#!!0    (  Z"HU2/3EY;+ ,
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MK;(T+7Y9TWN&VCG0^4XI>]BX .,+F?\&4$L#!!0    (  Z"HU1B.;@Z[@0
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M^@<A]87(C]5O*NYR(?)#]7+/XBWC)4!^?I_GXO=%^3.-]F<YJ_\!4$L#!!0
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MZN($7 >H]QEC\J.ACV9S%9O\ 5!+ P04    "  .@J-46=Y1T8H"  !A!@
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M)I^>X\N4,/X)ZSJV1\%99:PJ-V!R4')9O]GKI@X[ .(Y#(@V@&@?T#T"B#>
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M]K7-!>HYS9;H*N1J'R2C_'G#H@>6_L4IQT1'9445)O'B,&=IM*/7H![QOF/
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MRB]YLBK>[GE(\CR)BH]+1OE<% +\]WF2Y-LOX@:[U^A._@]02P,$%     @
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M3Y7<(V6M <V^5,6LO"%])NRZ;XR"KPS\S'RM8 LI\^T"K3D1!A&1HK=?2U;
MVAKT>D4-85R_02\1$^B&<0Z+I:>N@= 6P$V:,(LZC'\F3(!NI# [C=Z*E*:'
M_BY0;GG[C[P7_B#@#5$C%. +Y'N^?[M9H=<OWV3FU0L<Q7^<H+?\<33<H)U
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M5=T+U@,C=ZX[6DI#O99[W%+_C,HNH/=K225L!G:#MB.?_@502P,$%     @
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M4_RDH,H:X/NUE&8_L0ZJCY3Q/U!+ P04    "  .@J-43-SS&' &   ')P
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M*J?RKL=AY<!5Z0#J< "#&Y[*O0 _I1NV:;<?JV#JB-!#1%?(V>$-S3R X6N
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M-$9&63, [H-*!?#[6DKSW$DG*-^'YE\!4$L#!!0    (  Z"HU0D<J/-F@,
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MG-/[I.LQ6&^L6OK!\*@LC1F_7-"7 VKG0,_G2MFWC4O0?HN,_P)02P,$%
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MVGM^Y9[?9&=<)4UVY(9[USF/%0EAAI1.LX?3(K-3K.Q&BV5ZB#(56HLHO5P
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M4^]A_#R4X=;SM<;K?R?5X^7<<KO\=?FU<W)?KCC7]Q7#\U]02P,$%     @
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M2P$"% ,4    "  .@J-4!T%-8H$   "Q    $               @ $
M9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (  Z"HU0RO;_.[@   "L"   1
M              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (
M  Z"HU297)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T
M:&5M93$N>&UL4$L! A0#%     @ #H*C5'OGB48G!0  3Q4  !@
M     ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (
M  Z"HU2IU+#"- 8  -,7   8              " @6H-  !X;"]W;W)K<VAE
M971S+W-H965T,BYX;6Q02P$"% ,4    "  .@J-4?>QYL-<#  #F#   &
M            @('4$P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#
M%     @ #H*C5&CP@ +Z!@  _QP  !@              ("!X1<  'AL+W=O
M<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    (  Z"HU2^ X.^30(  &L%
M   8              " @1$?  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q0
M2P$"% ,4    "  .@J-4IVP.-+('   -'P  &               @(&4(0
M>&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ #H*C5&U%$NYM
M!P  <B<  !@              ("!?"D  'AL+W=O<FMS:&5E=',O<VAE970W
M+GAM;%!+ 0(4 Q0    (  Z"HU1M$X$4) X  !XD   8              "
M@1\Q  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    "  .@J-4
M_PB#1YX%   A#0  &               @(%Y/P  >&PO=V]R:W-H965T<R]S
M:&5E=#DN>&UL4$L! A0#%     @ #H*C5!/K=6QI"   M1,  !D
M     ("!344  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  Z"HU1 =.ML&0L  .4B   9              "
M@7QM  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ #H*C
M5':I*5-O!   .PH  !D              ("!S'@  'AL+W=O<FMS:&5E=',O
M<VAE970Q-BYX;6Q02P$"% ,4    "  .@J-4D@R3Q6($  "@"P  &0
M        @(%R?0  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0
M   (  Z"HU07CD>$D04  /</   9              " @0N"  !X;"]W;W)K
M<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ #H*C5%&8C2<K P  _08
M !D              ("!TX<  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q0
M2P$"% ,4    "  .@J-4^6$(M@8$   ="@  &0              @($UBP
M>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    (  Z"HU0%<SZ;
M&P@  *X3   9              " @7*/  !X;"]W;W)K<VAE971S+W-H965T
M,C$N>&UL4$L! A0#%     @ #H*C5(,S^#TH!0  J0P  !D
M ("!Q)<  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    "  .
M@J-4L-B[Q5(7  !94@  &0              @($CG0  >&PO=V]R:W-H965T
M<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    (  Z"HU1?SH^MLP@  $\9   9
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M970R."YX;6Q02P$"% ,4    "  .@J-4Q4>CLP4(  "T$P  &0
M    @(&YY   >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    (
M  Z"HU0*CI:I?P(  $D%   9              " @?7L  !X;"]W;W)K<VAE
M971S+W-H965T,S N>&UL4$L! A0#%     @ #H*C5-['5>$5!   ( H  !D
M             ("!J^\  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"
M% ,4    "  .@J-4"\%#V?@%  #&$   &0              @('W\P  >&PO
M=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    (  Z"HU2"4,V-$ 8
M *L1   9              " @2;Z  !X;"]W;W)K<VAE971S+W-H965T,S,N
M>&UL4$L! A0#%     @ #H*C5#0D!2J-!0  =1$  !D              ("!
M;0 ! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    "  .@J-4
M\@8TT\L$   (#@  &0              @($Q!@$ >&PO=V]R:W-H965T<R]S
M:&5E=#,U+GAM;%!+ 0(4 Q0    (  Z"HU2*\&T."0,  *L&   9
M      " @3,+ 0!X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%
M  @ #H*C5%)'[?"H P  _ D  !D              ("!<PX! 'AL+W=O<FMS
M:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    "  .@J-4>\4QZLD"   <!@
M&0              @(%2$@$ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+
M 0(4 Q0    (  Z"HU0AX&',+P0  *$*   9              " @5(5 0!X
M;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ #H*C5-V:QJ,-
M!   "PT  !D              ("!N!D! 'AL+W=O<FMS:&5E=',O<VAE970T
M,"YX;6Q02P$"% ,4    "  .@J-4: .JG$$"   6!0  &0
M@('\'0$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    (  Z"
MHU3\K>E1#0,  )$)   9              " @70@ 0!X;"]W;W)K<VAE971S
M+W-H965T-#(N>&UL4$L! A0#%     @ #H*C5,4],2S: @  #P@  !D
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M=#0W+GAM;%!+ 0(4 Q0    (  Z"HU3[??("# ,  (X*   9
M  " @9HY 0!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @
M#H*C5&H=:SHX P  J L  !D              ("!W3P! 'AL+W=O<FMS:&5E
M=',O<VAE970T.2YX;6Q02P$"% ,4    "  .@J-4=MIZ/VD"  !#!@  &0
M            @(%,0 $ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4
M Q0    (  Z"HU2DXAF$N0,  ,T-   9              " @>Q" 0!X;"]W
M;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ #H*C5 "WO; #!0
M[18  !D              ("!W$8! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX
M;6Q02P$"% ,4    "  .@J-46)!_HL "  !?!P  &0              @($6
M3 $ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    (  Z"HU3.
MG(RV0 <  "DR   9              " @0U/ 0!X;"]W;W)K<VAE971S+W-H
M965T-30N>&UL4$L! A0#%     @ #H*C5(].7ELL P  L0H  !D
M     ("!A%8! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  Z"HU0C\Z)2%@,  (@+   9              "
M@0!G 0!X;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%     @ #H*C
M5*OF05] !@  HB,  !D              ("!36H! 'AL+W=O<FMS:&5E=',O
M<VAE970V,2YX;6Q02P$"% ,4    "  .@J-4?-&22@P#  "6"0  &0
M        @('$< $ >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0
M   (  Z"HU19WE'1B@(  &$&   9              " @0=T 0!X;"]W;W)K
M<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @ #H*C5"ZUKR(^ @  @ 4
M !D              ("!R'8! 'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q0
M2P$"% ,4    "  .@J-4[*FG]T$"   (!0  &0              @($]>0$
M>&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    (  Z"HU2E9>NB
MOPD  %(W   9              " @;5[ 0!X;"]W;W)K<VAE971S+W-H965T
M-C8N>&UL4$L! A0#%     @ #H*C5'F@)3&: P  20P  !D
M ("!JX4! 'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6Q02P$"% ,4    "  .
M@J-4JZ^T'H<#  "="P  &0              @(%\B0$ >&PO=V]R:W-H965T
M<R]S:&5E=#8X+GAM;%!+ 0(4 Q0    (  Z"HU1+ZWPMXP(  + (   9
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M970W,RYX;6Q02P$"% ,4    "  .@J-4T%3_A-P#   <$   &0
M    @($%HP$ >&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4 Q0    (
M  Z"HU2JR>M;+0,  "$+   9              " @1BG 0!X;"]W;W)K<VAE
M971S+W-H965T-S4N>&UL4$L! A0#%     @ #H*C5&;^ILA' P  6@L  !D
M             ("!?*H! 'AL+W=O<FMS:&5E=',O<VAE970W-BYX;6Q02P$"
M% ,4    "  .@J-48 6Q01(%  "?$P  &0              @('ZK0$ >&PO
M=V]R:W-H965T<R]S:&5E=#<W+GAM;%!+ 0(4 Q0    (  Z"HU23; P=$@,
M )<(   9              " @4.S 0!X;"]W;W)K<VAE971S+W-H965T-S@N
M>&UL4$L! A0#%     @ #H*C5'":4U>?"0  -SD  !D              ("!
MC+8! 'AL+W=O<FMS:&5E=',O<VAE970W.2YX;6Q02P$"% ,4    "  .@J-4
M@F]PM/X&  #)(   &0              @(%BP $ >&PO=V]R:W-H965T<R]S
M:&5E=#@P+GAM;%!+ 0(4 Q0    (  Z"HU1O^PTZ_00  %<4   9
M      " @9?' 0!X;"]W;W)K<VAE971S+W-H965T.#$N>&UL4$L! A0#%
M  @ #H*C5$S='_0= @  E00  !D              ("!R\P! 'AL+W=O<FMS
M:&5E=',O<VAE970X,BYX;6Q02P$"% ,4    "  .@J-4/]^M)UT#   T%@
M#0              @ $?SP$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    (  Z"
MHU27BKL<P    !,"   +              "  :?2 0!?<F5L<R\N<F5L<U!+
M 0(4 Q0    (  Z"HU1OS#4VZP4  -8U   /              "  9#3 0!X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  .@J-49LT1.G0"  !M,   &@
M            @ &HV0$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    "  .@J-4$@%B4"$"   @+P  $P              @ %4W $ 6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08     6@!: *T8  "FW@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>438</ContextCount>
  <ElementCount>362</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>136</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Statements of Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statement of Equity Statement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement</Role>
      <ShortName>Condensed Consolidated Statement of Equity Statement</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiatives</Role>
      <ShortName>Restructuring, Business Transformation and Other Cost Saving Initiatives</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2108103 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2116104 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2120105 - Disclosure - Intangible Assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwill</Role>
      <ShortName>Intangible Assets and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2124106 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2132107 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2140108 - Disclosure - Derivative Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstruments</Role>
      <ShortName>Derivative Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2143109 - Disclosure - Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantandEquipment</Role>
      <ShortName>Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2145110 - Disclosure - Indebtedness</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Indebtedness</Role>
      <ShortName>Indebtedness</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2147111 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2152112 - Disclosure - Earnings per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsperShare</Role>
      <ShortName>Earnings per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2155113 - Disclosure - Share-based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SharebasedPayments</Role>
      <ShortName>Share-based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2159114 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2163115 - Disclosure - Other Consolidated Financial Statement Detail</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</Role>
      <ShortName>Other Consolidated Financial Statement Detail</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2167116 - Disclosure - Collaborative and Other Relationships</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationships</Role>
      <ShortName>Collaborative and Other Relationships</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2171117 - Disclosure - Investments in Variable Interest Entities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities</Role>
      <ShortName>Investments in Variable Interest Entities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2173118 - Disclosure - Litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Litigation</Role>
      <ShortName>Litigation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2175119 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables</Role>
      <ShortName>Restructuring, Business Transformation and Other Cost Saving Initiatives (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiatives</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2309302 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Revenues</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2317303 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Inventory</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2321304 - Disclosure - Intangible Assets and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables</Role>
      <ShortName>Intangible Assets and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsandGoodwill</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2325305 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurements</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2333306 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstruments</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2341307 - Disclosure - Derivative Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsTables</Role>
      <ShortName>Derivative Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstruments</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2348308 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2353309 - Disclosure - Earnings per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsperShareTables</Role>
      <ShortName>Earnings per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsperShare</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2356310 - Disclosure - Share-Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsTables</Role>
      <ShortName>Share-Based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2360311 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxes</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2364312 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2368313 - Disclosure - Collaborative and Other Relationships (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables</Role>
      <ShortName>Collaborative and Other Relationships (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CollaborativeandOtherRelationships</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails</Role>
      <ShortName>Restructuring, Business Transformation and Other Cost Saving Initiatives - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Restructuring Reserve Roll Forward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails</Role>
      <ShortName>Restructuring, Business Transformation and Other Cost Saving Initiatives - Restructuring Reserve Roll Forward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Revenues - Revenues by product (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails</Role>
      <ShortName>Revenues - Revenues by product (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Revenues Reserves for Discounts and Allowances (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1</Role>
      <ShortName>Revenues Reserves for Discounts and Allowances (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Revenues- Reserves for Discounts and Allowances (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2</Role>
      <ShortName>Revenues- Reserves for Discounts and Allowances (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2413407 - Disclosure - Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails</Role>
      <ShortName>Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2414408 - Disclosure - Revenues - Other Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails</Role>
      <ShortName>Revenues - Other Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2415409 - Disclosure - Revenues - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesNarrativeDetails</Role>
      <ShortName>Revenues - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2418410 - Disclosure - Inventory - Components of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails</Role>
      <ShortName>Inventory - Components of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2419411 - Disclosure - Inventory - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryNarrativeDetails</Role>
      <ShortName>Inventory - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2422412 - Disclosure - Intangible Assets and Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails</Role>
      <ShortName>Intangible Assets and Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2423413 - Disclosure - Intangible Assets and Goodwill (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1</Role>
      <ShortName>Intangible Assets and Goodwill (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2426414 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2427415 - Disclosure - Fair Value Measurements (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual</Role>
      <ShortName>Fair Value Measurements (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2428416 - Disclosure - Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails</Role>
      <ShortName>Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2429417 - Disclosure - Fair Value Measurements - Nonrecurring Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsNonrecurringAssetsDetails</Role>
      <ShortName>Fair Value Measurements - Nonrecurring Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2430418 - Disclosure - Fair Value Measurements (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails1</Role>
      <ShortName>Fair Value Measurements (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2431419 - Disclosure - Fair Value Measurements (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails2</Role>
      <ShortName>Fair Value Measurements (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2434420 - Disclosure - Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails</Role>
      <ShortName>Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2435421 - Disclosure - Financial Instruments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails1</Role>
      <ShortName>Financial Instruments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2436422 - Disclosure - Financial Instruments (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails2</Role>
      <ShortName>Financial Instruments (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2437423 - Disclosure - Financial Instruments (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails3</Role>
      <ShortName>Financial Instruments (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2438424 - Disclosure - Financial Instruments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual</Role>
      <ShortName>Financial Instruments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2439425 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2</Role>
      <ShortName>Financial Instruments Financial Instruments (Details Textual 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2442426 - Disclosure - Derivative Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsDetails</Role>
      <ShortName>Derivative Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstrumentsTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2444427 - Disclosure - Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails</Role>
      <ShortName>Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/PropertyPlantandEquipment</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2446428 - Disclosure - Indebtedness (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IndebtednessDetails</Role>
      <ShortName>Indebtedness (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Indebtedness</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2449429 - Disclosure - Share Repurchases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareRepurchasesDetails</Role>
      <ShortName>Share Repurchases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2450430 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2451431 - Disclosure - Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2454432 - Disclosure - Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsperShareDetails</Role>
      <ShortName>Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsperShareTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2457433 - Disclosure - Share-Based Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails</Role>
      <ShortName>Share-Based Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2458434 - Disclosure - Share-Based Payments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails1</Role>
      <ShortName>Share-Based Payments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2461435 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2462436 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2465437 - Disclosure - Other Consolidated Financial Statement Detail (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2466438 - Disclosure - Other Consolidated Financial Statement (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual</Role>
      <ShortName>Other Consolidated Financial Statement (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2469439 - Disclosure - Collaborative and Other Relationships - Collaborations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails</Role>
      <ShortName>Collaborative and Other Relationships - Collaborations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2470440 - Disclosure - Collaborative and Other Relationships - Equity Method Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails</Role>
      <ShortName>Collaborative and Other Relationships - Equity Method Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>2472441 - Disclosure - Investments in Variable Interest Entities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails</Role>
      <ShortName>Investments in Variable Interest Entities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="biib-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>2474442 - Disclosure - Litigation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LitigationDetails</Role>
      <ShortName>Litigation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Litigation</ParentRole>
      <Position>82</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="biib-20220331.htm">biib-20220331.htm</File>
    <File>biib-20220331.xsd</File>
    <File>biib-20220331_cal.xml</File>
    <File>biib-20220331_def.xml</File>
    <File>biib-20220331_lab.xml</File>
    <File>biib-20220331_pre.xml</File>
    <File>biib-2022331xex311.htm</File>
    <File>biib-2022331xex312.htm</File>
    <File>biib-2022331xex321.htm</File>
    <File>exhibit102biogeninc2006non.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>biib-20220331_g1.jpg</File>
    <File>biib-20220331_g10.jpg</File>
    <File>biib-20220331_g11.jpg</File>
    <File>biib-20220331_g12.jpg</File>
    <File>biib-20220331_g13.jpg</File>
    <File>biib-20220331_g14.jpg</File>
    <File>biib-20220331_g15.jpg</File>
    <File>biib-20220331_g16.jpg</File>
    <File>biib-20220331_g17.jpg</File>
    <File>biib-20220331_g18.jpg</File>
    <File>biib-20220331_g19.jpg</File>
    <File>biib-20220331_g2.jpg</File>
    <File>biib-20220331_g20.jpg</File>
    <File>biib-20220331_g21.jpg</File>
    <File>biib-20220331_g22.jpg</File>
    <File>biib-20220331_g3.jpg</File>
    <File>biib-20220331_g4.jpg</File>
    <File>biib-20220331_g5.jpg</File>
    <File>biib-20220331_g6.jpg</File>
    <File>biib-20220331_g7.jpg</File>
    <File>biib-20220331_g8.jpg</File>
    <File>biib-20220331_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1035">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>122
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "biib-20220331.htm": {
   "axisCustom": 5,
   "axisStandard": 32,
   "contextCount": 438,
   "dts": {
    "calculationLink": {
     "local": [
      "biib-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "biib-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "biib-20220331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "biib-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "biib-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "biib-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 675,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 13,
    "http://xbrl.sec.gov/dei/2021q4": 6,
    "total": 19
   },
   "keyCustom": 65,
   "keyStandard": 297,
   "memberCustom": 67,
   "memberStandard": 64,
   "nsprefix": "biib",
   "nsuri": "http://www.biogenidec.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.biogenidec.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108103 - Disclosure - Revenues",
     "role": "http://www.biogenidec.com/role/Revenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116104 - Disclosure - Inventory",
     "role": "http://www.biogenidec.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120105 - Disclosure - Intangible Assets and Goodwill",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwill",
     "shortName": "Intangible Assets and Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124106 - Disclosure - Fair Value Measurements",
     "role": "http://www.biogenidec.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132107 - Disclosure - Financial Instruments",
     "role": "http://www.biogenidec.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2140108 - Disclosure - Derivative Instruments",
     "role": "http://www.biogenidec.com/role/DerivativeInstruments",
     "shortName": "Derivative Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2143109 - Disclosure - Property, Plant and Equipment",
     "role": "http://www.biogenidec.com/role/PropertyPlantandEquipment",
     "shortName": "Property, Plant and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2145110 - Disclosure - Indebtedness",
     "role": "http://www.biogenidec.com/role/Indebtedness",
     "shortName": "Indebtedness",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147111 - Disclosure - Equity",
     "role": "http://www.biogenidec.com/role/Equity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2152112 - Disclosure - Earnings per Share",
     "role": "http://www.biogenidec.com/role/EarningsperShare",
     "shortName": "Earnings per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Statements of Income (Unaudited)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
     "shortName": "Condensed Consolidated Statements of Income (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2155113 - Disclosure - Share-based Payments",
     "role": "http://www.biogenidec.com/role/SharebasedPayments",
     "shortName": "Share-based Payments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2159114 - Disclosure - Income Taxes",
     "role": "http://www.biogenidec.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2163115 - Disclosure - Other Consolidated Financial Statement Detail",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail",
     "shortName": "Other Consolidated Financial Statement Detail",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2167116 - Disclosure - Collaborative and Other Relationships",
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationships",
     "shortName": "Collaborative and Other Relationships",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2171117 - Disclosure - Investments in Variable Interest Entities",
     "role": "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities",
     "shortName": "Investments in Variable Interest Entities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2173118 - Disclosure - Litigation",
     "role": "http://www.biogenidec.com/role/Litigation",
     "shortName": "Litigation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2175119 - Disclosure - Subsequent Events",
     "role": "http://www.biogenidec.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:BusinessOverviewPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:BusinessOverviewPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives (Tables)",
     "role": "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables",
     "shortName": "Restructuring, Business Transformation and Other Cost Saving Initiatives (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309302 - Disclosure - Revenues (Tables)",
     "role": "http://www.biogenidec.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317303 - Disclosure - Inventory (Tables)",
     "role": "http://www.biogenidec.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2321304 - Disclosure - Intangible Assets and Goodwill (Tables)",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables",
     "shortName": "Intangible Assets and Goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325305 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2333306 - Disclosure - Financial Instruments (Tables)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2341307 - Disclosure - Derivative Instruments (Tables)",
     "role": "http://www.biogenidec.com/role/DerivativeInstrumentsTables",
     "shortName": "Derivative Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2348308 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)",
     "role": "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables",
     "shortName": "Accumulated Other Comprehensive Income (Loss) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2353309 - Disclosure - Earnings per Share (Tables)",
     "role": "http://www.biogenidec.com/role/EarningsperShareTables",
     "shortName": "Earnings per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2356310 - Disclosure - Share-Based Payments (Tables)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsTables",
     "shortName": "Share-Based Payments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2360311 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.biogenidec.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2364312 - Disclosure - Other Consolidated Financial Statement Detail (Tables)",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables",
     "shortName": "Other Consolidated Financial Statement Detail (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "id525e35f363e449aa36c9833e703f6f9_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "id525e35f363e449aa36c9833e703f6f9_I20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2368313 - Disclosure - Collaborative and Other Relationships (Tables)",
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables",
     "shortName": "Collaborative and Other Relationships (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "role": "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Narrative (Details)",
     "role": "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
     "shortName": "Restructuring, Business Transformation and Other Cost Saving Initiatives - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Restructuring Reserve Roll Forward (Details)",
     "role": "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails",
     "shortName": "Restructuring, Business Transformation and Other Cost Saving Initiatives - Restructuring Reserve Roll Forward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "ic4b04ecc1818447ebb524096be801f20_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Revenues - Revenues by product (Details)",
     "role": "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails",
     "shortName": "Revenues - Revenues by product (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i45e6439716cb4f31b5a5f0feef64721a_D20220101-20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i609afa0be8424634b9ec333da2c2f549_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Revenues Reserves for Discounts and Allowances (Details 1)",
     "role": "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1",
     "shortName": "Revenues Reserves for Discounts and Allowances (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "id525e35f363e449aa36c9833e703f6f9_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - Revenues- Reserves for Discounts and Allowances (Details 2)",
     "role": "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2",
     "shortName": "Revenues- Reserves for Discounts and Allowances (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "id33287c4ca8e4b7c9960bc9a3c2091e4_I20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413407 - Disclosure - Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details)",
     "role": "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails",
     "shortName": "Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "iddf807d85db941d0a2233de6ebb901c4_D20220101-20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "biib:ShareOfCoPromotionProfits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414408 - Disclosure - Revenues - Other Revenues (Details)",
     "role": "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
     "shortName": "Revenues - Other Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:OtherrevenuesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i6985304f226c46fca0470a43faf8887c_D20220101-20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415409 - Disclosure - Revenues - Narrative (Details)",
     "role": "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
     "shortName": "Revenues - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "biib:NumberOfWholesalers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "wholesaler",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "id525e35f363e449aa36c9833e703f6f9_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418410 - Disclosure - Inventory - Components of Inventory (Details)",
     "role": "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails",
     "shortName": "Inventory - Components of Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "id525e35f363e449aa36c9833e703f6f9_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryWriteDown",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419411 - Disclosure - Inventory - Narrative (Details)",
     "role": "http://www.biogenidec.com/role/InventoryNarrativeDetails",
     "shortName": "Inventory - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i722a1d8416ce4b6b9e7ebbb4433afb51_D20220101-20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:InventoryWriteDown",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "id525e35f363e449aa36c9833e703f6f9_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422412 - Disclosure - Intangible Assets and Goodwill (Details)",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
     "shortName": "Intangible Assets and Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "id525e35f363e449aa36c9833e703f6f9_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i609afa0be8424634b9ec333da2c2f549_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423413 - Disclosure - Intangible Assets and Goodwill (Details 1)",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1",
     "shortName": "Intangible Assets and Goodwill (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:GoodwillOtherIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "id525e35f363e449aa36c9833e703f6f9_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426414 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "ia69f061a62954ac7af98aa5c677f4971_I20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AssetImpairmentCharges",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427415 - Disclosure - Fair Value Measurements (Details Textual)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
     "shortName": "Fair Value Measurements (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AssetImpairmentCharges",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i4a551835cbc34cf1af2a3029ace704ab_I20220331",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428416 - Disclosure - Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails",
     "shortName": "Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i4a551835cbc34cf1af2a3029ace704ab_I20220331",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429417 - Disclosure - Fair Value Measurements - Nonrecurring Assets (Details)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsNonrecurringAssetsDetails",
     "shortName": "Fair Value Measurements - Nonrecurring Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "id525e35f363e449aa36c9833e703f6f9_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430418 - Disclosure - Fair Value Measurements (Details 1)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
     "shortName": "Fair Value Measurements (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "id525e35f363e449aa36c9833e703f6f9_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431419 - Disclosure - Fair Value Measurements (Details 2)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
     "shortName": "Fair Value Measurements (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "id525e35f363e449aa36c9833e703f6f9_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434420 - Disclosure - Financial Instruments (Details)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails",
     "shortName": "Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "id525e35f363e449aa36c9833e703f6f9_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "id525e35f363e449aa36c9833e703f6f9_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435421 - Disclosure - Financial Instruments (Details 1)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
     "shortName": "Financial Instruments (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "id525e35f363e449aa36c9833e703f6f9_I20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "id525e35f363e449aa36c9833e703f6f9_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436422 - Disclosure - Financial Instruments (Details 2)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails2",
     "shortName": "Financial Instruments (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "id525e35f363e449aa36c9833e703f6f9_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437423 - Disclosure - Financial Instruments (Details 3)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails3",
     "shortName": "Financial Instruments (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:AverageMaturityOfMarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438424 - Disclosure - Financial Instruments (Details Textual)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual",
     "shortName": "Financial Instruments (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:AverageMaturityOfMarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i3803e965a1724d08a4f85f6e2e7521f4_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "biib:StrategicInvestmentPortfolio",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439425 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
     "shortName": "Financial Instruments Financial Instruments (Details Textual 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i3803e965a1724d08a4f85f6e2e7521f4_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "biib:StrategicInvestmentPortfolio",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442426 - Disclosure - Derivative Instruments (Details)",
     "role": "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
     "shortName": "Derivative Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "id525e35f363e449aa36c9833e703f6f9_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444427 - Disclosure - Property, Plant and Equipment (Details)",
     "role": "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails",
     "shortName": "Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "id525e35f363e449aa36c9833e703f6f9_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "id164d47b16824f0c874ceeea51fbbcbc_D20210201-20210228",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfSeniorDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446428 - Disclosure - Indebtedness (Details)",
     "role": "http://www.biogenidec.com/role/IndebtednessDetails",
     "shortName": "Indebtedness (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "id164d47b16824f0c874ceeea51fbbcbc_D20210201-20210228",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfSeniorDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRepurchaseOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449429 - Disclosure - Share Repurchases (Details)",
     "role": "http://www.biogenidec.com/role/ShareRepurchasesDetails",
     "shortName": "Share Repurchases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i927398c21f2c4253b9e5fc9aa1970ccb_I20201031",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "ic54a4fcce0664582818adb93f242f27f_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statement of Equity Statement",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
     "shortName": "Condensed Consolidated Statement of Equity Statement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "ic54a4fcce0664582818adb93f242f27f_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i609afa0be8424634b9ec333da2c2f549_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450430 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)",
     "role": "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
     "shortName": "Accumulated Other Comprehensive Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "if8f47af926b14294931310a85ceac0ce_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NonoperatingIncomeExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451431 - Disclosure - Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)",
     "role": "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails",
     "shortName": "Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "ia4e4d15b86ad443eb9d3edf6dee5f7b5_D20220101-20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454432 - Disclosure - Earnings per Share (Details)",
     "role": "http://www.biogenidec.com/role/EarningsperShareDetails",
     "shortName": "Earnings per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457433 - Disclosure - Share-Based Payments (Details)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
     "shortName": "Share-Based Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458434 - Disclosure - Share-Based Payments (Details 1)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1",
     "shortName": "Share-Based Payments (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "ic7e00bf0cede4201ac36bccc9be5e5fd_D20220101-20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:VariableInterestEntityDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "id525e35f363e449aa36c9833e703f6f9_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2461435 - Disclosure - Income Taxes (Details Textual)",
     "role": "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
     "shortName": "Income Taxes (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "ia5fabf9c71294456a0158d60a5f483a4_I20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsLiabilitiesNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2462436 - Disclosure - Income Taxes (Details)",
     "role": "http://www.biogenidec.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2465437 - Disclosure - Other Consolidated Financial Statement Detail (Details)",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
     "shortName": "Other Consolidated Financial Statement Detail (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:GainLossOnInvestmentsTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2466438 - Disclosure - Other Consolidated Financial Statement (Details Textual)",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual",
     "shortName": "Other Consolidated Financial Statement (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "id525e35f363e449aa36c9833e703f6f9_I20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AccruedIncomeTaxesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2469439 - Disclosure - Collaborative and Other Relationships - Collaborations (Details)",
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
     "shortName": "Collaborative and Other Relationships - Collaborations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i4afdc1a2dcdf424eabd0653274b690c7_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2470440 - Disclosure - Collaborative and Other Relationships - Equity Method Investments (Details)",
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
     "shortName": "Collaborative and Other Relationships - Equity Method Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i17a7835e9c634cd3898253b27970e1ae_I20181107",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2472441 - Disclosure - Investments in Variable Interest Entities (Details)",
     "role": "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
     "shortName": "Investments in Variable Interest Entities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "id525e35f363e449aa36c9833e703f6f9_I20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i179745ea816f45eeb6066bd1ea79e129_I20210715",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyEstimateOfPossibleLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2474442 - Disclosure - Litigation (Details)",
     "role": "http://www.biogenidec.com/role/LitigationDetails",
     "shortName": "Litigation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i179745ea816f45eeb6066bd1ea79e129_I20210715",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyEstimateOfPossibleLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives",
     "role": "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiatives",
     "shortName": "Restructuring, Business Transformation and Other Cost Saving Initiatives",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220331.htm",
      "contextRef": "i5177bf3a09ce4d90a64c0992b77a070d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 136,
   "tag": {
    "biib_A2.25SeniorNotesdueMay12030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.25% Senior Notes due May 1, 2030 [Member]",
        "label": "2.25% Senior Notes due May 1, 2030 [Member]",
        "terseLabel": "2.250% Senior Notes due May 1, 2030"
       }
      }
     },
     "localname": "A2.25SeniorNotesdueMay12030Member",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_A2020ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Share Repurchase Program [Member]",
        "label": "2020 Share Repurchase Program [Member]",
        "terseLabel": "2020 Share Repurchase Program"
       }
      }
     },
     "localname": "A2020ShareRepurchaseProgramMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_A3.15SeniorNotesdueMay12050Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.15% Senior Notes due May 1, 2050 [Member]",
        "label": "3.15% Senior Notes due May 1, 2050 [Member]",
        "terseLabel": "3.150% Senior Notes due May 1, 2050"
       }
      }
     },
     "localname": "A3.15SeniorNotesdueMay12050Member",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_A3250SeniorNotesDueFebruary152051Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.250% Senior Notes, Due February 15, 2051",
        "label": "3.250% Senior Notes, Due February 15, 2051 [Member]",
        "terseLabel": "3.250% Senior Notes, Due February 15, 2051"
       }
      }
     },
     "localname": "A3250SeniorNotesDueFebruary152051Member",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ADUHELMMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ADUHELM",
        "label": "ADUHELM [Member]",
        "terseLabel": "ADUHELM"
       }
      }
     },
     "localname": "ADUHELMMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_AccruedMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Milestone Payments",
        "label": "Accrued Milestone Payments",
        "terseLabel": "Accrued milestone payments"
       }
      }
     },
     "localname": "AccruedMilestonePayments",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AdditionalMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional milestone payment.",
        "label": "Additional Milestone Payment",
        "terseLabel": "Additional milestone payment"
       }
      }
     },
     "localname": "AdditionalMilestonePayment",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to product revenue reserves relating to sales in prior years.",
        "label": "Adjustments To Product Revenue Reserves Relating To Sales In Prior Years",
        "negatedLabel": "Adjustments Relating To Prior Years"
       }
      }
     },
     "localname": "AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AdministrativeSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Administrative Space",
        "label": "Administrative Space [Member]",
        "terseLabel": "Administrative Space"
       }
      }
     },
     "localname": "AdministrativeSpaceMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization and Impairment of Acquired Intangible Assets",
        "label": "Amortization and Impairment of Acquired Intangible Assets",
        "terseLabel": "Amortization and impairment of acquired intangible assets"
       }
      }
     },
     "localname": "AmortizationAndImpairmentOfAcquiredIntangibleAssets",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Analysis of amount of and change in product revenue reserves.",
        "label": "Analysis Of Amount Of And Change In Product Revenue Reserves [Table Text Block]",
        "terseLabel": "Analysis of change In reserves"
       }
      }
     },
     "localname": "AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.",
        "label": "Available For Sale Securities Debt Maturities After Five Years Amortized Cost",
        "verboseLabel": "Due after five years, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.",
        "label": "Available For Sale Securities Debt Maturities After Five Years Fair Value",
        "verboseLabel": "Due after five years, estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AverageMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average remaining time to maturity of marketable debt securities, available-for-sale securities.",
        "label": "Average Maturity Of Marketable Securities",
        "verboseLabel": "Average maturity of marketable securities, months"
       }
      }
     },
     "localname": "AverageMaturityOfMarketableSecurities",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual"
     ],
     "xbrltype": "durationItemType"
    },
    "biib_BENEPALIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BENEPALI [Member]",
        "label": "BENEPALI [Member]",
        "terseLabel": "BENEPALI"
       }
      }
     },
     "localname": "BENEPALIMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BasicAndDilutedEarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basic and diluted earnings per share.",
        "label": "Basic And Diluted Earnings Per Share [Abstract]",
        "verboseLabel": "Basic and diluted earnings per share"
       }
      }
     },
     "localname": "BasicAndDilutedEarningsPerShareAbstract",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_BiologicsManufacturingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biologics Manufacturing",
        "label": "Biologics Manufacturing [Member]",
        "terseLabel": "Biologics Manufacturing"
       }
      }
     },
     "localname": "BiologicsManufacturingMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BiosimilarsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biosimilars",
        "label": "Biosimilars [Member]",
        "terseLabel": "Biosimilars"
       }
      }
     },
     "localname": "BiosimilarsMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BusinessOverviewPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes an overview of the company and its operations.",
        "label": "Business Overview [Policy Text Block]",
        "verboseLabel": "Overview"
       }
      }
     },
     "localname": "BusinessOverviewPolicyTextBlock",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_CashflowsoperatingexpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash flows, operating expenses [Member]",
        "label": "Cash flows, operating expenses [Member]",
        "terseLabel": "Cash flows, operating expenses"
       }
      }
     },
     "localname": "CashflowsoperatingexpensesMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CashflowsrevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash flows, revenue [Member]",
        "label": "Cash flows, revenue [Member]",
        "terseLabel": "Cash flows, revenue"
       }
      }
     },
     "localname": "CashflowsrevenueMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CentersForMedicareAndMedicaidServiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Centers for Medicare and Medicaid Service",
        "label": "Centers for Medicare and Medicaid Service [Member]",
        "terseLabel": "Centers for Medicare and Medicaid Service"
       }
      }
     },
     "localname": "CentersForMedicareAndMedicaidServiceMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CollaborationAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement Term",
        "label": "Collaboration Agreement Term",
        "terseLabel": "Collaboration agreement term"
       }
      }
     },
     "localname": "CollaborationAgreementTerm",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "biib_Collaborationexpensesaccrual": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration expenses accrual",
        "label": "Collaboration expenses accrual",
        "terseLabel": "Collaboration expense"
       }
      }
     },
     "localname": "Collaborationexpensesaccrual",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Collaborationprofitlosssharing": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration profit (loss) sharing",
        "label": "Collaboration profit (loss) sharing",
        "terseLabel": "Collaboration profit (loss) sharing"
       }
      }
     },
     "localname": "Collaborationprofitlosssharing",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ContingentMilestonePaymentsMadeToCollaborativePartner": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Milestone Payments Made To Collaborative Partner",
        "label": "Contingent Milestone Payments Made To Collaborative Partner",
        "terseLabel": "Contingent additional milestone payment"
       }
      }
     },
     "localname": "ContingentMilestonePaymentsMadeToCollaborativePartner",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ContractOptionExerciseFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract Option Exercise Fee",
        "label": "Contract Option Exercise Fee",
        "terseLabel": "Contract Option Exercise Fee"
       }
      }
     },
     "localname": "ContractOptionExerciseFee",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ContractualAdjustmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual adjustments.",
        "label": "Contractual Adjustments [Member]",
        "terseLabel": "Contractual adjustments"
       }
      }
     },
     "localname": "ContractualAdjustmentsMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CorporateDebtSecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate debt securities Current.",
        "label": "Corporate Debt Securities Current [Member]",
        "verboseLabel": "Corporate debt securities Current"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesCurrentMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CorporateDebtSecuritiesNonCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Debt Securities Non Current.",
        "label": "Corporate Debt Securities Non Current [Member]",
        "verboseLabel": "Corporate debt securities Non-current"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesNonCurrentMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CostOfGoodsSoldCapacityCharges": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of Goods Sold, Capacity Charges",
        "label": "Cost of Goods Sold, Capacity Charges",
        "terseLabel": "Cost of Goods Sold, Capacity Charges"
       }
      }
     },
     "localname": "CostOfGoodsSoldCapacityCharges",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current provisions to product revenue reserves relating to sales in current year.",
        "label": "Current Provisions To Product Revenue Reserves Relating To Sales In Current Year",
        "terseLabel": "Current Provisions Relating To Sales In Current Year"
       }
      }
     },
     "localname": "CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DebtInstrumentRedemptionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Redemption, Amount",
        "label": "Debt Instrument, Redemption, Amount",
        "terseLabel": "Debt Instrument, Redemption, Amount"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionAmount",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DenaliTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Denali Therapeutics Inc",
        "label": "Denali Therapeutics Inc [Member]",
        "terseLabel": "Denali Therapeutics"
       }
      }
     },
     "localname": "DenaliTherapeuticsIncMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Instruments, Unrealized Gain (Loss)",
        "label": "Derivative Instruments, Unrealized Gain (Loss) [Table Text Block]",
        "terseLabel": "Derivative Instruments, Unrealized Gain (Loss)"
       }
      }
     },
     "localname": "DerivativeInstrumentsUnrealizedGainLossTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_DerivativeMaturityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Maturity [Axis]",
        "label": "Derivative Maturity [Axis]",
        "terseLabel": "Derivative Maturity [Axis]"
       }
      }
     },
     "localname": "DerivativeMaturityAxis",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_DerivativeMaturityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Derivative Maturity [Axis]",
        "label": "Derivative Maturity [Domain]",
        "terseLabel": "Derivative Maturity [Domain]"
       }
      }
     },
     "localname": "DerivativeMaturityDomain",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)",
        "label": "Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)",
        "terseLabel": "Gains (losses) on net investment hedge, excluded component"
       }
      }
     },
     "localname": "Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DistributorOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Distributor one.",
        "label": "Distributor One [Member]",
        "terseLabel": "Distributor One"
       }
      }
     },
     "localname": "DistributorOneMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DistributorTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Distributor two.",
        "label": "Distributor Two [Member]",
        "terseLabel": "Distributor Two"
       }
      }
     },
     "localname": "DistributorTwoMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DuefromantiCD20therapeuticprograms": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivable from anti-CD20 therapeutic programs for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.",
        "label": "Due from anti-CD20 therapeutic programs",
        "verboseLabel": "Due from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "DuefromantiCD20therapeuticprograms",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_E2609andBAN2401Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "E2609 and BAN2401 [Member]",
        "label": "E2609 and BAN2401 [Member]",
        "terseLabel": "BAN2401 and Elenbecestat"
       }
      }
     },
     "localname": "E2609andBAN2401Member",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_EffectiveTaxRateReconciliationGILTItax": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Tax Rate Reconciliation, GILTI tax",
        "label": "Effective Tax Rate Reconciliation, GILTI tax",
        "terseLabel": "GILTI"
       }
      }
     },
     "localname": "EffectiveTaxRateReconciliationGILTItax",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Tax Rate Reconciliation, NuerImmune Tax Impacts",
        "label": "Effective Tax Rate Reconciliation, NuerImmune Tax Impacts",
        "terseLabel": "Neurimmune tax impacts"
       }
      }
     },
     "localname": "EffectiveTaxRateReconciliationNuerImmuneTaxImpacts",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "biib_EisaiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eisai [Member]",
        "label": "Eisai [Member]",
        "terseLabel": "Eisai"
       }
      }
     },
     "localname": "EisaiMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan.",
        "label": "Employee Stock Purchase Plan [Member]",
        "verboseLabel": "Employee stock purchase plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_EntityWidePercentageOfRevenueFromMajorDistributors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity wide percentage of revenue from major distributors.",
        "label": "Entity Wide Percentage Of Revenue From Major Distributors",
        "terseLabel": "Percentage of revenues from major distributors"
       }
      }
     },
     "localname": "EntityWidePercentageOfRevenueFromMajorDistributors",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction",
        "label": "Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction",
        "terseLabel": "Percentage of stake in entity"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EquityMethodInvestmentsExpectedProfitShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investments, Expected Profit Share",
        "label": "Equity Method Investments, Expected Profit Share",
        "terseLabel": "Equity Method Investments, Expected Profit Share"
       }
      }
     },
     "localname": "EquityMethodInvestmentsExpectedProfitShare",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 2.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "label": "Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 1.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax",
        "label": "Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_EquitySecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, Current",
        "label": "Equity Securities, Current [Member]",
        "terseLabel": "Equity Securities, Current"
       }
      }
     },
     "localname": "EquitySecuritiesCurrentMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_EquitySecuritiesNonCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, Non-Current",
        "label": "Equity Securities, Non-Current [Member]",
        "terseLabel": "Equity Securities, Non-Current"
       }
      }
     },
     "localname": "EquitySecuritiesNonCurrentMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_Equitymethodinvestmentbasisdifferenceamortizationperiod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity method investment basis difference amortization period",
        "label": "Equity method investment basis difference amortization period",
        "terseLabel": "Equity method investment basis difference amortization period"
       }
      }
     },
     "localname": "Equitymethodinvestmentbasisdifferenceamortizationperiod",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated additional payments upon achievement of development and commercial milestones.",
        "label": "Estimated Additional Payments Upon Achievement Of Development And Commercial Milestones",
        "terseLabel": "Estimated additional payments upon achievement of development and commercial milestones"
       }
      }
     },
     "localname": "EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ExpenseIncurredByCollaboration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total expense incurred by collaboration.",
        "label": "Expense Incurred By Collaboration",
        "terseLabel": "Expense Incurred By Collaboration"
       }
      }
     },
     "localname": "ExpenseIncurredByCollaboration",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Expenseincurredbythecollaboration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expense incurred by the collaboration",
        "label": "Expense incurred by the collaboration",
        "terseLabel": "Expense incurred by the collaboration"
       }
      }
     },
     "localname": "Expenseincurredbythecollaboration",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Expensereflectedwithinstatementsofincome": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expense reflected within statements of income",
        "label": "Expense reflected within statements of income",
        "terseLabel": "Expense reflected within statements of income"
       }
      }
     },
     "localname": "Expensereflectedwithinstatementsofincome",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_FAMPYRAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FAMPYRA [Member]",
        "label": "FAMPYRA [Member]",
        "terseLabel": "FAMPYRA"
       }
      }
     },
     "localname": "FAMPYRAMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FLIXABIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FLIXABI [Member]",
        "label": "FLIXABI [Member]",
        "terseLabel": "FLIXABI"
       }
      }
     },
     "localname": "FLIXABIMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FUMADERMMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FUMADERM [Member]",
        "label": "FUMADERM [Member]",
        "terseLabel": "FUMADERM"
       }
      }
     },
     "localname": "FUMADERMMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FacilityLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Facility Location [Axis]",
        "terseLabel": "Facility Location [Axis]"
       }
      }
     },
     "localname": "FacilityLocationAxis",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_FacilityLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Facility Location [Domain]",
        "terseLabel": "Facility Location [Domain]"
       }
      }
     },
     "localname": "FacilityLocationDomain",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FacilityTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility Type",
        "label": "Facility Type [Axis]",
        "terseLabel": "Facility Type [Axis]"
       }
      }
     },
     "localname": "FacilityTypeAxis",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_FacilityTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility Type",
        "label": "Facility Type [Domain]",
        "terseLabel": "Facility Type [Domain]"
       }
      }
     },
     "localname": "FacilityTypeDomain",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FumarateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fumarate [Member]",
        "label": "Fumarate [Member]",
        "terseLabel": "Fumarate"
       }
      }
     },
     "localname": "FumarateMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FutureContingentMilestoneTypesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future Contingent Milestone Types [Axis]",
        "label": "Future Contingent Milestone Types [Axis]",
        "terseLabel": "Future Contingent Milestone Types [Axis]"
       }
      }
     },
     "localname": "FutureContingentMilestoneTypesAxis",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_FutureContingentMilestoneTypesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Future Contingent Milestone Types [Axis]",
        "label": "Future Contingent Milestone Types [Domain]",
        "terseLabel": "Future Contingent Milestone Types [Domain]"
       }
      }
     },
     "localname": "FutureContingentMilestoneTypesDomain",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_GovernmentSecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government securities Current.",
        "label": "Government Securities Current [Member]",
        "verboseLabel": "Government securities Current"
       }
      }
     },
     "localname": "GovernmentSecuritiesCurrentMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_GovernmentSecuritiesNonCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government Securities Non Current.",
        "label": "Government Securities Non-current [Member]",
        "verboseLabel": "Government securities Non-current"
       }
      }
     },
     "localname": "GovernmentSecuritiesNonCurrentMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_IMRALDIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IMRALDI [Member]",
        "label": "IMRALDI [Member]",
        "terseLabel": "IMRALDI"
       }
      }
     },
     "localname": "IMRALDIMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_IncomeLossFromEquityMethodInvestmentsNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income (Loss) from Equity Method Investments, Net of Tax",
        "label": "Income (Loss) from Equity Method Investments, Net of Tax",
        "negatedTerseLabel": "Equity in (income) loss of investee, net of tax"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestmentsNetOfTax",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_InnoCarePharmaLimitedInnoCareAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "InnoCare Pharma Limited (InnoCare) Agreement",
        "label": "InnoCare Pharma Limited (InnoCare) Agreement [Member]",
        "terseLabel": "InnoCare Pharma Limited (InnoCare) Agreement"
       }
      }
     },
     "localname": "InnoCarePharmaLimitedInnoCareAgreementMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_IntangibleAssetsExcludingGoodwillTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets excluding goodwill.",
        "label": "Intangible Assets Excluding Goodwill [Table Text Block]",
        "verboseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsExcludingGoodwillTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_InterestInSubsidiary": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest in subsidiary.",
        "label": "Interest In Subsidiary",
        "verboseLabel": "Interest in subsidiary (less than given percentage)"
       }
      }
     },
     "localname": "InterestInSubsidiary",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_InterferonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interferon",
        "label": "Interferon [Member]",
        "terseLabel": "Interferon"
       }
      }
     },
     "localname": "InterferonMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_InventoryNetCurrentAndNoncurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory, Net Current and Noncurrent",
        "label": "Inventory, Net Current and Noncurrent",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNetCurrentAndNoncurrent",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Inventorynetcurrentandnoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory, net current and noncurrent",
        "label": "Inventory, net current and noncurrent",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "Inventorynetcurrentandnoncurrent",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.",
        "label": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities",
        "verboseLabel": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities"
       }
      }
     },
     "localname": "InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_InvestmentsInVariableInterestEntitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments In Variable Interest Entities.",
        "label": "Investments in Variable Interest Entities [Abstract]",
        "terseLabel": "Investments in Variable Interest Entities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsInVariableInterestEntitiesAbstract",
     "nsuri": "http://www.biogenidec.com/20220331",
     "xbrltype": "stringItemType"
    },
    "biib_IonisSangamoDenaliAndSageMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ionis, Sangamo, Denali and Sage",
        "label": "Ionis, Sangamo, Denali and Sage [Member]",
        "terseLabel": "Ionis, Sangamo, Denali and Sage"
       }
      }
     },
     "localname": "IonisSangamoDenaliAndSageMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_LongTermDebtExchangedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Debt, Exchanged, Amount",
        "label": "Long Term Debt, Exchanged, Amount",
        "terseLabel": "Long Term Debt, Exchanged, Amount"
       }
      }
     },
     "localname": "LongTermDebtExchangedAmount",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_MSProductRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MS Product Revenues [Member]",
        "label": "MS Product Revenues [Member]",
        "terseLabel": "MS Product Revenues"
       }
      }
     },
     "localname": "MSProductRevenuesMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_MarketStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Market stock units.",
        "label": "Market Stock Units [Member]",
        "verboseLabel": "Market stock units"
       }
      }
     },
     "localname": "MarketStockUnitsMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mortgage and other asset backed securities Current.",
        "label": "Mortgage And Other Asset Backed Securities Current [Member]",
        "verboseLabel": "Mortgage and other asset backed securities Current"
       }
      }
     },
     "localname": "MortgageAndOtherAssetBackedSecuritiesCurrentMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mortgage And Other Asset Backed Securities Non Current.",
        "label": "Mortgage And Other Asset Backed Securities Non Current [Member]",
        "verboseLabel": "Mortgage and other asset backed securities Non-current"
       }
      }
     },
     "localname": "MortgageAndOtherAssetBackedSecuritiesNonCurrentMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_NeurimmuneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Neurimmune.",
        "label": "Neurimmune [Member]",
        "terseLabel": "Neurimmune"
       }
      }
     },
     "localname": "NeurimmuneMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_NoncontrollingInterestIncreaseDecreaseOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling Interest, Increase (Decrease) Other",
        "label": "Noncontrolling Interest, Increase (Decrease) Other",
        "terseLabel": "Capital contribution from noncontrolling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseDecreaseOther",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_NumberOfSquareFeet": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Square Feet",
        "label": "Number of Square Feet",
        "terseLabel": "Number of square feet"
       }
      }
     },
     "localname": "NumberOfSquareFeet",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "biib_NumberOfWholesalers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Wholesalers",
        "label": "Number of Wholesalers",
        "terseLabel": "Number of wholesalers"
       }
      }
     },
     "localname": "NumberOfWholesalers",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "biib_OthercorporaterevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other corporate revenues [Member]",
        "label": "Other corporate revenues [Member]",
        "terseLabel": "Other corporate revenues"
       }
      }
     },
     "localname": "OthercorporaterevenuesMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_OtherresearchanddiscoveryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other research and discovery [Member]",
        "label": "Other research and discovery [Member]",
        "terseLabel": "Other research and discovery"
       }
      }
     },
     "localname": "OtherresearchanddiscoveryMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_OtherrevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other revenues [Abstract]",
        "label": "Other revenues [Abstract]",
        "terseLabel": "Other revenues [Abstract]"
       }
      }
     },
     "localname": "OtherrevenuesAbstract",
     "nsuri": "http://www.biogenidec.com/20220331",
     "xbrltype": "stringItemType"
    },
    "biib_OtherrevenuesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other revenues [Table Text Block]",
        "label": "Other revenues [Table Text Block]",
        "terseLabel": "Other revenues"
       }
      }
     },
     "localname": "OtherrevenuesTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_OtherrevenuesfromantiCD20therapeuticprograms": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.",
        "label": "Other revenues from anti-CD20 therapeutic programs",
        "terseLabel": "Other revenues from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "OtherrevenuesfromantiCD20therapeuticprograms",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_OutLicensedPatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Out-licensed patents.",
        "label": "Out Licensed Patents [Member]",
        "terseLabel": "Completed technology"
       }
      }
     },
     "localname": "OutLicensedPatentsMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PayablesToDivestitureOfInterestInJointVenture": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payables To Divestiture Of Interest In Joint Venture",
        "label": "Payables To Divestiture Of Interest In Joint Venture",
        "terseLabel": "Payables To Divestiture Of Interest In Joint Venture"
       }
      }
     },
     "localname": "PayablesToDivestitureOfInterestInJointVenture",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PaymentDueAtFirstAnniversaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Due At First Anniversary",
        "label": "Payment Due At First Anniversary [Member]",
        "terseLabel": "Payment Due At First Anniversary"
       }
      }
     },
     "localname": "PaymentDueAtFirstAnniversaryMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PaymentDueAtSecondAnniversaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Due At Second Anniversary",
        "label": "Payment Due At Second Anniversary [Member]",
        "terseLabel": "Payment Due At Second Anniversary"
       }
      }
     },
     "localname": "PaymentDueAtSecondAnniversaryMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments/ returns applied against product revenue reserves relating to current year.",
        "label": "Payments Returns Applied Against Product Revenue Reserves Relating To Current Year",
        "negatedLabel": "Payments/Returns Relating To Sales in Current Year"
       }
      }
     },
     "localname": "PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments/ returns applied against product revenue reserves relating to prior year.",
        "label": "Payments Returns Applied Against Product Revenue Reserves Relating To Prior Year",
        "negatedLabel": "Payments/Returns Relating To Sales in Prior Year"
       }
      }
     },
     "localname": "PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PercentageoffuturedevelopmentcostsrelatedtoEisai": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of future development costs related to Eisai",
        "label": "Percentage of future development costs related to Eisai",
        "terseLabel": "Percentage of future development costs related to Eisai"
       }
      }
     },
     "localname": "PercentageoffuturedevelopmentcostsrelatedtoEisai",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_PerformanceStockUnitsSettledinCashMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Stock Units Settled in Cash [Member]",
        "label": "Performance Stock Units Settled in Cash [Member]",
        "terseLabel": "Performance stock units settled in cash"
       }
      }
     },
     "localname": "PerformanceStockUnitsSettledinCashMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PerformanceStockUnitsSettledinStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Stock Units Settled in Stock [Member]",
        "label": "Performance Stock Units Settled in Stock [Member]",
        "terseLabel": "Performance stock units settled in stock"
       }
      }
     },
     "localname": "PerformanceStockUnitsSettledinStockMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PlanAssetsForDeferredCompensationFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair values as of the balance sheet date of all assets of deferred compensation plans.",
        "label": "Plan Assets For Deferred Compensation Fair Value Disclosure",
        "verboseLabel": "Plan assets for deferred compensation"
       }
      }
     },
     "localname": "PlanAssetsForDeferredCompensationFairValueDisclosure",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential future milestone payments commitment to third party approximately.",
        "label": "Potential Future Milestone Payments Commitment To Third Party Approximately",
        "terseLabel": "Potential future milestone payments commitment to third party"
       }
      }
     },
     "localname": "PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]",
        "label": "Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]",
        "terseLabel": "Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]"
       }
      }
     },
     "localname": "ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract",
     "nsuri": "http://www.biogenidec.com/20220331",
     "xbrltype": "stringItemType"
    },
    "biib_RegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory Milestones [Member]",
        "label": "Regulatory Milestones [Member]",
        "terseLabel": "Regulatory Milestones"
       }
      }
     },
     "localname": "RegulatoryMilestonesMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ResearchAndDevelopmentCostsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Costs, Percentage",
        "label": "Research and Development Costs, Percentage",
        "terseLabel": "Research and development costs, percentage"
       }
      }
     },
     "localname": "ResearchAndDevelopmentCostsPercentage",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_ResearchanddevelopmentassetAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development asset [Axis]",
        "label": "Research and development asset [Axis]",
        "terseLabel": "Research and development asset [Axis]"
       }
      }
     },
     "localname": "ResearchanddevelopmentassetAxis",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_ResearchanddevelopmentassetDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Research and development asset [Axis]",
        "label": "Research and development asset [Domain]",
        "terseLabel": "Research and development asset [Domain]"
       }
      }
     },
     "localname": "ResearchanddevelopmentassetDomain",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ReserveforCashDiscountsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve for Cash Discounts [Member]",
        "label": "Reserve for Cash Discounts [Member]",
        "terseLabel": "Discounts"
       }
      }
     },
     "localname": "ReserveforCashDiscountsMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenues from anti-CD20 therapeutic programs",
        "label": "Revenues from anti-CD20 therapeutic programs [Table Text Block]",
        "terseLabel": "Revenues from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "RevenuesfromantiCD20therapeuticprogramsTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_Revenuesfromanticd20therapeuticprogramsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenues from anti-cd20 therapeutic programs",
        "label": "Revenues from anti-cd20 therapeutic programs [Member]",
        "terseLabel": "Revenue from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "Revenuesfromanticd20therapeuticprogramsMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_RocheGroupGenentechMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Roche group Genentech.",
        "label": "Roche Group Genentech Member",
        "terseLabel": "Genentech"
       }
      }
     },
     "localname": "RocheGroupGenentechMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SPINRAZAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SPINRAZA [Member]",
        "label": "SPINRAZA [Member]",
        "terseLabel": "SPINRAZA"
       }
      }
     },
     "localname": "SPINRAZAMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SageTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sage Therapeutics Inc.",
        "label": "Sage Therapeutics Inc. [Member]",
        "terseLabel": "Sage Therapeutics Inc."
       }
      }
     },
     "localname": "SageTherapeuticsIncMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SamsungBiosimilarAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Samsung bio-similar agreement.",
        "label": "Samsung Biosimilar Agreement [Member]",
        "terseLabel": "Samsung Bioepis"
       }
      }
     },
     "localname": "SamsungBiosimilarAgreementMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SangamoTherapeuticsInc.AgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sangamo Therapeutics, Inc. Agreement [Member]",
        "label": "Sangamo Therapeutics, Inc. Agreement [Member]",
        "terseLabel": "Sangamo Therapeutics, Inc. Agreement"
       }
      }
     },
     "localname": "SangamoTherapeuticsInc.AgreementMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]",
        "label": "Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]",
        "terseLabel": "5.200% Senior Notes due 2045"
       }
      }
     },
     "localname": "SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]",
        "label": "Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]",
        "terseLabel": "4.050% Senior Notes due 2025"
       }
      }
     },
     "localname": "SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]",
        "label": "Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]",
        "terseLabel": "3.625% Senior Notes due 2022"
       }
      }
     },
     "localname": "SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation expense included in costs and expenses.",
        "label": "Share Based Compensation Expense Included In Costs And Expenses",
        "terseLabel": "Share-based compensation expense included in total costs and expenses"
       }
      }
     },
     "localname": "ShareBasedCompensationExpenseIncludedInCostsAndExpenses",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ShareOfCoPromotionProfits": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of co promotion profits.",
        "label": "Share Of Co Promotion Profits",
        "terseLabel": "Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA"
       }
      }
     },
     "localname": "ShareOfCoPromotionProfits",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ShorttermderivativeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term derivative [Member]",
        "label": "Short-term derivative [Member]",
        "terseLabel": "Short-term derivative"
       }
      }
     },
     "localname": "ShorttermderivativeMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SolothurnSwitzerlandMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Solothurn, Switzerland [Member]",
        "label": "Solothurn, Switzerland [Member]",
        "terseLabel": "Solothurn, Switzerland"
       }
      }
     },
     "localname": "SolothurnSwitzerlandMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_StrategicInvestmentPortfolio": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Strategic investment portfolio.",
        "label": "Strategic Investment Portfolio",
        "verboseLabel": "Strategic investment portfolio"
       }
      }
     },
     "localname": "StrategicInvestmentPortfolio",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_StrategicInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Strategic investments.",
        "label": "Strategic Investments [Member]",
        "terseLabel": "Strategic Investments"
       }
      }
     },
     "localname": "StrategicInvestmentsMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of Activity Related to Denali Therapeutics Collaboration",
        "label": "Summary of Activity Related to Denali Therapeutics Collaboration [Table Text Block]",
        "terseLabel": "Summary of Activity Related to Denali Therapeutics Collaboration"
       }
      }
     },
     "localname": "SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of total product revenue reserves included in consolidated balance sheets.",
        "label": "Summary Of Product Revenue Reserves Included In Consolidated Balance Sheets [Table Text Block]",
        "terseLabel": "Total reserves included in consolidated balance sheets"
       }
      }
     },
     "localname": "SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of share-based compensation expense associated with different programs.",
        "label": "Summary of share based compensation expense associated with different programs [Abstract]",
        "terseLabel": "Summary of share based compensation expense associated with different programs [Abstract]"
       }
      }
     },
     "localname": "SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table]",
        "label": "Summary of Activity Related to Aducanumab Collaboration [Table Text Block]",
        "terseLabel": "Summary of Activity Related to Aducanumab Collaboration"
       }
      }
     },
     "localname": "SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table]",
        "label": "Summary of Activity Related to E2609 and BAN2401 Collaboration [Table Text Block]",
        "terseLabel": "Summary of Activity Related to BAN2401 and Elenbecestat Collaboration"
       }
      }
     },
     "localname": "SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_TGNMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TGN",
        "label": "TGN [Member]",
        "terseLabel": "TGN"
       }
      }
     },
     "localname": "TGNMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_TechnologicalAndRegulatorySuccessProbability": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Technological and Regulatory Success, Probability",
        "label": "Technological and Regulatory Success, Probability",
        "terseLabel": "Technological and Regulatory Success, Probability"
       }
      }
     },
     "localname": "TechnologicalAndRegulatorySuccessProbability",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_Termofcollaborationagreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of collaboration agreement",
        "label": "Term of collaboration agreement",
        "terseLabel": "Term of collaboration agreement"
       }
      }
     },
     "localname": "Termofcollaborationagreement",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "biib_TimeVestedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Time vested restricted stock units.",
        "label": "Time Vested Restricted Stock Units [Member]",
        "verboseLabel": "Time-vested restricted stock units"
       }
      }
     },
     "localname": "TimeVestedRestrictedStockUnitsMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_TysabriProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TYSABRI product [Member]",
        "label": "TYSABRI product [Member]",
        "terseLabel": "TYSABRI"
       }
      }
     },
     "localname": "TysabriProductMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_UCBPharmaS.A.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UCB Pharma S.A. [Member]",
        "label": "UCB Pharma S.A. [Member]",
        "terseLabel": "UCB Pharma S.A. [Member]"
       }
      }
     },
     "localname": "UCBPharmaS.A.Member",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.",
        "label": "Unrealized Gain (Losses) on Foreign Currency Derivatives, Net, before Tax",
        "verboseLabel": "Gain/Loss on fair value of foreign currency forward contracts"
       }
      }
     },
     "localname": "UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_UnrealizedGainOnDerivatives": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrealized Gain on Derivatives",
        "label": "Unrealized Gain on Derivatives",
        "terseLabel": "Unrealized Gain on Derivatives"
       }
      }
     },
     "localname": "UnrealizedGainOnDerivatives",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_UnrealizedLossOnDerivatives": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrealized Loss on Derivatives",
        "label": "Unrealized Loss on Derivatives",
        "negatedTerseLabel": "Unrealized Loss on Derivatives"
       }
      }
     },
     "localname": "UnrealizedLossOnDerivatives",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total upfront and milestone payments made to collaborative partner.",
        "label": "Upfront And Milestone Payments Made To Collaborative Partner",
        "terseLabel": "Upfront and milestone payments made to collaborative partner"
       }
      }
     },
     "localname": "UpfrontAndMilestonePaymentsMadeToCollaborativePartner",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_VixotrigineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vixotrigine",
        "label": "Vixotrigine [Member]",
        "terseLabel": "Vixotrigine"
       }
      }
     },
     "localname": "VixotrigineMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_WarehouseUtilitiesAndSupportSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warehouse, Utilities and Support Space",
        "label": "Warehouse, Utilities and Support Space [Member]",
        "terseLabel": "Warehouse, Utilities and Support Space"
       }
      }
     },
     "localname": "WarehouseUtilitiesAndSupportSpaceMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_WorkforceReductionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Workforce Reduction",
        "label": "Workforce Reduction [Member]",
        "terseLabel": "Workforce Reduction"
       }
      }
     },
     "localname": "WorkforceReductionMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ZINBRYTAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ZINBRYTA [Member]",
        "label": "ZINBRYTA [Member]",
        "terseLabel": "ZINBRYTA"
       }
      }
     },
     "localname": "ZINBRYTAMember",
     "nsuri": "http://www.biogenidec.com/20220331",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "JAPAN"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Currencies [Domain]",
        "terseLabel": "All Currencies [Domain]"
       }
      }
     },
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_CAD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Canada, Dollars",
        "verboseLabel": "Canadian dollar"
       }
      }
     },
     "localname": "CAD",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_CHF": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Switzerland, Francs",
        "terseLabel": "Swiss franc"
       }
      }
     },
     "localname": "CHF",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_EUR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Euro Member Countries, Euro",
        "verboseLabel": "Euro"
       }
      }
     },
     "localname": "EUR",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_GBP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "United Kingdom, Pounds",
        "terseLabel": "British pound"
       }
      }
     },
     "localname": "GBP",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_JPY": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Japan, Yen",
        "terseLabel": "Japan, Yen"
       }
      }
     },
     "localname": "JPY",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r133",
      "r299",
      "r304",
      "r310",
      "r471",
      "r472",
      "r479",
      "r480",
      "r555",
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r133",
      "r299",
      "r304",
      "r310",
      "r471",
      "r472",
      "r479",
      "r480",
      "r555",
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r56",
      "r58",
      "r131",
      "r132",
      "r316",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]",
        "terseLabel": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r203",
      "r387",
      "r391",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r315",
      "r353",
      "r406",
      "r408",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r593",
      "r648",
      "r652",
      "r690",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r315",
      "r353",
      "r406",
      "r408",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r593",
      "r648",
      "r652",
      "r690",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum",
        "verboseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r203",
      "r387",
      "r391",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r200",
      "r387",
      "r389",
      "r595",
      "r647",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r200",
      "r387",
      "r389",
      "r595",
      "r647",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r315",
      "r353",
      "r397",
      "r406",
      "r408",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r593",
      "r648",
      "r652",
      "r690",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r315",
      "r353",
      "r397",
      "r406",
      "r408",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r593",
      "r648",
      "r652",
      "r690",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r57",
      "r58",
      "r131",
      "r132",
      "r316",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r148",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r148",
      "r153",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r201",
      "r202",
      "r387",
      "r390",
      "r650",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r201",
      "r202",
      "r387",
      "r390",
      "r650",
      "r675",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r148",
      "r153",
      "r293",
      "r407",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsAbstract",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r134",
      "r135",
      "r136",
      "r137",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r568",
      "r570",
      "r573",
      "r690",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted Average"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r38",
      "r558"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Reduction of accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r20",
      "r204",
      "r205"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "auth_ref": [
      "r17",
      "r601",
      "r627"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.",
        "label": "Accrued Income Taxes, Noncurrent",
        "terseLabel": "Accrued income taxes"
       }
      }
     },
     "localname": "AccruedIncomeTaxesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]",
        "verboseLabel": "Accrued Expenses and Other"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedLiabilitiesMember": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.",
        "label": "Accrued Liabilities [Member]",
        "terseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "AccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r42"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "verboseLabel": "Royalties and licensing fees"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "auth_ref": [
      "r66",
      "r71",
      "r79",
      "r80",
      "r81",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "terseLabel": "Unfunded status of postretirement benefit plans"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r36",
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r71",
      "r79",
      "r80",
      "r81",
      "r82",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "Unrealized gains (losses) on cash flow hedges"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r63",
      "r64",
      "r65",
      "r71",
      "r79",
      "r80",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]",
        "terseLabel": "Unrealized gains (losses) on securities available for sale"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r71",
      "r79",
      "r80",
      "r81",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from increase (decrease) in value of excluded component of derivative hedge, including portion attributable to noncontrolling interest.",
        "label": "Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Gains (losses) on net investment hedge"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r23",
      "r69",
      "r70",
      "r71",
      "r629",
      "r657",
      "r658"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "periodEndLabel": "Accumulated other comprehensive income (loss), net of tax ending balance",
        "periodStartLabel": "Accumulated other comprehensive income (loss), net of tax beginning balance",
        "terseLabel": "Balance, January 1, 2018",
        "verboseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r79",
      "r80",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r68",
      "r71",
      "r79",
      "r80",
      "r81",
      "r140",
      "r141",
      "r142",
      "r478",
      "r653",
      "r654",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r61",
      "r71",
      "r79",
      "r80",
      "r81",
      "r478",
      "r540",
      "r541",
      "r542",
      "r543",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Currency translation adjustments"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "verboseLabel": "Other Consolidated Financial Statement Detail"
       }
      }
     },
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r21",
      "r421",
      "r558"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r418",
      "r419",
      "r420",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentForAmortization": {
     "auth_ref": [
      "r116",
      "r265"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.",
        "label": "Amortization",
        "terseLabel": "Amortization"
       }
      }
     },
     "localname": "AdjustmentForAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net income to net cash flow from operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r410",
      "r415",
      "r422"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "negatedTerseLabel": "Compensation related to share-based payments",
        "verboseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, after Tax",
        "totalLabel": "Subtotal",
        "verboseLabel": "Subtotal"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax": {
     "auth_ref": [
      "r514"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated gain (loss) from increase (decrease) in value of excluded component of derivative hedge.",
        "label": "AOCI, Derivative Qualifying as Hedge, Excluded Component, after Tax",
        "terseLabel": "Derivative qualifying as net investment hedge, excluded component"
       }
      }
     },
     "localname": "AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r219",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "verboseLabel": "Mortgage and other asset backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r116",
      "r271"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Asset impairment charges"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r126",
      "r188",
      "r192",
      "r198",
      "r236",
      "r299",
      "r300",
      "r301",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r310",
      "r311",
      "r471",
      "r479",
      "r533",
      "r556",
      "r558",
      "r599",
      "r626"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r54",
      "r126",
      "r236",
      "r299",
      "r300",
      "r301",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r310",
      "r311",
      "r471",
      "r479",
      "r533",
      "r556",
      "r558"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r520"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "verboseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r212"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r213"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r210",
      "r243"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale [Abstract]",
        "terseLabel": "Marketable debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available-for-sale Securities, Debt Maturities [Abstract]",
        "verboseLabel": "Summary of Contractual Maturities: Available-for-Sale Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r217"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "verboseLabel": "Due after one year through five years, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r214",
      "r217",
      "r622"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "verboseLabel": "Due after one year through five years, estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r216"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "verboseLabel": "Due in one year or less, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r214",
      "r216",
      "r621"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "verboseLabel": "Due in one year or less, estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r207",
      "r211",
      "r243",
      "r605"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Marketable debt securities",
        "totalLabel": "Estimated Fair Value",
        "verboseLabel": "Fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r209",
      "r243"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r209",
      "r243"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r411",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r495",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition, Contingent Consideration [Line Items]",
        "terseLabel": "Business Acquisition, Contingent Consideration [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentConsiderationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r457",
      "r458",
      "r460"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "periodEndLabel": "Fair value, end of period",
        "periodStartLabel": "Fair value, beginning of period",
        "terseLabel": "Contingent consideration obligations"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r457",
      "r459"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "verboseLabel": "Contingent consideration obligations"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "verboseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash and Cash Equivalents [Line Items]",
        "terseLabel": "Cash and Cash Equivalents [Line Items]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "verboseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r113",
      "r118",
      "r119"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of the period",
        "periodStartLabel": "Cash and cash equivalents, beginning of the period",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r113",
      "r538"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r33"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents, at Carrying Value [Abstract]",
        "verboseLabel": "Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedging [Member]"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r462",
      "r463",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "verboseLabel": "Collaborative and Other Relationships"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationships"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "verboseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r47",
      "r292",
      "r608",
      "r634"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments, contingencies and guarantees"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r140",
      "r141",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r19",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r19",
      "r558"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, par value $0.0005 per share"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r75",
      "r77",
      "r78",
      "r90",
      "r614",
      "r642"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income (loss) attributable to Biogen Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r75",
      "r77",
      "r89",
      "r469",
      "r470",
      "r488",
      "r613",
      "r641"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r75",
      "r77",
      "r88",
      "r468",
      "r488",
      "r612",
      "r640"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r121",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "verboseLabel": "Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r398",
      "r405",
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "verboseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r93",
      "r595"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales, excluding amortization and impairment of acquired intangible assets"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total cost and expense"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "verboseLabel": "Cost and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r122",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r329",
      "r336",
      "r337",
      "r339",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Indebtedness"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Indebtedness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r125",
      "r133",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r319",
      "r325",
      "r326",
      "r327",
      "r328",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r341",
      "r342",
      "r343",
      "r344",
      "r550",
      "r600",
      "r602",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r327",
      "r341",
      "r342",
      "r532"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "verboseLabel": "Debt instruments, fair value"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r44",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Senior notes interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r45",
      "r125",
      "r133",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r319",
      "r325",
      "r326",
      "r327",
      "r328",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r341",
      "r342",
      "r343",
      "r344",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r45",
      "r125",
      "r133",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r319",
      "r325",
      "r326",
      "r327",
      "r328",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r338",
      "r341",
      "r342",
      "r343",
      "r344",
      "r368",
      "r371",
      "r372",
      "r373",
      "r547",
      "r548",
      "r550",
      "r551",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "auth_ref": [
      "r224"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Gain",
        "terseLabel": "Realized gains"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "auth_ref": [
      "r224"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Loss",
        "negatedLabel": "Realized losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Marketable debt and equity securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesMember": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions.",
        "label": "Debt Securities [Member]",
        "verboseLabel": "Short-term debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI, Cost [Abstract]",
        "terseLabel": "Marketable equity securities"
       }
      }
     },
     "localname": "DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "auth_ref": [
      "r430"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "terseLabel": "Decrease in unrecognized tax benefits is reasonably possible"
       }
      }
     },
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r425",
      "r426"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax asset"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r116",
      "r127",
      "r438",
      "r444",
      "r445",
      "r446"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r425",
      "r426"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "verboseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r436"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "terseLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r435"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "terseLabel": "Deferred tax assets, unrecognized tax benefit"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r116",
      "r272"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r116",
      "r185"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r55",
      "r58",
      "r59",
      "r497",
      "r575"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Fair Value, Gross Asset",
        "terseLabel": "Derivative asset, fair value"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r55",
      "r58",
      "r59",
      "r497",
      "r575"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Fair Value, Gross Liability",
        "terseLabel": "Derivative liability, fair value"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r58",
      "r496",
      "r498",
      "r505",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r515",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "verboseLabel": "Derivative Instruments"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r494",
      "r496",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet": {
     "auth_ref": [
      "r503",
      "r512"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of gains and losses (net) on derivative instruments designated and qualifying as hedging instruments representing (a) the amount of the hedge ineffectiveness and (b) the amount, if any, excluded from the assessment of hedge effectiveness.",
        "label": "Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net",
        "terseLabel": "Gain (loss) recognized in net income, excluded component"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r490",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative, Notional Amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeRemainingMaturity1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Remaining Maturity",
        "verboseLabel": "Range of durations of foreign currency forward contracts"
       }
      }
     },
     "localname": "DerivativeRemainingMaturity1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativeTermOfContract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Term of Contract",
        "terseLabel": "Remaining duration of Net Investment Hedges"
       }
      }
     },
     "localname": "DerivativeTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivatives [Line Items]"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "verboseLabel": "Designated as hedging instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Developed technology"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DilutiveSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]",
        "verboseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "DilutiveSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Abstract]",
        "terseLabel": "Disaggregation of Revenue [Abstract]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r387",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Revenues by product"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "verboseLabel": "Share-based Payments"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SharebasedPayments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DueFromRelatedParties": {
     "auth_ref": [
      "r130",
      "r302",
      "r304",
      "r305",
      "r309",
      "r310",
      "r311",
      "r554",
      "r606",
      "r636"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.",
        "label": "Due from Related Parties",
        "terseLabel": "Due from Related Parties"
       }
      }
     },
     "localname": "DueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r130",
      "r302",
      "r304",
      "r305",
      "r309",
      "r310",
      "r311",
      "r554",
      "r607",
      "r635"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to Related Parties",
        "terseLabel": "Due to Related Parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]",
        "verboseLabel": "Net income per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r91",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r154",
      "r156",
      "r161",
      "r162",
      "r163",
      "r167",
      "r168",
      "r517",
      "r518",
      "r615",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Basic earnings per share attributable to Biogen Inc."
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r91",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r156",
      "r161",
      "r162",
      "r163",
      "r167",
      "r168",
      "r517",
      "r518",
      "r615",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Diluted earnings per share attributable to Biogen Inc."
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r164",
      "r165",
      "r166",
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Earnings per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": {
     "auth_ref": [
      "r538"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.",
        "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r428"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "verboseLabel": "Reconciliation between the U.S. federal statutory tax rate and effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r128",
      "r428",
      "r447"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "verboseLabel": "Statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r428",
      "r447"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "verboseLabel": "Taxes on foreign earnings"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization": {
     "auth_ref": [
      "r428",
      "r447"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depreciation and amortization.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation and Amortization, Percent",
        "verboseLabel": "Purchased intangible assets"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r428",
      "r447"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r428",
      "r447"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "verboseLabel": "State taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r428",
      "r447"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "negatedLabel": "Credits and net operating loss utilization"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r42"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Collaboration expense"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "auth_ref": [
      "r416"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Amount Capitalized",
        "negatedTerseLabel": "Capitalized share-based compensation costs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r415"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, Tax Benefit",
        "negatedLabel": "Income tax effect"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r79",
      "r80",
      "r81",
      "r140",
      "r141",
      "r142",
      "r144",
      "r150",
      "r152",
      "r170",
      "r237",
      "r367",
      "r374",
      "r418",
      "r419",
      "r420",
      "r440",
      "r441",
      "r516",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r545",
      "r653",
      "r654",
      "r655",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity": {
     "auth_ref": [
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.",
        "label": "Equity Method Investment, Difference Between Carrying Amount and Underlying Equity",
        "terseLabel": "Amortization of basis differences"
       }
      }
     },
     "localname": "EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity Method Investment, Ownership Percentage",
        "verboseLabel": "Percentage of stake in entity maximum"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r34",
      "r189",
      "r232"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Investment in Samsung Bioepis"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r531"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 3.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.",
        "label": "Equity Securities, FV-NI, Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "auth_ref": [
      "r231"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "totalLabel": "Net gains (losses) recognized during the period on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]",
        "terseLabel": "Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLossAlternativeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": {
     "auth_ref": [
      "r231",
      "r644"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Realized Gain (Loss)",
        "terseLabel": "Net gains (losses) realized during the period on equity securities",
        "verboseLabel": "Less: Net gains (losses) realized during the period on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r231",
      "r644"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "terseLabel": "Net gains recognized on the increase in fair value of equity securities",
        "verboseLabel": "Unrealized gains (losses) recognized during the period on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]",
        "verboseLabel": "Summary of assets and liabilities recorded at fair value"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r520",
      "r521",
      "r522",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Fair Value by Asset Class",
        "verboseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r520",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r327",
      "r341",
      "r342",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r521",
      "r565",
      "r566",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r520",
      "r521",
      "r524",
      "r525",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r327",
      "r398",
      "r399",
      "r404",
      "r405",
      "r521",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "verboseLabel": "Quoted Prices in Active Markets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r327",
      "r341",
      "r342",
      "r398",
      "r399",
      "r404",
      "r405",
      "r521",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "verboseLabel": "Significant Other Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r327",
      "r341",
      "r342",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r521",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "verboseLabel": "Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r526",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "verboseLabel": "Fair value of contingent consideration obligations"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r527"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedLabel": "(Gain) loss on fair value remeasurement of contingent consideration",
        "negatedTerseLabel": "Contingent consideration",
        "terseLabel": "Contingent consideration impairment"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r327",
      "r341",
      "r342",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r565",
      "r566",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r528",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "verboseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "auth_ref": [
      "r495",
      "r500",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]"
       }
      }
     },
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r219",
      "r220",
      "r228",
      "r229",
      "r230",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r244",
      "r245",
      "r246",
      "r247",
      "r338",
      "r365",
      "r515",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "verboseLabel": "Estimated life, (in years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r264"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r266"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "Expected future amortization expense, 2020"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "Expected future amortization expense, 2019 (remaining three months)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r266"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "Expected future amortization expense, 2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r266"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "verboseLabel": "Expected future amortization expense, 2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r266"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "Expected future amortization expense, 2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r266"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "verboseLabel": "Expected future amortization expense, 2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r259",
      "r261",
      "r264",
      "r268",
      "r596",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r264",
      "r597"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Cost"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r259",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r264",
      "r596"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.",
        "label": "Foreign Currency Contract, Asset, Fair Value Disclosure",
        "verboseLabel": "Derivative contracts"
       }
      }
     },
     "localname": "ForeignCurrencyContractAssetFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.",
        "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure",
        "verboseLabel": "Derivative contracts"
       }
      }
     },
     "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r534",
      "r535",
      "r536",
      "r537"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "verboseLabel": "Foreign exchange gains (losses), net"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r58",
      "r398",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "verboseLabel": "Foreign exchange contract"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignExchangeForwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.",
        "label": "Foreign Exchange Forward [Member]",
        "terseLabel": "Foreign Exchange Forward"
       }
      }
     },
     "localname": "ForeignExchangeForwardMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": {
     "auth_ref": [
      "r496"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.",
        "label": "Gain (Loss) on Derivative Instruments, Net, Pretax",
        "verboseLabel": "Gain on interest rate swap"
       }
      }
     },
     "localname": "GainLossOnDerivativeInstrumentsNetPretax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": {
     "auth_ref": [
      "r496",
      "r504"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.",
        "label": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments",
        "terseLabel": "Gain (loss) on foreign currency derivative instruments not designated as hedging instruments"
       }
      }
     },
     "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestmentsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security.",
        "label": "Gain (Loss) on Securities [Table Text Block]",
        "terseLabel": "Gain (loss) on investments in equity securities"
       }
      }
     },
     "localname": "GainLossOnInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r116",
      "r345",
      "r346"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "terseLabel": "Gain (Loss) on Extinguishment of Debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r251",
      "r252",
      "r558",
      "r598"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "netLabel": "Goodwill",
        "periodEndLabel": "Goodwill, end of period",
        "periodStartLabel": "Goodwill, beginning of period"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "verboseLabel": "Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r253",
      "r255"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "verboseLabel": "Accumulated impairment losses related to goodwill"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "auth_ref": [
      "r254"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Other Increase (Decrease)",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "GoodwillOtherIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "verboseLabel": "Summary of roll forward of the changes in goodwill"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r494",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r116",
      "r269"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)",
        "terseLabel": "Impairment of intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/FairValueMeasurementsNonrecurringAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In-process research and development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r188",
      "r191",
      "r194",
      "r197",
      "r199"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income tax expense and equity in loss of investee, net of tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r85",
      "r116",
      "r186",
      "r232",
      "r609",
      "r637"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedTerseLabel": "(Gain) loss on equity method investments",
        "terseLabel": "(Gain) loss on equity method investments",
        "verboseLabel": "Income (loss) from equity method investments"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions": {
     "auth_ref": [
      "r116"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.",
        "label": "Income (Loss) from Equity Method Investments, Net of Dividends or Distributions",
        "terseLabel": "Loss recorded on Samsung Bioepis joint venture"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r276",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r431",
      "r432",
      "r434",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r128",
      "r429",
      "r433",
      "r437",
      "r442",
      "r448",
      "r450",
      "r451",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r129",
      "r151",
      "r152",
      "r187",
      "r427",
      "r443",
      "r449",
      "r645"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income Tax Expense (Benefit)",
        "verboseLabel": "Income tax (benefit) expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income tax assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expense and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDueFromRelatedParties": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.",
        "label": "Increase (Decrease) in Due from Related Parties",
        "negatedLabel": "Due from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi": {
     "auth_ref": [
      "r111",
      "r227"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Increase (Decrease) in Equity Securities, FV-NI",
        "negatedLabel": "(Gain) loss on strategic investments"
       }
      }
     },
     "localname": "IncreaseDecreaseInEquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities, net:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedLabel": "Other changes in operating assets and liabilities, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r163"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsperShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "verboseLabel": "Stock units"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r260",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r267"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "verboseLabel": "Cost and Net"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r260",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "terseLabel": "Total intangible assets, gross"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r258",
      "r262"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "totalLabel": "Intangible assets, net",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "verboseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r83",
      "r184",
      "r546",
      "r549",
      "r616"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "terseLabel": "Interest Expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Income (Expense), Net [Abstract]",
        "verboseLabel": "Other Income (Expense), Net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale.",
        "label": "Inventories [Member]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoriesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Current [Table]",
        "terseLabel": "Inventory, Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r27",
      "r249"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails": {
       "order": 3.0,
       "parentTag": "biib_Inventorynetcurrentandnoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "verboseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r3",
      "r52",
      "r558"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net [Abstract]",
        "verboseLabel": "Components of inventories"
       }
      }
     },
     "localname": "InventoryNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r29",
      "r249"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails": {
       "order": 1.0,
       "parentTag": "biib_Inventorynetcurrentandnoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "verboseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r28",
      "r249"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails": {
       "order": 2.0,
       "parentTag": "biib_Inventorynetcurrentandnoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "verboseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r248"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Excess and obsolescence charges related to inventory"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r95",
      "r183"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investment Type Categorization [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, All Other Investments [Abstract]",
        "terseLabel": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "verboseLabel": "Summary of contractual maturities: available-for-sale securities"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r520"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Marketable equity securities"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "verboseLabel": "Litigation"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Litigation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r41",
      "r126",
      "r193",
      "r236",
      "r299",
      "r300",
      "r301",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r310",
      "r311",
      "r472",
      "r479",
      "r480",
      "r533",
      "r556",
      "r557"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r26",
      "r126",
      "r236",
      "r533",
      "r558",
      "r604",
      "r632"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r43",
      "r126",
      "r236",
      "r299",
      "r300",
      "r301",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r310",
      "r311",
      "r472",
      "r479",
      "r480",
      "r533",
      "r556",
      "r557",
      "r558"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r520"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "verboseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r16",
      "r326",
      "r340",
      "r341",
      "r342",
      "r602",
      "r628"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "verboseLabel": "Notes payable"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "auth_ref": [
      "r294",
      "r295",
      "r297"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "terseLabel": "Loss Contingency, Estimate of Possible Loss"
       }
      }
     },
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyInformationAboutLitigationMattersAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency, Information about Litigation Matters [Abstract]",
        "terseLabel": "Loss Contingency, Information about Litigation Matters [Abstract]"
       }
      }
     },
     "localname": "LossContingencyInformationAboutLitigationMattersAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r51",
      "r126",
      "r236",
      "r299",
      "r304",
      "r305",
      "r306",
      "r310",
      "r311",
      "r533",
      "r603",
      "r631"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "verboseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash flow provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash flow provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r113",
      "r114",
      "r117"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash flow provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flow from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r73",
      "r76",
      "r81",
      "r86",
      "r117",
      "r126",
      "r143",
      "r145",
      "r146",
      "r147",
      "r148",
      "r151",
      "r152",
      "r160",
      "r188",
      "r191",
      "r194",
      "r197",
      "r199",
      "r236",
      "r299",
      "r300",
      "r301",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r310",
      "r311",
      "r518",
      "r533",
      "r610",
      "r638"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income attributable to Biogen Inc.",
        "totalLabel": "Net income attributable to Biogen Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsperShareDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "verboseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r73",
      "r76",
      "r81",
      "r151",
      "r152",
      "r475",
      "r487"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Net\u00a0income (loss) attributable to noncontrolling interests, net\u00a0of\u00a0tax"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedges of a net investment in a foreign operation.",
        "label": "Net Investment Hedging [Member]",
        "terseLabel": "Net Investment Hedging"
       }
      }
     },
     "localname": "NetInvestmentHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Rest of World"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r374",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not designated as hedging instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net",
        "verboseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r16",
      "r602",
      "r628"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable",
        "verboseLabel": "Notes payable, carrying value"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Current portion of notes payable"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableFairValueDisclosure": {
     "auth_ref": [
      "r40"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of notes payable.",
        "label": "Notes Payable, Fair Value Disclosure",
        "verboseLabel": "Notes payable, fair value"
       }
      }
     },
     "localname": "NotesPayableFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenseMember": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing expenses associated with normal operations.",
        "label": "Operating Expense [Member]",
        "terseLabel": "Operating expense"
       }
      }
     },
     "localname": "OperatingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "negatedTerseLabel": "Operating Expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r188",
      "r191",
      "r194",
      "r197",
      "r199"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r553"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r552"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r10",
      "r42"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r53",
      "r558"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "verboseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Investments and other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r63",
      "r64",
      "r69"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "verboseLabel": "Unrealized gains (losses) on securities available for sale, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r71",
      "r79",
      "r80",
      "r82",
      "r539",
      "r541",
      "r545"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "terseLabel": "Other comprehensive income (loss), before reclassifications, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r62",
      "r69"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "terseLabel": "Unrealized gains (losses) on cash flow hedges, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r69",
      "r72",
      "r502"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "verboseLabel": "Currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r74",
      "r77",
      "r79",
      "r80",
      "r82",
      "r87",
      "r367",
      "r539",
      "r544",
      "r545",
      "r611",
      "r639"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r74",
      "r77",
      "r468",
      "r469",
      "r477"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income (loss), net of tax",
        "totalLabel": "Total other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "verboseLabel": "Other comprehensive income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "auth_ref": [
      "r67",
      "r69"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "negatedLabel": "Unrealized gains (losses) on pension benefit obligation, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r495",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other Current Assets [Member]",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Component of accrued expenses and other"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r42",
      "r558"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Total accrued expense and other",
        "verboseLabel": "Accrued expense and other"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "verboseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).",
        "label": "Other Nonoperating Income (Expense) [Member]",
        "terseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]",
        "terseLabel": "Parent",
        "verboseLabel": "Total share-based compensation expense, net of tax"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r101",
      "r105"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Purchases of treasury stock",
        "terseLabel": "Payments for repurchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r110",
      "r281"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "negatedTerseLabel": "Payment"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedLabel": "Payments related to issuance of stock for share-based compensation arrangements, net"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r98",
      "r102",
      "r208"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedTerseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r103"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "terseLabel": "Payments to acquire additional investment in equity method investment"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "verboseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r18",
      "r558"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock, par value $0.001 per share"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.",
        "label": "Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid research and development expenses"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from Divestiture of Businesses",
        "terseLabel": "Proceeds from divestiture of Hiller\u00f8d, Denmark manufacturing operations"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfInterestInJointVenture": {
     "auth_ref": [
      "r100"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of an investment interest in a joint venture that the reporting entity has not previously accounted for using consolidation or the equity method of accounting.",
        "label": "Proceeds from Divestiture of Interest in Joint Venture",
        "terseLabel": "Proceeds from Divestiture of Interest in Joint Venture"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfInterestInJointVenture",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r106",
      "r109"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsToMinorityShareholders": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from (to) a noncontrolling interest. Excludes dividends paid to the noncontrolling interest.",
        "label": "Proceeds from (Payments to) Noncontrolling Interests",
        "terseLabel": "Net (distribution) contribution to noncontrolling interest"
       }
      }
     },
     "localname": "ProceedsFromPaymentsToMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r98",
      "r99",
      "r208"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from maturities and sales"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "verboseLabel": "Proceeds from sales and maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfEquityMethodInvestments": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Proceeds from Sale of Equity Method Investments",
        "negatedTerseLabel": "Proceeds from the sales of strategic investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product, net"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r2",
      "r73",
      "r76",
      "r81",
      "r112",
      "r126",
      "r143",
      "r151",
      "r152",
      "r188",
      "r191",
      "r194",
      "r197",
      "r199",
      "r236",
      "r299",
      "r300",
      "r301",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r310",
      "r311",
      "r468",
      "r474",
      "r476",
      "r487",
      "r488",
      "r518",
      "r533",
      "r617"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income",
        "totalLabel": "Net income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r277",
      "r677",
      "r678",
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r35",
      "r273"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Fixed assets placed into service"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r12",
      "r13",
      "r275",
      "r558",
      "r623",
      "r633"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "verboseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RealizedGainLossOnInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of realized gains and losses on investments reported in the statement of income.",
        "label": "Realized Gain (Loss) on Investments [Table Text Block]",
        "verboseLabel": "Proceeds from marketable debt securities"
       }
      }
     },
     "localname": "RealizedGainLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RealizedInvestmentGainsLosses": {
     "auth_ref": [
      "r646"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment.",
        "label": "Realized Investment Gains (Losses)",
        "terseLabel": "Gains (losses) on investments, net"
       }
      }
     },
     "localname": "RealizedInvestmentGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]",
        "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]"
       }
      }
     },
     "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r71",
      "r79",
      "r80",
      "r82",
      "r539",
      "r543",
      "r545"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "terseLabel": "Amounts reclassified from accumulated other comprehensive income, net of tax"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r108"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "terseLabel": "Repayments of borrowings and premiums paid on debt exchange"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedTerseLabel": "Repayment of borrowings and premiums paid on debt exchange"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfSeniorDebt": {
     "auth_ref": [
      "r108"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.",
        "label": "Repayments of Senior Debt",
        "terseLabel": "Repayments of Senior Debt"
       }
      }
     },
     "localname": "RepaymentsOfSeniorDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepurchaseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments represented by an agreement between the entity and another party for the sale and repurchase of identical or substantially the same securities at a date certain for a specified price. Such agreements are generally short-term in nature.",
        "label": "Repurchase Agreements [Member]",
        "terseLabel": "Overnight reverse repurchase agreements"
       }
      }
     },
     "localname": "RepurchaseAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r424",
      "r594",
      "r692"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r424"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r279",
      "r281",
      "r284",
      "r290",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring, Business Transformation and Other Cost Saving Initiatives"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiatives"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r116",
      "r278",
      "r285",
      "r287"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring charges",
        "verboseLabel": "Expense"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r280",
      "r281",
      "r287",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r281",
      "r286"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Restructuring reserve, ending",
        "periodStartLabel": "Restructuring reserve, beginning"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveAcceleratedDepreciation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan.",
        "label": "Restructuring and Related Cost, Accelerated Depreciation",
        "terseLabel": "Accelerated depreciation expense"
       }
      }
     },
     "localname": "RestructuringReserveAcceleratedDepreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r22",
      "r374",
      "r421",
      "r558",
      "r630",
      "r656",
      "r658"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r140",
      "r141",
      "r142",
      "r144",
      "r150",
      "r152",
      "r237",
      "r418",
      "r419",
      "r420",
      "r440",
      "r441",
      "r516",
      "r653",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r388",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r84",
      "r126",
      "r181",
      "r182",
      "r190",
      "r195",
      "r196",
      "r200",
      "r201",
      "r203",
      "r236",
      "r299",
      "r300",
      "r301",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r310",
      "r311",
      "r533",
      "r617"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "netLabel": "Other Revenues",
        "terseLabel": "Product revenues",
        "totalLabel": "Total revenues from anti-CD20 therapeutic programs",
        "verboseLabel": "Total revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalty"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesMember": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.",
        "label": "Sales [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "SalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesReturnsAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A revision in the estimated reserve needed for product returns and price or other concessions granted to customers.",
        "label": "Sales Returns and Allowances [Member]",
        "terseLabel": "Returns"
       }
      }
     },
     "localname": "SalesReturnsAndAllowancesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "verboseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r71",
      "r544",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r215",
      "r218",
      "r221",
      "r222",
      "r223",
      "r225",
      "r619",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information about a contingent payment arrangement including the terms that will result in payment and the accounting treatment that will be followed if such contingency occurs, including the potential impact on earnings per share if the contingency is to be settled in shares of common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]",
        "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.",
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "verboseLabel": "Summary of fair and carrying value of debt instruments"
       }
      }
     },
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]",
        "terseLabel": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "verboseLabel": "Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "verboseLabel": "Summary of share-based compensation expense associated with each of our share-based compensating programs"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r496",
      "r505",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "verboseLabel": "Summary of the effect of cash flow derivatives designated as hedging instruments on the condensed consolidated statements of income"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "verboseLabel": "Summary of fair value and presentation of derivatives"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "verboseLabel": "Basic and diluted earnings per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "verboseLabel": "Reconciliation between the U.S. federal statutory tax rate and effective tax rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r410",
      "r414",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r410",
      "r414",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "verboseLabel": "Share-based compensation expense included in condensed consolidated statements of income"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r2",
      "r126",
      "r235",
      "r236",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r520",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "verboseLabel": "Summary of assets and liabilities recorded at fair value"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r259",
      "r263",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r256",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "verboseLabel": "Summary of roll forward of the changes in goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r11",
      "r30",
      "r31",
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Components of inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.",
        "label": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Summary of the effect of derivatives designated as net investment hedging instruments on our consolidated statement of income"
       }
      }
     },
     "localname": "ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the notional amounts of outstanding derivative positions.",
        "label": "Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]",
        "verboseLabel": "Foreign currency forward contracts that were entered into to hedge forecasted revenue"
       }
      }
     },
     "localname": "ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "verboseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r36",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r280",
      "r281",
      "r282",
      "r283",
      "r287",
      "r288",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r281",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Schedule of Restructuring Reserve by Type of Cost"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r48",
      "r123",
      "r171",
      "r172",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r356",
      "r360",
      "r365",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "auth_ref": [
      "r471",
      "r472",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table]",
        "terseLabel": "Schedule of Variable Interest Entities [Table]"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Estimated future amortization for acquired intangible assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r116"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "terseLabel": "Employee related costs"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]",
        "verboseLabel": "Share-based Compensation Expense included in consolidated statements of income"
       }
      }
     },
     "localname": "ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r409",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r120",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of significant accounting policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r50",
      "r79",
      "r80",
      "r81",
      "r140",
      "r141",
      "r142",
      "r144",
      "r150",
      "r152",
      "r170",
      "r237",
      "r367",
      "r374",
      "r418",
      "r419",
      "r420",
      "r440",
      "r441",
      "r516",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r545",
      "r653",
      "r654",
      "r655",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r170",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r18",
      "r19",
      "r367",
      "r374",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "terseLabel": "Issuance of common stock under award plan, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued": {
     "auth_ref": [
      "r19",
      "r367",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.",
        "label": "Stock Issued During Period, Shares, Treasury Stock Reissued",
        "terseLabel": "Issuance of common stock under stock option and stock purchase plans, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesTreasuryStockReissued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r50",
      "r367",
      "r374"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock under stock award plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued": {
     "auth_ref": [
      "r18",
      "r19",
      "r367",
      "r374",
      "r376"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.",
        "label": "Stock Issued During Period, Value, Treasury Stock Reissued",
        "terseLabel": "Issuance of common stock under stock option and stock purchase plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueTreasuryStockReissued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock Repurchase Program, Authorized Amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Amount remaining under 2019 Share Repurchase Program"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r18",
      "r19",
      "r367",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "negatedTerseLabel": "Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r19",
      "r24",
      "r25",
      "r126",
      "r206",
      "r236",
      "r533",
      "r558"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Biogen Inc. shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Biogen Idec Inc. shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r80",
      "r126",
      "r140",
      "r141",
      "r142",
      "r144",
      "r150",
      "r236",
      "r237",
      "r374",
      "r418",
      "r419",
      "r420",
      "r440",
      "r441",
      "r466",
      "r467",
      "r486",
      "r516",
      "r533",
      "r539",
      "r540",
      "r545",
      "r654",
      "r655",
      "r706"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "verboseLabel": "Equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r124",
      "r352",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r366",
      "r374",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "negatedTerseLabel": "Stockholders' Equity, Other"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r559",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "verboseLabel": "Taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TrademarksAndTradeNamesMember": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trademarks and Trade Names [Member]",
        "terseLabel": "Trademarks and Trade Names"
       }
      }
     },
     "localname": "TrademarksAndTradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r219",
      "r220",
      "r228",
      "r229",
      "r230",
      "r338",
      "r365",
      "r515",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease": {
     "auth_ref": [
      "r544"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the cumulative translation adjustment from gain (loss), after tax, on foreign currency derivatives, that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.",
        "label": "Derivatives used in Net Investment Hedge, Net of Tax, Period Increase (Decrease)",
        "terseLabel": "Gains (losses) on net investment hedges, net of tax"
       }
      }
     },
     "localname": "TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r49",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockRetiredCostMethodAmount": {
     "auth_ref": [
      "r19",
      "r367",
      "r375"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.",
        "label": "Treasury Stock, Retired, Cost Method, Amount",
        "negatedTerseLabel": "Retirement of common stock pursuant to Share Repurchase Progams, at cost"
       }
      }
     },
     "localname": "TreasuryStockRetiredCostMethodAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r19",
      "r367",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "negatedTerseLabel": "Repurchase of common stock, at cost, shares",
        "terseLabel": "Repurchase of common stock, at cost, shares"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r49",
      "r376",
      "r377"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock, at cost"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r367",
      "r374",
      "r376"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Repurchase of common stock, at cost"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r280",
      "r281",
      "r287",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r398",
      "r618",
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "verboseLabel": "Government securities"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnDerivatives": {
     "auth_ref": [
      "r116"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.",
        "label": "Unrealized Gain (Loss) on Derivatives",
        "terseLabel": "Unrealized Gain (Loss) on Derivatives"
       }
      }
     },
     "localname": "UnrealizedGainLossOnDerivatives",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax": {
     "auth_ref": [
      "r501"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.",
        "label": "Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax",
        "terseLabel": "Unrealized gain (loss) on net investment hedges in AOCI"
       }
      }
     },
     "localname": "UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r134",
      "r138"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Total Reserves",
        "verboseLabel": "Revenue-related reserves for discounts and allowances"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r134",
      "r135",
      "r136",
      "r137",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r134",
      "r135",
      "r136",
      "r137",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntityDisclosureTextBlock": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.",
        "label": "Variable Interest Entity Disclosure [Text Block]",
        "verboseLabel": "Investments in Variable Interest Entities"
       }
      }
     },
     "localname": "VariableInterestEntityDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Variable Interest Entity [Line Items]",
        "terseLabel": "Variable Interest Entity [Line Items]"
       }
      }
     },
     "localname": "VariableInterestEntityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r163"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsperShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "totalLabel": "Dilutive potential common shares"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r155",
      "r163"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsperShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted earnings per share attributable to Biogen Inc.",
        "totalLabel": "Shares used in calculating diluted earnings per share"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "verboseLabel": "Weighted-average shares used in calculating:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r154",
      "r163"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsperShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average number of common shares outstanding",
        "verboseLabel": "Basic earnings per share attributable to Biogen Inc."
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3444-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27340-111563"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583714&loc=SL75117360-209713"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117546-209714"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "http://asc.fasb.org/topic&trid=2175745"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20,22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "c",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613674-111683"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5747-111685"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6228884-111685"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(iii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5629052-113961"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Subparagraph": "(a)(1),(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80784-113994"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80784-113994"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10(3))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62586-112803"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.3)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.3(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r693": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r694": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r695": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r696": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r697": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r698": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r699": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r700": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r701": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r702": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r703": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r704": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r705": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e689-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>123
<FILENAME>0000875045-22-000016-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000875045-22-000016-xbrl.zip
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MF@C@>NF/T=QM [%=2<JV>J %N8DK'A""1M>"!6-NOD\\%$D<-P_H;SJZM7I
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M6ETBLP'!?)/"P4H40V@@H6EBD'I"$'JKCU81+1>,T5WLC;3^%+ENX6 US0F
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MV0L#4LB]DM0(F>A\K3*$,N'K"UX+(.!=3K$YJ(URE1PJ0FIL(S4[D$A^':+
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MW& +/)Q2E1.:ONP5@(L7?0AB*''.L@_512CH&+(O%!8CP)K5)P1'>8,M;Q7
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M:]94^&PI_'ZF"J/8#,52!E\1DVV6$C3RW%P8%H6OD_3:4OA](WCGH %7C@E
M8[= X9JQ<I> -("=:Z\3:[;R\S,4KDG]KDWL4T$0SIEZQ5:-Q>L?\6U+X76J
M%U@7UFBJXIQ$Y4D$_2EG7P$ /1HO:.TV:5DKUJR5 %X7"@,EJ6193%#'!X@F
M5PZ^.E=<,=X.BL);^7DMO3 G8T-,R:@;YN9S2YD21E).:V(U@!TSKQ-KMO+S
M,Q0FM#G:DIN7HCXXHC=.(&=C6XD6AC7_,B *7WVER1+;W_I,+D;K2R5PV>=
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MU=XKF@MXA]*JS:Q^'M>XC]Z6@BNEX!)7P><N"U'UA2%PE8M)U6,TB32.41M
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M#$2N]!7="3U:9E>3IACJ,P90B+FFC!CLJ!IG6X-MJ1%%,%(QU8@YLZ, $.T
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M2O15+@K3W65ANG.X;NB\'V K\_=#:Q_"(^/19'HPF<OLCGJ]!Y/1>'[X9O)
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MH1M;&$('HUEV_2J3HP,DM'LPAC#:H!0_]0@W0>MU^RAH*"!6SX?+!*  BI@
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M0T\AN"JCP,'U:,[P+%$4Y\/E1A,00J9EB1)?"D_GLA;)3=-<!$-<RN50L,I
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MFH.X&CE3M)GLFD6IIHZ)#+&4,,08I4ASG2%.@1IDQ!J"W<HZ7:49F3:P&3G
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M?)X1K'("6IF*6W*/[]+*2 I^I5Y[OJ_A0Y=XW6W#,\3MCG-QZ4?#OCT<]6M
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M7.F$M,,8X92,!ITY:C-%X--R4V7_RM-:+"K6>>?6.4D7B"51@8*B=;F-0 Q
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M[9JM<D'9JOU]D/?4W@E#*B3HITA0J[;]=!F6]GMCC)M M@)4,P'5E).]7J4
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M,DPT&YA4*( ^$0_"(<.T0IHHRGB$=VS>RD/$E SSS)5("[P6>'TR\#H#NK+
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MUI8+''E(G"=N@U:8>8NM""S(5#(^2P*S'R8R/L+HP FQ2' K$"=4(). WT8
M7"LU=@93H+9D319>6]"UH.M=\-H@J(A,)"99Y-Q8RZ0WFK$($)MD,H77+C/@
M3B1\<*2>X A$5BK@M8Y+9+U,")1-4Y0,&TI;7DOQE'Z?R\=KF_/?OS93#OX-
MG4_K_X(?9T.^]%T^YADX-MKU?[GZU_7SYRR7E<N>V&7S+6Y \/>\%LU>ZR#&
MRGK?/X8!G(+E5[W^, YR,]SA41Q$\&(6_$GNCPN>(^0"]LUO#60T;7-3IV=[
MOF.[,'QXH>F9NS9OD8UA"652]%QP>+*S5QH\:E_ZP>\>BX/3-94=_4E_T,G
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MZ^S^_:ZSM_7RP[L/>Q_WMMZ0O;_S]_W5W?NP@^&[<-X6N_O[_Z3=3EO ;_<
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M1%_6I9<"L$ZOK4L+;T6,'LFD(^(F,.085L@$9TR*,@GG<\_'69KL%IPJ./5
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MH)'=@]^J@U<[>Z\WWMWP";#=WZJ-K3?_WOYC=_HGIEC?;^V=W^QNP%AON&P
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M-^\!T(6.'UZ61-X\=T9!\C:&^/E*YO\<H@#KZO<-BX*;-@3V7'<7B?FQF0(
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MD"9EG0:H,3HCC(Y>:M@<15;2E7ZBD8 -@;@@T H)TB>1E),1#1!![0+<I4X
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M6^M_?=B^"LB]",VYBPNX#MZ=2[FW6=:J=[<;G9IP)R'<\5B3;"&XJBL3U8Q
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MQU'M?1Y4_]MK9W?UH/I[&#:KWZY<^K.Z;VF2NR!6_>>2 :PK&(VY2NV;&52
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MB0%<49&>]@H0165*/" >.8BT911IXPDRQ*8 7-L)^U2""M8O02>7S!F>%4_
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M0S&@[UZ.&XPN29Q)+#I@"5(S3",W!I/D).%S1V;.#TP%@.8'H-E4$&=%9G)
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MI1,4.\%CR!H?;YJB\%=0ZI9EO"XL=84!+$,:IZU<ZI7TW& D @@B3U0@ Y0
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MPP*&3PN&I9CK24!P--Z$7?#$18(PE@""2E#D8.F0)IQKFFB@-&8REUF%EPL
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MA@@64D1>F(1XU!0Y:B.REI,8",V,D^!LD$DEJJ6R?*%E>D&,[B*B4XKH:#S
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M^KQEL7CICY#%42\]:6V)U18)G@@H1FZ0C<(BP[Q3N7['D,I+UPOLI;\<,5P
M*2R^[FP$;=37=9XX$H)"2IB0@^H.F<0B(M08'C%UMFHGJ_D$45LP7W?A'=SW
M;1A1ZP3\VY(%4[)@%B8+YE7J*1]PQ$$'9:S@7D<3 0>5%L2$X*EB)6*R"/KJ
M8BQB F:%#9%CY+@0B"MBD0T^4]T[&D,$%XWKE75-IJ9F*_;A2Y*[TH[P.85T
M-))"HQ366HUB%!YQQA1X;]$A3XVW&GO-]$.[$18Q?::<ASG+:8FF/$(>1Z,I
M007+=?+(6:\0=S%W.E8$*192B#82S:K,J?%#AA)->9':LD139B-HX]$4IG7P
M D4%.H\G09'S6"&)X9,HHXK29.M4SB/3^>7ZP"5SX,$(XS#1,6IC$H_<>JZQ
MYI%JS%G0/H14_. %0)K=\9H*FY3F+D3$\RD)YY0AJU-"VD5P@W//J)CCMJKX
MP:]:[DKFP%,(XYB_"UK?>1>1=P;\71TELMX%%!Q)B@D55!1+49GP<D1Q&E]W
MWK)8?-U'R.*HKZN"DY1J@12().)"&J032"51*:9 L L&3' R02T67_=%:L3B
MZ\Y&T$9]W9"$3S@*1&3NZ$"#1+"$# DO!4G)"BU3MD#E/-3>"\L<V 'WZ= >
MQIIMA1I<,W9JMMN-9[7,1AQ#22<HZ00EG6">RDL$B@7U3G%L.9<.7 #CN,0\
M8D4ECR6,L@!*;&=_8ZS96Y!<28X9PD1J,!<514ZQ@$04QH@40(_);"X6U^T5
MBUW))GA6&1WM'28$(8(;B92*#F24$.0,)H@ZYDF0TA+G2CI!D=-[1UB*G,Y&
M3D=U:7"&8V$1E2$@[E5.^R$2)98;4C$=4Z:R+W+Z^N2TQ&!F)'*C;8XP)SH)
MI9&@N<T1#AH9#OK1:FE$2-JGG-DS%_/UY?K()=W@P0"C(Z-4FB $XYPD"AO4
M@Z<EA2?@=B59_.2% )JM,3^9658E-Z$D!495YH$.QB'FE),F)LYC *!A9!YU
M8D7P%D7PBJ?\K%(ZZBD3$$7E:$0I$HIX-""EC$M$6,!12AEIB,4"7^ADA'D+
M:DE&>)1 CJA-+8-PQ%K$F,[VN<II>N <2^%H\LH;)T+.#%(E&^%UZ,OB"<](
MTD8]8<:-QT)0)(,EB-M D)-.(FV)"UII@X7J&ZC+X0L3LP2>\'[[S#9K)T_1
MHV;P\;V;^2P_ >K]'_5%(:W$QB:+7=2<<LFX,]$SQH*EGB;!S=.%!*X[(:W>
M"0KMJB]QOD.!XZG@>'LL7F )9A9T)Y)8>@3KFI!622*1&SH3%HVF ,=TE3.Q
M9J;LP#Y%?Z_G(V,N0%6 JI1L+"Y C89*E,,^1.F0\H!-W"B+# ?+T1IBG8H4
M8^,FUT07<%H$P7T-X#1-W&C>Z%3B1H]"IU'S23IOJ)0HZA00=YPA2ZA%1#BG
M,3>2*;*RSB9PT=X6-RK 5(#I)5E-MP?2BELW.UP:C;)Q\.&"4!X13ASB.%FD
MHU,H12PSSZNRE/7=.C9MG.W) 6H0A!O>;[BA185+SUE2<NU)&3Q+:/=RZ.S9
MVA"7>[Z0?LL_[1@>_]MKG%T\6<_P\M69%8<MU+ZZI0;QCGVU6GM\/MQ]CQ87
M<G)>7U,SK@333'K"/>5)*NM=])8IYBT-(O#[VG5;U5ZZLM_>?:LW<HR^F&I3
MF6J?QB+P2A,ME2"(11'!5-,1:>X3"E0YF:0VW$IP(=FTX??2[K @PY,B@VLT
MW!@LC+I_)4S^-"@R&B9/PEE*0VZ%A 7B!%X9H@B2+C&!=7(&IY5U4T"D@,A+
M I%2,/@DX#)BHCB2-'>4]&/;W!F!#"P\$EP'HPV1BBU/86\!F/D_QH+X+P48
MI@2&T3"S%8DJ[AABKF(WU0I9S0C2*CH)-@CAE*^L<[;X3:E>2'BG54H>'PPT
MG&!*/;$X.BZ4M!I;;!174G*:V+T[XMT>*"D'7K-"HL]C411N68+%"<@9FSD-
M<$*6,X.H\X11&RE-@$1DE4Q_X%4J.99"_DHX8H[B.!J.X"89YHE"5,>(>+ *
M:8TYPH8Z^!=C(?>%)6(2OVL1Q@5(4YNS-)8LM4=)XZAR#,1H&PW8Y1Z4H^4)
M@10RY"+#BGK0D3(G^2M3.@N]-*UXM_M;+-+9"=VH;QR%2)))GOMX,<25"\C8
MI!%)1!-L8F"Y8S-9Q9A/*"M>1/=X.4L=9YE<<S-YJ?^LH_E+O]^:(/<R$V4?
M-PLO"JQGE4-;0@A/#]A^+(0@(T]$4HZ<P[D[##?(,9EI$4FDP;#(':M""'+J
M9DVS$)5YY/L7A"L(-U.$*T&:.0+>:)#&1"=2ACD>:03 <PYI3 C"U)H0A/ X
MY!8\$C^P\KO 78&[!82[YZS6+&&P>>+=:!@L*HN594@I#Z!'K$;:2H9R/%H:
M3)258MHP6(&Z G6+"W4+XKL6OW66L#8::)3)$(<I1D%@B[C/9&H>1T0IED(P
M1YTE5:"1ZS6Q/(9<%:#\K8KAK5>CSMNUT>K9:MC_^2TTOJW_!_X,QWIB.X>-
M5C4:4P'?!*&C0C%G'RQT! ^EKKKLF\89#-S?7>M'LQSN]4Y@>!>U=JJ]A2_G
MN>_99FW'G@W;P=5^& 4(9 5ELZ"6"Z9K>^-QR^K)^\M8[YW &/U(=P"BE$O,
M8N,C#P9;R3TVACJ5]1\.7S9!E"DFN35+?L&R3-^4XNW6M]@].XFML^[;INUV
M&ZD1PQ\7UP8_&/O%)I@M^WG<^W#_/YIM_W4YQ;@9_^_'BX-_PZD#^*OO?[[,
M8ZN?;/&#S7=?ZYN?R.>3=R<[^Y]H_?T_QS >_OGXSY.=RY#JFU\OZ^=?F$D<
M$Z_!CTK@3/$HP)ER#$E'+<7@3+$ D!L!ZTYAGL\ZO;ARV_:50\7:: 58@3>4
M5WS[3Z)'KK;T;8JDVL#[1Q'&?@9X#49J+=E&I_;--GO]1H=VR-D&V[![EC=Y
MN]>Y@VVP9F_L]6[>Z^ZBVL-#R3@9[*Z:[<1:MY*>Z@:V"ZJDV6R?7VN@. 0"
M *[J;C>Q"Z:I:4^[\<WPQ>^AT3UMVHLWC5;UG-6/?A],_P#I<G>#$7"J%J3_
M\>_GC7!V],:8-2%)UK*#8Y3!C?N?DK5* 8\ :O\S3M8,Y;=^C-?( S\3[&%7
MO6NPA*YQ;,I@RV Y8?>Z[-(6ZD\VHB=;2 ])7#!7] ?6?SWLM'NM@ :/$JK_
MC%I.UR?'@RZ(G6FF!\P=Z]T3\QAL=#/B[]B./ZHQLEK+)L5L)VNF<_(LW []
M.=F,/IZXV!E."[DQ+4LK)9,?^9?M5@TNW03CO#L6+)D95\A/&6>68'-L#>VH
M_[C.;^OOLBWU3[:E[C%I]YJ)US>C/TB#JQG-)^5E Y8-N#@;\"=0_]#)6$AK
M:1.<0KA<NQ5K%]%V:NU.K1F[LTBZ&C>97/Z_V\-03Q*VGK%--678^O%S\*B@
M];,\_!1!ZR"HB$PD)EGDW%C+I#>:L:@P2S+U@]:# -?#20NOPG3_-N 16[NM
M^!FV]@VJ^M<0XO[T_0#N<[ ?&O7]?YKUS0\7N_]^/*I?OCNN;QZ<U(__@;&&
M9IUNB[$0]_Z[K_!,^3.XSR=<W]P6!^^WV,Z_.[A^\IG">Y=U^HE]/FZFG0:^
MR.'MG3W,ZOM;>&?C2W*.Z40"DIIRQ$TTR ;B$9.2)^^LY;9B,\283LT#_6B)
MFNWIW:WC*>A8T'&9T#&;E95569!QALB(1Y#14.DPEAI1;%4NP.=(Y\[>+!A'
M!'8V"--'1CEUSNJ"(6-AJ)[^44N&0C'V%AW2Z BD$:6,H2HB^%^".*46::$9
M$H9&[;7#%1\B615\ZA9Q!;D*<KTZY"J&V%.@%A\UQ*1(*N& %, 3XE8I9+16
M2#NA'6&1:AR'J#5EM>=S$>XOWTG4[1%(F\YBYRH(>78$ANSA42TUOO7?F0G#
M.KV_USZ[ O77[F1NY)4%:-OO+^D[6-&,<MT1 ZV@V?W1[&(LX,:2%]PGCTC2
M&,&J*F1!82%",8_6! ]8M[)N-)VZ,N@^@C+GB%J1[T64[VMF3)'M:61[-&1D
M(S=8)XI@91WBTGOD&+A;)!!B@\')6@RR;=C4=LKSRW:ABIFCEU$T\1-(ZV@T
M1$B%O4P.11,$XLF!7\%B1!1K81EE."6[LJZEGM!BL!"I%:$LZO.1 CGJZ!-/
ML?2@.;%Q#!Q]G9##5B#/HS*PLEI@"0*I\#P$\L5Z\L5Q7SC#OBIMGPJ6BH7P
M:$"JOQWSU6W45A,>D521@X60(M(N,10Q9DH(YH7+Y9]Z"<SYXJHOJT07\^*!
MTCSJG0>9B!1@5*1D/.)!Y\:]X*(3<,\-"5S[E$":S1I;>&DN?L"LB62*MGUV
M^1SUQQFVF9$W(6DDS;7>##EI,)+:8J^=,AKCE74ZEXXG10P760R+BGR@"(YZ
MX)H+CQD'G4BE Q'T"ED3'1(D)L^#4]91$$$^C]8"KX95>832X>G+>R9ST."[
M:&A>7X;[+":IN$13AU^O_E5RK&8&_'MCD8Y@M4[81B0"MX@3RI&Q42'/:72>
M2Z7S60BK&/5GG.P^ \%:CCJA K,%9A<'9F^"ZPU']@_;;12XG27<CH:BB,$F
M2.,0,YSGDRYP=55R*"F:I"7)""(JN"7FQ</M8TA5GQ\\%R''?^X8^=)"#\44
MG2,VCH8!-8W,:Z,1H]$C+DA$FEB+<*:2%M%HPV2NN^33MQLM$%@@L$!@,1,7
M%0I'P[&*@4]N@D:2@X7(G?, A2RB;!ZR:$3DBO:A4,RTC\BS0.%-$NJ*9/:W
M&\S+2\;A:^%I[6&\XM=]$%FOG4#Y6#$!CS$>KM;.X<OV]+33_EYQCC4O:D]$
M73TXFJF>;TA.O9MV?CS8+981S*9_$WJ=$QC&T7(BP(.IJW?V-RYVSK]PJ;#R
M22$KE,CM80FR6GBDA+8I42^TURMW,HY;@ #I6?):&F[A9SI1S;2E3#IIA*F6
MC0R7;8#P9=D>MVPA65B8"%-*L$.<"HTT\PY)S9T/6@1%\,HZP6.(-?+O6C6'
MW;4Q0NW)L+98S/I_=]H^QM"MI4[[I':U;>9)GO_Q6K>RW,%GMW6-3O^U<^7C
MW8TOS K+C8LHQI@0Q\(@N))#+G(?,+$PN6:YN?)/;VS+DQ\I 966S#JTTJ!W
M:5WX7B=V>\TS,&%JPWY0M4/84OT/F["Q\O<6EQ\?W(,UW'<1IB7(EW*-&O4D
MS.BWW_3!S.A\3?#[,:-/]QG33T#CG@<K[WO9"6& X>X _(R+\<T75O3P%'3S
MR\>H"YY][0R =/^H$V-MI[)0:EN \>'*[[C''+W2G?7\%.VW]3-X/J+G9VEV
M<,_F!H4F^[;9(T\NM', @A=%X/WW3TW7PN5=V&IG?SCP(,?[KE."X49^!_NX
M:K/;"E<!IMM/45_&><!Q_7AG?YO7+_]L?J:?Z.?C#^?U_7^.ZIOO&CN7G\[K
M]",XZA^/ZW"MT?. ';KS?>?XD.V<_'-\L'_0J&]NP/VV\,Z_VY?U_0UV\![&
M]WX'US?_F436+2)AX-)CY&..)A)-D*5$(VHEY1%VO<]I(^ QK<E"2/NBSCM?
MVW%FLB:JX*RE+">]*2V(523QP#A5VJ61J'=!K 5!K-%$MV0QM<[;3-9H$8])
M(<>I1)1Z&6(D-AJ^LJZ)F9;284[ M'3V\[*9R!]OA&,+(\6B6H C>2$C 'K]
MF.9FADAJ?(\!7<9.NT#K-- Z3B3)I8X$P!1)A27B2F2V'":0Y%$8'"2+F.60
MIZ:$_EXJVN>.;/.T?J:1UB*5TTCE6&8_3Q([JY'!RB!8/8(T9PJ9R+"4DF A
MU<KZ7!BLBD4S7XNF?ZQ<3)K%,6FZ\,SPZF%HF=-/"EI.@983"+:D#,$[BA$1
M!"/.!$862X(BES(%J;&&10.TG%4XJ]@ORV*_%-%\9M$<-62D5281F1 FSH$A
M0W/F*DN(<$^BC902%K-H3DE]]^H,F9EDN-.U.2?>C1@QV:6O<DC.JAR2?I9K
M+>8<DN&Z/^50ITQDK3W'F.Z<O@GY_/T4_M-.(^<7-B]JG=BT9S"A[:L<1M_N
MG+8[^5W7;H7N:LT>QI:_J.4BG$-XC;*>@S49R6V$0<=.S<(ZG8U_8R05.>_'
M#-V-5L]6PGM]1PX>@>>4Q--VMY&_\*8:9^-;O,I$_-^;&:2#/$9\]1/KNNUF
M[^SVGXRE5\QSJU_+H^A/T;6_1YTK',OSWXGV*ZIH=-_8YKF]Z*[\=E.F0: '
M%Y<JR_#8%-SZH"D]7<8(/&<?7T#GY@V6%PF,I=C)WX)QV84:3PTP!JR*_VE$
MD^D;G:7.)AZ9,L81HD22!A12X/(+>-95#G@6GK?9(&F=@;]EUV]-O[_GQB->
M6!5FM_$FP]0?V[OOM^JU[?K;M=I&?;.V]^F/O>W-[8V/VUM[R_$$]=W]K;V^
M^M_?K;W=K6]NU?>V-O.KO=V_MC<W]N$?[[;K&_6WVQM_U?;VX8V=K?K^DCS>
M+[V6[87&60RKM0%HQO#K)+080=6^ 2J95=2&J,!!Y8P+)\$F)M8$&7PD3-R5
MB+]8E2%[9UDK'<+5KU5?W+/&9=%*"C:F*+C+Y7S='\_>^/'L-5#39ZG=;+2K
MFCS?/@&]W@6]"U>^^E87E'N>X=9A[?],X4PQC5E&/DL4Y0%KRY,&S(LT*D'!
MJ;H7]?"/%;M:L+^'8W[1);R/J 3;N=S]\"5)*R5U%(44!>)&@M:G+N7D&VM#
M$AI+M[)NB%D38X[0,".XVD[3++E*/M?Q2"6PXQ9KIZ/5A,F4B(J,IGM1:98E
M?\"2X_KAEV",2(E%6&V=&W\[@8P) 6%-HI9<)D#=W&^2$#R!*GJXZ*NYQN@T
M^FPK-R]6:^< 5T=535&CY9N]G&T/,-:WU<$X[V08J6SVOA%_'39&C/IN]4.
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MG>.#D_K)/ZE^_)7FIDI>).6,1II0@[B-%KE@%0K48DF9Q\JIE:OXRD9V4J+
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MFA-.G(<7A+GHK+&*>J)*RND"(=]8PR-J<8@V(:\Q0=Q+B@QU$25I0XRYZL$
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MKI1$FG! ,<N#94FZJ./*.BY48LMC5IAHA5=@11#.N#72:FYD!('-4;$H7 F
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M/NRD;G^X/X 9T>5$YL<0N(C=_8V+G<MM>/_#195ME1077B-MLNF3DD..,HO
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M1.2Q2V";$8ET""!^6E)-? HVD:JRYG:M6^']-'L#AR2#"\$E\#,E-9IFNKB
MG629,%&-QF'-SXRQLC=FOC<NZH=?8I#&:\N15Y;DO:&0$1(CGG02C@CK+=CM
MY.Z],05Y7"=V,^LOK%'SHL)B0-N,:->A<0C*%;OKE7TVQ,4*EJOH5 YG#?FS
M^E2P8++DR%:^^7DCD^.=9 "^C#<N<)HC97V6K0HVAT Y."']=76@.J8EX;JB
M+@;KYV24L6\ZQ3 ZV*=7 ?V65=/J "=(-(: XM::YX,6F;L><9_ $6,  3\C
M\AZ*]T;;-Z[D]T,/1#U=P+IN=*M@]%9_EX2<VM%NP;1O9)[;(MRW"??^#MWY
M\"4H;@PL"B(V:L1MP,C2$!$.7%#BM=19N.DDE_RAN"^PI!'V Y-.P0V%=3@E
MRU/6 $Y'5NT'0FC9#\^]'W8WOF@;F,N%M8DJV _86>14\,B"^8:3PS3T<X&?
M!.O!\82=<MQK#>*&^52EPL=^7'#($-JU?<KD 49-.)B8Y/^O#GH0M'UE1E?@
MN''::30'SN%YA<-]$_LLDY0VV\.#E(6E) 4;YBK(U#^2VVYM7"'^7;EN%?/T
M*V8E)8!^/A!BG/*(!<T0]T0C#=X*O!(N.2VBB/J5L)+F?3[)'?Z)D9.&5+?7
MS)U[,8W^H,=>%J)1HM>8>AB]XO.3-HHU8I:%NG.9Q@H>L"++,MAEFMAE&BMA
M:T;?_O%B#7:9)E:L@<GS<*9900K3;&&:O9/=M J W#"(?_"<;E6F4'[G[W[@
MY=?"/+LH:[,QZ 8U].G[L;T?*]:*W6YM'\Q6F)9?:]6UR](]X]+U<T.KI>I/
M_E3K51B&"U-I82I=6 0H#,-%;HO<%KDM<EODMLCM'.3V95K!D^LX*U>CGXP
MKD;N<3CI3*(0+A;"Q=D3A\\\5[$J+.NG'&W\:!#ZKMT9/[6%=W;3OOW^-SQC
MKAOHU^)MQO[_+GM.0K]<^+CY]6#S3_CL*]_=W[XXV/] /Q_#/4^VV<'FQZ\'
M_^9Q[Y#/=)N,E@OO_OOQZ\[)%MW=/Q0[QW\VZYL'#7B^QN?C\!7NUSS8/SKY
M?/G/\>?CB;3AV#-,#)$H&IQI&+5!3GB%DI$J1:VMSD2[9%*Y<*$-7VAU\1K(
M&*?)M".!,V.- 7#B45@-N"6="BJ0%'1*]V V* BV" @VRI3D+>8IDKQL*0&"
M,8PL:$^4J%%"":$H[U.%ZRD1;+& JEBWQ;HMUNT3T=[,P+P=H;VIZ!>N553T
MNA$F#[;TU8ZN-C2\TTYG]OL@CS_X84;ND'0B%#7Q(#4Q2E:5/-$\!HHB4QYQ
MCBFRRD44DC;21V*B43EY=P8\F NF.8J)N\PF[C0P-@,;M\#88L'8&+V78LG0
MJ"4B2F5Z+^.0E<DAI9EE-%)%8ZXXFX(8=,'@ZJ4;NKL3B^:*85L,VR?0")@3
MRH(BV.G(M=?&2IH"%=8J[]F]&C[>PN<XD<7Q&BWT( 5JN]5/?MINQ6&&TR"%
M<*,5^JE0PT2H=YWVR8TTJ$$65#V>%:TQI=:HC[6QB,DY)I'AC('6( S9"*\"
MD]9@)Y65/&N-&5"U+I@Z*=;O,EN_4T =-^"]>Z>#U9P[Q5V,C!(KP"@2PMVK
MV4Y!N"5"N,9-A-/&&&]30 1'@W@0&%G.*1)<XA1QH)'$R;2W\XT"/Y@8=P&+
M*G,=AOW!(0HV;K^8O")J&%9*-IL6YK3_INUT,E5%GP=BE">VS_YZVJR85\%W
M##\HPY[R^:K+3F+^G?S$]?99K!&Y6GM[]6#?^MRT?3O_XS5>C>[J<SS!G>,=
MD('T":#N6[.Z=FO-ZLWMN%BDS$-.M"&]329)JPK3A_1BF:&YOTA72/\"J)K_
MA>W7[+;[)')]"KD^M\G/*_57:[UNSS:;%WUA'%+ 59P%[5;L4XK50,B;H+M6
MQRCPQF[0:72_7J>A\0"$H#]KSC9ADV5>U!C/:J?M;H48?7*QBHZLE7G$!N0J
M_4IKZWW6I+E8._6KO6X2J=Y[DR[:<N5"='MXV(G5-,*#]['35H;#%<U9NW<&
M MD*@PGX&>59II6=AG?$),.33UB!^<1E3(80<!J9=9)*(56\+P_-E235!T_2
MMX *K\ADIH4-7C__DKS6"5.%$G48<?#5$'A7"7'#*9.)J< Q.&>KC+$)8;T'
M<\V0D'NMXL0E3]P*K[W7*A)EC17YEO?EFBEK/N6:B_K&EQB]=H8:I$TDB+/*
M(><2$8<IR*'U/+>_):M4Z@DDXC/@DZD_F+/J02PM4_8(N96:[GK+D/;9Y@_&
MRCZQ$:#CM2^4#3AY V[AG<,O,;D0,:&(^N 0C\XBZYQ'V GEJ&/@30G8@'2-
MS@YQDC51!6<M99P;J[0@5I'$ ^-4:3=]#E;9,,_.1/V)Y,-TBG%BCB")242<
M!XVTMQ0Q2UV@1C-F\B&4NDM=W:0GO$%)6Q'U99;93NAST=K:CP/%RA:]@W=P
M8!W"?S,70)\$%VSA&UP 5S Y 1EOVI%Y^'E@C5:?TOF&93DPY'AFUQE:L6_Z
M3(K?XH!49Q#'NO:K ?$"OOJ)=>" ]<YN_\DD;J"Y6:R4C4S1M;]'G:MX["&8
M,>"W?T4VD\N]L<US>]%=^>VF;0Z&^>#B4JWE>1R=@EL?-*6G*S:!Y^S["2%O
MPFKAWU2M8O*W8%QVH<93@ZT.\/H_C6BDT,F!$-K$(U/&.+#C19(FVABX_ (F
M145MEH4HN\%]-]>N3T5*-6$]B!=6A=EMO,D>_1_;N^^WZK7M^MNUVD9]L[;W
MZ8^][<WMC8_;6WO+\03UW?VMO7Z\<7^W]G:WOKE5W]O:S*_V=O_:WMS8AW^\
MVZYOU-]N;_Q5V]N'-W:VZOM+\GB_]%JV%QJ ZJNU 6C&\.LDM!A!U;Y"%=CA
M&*RW+DFNN'*!9]9CCG4P7F-^%[_<8L6>]BHFN:IQPLN*+1TU #R&89P!,UZX
M>L+&U1/6<LN;;L\=9PX]T/&@FZOHS7C,MQ\7[N7->VH[9XW8K0@G0[L* [53
MZH):OW83"TY+OCZH[V;#ND:SD7_S$RZ^&R&G;I],V Z8. ;L]7VR/1>;[?/:
M>;O7#-7]7?44.?9RUJA"8Z&14NQ433+Z5,,_'UIES_0?9$YDF!/MX>W6WC#&
MNYO>#0._?P^LDG>VT?DG4RJ_:A[,\R]1&<ZP](A:[7(_18*<@%<25@;G]FN>
MJGOP8 ZL/@9RMM@R?@]FS&MTVWFKGX+]G'N%]9%\"C$<(LCUX.9D-%D=\'97
M0SIJ=^-(LXHAC?FUGXPS;2X/GR;5:XSJ)6&F6ZK!+A53:358^7#2OV7HNSZY
MT/^7[>DHREY$"_K)4_'' #+WJL.R*:@Y9L&^L7P$&QL3(N+/MH$6E#:C/R=C
M1P(OF4GC_GD<U0R]M=VCVKML^4_HV?QFQL(V(VZ79V/7F?%8IK[E=+JMRL)2
ME1F]"!OQSFVWT1WQ;1L30@0O7.O=524QZ#@Q\*N?L$;BE91!+%FEPS1'BQ%3
M[[63VBD>N;!<",RI3#I)^$A/G\#R(_YQ/7I2">RRGP0.<G5WSNOO/UU^_G=;
M'&P>G< 86'Z]L_E!?-[?.=_9_/-KG7ZZK/^[=3Z:J[MSN0'CJA]]/FY^A;%^
MK6\&>/WUO+[9/(+/SG=./C 8-_F\_T?::8PQ-F!#\G()% S.72R-1EI%BE2R
M1GINK;-Q95V9J1D;[K/MG[7JX&45%KS<V@$AA%%1:9*S$32)5H [;Y3"P9"8
MI)X^%:J@QZS0@XZ@AXPR,><TLC(DQ+4PN2]11%8D;R+Q(:6TLB[EA,25.]%C
M9LG\/[=49VM0+YMI=ZWU>Q4^[F=S/-K$^_%5>I?;<T]S;^GM(9V(-#8FEP3C
M)CJM0.4*[[34.GDKBCTT+T0;9[!2RC ?G(2-D[MZ"T^0,S$A3SR-E#M) \O%
MF>-]!9?%')H@F[,7P44S*I(3-GFBJ(V>QQ1=D(DX(;4%/\4:58R*^8G@J%&1
MI R!2X&4#1YQ"N:%QCR@J#$((?B1+!L58D*KUT6Q*98P^O77($7BHD3 )L4&
MO>_T8J@-TENO3*5B(\T(H.$!J7/84BHI!Z &#X)R@JD-2F/*'U#T-!&@?VSS
M M)3@'3][;B=)'!(RBM$5 20SCDY6@D!<)T$J-$8N3>Y'_=XTGFQDQ;83C+>
M*@=6D>$^<:JC(41:GPQ6G,([?D9V4A'#!XKAJ*VD:8!5L019A3GBBA.D/;$H
M<AV4H DL*+>R+J=U5TK\Y5F/UIKMUB$ZBYV3ZYFJQ;28$:9A*Y30(!!&:\Y!
M6KB6)@C+E;>1:5M,BWEBVMZ8:<&<"%%8@8AP 3 M2.0\X[F@#0?),"/29=-B
MRIAR,2WF3/JOC+4Z\JC PA=".A9"C$$D2PR/E,W>M+A>0)H:WV- E['3+N(Y
MG7B.FAR">6,=U\A)!28'L1H9*1BR+-<0JZ1 1%= %#4E]/>YF1TC9:&LDK]Y
M6")/GCQV$\2>863+E]X\90)BOTWPCV8'3Y^%6/;*\@5,2[K@,Z4+%F>F?8-9
MDUE"@O1$>VXH.#*<)AFET33JQ'DY2YZ3I;0['B/%"GMG@D$\"0]_)#@R1!HD
MN!.21J4\454_-U,\F;FCUA0R*)GQVDBC5$A<F^2\X,E@K9,DX*[&<I@\/QD<
M]5:L<)QCG9"G2H ,AH T50SQ",#.F<51VI5U/BT5[3,$2(>5KS"F>+=POHYO
M%L=NSL;ZXFV)A=B0\Q[&LGRS3%>9KKE-UP+ZT%,&I>YBQR[AJ!*.*N&H$HYZ
M?E<X8,L3E5K+$#EWT5IK4M#PW"PR'TP)1\TKKWK_\]EHXREOJ%?!..2"SM5:
M,2)M,H^6XI9Y$0,3.OO")1PU?]2:)B0L8^Z4[#'QF!O-<@&+M )PPFGB/"WA
MJ'G*X$AKI!BHT)1)E))3_>(&EQA'!K:4M]ZF9'DN;EB\>-02&T>EN*$4-\RU
MI)VZJ#*9 G626Z\TT\1[&I0 :><NE S$N:*T'[.4<#1<19*05AHCGAA#3E*2
MC^^HXHD'DAF05;&4%@"^II!#;T@0)*EDK>0X!JV"U,9X:@7GDCQ!"F*1P^GD
M<,1:4D(G+'%$N?T5XM8HY+@PB!AK&!5>.L:RQS(O>HF[>T5.[E=1;82?=@?0
M8F7]3D9RPF^C)A9*$R,?3DU,[\4O;];Z4SS^]^^/NW]O?=S_O%K[^Z^-^G[5
M'F#KPZ?MOS-[_H_&D<_!N?UWIWT*:WCQ=].VSC9:8>N_O<9IMO@V&UW?;'=[
MG44AU.;U'Q*Z3>J;_G)G\RNN'__3K!]_^'ZP><CK_X*4G&R=[UP>'-<WC[[N
M@@2-$FI_/OZ$ZY<[Y[O['VC]WT^TOOD.OG=(/E_^ V/8N*R?[.#=]Q_X[K_O
M0-JVSW?.OR2:B?Z90$D%<$<$!@'3/B+"G1,^:26)NP>A]H+29P_7/[<NM3GX
M!Y9M'.Z!BA3_JK'-6>VHT3UK=[+ PT;LGO5;V+13;G?8.^GU&^2$> H_:53B
MO%;;N.63W&'U],Y[3]L3, @J(A.)219SNR;+I,^M?:+"+,ET[SC;M1%O7ALP
MO&[&JS;) 'N7U?NW"M!2=&>:@U#Y[U_ *C&<>X*"4:"S.(M(<V61M9AR+*WQ
MAJZLTU6LZ9W=Y*;LYR6QL<EB%S6'43/N3/2,L6"IITEP<U_;INR0)]XA_(O7
M7C'#*6+&6<2#D,A1II&A(.'>6VF(KG8(GE2X.8-^@^_NVY=K]2:L#2,$9^TS
M6+WI]N<,.A6.&N%7(RN;;>)F._;T2S#,89<HBDYYV&S:(B.]0RX1L#D!+V@$
M.%)RC=V^TW+#-]"657^XN?88+&O^TS6_W+K\$KUR06*-F+(2<99@S6W$"'"'
M1D+!XY#9;=(32#U_K/F@$<]IIP%@<1%M9[ +^L%3P/Q&.RQG,_(]N/W94:_3
M6JWMG3?.+F.GF5%SQ[9Z"6:AU\G%/N^LKUSX)6T.M0TV:*;VSA+;[9V>@L*N
MNKND'CQ?K!UVVN=G1Y6R")U>;O0"BJ'=-TU/&Z<Q7[!J_)1M9-=K-*MF+[;6
MA(>.J!*MFFO  QTV?+=V<F/FTF#F\@Z:/-5KM4^G U3IVQ2KL-4:W:M?GL,>
M'#29B;5;\:;[WW0V:@0ER2-6@6GN.1%>,Q("=XQYYJ13Z2=*9KO^;H@XKM%P
M;\ O!36ZF_;^VX.)>!?C/:T:_,I IWZ\3;\04._&*8T<Z)?<+SN!R4LX6,#:
M)N4PCCE6PPP#NV:"W=NMYKB6<F.-:^U(I]MSJU/M%C _K.&:))PX___LO6E3
M&TG6-OQ7%,RS=$<XF=P7]QU$8(,]]-L2;2.W![XX<@5A+3Q:C.'7OR>KQ"8)
M&V$!$M3TV 9)5<K*S'.=ZRQYCJ#2,((]9I0 5PFP9ZK=\C"[Y7SS](LRVBH@
MNP@3DCWL.0ZJC$)4B>"T$ $'!1S8X)_O%B#!I_#+46\T - :#2\ZO65TN\ ^
M &)?1K;FV2 Q!@D6M^=)*AZDM(+#N#SV0L">$;3:( ^T0?:_?^$Q4!JL0]@0
M,)*8M$@G)I 6/G@@KY[B7 60W&E_V-!I=5N#X9B]%+MAO3:K/<UM!A3HPB,;
M:O;DI-_[#JLS!$-J+B[,HN'14TZ89=R&;/K%Q"V#[Q34\CM7(7G;*^+6Q??M
M9//[$&R[P?M^;[ :+;,??3?M;M7%%\=<@HEPB'E/\N$? <H)["'BF+!&1:VU
M6=N0FO[0X)[3)0-,1 ML(DDJ<)SM7,V<YIIA#?K&WA9NDM62__*2?Z!?F#7&
M"!Q1H!*6W'C@(]D/%[6Q-$IEO+&PY$K]P MWTW'RJN;M26%FG)>=#OVUA<ET
M]V2\-#?[J5]CMNNUG=*L&L3<E+&646H(. ,P5,*,K65U5;B0T[B]XY@3@]T;
M813PO6 E]";-E;^+D8.*ZXS:PQ:"@0085@T,HL)AD_J]3G$[8.$PO,W#V/5G
M17OVYE'LVY,(6M/#38JK!L53Y_L431P?'_/TG>,X<\B >6$R &,XJY]^ 6I+
MB/$*:><9XLX$9"D(1?* @8DGPA3.]:QOBZ"Z,?;!=BQ*Z%RTU74Q[XZ3-BC2
MD#<)V*G?\OX+Y7Z\?8\7(K!YTF^U2WV;/_EN:[/<97E_YQ?^+KP.F\5+MEW;
M Q;7+GKC%GNVV,@7EN65A.2W-K<^_6?[K_IZ[7.LQ<&PV+3%Y_NQ8[-YWI\2
MK,+8=+&6MUCA6((OO/84J=4?#$'WM]/X"=B$UV,RZCM'C%<O>8R7X,MGG>G)
MD-&EQ8UAMB?CMBCS#P;V.).ST]C:?M/<WFIL[^T]^2P]:EA]*[HEC*#OOAT#
M[/$F.>A\[.QN?2*[G_]L'30_G ('Y WZL770^?3]X/C/KXUS?U8_WA23 %O?
M^J=S\'Z?-YJ?Q'[GSW9C:Y/7SP_9P?L_.P?-=YV<K](XWSFK;[53_1P ^/"+
M58"C@2BD5/:O,^>025@BRKT-">Q%+TBI%EO=40R;64T9&R4P$.T(-5P!2TR:
M"B,=4<0*YL/=(^ZW^1A_;<_=U[.Z_=T?Y8;RM=W<EOU>KE.Z_O2>TW?1]4%I
MG17Z*EM^8T\E**?L0[WYE!=]LX<Y?I9C)!1S4=N+W:S!&KUA'!2**7^$8D%N
MOI,M"F\'1Z^*GVQ6LZETVIZ,P"JU0-WN<.]\A_7::D[W)O#+0R#-AUE1 ROH
M^M8)*&#;Z8VZI>E^;_89.!51":Q#)CH^&>^3]UA)Q9UD(8ZC3_0B^D2IGFUZ
M%\Z;OWK=PV;L=S+X7>R ' D?K4JH^]'Q\7C_^Q?M3>1>4$29C<5!(V1)TD@;
M@#M%<J>O $88Y;=6*.Y<$=!2AB8E(*?2Q(L%*>3!/MR>BLQ(C:5(V,(N2M$&
M^ <,?,99AG%3[:F'UKGXBS8$8U";*(+"1%Q+AJS6'$FF=0R$IT3DV@9HJ'5U
MUSTU"Y>OME#&U]J)/2O;9/T:)A') U>.2$UYPEXK[F.,5I#DG'?^SOOG@HM]
MC!<#VTWE(^3-5.V>6;NGL;7#OI 8!0DNV\),YJ)<!&F+$Q+&A^S:)SXFL'P$
MN;7CY7CWK-=VI\D J&RP)6,W)PUF,;Y )-A2L(QN6.OT0BNURK[Q?^37!R-_
M]*JP-(MMEJE&KYLMW<M;]6-J1S\L74XY<_G"2,WW"\##"UC+6[8UR""7<[/&
M'X9QA./1N(XEL(I6;HD.=O%E)@]8W.-4H%Q]_#9YN&N<?\FXQ4[W<KH*!SXP
MJ!@[,3RD@E@LZ<BR?%7GX2.,OW-2).%5.N)V*3^O\R^1!6)I4LA%(X!W1(F,
M)!C1H, >PXP+#G:5OO4 ST]91R'5#Z(A%K6!*@TQ_][9W=K^_H5K#)1.)D22
MQ6#1"XLT("*2G$='!?76"] 0]-8SNI?! Z"E[5&9.C,^8YE1>M0]L:UPB<7K
MV0=?8%,IVS_7(;!7X)ZCUN H+^LU+7):)K0?=DL% - 6T=!^KX&*ZH.*@GWY
M<]?ES?)J/!_O/>D-"A!]780U6M_B'Z>M,#RZ.']U[:KRB,QK?'6)=8->>S2\
M_9)KIVY\S%/RE!J#\HD)NO;W4?_J^-!A1*X?[5=D$XSXM6V?VK/!VK]OJD;0
MB^.;2Y55X=04W/J@Z?Z^F\DS<[,<-:6:#OGH0\%#7H^R>R%_"L9EEVH\M:-^
M1L5__=R9KM8VFODP5M[E;S.@%N>Z[<:MU.6.&X]X8558W,:;[3E[L[/[?KM1
MVVF\72_.2^U]>K.WL[6S^7%G>V\UGJ"QV]S>*_&ON5M[N]O8VF[L;6_EG_9V
M_]K9VFS"+^]V&IN-MSN;?]7VFO!"/A"V(H_WVZAK <H!C%]=.7-_GX46$X?^
M2@7Z4X_O/7R\CP&(<V5[4TX)%]89A7FTWG%BL3$I8+"I*"5S9_B_MZWNX*_>
M8! 'N]WM&THO'[>M2,PM)*:Y__T+ =*H/>?(PD+F.B,8&2L4DL)JY@W&A +:
MLUOCOA<$>)0S=;.!>)-T9)3-G&.:&6<Z W9H23F DL ^/"I\=->82:L[;8G"
M:V7S<;#&>IU8^VW\QN_E.;S\]BCGH&?C<A!#D7O1:[="D6<Q&,(_E^1[?(=T
MQU,NQ?&8PL0>E"GO)5TN:'RW%FT?&#SLI':F4YW6J%.0N/S!TS[@ >JE=!%3
M+H/,F>\!6EP:XKU^"Z3YPF!O#08CV_6Q.&-8>IHN;7AGV_FM00ZR]_(Q![CZ
MM#4\NFVJ5],L+Y*_!W$X+$/Z99YY>]"K=6R(#V-4+1R:KAM5%1+=ZJYM?CAK
MG'Y1DGF"K04+RAK$79+(!J^1T%AY;ZA+R8-!Q7[F<2L.,Q3[II;%\0<VU57"
M4]L.AE<O7XAV1HU\2'>V;3\\LD/8E/UX+:X ;UZXCXKD$L"87%'P5S)"%[XI
M=\:/N5TB9[4G9^_)3Z)^^(5%KEE0#A&8:L2-!HN..8%T3"D&Z0(6.3#U,QL_
MP](8R"<@>SI2O!K*<$9VTWUK6!AUA_RFB]HW*-?&>DW5A+I"^94GS8$BMQ:Z
MR$4MFON/FGJS-^SYKT>]-MC'@YP%.3S+D+5TR3BB<7:1[?C/4>,8).]\G]>/
MCUIPOU.X3M3A]8/C-\>-\\/3_?.O(B=I3TKUP>=M6C_>.6\<'Y[MO@?IWWH#
M8_P*[X-$OX?OWGISO-O\"I*>I?KPM+'Y15$2O4N@:8#G(BX51DYRC*AQDCG"
M-$MB,AE'2"PHPV"9Y<Z@@5EIDF8"5H%[2JG_U62<)SOF>)1/0 !1&6>2#%:3
M+>YT:[M^V,NG,4 H< %\;WJV'S*X;;4 2(>]/L#O:'@$1/O"[]D[[-M.Y@O]
MR^<'4V;>\\N&*F:TIR11SZE@SD21O+&6@,KVWA7YRR"OMQ[[N2&V5TOQ=SF^
MS<LQE_$<LA*9S$\@V]O?OV :&*&!HJ3SF4+//=(DY-.%3'AB(F<L'P>:E<OO
M;L9R0!UVL@&2EZ3V6[&G)D6E-EZ@W\L8[P\_4PL]H(S=7@[8?HN%Q?C]I%4Z
M,@N>N5[;!+(Z."K+S5Q*8VU49B/_]/X7^<G].(3=G@_/WNW"<3C@XN62)X]O
M,L%:;S\3E^\]F) *C9G DE.:3T\&F'QL')5&:X\]2U[-?:J_V8\6E-=9(27%
MXPPV/2@W&.A*<-C'EXCC;;';W(3OV2&-\WKFLV ]2,.=1"KE/'^?%-*)$I0B
MELR$%&G4LYLF7QYO*A=[IIB /60+GOMK9OC"=\[?8R/\7:]_)0"[Z6TQ]F([
M51OHYQOHPREL(!RYQ2[G4G%"$$\$#*(0,$K)&BI$%#)B,(@P_E'1HFOG)GYN
M:!1GCV)I:'=[,Q!RUDZ<XQOH>GF"Y'Y;-9LP2EOFG.:6RGQ(T&@IN%<^*JSN
M>G1IMN;_>.$HO*( 5Y^IR, /=FZC6:=?K 6EK[0!"I /CV/LD5$6$,]'(/@1
MK*M,!NBL\B879*!TU69-^,VVVD7@\*X*>5;=I=6LA'*]?EW9)@.0\Z0?CV)W
M4+:8*;T/.0;S^Z.:N?XHAE$;H/S:$(L1WAA@.;X\NB+T^W*-7R\:AU\,5\DY
M%9!/PB$>,0.!8 ZIH*6+5+)(U'UK.3ZY&9AS9%*OW>Z=%O"?ESMGO71@T'"7
M,G^R\+4-BB.KUS9VZ4CS-S;VA5NMG3?V9:''G"KCSJY2,%_/%9HNQG25").K
M[^0JSVU[,HBO+W[XXZ)W5:M;/&-QT1_CF1]GS^14D8G2L\7WE6^/LTB,6=>"
MY422<<7^\1>/<TS6BQR3B;*WY7N,K$LC;WT;KY-[OB<8O=>5/QJL6:=&K,Q8
M,;[?7:MY_=%8"5[GLMJPBQ^K!@@Q=[KKZG77NXWW%,EWO^UT+TR6:[SFH9M_
ME)IBZ2;C4[<?QR4MBH2;DN[%P>\Y0+H7/1A<13FES4NBG&-)>V!]O*HU2L79
MM-^K6?S!++[-F0SO@+O4_A,#4)1JXJXF;GJV\MSL=+_%\;&58LJJ&;N^U=*H
M\';L#>UP5!BC?_<&P]*U6TS9F]B-J36LY7HIU6:[-G5OBRZ0_JS6A#L/VJ63
M?O/RB-3C-8):TOEIYL+.-R;A)YI_;.<4P?R38:U(0JA=C'5Y:<'L3C)ORO2[
M5]/UWWYA7]S>^J?XWQ]WGL&9+7GFG<='Z8SUO^[>_FC>.5C^MF"_S>%DMIHR
MCPEEN=]4PDI'YH)2WO# I)8_Z$<T@&>%GWY0O/]'WC)0"+L)U,&JQS_&_8EV
M<#WW&&J^:=4_OSO>;7[ NUMY/!_@LX?GC6: L7[\6J<?CZ;Z$QU_^%ZG[X[J
M[W>^[W^NB\;6!]XX;L-SO#F&[R!%7Z/W'\X/WK]+]3U\EGL3P;^LT=S&]<TO
MUDG%3>2(ZAQTPX0CG8A#G@MCN&!".34[Z#9E=2Q,1!;;/FSNIMT5W+TLN)LG
MI&:P,HX''Q3CV'LME;1$&R)CS@..]^A04H'<XD$.3X"<,CGX:2@B$DO$@Q+(
M\ B_)A]84$E$)]8VQ.W9VR\/ZLKK7C;4S3L'SPKJ+'& ;%(9FRB74CO.B+3!
M"<>E<]%54+<44$<GH"Z9"*"F.'(NF5R4GB&K-$>>)JXQ$'*6:XY3L2X6U/=U
M]:&N8G7/D=7-8\1ZL'.TX%YC1SBAR="<DYNT-R1)YG1EQ"X7Z/$)T,-6:"U]
M1-$(C3C1"MG<:,%1G)*E5EL"1BSG,_C="ENQY7@JO*OP;EZ\<]0D*_-)MUP"
M$A/G@\?$8D5<4(%7>+=D>/>]_O9F4W'&K>1&&F2-#@!XU"+M"4=,PL)QGZ3@
M(1]'-C,RG2O$JQ#OQ2'>_5L+5XCW-(C7NHEXEFD>9<1(*)*K,">'+/$4N5P&
M,2E*3**YVX.<43%W^1!OOF2T$H[H.A4K$('>_5FN<LW%U"O[UK?M8'!92G8A
MF0OT[@Z"6Y%^]=&.1:VL<R29X#C#6(/0,)-$"-;R0/@=RG+< GL_PKHWQ;I^
MG%S6"@+O X&MJ4AM8LEZ%C0B.GK$16#(R C$SRHI#664&E+TN_FE4.VTC#RQ
MW^X%B/8\GBJ/HY="YS-\/!0Q>A4Q!MJ?\BGR^5O05P+]: (]&96T3%"O@T).
MY<-.GG+D1.!(ZYA<I-AQKM<V&%_G"W+55U*]I%*M TX$.PK; 4P3RXSTVG$O
M+2-:.\HJJ5Y>J9X,P F,&:AJC"3\@+B4"MF8G33>2F=@]2S&N<K';56Y*J%^
M)D(M--,,]D)0U/ D)"R_93AY22,0./NSUNR54#^A4$\&F$"673+.(1<Q<&^K
M#'*Y"[.TW%'+"07RM;:!;^W%4 GU,@OU/*:U=H(G2YG0D?%(E(TR:,6,,XXQ
M^*<RK5= O*?B*=3YQ+6E""N1Y3N7'@)#"ZF8@(]IKN"_M0TZJZ%295LOM6S/
MH[#O4_2C4MA+(M$3\0*<<]V$X,A@#<8U5A$91BAB-K$0 [66F]P]:9ELZV<<
M%2@+0@VN.?US2Z!<X7JN.B=5B&!!6+> ",%D-?F;2/8.UO8.,=+R-.OP;WC>
M7JC [S[@=S85*>"*"I:T1<)%E8O5@[7"740R$"H"D-7(?;96%I4"7#&:9;56
M%A NN,5:J>3]Z>1],I @8]#Y= ;2R4G$E1/("N419M@+XIAR+#>GT#,$OK)>
MEEK6GS*&4$GXTTGX9% A4!."%@E% &Z4VV\C39A%L,HN,*<Y41(DO HJ/'<I
M7WA08;%2?KW<;VI]CP&=QWZODO[YI'\R^@!"SZQA&@4C+>*,2^2L#2CZR&CP
MRD1!UD#2-27TCPH!GC<"+"  42' LB/ 5(!",>T#%09)GP3BUGADN21($&LH
M\XH[ARL(6&4(F,>L7T"DHC+KEU#H)V(8RAL<(S=("*#^G('X6P[*7SMI28CY
ML'*VZ^6,M(,GL>OO$;]0ZVH5PA>Y_*0O]WCMI-CD2Q.K^+53;:N/A4]SUJ'"
MN'M@7./M]*&&R*F+AB ,QBSB@25DF,>(&6,X,-R@F%K;,+]VJ&NU"I6\=.%?
MUM,0E<C?3^2GCCT071260@R@&W%*+8*-JE'B 591QB@L U8C%I9,60G^LQ/\
M1STP40G^_01_,HA!G/2>N(B4IPIQ83$RP7HD"6$V^" ",[E?^?3YQ4KN*[E_
M_#,5E=S?3^XGPQ?><TL8LSFYFB'..<B]40EAZVFDUADFTB(/3U1ROQIRO_S'
M+BH$N!\"3(4OB"!1"F$1EPD@P-&(#,D08*+ 'C:XPV%1YRLJ\7]^XO]P 8^[
MB/_?O7X>X.9PV&^Y4='OLMG[VV9O<(4,\R+#1(PC!(Z=D S%2 D@@TC(4D>0
M-5YKSD,25N1S&@M(75RRJDY+'_2X["5TLT_T@S02NK%"XR:R#)8A]$:Y7=_%
M [_L$GX+GZ3GI22,RR7B).>4>YZ,-YZY2!451$A'B;ZEWWU5X^])=,%T*Z+(
MM!5:4)2PE(@SJY$6TB"J8Y">8$F\7ML@9!'A[L4)T=*6M:\@M8+47W2W<2RB
M3\0)YC6G45MGI!7!)LR(U83>CJ@5D#XBD$Y&V&ATPLGD$.$^!]4I<&I+&'+1
M."I@R4S,CO994?5?\KA5:%JA:86FMZ(IL5X3%021E/# J>&,&H\],UI$R6V%
MIDN!II-A2^UQY$$DQ#RSB#O.<T&WB*SRC"8OM2G*-)(*32LTK=#T\<S]: R-
M@F/BD^)610?6(]Q%4R"H2C!<F?O+A:N386$B< J&1.2(38A;AY%38/A+E3 6
M@1)+\-H&9Y6Y7T%J!:F/ JG!!*]R W=A$V?.V,AYP#37PPM<Q%A!ZG)!ZO0Q
M06Z%-RR@E 1&W!"*3"XI+KRS+NB0DA?YQ!!>8*"] M4*5"M0_0&H"BHB$XE)
M!G!JK&72&\U85)@EF4P%JLL&JA,I"H(83'/C%>\X15P#6]4TEX'F3KJ$HX2E
MS7$IL8C.*T\/JD46P[^++!?X-[2^;?P/_'4Q\([M'[:ZQ=?+FS#F(VSZ/MRE
MN/3R0<OAPD.V[<D@OK[XX8_0&IRT[=GK5K<0K^*B/\9W'S]]/ADZ,=3B^\JW
M_SAMA>'1:V/6M6#9$S?.O!A_<?DN62^<=!.S7[['R+HT\M:W\3JYYWN"T7M=
M^:/!FG5JQ,J,%>/[W;6:UQ^-E>!U+JL-N_BQ:H 0<Z>[KFR*EYK-8W:Z-;AU
M.Y>>7LB!]3M-1:DIEFXR/G7[$89R'D/MO6UU![7?,HV*@]]K0/#VHA_U6\-6
M'-0VO]E6N]!QJ=>O[0&W>E7+!0)ZJ09TJYK%'\SB6SLXJKUK]TYK_XGA, ZJ
MB;N:N.G9RG.ST_T6!\-.+CQ13%DU8]>W6@("#1MM;VB'HT&>E;][@V$_#EO]
M6$S9F]B-J36L_=V&;ZFF[FKJRH(]_JS6A#L/VD6MG]IF.!Z5>VTAO5A7>7Z:
MO:%MWYB$GVC^><RR):(%/\G\WHH^=ESL7R1_XP4D?S^JK^Q1INM67]GC>+P>
MY1GGR7-Q.G$594@&<Q6\T1A;%A.7CEFNRCP7/*O7>N7GVNW4O^\VWWW=__R!
MU\_?= ZV/L(]_FG586S[YYOLH/GI?/?SG\=U&,>DGVO_?%O4/W\\.M@Z/*^_
M/_C:>+]-&_FZXW?']:W0;L!W[\/]X9ESB_7)]&N<3$PD!I2()HBGE)!-(2 5
MDB/,,FT)SS6&Y^V8\C1!@ J%GB,*S548S'/,G#"$&\<YUP ^CI,@>+0RV'%^
MR$P8JOSN3X%'DUG,7CILN=0HB: 0#Y(A([B#S84#=9H;$17@D3+K^.YN]R>*
M2-[E:RND>JE(A544E@:J@Y:<)VR5$I@ISK"D@@52(=5R(=5DAC"U#-#)1F0<
M,XAKE9##C.9B!SYX)ZR(9LXSS!5.+8$,5S@U46Y1:1VI3<13RZD+-E!+8+=;
MG!N>CS,9*IQ:&IR:S+@UE#'B)$?>1(]XQ!19P2E*3C.6/,DYN&L;4JZS90>J
M"HM>.A89@T7042I+/!AXSE(1@J=4,P5&0JBP:,FP:+HD%$DJ&"!-L( 2\5P0
MSFBKD*<*Z' *RD>WML'ENJS :-D$M0*CFV"4LL/;)D.E(_E<IV&$$6RU\-%Z
M[&,%1LL&1I-5J$"#A%R)FAD.8!2C0<:#!2<<98&J$&D4:QO4+)6OZ1FW"]_]
M67.-FHNIUX_7^HF7_6H6$KBF,^=P,:7UE@Z[A/3P7W!!*<))=(XY2TCVD1.#
MI:=%:3UR45J/+*BTWIMB^2:[#56 =B] :TVWU:!6Q$ P"I$7;34$LEP'%+ V
MEIE /<_G@.9(6']\^O1\Q'$.::3$.P=*)UEL.'78,1VB$$H3RS"6^ [26 GA
M$PGA5!D>&JC4QL!*<8$X<Q*9Q (BL)Z$1JI2Q""$5,\P<7X84J]D\5%D44F=
MNTFI&+G@2A*+7:[W$2DQ$@8J*UE<7EF<#-%8;S%ST2+G6>X](7.9V4!1$H22
M%!A1$F21TGFS6RI1?!11E-;!XH5<?L[S!*#JK.(.<R68P-[H2A275Q0GHQ 6
M%I$I&1!5G"%N\W%*3P(RPCN59,322A#%&99V)8E+8"^&Q$Q,P4E!,'?>:2'A
M5TIER@$E:RM[<05D<LH;SQ05EH'!2!U()H]4(B>-1 EC;Z.A48KLC9\GAZ$2
MR$=1C<F:J(*SEK)<74!I0:PB"6Q^3I5VJ5*-RRR&DWYH0121CB$99$0Y>1Y9
MDQ0RANKHN.?*9+\-9C-"] ^N'9^QOWFSTQMUAX-K[N08:JG?Z]3L523FL5L^
M/W_L6H#ON6I?OQQ@=C;E@W:">I)<0$$2GG,A@>>[$)%+L)#<&I,LS6W?*HM[
M&45SX8[H2C2?3C0G/=,A )V0UB%G*(BF2PPY%1T"PTYBSH%I)%*T8ZML\&64
MS84[IA<KFV B=.P0QOE]^#JUOL> SF._5\GL?#([Z<'&-#&N(T4N]\3A6H"%
MGFA T4:!M?=1.3 -_L^_-"7TCTILEU!L%^[$KL1V^<1VTMNMB @*"X5@H;.W
MF^K<])PCIJU3P3#M,@NNQ'9YQ78!#N]*;)==;*<<XA1X,+4JH!03!G4;$C+.
M@0F;N)9:>VRLK>1VF>5VX8[QRH)]2OF<\)0G8B-3S")A<O<(1PTR@FBDO5!6
M>D*BYX4)^P3NI7LXRM6Z6@4_>2Z@YLO]7#LI-O1C.\4?N1/ZTH7?GR9=NX*M
M>\!6X^V43YQH:[D( ?F@*>+81@ LQY$SEF"KK$TA9I_X'-T9ENO,VPN1V&7-
MZ*[D]'YR.ND@3PD'+4$PH^(<V+].R DK$0V2\7R"@E*04\+-O*G;E;@NN;@^
M:M)W):[W$]=)WSC8 ,Z[P)"CBA9].9 F*;>/QP$TK8]4AOMD=U?2NN32^JAY
MX96TWD]:IQH_*B>]93KW)PN@7+E!CK@ (IMM>FM\XN$>">"5L"Z[[?HTJ>.5
MV-Y/;*=<XCI1[F, %BR$09Q9CYQ,+-<+%EPD83FLUWPYXI7,+KF"?=3L\@M)
M_;O7S^/:' [[+3<J.H,U>W_;['6LA'A>(9YL9J>DM)83%%A._;(YI&5(0DD+
MP&,693(F'TKF<[>S7ZYR)S]SI<,XEZ'!0MWV_=%%=P6RL.X*R]*J]%$F\R?5
MJ)Z\(^FR87H(+!'# R>2<&$ XI,WUL; )3<ZEOT9[@#E59&J!X3NZ?X,H&V#
M4L*A2%EN/BH%<BD%)("$:1-$2"GEV,']/))+U\6Y KH*Z'[5X%38.J6QMMQI
M3KTQ5,1@L1*,:.U-NAWIJKI\3P%YDV$81CSG01M$K '((\D@RY)#4CFB??;S
MX5PJP,SPZ_[$XJS@KH*[E8"[>7B=]CKXG$]@/0\1J!SGSCKJ&7&$:EKQNJ4
MN:F#'8%IS[U ,D:&N 9RYY*/**1@),'18I;[;K%U4Q&["NF>+]+-%4G@43$B
MM,0I<>FQ]4[K@#61*<A@*V*W9)@W50,J"JXTQ<A@%A!W$B,=>$!1&*>5Q<&P
ML+8A^?R=*"JXJ^#NV<&=H,X&G)/:&>$\:F.\)E8X)X2USOV V55P]Q1P-Q4Z
M54YJ(SA'V.3#NSYDO-,*<14]32F:&/W:AA'KI,*["N]>/-YIRDRDA'*O,;<T
M6JUQK@L916[G&G6%=\N&=Q-19DT,L\Q;) E/B'-.D>7P*Q6!^I08=KSHW;I:
M!*^(0/^[R$> ?T/KV\;%X!NC#@B%G_X=/G0Q_K$T\'S.ZZ0W:.6'?=V/L"EA
M#_YQV@K#HPN?S[6KQH^+KRZQ#IYL-+S]DFL/Y2-(5?]!I)[@GXD]S0.CXG(Y
MRPF[]O=1_TII'$;D^M%^13;!B%_;]JD]&ZS]^\:#=5K=BYM+M9[G<7(*;GW0
ME!8&;VK&<Y8;":"HUR^.AKX>=6$KYD_!N.Q2C:=VU,\8^Z]6-%+HY"QPR\0C
M4\8X0I1(TL0B%OP%)+29]WJMEVIO,SQWAX/_^;?=N+F@\V\\XH5587$;;]8$
MK&V\V=E]O]VH[33>KM<V&UNUO4]O]G:V=C8_[FSOK<83-':;VWNEBZ^Y6WN[
MV]C:;NQM;^6?]G;_VMG:;,(O[W8:FXVW.YM_U?::\$)]N]%<D<?[;=2UH] "
ME?RJT/ZM[BB&WV>A!6#J^ /%9BY5LI!84% DA/K<VH19:9)F@F#"/:747[K.
MQU@\85$1I5QB%AL?>3#82NZQ,=0I9;'"H<AKHQ=Y;;2D&C\^#KX[ O)P!Z)1
MR%031O*FW?-?5Y-@M.-_/IX=? XGCG)Y\'F;UH]WSAO'AV>[[__\VMAZ V/\
M"N^_Z]3?PW=OO3G>;7X%$M).,&91/_PB8+YMTA3IF'(J*79(8VI0T!$LW< "
M87ZM%H&%G>1MVQ_%FRJN8_N'H RRJC<7!D +(*X[?$UIU@Q/J?*:1[&6>NUV
M[Q0(1ZV@"[7!J -CAIL,:K M:G8Q]49?WT72CT>#82N=P8R,AW*#3L',M.W)
M(+Z^^.&/T!J<M.W9ZU:W>+3BHC_&$SYF(UGU3N;3Y2\LW[[2RNNXU,SCK+WQ
M-X_?7B_>FB!YY7N,KAO);WT;KY-;W_O);;%6][KMC]\3[/8OO>]@"5\7G*W2
M8.5=;SO#:W"QZ0"OXW)\<IQN.L'>B2ZP9>(V_=[I+Z:C/J)Y/J6-2_-\IUN#
M6[=S.>\?EFQX!L]:ZN':WA!0MI-+6?S5*U7X(DI5F,FC V/,_*E)^L<4.UNZ
MB;LHD_UQ2FU=XSVULGGC#>93&T_Y;W]-502Y1<[$+#F[]QK<R2>P @OPKM<O
M^$,3C+A8J\/GCP:U;2 ^X2J3_ Z;^$&0\9=6[.JCSOJOAWW89P&-9S84_YO+
MO?-K2TF%LMX]\%)FL^(.2W6GI[[+M#XO0;CC:8FEI16+7J:EC'N\MZWNH#15
MXN#W&ECN@^A'_=:P!6:0_69;[<(@20!J ]N.BY*&59F>4D]>&'3Q^PGHRO@K
MY;)N1U"7_WODT-J"473.T-JOS\$OA=0>Y>'G2B'(I6<-EBHZSJVAEC.JE$]4
M>(%EBC,=7G>*K35ZW=Y)S'[F[F%)\[;+K?Q,HFB?3O>/_7GC_9_M_>,WG483
M7F]ZT=BJG^V^WZ$PUF/X]_3@^"N=C*(=--^T&N=UO-_YIU5_OT\:[]\=-<Z_
MXOKY#M\_/N@TWM=YON=N\R#7.#R?2)+BP5GB?$(R>\JX(P19'@A*C$3"?$C*
MN]D'?FX-H?VR5#Q%KL +2@5X<9%^:U/BV&'LM.5*6*LH80PS&['$29K[EX2H
M8&E!L$0F*YHGG9AD$>5Z=HA3C9')+0FT-3'B% 31,L/2TE>!6#GC8 YS;]6X
M\-@_-+3?:RYV8VH-%\*(9Q7TN$T'+KZ8QZ.0P,?E@#<Q]B*@^7T,K6_*I:L0
M=@Z$;;R=(GY*X'SJT2!#I,\](RS2'E/DB708]J]7B6>$G4X6_?&!H+OL_*H@
M_8.)WP*X3B5^#R!^DP1'<"]=,F!HB9"3%S&(GQ 886D4C\+X0,4]Q.\%$IF)
M$ %;3(3@83[Z4W1\LI$M[?(^%_(Y[:?V=G!42^W>:>THAL,XF(."KLI#?XS?
M8G=T%Z=[1:[O=F8A2D.%3@EX-2'189MT$$)J$X-F?FYR/5Z@0:7.YU'GK2DV
MG1CA$0@7"L%;Q+TSR&$1D<4,5D>PZ%5N=HKG/E]?T>DG]AUJ8RV67FNJ.(W<
M<JYE/D#L">&:^/O[#BO1NY_H33)I3)65B4LD*#&(BZ# D,VU)RU6P;ND?'0@
M>FR.8X\OD$6_0'?@[H7GOC9V E8T97%G*Q?,4R[7:NR%J%!S+M2<COMBY[VW
M$6B*S*WM<AL:YW5$F$>G\]$L&XL RQQ')RNJLO)4I1*ZA0K=)%4AWD4KC48R
M4! Z2R(R),%/D6)O:*":LBQT=Z\T6#&5%\%4%IW$5]&51=.5*D'D :%T=SI\
M:5.T*G".O/$!H%10Y!S18/]%+[$@SMT6/ZGXRY)&+A=-7RK96Y#L3=(8KP11
M6!)D+36(8Q:1EDD@K;73- FME,^R1ZO89<5EJB2LY\5HJGR0!6#JWA2?81@'
MPXU DCB+> H,:>8DBMP[)QD/VLK9_0HK/O-"^$PE>0N1O*GXD3<\1J%1X+E=
MJ%,!664\BMK1$(E,U.70[0Q/:,5FJDRL*A-KY1CH="96-PYKK>ZW.!@6E3J*
M=*QGF(U5N1$?^/@KLY93AF4DE%.2# [<"2."ETZ"75RY$9_XG%E6_&<WB\CZ
M**7ADB*IDD<\Y#-FGDE$";P>@G<DIK4-4OD15X9W&ZX4YLJK$!G''!NC/,8F
MQN B%T0OTH^8>OV.'<*7?A^^3JWO,:#SV.]50CFG4.;JSM>%TD3#O&<*86S!
M&&9"(FNH0DI;+B7P="/%&M!O30G]HZ+E]^1MRS?@E_S)RH:J;*B;L*36E5@!
MJZ+9&]KVM2*S997#P:O"JNJE[.E?A(FQL,I$R](59*E+%SUYNY!E.WEC>>2!
M"*>E#9RSZ$Q@,2098A1)N;O8=A.L,@ZO>H)4C'$NQOAARHRC(3H1K$=8<XXX
M=@$Y)PE*4C%N.=&>YEX@<F'G;YZ^4<BO5#M:%@Q<AG)(3PYU2Y=('!4VR3N#
M8Z+<&>:4Q($*C@.,4VO["_62*M#[!=";,I.I#EQHC()Q"7%EP4S6QB/)<GVD
MQ*.P.7)%GD'G\B4E]#_OTW2]ITC9/*'8ZC_MBP-2N[8QW7+A6D\*PG./IW+&
M40;>UU1-M*E ^979H".4)D;>OTL%O5/[%4+72_4Z_??VYL?&3N/]7NWO[8^U
MO?]L?MRNW6PT\;"-5;9MOPL3-_@[]O>.;']9>J5\KV]M?COHPGW/>_ =GWCC
M^)#"9]L'S:]X__CH:'?KGU;C\[M6G>Z?UK?V:?W\$VV\-?C@OT?8=_[IVL]F
MM'M\U#EHPG5;^S"N?^#[/[9VWV_SQN<=LO]YY_S@>/.T<;Q_WFCNX_^>[]!\
M,B$PJGR42%H!_$GF@T$:*T 6X@7L3TZ$G.J5\K KM.>/8ABUXVZ:7*LW=M#R
MF]VPU<HMRL(R];IYDO5KG'XAU%H9"8/9)!YQ%RURE@24L#:."B9CGN [];J1
MD[UN>.&'>!#N<L=F-\6"UVPWU$*YY+5!W@>#6F\T' SA]7R(<S2 U^%;>Z-^
M+8YW3.TD]LO/UD#?^-P[('.?Z[_#178P;J4SF.YUL[$Z#6VD7"?BO@U;JLXS
M+[+SS&.X9<UM7LX5: &P3+TP5B\-Y1>[ "TD(O&3OAXOL*G'0CIZ5.T\E@:K
M5ZU?17'7UZTA?*._@^>JL"_L$$;PU%@QI^PLNG%.%?=<*H]JHT@:+7(I[7#8
M;[E1:2D,>[4WK=YA[.9^9.L/V&GEA40DGV],\5Y.DI6+*=[;);+_^<_!0;,G
M=M]_$+M;C4YCZ^"X<0SW;'X2^\U/,*ZO9_4FW._]SOG!^\;1P=[XFO_^>>0Z
MH;U[_)4?;'WE<%_<Z-1I8^L#:33;1XWF/YW=YL[W1O,0OK_Q=9^^:__WO#ZL
MMVZZUZ475&-C4<J%>;D7&EGA XJ1:I^H5M'3M0V&V;I>V:)^=\T*74H$O@U*
M5BPT-P=B)&NB"LY:RC@W5FE!K"*)!\:ITB[-G]M:(<8O($;C[4W$4!JK%$A$
MR4B*N"* &#8XY$U00E"O:6ZFQ$EU-/Y9>3OF-&BV8K?7:74?QZ29:KTU(Z;[
MX#;-KWWGJF_153)J/A>_Y)@(C,P>QEIWU'&QG_,X04MT<G?-J<A+=8#L7MJ]
MG,@%FP1L4L%?+.AFN9Z-8CEW4Q%''>Q>+6(18JL(P%P$X-.4R9""3"H(CP*U
M!'%C#-*!1A24DJ#["9 #OK9!N*K:ZBP!V,TGFK_*O2O1?%31G.3F@*:>ND01
M3H$CKH,!;AX%$D+D4KB> <"": HR;XIPQ<V7F9O_$ "V4XJ^.*12Y)6TOL5K
MS<,?BYM7AZ6J@XO+]\GG:^(T6YV(<JT/L') T0[[+5]DE U[_FM! >9IQ%09
M-#]A39I@T+#$$.<-EY9H%H0AH&Q9D-C9=)]VH/V8R[38]MO"(BWYTN:U$%RS
M=Y$F&L/?]BQ_>+,/TW!87%>Y.>>C4H=35HYR(1!*&0*K)B*NDD#&&X*$$=@G
MSJ27?G;O@,K&66X;!QNP:128,R1ISB,V1@83@B0>)^?$_/&%2EH?75HG#1]8
MRD"8H<A%H1 W'",;%4<N.1VB$#8(757K?:%DJ&[[7^.P(C\/ Z?,1$.U%,)9
MR1D#-"4Z84^4HPYK0BORL^QP^G6*_!"'O>5.(B,UP&G(C9L9H<@229,Q1$OE
MJK[IRX%N\TFKET$S&25E8*I8Q2SWBGMN6(+_Q\@K\K/\TCKE]17! \ JE%0"
M:154(Y.\1R19JR@G,LA4M5E_H>3G[]@O"OAU?;S.@&J#.!RVR\.$Q<L5)5H<
MR(:0G"(*YS8$'$>CG1;>8NVC<B%6_J#E!]GMT[^:.[F .@"M)_7FA],O3F+&
M"==($8J!$U&%-"$!46\,3EQ9<2^4K3C1DXNKL2D0ZHEFW/ @N'&:&6$D-2Q8
M)6+%B59!7#_<%%<."\ILSE UN5F]X!Y9QBD*A% :59*,T8H4O:1 ^-9%^/ND
M-P09:]GVS72_1V) OU9\[#G0HX4?"9J99#0NG#*5:;09CD=E#X0*9.<#V>]3
MG(CJH+1V$G'"'.**)Z2U5,BYP Q+U"<5,LB*Q18D7)9Z@[/$_G&E>PG9U,*/
M[U32_5C2/4&A0J+2JN10I+D%II0:.1- NIGW,O&89+BED_>/I;NJKG=OIQ.A
MZW05O$ZE7%Z6J[JL2]4]O*QN-5V^ZG$)V$.5AZT8VMW3P&]#\0J[Y\/NLREF
MEK@3FCB*DE. W0)6RGD2,H!;)X.-%LORD(9\H<6B;R=O2X,,SY#=5<CPZ,@P
MP>I8T#8*EA##+".#HF"S!8R<-LY)A0VC-)\1F;L9Z+("P)(2OQ^755Z9LJ6;
M'= %PT$M?O?M42X9F/J]3E%.\'HQTEX:]Y\L2@EEQG>CR&G-16^!+.;K6OU:
M+(ZL#&JG$=ZRW6$+71Y=*5YJ=7/I]:(-2W>X?K.<Z:R)O&LU:K:VL?K5J-FM
MU:B+ M3HS>;>]E;M[\W]^G:CN?>H]:BW6@/?[@U&_;B;WO8ZN;]<L3T^QJ)&
M[=O>8#B8"HL,EJ?J<7V,^"=P[:$ -"6-SD'G8&L'UX_WR?XQ?#]MM.K'_JS^
M>0>TP8?3^F35X\X_Q[M;7[\WMCY1N/)K_?C#6>,8-$7S*]NG.V>-\YWO^S#.
MQM;FZ7_/]W']\(O'@@;0LH@9%A#WT2-M< (KG,<0B".6Z5))M[HCT*.Y4Y\W
M7H44A&/6<(JE-LK8R!.-UH#*YG>ODGRKR<*<70"TW%I58O;F+C8'<GEWU*YO
MH-JX6>%C;N9KI;L[)^W>68Q[L?^MY>/5#KX^Q,TV;.'BI]WT,?H>X-<Y['$8
M6J_<^"]YFS<^?.&YB2702B1H]B<'EY"VTJ*(G8O*$"Q,6-WBWDW0AV7Y[>P"
M&5?;'G5@T'"30:D$Q_O:7]_7X_[%67&6VG5<^QLV<\AOY(]W"R)ER_-=\$\!
MFEGCEMJV*O<]Z[VJW'=5[OL7? 95N>^7FENP#.6^?Q(,K<I]_^)-5D>6JW+?
M2P4.LSVL'^,@%L!:-'>)WV*[=Y))6NT7@.)ALXR>1U'E%]K%-5@5I(O"BF"Y
M)&!)"086KJ&)>A'-_.E58]-U[(V?LFS'MO<2>>;O9\"./?,LCZFQM?U]__/'
M#KR'#][OP#7U[W O4J>?^/[Q/QWX\W7:,^_/]CO;N-Y\=W3P/ANW'[_"YUKU
M\W=@#'\Z/V@>M1J?#^#/Q_9_SW>F#MUIC!.-E"//,44<"X*<U ))0X-)C 6G
M'2"^6%?/,YMJ(1E42ZD ?M*<]5GT7IT#H#"1+ 0169""1\6UXY0F(G"@05CC
MY\X0JP#J00!J\IRA8=C[) F* 0?$.0W(1,:0MT$;RG'P,JQM,#9W2D$5%UQQ
MH_B6)+ (!G'W\%7M,'9CW[8+_FM#I]5M#89]F^-YU:G#!6$JCRDI'PAA5O%
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MCKNX,L*FE<./-ZE^,S]M$Y7^?5.AS Z(?Q>&>!5??W&.;MCN9W?*&W!EHYT
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M_\;MT573C\[Z;K_W!28A^="UW*V6N[\N6]<[)YD-FC@OD?>&(FY@<S%8863
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M0*D<:2H4XMP*I*7&B.3!LDPQ:3@8=X%K7N%G8'6?&F35ZOC8ZKB(M7)O,AI
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M_(NWKC^?*("T>6RP+(GBB&N*D<R-05@3'%PF-7,N=G2]G9L&A 4VS^&P8<&
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MFW)TAD62BQXV_$6[XR^&CYC9\.1U"$EV/L;$T<AA.EQ,& *3=):83'6OG0A
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MFT"LL@1I3Q3B@ABD"=-(4L4Q<XIAREZ\9'(MTU>=.?-,]X(Z<V;^X(='%MJ
MI<.*"TJTR^+Q3F"Y948+7V?./*UA6CSQ@54A+'B#O M@F(C/P$3E#A8'B^ D
MD<1&PZ3N?0!;9\YLN%]\U\R9!(/KU)D:3/ZBA_4_R'0OI\YX$ZC"E",L<<24
M>8Y@RW7(Y0)[IX)F(3*+J_N>UM>Y,S\AA*K5\;'5<1%)91IGL8$-4CJGB,=$
M9"F40B:/)]B&.FMM4L=[YB#78&ECP=),G/#FSJ,E 8:Y6F8IJ5'.(YG5H()T
M-G<&T\ SS22E-#,,M#:3*L]Q'3)[2GOZUQ*\X3HC)&B-1"8UXLX&I!S)$*,
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MV/_S_7_I[L4_=\O0*2QIBEJ"A3*ZHZ,@%Q*Z+-\S)GKR&/"09Z5^UN)MS:G
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MW;&/5;'OBY'^6<2-Z^W@#CQ!7UOG.R<\[@.!!^1M+%H,F4?:<HIRR9P5SGJ
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M!)E/6D"E[Z) F_]EF6P7F<RD.-"6*'L3A-YP26Y+B0^7'-ST\.G$(7L:W^F
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MJJ^F$1Y:>! DR+ @_.$W-[KB)_\O:%&!B*^F'FQG5G7^'\@1@4<D/ .315V
M!) GKFV?>#2T)R*)28*A%C-(2(2!/7,%9%4UK_47).R <6Y<SY.+GW*JGMG2
M_)IAUJ/1@LO(4CC79'(EO&'-NL'85P+:W,AVBL6O&4<&C@7C $-D$8LY-X0#
M\\KV1M(B;*JXV@V]E*4KKBNH3E%>A*;[GNV S)=\%NBLSI.M 3*(74YYS; L
MFV'](;)[>V8X1K97L][#Z"]YS$\QS,4Q@U7&<$K!4: )LV+#$FM6'2'Y8NH[
M(&OP-=+0RUF#;/KES&A#%2H0#Z4GW-*NB7GD&@=1G)J[TA5Q&08W\55-LILZ
MO]1"#,%&27R0DH8'Q91^\P,;5>#GQ9_M;A7XJ0(_CQGXR8JJS8J)I"EE=XB*
MM.9'15J%49%FYRFC(FW::>M6Q1[=)]^N[V;]I>0C,'(";W'+FX\:3V5/(M@X
M#?H0>;PSSR@'*]X".^4W=JGXH/\;IW[V;;!O/3@%H]SQI.Z7YI(Q&.7DB= =
MYY)*A2XA/DA((:.4J2N@-?Q'C-!+XTQ9G4?3[?A<6DFS#MY?FGD:O?K>(F?[
M(W,1JW?(+!0 O-OJEU[G(V6YB*(+M&5R-&M?)_)S=H&8- LUQ?F*=<;=B0O"
MNP@VBX1DB$Q5<I"B?-=H)".,S<+]2T98Y%"?47REMVFG]L67\_Z;LZ,['-GM
M^4=VN^C(;K5:U9']4*G;KC<*PNAR\18+6HIEZ&>C90+6&1%<'7X+LAFRHG6I
M]4AS&IC TM>XU,)(N5G6)<%X*)Q9CHL1TAEJ 6T&PE)> :#""/Z$+EC;NO2"
M >AD'&59<' -131Q8['PQ#(<FSKMAT,]Q^<4LE5G;S;^1FYGWDL/.+4JYXAV
MCNQ5SI'*.;(BY\A<-6M=";'G$Q<%SG$2.0FHPU8_!F%Q-5U&CF^<RGC^X>CD
MK/^U?P>=L3-?9^P4Z8S-7J4S/EA9(4-]1F=4JW>+=9X--BRTR5.%QKFR?5]X
MUG#J Z6<2G4T_2:[B_TF2Z[+?#U=>]/RZZ,6<IB/EBO-1:<3".T=D,HH"2OX
M^CL1CBFE1*5]Q&#6LP,/:PU)A2*WP8WP/!5S3_R4,U0\?82*%I :/IZ$F#$Q
M!74+V>92L!-03X^F7Z 0FW.6T2MS+OW(G:N"E8;_0 DE=7-6=Z7(IG1,3C4,
M)J>?L]]2_D8)ALBBF#AA>I-F^0Q]2:!X1\G@F]1[BSG&<[\+2B)1W(5DU[XX
MZ67E+#KZ4291L?O7"VY$:%$6+C"!+V[T \!\F*@"7QH (8:4@D+\D_*,%]CD
M3QH&P!A*N"QP[<)]Q)T^T!!F&4ZI*D!M9!P0#T>F^1GLD]V3\S)\R^)(G)_'
MH3);G$S5JQU2,BM;1+0.1X$/%M>'*QN><RA?R/9@IQ_Y3MW:HHNO2I,2LOXT
MD TDSE*EY!M NC2#Y@YY,_@$)?/!1AC#X;C]KQ1^X!G[DM=EY/2]G_#WL0A_
MCZP#-T*A4$H#1T("+"GS7\PW>W;GFSV[O[K9L]/EK-M- D8IWS&OTN#[H,IX
MK.]1XO+Q.27[D@['^:^H )SL'^B21\>S([(9T".[;8^G7N .38\H*M-J0Z<I
MS+RMS2"?7 Y6W]/O 'UE_8H3 /_:EX(U"G'M MD<U/2OA1>0[8"ODZNI-3JZ
MF>OY0H&)SZ"RX,H"4T214;#I4NQW2H4>:"_PE-(23Y7^#(\ ;V0<O)RM[YJ)
MV:@+<YF&K(Q0>7)(-@450G889NV/X;4>3J.DC-/7NJ$WG8GZ9MGF1AH*1OT)
MK(;PT XDI9X.9[4%J8C*CN(0+!$D8I1,,'G58)<:? DU;OQ)D1*^#:]!C1PH
M#%1'GE%6@EQW6%00#^-,E-DVK) 1&NS#,+E4=]+"::9BHQ.S(-%02'DH%1++
M+&1GDQ:2Y.C#%7T"QMED59[F>3<$I-J33&'A@.-@ ZFX?K*L)AF^"K'E0FR]
M*L16A=A^E1#;FS39K)16YYO#D\,/_?='->OH^*S__N"(CK6W[X_^W7]SE_RL
M[GRCLUOE9ZTHNM.IM[+!G33U\2X!'947:7BD5;HF,H,949F)H["[?$X6T8)P
M7EF#) ;F#[PQG#'FK3=?3D\_'7T%PR:[&FFI[ON/^X<G%T?GM2PJ4 ;>)5/H
M66Y\GVSZ%9R,'EXT<X<5JW)J+RAI1@:O-4@BN"U:*@$+"966CLF5R#AC9,PJ
M'= 0MN(0PR_S \_ZPQ1IO%MZ5LE#@@^W\,[!;$Z Z>&<%!,WVF1;[QYHMQL5
MHEB)75.&((4[_)\7M^NVC?9>T8>7*F[K[C5ZN_=?RCPT;;$J>6:*P3[Z1_</
MFCOHX-2H"1^D(^I!JN:Z5&6$IP"3 H3SUEG@(%Y%&"23>\$S;H!H1,R3Z K]
MOW#4G!U=?/QW_\3T#\J?K+^^[!^^[W,.R[O^UR^?^CF9*7$;&%)EY.90UZ@R
MC 1/YI2T-7N8H!K*3\D@2\D8E;Z?J6K!G4P&P@MNZAB<M"9). DB3N)AE[0;
M.4D4$>3"C6"M!26,F@R.)CLQF@QB9U#N-)R0\G(1ZO,\VV%OONVP5V@[M'<?
MRW;8+%O,#2Z%KZ,>YXJ[/H384.8'[OX9_D!'L[DZS&+EU!0IE /L%-R0BDW<
MBLJQBWB<MF1H JFQQY@CPU!9H<MI-^9^G$B*%>VH8HK]<2<7?,[7]N0M@EK=
MQGU:!'6:]9W=]KUZ^2SN\P,;YM$[!#5WZMW6_1H/K6FPRS5?NEN;[(UOC%?<
M5?$^S91ZR]" ]]P:J3"CV^R8WIT+\NX<LW?G,.O=F>TV5D8N*)[_UA'8NJ[G
MH6$TTUWN89VU"GH8TS_+]Z-[&/\\<H/B8OJAQK,$V6Z?\C($?1JZ/0G?F8V%
MEME7<^=^R_0W4O1^D(G8TC*H(9;%(_1UO:5G^.VT>Y2NKD_2%WQN5]>'TV#S
MFZ*W.YT'MH]?:AL]05?7NV[N9]-V>-5\^"1S['0:]?8RS;E7QVZEU<:**;H?
M1%R>@SF'OI$/_3@-D^=)A<?OB/PD<K#3J^_=3PQN1/_JDO:A[K;KS854K_9U
M@<(WUZWU1%O\84?L9N[_5J]S"RN610\J6LFG7; GV0;M;O>V!:L4ACM1E",/
MOT=S/>BK-RNE![P%"S(,$O2GJZD;BUEP]=<R/!^%2ILODAOMU@-%\F,0:AW&
MZ\9L@TTP;]?/[4]"A0;HPHUESK-U,C6=>/^@H.7B(&E[X^+*JTB]3?-GBU+
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M=Y,%>8CE67V--1ST][XJ0?)5"[0>J<#-$=D<D;4[(F0V_T+PD'OPLR 0<2'
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MI,Z4JUQ_V&MA<>!IT[#.HBN6^_\+84_[UIQ;]GOOHK2FA.$Q5/B.$M$3!-R
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MS;#OLQ]+(UNRM@P7%([P\@J^Y4@P.H>-L]%JX1-&_Z;3+@,WKG*$02/T4++
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MVHVDO,X6Z111%XNSG:<@G4.F$F9 %F;FA$X]4 +0H8%&#=%@=#+X"$PW"?^
MK8/--M+P!-+@N)#E55T9W!WHX3QR'#B[6[33I6[@$O9S4AD-<8%X)LUOM#-
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M.B;(,H.C5XC0S\'+X82=_1TV0,Z(JHA^@R *)K25(TZ2"<3.MCACCF4*&0$
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MS$P2P>BXA\\6G6VY-=NB?:M?/(KQ&1T'MVYI^NQ+W6.ST@( HU26\Z/8S4%
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M 50^%J".H.,=-(H!3C "A#3!A &B&S!9FR/[N5W&TYIOK4L7&$[@64Y>L+L
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MJ[J.._R]YZZ*5Z(:@.F4%#=#0RJJ3L@MNN02>( "P802LNZ!V0)8W0PNWE1
MLG]+H0ZX,#XYT_%S;X+&W3$7EM1R4J#<[\)#>=GEGR:?L'I0&HXWD2P#Q"[E
MM[H*9R='P.' @1H78R;S4$G:.\=OW_TAGLV?OKBK\BK0"9.=4GR%E^V6P4;8
M_$.$%60K">T-@"D[Q?:(QJQR%3)50+V'0$MLBZ=(JCMF[M<<8ANJ-LH=$&J@
M/MQ\;ZUHY1+_CC2T1 \A"1IT$876K98-$X COW]2*-T:3"Q@EQJ0UP)8V_=G
M0!WB?TNJ47H]FV[*;GS*1C$8W]$B<*R]1*/[,UCKPLY,-R<W/R?Y<@%!#::B
MH+_FU.M?,L6D.:7.GWB"*$U4A#]G?B(#ET,+[ J=LWBQ$/ O,//SO[NYO/FY
M9&IVUN'+,FX2)?J.L35YE.M#Q"TV2"U<4IWFVN5 M8ND\J&D$S=!XM&QV\%A
M=M?1AG13O@D].$_UCFAR*7LBA" FM7&BOV;5MDXB8X,2&5QN:*6(N(+,!@#_
MOK@"'V(R#2X9NOK&Q$ ,5&"=1Y7FG*K!KI9WWW@F/[(T4M17$:!G0,:,&S9N
MJ$SEY0*)0?)29]]XH#UI4Y@O(&H3Z<9 F "WFX8S[RX/L4F+1*.P<2&_LPBP
M]J-G'B/7\]\-GC>>Y=RQ4Q@I*\LGO9;('_YO\'#_Z02,=-%3QIX_R5 +9CQ&
M2DUW#!"/IZ]SU?+"H"&R,(@I669<8<7</M19:)!4XM0UUOADJ!IR/VH2F'%:
MKI)WP]Z8:IJ@-LUG9@*R"8#7X4(APC 0]S5>XE#PY:E_!\@3$6V&G<5S N&X
M"!&):%&J Y@YN>^9FB?H1A0IVKN<)?,=WFSUQ/]$VCX!\V>DUYIY5X5K-4%H
MPZD=*H85V.AKG,PQ+:Y*G4+(AM?8T9:/-Z$,*I-QV5<*F/5&AFF1(:<(]&\[
M6ACYMT$RPAS"@!B;O^#T(7#(O$AF-/488C/MWM3Q<7-&'+OM$?K!*3@'_B1&
M:$!\ 5->S!B;MN9#!_.:&  6,[2PS%-2!4*4P1ZG;_TY$9!.-G5;$-#-"0EE
MU-B6%YH&AF>W1YR3#DPCD&.\YX3XWZCIPK$R.O@KO N8F.@\'L=@G\CV4SI2
M(,]RKQ4E,CS+L2&KHXB7PW0'8WS01%]DA(Z3)0EH?Z2=0M-&(->171CT[8"Y
MF!<K%Z325!.8N_*3NK3O?FS1H1'[&<)Z)J!)->:.QHLS0PD<9W27I;$WCU*2
MRIE6#WUJE ,$%_:((IY<G2+:] "7!"]*3Q_A!U66$>U4Y-PIF($89FG!>D4X
M(Y73(N!@S,N%3CL[0FFY/7=2.DQ_:>R-?)CM(/Z2%NGQ9M-'S11=0"2<DN0)
MX#@_"46P]7CH2TK%.10$PC^?Y=1C .R+BK?)>ATI[ A$9JG)@:6%HT[L2XY9
MC=@5?9?2E52&UZ=5WW+#'X&_-;7&)X<-IOQ-T:7"[AW#I> Q>$8+)4M$?=#8
MA %].+@5=_>(<-1AL1H6Y*V&L4!_D-M"$I5NYX$4PMJX/-.5V\H9RPE;=1EE
M&49)KKI=G P>2@KH'+&SEWG;7%[2N&H/+Q"5H[:^MDL)_G:,-48R2SWQTZ6=
M 3-FDO;$AW.+!4^%7@35AU,0372XWU$./(B*L<</A+#MR$OT?*,@#<5*8--C
MP-7;RX?C)5W<8(0(0HZ,1B.GDJ'BH7I_(2YG6LH4QZ:)G:J)]%I<]I@\3/7I
MP832 K&H!#!:"6#VDNNIP1'FQ.@(>&R;K);N:J<ZOB_C!YW6-HXN\.Y7KQWL
MR0\.35KK*8-1N0?.Y^'P8+"6576!0ZYT-E]4(\K2P<_/"OPH-Q=(#:QI(5)F
M#O&5P/GN,?C.L9$G_R,IT@$($BT4=N"+&N6E"SV#-G+[J91RACB='5JQCE8<
M=&C%#JVX-9[,^\MU72Y,'04.Q!LV=@,'$]D^//&W?+K^"20Z$8%5@/*OV66R
M?2[.2Q0=98 ]_B\8P^=Y7"!B_06VE0$YN6CE JG_&;5JN%&Q5M4>Z3/V'YA3
M'A.X#I]6_4X-=CF.J8LLZ.04PE>)$NE$(,6QQ@OR<3L"A\-Y'FSA\1L0)4@)
MC[]0(_DG9;0Y"P*@C*P\B&K$]\4@2@:JOL#Z@L%U1)3/T7*.!"G*<>)#O>>]
M1>N0P ,QW8RG1*$LDXQ5P%([19I7\+).[<K0V<%>>[S2NU0Y*G@Z.ZBKG(=!
M%.$UPG!B1P-RA>8<R >C9^1JB'JMGBBT53W78(H:+WS4]_Q,-2VPH!6_30>K
M!'PR[4J1!!!:NTM,PEJ;O <R2I#_2-?N8-TN^_AOH_-X(G,68VJ>G4+>ACZT
M$W<8=I[=A2H%I$2F<^MQ[J@)Y#%!TBD9B?RJP6!!0&9("?I_ITN)9W K$R4U
MY!^H^]3GYV#'2ML_WZKG[HFID F6L3F5-EI(#UJ=GKI2XU;84++)E[Q)-9?7
M\YUH&O:MNMU[0CX;G8,ZL#?5OJU6FN2@^Q4':YEQ1,L?]:$44UO#8%AGV)J^
MO"@@J2<Y.'#+,>(YYF3:.8?6DI;A(,^9+D^\.M):?JP^(B.!3,UJ(,0(@E$.
MY--AR0?AMF0\8N(IP>='!@#1N<;<^#@_S5 <)?@X\5PGCMP62T:-,;G ?_UC
M2464GQ<MDCO;7/"XFW:),E"PQLV$6<+6H]FB?L\* PLP>%$#9L$]M,2_Z^=0
M7V<]OK7MLUO5,;-!;7YJT!"@'Y/7DKD..!AHZ_KTKGU2V&P9,POGJS@%WB>"
MWH3T$>H@)DEYOD-I+9/)QEZW1T;Y*0-78SCM&1Z@99GP@C]UZ-)-8)$5,>+Y
M,H7CR>\=5E#P-$>(Q["/0M9XLK0^YDH9VPX)=?,SUFCDV%61\\P=YZYP%92E
M1D[2@&*(;MIN?MK82^-<[ 09L;'RIB1!,56ITISH,D[3_*+F+<*Y)B!(CG0J
MUA]R'R,NODA6N8D82=W#<UTM"R@4!\=!$V2RU]YO@A5N8)>0\%K!,I\24J=#
MZ&W67! MFZMV@%^488B24_P-:GC<!-)K<X^<W^F,OX94T0(U?O79>^#B6V(
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M4^<AU<;S%?:F=^Y19_4ZJ]>MOLX]ZJ:J,Q0[;"B^5?=(X?\"!I>'-P?X6V_
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M%<O@XP$'&#P<CXW.'5\RW+;C0,)!BTJ@_]_WWT9>V_X#B1UY_QW==[#;MOM
M0@*R0^\%]0/\;A#GX\$9!2/]#LVA=>+YE_N)RMR2%6<D*=^4<]:D3WVPA.%_
MHY=9]CU#4AJ"])?#;8(M5A''SFWP27[>GN@)<5)$0;@U0QK3;0YM*5GR,!U+
MY0@'#@Z &#YPZA%'N#=3Z(VT@3EU)^ 7^?A+@"*'A,+^;0Y$2\X*O$R)UP!
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MVC$ZM7V]_A'#"O_UM_\/4$L#!!0    (  Z"HU18[0-"!)(   U!!@ 5
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M/BD+&E!P/%A%243&$&DC)8[Y0" !<SE2RX$VNA>V!GTD K4OMMV5.+ZKQ'V
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ME&F3C>4D,I-0TPUHS#"T;H,QY1=.&]E&/#9%^N1OCJ:L67&@['RB] 4\/_Z
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MLDHA]&O-O?85^[W&*]&_JTZ\?<_MG7DG%]]4B$:M?%[5F-/#B)>[6E'OJ$F
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MXOV:.)[2/!L2A.2.I9A8:I/:\RC$ZH&$X,-+U2;L:2!-S[LS_&DWQI/Y"]S
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MPG*1,[<YE&U#;=N<[N=#@+WDVR&'X=?Q/$_S;+X:8T7^9N;9Q @\HZ(32$=
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MTR\+N(LO;_8B_OMZ-,WI0GB!=18I\%";WMD<R=7W"2(*]%[17MRI)>T64.=
MC58R[^# O%F%6\E(NN7NZ_)J<G4U&2_P7B3&O0N:"*L4(<RN5J3&#%+K%.BT
M=DSW*?9\&MLYD*.Q!CK<BSV^L[W-56"C\8?;+>[VSZPWNU*R)Q?/0DEDQRE;
M"]<2EQ +2S*C=YGU.6Z?C_D<.'4@C76X8+O-R5^LX>67A7!6S?18YBS2R<F*
M]O09, _!5) N%;(G"XNZ3TQE"ZA#Q>0[<*21I$\E,G_/BUC;7S7FQ+(MV?D"
M3.M,'I^L]TK6 J(+WDDCT/2YM=N,Z?@U+WMJ_3Z;VDB_@X7S.+)5L&$(MJ[1
M^VWHCA/!;Z7)00390PV'I@I:([16!(\.2/+;H@<?'4)B%C5CTJI.[=(/3Y$G
MHOK'8,@NTF^>Z$^*88^C6X]]M]QXD03H($VM3RK@N6$@0I%2)G+AQ+#2G2=?
M=7CKM)U:)MUDNC%.TCA,>Z<KVW(LV>3JTS1_K-]-G>!,?R[7[+4]HK<[OJ%)
M4'>?5=V+]7IF3-+!TG^Y*F29<B=0<T2F:R:/N-CQ7<WZ(VY[V:T]S9&X9HNH
M[G6M,XP!@J2-S#,I0G:&--7'P]@5:</.D=O>]WN>OR[O\:\+953)4@>(4NJ:
M=,T@Y&R 116B%"2S3DTT=P1Z^.VQ*\>V=(5LKK8.L>9=X3K+951, 2[R^S&2
M5%!*,(GKPF.*!KM-R7L^RW:7R[9WO,QE4@_%6/VR41DM>TS<D5$HR65OH-ZC
MU1QY!RY)!]QD*WP4#DN?B-H>H,_\JSR4.CN$=N\#^X4D.4!VJW&L;_)T-$DW
M:XF<MAJC:\L38>OG6TM"8P+#<K'&1*53GYG(+5=QYEP]FL([Q(H'G2DZ^U!;
M\(#S*8 2O,[P(H>%AV P.H9L6)O]IOOE=T*VY@KJ4.&QJXT2E(FHN ;)D#Q>
M6=.3-'=@:VY+5&BTZW/^GI"-LG['F]J G-@ZGT]'X7I>@\CO)V^P[A07TJ,O
M@JQ.$04=;(*L.I]JGJ=&EU G9*I/5OR>P']\DLW4^O!K-0?Z6I?W&29$H16=
M3.@M>3\Y6PA66K L>LD$TYGWJ<W;!>6A+A!/T4_=74TG<]DXI[75!]5.<?,O
M=7V3<<WB6$3!:1THF'?@(UE#RG!:FW82 K/1NQR$97WZ7V^%=:PKQWYD>)#U
MT$HI'>Z6[F%:Q<^'@.IZ__@HK"-=/+93WZ27[ ]&#%'0,1D+".%#'?[@ ',A
MJYB^#EVB,<ST.;L.2(BGKAD/S(==1-Z!!W>V23+$_AA/,U[6%*U?QY_S;+[H
MZD\HZTZYNB"+4G)O"67DF21@70$O-?TRB2R%2=F8/J7)NR(]O$G=0,&;+9KV
MVND;>E\#(]RO</;QE\O)GW5<;5Y:].M.PU42"C4PINNY:^C#0K+V)-I$_F[D
M[G[/[?9D&@+TS+C47#=]-Z;M5[;KT<C_WS5]&^5+331=##C//_\5+Z]33C="
MI'^+?D!_X%%7\_?)N)KMI*3+Q6ST99.(E3"L=>2":@2O72V?$!Z\=Z9N_@Z-
M42;J/C4*)R6&,_L,CB_0G7C5X2+FJWE_I,V<7N8Q_<.\MB2?O4C_^WIYRJQ'
MH-HDA181:E=,4%YI"*Y>G"K-K X%D^A^4SH YYG1M+5F.MR)W$'[?DKX+I<#
M)^ZC3,DQ7X2!'&I'^QP*H"P%M"-OFZ-#AMUMQRWXSHPWK32Q\?JC<9K;_4O"
MR?5\4OKGOK5X;9.$N.;K?U@1'3W7W@3NE- Q2,>%8CYG%4SBZL$M[7, M$T,
MN.7MZ^OYZR%87H]O3^X[864IHXZU,6NBOT$=5DA\9P*"#A)UH*\J]$FC[K6B
M?7=LLDKJ\!&<+VR2^IYU.S2M&9+5H< 7B;0U1$G62!20;5#"V<QBZ5.UO1'2
MX??ED^#A_:V]C<HZ>/U+,._QKQ6>E:5R4:ROU>:D:.GJ$.C,P=MB0+/D..U%
M3+D^3M,&0#]XU$Q='1S^M_ES'E_GVJM)NI)#@E+;Y:A%M)7L6P(30Y#)1=TI
MPKA&\(,GSU=(!R?U]7K36_%U1OM=\MHG!Z+V:58J<')T/(?J2ROZ7RY,],GR
MN _E!U4:J*B#0_I[GM_:IA>9/"<=/".?V!.!BQ3@5(F@J]<LR5L6G?S.KV#\
MX,J>JNF0AW=?0D/ELDP;",$5%R0#PV@[5-)X\%PPH -3U\[Q!CMEF^T%^U"Y
M/R?)OL,I_-M(&I)<ESJ1';2G UYI&R"$),'Z@B$EF:WIU-WB%).&#LB.G;*(
M=M'2P9)%AH#ZD46TL_H&98T\1_8'(T91&:U "UK4@2I"%<!D'2#/BB>C?59]
M@FW?2A91>S[L(O)3R")B4:M4H9*;$$!QEL %A:"Y9#[K4,_S'UE$SU7POEE$
MNVCG!+*(DF59I>+ QCHA(M5[3Y&PUH<Q63L9DN/Y(XNH.9>:Z^;LLXB"]2%*
M,A Q,$L&8G3D]KHJ?9\P*N.LZ5.J>E)B.+//X/@"W8E7!RCG'NHU+6RAE#(Z
MLGC JHATUA!_T;D S'K,/KAL"W;Y)O9!_?WYIP?3\0GQ<ST:8 #ZKG[N?OB/
MXQ ?CB^-B+J'LKM<ANZU"L^9%,Q+<([5<G$ZVH*G;SXQQG5..@I_F)X8IT#5
M)USU;Y6IN^CXA!BZ,EFXYREQ[R#+0(*S@<XBYSVX2#Y!DH4I)4^*H<>R70_)
MDD8$?8:*#]5*\6><UE;D,[*Y%FT@]\@;W?2H)KF@@W#>R^\4.2D1M+1>6J69
M\B+)&+-P2A9''+C8]- ]7>SQ?)1&E]?5RWF7X_64%IQG:_>F=OJI%"$_9D&A
ML@;Q9@7B]EHO62VDYA&<,I*HBH+XHLA0Y8&VV&!*M)VJ"QJM8*]VKR]Q-HHO
MQNFG"B2G^R]Y$6;S*<;Y12)+7=3)'8IK^J CTQ "4Z"SC(I+Z^@//$7=75YX
MA,XDQR#45VUB>^BB0YSTJTR*&U QB:#JQ;CQMDXRXPQ0YSIRC"=34F$&^]14
M/@KG</3II[EM"2S/$GL'<^SKK!HZ LC%Y[2H* LQOS902:P.?PJVU.$-G/<)
MJAPYX:F!:K9F*^TBUPY*_L\\^O"1:/WB<Y[BA_S[=97&Z[*<[436V6R.XQI!
MO%FYI24&CPY,3&2"A9@@,"[ V:*9QE)2ZM//85>D9[A-=%56ARC94+P+V5VD
M'*160M:Y4!'(DM?@T4:H[K UJ)VR?1K2[03S\#M07ZT_DV*[JZS'T.H')MV-
M#+P.-O+ (#M3$_J2KHV8+ AM!1K)M.HT*'(SIC-G3B-E=-B&Z+2=+C)G\/+5
M<AC=<G+A5[=ABY\1JW-:S;%[,9WB^,/BWYM=>.9S"2J#$[4<2L?:!"4*L!E-
MS%Q8+?N<>OMC/\)$Y$9,>%AD=$@U'LK86AD,#S_*F]SFBRB<=277"2(UXA9E
M %\4!VY$2C*HH#I=:#X3\-E0[A *.YS=M0GXA1-1+;KQ,.GK9U$0@D(/D@4G
ME-,JRS[%+#L"/?,3M*?:NDZXW#.\MDPE0&W)J:;-6"CBBM*";,FB-7VVR0KM
M@A2LTUBRINLX6!O<8X8T3X "IU(+L^?"7WYY_ &+J^ <H]:Z&)"^SK&4M4I6
MF0)U>JWST@2T?=KO=ES4\>>%'IZJ]S/]3H0R/9)C'T7V.]Y<'@_!US7SZ2F$
MQ\EM.AE*#*+JGOH\!N^,UR8[R4%S5D<""P:AT"FGC7 N)K*8;*>Y;T?AVQ,)
M2M\LW7918^OIJ>])O/_*LWD=-D_6_BA6H[S.GOZ#-+:N<T'!4HZ%CB2N#:AZ
M."#C!:2R)2:5[(,@]H:[]"%O.Y6+].<J:-)3N@UOQQ< _XG3_\KS!Y"(S@:E
M=:3"Q$#91(:T)+HG*XMS3D7EV""%/_[\<U)Q PFV_J9I1RN3Z16.8[[%]2[/
MYY>97.S%C]8%;%IR68H 9DJ=)*\Y;6M:@0_*JB3HM_4P/0]^Y3FIOH^<-X;.
M&J?X/0@J[],<<O/#FJ3Y#<1Z+]&/BR2$CSP[=(HQ&ZH/4SMW*9&BC/9B\V/W
M+/<FD4V^9*+;]/.(R''SFFJ D#6S;/-QN7C0PA9YF^/DP[C6FBYG^+V:S.9W
M&GE$B<(X3I0,B'627P+GA00A$!4K.KE.]7"-%[)W<.Z)][\8IU=?9>+^.OYE
M-*;O<X27-Y7FMT'TDC%GH@0(G2,9=8'VZ! ,).-R<IC)'>Z36]UV'4>H$SPB
MOQ]$ZX['B1XEW4O<J\#X@V6M&UFB+AR91V ADG41,X<0B@>FJKA\H)_V::@T
M#-_A&7E,%MQW]]JKL$=L81#*F[F:Y.'2 6H\V!QRO6]DM=.! HF)/D]K1':=
M^E#LA/,'\?JHM,-U;ILSY!5^&LV773I>7$VNQ_,+Y41$I6K.5A2@"MG;P3$#
MNA0=@_">O+(3MI4>+.B[IO0ID*3A)?/":]SZ=2Z;&]26,POD).J;3J'<U/&M
MRM&!82R0/Y,@:*GJ9 +NE+>&WV_WN\%7?R: [Y*(!]-8AYZ=@SX>.@E6?:W7
M ?+[AHK.2FK4'M!$!RI9NTPO<\Y%7EQ*)O:IDVF#_[ND[1$I\)#(NEU.3IOS
M8'G9'6LRM]*ITH^^3MKQ:SJ; IU,\@6=$KF/2=ME.8?*T#DIU__HO#B5?)UE
MZ=7-YO';>J>I5Y=*UAE&)&'CC (EA ,4Y'=JPPSG=#3YT"??9@NHX^?+'(TQ
MCPZ9V%]S'4($&Z"M;DV&@.N:\[(5WG$27IHI<QA)]M#$P>EBLA)!^@C9L#JK
M31H@VZ7FEQ% 876QJ8];?@2:/)&G<AR6[** +FUP9ID>^+$6D^;/^7+R:='U
M=VE@WDS2=0Y#U,!*;1*$/(#3FESS[+64'DLR?1I;# !W>#>BH3H?]*MIJXL.
M]R#O\J)_XS_(+YGB)0%]D:Y(XM4EJO?X:Q=[!=;D6(*-#(RNH<Q4DRV0.> E
MD$R"T.E^&D,K4WX7F.=$H7[ZZ;#W?-5H5W*G:\(>D%O-R)TN";Q!"S$FH6E[
M1=.I>\YQ.QSWH\*SI7OT1)=[#97WS'3AG5-=[J&]E^M2-.,L&1O1,%5SEKR7
M*8K"?%(2N=N<Z\)/+-E%HBFQ9D*:$*HW58<TUO;J5FBBD.%,V3YQF1-)=EF&
MG*^OKG#Z9564MRGV_&(VF\11O?+[S]'\XT^C4G+]%M],)Q^F>'4;0M3T'0ME
M$4+D$53A9%5Z$JEDJ?A:/&H3?XKW[6%]^WDKNU#UZQN%HZGW>#DKD3$22M 0
MA#"@3$US+G4Z(NU<4CL;=<E=ONM3RUDY-@.>EZ^RB_J.GZ^"LD2&Y$<CF9:@
M-!F;B%;0ARH=4THX,E2^JWR5;Y)TSU+G-Y2KHAU7(9<" HNC9>4,SN<(1BHT
MW%AI\91-G2/FJIP8G4^!(*>2IU)<8J[H!,E+\B61,),OJ"!QYY#L(C1N6./5
MD\]3.1$2'DQ;'7)4^ES(*>5HWV,!N-42%*</R-50NN0Q>*,6TVQ^7.V?HG=T
M.KPXE:O]%W_B-+VG/[RX'W+:Q%AR J6* ,50@TLU+$_+,'40-/8:X787QGE=
MW^_$BOMV[+.UT\%'VB"%.[WB7GYYV$JNKN!V&>/TYA+'=ZHCAZRIZSU_CU4=
MJ1_&\\DRK.CI\)K^5EB,7BH9ZA!9N^B7QPQXJ044QEBPJ'+"3C>$WPQ[G^JN
M<=KDW47!K>OM-[0 ,"D2#)M 8U2@0I'@O>'@-!8A>%&*#7.$3J6)PO$5-Z#Q
MPBY2;]U-8U"[C\"0F>QJ9XA%,K62X$PQP+3#.@DKEC2LCN,TFZF<%DF::^1X
MO3IXT*6@2I!5=K6:Q)*GGLBGTM9Z;5E2(0[BS0GWZC@M\O313</X] "4=>+T
MFN8*:ZLA!2PEDH/P!7P*$D00GF>)J-.P+DY#W_B#/QTTTSK,>^-)5X1OKJ?Q
M(XFF2F"%39 7S+2V(+%ZQ\(*0&(#$+[@E)+6HQ[$FB=>]+V3I:4>-@9J&V=6
MK8<F_Y77R43O\U_S:[S\&LBPQ*K-#VN25S40Z[VT*I6\83YJ+9U7Q7GD)<:@
M<O92>I/TQ>;'MLBFI^>^FHSG(R+D.'ZY#:UF50)JCN1^V0B*&P.!L0)1RRB1
M"15UGR3&K;#VGGR2XS1CO:[X8SR]B=?=EB?.?IV]I=^?C#%<?GDSF<U&-7PG
MDL^<3'N"*E3U1Q&\$0&D3;7)F@RE]+E$?1;<8V5^MF#2@^$HW?75(5OIIUSR
M=+J ^6(VR_/9O_#R^B9<_&<]K"]T,*09<@.BJ! 3J_=QY$A:7_N&Q4C;5I_!
M* / G1>!VNJB0S3RYW]?C^9?_IGG'R?IU_'GO)R%,;L(*+E"QL!*F6M5-L'R
MY #0X5R(P,XPT6<'W@#HG&C10N8=LH >L/6W$8;1Y;*=9)Y?%!NM(YL,M*Q]
M)&-R@(K63=X@EUIR\@7[M)-[ M@Y4:.E#CI,#WELX<M+1F&(HI%T%[@7Y!<$
M#IZ9&C]'DY.09,'WF7:T$=*AT@KZD:&-M(]]T3^;SB]NZG+>Q3S&Z6BRNF3)
MODCMP9E00/E,OJ1'!MP9)905Y&$.ZO)';[C#%_K5?:YLA'"LB_Y&FIVTE'!#
MXV(!:(7CC_'L4XZC,LKIYA[V:5"[W+@/4_\F.(>]*F^DJDDO.1^,! 2,A3HR
M.24,9.MD"2@Q ;'>*Z?)W&&#[,M35/Z&F^9#ZGX7\7;2^2\3\IEQMJZ<9+I6
M[DD!48I4)U;1%H<J ";.BM!T*/I!UN-."O\:P^$,Q8;*>43=>TBV8<!AB>@F
M8>U1G^;A3W.NP>0%ZS$X*8OWP-'52R5>P"OKH=2<\,Q22L-&1P]DQ/.1GI&5
M<"A]-71/*^Y-N-:7$@.0-;<HMF,Z@EEQ,-U.NBJF\7'T!,*B"56=Q*ESUH10
MJ9I.8P&C8^14"X9RT(BIDZ7,-F/D!!FSBSY:YZJ\PZO9]?C#R]%D-KH:7>+T
MQ8=I7EAKZY-6.F]2"I!SL;3MU@:[O!C@B24?Z1R68EB*RE-O.JRETE(EDU[R
MW&BY-+[S?3W_F*=TX,XFEZ-4"YH>]BY=7H3N,4UFYW<TN2'>;V7W+HX-<UIK
M9G*L]:G,NJB5*P61%<5B\A<[OVW/K.J;SB^W,W*3-]ED,K6,IQVJ-N'T1DC0
MB%I:&8P?YF+NGA/] ,O^<==YGM)WN;0(;ZN';^KJA$"NHR67,;)4=V--OJ1U
MP++VL0X#YJ+/)?%3R(Z0]K(?$QX&81N*OL-][^UQO42XQGN1;0FVYEN1;Q@)
M5ZH=SJ*$8E#29VN$$GV&9VY"=(Q[FI:Z>T",!H+OTJ=RB6/=V,*X0 P7 I"+
M4D=["G!(AII%$U3B'I/NU1_W*R!GI_[GB[G#Y>W;O"RLOV7E/TA$L]\FLUH%
M+9,AWJ6:B>(\**VKL<X,9*LS.JNER'UZTVR%=6:,:*>"#C>W-68X^C!^=3V=
M+L)(4QS/:,$D[0JR8GR9RZ0.2O_KPHOD<J$-S*6:DL*8!TR!@[&QV$";&^^T
M8^P \LRXTTL]'5H:+ S[WR?CR:=<FV&./WPED M4-I(7D "#0U YDA1X,""0
M!9=Y-BKTV6JVXSHSOC140H>!%IN!>6%#%%9"2+%Z_"+5+EL<K/$J*:N]BGW8
M\;T0HXWH'W+"M$DTO!U0_,OGWT?KO>W%)4EDO.BL>RL$'C-F@1 P<U EDV5E
M50)94HXQ<EM<GPYG.P+]YAW<GHKIEK#Z.-R+VH0E\2 @5/M*"5<@F.( G3*V
M6*U2.3QICM 'M*=*=Z#/3OHX$%?65OH-1MI1=7&T+S)2#2AE''C!#4AG69$L
M2:[['$E#T'U_W-E+/SUZ(SZ"L9:#W$/IK7*V]GQ/)?K:9(?.;&<S^7@Y^\*=
M=+)3J\-!^+X_'NVIHPXN^(L8I]<YW<GH7KI[MX8?+916FSVPH@,H;6CCI(5#
MX2%S47A4K%,+X:>@??-63EOA=]AG'I8&U3Z&=93)]'.>O<3+1;40>6Y*.B?)
MV2_U+A8EN!P8;88IF<Q48:%/4'\0O,.SI+%:)[UUTL/(6156O\V7]9KUH2@N
MHH[<B5+KBHH$5;O%!&D0N XVZ"*CZCSA=".T<R-,6UUTV&56RW\[^8*7=V$I
M)/<_6@51U) #]YPXS!CI-!OCK-.RT_WQ!D#G1HP6<F_=&>/5Y))^-)DN=KB\
M:IB+%2A>7IB8HI8\@M"< 7EK$5!9#BBS5JKHFKH\*-5IVUO.1<MMQ=DK9K]Q
M[1<L<A&X=A 6>5@BU/%(,D').DN>B9'#,K&?%[/?B.M<Z-%!"QV"]@MTC\#"
M[ 4ALT#NMJFPB+HQ:Q#&T:8EHDKWVRJU),=WPHH]Y=XA7G_C?RTK#HPQUDAR
MFX/SM(%QU.1[V=I2SC$>N)3*][$AO\9QJ*+>QM[G'L(\=OGN>@DK;^?=QYR_
M'NGJG1&&1V(\EEJ23G_!0'N7Q205RL(=]@E:;$)TM.[=>RAYTD'8'7S-QW"M
MLL2'(.O:1WLSMN-TPVZCPP'$V$,!AZ6(L8F<7,N@6+T(\9*S$YD'(QWJS'CM
M)'D6U'BBU?2AF;&+W#LP8ED)L+1J[M@YJQH0[91'26OFT=3FM#Z#=TR!=-X6
M%3'J3M=O6V$=WLALI;_'K,LFPF^8NY[RZ.*W_ $O?Q[/1_,O"^X+KF)"0?8M
MRUA[A!+WO:!%BA1E\(GGK1WL9SG^[</D\]_IT0L*_%O5?X3E/R[T_LA+OV%+
M85\1-HPM5BA+%"N^#L$QP!08IM*[;S[L0;^W"B8-Y==PWWZ QT:EG!<.,HH(
MRBH):+D$;P-36&*195MOIU/1XX93N9L:=Q%;ZU+67R?CT>P=CC_@U>2G/,;+
MT8MQ>H<?\GJ.>;)9,RQ@>#U2=,R 7!J0B6,1!ID8V/7XB1<=[AS=3_R33K([
MN:K5?3H8[_Z2P]:M#NIX+(*UP83 @_ *H_/1695SH%\(7C@?7KC:J!/R(Z$F
M1(]%%P<D?6(8=PX"%XLR:9%J-5&P?6SB]I6K U-S.%FA49/EF4,RH) '\(L2
M.A:BX2%H&?KTECS5]*D]6?',#*E=U-"AEG50/B!J*[1C 5BLLY)5H"V=CFD0
MM/=*VJV*DM]3ON8!B+*7"GH%%.XV1IV,X^K21)2"Q1D-/%>'EA.5@\FU-5:1
MO#@=T/0I7=N,Z9NG1"-Q]\MFN3.CX XV&U.RZ",DE )4*;4MFB$SK5@F LG"
MQ#ZI<MM0??-D:";R#@FV]\(J9.4SBY(.LXC5 0@97/(*;"FT7"]ER'V*04[F
MRG(?1>\AS&-?63[JT0OKHV()K+?DT4?K::>JJ> HZ+1*#EG8EL7P+8<7=U+=
MMO#B#B+L&8X:@N-<PXN[J&!C>/$9\NNI3W+(4XG"@'#:@Y*BGAJAU#I5M)IV
M,%&VS?P^%3WN$EYLH<9=Q';H\&)B7#+" <5A B6TA:"<@:@Y_5AI6O:W'E[<
M2?R[A!=WD=VAPHMW<EL_9QRGA4NP2'*G1\\^CC[-OLI^G>W1&^^YKVH2:FRR
MSON=\A3SG-O$K"XJBH \:&2D5S21R_!5XO!.+]W/6/[JK7>' A(;JTF_X;?O
M=":9W1J:1@:O:&50+!%7>4><E5:"]"46X7G)L4]F1\M5[#=F<IGP_>O2%THO
MOWRELXLB$V>.M@=2?.W9$C0X:048(8N+9)\I,VPVZ?;W'-Z]/!J-OAXNV4[Z
MK6=FKZ"-5M#"%_JZXU?H(OTG>=KA):.]7M%V 8$)!)N=(K/ .G$_VK^=&YM?
M]9W3HY$.6AM3*W2DV<M<YW?_.9I_'(UG:R=N-B$UU6C+1<Q28_$,'*LF1U$,
M0K0:=' D&9)!=F87HCSYQN^<+VTUTF$N=B0P9#A.2KF>7Q.Q\^=\.?E4(<;)
M;#Z;+JL0YY.?1S,<76A3&&H>P*'1=105<9SG#!AC8(DV0L78(/KL^N;OE49=
M-=2Z&O"/3R3&\9P$],_199[-)^.\&@D]^R>F_'[RE4S?X'0^)F=%>10AH"2<
M)M?"EPC><0EDZ\;B"I/N_F7<!DX]Z_7?*['ZZZIA#>+#XLB;-O#O\_3J0EFK
ME59DC?E8TVF" ,>+ $)+ I)>TMXZB$*;W_&]\J21U#L4&]8>"O3 CR2.GV[W
MQ'6KNNQ0U(HJ8-+S6B3O"9Q.9*\SGK5+/NH^\XFWPOH.6=1>70TK%1<4KV2>
ME*^,>5P3_8+.SF*"+5!3$D A0?0J.C+RBQ!DNH7@AUD\V][R'=*BK>0?4L+N
M>=:LIF7-=SD="X^<-@4'W-#JE=&+ 6H.$(6O/)8ZEX''T#->_[V2J+^N'K++
M[<6N%RDM-(.7]Q%?1..*-TH"RYE5 XN\P>(5^!RSUD(4[^0@"FU^Q_?*DT92
M?T@&W]62^?FO>'F=B. OXK^O1].:-_-F.HEY-GM%[M\%G8V*2Y)$#CF"2IF,
M,$?0Z=3,69 A%COUN-T#]'?(P$.K^I$ X]ZIM17$Z_*/R215L;W+T\\CPO9N
M<IDNR$0KCF0"+CD-2B0%@24/9,(9EB1&O_7^?9_+FTV8OF.2-5+4(QS:+TI]
M!U<%\PH_81S-O[SZB-,/>7;A#?-D[]7&&)ZPF5+ 2Y9H*T;FA=/&VJ']HK:]
MYSLD1FOI/\*,O1-QE^F@-3?\%Q+@X],D:?6HZ9Q6 NA8KF.N&0/O$@=>6Z]&
MEV3V?0:R#8+W'5*KG_H>(=G>Z;V#4/Z>Z3OY:?1YE/(XS5Y/?QK-YM-1N%Y(
MZP(9\I*D@(0E@PJZE@.Z4(>6YL)X0A9[C<G;%_L/>AY*\8]P=^\&?"_2_[Y>
M OUE,GUQ-9G.1_^]O'FVQD9#/BLX;PD9UJ^*:P/9Q\"5XMQT2IW9".D[9EH;
M-3U"H+T#YC]=YTK^56/9&@@9Y3J$&:TV40*G#9B\"B3;4.8,0AJMG&;&RSXG
MZJ-POF/B[*^>1TBS=P\_0O5^\C6F=>?"I7S6K08M,FN%@N10@=(*(405@"<C
M6%29:[^MP<->-!H"\/LF5G,5/D*U9T?<;VI.;F;)-Q#=LFY%<Y2%D2OC#-+7
M$UP$-,% *H*AU^3PFCX%?.W7<J@:L).A[9'I<.P*M*\MU]O*O+O-WJ+EAB-W
MH%E-2D43P2DC07CZ>'-V7&.?OKI;0!VM8NW(='G4X=A?;5VF.S\*;564,@1<
MUR:<6^$=IP]G,V4.(\D>FC@X78)V:%7T$+7RM,,7#P[K)1J/H03)+9D0YT*3
M)WIR'H<ENRB@ SNV7FBMRM%XRI&\EUS3PVKU<"3'5Y0 ,B;%<M"I=*JB'P#N
M&+-;FZESE\O%9^BB0WN>=_F2?NO#/_(X3_&2@+Y(5R3QV@._'L<KK.O>HDIH
MPYBN=U1,@')U+)*2' 1/(12KT8H^27P[P3PG"O733X>]YSW]N=?EC@FWV&I+
M<EIR9:'D%(#@< B.&*XC+XDD8G3LL]L\"N>'.=Q(53UZ_SP0!CZ^_A7=A\#M
M:AKO"/@XQG(#5=\/J1] 3QVVIUUA1Z.-E8Y#"MF"2CI", XA6Y=MS,)RVR>$
M>A*T>L*X/CZK=E%/\_K.6MNU;K@>N9%)% C%2<)!?_'%)7 "9932NNB'I8C>
M>>@1!B+UE/ZD@>A:%W$O^W2\_TAVU:=\/1_%&5EQ*UPNN2@M2Q"3LS4!IS9#
M- *R4HJ336Y]'%8"M^4E9ZSB5J)M_=5NP\6E3#:)6BU.!%2!6T"9(F1/5E2T
MF;,2VZI\1_#O\&IV/?[P<C29C:Y&ESB]*?Y:K4!(+[5E&0(*69T+ T$J1BO(
M6A&_BI;#JAV>>M,9,[>ID%N7\]:&0H^35Q:G6"@,9#$1%+-$WJ(T9,VUC0JE
MN]]J>:/J-[SBK'7>0JRMJVO_>/7RS4><7N&[O[WXV_JXU"P3"(3HR+!2,7AP
M.0KP 9G1CEN3U2 U/_+P,U;POJ)L6"N[(MRB4=@]SOWM_E9CLA/&Z@P\25]/
M) =!8P&)PD2//AN=!G[40]YWQ@3H(/#6-:^+!F'35;P8QRF-9G'R.4^_K"-[
MI78T4G3:.$M;49&UX6>)( KY6)DK1@?0(#(\\:(S9D%+$;>N;_UU/)Z\PFE>
M[E._D>TQK]5&RQ_>YZD4D;'B#?CH&#G9J,![8JQ-(19?L&9T#^+"+F\]8V)T
M$W[#.M79='[Q9CI)UW'^>KJJ(%I$7+CW(1I9P.;@B+5TAB$+$:Q#SH1G)1<[
M)$A%+[@3H*)?W0].;4+PG0?4FRBFH:=P!\_=8K/55=004+M$S'=AS4,XAXV'
MM]'40[4W$G/#8,=V<%I)XX0G-X;; ,H6VL&4XB!BX=P;DX,>-)?G%'6_(6A]
M0-7O(MWF46EAF"?+YN6+WX5B?'5BY4R6K. "R(C)=?"= Z?H<-1>"!%D=#BP
M<?.CCS^<7=!0[I.F0FL=F7[QTQ__Z^??_KDV:VQV,@0.T?C:&,,6\,4(6A@R
MI91(4;M!ZOOJL=^\VIXOI,8;[:T=\G@5V\.?YOP[7BWW'QES\-YY,-Q@S?ZI
M@46N(;'H0F2)%Y6:[<7[(/UAY1U.T0U#B17W)ERK+W (LN8FX79,A[<+#Z?;
M25?%--[;GD#(G Y1)K*>M*(O*>=Z?1L$I"BTI0T\/ A*?6.4V6).GB)C=M''
M(>]6?4&/U<!F6+L,<+*H4# 'Q5AC=(H^9S[(A#F)Z_36BAAZ<[Z+%%N;I ,C
MZ"(9ZU1!(+N-@7*UO"S028LE216L9=D-NT0_M2N+GCKO(-O6'_>3U^+.T2)K
M72'+EL"A<! *R^"9D,RX(L- )^5T<@_ZJKRA/!LFXM8UOZV6\^*4<N29<6XM
MD,=KR% V1+;D%+!@E;2AR*P'=589=+S?O/:'I_%,%32\IKX!L:;C !C-?80[
M  [O$#Q3!?>5N(?\&IOR=^&(5%PN-A(<'4"5K,%'M""]E[2G"6O#H/XTIZ'&
M+49Z6RWN(K;&VOLG_C6ZNKY:1[M$EH43AN!S+?,1$H)P'$R))4@F%:9!9>:#
M]/?5JP][_#Y;^),6DFMH0R\<QG5UV+M(1OYT-%GR,IO,:F"Y($^@6)VVG0HM
M2TMC+/H0Q:!&G<,"@(]!^''>-E!-PW2@97!AB>./\>Q3CJ,RRFEE<@X!U?PD
MW@CG"(&Z_54UZ27GYA<+F\ 9C45QF<$X3GMA9 X(4>W$+[+SV?# &FX:AU7^
MMI#;@72_BW@[Z?R7R31'G*W=0>X-TC(07,0,BM.Q13Z@ 6F%\I)CL*R=)_8X
MAL.>_(V4\XBZ]Y#LZ4SFW= OL^N(WB?>>:!9O;NL_-[07K1*2:7)3L2D9!&(
M/@65O G6D"O@!@SM?>+MK=JM;7C-;S=MO$2(6+074&JUG#)!@3>>7)IL<\G*
M*\;[-'D9CG'?8MW'G__ZSW&>5E7<SN&[2$$J&U#5#AH*5#7L7<X&ZKAN)QVB
M**&+, 9#/'SN;"<NW2_9[:.D#FU.'@?ZTZB4/,WCF%_F^9\YCU_A=/JESGNX
MFEPONC'^0?O']++^:/F$"U<B]R0:L%@X*(ODADHN(7FF26S66=VG.VNK%7QG
M7.RLXN89? L(5XM%C&X6$7 VFJ6;E>"=)L;D<(\FZ2);JWTMGY8BD^!*(3-&
MQ +D]*8LG$VTGF$Y?L\#<':L.I@V.K11:=!;/4I63 P<>*GW3PD=^$3[DE-9
MHTM9R_MCJ;_CIOH'VN .K-:&-0F[S:1P/";AHX(HDB0/3UI E!R"D,B#-L&8
M/FU73G2DR"G1:R?E-,QC7(-<C-_*:0&16$ZP1G4&]^ORZWA.V_%L_NOX/R8D
MYW\16/KY!>>^!.X\L" #*%W3N*4LD"*+P86$*O;I-[TCT+-E54^%=9AAO(GV
M$36S-;5<LE! ,8\0O!6@56 L"^9\IQYVW]LNU$(!K6NSW^"7>KTT>S\9PN Z
M $)FXT%FI#-663ICR?,%H12256@9XV*0*;[3:\^.$)TEW[J >X,,:G_.6,<\
M3"=E-'_W$:<U%)*S4D5#SJ8.-RUU[ RWM,^AD!P3FH&E_,/?>9[LZ"3SUM.%
M[X25R4-<@+HD*VM&P$;C#Q<F%F\52T F.0>5@X20C87"DQ!9%X=VZ)#J;>\Y
M3PHTE&W#.<++KC.?2"2+"-,N8[#)C)9<B@1!A0R*'#/PFO["BN *8Y)TW UB
MP[->?YXDZ:^)'M-]MS8/OPC<D/E3FX77AC4J,09H!9*=[(2UEJ.3?2X]ML(Z
M._ZT5T;+(;ZW3E;^A*.T@O-B=7/Y8C;+9#D+%:V3A4.M'B#+F1!Z40P($8T-
MDA<O^MP5;D-UMD1IIHJ6(WV7!=,Q3J_SPRWP@DSF0G]6DPIM'851!R(R;B!I
MY#&$E)D:-N9YTQO.3MGMY-ERIN[2)B8GZ:H.EGN1TD+(>+D&]L<G$GG\.*+]
M:W%+6^[L9$345Y.KJSR-([R\61*YW4)+TG&"*!;3*9P#5'0(%JXC#XK,JCBL
M!UU;7.?)J"/JKN5\W)5A/IY/,<Y??ZH+^?FOBFZ6?\GY@E:?ZG@=L$%)<L70
MDBNFZ.Q,QC D1UW@L&+0C:\X3W:TD6BG.;:#YED2WTHIM%8EZ_!!HP4XSW1-
MU"[&^U@MI2Z6R,F.)#V04=)#03UFVSXICE6:?\W9\UA %$X'K#2FMNKF8%(L
MV2\:=A\I^^V@@T$/1)X.2CF549Z_X&CZ+[R\SB^_+"ST5Y<XFRV2RKW07C):
M XN1ME1,&H+$ -JQ$HMAQ=WOM-R(8ALA';],IYWZ)SW4T&%@S VPI?_VSXRS
MZVE.K\=O<]TR1^,/+VLNT!_C29CEZ><JB%_'GZ[G]-NTJ8XN1XNPY-U5K9+8
MAZRKZ^"B7BL[SH2C1@3:1,M3T/ZWQ&Z-14IT'K00M8]V%E +;"&C"CJGPG+N
MDW3Q;;'ZB0%+WQBI=U%ZEZ&XG^DPFDQ'-[,04PS!9EUJ2_\ M?0#@N,6=!3H
M5;)1RD&M]9Z11G8/RN']BM/0\H,$LWU4U*$H8!5#R>E]CA_'D\O)AR]O1Q\^
MSM?PLC561)[!6U6+Q6O#)6\RQ&A+0)ZU+GV,P"> _>!3<_4=;ABJ+)SQ0@NN
M26Z*N0AUH:!#*E@SG)@=U'IC9TZ=Z##4;D[%_N(_A0&G ^#^&'#:0-7[#CA]
MAIY.8,"I< 0U*P8I>E%OJB0XS0T8U$YIY0O&067EWR:MGC?@]("LVD4]/0><
M9G2&UH@0!-EJ]-YZ2/M:V"02[<PL.#VP@?RW-.!T)^EO&G"ZB^C:]^Q\HLD@
M&NYT]A*8U 84.8[@%"<N\V*<DUH5-71JX*DT;3RXLIL*^90ZTQNI1"8[&;@E
MCXPL<P[.JP#6&.7( %,V#*IX^ XZTS>W80^JO,:SAYYHF3H$V8]N\\UT.[QW
M^',4<]AN\YS+R+1GP+&&/4-2@,4I<%(%SGF6++?;D<ZIVWPGQNRBCX,WI*8E
M29N2JX&E3':Z<>!B-"!UD5EZC2(/J\(Z'=NFM4IV,F-VD6?CQIF/#NYB18JL
M8CU1$_EA7DD(+M;V,@F554(9V:X%WFF./>QB=NPM[,;#:S9/CAH"ZKL;9;B3
MI@;-LWN.F \VRM#99)S/M=&*K%EK/H"O\]ISH1./9YME&-2FY!1UO^LHP_:J
MWT6ZK0_XK\>[98<Z8[%U]$GM"F#JI8XA!17+@D])E/L9?]_2#+R=Y+QY!MXN
M0FH=:_KENE9@UQ3ET?A#M1K6:>@UBKK,6N#.,3(2"C!EJQ7J"WA9"DB?-.%T
MT<MAT::GWW6&9W,/*3?LGS$ WMI$'0#P\6/[670XQNG<15?#>;"'H%OOXH.
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M5YCGP;@34V?#UM@/[\PW(5Q=FC.5G7891*JIC9E;DIY%D"IB#,AM[C3)8R#
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M.U*D):12*(RQ#5BAR_,%#GP![W0-[F[WN&QD@J1:KJ7]JE5,])&<+"FO&<Y
MA>W !NDI?!CDC-B18T<>3Y-6,;?$''B6Z@GSN(=U<$T ODM-^;B8BR%ON)D
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MKW5_S60]?3T+_#]VW]Y]Q_[9[=;W%4[8MW%PYWCGQL'"CA,V=IZP<>L'"V<
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MM44.J)/YE(.+JI^MV'I:+ :Z37DH#(EL[TG[X+XV3OZ69E,N76,H8Y4&.=B
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M#?F*:\#N);?$+['K_8D6XCAHLC?QL/\,&G;=^WBQ26!&R!0U.PY19/IHZE
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M,71/JB:>TI-S<?CSJ ]",*#1<'3GWF-W=\78J&<?N/798A8X]34XOXSOD5R
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M#5[%-/-63F^)Q$$30DNA]BQ@Z6=IK\L'F(?E:]<N.YZ=+Q[R'[ANA/PS$R:
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M'7>7>?W7 \=?5=XF3*5Q7VW&0Z#60DT<[#=7;_++<8#2&^Z1:?$>MY(G8B3
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MP;D0E)P8;;IQT1))NZH:@:L(Y-LX(,(Q/X!PU+.RDH^0S[XS'6,CR.I-H><
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M%<"&U2-"QD3I\J0,=P+W8GEZ8)'M#:/RO%);:TF7F.?P3_?V&$Z=&A_H4^.
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M86(]%0-Y#!SGBY2VB8U*?=92;.B6R59U5?'RSGJKA^_6?XL +?\3 0+__R?
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MH]DP;+\G)/3CH]8,84<)4H'O5T-RQ-K.0:= UD9I:P2AKF_;3EV9.O,JD44
M=?C V_KCZ,@L'SYF/(H923=B((%:<? "IEW%J"G'_=NP5TI]_Y?*H=AWY!?%
M<U=&I>]F2<+D8X?T7KP<[>P09"F:D&R81WQHS[H1-KBA1F=5A,.!@/!)G5U9
M,M_.YTM9A)-/M+Y^<3C&[(+RGILPV"[4-PKJA%%[EJ^.L&#GL][8N.+Y7-J
MKFKDUNS1%T^ER[$#%Z+0<05("]0SG%/\X@PZ7/VPR7S@K,2\$/-X(U72 1!F
MJE/<HF)+*O*+^Q^&)8EX?:X_ U_A?MS)>)L.]'YG A#F^SJ*.@]S- KXLWHQ
MO*7A"5WQM)]OZ&3G5L)#J:W.ACMZ 9YZS=]#,<4E<\#U%P>TD>)^<9JB57)
MKU0[P8XP*% #%'6^A9B3Z9#<[#/UEJ9#UPIA("6RU&4O5>TQG+;@D'2Q2E!'
M.\'YC?W5S<,^6Q?;#:8L9DW,]Z?-&X=\L)K/2L.H@CT Y28VB+A_.5>N&CXZ
M[+6I+FQ=(ET<_UGD=PI<]B[OW$0$WT\5DZ9J-3J*A/0WK[<#)2A@T01C6M3[
M6/B'V/P3GKMJ?FZ>,%G_:KC1R6?JA;OG<^U.4^?]PNB5&Z[[.H[[&KT1W-8P
M(6%4P@POOC<2<E\F)(4CRN!),U;'QQ>U.[F5D&TDE(P!R@?Q:5MJ>S]58HF3
MHM,8?3D.QX/FF[GJ9%/2_;C81O5S]-$'T4FN_65SA/%85 %3B?R2L+\0<3%8
M5-CIF-HK9H N(5UP_3?5 #90I>&Y.@U\5_.P$GZ"7^[SKW98MQE/=48CZ 8D
M;.@Q_!^TW,2H:X/)I^;HM#\M;I,+_/>XRD@$=*4,@Y,I2''-,F7*4"[]K,SJ
M3*E_N>![2RM;<]RAMS#Q6.?U/!V+XQ8.4J9T+4>2Z20J.:,F5]HDI#>*#7M6
M7\R&58D2=N-F(MJ5 @2/LV&VN5'@ H$TQ,3^1 U&@WN1U.,DR]&JS8;C;:A=
M<SF!/@];/#/;J]\<_#CY<WG93'N:[RQ!%_$,_F>S!I$O]"XB9KSJR%5M"2.A
M^'>SOZI[]\X]C1,6R=SWY;3HA(;N*W_!K1G/QD\1=LLD"5M V@W;F;55[#NC
M6[>%,5NY'S[+[#0!=:;>0Q%VS:;K[P@+^1P%\N'7:JI49_($54"_NU* 1#9
MEE>^^5I>V+4L'O!0YM'NK.\'O7>_>/76BN=?.&)Q^U(RX5X-_1/J0&!ZH*'
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ME>(W8(KGJR%3AD<Y"4&M^E88.XZ6]/AI5O"IV)AT.7/.ZR'-H,I7+$-<;^K
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M'KOIR_4!NQW+6)W-\9\N>K?$,9((TUEJ,8>3.J1*K+<'_G7WM?ZI'75/[S%
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M4%6Y D#S6AB( -Z!)Y8K6.Y[3G<<;,17\V,C@? E,C >YV'XNVVX>P:8FP3
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M'7U_\%0CWPR:NELV>JJ_\VS)IQ[-*/W" $.OJ#NX[3-S;19$K^M5!U0/_P;
M<OX66**3D=N EN'NZ TRR#  97U,T]V74P-BG]O'G-=]B+IR8B+YF@%KA!Z
M,*@*_KHI%H7N7&\4@RE&11%-\5BZ7BU*=?#G[8IZC)RT^>EJJ+*?8+Z_/W=_
MY!S^T:^U27VJPTJZGK?F-_XYYBZ\9# ^T$).K/*>^Y-#\.'%4+PS4(FN457^
MA:6?UH/J5O3/A<9M,0DO68&%%QY?>[U+2U_E?J9UM\$X*8$*N2 L3FENA&5
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M5W1NW.,Z\R7*LRS@,D0&#QZ)OXY?GXR.QOCBUN.-SK)LN-L"KC+!(F-0S,'
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M?;.P$>@^\7]BM8L$ME@H9$Z$C=)9&$UV:Z!-[3I)=-OYI>W+ IQH&2YP\"6
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M\ CVKO>2Q_JV.-SX](6JN7USLD?GTN1E>H QD@?4Z6(*]<$B7(NKN@8/9*5
M-R!M.!O?[$K&("6@MU<HE../M@0\5/LQMY;DR[++KM04F*CE?9??)H%[ZGX/
MEM27G/MVD&!ZCD!\^^)^JBWC#>(FWEWZ$OUIKVQ;8& YIR&+-N&^$$0U8>FZ
MA9Q<Z=VPQGFBATGM.,EJQ/ T\R[, **8:YS<"VQ%NIQ2&R0#:ON7?$D-8;Z'
MM<E9HL_-._R::QX*5X7<JKA/6YT!"4:P3*!.>0'P92'4.5%IQMZ0/SDXRSI/
M'7CFZ]0&;0-U_1]ZI7!R1GQNL@(7/A@\D6H[%Z-#^70D;O>S3("S<>60@#]
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MP,12(@D;&T'&TZW\1Z^R("%AUBXG;+<>OLD:-%$_/UB]3GVR>6)T\MB"2T^
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M&>W&A,6I"5-(S3/V*>/#$FY>VO? K0,#W:Y>?+1P^=W):8IN $N&&<MY!/%
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MY$#G"2!^3 N,?N$_%-3O>Z1;R7K0""JM+X&/!WW<_"(SQVF5CK3X6MY-G!'
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M21Z2K+4L(,5Y& '^6.9";6^QH%EX&[1&^N8[\NM+/Y%$@0O"*,NMA;!@E>C
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MV?V03DJ>ZQK CS_XZ;OS\C])2=)W&JMO%Z@2*;]>O'CN[(3:C)+-LH,50C8
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MJC2YEM&V=>CKZXR/HD+0*KUF4K=M!=(6H*(B]#4@SL^6B3U0(/WF< .C7G/
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M""=!<@WNUWWP4R#[#>,)*^W1260\DF:)@@X@&S1'NB=UEW3I7("SO9""#Y?
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M7E_Y"$C%'EF6NI@,8Q+?EVJZ9MPZFN!AL04ASS*RB%12&=8JU->MVZ]P(&O
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MXYS/+/DY]]M6\UWJB9="I78=WF.ND>D1EA1@ \2O<\(W=XV8,5,Y600?')%
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M+X*/%/LEK5%9_Q)XV4W8L:5)U&2VF#?UVFN<*,';-_(")I&Q.O%#IEH]TSN
MJT67SLB>"< HH,3.%V1MR\[:M/-:WHB5_M5LV6>ATCO?3MA]S[_. Q"U_%
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M8EX3_BUY1@ >8;OIPW^W:$YJ!K6&,,$'QW14& \X+#59]H<3<]<'V;$97WG
M%H.WV],))_Y1F?&'N+<H]<_4!X]2AMM9HXWJQB&;4/-6E$,R4]AX#YA2G6,K
M_/;E]$X#?%E(DE51$"8@"8W3-PAPB:&^<"_8>6([WS@V!I0F7(OUI@8TX$4#
M!YD;/OL)HSW&E$LKRJ,I>D\J=Q5NJR@W=_4](.TQ?EKJN7I,B0:-_Y&EO[,
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M%H(WY@-FGU4$H2R'9IT5:->H[2DUR)3SE(M(\R]L>QFO:[MOX:#&1?*C@W+
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M8CHKRYIP45<@JW%%C6,]AL8AF68*L7J)4<.<XOW#F2Q#[.8;\^^W7G$=-3X
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M+SS 50@<26@@R"ZVUDHZ?IV?>0SUGH_R.3CLH_(XW5/Q6L\!%0YE3_B532T
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M(XQ>_M'7?_^//Q1D_<B_ 5!+ P04    "  .@J-42BWVU'/4  #) 0$ %0
M &)I:6(M,C R,C S,S%?9S$R+FIP9^R[!U13P;<W>A 0:2)=0(@""HJ 2E-$
M@H4F(C9 FE$!Z<1.T)B#(+T)*"@H40%1*9'>"1T5 0%IB1("(C5R(A".IKW#
M_[[WW77;>_>^=;^WWOK6=UB3D&1FSMY[]OSV_LW,X8_PQX%-QZULK0"!=0+
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MX>'9-":?=6Y@F>%NRPJ(W?1&7"O]$SN4IR R5D<*)RH4-F['ZT+.<2MLKO&
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MV=2S/D.WCIYD.D3=NG=\TKH?;WWI5LB5:R$!6%RRI@BWXLQQGJ$ '5V*;<+
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MK]WGR;($;8\916-E?W^'%Y5/L3DN#9\TW$]X/Z6<4O1-.O3)W4>MA'V,0,-
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MCT G'WB LD%H91:-(^Z_A(HW#6I\/$$NI9HED+VM/I<JF*5]&RYS_F_.(&=
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M&2^!-F+D1&1VD?N6/VD89@]/)5]K7?R^(SO>]GK-^?>;AI^I+[?/^K/,V9>
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M-(*]*(DO]3,9=G9Y[N4)3H[-HDMU%B5Z?B:(5!&_>V=9VR').6C(A.#CX;M
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MHG<5]Z.8Q_H-CN8W1]+4$+4@HDN-X!IR-$&[;5=[BWR,A.NT7NV3[*K$:!C
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MN:C0 17(5G4M8/Q:A(01I;D+2ZW_ EZ.3-/W9@6#+?V!"]4':XZLP_3OI/1
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MV#H!'XDINYNI_A3CZFV7IPO;>%+?GPJG37R\6/G"9++2KQ)SP[=M/'?5G2<
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M!ASR4>@K"W858'8'.F$C[^=$5/.R#_<LZX9UL+7?V!Y]Y!B<K'0J<>ZNJD(
M[XN538O*C[F6DYO6FJV*<>>[??9\+'_)5:^WD]?(JB-<9L?<?CMV+J.YMAT.
M:7<XEIR]#H.E<Y[Z:.X2)EO0%*DI.!Z 1-&KR%S1<4T@Z+SYT+.T]/+'L%Z\
MP:"H^4C<!ZX)E+H1*+11A?L6I@T),:QK^,?$<NT&9;35>Z"_#N0IEY4L36D2
M+YS2N1[G<.:A^^RUN*L>6^/*);D>WO*M>0WOT5'YCG3&KVI8A&&99DM(CG:M
M*>MJ(%<C2@QY'1^-$M#CRU&;^$1%1>B,/L^PTYC:GC9'K7._>G+N9/:DO_2+
MD"/QQU_#3P<8/_TB'W9)TM4YA#??JJ/2E-(N8J\_&5YYPN5MO4SX,<7"SR;/
M'?POG'\*+T7'T!=!/C_Z&'-C?>8*V(XM3*)1R!SKBX ?&2^8$ZTGEQ68;>\5
M5'6VU5CLMMV(J;,RZQS_'*U48:!=2NOR-L0SH@=R8)'I!CT>@*VU15[';=NH
MN(O>/<K%6(<]8=O[^C!T:T#1GCFIYDOT4Y;" ?>P-Q9TE&-V2F1>^3QN+>_7
MD'4<:5>:ZG>:/I>V5AZI&6,O?9DQX3#JH&I9<-_E1<A^>Y5A_3-=NAR#N7WD
MEUR-&H>W0"/V\*C\#YOOR%)U]DX+I@BGW$#'%HWAY!L(_P 6+W25;+V3BCC3
MM\PJS!QHBF_;]U(U/6Z/QZOOAB:[;UMK<$G?6T6"?)IT5BVQ&,\64V*^X#PC
M7MME88DH)H:A%3/;\P)]_4T(&@3!P"%;HQ2WZPO%JRZOA4LZ<W<5[3[3_"SZ
M->+MG;_(ND7BC>/D357"+G$7'ZKAZNGJGU"B&5'R34'^-LB+$_J1Y!2\*-H^
M;Y"]&1"FKU@PQ!LL>-TK\OI0]&2O"ER28E;^[(?#QGV^PRV$G[GP-"UP[1F,
MH]91:4$ABMA7D<+1ALYO&V52%!+K:'LO^<S%/PH)?K^,L<+67D"27Y"XL>27
MQ.*;[Z#/VEA6L X\AT8 S^F!PYYKL1$1_@+/N]#V&6H-7@$YGEJQ<D_<V3GW
MN&"(?8_'<Y4&4))(%_Q@#I3>60?91Q@132WLRWIR^;_Z#/:7=&@@Q!VG/()V
MT>*-GXZ4YIY9W).9\?,'45MCTU*5Z&KM.FQ+.1!@1(]@"P>@Z/B(&V![SA16
MFFWKX>PS<63U?/.=R)A/4:YU;R45$IZ8$#K78/O#B-'H(P'YK91<BQV73=_6
MI.1TCU6>2=-<OLY[2W;<IIE4:#&KQ% _3H^@A=(_,\.[EA%"OT@R&&1@KFV'
M)AP^PU"<'1+*RAFT5_QQN&:NKRA!9M@P+([_X45?_#,B^0.1;N(#*-JPA5=
MOC8J=@A.5JJ;JI9@6])+R@CTW"90FG$F'7W"GVJB9.F]^>QB99+%/E*5.?7=
MA+'6[(_7"$*)33NHP'D!99B;Z@/(6OP6I+? _$Z/^TT$2K#0(I5;5J3?I>LF
MZN*3T7T'\K^5C1]N<%L4C3/F]FU$/X#LL<+>!KBP-# ]V#(H/Z%"[;8EH\+8
M:HP,B\+.&WN):5.4L!N91SUR N(-XTW<KIGHNW,M@?^N&Q>)"ALGZ?"E2G7S
M@)QZI,'&Z39-+/E-16I_B)X*O$'?J@')5:WD:>=8_PLCWS'O<%8-T[U3ISY
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M3S]?=83:3G-F3-H5=K%-J$3@Y/+'=''Q(T:BV0^R5ON4$Q-WM'2>^:2LL+^
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MWRS\B&(\<YTP?J;O61>)\!@W7#,L&<S!A8H.J5*_^+E)A\,^"B]/<626NQ9
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MQ##2Z?3;F+@LS-/BF#7^J4D!T:QB;NMS43,X)1^233VE8 KQ_'_5=!A'2MF
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M;32DM/OJ6G(<J6NR_U7;NQKW3Q;OO_WW>J'>ZX@Q)Y>S3UW672<" >OH&$X
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MEZU@7Z:=CMF';@9Z3%CC-VV//IZ[>I-[YD&+=W O3_N[2^XKOFLA@^&JU5D
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M"#6Q#WU',P5I4XF- 5>F$;>?G?O.,\=G#MT\]]:^2MYH(]/NFNL8DH]143)
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M,41*#YU\4/SUH.I(\J%S;Z5FX$WD556V#YG1K\N1,^>)#+*M(6$;YI_!>WO
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MO.I]'OT@+:<W,#1PM5*K1+O.3"-VW&KB9=/TS=UT>*6)"#!Z+<RFSMTB8$3
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M;?NF3!G]=3*;/A;V('*B1XXR' 2*13S:W\<? C###DWO.0NM=&5;TV&!(53
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M[DZ/G_FRLEG'OSXI%@%/,)R#.-H\O+*2;T]4 Z/)G(/4M3-665&PNI=G +;
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M $;>7%MV>K;?L=K_24T=M6IAK9I?5_ EJ]+OQC\2_JV7>##$NPC%92<&KN3
MP]YE[,"GH<'3:Q9-J#N+,/_0" %DWC6H,%S.RYNP53]Y"+4VJVKJY+75N.S4
M0\(<DMYWY$S?/AL)?* J>_QX97>9Z8U+KZ4#9U[]^W7^_WXR<&YP,TF.:QE%
ME"H9ALBN_,WE%UF.0ST.'WX[;[^G'[XFYS298PSO<:<N\3"+BGNTN__5&J'[
M=#4;N;B4F_ Y\2Q7KPTG3CV#&>D)OM#/].M$B1/\.C&*E2#Z>6Q :/'8#YH_
MW%P=O2X[@/7@8%7U]MQ$3>SZ$2/:6HG%YPF_J"-T5C5;@XMF=!2PJ#0L+Q@;
MK6-26E>+:'[G&DK=*_"3BTIHD4.$PA?%#DW+S7O<D[6=5W?ALLD<%XHFV(P8
ME?$421S<;Y*L?X"<2[NKHXEG)URL1Z:A&\$<K^8(]ZOGY'[DG&\QWV@L[2CY
M<&L*ND9C'9JRZ/X0_C2N*'Q921EI66BFEZ/:YU'?R4HTV@<ME :A? __>/:V
M;C5:X77'A*CY%3GGQ-=X#V&,*&D@(X6L(P)">I7A$; R:RZ#'TP:V$(\F<,8
M+&)JX5&!5\>E^RO4)^#/I0VU-7(*V=+&]Z-E<O1C5T\&C[?<Q.Q]03%%6'<@
M.A9=:CC'9&%IUJRP4Z=H_E<_U%Y-/E-'L2C9=T+1,V#PG9B9S4)]Z#J 4341
M[>;00>7LQ]$Z85EC;C6O7/@2%@>;[4CZ ;7/*1P:*#46H+/V\Z*UL1=>WK;4
M![P16NA@4N]B\.G.C<?TCP^GS@4G2O\>?B/S?4S%O4EGJS":RJC4+(RN)"=D
MX3B>PXMXC6;)H6S#Z$7\'4T;DEJY<9:+TV.F)HN0(E[9RORB-+IJRQY;!%(;
M+R#@9@V/PG\?7TO\^S,0)"UX"+=:8!R<!]UNRW2_&W@U<T57T/*)B/(1)_/U
M\<9KDT-\99U&ZE][A6#[S?\#BI]K)LF:X.1E$5#M* (>4KPH^E"_"- C"VL=
M!-U V+%_!\E9,R,"Q*F34@B*XWQ$P-XUT__C?U3$OG[^5Z1WG^H5J/S]F0$*
M,Z[>_3K_#*D-K')(:-2$\CI!- D]3)BP_S15/DC<%<J2XMIG^>%?80L/%1Q@
MY_>J=*,?%.GM+?V"#Z._&."BV,B5)3'"9.K%W#/$(YSJ)H4-K9V:0VVI"A?'
M+0:#;)Q>!DBX]P<OY3@M87=M?NXX79/^WO2XON^"9%*QOKWX :#ZGU*2,M#?
M+'60KDWUZQTU;",I<]7B2!+0;\'6EP(G3FYI:;^-7=!@BX]Q>TU!0YM=6$]<
M\^J[6V33B46PK 4RP"EDNG<3-9#7:P('+B^1OXO@P(S^=DNPYGHQP8>UZK9Y
MIN?SK)>C>_H\'*M)?CG6#P<-%.NVWG]DU+7%@D=MH0\7\8Y!!GQK'/R>NM)6
M^OMI'2BR*&#YJB<EYLH+32/*N=JX]DL7[EH^W)QN?[6B>'H?\+M&_7>=G0BX
M?1EDI%OMJ'Y.'X-[K7K*"[X/!5[.)V#;R(KAW2[VE6FAU:KNEJG*+R2T].7O
MK%VC>W-W(+QR(]>+A< A&MH0T20"$D&=GZ8A-MX4P:[^D,J<'P.Z@=-;@2PW
MOZ)N=:?XG[Z&#<0?B)9E(N#>)[#Y #AWX>_7))Y[?>#[3-#G!CA87@ZD5@1W
MXS1ME&K)419=.X,M3%;U'J[I'V F.$ZEF&?V.1;$&;=KZ'A1Y%+N)/SV:J9S
M@H<$BJE-.EM*N<MW0%_CNMTXUR_K&BOJT2HVAZ9"UE_B6AO/'L %&NT\L_?[
MWK6'97+__F0)FK<P@&$\IZ-LP#QDW]K&G5O$H+>XK@SOE0XXO99[(:MP]"OT
M(0S)F0*\$]_OO3O2?/_6#F+ZQ[[8WJ[36Q$E0.$+Y)@(4 &;@ZF!Y2S\L$R[
ME8Q@L\+E9KW.EA_MUZY0.90#58E$D^3Q#A'@PC\\99,T!V\2IE"L(&^^(:D7
M07;8$DG=\TB:!!F^90>H6MB_ ;I=+ (NCG4+7_TA*NV]0'QXWO_)+U;:T/)&
M]>"1X#9QP*I$CH5K):L0ZCP@D$E!?\].:6#VZL$(9>@\'A/88-;CQA$^4SG'
MB4R0,^58BJ6EX<00Z*BP;*="F^8[<$I@\Q;P#$;MJS\==<4C)9?O3(SLO_0Y
MX-.6MG&M/O3/WA<'<](#I-TD+\AL=J24PQJD=_3RH69Z*JB(":#'HE'4\OK+
MW%,SA9VT;[S*KW0:^<RM)Q7"CV456R)#R\U^'K'T,ZE9P!D;"K3,$#,Y)SCY
M5@N30UC;G?L^K(=>LN[)SX4=4CLJL>&F;2LDQS%C1LQU<?Q:<8"M+.2IK=;2
MJ-2WOO^*ZPYQQP3U#K$+-G6E7=NK/$8>QNMG>(='TN?*^48"26$"K'"2U$LO
MQT89<);O7.E*C)^[\K8RIWMO7GJDIP<V-]*\?(?W ^:C6X_D5QE__H_AI.]M
M$?KT[AL2I-)$P/;3U:>=N(6P X9_)?5W-C#Y/V;-_Y9FW ]+@>]DE^'&3CC*
M^.-_MVLD\?9?A&0V6B&7ENV"&WOA*'_D2&,$DMK$_6MOE!P,'@4925?S-Q+W
M0.?Y5@)52"J":\<:ZI!CVZ,E"7LMH"LY%M7]#(]Y/-ZLP$FJ?JO]]TMZ$6'.
MK](WC1&1S#X0;L>M (.PJR'3'T<@*@L%"%PX-M79Y-9Y-<C,,V'4O7_P>(IQ
M0^F[8L.JT"G]5^Z2P=Y=-9,2KQ! LR7U4SF'L4G4%43M O@+DDL,-%!C\?5F
MX=?/<Z_ULY*L*K*C6[SO>046;31AU<38NTWY*NB>6ZN4_\(FM@V31*\J%*A@
M8%D7+I9G)KQ'O5A$C0(5J'Y"/<?43EM3SGQ,<:4VKLT3+I [=2! [G1>IU2]
MHAY^4]W'N+T&OFYD;;#9HA$##]$1]&F;'^GDN4-YW)Q]4!8#G=RXEBO9B*[4
MT4YH]>)<GWEITAS@*3T:'KQ>BOA>9<=TB$-6[%(J9&C0AE:@,HHP5;'-V#4?
MJVCCU2PS%%2W/\8GYHOY^[E<3W]J8YHCMZ/M4C$CO!NXX8+X?ZFP!!. 52*&
M0E/(WIRPDAAPEM4;CQ%;2K9@VUP_F^]0F+KFNV9NZ7]A[\WCH6S;__%1N175
M5$BR3&4/38549"I)"$G(.FU"0IL,QEQ%E@A%*)61)<DRV;..74*R#F.9&52R
MSEC&,-?,?"\]O^=Y[KKOS^?UN>_G^?X^G^_W>__A-3-FKO,ZKO,\CO?Q/H[S
M/(_S76YI+!DYH'<M=-\'F>H5H[\8YFGV.*@'U,7IK._**N/W<W3-;GQE4J+Z
M,5GX4)G5Y7T;RMZ4Y9]GQJZ,XJO#G<35+FS 0BS5OX?;C=^BO7UO/PNH&430
MB^XY=9X_$.1GHN6Q=TCN?!7&9E]X@\75E9U6?5#<'$!%WC]X,GZAAB#Q;2OG
M@=5I6R/?I#$S^V/1+VMJ'>3/21E4V8UXB?#-6DU\9@1P!5/I1ERA(U1B3Q&S
MF?/N%O*^@P0CKLK/JJYCU$&"Y90VVNWCV:QY>7#_\!/E@9._U+NU[ @@\J_?
M"Q@KSR@/$<%,4SH$[WE6/%C'XY@%-YC?1CWLM-Y_\F+O4>7QM[C,](OBRN[1
M_\1X?H>T_%X6]8[@C&DX:N8 #]:7 C23LDA16 C%'[5R!V2XE^\<V/EG]HW/
M\6!WT3,KRGDP0@X/EA@Z^YO_P*:<_V[C02S(!VY31BZQ44MKLK^\\X@@SJR
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M*Z0AXSX)ZM(IU4@1H406J@8!OY6>T-8MLJE1X_-[;W?-#U+,\T<S^,5'2/%
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M#7N_MH!?8N%]S:#\(-_5FRK3XIB8\+SCGUX[",2>B:BU<H*<CJT8*-$*64N
M_RA%EZTXH-(2WAYYWT&VO^=;-">YQ<^8T4H-KD&2C6B[BNF:P\C@SUU8Y)"1
M:>ZXS=6#+UJ>%@?[Y$1^+(PZ8&%P:K651-"9D4UP:SW890RR:G +RXLZJ4"#
M'B??.7]2XFC'MHZY<)VU$P4%01H1BG&R+]Z$OMGK([C8,1P';AQG;H"P>J<K
M>BOH2E^HW>P@QU#.8$7Q8#6X0UWY75V"]3D!ZI8+RN):&ZVV']EV,W[))Q0V
M2^G%,\TX":B+^* << <G'B?J4B'\:1,M6S8_9W#&[F/E2O4.PQ:5F0UO--\W
M]YQ2NP.KINM/B+/EP0.<!-"(O1.C2Y.]S84Q_.I K@Q]CEPW,>XM]T6G_61N
M<_LK</W&3B1]DH"&.($>W0O<4,-=DTSEP39_TU&-H^)2"< YNS5SJ@IU%?NZ
M"MP.UA^^(4@>Z&\4YAL=JR%7E,#X[NP6./SST/\ZF+>+^3%U;OM_] 3Z_Q/D
M_;_R1S!EB2[C 66)C5A:3=C]X^?$?Y85^ DHIEQ_ ))$^.X_<_=?Y25%&W^=
MX87-E_PGB*?]>PE)A]]+]":N^%6V2&/<\X<$7.)ZPS^S]+@<1;4"[Q" \0E@
M=$=9]0\?[VC%_UW.'U3*M?A'C;NC7?UG;OV7=_HS$OP%8W_!V%\P]A>,_05C
M?PS&T+NYW11I@&8'GN7![GEQ-YH6 K6YXMCI(F\ 0]S2,YA0\-E)?-#ZX3EN
M061ZH\DWAW:?\OQ0C[2+!PO2/T6J#SS*TL-00 T"QYP' ]_P8,PW*%H6,(;G
MP3Y;\6 %5A]XL%HS*GH) HX/GL#BRF=L?0&0$@!!0Z_B\GE.004\V!N !XM!
M<[OT?VQG2)&.Y/!##1TD@G< 9XCI/J,#([YRHL, O9LX;PH];@8/1G[]<R-Z
MTM!%B40P#1+@(7Q2$C&+@X.1EY+*/+A;2=QT'HQK ; M$#^U$9)<29R##//Q
M&/0_/DYR ->C"E*HB<?+)S76V/!@72CH$0@\V)7D'YIAB&#$N/[0-2_0W,.H
M_&M "PLU<R@JE$%DN:*7TGBP10M([\\ /S6Q(W(%#_8)S36';O]>@!D!7R0*
M</5SS1PT>;!UKCS8F>5R9CN)G#>1/S;SZ\Z$<=L@$36ACGG/-%2NY\%^W?-F
MOVDG5!NZ[@BP: ))L U!WH_Z B(6I1O_T_&#6MFH?Q<81?)@2ET0QJ_\?V3X
M?H#*BI,_RH@^QJW'"Z-H3AA-RRY4CDX-T^VD7MZDCOOT0/K'V]D'2:F/&:U"
M3N^Z[E4.'1A3)]M%VRJ7.XH0A0W/-FNXS%1;X1XP#RHF5>1_^SWX)3R';#D%
M-6,,0A*?AT:U#>F@L/$KHD=<]6I--+XW9='#=2R6>9N2MX=@U=-^LV#"0 _K
MH8>#H'!C$S<5TA2HXXJET<R&!12")= K8E4_9_;#=P)_??4'O_IA!KQ"D' -
MHD$XH!''@[V3:N4&2OD4(\(@3W2@?"V\L_A0RF./2:3K?%&>%;LM5;*#W'5J
MI "$!A5QS4Q/E&TP_L-Z!.^X24?&UP8>+*^U&L\ZB1/%M52HL A#M@.&4EJZ
M=.!>_.H$W_L6'QIOWKS6)!KS9D+'L69$WNKSA4J$<=(=%,K3-)A"OX%H2-.1
MBV/Z<Q)P?-;&LSVLBT?H7:10C\F'S^^5%I=8W!V1$CK\<K7V3<M;P!:(KU7R
M8+E7\7W %AT$5IJ3IBW#-^"'J&E\16\(V_'@QHP>/VEIW<>NS^<M#23#7P8=
MR<ZK^5XC>RO&J1Y1V%J+#B6DXE?@6G)M&FA9TH.4QK+'1V@]\UJ%\1<:FM5:
M=C9L$-P7V-!LXEJ-N@#99P97L(I.&A:8Z&((,*=8')KI5HPR,[>PU!98X>+
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M4'2M,MT$#)*:E_9"&C:N]NV[651 <97_0T@^3<@'<((A*GNLW$\<?6!YWR
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MK2FQ/%@YX>F<HX@9NMNI_?L>X]^975G:^WLJCK4*(<[H7415$^=>/W\RO6"
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M.^K!JE*P>'DZ5+$R4IIV*'J$EW/8H62$L'-2<,V WF*]6Z_9IU#TI.9QC]F
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MQ_N=K6P IDG+Y]C _70V<(ZP8LH&"E ^^XE5J_#]4&\VD$5@&;.!V50VL,.
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MR1SG*"S23MN69Y.6_H_?VM3(;9MQE3G44J!NL3U34E=@Q8#% ]/*#7%P]1?
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M\DI U-J?0K8GB)DCR=WP(DHC^3UR#CDA5]N9"=X57ZX)'=;X6D-Z\&Z\=EU
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M4%)G+=>JEZ=B*K!SQS^9<W@[UDUBRW6D*GM[BRQ\F0)<0H3.EMN^9J Z<]3
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M!D%L<=&BS*40#@XCY?"&V\>EV.AZ8-\'E:81I"3X!SU\7.CHNED=6DG3JKG
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M>X?,@3VWDS7%M;^83)7NB D6OT]L&;359(39,(62GR;_0;.5KW]B\R$2_"B
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MUXVPTS(=+2T]Z.[)3[Q^"'ZY9A\#N^G*7@(,6F>!,YAX4C6B]90:+9\M'K<
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M10#R3D$B*I0<RP".F$PX<?,$=VG,)UIF;HD_P=G9S\T<2U9?.MXI>&\P8??
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MBH>5/#V_MHP.HH"K%_E/;XRM(%3P2G:_H,C8TPR[3F1W\VP)4T(Q2%^$?'V
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MR9K7.+VZK+,:OI.262+5A%->V]0 ,JA/XBM+K3]ZB\"@R1$#B&+"WA-!5'7
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MR@0-<U.G5:L2,)>:/)[CQ>K><&SK/";NOK/)*YD^=3.VA,6Z<,ZR2O<N.F+
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MBF[<)+)^(7\3$Q416[]9%_)/73<(\O,+B@@+"8O\PQ>O'I#<N.'$AKO\?&K
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MQG/"P+$D=+E6 N@K$7\7E<15APEC)=-R+MR'7GN&@[V.?<>WO"5SN7\->?(
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MP8702)N#":R#EC]PS_#?$DH^)WS2F)A\\O+'](\)C#)ZXC8/J$ JX@RG\.;
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M5D1OGEU=^/:E_FM%7LE8VQ#6H;#$HMR,K1'8SRHAIZ.J2C1[WLQ]:[_+0V)
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MX3 U=55^H[I]L%$G_79-T#'^RN67=YM?5^T>^"IP,L0+F^1 F9?,F'F<(LQ
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M7:HGF-1U(0U:^%28[,WS@D(,JYD#%#I</\('&<>B!L<# ^%N>J <.)E &=3
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MQG"N:Z[/Y_I\WI_W^SKGX QQ)H#MIH8FA@#7)B[@.O(%<'X!VTX[86\Z \X
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M;AS(\ASH6TB@IYC=\/YR=K9T]/H;LC8;!!O1]2JP/WLK@2&+;\5 5R@B.5"
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MOQO-D@,(>$P*LP11?_8B#A6Q_RX.NMU"+Z^#,,(4#^J@_Z>S3UC<W\X&+3C
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M@LW3#@5^>JL%N^+/^,69UFH,\J0+H[&O_"0>Z&5(CQ$J.U.C?"-"^X@N.2H
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M54Q4949_;G7'?T8#Y?W_ 5!+ P04    "  .@J-41C5Z9UM>  #CE   %0
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M="=!9J12$I6'OBV?AIX!2^^FS'*!2X6)TQ\7;J&?DCX/D%R\?[[,C4%%$_C
M^M.(B?-0Q5GUH @;A,P1I#_6I</>,Z(L2;']BG/CO"O^J'+'_J&1CTN"U8;[
M[U!:@/GM52PL',T%--LY::29L, J+G"BSY^.94L.#NNP91<N(%[LRY;JK5T/
M4[C >CR:*I(?3CY;J]2E!][?>\'Y_$"*WYZC.VECQ_*R@[%\ZF[2/*OQ]/@F
M[$:V(YUDPD WYT=(!**;EE=/2$T/R80Z6EOJII2:7"F5LTG3KC/[O!+U7DD!
ML*V)>*"K;,L<M^Y>JK)*2=$0"L+A?//H>R:4#W].-=QD]RN +0=2(YHP#U#B
MI,OBH22)VNU.@X'IMIRW^*V9@2DMQA*V/;]8CI/+-LY#]A<3/+^TF$?S/_MT
MP=*AGE..F PUX 8+1;#.$5J)Q0$SVO1:G8C;7" 2[<Y!42G1CJ;??(X'AII^
M?U4A)T$1N@(6E^^.D+1,^A$@>?S=*?'O8BY.7?A#E_T/@78E!:6VPGUR22*2
MO">!'TVB"=@#@1CF(*/O 6DX!UZ#)? 3]:Y\H,M12/G2R!UK7QW=H;8 XXS>
M6!%E&/MDXSIYYX'Y.*VQGQ@F 7)$' X)R"$C^"#H#,LC,#"PL0Y59!?"WNHV
MK!.1G-M$'#A-F4[4N>O_OLTG1S;HB<Y /?[MZ6K7LS$@,JF<H+LL%;"^B2)O
M+,;>7%N+$6QD[?-(JI6GCW6D:W\C*)>FG(\E8LKV%ADZ1C;UJ%^A"K1\;P@#
M^):D;!D:$7Y"WL-]_M-:&E4);<5651DQ7]CXM_*QK8_JEK)+(!Z6Z#1V/6GX
M%5JX^BC+ _X)TLVQ\=CBLAA8(S#)SH]!('JX^*=/)#L%^ X.3AH>;W]?QWPT
MF.-JM=-#XQEV_*),_+O [!$YMK0@$]$S1!AO"CF...^CH1N=3X)QC]AHR"J/
M?;C\*$U9HV[UZ>RKDN2@M$0,Q91_63_$].%,?Y7\M2, VIPT_)94.E?$VDBH
M(TES <_Y^[8$% /U@*#2[_ YV3CS>K?C2N%0O<_I&R+9>;*VFUU/VDU?X S/
M7@4E(//C#+%OEIO*5J_)2:H'D7,8V1OW#6XCJ9"&*TAT,VR_'=,0D>P ^S#T
MG*7)-@1YH)3Z2N/GN+LT9;1M.<L\:N?8M]S-Y27?10XX=JE9%(E-'<=(GT@!
M-L/5;&TN\-B5VLD"!KC Q)-78F3-M&#A?V$Q]N=D@A<QD#LX2&+>XI2"U&N@
M"P(AH:!4&5L-W8]UAW_"_1_B>F!CHT663L+8/)(<[V*/C+9X322><]WQ>;T:
MOT1O8A3 7J*3V))*S$%.4C%.FBV$:!P UEM=A-SH-YL5FW^]?@.9.T&7-A2]
M#=3.5]_KU)IQ(>5M:9/]0+KEQI5C<P(OBLI<&"[P^A1Z0A.*;K&(M#^!EX:(
M051EV0.+TXF,N*R,V--S4U-B#LHG:;\"[W\5NE*>:, ?<2KD<+&WR5-FNS1@
M%T^@@ 7$8/3P*X2@B",9C@LEDOR3^3P=ZL&$*^@=VKT]M2-PU^7*LI='KP]J
MA&S;<:-\NU/,Z!TQ:1Y&?A1I^"6J-*(5W5]&6YX)8CF#]68SA,U935B1^O3
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M94YQ<DD>#PB:> <&&.:-UU'^%4N57SRD8=JUF=CI>/".:Z+=H^1K!ZW4P^(
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M5HHOZ\+.)C57BX8<J7--$7FX#VM(:$71[6<#F+50]C 81BD69$OU-7$!4;P
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M,B"&:&K2XORJ5JHV%ZCUH\!'\S%I\3,_JF \DAWQ8$<%GX&-.I.413LC1RZ
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M@5#D&Y?.V$K*S!C+?. 3E:@8>'TPUNM84@MJ8Y[#8&=IU*^=GW WU;TK%=+
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MDD\.;B'NPX[+19AQ@#91O6/WWJ"8_)FR^T.8/.H)<F&XC1F!2.C"%%.X,GR
M[<,C&V,XMJ8PNXI]IQ\66J.L5-GG&W#/?\PCT3/CO.202;=^IIE"6KA1QH%-
MET^?5*[LR\4UC6,80IPSQ)HM>J.#IF.".8]QHN,>!<RIIL80&:.C\ZI\P/O
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M07[^**5UO[$&)#[2J7]/&A*19SX_SWZ&;@K>4QZ<X]S:J^$4F-@7%[;FWL1
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MM*61K'=VMC_N:H%,TI??1BR.92GO10R,0B*?8*5=0<5QQ*H9HS2N',:T!XG
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MSW/.^=[OG/L[W_M]][W/\-N0D-EKUEI[[;7^_]E[PNOC#0/KCYI;F@-\J_B
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MHJ11O?QPYGEQ:O#+9!NJV>HE@U"S>_2^2CGO@P#:@CS\FEPR6\A:3Z@F2_,
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M(!38GK43&6ZV%/)F$?Y<A8++G^..]KCG93'0=YZSE%^U@/HC1WIT/]1N-7_
MET(XL7/3$R&R)[%O52_S ><-V@U#.=@TXDW8>&=8,#+0^3AJ70.-8>RU-=A-
MZ5V8JU2C]NI+^ZKOIA@URLJ3P%X3,\3YHOUQA^I39YX1?9TV/5N>5#G8]'+6
M?XU-ID.XN^]%JYC@Y"/?3[1_C!4NN'_O@!(RF$&L(PACTC,U=.+VI2;,,%A\
MA!X#)&JJ-L'9=3T5.O6W=#"0IU<%*GIFQGS \L>=UO COB^.J7R)]X^4$I9O
M7B"^TV!+Q9SD).'M&2CF77B4,;LT0FH$8TH-.G#C3;VIVV\$B/CX2,3WU'YN
M-0PL*0D[%XM5_WBJ:>P$V7((EU5G?)TD&+$H+G'N !B@Z^.J/[*]<QUQFU0Y
MF<]N@K\:@76/T.]X 'LOR)2%=.A(.15!<Z70\,'T+CNN)(:.H<^5W,H^5?&!
M!R2 QE@=+.4ZF.--'VR\GJ (!R..MX;6("!O-0:$55/JV^)*EYE)ZL40=N-D
MJL+D?&Y]Q?>*EO>?O#N/RWYZ^O+4JT,_UB9L)8LL"2#)-POI-_R$BF3?A+YL
M)/L&L9Q7;@K233>)1PXIE':8&(W<Q-XQH!P>0@EWR/](U;KYLW1FQ\71 #[1
M8^9!]_;9,!,X42#M.9+"C9=6<A"2?5596-I[ A(0=PM9LC/*QYL#(F;0KO-)
MUZ_[_F0C4[ZR]_W)_2@=O"TG$?3-15431=F[6/*$(0>[$"3'\$,^57=R)\^K
MPY@UA5FX!W6BNRS\J[\UZ:>]CHN4^%@=M;._6M^"N1V98X'LT_ NU@E<$W.*
MDTOVB"1HXAT88)@/7D?I1QQ-;F&?AEG[)F*;X]Z;KLEV]U.]]UJIA<4#@+]-
M]V("33S2E \.U=<=UE&<6.YK#PQ>R+T\J?#$#GV!'*$<F#'DB-H6\*WRI;?Q
MK#R_'E\KMPLC -(R>, 5;"2Y,(NM1NXC0T2<E!TTSFSJXW8RQ4OMK;S&?SEV
MMO3_F.O_$.33.-9J48_B!X>3D.)BQP/ZZX;GP@FKV"A$<ZAODB #A<>M>?C<
MHXVEY5ZZAM(A+:0@KTYVPVOR7]NE4:Z_K'M&#Y3&N=7K.CG"8+VM;(>#:7-&
M8:7E,>T)FB7E5AR ;V9T<H4&&8>8#R&03L,RLIG9UBX-X*HJ+0]EH][W9U&W
M54HPLD[V%L9Z*CV*#Q-LYDWHLZ<UK8E^A4UVK.O<.A"B+)-J]MEP92(0S %E
M$8S=08D2\-*M4A:&9>0K2Y>??\E"/Q[G 7F<'X/DJ0&3F]\[S;!23DY'WRAL
M=0OR%N!/M-PG8->^V");;ZOU%@>>*ZXJ04B7_;?M^8G&(9^//!=/!#T3X"V]
MC61)0B_$I:+?1<R<](*((\=?T'!LH]%*ZZ!:D3SWJFV=+V\Q?XQ06\-&RNY"
MA:K?7[Z]:NC[@H5@PAK-JLW<+^12;"P2J\]!.;)WW*&1H-BJS7C3B#KNUNCY
MVET>7Y%:-OK0K5C"R7A@0&UGW2H'^B630M5C]!G,A>EGFE!ON&HT5A*.;CIN
M^;U?!..<H6+.G4I1U>@[.WP(^.PO?E"3GZ8DRQ5R85T@?!HR902.LZ6TF% '
M 87C;QQ2*>\E5<GBEF@%7LN$F#=.3WNE/ K5N]^7,/:*4:_L33^=*+Z'=((1
MQ)8JK2<7D>FRH^)]I4P>P,G4X6H-P11+]2Z\APLMQEEH89*_0?M%07%(Q4'M
MS' CJ6M&_N*/SNT2G)S2Y)]')A,2&UJ(Q0= 7_%^_R4FFH/DA>'<J%SX> ]E
M,,#QJ3A-U"#EQL,ODIM+RWLV8JY YF\=/\6]$-]EZ?RM<0/9 J_]$JS5I\7M
MK2-ZS/. 0OKFDOD2GWF3(I%*^3VMNK&I9#- ^N2_OQ%$"-\4(J) MS9XC^*H
M#5LZK;97]KP-G8.NN]FF2'$<"VNZN^B#9NG8<OI8<PK6HLU/PG[:5UZ^:<'>
M.#E22:44UM[GU@^MZG6P%JRF"II8,$I'S+KO4K>6%!2F=AZ,N $UZR^T;3[4
MK5T'^-V?) N9KL=I,4,1=PUSAWC *H+J)$(>OIJX0HXUJ3L*L;=32LH[,L*/
MN:7[^!^@[]^7W:J!G'N93>"$@L,)Z!*-.-!;//8&*H&K"A.'"R=D'+AWW78.
MX-P.?R4TO*)PN7OZ77F LUK9ZKV[\]V\4X%E%M,;3F,=9B/#$WJ8T'ICG/Z!
MI6_!.-U@AUG[7M%#-B(/?Q'[PG&@EK)1="EI\'@BW\:;TM*'@RY- 5/FF-H$
M>"MJQFX80VFK0158L*4MF#L[JA2=V*<=)ZH4<0,US]#.-X]T86<N&$I.]O+E
M#B=W8-5DS"_8'OKY>OC^S[:9.PRO1J(H>C@)_<XG):I*$VZN!OD7.8HUMBB4
MB<_PWK08KQFT!5:\YKN9>LL[74>'%E-)^]."?'9HTQZH3<$#R4%65AAX&X8>
M9,B66M56;ZI>$#$JG]!(E4AK4M[<4W3'G^G[U8-A_=;96C1%_7"GY7?1QI<[
MFY9NN_,OJ#)#5E8A\%>A"+:T;#T5L@;[4Y@;*N"DT1:=ZF4P2B_7FATH\SA+
M)+@O:JPJV.>1PR&A79J7/2ZG6MZ7T?\46(ED*N$[K/UL:2+-C5[WBM#H!S<S
MG\,I+[]-)>&W?37Q$;UA$T'7_HX;Z\+J>ZAL2R['W(LL/?+YH\$[^3'0#7Z)
MAOQXP(R@4:PLIG^\UC,W?K^A_V7"G9\;/G,'T.L#B+"&'5MFO!8%G4)15(]W
M:5>)P-/#TF318JS2P&2ALR/.ZES".86[VL'?L_5DYO/ZNAEQ8U&;5!6 92U:
M6R-JH'1$L)8:Q97C%"+DA2C.-E( 0_/<VDT.T6RB=DV7&%>:2$5M_MGR7FK
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M(V0?E2NDS0,T\SBI9/IM')H''"MYN+ !CZ2NU2OWG2.YC=2B)?II*(UY$=[
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MB?E7W9])YZGBP_D/KNUIS30RLY_JM,+J"=J;22-\_[<]4+7LX)6RE\(AH#A
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MQP.6,W%=RFMCFIP%D4K<5F75LO3M'\YBM2@=R+7,U.6QIF)@J>ICR2,Y$SR
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M+7JV7=P=_"S<I./=L+!*;%&'Y-7SW/K=/* 9$:>\$>XIC25<S:%/FQ*(O_
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M=>(!3/=$U,/#DF5NC+8R$=I*C-DHHW961+(@#O\'6?V?\$#P!O\/4$L#!!0
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M1$7$?AW\:N3?;MT@R,\O*"(L)"SR=V^\9D!RXX9C&V[R\ZD!&R3Y^"7Y>.T
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M JK-QAX;\BTM8"#O9K-4G_> QI.V0X:-K3K6#_@R\"=W;WN\B729,+)AF/F
M\Q+I@R8?[IH,P&^]2Q6."?4X@=C<06.8^>O<\%%Y%>DMW:DG</%@\[V,_9WR
MBD1PV-P*-K[8:.*1]LREIX2@<]N>KL^K'>[*^18LA,IWB_(-NF ??R/==OID
M_YL$D?*4^X=4X,$,8]G"C,G(PO0<=R0S>8G!XL,/F<!>T[0-*FH;JC-HOVV
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MU_'Q+\\]&9;VJ]#\U%#-."!.N70@]U2JQ#[B24886[JFG51)6I2?DABI8?(
M3KX!5W<"(MMI?L3Y>=+B/3:MSO-WZ#TKKPJO.ZR7'[5?^MK^8(G?S^X1GE_0
MYE^!@PGV#5VXQX? ((G1X#4FD@/C K4DM@0Z,43^'.+^1((F9I)Q\^%[J>TU
MM4-;T9?HUH7N;Q.?2>RQ\QCOE"79X/1RP%9C6N*!-H+?"@^H6-Q>O5(=N&)>
M*5JON*_7,"&39 7(./[G"UX4/ZX4'0OZ]$'[E*=0;)FLUF'Y\ZA%#K+M5I\R
MV7TFLNO>CT DR\"9,\):5G(0ZWX<^=VUWNN6#7OK_&0]A5S1FL)MG]@P[.8@
MW$P1-K=AU$Q:?;I'T:DNK\@</!Q]D]YMO-JW_<@GO3;@:LH\:9/%%JPN,P(V
M%Y4[P0,VX-7G8?+PP=R;[MZ2J5^!N9-173N0%W7<)S<P^-"BY<&B7BWX6B\V
MGA,!4I.1U5J)8(!$PDU$,E<=(E KYN3<N/=\=H]A?8Y^P'<\)W.Y^T:]>8"'
MQFN! WO+? (R@746,P#*8AUEP\,3<13?>W-VL9%E;,,XU>&"WMB@["<?78J[
M@'GF/M9*WBJVEO;Y1"K?UELR,D?#+BX "];HUF1(!['D0D63^UH0Y39L&1OF
M[H$FY7/L4^YS3<K8L9:G2(];MA\Q2[^92LT/\Y50TP<P&G+6OSD?^?Z"FO*]
M;^DNP[^3((:DIB%?!6;$-FE#W<T@_P^.<HLS F$>2#V0%>^_A+3!2+1,6VGV
MO#)T=^NQD'(])<SG@K08HO<I^<$89&^/AG:B%\-,V=(;^MHM-,NCIQ23.RF2
M65VJVX<J[P8S@S[X,1P*/1S$,C2/#MI-BW7F[.Y:N^/+OZK.#/^U"H&[0H]F
MR\BW4^@.X&@&4[8.2IOJ,6A>!V.-2AS8H7*/"D1OC,3.--T(_-WMR*8]VEY^
M7IEV*7+&;T/K8:02N<NR9,L0:#Z+;<_QG5>A;F8VE)$SOI"&V_G!/%#L)BIZ
M46\:._,18^RGMC.]%GT_IL;VW1N35XHSH ^4@Z1?Y0%+POL3Y-&CLZV72Y(L
M38.]\'>_R[[CCB&WA! @+1>VW&PK@NZ$(*N?^*C7) I]I<J0Q*HP*F/S%1[N
M6/NSR6>5[NG=F"XRDELI'?G$2)R)W::N!*SKTOHZ$6,UD\*ME%BN J<")B\$
M"?9^)3"BU*??_ @-%;OG:[59O;ET[/;O/0W28W9;3FO4/;RJ]0[OI$M%0QIA
M2S06R-X-&\@$9\@P72R!,_$X*N:\ '2-ICPU*;'E*P^0?-8?]*.SIKXV?<DH
M"U7Q?K!8/?A&N<R*9M+11$20^ZI$"SP^CLDC1.8X%,:P::&4AW4U&G2%G9>G
M._1T-EI$8@Z0R<7T$V4&9*4]TO4*XXO6EP#O< &?-S \1/K^2O["D&UA.#]]
M[+0&W]?0FP[ ;7>6.G<0+0$&](T26I!5!JW/@C,EDG!(H9<7!!?N'*QF1$><
MS$O>NY^_<T0CZ$B$M7@PLF9M$49</)SJW-:83+KW\RJJ070?,HYXZM2GTJ6
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M^&?;C2.E%C1&_(&Q?V?<P))9RK>7J-8;S,5@B"F\U4N'EGT1 :EBJ![_S^_
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M6DV.X=-R%J5T\4*M_^YM*_^+!Q0-_Q]02P,$%     @ #H*C5)NK,"307P
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M45?[]0]VM;V]Z%>W(O?F[TPV C0AZ6#5;G-M[A4T=)0.ZS0P;Z6A(TDGBP3
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M;_/6M[YWSKGGWK/.=^_ZWEWO^4>O!<E.5>_JZNKZ=55W"5K1:XR(1&I9^Q3
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M?%]+K2Y]L_RU96M:HR5.(\;6?(>WB<$!?'5*EN/$C[V6;R*KOIWLC8KFON$
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MX?Q?R;"6_YID6.SESHF#8$G(C5"U@_P;@@MN9UKL ^?.$1=4.H4P.9&^_*?
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M.= RO/T06'C&.PMF<EUP-,Y>Z#\_0@N:]?('*9ZB&\ V;.F?3QWIL#3+#I1
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MFBG;1JX47\S/XD/NJ05P+[X6:S)X0$9H\8^^HM7B1Q+ARO->>F5W3P^=UG8
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MHM*;*(H4@5@V(")$0$%!B(A($Q 1"#6*4@61KB!$FJ" D1*0&B%TI$B5&A)
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M*K-1PA/#? =S@#T5_078*(,[ P9?X!F*/A[*[:?'&5HI0VZL(>QZ16;%:A5
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MMI\,<__/%G#]."D(:;.-&GLX 42?16:P&8@^"KYJG(R(#%#2BHU5ZH-]&F*
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M#<I!0C!B/%#U/$P943I("@1TVV\( O((QR\;-)6&^F*+6S$QJ^Y_B*HYC9M
M3R.H^UR9_+U?[:!+"F]FUC-F5859%SY) 6A63$<<"'B,:5;.#Z0L=Q:/-T_-
M2D, X;W\0S-MO,.W7K+(SSZ,,V.3-!2)_EX-2:NX8(WC-UPP[[X\06X)3PXU
M;DPXR V!2V&-'P_I*5"7IVWEM;<UW(N+N00D>^KK?UNW7YRV^VS95T5799B3
M66%N)*YB.=]<IQ,*/O?G=82#2XUZ"ALF'D#$7^[F-*\AP_"H WYZN%@#,BSD
M=H]DT+F+!4HY$7P/KCU_ .,SU]\9&M%S0&2TI7UN,CO)-M[^0J5<3>VIUA?7
M?"H&_#ZIRR$:1CDH9OA\?\:Q<07%.:_/#>_(WC.2 L%GAB/PV57F9*%:@HB?
M?A*2 4W#UGF^W;_P5<]8VIKS]<R!(,XA-=49XYQ>#\VD)U_GG0/&K]G<O5O+
MM.V)*L+2WI7=H7H-=J1U&%FP-  ',.*#^TVIU7(%P3!LPRULPNB26LP5SBW!
MD:%CZZ3W:<$68:;;#MMYW<@)+9.'0R#J22]J[T^V2MA]Z0H^'"P9GGOA@I'O
MB87JE9/ABT?8D-OHB 3S.TF/1P7/B9]D^0WZ>75BA]W&3T4<:F7M[<#>];@B
MW9?AZB"(&;G:L>-IC4TLTJ<@I73286@!G+8B]?\ G#]0_;C'WVJV=W-%+!U^
M7%W42]!ZF@0%M;J B*9J@^R5!6VN^>,1D<F0^2PZJ'9KKE3NH<"H&< Q^KZ
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M$6W3]T7%F4E:A^RMA+!])@;A^G$E'Y)-BRU-!U)';&R:KOB5\-L6Q.S2%>@
M-M=:;>IW/K(*$_4[;[!+V$X[?%1!<\&N3)S7\^TS?NY[=>-)*REF1,6'+$D
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MSIXAD6_!423X9C]]0#^3<9*"B4@\W>.GXG'*P:O_9(P^1QV?2)NP]XVX&_A
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MP61/@XK7:#F<51@MV?KX=E5'ES@[U7H#O1/QHPE%UUM;<ZUTX/,\:4A?/.R
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M'3ECZSUVJ6=T]"KTW\[YVX&!20J9)?Y%!A$PLN4B3<N-#;EY&PW>Y0Y$42^
M![%F=,,,*%42%!CK!U;7A8)12\:HH1C&9W* &*H9Y ;7QE6M8^GA<NO;& =^
M>G-Y-9NU<V;C!E,(S*=@%YG19A/8@&)0>53!0( _M0'PL)486<!U#VHBX<WW
M<SUT. ^H2EYGL_8%7&1N!GNF=;)^V_AE,-B01T&XB=%*T%%LDL$!BV/7.7^8
MV.KL0-S$&U#*_%;1E'H,O$5V?"P!6L:2>;@T9J:(5O?3 YE;! [Q,-!JH,''
M+X&>/H:)</KQNU12!TVR #46O7@7QXB[BJ!D4'W 'B?QZU?_Z=( AC4XL8NH
MYN4H.M\)-H2YRX>9BFF  D?6&&C5#1/@H E3F,Y*D.)C8EG#B5^C'E&$67H$
M>@#L#242Y-=.W3'B3^NP?!C9%0[>7%#:S;G#F>+A.(G</YE5//()Z,!8^&\%
MN(-(%!LBH0PCMR[938MLZ-"0E=_66J:F& <4V!#)U3$X_0"!#=&3P'2J_]F\
MKFH(@$T8"OWV5+]/E"A&K"J:C&F#QO08::,,T.V'?C#W:FF7AWZ5UK@IMMM%
M'%LL?63!)BA)53]F]ZE-0<-G&GS&2+E=!L<&7GW?C\P5&M3)S\HT=C2WK"__
M5)'F,':+E^=*TX2_S/UYJ&F?R'C7_8KDUY%>YTLZC\>+9MNK\I=E.!'.++50
M2[(<I0\^"I1^??"'K?HBW-ACV)+?%*NN#;P/YP*KC_WXE>\3V$12_0:V58$N
MNF1DC6J(&O@FG8Y+Y)FY\<_6)E!"6#NJ0(G7#IN[V T*([59J@]N+VJL@K#D
M-PZ: (+[N53<67('ZP*<?@^1I,53YTJ30LT#K.R&$^!]/0-]]-,(]R?AS$C
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M!4&SSCDC8^V3GR9U'XWM,96Q6%QMP*04)3V:[*C8(2O^#<\_R-5@F]'7.]6
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MS[#RD[1H; 2U\'MT6,IUS4];-8] #.N)\ BZJ?!XHV ^[\,&\N_8X@!;+'>
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MS>2'J(K"M5FY;AFSZ2BK$TP$*%_'+JSB"D%4Z9$'F>P1[.\!4-?!NVP31DG
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M]$S96@8_4ZF>$7G>1XQ.(Y(L2U<#W6^_42S[:7Q_PL/XP4%7O0?6,X $-C*
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M!JO/T'<="99Y<G7^XPB-8+O#;D;'WNI8W3YQ,JX737<8& ]BMH EFS A-6I
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MM&XL;@2Y@@.Y-.GZVK(O%)^WR'UV_G+ULZI8SRU&E^R*S5:ZY.<A680D+$C
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M,(5E&[\8]D<@Z5#*B?>]EN@Y_<!)"L?ONY^KT6SIMX'EH]XW\<NJQNL!;@D
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M]\/+R>F\DQK"(>%_NH/N?\?_Z%!2#/XO4$L#!!0    (  Z"HU3HTK_,!*@
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M6=IL8Y /SFJJ,7V*O4U703M^9%DE[)[Z5KCM8\6@Z"'7/G7K,O&Y$_8R)[.
M;=PZMBX/2/6F];* 41[P\]$+<;+VJSLB_T(Q#>/D@I?L85]PC,2\P:D$:8&@
M)P(A4:!T%5L=/8+QY8YS1S[<'^":FBRS]-*FEI#F> ][\D=[P,_T\]Z[NC:I
M"T@.I2< [!6(Q)929HYQ,LJQ,FQAQ.)PL,GV$NP#76]3:IM^^0:V<H,O;RY[
MB],MUMCOUI%S,>MM9:OSZ&N;+7^/+PH^*ZOR9'AR-V5!::THR'H9&7\2+P,3
M(V@J<H>6?Z4S[N?E))]9G)L3=U$Y19_&W?LJ[/4QW4@@]G3DT?(@L\?,'AG
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M.RT?\6403N_=]DR8Y$\<V3#,?,1YA_;!D(]UT ,)6Z.H0G%A[J=0F]MH#..
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MF9IZ'I "&F/UL.0;8$'@_'C[C11E. )QO!VT$6GR!# @K)[1VIM<M<9,TZR
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M^\&5%)I$G"D?'&EP@*JG_'-MI"\L8KG0:U;IF1/Z$BE6-2QGPA6U*_1[[:M
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MJ(& EK0IWP\>\+D>Y %Y 60F9>PLD\M!N.#EYX=;(,(H2=(#:HB?C-@SO]M
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MIXERWK!O%\ [6"U&F3,++R=O'UMJN9FC>O[+8XVOLZ4&.9_84L<OM'>//D@
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MBT823&'0Y BM6)S;>_$PPRFZ[@@CN&N@U5@N*\=E+ELE<](R9K;9-L#[<*]
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M [>*!PRDL+-X0 7_SRZ=&6-M'N"*P&@'UPX)A+O+WK)_GLN 2.%:GN0!.WC
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M=MMO:^W3@;NXA)E^'V\JU+W0D^8+P7RV<+1CP69&2PU*Z+X:V'MXP0 !(\9
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MET^EFC%5O+Y^73_]?9CX+T+_6+=O#"OP+.+0MKB]EZ#SC\F,8HTY01:"^Y/
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M(!6V1\-1IY" "@M]OM< =CW.HZ%Z,P-9YR"'H'/+[L17^V:>[1>DV7GLBTU
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M%^?>E9=?\XC@SO#O+_]]_UC@'^(5MXL&^-M5E!=TE,RJE,]E#@0*YW5>H.O
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M +YMF$VF?]XT'7M9LF4Q?/9=P5/;L0!9G=SN?9N/+HC$11T(3@D5BR42&D
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M\M^6?LZN2G3"(  9,V*UBX'5^+&:^X(QQTK%#%X7NNZJ,OO@Y\(M[0SJ*@I
M/;*+=_IV%?U?EX_.P.2!P [\_G_"!<8L*'3L)\U'H*_!MG"C.+,7=:W=G+XJ
M1=HDR7F6/]URG7T8-6 &F!7H=VN@T6<]-$)#HQ,<MX9L>&E4M:$< I& 2.7_
MKU8<JA%(<R5:$8HX"VBF2 V8=N0J$Z_JW6U[^</[B>>- :OP_O>O3$Y\//ZV
MMEHBQ0VJT_!_6+2N//JQ<\OH=>E*79=1@\' UVDEGKRG:CL04^>X^70$XYC
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M'+>O23[4N[)D&S5B8449*_O%(N_1M2#Q/U'KJR[4D,*MPD2;K:+!J3W"G.4
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ME<V:-M;43H7 //$#, I,H 3M("G7$S?C/\(X*(0D0&Y?M3IIWIC9Y,^]K67
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MNE^FD^KR=C4,YSJJDYR-V0K*B$B2788GWMR8@;T:5>S(A"MY15=2)OJ@Z*R
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M06^7[T\0ZNJ=08!0># @8^4NA63P\&O<N)IUHDB22B<!NDM9U' ^01O_'M%
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MYZ](J^Z]O4'FR,.7[^N$U?;9TV4O!'6*R*GK4348:Z']+;+_M<#"_[<B^X_
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MY\<A8O'\8)T]/,0%B.*<.E"4#4(6,-(?[42R]XPK2U$<O@9Z<MX4?U2YX?3
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M K&QB<HP\M4.\U1^%^$AW:PK<.%@[=V4_<WR"D2PW]@,'GRQP7C3QE1:.B'
M=6OZZK3JD9:,^:#UZ&SG2*^ \]:Q8<F6$[:='^-$"A\^.*P,3V8HRQ)63'HF
MAJ[<@=0$&H/%A^\S@+.F9BN4V]!7@6R\B<30?7PK$#$TFOF0U>2=]DC+@)?'
M5;_<#[HG+:+0ND1XI\F6CK7C).&<& CF76B<,;\R1FP&8\L,NK!3+?VI.Z\'
MB_K[2][OJ__<;AA26AIQ)BY0XZ-]RW=;DM4(-J?!Z!I1*&I90O+,83!XG[^'
M_MC.[HV$'=(?2'R./_AK85KW!/6.![ /@$QY.G(.+J>B**XT"CJ2V>/(E<+,
M8>862F_FVE=4\X $T"@0&4B^!N;YS0TW7TM0@L+@@;>AKX=)G@ &A-12&COB
MRU:921HE], MTZF*TXOYC143%6U5G_RZ3\A_>IYA_\IT<D."-DET11 &WQS8
M;O09!4;?A(%<&'U#66YKFX)S)ELE[HTHEG49[Q^[$7C'@'QT!"'2I3"9JG/C
M9QEMU_GQ8#ZQX^:A#PZBF0F<:)#Z H9PHY4U#(+15XT52*W"PPEQMX@E3U,Y
MT1H<14-Y+"9=NQ;PDPTO^<K^*KM#""3.@9,(!N0C:@EB[#TL!?R(L^,M&&/X
MZ?XU=_*GSVI F/5%.=A'#6)[+()JO[7HI[V.OR?YL39Z]V"MO@5S)[S&0M@G
MH3TL6VP+<X:33_*^A]?".3/ "'\<4GDRGKIYZ:"F6>=60H?+@1L>R8X/4_T.
M6*M'W > ('3O<@)5XIX)'Q2NOV\4J?1C=: S)&PI_^*TXC-'U#E2E$I(UH@+
M8D?PM\H,/Z-Y!7X]OG9N#T80I&;Q@$N!]TA%.6QUT@")3L!*.]*GF"T#W&ZF
M1)F3M>_4+Y?NML')A<'J4/_F[^T6C0A^<#0)+BZ./&"P870A$K^.C8 ]IP],
MX^7HD?'K'[_P[F#I>)6M)W?)""LJ:) \<5K\5_=H?M!?W7=*#Y3!>C;N<W6!
MP$8'^2YGD]:LHDJKX[H_J%;DF_$ KI71S14>9I@R']/!.6H@(Y>9:^/>!*ZK
MT?%6V=]?=1IQ6[44(^_J9&&DI]JG]#@!O6@\-W]2RX9PI:C%D76-VP#2R:O$
MNH-HKEP4S#GH.7@C+U"R%+QPLXR%8>T/D)]36,Q@H9Y.\8 "SN0P:6;(^,9$
MMUF@M*OKL3>*VIZA?H+\B58'!1T[E]OD&QUTWF+!,R4UI;#H<OJV\WVBT:W/
MEB\D$D&?!&A[?S-)"M]/YU)0[Z)H=KYTPMB)EU0L>_]XI4UHO6B!5\V.[HR;
MS,DQ2GO$6/E=>I':1,;;RX8!+UDP)ZS3JMG&_4(J"XR#<_4%N)GD%V\Z%AI7
MLPUG$M7 U8Y9K-_C_16N9>.//4LD78V&AM1W-ZQSGKM@7*1V?(Z&.3>;KD7O
MCU2+"92"8EI.6$T,BF+<LE3-N3,I:IH#IT=-@<]!$D>T^*G*\EQA=]8Y_*<1
M$T;(%%M:ATGOPB.P_,TCJA_ZB37RV!5JH>\J/O:-Z_-^:>\BC=ZJ4L8!<<JE
M YDG$R5^(]HR0MG298VD8M*<_+C$0!F3!W"RD5R=$8ALI=&#\W:GQKH)+TWS
M-^F^+"RY57%$-SMRO_35_4$23\[L$9J>T>)?A!<3G!LZ<,2'P0")P: 5)HH#
MX\)H?G0^=**//!SL\ER"*F:0<OWQ%ZEM91_ZMF NT<W?NGR*?RFQQ\KM6[,L
MR0*GFP'6ZU/C#S00O!=Y0-'<MM+%4O]%XV+12H7?VO?%I9+, !F[?WW#B^*_
M*49%@YX=T&]*XVBV3%I]O_Q9]!P'U7"C0XGL\CVBY>ZR/XJ%=. ,L!84;<1:
MGT7\=*J\>,."O65ZK))"+JI_R&T<6=?O;"-42Q$RMF"4C9GUWJ5HEQ86I78?
MB;I.;]5?ZMAFVJO; %QY.$T2-MF$U6&&P\,URAWA >OP:M.P>/AJ[$%WJ4O=
M511X.Z7T0U=6Y''/3/^@PW.'#N:V:\*OO<C&<\+!T014J68\Z"<1=QV1P%6#
M"*-%/^2<N7<]=P]A/8]^Q3>](G.YOPUZ\  W]7*! WO?>_JE JLLIA^4QCK*
MAJ<G_"B^_?K47#5+WX)QLLD1LZ%*R5L^J@!W/O"ERU ]>8O82M+PB42^+3=D
M9(Z&7I@!9LPQ]0F0-H+F.(HA=]0A"BW8,A;,W5TU2J[LDRX_:I2P0W7I*+<;
MECV!M'.&4M/]?/FCR5V!ZG+FYQQ,?[X>??BS@W:'X=M,$$.-)J'>^:=$UVA!
MK;4@_S)'J<X!@3#V'SV0%NM+0UD$2M1-F&FTO=OGXMQF(N5T4HC/$6721^]0
M](8QR-H: ^W S(4:LJ77=32::!1&C2LD-%,DTUI4MO45WPEB!GSU9MB\=;,1
M2]$XVFTU(=:<L;MEY;87_Y(:\];:70C<97H46T:^D4*W 0=3F+(54-)X&[)V
M%8S6R[=AA\@]S1$-&XC^7A/F_\395'B/UD7OBZE6#^7T/X54PD@E<H=UB"U#
MH'K.-;S"-U^!6IDOH)2,;S-)N!U?C?W%KJ.CYG0GL-][ O6]57<D?\ \N%=F
M^?FCP3N%[Z GE(&B7^$!-*']<?*8P:EZG_S[APR#+N+O_)3]S!U";0HF0)J.
M;+FI>@3='D%6.]&C6R,*S8[*D,1* I6'IHO<7+#69Q+.*-[5#9O(U9-;+!CH
M9<1_C]ZJI@BLZE [FA%#96-"]91H[F9.$2Q>"!+L_8I@>(%GI[$I%1V]9[;4
MJ-)8.GK;S[8JZ2&K3:?4*QY?T?R,M]<9Q4#JH30J"V3OA@?( +>/83B7#U?B
M;^A[9P6@JU2E\3&)3;,\0/)E9\!R<UGEAV2:7AJZZ$MWGEI06*',HL;]H_&(
M )<EB3IX?NP2!HC,;U HPZ*.4AC:4HUL"3TK3[=I:ZXVB0@\0";GT4^\1Y(5
M]TA7;OXV9WX)\+@EX/D1AH<(K[7B+P19OKW%3Q\ZI<XW&W+=!KCIPE+C=F,D
M0+^.04(=J@19_S(H5>(^#K7^S7G!F=L'2QE1X;99"7OW\S</J >8AIN+!Z'*
M5N9@Q,7#I<YYA<FD>[PJ&45&=:!BB"=/]A;0_&B")7FOK--N^^]0R+POK2-S
ML[7Y6N)ZXY-<\5IU&+2D3?@F>,"7:I 'Y/B2F92ADTPN!]:"YY\?:*#C!TF2
M%^@UT>-AN^9VZHM;F%94=G_'=HH]<#7>8_D^T J[>,A<I&'_Z"V\)[>M9@LG
M7!\![435V<#*5#+XO9>!4<![39K!B'!Y#4;T^::AB.ZN"5>$QGSJ*.G1N_"Z
M\"*^LLNK[ES197@D1CFIH+?$H-K8"BV4$8F0F4E7@V[2]SD%BGC;8>N90Y;%
M%45E597AC+P7#]52K^RL*DY[G/Q;[Z.(.CHJ!MR"<B<,57)%ZEC(65@/*ZNV
MN# P,*/?_,T'L9FK@>5OD!J83C:1WNV?AJZIW-2B_.E9@.6#%'+C[3O;)3H)
M= P!TDJ8\V<9X!MY@!SH@8PG*+[XRMV*LX)TB4VCA(V?,BG'R6D=OE=\-TDU
M\#>I3->@1XS&W]1.WCI(X0KK\@"M DXJ:>XV%L4#CI<^7I+%P= EL+;O?(_;
M3"E>F3M)3V.>AV09;\7!%HQ8C1!TMKO%2.#ZP27Q[+;U!'_?'4\];ZNF^/WX
M]&2XKMG<0G_)<:Z(%<A6XA#9[HR3=2CAO)">#Q"*L7ZVKF8'X71WUV:-'AH/
MZ(OU=$*T'6Y1UY[P,/?B?\O)(L'R5@#?0Q$(X:UM@XR=R,PC_S#97G:?XI#4
ML%J<;!@H\CE1S]L8-#[/]+N0)76_5O)9PF<4I(MD2Z.8L!0/#^!^3%>!QN%N
M(,C-L)X'D%5:6U)5GM+-%^N<O\_.5##?'%S2UHW-*MI?;5ZZKTC8,"@FZ\%W
MQ+(\LX.35Z. ;T 43L%EWQ<99T=II5($O5%^-65=-/90;(JWU.;S\5;\P4E6
M6\Z]%ZG\V:BECC_(;5@C6Q1(@]34018#ZTZ@UO:71NY29.^>=,'I0BZ^5/^@
MQ6.08[;E9??HKL:6*V^.E>\;CELFW]7B.V0"<_'P06S*F$0S0HG[&<8Y48(,
MQ4LQD";!D,+6:+52AW[I3E9]+4ZSG"\1-]C_*-)R:M^.9"'UK4([ON2TPWXB
M!D^.6K E<YGDM>,/WJ@!B]I/],4&BK3)K@&V)I1-%9=C@G/#^/Y3\4V/OWRM
M+/S%[#)3#[>+=(]O7"0<@=^^WS07TFE&%>:P93WK3!1[V%94Y&W,IE<D1L6/
M5%S2MR$LQKDX1K3:YCS_C3SM+7Z?UX\B-$7R+-+QO902S]H$:&<+K82EPVWC
M >^BXOO'Y*/P"CC7]Q"1@6Y6U(\;/_[5/[C\VZ"+C=Z]S(X/B4YJDF*%SP(
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MUFDT'6;\4?4Y+<1[>Z8=%WUJMCF<ND:??U2:O*@GK/J;TWR6B$C*Z6\O\GC
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MKK2R+PO!$IJC?/!<-.DEO?JMN7/6V:YC;\7R::.072.Q5N #Y9LR=F??"<K
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MO_"""^8!9?M1J?W;W, ZU"]E%*T=/5GRXSOBY[Y,KKI00:>9[&KY?XHEPM^
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M[TT;Z8#^%^5*OF+$ZIIXYU'5['&.9>0:K8J)BEQR!&'UUO0^/+/Z#!%R;!_
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MA(5$UC^L#_(?73?P\_+R"PEL%!#ZER]N#2"^B6=YPWU>'F5@@S@/KS@/MP%
M(3+R_T4\'N!_OW@V\/+Q;Q1 Q!!&;BC>@HC/RXL(S8](C/S6'_D]P"?.+[%C
M_XF-DE97!)1O21UX^/3-)I63^;72UAV0ZL&KMP,%A61DY;;*J^U4U]BU6T=7
M3__0X2-&IXQ-3,W,3]N<OV!K=]'>P>7:]1NN;NXW[]SUN>>+][O_Z'%0<$AH
M6'ALW+/G\0DO7B:FIJ5GO,U\]_Y#06%1<4EIV:?RNOJ&QJ;FSU^^=G9U]_3V
M]0\,TD;'QB=^3DY-S]!_+2VO,%;AWVOK>O$ O#S_Q_5/]1)']-JP;@.!=;UX
M-OBNWR#.Q[]C_T:)$U8"5VY)*A]XN$GJY-,W^;6"*@>M(>FKMSN$9%1U:&KT
M==7^HMF?4RSP_Y)F_T.Q_ZG7("#"RX,8CU<<0 -L5FJX!O#?H/&.B\$:BRPI
M\AAZSH-I0MC"?LX%7//Z?U)&N4 D49\+U)W4\5#("Z7C;Q\U2A\:^O%9I-"^
M+:9Z5[KWZ<OU#\O*FK%,-4X'!;(B1: E<PT.,B^"M3K+>8\-M\:8QH]2&F6P
MV[()9K]&]CS=[<".'VF3.?>Y4S^I0GC"1> /E7%M6(L20C2$"SE"TTP^&&1@
MX:>IL&FSKRA]FYN2,ETFW$?AJ)Z\<=SI:Z4B;RV_AYTCU(O0*JY6E[!?$%!<
M@%\=WN4ZAI+G_ "+* $<M>GX%-2#*%X+"!N -4E4"'UD-C&<$?=-Y+6&G)S!
M=X$..XXJM/#\W9"[_-NJZUZ^]X<\Y[WW/E5]M:8<%X\^TS/(BN8"@99<H%:+
M?$T;WBW&DASL8TRSR94BQ)V$B_"L;]9,XFI4L98UU7DJM#RHM;@X]T7+SCTN
MI6;G4YLV]GY]E?I!3!A>HE>,Z3<MPKH"H]@00RV8,]LPL@/VI5_JJV%4:W=?
M.X#)<ISF[.D:*_[TO.U,I,K=R$]?<!HR>QIB>9C%2A5O6K+-:5/%22;=RH\M
MM<)_['JIH@I,'"S;:S8I-VX7A4AG0O:B""'OA\DN)!E.?[4N9/AF])A^G;7[
MEUMI[KZ"4JLHSVZO;#L/\U]1.;=S[W3O4O309IQ =+O"^8S.=PU7A?.@-%H+
MABY[_COE+!W7D.-J\ZFREV!R/7[KPHW*1'>%;WZN#]4. ;L4SNUF%2^)L11=
MH1!:9@R:&L4QA"/&Q 3L9^0I@2O.&R?KRI_7Q>U,TFW[E.EPEO[D#^':/4]?
M34[<.8ZR1T0T([LORG :*1\S&\4&,VN(J*YB9Y>:$>FD\UW+\T[F#(^P+>^$
MU>._,OTX,@(C%7F!))GL:C6"%F07OL)DZW4YTC&/LW5#.J]\XGF8,J &:FV-
M>&;]C6?RX9>\8#(UD_11%G%<4>1!BN!-$W8LZ)HG!HO )%J3P?&[&LZ&PPQ7
MG KQY^&!R=:8M2F/.B[@*0:KDN>>0O6<32$/F%>G.(K=E#'RXVK)Z4NZ^7#G
MVOQ 7Y]]*0(,F^-^DRH"@"O1P\>C-4KXSEE=!(A-L5(R+@%'XLXO8\3A!PTE
M[7ZTUGLMYX(/B]RVN'XW]D/93/K[[:B;K#ADJHLY710)0WUG3@,7*&B.-)1G
MG:27/C+4P]]8:J3($(2AMV[S*S@YM?@XC[N)5P\Z.<84O'2-=0QM^'#&3(CU
MM3@,*J7M)$-IC&5X*_T.1["4"_ ]@">9AH/ZD<K?JW7WYF?V.^!!!ZCXZXL1
MQW=:*PH!2X-?K?'C_6*;[5]\" ?8]^ WN? DHK,HX<0H-EAI0TSC)=6N98LL
MDAA\U<M99[EGT7JGFY;\=$]OO\7VB]^RLR7OC6Z2RVOC H,*'.&C2'P=8\>S
M,-!B+1?82J:&)YJ00#JFJ80C"3F=(W8-^M=4]*AS 3O)HOM6XKN:*02-!8_E
M$O(1D%I!^G4+_.C+3F8\8B4&'$%'HR%K++P+7:/=WSZF/Z]/YP(<P1Q:7K D
MX2AT>V9$[D%>Y+T1]=+>O9R.;5ZX/;;W&)TGWVRK9K.>AC,5:-J-HNAFLAA+
M/7?V2'2R5S8<42]S/VO:RBE@K.WAM;\X!=_3%/RVQ-]IG,U\7.#90<YWD*&L
MSWEFA-U&'$9!YI2!H]1VEKBK%;N I?WZILL8Y9&AHKO2@7RX?VV^@\[KL:_9
M:]>SL]?J3IE,Q?)OT$@;%#^?^H2'*7M!9]C7J/=:68AIK]?>D387T4%'ISW!
M@@+G_TB?Q[FT$FT1WW,RV/6>V$\6!ZG)1"4Z.L+'4I2S'=_I7GGB'?[VRMQ"
M4%53B$CI4R.=:P8;+T;F"YS<RO?2>M/&-XB7-!"48'/$LM_8L=4H8@L7@#"+
M@4<H@3JD0>&QZB!:3*@,*.0M?PQGUR5BH]N8\:Q4\IWCT+.P[7;NLG^XVJKN
M?RW6XW6P(46Q-W?!4\?K_M>%!^H#?J+%G6:0/EHS2/4]%;K5F=FMJX@V+XBS
M[L&]*2D-\K6\=4OCU(F9BY! +UF,N(NU\1'-ISW <#=8NQND!J.+3&NUPSG\
M]'LO;WF,FA1\#&RQ[VB8*@].^O!BQ7UD8=?KX?B[OB-92QI[/"H1%0)9%J7L
M3"Y +4K9S4Y"N^7UMXRV-U."R/P<1;?51/6ZO! +SS5">5LJWV+VS7/M#V[N
MO6="<0TSOVN=?2_0_+)8O[.^39=/DERQI<JYP(7!Z\.BC46I9N-*'[Z:J4R?
MK[PSBH5/LB2S\<US6'?.E\Y<;</6GYY+A'<##._:H>2RMLT'O_?]M&-)5- F
M&[&/4)!UN[@#IPT+8=HC41O0KMI;67H/8K;@CXZ*V'9,QROM+:W [%W"A NW
M/"^5="@TH;\__NUAZ._S8IUBT=A?Q@97N,#5$L0VZ9WG!+Z D'$>O.<G@KK\
MOI!II*Z7!96/(D(PIAV-V$JF*9(:QB[(#CJ/>WOEC27-]?ZVC1=^\7*#8K!X
M?(N74UXX"#EI*=10(+M%8<1-=K/4F(<M\X9NKO8.WJBB:W(D\G&;XSY87-G[
MVK.W:RZ&$6]QQ?O;J>FB'Y??#>IS0+ 67:T.^W($24P%8B,6ND 13X?PLDXP
M.(H+1FV]5A1:X9^\8HFQZ?"^MUE8:Z+R^TLQX[(+[8>.H>HPCXBZ$*:9 JN[
M-B.I/%X)TX".(2L0_.CHYAT/AZ762E[BM'(^MG_+$GU2%&IRZV,6(' :8#?U
MZE;)UO>*?9A=J\J)RKXF\*FR[&*:$W3@VW'I8\6M51.5OO?BTO-//QR-UQ/)
M3;^VQ91/?(2LS=)D'F'M0GPA!ZQU!=W]Q1@4"*+G!:)=-;6%W5"B1(6;J]:*
MNWO],9C8A:7SB0/VUN[#3Y\JUK*'@-LND;E]+$FPSI:<+\"2CF $(^.X$61[
MM)MKN^$[Z803D&O0WA5![RM0U/"WX)&%MIZ,&VZTET-MXG%!@V4SC0%HTV+,
M%K<CV^+I'@[#&4G.WY2+';.>1[;NF HKBVJ=.YRG@(P821RJED;>[Q*;.;O8
M>2P/JK]1PWU<4&;7U;*.Y8K'X7ZM/]_@KF4X8)YY>03=27EC-HM]28).M,,J
MN+EC3'>P5HZ(8IUB9Q.W68XE^S8ZW"-?3YMQ:,KZP[$NWCR;4O?$_68!7Q%[
MQOQV6_C6B>35^',?#/(8T?%B@T,<D2G(;EZ8><I!.[P21WV?XUF)'G5V,(V?
MZ38:T^VHK!F?2)YSN6B?I/90]1>2.#]2(&MP,*21DH^=4Z.C&5F0;,CRL-U%
M2#]8K7N9?=1.0L$C3+KCY)>)@FK*"W;OQHK%1VCI.:(*X2"$"RL>-K(LZF5A
M:!:*SLLOO(]?OE%JCFTQN3K!<P-8JAGOJR-#YS']D@P]-C+3U&A4,8IU #.W
M2N,BG FHLX)60-IV3EU0USSEQI/?"JO[V]J++"/!=J-+BLP;8.U.\%I>$!HZ
ME;0XA#H),=X2#?!&-.^X,0M4%"9W.)G@H0<YGE6U9[4/UP'[587X;IE^5'YO
M?)F'*0:"5S+LO[R;\?TXY%B7\3;%;X.R]GN7&I1#Q*F^96V)_KU9M%;OKG/%
MMT_^&'#*SH^;VFHN_3L&";RC\ GF<4YOBC [#G1?E.1\76N>YX'BC"'68%^3
M=N#(UEZ)SC&;ZNHN+8<6*T?;6)UN_LJW5[56K^%J^)V_KH$L\<4F+'1:T684
MVX 5X=2C"Q8J(/U1YQ(2@EIU7V'L&$K8>>I(3E6!#NEZ\MRUIU3-<G>!)$'U
MR>.3HDK'#<O9[ZIUP7H]XC>*..A&ADW()60:#[0S;Q0]!Y;X)\US@2L%\;.?
ME^ZAGY._#I!=O(:3<R)1$41>L-8:F>)<5%%F+2C, F%3!.E/=6BS]H\I2E!L
MO^-<V>^+/BL]L']BX.T29['Y\7N4)F!Z?PW+$8K@ AJM[%3R7!"^@@N<Z?.!
ML"R)(:HV2V;I$N+%MUF2O=6;.!0NL(F I@GG!0^>KU;HT 4?'[CD?'$@Z>Y^
MHSVC$Z=RLP*PO*JN4CQK,5!, W8+RQ$B'Z>C&_-"Q/'HAM6U,Y*S(]*/'"W-
M=9)*CE\KD;5*U:HQ^?H[_(/"5L"V*B141]&6,6G9N5)AD92D+NB'P]W.A?9/
M*9[XFG)DF]U/7Y8L2 MIP(2BQ,A7Q1Z1Q:MW.0WATVS9[PAJ&?BD)D-QVZZ?
M3,?I52OG$?O+<3>_-9E&\+WX<LG<H99=ADP9:L"5(QC"O$!L)A7YSFE!U=HA
M][E &-J-C:)1(AR-N[U/XQ\9][S^)"M.$;P&%I7M"Y$P3_CA*W'Z_3FQ'E$7
MIP["L:L^QT"[XOP26Z$^V01AB0UG@1\-(G'8PW@,8XC>%TJF9G/680G\0O.7
MP[L8P8I7QAY8WM;6&6GQ-4SOC1)6Y&"?;=DHYSRP&*TY,8QA$&%'Q.&0A!PX
M1O"#;9CN>#R^O@95:!?(4G.E:H<DYC20!JPIL_':_CX?6KRS9?R>:0_4$MY9
M5UX_'PDB0>4$^S.5P-H&BIRA*&M[=35&H)YYT#VA6@Z::$O3ZB8JEB1=C")A
M2@\4'G$,:^A2O4;C;^JI"P)X5R1MZ>HA=P6]J'T^LYKJ%7$M1185Z9'?6(1W
M<E'-3VM6LHIA'J;(+'83F?H:+51IQ'3G#(.0*38&6U0:R5'')]C=I1-)[BX^
M:5.)3KZWAX:FCYQN_5##>#J4?=UBC[OZ"^SD9>F8]_BL,5F6E  #T3-0B& ,
M.XXY'QQ%USN?!:.?LM"P12[K1)G1J*)ZS=KS^=?%B7ZI\1B*,=^J7J#QD[G^
M"CG/DP#:E$Q]1RY9*&1N(=:0I;C S<7'MD04'15*5.IW^)IHF/%'I^/O@I%:
M;^M;PEFY,K;;KY^UF[W$IL[? ,5AT]-TT6[S;:5KGK(2JGZ#V?2L+0>'=I*5
MR-1/9,@$VV_'.()(=IAU G[)U& = 7G@I-IRPY<X_U%%M&T9TS1\ST1WSO:R
MXA[APXX=*F:%HC.G,5)GDH#MG$J6%A>(O4YK9P(#7&#JV6O108W4 *%_8S/T
M86> ES&P&SA$9MQCEX T3] %@9!'H&0I2P7=CW7C#'/Z/T9W<0P-EIG:<1.+
M2'&\ES4VWN0Q%7_A^NZOFU3XQ'OCPP'6"D1F22@PAM@)13@IEB"BL2]8:W$9
M=H7N-,HW_GSS%C9U@J]L+GR'U\I3/>#4G'XIZ5U)@_U FOF6WZ<6^%\5EKK0
M73B;DJ"X!A1DMHST/T.0@DE^-$69P\NS\?3HS/0HZX69&5$'Q;.C/_&/OPM>
M*XO7YPLY%WBBR.OX<T:K%& 70Z2 ^:0 -/4U0E#$D K'A1(V.,QXF09W88*W
MZA[;MRNE#;_W:GEILM$?0^J!.W??*MOE%#G^0%2*AYX73J8FHTI"FM']I:.K
M<WY,9[#69(ZX/;,!*UR;AK_3T,L%-GH5A54:2GV9;-6Q71V_*:JQCUX.O-VI
M<O2S4@;3B-A AJK)U%=KBW.\7$!8GZG)]*"](HIS@<>E3-GV7_<&TU$WF=JO
MD@H+?1-^1I<-CU2-A@._CS(2$65MI]!%LG-(L>Q;:[@-GLW&HT;!&D</=?@*
MW?=XE_*#*+T%A4,Y-P[8?YU0+RXS2V@M<:WGO[#W^-%DR(+ANEZGV!-LH=5P
MM#L([\(%%;<+N=D9>J?1T'PLV=+.<?JF35^S[OCJ_EC<L+![XO*%'W9;A9\0
MLRHJBCX6QW,X/P]M#]2+=7_[QWMYGMAO&  X8)Z-H 9,J07%6=JN8V!(BG;G
MRKRL5>27S)FUO6\4>W*^;MSM</CJ#=.M?-<D/ZL4 S?MVDBEOG,""#?+IRM0
M]9$T1_-$/.D@%Q"R&&6'1!._L!\Q*/-YA1L,FRO:(^:&"CFE$B[,X.J(=PN+
M6GNTKE61RZ,W73W9V7HPZ+Q5=RQ^0X!!"$>(G[F3"]3[$)O +> U'(Q!AI5!
M9G3QY!$<2Q4U@/5F;KYFNF00HZ>MO^"">U%UOQ<S;\Z40/J<!FL-#(R9"'FJ
M:^4T<B@P*!:,IFER&IF8IP4:8TS3 <+X,$G[J$%'GT)9GL?W2G,:1<H^V:C^
MR$I\FO>V-RE-TSN/U[_[\3B2>6$0^ V.YK$D[W!D<%'@]3PYL.XG4XQU\&RJ
M=W4[DK(6D[B ((IUNK?>>[%(NY^S^/*599\W.KP".[3$D(.QR&0*L$GCL )=
MW:FG2#-)\6:7,Q0203AV*,(*^EGLUICC(WQC^T-EF>O;5\RW;4@/5NHS!@C7
MJ3$#LAQAN<3>L%0"DG<#2_!75^L=SK[![<ST0:J;@/CX^VU57MO"6_FZS/U4
M]=Y>X'<PN_I#7['LD(H'HQ[IX $OC>;-'TQ#@#4_<_[H+>C.V-XD6B%M&&N;
M4&_E<<0T;!G4;[,X=K+)7&7$^JSU79^[<LPA&]=>'Z.S=$RPC__I,=-.@ND5
M']\;MWP]</@850%VL?5IC@X/#5V J\'"&@(/B:HS*'&T9\Q0H2D<XF(8SCB"
M#310A^I$!2SSD]^&M<Z>\58O*TOPO+ZA\(/&<RC]55\9/%F/A1+QZA<AWR%B
M*SLGP\F>G=E"F?#++\ -/:U0*(R,''N7<S;Y9DK$J")O0WR['VWX=AM';F+_
M%ZWG7T]_&/L0FQY@8BK%L]0W9XE4((.P/7,?8FZ6)/)A!?Y:C8(_O<:?[G7+
MS:2C'[UF*KUM!75'S7H/5M7M,GG&DT \MV_[*T'R35+_AC[&,_9[M"MV\&3S
MJ"=QVR.J0*B/\UG4YD8:_8C'+C]7Q8]!UR6;M/BN'JMYG'"X279K'MAG8(Q,
MOLA E%%#XGP*R=MI>\K:M/+)YM2%VQLQ&0[!;MY7+"+\XLW&SW5\CA0J>/KD
MA")B3%^F&<*8= SUG3C]B3'S="8/L5</\9KJ[7!6?6^Y=H._-A:ZZ5&."I^?
M-QDR__FH+=C,^\T9Y6_1MT,EA;:V+),^JK,D(ZS8<01[.HKQ&!ZC+ZR.YC6!
M$:5ZG?C)YK[$/??O"GMYB4?WUGUMT_<I*0FZ&(E3^VS=/'&.;#Z"SZP_<B]/
M(&1%3/SB"?#N0:_KNJ-[NC:3=DM^(O/83?'6(&7="_1'+L Z"C)D(>TY))T*
MHSF2:/AD6K<=1P([AYU;+/'/LBZOX@(QX!&<-F[P'ICM.3?<="]& ?9#)MX2
MVH@4>7Q8$%9):&B/*EUCQ*D50[AMTXGRTTLY#>7CY:V57SR[SLI^24ZU?FOT
M<U/,+K+P*C\"OIE(/^HK"H*^,?U9"/KZ,IW7%P7G#+>+A8[(EW8:'!Y]@'ND
M-WAJ!"74N?5GHN:#7Z7S>Z^,W>41.6/B^^08AA'##@-IKQ$(/[*ZCD$(^JHP
M<;1*(N(0CPN9LO-*9UONALRCKR_%W;OG_8N%A'Q%7Z75<90VP98="WKGH&I(
M(JS]S*W$$0>[  1C>"&OZD<YTY?48.S&PDS\LWJ1_::W:WXTZR:]BPH5_UP3
MMF^@1M>4L0>),1^6#;R?>0[?S)AAYY#=0XD:! <Z&.1%T%;\&4636SZF;MRQ
MG=3N>/3!]7B[IXF>1RU4@Z(!X#:F9R6&)A9JR ,'ZAZD:BM,K?5W^/@MYUR;
MEG]EA[Y,#E'R21]Q1.V^^Z,BU?/(PE9>'9XV3C>6'Z2E<X$;N%!R829+E=Q/
MADAX23MHDM'<S^EBB)7:6WA,_G;L:AWXN3A0Y>O5--%FVH#B!:EQ2'*QXP(#
M]=3%8.(&%@J1'.J?)LI P5$;G[]V;V=JNI5N'.R4$I3?JD9V)6CPWMFO_DEW
M[>!Y'5 *[]IPT,D1!AML93L=#%O2"RO,SVA-T<P'_:, 0@N]BR,X3#=B/(?
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M*CZ^52X0JYX%]J\BN#5MGG<W3QB!C0=<X(MD#WGN02^XG-Y7?H['6.J_;!-
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M[K3?.97]/?-]J%EYGYBT1( ML/YGD;28@26.X&_(CA$/I>3059JK->E5R5R
MI9:8DQE'XP(R[==Q^7M?/9K(5*AVB:.$+R!^VHXM%&-+H<)!^-;>V;)_4I8(
M? 6AR;R!$$ZX6".:=2C!IP4F<P1;F'IX 3M.;1#+X[WVLP+_3"LX(LOOU>0$
MN[7!XV',PF1*,2/#3[:I_;<B>KX-_;.'2E>\V7U@X>;M6[X.F=[L@-]='#D/
MQBTN\%H]# G!,0\2*\F4M:]O;HP+',=((I(U]:%_ZU7=#H>UY_<T<T ,%]@
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M]L3-9]Z#'@H^5X&U6>ZA/]JR'\VYAC=YEF*C@J+.-*I0&[X8=AO]>B_'+N+
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MT'KECK7%21\U N[\P*=CB@/FW>=EQ<OW&;__N,^X3UJI;W.WQ]NQOHGRI_J
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MSB"[+XPVDH/\@27P,_.N$M'M,*QZ8?2.K:^>P7!+@%EZ;[2D*H)_LG:EDNO
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MF)3(DPM 8HP$@.YJ-P'P&"T=H9_!&B/PYRCXZVLO]K=L[$Q4&A*T%:5F-P3
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M:5PWU.M7$2"\ ?R"9:D2@P7 (9(#(M>#7BV=Z4%]1OO;'O]PV)+=L<NK,@7
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MTJ_:RT['F3:?#'TME7,Z^-'!C1%+>I'@GP^*Z[&T:DS%F)6E#=&'>B>]5*;
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M$F\(YNU7[AM%$D?&E\!#*.(.JJ$Q39.TS_^#QZ/:#3QSN9G;$=":T&)? YU
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M@NC>=/XV 4&670_W4T]M _@G_,7.-L7-+7C+YUZK(:0%Q76>>FCK=!?WKD5
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M,PVH?#76=?/3WCI 37\'6+/OH)EW,1#63OTIT&Y]\ORZSV>R_>TSV>/  9I
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M_\1 !(41@$WF6AC4N? 4Y^_ZMP&:Z-D-&@,!3,!#MP?UV_?8[QV$GUY#TO8
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MUSDBW*2._MY)>/PJ*4'M),]T?:YM9SB7W#8%Q&V?!.V\\-/W-(4N^YPR6?$
MZH<5Z%B:F!7I7(N<F]Y#%>WTV=AM8E0#Q7Z1C[NE]_CEKSP)KU%>]PM@(*Z
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M],>.^%7Q^:K,88"0,++LS Q]44!O<KF.DYEI0:>0H]:9,._X.A8(1FPDPE+
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MH4 <[;T) T'^B!K-4%,&VM<8B%?-:$C^/\*"_VKG7^W\NAWN)11)UXFBZ,=
M_"* H^\Y2ZO__3+UV0). W"(C(*[5.C9KF(V!A0, -5' 9GH=?&C%+\:OU?G
MO)/61LG2IN8Q%X/B[9K8\13A-O9[-R2F/3Q$%J?*@#>;T^I<1BLEU.__:W7J
MN,EX8ML_7)6]#$3+_$+P[YQQ!#(O+82!($YN8E- TZTSI/2:V&G.>IC1@@:;
M<G\[\O4_A3+3TS1!*0;BV!I!CRHX\H^:IV=I- ;"SQ\_,5R^5?,T_F?-TS45
M;KC7NKPT6$=K6G\CA].B%+$D7 LRLEM?'=#!MOY9$=<_K_EK#53M!B8H;?2@
MN$ HD EC^8=O-GB 1OFMNY?#O?UA;9]<O74*+6^K06EDY__ F7!X316A?F9)
MP5.B@/LL.0X,8G\&R;,9B/@^OUKTLLS/PWN^X:-.M%<,Q,8^=(*> *QF1O5F
MVO_VH<O?3Q#EPA\=G_U?41-62 T*DFD,38MT!>K8Z<>%J? B'<&V_%NI9"SI
M01$MON\):N'1SU+)Y^975J!]/ Q$E-=6J62GGZ62NTE&M&A%],\DLM/UL-P:
M ZKQ<K[:,,6BGP$4_ZSN\Y]^?!+A:3@,MS&-6C]FA]P4Y":_^.-W*S^,X976
M*T,[H+H(V__($%9(SK<-;I-6#&C_#]RJ@H:_K;HH7V&@1W_K7Y'86PM5%RI^
M3T_L] JF)E?NW2I? _^DEIV*&& @9JX;=3U(8F5Z?:^RF5M+_FC34!JWJ(]\
MGHXP<O_4FR3]6"J&S;,CL7/J61J+\? <V;9_7<7T-W&57X5,)-6"Z0ITHU'L
MYK:M2V7?P803RPI5D!OH;*=0H!H\CR(VP)_$9ZP[-#9Q-:C5'1HP^83W8 3[
MVE(8:L8V"'Z9-8!R].)_T2BJQ_<@ _&6'P5*(&G/ 1S&&4; JWH0.[R8&OF1
M?QK4,5[5AS));71$!]S(-7@W7*1[CX=O\M\!2#YHZ$K[[R) OP[OM"6'KZ$#
M@)E=X=">0 ;B"')^1!!H[^*$06&KBO_EP#\-!AGZ< $?:3"9/2<'D&Z@*/L9
M"'-P' IXC:4AC> )ED/]:9PS;R;EMZ,;N+G1@%R5VPI";<)P^^Y/XTC<6'7D
M'!Z>^W8V)(V;';J$ZJM49"#>O1=C()BWBJN_8/]-U.D_)REK$QZSFZ U]-AF
M*[X#+!_^UX0B]E!E8('P8=@.S:9R46IAL-^U!T'<$2ZJ*CFF136 6&!N+E)3
MBUX71M/W1Z^4&T3<?2V8Y/KIN\F#./M;U:>\*F>/>1NS<SNKV;_18'_18)BI
MD^[1FC7):_4^,LK$1>TU#)[+XTO_.+2"0A%&G2@*N.W ]ZF?)5A]G_3]$XN4
M0<!1)![@?^:*6(<"$V_@1>'O:T.+@9^U>1]R_OLURY6AW?"TB;4""U>[4:N*
MDN/\?_AJNC@/TLQ"@R+>/V ;(,K#2[.A)\$-4AY ,?\3I9/^"5H-NY*L:5S6
MD.XAX/NN/@;B0F1ES1-XIMUA.=2\JF8 OSIL?9UDNDEVXLGX7U 2OV^?:WNM
MQ%--E6TF:C*D]]F$<([;(-KT!N^9+!Z]$Y'IA_:?/W3WD7D:5<(NSBHI:(R.
M.D=6BTKV&%[L[,<<_V@O'9$L'O&B6N/HT]RFYOSMGJL-QPKP]T]1-?K-S?HQ
MY[3[:6)J*8*E9M]"N$A93U40G]\;GXZEL!R<#Y-LB+&2C_,Q;)11N+<:4GZS
M8"A[S9;HX'-KDN3IU.LXN&RD/68851DO5AB4O93.1'#JQXVUU<JP58W16;5R
MPW5*W;6U,^EW!GY<;:J[)5$6H/B+QE4C53+S:%&8&C?X&+1L&!:.URWG"#J@
MM.?SU\!#9\]&YI3LO'M =C?1$#H(BM4(GZTLSB,;U=*5:_0':]\?+!"_&V$E
M&G;3;4>HZW28?0?>7EM*J[[M"XI=+MYS34?A:GOH6;'G/9WGLWE=&T.:K:N/
M[_GX;!$1&G;9M/[.\2G]=\>/I?DHW;X?6;H1;Z>7HFU>*E)E(7ZC>=+\E&W]
MP(J8VQ"V--+9S,#+I2??$UN#]D?N]Y69C_1X--H6,-&-.U)TNIF_1= NXNFN
ML679#Q-/&J=5#(7H+WK?^)R)]^%I)$[:O-?Y0K02X8BHFG##O:]D;G8B>8^S
M^Z&LZ?PN#M?']:GN83G)O[C?9O7<>^906.9N)<>W7QNHQ;C$<D\&XFA]'@-A
M81].Y^\F>6P69]T?M6IL2N/M>3^10TO,R1\T+S0(J3*HL3BL7.E[+ZU?+GFA
MO&<!WM\"R'T0OT?;6$[YL #I3&21N_.@?.W'C5/5N;5I%Y7E0C\B3BAO9(\(
M02U8WDIA#^=RBQP/KX.K'WZ(; :\^7#15?#$%812T.MTD;T1H2]/MSA[W><8
M&JFQ4ET>5%?)$,RK=*M/"[CUI'L?WM^'>52/:6:$M7(7YER/FA#F7 &YNS0I
MLM K^OU+E>+5P8>ZCI.:?%? G?X2K\TU%5MY+$)K?YFKJM=J26L:6RO3I&Y,
MAFV:>=JI[.,)D$AXE;P8Y7[=Q/A,1;,9,1N;%-B:KZ_N-1WSVZL<TFF< I!F
MX'/\@@I^\[#D6.D?T&JY'.;K1PYN-JRHQ3[#3[BS:_IJ=&TE.<KZ%OZC4C0%
M-AFL0&/%5J%HA7\4BM[W1Y3RT6,"&@U@F@DC:*?QBHHEW$BK&$UR16.B@$L?
MW66]\F=EK_^\KD/_".D"DJ(&:YH[]][]K$W+U_?'[U3KL,LZ=V #<'1X%*"(
M?\*/:RRLP4TV!ZY^^E]4,'^ GA6<'XJ0@EIVW@%].8/?Y(I>%V2'UQZ>ZH9^
MMYP O_,18"NZ]O/HX#;*[RM9;.NBH=K5>#V>]BX/-N#W.Y:KNF4%5(^ZQ)05
M1?@ZS(W)"NFZ$1YKF$OV06?!C2_FVT@;89# C*],65\!BL>.1T>UZ+NY@([4
M+Q*33UY.:2+WR+[=:RDV.3T=E_O1KC2F")#.S!S1?O3HU+>\;Y-O6D]%ZIDS
M>1:'XN?Y/O0DC$CTQ6J;*19TKI<[KHTTS:R*6T*X@&C%\X]4E0HJXB)]'/*S
M\FGW6Y>JL7O56,'8FABO]RG4BR8V18M8\JDN>:%=DZ%LQ>&15ZJ,M_&I/F^5
MM![KJV=GL=ET>J+"3+*\58PO).W]/&0ZWU?H:UQ6%NGZ^G,M19+_,TD@Y\'Y
M>KV(CAO+:]=+,PQ3WR</ZF,*C71<@ITN=Y9YKWE%YK8F\NZYIN\@,C!5EJ>7
M:6L7Y:8]$0Z JM3['O,0S_MH'[*!>2>APV1R\$992,TGRF,NQT=<]Z[&-.AZ
MYK"BR?5/R"GCS[SP=;@#(4('M&.?FNGI=%UR$/KXAO\,1\/!$[41D3>2/&?-
MO=7555)V7,C_V!$NDN#ITQU=U&-;61DGQ9H1-RYY_<79S]-:MP<*EPK#S?)I
MYNEFH^Q[,"?([,$%.LA:-)? A4]!6*K #:Q6S*@T(FJ/R*TO=YL>)3SP"EY%
MLMFC=J&L<2P>R4LU6&[>NN'#9-[ Z0ZB@PM=VD8J^TZ\(^6NY[GARQV/F>\+
M"QRM%<^L_458=,#5JC%M?+%_L"TVWM3^GOI>NYK,Z@3/@OR*^4R*^8!+.ZQJ
M5_?M_XU<*D 17H\L7]V*Y%I,,A =+&CNO@$LZ:H3Y9CP$0;BTS)L-)_AHL=A
MGMG6BWJS6@ZSEZ/%7MK+/TD&.6KMTS\N1FD#%4TAG?DOV'4E_,^+45S_R3Z?
M\Y"$M!)D?N98OQE'4HXYHT;1<2C1#\G!4#PJX>\GUK;"YAWFOXTK6"JG//M6
M\?SZ/WY'63P!$P-[7HA%> .6-HWJ,*CPHZRW&KV-2OO]V;2_7P\6UXH$)8SJ
MEP*$$?0/NYZ,+7'2(Y<@CF9-#"Y73ZS)Y+9@,L?W#5S'',T"?N02T+@23N64
M8R#H^[RH^'TS%SEJ52('(TTQX<'C<RLU=U7((TG*M"84J1N['?B' ZCOWQQ
M!+V?#J!2!F+\)IG.32U:UQ4HHZ&^TO2HIIS]OJ@IGR=;/B"2V$\?D!GP#Q?0
M3IBU__0!X2!Y-+)#X]]^A"K(58T=AZR_(__;EKB NZ-E^)HM;]._FOE7,_^T
M&>HTQ((D\U:-<$ <8,IUTKW<]:\.M,NY5QD(ZTC5['47Q=K@5)*WT9B\;SZ\
MBRI0RT[FRC"#;T&M1DJ E6K-,Z.@7>K8T)+P4%_$&HWMM6&M\][#(MFV[L0Y
MWR=;5_YP4%_^RYUF-,Y.X_6&]!* [V_286Q^U+>PYGL2_K4[?H+2 '<"@ )5
M??U'L;17V/4)O!P&^7QD69>!&"33]4)M8,A[BF+^VU*.;@L/KA< #^[649ZX
MK:,\%"ET-HKDI$>+[]LZO?EHZ_1FI4 MFB+Z$0A&;EY7ZZIA("C',QB( '04
MZMP,W+(+ZNV_%"F>#R"4C2QCQJ':%A0#<3$);YU)#H18*[8Z@5JXVL5 K"K-
MK\K PG4BE8$H$J6D$&B7X<>X0R/A<QA+=2ZC50Y0\6]3WWD]FD#7UOB.XZF"
M73_+5#3:_9-Y)0W#5K]1RN ?V?GK24CX+QT]FBSMS2;SEA?_'1WQ_SR+!^&E
MS32\Y9)%KA^#AW#K=*DJ.A1%,ENBJ#EO=0'[LR[=.P_X)Z)B]!*9%B3SF (M
M"K]. PS&^<63\6_#J_ZL$/V??O F &$8"X_N5OF1J9_E1[3_V;P&D'DA33OL
MSZ2@?!(# 6G9 :.Q$VWM9^&&$]EG$/\[&5NN4^I<K)=/?;;]^Q^:]C;7S'XT
ML,H]B!4YY+:#M=@O=*VJSB@USC+OO+HQOJ/ 1UHQK7LU,_YNHON%KB]?180_
M7IGPD2@]^G5,L3WO5/7'T$@?<1UY%S:YA=KD]_BN C8)0O]<#*>I%N+8\3'Q
M+\*!.^_%ZG:NJ9H_LD^=[1K2XLH-&^9Q0[@J(L@:<@[>,SSNN4Q<65E9-Y_L
M%-SO?=U@O[ZA=4>!M_WN->U$B2EEX[ C)1Y\EZ?;3_')FT3:+IR)^P$SY#O_
MPHO_:_#"X&VHCNR%SH^[?F'%JS?.^63D4VU\NYR%BJ,YOSTHF[@O,3$NLLZE
M^L31UX]F2V)>8""HW!Z<8\CJ>_0(=!V_\*ND@PKFQ\F\SUUWHT:E;'LUV6K9
M'6<%CPN<EGB>]U6Y<4;M#$FCH;GM*0,AZ%AY&K.35)$48!DW WKK]72XGD_3
M$+<ZQV]5^_ER]O+7^>[MZCYY5'D/ 6A/$,F)T!=$.SK:\G#$I"O;<?4Y[>0F
M-DB.;G3.F_V,4[Y_I+&Y(O&;-^O>%";J6WF/P#J]_J(OR((&&E?7;? P]8CY
M3(R:4/<:MS/PR_DNXDZWW(K5PKGB$;Y7.KD&>VH?IQ[>B=FG%US=F70D1B(Y
M4]CH>%N208C62;VX?7/21J5:5"W)*ZD^K0X!=3<#A'/X]R641(8J'3UX;/),
MR=VLB10'TT)R5*].4@CU(-0%"*/LI03&L ' ?20/4&U*JM$E,:VGX(;G"T\Z
M=,IL9R"2&YV.)+^>EBH^<GS:5D*V8!K]:?4E9B\]!CKI.V"BEFBO$%*NZ#+$
M_&4CUJWQ9)>TD^B@ZH#DTTJ[2T:6EN&O!0..5 2NX^@P*7)0)^U%?]Y8J*">
MMC-!58>S7W5TPJ7WY?=4D*WFV./UR^N^B/K>;F#AN\;U<O?-\ :\Q7<BI 0U
M8_E0=UK$KA<$U@V+G'4L(]@KEZ7ZNRIG*KGKV81.R,21F7:GAM)J"<?E7R@1
M)"=[<OG<F;0>I;7L5BS@M]/4;-&X-"FP@ILT=,^3S]CKNM>'G\]?P?!D9K.2
MF.<-9P=Q);MNLQ+DBG)V1]$H Q$T++^5Y6R!#=DQOH[;NH8N1(T;L+:O/$!6
MG6!9KRU(NA>\V#%QC;6NP-U?B?):./BM&1A%]A[36+"E[J?M1_>[FP!L0#60
MCIZ#I,FZL8Y8N^ZEY$1]AZ0[J<_\;^5\.:?:<+NKW9?/HV^=AQ[@>X(]?/,*
M#-0AOA(P6;8Q/T"J^S'C)-S+$F=:5O3BUJL0^_M[G5?$A80T,ZC"LP#ING?;
M$[=2ZR_ LU+K,$AXCK\\VRK-(^1JEZNRLN3$?>4L=YW2[Q/38G9"=24B<;TW
M2&&G,W2Z-O/MS4^]>F7;O*&IJ=[?H%DDDNUH)97T_['W[N%0?O_?Z$@(,>1\
M'(4H(3D5,IV$I*F48TRB'"8DR<B8*>5\F"*4RA0Y)2;GRF%R+HJ0\V',H*(9
M[E&F.W/PW+[?O9\_?I_O;^_]V=>SGVO_GN=[78VZYNJVUGJO]_OU?KW6>M]K
ME>Y%R1:(A9VUKMAI=C7EW O;WZF%@U]J8DX%_YX+G<\G\L64:"IK,#5\#V4C
MX3)%SE^>;;V+M9@:B9E1"F(,300Z>;P7JOFY#=;D^SG]XSO8T8^A27_B:9UI
M*R%QZI;]^*W?S9S-%=Z:_HJX?G?!.0^K?&2?)RM7U4]$Y';2*HDO=HO5[3K4
MH !0V1@6H2T**0?6-[-_OXTGU@3ML1OK5SNV:*/G#;^_T3LH#ZTG??-ID*K<
M>:N(=E*%3@=)A-^GKL1[L"+?K\TR3)JN>'3<;+AM_(6G;X?GJ&PY3/NFB.*,
M3M+*LL6O^5E647+@3J_!@H'1$DMW-NZ%OH?-XOB1R'V#RIG& 2BQ1Z'L@*:F
MOG8O-J5A]LD*?F7%KV\-]LJ<2>*@\5](U2OD5G@*WRBYPUIP\+(!M?.&V9L"
M]]0]P\?MSC5\E#=UW6#V4?JFZXO'7YMT6 QKA3I63XU(S/9(DS.#Y2YVZ8<<
M3(LS[QSY]I@Q/D0Y;&W&;UZ#U4#<I/?V,OX#J8+\+IGS2>=,G#F8S));P8AC
MR+*]=<A+B5[35O*G9F\IP=[T7!570EIP4;3&D.8F[2^XK70/&4SQO,N VX)\
M^V"*<=N<UO$2#=K]E)B#G<)5M+&'E_1D/*1CKJ1HY=W7F(G:SOMS%"F>R<AP
M.75L]7L-72PR2P7N $]QNC^0$9:36<Y</(H*5_&L9HQ?'W YFJ1+?FGM^M_+
M(!A+X%8XE[0/2E;&$,I_GB:G8/[Z72Z]]\_V"L+TO:4K%.Y]5S0KGWT#^D5S
MK:NN_UF!Q?_S@Q__LG#"RR5W($"#WUS2WO4NH/YQ.M'G!F,H\67P)[*_$F^S
M5/CV5 X>6<):O\KLL^TT[6^+O;\('(IVZ4H17V)^O0I@_7B:@'\<3].*A9!-
MJP;US\J/,2P!X@&F2*![V>_[^@6-/?&_8/\?ZU81&]I2PBHY'J^.)=+:RU+K
MQ\"L**7@;QD1#Z5K(I4VG)_)V-IS\+M1TC?_O#P3FJA]06D$OM9AV:[DA).]
M>6WR4LC/RSM.39E+IIR]/RMUY>#SO)?I&.:A-=B9U^8WGOP:WG)7("O2H4*P
M2"<G/*OT14")UHWK!:'!50:C64H/!8F';[]?';RQXVK'4.WM^D:(UQ9J_*4L
MHXHR?0>YC/L&T9C#_[A6S^BO7T4E(V=SVJ&IMFV$M._R*6]"!W%T 2*MV?#Y
M\_])P8?@OU#)F7_E\3"]OY(F]HV_DJM#0"__&(IS%9UC#6\+^:-#8(+\H@X3
MR.P'$;?_4L\A]QF;02M*Y.I-DR3!-=C9)*,B,%<O>\!-7+[-6/&Q]0%8UNFC
MHN^_UEH+\3\15"D!T?AOK4A!:]4I,&ZY1SM]V=(E57ZC3ZQ?I-(I 8V4= MG
MF7;ODKYP/Y,\\O4Q>[?1R4;SSV.*EVV.O;BO,?'D97I]A(NS0[=3?-[;-5@:
M0H"OA^]11SZB$3H(8I#W8&K9+)0I<?SIZW'5Y#>2H-KGV;";HVH_Q)NGX"SS
M-H1\0),PX)5LEE^Z\+MB+*#6;,;0JG_WF8.Y^[2N7A$Y?>!%[ TYW1>?TZ\$
M_G9TGURJ:6BWD"L9NE8@7_CDY4 CQR/JCU*UBS>K>UJGG3A:W]G/W0T.T% ,
MSZLJ_N5:%9QK"GO3#MX/ NR^7[4,?K_DE4V#@]LCF(DS*,D _+978+CWI3%F
M\>O/U8U^;4/R+F,I1RZZZP5\==NTOU+X1MJF\L WN9Y'4S!GRN1$+T]DDCS5
M&+^&3\3]6F:TU 2<CMVQS_9:WF+CV?(FOYA3[M;Z0'9B@P@=LR2,[3WT=L T
M:,\\<T7"FBVC^NI8T>:4HKL'2Y%P:S5PAMZ;"D%&/$&":Q3Q\L>-EWS'N"<7
MU>>U+V^)O@F3WV4G)J!U4[2\SCF]B*F:K4^.F@_^S?P:MC-<#74IXVMCV1"O
M;*(]K_'VC M#DW.<*PCXDJ2XT=./[$T<,,T!Q0ONV]\$%'<636R!)<TP^O?%
M5A[BOMM\USA=",N[&-?N77&?5R!:THDIS.%*&"F>.[&E2!N[M^D3U",I2"0\
M????0?9?X,ILS;]:*0N1)LQFE?!U"?-V'!0<8OV%17PE_'&>X+KH^,S_I\CX
M5ZBR*O*7JJ:FHAC*; D40?\\Z#[7"()//QF^W)_\97<(N^>K_K3][:*Y_Q6S
MA5<G!_8#DF=<(XXG:.S)>V:3 -0T,CH6'$]3/]4DA85HU*;[+BGW7+C4"]N<
M*T!6+<^F;<\&R!ZLP?),%JG]1GGL4Y1L:6CI]]7 *4>,3M:4TP.W[(\HX^!I
M1;.)F9S9SO[4RQ+N5X-VV)1VTEV<^\>H=0\';Y7LW#L6OBTCT)Y#E222LPF:
M2X9CL93I8F4"@U4 $H^"-YLL >Z8=95(Z@IJDZ=;X-N+GU[6;=DTZ6VC[>,1
MUOH<,R>T4(#E_AK '29_'ZHS<[=^$QD@L;"Q(6YL;L;MBY\8S6ZS,$ID/V;)
M$))<4I1+B)&J5HHXWPIRP.KR OK/I_Y>&O$'@:_Q-(?ZK?3MN73?T:N_-VI)
M=6JF=D6DG]QS^Q:)R!?"PJ?);139!7F"*M)_$U[5U=;?K_H+*M9@Y>SK!V^)
M&C9!/VV7LX(ZB=EJCKAA^"?O5RM_2O"+^C6Z_??/D:RJ9ZLR0BL']?26QUA^
M?7Y]V)Q?D8&<98?)3-</-E=MO:*>WR__%;PXW/B<Z _-+.2N'^@DSI9J%$_S
M6!>(@O'2D'XNO )3FV7\5N[!FM<#UHH>K]K>GL@YF/33K?-,A%#9M!4BQU;E
MIMP(%$[V*TLCXS/4A!4XD;)I#88!:U*O4H\,F' 0PH06H9+Q&FJZ9HPMY]S[
M>YUWJ :*857^6O?.*<2NURXA:NKN-*CE865.#'/W69-H3'6J0W_V22"8%*9E
M]DK#;N:GUITJ;]O3D?OV.QX5SK*4:04#94NX.W<^]_OD6&\8[VI9R(S F&*I
M+IB.P6;OGQ,V-S*M]=Y>C=<_4OZ[/_"3WJC7_.BX3P$T2(HE<7Q#C\T!YAIL
MD\&=0Z]Z9MC>S6H_QBB!R-'?[ZC5(4Q'&B%U_<"5@"=Z-,/$!OO">>,%@B3W
MX)7X,WW/DW3[MHBD.<EN<XRQ:V.*Z]EGG;PJDD%HMJ6$)(<028I6%FNPS3C[
M0DRN',"]X55T>::5<O%>C6Y>V_LE+7OCHXKWJKFDR>]ZMNS$ 8(W>1PQ$SO,
MW!_*N5044]9@5SNLOATHK*/I_4BU/9&U5S/);AI[*N^QM/J9VS=1N L-J[*A
MOZ[L-<0HG0XMV/OFJ.3SS#_Z"NHNP1C/*<O.3'NTU\+@E;.AKWLOZ@Z>+A'5
M[3HF.IZS?/JK2PWS>6WFV !*!S) )MC;[H7DO;8BT G*N+WUP!-N3HI4;3S^
MY"?9*V.MFT\PE7Q]M$*?/SQZT=JOZ^-N% :*SX$LE"C6<&:I0TWIH_NW.#[<
MJS-O\EE;5OK$[L-6?J#G(:#U7L8"1H^=!%(Y5OP12ET>.-#IM76P00\8\@XJ
MM*[65_;XSF"6-=2\]CUR-SM25C7H@MQ-JQCH$23X$TAF$\#)&>0F;,_2R2_6
M2M@?![]P]4H7Y(=F)SJ]+2^HS*44;[<9>WE40&!<S%6([%6P\R?MM;><?)'R
MM?$DQ]+MY(U3BWV8+.8"^<W<0,DAU<.[G%X\UCZ==_IMX]CU1PX7(W6BM/-K
M.\]"0R'GA,A@\^F]S9->SMF'6:CF3WZ<HWT]/C^?;@+.^7!86=%EXY'DS-(?
M(9O (K8G+P&O@CL\U"3#[WN%<V!1TJST0VDDN$$&;;Q>U^21>!;:>O'ZFU,<
M>O&S4WO.QN_;;/=G>^/FLJY:2YG$%/<[?[:\#0WJL*BWUQG4JR$;^O1^++,5
MC&_MLN^Q8HZ6:#WJ\S1[:^[[Z_4I&[E%]=W_Q1:)_G=>5!:OXVL.USAN;SWX
M)3PJD5%=?>_:#[>+VOIWTCQ;X+2)MHK.TX&9LJ?M;=PDZG2*H>ZV_:>'7:Y"
M$RS\"YJYQO5K>4S^<2W/LOM?%Z5QY@F498<S_SPV(KHH'N+F3DX0W%"V_V,;
MC_N=\']<4(TG-+=0(6ZS?C_UIW_>3RWXUV5IIV;T\AD:X9]7E_0J0NT;0VQ%
MC-OW1W]];7.42__;QW:R([A2\7S48ZC'#XL)WZ^X=)C^Y:O>4#]NABL%L/O]
M&LT_MLL0[./LA]I;IO%V_0^XX/NO.W:]?]W8^^ZE!(W6?@T6[/#3MAE<K[):
MXE$07\ .B"E]UP2N_.W:^"$2:%X$&;>3P-Y7Q$^W0:</_JM9I3780,S(O0B$
MG+Y DVD%2:/T'!)X\8_Q+TFHZ6^'5_])]?Y%1?QWM7\QK:NYD#I)+Q+_Y\UV
M7[&=?/O'*-#E*_'#>HEE8>\WJ;\]DO\EY>3_[97N?Y4#W*R_3JH$W9";/HA<
M?ZD!$4!;@W'O?UF#M1I^(#V]!C5L@?C\[U<<_@6N5@W^"P1>58@C+)\FC*=S
M^P"\)N$#9/>0SA5KH_4=Z$U<U;\MCOZM\OY_K/+^UUH3_'<MR[]K6?Y?[$U;
M!X$\:,*K>8\)_N1$%[0LSHV.5)YWJ;O2KEJ+5V8IC#"%VSOF$HX>\!DD7K5?
MP$#N$;\5_X'RZU33CC48[?+Z2Z.I-C <Q)HE#_$R"-_S<1#[:QGYYPNI[]&5
M(3S9D"0"Z('@FZ)]3AU J$+)Z2[%E[JJ2Y5=@P&U2&X@$;RJP(#\WD:%3N++
M=T)>YS+RY:1()Q*8-1PUYR>9MR.Y^L1_U*FIQG*VK\'ZCH*0 \56K->JL4UE
M!5B]W'WB;,<U6%XJ"PH8<9]_OH+]7Z.CI1]QD/=LS.$]KB&,U;>C18(;HEB*
M >[(N%TAS(LHA5=/"C)'=OLM RYIPL)ZOTXW<%I)PN'[9=CI+)U.I?!B]8%S
MP$KN$[FDCA:[''FM-_LW[7L*SZ7\AR'9_HN&&8&Z@C.DOXSIU+^P$$<Y"09^
M^^NHSA#^HXV:.B"OVO=7XR/^HXW(%<5/X6F$?_?SW_V$^NGEPQKGBYIR]N'V
M@_> @98Q!!&ON;\NJ>$$6SG#$]OXI'^KZ!6?;48UE19W,>M!,(-H?H*BAQ!Q
M G2.6J"X*U>-KO EV#O'3/]*X;9'LFGQ.E:?17K1_UM R/_$CG831"&"1ZU"
M-Y,3;^BTH\3!'W3]CORG"Z*1?L(%]!G]^O?Q&G:YKE--^5;#7^[_3;F F^%X
M$9I=UV#>AB/QG=>1F_C[N#Z9#9@2=UYA;[.ZW&?#\$;/I\W;7&HKDEQB-VV,
MRSY_7G*"WI1&_K@& \U"6L=LVZFC,_0(KBRJ,RMT 2'#-\6AA\MQCN3)XJC2
M*#W,+8G:G)3(M"F-E\Y&-P6+.Z0WW(PF<)0A%F(+\0/D^,*P"Z(2,BDF.L0)
M8-RRLJ75\ZR_.0Y6%^H(]E;6I^WKB]CPC"VK):5X[UPG$\J&0DD0,<7@W^'-
M4'&4FB+FJ0*L2YMA@-PP6SE .>[9]5<?GJ2;.)O]M- [/WW70OG/([[8.(VG
MPX;T5LPK?CNB%MT2M?<760$<ID?A3%G50SNE&P[FH9_[EUP36:4%NTV*^P7H
M$N9R@E:0X%[#9G7Q.NA!&WZ?ND4=$)>M_B9L>B_M]9 3*L6S>\OD.SGE\_6C
M1T\([%5Z"J^R4J$OP7$'@+C,F=Y-"PA,?WBCF3AOSU(7EOLC,M]-,[I<T.#4
M?=I-S;T:ZCL1"5[[ 5(+!?:#)&L5]8)W^Q P10Q[@7&9.I+.R^V?VIX58';T
MY5*-=-K@Z4Y%V&.Q6:0/Z8\)*I; =OR%Y)DW>R"K15J*^98X$59=LVAXQX!,
MAY?TEVJS+UG4'K.8Q2&'L-W$JTOC7X/'WX2E^/J9"'RE*B*G"PFOUF#O4*-^
M+81:8CLIK7;5MI6HYN'J.,V\[JG\9VZPG5GQML8N:(O@5=]T.3_I![=O%EW9
MJ#R'O(@$=V5S97ZR.\'7%)CU%JX7I9+UA>T8Z4TS5,(ZG?R\5",>?KK#P[<I
M9NN5#:5&KMV[SUS:N2%]OP,;S<O&Z7$L^!])8D@_3W=Z;_L>G Z0EID?H*[1
MU*^9=C2GJ_TR?U3U<G]TKFW*WC_G[E;N6=1XS-W/"5JXH<.5M>6+2W"0^%YD
ME<%#]:(HSFYP!!R>0;8E:PE36^\Q-B#@HIW4U_58UBX8-^GIW>O'-&&KR6R(
M L:LWQ#PBMRF;SZ]!$544AT+''#M'S[=SU6C4<0"+3H*0OW[[15)794QC@GN
M.V &+MJ2QDF0UO!!@+HH1NSZR>] ;2F=/(JB\R@)%!JB03Y7L[_HU>N*+]<2
M>QBV80'AJF&'T]/DDH(N$&O2!H@G!\NL!&GBJ2AZX1M,_OS5U@*!EV#:_+9;
MZ1W4C_=%RU4V'E;_@_X:5/*F5VD[Q0HYG57[@^-#:#[;9 V%A"M?$G3V5)G^
MEF"UPV<:(1RX/*9" %'!C**C;X?E]PCXGWK*L3K]JOM9Y^:T)(%5U-_5)%YG
M.>?XXY3*.H8F0$<F46KB.X(,FU?W?QH>O?;S>J5C6/$Y'VO'FNI-/R<^I!WK
M2#DP.QWF58I^N :3X.Y_CA]$ F$N[=$.,_J/;]20&53@]L%:T.<YM1AKPIET
MWAN\:*J;;R5^4PN+^^@GM*]K^V?X,\HE*JAOR)6AL)^#;RX"XN\HBBL2"AUC
MSR\YRK2J6P)9^4\] XN-/Y''IQ,-5.):-!5:,NH$31?0-</,7HXVO[E)N J\
MQSG'#>YOD,X/- _"%$TLG/JD.?FQ^%RG[,G\#YI"&VEG6&A3R'J="$&<#,N6
M+^K(4J!?+]@PBJVB>5:K&P(B24'$[*B\P.O91GO3I[Q_'NVYE;_7:DED:>>]
M7R0&I6R>4"/"* $(,\/M!*%Y][@WY:"@#4N>P]RS0[EK^2<J+L!=OPM7^/'.
MQ2NA[3 41P,_AJRR9?X KB.)U,J(-A)XC*MM4+#_SHTZMBDS+7CK^%>=S,C-
MIUFOPZI$K&2\"M!/J,#E(NX#$0B_&$T@Y(H.SI0C_H)=7%/.97YWDSX0T0Y/
ML$"V/_+.PRD,K^R'^E\4Y1V&D8R-*AHO:)\-'CB2&]@IF_#5KJ[C8$N%QJV?
ME%CD-#T$U"(GXUP*0#QBS/S4P#7>5=[E:K0"]O8[]YXGSZ8F9&XF$\("[Q9/
M<Q>['BA-)K'AHY9L.-#)Z*>J!D$FD_, NT^ DZPH5U9'44'@C2U:\@&$H"#!
M^9Y4K>2KMX+^7!=3M#MX, U_ Q)UM_#ZH*8G[V[1.O[BK &UNC1K(UQTDKXX
MC=+ZP_7>U*B\;X#I0W#;T%"?3\!&YDUU(V*FEB^,H\).Y!7R!?@?"*)+UOOX
M?539:HHH]EB+7?[;85-[Q4-DS:!4X7<?/[9-[XQ!!=(I%T+ '2(,3RCX%/JL
M#M-1(P,SA\">SI8ZEAMF6/1IH+QXD%523Y+U>(CH73EGRXRKK.%[GNAFTBC'
M!G!A]$XC1CGT^\J$%)7F)IE^D^Y'G[S:#;8L+W0-Z>*':T]>F9LQ4%P672&G
M$*933K:OGZ4&XU&>QF@?01'EQ1*2;SYU?0T3^'Q2Y/N3O[OX]I\N+ 9P#4 )
MJ"%AR'3[<,%@9C[^ Z'R <CA[.<ZL#*'DZL)$OY>!I7]-6NP#0O9'OC!RR6X
M;K7)1WL*WZ6^V3#W*D()Z:#[%/YA:62@ [$%$OO55, )HA<!A#&/5GF$^*^0
M4;AKXT"#);!A#78*0Y2VI8N_SCQ1\0*_:.*Z8=LC@MZ-[/BYJX(/HV_SQ8LN
M0EU1Y3U=@_GUJD$ 66G.E<DE)#2IL]:/K8@+24QF^1WI=SK>@,GK#;[&^9;F
M5JME5 LL%/6^VW<8'>R.4P:11=Q3;T&:-U#4>A([Q#GA:?V['?CN_./%.?<=
MI_6G&#HYK V)=W:="?+:*]?_6:0;XCC'#1.HM?QZ()=*,V<F<S:@ $^<!"U:
MQ>%S^(XFG7GKK>K;_*?]_4+5<^VK1V?;1NX^F<++/DG!+(A! [^/G*X8Z^7*
M=L!'Y4-$H%C7P\MUTN$)7MJ#+HY?PKWI:DC4:X"=Q3IVJ;$6\X>66&Z^*W3K
MQ#$EAUCM@^J"D-SKK5^_V!3?82T#H!DETQ![T2@LFB8+3X)QXWP98D(.B:E/
M*W/FVQMLMVD:#LF2DT'WR%:_3(SS5NY4/"EM.Q\D*_ G$S)<&^@-_3S-*[8V
MPEJRKX,*'/D%@O0:[-)K?8U!:YV *66P*A^\Q.EPN> F-B_3&[D[1UQKF1:Y
M,11A^5'#(O,TR9;_CJI*"8;+8V]92^ BH7[9VW*LL.*M4[+BM,;3O71V;+F'
MJ'?ZIO,#%RH'[EN)SU:G(19UZ\8'AYH*_^8ZQOH'-&1/\-*0EQ$Q:["ZJ7M0
M[]%0F]>P>K8L2J)!@ZJ5)BN")EE5WED <5:W JT\CZA'EA\.)HF//#P59B#[
M_)B(BPNG/PG&#>=!_AE(&.ODBS6S.EM(@ T5 K2J@B4&^1G7IC;9BY5+GEF#
M28]/+N3N[&.4GPZXUBC#2!I:NM*[I6KQ_JLC%T[JZNE\7V+NGZ&.:;)=0&U:
MHR5;C1>O,B,W&#M8>S=7HA*\700&72LSL/03O6)@NOEY4ISN!6GXXS^WWNX@
MV[&6FLFW(=@RW0]W!Y]!SN>EU0#TY)G")29_C,DUSKYU'-EITUYU+.7\?;G3
M:F)U7?NF71P.(+()P*&E39#7G($R^Q-EY*@#^RYD <\);%B+EQ883X=OP2!D
M*+0P$,\R\6V A\KJH&K2[<N1-^ZUOE$DE$V=$=I&.069<A]\3+"-I-"  "S;
MIW:" L#">#M_WP#7,A)YQ\HPLKC33[*D9-?Q(.94@-(6K4BSF(]=,)VO:K:S
M$.PKT""?VP7]HW2&HH@?(*A1IA/&ZB &1I5:)/&W]":NDIB:-$OD]G?6Y_NK
M?W@NBXOKWM=9S/QP_>1'.]=!I,_WIW!-\!$KFUT D!G$ %8V;9@18)[4M.-3
MWGR$"UK8B2Y,\F7_SG@@-$=BOVQEE <=R4"8X*HB$3I4=^X?:,!A;I -+D"N
MN@8;UYDQ;X<G(@#;J-(0./XS0=Z$&>+\);ZS5P+)W2;O8=/0;Q)JMQ0]EU]=
M?\KGTFCUYKN8E:2_MXK]7_Y#?L(-@J+E'.^6M1JVUP6,GC$DHGT&?^F?F#DQ
M&(2DR0_Z+AN<OY>?M7\^L&O<T_6BO8C2QC2,,1^A B$.--_Y*6NP[L.0O)H]
MMC+3^N<7O4!5VYG$L\S^HWZF:B)M2VC6SAP,!X)=X_FW>M\(&Z'I<4&>1R4T
M&?=;([#F,\/CIM$13G4#U:4HT*;&E<MY..M*)T:-O2C_=E'I JS'7C!G==MK
M%G;S]0W']N:<+IR:Z NE%/1; *\9\A8&KH$5.1[+'XY1P[QM9%VV?OF[&[G_
M,SX$*T0MA9N+;J=P=HS]YC_V(^\A.Z[#S.PR7W\--GIBF/)K9G]D)N'<1>JR
M83Y_$]^.[PSQ)\K9-9@LQ>Q&"./4&DPG&\C@=UV'D*%(46\50?YVFZV[!LOH
M!NW78!<M#Z[!!E+D>/#AF28]POM6";["'U(9UH=/2UB#;>'&).F2NU #+4EZ
M"#J<:+4#J'IG\:UM26V!-;^*B#=)?N+D1GG S1K*8IE4'9OJ2OB(OR_PAP!Y
M!1$*J%S\%$*(@L&LP3;AFRU6W@#9$"GFM]+A3#D(2R^,3M:^\8MX,=:1LS<=
MZ\GT]=P?'-S=UF=^OR=B\8C@ @7<T=M!'#/[QA<-HY/&*'S1;M;975:.!=C3
M QU3BE\N])49TH:N)0P:+&H8G6O7V.:AJ;GC@-:4E-[FQ_QH0K-)D\9ZP15>
M@ZL!#G!.&7*E>]#)RK;,<'KJ8<\FEG !J]OF\Z?.N()8QLMKY,H)S:ZM<1,?
MBWN.KCS2\-G(V[\&$Y[EHL!$) -#)X Z9.8^6J()-8%014S:#L0G-%B^\#H<
MN7->02SXVH#6/1G9O@=>#N&^?]3T#ZHJPSAZ;%\H!ZI!2%9)O$W $"4"3[IC
MP]J;)&N'Q^R_J5SVP6[,L-53A7D'??_SW2?D&*C"CH),UHJ[!-AR961FBKCR
MFNPG@^7A5*% JE2X(L1&2/$S#C65%_OZ?W*0)^YTR^J9$/?WA>U*?WC,5N":
M8A<IG8MA_:2;,W0X._%]"" DNW5\/KY-'S/C2+J-]/L1>3&H'W1H7][?,Z>I
M5="PG:5]_[RM_NSYZ12782K@&3+2'W*; AQRU*/!&3]I;C6.>M-RO;$K!$;Q
M5AYS\>'S]_<FNJ;]M([VANFI NE&'YY*UM&^,=;)TCMP$.CJG<EN7P+U?*F;
M\5M_..L5>^#V0OH]>MN/UBF52%F['!PUT#D7*+QNKVE_-T+(3TSI+7%$A"^V
MG]7*)O(>65O@K'C/N*8%('KF-V,IK,3?RSK^D.-J]*>VZU4./J7NSY]5"+U+
M'#VU+)J8MJ&R>+5S.ILI!-QF)X!;G^'["*)6X=XO0&2;^Y[ ''R57%?D(6''
M3U]5Z>:HA[[.S4>/.C>?UOMYF"_:^,(=^M\(B"(^1]:MP5H+S1&25M$1&!I%
M"'.2^"LZH-I1>7%L85%X7NMX_Y$/&K2&CF\:-P4P?(E!:';*^4-KL!H+1\ZZ
M&CUJY2=<-4.4PQXS1'!U6<?FY:^+D\'(PBB]TE"UY[O;+M:\O;6\(>3BO0]=
M'8H\J,F-#%ZIM34NG->P!KN,AMB&'"Z25THCQQ*D3/:;OW,/87N^1(Q>KU/&
M93@B'FZVU^(\/QEQO*=5<:.D'@UQBU+5VU:Z!)K_8$/!'1/'_VAQD#0CPNCV
MCJ93X>.'[ZY^361S:H:N1>P4WX/R5ZJ]Z?J@UF#SG>&WA&8*I1K>2AJK8W>L
M8T< XD[.PWK@6RH.0U/SL,]\)UG1G?^^8Q^,4ZD9;(NF7?,>N[D/ 6HU( $W
M$KB#R+"DD<9%W*%&!Q?X4J]9DODO/,QN!W"0X F6AGSV@'N,-L:_.UA:F).O
MU+GW4W05Z_ TDBOK=!AZ(OH'8G.3#'_2"4-%F(Q')4\*TB\53>LK=^E[T?PB
M\UZ]KI#:_W)W@VOMGKQX=-:YV=TAG]"@.96_B<;1P@^3  ?B1AP6+*.'))F-
M396^_''/\S"-E.1>^/"2O-KIK[*C(2%[.N(#-]^U]DF/-%U]1BC!?R(!]DLC
M4!H_QT(FKT09QJ/%JRU+/]3 I3%.@2[+FA^7$QHX\7O..6H-;,H[/;J+]91Y
M *&,_<87KZ,34TFOAF-P^AQM[ D5U-@XO2A1!R1<!#I6I0:PQFVUKQW=V>P=
MAR]75QYFW^S7VU!YN-%N2RQ/ 32BH1/414 4C;J)ZP(^"YT)D9E?/2(%WFZO
M<P^J>;0P?$OD4>BL>Z?JR5)K>D7>S=);61H5W!.@$PTY%L%6X.55P\%]YNP"
MT+, 0HF9K#>A/JR(=VPO!*H69PHT/0_:UK=B$^[YR2)AJWE0M5W+#,;PH58L
M,NQ7--J>)9F!(7^W>-+(3%VI/.?FY7Z\TL;JQ+/T(^%:>RKO'A39*&4#<\UK
M"N65K<%HBP2@2I] NX.D/2;0)/D=R4P*4 OQWC58-?0'-XK[1!I=@[U=MJ)H
M!N.CIRYAQ[U6IHF@(Y(FWH^D^1*@<&^QX66'\!IYB5^CDYE-[A!S\ON))^A\
MG*PB?*I3^F8BL*P0@\0@QT1<H/G_ PZP=W[!$;[B]O03+M4CY0+XRORN:G7G
M\M4&,V88^Y;4Z\MMC":WNYT]A[[E(*?)A!H24Y!C /YDG^QK$L*NP3B2XW0T
M$T4C;<*.(1FE#F2FOCQSXIS[5_J.S9;O$ T)SY.)F>V1F5E%WD O7_()1=WL
MK:,U,H%2*7N]22J'%E-8$!%4KI7A<00UE7DAQNV8Y"&#&](9?/&2DA$LA?V2
M=[M)&'MCWJ#A5#C'Y7NN#M$N]C:*EUT0E[4\^W365GFO]MLKT1*PZ'T<>T+S
MZ?6EX%%->NJW9CB1HN9TA!5+B@WB'LE5<10\^?9M0T4NLVPK1S=FLOW+DH5%
M,C;YTQT_76F'5/A(-U_,G*/)IXK3+9&CK73MP47R](_B,JX;[4G$P8;^<$?M
MN<T7C-V];%1?E,O5OA8ZT6]\]\ ?_'"SEQP+P54SC:)[1ARNK6\$((KL%A*6
M-X&2NE25B]K2+=BMCO_QX'G6_M8GE:^_=U17BUMZPOF2\</3_?K]DZ:4D:L0
M9CF[NH2,+>:Q0D9G<HY'?W,]<U1T5E>P ':&I<#LG%X:->2+#G-<^?W6&W@U
M7%L6VAT@M_6JNOLKQU&FRT[X J1$S3KAX5:,^-$Y1I".-'D,[^%9:63P0ASN
M#$VR!Z'9"2_&GR*)- C1ND,4,.94V>W@V8(?4Q:UV;2FF@)7;5I=M<> T.3@
MX^L9NF]>M^PRMG]S8G8BR147PC%J-NWE2O_DBQ&$&HXO4I7P^V)ME+0@:O)K
M0]-=X FUS9(,FF4?>0,B3-N:=-9@<3LJE04#4HZOP3#JLBFZ\2'65\X?NM4#
MB+C#YG$^4#I:7N\2J--Q@Q0;#B>NIC+C8E] K/X'W_@S%UY*!:..UT_(=#TZ
M4U<3=2INIWBBF,&BZ_F9[X9II)I.QC#'E-_[&UV#[*"DY!@D JM#+>*]X#'E
M;[UUK^/.%PJ&S,9C,@SFEH<T&)RXSV'H'"IP''4'#3BMP9))P#%4+%^4]]C:
M#/_!!2%:0XT[&=!ZY M>&>-BK#A79T3U0)NXIW=J4Q\/E#6+/2O<H_94U5FD
MDSH:TH:L0#93P>V=C%+.*>ZI?J[?-$F02PBR;+?>EJITK60%9JAR,.W@#HU=
M'BD:2,&NX"\"5/XD!7 +N8-4N\1[;*7#4<+=8$7$X6Q?X(?X @-<%]HGIX-?
MN);%"[G*C3F+^ZJ$9G?73*:\K"BM##G.@,=TP1>B\?Z$YE9;F@Y7GS)R#H,X
MOP:[\X.O8MR"!(C!XVPR@UQ-K&,NS4521\<K.I9V4AR^"_YT1J<@ZM!<6?)Z
M[OX!J50$)^0#(/@.6;72D5'H<)%&%!T)M%B#)2X9ZD_Y-61YS(4&74YYF:!Y
M;N].E!6QH&D#Z,=.Y\4V*7,/L+XQQSGA:*X/$)>!"2$\PT@ 39:.'K:UJ1<5
MC!PD[ZG4/O78?=\W^2.M8Z#9RH\),:2-X=#LWB T'^0;>N$_*\<NUM.(2<K>
MRLXE+ 4:(I5T;&@;]M[9\V_\D]OZ\S:]V]/A*U;\9DP6K@8]=H+KR"MH$H)R
MMP/?$OJYD[\=/]BD <Y-D^/QTOTX&UJ(,MA%"ZYIE'?(4(S>R9Z/S#U4&2_4
M$RIYX,"<K* /?U,&Y%\5 )(YP+' F0-$ILA,T-&9F?BDX/#[7R[_(L>N#M;>
M;YEBKSP;Q]7&-2,_/TTA_2)2[N^]RR"? !]!#U.A?ESF:K/BZFDH.:XCZW(6
M7V[(P(0BA\TX#KJ1)[^OVDPV?-K,<HR2RSC,>2.7^5#IOE0D_342-%WI0TXG
M(D5WN<4_"2C!%NH55_VTT6!M+QQ7O+[W?.AWV[+()0:5<YBPOG4T782N/$'F
MW  )[''0@6/-5?U2-$RHPNE$ >%6CJ$!>2,3$^..!N30B.*#RL>Z-Z9]OW=G
MI.N*N?0!]?7;U>Y#O7PZOP:K*.)N63K+(T/A0TC(">*_H5MZFC8I8)S'5,>:
M'A8K+6K<>QX1JZQ+QQPVWI5AL37HA6+]3I(O#S+3=!ZULI-)H/%\3H$.,XT7
MG&B>VZ9^MRMX:0'J54\]QFRW[=LC&N[@<.V>;>96'Y7=!]Y<WB#*30722E]@
M,_B;$X>XXV]"A,J>S)KUO#\HSP)_[#3*J#DK#/LP]D+D(#H:FKZH8/XV3^AO
M8;R1%U<IAX[YTR!0:%4Y_]&UZ?YPK>W)RV373XEO=MVX/#EVTT)?DR^^ KG/
MJR&N)X;V STFO[I_VQK,5=F12#3@2I<VTQXE]\]9%0S.UL@_F-CT<W.,9DJ\
M9@X;-0Z15!'.#GS+#>=;41Q;G%WVB4;6Q=FL)IG/)M'R2V<'34ORSP;(C_7T
M[+AT5^/B+MIU@Y7N#5WPMGOX#TC@S!H,^@6BU"".)1;%OL.[N]@D@?U&NV]Q
M(L$$&6<Q8G?M89!<T%RM3\D>K0J#SE3VD_2C92GE>I_QVPG-NRF!'DN2^$\(
M9<(EXKA@2RU"C>*W%%L!7O!T:K<07[BAD%RF4U%7^SK=UVTCFVY;Y^<VHYUP
M7?T.+%J'HTYH/D2X%#*>2Y">)PBLD*1375K$+_&U/W//3I>ACC14.%"0C!Z?
MIAA#(U^.">C?+3#W>":%$XY;?Y6!RVM:@P6BDA U(6V0]OG-' 5\FG,18!'P
MH_5&1 (\ :^$,5>X(5E7.%EA@^V?MVE_F33"FRA(%O:)%1./SOP?LS#\?U[2
M>!]1C>;*$-B76;U0P%%4,)2Z(O9^=L6,_NG5GW9KL%B/R%"VTL7Z+-O;GSQN
M:H]\=,'"S"9N&I\+X5J,LR$:\CQY#?9U&S2DV9P5))&Z[+F^<.%S'1*A!:==
M--&?7?==(ITINNS;/^=^M9_YS8ZKIX#:M3KH0-.@&G/.0J@SW++$@,)A(Y7W
MR$J"<Q"4Z1A38,[S*J+SP6Z'IBJ(&CE/>?#>NI;3[VG\=)].J*N,G3HH7J^E
MZK+ PY_G"JS!TI>F21R5:BIO9QH%5?JS?#^V*#F?^:(K?^[&AX,>Z,4.9&IO
MT_0#6GYL&2- U^!B5483:>H^!9:7I#=-K!.;Q>_'B8&>'$>N*DOA'2(5K_[(
M&2 E_1H>X!XL:'YQ;M1TLNI>DZ;IRWM=2>^\:RT63Y^9W0+WM(%=X)J#$=/D
M.TBX"2(6(=& E,R@43?[#[UUOETP7B5;5567Z!TGM\M!JB*O6"NC4RMGMD&3
MH\7OS=W *\!Y<M!8Y#O$>3!^YI-Z]W$6OE&R+*+J3&WU60]O[8K[XTNI9W9V
M:6X)ZEILWD8Q1D[G*!  #RJH2V6<1&*HXH3F"]FM;R>'*&5N 5Z2@_B-V.!O
M)^XQR-HQ>[^^29K:E[7/#-:3Y":X15 ZILD,@IP!_A!)GC"=@)1 !J/B5POB
M;UEK!R)43$A"8+^CSK':ABI2<+YVS? ]-?KQ4M6^%V9'W?=\?,$5UD#D>5FM
MYP5^)T*&@EF"N$B3!:CI5XQS YRSKJW!)+ U*WK59K7@:YB*[P./CUT&16/+
M1Q;KFYV%9$(J)MW'T1[V%Z-"5#]_4K)_EBFH5Z*X\^!TS%Z-+YE_(@%..Q4X
M0QPG\L5.<9RYXN _3H3^@I?&6DZ3$W^)(R3]LY B#99ED??0\TO&<3G+$P[+
M#;N.?KN*:]FSX=8!]4$Z&32/YXL:TTE2"^Z5_)Z<+&+A#Y>X'^Y =APN^N5\
MCMJOY[/9 \S@?B&GFV;;7IP7J&TJ!0COT+<)<.O-ASE6.&LPM,#?>E-MWVQ_
M68-IWKBX@W^0EK-+JKQ^@;G(!5>I]@>U$:K#=W$*P#!3@B.!4P*)K&SV+\@D
MMP(12M<<10YGG+/(7&H-TCD0)-S1-159SBY\_,)@<X(LEUN2(,3I:#K'RX3L
M!.I%<.4R:.%$9DD9?U(!61722E$TGN*:@G[3\(T!8VGYO(ROTB&1Q0L*W^<*
M,A4(V<H)796U"I8P$2JRJH[Q#?!CGP2UG_)[T+ &11.$,/9"'_/:?EGJA&>R
M?ZYM9O:G-^GV:$/-Q_45W]1@<FW\CC48<")DI)4ONHKS6(-M)@#'X$)%::9[
MR5Q'H?*JZ#"YCZP_N6YVBT7W@@9Q\S"[0QH;)5X+*E(KD"U(4#>D&2D#/FI&
MU\*9GC1J2JX,1_METR;6!:R9OHQG7%"_>#+F>Q!JM.! DWW:&8&1/X_>_<'0
MUF C*B<ATW2N5UG@-%DA,_ [E.E7YD@X#<CNA,M@;5OY"H1;ULI?F,Y3+:X?
MU7V9&\/V9#[8.MLD8YEH(K"8!77Z,IDKO:T?N7V ;=80:RY3:9C4M./LQL>Y
MPD5I-0P+ G>+,5^4683O]9+GW=<$1791)1O49F19)^)IEDN*/Q3,J&/)FL<J
M)R+K+@]7Q%\*V3;;#4<N@')MA&9%0@@JE5 7P@BEARCB/[\]D1K$$J35M3F&
MO&O2^V*U3T4[KB2J:)<^^[UT58VG#E$#5S#X7NSY-FXOX,(7\^!<!NOX$E<&
MH0R<K[X5'&034VK?"M>$B:00:*H#3I=?89.B]CYB)%_6/S$B[22LJAJ\[W(.
MC&<#W@-FWE$5^ @,00R_';PPX Y\2_A5\FLRS*Z)>,T\*^.H3Y:.>LI+6T4K
MX.!+\DVD %^!_Q$I8H4$1*8+XR,*L:B6V@V=!P9"3$L;#S+U[Z??35S2SKID
MTS/H?%7Z4![M[ $PC!;/^ !%3P<K_AU!''<=A-*X4-& :2/F'%"65B5R!Q?*
ML?8_.1_V(31(M67,HVR_S^M$@>C"(\Y[OUVZX0X*<(+QXV@ 4F$C.O3AV]:;
M%VK1&PF!:[#;N;IO@&^)UQ[L*C-5TU\I-6[T.16MVK4KY*R7T7:'MN:'ON$'
M^F'X.WWH7 4*X(7:-$5HWJ._!@L@PG&6Z:BTL?@$ LW+C2OE&\+<Q-\6O*SB
MX&\/GWU.HNRRLSXJL.VH.!J-;^=OXA7P$?B/4S+ -V8BZS'V-_W\P!&^$6NS
M^]DG]X67#WDRIY-Z%'V6O2?G-.]/T/<SN\_#+O)'D0!J:52%S07*LVFHL=)I
M7EU"QVWL,%YM<&O3/TLE)CY@(C%:8:WI"6YG6RJ.3*CX=VIRM G-6H3S2R.E
M=,_A#FH,95/P5U;[7&)E1D>N/LN4_Z:D_3)V=^M^;O\#J928;6.NJD::2:LG
MDF#3^I2+U%O.A&I>+_-AR'0090O92BI7Z@U+A_VDCYJO31T;&F9\15>EG(CX
M$X,TKN4UG"15+KVKYA53V7UH01_ZN=P-ZN*$+9!Y)L.>)5/KQ%%5?RA^:S!B
MQM?()O0CKB6;6_,SHIDRULV^R4)S%1QF%!BA9' -U@N&T- Q;[<W/@7#.#O[
MK+N+SZ&4'<W'Y+=:+CIK^KQ_;]R2A)Q^0:K)9@IPS/%]R$KS6WCQ=9&O< PD
ML=@#K;G[:OA=U6_X P/JN]TE!MJ8DBA6VZDUV-A3^#.^!/X]H2K['7PS=KP9
M+<97''>=1TIS/5^ I(ZQ\#EF^R^+\I(2(84!BTE[C;/W=85EQZ64Q&[*Y,JP
M45"XN^!;T*^^M4'T)HE026G&D$0#WZ9EFCT*E57?,V1P^?206UZN';WB37WZ
MT.8/FWU-0O4V2VW:_*Z*#9&'F)?\9D(EJ8WI,4WJA*<11O%[^DT\]I]&B7M@
MPT[5-S;$+=BF3>IOF9ILG^WIHRQZ&VY[85SY8H=W'4>1T'R8XKLT_O,82VB)
M,<"2CS[VN\5E_B*= E]8U9[*+OG^\[6/\H2[9Z=JL:HF,[K -?_FU9<PD0QL
M+W^3$<0YNEF$5%.RT@A.C242VYE(=E]JRT'<PFMB;LAGEGRD1L]65M0G">E_
M9IP1^9'AU4VGCBBP][.HC$PX0X^^='-U_^^69$\#?>N!%IGJ0CW_"Y9Y1MV4
MGK0CWF\NNFP1GC6+)-_%A7&B(%4&J;:8,S@\Y.0*_'$(.]Z4?Z=(6;EXTT*D
MP8QFY<?YML-?ZFV>51NJF(_J>XJ)QXT&W7ZRL(F\OG =#('IB29!_B1!PLHH
M#PQI7QW\3;P 1A9AK$WB?M*&:IZ[=5[Y_*Y.7^(3\['S@&[N:=G#FG/XBQ-/
M:V"^H A_TT5HJ)\!R;*GV'R^++Z,C&F29SEGTA&2(+'=RWJH1O_PB88!S]E*
MUZ)<YI.@F8A+' -<HDI NKEN ?X-.=5T"30<YFZAM/(-Z@%>)U,\.OSY_-LZ
MME?)3*-YLW+C<-S+)?,[R\\'\VHPQX-W6C5O30G>^%I)\[OAF#&[B9>S!O/M
MO:6 K.YD"K"B[ %H1/IYL0.>D<HT RY#\?2DAN1O0XU]1Q(]'_C>/+#]II7'
MS&^N-((OVL<YBKLPA/1'*N*TATT(*M@D&X(42&S&6P^9N-7LD=4U+GCR)?3-
M.X21XT0X&<5+I9PW'%5@"P#!^=/$4<OI3]FQ92NE-?7#Y*;A_7/LTKV3B0;!
MB[[ID>\GY@[O.SLU?FAQ'XAA=ZV_>H[3 SDL<[8[@&:$L6;:F]2&3"$X:;D1
MDM:@\^)[3G9\C=KA _5IO^2RQI9UO;YVN:0>](6KSYUL4Q7CV3V%/\8K08BR
M?D$-$M+  9H<=ZX6",.9SMQ^X;G@&)&'K7*N?155_^!Y4N0C1X=G%S[.[WKX
M476+HG>FW6PAU+X\H=GH&T@NP3DCJWC]$A@T?V+(2A.>8FK'-8\N"9$,OM0O
M/^OVW@'689;08:=T#"!+<EUY#93I8G1='5, 0$Y3F<,0G8Q?@\%PC@&TU]=0
MHEA;U)=PJI1GP_'E0 5CJMX?>4[?D';J];<K<^+F_>C-080 Q A\6J2-D$"J
M,V<V1K!N'^[3<%B2!./Y<C?< V]<?'TH=2-[[/A5E9FO)D?L[BTV!W7!/L%N
MP%N@)&')M@,M.3M[.=)8^'39';388AF9N=B@4N(YL2#_TR;*JFHBOW$B_5CS
M7,[1.?[IUN#/+X1U&,\@3^SA)2$O6"*E PA5?BWB3^0[VZ\;N6%R+A70)SU<
MJG/'D+NU=H043Z)DC>AN JZ#@L+-&V$B/53 !@7N^GT3"47#Z#"-> =O"@Z<
M?@-2Z5%JQQRO]J) GS+W !OFHL'D=71T!@,6G25K=4ZUR6GI2>8$^),O/K[>
M-!A*]W0ZPM)I1\D3_/S=7[X-;J2/(V-SN*O;GX3+%BIIIO_9E;+73>#TPL>;
MQ,9VF%,#E !QE.DLI\DI]Q&</,L@F\8\REP,:9#(PYT<9EP3?1[V9@U&1PLM
MM!2C7 ?/6@9URLTCJXG<+22V%J]D%DA=@[61XY4;T_*G]46OH45^J$NQ"DOR
M/.=O7!D3>F'O$R;_'4C:3:M(,_)RA#+V>LEGWAJL=3,4\V8ZO"+*I5[$_#!>
MFV7U]C#7?/#99[_!7Y\.B9*#E"/=74\]33.KS').L_>4&RD^U',6U<#O00(G
MJ:-Z[++/#6YTTFV*5#B:T2LX=CB<_L2V/7?3D-4^H90MNQ8K'YI&.5R\MV'\
M>,][UZ.R"CN5KL*@2>7P15<X.OB6ZQ8,0E5$J_F *4+N7&<HG22],/9IJN3%
MCRT=FU(FIJ8<=O5OW#SN=+U]8OQ,\#YV$CC30@#0AJ V):4!4P@Z'8<25O'X
M_.I4N4F93,=;\JV:**1DH$)!TJ8+@WXU'DY9FP4?;O13-7K?6X8?(0$08QRU
M9&]!P<>@O"6U>'F%(-^[RUH.Z(A].A4X5EO>!^M_L(N1E^5\9G/]XV*;"8'+
M=S>)U/9Y&7$0?"JA"LWL#J'#P9,Y7YN&IV2SQI!;_/DZ0'!!WI2KRJVM-ZM=
M@".>YPYOW?PH>U;C+I;L]_<.Y_R_^, _(OZJ>&VX;B <4'$%2^A!:%=>,;)J
M<;'A8)3I8#QWJ_EI7L[1)Z-Y4^6"3*UR6G,'AK0&BPOG/4%^9Z[!EEOJUV S
MF:M3B+37Q[+4I7(-=CS/H%YKA/>68H,Z,W\<*[!Z6YKR*&!Y,;?D,:14_QCP
M1==@%?60W_07__BUVJ0..@*(:3,BRZG5HHG(.4GP]QP#8[HP'G#P4' >YWBR
MQ9[VQL=W)@YX=MYZ/#QARIHX^V3.;6K;8\#TK(WL0,VOB)]VJU;Q\6$]:OD6
MD;GJ9R[J7'M>=JWZK9AN7M.9W^L'JL/;X.!6%Z[,##N+5P+AW<.LU?@XY'0Q
M20ZO!.J=8Q$2=Y&MX-/1.@X)-HI?+J5=BF/;*=-U,K)VJ<SI=ZJZE$-^'4CP
M-8Q!OHKG2M?3T(P*CI6_S#Q?'JCK-!2UO61H8/7CT4/?+UI9F,39=]1=Z9;U
M4K!N[[-G=A+[J*,8]@D>9+(+E#O.:[ -R$LAD->VF-(</ \ML"7T.,Z+/R__
MWE,]@'P4L:M2K=_83/R\'TR@W8E'IER ?*R4_1.T7H,)( .7XKZU>\E$GY X
M6/WLY=0(HKKU=;O.(S^3/:GU1!4@[+V)P((I2.7L@WJ[E^+7.T[EB\,Y$5/<
MT"%N^"6^ JONSH"CN@1KDI^D>B[ 2<FJ#[,MLO/WCNK:ZW,5OU.C_::70'-#
M_J:Y:;C"O)<E0&(\(F"@-')?8?5B-\Z)996GDN#KIAF='GB<&'?R^JN=H3&;
MZ'762$+S1LBF]Y$U(AUD:7S?>C''Q?%4=(>UWEL'DA1&"G>8)9$]-F>7KNTC
M5\8-W2XMZWU2TOA+Q@%%BC)R^O[41M <0KD.'@2S4,X?-?C=D9-;QE*A\5]F
MR?-WL3*_5IFLQH]HV6DD.90HME6:?=&0VO-G&Q'4C.] "N-'",!15+PU##1G
M.<^T>FD"OUL\T *8WSFV]\-1HICK%MB!*>>8L]ZRWUGB"4-G6C>D''3RZN3(
M0$8R)EP@@#H>V(<4'^KMW^JRUKOE"<"]2+[^8#BJ)CJC=]F(]RP<F5G'-":4
MCM<3/CTI35-@WX2P;ANAV9S@3TG.7H,AK$X!UK];ITP&)VKKZ"@8MOXTP%U]
M)).%N5<T8:/:TYEU[WZ]^DM_P=;U/&NMQROE;R$T7VK2Q[=0E9!!1&6<)T".
M:Q(/P&\=T&:EEJ4X>4Q-3!UY&1JPV>>.UF9VX!\,7]03LL\TR.1XXS;Q\AI<
M@-M\L0 6:?I+%;Y?W7Q WP2Q,?!*YW/>4WM1A=,=TGY^(;OU9!]*C@P+V7W"
ME^$[_RFI*6R)NB^]C#K & 6PGY7[<*+:S!4BE.-*2Z87V]M7)M(GCM57-HLS
M-L[JEN>S,;R,=88_*M[J#B63-9@?8=UI]Q=A2>W#4SK#D%2J"5[D#[R8DC4W
M5RF_>"\C,M7ZB)[RS-RIC ,(=<BX%&LS0/T69PNVE*V'W&1"AN'L07%ZV>%6
MI%R#>>&Y3WNF%H[4%U9K/<EQ\VD\NT>O7NIX<$E"_VYK(]YCPIQ]4!2_/41Z
M#;;@$8:NL%;EI4%=,-R$[^?K\5Y9&0$_&$@I;NA3#_\F@^&@FJAV1^>>"=V;
MCIAOT0^?V]B<)77]/'0Q@JFE[M%* AP-1QZUH"OT.[DRI%:J$+X7"%P8^CI&
M$"&TV)98?R^JQWQP809=#8Z;GR1MNYS"5#PG!AOFY5B%3E/BJ*_(K015[A'6
M]8=/O^?XM3"W1#NX#(7DU];4)%[[+FZ5_OY0WJTOZ4(X;VB*!)L(1$0UG+F^
M)R  A,>VX*Q "BM7A1 _=H?-W++ SCD3(;6?>^R=C&J9!:WB][TOW/?O;N1"
MUA7^1FA6^B5QHO<,A*Q&MYW,-A?V#[?E6@RO8,Z,?X[.9?-=$SH5=8_N)5?B
MMDZOP41QUD!C?(R5$"W:\DC?M=(SM?V_4K=U66(\]DIY7TC2?6?W67)#,4P,
MQFT&.AG#@"EAFND8UO8#H)Y0N,N'N"/PJ*W%N,+JT&ICT_W5N\>9,C49)C85
M/?3.;Y:E*]8-7\?9QWFDEVNPP''B^(WQ=RIX74^L+-9BI@U27G5^UQ,,AACN
MO ?=[%#.+Y>?&_%^BM2Z;8W*-ZTQO%("#2  U=E\Q0B^$IDO16*\CR"T#*_!
M[MSFN##K29\ZV81%W./(*$*R9=584SPPS-4B .OO*0,/>/$<-,-H7;]?"N&8
MCUV'FW=1?T9&_0Z:[#'*#63*"OQI!7J=*L#0-9C(8=SQSUR_:SDXJC3RTO[M
M/YJASIZ_[<317K:UNI+Q>Q:]TT5WW[A,[6[1?+[X_A>NV&Z^F"9'$"<)#/9[
M81]S(S+:E@/,&.K^U?7BYW\K&.1GIAAPC=Y9>\Q8>B#<^*,$X,0ZMV!S^ZY%
MZ[$+0*1P8QBM.^LU,/3&KWAB?C7WGE[0Q-!P5KJMU8',0R>M.W0+[C,5OT%9
M H0H-4.? P<Y)\%Z0(<FT<G=GE-&&EG"!4"<A(JY45+[WOK0.;2CWF&EECF?
M,17_R<=BL#]+M*(8KE[9^C&<2!G<Q=+OSL,66?&<7?ZM=O6Y&KW^?H-*VOX?
M."GOZ\4EKU<97&E30]RIO?X6P55]P[I*M:MS\!V" -11^!^;N_[U;Y-=H[!?
M,Q"10QI2,N]/"D7?SN=W4S94P\=<W'CD:I)@)%HZ? TF[@&&N;#@["<#D:N^
M,DIYM]\''!>O/>1QHT/UURY;V0!JY=*[1AWV@R^4R_N1[Z;0;4'H%BD0?8JE
MP'[2]_/:@W*)MNM0:.[Y(YYH'V+DLT4]-H%^$[FC:4.S:2=7Y0<GLG/C<8:U
M)M?]@JS?G+,6Z2F,U-)4"@Y$L"1_\B7J&QM!;=.VL5E*I7YI0'I RO%/2@#7
M*^ .69M+,@ZF/MK;N9=<; U?7Q:LLGU'B//:"1H#G;2S!46Q#2'E@6\IR2:6
MG.YDT-2RT8Y49Q*S:&]M7WGXB)'BQIM/55V4UI=,#)#>Y!%TAWMV&N4BX78$
M7JYQL+ISH'P:$OF&E[-&Y^QS]KY<7)RKNQF2>N)"JAWLY@$M*7@\P3OD%AHX
M@R(B@6.]\21Q_D;N55ZZ 1Z.S:?IUV8$/.\&>MUS4!4HO[ES!Z]]*-F(><7<
MV7,]QF_+%N-[K@05BI]C!-L&FI'I;'25.=.29>C(BH_APED*3OVF%.F=KP8,
M:HI?BH&7+YP^X'NY4]%GR#AI=:"-"AP@@]L5$JQ0I3]6T<TD*3"PN\V\+((,
M^C2CMX1_4CA*>9CFEMO2M;Q72AW2&0IIF4SD%LIYY,AO^F]&OA]'"G<$E'L>
MB!2OGMPSU'H,*&THSI+VT/4(V]A%]_=-V;RKF'XPX^?5JP(L(E>!R)?3X9JA
M&?^MO3?_AZJ/__^G199B[#M3(162K$5.7;+EDBU)8BK98ZZ2;-.<(FN6<.&*
M&))*ELF>3*:QC"U-D7V902DRS%"G4[/X'N_O'_"YO6^WSX^?'\X/?IACSO/U
M>CX?]\><U^OY$N6706C8"9BMN$E<QK.X'I#M0X5) YX/E@BI0M.I?'U2#@&1
M=:HD\CR%H#C>?I:A-L&3'C8FR40Y=5V(3"8#<R19>-WS4Z.Y^7>,X?+=,.W6
M@,.V"SW6%>]V=1K2WFW!>#H+TS"-($^J4"#ZE8OG7:;PR_4B,J5@8"Z"_.SO
M$622*'/Z%R^0BE#GWYGNTS\B7W#XQ;U>S'];#]:V/U<W1@IL+5S-/<.SX->!
MP4ZP5G,7,!'I!2_.@O>*,8,_T<((OW?6Z=%JKXY"5?1R[,5#CITOO% M>O]=
MY9:27_%7YS-YD@R!*(6S.K?2POG>"8@:LW;2U/>_#LF4"2D6@^.KOM$K[:+U
M+&[EV\O4'M5JVFK_N> G8VP=DN+G@)=P*&^>,3_'<M>B0'HH0H?>%+S6==UX
M>*;\>IS%9&%E?G;TV-7YV >MR<Y;C+:L SR5D.I%",/^BQ1WH??!@%Q&2HW%
M]S#3)M^1G])]J*6.[;XCY/O,K]TX>/\&BB<;"VT>7,DL*<AG=;"3F$[4-Z#-
MZ*%0'GH#)78#D"ETW#'B51CDX4IN_;3;2D=3&G=^7C21IJ E/ 8BYIV9#;*=
MB.-#T#U$0$IA)38*]J!AKI%;I;_-Z Z7#MT;=;&773&B1D"2GEK7.Q5=3UZ4
MVWY#&<>3S!>(QC_!.[3"F<\$]'P#ZFV26MA7:AE-^1E/PS78O(/_Y-L&*HBK
MM.?.I40-Q=V7=^Q  <8\Q\HEP6X$#/88I3N=:\V;957?_%;@*7KEP4G.5K,R
M];ZLQ_M_B.FL.L%'_<%D#PS[U&I:/4^O8';"X?CNI;7%\8!C]L/7!",=EWLS
M>Q@+E^;[U@UI(8L8%.$MHTZA QC? EP"Q?#20QNH69=]A1&7+.1>^%Q<DC1^
MT]69?Z3,(4(WQ\#P]-J.0YZ*Z>6W:HY0_#+A?<1E#ZY"5'@709Q?3$ [/@V<
M,:F/HW=.F#3.5;MY-;0V)02<NG.R8FK*5M;KD/^Y#&/WB'\4#[NCMLV34K"U
MSWAR7M 8/WX%\/\&!I+&M\[/HM/)HD(9F?J)!*60$/&VO,LV#:_J_#_YF+T[
M76LO(W>I6EE5]<J;G?.V/!DLU/ );\W&0$3^OY203-'S^ CX.#L5+?P]/&KR
M1([;![)7@.[AE/('MGNG+OS.E[3?77#\W5O6?!#=6INGLNGR7QZY&)1'$2([
M!<U6MCYK><762NK2E_3Z)JY1-""XJ[;4+EFK24.=F;S>%8-E(8B__3D_%0S!
M2L&1-(8L>4N-9U1\>\S60(+:*&_/_&T/J]:Z(??[.YTA4P/A3,U'9M<"XO9O
M2T38-0(QGPWY-/J$^1QEV8 ;BE=@$Q,).CR-VL$(<8?S<$350&S)]UO'[EUC
M]Z->N1ROW[6KZX"NU=<T9:XT.1("^'<1E<&..9P<:<".E\WF0Q8"K3<.=)GO
M,1G5$17!,0/M6Z4=*OM[M8I#2XG!]2Q'5J/-//'*_SW[2B>F8];.DST1^XK4
M!,&_Q\.-A_"!&ZCLKCDZ5XFT@?I1^OTAJ=\ TTVLY-&7\?4"ZP:0BNE5,Z6"
MOW5]$/"O+4!@_+0TY63E^E<FA9>GCQC2L0&$X,I%L27#/Q\9\L2**]< .4ZD
MP,8,QP;>[7^<^B=\;??CU&XX?IXNAM=E2[1PS+MCR#&$I-F!O5_/CN 6 *W&
M<K*C[F!SW6-#3#F*@$7*I>_FN@MB<Q(5-S&!T#/FY9DW87@MKBD/> G'<ZV#
MP+&FR- :S^FEIMJG&9K%"K&>"DY>A74<(\<OAD7<+-0?DD LG%,&I;<@ W<1
M?K;9_CWN!L_= 2T3Y"/;P&E.-%9L"'& (XKV&CNT)N_R,+ 3R>OIZ7,6-;TG
MUJ$-$+$(_"8#;%=L,B!B:23XY(#,F_#\.5H6USNJS'D41SY9@;_Q\:;A]=F*
MR[$Z:CK+S2)KR9>;#0\:9KWQ[U&D DX@M060$>QUXBK#1('H=^Z9J"N.IG.8
MY?FY%/*>.7V)I?P',Z=?6[<7%AGU:I[J,O)7R)[VM+1U<+;=<<>RC_\0"$8G
M81L8RV5,QL1\QX5_Y8M5.;CXZD8H.YHVJ3BS1?-C7S=*T2O&,D9Q<K!M![\8
M"=E+AA(90?_MG? B0M+)_&<1(461U O-G6HVP/C767B0=>WAS9MD 7VH]$B7
MV( &_>;%?LVGKEEOO7<<>?:9HLS#P^E<44$?L<&6I_*%#?VYS-EY 1X*8-+'
M_\QX>MULD^;@,\-;['H/X$3)]GZ*4OW1BF8:<C]_\12\(*-"YBI/,N<T;,6U
M@,^%NIV&A<)G;V.Y!T7 V-BG04<T(X^\4NJ5JI_JZ[;03+L1N*T:CN8J@=1_
M+(WQ1^KA+YQ8@=BX:0<F.68X=4F>(6&AS2;:O6;_2IRQEMY'-)W(?48^4)1M
M-WA5C>K9GAA6!FU!QC03_P^_#*%>>@81#02"XD$$!9C/-9]:NJ"06?HAAT ,
MOZY6-3BV-%*Q_]K)?_;>.HN/N^)[I^J%92VLQ3V)W\U_;"D2B&W MCNIG0]N
M0W/DTPJ>$JNZ;A0[W\T)CTXR2Q]:\)1[Z9*5^_)L*N\#\@]QP7G$!BSB#.$#
M:!:"WHOIW1V9&.\)&$>]\$F#C[D0*F/3VO2Z]>YK>QFCK"-V9CB#EI[=J$TO
M& $R*RF-%-:9' *=PG;)5*)6P?-=/M+WD;N)6;B^MBZ*^RY0#RKN6YJR#=IE
MH!0:5H*_4SA^]<:-VD3 %LD*<R"8GDE4 W' I *3TH55!X/AD%ELISC:D2U?
MR,\/$8:\JVE$S2';!2MI>\M%6;4APY>T+=M285LF;GF=<Y K$/_#SP69I91Z
MB0<!,)5[9 P;U=P!??ALV?+X=ALKHDBM+^Y=SL2.T!+Y?7KWX_<8KQ#9N%76
M-O97J)I?2PD%)VQG]ST-XQV=QRK#MN<&_?[95G7CVYI!Q@G+Y>3)K%'86_%6
MB82M0%0?S9,/$(CY<B7@ (@Z0F$VQE#N';*P>KZ4-U R0: +9,AV0N4_1DI2
M+DP<F;QWLNT;[?I[0^PUGC.,Z+:0[(=-TQ_3W:&/R'+SV8E?W0,F,W._3L /
M*^"=-G7W/5YYS@16'=(]A0[9I2^OE_:\=/1+_M%=*NL> O%?R"B9$7HQC5]Y
MTO-4C+JE3E3A7'I3\XOOQSY[.,,!<WD53ST3DLZV))AX3;ZK+9V(UT3_][G8
MD? <NX2M#^!)QT**E%$+ISF^3__L:#M+8FDMU*KSPJ>)7%[RNL5C?<O9=_DR
M]D;M^_]M<K (-$?@K!A1E3@67#8?L&S,).XD]/K() Y!37#%G+T ,XXW:+MG
M-+.+HU<C<^[-FU3G23W=!_P2H]2W50]67;>7@M:"75$><\)W!3)P9#L@)]A_
M,6JR\P\A:[OE;D[H2&&H_Y]&YLF%J6CYVF[9@_1758$E!YE^R;J@3)LL[ 05
M\1,V4('5VP02COP*@D+0N6)5^$O-Q?,\;_;Q_*0A%E$<KU^A8M=PV\7;(_S,
M8Q''R5#IPZ\F^A?L]SA-\3$>@WBK)Q/?_T@\P\7ZWKZ6+^^1EZ.;Y23S_&J6
MFOVNJB>2)ZG;I4[([R<] D- .);(T^W'PI?1<  &MJ+4/N;B>'H4) U8  MC
M@C4,0!PJ.5._9Y)(C'Q8;#+Z)DI#(.,$__4C$_;$(,8P"_1#%!L'7HDF7N'B
M\MK <1Z#V+MN>HVQ'DJ+'D 1H@6C1#D*LY2H!#*;30"V$S@.0C_)L,'L=GZ!
M+V?Z4QY6_*9C](JQT.B^6L3,RH@H?3(*5; WR=2\?.-=2 ATD/\"""/&$=GN
M (+<U - *".C0)NV?Z5-2KM3?QOO[R'R'EPIHYPRV=:ME?NSO)1K9GXOP1-E
MEFY/+Y 'E/EU%'^ZHN 3@QV^HXC]G8II1%A?:L:+0)/"4E+:5!@G<:!1T%ST
MAXE61]74R[X'6Q3??\LIEKBY.5^1- X#F0\I;,]5><%[L#$I[2>04JP'_V92
M6, ]L &31GJ6[SFL=\VDD+[+J<TF05E*>4K_06WBJ;_>+NR?0R'VH7'SA0"A
M"Y%:CXR;=&3R*Q,T&?3YXU<Z9Q9G1-F9B?H_!WP<3MB9BH=<WD7:Y;E=^,'!
MVG-B]L)JP/(X]Y:@E]+83'6TA1)@&4[9W\,6!TI[PQ625U=='42-CH8.W>[T
M^#"M>V.<'+1^.-=C9^(7.^UU!\AE$&0^/L;@R:U"D\W\0H$.3X;]*SV_.\8M
M^!Q%GJQ1$7RL2J F?R((%P@U/PBMEY+;+G1)[4'M%Z'87V]QL%8^:Z=IY@8J
M.%-6,(7!M*D.A'(=>$<;/EAX/>5I?PQK^*^JZ-I*U8[R+S..)ONB_*^3:R4X
MC^(1K/K 4T*2?6ESGS=B0;J.^2?,8I-GCK0,&;^YHJ9OP[D#N\QM*9V9=C@<
M9Y0!CT=[77"5M+/+U#:O'8A.Z@9@O0U4!V-\7;!3.YJ[%V_/H3T+85.LX7V_
M)J9BP/8W.)>VS"YPXL7SVL;R1W4#H="^[?W*;UZ!__9I"NDD<I)H#/@@ O(@
M] _[S5>6'- .9 #US7>P-NRJ D;2M9H?:,7%"5][\82J]. !O:*/Z1>TUN8M
M?;/6#PL]P;J,3NM1F-\<MSHD2573E\TCY5K",TVL.9=NN?_<0[@B'!:X;<4I
MD2B%U^9$SJZD<)S>1D::*NLG-[PR5ML7.VTR]SY(;^$$IYYZ(VM@I]SE?[/D
M/K'[1/:2XR$J$H]\03?PDD8IC<+,_^IL?<YSFXLJQDG IAT^ZF]&(N[#S@^&
MM(K27/MJQ4G<;K%[92A[5YV9RO4RR%C0@6%?S]QL8++3HW<#=>\ESYRMS3NX
MVC0_@/R%6];F.BRWMJRU,3Y'%T:M&Q:@_H0SFWFR#$B;7PH$T&4)0T21ML.]
M53"6*GXPJD\%)Q$L[/[1/]EO]M70=DRHIXV$Y%\.+'/3+=AM2(+M!D,=]05B
M>[CN2T2EMD.$F0V4F@)-GV/:&<+,C+^ 28H0-Z<:P#&?[)IJO2D0-DNW77+P
M<,&BULQS)=//IM6$ 6 L0"!QD5_J1"7I<$4(=((Z1A:LK_V,8)\;-,S%$)LS
M 2X 8@M5WGR/%(@C6IFSF]/-?V2: ?SX]FD+),PRYCKBI?D9 M$0;$, 2VE>
MF_TKWN*8WOO&JIK<B%C(Q;CS%J<V=?" WT&_/&-=R03QEF1GNZ]@$&ER"++C
M9^#(HD\%@X!2J(6Q?B==LKL4WFU)C+CY.G<Y\7#%ZXD#\IKO:A<\3Y]JI5WT
MKQ),,>H;\UDXK@K>F?]P=6]Z(4T@].E'H6F^8N*25Z3\VCK-%:?7_5J,=QH.
M4*<@LWN,3_3]Z)>QM.[.+]Q 75$R^I;;H=?UK+."]'#OK95L(Q_5E/5?21,W
MS&@G@!L\;ZX+?B=;GR4ZBQ[WZ!0<7;.X/3^@[_R)K#\+_^BO*%@:['6O\8_V
M32EM=M]5HE1D6CM1^)^4#V9SL?(U"K,(4Z_?E1[.?-:)2;M04TJ"SQCGT%["
M /5830LZ\4':"J6X?>(\JP>5G38Y&C3UN&US@_9QP8<F!OLL'3Z S']FF4LN
MT9ZML/R3R=CZ[7TE]]_A1C,/SQ$7X9.Z"HI-X:/;MNUMQ<(F(0*IS;>[/$XD
M3POPWT EI%D:1[4*%&PGFO@D;CCW+\<-5,CT>A@7R/K5&C!SQY+"\6"-<[6B
M ,BF$&(/$TR"ZGF:\7:9;J!RD/PZXVVHC_N]8]TAJMFUTB]M3B1\C-^!JO2E
M6;@C(0SA9UD>CPJ?"T R8QPWMU!;$U5F ^/FQ$\/=<;H)T;(#LX6#[ZW\4MR
M"SPW_36]KZBVI_/(2V[/6T)((#!.Y$CHLU8(JJ'(E[P*!F;*@^VE:\#\I$"*
MP;IMV,,UL<1JO%MO8LW?^L/W'[$0GMWLH<\^76TUR[AK9'[;T/8C8<O4A: 1
MD]KM&8HY-I=0V]:U6S2+'5'1JSR9)*B+O8%"G!WS/B@&7"-.NLT_&V?M@4.#
M*N!NFN!@6_35/)LKK9_#6Q9RQUX<?!YPR\]=*%EX@0(?$.;)CS*Q--SX5^H?
M[+(+]Z\H2ON,82M,F=W!E2^=G7;KR)]HBK]>8;MK;7)GSV736S5J+N^L[TBT
MMJ]<A)LS@%K$XO=AV(X:'(<^Y-&N6)K",@)YVTD#"*@%GT:#U^C]$-90Y1>/
M&&DQUY:+ .@C=#L !]#OQ"/ZLKE#X9E .:"=PDY<G81(/^D011\FDW3"D-M.
M?_Y:].^6/]C_;=N7_\,E_#6?1LG OI3(XN1TO?9(HUS;0"U77QGM'.4$OP[@
MZ52? VNGJCOCSN,[_ZJ[]D]_"^$<S79'"Q$.!.!]JWP,3N KCCC#]%$JL6F4
M5XSKHG,/_$&<[*, D@&)9G!TN33ET>U[1KC?W U4V@;*]@A6Y*7BHT)Q]X7S
MN0-G)/J71CQ2;WETF.+.,1[^H;,]YO.7MU7RKK+S<IF,28#K<?XUQ_C>A7,/
M$1W_[A[/RM>[KIB*,?B@&SOU8@67&Y[SEO1A0G +O(+];<&X!T)N/]!\,RKV
MH_%MBO"\CZGXN3-2Z05P="L8XPH46#YX=, JP?"1W,'SJ;DMB[TSS^I?-U3[
M+2\.G?OI^#M!U@5["3PN= -0;Q/"'^(_%4A$W6>B:12T8V644U=,R*)@]R!S
M^-"U@I7Q'H94P8C=%^M+AR?5(@\<O"$J7//XC@%!!:GK'NV8I )T>V;B#";)
MGKV::!3BK7-RD#6>ZCD^V?FR0RQ/*_G\Q[/2]O/9CC=\I/C98 !]"V&P[1"?
M1,8PT2_Q5IR%3+^G412?I'.MXR^\+ARL?ID]UA?ZB_9"SD\JQ>1+Y*4L[$,B
MVW$G!=9;Y<GBH/V8QM4$"K/6878Z[#MVI*J!)!Q,V6IA&O[,#O+(IJJ&7^S"
MJ?:K%J("K'7OIFQ)IF)50&H04@F<[@/L4YA$8K-V!]^UXRU1NA&=7N 4QPO:
MEU/NY>-);W;)GOC>D\'9YYX1.*RBH:?D[T[8)HG^J*\.4H^#OIDIC,9?"2 .
MJX:7JO]DJ0OK.!P#$\D7_N1.J'CA+Z+$Z_[66_!3<&-%[XWT9E9N36D>6ZD.
M)54_J7O3G!'HG_;D0]_=W$]I<KO9)U4E@T_SR/#MN57XH"T+D1.A_?Q*@A!/
M8[,GR1(@0E9C>W3^$<I,,G+ Q,^HC9![2#]^/>QPC [3^NTCKQ'>8GE9:<N)
M$G0PQX.GTH&4P(<<I^0(/4\PP-'!=BBBLB.B.LJAP])RY.: Q!_7&PZ+4'/0
MUHJW*E+NAU&36'<88.I3*4G$'7OXQ988O-E@ V:[5^!:T+D9Y8^A">4-)MDZ
M.K3[\H.%\;6Z(E?>>9EGA/18[H1#H$1^8MLNGBW<SXT!J2<:T6FO]\67]M:H
MG?XUVY138A+OZX>S&(UU.^.NL..4&(%PMG,K?QY[B-#W&N3)M0K$>MFONZ%/
M(QNHL/O$\>991IK2*D&99\@6CC-BV;H(>M=%FLF?(G;^N#'8=Y_2GW[*S]-K
M9]&=;:O$\4DH'#;D[L=+?P #]._X[%)&QUL8!$*OU5-Q*X>Z&IPT^OH7IGHU
M2?E9[[W'UC/NB,V!OB"L;;J\^6:/;XDP6B( :PG'#74K/_(0[(L;]6QK25V(
MXM%UGT2Z]30MM=V\H[E'<NN.J2UIN#'B+(8G:\HDIO <F:1)8:B&O4IS$N5G
MCV"W1]5:J,BGU'28+ IU-?XP>;8\6(+5[#Z(6L8/,/&-F[OYQ)^#__/+45F;
M%-S,26K'LL^K$)/8L,-\4@I98Q8A(LI;HGCPK4K<95U_])%;<4<?GGXGN885
M+>HL0/UR &$3#X%(5A F)XBKXO-78<JX0A=6]D7<&:=M;MT7(#5 ((K@ZG9H
MB!) VDGHD^)MR\,E^4AP4J.>6;&+?J5%W"_$L:RSRCW#+":;0L8ZZDVS;O@E
M$7_BQ>8 9AK0_(Q&F6R&S#BF:4"@M[9-$WR7/3FWKYF)E5M25TW/[CC[9BA/
MGGM59'RB)J?[@:7KTF<A5RE" *R#S%$]?M/FJNX=KX(1;7+)E.0%<VUI7M[;
M+K3$TP!V1E!%TWD+Z^./'"'K)OEGUT0JXB4D3%6;'%&$QSP[^#H3A^ @NI&2
M ,C@#8*JH\([8\[^"6MY@K5]K=)O7V;0+Y-I<TXC33UJ]XC'6\P=)% ;*'],
M?#$&WL9VLVH=LM">]=KB6Q+47# \4P+E]=G;G?J5W6^X]VMPY5&14I=_7I3@
MC[([H*M("LU'=3"!A#9SO.7F+H3%@IG&FJASW9[Q[99F?*+1_ILMGU\U95P.
MU1LIKITZ=:=M:*^.:GC]<3T\BM\,A)+@ ^"R#">$2MP1X:4?!S2"5+KL13B\
M\_7?\N<*,O+^##^<J7W>EN$G;_J"I)BC-7?I7=VQDB 4\%<@B;Z3 >MKW\,!
MS(?R&ZB&[J0VM5[M;L2Y VR2KD#DB"ET#Y0RC18O;]!,6G-U8N1I8C1061I"
MI/]9++*=,(A$B.*/$X7#H4[XO44LYW#08U 13M0[^+YO6_2>0Q#;.F"7P>_#
M*VM9?6'7U:$O+U&'3)>+N$ SZSREZ7N4L.!0'*P@D/PX![*\*+^WWB:QB%>Y
MIH40^/,K^/#+;V('!2>G@-2;<6'H%O\YWHJ)E>?] T?S22]XAIRS/AILDPI<
MI??85-"%?WVWGLT>//_PPQW3]B^/<X)7;28,%L\Z"],IC=T\Z>_0 7X3.:@<
M[P9_8;_X'-5OU6CRVBF=IS>GPY(Y'\?0_+UCI3WP2;;^PY?9\NXS72<T"ZK9
MO@)1:ZXH3P1VYP@SO\:UH;V]@S#R1L,OX5S39+)'Q5)^V][F\PLIKG-+2W/V
M=\Z^^@^5=A=/T]B^T':5_WBSX3_5>@,5B(;UGE*X6P4#6+:S.2->7>(#)8"K
MKSS7/9N10#+Z55UQWUZV$-Z5JN3GUGD/K9_P.Z6F$-K.K]Q A:XF4=ANI&2
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M;'/D<@X['[++AU@<(NV-N4!.\UAH^6].34[H]0JO-V_><;PZ]FH]NM&_SZ_
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M41YI7D%\/IE\8/ZVEW4]Y\![^[:FVI94G<1K35]U6OH-KG0NW %TPSHQ'#&
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M>U_3U-S2VM;^\5-'7__ X-#PR"B%/CGU;?K[S(_9.>:OI>7?K!7XS^J:7@*
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M6)Z8,'L['V@.)K:!FT%/'(Q!;BN/6'3QB!F.HXD:Q0:P-WE:+YFGF.B;_O3
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MI/(SUAEA/T3>6X^^-,_$\,2RUKHB=D.8Z1J]TH1)1[DO%[Q+X6U,PU9;YO%
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MP6M&]\MU=E5?35LLN$6&36H?X($$5<(JJ+<HJ[4 )-Z.G-\Y$:PR-J^U/=%
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M1V!'.B=$)'* ;P#<M:X#Z!0V#@::?PPR4M,"V%7_QSLPT%"_\:5AH/GGY<!
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M7;M0;R=JO,>+9)[-11TC+UTU7]@0T+="SOQ^QO(31PP2!(64?B(Q3Y,O:<&
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M,&0];XA1&C2T5#0//^]SOS3KVQ-D1XG:((;F#XD9<Z(JB 5I1-XJJ!H>ML>
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MP&2]) ]&M]+>5.56X>66F.9)61[@DQ>"P-^1F@@PURLG*6+84'W&XYGHEC7
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M$&E2!JK_C]]G_?_V/V^DM>'_ %!+ P04    "  .@J-4\#+3;PR6  #&O@
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M;Z_"*+B[6)L8;!]0>9+DL&@V-W]&RYYXK;S#F7V+UP)"(ZNDID,.//DH).>
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M1/W6ASJXU517)NY\7_<L;M.CU^OIL[<W E.3(6KO2&ED*D5ON)-.;-(;UN_
M;";LPA](:02ANH;]ORC2]:;0R'%..<U>\]3>.#O-). 8_8#%'!#H;+F[2,FZ
MFU+IT +">T3:D^!=;92.I 0T9%-(C"=O(&S^=4/J7I9H)3Q%ZU*Q,9;^\"%+
MO2%LVD6CMNZF&--ZMY5.^(3?Q?.\:,('XA:T_T("*+E,D>9]I;Q=(@MQ++P(
M7WYF;7D')^3!2>R3J!TN069L"0WUSSIJ[7\:[,<VO!!&C)F(5V7R 88D&^#X
MP5)0H0W"55K']\.8$M]:X<?5CHWEX^[#=A+'+S]\<-CCJ[PG,.M/>R_+FD"J
M$L&FK>0KZ*@SA''*V\$P/=X&6.'(EWIM.D89K\N<K%XE105F1XHKDN89.^_+
MW_01?7=IJ^!6E=J@U5$:IKT'WO5@[?W?\[S]> ]N'/X@'Y 4%WWV SZ4"P\,
M#+1/.9_>E^/W^MG\I9CQ5M%P@\3LHW+W/R6ED .Y6)[8#V227X1%0;:0+PB=
MZ"3>OX!B=K7EDEKU8LB;"-MG7.-=3V:J?KYAF^I4I=OG8<L[=2Y(02B\'/<$
M0#LLA6).,->G^)-\TWH]7"Z,[FC+_:SW;F?,U_TF6=2P#>:114[6+4@',RA)
MCD@VWA3Z\W#(5]FR*M/S2F#/9)-,:T;2C4HK>_\O_VO6&-*.C4-#KY?<[#%L
M0;8%P]D*I<<@.%$>5]TH+>_/O64X0:["<&+2';@14KRXJ\R:*(7HQLEOA5^>
MY&]^51;J;'WSKRO!;VB0;(']B(W?RC,0&J$LVZ-_(R@U@D3?R $^\,:/#SPA
M\OHOR%H2CO#>,?4X:WM['R_Q@0]$6>[[=#[0T].,GKQ;S3&JYIYQX"#TF96.
MIE629]/!*00D*P8?]%JO_F@E+Z[5VQ'%![:C1H=)' Y'G6==![;X@]\,^,"G
M'H3$O4(0A%>0SW,"V?8X>SFP!&_'!]!\X/=Y\/>V?W;USZ[^1E<S/!E"+S+Q
M*^I=$')&YFPC(QYK>;L> 2&4\?RC=HI.Z)WI!D^2 S<9G"Q"L86[.'WO3Z3$
M+G(N!!Y-<!V,STEQ?^N*?W6#)/!\^EQIQ4QWB'W.$F8RU-12SGDN:NS?KR$Y
M/R,,7-#EOC%3A_(_<Q,:-L$WVM4.?#74"BBB,Z.BW4[V5;S.=&]X>:NWT,[
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M<;1J?]IE()(L<=4LYH>;N?^M"XL'R-O?#?08O/NL)'18+ K2.>FPM17+2]8
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MLI"YS*&3\657?:?L"S%9(0'7587[[D\]L2E?*O-PR0P8EF12X*P+6^OVYBU
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M1B+2Q:!LB%$V7EX;A/#K((2+^X?17[(A17G3]J")GT./_NUY@&MA#+XLL$5
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M ZK!#C@;IWO[F^Y;?SSY[D=_VF#_PJS6VG5C][&J]R!%>_+I7],<J[VLW?=
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MZXGRN9=<<,P]880-\2L(U!R(REU\5U':+U-7RUII9T- " S#" $F=!3Z#/"
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MHJ'YMWU3JC!GZ/9EOI3SKK'/,)?>BS_C/+EM-4E@.>^QKC;Z,'"3?HO55Z=
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M;%._!\D<?G5,JEO2[6P'8=_%P'V@8VEAV6FQ7H54<9E51X'O#1+)V#UX#'N
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M.-']AN''$"[-?V&7?L=_JU)6O*RN7$A+TXVDU68G8,D:302T9,T%?O"!+Q]
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M*&$RVI,6[^F<7$=]RBA9+HV/?(/)M0U1W15EWJ[Y==?'C5>?F>;I>(QNHNQ
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MOO*!W&:$%7YW-&[<+_")4OWHS;A;TJHW0&.PU&SD<^)W! <2FK']*B,)S>!
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M#B?PM]EQ/G#Q:0(<:83O_ZDO'5;#.;R];<J/-'YY?/WK8_7S!_J_+R9 1#[
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M"3*/==-@I6.AV)@_^V?L14!D]FLD*F6('VFE$PRKUW O;1V\C>#>:>;QVOF
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MU=HC0&\2M D57\J9 1,)MDR3)OF,#5V!VRY[Q,N??%?F@!$U/BN0?/HZ.&
MB]MRSB*)N:9W=@9Q4V\G+.CM*.*.U $8C7^]]U7!,6:3I$R-:/9CFR\9?C&R
MJJMWMX;,6P%N!-.O7"<Z*9*J$,&]-7J#95R9.]E31NV-4CD:_V6Z_$K#*Z/^
M4/TD*:-ZV['<S^GL>* @3?N9U)^XW?%/-DX08_P1+2AG='^!L+@^']"*1L^>
M0/CPUW%RQ@CNMSPXT+)H]F6 US6>D#R9&<UE_G[V=QO_/[N=Z-'[GXO.AR$5
M/I"8'X+Z<5,)RQE9\!QX<-R*&!^R_Y^X._,W[E*N_XU&ZD(J'TAN1+%U^OC
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M$Y?V-?2R7:;-*C^_UO)\'A"0/6WMXF((MU!Q\6) ()8R(BD_;K 58 '6\=V
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MZ$_&>V72HREU<QUWD3;5J,T^!U4S6?ZN$P4Y'I\UJMV*,Y)ZMO^,KTONF3]
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MTD9"?NGK-J1W5]DWY"=]YN)>*R5W/6Q>*:Z&A#B2O] ;R+3G2/%&2XXO?X(
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MQ3?#3+XMKEO8.7WI_#=G98D'^.*&AJJWU9E\_H_]VR)-TWQ?77^S52CM,PH
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MYQ6GI$=KV0* 5V#$UY^$*';:7W&^GO1$CXW+L\(=!B\JJN_6'S,HB#D@=_-
ML/3C"WO$9N?TA)?@Q03'ACZL\5%"D/18\"H;R8-Q@58:7PJ=&J9,W')[)DV7
M-,VZG?%9=GOMNV%5]#70NLCM8_(+Z3UV'M\ZMY!M< 8O":TF].1#;43?)0%0
M.;^]9JDF<,F\2J)!>7_OOJ1LLA4@[_B_ON$E\-^VQL83O/N@_2I3**Y\3NN(
MXD74/ _9=J=/A>(V'=UU?R40R3%RXHUR%K<Z2'8_C?[MTG#UC@U7=9;10*54
MMC[DMT^N&W%U$&NFBIG;L&H95D/WJ3MJ*BJS!X_%W@:[39;[MEL.&;0!-Q[.
MDC=:;,;JLR-A<]'XDP)@'5YS%B8/7\R]0+>6;,-*S+VLFG<#^3$GO?,"@X_.
M'SE<W*L+?_8J%\^+)-!2D36ZR80 Z:3;B%2^)D2D5?Y4<.7?]]X]CO4^_@7?
M\8K"Y^\?\Q( 'EIU(H?VEGL'9 -K''8 E,,YSH7=$WD<WWM[9OX]Q\2&=;;#
M&;VA4<57,;8,=QGSPFV\E:(JN9H^<2I-2/6.O/SQL"MSP)PUNC45VH%@.M/0
ME+X61(4-5]Z&O7N@2<6=>];M9Y,*=KPE%^EQQ_8KAGG)3'9V1*B4ECF T5*P
MON1D^?LU[>'O/F84R[^3*(FDI2/?!F;%-^E!W<T$X16>2HL3 F$>2#N4D^C/
M1-I@I%N^6VGWO-WGYMIC(>MR5DS(&6DQ#/9M]84QR-X>#>U$SX>9<>76];5;
M:%?$3BFG=E)E<KK4MP]7106S@[[XLAR*/!PDL[2/#]I]E^Q\N;MK]9Z/\+(F
M^^[?4PC<=3"6*Z_83@4="&-9["WU4/I4CU'S&B'>N-2!&Z+PI% B?#1^NBD\
M\+&KY<8]>E=]KV;;/50P^1C2 ".5>!3G"%>>2/>>;WN%[[P!=;.?0UDOO\VE
MXW9^,0^4O(V*G3?XCIW^BC'QU=B9^0[](*[6]M,'T[?*TP1OZ"42O"$ F&('
MDA318S.M?J4I1\R"K^*C?F_YQ!]';KY%A'2=N0HSK0CP#(*B>>JK09,$](LF
M3Y:LQJB-SU9ZN&'M+Z1>V'K?(/Q[L;'"4MGH$"MY.GZ;YE9@39_>UXD8KV6(
MM5+C^4J\2IB\$*6Y![82(LN\^\TMZ:CX/;]J#C:8R\5O_]W3*#=NM_F<5GW&
M#=U/^#/Z-#2D%<:D<PC<W;"!3''[6&;SI7 F_H:*NR@"W:2K3#&D-_\2 #(O
M^H-6.FL;WF4RC7-0E9\'2S2#PRODE[13CB<C@MR6I5M@_SBFCI+8WZ PEDT+
MM2*LZ[U15]A%1="AI_.]133F$(52 IXJ-Z)LW2/7H/1MWOH:X'57Q/L## _1
M/G^3OQAD6W17&!P_IR7T*^2V Q#AQM'D#Z*E"0%]8\069+51ZXO@;.D4''+]
MF\NB<_<.U[!B(T_GI^X](-PYJA5D&6DM%8RL79V'$1</ISK7538;]'I533.*
M[4,FD,Z>'2IC!C!%JTM>V>?<"]RIG)<BIR\?T=T9FK;>_"Q?JED+!BTY"Z'O
M N#S>X( */2GL*GC9]E\'LP%+S\[U ;BQ\@R5\"F^*EPP_E=)E(VEO4-@]/8
M?LD'[N9[;,LQ=MBE(];B;0=H=_'>_)XF55ZD"0+:A6QQ@)FIS*UR'].#0>6Z
M3-/)C75-:(EGF\>C!P>^NR.T%[)IY$=O(ULB*X5JKZ]Y\B568$O0>-D$7^DQ
M3<8J,XP5@Y"?R]6$(L!]+AAQ7T=L*WO<MJJ^LK:Q(9)5\ORA9O:-78U5.1F9
M^X<>1;> R 2"*M*3.-[ %V_A&/V"^;":1I<;"PU7]$K?_!!*?&VL<)OLZ&RF
MA=SNP!Q44\/F+K6/3X-L'V11VN]%Z4CW$T$T$=)+G0_DF.+;!8 "P<LHF;CU
M^1?^-IP=9$#JH!$W?<RCGJ3D]/G?\-\LVR;<H3[;A)H\./6F^<?=PU3^1@,!
MH%?&RR;/W\,B!<#)FHSE+3@8ND3^[CO'\3NI5:OS9\$<]F5H"ZM(BM"%EFP2
M@RX.=AT4N7UX6:J@9STQT'_G$^][&ED!/S\^GFCIM+8Q67:>K^1@N"H\$M>3
M=;8%N;$DY.L[",E:_ZNE:2?Q_." DO97I@ 83O1V0?0<[=+:\=W+VD>XB)=/
MANFM"/XK521$\'<;A'$JKX3RTT*G-H7JE-ZV5I5IAA'_E&;L:TXPO\P.N)(O
MF](L\S3U$Q(R,.+*(=DP%8\,XG_(58>FX&$@R,.L50!0U+N[LM6?@-9++:[3
MO^;JV6\.+^\P2,RO//#>NF9?Y4:SX(3\!].(%45V'Z^D21G?AJB8@=.^OU&2
M([6;3A7U108TU0XPN>.)6;ZR2I>3[81OI=NI7BH7;_C=KJ>%/\QO^UML42%M
M<D<?19+0<@KY=W]I\CYUR_VS;C@#R,V?'AB\= )R+K"][AD_T-YUX\V)NGT3
M22N4^WI"1RS@6CQR#)O%D.Y$J/ _P3@G092G^FS%,*59LM@FO6[Z^!^#'XU?
MJG)L%ZJE3 \\BK&=V;<S4TQKF]C.SX6]L)R(L;,T&ZY,,9OR]_$'7^2H3?-'
M<*F-*F=A.,K5A0KH4@ILPOP$?N1<<D?&YR\-%7_8 U9:D8XQGLGM2\1C\/0C
MEL60?B>RHI"[Q;O%8NM7KAW=Z!YZ\RLRJ_YG-B[]VS@6[5J5(/'>X;+PG9(=
MJ@&?UM,0NN(E-KGX(6JU=W,JM*N+6<W1Y_<(@+>QR2,,Q5B\,LZ]'"*Q4)U;
M39*F3GX)O%7W;<S-P3@NK^]=FHNFC&3%TR# &T"XX;\@0&LRI$MB>G..^!&K
M"IGVX"ETG(7&UP FTR"0ZT":M"N<O6XEWE$QW*]MZTFMO;/'*?C[@[;]I!P"
M[?Y!PR=@-[N91Q( WH2QF^V4LC><?5CIKJTFL6UZB]5VF(#E9[XE$RNE%JWA
M+D]>) 0G.-^0B,O1^M#+M>$J" "^Q %P$?9 52F9*QMKQWNE0LLH>U'8=I.5
M-V5<?WZZ8SBQ "5^HC[HH5K)W@:TNZ6& ,C?(M-,:E/LRUJQX<KJLTG_V+TZ
M#ITF5WAS9<D,IV=%/]%258_55^W+OX2HV,3KA")\L]VZL4W]QA7ZE4TN3^)U
ME>6%9A#J!%H4$;1"QZ"%S.^PSK+C( ?#[0.+(40%W 6669+1S'"IQ_E\_Z_O
M?,M57U]WU#R2=-ZY.X!Y>)6KLCB%II@Q=+FRFK3%)*2?P]GS9);)CX>W DT,
MPI^02+=>W#DX.]C[V2[4_ZB0LU:60Y+=+CON+#0A $3S_AXBP4%*]O^U*(8?
M%P#5YFAI\C6CZ*9M3OU\97>?K26K1/EJ'X1^1%%$&L4J\63\5R6F<M2'9N,$
MBSE\-QZ&_VK4_!CG*G?S8),I_R/^4#5+,5(WVU]MGV/%P,(NAE30Y-GV<G<K
MN=?'&FP^B*G>.*((AR4F#KV5K\C5(+,P\RP0X)YB!80I@+/XS1:ZM?UI,Y\S
M'+^G_::[;$\Q-M#$E;3K##E=$<4UP-0;VA'&3 </P1PX!,3PQ4TXDC^)THU(
MEG_[&SI)E'L41+9GC)1<'O%*_EXSB+ERYX)V] ^9^OSB=_:2GBI/_. DT8)0
ML##$;>.EX+:78O6[<HW U'LKTDFYZH--![!]S=?.#=U"B)Y8(OAX'-VU\VK4
M#X6?7D<N;#2EQ6B0]\/KJQ@!:;DCJ[+FTV%,$OE0SS)*7L&2_5'K$%NYUJ@X
M=:T1XU(+L_<Z*COROP9]KU:LE2S=6>+_XZ5+][,$VFZQ61(3 ]O] E0 :O+%
M96 ZU[(?+X;OJ(]M[U/&$NGB4'=;V/#DGL13-3!_]47YL%=?N86ZV?O0:S)#
MZR?GW;JCMWD_=/#'=R!!1V(R 8Y:?Z0B'P[:&L)\K3](8M3&<!%BB55QMU"*
MAM4%V,0C:3/SI>$89+K<]A1:B8-*V<WTAY%BSRYJF''5M*^Y'-7GB'XX]_"+
M &CU3OV%8BDBP)O4V V+G,V3,.L2KWXND>W-W7*6W<++P^MC^=*0+I$KM]#-
MP+1A8M3UWH$_WDT1-N-.QAY+;S]86F8Q%IA_A#U0\E+C6'S!K03K2\)Z/]XA
M(-,&AO4S5BIMA&G)"K/I#S$P'>Q UY!20A(]#KE4_S8R\'R7Z/#D2JXYT?#\
MIBTCNO[K]G6$UW)EB]DKO"SD7_ZZH6D[H<6<C"'%3=&IJ7PUW*F11>-?@?XG
MWWFS8M(C[F@/9>85AM\H?[]T/UKDQD*ZGI#[4^>7A)9*_NZO,$^3X+WB1I1
M.IPVL^P9YHNIB&.+;;?SU<_W9FA]F:TPR?_(E3U^H;-[[$$"P$&S:WCI>%G^
M.$*4A/2FIGB[IK=2GC&KUJI38LM0A781JGOC+?JTONS]L#WX^<'B'5Y3&N3=
M,,I3WR+F_^Z%C+,6YZE3)$A'K(T(.9$1*XO)KM;Q= >5EK7W8QC9G_/M<Z>I
M1[7*=*ILN96[RBQ.T_8%>J;V(Z$=-LP5L/OO"?DV+)%="Q6^H,X-UVMT8%[Y
MU/NTUV=P%Z?'QQ>WE9SHM9Y5VARG=+=K _4Q$G0@0CM3N;+W<=>(,..#%_1=
M/)4BG? W>M3&"V)R7KE 9AX1^O3)+/TK!A(GI*Z>1_7%+QS5L?86&C5..RFT
M3.5N*1N887? 79-AF@N>0"OXNT:3VZ25*+^:3*!W^;.4^S4]#!4#4\DQWX'&
MDR1V6)WSTNG=W\1WMUF_>H?>PA6"SL.*1\,#M/%[30GEQ!@R70+RY=BZ_9J4
MAY)! 6#?D,4QJ-97L5VXQ3RAI/;D2ITA0\>K^?=0W><4%-Q9-*"^GI="IN4A
M*\VX6S =M]7S;H)M+37UBY%\PSE*$-&@&WN[ZTR4@FO2&]E*WC-#9>Z(>.C=
MA+T#>F5G.Q (_A9X):$)M+?4RLP7'&5L$M1')\Y3,22(Q#!KES+MO5Q05ACA
MJU;S[%6;>4*Q0?,MV8HRF\R>7L_K@,4#B R+_S?W>>,(4!^#2C%B9T ;< 0&
M84OW#[2?NA%+;?G++%ABKQ0YL.6)1G7RL:ORI_]H9<ZFR@N J. 0*2=J,Q+1
MI,[=PZJI9"#OXC=#TV]\! !0'>%_.FV>X'7\.4HT_[?LH(N-3HO<]S<&V\4.
M%;<2:"0JZ((8FV&,,*.+8/EU&\,YYU$@7/''MA9VD>+VS#HO^35M=SH7"BX\
MJLE<,MZHL=]E(5]</.O\M^<E N Y$CR)IBSR-U9SK'&*A&@B>)*L.GLP*Y*O
MY.;JBRKPH4BMW#_H:EMAO"/Q@X:O,O>=R].@:X&?YUTJCEB(\XK(M*>(2M2\
M%6S^5%X<7Y.K'MMA-JG#6FRGRILEX"P95*6+<[5FB0I/TZR4Y#YXQLL49JTS
M1K^/>K >>>47"\47S_G;%;8;S$S_TBLMB&C)>\7T+H>VL_9UV+%.W*#W.!+>
M)KIT^+V(<HVRN)9PG/<A?6'FA0C_';^'6 73 LHJ[54LQPK?FWL@M;U)DJ5Q
MBF)8N^41^U?P]KJTR6.:=2D'% />?B#O36)^^+#MP:8?"7K/U_UO:AL6F 88
MYM6*IIH4'Z]C:6T[USN?V7U4+%*ZP*9@UO5BO*=ZULO9&G9FO_"T&Z6UO//)
M@?WG@4UVR.0++^^*>PV55C.K,L-J6#V2K\]<*#CR:<YZPS;PJ-J;Y=.B'@C+
M?MSAJ\83PK9_#WAWU;!#?\FNN_VL""@^YWA$U(IPV;/(Y6.A7^CI;^.?HZ]%
M8MORWLR? VV&"U[>W?ES32&>/K[]%42P@3M+7G ;&R^QW3@7^EK8Q"]!#R =
MY#T6 %ZD* %08=;&$0"QZ/55_HEW'-S:UXAQU<4-O](/#^>]H7Y[W]'S^7?N
MU5!ORL:?<0G['2\F_LO6R9:S-E^,C3:-OR^,77:S5\JUU.SP#BC7/S#7K@?D
MBED,!24 >B__I0646YD[B+"*\]XXVRA+2I^VN7%^.5G."N0]&+PEI3'<.7:A
M8OR_2Y==_2_CGWO_Y=;A$VOCY[[>\K=/S#'5Z67XAX1OTWUCK:G_=%-N1M"_
M/+\K5-$ASS*6ZRQ+*?!0"U92?Y[">#Y@[*'2QM9_Y7/0H3JC(LUI<D T7DA7
M*_JTF,FU_R'5_]&-) M340>4,V12]&V.DK1Z!BXX[KL8ZGA?>OG][KLK6.'G
MS(OC1T3E'?_3-G6XXA-9%0!INL6$T548MV;M2+=($C!LW!$ '^6&R/-WA@G+
M^2/UIX6LY/_3-C$XO;4<%@#?X^>H[,._D&MG_"?T84))RQ4 OX^O8#CJ*T3>
M#I.%1X"CE?Q_UB9$)X HPA^-V[6\U-M]_$?9JR= F&^1N0\/N_&[WL-T^X3#
MG8+_+1NT_T":#FX(M$1#C%%;L[V3FC3ZKF>ZUB96H3:YYERUOAQ>Y&>Z%E$>
M^/FYM<Z[Y&<5)YY? Z;$JD@M:&A'7RQ?GGN05X/?"2WRQ>F<P]AQ]& (.GE2
MN ZR8QF=^6)4C=DPF[LNT7DPY<VK=H/:+M_K@9GS#HH9/WH](K]_,&^6GDA5
MQ+:U\H5!?.&4 %#ZE;D6FOARMM)O:UE!,)1 &5:BV%T+G2]*^(QZ3DHR3H7V
M]_$W*A?_&@Z5X-CZA69;O'AMD)R:;(**71MZ%670HB7"P0TGBDM&+57NNG2S
M077DS=]:GKO][_[/5\+5L64BI.O5%5--OF^Q[>NB%M%AH-JN6D4DUV?*/L<Y
MACE1VG*DH=1=SU'WF]"?WQC(<+4+'7-1@A>S0AKU;B-*!W)]6693O8DW:'WW
M!8"D\?C5\ 7#:ZG=6^^FYBNPMR5&'0JTI2CQO3C-PO,$=:X3Y \VT,L*6>D,
MW92J]RJMV1:9:YF%#!7.UY2!R?ZSX4_R=8-Z&J.HFLH?2$_)U\B002Q7+HM=
M!M7FXV0@1U;QZ<1V=9U(.ZZ*=#Q7K<CG"Y2IUV*XAAL99MF$W-V[Q2U<-7J;
M*B[K[[.CD!&#? \-VB'&)/@;?[&$.QR*7:'8*:,V1 QR\^+VC,92ZUX]M4+W
MIW(RV9U[GR]%N__6[R?39AP4;2%XR8M4)[+O@RE/,)<9R$BJ#%>?@1+RH!PK
M;WH6HE H6E&B?62TR?U[H"JNN.O3;J$5,>8+>-(#O+B_:VVM*YI[F...N_(.
M[%A-UFQ,;S/-S)49JG8Q<AK\Q#DJ?*J:>*W/PHA<>ZBN5T6"HP;[Q(%\A30^
MY3',->/LY)[_VF@53A^W+0O!DAJE2V8UE JN';]$27XJH7/BX?U=U@< F8LP
M\1(]R'M"QA!5_V[M5V*8]SA27 /0.]X0+^>3NS?**;$K5S?0]*/64*"!P66I
M:<W>&9\G8'SJQ%V7,,EE0KD95[Y[*K;=B$)UAT$.RZ<B*M4*6\E)6\.B;>*Y
MAPSO,8R8#M(=V?MS/M[).9"@V3FKNUY1]&V*G4?!$;&QZM]EY; $=7!7UY_$
M*E[LO/<-CKNO,T*VVDBQ,+JTT>25S^T,NL?ELNC7E6E8@]P-[J=PE3]L7]@>
MB@.RUXK(I@1:'7\#B(["&_+;@[&6K5LO/J*D,MOH;J5'JR8L]DM]75BJ[-;I
M4)EX\B11-<U.:^D((O_K?W I8]%<.2K?-K=4 'A.5@J  IWW XU&_(V+ D +
MY20 RA==!,! ^L79?YX6;KAV=?7%KBDR19_S>[9&?_[%0,M ]N=8"D]-"Q\$
M[C(L,7CE=&7\?O2*DKC>&>4SE@]KQ=P8U:14#%X1F]9-]UA6:-++.=*(DOHV
M 5Q)X#8S)JC;DE]ZW/^N+D2::6 'PWR6]@@IC=^/,X%@5!/-X#TS1]%2X_9Q
MC5D.A9U&LMSK R&>NG&XRSKE+TUR"]:7JNSW:>K-CLT*3K.1/\&Q%]:HO(L7
M %P<[[F%)+Z;N'$%DT*L0K1['&K%RWP9UBSZ1:F*OE2[Y&7K*7+7SD K[BY@
M=PT((9G](TX+$6]GN/*^W'/$\MBN_5Q_F,">K'D(/6& [+PK-<DA,W^4_+NQ
MQUOX/69[LH2]M;QNSEI(@](MJ9NYLN#BO5MJA^Q8R'N,+\O+7YQ^GQL*#)JG
MIYA6/;;?\< =]T8^<<>N"W<Y\3^:ML(Q<G[<[>_?IEPCT%XZ98;.RCMB$^D#
M5O(^6QRMX[$ <!U8?BY=@@P@C L ]BE>I+E9/C:1G0N]RM;*U6PRO:C<'U U
M_LSR['#0^HE^RAC%1FO),SC(RZ'XO=GN;_O0[/U_MWWQ']&UR67UQ,K4]C>8
M%;3X-QNQ!-R>4I^1VTZE>0V1GARK9]]O?$Z@J9&J\B[=;8\4ZT34AK438N$P
MF.&J2H 8]D?>V\6S-I!5$5?T*TZ-CE"9^U(^P#W J'S=<T,392A.:1Q&36]T
M"Z+-[ZLQTY_92F .@?I3,UPU&1#3CBBO30ALM*&397&J(XV(*8(*%"'A>WNZ
M(U_Q]O/:E&F;+.QPQZY$V^C(/S]SFMP!Z2%,*D*-+\/_C!9KM&2M3G6E&.#,
MZ-+BLST19;^<$^8SO[P1OI_L\CWT2E'YR\J&BJ+B?<!-@A>5DDAS9KX ]8_Q
M"LC7B*H"H-6.1I1-3'_ICQ[+<B+X<@Y_KJG$_YC3>^50>70G[L.^6LV=1Y$J
M7+]ZN.HNYH]MG6GER+')8QRV)SGM5\= :O9X)W'SE?OOF[+OV/L7Q+B\.G-]
M!"6[]VVJ"88O%28 'FW!P770S7;R6KI?E1"[MI.01) B>).B+;9!5%9BA\S/
M7 6P)LLPC^0W,-Z]DS)NW9![[*'^(5KH>2WV^J:S4(0 $!,AM!A8;.,>Z;=0
M1Z1LI<9>8QV><\7Z.[%(;3QOJ\&0 T_ILH<:NB\P/,9H'SY(G\H7YQSSN5R7
MU&%^8LY6VR-X_P&UB%\L#E^BB^/*]8'^@-+MU')$5^KHV7;B1@MY*(JAG9M<
M@A^8-!,^VV]\2"7022?Q? (5E>*;9Z9^1LMA3[0S<[M'YRD >>EGR>(&5]]A
M=;F!^5L1'M42MK=^:E:3[]S;\2[)^H67X?[@-JFZZS>S^_]CU(Q\@$![3:Z2
MYLK?;'4-+(PR04*ZP^D,TD8*_TNN< .(2L;M8#EU?IO;H9AXZUU)0- \*?.
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M=LVUK_A^\6\?P#_[HJVH\H?N?: .-XG#1GCK\_>$AD ALN]#CM(M5$@KHK>
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M=ZCPV;L=DILW*Y_;-_!"Y=1/B5W 5<J@P#O@-;KV7(T8:&95U:<AT[9:BI7
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M2T3 ]N6EIZHVQXZ>=P54.4*QXS_K,K2U%'R_V+([#)[7J' 1C\HXS[B(;\^
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M=12[Z2LQ9%O>]'D?KW(OL.%DGPR[%^&S$BK-?KE9["2M$ACL8/)RXH!K'=O
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M/:OKPI2S=_^/P]M(+U'4:&#!-QCF%!0.O_2J_8^1/_@HC,D#,6?]I<S8$5-
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MBQC(@_^7?N:*-I$=/KUV]--[8,+9A'V.<^%YF.IBW/+)W^OT;W;S$!0:0S<
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M7H6%I/NA%UP$9 FP+)'T/O*R&1>QD,=%#.6N]6[G(GX--!%AD]?7YP>5UT]
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M]E8^\<C>P\22\EW],%VI,\E;CS0P0 ]40WB@Q\S8N_36>X]D[ITBK\DV$BC
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M\")THGE'R-O%B-<>)Y<2ZB!73GLMS!(M-^&NTP<:C#;R]S00E+JN+&*0@93
M3&S)N>':U"-J3PQ-TX*33?^)AEZVNI5O_O4VI?\I_U^*I'CH?P%02P,$%
M  @ #H*C5(2^@DS+\0  YB ! !0   !B:6EB+3(P,C(P,S,Q7V<X+FIP9^R\
M!UA3W;LON!$0:2*]"5%I(@+ZT021J$@3(58ZYE- 0)HB)6A,%*4W!0$%,0HH
M(B72$9#0$1&0(B64D( @2-D1"%O3[N;_OW/NG#OGSLR9Y\QS9^YS-L]*",E:
MZVWK][Z_M5?@CG*G@5VG+6TL 9YM/,#?\ _ 70%VGO ,NNH%> 'PQ<,=!\R!
M;3Q;U];CMJV+CW?KD9^/CY=O.__V[?]H H([X":P??L.X1V"0EL7_)N(L)#(
MUHNM0?[9=1L_+R^_D,!V :%_]\5M L1W;*O<=IN79Q^P39R'5YR'VP8@8!GY
M_R$>#_!?+YYMO'S\VP5@,83A#U3M@L7GY86%YH<EAM^]"[\/\(GS2^P]?&*[
MY+DK OMN2OUU__&K'2HGRYJES_>#JGI7@R,%A61DY>05U-0U]FL>T#<P-#IB
M;&)^RL+2RMKF](6+EQP<G9Q=/#R]KGG[^%Z_%1(:%HZ)N/W@851T3&Q<?&K:
MD_2,S*?/LG+S\E^_*7A;^*Z\HK*JNJ;V0UU+:UM[1^>GKL\#@T/?AD=&Q\A4
MVLSL][GY'PN+]%]KZQN,3>CWGRV]> !>GO_M^C?U$H?UVK;E X$MO7BVA6]]
M0)R/?^_A[1(GS@E<N2FY[Z_[.Z1./GY5UBRHHG<>E+X:W"\DHZI/5:-OJ?8/
MS?[O*1;Y_TBS?U'LO^E%!D1X>6#G\8H#2(#-RHW?#_POT'AGQ:#]JRPIT@QR
MR8]IB=W%3N<"WL31.0J-"R3BC+A RTE]/T5B+!T3?-0\?WQ\XI-(A7-O2J-F
M?N#IOUOOU]9VHIEJG'X*>(Z0@)0L-=5C.N&;]=>)#\WD4ZPR:)1V&?3N8JSU
MKZF#CP^XL#.F>F7.?AHPRJX7_NXA<$-E5A?2IL3@S* *CM "DP_",]#0XUS(
MJC-<E+[;1WD?728^5/&HH8)%VFG/&I$W=E_CSF);1:CU5QNKV4^Q""[ KP%I
M>L\@%#@3^$K*/8[:0L8+Q)TD7EL0?0]MF:48^\#Z^^3KM"\B+_?+R9E^%>AW
MY*B"*^EOQWT5WGST"@B_/>Z_'*CS6/7YGWUI&<@SW\BL9"X0:<<%FK5)GKK0
M 3&6)'F$L< F-8C@U+%.T,_PHL6LS:0J[?/3[C]BZZ)ZJJI*GW:K'_2HL;Z8
MV[%]^//SW'=BPM :O7[&J&,5,A"@H6/,M"'.S[:IO5 X_?)($Z-1=\CS+U21
MZP+GX.!,U8?TWC.)*B&)'[J"]LL<;$OE858IU[_J+K:A_JC*MAS:]]!..WY"
M\YF**O!=KU;'>EYNUC$)ELZ2%$ 1@I^-21X$&<YHHP%H]HIVS*CEO&_7S3S?
M<$&I383_4$"QHY_-KZ22X-);0YI*?KJ,$[!N5SB?D&7>\:H0$<RC=J/HLA>_
M4NSI06TEWA<^- QC+;TRY%>N-63Y*GZ)\+ZO=@305#Q[@%6U)L92\@9CJ 4I
MR.DDCAF4,",FX+RH0(G<<-\^WU*7WI*FGFW0^Z' Q9[^Z(9P\\''S^>_WSJ.
M<(9%M";YKLIPVBGO"]K%R 5-.,1@E;M'TY1T]L7!]64W&X9?W*ZWPAH9GYD1
M'!F!J7IB)$&FN%$-JPTZQF\PV8:#KG34PV*#F($K'WCNOQA3PVO+)SPY_X5G
M_GX7,9HT74!X+PL'KB@\D1+^NB4[%>]-%(-$( *UP_1XR'YWLTF&=Y *;LYX
M;+XGY<\/OQ8NX"\&J9*6'H.MG!TQ=YA7?W"4AB@SI(>-D@N7#<J@@3_+8R,C
MSC4P,.Q,^TVHOP=<29X\GKR_FN_L.2< UY$J)>-QSR3MXCI*'+K35MT70>T)
MZSX;;2P2;.L5DOJN=C&_< _B.BL--G459Y B86;DSFGC N6=B68*K)/TF@=F
MAIAK:^T4&:PP^,9G>2-(3BTCS2\DZZJ>FVM*^3/O5-?8MG=GK(58GZOBP!JJ
M.@G,8ZQ#\O1;',$:+L!W!YIGFI&-$O=];330*2L8=<'@7<"JST^G7-]J;RC>
M6R-_/H^9'17;Z?ST73S #H->E4+SL,ZBV!,T=+3RMI3VRZJ#Z[9%!#'H:H"[
M_OJWU?/J/MH*"]^&1VWW.'TI+I8,H^V0(_9R ;(B1_@HO+Z.L3-8*'"UF0O(
MDZ;CLRP)>#JJHYHC";J=Q0V2[S;5?]/@ HZ2E;?/B6MV4K#[5_S6JTDF^.EZ
MPJ^;^/?A[!S& U;6/1-D,A(\CX8TD4VZHWTS1LM&="[ $2RA$J,EL4?!X,4I
MN3O$Q+ IC9IA'4[_[H"@@PYAC(&3KW8WLEF/XYF*5-UV460G28RE4?K3)#DG
MH!A*:)6Y7;1PSNW>3.]]SW\$!=_C%YC=6;_S.#OYN, 3/<Y7/&.?$>>).7HW
M;A(!VE#&CD[WL<2]S['+6;HOKWO,4!Z8*?DJ_U4&C?Y9[J?S^AWJ#-!\8N_9
M<LKR1RK_MOUY9/&+N8]XF+*7]"?#S8<]:V.LA@-TIGH]1,FN;@>C!04NWLA?
M#O+HP3G L>=FJEF(&R6)XZ=S<,IT9$*HG2AG#V; M^'$6TSPQM)*U,>.&)&:
MQ^;ZGJ;;G1++!$[*\ST[OV/[*SA*VK#*D WLV2_LU$8$KIL+@*C52!-*I#Z!
M+#S3&$5-B97!"P4J' MR'!2Y8-#^^DF-Y%O7\2=Q>QQ]96]X.Z@>?BGV+4"O
M[872<.F*OW[ [<\K=S3&(D2K!JQ!(Z16E&KA-'ASH&#(0 EI4YYV_EO0J^J:
MJ'"[FS?WGSJQZ 0*#)/$<)JL[0^HH7WWS [@FP_@IZ.1E5;-NO$<?GK8LYM^
M-,OR]Y'=SOUM/^JBL]\]W?"=6M%\.9D1$CY5M+;_H%\#K$(DR[:&7< %IBM?
M'&!G(WV(H]VTODY*%(F?H^2SF:710HRQ]?^#K>O-Y5LMOGZV[\YUG3!+BG><
M3<CYXK!(F[_%1MV-+@R&9LM5V:F<C5PA>TV*ME?F6L\JO_MLK;)PL>$6#0V=
M9$D68SJ7T+Z<KH%27;.>.?\U[-LQ1F#S>$YM[TZ]KR-SCBR)>NI\._H! CS?
M)^["Z46#J+Y$Q#:DMZX\R_!.RB[,49J(0_]"AK).33U*9PT5+]R=7B/I4F%)
M+SS^Y7[L[XMB V+)Z%\6IE>XP-5JV#?Y V<%NO"@!1$Z. >C+G\X:)5H$& [
MS4<1P5I0CR;(DZA*A+:92[)D]]G  .),]M+P;X<,X:?/MBE%BV=T![@1X_&@
MF[9B$P5T7!6&P^0 2XUI;$<<O[XY3+[VD:[%D2@+VIGVSO:*SDO_X<&E%$:&
M[97 +Z<6*B?^?DLVXN#QS<A&#2B<(TA@*N+:T> EBG@^B)%U@_"TH&B$O&=E
M;/W=G T[U(7^P+"=PMK?&[X^$[.HO=1WY!BB!?4 9P"B.BF0AG<GG,HSE%%M
MR!22(C:"CNS<>W]2ZD_ULR#MDO=]7XI$'U7&6MY\7P0(G ;8'<,&'V5;A\7>
M_?SSL22IV%/@0T.M4YX;^->7X]+'JGH^?F\(#TO++SM]GY9A*%*:[[G+BD]\
MBJ3+TF*:L#3A6"C!-WOC?>^*,2@@2"=&(KVU=(5]$*(XQ>N;YY4.#-]%H5)7
MUBYFC3F?]YU\_%BIF3T.!'LDEHZP)/$M#J0R 99T B,:'L<'*_M-M[-Y"+J5
MCST!>D?I; @&7@&3)K]$3ZWT?GM]S8?Z;+Q7/"V*7+O8?@]I587:Y6.R.X/N
MYS+Y.MO]R[XJUZ+TQ)Z]/^)JDWJ6C(F*\(B)N/%&:?@Y!-?)T60367[3=\W;
M;@=%%0Q>K>U?KW\8']$S]RK(\[4+ZDF 7]2M%Z^L?Z*?$< 3?9!*T-(QIB^^
M60Z'8)UB%^-VV\WDA+>[A)&\\A9=.HINN+9DV!136A[Y7B_GJV0OV@3WQLM_
MS]G,./O.E,A(SA CCW-$?H".R\+,4RZZ\0U!TX4E_@U(FKN+5<;BD/F,07]#
MT^SWG"4/)^=LM?NJO^#$^9X"GL>38]HI9>@E-3J2403*QJQ/.CJ!1M%J0^OL
MHXX2BGYQTOTGN[Z7-U*>LH>WUZ\^0$HOX52P>F!07-6DN5WE, M%M55R7W\:
M>/SO:S4VZ&[+J]]YK@%K3;,C+23P(FI4DF'(ABT]G8RH0K#^0BUM4KDP9P):
MSH$;>.H>3DO4X#+EVJ/?BIN'>_LJ[1+Q?>:7E9C7\,WJ>$]B%!(\E;TZCC@)
M,M[@3#'FU,"T&5M$$JIT,@?K9PBZVJLZL_HF6X##JD)\-ZW>[RNT^)N'*8;'
M7WGMW/5V,?S]N&O+ZS<O(K;MTRWT:$*X))P:6=>5&-4IHO8$#IZM"CXY,>96
M7);V0]Y&^G<*O/".0B>8QSG#+X39:7C?54G.YS^=RSQ@F@7((H]TZ$9.R0]+
M#,Q<:&P<U';I/N?JD*H_Q-_PYJKVIF=0$[_[YS]XEOAJ!QH\K72!AFY#BW!:
MD>4K]: 1S;V: *-6RV<(/8,0=O]A4O*Q7)_@E;/D^7A:J\Y7(%M08_[XO*CR
M<;,Z]MM& WRK(>X+11SO0X(L2=4D*@^H3J0AE_#5=[.7N<"5\HR?G];"D.FD
MSV,DCX#)G))$1 *.%]]\'C9Q*:*RH!DOS,)#5C#2G^K791V>49*@.'P-\F87
M5GY2ON/\R#30(\UVY\-"A!9@=?L/FB.4P 7V][!S24M1F'HN<&8D%$2S),:G
M=5DR:Y?A* YF20XW[N!0N, .+)(J3(PF7VQ4[#? /_SKLKO36';(8?.#M.^G
M2HONH7E5O:5X_J2 *6WH72Q7D'2<CFPGQHACD&V;?\Y(_IR2?N!J9Z.?77W<
MLUKV7*YVD^7GW_'O%.4!AX\QL?I*#HQYNX&->MOL; W!B*"@X%+P\ ^E$Y]?
MF.QVG MGR>*I,6VH6(08Z:K8 Y)XHZ;;.";/@?T6J_8:D]UA)NXP.,=T7=@\
MYS[E_'?:]2\=5@E\3[LNV[@TLVMADR'&O#F",<Q+N$Y"9?B2-MBH&W.;"\0A
M?=@(*B7!U6(H\#3F@<6WEQ]DQ2F"GOC*VD,Q$C:9$^$2IPO/BGT3]7#KQQZ[
M&GH,[UA55NT@-"*;*2RQS1Z8:!-)0QMC4(QQ^D@L:;J8LP5+^"[J73F,ASFD
M=&7FCEVPKOY4=[A9_G"2L!('_637=CGWL=5DK>^3* 8.<H4##D[(D3/8".@"
MTQ>#P;0V(2H<(UEJWM.Z,5DE;82Q\Y2?&;IW0]]U!Q;+1#S1'6O&OCW?X'4Q
M$0\O*C?H+E,9W]Q&D3,39>UI;$0)M#+U?#,;Y<#OO7G:0SBEZFRG) *JYJ\*
M$]>XMD%53RI_Q[>6*(!W0]*!KA$3(A@P/1+Z4TNC/JV[TK8^/_$+"_M6+JGS
M<=-&417$PQ3YB=Y!FGZ)%&HP9_IR)O&@%3H%75F3R-' 9#J&T'$$7X_0O!]9
M;N'!X^,+)J=[WC4Q'H\7>]D>]-5XBI[_6SJE$%,T(\N2$F# >D8*82T@UQEW
M/1JRU=T>G_R8A81L2UDG:LUI2AI-?]*77U9E1>1FH"@6?)N&D1:/ED;KY?Q/
M D@KTO1;4O5*!7,7KHDDQ06NKSYTP"'HB%B<\JC+YRRSUS<&7'^73S4'GK\I
M7%0JX[#'R][QYV7V]/(UO#AD=9HN.F2SN^:/OZR$:@2YF%ZT2V]<G:1,FOY
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M/>B-M@Y\=6;?E^3@6$DA^>YUPGL-EF3".78:UIF.8#R$9N@KFS1B!SZAQG
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M]P&9<8W[H>XF/.\&6['9 8$P#9@^FIW@MXRT"A)KGK50ZWFOY^K28R;A?$&
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M1UJ*!B-K-I=@Q,7!J<YED\$ O=Y43>O&]"'CB1<N?"M=]E_FKRI^8YM]/^"
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MPS@G3)"B^"@$+8O1)3"-^[NIX[^UYQJ^5F9;KU2)&AH_B;:>USN0(:"Z1^#
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M[5(\O\)C2-?Z8O'@!1*DT9@$UG"$^9E'QB#S=I>,]YM3:B#J <OAIW1B=>9
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MHO)-;S_+L':+X&3/DJ+]IQ!:)1 QDOIF&S4G1$OP45V+Z$E<E=<3K9N99+]
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MYXO@LBGPZ O(#@PSA>Q8BR&77C%Q#XA;Q^UOOAF0S?0_V"*UZN%SW876T49
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M_R+Y%A7I4^> 9U^FG:R%76):J=M=Q"=UL8C7;V=EA^ O<"Y#!F#.LAU3;FI
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M:>-%5YN"?%<#;0X/$'J_XG)+,V&46=]"A O@EATMVI,0^>1T#D7_MGS^I?>
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MVMA+I$<(U;%HQ@TD,X3T]G[">]&!U0/$#=2.8<'/\RFJQ@521]5O'3!^5?+
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M0%K><Q-[G^:6/Z5D3/>W$M9\T%&++Z(?=O&.\-^3:.4(X()4(ER9Y$>8YEX
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MB@-N!PK- ]^-*F;*YMW;>S_'9\[.Y.]3.2'@+N1\]03 :NN%-*X:-4X$!E?
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M6:V_+F29OY?ML;*!9&/AY7( K!)Z$+N QLT=U:(KGT31;$;"P?R.\F"2LNA
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M85\5P0G4FBUE8Q1B,/VW832]=4#OWYK&9\5Y^7J6H44&ODT>>V[\F(E'ZBN
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MWD7.6?P8VEV,]N*?S"C9SJN^_WAZH;7SI?O2=DD86N!?,T=*U\S>B*DRGU*
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MA_6#4TKRBR-HXUV98'007D_E6S)-8>60EL7@-N* F\E-[TRGM.Q $UN-Z!0
M"+'__#N5)A%GQ@=%&>RGZBE_7QL;#(M8*?6:4WKLA+Y BE4-RY]R0^T*_=*4
M&VB\J,BOS]?/_801!&GY/. R-HY450AKD,9(#").VHDQR^H9XPZS).I<; -F
M_[@-]XU_6QI_$Q[4/=-OU8GB!ZD92')QX@'C'=2E&,(&&(5(SAB;(\@Q8I(W
M/GCF-\#6\:W;2!Z2$592U"3YX+7YK^W5:C!8VW]6'Y3!^73N=W>#P$Y'^2%7
ML][\JB:;$[K?:3;D6\D OI<YS!6>9)JS'C# >1J66<PJMO/L C>TZ/BI'AQM
M/H>ZK5:+D7=WL3+65QM1?I!JOVPZOWA&VXYXM:K'B7V=VP$RR&OE;8?LN7*Q
M2,W!*"08^X*2M>"E6W5L#/M@L/R\XG(N&_UHE@>4<;Y-DGY,F-[\.FR!E79W
M/UZDM-,G/%"0/]WFD*#3X.\^^4Y'G5<XT+FFI18A72Y?=E>D&T>^MWXFD0[Z
MIT([1KM)4H11!I>"?AV[X!# (-)//J?AX(/337;A[:)EOBV[AG-OL;[1*?W1
M]/J[C"KUK[FOKA@%/V<C-6&;=LMV[@=2'38)\=5GH (I,-F<'I[4LAUO%MO!
MW9FPW+[7[R.2RZ8?^-1(NAM/3&C\U;'!=?Z2:97ZB?D%S(6?3[49HS'J"5@I
M**'GI,W7<5&,1[Z:)?='EKK6V#FJ.? ^1.*H-C]-19XK[,F^0'@W9<8,FX6E
M=5B,(0(*Q]\]I=8P6MXBCUNE50:L$1*+W)^,2OM5:7YNKF6:B%,NF^2=29<X
M4'Z*&0Y+UW62JDGS\M,28W4L'L IT./J3$%D&\U/>#]/6J*'\,H<?Y?N\\J:
MR,:CN@4Q!Z6O'0R1>.B\5VCNAS;_,A),B&_H(!H? 8,EQD-666@.@@O4TOA2
MZ.0(>3+4[8D$3<PPZ\:##U+;ZQI&MF(N,RQ?N;U+?BZQU\;C2[<LR0JOFPNV
M&]"233J(?LL\H&I^>^UR;="R:;5HD^*!_OU)V20+0,;AO[X11 E?E&+C09\!
MZ(#RM#TLD],^*G_>?IZ#[K@YH$QVFXGNN?L[",W6<^2,L9>4[,1Z'T?_<FGR
MNFD%;YVC-U'(5>UIW,ZI#:.N=D*M%"%3*V8=W>+S7<K.VLJJ[.&CL3<8O08K
M ]O-/^MV %?3YDC"9EMP.JPHQ%Q4[A0/V$!0GT/(PT=3;X9;6_:>*NSMK-J&
MH?R8$SYY02%'Y@\?*N[70N[U@@F<*)":BJ[52@8#)9)NH%*YZA"16O5=SI5[
MU^>O"9S/L8^$KA=D+O? N#</\-"H%S#95^$3F VLL5F!4 [[&(Q,3]0Q0O^-
MV?DW; ,KYIDN)\RF9F4_^=@R_$7L<[>)=O)6L=6,R9/I?%MORL@<"[_T _AA
MB6E/A7:B%IRH&/) &ZK2"I:Q8OTUU*+L#I]Q^]ZBC)MH>XKVN&G]";MPP4AJ
M;I2OE)HYA-60L[S@:/[K)37MU\#"'69 -U$,3<U OP[*BF_1AGI;0?[?'.4V
M1Q3*-(AJDI,8L("VPDJT?;70['N]W\VUSTS*Y8P0GQ/:;(0QH.2'8)"M+0;:
MA9D/-X*E-PQTFFE6QDXKIG93)'-Z5+>/5-\)805_]&/:O?*P$\O2/#9L\U6L
M._>OGM7;OOPKZJS(]5T(_!5&+"PCWTEAV('C62S91BACND^O=0V,UR^U@\/D
M'A6*1HS%S[1$!#UT-1?>J^WEYY5MDR9G\"ZL"4$JD3OLP[ ,D>8SW_&"T'T5
MZF4]@[)RO_S(P._Z:!HD=L,^=E[W*V[F$]; 3VU79@/F7ER=]?NWAJ\59T ?
M*!?-N,H#%H0.)LECQF?;_4M3#AN%>!'N_))]SYU ;PDE0EI.L-QL.XIQ&D56
M/_E)MT44^DF5(8G58%4FYJH\W'"VSJG.2G=U([X6Z\LMEXU]9B;/Q&]35P+6
M=&@#W:B).KI0.R6>J\"I0L@+40(^J 1&E?D,FIK3[./W_JPU;C*5CM_^JZ]9
M>L)FRUF-Q@=7M=X33NM0,9!&^ *-#<)_(08RQ.]G&LV7(IGXBWW<>0'H&DUY
MFBZQY2</D'P^&/R[NZZI(7-!/\>^ZL-PB7I(1*7,LF;*L614L-N*1!LR/PZI
M8^6L+U XTZJ-4AG>\T:O)_R\/,.NK_N-6336A$PN89RLT",K[95N4O@R;WD9
M\(X4\'F+P$.T[WKR%X*L7T7R,R;.:O#]#+MA!]QR8ZMSAS$28.# .+$-7:/7
M_CPD6R(%C]Y8=%'PQ^U#M<S8J%/YJ?L.\G>/:02;1UF*AZ#K5N<1Q"4@J<YU
ME<5B>+^HH>K%#J 3RL^<^5RV$+@@6%/RPC;G=M NQ;P4:1V96[W=U],WFI[A
MBK=J(* E;<;WE0=\> /R@,( ,HLR<8;%Y2!<\.(3DPX&89PD>8G1$C\=L6=^
MMX&XE7ECT_ ,;E#LGKOI7NL*K UN^;"E2,=!:B3!A]O7LI4398""=J/;[!!F
M*AE:X6MH'%RAM6 X)5S?@A%]LF4B>GCHJSM*<S&;2KK_.JHMJHJO[LJ:)U?T
M-V()*B<;]),85Z>O+H0S8U R/YZJ0[<8^UVP(GX.N';6A'5U8U5=<U,4L^19
MFGKVU=W-U3D/,@]\OA_=QD G@%O1GL2))JY(&UOO)\*'5=1ZW)@8I*)7^.*/
M4N!JXO@[I,;F,LVD_PK*L6]IVM*C\NYQL/6]+'+G[3L[) :)# P1TDZ=#V(;
M$CIY@!SHK9=,5'KVD;L-;P/IEG=1B9O?Y5%.D',& JX&;)'JX.]2G6NQGS*>
M+FK]%GF(PA76Y0':99QLTOQM')H'G*A]L"*+1Z!+8'W=.8[;3:E>G3_#R&%=
MA&29K\3!'HQ8BQ!T?KC'6.#&H17Q@KZ-Q*" 78]\;JME!7Y_]W"RK=O2RF#%
M:;Z*C865.>6P)_-,&UJX).Q3 X1F;OS9UK*+>&YX2$'STP(/&$GT<4'U'>G1
MV/G5V]*7_Q4GGX306P'")XI &&]]&81^,J^$_-UL1UT*Q3&C8ZTZTP@K\CY=
MW\\4-+W("KR4+Y72*ODX]3T:TM6#I=$LA(I'!7/?/E6%II%A(,C#J)T'D%5[
M>[)5'S$LE]M<9W[^:&05'5K9J9N87W7PC67M_BIAHY"$_'LSJ-_RK %.28LB
MH0-5.8ND_0"]) =*+XTBZ(<.;*D;6H G$K/\I!0N)MOPAV;8;+U0(=+TJU-;
M@W"(V[%>;%$@35+7 %D,;#N)7E]?FKI+D;U[Q@VO"[D%T()"EH]#3@765SSC
MASI[KA8=K]\_F?2;?%>;[[ 94HM'C>.RZ!+=*&7N>P3G1(DR%%\E[(($4PK7
MHMU+F_BC^ZWY8W6.]6*-N.'!^S'6L_MW90II;!/:]:&P'Y$3-7Z&:@5+%K/(
MZ\<?_-!C5JWO&,L=%&FS/6.P%E1 $Y=C@?.3A-&SR5T//GQLJOS#&K+0B'*(
M\4SN7"8>13Y^U+P8TNE&5Q;"LCYM9DJ?8!N:WFW,EA<D9N/W;'S&EPD<QK4Z
M0?2-W47^FR4[MP:^WTA%:8F46#TE?*;4^+2F0KM[%FK8.MP^'O Z-GF4+A]+
M4,2[5T#E3/MN)8.DZ1,?@T+KOXR[V>G'Y0TTI+NH2XI5/@X&? "4&^$CBF%)
M@K3*%WS8A_V)U84+MHR3F#@SM4^!"PNZ0;!=^91-X=P5"Y&NRI%!36M/2MW-
MO8XA7^]U'"C/ :EWC?<\8O2R6CGE/, ''+_622XK8N_'2?0H&<1V:"_5V& #
M5Y[XE4S^+C5KCW!Y]#PA),'IJFA<CL;;?M@*EN,!7-&#C"5D!JI+2;!4K WG
MA3+U0=GSPHYKS+QI_<9S,UTCB07V(L<;@]-42O8U8=S-U7A OJQD:WF'_$#6
M;RM82H=5_K?5JV/0*5*E#RQ%HCL^>?4=(U[]4'75MN)CF+)5_([K*+]LMUY<
MRZ!^I4Y5B\NC>"U%&;Y9E"I(O4-D6&!B,'RF-YEG6'&0W9[M0TMA1#F\,],H
M26]VI-3C7'[ IP:_BJTOKSBH'TXZY]0;N'!H%59>FL:0C>A:L)0Z=2D)[6]W
MYAR):? M+33(0#?B47EYZ/.;QG/#_1]LK@<<X7/2R+)+LMEM \]!DSQ ,&]]
M$PEQ4E+ SR4AP@0/J#'%2) NZT6W;',<Y"JZ^RJ5K!)E:GQ1.K=>W4HG6R2>
MB/^DL*!XYVVK?H+9#T(O 8'_&OOY<;87O&6XQ9#[CF!2PY2/TLH.4-GO4#FT
MN)LN'CQUIK/"W4+ZY=$FJ[="6Z\>ED?<$AN'4>+*PVHD)G:>R0#@D\S <#G&
M'&&+F5;=8/KLAP<.7]-_T5RVI^CKJN-+.G=\=KPDB&]"J#>T,WPA@V&"<. P
M!I8K8L 6^TZ4:$8S SJ+:.6"\!$&NO/!:,G%4>_DK[7#V$LWG36COTDVYA<W
MV(IY*C_R1Y)$&TK.; ]^&R<%O[T4I]/S5(^1>ONW1-)3U>&6@[B!ULMG/X>B
M!(\O@[X>1W;O\KKS3>Z[]V%G84-JC!KI !)?Q2A(PQU=G36?@6"2P-M&IE[R
M;QPIP'X#2@FVM(]3U1C5+S4S>K-#>6?^I^"O-?)U8J6[2@*^Y;KT/DF@_B4T
M5[Z 1>SN#!4PU+DBD@B=:SM $")T-<9V#BCBB#01J+<C?&1J;^+)6H2_^MG[
MLE9?N%UWL_6EU69>;YR:=^N-WN:39A= Z$(S'(C)(.*U 6AY+N*TM>!\70"C
MG%X7 Z.$$JOC0NWE]]04X!(/I\_.ET9@T1G2VU.H)7;*9=<RTJ*$GIQ7,X)5
M-"^['-%A"[X]F_:1![3[I/ZT9\JC&-<HL9N6V%NF$-8E4O-,--L'ECW#:N/D
M$71P7 E(BPA++_;2L1W8&%7M!L:WAFEP"_Y$[-&,3N/2,K/QH/S#K*&27+6C
M\06A"987^+6_-: @PR:ZY1-F*G5TP9P9;C48IFLXW(6I+4\)2_0P<:GYI:?K
MV9!H]^C24U/BGG.;94>U C;L[XJH@Z6*6;\Y6>AU_KJI93O89DK"EL=-TRBI
M7!7\R=$E_9]! 2<:?)@Q&;=N:G[.S"N,N%KQ9OENM,#5Q0QM/O?'3KE@6Q7W
MKT\(3Q/EO(!OE4 [V!U&V;,+SZ=O'5WJN)&O>J[_@<;'N4J#_'>PU#'G[M[Q
M>PD &\.JY600I+@3*,%RM \EQ<<UHYW\9*%ZK28EMLR^T.;6UGWQ9@,:'_>]
MW1[RS+AXI_>T&NDO!.4IKU'SZVLA$\RE><IT.;1#J(,(.9)0OY>272WC:7;*
M;6MOQK%2W^<[?YRB'-$HVU%M#5?M+C,[1=T?Y)DZB(9V6BW\9O2N[Y!OPQ%9
M=5#A<\J/D4:U+NP+WT;?SL8'\-+,Q,32MI+C_99S"EOB%")[-E$>HAEV1&A7
M*BQU%W^9B# ^)* C"12R1,*Z]ZA,%,3DO'"!C#QNZ="FLG0NZ8H>%_<Z9S\0
MOWADAZ4/WYA^^@F^%0HL6S8TR^I"NB8C-)=Q'",7X!I-ZI!0(/]L,8 :\N?(
M=VO[Z,JZAF+C?D/-)\I9X?5.RZ?^^B+R5X?EBP:,+,P'G4,4CT8&Z.#V&X(5
MQ!@2313R8UN[_9R2@9(9/,"V*8NM6Z.C;+T8NG!<0>71I?H]]!W>K;\^UW](
ML4<Z"P8V-G)22-0\=)41+(OMNJ&:=XW1T5;;N!3%W?.#'$S4[<7=Z#E]1\XU
MJ4BJBO-DCR(\*G(],F'?D';9F2X4BBN+1!(&I+ZF5&4^9ROBDJ !&G&>@BV'
MRNE&G>*&_1<+R@IO^:G4/GG189I0K-L:*E599I79U^]Y!3"[!Y$0\==SGP\>
MA ;H%+(>ZP&T"0_20=G>;QA_53VFRLK'.4:)K4+4D.PCM9KDHUXRI_YH9,ZE
MRO" .R%AXHZ45C2J117>RZRMHJ,C"5N@F2)?'@#4W HXE3X/>A][9B^8_TMJ
MV,5J1YOTUR+=[4(FQ>T@M9S"<$&-S])'%Z)?(?)K-4>PS]DSD(H_MKVPISQN
M[YS3LG_+=L>SUQF+]VLSE_6%U0ZX+.:+B&2=^_*LA <\0S-.8,A+7.$:MB5>
M'HPF,DZ0MLX99T5Q%=Q<_>P+?,GBO^\:NUI7ZN],?*OFIP@WN#P.OAST8=ZE
M\K"9".<5B?H8564_;X&8/Y43QU6'56.[C*9V,)<Z*3)&"7AS.D7A_(\ZHT2Y
MQ^D6"M)O/>,E"[,VZ&/>W+FW$7WI)].>*Y*SWA6Q&\),U^F5!D0TY[Q8\*F
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M_N<E&IF8N!K=DY1C#(G(E8GGXK,)!DV9.D$711^ >@=\(@Q?IVA_O55:YS>
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M'N5H,%Q^D3#EM4$R].UO?0IS;I6GF/N[(6XF6G\[EW!Z^</HMZ436TY!UGI
M)B+Q3Q("=O_$MM0@^'W Z+]XK38.J2ZP-I;F^1LAA_ZXN=JS[K0\N;7$"R=
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M1JK+P I1TCJW0S'RW5QYJT^(4^*11(M=7X>L#4)HTLNPA>U37 $*GB.ER7K
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M8AR%$J_,*MW)O4,N;O=N)"OJ^1A7.#W*4GWA)_UP<S4>4*N(05UB&%#(38$
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M1ICVTU9\2-$QS%'7%ZZ>S!^\O\DAN/Y)JS$, ,LSD3:"OQ3H_9X9P_DD@0!
MX+3O<#H?XFS->^P3^*%>E@]IC\W%C(".^8W<!'[D-G11F]@$[0!CJ_3P!CCH
MXS>@3KY%#Y(9=WKI&V@23Z[8S&6Q$ !B*E1^*C#]G1JRK"K 1[N^FABCU=CC
M\!7;#=7M,.X5K5AIK-_,+8&Y\2%C2JP04+$>-8 R<@!_"0 $S(&'^<C(QNU(
M)YI>PX0=''LVJ3GE]C%"(3=NFEP5L[@G(4>E\=D3P8Z@31MPC#NX!IPP<H0G
M#*=9QS^TLV*V-; +82U$<8Z+3]32/1=34?9M1V&S3QDWW)\^N.WD=K7D -0
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M )D7H"1S8>=16'>4F:<Q)/T#:\_UI]<W:E:S,0!HJ.!'#?:G*^68T"6X6W>
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M-*&XK[<C<3>N%0\0$A%ARB-.0HBH]*#Z1B*8^I1Z##,I/&0C[#TP3$W&6Q/
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MF8="F<9AJ'?_4H@BJ=R=*!20,,0ECF0<,*.RZXYQ3<T9VEYC.A;H7^J85</
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M-<45:$D":Y:NP)HGT! %MID"RQSL<@5:L@;8(YWD:^!V:)N4A>..K),R_=3
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MUZWPDQ8XN-?E@A5F4(&VD(8+^\I 7D?@?Z2EVBWB*[XK4T!C2UN]8[=3*GO
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M$7 0F6AX6Y]J.E(*7<A83:&_?5:#D\X4MV#9/*LT[=>;]_<W2_)MYO'4#Y.
MPT3$:LZ;ZE('(@JA\&(1",ZY)$;EABW:G)K<5+ALJK*8,6O@I+KG:V!960/6
M)P2!A@QV,5^!"K7YF5$;1FUJVSAG=JQZ-BX8MJQ@8\55=]4:LT>-6*G&RK;=
MZC1VM_:0Z*:PQ&V1?\GT*<GR/K^MU_V;U<]V/[]:",D6#_>YWLXI;Q;-G7JW
M9A:G@@4Q#: 74*QS6\404X&A]$A(<(Q"W\Q9= =I:@+?0 ,;JT +']SGH#)
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M?9CHI-T((Z3FR4$"I2\"'H:,1"*T+/)CV/3T/+GW-]>O;M[?W-^\O0/7']^
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M$RZ,SZP()$2FD"$D-.$J%;G7477'.E,SVW9B'K0("<HAZ\+5C7$BH#4PQ80
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MN80I(BG799HCBL/ZN_4O/#7;JI7V#E3R5@=+.XEO;>EV90_<>&,(9 <FD]M
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M9X^BIX'.OH^&/>'M'*C#:,#!F*B/:OMYK;;LYRP52!-1*)AGN3!N/%.0Z5)
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M;MC8T/1*S&UR]/^:;[^_G6NM;/^'MO7H[KDL%4D2D7.H"]O#$),,,LY2J.W
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ML(S\J3]%)&!BWUGU+_:\''_Z9%Z67N7V/2K]%PZ(I/UGN?J7+LTK\$7)3=T
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M!'75B;TVP!>T9W>: 3<C(C2N(]-#"$B]K0@?C():$4X#3VI%^$#QU(KPNG?
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M$QF-%$(Y(['P"\[I&VQN5'(H*RA:83WW\WWH.F[K V$V]N[^$*Y.SA$ZE[L
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M $_)Q?6V 0T N^#@_3YCM8,XH6E$M280YX9CS Y10RII E&:"J%UG"91[-P
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MC>"FFJ^1^6^_?-]6D?VC<*L+>#*=31T_,$ZUT0"XCE3C;X! +U3T;SATIZL
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M(NGE_APHQ]P< %8^84N_MKT[]HW:W6[6GL%YA@P-G"8W1I\ _)&YN]$ UBJ
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MUTW^:WO\+1A)9)RGD&!I3QYS!(FF E*F=4XPC7CLY;)Q'GEN3IH]P4%3\OA
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M;>PAM942? Z)E$^!Y2"(3555N><="U82^2P@_7603]\^8?'CLSH<5CP^?_G
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M44U:8+N*-]487K.'8MUT\JY+.&S,U><ZDDSX!OAM!%YL7L?>$8P^I8,W *-
M/LI.(*RD+[(E& 7L4WN#<08;MKS8J-3WRVJ]JH\C/A1+]7ZM[JL;*:B.<"RA
MS#(*,6<Q)!(SR%BB52R27+AU[CTSSMPHODXBV,D)_K"2@EI43]8^!:P;[P:
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M#^(4&<$Q,^:0&=2 23-#J',GRY,SJZI>+4O6<J_\B3[O!;@AIR+/0P[2@N9
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MFJD!Z&$S>LC_PBVF.[NOY\O!D7S-2RP8MBUWW$LP?UY57;/7[K XS03A*2I
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MYY*Y=W']RC:H8E/_R3&D_G_/W J?N/C^/GWI5IM95%+%E!@$EI /$1>#2S!
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M!XPM^082&N]8Z<6N]4P(Y6SA6\G-%"J#L=J5860FY*BL$G4:NSY U+3%'BT
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M3[0 FFVFDB7.Z T?X)[648^_:]JTB/& 4H.U31R!)7EIB1_YCH"?,1NT))X
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MCJ1BCD%99U*=O(0AU$U[8U8+&X]"\$@QM6)PWEC5\[-4#)7WJ:]1?N=6?8]
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MS?P4/?3U3&2O+/$6J"_7<M*AWRP9Q^4D5,/*2"7J-&N^3L>TU0F5@',$JYN
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MTYVFU47D,@?B#><):$IX\J ?!U:H"-)(00EUG*1:1_\@ H]7* ^^YK(^,=-
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M^5A[R750/M8^3)[:9/G@3M=GRT^7D\9/<"M=]?H)6EA26 JT],82&GGD8A1
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M&^#>V3KXS7G5YM#?0U17[FH?B!Q*A5W@<8B X->[KDY*8 @FU8"4)U#"43Q
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MXKQI(QF3Y4X@Y(CD74B+Y&I:!;QD1CM&JF+:7(\>3&(O5UR#XFKWZ\Z0"NO
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MEPY[1CB3D'$KZWI'Z&GZ>@&>PX,,'1]1!Z,UH"L)E WD$R5G@%O$H(ICPKV
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M4#?V!(-F^!I:,QV@;6^IW)VG^0&OUD)<?IE^NW$*@F!6DTF6+A=R"K*!F'.
M1$ZGK7-C-6_3_^\T>L>M'>C4X[^ ZCL ^!8V;GN+&>],9!%X$+5^K7:,Y4(
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M+*=X-I?(.87$NLU%Y1ZBNCHOC\' [O/R/,%W<!8^VH7K@J+P=9UHQ= 6=+X
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M1._[$D=.4D%_2)I8+YFET 9BDH5V6NTX1XX-8(JVU,G9G+=Y!C@^3:F9V1I
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ME].U^K)'7H0@+ A5:XD#>",B2)N3<DQ&"EJ;@&TO<<=WF; G7!XVY6UNNU$
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MZ&H1EF5M$OKZD'[8T_MK07RO&'@UR*_'7Y)MNEI.K&).\6@ .46,*B!-S>H
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M&P7D<;#%*"F8.WLP>6@$$U0+=$!XNN(J4HH]Y08IA%OTQO$-EZ^5X6"0A?J
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M"MME,K/ >P))V>"^"^LH^*^12B]X@7N!+L=C;@QCCY2+@03SL.T1AWVNDP.
M&]E9V^R/OY:%SR.2_9%QF.^B+TM"=UCR;J>#_A>4C_=UR]86X'7@F1S(LQMM
MNWT/.0-.\IJ^V#I-&;VU1=KS/%>F'4-U![[S4ZXGH2_?Y?CCCRU)CT90U&R1
M\QY$:LYKH0*X@7X6/5/0H DZ&P,L\)*;3%YKMIX'OD86L*][JC:*?:R04(K
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M[!.V<2-N&4FN#E:7*G2 <,K,PRH/7<1Z\'I=_NDO^[EKAV=_ 5!+ P04
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M$J"[VT4AEDTP(Y< 47.P^%F9@S7D\L+.E2@PY""#R^R0,I$V65=F8!1?1D<
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MEN":6*' L1LK4YR.&[=U4J$TW2T%B5>@5"I?SSXZ4;.3%]%R1/+J5G7.*HW
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M.,HIJX!3%P^8U_2%7!5%IP&.C?2\\JS]WIEUYV[$!\IW.T&[7)J1X-U8V:"
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M_N'_ U!+ 0(4 Q0    (  Z"HU05@&Y*/'H# #PZ)@ 1              "
M 0    !B:6EB+3(P,C(P,S,Q+FAT;5!+ 0(4 Q0    (  Z"HU3(QTR$0AD
M $(C 0 1              "  6MZ P!B:6EB+3(P,C(P,S,Q+GAS9%!+ 0(4
M Q0    (  Z"HU0\O0@=CR0  $=I 0 5              "  =R3 P!B:6EB
M+3(P,C(P,S,Q7V-A;"YX;6Q02P$"% ,4    "  .@J-46.T#0@22   -008
M%0              @ &>N , 8FEI8BTR,#(R,#,S,5]D968N>&UL4$L! A0#
M%     @ #H*C5*0RP]*CO@  HO0  !0              ( !U4H$ &)I:6(M
M,C R,C S,S%?9S$N:G!G4$L! A0#%     @ #H*C5$<Z;-@=I@  IM@  !4
M             ( !J@D% &)I:6(M,C R,C S,S%?9S$P+FIP9U!+ 0(4 Q0
M   (  Z"HU0[K$?[ZHT  -VV   5              "  ?JO!0!B:6EB+3(P
M,C(P,S,Q7V<Q,2YJ<&=02P$"% ,4    "  .@J-42BWVU'/4  #) 0$ %0
M            @ $7/@8 8FEI8BTR,#(R,#,S,5]G,3(N:G!G4$L! A0#%
M  @ #H*C5(/$1) 6.@$ S)L! !4              ( !O1(' &)I:6(M,C R
M,C S,S%?9S$S+FIP9U!+ 0(4 Q0    (  Z"HU1JCC1MQUP  !F+   5
M          "  09-" !B:6EB+3(P,C(P,S,Q7V<Q-"YJ<&=02P$"% ,4
M"  .@J-4*X^'I#Q7  #,A   %0              @ $ J@@ 8FEI8BTR,#(R
M,#,S,5]G,34N:G!G4$L! A0#%     @ #H*C5$8U>F=;7@  XY0  !4
M         ( !;P$) &)I:6(M,C R,C S,S%?9S$V+FIP9U!+ 0(4 Q0    (
M  Z"HU3.$[;R\UT  "67   5              "  ?U?"0!B:6EB+3(P,C(P
M,S,Q7V<Q-RYJ<&=02P$"% ,4    "  .@J-43$BP7)E0  !<>   %0
M        @ $CO@D 8FEI8BTR,#(R,#,S,5]G,3@N:G!G4$L! A0#%     @
M#H*C5)NK,"307P  '(X  !4              ( ![PX* &)I:6(M,C R,C S
M,S%?9S$Y+FIP9U!+ 0(4 Q0    (  Z"HU0[6TOO;NT  #-( 0 4
M      "  ?)N"@!B:6EB+3(P,C(P,S,Q7V<R+FIP9U!+ 0(4 Q0    (  Z"
MHU3HTK_,!*@  /G)   5              "  9)<"P!B:6EB+3(P,C(P,S,Q
M7V<R,"YJ<&=02P$"% ,4    "  .@J-4J-'7SVI7  !J@@  %0
M    @ ')! P 8FEI8BTR,#(R,#,S,5]G,C$N:G!G4$L! A0#%     @ #H*C
M5$@_3@'K5P  4G<  !4              ( !9EP, &)I:6(M,C R,C S,S%?
M9S(R+FIP9U!+ 0(4 Q0    (  Z"HU3:_]_^4?<  &!! 0 4
M  "  82T# !B:6EB+3(P,C(P,S,Q7V<S+FIP9U!+ 0(4 Q0    (  Z"HU23
M <YELIH  /'/   4              "  0>L#0!B:6EB+3(P,C(P,S,Q7V<T
M+FIP9U!+ 0(4 Q0    (  Z"HU3P,M-O#)8  ,:^   4              "
M >M&#@!B:6EB+3(P,C(P,S,Q7V<U+FIP9U!+ 0(4 Q0    (  Z"HU1*U5 6
M+5T  (!]   4              "  2G=#@!B:6EB+3(P,C(P,S,Q7V<V+FIP
M9U!+ 0(4 Q0    (  Z"HU0>&#S^YZ,  /;2   4              "  8@Z
M#P!B:6EB+3(P,C(P,S,Q7V<W+FIP9U!+ 0(4 Q0    (  Z"HU2$OH),R_$
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M8BTR,#(R,#,S,5]P<F4N>&UL4$L! A0#%     @ #H*C5+)>XVTX"   /BH
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%NA,    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
